<SEC-DOCUMENT>0000950123-23-009093.txt : 20240102
<SEC-HEADER>0000950123-23-009093.hdr.sgml : 20240102
<ACCEPTANCE-DATETIME>20231027164106
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-23-009093
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		24
FILED AS OF DATE:		20231027
<PUBLIC-REL-DATE>20240102
DATE AS OF CHANGE:		20231027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CG Oncology, Inc.
		CENTRAL INDEX KEY:			0001991792
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				371611499
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-06934
		FILM NUMBER:		231356058

	BUSINESS ADDRESS:	
		STREET 1:		400 SPECTRUM CENTER DRIVE
		STREET 2:		SUITE 2040
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		(949) 419-6203

	MAIL ADDRESS:	
		STREET 1:		400 SPECTRUM CENTER DRIVE
		STREET 2:		SUITE 2040
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on October&nbsp;27,
2023 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8195;&#8195;&#8195;&#8195;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES ACT
OF 1933 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Exact
name of registrant as specified in its charter) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">37-1611499</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(State or other jurisdiction of<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">incorporation or organization)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Primary Standard Industrial<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Classification Code Number)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(I.R.S. Employer<BR></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Identification No.)</P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>400 Spectrum Center Drive, Suite 2040 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Irvine, CA 92618 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(949) <FONT
STYLE="white-space:nowrap">409-3700</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Address, including zip code, and telephone number, including area code, of registrant&#146;s
principal executive offices) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arthur Kuan </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>400 Spectrum Center Drive, Suite 2040 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Irvine, CA 92618 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(949) <FONT
STYLE="white-space:nowrap">409-3700</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for
service) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><I>Copies to: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cheston J. Larson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Matthew T. Bush</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Anthony
Gostanian</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham &amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>12670 High Bluff Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San
Diego, CA 92130</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) 523-5400</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Charles S. Kim</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Denny Won</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kristin
VanderPas</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dave Peinsipp</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>10265 Science
Center Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) 550-6000</B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this Registration Statement
is declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If any of the securities being registered on this Form are to be offered on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is filed
to register additional securities for an offering pursuant to Rule 462(b)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and
&#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">Large accelerated filer&#8194;&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Accelerated filer&#8194;&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer&#8194;&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Smaller reporting company&#8194;&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Emerging growth company&#8194;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the
Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Arial Narrow" ALIGN="justify"><FONT COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and
may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities
in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#cc062a"><B>SUBJECT TO COMPLETION, DATED&#8195;&#8195;&#8195;&#8195; , 2023 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g03p01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This is an
initial public offering of shares of common stock of CG Oncology, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are offering&#8195;&#8195;&#8195;&#8195; shares of our common
stock. Prior to this offering, there has been no public market for our common stock. We anticipate that the initial public offering price will be between $&#8195;&#8195;&#8195; and $&#8195;&#8195;&#8195; per share. We have applied to list our common
stock on the Nasdaq Global Market (Nasdaq) under the symbol &#147;CGON,&#148; and this offering is contingent upon obtaining approval of such listing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an emerging growth company and a smaller reporting company under the federal securities laws and, as such, have elected to comply with
certain reduced public company reporting requirements. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Investing in
our common stock involves a high degree of risk. See the section titled &#147;<A HREF="#toc551455_2">Risk Factors</A>&#148; beginning on page&nbsp;13. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See the section titled &#147;Underwriting&#148; for additional disclosure regarding the estimated
underwriting discounts and commissions and estimated offering expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted the underwriters an option for
a period of 30 days to purchase up to an additional &#8195;&#8195;&#8195;&#8195; shares of our common stock solely to cover over-allotments, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters expect to deliver the shares of common stock to purchasers on &#8195;&#8195;&#8195;&#8195;, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon
the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Morgan Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>LifeSci Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is &#8195;&#8195;&#8195;&#8195;, 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_3">Special Note Regarding Forward-Looking</A> <A HREF="#toc551455_3">Statements
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_4">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_9">Management&#146;s Discussion and Analysis of</A> <A HREF="#toc551455_9">Financial
 Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_12">Executive and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_13">Certain Relationships and Related Person</A> <A HREF="#toc551455_13">Transactions
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_15">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_16">Shares Eligible For Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_17">Material United States Federal Income Tax</A> <A HREF="#toc551455_17">Consequences
 to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_21">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc551455_22">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this
prospectus, or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of, any other information that others
may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any free writing
prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this
offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the
more detailed information and financial statements included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should carefully read this entire
prospectus, including the information in the sections titled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Special Note Regarding Forward-Looking
Statements,&#148; and our financial statements and related notes included elsewhere in this prospectus, before making an investment decision. Unless the context requires otherwise, references in this prospectus to &#147;CG Oncology,&#148; the
&#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to CG Oncology, Inc. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone
bladder-sparing therapeutic for patients afflicted with bladder cancer. Our product candidate, cretostimogene, is initially in clinical development for the treatment of patients with high-risk <FONT STYLE="white-space:nowrap">Non-Muscle</FONT>
Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for high-risk NMIBC. There is significant
unmet need for treatments in these patients given the limitations of currently approved therapies and patient reluctance to undergo radical cystectomy, or the complete removal of the bladder. We are evaluating the safety and efficacy of
cretostimogene as monotherapy in <FONT STYLE="white-space:nowrap">BOND-003,</FONT> our ongoing Phase 3 clinical trial in high-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients. We have completed enrollment for this trial
and expect to report topline data by&#8195;&#8195;&#8195;&#8195;&#8195;. If successful, we believe that this trial could serve as the basis for a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA). We are
also evaluating the use of cretostimogene when administered to this same patient population in combination with <FONT STYLE="white-space:nowrap">FDA-approved</FONT> pembrolizumab in <FONT STYLE="white-space:nowrap">CORE-001,</FONT> our ongoing Phase
2 clinical trial. Moreover, we intend to assess the safety and efficacy of cretostimogene in treating a range of other bladder cancer indications as an alternative to BCG therapy and in patients who are not categorized as <FONT
STYLE="white-space:nowrap">BCG-unresponsive,</FONT> including our second Phase 3 clinical trial, <FONT STYLE="white-space:nowrap">PIVOT-006,</FONT> evaluating adjuvant cretostimogene in intermediate-risk NMIBC patients following transurethral
resection of the bladder tumor (TURBT). We believe cretostimogene, if approved, has the potential to serve as first-line therapy, thereby alleviating the current need to prioritize treatment recipients and ration administration of BCG given its
significant market shortage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cretostimogene has shown clinical benefit and has been generally well-tolerated as both a
monotherapy and in combination with other therapies in clinical trials to date. In <FONT STYLE="white-space:nowrap">BOND-002,</FONT> our completed open-label Phase 2 clinical trial which evaluated the use of cretostimogene as monotherapy to treat
patients with high-risk NMIBC who had failed BCG therapy with a specific high-risk bladder cancer profile designated as carcinoma <I>in situ</I> (CIS), 65% of the 46 patients with <FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC achieved
a complete response (CR), meaning no detectable tumor lesions, at any time after the administration of cretostimogene. The duration of response (DOR) was also notable, with 44% and 28% of patients maintaining a CR at six months and 12 months,
respectively. Cretostimogene was generally well-tolerated in this trial, with two Grade 3 (dysuria and hypotension) and no Grade 4 or 5 treatment-related adverse effects (TRAEs) observed or patient discontinuations due to TRAEs. We have also
observed encouraging interim results in our ongoing open-label Phase 2 <FONT STYLE="white-space:nowrap">CORE-001</FONT> clinical trial of cretostimogene in combination with pembrolizumab in high-risk
<FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients. In this trial, 29 of the 34 (85%) patients evaluable as of the March&nbsp;3, 2023 data cutoff achieved a CR after an initial induction course of therapy, with 82% (n=27/33) of
patients maintaining a CR at six months, and 68% (n=17/25) of patients maintaining a CR at 12 months. Cretostimogene was generally well-tolerated in this trial as of the January&nbsp;31, 2023 safety data cutoff, with one TRAE leading to a patient
discontinuation of pembrolizumab. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to evaluate cretostimogene for use in a variety of bladder cancer treatment settings, as shown in our pipeline below.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Our Cretostimogene Pipeline </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g89m10.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">*</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Planned clinical trials to be conducted under existing Investigational New Drug application (IND) previously
cleared by the FDA. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our product candidate is differentiated by several strengths that support our vision of cretostimogene as a
potential backbone therapy in bladder cancer, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Demonstrated monotherapy clinical utility and durability of response, with a 65% CR at any time, in addition
to 44% and 28% CR at six months and 12 months, respectively, in our completed Phase 2 <FONT STYLE="white-space:nowrap">BOND-002</FONT> cretostimogene monotherapy trial. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Observed tolerability, with two Grade 3 TRAEs and no Grade 4 or 5 TRAEs or patient discontinuations due to
TRAEs in our completed <FONT STYLE="white-space:nowrap">BOND-002</FONT> cretostimogene monotherapy trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cretostimogene is administered intravesically and uses a similar route of administration as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> BCG therapy which urology practices perform regularly. This is unlike some treatment procedures that require a urologist to perform a cystoscopic examination
that involves local anesthesia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential for deploying cretostimogene in combination with other therapies due to its observed
tolerability and novel mechanism of action, supported by 85% of patients having shown a CR at any time in our ongoing Phase&nbsp;2 <FONT STYLE="white-space:nowrap">CORE-001</FONT> clinical trial of cretostimogene in combination with the checkpoint
inhibitor (CPI) pembrolizumab as of March&nbsp;3, 2023. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cretostimogene&#146;s potential broad applicability across bladder cancer indications, beginning with
high-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC, and expanding into intermediate-risk and BCG-exposed and BCG-na&iuml;ve high-risk NMIBC, with potential incremental opportunity in muscle invasive bladder cancer (MIBC).
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bladder Cancer Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The human bladder, which functions in the storage and elimination of urine, is a hollow muscular organ composed of multiple
tissue layers. As shown below, the inner wall of the bladder is the urothelium, or transitional epithelium. The interior space where urine collects is known as the bladder lumen. The internal side of the urothelium is lined by a glycosaminoglycan
(GAG) membrane, which acts as a protective barrier from urine as well as infectious agents. Between the thick, detrusor muscular portion of the bladder wall and the urothelium is the lamina propria, which consists of connective tissue, blood vessels
and nerves. A fatty connective tissue layer makes up the organ&#146;s exterior surface, facing the rest of the body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The Anatomy of the
Bladder Wall </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g59q43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The American Cancer Society estimates that in 2023, more than 82,000 people will be
diagnosed with bladder cancer in the United States and that it will result in nearly 17,000 deaths. Notable is the disease prevalence with an estimated 725,000 people in the United States living with the disease. The relatively high prevalence rate
is driven in part by chances of recurrence, which can be very high for NMIBC. It is estimated that approximately 31% to 78% of people with NMIBC will develop recurrence or a secondary bladder cancer within five years following treatment, depending
on risk-factors. Bladder cancer is the sixth most common form of cancer in the United States, and men account for three-quarters of newly diagnosed cases. The global bladder cancer treatment market has been forecast to be approximately
$9.9&nbsp;billion by 2028, according to Evaluate Pharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Bladder cancer is a heterogeneous disease and involves several
different cancer <FONT STYLE="white-space:nowrap">sub-types.</FONT> In the United States, the vast majority of patients with bladder cancer, accounting for approximately 90% of all diagnoses, </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
have urothelial carcinoma (UC). UC is further segmented into two subtypes, papillary and <FONT STYLE="white-space:nowrap">non-papillary.</FONT> Papillary UC involves tumors configured as
finger-like projections extending from the transitional epithelium into the bladder lumen. <FONT STYLE="white-space:nowrap">Non-papillary,</FONT> or flat, UC, which contains CIS, is restricted to the transitional epithelium, and is generally
difficult to treat via resection. The 5% of bladder cancer that is not UC includes squamous cell carcinomas, adenocarcinomas, sarcomas and small cell carcinomas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NMIBC is often used to describe earlier stage disease that has not reached the muscle wall. NMIBC accounts for approximately
75% of newly diagnosed patients, and includes three stages: <FONT STYLE="white-space:nowrap">CIS-containing</FONT> tumors, Ta and T1. Ta and T1 are papillary UCs which have not spread beyond the lamina propria. T2 through T4 stage make up MIBC,
indicative of more aggressive locally advanced and metastatic disease. Bladder cancer has metastasized in an estimated 5% of patients with newly diagnosed disease. The graphic presented below illustrates the differences in disease progression
represented by these stages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Bladder Cancer is Classified as either NMIBC or MIBC </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g12m13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NMIBC may be further differentiated by the risk of progression to MIBC. NMIBC patients with
high-grade Ta or T1 stage cancer, any cancer containing CIS (which can occur in any grade of NMIBC or MIBC), and large volume or recurrent Ta stage tumors are considered to be high-risk tumors. Approximately 40% of patients with NMIBC have high-risk
disease. Intermediate-risk NMIBC includes mostly <FONT STYLE="white-space:nowrap">low-grade</FONT> Ta tumors that recur within 12 months, solitary <FONT STYLE="white-space:nowrap">low-grade</FONT> Ta tumors greater than three centimeters, multifocal
<FONT STYLE="white-space:nowrap">low-grade</FONT> Ta tumors, or high-grade Ta tumors less than or equal to three centimeters. Intermediate-risk NMIBC accounts for an estimated 30% of patients with NMIBC.
<FONT STYLE="white-space:nowrap">Low-risk</FONT> NMIBC consists of <FONT STYLE="white-space:nowrap">low-grade</FONT> solitary Ta stage tumors and makes up the remaining 30% of NMIBC cases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Treatment for NMIBC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regardless of risk stratification, treatment of NMIBC generally involves TURBT, a surgical procedure enabling the visual
inspection and biopsy of the lesion along with removal of the cancerous cells allowing a patient with NMIBC to retain normal bladder function. Use of TURBT alone is associated with a five-year </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
estimated recurrence rate of approximately 44% to 63% and remains a backbone of early NMIBC treatment regimen. <FONT STYLE="white-space:nowrap">CIS-containing</FONT> tumors cannot be resected
using TURBT. Progression to a more advanced stage or grade subsequent to initial diagnosis is also commonly encountered. As such, in both high-risk and intermediate-risk NMIBC patients, surgical removal of NMIBC tumors through TURBT is often
accompanied by the delivery of adjuvant BCG therapy or chemotherapy, intravesically through a catheter inserted directly into the bladder, also referred to as IVE delivery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">BCG therapy involves the use of a live, attenuated mycobacterium to induce a
<FONT STYLE="white-space:nowrap">non-specific</FONT> anti-tumor immune response in the bladder mucosa and provides meaningful therapeutic utility in the treatment of NMIBC. Further complicating the treatment options available to NMIBC patients is
the ongoing shortage of BCG which has restricted patient eligibility to high-risk BCG-na&iuml;ve patients only. Even among these patients a significant number of newly-diagnosed, <FONT STYLE="white-space:nowrap">BCG-eligible,</FONT> <FONT
STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> patients in the United States may not receive sufficient BCG therapy, if at all. Moreover, patients with intermediate-risk NMIBC may not have access to BCG due to the shortage, despite the
likely therapeutic benefit of adjuvant BCG therapy, because high-risk patients are prioritized in line with guidance published by the National Comprehensive Care Network and guidance published jointly by the American Urological Association and the
Society of Urologic Oncology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Treatment Paradigm in High-Risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> Disease and Its
Limitations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current treatment for high-risk NMIBC typically involves TURBT followed by the IVE delivery of BCG therapy
to induce a <FONT STYLE="white-space:nowrap">non-specific</FONT> anti-tumor immune response. This treatment protocol has demonstrated therapeutic benefit with nearly 70% of patients achieving a CR following an initial induction course of therapy.
However, approximately 50% of these patients will experience a recurrence of the tumor and few treatment options are available for patients who become unresponsive to BCG treatment. While radical cystectomy is the current <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> patients, only approximately 6% of NMIBC patients elect to undergo the procedure in light of the
significant social, functional and emotional burden associated with it. In addition, there are only two <FONT STYLE="white-space:nowrap">FDA-approved</FONT> agents for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> disease with limited
utilization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management team includes industry executives with extensive biopharmaceutical experience. Arthur Kuan, our Chief Executive
Officer, was a founding member of the Ally Bridge Group, a global healthcare-focused investment platform. Previously, Arthur was a member of Themes Investment Partners, a healthcare and life sciences-focused private equity fund. Our President and
Chief Operating Officer, Ambaw Bellete, has over 30 years of industry experience, including serving as Chief Operating Officer for FerGene, the Ferring Pharmaceuticals subsidiary responsible for the development and commercialization of its bladder
cancer treatment, nadofaragene. Ambaw was also the President of Photocure a company focused on the diagnosis and treatment of bladder cancer and has also held several global leadership positions with biotech and medical device companies. Our Chief
Medical Officer, Vijay Kasturi, M.D., previously served as Vice President, Clinical Development and Medical Affairs with AVEO Pharmaceuticals and SVP of Scientific Affairs at FerGene where he led Medical Affairs, Clinical Operations, Regulatory and
Clinical Development in connection with the nadofaragene program. Earlier, he led U.S.&nbsp;Medical Affairs, Oncology for EMD Serono, where he had broad leadership responsibilities including developing and managing the global medical strategy and
launch plan for an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> agent in bladder and kidney cancers. Our Chief Technical Officer, Swapnil Bhargava, Ph.D., has supported multiple INDs and BLAs and has
contributed to bringing multiple modalities to the clinic and market. He was previously a Senior Vice President of CMC Development and GMP Manufacturing for Abcellera, leading Tech Ops. Prior to that, he was the VP for Drug Substance Process
Development at Seagen, where he was responsible for leading cell line development, upstream, downstream and conjugation process development and analytical sciences departments for early and late-stage drug development. We believe the breadth and
depth </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of experience amongst our management team will enable us to bolster the cretostimogene development strategy and, if approved, its commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are backed by a strong set of healthcare-specific investors, including our 5% or greater stockholders, ORI Capital, Decheng
Capital, Longitude Capital, Kissei Pharmaceutical Co., Foresite Capital Management and TCGX. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and
strategies and have purchased their shares in prior offerings at prices lower than the price offered to the public in this offering. In addition, some of these investors may not be subject to reporting requirements under Section 16 of the Securities
Exchange Act of 1934 (the Exchange Act), and, thus, prospective investors may not necessarily know the total amount of investment by each of the prior investors and if and when some of the prior investors decide to sell any of their shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend
to become a leading company in the development and commercialization of innovative therapeutics to treat cancer, with an initial focus on bladder cancer. Key elements of our strategy to accomplish this objective include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete the ongoing BOND-003 Phase 3 trial of cretostimogene as monotherapy in high-risk <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC and pursue FDA approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand the development of cretostimogene monotherapy as a potential backbone therapy across NMIBC indications.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to evaluate cretostimogene in combination with other therapies, such as CPIs, to potentially further
enhance its clinical utility across various stages of bladder cancer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Build our operational capabilities to successfully commercialize cretostimogene. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage our chemistry, manufacturing and controls (CMC) expertise and relationships to scale
commercialization efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ability to execute our business strategy is subject to numerous risks and uncertainties that you should consider before
investing in us, as more fully described in the section titled &#147;Risk Factors&#148; immediately following this Prospectus Summary. These risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a relatively limited operating history, have incurred significant operating losses since our
inception, and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require substantial additional capital to finance our operations,
and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We currently depend entirely on the success of cretostimogene, which is our only product candidate. If we are
unable to advance cretostimogene in clinical development, obtain regulatory approval and ultimately commercialize cretostimogene, or experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cretostimogene is based on a novel approach to the treatment of cancer, which makes it difficult to predict
the time and cost of product candidate development and subsequently obtaining regulatory approval, if at all. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines
and outcomes, and results of prior preclinical studies and early clinical trials are not necessarily predictive of future results. Cretostimogene or any future product candidates may not achieve favorable results in clinical trials or preclinical
studies or receive regulatory approval on a timely basis, if at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Use of cretostimogene or any future product candidates could be associated with adverse side effects, adverse
events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials, abandon cretostimogene or any future product candidate, limit the commercial profile of an approved
label or result in other significant negative consequences that could severely harm our business, financial condition, results of operations and prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition, and if our competitors develop and commercialize technologies or product
candidates more rapidly than we do, or their technologies or product candidates are more effective, safer, or less expensive than cretostimogene or any future product candidates we develop, our business and our ability to develop and successfully
commercialize products will be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our clinical trials and preclinical studies, and these third parties may
not perform satisfactorily, which could delay, prevent, or impair our development or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties for the manufacture and shipping of cretostimogene for clinical development and
expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of cretostimogene or future product candidates or such quantities at an acceptable cost, which
could delay, prevent, or impair our development or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain, maintain, and enforce patent or other intellectual property protection for
cretostimogene or any future product candidates or technology, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize
products similar or identical to ours, and our ability to successfully commercialize cretostimogene or any future product candidates, may be adversely affected. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate and Other Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We were originally founded as a California corporation on September&nbsp;24, 2010 under the name Cold Genesys, Inc. On
November&nbsp;30, 2017, we reincorporated as a Delaware corporation, and on March&nbsp;31, 2020, we changed our name to CG Oncology, Inc. Our principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618, and our
telephone number is (949) <FONT STYLE="white-space:nowrap">409-3700.</FONT> Our website address is https://cgoncology.com. The information contained in, or accessible through, our website does not constitute part of this prospectus. We have included
our website address as an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We use our trademarks in this prospectus, as well as
trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and
<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not
assert its rights to these trademarks and tradenames. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS
Act). An emerging growth company may take advantage of certain reduced disclosure and other requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, as amended (the Sarbanes-Oxley Act); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the U.S. Securities and Exchange Commission (SEC) determines
the new rules are necessary for protecting the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
stockholder approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may take advantage of
these provisions until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the
Securities Act), which such fifth anniversary will occur in 2028. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, our annual gross revenues exceed $1.235&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we
will cease to be an emerging growth company prior to the end of such five-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have elected to take advantage
of certain of the reduced disclosure obligations in this prospectus and in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the
information in this prospectus and that we provide to our stockholders in the future may be different than what you might receive from other public reporting companies in which you hold equity interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for
complying with new or revised accounting standards. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth
companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. We intend to rely on other exemptions provided by the JOBS Act,
including without limitation, not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a smaller reporting
company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our
voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual
revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriters&#146; over-allotment option of common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:pt"><BR></P> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares (or
&#8195;&#8195;&#8195;&#8195; shares if the underwriters exercise their over-allotment option in full).</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds to us from this offering will be approximately $&#8195;&#8195;&#8195; million (or
approximately $&#8195;&#8195;&#8195; million if the underwriters exercise their over-allotment option in full), based on the assumed initial public offering price of $&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set
forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently intend to use the net proceeds of this
offering, together with our existing cash, cash equivalents and marketable securities, to fund the research and development of cretostimogene and for working capital and other general corporate purposes, including
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> activities. See the section titled &#147;Use of Proceeds.&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investing in our common stock involves a high degree of risk. See the section titled &#147;Risk Factors&#148; and other
information included in this prospectus for a discussion of risks you should consider carefully before deciding to invest in our common stock.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market trading symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;CGON&#148;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares of our common stock to be outstanding after this offering set forth above
is based on &#8195;&#8195;&#8195;&#8195; shares of our common stock outstanding as of September&nbsp;30, 2023, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 366,277,131
shares of our common stock immediately prior to the closing of this offering, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock issuable upon the exercise of stock options outstanding as
of September&nbsp;30, 2023, with a weighted-average exercise price of $&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock issuable upon the exercise of stock options subsequent to
September&nbsp;30, 2023, with a weighted-average exercise price of $&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under our 2024 Incentive
Award Plan (the 2024 Plan), which will become effective in connection with this offering (which number includes &#8195;&#8195;&#8195;&#8195; shares of common stock reserved for issuance under our 2022 Incentive Award Plan (the 2022 Plan) as of
September&nbsp;30, 2023, which shares will be added to the 2024 Plan upon its effectiveness, but does not include any potential evergreen increases pursuant to the terms of the 2024 Plan); and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under our 2024 Employee Stock
Purchase Plan (the ESPP), which will become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our
amended and restated bylaws, each of which will occur immediately prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into
366,277,131 shares of our common stock immediately prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a&#8195; <FONT STYLE="white-space:nowrap">-for-</FONT> &#8195;reverse stock split of our common stock, which
we effected on &#8195;&#8195;&#8195;&#8195;, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding stock options described above; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their over-allotment option. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables set forth a summary of our historical financial data as of, and for the periods ended on, the dates
indicated. We have derived the summary statements of operations and comprehensive loss data for the years ended December&nbsp;31, 2021 and 2022 from our audited financial statements included elsewhere in this prospectus. We have derived the summary
statements of operations and comprehensive loss data for the nine months ended September&nbsp;30, 2022 and 2023 and the summary balance sheet data as of September&nbsp;30, 2023 from our unaudited financial statements included elsewhere in this
prospectus. The unaudited financial statements have been prepared on a basis consistent with our audited financial statements included in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring
adjustments, necessary to fairly state the financial information in those statements. You should read these data together with our financial statements and related notes included elsewhere in this prospectus and the section titled
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future results, and our interim results are not necessarily
indicative of our expected results for the year ended December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except for share and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 10,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend on redeemable convertible preferred stock issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative redeemable convertible preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding, basic and diluted<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,807,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,669,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares of common stock outstanding, basic and diluted&nbsp;(unaudited)<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321,329,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">See Note 2 and Note 12 to our audited financial statements and to our unaudited condensed financial
statements included elsewhere in this prospectus for an explanation of the method used to calculate historical net loss attributable to common stockholders per share, basic and diluted, and the weighted-average number of shares of common stock used
in the computation of the per share amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Unaudited pro forma net loss per share, basic and diluted, attributable to common stockholders, is calculated
giving effect to the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock. Unaudited pro forma net loss per share attributable to common stockholders does not include the shares expected
to be sold and related proceeds to be received in this offering. Unaudited pro forma net loss per share attributable to common stockholders for the year ended December&nbsp;31, 2022 and the nine months ended September&nbsp;30, 2023 was calculated
using the weighted-average number of shares of common stock outstanding, including the pro forma effect of the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock, as if such conversion
had occurred at the beginning of the period, or their issuance dates, if later. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:75%; vertical-align:top">(1)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except for share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Pro forma amounts give effect to the automatic conversion of all outstanding shares of our redeemable
convertible preferred stock into an aggregate of 366,277,131 shares of our common stock and the related reclassification of the carrying value of the redeemable convertible preferred stock to permanent equity immediately prior to the closing of this
offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Pro forma as adjusted amounts give effect to (i)&nbsp;the pro forma adjustments set forth in footnote
(1)&nbsp;above, and (ii)&nbsp;the issuance and sale of &#8195;&#8195;&#8195;&#8195; shares of our common stock in this offering at the initial public offering price of $&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on
the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase or decrease in the assumed initial public offering price of
$&#8195;&#8195;&#8195; per share would increase or decrease, as applicable, the pro forma as adjusted amount of each of our cash, cash equivalents and marketable securities, working capital, total assets and total stockholders&#146; (deficit) equity
by approximately $ &#8195;&#8195;&#8195;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price of $&#8195;&#8195;&#8195; per share would increase or decrease, as applicable,
the pro forma as adjusted amounts of each of our cash, cash equivalents and marketable securities, working capital, total assets and total stockholders&#146; (deficit) equity by approximately $&#8195;&#8195;&#8195;, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The pro forma and pro forma as adjusted information discussed above is illustrative only and will be adjusted
based on actual initial public offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">We define working capital as current assets less current liabilities. See our financial statements and the
related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties
described below, together with all of the other information in this prospectus, including our financial statements and related notes included elsewhere in this prospectus and in the section titled &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; before making an investment decision. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected.
In that event, the trading price of our common stock could decline and you could lose part or all of your investment. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial also may impair our
business, financial condition, results of operations and prospects. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History, Financial Position and Capital
Requirements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have a relatively limited operating history, have incurred significant operating losses since our inception and
expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a
clinical-stage biopharmaceutical company with a relatively limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2010, have no products approved for commercial sale and have not generated any
revenue from the sale of our products. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, conducting research, preclinical studies and clinical trials for our product candidate,
cretostimogene, establishing our intellectual property portfolio, establishing arrangements with third parties for the manufacture of cretostimogene and supply of related raw materials, and providing general and administrative support for these
operations. We have not yet demonstrated the ability to successfully complete any clinical trial beyond Phase 2, obtain regulatory approvals, manufacture products at commercial scale or arrange for a third party to do so on our behalf, or conduct
sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and
commercializing biopharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred significant operating losses since our inception and expect
to incur significant losses for the foreseeable future. We do not have any products approved for sale and have not generated any revenue from product sales. If we are unable to successfully develop, obtain requisite approval for and commercialize
cretostimogene or any future product candidates, we may never generate revenue. Our net losses were $12.8&nbsp;million and $35.4&nbsp;million for the years ended December&nbsp;31, 2021 and 2022, respectively, and $&#8195;million for the nine months
ended September&nbsp;30, 2023. As of September&nbsp;30, 2023, we had an accumulated deficit of $&#8195;&#8195;&#8195; million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development
activities and from general and administrative costs associated with our operations. Cretostimogene and any future product candidates will require substantial additional development time and resources before we would be able to apply for or receive
regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory
approval for and potentially commercialize cretostimogene and any future product candidates, as well as operate as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To become and remain profitable, we must succeed in developing, obtaining regulatory approvals for, and eventually
commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of cretostimogene and any future product candidates,
acquiring additional product candidates, obtaining regulatory approval for cretostimogene and any future product candidates, and manufacturing, marketing, and selling any products for which we may obtain regulatory approval. We are only in the
preliminary stages of most of these activities. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to
successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with
biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or
increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and
development efforts, diversify our product candidates, achieve our strategic objectives or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if this offering is successful, we will require substantial additional capital to finance our operations, and a failure to obtain
this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The development of biopharmaceutical product candidates, including conducting preclinical studies and clinical trials, is a
very time-consuming, capital-intensive and uncertain process. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to substantially increase in connection with our ongoing activities, particularly as we
conduct our ongoing and planned clinical trials of cretostimogene and potentially seek regulatory approval for cretostimogene and any future product candidates we may develop. In addition, if we are able to progress cretostimogene through
development and commercialization, we expect to be required to make milestone and royalty payments pursuant to various license or collaboration agreements with third parties. If we obtain regulatory approval for cretostimogene or any future product
candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reliably
estimate the actual amount of capital necessary to successfully complete the development and commercialization of cretostimogene or any future product candidates. Furthermore, following the completion of this offering, we expect to incur additional
costs associated with operating as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our current operating plan, we believe that the net
proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations for at least the next &#8195;&#8195;&#8195;&#8195; months from the date of this prospectus. In
particular, we expect that the net proceeds from this offering and our existing cash, cash equivalents and marketable securities will allow us to &#8195;&#8195;&#8195;&#8195;&#8195; . We have based these estimates on assumptions that may prove to be
wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds
sooner than planned. The net proceeds of this offering, together with our existing capital, may not be sufficient to complete development of cretostimogene, or any future product candidates, and after this offering, we will require substantial
capital in order to advance cretostimogene and any future product candidates through clinical trials, regulatory approval and commercialization. Accordingly, we will need to obtain substantial additional funding in connection with our continuing
operations. Our ability to raise additional funds may be adversely impacted by global economic conditions, disruptions to, and volatility in, the credit and financial markets in the United States and worldwide, and diminished liquidity and credit
availability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. If we are unable to raise capital when needed or on attractive terms, we could be forced to
delay, reduce or eliminate our research and development programs or any future commercialization efforts, or even cease operations. We expect to finance our cash needs through public or private equity or debt financings or other capital sources,
including potential collaborations, licenses, and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or
future operating plans. Attempting to secure additional financing may divert our management from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to
develop cretostimogene or any future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future capital requirements will depend on many factors, including, but
not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, type, number, scope, progress, expansions, results, costs and timing of clinical trials and
preclinical studies of cretostimogene and any future product candidates we may choose to pursue, including the costs of modification to clinical development plans based on feedback that we may receive from regulatory authorities and any third-party
products used as combination agents in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of manufacturing for cretostimogene or any future product candidate, including commercial
manufacturing at sufficient scale, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory meetings and reviews of cretostimogene or any future product
candidates in any jurisdictions in which we or our current or any future collaborators may seek approval for cretostimogene or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of obtaining, maintaining, enforcing and protecting our patents and other intellectual property and
proprietary rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a
public company, including enhanced internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with hiring additional personnel and consultants as our business grows, including
additional executive officers and clinical development, regulatory, chemistry, CMC, quality and commercial personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and payment of milestone, royalty or other payments we must make pursuant to our existing and
potential future license or collaboration agreements with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of establishing or securing sales and marketing capabilities if cretostimogene or any
future product candidate is approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party
payors and adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and strategic decision to develop future product candidates other than cretostimogene, and the
timing of such development, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients&#146; willingness to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with any products or technologies that we may
<FONT STYLE="white-space:nowrap">in-license</FONT> or acquire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Conducting clinical trials and
preclinical studies and potentially identifying future product candidates is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory
approval and commercialize cretostimogene or any future product candidates. If approved, cretostimogene and any future product candidates may not achieve commercial success. We expect that our commercial revenue, if any, will initially be derived
from sales of cretostimogene, which we do not expect to be commercially available for several years, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional
financing may not be available to us on acceptable terms, or at all, including as a result of financial and credit market deterioration or instability, market-wide liquidity shortages, geopolitical events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Raising additional capital may cause dilution to our stockholders, including
purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity
offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred
equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Such restrictions
could adversely impact our ability to conduct our operations and execute our business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we raise additional funds
through future collaborations, licenses and other similar arrangements, we may be required to relinquish valuable rights to our future revenue streams, product candidates, research programs, intellectual property or proprietary technology, or grant
licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we
would be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, or on less
favorable terms than we would otherwise choose. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development and Regulatory Approval of Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently depend entirely on the success of cretostimogene, which is our only product candidate. If we are unable to advance
cretostimogene in clinical development, obtain regulatory approval and ultimately commercialize cretostimogene, or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently only have one product candidate, cretostimogene, which is in Phase 3 clinical development. Our business presently
depends entirely on our ability to successfully develop, obtain regulatory approval for, and commercialize cretostimogene in a timely manner. This may make an investment in our company riskier than similar companies that have multiple product
candidates in active development and may be able to better sustain the delay or failure of a lead product candidate. The success of cretostimogene will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful initiation and enrollment of clinical trials and completion of clinical trials with favorable
results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of regulatory submissions by the FDA or comparable foreign regulatory authorities for the conduct
of clinical trials of cretostimogene and of our proposed designs of planned clinical trials of cretostimogene; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the frequency and severity of adverse events observed in clinical trials and preclinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and establishing relationships with contract research organizations (CROs) and clinical sites for
the clinical development of cretostimogene, and ability of such CROs and clinical sites to comply with clinical trial protocols, Good Clinical Practices (GCPs) and other applicable requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrating the safety, purity and potency (or efficacy) of cretostimogene to the satisfaction of applicable
regulatory authorities, including by establishing a safety database of a size satisfactory to regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt and maintenance of regulatory approvals from applicable regulatory authorities, including approvals of
BLAs from the FDA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining relationships with our third-party manufacturers and their ability to comply with current Good
Manufacturing Practices (cGMPs) as well as timely making arrangements with our third-party manufacturers for, or establishing our own, commercial manufacturing capabilities at a cost and scale sufficient to support commercialization;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of cretostimogene,
if and when approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining, maintaining, protecting and enforcing patent and any potential trade secret protection or
regulatory exclusivity for cretostimogene; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining an acceptable safety profile of cretostimogene following regulatory approval, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and growing an organization of people who can develop and, if approved, commercialize, market and
sell cretostimogene; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our products, if approved, by patients, the medical community and third-party payors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we are unable to develop, obtain regulatory approval for, or if approved, successfully manufacture
and commercialize cretostimogene, or if we experience delays as a result of any of the above factors or otherwise, our business would be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Cretostimogene is based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product
candidate development and subsequently obtaining regulatory approval, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have concentrated our research
and development efforts on cretostimogene, and our future success largely depends on the successful development of the oncolytic approach underlying this product candidate. In particular, cretostimogene is an engineered adenovirus designed to
replicate and eliminate cancer cells while also stimulating an anti-tumor immune response. To our knowledge, there are no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for the treatment of cancer that utilize an adenovirus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect the novel nature of cretostimogene to create further challenges in obtaining regulatory approval. Few viral
immunotherapies have been approved globally or by the FDA to date. While the first oncolytic viral immunotherapy, talimogene laherparepvec (Imlygic, Amgen), has received FDA approval, regulatory agencies have reviewed relatively few viral
immunotherapy product candidates such as cretostimogene. This may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. Further, any viral immunotherapies that are
approved may be subject to extensive post-approval regulatory requirements, including requirements pertaining to manufacturing, distribution and promotion. We may need to devote significant time and resources to compliance with these requirements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, cretostimogene is a live, gene-modified virus for which the FDA and other comparable foreign regulatory
authorities and other public health authorities, such as the Centers of Disease Control and Prevention and hospitals involved in clinical studies, have established additional safety and contagion rules and procedures, which could establish
additional hurdles for the development, manufacture or use of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory approvals for further development, manufacturing or commercialization of our
product candidates. We may also experience delays in transferring our process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, and the
results of preclinical studies and early clinical trials are not necessarily predictive of future results. Cretostimogene or any future product candidates may not achieve favorable results in clinical trials or preclinical studies or receive
regulatory approval on a timely basis, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Drug development is expensive and can take many years to
complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials or preclinical studies will be conducted as planned, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
including whether we are able to meet expected timeframes for data readouts, or completed on schedule, if at all, and failure can occur at any time during the trial or study process, including
due to factors that are beyond our control. Despite promising preclinical or clinical results, cretostimogene or any other future product candidate can unexpectedly fail at any stage of clinical or preclinical development. The historical failure
rate for product candidates in our industry is high. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The results from preclinical studies or clinical trials of
cretostimogene, any future product candidate, or a competitor&#146;s product candidate in the same class may not predict the results of later clinical trials of cretostimogene or any future product candidate, and interim, topline or preliminary
results of a clinical trial are not necessarily indicative of final results. Cretostimogene or any future product candidate in later stages of clinical trials may fail to show the desired characteristics despite having progressed through preclinical
studies and initial clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising
early results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A
number of companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Such setbacks have occurred and may occur for many
reasons, including, but not limited to: clinical sites and investigators may deviate from clinical trial protocols, whether due to lack of training or otherwise, and we may fail to detect any such deviations in a timely manner; patients may fail to
adhere to any required clinical trial procedures, including any requirements for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> our product candidates may fail to demonstrate safety, purity or potency (or efficacy) in certain
patient subpopulations, which has not been observed in earlier trials due to limited sample size, lack of analysis or otherwise; or our clinical trials may not adequately represent the patient populations we intend to treat, whether due to
limitations in our trial designs or otherwise, such as where one patient subgroup is overrepresented in the clinical trial. There can be no assurance that we will not suffer similar setbacks despite the data we observed in earlier or ongoing
studies. Based upon negative or inconclusive results, we or any current or any future collaborator may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, which would cause us to incur additional
operating expenses and delays and may not be sufficient to support regulatory approval on a timely basis or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a
result, we cannot be certain that our ongoing and planned clinical trials or preclinical studies will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory
approval of cretostimogene in those and other indications, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical
trials or preclinical studies could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before obtaining approval from regulatory authorities for the sale of cretostimogene or any future product candidates, we must
conduct extensive clinical trials to demonstrate the safety, purity and potency (or efficacy) of the product candidates in humans. In addition, before we can initiate clinical development for any future preclinical product candidates, we must submit
the results of preclinical studies to the FDA or comparable foreign regulatory authorities along with other information, including information about product candidate CMC and our proposed clinical trial protocol, as part of an IND or similar
regulatory submission, and we are also required to submit comparable applications to foreign regulatory authorities for clinical trials outside of the United States. The FDA or comparable foreign regulatory authorities may require us to conduct
additional preclinical studies for any future product candidates before it allows us to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays or increase the costs of developing future product candidates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, issues may arise that could cause regulatory authorities to
suspend or terminate our ongoing or planned clinical trials. Any such delays in the commencement or completion, or the termination or suspension, of our ongoing and planned clinical trials or preclinical studies could significantly affect our
product development timelines and product development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not know whether our planned clinical trials or
preclinical studies will begin on time or if our ongoing or future trials or studies will be completed on schedule, if at all. The commencement, data readouts and completion of clinical trials and preclinical studies can be delayed for a number of
reasons, including delays related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to obtain animals or materials to initiate and generate sufficient preclinical, toxicology, or other
in vivo or in vitro data to support the initiation or continuation of clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining allowance from regulatory authorities to commence a trial or reaching a consensus with regulatory
authorities on trial design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting, and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining approval from one or more institutional review boards (IRBs) or ethics committees at clinical trial
sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs/ECs refusing to approve, suspending, or terminating the trial at an investigational site, precluding
enrollment of additional patients, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from the trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs to perform in accordance with GCP requirements or applicable regulatory requirements or
guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining sufficient quantities of cretostimogene or any future product candidates and related raw materials
and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">n-Dodecyl-&szlig;-D-maltoside</FONT></FONT></FONT> (DDM) or obtaining sufficient quantities of combination therapies or other materials needed for
use in clinical trials and preclinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients failing to enroll or remain in our trials at the rate we expect, or failing to return for
post-treatment <FONT STYLE="white-space:nowrap">follow-up,</FONT> including patients failing to remain in our trials due to movement restrictions, health reasons or otherwise resulting from any future public health concerns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients choosing alternative treatments for the indications for which we are developing cretostimogene or any
future product candidates, or participating in competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the clinical trials or preclinical studies or costs being greater than we
anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients experiencing severe or serious unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies that
could be considered similar to cretostimogene or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or extended analysis of
the resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer of manufacturing processes to larger-scale facilities operated by third-party manufacturers, delays
or failure by our third-party manufacturers or us to make any necessary changes to such </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
manufacturing process, or failure of such third-party manufacturers to produce clinical trial materials in accordance with cGMP regulations or other applicable requirements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials must be conducted in accordance with the FDA and other applicable regulatory
authorities&#146; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and ECs or IRBs at the medical institutions where the clinical trials are conducted. We could also encounter delays if a
clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a data safety monitoring board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities
may impose such a suspension, including a clinical hold, or termination due to a number of factors, including, among other reasons, failure to conduct the clinical trial in accordance with GCP and other regulatory requirements or our clinical
protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a
benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend
clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, we and our collaborators are currently conducting, and we, our collaborators and any future collaborators may in the
future conduct, clinical trials in foreign countries, which presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocols as a
result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, and political and economic risks, including war, relevant to such foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, principal investigators for our clinical trials have served and may in the future serve as scientific advisors or
consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or
comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory
authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing
applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of cretostimogene or any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may make formulation or manufacturing changes to cretostimogene or any future product candidate, in which case
we may need to conduct additional preclinical studies or clinical trials to bridge our current version of cretostimogene or future product candidate to earlier versions. If we are unable to conduct such studies or trials, or if we otherwise fail to
adequately bridge the current versions of our product candidates to earlier versions, then we may be unable to utilize any data we have gathered from studies or trials that evaluated such earlier versions in our planned regulatory submissions, which
could delay our programs. For example, in our ongoing studies of cretostimogene we are utilizing materials produced by a different third-party manufacturer than the third-party manufacturer that produced cretostimogene during the initial clinical
trials for cretostimogene, and we are unable to demonstrate full comparability between lots produced previously and those produced by our current manufacturer. As a result, we may be required to gather additional data utilizing material produced by
our current third-party manufacturer before we are able to submit a BLA for cretostimogene, if ever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of the factors
that cause, or lead to, the termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize cretostimogene or our future product
candidates. In such cases, our competitors may be able to bring products to market before we do, and the commercial viability of cretostimogene or our future product candidates could be significantly reduced. Any of these occurrences may harm our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may find it difficult to enroll patients in our clinical
trials. If we encounter difficulties or delays enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Successful and timely completion of clinical trials will require that we identify and enroll a specified number of patients for
each of our clinical trials. We may not be able to initiate or continue certain clinical trials for cretostimogene or any future product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in
these trials as required by the FDA or similar regulatory authorities outside the United States. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and characteristics of the
patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit
clinical trial investigators with the appropriate competencies and experience, and competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the product candidates being studied in
relation to other available therapies, including any new products that may be approved for the indications we are investigating as well as any product candidates under development. We will be required to identify and enroll a sufficient number of
patients for each of our clinical trials and monitor such patients adequately during and after treatment. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting,
which could adversely impact the outcomes of our trials and could have safety concerns for the potential patients. Potential patients for any planned clinical trials may also not meet the entry criteria for such trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, other pharmaceutical companies targeting bladder cancer are recruiting clinical trial patients from these
patient populations, which may make it more difficult to fully enroll our clinical trials. The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of
required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. If patients are unwilling or unable to participate in
our trials for any reason, including the existence of concurrent clinical trials for similar target populations, the availability of approved therapies, or the fact that enrolling in our trials may prevent patients from taking a different product,
or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of cretostimogene or any future product candidates may be delayed. Our inability to
enroll a sufficient number of patients for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we rely on, and will continue to rely on, CROs and clinical trial sites to ensure proper and timely conduct of
our clinical trials and preclinical studies. Though we have entered into agreements governing their services, we have limited influence over their actual performance. We cannot be certain that our assumptions used in determining expected clinical
trial timelines are correct or that we will not experience delays or difficulties in enrollment, or be required by the FDA or other regulatory authority to increase our enrollment, which would result in the delay of completion of such trials beyond
our expected timelines. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Use of cretostimogene or any future product candidates could be associated with side
effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials, abandon cretostimogene or any future product candidate, limit the commercial profile
of an approved label or result in other significant negative consequences that could severely harm our business, financial condition, results of operations and prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As is the case with oncology drugs generally, it is likely that there may be side effects and adverse events associated with
use of cretostimogene or any future product candidates&#146; use. Results of our, our collaborators&#146; or any future collaborators&#146; clinical trials could reveal a high and unacceptable severity and prevalence of expected or unexpected side
effects or unexpected characteristics. Undesirable side effects caused by our product candidates when used alone or in combination with approved or investigational drugs could cause us or regulatory authorities to interrupt, delay or halt clinical
trials and could result in a more restrictive label, or lead to the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of
enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition, results of operations and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, if cretostimogene or any future product candidates are associated with undesirable side effects in clinical trials
or demonstrate characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less
severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for such product candidate if approved. Unacceptable enhancement of certain toxicities may be seen when cretostimogene or any future product
candidates are combined with standard of care therapies, or when they are used as single agents. We may also be required to modify our development and clinical trial plans based on findings in our ongoing clinical trials. Many compounds that
initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented further development of the compounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">It is possible that as we, our collaborators or any future collaborators test cretostimogene or any future product candidates
in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread following any regulatory approval, more illnesses, injuries, discomforts and other
adverse events than were observed in earlier trials, as well as new conditions that did not occur or went undetected in previous trials, may be discovered. If such side effects become known later in development or upon approval, if any, such
findings may harm our business, financial condition, results of operations and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we
are studying cretostimogene in combination with other therapies and may do so for future product candidates, which may exacerbate adverse events associated with such product candidate. Patients treated with cretostimogene or future product
candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. The inclusion of
critically ill patients in our, our collaborators&#146; or any future collaborators&#146; clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the
gravity of such patients&#146; illnesses. For example, it is expected that some of the patients enrolled in our, our collaborators&#146; or any future collaborators&#146; clinical trials will die or experience major clinical events either during the
course of such clinical trials or after participating in such trials, which has occurred with other investigational therapeutics in the past. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if cretostimogene or any future product candidate receives regulatory approval, and we or others later identify
undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against
its manufacture or distribution; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way such product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning
or a contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a Risk Evaluation and Mitigation Strategy (REMS) or create a medication guide
outlining the risks of such side effects for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product is distributed or administered, conduct additional clinical
trials or change the labeling of a product or be required to conduct additional post-marketing studies or surveillance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly or the product could become less competitive; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any of these events could prevent us from achieving or maintaining market acceptance and/or physician adoption of the
particular product candidate, if approved, and could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Although we have completed a Phase 2 clinical trial for cretostimogene, we have not as an organization completed later-stage or pivotal
clinical trials or submitted a BLA, and we may be unable to do so for cretostimogene or any future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will need to successfully complete later-stage and pivotal clinical trials in order to obtain FDA or comparable foreign
regulatory approval to market cretostimogene or any future product candidates. Carrying out later-stage clinical trials and the submission of a successful BLA or other comparable foreign regulatory submission is a complicated process. As an
organization, we have completed one Phase 2 clinical trial of cretostimogene, and are conducting and plan to conduct additional Phase 3 clinical trials for cretostimogene. We also plan to conduct a number of additional clinical trials of
cretostimogene in parallel over the next several years, which may be a difficult process to manage with our limited resources and which may divert attention of management. We have not yet completed any later-stage or pivotal clinical trials for
cretostimogene or any other product candidate. We also have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted a BLA or other comparable foreign regulatory submission for any
product candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many additional clinical trials of cretostimogene or any future product candidate will be required or how such trials should be designed.
Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require more time and incur greater
costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our ongoing or planned clinical trials could prevent us from or delay us in
submitting BLAs or other comparable foreign regulatory submissions for and commercializing our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We intend to
develop cretostimogene and future product candidates in combination with other therapies, which exposes us to additional risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to develop cretostimogene and any future product candidates for use in combination with one or more currently
approved cancer therapies. Even if cretostimogene or any future product candidate we develop was to receive regulatory approval or be commercialized for use in combination with other existing therapies, we would continue to bear the risks that the
FDA or similar foreign regulatory authorities could revoke approval of the therapy used in combination with cretostimogene or a future product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing
therapies. The known side effect profile of checkpoint inhibitors we use in combination therapies may otherwise negatively affect the results of our trials and could limit the number of patients and physicians who choose to adopt cretostimogene, if
approved for use as combination therapy with such drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop cretostimogene or any future product candidate for use in combination
with other drugs or biologics. Developing combination therapies using approved therapeutics, as we plan to do for cretostimogene and our future product candidates, also exposes us to additional clinical risks, such as the requirement that we
demonstrate the safety, purity and potency (or efficacy) of each active component of any combination regimen we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the FDA or similar foreign regulatory authorities revoke the approval of combination agents, or if safety, efficacy,
manufacturing, or supply issues arise with the drugs we choose to evaluate in combination with cretostimogene or any future product candidate, we may be unable to obtain approval of or market cretostimogene or any future product candidate for
combination therapy regimens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, if the third-party providers of therapies or therapies in development used in
combination with cretostimogene or any future product candidate are unable to produce sufficient quantities for clinical trials or for commercialization of cretostimogene or any future product candidate, or if the cost of combination therapies are
prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Negative developments in the field of immuno-oncology and, in particular, viral immunotherapy, could damage public perception of any
cretostimogene or any future oncolytic product candidates and negatively affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The commercial
success of cretostimogene and any future adenovirus-based product candidates will depend in part on public acceptance of the use of immuno-oncology, and, in particular, viral immunotherapy. Adverse events in clinical trials of cretostimogene or any
other adenovirus-based product candidates which we may develop, or in clinical trials of other biopharmaceutical companies developing similar products and the resulting publicity, as well as any other negative developments in the field of
immuno-oncology that may occur in the future, including in connection with competitor therapies, could result in a decrease in demand for cretostimogene or any other adenovirus-based product candidates that we may develop. These events could also
result in the suspension, discontinuation or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of viral immunotherapies is unsafe, whether related to our therapies or those of our
competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our, our collaborators&#146; or any future collaborators&#146; clinical
trials. In addition, responses by national or state governments to negative public perception may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory
approval or otherwise achieve profitability. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay
or impair the development and commercialization of our product candidates or demand for any products we may develop. As a result, we may not be able to continue or may be delayed in conducting our development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Adverse developments in clinical trials of other immunotherapy products based on viruses, like oncolytic viruses, may result
in a disproportionately negative effect for cretostimogene or any future product candidates as compared to other products in the field of infectious disease and immuno-oncology that are not based on viruses. Future negative developments in the
biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of cretostimogene or any future product candidates. Any increased scrutiny
could delay or increase the costs of obtaining marketing approval for our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be successful in our efforts to investigate cretostimogene in additional
indications. We may expend our limited resources to pursue a new product candidate or a particular indication for cretostimogene and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater
likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we have limited financial and managerial resources, we focus on the development of
cretostimogene for specific indications. We may fail to generate additional clinical development opportunities for cretostimogene for a number of reasons, including that cretostimogene may, in indications we are seeking or may seek in the future, be
shown to have harmful side effects, limited to no efficacy or other characteristics that suggest it is unlikely to receive marketing approval and/or achieve market acceptance in such potential indications. Our resource allocation and other decisions
may cause us to fail to identify and capitalize on viable potential product candidates or additional indications for cretostimogene. Our spending on current and future research and development programs for new product candidates or additional
indications for cretostimogene may not yield any commercially viable product candidates or indications. If we do not accurately evaluate the commercial potential or target market for a particular indication or product candidate, we may fail to
develop such product candidate or indication, or relinquish valuable rights to that product candidate through collaborations, license agreements and other similar arrangements in cases where it would have been more advantageous for us to retain sole
development and commercialization rights to such indication or product candidate, or negotiate less advantageous terms for any such arrangements than is optimal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we may pursue additional <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of
development-stage assets or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in
the actual acquisition or license of a particular product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify
programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are currently conducting and may in the future conduct certain of our clinical trials for cretostimogene or any future product
candidate outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are currently conducting, and we or our current or any future collaborators may in the future conduct, one or more of our
clinical trials for cretostimogene or any future product candidate outside the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory
authority may be subject to certain conditions or may not be accepted at all. For example, in cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States, the FDA will generally
not approve the application on the basis of foreign data alone unless the data are applicable to the U.S. population and U.S. medical practice; the trials were performed by clinical investigators of recognized competence and pursuant to GCP
regulations; and the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an
<FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the relevant study was not conducted pursuant to an
IND, the FDA will not accept the data as support for a marketing application unless the study was conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary.
Many foreign regulatory authorities have similar requirements for clinical data gathered outside of their respective jurisdictions. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials
conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data from our clinical trials of cretostimogene or any future product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
candidate, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and delay or permanently halt our development of such product candidate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated
with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with foreign manufacturing, customs, shipment, and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inconsistent standards for reporting and evaluating clinical data and adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminished protection of intellectual property in some countries; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">public health concerns or political instability, civil unrest, war or similar events that may jeopardize our
ability to commence, conduct or complete a clinical trial and evaluate resulting data. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Interim, topline and
preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material
changes in the final data. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may publicly disclose interim, topline or preliminary data from
our clinical trials and preclinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the
particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim,
topline or preliminary results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline and
preliminary data also remain subject to audit and verification procedures that may result, in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be
viewed with caution until the final data are available. Interim data from clinical trials that we may complete are further subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more
patient data become available. Adverse differences between interim, topline or preliminary data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in
volatility in the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, others, including regulatory authorities, may not accept or
agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the
particular product candidate or product and our company in general. Moreover, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may
not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions,
views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the
conclusions reached, our ability to obtain approval for, and commercialize cretostimogene and any future product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in methods of the manufacturing or formulation of cretostimogene or any future product candidates may result in additional costs
or delay.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As cretostimogene and any future product
candidates progress through clinical trials to regulatory approval and commercialization, it is common that various aspects of the development program, such as manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
methods and formulation, are altered along the way in an effort to optimize safety, efficacy, yield and manufacturing batch size, minimize costs and achieve consistent quality and results. There
can be no assurance that any future manufacturing or formulation changes we may make will achieve their intended objectives, and such changes may also cause cretostimogene or any future product candidates to perform differently and affect the
results of future clinical trials conducted with the altered materials. Such changes or related unfavorable clinical trial results or changes in the CMOs we use to manufacture cretostimogene or any future product candidates could delay initiation or
completion of clinical trials, require the conduct of bridging studies or additional clinical trials or the repetition of one or more studies or clinical trials, increase development costs, delay or prevent potential regulatory approval and
jeopardize our ability to commercialize cretostimogene or any future product candidates, if approved, and generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>A
Breakthrough Therapy designation from the FDA may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that cretostimogene or any future product candidates will receive FDA approval.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have obtained Breakthrough Therapy designation from the FDA for cretostimogene in combination with
pembrolizumab for the treatment of NMIBC unresponsive to BCG, and we may seek additional Breakthrough Therapy designations for cretostimogene or for any future product candidates where we believe the clinical data support such a designation. A
&#147;Breakthrough Therapy&#148; is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, where preliminary clinical evidence
indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates
that have been designated as Breakthrough Therapies, increased interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients
placed in ineffective control regimens. Biologics designated as Breakthrough Therapies also receive the same benefits associated with Fast Track designation, including eligibility for rolling review of a submitted BLA, if the relevant criteria are
met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of
our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for cretostimogene or any
future product candidate may not result in a faster development process, review or approval compared to biologics considered for approval under standard FDA review procedures and does not ensure ultimate approval by the FDA. In addition, though
cretostimogene currently qualifies as a Breakthrough Therapy for the treatment of NMIBC unresponsive BGC, the FDA may later decide that cretostimogene no longer meets the conditions for qualification and rescind the designation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may attempt to secure approval from the FDA through the use of the accelerated approval pathway. If we are unable to obtain such
approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary regulatory approvals. Even if we receive accelerated approval
from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may in the future seek an accelerated approval for cretostimogene or our future product candidates. Under the accelerated
approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that such product
candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the
context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate
clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a
direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the drug&#146;s clinical benefit. If such confirmatory studies fail to confirm the drug&#146;s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of
the drug on an expedited basis. In addition, in December 2022, the Food and Drug Omnibus Reform Act of 2022 was enacted, which, among other things, provided the FDA new statutory authority to mitigate potential risks to patients from continued
marketing of ineffective drugs previously granted accelerated approval, and additional oversight over confirmatory trials. Under these provisions, the FDA may, among other things, require a sponsor of a product seeking accelerated approval to have a
confirmatory trial underway prior to such approval being granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to seeking approval for cretostimogene or any
future product candidate we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide
to pursue or submit a BLA for accelerated approval or obtain any other form of expedited development, review, or approval. Furthermore, if we decide to submit an application for accelerated approval for cretostimogene or any future product
candidate, there can be no assurance that such submission or application will be accepted or that any expedited development, review, or approval will be granted on a timely basis, or at all. The FDA could also require us to conduct further studies
prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review, or approval for cretostimogene or any future product candidate would result in a
longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate, and could harm our competitive position in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Disruptions at the&nbsp;FDA&nbsp;and other government agencies caused by funding shortages or global health concerns could hinder their
ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of the&nbsp;FDA and other government agencies&nbsp;to review and approve new products can be affected
by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, a government agency&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may
otherwise affect the government agency&#146;s ability to perform routine functions. Average review times at the FDA and other government agencies have fluctuated in recent years as a result. In addition, government funding of other government
agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the&nbsp;FDA and other agencies may also slow the time necessary for new biologics or
modifications to approved or licensed biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.&nbsp;For example, over the last several years, the U.S. government has shut down several
times and certain regulatory agencies, such as the&nbsp;FDA, have had to furlough critical employees and stop critical activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the FDA postponed most inspections
of domestic and foreign manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, future pandemics may lead to similar inspectional delays. If any future
prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third parties to conduct our clinical trials and preclinical studies. If these third parties do not successfully carry out
their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, cretostimogene or any future product candidate and our ability to seek or obtain regulatory approval for or commercialize cretostimogene or any
future product candidates may be delayed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are dependent on third parties to conduct our clinical trials and
preclinical studies. Specifically, we rely on, and intend to continue to rely on, medical institutions, clinical investigators, CROs and consultants to conduct our preclinical studies and clinical trials in accordance with our clinical protocols and
regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have and will have agreements governing the
activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal,
regulatory and scientific standards and requirements, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. In addition, we and our CROs are required to comply with Good Laboratory Practice
(GLP) requirements for certain preclinical studies, as well as GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for cretostimogene and any future product candidates in clinical
development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GLP or GCP or other requirements,
the clinical data generated in our preclinical studies or clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving
our marketing applications, if ever. Further, our clinical trials must be conducted with products produced in accordance with cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the
regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is no guarantee that any of our CROs, investigators or other third parties will devote
adequate time and resources to such trials or studies or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise perform in a
substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may
also be conducting clinical trials or other development activities that could harm our competitive position. In addition, principal investigators for our clinical trials have served and may in the future serve as scientific advisors or consultants
to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign
regulatory authorities conclude that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
itself may be jeopardized, which could result in the delay or rejection by the FDA or comparable foreign regulatory authorities of any BLA we submit or any comparable submission. Any such delay or rejection could prevent us from receiving regulatory
approval for, or commercializing cretostimogene and any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our CROs have the right to terminate
their agreements with us in the event of an uncured material breach and under other specified circumstances. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties
on commercially reasonable terms, in a timely manner or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#146;s time and focus. In addition, there is a natural
transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
clinical development timelines. Though we work to carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter
challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We rely on third parties for the manufacture and shipping of cretostimogene for clinical development and expect to continue to do so for
the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of cretostimogene or future product candidates or such quantities at an acceptable cost, which could delay, prevent, or impair our
development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not own or operate manufacturing facilities and have no plans to
develop our own clinical or commercial-scale manufacturing capabilities. We rely on a third-party manufacturer for the production of cretostimogene and a third-party manufacturer for the production of DDM, and expect to continue to rely on
third-party manufacturers for commercial manufacture if cretostimogene or any future product candidates receive regulatory approval. The facilities used by third-party manufacturers to manufacture cretostimogene or any future product candidate must
be approved for the manufacture of such product candidate by the FDA and any comparable foreign regulatory authority pursuant to inspections that will be conducted after we submit a BLA to the FDA or any comparable submission to a foreign regulatory
authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of products. If these third-party manufacturers cannot successfully
manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or maintain regulatory approval for their manufacturing
facilities. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any comparable foreign regulatory authority does not approve
these facilities for the manufacture of cretostimogene or any future product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to
develop, obtain regulatory approval for or market cretostimogene or any future product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being
imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of cretostimogene or any future product candidates, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect supplies of cretostimogene or any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our or
a third party&#146;s failure to execute on our manufacturing requirements on commercially reasonable terms, in a timely manner and in compliance with cGMP or other regulatory requirements could adversely affect our business in a number of ways,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or continue clinical trials of cretostimogene or any future product candidates, or a
hold on clinical trials of cretostimogene or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving regulatory approvals, for cretostimogene or any
future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease development or to recall batches of cretostimogene or any future product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize cretostimogene or any future product candidates, an
inability to meet commercial demands for cretostimogene or any future product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our IND for
cretostimogene was previously placed on partial clinical hold by the FDA that was lifted in March 2020, primarily due to CMC-related issues attributable to product supplied by our prior third-party manufacturer, who was purchased by another
third-party supplier, resulting in clinical development delays. In addition, we do not have any long-term commitments or supply agreements with our third-party manufacturers. We may be unable to establish any long-term supply agreements with
third-party manufacturers or to do so on acceptable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
terms or at all, which increases the risk of failing to timely obtain sufficient quantities of cretostimogene or such quantities at an acceptable cost. Even if we are able to establish agreements
with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to obtain adequate raw materials and other materials required for manufacturing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our schedule or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to successfully scale up manufacturing capacity, if required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Further, cretostimogene and any future product candidates that we may develop may compete with other
product candidates and products for access to manufacturing facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also rely on a third party to store and
transport cretostimogene at temperatures within a certain range, which is known as &#147;strict cold chain&#148; storage and transportation. Any failure by this third party to store or transport cretostimogene at the appropriate temperature could
impair the quality of cretostimogene or cause cretostimogene to become unsuitable for use, which could result in lost inventories, increased costs or delays in clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any performance failure on the part of our existing or future manufacturers, suppliers or vendors could delay clinical
development or regulatory approval, and any related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant manufacturing of cretostimogene and DDM. In addition, there are a
limited number of manufacturers capable of manufacturing viral therapies such as cretostimogene, and therefore any need to switch third-party manufacturers may result in development and commercialization delays and increase our operating costs. If
our existing or future third-party manufacturers and suppliers cannot perform as agreed or cannot fulfill our commercial supply requirements, we may be required to replace such manufacturers or suppliers and we may be unable to replace them on a
timely basis or at all. If we later switch third-party manufacturers, we may be unable to demonstrate comparability between lots produced previously and those produced by such new third-party manufacturers, in which case we may be required to gather
additional data utilizing material produced by such new third-party manufacturers before we are able to submit a BLA for cretostimogene, if ever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our current and anticipated future dependence upon others for the manufacture of cretostimogene or any future
product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third
party will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Because we currently rely
on third parties to manufacture cretostimogene and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in
part, by entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of
the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade
secrets become known by our competitors or other third parties, are intentionally or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based,
in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets and despite our efforts to protect our trade secrets, a competitor&#146;s or other third party&#146;s discovery of our proprietary technology and confidential
information or other unauthorized use or disclosure of such technology or information would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We have entered into, and may in the future enter into, collaboration agreements and strategic alliances to maximize the potential of
cretostimogene, and we may not realize the anticipated benefits of such collaborations or alliances. We may continue to form collaborations or alliances in the future with respect to cretostimogene or any future product candidates, but may be unable
to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into, and may in the future seek to enter into, collaborations, joint ventures, licenses and other similar
arrangements for the development or, if approved, commercialization of cretostimogene and any future product candidates due to capital costs required to develop or commercialize such product candidates or otherwise. For example, we have entered into
license and collaboration agreements with Lepu Biotech Co., Ltd. (Lepu) and Kissei Pharmaceutical Co., Ltd. (Kissei), pursuant to which we granted Lepu exclusive rights to develop and commercialize cretostimogene and/or DDM in Greater China,
including Hong Kong and Macau (the Lepu Territory), and granted Kissei exclusive rights to develop and commercialize cretostimogene in combination with DDM in Japan and other Asian counties (excluding the Lepu territory). We may not be successful in
our efforts to establish or maintain such collaborations because our research and development pipeline may be insufficient, future product candidates may be deemed to be at too early of a stage of development for collaborative effort or third
parties may not view cretostimogene or any future product candidates as having the requisite potential to demonstrate safety, purity and potency (or efficacy), or significant commercial opportunity. In addition, we face significant competition in
seeking appropriate strategic partners, and the negotiation process can be time-consuming and complex. Even if we are successful in our efforts to establish or maintain such collaborations, the terms that we agree upon may not be favorable to us. As
a result, we may need to relinquish valuable rights to our future revenue streams, research programs, intellectual property, cretostimogene or any future product candidates, or grant licenses on terms that may not be favorable to us, as part of any
such arrangement, and such arrangements may restrict us from entering into additional agreements with other potential collaborators. In addition, our current collaborations limit, and potential future collaborations may limit, our control over the
amount and timing of resources that our collaborators will dedicate to the development or commercialization of cretostimogene or any future product candidates. Our ability to generate revenue from these arrangements will depend on any current or
future collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a collaboration, license, or strategic transaction, we will achieve an economic benefit that
justifies such transaction, and such transaction may not yield additional development product candidates for our pipeline. Furthermore, we may not be able to maintain such collaborations if, for example, the development or approval of cretostimogene
or any future product candidate is delayed, the safety of any such product candidate is questioned, or the sales of cretostimogene, if approved, or an approved future product candidate, are unsatisfactory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, our current collaborations are, and potential future collaborations may be, terminable by our strategic partners,
and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and, if approved, commercialization of cretostimogene or
any future product candidates, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to cretostimogene or any future
product candidates, could delay the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
development and, if approved, commercialization of such product candidates, and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Cretostimogene and any Future Product Candidates
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Even if we receive regulatory approval for cretostimogene or any future product candidates, we will be subject to ongoing
regulatory obligations and continued regulatory review, which may result in significant additional expense. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any
regulatory approvals that we may receive for cretostimogene or any future product candidates will require the submission of reports to regulatory authorities, subject us to surveillance to monitor the safety and efficacy of the product, may contain
significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS as a
condition of approval of cretostimogene or any future product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, if the FDA or a comparable foreign regulatory
authority approves cretostimogene or any future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be
subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any
clinical trials that we conduct post-approval. Manufacturers of approved products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP
regulations and standards. Failure to comply with regulatory requirements or later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or
manufacturing processes, may result in, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or
planned trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitutions, disgorgement of profits or revenue, warning letters, untitled letters, adverse publicity
requirements or holds on clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA or other regulatory authorities to approve pending applications or supplements to approved
applications submitted by us or suspension or revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions and the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The occurrence of any event or penalty described above may inhibit our ability to commercialize cretostimogene or any future
product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be
promulgated that could prevent, limit or delay marketing authorization of cretostimogene or any future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
product candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States
or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve
or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion
of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA and other regulatory agencies strictly regulate
the promotional claims that may be made about prescription products, such as cretostimogene or any future product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other
regulatory agencies as reflected in the product&#146;s approved labeling. If we receive regulatory approval for cretostimogene or any future product candidates, physicians may nevertheless prescribe it to their patients in a manner that is
inconsistent with the approved label. If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines
against companies for alleged improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> use and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The government has also
required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of cretostimogene or any future product candidates,
if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Patient Protection and Affordable Care Act, signed into law on March&nbsp;23, 2010, includes a subtitle called
the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT>
reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a
biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still
market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety,
purity and potency (or efficacy) of its product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe that any cretostimogene or any future product candidates, if
approved as a biological product under a BLA, should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise,
or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once
approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products will depend on a number of marketplace and
regulatory factors continue to develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The commercial success of cretostimogene or any future product candidates will depend upon
the degree of market acceptance of such product candidates by physicians, patients, healthcare payors, and others in the medical community. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cretostimogene and any future product candidates may not be commercially successful. Even if cretostimogene or any future
product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors, or the medical community. The commercial success of cretostimogene or any future product candidates will depend
significantly on the broad adoption and use of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
resulting product by these individuals and organizations for approved indications. In particular, given a significant portion of large urology practices are concentrated in a relatively small
number of urology physician groups, market adoption by such groups will be an important factor in potential commercial success. The degree of market acceptance of our products will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstration of clinical efficacy and safety, including as compared to any more-established products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indications for which cretostimogene or any future product candidates are approved, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limitation of our targeted patient population and other limitations or warnings contained in any <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of a new drug for the relevant indication by healthcare providers and their patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in
relation to alternative treatments and therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government
healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of our products as well as availability, safety and efficacy of competitive
drugs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our or any current or future collaborators&#146; sales and marketing strategies; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable publicity relating to the product. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If cretostimogene or any future product candidates is approved but does not achieve an adequate level of acceptance by
physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our
products may require significant resources and may never be successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The successful commercialization of cretostimogene or any
future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage
and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and
Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as cretostimogene or any future product candidates, if approved. Our ability to achieve coverage and
acceptable levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Accordingly, we will need to successfully implement a coverage and reimbursement strategy for
any approved product candidate. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients
find unacceptably high. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we participate in the Medicaid Drug Rebate Program or other governmental pricing programs, in
certain circumstances, our products would be subject to ceiling prices set by such programs, which could reduce the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
revenue we may generate from any such products. Participation in such programs would also expose us to the risk of significant civil monetary penalties, sanctions and fines should we be found to
be in violation of any applicable obligations thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third-party payors increasingly are challenging prices charged
for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a
third-party payor may consider our products as substitutable and offer to reimburse patients only for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our
products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that
are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not
be able to obtain a satisfactory financial return on products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There is significant uncertainty
related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in
determining the extent to which new drugs will be covered. Some third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices or drug therapies before they will reimburse healthcare
providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for cretostimogene or any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Obtaining and maintaining reimbursement status is time-consuming, costly and uncertain. The Medicare and Medicaid programs
increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors
in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide
scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations
regarding reimbursement change frequently, and, in some cases, at short notice, and we believe that changes in these rules and regulations are likely. For products administered under the supervision of a physician, obtaining coverage and adequate
reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available,
which may impact physician utilization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Outside the United States, international operations are generally subject to
extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of cretostimogene
or any future product candidates, if approved in these jurisdictions. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their
own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside
the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce
healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs, surgical procedures and other treatments in particular, has become very intense. As a result, increasingly high barriers
are being erected to the entry of new products. See the section titled &#147;Risk Factors&#151;Risks Related to Our Business Operations and Industry&#151;Current and future healthcare reform legislation or regulation may increase the difficulty and
cost for us to obtain coverage for and commercialize cretostimogene or any future product candidates and may adversely affect the prices we may set&#148; for additional related information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We face significant competition from entities that have developed or may develop product candidates for cancer, including companies
developing novel treatments and technology platforms. If our competitors develop and commercialize their product candidates more rapidly than we do, or their technologies or product candidates are more effective, safer, or less expensive than
cretostimogene or any future product candidates we develop, our business and our ability to develop and successfully commercialize products may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The biopharmaceutical industry is characterized by rapid advancing technologies, intense competition and a strong emphasis on
proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with cretostimogene. Cretostimogene and any future product candidates we
successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially
available in the future, for the treatment of indications for which we are developing cretostimogene. In particular, there is intense competition in the oncology field. Our competitors include larger and better-funded pharmaceutical,
biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions that may be active in oncology research and could be in direct competition with us. We also compete with
these organizations to recruit management, scientists and clinical development personnel, and our inability to compete successfully could negatively affect our level of expertise and our ability to execute our business plan. We will also face
competition in establishing clinical trial sites, enrolling patients for clinical trials and identifying and <FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property related to future product candidates, as well as entering into
collaborations, joint ventures, license agreements and other similar arrangements. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If cretostimogene or any future product candidates are approved, they will compete with surgery, radiation, and drug
therapy, including chemotherapy, BCG, hormone therapy, biologic therapy, such as monoclonal and bispecific antibodies, antibody-drug conjugates, radiopharmaceuticals, immunotherapy, cell-based therapy, and targeted therapy, or a combination of any
such methods, either approved or under development, which are intended to treat the same indications that we are targeting or may target, including through approaches that may prove to be more effective, have fewer side effects, be less costly to
manufacture, be more convenient to administer or have other advantages over cretostimogene and any future product candidates. To the extent Merck&nbsp;&amp; Co. (Merck) or another manufacturer increases the supply of BCG, there may be less demand
for alternative treatments such as cretostimogene in <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> or <FONT STYLE="white-space:nowrap">BCG-exposed</FONT> patients. There are numerous companies that have commercialized or are developing
treatments for NMIBC that we will compete with, including Bristol Meyers Squibb, enGene Inc., Gilead Sciences, Inc., <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche AG (Roche), ImmunityBio Inc., Johnson&nbsp;&amp; Johnson Inc., Merck,
Protara Therapeutics, Inc., Pfizer, Inc. and UroGen Pharma, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our competitors have significantly greater
financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for cretostimogene or any future product candidate, we will face competition based on many different factors,
including the safety and effectiveness of our product candidates, the ease with which our product candidates can be administered, and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these product candidates, the availability and cost of manufacturing,
marketing and sales capabilities, price, reimbursement coverage, and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive, or marketed and sold
more effectively than any products we may develop. Competitive products may make cretostimogene or any future product candidates we develop obsolete or noncompetitive before we recover the expense of their development and commercialization. If we
are unable to compete effectively, our opportunity to generate revenue from the sale of cretostimogene or any future product candidates we may develop, if approved, could be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If the market opportunities for cretostimogene or any future product candidates are smaller than we believe they are, our revenue may be
adversely affected, and our business may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cancer therapies are defined by lines of therapy as well as by <FONT
STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> or previously-treated status. Often the initial approval for a new therapy is in later lines and subsequent approval in an earlier line may not be feasible. When cancer is detected early enough,
first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, including surgery, radiation therapy, targeted therapy, immunotherapy, chemotherapy, hormone therapy, or a combination of these,
proves unsuccessful, second line therapy may be administered. Second line therapies often consist of additional chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. Third line therapies can include
antibody and small molecule targeted therapies, more invasive forms of surgery, and new technologies. In markets with approved therapies, there is no guarantee that cretostimogene or any future product candidate, even if approved, would be approved
for second line or first line therapy. This could limit our potential market opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these
cancers in a position to receive later stage therapy and who have the potential to benefit from treatment with cretostimogene or any future product candidate, are based on our beliefs and estimates. These estimates have been derived from a variety
of sources, including the scientific literature, publicly available clinical molecular reports, patient foundations, or market research, and may prove to be incorrect. Further, new trials or information may change the estimated incidence or
prevalence of these cancers. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become
increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition, results of operations and prospects. Further, even if we obtain significant market share for cretostimogene or any future
product candidate, because some of our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may need
to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market, sell and distribute our products, we may not be able to generate
product revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no internal sales, marketing or distribution capabilities, nor have we ever
commercialized a product. If cretostimogene or any future product candidate ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize
each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or
in lieu of our own sales force and distribution systems. For example, if cretostimogene is approved, we will need to scale up a cost-effective and reliable cold chain distribution and logistics network, which we may be unable to accomplish and which
will require us to rely on third-party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
distributors. Failure to scale up our cold chain supply logistics, by us or third parties, could in the future lead to additional manufacturing costs and delays in our ability to supply required
quantities for commercial supply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no prior experience as a company with the marketing, sale or distribution of
biopharmaceutical products and there are significant risks involved in the building and managing of a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate
training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the
commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition,
our product revenue and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third
parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third
parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our future
growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our future growth may depend, in part, on our ability to develop and commercialize cretostimogene or any future product
candidates in foreign markets. We are not permitted to market or promote cretostimogene or any future product candidate before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such
regulatory approvals for cretostimogene or any future product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing,
among other things, clinical trials, commercial sales, pricing and distribution of cretostimogene or any future product candidates. Approval procedures may be more onerous than those in the United States and may require that we conduct additional
preclinical studies or clinical trials. If we obtain regulatory approval of cretostimogene or any future product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for approval of drugs in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of additional third-party patent rights of potential relevance to our business;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with export control and import laws and regulations and unexpected changes in tariffs, trade
barriers and regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and
other obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing, and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, public health
pandemics or epidemics, or natural disasters including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business
Operations and Industry </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult
to predict and could cause our operating results to fall below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our
quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control,
including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development, regulatory approval, and
commercialization activities relating to cretostimogene or any future product candidates, which may change from time to time, including the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll patients in clinical trials and the timing of enrollment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies or clinical trials for cretostimogene or any future
product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to cretostimogene or any future product candidates, if
approved, and potential future drugs that compete with our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing cretostimogene or any future product candidates, which may vary depending on the
quantity of production and the terms of our agreements with third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> develop, or
commercialize additional product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for any approved products, which may vary significantly and be difficult to predict;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize cretostimogene or any future product candidates, if approved, inside and outside
of the United States, either independently or working with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations, licensing or other arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential unforeseen business disruptions that increase our costs or expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty or other payments payable by us or due to us under any
collaboration, licensing or other similar agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The cumulative effects of these factors could
result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis
may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or
below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur
even when we have met any previously publicly stated revenue or earnings guidance we may provide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our success is dependent on our ability to attract and retain highly qualified
management and other clinical and scientific personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our success depends in part on our continued ability to
attract, recruit, retain, manage, and motivate highly qualified management, clinical, and scientific personnel, and we face significant competition for experienced personnel. We are highly dependent upon our senior management, as well as our senior
scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our clinical trials and preclinical studies,
regulatory approvals or the commercialization of cretostimogene or any future product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at
will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or any of our employees. This lack of insurance
means that we may not have adequate compensation for the loss of the services of these individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition,
employment candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, either because we are a public company or for other
reasons, it may harm our ability to recruit and retain highly skilled employees. Our employees may be more likely to leave us if the shares they own have significantly appreciated in value relative to the original purchase prices of the shares, or
if the exercise prices of the options that they hold are significantly below the market price of our common stock, particularly after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will need to expand and effectively manage our managerial, operational, financial and other resources in order to
successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management, clinical, and scientific personnel in the future
due to the intense competition for qualified personnel among biopharmaceutical, biotechnology and other businesses. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract,
integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our
ability to implement our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may encounter difficulties in managing our growth and expanding our operations
successfully, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2023, we had 58 full-time employees. As
we continue development and pursue the potential commercialization of cretostimogene or any future product candidates, as well as transition to functioning as a public company, we will need to expand our financial, development, regulatory,
manufacturing, information technology, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various
strategic partners, suppliers and other third parties and we may not be successful in doing so. Our future financial performance and our ability to develop and commercialize cretostimogene and any future product candidates and to compete effectively
will depend, in part, on our ability to manage any future growth effectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to various U.S. federal, state and
foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our business operations and current and future arrangements with investigators, healthcare
professionals, consultants, third-party payors, patient organizations and customers expose us to broadly applicable foreign, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our
operations, including how we research, market, sell and distribute any products for which we obtain regulatory approval. Such laws include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and
willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the
purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A
person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which
prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or
used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and
civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics
and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS), information
related to payments and other &#147;transfers of value&#148; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain <FONT STYLE="white-space:nowrap">non-physician</FONT> practitioners
(physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives), and teaching hospitals and other healthcare providers, as well as ownership and investment
interests held by physicians and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; some state laws require
biopharmaceutical companies to comply with the biopharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information
related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; some state laws that require biopharmaceutical companies to report information on the pricing of certain drug products; and some
state and local laws that require the registration or pharmaceutical sales representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Efforts to
ensure that our current and future business arrangements with third parties will comply with applicable healthcare and privacy laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude
that our business practices, including certain consulting agreements and advisory board agreements we have entered into with physicians who are paid, in part, in the form of stock or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
stock options, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. Due to the breadth of these
laws, the narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of
these laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages,
fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and
future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly and time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in
defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with
applicable laws or regulations, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us to obtain coverage for and
commercialize cretostimogene or any future product candidates and may adversely affect the prices we may set. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit
coverage and reimbursement for newly approved drugs and affect our ability to profitably sell cretostimogene or any future product candidates for which we obtain regulatory approval. In particular, there have been and continue to be a number of
initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act of 2010 (ACA) was enacted in the United States. The ACA established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#146;
Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded eligibility criteria for Medicaid programs; expanded the entities eligible for discounts under the 340B drug
pricing program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative
clinical effectiveness research, along with funding for such research; and established a Center for Medicare&nbsp;&amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the ACA. On
June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, beginning
April&nbsp;1, 2013, Medicare payments to providers were reduced under the sequestration required by the Budget Control Act of 2011, which will remain in effect until 2032, unless additional Congressional action is taken. Additionally, on
January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. On March&nbsp;11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory cap on the Medicaid
drug rebate, currently set at 100% of a drug&#146;s AMP, beginning January&nbsp;1, 2024. Further, there has been heightened </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional
inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government
program reimbursement methodologies for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Most recently, on August&nbsp;16, 2022, President Biden signed the
Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA (i)&nbsp;directs HHS to negotiate
the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii)&nbsp;imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits the Secretary
of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented.
On August&nbsp;29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The impact of the IRA on the
pharmaceutical industry cannot yet be fully determined but is likely to be significant. Further, in response to the Biden administration&#146;s October 2022 executive order, on February&nbsp;14, 2023, HHS released a report outlining three new models
for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the
future. Additional drug pricing proposals could appear in future legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or reimbursement constraints, discounts, restrictions on certain product access and marketing cost
disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our
business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be
included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for cretostimogene and any future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect that these existing laws and other
healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that
we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability or commercialize cretostimogene or any future product candidates, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit, delay or cease
commercialization of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We face an inherent risk of product liability as a result of the clinical
trials of cretostimogene and any future product candidates and will face an even greater risk if we commercialize cretostimogene or any future product candidates, if approved. For example, we may be sued if cretostimogene or any future product
candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure
to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be
approved in the future. Claims could also be asserted under state consumer protection acts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we cannot successfully defend ourselves against product liability claims,
we may incur substantial liabilities or be required to limit, delay or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome,
liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of our management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or product recipients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant negative financial impact; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize cretostimogene or any future product candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in our stock price. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently hold approximately $10&nbsp;million in product liability insurance coverage in the aggregate. We may need to
increase our insurance coverage as we expand our clinical trials or if we commence commercialization of cretostimogene or any future product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient
product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of cretostimogene or any future product candidates. Although we will maintain such insurance, any
claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will
also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not
covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our insurance policies
are expensive and protect us from only some business risks, which will leave us exposed to significant uninsured liabilities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently
maintain include property, general liability, employee benefits liability, business automobile, workers&#146; compensation, products/clinical trial liability, cyber liability, clinical trials, directors&#146; and officers&#146; and employment
practices insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. No assurance can be given that an insurance carrier will not seek to cancel or deny coverage after a claim has
occurred.&nbsp;Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We and any of our current or potential future collaborators will be required to report to regulatory authorities if any of our approved
products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we or any of our current or potential future collaborators are successful in commercializing cretostimogene or any future
product candidates, the FDA and foreign regulatory authorities would require that we and such collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing
of our obligation to report would be triggered by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
date we or such collaborators become aware of the adverse event as well as the nature of the event. We and any of our current or potential future collaborators or CROs may fail to report adverse
events within the prescribed timeframe. If we or any of our current or potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal
prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We and our service providers may be subject to a variety of data protection, privacy and security obligations, including laws,
regulations, standards and contractual provisions, which could increase compliance costs, and our actual or perceived failure to comply with such laws and obligations could subject us to potentially significant liability, fines or penalties and
otherwise harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and our service providers maintain and will maintain a large quantity of sensitive
information, including confidential business and patient health information, in connection with our clinical trials, and are subject to laws and regulations governing the privacy and security of such information. The global data protection landscape
is rapidly evolving, and we and our service providers may be affected by or subject to existing, amended, or new laws and regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. These laws
and regulations may be subject to differing interpretations, thus creating potentially complex compliance issues for us and our service providers, strategic partners and future customers. The cost of compliance with these laws, regulations and
standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of
personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As our operations and business grow, we may become subject to or affected by new or
additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, numerous federal and state laws and regulations, including health information privacy laws, data breach
notification laws and consumer protection laws, that govern the collection, use, storage, transfer, disclosure, protection and other processing of health-related and other personal information could apply to our operations or the operations of our
collaborators and third-party providers. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data and CROs) that are subject to privacy and security requirements under
HIPAA. Consequently, depending on the facts and circumstances, we could be subject to significant penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider, research institution, or CRO
that has not satisfied HIPAA&#146;s requirements for disclosure of individually identifiable health information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, certain state laws govern the privacy and security of health-related and other personal information, many of which may differ from each other and from HIPAA, thus complicating compliance efforts. Failure to comply with these laws, where
applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. By way of example, the California Consumer Privacy Act (CCPA), which went into effect on January&nbsp;1, 2020, gives California residents
a number of individual privacy rights related to how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has increased the likelihood of, and risks
associated with data breach litigation. Further, the California Privacy Rights Act (CPRA) generally went into effect on January&nbsp;1, 2023. The CPRA imposes additional data protection obligations on covered businesses, including additional
consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations
and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Similar laws have been passed in other states, and are continuing to be proposed at
the state and federal level, reflecting a trend toward more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
stringent privacy legislation in the United States. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability
from failure to comply with the requirements of these laws could adversely affect our financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compliance
with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, store, use, transfer, disclose and otherwise process data, update our data
privacy and security policies and procedures, or in some cases, impact our ability to operate in certain jurisdictions. Failure by us or our collaborators and our service providers to comply with U.S. and international data protection laws and
regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial
subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose such information. Claims that we have violated
individuals&#146; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and adversely
affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our information technology systems, or those of any
of our service providers, may fail or suffer security incidents and other disruptions, which could result in a material disruption of our development programs, compromise sensitive information related to our business or prevent us from accessing
critical information, potentially exposing us to liability or otherwise adversely affecting our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the
ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary and confidential business information and personal information). Our information technology systems
and those of our third-party service providers, strategic partners and other contractors or consultants are vulnerable to attack, damage and interruption from computer viruses and malware (e.g. ransomware), malicious code, natural disasters,
terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated
nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. In addition, attacks upon information technology systems are increasing in
their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain
unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience
security incidents that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to
circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and certain of our service
providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any material system failure, accident or security breach to date, if any such event, whether actual or perceived, were
to occur, it could impact our reputation and/or operations, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose
existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on a third party to
manufacture cretostimogene, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any actual or perceived disruption or security incident affects our systems (or those of
our third-party collaborators, service providers, contractors or consultants) or were to result in a loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or damage
to, our confidential or proprietary data or applications, or inappropriate disclosure of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
confidential or proprietary information, we could incur liability, the further development and commercialization of cretostimogene or any future product candidates could be delayed, and we could
be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. If our third-party vendors fail to protect their information
technology systems and our confidential and proprietary information, we may be vulnerable to disruptions in service and unauthorized access to our confidential or proprietary information and we could incur liability and reputational damage. If the
information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant
resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. Some of the federal, state and foreign government requirements include obligations of companies to
notify individuals of security breaches involving particular categories of personally identifiable information, which could result from incidents experienced by us or by our vendors, contractors, or organizations with which we have formed strategic
relationships. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our
data privacy and security obligations. Although we currently hold cybersecurity insurance, the costs related to significant security breaches or disruptions could be material and cause us to incur significant expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business is subject to risks arising from pandemics and epidemic diseases. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> worldwide pandemic presented substantial public health and economic
challenges and affected our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. Any future pandemic or epidemic disease outbreaks could
disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for cretostimogene or any future product candidates for use in our, our collaborators&#146; or any future collaborators&#146; clinical trials and
research and preclinical studies and, delay, limit or prevent our employees and CROs from continuing research and development activities, impede our clinical trial initiation and recruitment and the ability of patients to continue in clinical
trials, alter the results of the clinical trial based on participants contracting the disease or otherwise increasing the number of observed adverse events, impede testing, monitoring, data collection and analysis and other related activities, any
of which could delay our preclinical studies and clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition, results of operations and prospects. Any future pandemic or epidemic
disease outbreak could also potentially further affect the business of the FDA, EMA or other regulatory authorities, which could result in delays in meetings related to our planned clinical trials, as well have an adverse impact on global economic
conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our business could be affected by litigation, government investigations and enforcement actions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently operate in a number of jurisdictions in a highly regulated industry and we could be subject to litigation,
government investigation and enforcement actions on a variety of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims,
privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims and legal proceedings that may arise from conducting our business. Any determination that our operations or activities are not in compliance with existing laws
or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against us, and remediation of any such findings could have an adverse effect
on our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Legal proceedings, government investigations and enforcement actions can be
expensive and time-consuming. An adverse outcome resulting from any such proceedings, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare
debarment, injunctive relief, product recalls, reputational damage and modifications of our business practices, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Even if such a
proceeding, investigation or enforcement action is ultimately decided in our favor, the investigation and defense thereof could require substantial financial and management resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our employees and independent contractors, including collaborators, principal investigators, CROs, consultants and vendors, may engage
in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
are exposed to the risk that our employees and independent contractors, including collaborators, principal investigators, CROs, consultants, and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include
intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (i)&nbsp;the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of
true, complete and accurate information to such authorities, (ii)&nbsp;manufacturing standards, including cGMP requirements, (iii)&nbsp;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United
States and abroad (iv)&nbsp;laws that require the true, complete and accurate reporting of financial information or data, or (v)&nbsp;laws that prohibit insider trading. Activities subject to these laws also involve the improper use or
misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our or our collaborators&#146; preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in
regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in
controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk
that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in
Medicare, Medicaid and other federal healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity
agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws and curtailment of our operations, any of which could adversely affect our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may engage in strategic transactions that could impact our liquidity, increase our expenses, and
present significant distractions to our management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may consider strategic transactions,
such as acquisitions of companies, asset purchases, and <FONT STYLE="white-space:nowrap">out-licensing</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of intellectual property, products or technologies. Additional potential
transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships and collaborations, joint ventures, restructurings, divestitures, business combinations, and investments. We may
not be able to find suitable partners or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. Any future transactions could increase our near and long-term expenditures, result in potentially
dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses, any
of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be
successful and may require significant time and attention of our management. In addition, the integration of any business that we may acquire in the future may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits. Furthermore, we may experience losses related to investments in
other companies, including as a result of failure to realize expected benefits or the materialization of unexpected liabilities or risks, which could have a material negative effect on our results of operations and financial condition. Accordingly,
although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our ability to use net operating loss carryforwards and other tax
attributes may be limited in connection with this offering or other ownership changes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred
substantial losses during our history, do not expect to become profitable in the near future and may never achieve profitability. As of December&nbsp;31, 2022, we had net operating loss (NOL) carryforwards, which may be available to offset our
future taxable income, if any. Our NOL carryforwards and other tax attributes are subject to expiration, review and possible adjustment by the Internal Revenue Service (IRS) and state tax authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, under Section&nbsp;382 of the U.S. Internal Revenue Code of 1986, as amended (the Code), our federal NOL
carryforwards may be or become subject to an annual limitation in the event we have had or have in the future an &#147;ownership change.&#148; For these purposes, an &#147;ownership change&#148; generally occurs if one or more stockholders or groups
of stockholders who own at least 5% of a company&#146;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws.
Although we believe there have been one or more ownership changes resulting from past transactions, we have not determined the amount of the cumulative change in our ownership resulting from this offering or other transactions, or any resulting
limitations on our ability to utilize our NOL carryforwards and other tax attributes. However, we believe that our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as
a result of ownership changes, including potential changes in connection with this offering. If we earn taxable income, such limitations could result in increased future income tax liability to us and our future cash flows could be adversely
affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have recorded a full valuation allowance related to our NOL carryforwards and other deferred tax assets due
to the uncertainty of the ultimate realization of the future benefits of those assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to obtain, maintain, defend and enforce patent or other intellectual property protection for cretostimogene or any
future product candidates or technology, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical
to ours, and our ability to successfully commercialize cretostimogene or any future product candidates may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We rely, and may in the future rely, upon a combination of patent, trade secret and trademark protection for cretostimogene and
any future product candidates and proprietary technologies to prevent third parties from exploiting our achievements, thus eroding our competitive position in our market. These legal measures afford only limited protection, and competitors or others
may gain access to or use our intellectual property and proprietary information. Our success depends in large part on our ability to obtain, maintain, expand, enforce, and defend the scope, ownership or control, validity and enforceability of our
intellectual property protection in the United States and other countries with respect to cretostimogene and any future product candidates and other proprietary technologies we may develop. We generally seek, and may in the future seek, to protect
our proprietary position, in part, by filing patent applications in the United States and abroad relating to cretostimogene and any future product candidates and technology, manufacturing processes and methods of use. We may also seek to protect our
proprietary position by acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> relevant issued patents or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
pending patent applications from third parties. Currently we do not have composition of matter patents covering cretostimogene. We will endeavor to seek additional patent protection to cover
features of the oncolytic virus and formulations in the future. If we are unable to obtain, maintain, expand, enforce and defend the scope, ownership or control, validity and enforceability of our intellectual property protection, our business,
financial condition, results of operations and prospects could be materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in either the patent laws or
their interpretation in the United States and other jurisdictions may diminish our ability to protect our intellectual property, obtain, maintain, expand, enforce and defend our intellectual property rights and, more generally, could affect the
value of our intellectual property or narrow the scope of our protection. We cannot predict whether the patent applications we currently or may in the future pursue or may <FONT STYLE="white-space:nowrap">in-license</FONT> will issue as patents in
any particular jurisdiction, whether the claims of any issued patents will provide sufficient protection against competitors or other third parties, or if these patents are challenged by our competitors, whether the patents will be found to be
invalid, unenforceable, or not infringed or not owned or controlled by us. The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, defend or license all necessary or
desirable patent applications or patents at a reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent
protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our
employees, licensees, third-party collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby
jeopardizing our ability to seek patent protection. Consequently, we may not be able to prevent any third party from using any of our technology that is in the public domain to compete with cretostimogene or any future product candidates or
technologies. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable in light of the prior art. Furthermore,
publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing, or in some cases
not at all. Therefore, we cannot be certain that we or the entity from which we purchased the intellectual property rights to cretostimogene were the first to invent the inventions claimed in any of our owned patents or pending patent applications,
or that we or any future licensors were the first to file for patent protection of such other inventions. If a third party can establish that we were not the first to make or the first to file for patent protection of such other inventions, our
patents and patent applications may not issue as patents and even if issued, may be challenged and invalidated or rendered unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual
questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our current and future patent applications may not
result in patents being issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any issued patents may not afford sufficient protection of cretostimogene or any future
product candidates or their intended uses against competitors, nor can there be any assurance that the issued patents will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing
competitive technologies, products or cretostimogene or any future product candidates. Further, even if these patents are granted, they may be difficult to enforce. Obtaining and maintaining our patent protection depends on compliance with various
procedural, document submission, information disclosure, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. In the event
we experience noncompliance events that cannot be corrected and we lose our patent rights, competitors could enter the market, which would have a material adverse effect on our business. Further, any issued patents that we own or may license in the
future covering cretostimogene or any future product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or other countries, including the U.S. Patent and
Trademark Office (USPTO). Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or
<FONT STYLE="white-space:nowrap">non-enablement.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
In addition, patent validity challenges may, under certain circumstances, be based upon <FONT STYLE="white-space:nowrap">non-statutory</FONT> obviousness-type double patenting, which, if
successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO. Grounds for an unenforceability assertion could be an
allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Also, patent terms, including any extensions or adjustments that may
or may not be available to us, may be inadequate to protect our competitive position on cretostimogene or any future product candidates for an adequate amount of time, and we may be subject to claims challenging the inventorship, ownership,
validity, enforceability of our patents and/or other intellectual property. Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect cretostimogene or any future
product candidates. Further, if we encounter delays in our development and testing of cretostimogene or any future product candidates, clinical trials or regulatory review and approval of cretostimogene or any future product candidates, the period
of time during which we could market cretostimogene or any future product candidates under patent protection may be reduced (i.e., patents protecting such product candidates might expire before or shortly after such product candidates are
commercialized). Thus, our patents may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or afford us any meaningful competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, the claim coverage in a patent application can be significantly reduced before the corresponding patent is granted.
Even if patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage.
Any patents issuing from our owned and any future <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether cretostimogene
or any future product candidates and other proprietary technology will be protectable or remain protected by valid and enforceable patents. Even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by
developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition, results of operations and prospects.
Furthermore, our competitors or other third parties may avail themselves of safe harbors under the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Amendments) to conduct research and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The issuance of a patent is not conclusive as to its inventorship, ownership, scope, validity, or enforceability and our
patent rights may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a post-grant proceeding at the USPTO challenging the validity of one or more claims of our patents or patents we may license in the
future. Third-party submissions may also be made prior to a patent&#146;s issuance, precluding the granting of a patent based on our pending patent application or patent application we may license in the future. A third party may also claim that our
patent rights are invalid or unenforceable in a litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In addition, we may become involved in opposition, derivation, revocation, reexamination,
reissue, interference proceedings or other similar proceedings in the United States and/or foreign jurisdictions challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or
invalidate or render unenforceable, our patent rights, and may allow third parties, including generic drug companies, to commercialize cretostimogene or any future product candidates and other proprietary technologies we may develop and compete
directly with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Moreover, some of our patent rights may in the future be
<FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. In the United States, each <FONT STYLE="white-space:nowrap">co-owner</FONT> has the freedom to license and exploit the technology. If we are unable to obtain an exclusive license
to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patent rights, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our
competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of such patent rights in order to enforce such patent rights
against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be able to protect our intellectual property and proprietary rights
throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Filing, prosecuting, maintaining, enforcing and defending patents on cretostimogene or any
future product candidates in all countries throughout the world is expensive, and the laws of foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States. Prosecution of foreign patent
applications is often a longer process and patents may grant at a later date, and with a shorter term, than in the United States. The requirements for patentability differ in certain jurisdictions and countries. Additionally, the patent laws of some
countries do not afford intellectual property protection to the same extent as the laws of the United States. For example, other countries may impose substantial restrictions on the scope of claims, including limiting patent protection to
specifically disclosed embodiments. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our intellectual property in
and into the United States or other jurisdictions. Competitors may use our intellectual property in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing
products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or patents we may license in the future or other intellectual
property rights may not be effective or sufficient to prevent them from competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us
to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, some jurisdictions, such as Europe, Japan and China, may have a heightened standard
for patentability than in the United States, including, for example, the requirement of claims having literal support in the original patent filing and the limitation on using supporting data that is not in the original patent filing. Under those
heightened patentability requirements, we may not be able to obtain sufficient patent protection in certain jurisdictions even though the same or similar patent protection can be secured in the United States and other jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Proceedings to enforce our intellectual property and proprietary rights in the United States or other jurisdictions could
result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents and any patents we may license in the future at risk of being invalidated or interpreted narrowly, could put our patent
applications and any patent applications we may license in the future at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property
that we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant
licenses to third parties, including governmental agencies. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which
could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results
of operations and prospects may be adversely affected. In addition, <FONT STYLE="white-space:nowrap">geo-political</FONT> actions in the United States and in foreign countries (such as the Russia and Ukraine conflict) could increase the
uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any future licensors and the maintenance, enforcement or defense of our issued patents which could impair our competitive intellectual property
position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Obtaining and maintaining our patent protection depends on compliance with various
procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with
several procedural, documentary, fee payment and other similar provisions during the patent application process. In some circumstances, we may be dependent on any future licensors to take the necessary action to comply with these requirements with
respect to any licensed intellectual property. For example, periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent
agencies outside of the United States over the lifetime of our patents and applications. In certain circumstances, we may rely on licensing partners to pay these fees due to the U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent
agencies. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result
in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical
products or technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with certain
foreign filing requirements during the patent application process. For example, in some countries, including the United States, China, India and some European countries, a foreign filing license is required before certain patent applications are
filed. The foreign filing license requirements vary by country and depend on various factors, including where the inventive activity occurred, citizenship status of the inventors, the residency of the inventors and the invention owner, the place of
business for the invention owner and the nature of the subject matter to be disclosed (e.g., items related to national security or national defense). In some, but not all cases, for example in China and India, a foreign filing license cannot be
obtained retroactively in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment of a pending patent application or can be grounds for revoking
or invalidating an issued patent, resulting in the loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the relevant markets with similar or identical products or technology, which could
have a material adverse effect on our business, financial condition, results of operations and prospects. We would also be dependent on any future licensors to take the necessary actions to comply with these requirements with respect to any
intellectual property we may license in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Public health pandemics (such as the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic), geopolitical instability (war and terrorism), natural disasters, or similar events may impair our and our licensors&#146; ability to comply with these procedural, document submission, fee
payment, and other requirements imposed by government patent agencies, which may materially and adversely affect our ability to obtain or maintain patent protection for cretostimogene and any future product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in patent laws or their interpretations could diminish the value of patents in general, thereby impairing our ability to protect
our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Changes in either the patent laws or interpretation of the patent laws in the United States or in
other countries could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the
United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&nbsp;a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act
(the America Invents Act) enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file&nbsp;a patent application will be
entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us or our licensors could therefore be
awarded a patent covering an invention of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
ours or our licensors even if we or our licensors had made the invention before it was made by such third party. This requires us to be cognizant of the time from invention to filing of a patent
application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors are the first to either (i)&nbsp;file any patent
application related to cretostimogene or any future product candidates and other proprietary technologies we may develop or (ii)&nbsp;invent any of the inventions claimed in our patents or patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The America Invents Act also included a number of significant changes that affect the way patent applications are prosecuted
and also affect patent litigation. These include allowing third party protests and submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant
proceedings, including post-grant review,&nbsp;inter partes&nbsp;review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a
patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court
action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims or any patent claims we may license in the future that would not have been invalidated if first challenged by the third party as a defendant
in a district court action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the patent positions of companies in the development and commercialization of
pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. We cannot predict how
decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patent rights. For example, the U.S. Supreme Court held in <I>Amgen v. Sanofi (2023)</I>&nbsp;that a functionally claimed genus was invalid for failing to comply
with the enablement requirement of the Patent Act. As such, our patent rights with functional claims&nbsp;may be vulnerable to third party challenges seeking to invalidate these claims for lacking enablement or adequate support in the specification.
Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our
ability to protect and enforce our intellectual property in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant
governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have or may obtain or license in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2012, the European Union Patent Package (EU Patent Package) regulations were passed with the goal of providing a single <FONT
STYLE="white-space:nowrap">pan-European</FONT> Unitary Patent and a new European Unified Patent Court (UPC) for litigation involving European patents. The EU Patent Package was implemented on June&nbsp;1, 2023. As a result, all European patents,
including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC, unless otherwise opted out. It is uncertain how the UPC will impact granted European patents in the
biotechnology and pharmaceutical industries. Our European patent applications, if issued, could be challenged in the UPC. During the first seven years of the UPC&#146;s existence, the UPC legislation allows a patent owner to opt its European patents
out of the jurisdiction of the UPC. We may decide to opt out our future European patents from the UPC, but doing so may preclude us from realizing the benefits of the UPC. Moreover, if we do not meet all of the formalities and requirements for <FONT
STYLE="white-space:nowrap">opt-out</FONT> under the UPC, our future European patents could remain under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the
possibility of a competitor to obtain <FONT STYLE="white-space:nowrap">pan-European</FONT> injunction. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and
cretostimogene and any future product candidates due to increased competition and, resultantly, on our business, financial condition, results of operations and prospects. The UPC and Unitary Patent are significant changes in European patent
practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation in the UPC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Issued patents covering cretostimogene or any future product candidates could be found
invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our patent rights may be subject to priority, validity, inventorship, ownership and enforceability disputes. Legal proceedings
relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and likely to divert significant resources from our core business, including distracting our management and scientific
personnel from their normal responsibilities and generally harm our business. If we or any future licensors are unsuccessful in any of these proceedings, such patents and patent applications may be narrowed, invalidated or held unenforceable. Any of
the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If we initiate legal proceedings against a third party to enforce a patent covering cretostimogene or any future product
candidates, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge
could include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <FONT STYLE="white-space:nowrap">non-enablement,</FONT> lack of sufficient written description, failure to claim patent-eligible
subject matter or obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading or
inconsistent statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of a patent before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms
include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review,&nbsp;inter partes&nbsp;review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g.,&nbsp;opposition
proceedings). Such proceedings could result in the revocation of, cancellation of, shortening the term of or amendment to our patent rights or any patent rights we may obtain or license in the future in such a way that they no longer cover
cretostimogene or any future product candidates or prevent third parties from competing with our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question,
for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at
least part, and perhaps all, of the patent protection for cretostimogene or any future product candidates. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Patent terms may be inadequate to protect the competitive position of cretostimogene or any future product candidates
for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patents have a limited lifespan. In the United States, if all maintenance fees are
timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> or international patent application filing date. Various extensions may be available, but the life
of a patent, and the protection it affords, is limited. Even if patents covering cretostimogene or any future product candidates are obtained, once the patent has expired, we may be vulnerable to competition from competitive products, including
generics. Given the amount of time required for the development, testing and regulatory review of cretostimogene or any future product candidates, patents protecting such product candidates might expire before or shortly after such product
candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. If we do not have sufficient patent life to protect our
products, our business, financial condition, results of operations and prospects will be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we do not obtain
patent term extension and equivalent extensions outside of the United States for cretostimogene or any future product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Depending upon the timing, duration and specifics of any FDA regulatory approval of cretostimogene or any future product
candidates, one or more of our U.S. patents may be eligible for limited patent term extension </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A
patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended, and only those claims covering the approved drug, a method for using it or a method for
manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection
Certificate. However, we may not be granted an extension for various reasons, including failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to
expiration of relevant patents, or failing to satisfy other applicable requirements. Moreover, the applicable time period afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent
that we may license from a third party in the future, we may need the cooperation of that third party. If we are unable to obtain patent term extension, or the foreign equivalent, or if the term of any such extension is less than we request, our
competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may be subject to claims that former employees, consultants, licensees, collaborators or other third parties have an
interest in our patent rights, trade secrets, or other intellectual property as an inventor, <FONT STYLE="white-space:nowrap">co-inventor</FONT> or owner of trade secrets. For example, we may have inventorship or ownership disputes arise from
conflicting obligations of consultants or others who are involved in developing cretostimogene or any future product candidates and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims
challenging inventorship or ownership or our patent rights, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as
ownership of, or the right to use intellectual property that is important to cretostimogene or any future product candidates and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to seeking patent protection for cretostimogene or any future product candidates and proprietary
technologies, we may rely on trade secret protection and confidentiality agreements to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, and other proprietary information and to maintain our competitive position.
We seek to protect these trade secrets and other proprietary technology, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees,
licensees, third-party collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Trade secrets and
<FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We cannot guarantee that we have entered into applicable agreements with each party that may have or have had access to our trade secrets or proprietary technology and
processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized
uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. We cannot guarantee that any potential trade secrets and other proprietary and confidential information
will not be disclosed or that competitors will not otherwise gain access to trade secrets. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is
unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, others
may independently discover similar trade secrets and proprietary information. If any of our trade secrets were to be disclosed or misappropriated or if any such information were to be independently developed by a competitor or other third party, our
competitive position would be materially and adversely harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may be subject to claims that third parties have an
ownership interest in our trade secrets. For example, we may have disputes arise from conflicting obligations of our employees, consultants or others who are involved in developing cretostimogene or any future product candidates. Litigation may be
necessary to defend against these and other claims challenging ownership of our trade secrets. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable trade secret rights, such as exclusive ownership of,
or right to use, trade secrets that are important to cretostimogene or any future product candidates and other proprietary technologies we may develop. Such an outcome could have a material adverse effect on our business. Even if we are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may be subject to claims that our employees, consultants, or advisors have wrongfully used or
disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some of our employees, consultants and advisors are currently or were previously employed at universities or other
biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or
<FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any
such individual&#146;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or
development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as
our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to
determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party
patent, which might adversely affect our ability to develop and market cretostimogene or any future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of
patent claims or the expiration of relevant patents, are or will be complete or thorough, nor can we be certain that we have identified or will identify each and every third-party patent and pending patent application in the United States and abroad
that is relevant to or necessary for the commercialization of cretostimogene or any future product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the
earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering cretostimogene or any future product candidates could have been filed by others
without our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
knowledge. The scope of a patent claim is determined by the interpretation of the law, the words of a patent claim, the written disclosure in a patent and the patent&#146;s prosecution history.
Our interpretation of the relevance or the scope of a patent or a pending patent application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that cretostimogene or any future product
candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending patent application will issue with claims of relevant scope. Alternatively, we may incorrectly determine that the Hatch-Waxman
Amendments are a defense for a safe harbor to infringement of a patent we consider relevant to the research or clinical development of cretostimogene or any future product candidate. Our determination of the expiration date of any patent in the
United States or abroad that we consider relevant may be incorrect, and we may incorrectly conclude that a third-party patent is invalid and unenforceable or not infringed. Our failure to identify and correctly interpret relevant patents may
negatively impact our ability to develop and market cretostimogene or any future product candidates. If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. Also, because the claims of published
patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. As the number of competitors in the market grows and the number of patents issued
in this area increases, the possibility of patent infringement claims escalates. Moreover, in recent years, individuals and groups that are <FONT STYLE="white-space:nowrap">non-practicing</FONT> entities, commonly referred to as &#147;patent
trolls,&#148; have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#147;invitations to
license,&#148; or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others. We cannot guarantee that we will be able to successfully settle or otherwise resolve such
infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing cretostimogene or any future product candidates that are held to be infringing. We
might, if possible, also be forced to redesign cretostimogene or any future product candidates or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Third-party claims of intellectual property infringement, misappropriation, or other violations against us or our collaborators could be
expensive and time consuming and may prevent or delay the development and commercialization of cretostimogene or any future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success depends in part on our and our collaborators&#146; ability to avoid infringing, misappropriating and
otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries,
as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerous U.S. and foreign-issued patents and pending patent applications owned by third parties exist in the fields in which
we plan to commercialize our therapeutic programs and in which we are developing other proprietary technologies. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market
exposure as a public company, the risk increases that our therapeutic programs and commercializing activities may give rise to claims of infringement of the patent rights of others. We cannot guarantee that our therapeutic programs and other
proprietary technologies we develop will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued for which a third party, such as a competitor in the fields in which we are
developing our therapeutic programs, might assert as infringed by us. It is also possible that patents owned by third parties of which we are aware, but which we do not believe we infringe or that we believe we have valid defenses to any claims of
patent infringement, could be found to be infringed by us. It is not unusual that corresponding patents issued in different countries have different scopes of coverage, such that in one country a third-party patent does not pose a material risk, but
in another country, the corresponding third-party patent may pose a material risk to cretostimogene or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any future product candidates. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents
that we may infringe. For example, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover cretostimogene or any future product candidates or the use of cretostimogene
or any such product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event that any third-party claims that we infringe their patents or that we are
otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court could hold that such patents are valid, enforceable and infringed by us. Defense of
infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a
successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products or technologies. In addition, we may be required to pay substantial damages, including treble damages and
attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products or technologies, which may be impossible or require substantial time and monetary expenditure. Such
licenses may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive,
which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms or at all, we may be unable to commercialize the
infringing products or technologies or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. In addition, we may in the future pursue patent challenges with respect to third-party patents,
including as a defense against the foregoing infringement claims. The outcome of such challenges is unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even
if resolved in our favor, the foregoing proceedings could be very expensive, particularly for a company of our size, and time-consuming. Such proceedings could substantially increase our operating losses and reduce the resources available for
development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of our competitors may be able to sustain the costs of litigation
or administrative proceedings more effectively than we can because of greater financial resources. Such proceedings may also absorb significant time of our technical and management personnel and distract them from their normal responsibilities.
Uncertainties resulting from such proceedings could impair our ability to compete in the marketplace. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities
analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. The occurrence of any of the foregoing could have a material adverse effect on our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may in the future pursue invalidity proceedings with respect to
third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses, and could distract our technical and management personnel
from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it
could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution
activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater
financial resources. Uncertainties resulting from the initiation and continuation of patent proceedings could compromise our ability to compete in the marketplace. If we do not prevail in the patent proceedings the third parties may assert a claim
of patent infringement directed at cretostimogene or any future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may become involved in lawsuits to protect or enforce our patents and other
intellectual property rights, which could be expensive, time-consuming, and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Third parties, such as a
competitor, may infringe our patent rights. In an infringement proceeding, a court may decide that a patent we own or a patent we may license in the future is invalid or unenforceable or may refuse to stop the other party from using the invention at
issue. In addition, our patent rights may become involved in inventorship, ownership, priority, enforceability, or validity disputes. To counter or defend against such claims can be expensive and time-consuming. An adverse result in any litigation
proceeding could put our patent rights at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation and
proceedings, there is a risk that some of our confidential information could be compromised by disclosure during such litigation and proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to
incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities
analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources
available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to
sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and
continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our registered or unregistered trademarks or trade names may
be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing, misappropriating or violating other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name
recognition among potential partners or customers in the markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an
opportunity to respond to such rejections, we may be unable to overcome them. In the event that our trademarks are successfully challenged or determined to be infringing, misappropriating or violating other marks, we could be forced to rebrand our
products, which could result in loss of brand recognition, and could require us to devote resources to advertising and marketing new brands. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given
an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. Moreover, any name we may
propose to use with cretostimogene or any future product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The
FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed
proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe, misappropriate or otherwise violate the
existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a
senior trademark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may not be able to obtain, protect or enforce our rights to these trademarks and trade names, which
we need to build name recognition among potential partners or customers in our markets of interest. At times, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition,
there could be potential trade name or trademark infringement, misappropriation, dilution or other claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or
trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to obtain, enforce or
protect our proprietary rights related to trademarks, trade names, domain name, or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Intellectual property rights do not necessarily address all potential threats.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual
property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to cretostimogene or any future product candidates or
utilize similar technology but that are not covered by the claims of the patents that we own or may license in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or collaborators might not have been the first to make the inventions covered by our
current or future patent applications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or collaborators might not have been the first to file patent applications covering our or
their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending and future patent applications that we own or may license will not lead to
issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any issued patent that we own or license in the future may be held invalid or unenforceable, including as a
result of legal challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may have access to the same intellectual property rights licensed to us in the future on a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we
or our licensors do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to identify potential patentable subject matter and/or may fail to file on it;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents or other intellectual property rights of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file&nbsp;for patent protection in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file&nbsp;a patent application covering such intellectual property or disclose information resulting in a loss of protection for such trade secret. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Should any of the foregoing occur, it could adversely affect our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and processes for our
development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The growth of
our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use third-party intellectual property and proprietary rights. For example, cretostimogene or any future product candidates may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
require specific formulations to work effectively and efficiently, we may develop product candidates containing our compounds and <FONT STYLE="white-space:nowrap">pre-existing</FONT>
pharmaceutical compounds, we may develop combination therapies with our compounds and third-party compounds, any of which could require us to obtain rights to use intellectual property held by third parties. In addition, with respect to any patent
or other intellectual property rights we may <FONT STYLE="white-space:nowrap">co-own</FONT> with third parties, we may require licenses to such <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest to such patents. We may be unable to
acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In
addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights and
may need to seek to develop alternative approaches that do not infringe, misappropriate or otherwise violate those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such
alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which means that our competitors may also receive access to the same technologies licensed to us. In
that event, we may be required to expend significant time and resources to develop or license replacement technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, we may collaborate with academic institutions to accelerate our research and development under written
agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Even if we hold such an option, we may
be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our
ability to pursue our program. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> and our competitors may also receive access to the same technologies licensed to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be
more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize cretostimogene or any future
product candidates. More established companies may have a competitive advantage over us due to their size, cash resources or greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor
may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding cretostimogene or any
future product candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon
development of certain programs and our business, financial condition, results of operations, and prospects could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This
Offering and Ownership of Our Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>There has been no public market for our common stock. An active, liquid and orderly
market for our common stock may not develop, or we may in the future fail to satisfy the continued listing requirements of Nasdaq, and you may not be able to resell your common stock at or above the initial public offering price or at all.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. Although we have applied to list our
common stock on the Nasdaq, an active trading market for our common stock may never develop or may not be sustained following this offering. We and the representatives of the underwriters will determine the initial public offering price of our
common stock through negotiation. This price will not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. In addition, an active trading market may not develop following
the completion of this offering or, if it is developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market
may also impair our ability to raise capital by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If, after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance
requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our
common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price
or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the listing requirements of Nasdaq.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur
substantial losses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our stock price is likely to be volatile. The stock market in general and the market for stock
of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock
at or above the initial public offering price. The market price for our common stock may be influenced by those factors discussed in this &#147;Risk Factors&#148; section and many others, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of our clinical trials and preclinical studies, and the results of trials of our competitors or those
of other companies in our market sector; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll patients in our future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of cretostimogene or any future product candidates or
additional indications thereof, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success or failure of our efforts to develop, acquire, or license cretostimogene or any future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">innovations, clinical trial results, product approvals and other developments regarding our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, or
capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing, supply, or distribution delays or shortages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achievement of expected product sales and profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or development timelines or those of companies that are perceived to be
similar to us, including variations from expectations of securities analysts or investors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the biopharmaceutical sector and issuance of securities analysts&#146; reports or
recommendations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our stock by us, our insiders or our stockholders, as well as the anticipation of <FONT
STYLE="white-space:nowrap">lock-up</FONT> releases or expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry, geopolitical and market conditions, such as military conflict or war, inflation
and financial institution instability, or pandemic or epidemic disease outbreaks, many of which are beyond our control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of senior management, directors or key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property, product liability or other litigation against us or our inability to enforce our
intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our capital structure, such as future issuances of securities and the incurrence of additional
debt; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting standards, policies, guidelines, interpretations or principles. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following
periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs, divert our management&#146;s attention and resources and damage our reputation, which
could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We may allocate the
net proceeds from this offering in ways that you and other stockholders may not approve. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management will have
broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section titled &#147;Use of Proceeds.&#148; Because of the number and variability of factors that will determine our use
of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by
our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates
of deposit or direct or guaranteed obligations of the U.S. government. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value,
we may fail to achieve expected results, which could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>You will suffer immediate and substantial
dilution in the net tangible book value of the common stock you purchase in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial public
offering price of our common stock is substantially higher than the pro forma as adjusted net tangible book value per share of our outstanding common stock immediately after the completion of this offering. Purchasers of common stock in this
offering will experience immediate dilution of approximately $&#8195;&#8195;&#8195; per share, assuming an initial public offering price of $&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of
this prospectus. In the past, we issued options to acquire common stock at prices significantly below the initial public offering price. To the extent these outstanding options are ultimately exercised, investors purchasing common stock in this
offering will sustain further dilution. For a further description of the dilution that you will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>After this offering, our executive officers, directors, and principal stockholders, if they choose to act together, will continue to
have the ability to significantly influence all matters submitted to stockholders for approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the
completion of this offering, our executive officers, directors and greater than 5% stockholders, in the aggregate, will own approximately &#8195;&#8195;% of our outstanding common stock (assuming no exercise of the underwriters&#146; option to
purchase additional shares and no exercise of outstanding options and without giving effect to any potential purchases by such persons in this offering). As a result, such persons, acting together, will have the ability to significantly influence
all matters submitted to our board of directors or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business
affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from
making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We do not currently intend to pay dividends on our common stock, so any returns on your investment will be limited to the value of our
common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid any cash dividend on our common stock. We currently anticipate that
we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, any future debt agreements may preclude us from paying
dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their
shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause
our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sales of a substantial number of shares of our common stock in the public market or the
perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity or equity-linked securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on shares of common stock outstanding as of September&nbsp;30, 2023, upon the completion of this offering, we will have
a total of&#8195;&#8195;&#8195;&#8195;shares of common stock outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of these shares, only
the&#8195;&#8195;&#8195;&#8195;shares of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable, without restriction, in the public market
immediately following this offering, unless they are purchased by one of our affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our directors and executive
officers and substantially all of our securityholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the representatives pursuant to which they may not, with limited exceptions, for a period of 180 days from the
date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC and Goldman Sachs&nbsp;&amp; Co. LLC. The underwriters may permit our officers,
directors and other securityholders who are subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time in their sole
discretion. See the section titled &#147;Underwriting.&#148; Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements expire, up to an additional&#8195;&#8195;&#8195;&#8195;shares of common stock will be eligible for sale in the public market, of which&#8195;&#8195;&#8195;&#8195;shares will be held by directors, executive officers and other affiliates
and will be subject to volume limitations under Rule 144 under the Securities Act, in each case based on shares of common stock outstanding as of September&nbsp;30, 2023 and without giving effect to any potential purchases by such persons in this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, as of September&nbsp;30, 2023, &#8195;&#8195;&#8195;&#8195; shares of common stock that are
subject to outstanding options under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
and Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After this offering, the holders of &#8195;&#8195;&#8195;&#8195; shares of our outstanding common stock, or
approximately&#8195;&#8195;&#8195;&#8195;% of our total outstanding common stock based on shares outstanding as of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
September&nbsp;30, 2023, will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to vesting and the
<FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. See the section titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; Registration of these shares under
the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders
could have a material adverse effect on the trading price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are an emerging growth company and a smaller
reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of
the fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer&#148;, as defined under the
Exchange Act, our annual gross revenue exceeds $1.235&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior
to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging
growth companies. These exemptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal
control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules are necessary for protecting
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
shareholder approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have taken advantage
of reduced reporting burdens in this prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that would be required if
we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active
trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this exemption and, therefore,
we may not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required
to comply with the auditor attestation requirements of Section&nbsp;404(b) of Sarbanes-Oxley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also a smaller
reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting
companies and will be able to take advantage of these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting
<FONT STYLE="white-space:nowrap">and&nbsp;non-voting&nbsp;common</FONT> stock held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;is</FONT> less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and
may lead to entrenchment of management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and
restated bylaws that will be in effect immediately prior to the completion of this offering will contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in
our management without the consent of our board of directors. The provisions in our charter documents will include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders
to change the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect
director candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exclusive right of our board of directors, unless the board of directors grants such right to the
stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to
vote to remove a director for cause, and the prohibition on removal of directors without cause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine
the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to
vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an
annual or special meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the
exclusive forum for certain actions and proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may
delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of
directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise
attempting to obtain control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are also subject to the anti-takeover provisions contained in
Section&nbsp;203 of the Delaware General Corporation Law. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three
years or, among other exceptions, the board of directors has approved the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Our current amended and restated certificate of incorporation provides, and our
amended and restated certificate of incorporation will provide, that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders and that the federal district courts shall
be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors,
officers or employees or the underwriters or any offering giving rise to such claim. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our current amended and
restated certificate of incorporation provides, and our amended and restated certificate of incorporation that will be in effect immediately prior to the completion of this offering will provide, that the Court of Chancery of the State of Delaware
is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and
restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty
or liability created by the Exchange Act. or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, our amended and restated certificate of incorporation will also provide that unless we consent in writing to the
selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may
limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other
employees and result in increased costs for investors to bring a claim. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.
Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be
inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving
such action in other jurisdictions, which could adversely affect our business and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Participation in this
offering by our existing stockholders and/or their affiliated entities may reduce the public float for our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent certain of our existing stockholders and their affiliated entities participate in this offering, such purchases
would reduce the <FONT STYLE="white-space:nowrap">non-affiliate</FONT> public float of our shares, meaning the number of shares of our common stock that are not held by officers, directors, and controlling stockholders. A reduction in the public
float could reduce the number of shares that are available to be traded at any given time, thereby adversely impacting the liquidity of our common stock and depressing the price at which you may be able to sell shares of common stock purchased in
this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Risk Factors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote
substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As a public company, we will incur significant legal, accounting
and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect
to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring
establishment and maintenance of effective disclosure and financial controls and certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas,
such as mandatory &#147;say on pay&#148; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of government intervention and
regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial
compliance costs and to make some activities more time consuming and costly. The increased costs will decrease our net income or increase our net loss, and may require us to reduce expenditures in other areas of our business. For example, we expect
these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or
estimate the amount or timing of additional costs we may incur to comply with these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors,
our board committees or as executive officers. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes,
anti-corruption laws, and anti-money laundering laws and regulations. We could face criminal liability and other serious consequences for violations, which could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S.
Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and regulations, including the U.S.
Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the
countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing,
soliciting or receiving, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products
abroad if and when we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or
government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly
authorize or have actual knowledge of such activities, and any training or compliance programs or other initiatives we undertake to prevent such activities may not be effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties,
imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to
countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed may impact our ability to continue activities at future clinical trial sites within regions covered by such sanctions. If we fail to
comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. These export and import controls and economic sanctions could also adversely affect our
supply chain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We and any of our third-party manufacturers or suppliers may use potent chemical
agents and hazardous materials, and any claims relating to improper handling, storage, or disposal of these materials could be time-consuming or costly. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and any of our third-party manufacturers or suppliers and our current or any future collaborators may use biological
materials, potent chemical agents, and hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party
manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable
environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, neither we or our third-party manufacturers and suppliers can eliminate the risk
of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for
damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury at our, our manufacturers&#146; or our suppliers&#146; sites, we could be held liable for damages or be penalized with
fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. Although we maintain workers&#146; compensation insurance for certain costs and expenses we may incur due to injuries to our employees
resulting from work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with the storage or disposal of
biologic, hazardous or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we may incur substantial costs in order to comply with current
or future environmental, health, and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with
these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operations and the operations of our manufacturers, suppliers, collaborators, CROs and clinical sites could be subject to
earthquakes, power shortages, telecommunications or infrastructure failures, cybersecurity incidents, physical security breaches, water shortages, floods, hurricanes, typhoons, blizzards and other extreme weather conditions, fires, public health
pandemics or epidemics (including, for example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic) and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party
manufacturers or suppliers to produce cretostimogene or any future product candidates and its components and on CROs and clinical sites to conduct our clinical trials, and do not have a redundant source of supply for all components of cretostimogene
or any future product candidates. Our ability to obtain clinical or, if approved, commercial, supplies of cretostimogene or any future product candidates could be disrupted if the operations of these suppliers were affected by a <FONT
STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption, and our ability to commence, conduct or complete our clinical trials in a timely manner could be similarly adversely affected by any of the foregoing. In
addition, our corporate headquarters is located in Irvine, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain
geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Unstable market and economic conditions and adverse developments with respect to
financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, the global credit and financial markets have experienced extreme volatility and disruptions, including
severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be
adversely affected by the current or anticipated impact of military conflict, including the conflicts between Russia and Ukraine, and in the Middle East, terrorism or other geopolitical events. Sanctions imposed by the United States and other
countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic
instability. In addition, in 2023 the closures of financial institutions and their placement into receivership with the FDIC created bank-specific and broader financial institution liquidity risk and concerns. Future adverse developments with
respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term working capital needs, and create additional market and economic
uncertainty. There can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic
downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market conditions. If the equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause
short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly, more onerous with respect to financial and operating covenants and more dilutive. Failure to secure any necessary financing in a timely
manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay, limit, reduce or abandon product development or future commercialization efforts or grant
rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves. In addition, there is a risk that one or more of our current service providers, financial institutions,
manufacturers and other partners may be adversely affected by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Changes in tax law may materially adversely affect our financial condition, results of operations and cash flows, or adversely impact
the value of an investment in our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New income, sales, use or other tax laws, statutes, rules,
regulations or ordinances could be enacted at any time, or interpreted, changed, modified or applied adversely to us, any of which could adversely affect our business operations and financial performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our
stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The trading market for our common stock will depend in part on the
research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or
industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our stock, or
if we fail to meet the expectations of one or more of these analysts, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which
could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>If we fail to maintain proper and effective internal control over financial reporting,
our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to Section&nbsp;404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our
internal control over financial reporting beginning with the second annual report following the completion of this offering. When we lose our status as an &#147;emerging growth company&#148; and do not otherwise qualify as a &#147;smaller reporting
company&#148; with less than $100.0&nbsp;million in annual revenue, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards
that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the
Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors
are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over
financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude
that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm
begins its Section&nbsp;404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the
SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future
access to the capital markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the past, securities class action litigation has often been brought against a company following a decline in the market
price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, even if ultimately decided in our
favor, it could result in substantial costs and a diversion of our management&#146;s attention and resources, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains forward-looking statements about us and our industry. All statements other than statements of
historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our
ongoing and planned clinical trials and preclinical studies for cretostimogene and any future product candidates, the timing and likelihood of regulatory filings and approvals for cretostimogene and any future product candidates, our ability to
commercialize cretostimogene and any future product candidates, if approved, the pricing and reimbursement of cretostimogene and any future product candidates, if approved, the potential to develop future product candidates, the potential benefits
of strategic collaborations and potential to enter into any future strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts,
are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In some cases, you can identify
forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148;
&#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus
are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial and other trends that we believe may affect our business, financial condition and results of
operations. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified
and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual
results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to
predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events,
changed circumstances or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled &#147;Where You Can Find More
Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, statements that &#147;we believe&#148; and similarly qualified statements reflect our
beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be
limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned
not to rely unduly upon them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates
and research, as well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. The content
of these third-party sources, except to the extent specifically set forth in this prospectus, does not constitute a portion of this prospectus and is not incorporated herein. Internal estimates are derived from publicly available information
released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In
some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same
paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
addition, while we are responsible for all of the disclosure contained in this prospectus and we believe the industry, market and competitive position data included in this prospectus is reliable and based on reasonable assumptions, such data
involve risks and uncertainties and are subject to change based on various factors, including those discussed in the sections titled &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; These and other factors
could cause results to differ materially from those expressed in the estimates made by the independent parties or by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We estimate that the net proceeds to us from this offering will be approximately
$<B></B><B></B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B> </B>million (or approximately $&#8195;&#8195;&#8195; million if the underwriters exercise their over-allotment option in full), based on the assumed initial public offering price of
$<B></B><B></B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B> </B>per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price
of $<B></B><B></B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B> </B>per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this
offering by approximately $<B></B><B></B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B> </B>million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares of common stock offered by us would increase or decrease, as applicable,
the net proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $&#8195;&#8195;&#8195; million, assuming the assumed initial public
offering price stays the same. The information discussed above is illustrative only and will adjust based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public market
for our common stock and to facilitate our future access to the public equity markets. We currently intend to use approximately $&#8195;&#8195;&#8195; million of the net proceeds from this offering, together with our existing cash, cash equivalents
and marketable securities, to fund the research and development of cretostimogene, including certain manufacturing activities, and the remainder, if any, for working capital and other general corporate purposes, including <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> activities. We expect the net proceeds from this offering and our existing cash, cash equivalents and marketable securities will allow us to complete &#8195;&#8195;&#8195;&#8195;&#8195;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and marketable securities to <FONT
STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe, based on our current operating plan, that the net proceeds from this offering, together with our existing cash,
cash equivalents and marketable securities, will be sufficient to fund our operations for at least the next &#8195;&#8195;&#8195;&#8195; months from the date of this prospectus. We have based these estimates on assumptions that may prove to be
wrong, and we could use our capital resources sooner than we currently expect. Additionally, our expected use of existing cash, cash equivalents and marketable securities and our net proceeds from this offering represent our intentions based upon
our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress
and costs of our development activities, the status of and results from clinical trials, as well as the progress of any current or future collaborations that we may enter into with third parties for cretostimogene and any future product candidates,
and the amount of cash used in our operations and any unforeseen cash needs as well as other factors described in the sections titled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; The net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities will not be sufficient to complete development in
all potential indications of cretostimogene and any future product candidates, and after this offering, we will require substantial capital in order to advance cretostimogene and any future product candidates through clinical trials, regulatory
approval and commercialization. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations,
licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management will have broad discretion in the application of the net
proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of those net proceeds. The timing and amount of our actual expenditures will be based on many factors, including the anticipated
growth of our business. Pending the uses described above, we plan to invest the net proceeds in a variety of capital preservation instruments, including short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit
and direct or guaranteed obligations of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain future earnings, if any,
to finance the operation of our business and do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors
after considering our financial condition, results of operations, current and anticipated capital requirements, business prospects and other factors our board of directors deems relevant, and subject to applicable laws and the restrictions contained
in any future financing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth our cash, cash equivalents and marketable securities and capitalization as of
September&nbsp;30, 2023: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to reflect (i)&nbsp;the automatic conversion of all outstanding shares of our redeemable
convertible preferred stock into 366,277,131 shares of our common stock and the related reclassification of the carrying value of the redeemable convertible preferred stock to permanent equity immediately prior to the closing of this offering, and
(ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of
&#8195;&#8195;&#8195;&#8195;<B> </B>shares of our common stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of this prospectus,
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The pro forma and pro forma as adjusted information below is illustrative only, and our cash, cash equivalents and marketable
securities and capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our
financial statements and related notes included in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other financial information contained in this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>September&nbsp;30, 2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;par&nbsp;value&nbsp;and&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, $0.0001 par value; 366,277,131 shares authorized, issued
and outstanding, actual; no shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; no shares authorized, issued and outstanding, actual;
&#8195;&#8195;&#8195;&#8195; shares authorized and no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; &#8195;&#8195;&#8195;&#8195; shares authorized,
&#8195;&#8195;&#8195;&#8195; shares issued and &#8195;&#8195;&#8195;&#8195; outstanding, actual; &#8195;&#8195;&#8195;&#8195; shares authorized, &#8195;&#8195;&#8195;&#8195; shares issued and &#8195;&#8195;&#8195;&#8195; outstanding, pro forma;
&#8195;&#8195;&#8195;&#8195; shares authorized, &#8195;&#8195;&#8195;&#8195; shares issued and &#8195;&#8195;&#8195;&#8195; shares outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price of $&#8195;&#8195;&#8195; per
share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted amount of each </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">
of our cash, cash equivalents and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity and total capitalization by
approximately $&#8195;&#8195;&#8195;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price of $&#8195;&#8195;&#8195; per share would increase or decrease, as applicable,
the pro forma as adjusted amount of each of our cash, cash equivalents and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity and total capitalization by approximately
$&#8195;&#8195;&#8195;, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters&#146; option to purchase additional shares is exercised in full, our pro forma as adjusted cash, cash
equivalents and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity, and total capitalization as of September&nbsp;30, 2023, would be $&#8195;&#8195;&#8195; million,
$&#8195;&#8195;&#8195; million, $&#8195;&#8195;&#8195; million, and $&#8195;&#8195;&#8195; million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
number of shares of our common stock issued and outstanding, pro forma and pro forma as adjusted, in the table above is based on &#8195;&#8195;&#8195;&#8195; shares of our common stock outstanding as of September&nbsp;30, 2023, after giving effect
to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 366,277,131&nbsp;shares of our common stock immediately prior to the closing of this offering, and excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock issuable upon the exercise of stock options outstanding as
of September&nbsp;30, 2023, with a weighted-average exercise price of $&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock issuable upon the exercise of stock options subsequent to
September&nbsp;30, 2023, with a weighted-average exercise price of $&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under the 2024 Plan, which
will become effective in connection with this offering (which number includes &#8195;&#8195;&#8195;&#8195; shares of common stock reserved for issuance under the 2022 Plan as of September&nbsp;30, 2023, which shares will be added to the 2024 Plan
upon its effectiveness, but does not include any potential evergreen increases pursuant to the terms of the 2024 Plan); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under the ESPP, which will
become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If you invest in our common stock in this offering, your ownership interest will be immediately and substantially diluted to
the extent of the difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2023, our historical net tangible book value (deficit) was
$<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B> </B>million, or $<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B> </B>per share of our common stock, based on <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> shares of common stock issued and
outstanding as of such date. Our historical net tangible book value (deficit) per share represents total tangible assets less total liabilities and redeemable convertible preferred stock, which is not included within permanent equity, divided by the
number of shares of common stock outstanding at September&nbsp;30, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On a pro forma basis, after giving effect to the
automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 366,277,131&nbsp;shares of our common stock and the related reclassification of the carrying value of the redeemable convertible preferred stock to
permanent equity immediately prior to the closing of this offering, our pro forma net tangible book value (deficit) as of September&nbsp;30, 2023 would have been approximately $&#8195;&#8195;&#8195; million, or approximately $&#8195;&#8195;&#8195;
per share of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After giving further effect to the sale and issuance of &#8195;&#8195;shares of our common
stock in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30, 2023 would have been approximately $&#8195;&#8195;&#8195; million, or approximately $&#8195;&#8195;&#8195; per
share. This amount represents an immediate increase in pro forma net tangible book value of approximately $&#8195;&#8195;&#8195; per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately
$&#8195;&#8195;&#8195; per share to new investors purchasing shares of common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dilution per share
to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without
giving effect to any exercise by the underwriters of their option to purchase additional shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of September&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book value per share as of September&nbsp;30, 2023
attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September&nbsp;30, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each $1.00 increase or decrease in the assumed initial public offering price of
$&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted net tangible book value per share after this offering by
approximately $&#8195;&#8195;&#8195; per share, and dilution in pro forma as adjusted net tangible book value per share to new investors by approximately $&#8195;&#8195;&#8195; per share, assuming that the number of shares offered by us, as set
forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
commissions and the estimated offering expenses payable by us. Each increase or decrease of 1.0&nbsp;million shares in the number of shares of common stock offered by us would increase or
decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by approximately $&#8195;&#8195;&#8195; per share and decrease or increase, as applicable, the dilution to investors participating in this
offering by approximately $&#8195;&#8195;&#8195; per share, assuming that the assumed initial public offering price of $&#8195;&#8195;&#8195; per share remains the same, and after deducting the estimated underwriting discounts and commissions and
the estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares of
our common stock in full in this offering, the pro forma as adjusted net tangible book value after the offering would be approximately $&#8195;&#8195;&#8195; per share, the increase in pro forma as adjusted net tangible book value per share to
existing stockholders would be approximately $&#8195;&#8195;&#8195; per share and the dilution per share to investors in this offering would be $&#8195;&#8195;&#8195; per share, in each case assuming an initial public offering price of
$&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The dilution information above is for illustration purposes only. Our pro forma as adjusted net tangible book value following
the closing of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes on the pro forma as adjusted basis described above, as of September&nbsp;30, 2023, the
differences between the number of shares purchased from us, the total consideration paid to us in cash and the weighted-average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new
investors in this offering. The calculations below are based on an assumed initial public offering price of &#8195;&#8195;&#8195;&#8195; $&#8195;&#8195;&#8195; per share, the midpoint of the price range set forth on the cover page of this
prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:1pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8201;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8201;&#8194;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the underwriters exercise their option to purchase additional shares of our common stock in
full: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the percentage of shares of common stock held by existing stockholders will decrease to approximately
&#8195;&#8195; % of the total number of shares of our common stock outstanding after this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares held by new investors participating in this offering will increase to
&#8195;&#8195;&#8195;&#8195;, or approximately &#8195;&#8195;% of the total number of shares of our common stock outstanding after this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The foregoing tables and calculations (other than the historical net tangible book value calculations) are based on
<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> shares of our common stock outstanding as of September&nbsp;30, 2023, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock
into 366,277,131 shares of our common stock immediately prior to the closing of this offering, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock issuable upon the exercise of outstanding stock options as
of September&nbsp;30, 2023, with a weighted-average exercise price of $<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B> </B>per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock issuable upon the exercise of stock options subsequent to
September&nbsp;30, 2023, with a weighted-average exercise price of $&#8195;&#8195;&#8195; per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under the 2024 Plan which
will become effective in connection with this offering (which number includes<B> </B>&#8195;&#8195;&#8195; shares of common stock reserved for issuance under the 2022 Plan as of September&nbsp;30, 2023, which shares will be added to the 2024 Plan
upon its effectiveness but does not include any potential evergreen increases pursuant to the terms of the 2024 Plan); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8195;&#8195;&#8195;&#8195; shares of common stock reserved for future issuance under the ESPP, which will
become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the extent any outstanding options are exercised, new options or other equity awards are issued under our equity incentive
plans, or we issue additional equity or convertible securities in the future, there will be further dilution to new investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>You should read the following discussion and analysis of our financial condition and results of operations together with
our financial statements and the related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and
strategy for our business and related financing, and includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section titled &#147;Risk Factors&#148; our actual
results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. See also the section titled &#147;Special Note Regarding Forward-Looking Statements.&#148;
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are
a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Our product candidate, cretostimogene, is initially in clinical
development for the treatment of patients with high-risk NMIBC who are unresponsive to BCG therapy, the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for high-risk NMIBC. There is
significant unmet need for treatments in these patients given the limitations of currently approved therapies and patient reluctance to undergo radical cystectomy, or the complete removal of the bladder. We are evaluating the safety and efficacy of
cretostimogene as monotherapy in <FONT STYLE="white-space:nowrap">BOND-003,</FONT> our ongoing Phase 3 clinical trial in high-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients. We have completed enrollment for this trial
and expect to report topline data by &#8195;&#8195;&#8195;&#8195;&#8195;. If successful, we believe that this trial could serve as the basis for a BLA submission to the FDA. We are also evaluating the use of cretostimogene when administered to this
same patient population in combination with <FONT STYLE="white-space:nowrap">FDA-approved</FONT> pembrolizumab in <FONT STYLE="white-space:nowrap">CORE-001,</FONT> our ongoing Phase 2 clinical trial. Moreover, we intend to assess the safety and
efficacy of cretostimogene in treating a range of other bladder cancer indications as an alternative to BCG therapy and in patients who are not categorized as <FONT STYLE="white-space:nowrap">BCG-unresponsive.</FONT> We intend to evaluate the safety
and efficacy of cretostimogene in: (1)&nbsp;intermediate-risk NMIBC patients following TURBT in our <FONT STYLE="white-space:nowrap">PIVOT-006</FONT> Phase 3 clinical trial; and (2)&nbsp;high-risk NMIBC patients in our planned <FONT
STYLE="white-space:nowrap">CORE-008</FONT> open-label multi-cohort Phase 2 clinical trial. We believe cretostimogene, if approved, has the potential to serve as first-line therapy, thereby alleviating the current need to prioritize treatment
recipients and ration administration of BCG given its significant market shortage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception in 2010, we have
focused substantially all of our resources on organizing and staffing our company, business planning, raising capital, establishing and maintaining our intellectual property portfolio, conducting research, preclinical studies, and clinical trials,
establishing arrangements with third parties for the manufacture of cretostimogene, and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product
sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have incurred significant operating losses and negative cash flows from operations since our inception. Our net
losses were $12.8&nbsp;million and $35.4&nbsp;million for the years ended December&nbsp;31, 2021 and 2022, respectively. As of December&nbsp;31, 2022, we had an accumulated deficit of $81.3&nbsp;million. Substantially all of our net losses have
resulted from costs incurred in connection with our research and development programs and, to a lesser extent, from general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating
losses in the foreseeable future, and we anticipate these losses will increase substantially as we as we continue our development of, seek regulatory approval for, and potentially commercialize cretostimogene and potentially seek to discover and
develop additional product candidates, utilize third parties to manufacture cretostimogene, hire additional personnel, expand and protect our intellectual property, and incur additional costs associated with being a public company. If we obtain
regulatory approval for cretostimogene, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing and distribution. Because of the numerous risks and uncertainties associated
with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we do not become profitable or are
unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To date, we have primarily funded our operations with proceeds from the sale of shares of our redeemable convertible preferred
stock and previously outstanding term debt. Through December&nbsp;31, 2022, we have received aggregate gross proceeds of approximately $202.9&nbsp;million from the sale of shares of our redeemable convertible preferred stock. In addition, through
December&nbsp;31, 2022, we have recognized $24.8&nbsp;million in research and collaboration revenue pursuant to our license and collaboration agreements. As of December&nbsp;31, 2022, we had cash, cash equivalents and marketable securities of
$143.5&nbsp;million. In July 2023, we received net proceeds of $104.6&nbsp;million from the sale of shares of our Series F redeemable convertible preferred stock. Our ability to generate any product revenue and, in particular, our ability to
generate product revenue sufficient to achieve profitability, will depend on the successful development and eventual commercialization of cretostimogene and any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our current operating plan, we estimate that our existing cash, cash equivalents and marketable securities as of the
date of this prospectus, together with the estimated net proceeds from this offering, will be sufficient to fund our projected operating expenses and capital expenditure requirements through at least &#8195;&#8195;&#8195;&#8195;. However, we have
based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. In addition, we could utilize our available capital resources sooner than we expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain
regulatory approval for cretostimogene or any future product candidates, which we expect will take a number of years and may never occur. As a result, we will need substantial additional funding in addition to the net proceeds from this offering to
support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through equity offerings, debt financings, or other capital
sources, including current or potential future collaborations, licenses, and other similar arrangements. However, we may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at
all. If we fail to raise capital or enter into such agreements or arrangements as, and when needed, we may delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product
candidates that we would otherwise prefer to develop and market ourselves, or even cease operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We do not own or
operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of cretostimogene for clinical testing, as well as for commercial manufacture if we obtain
marketing approval. In addition, we rely on third parties to package, label, store, and distribute cretostimogene, and we intend to rely on third parties for our commercial products if marketing approval is obtained. We believe that this strategy
allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development of
cretostimogene. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License and Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Below is a summary of the key terms for certain of our license and collaboration agreements. For a more detailed description of
these agreements, see the section titled &#147;Business&#151;License and Collaboration Agreements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lepu License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2019, we entered into a development and license agreement (the Lepu License Agreement) with Lepu, under which we
granted an exclusive license to Lepu to develop, manufacture and commercialize </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cretostimogene and/or DDM to treat and/or prevent cancer in the Lepu Territory. Lepu paid to us a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $4.5&nbsp;million, and Lepu
is obligated to make regulatory milestone payments of up to $2.5&nbsp;million and commercial milestone payments of up to $57.5&nbsp;million. We are entitled to receive a high single-digit royalty on net sales of cretostimogene and/or DDM sold in the
Lepu Territory, subject to a specified reduction. As of December&nbsp;31, 2021 and 2022, no revenue was recorded related to the Lepu License Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kissei License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, and as amended September 2022, we entered into a license and collaboration agreement (the Kissei License
Agreement) with Kissei, under which we granted to Kissei an exclusive license to certain intellectual property rights in Bangladesh, Bhutan, Brunei, Cambodia, India, Indonesia, Japan, South Korea, Laos, Malaysia, Myanmar, Nepal, Pakistan, Palau,
Philippines, Singapore, Sri Lanka, Taiwan, Thailand and Vietnam (the Kissei Territory), for Kissei to develop and commercialize, but not manufacture, cretostimogene in combination with DDM (the Licensed Product) for all uses in oncology. Kissei paid
to us a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of $10.0&nbsp;million under the agreement. Kissei is obligated to make development milestone payments of up to $33.0&nbsp;million and commercial milestone payments of up to
$67.0&nbsp;million. We have also agreed to pay Kissei a royalty on net sales of Licensed Product outside the Kissei Territory and outside the Lepu Territory, including on any U.S. sales, in a <FONT STYLE="white-space:nowrap">low-single</FONT> digit
percentage, subject to certain capped reductions. We are entitled to receive a royalty on net sales of Licensed Product in the Kissei Territory in the <FONT STYLE="white-space:nowrap">mid-twenties</FONT> percentage, subject to certain capped
reductions and offset rights. We are obligated to supply and Kissei will exclusively purchase its clinical and commercial requirements of Licensed Product from us. During the year ended December&nbsp;31, 2021, we recorded $10.0&nbsp;million in
milestone revenue and $0.4&nbsp;million in development income related to the Kissei License Agreement. During the year ended December&nbsp;31, 2022, we recorded $0.2&nbsp;million in development income related to the Kissei License Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Through December&nbsp;31, 2022, we have recognized $24.8&nbsp;million in research and collaboration revenue
through our license and collaboration agreements. We have not generated any revenue from the sale of products, however, and do not expect to generate any revenue from the sale of products in the foreseeable future, if at all. If our or our
collaborators&#146; development efforts for cretostimogene and any future product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales, payments from existing or potential future
collaboration or license agreements with third parties, or any combination thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our operating expenses consist of (i)&nbsp;research and development expenses and (ii)&nbsp;general and administrative expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development (R&amp;D) expenses consist primarily of external and internal costs incurred in performing clinical
and preclinical development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our R&amp;D expenses consist of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external costs incurred under agreements with CROs, contract manufacturers, consultants and other third
parties to conduct and support our clinical trials and preclinical studies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">internal costs, including R&amp;D personnel-related expenses such as salaries, stock-based compensation and
benefits, as well as allocated facilities costs and dues and subscriptions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expense R&amp;D costs as incurred.&nbsp;We currently only have one
product candidate, cretostimogene. Therefore, since our inception, substantially all of our R&amp;D costs were related to the development of cretostimogene.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although R&amp;D activities are central to our business model, the successful development of cretostimogene and any future
product candidates is highly uncertain. There are numerous factors associated with the successful development of any product candidate such as cretostimogene, including future trial design and various regulatory requirements, many of which cannot be
determined with accuracy at this time based on our stage of development. In addition, future regulatory factors beyond our control may impact our clinical development programs. Product candidates in later stages of clinical development generally
have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our R&amp;D expenses will increase substantially in
connection with our ongoing and planned clinical and preclinical development activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to
complete the preclinical and clinical development of cretostimogene and any future product candidates. Our future R&amp;D expenses may vary significantly based on a wide variety of factors such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope, rate of progress, expense and results of our clinical trials and preclinical studies of
cretostimogene and any future product candidates we may choose to pursue, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing cretostimogene and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, if any, of obtaining third-party drugs for use in our combination trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent of changes in government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of cretostimogene and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt, and terms of any approvals from applicable regulatory authorities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we establish additional collaboration, license, or other arrangements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A change in the outcome of any of these variables with respect to the development of cretostimogene or any future
product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses consist primarily of personnel-related expenses such as salaries, stock-based compensation
and benefits, for our personnel in executive, legal, finance and accounting, human resources </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and other administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters and professional fees paid for accounting, auditing,
consulting and tax services, as well as facilities-related costs not otherwise included in R&amp;D expenses and other costs such as insurance costs and travel expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate our general and administrative expenses will increase substantially in the future as we expand our operations,
including increasing our headcount to support our continued R&amp;D activities and preparing for potential commercialization of cretostimogene. We also anticipate we will incur increased accounting, audit, legal, regulatory, compliance, director and
officer insurance, and investor and public relations expenses associated with operating as a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other (Expense) Income, Net
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interest expense, net, consists of interest expense related to our previously outstanding term loan debt and interest income
related to interest earned on our invested cash and cash equivalents and marketable securities balances. We expect our interest income will increase as we invest the cash received from the net proceeds from this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other (Expense) Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other (expense) income consists of miscellaneous items, such as the amortization of debt related costs and other items not
related to our core operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2021 and 2022 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our results of operations for the years ended December&nbsp;31, 2021 and 2022 (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2021&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;Change&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8194;22,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8194;35,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8194;&#8196;&#8195;450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Collaboration Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and collaboration revenue was $10.4&nbsp;million for the year ended December&nbsp;31, 2021 compared to
$0.2&nbsp;million for the year ended December&nbsp;31, 2022. The decrease of $10.2&nbsp;million was due to a decrease in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
revenue generated through our license and collaboration agreements. During the year ended December&nbsp;31, 2021, we recorded $10.0&nbsp;million in milestone revenue and $0.4&nbsp;million in
development income related to the Kissei License Agreement. During the year ended December&nbsp;31, 2022, we recorded $0.2&nbsp;million in development income related to the Kissei License Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our R&amp;D expenses for the years ended December&nbsp;31, 2021 and 2022 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2021&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;Change&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External clinical trial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities-related fees and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">R&amp;D expenses were $18.3&nbsp;million for the year ended December&nbsp;31, 2021 compared to
$29.0&nbsp;million for the year ended December&nbsp;31, 2022. The increase of $10.7&nbsp;million in R&amp;D expenses for the year ended December&nbsp;31, 2022 was primarily due to an increase of $6.9&nbsp;million in clinical trial expenses related
to higher CRO fees as patient enrollment increased and higher CMC and consultant and other third party expenses, an increase of $3.4&nbsp;million in personnel-related expenses due to increased headcount for R&amp;D, and higher facilities-related,
fees and other related costs of $0.4&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table summarizes our general and administrative expenses for the years ended December&nbsp;31, 2021 and 2022 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2021&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;Change&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consultant fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities-related and other costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General and administrative expenses were $4.6&nbsp;million for the year ended
December&nbsp;31, 2021 compared to $6.4&nbsp;million for the year ended December&nbsp;31, 2022. The increase of $1.8&nbsp;million in general and administrative expenses for the year ended December&nbsp;31, 2022 was primarily due to an increase in
personnel-related expenses of $1.2&nbsp;million due to increased headcount, increased professional consulting fees related to legal fees, accounting and consulting fees of $0.4&nbsp;million and higher facilities-related, fees and dues and
subscriptions costs of $0.2&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other (Expense) Income, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other (expense) income, net, for the years ended December&nbsp;31, 2021 and 2022 was a net expense of $0.2&nbsp;million for
each year. For the year ended December&nbsp;31, 2021, interest expense, net of $0.4&nbsp;million, consisted primarily of interest expense and debt fee amortization. Other income (expense), net of $0.2&nbsp;million consisted of income related to the
loan forgiveness under the Paycheck Protection Program of $0.4&nbsp;million offset by success fee expense of $0.2&nbsp;million. For the year ended December&nbsp;31, 2022, interest expense, net and other (expense) income, net consisted of term loan
interest expense, the final payment accretion and related amortization of $1.8&nbsp;million, offset by interest income of $1.6&nbsp;million related to marketable securities balances during the year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and
negative cash flows from operations. We expect to incur significant expenses and operating losses in the foreseeable future as we advance the clinical development of cretostimogene and any future product candidates. To date, we have primarily funded
our operations with proceeds from the sale of shares of our redeemable convertible preferred stock, and previously outstanding term debt. Through December&nbsp;31, 2022, we have received aggregate gross proceeds of $202.9&nbsp;million from the sale
of shares of our redeemable convertible preferred stock. In addition, through December&nbsp;31, 2022, we have recognized $24.8&nbsp;million in research and collaboration revenue through our license and collaboration agreements. As of
December&nbsp;31, 2021 and 2022, we had cash, cash equivalents and marketable securities of $53.6&nbsp;million and $143.5&nbsp;million, respectively. In July 2023, we received net proceeds of $104.6&nbsp;million from the sale of shares of our Series
F redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January&nbsp;2021, we entered into a loan agreement with Silicon Valley Bank
for a term loan in three tranches. As of December&nbsp;31, 2022, we had drawn down $15.0&nbsp;million in aggregate principal amount under the loan agreement. On May&nbsp;12, 2023, we repaid all outstanding principal and accrued and unpaid interest
under the loan agreement. See Notes 11 and 14 to our financial statements included elsewhere in this prospectus for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future
Funding Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect our expenses to increase substantially in connection with our ongoing activities,
particularly as we continue our development of, seek regulatory approval for, and potentially commercialize cretostimogene and potentially seek to discover and develop additional product candidates, conduct our ongoing and planned clinical trials
and preclinical studies, continue our R&amp;D activities, utilize third parties to manufacture cretostimogene, hire additional personnel, expand and protect our intellectual property, and incur additional costs associated with being a public
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in
the change in our outstanding accounts payable, accrued expenses, and prepaid expenses. The timing and amount of our funding requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, type, number, scope, progress, expansions, results, costs and timing of clinical trials and
preclinical studies of cretostimogene and any future product candidates we may choose to pursue, including the costs of modification to clinical development plans based on feedback that we may receive from regulatory authorities and any third-party
products used as combination agents in our clinical trials </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory meetings and reviews of cretostimogene or any future product
candidates, including requirements of regulatory authorities in any additional jurisdictions in which we may seek approval for cretostimogene and any future product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of obtaining, maintaining, enforcing and protecting our patents and other intellectual property and
proprietary rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a
public company, including enhanced internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with hiring additional personnel and consultants as our business grows, including
additional executive officers and clinical development, regulatory, CMC quality and commercial personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and payment of milestone, royalty or other payments we must make pursuant to our existing and
potential future license or collaboration agreements with third parties; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of establishing or securing sales and marketing capabilities if cretostimogene or any
future product candidate is approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve sufficient market acceptance, coverage, and adequate reimbursement from third-party
payors and adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and strategic decision to develop future product candidates other than cretostimogene, and the
timing of such development, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients&#146; willingness to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with any products or technologies that we may
<FONT STYLE="white-space:nowrap">in-license</FONT> or acquire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based upon our current operating plan,
we estimate that our existing cash, cash equivalents and marketable securities as of the date of this prospectus, together with the estimated net proceeds from this offering, will be sufficient to fund our projected operating expenses and capital
expenditure requirements through at least &#8195;&#8195;&#8195;&#8195;. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. In
addition, we could utilize our available capital resources sooner than we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have no other committed sources of
capital. Until such time, if ever, we can generate substantial product revenue, we expect to finance our operations through equity offerings, debt financings, or other capital sources, including current or potential future collaborations, licenses,
and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent we raise additional capital through the sale of equity or convertible
debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or
licensing our assets, making capital expenditures, redeeming our stock, making certain investments or declaring dividends. If we raise additional funds through collaborations or license agreements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, or
even cease operations.<B><I> </I></B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Material Cash Requirements for Known Contractual and Other Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Leases </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
have entered into various <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases for our corporate office. The leases have varying terms expiring between 2023 and 2025. See Note 5 to our financial statements included elsewhere in
this prospectus for additional details. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Costs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are continuing to invest in our cretostimogene clinical trials and have entered into contractual obligations with each
clinical trial site. Each contract shall continue until the completion of the trial at that site. Our clinical trial costs are dependent on, among other things, the size, number and length of our clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Capital Requirements and Additional Royalty Obligations. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We enter into agreements in the normal course of business with various vendors, which are generally cancellable upon notice.
Payments due upon cancellation typically consist only of payments for services provided or expenses incurred, including <FONT STYLE="white-space:nowrap">non-cancellable</FONT> obligations of service providers, up to the date of cancellation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to our obligation to make potential royalty payments under the Kissei License Agreement discussed above, we are
also obligated to pay royalties and milestone payments to the initial supplier of a certain cell line we use to manufacture cretostimogene, in an amount less than 1% on the net sales of cretostimogene, worldwide. These royalty obligations last for
as long as we use the certain cell line to manufacture cretostimogene. The timing of when our royalty payments will actually be made is uncertain as the payments are contingent upon future activities, including the successful development, regulatory
approval and commercialization of cretostimogene. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides information regarding our cash flows for the years ended December&nbsp;31, 2021 and 2022 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2021&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2021, operating activities used $13.7&nbsp;million of cash, primarily resulting from
our net loss of $12.8&nbsp;million and net cash provided by changes in our operating assets and liabilities of $2.0&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.1&nbsp;million, including
stock-based compensation expense and amortization associated with the term loan final fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended
December&nbsp;31, 2022, operating activities used $29.8&nbsp;million of cash, primarily resulting from our net loss of $35.4&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.2&nbsp;million, including
stock-based compensation expense and amortization associated with the term loan final fees and mark to market success fee and net cash used in changes in our operating assets and liabilities of $4.4&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2021, net cash used in investing activities was $0.1&nbsp;million, due to purchases of
property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2022, net cash used in investing activities was
$55.4&nbsp;million, primarily due to purchases of marketable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2021, net cash provided by financing activities was $15.4&nbsp;million, consisting
primarily of net proceeds from term loan debt, proceeds from the PPP loan and proceeds from the exercise of common stock options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2022, net cash used in financing
activities was $119.7&nbsp;million, consisting of net proceeds from the issuance of Series E redeemable convertible preferred stock and proceeds from the exercise of common stock options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our financial statements are prepared in accordance with generally accepted accounting principles in the United States. The
preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our
financial statements. We base our estimates on historical experience, known trends and events, and various other factors we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While our significant accounting policies are described in more detail in Note 2 to our financial statements included
elsewhere in this prospectus, we believe the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>R&amp;D Expenses and Related Prepaid and Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As part of the process of preparing our financial statements, we are required to estimate our R&amp;D expenses as of each
balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated
cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our R&amp;D expenses as of each balance sheet date based on facts and circumstances known to us at that time. The
significant estimates in our R&amp;D expenses include the costs incurred for services performed by our vendors in connection with services for which we have not yet been invoiced. We base our expenses related to R&amp;D activities on our estimates
of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct R&amp;D on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in
uneven payment flows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There may be instances in which payments made to our vendors will exceed the level of services
provided and result in a prepayment of the R&amp;D expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of
services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future R&amp;D activities are expensed when the activity has been performed
or when the goods have been received rather than when the payment is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Although we do not expect our estimates to be
materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low
in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We periodically grant equity-based payment awards in the form of stock options to employees, directors and <FONT
STYLE="white-space:nowrap">non-employees</FONT> and record stock-based compensation expenses for awards of stock-based payments based on their estimated fair value at the grant date. We recognize stock-based compensation expense for all equity-based
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
payments, including stock options. Stock-based compensation costs are calculated based on the estimated fair value of the underlying option using the Black-Scholes option pricing model on the
date of grant for stock options and recognized as expense in the accompanying statement of operations and comprehensive loss on a straight-line basis over the requisite service period, which is the vesting period. This model requires the use of
highly subjective assumptions to determine the appropriate fair value of each equity-based payment award, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Common Stock</I>. See the subsection titled &#147;&#151;Determination of Fair Value of Our
Common Stock&#148; below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Volatility</I>. Since we are not yet a public company and do not have any trading history for our
common stock,&nbsp;the expected volatility was estimated based on the historical volatilities of common stock of comparable publicly traded companies, for a look-back period commensurate with the expected term of the stock options. The comparable
companies were chosen based on their size, stage of their life cycle or area of specialty. We will continue to apply this process until enough historical information regarding the volatility of our stock price becomes available.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-Free Interest Rate</I>. The risk-free interest rate used is based on the published U.S. Department of
Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant&#146;s expected term. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Dividend Yield</I>. The expected dividend yield is zero as we have not paid dividends and do not
anticipate paying a cash dividend in the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term</I>. The expected term for options granted is calculated using the simplified method and
represents the average time that options are expected to be outstanding based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term of the award. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">See Note&nbsp;9 to our financial statements included elsewhere in this prospectus for information concerning certain of the
specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted in the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We recognize forfeitures related to stock-based compensation awards as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We classify stock-based compensation expense in the statement of operations in the same manner in which the award
recipients&#146; payroll costs are classified or in which the award recipients&#146; service payments are classified. We expect to continue to grant equity-based awards in the future, and to the extent that we do, our stock-based compensation
expense recognized in future periods will likely increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of &#8195;&#8195;&#8195;&#8195;, 2023, there was
$&#8195;&#8195;&#8195; million of total unrecognized stock-based compensation expense related to our granted options, which we expect to recognize over a remaining weighted-average period of &#8195;&#8195;&#8195;&#8195; years.&nbsp;The intrinsic
value of all outstanding options as of &#8195;&#8195;&#8195;&#8195;, 2023 was $&#8195;&#8195;&#8195; million based on the assumed initial public offering price of $&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth
on the cover of this prospectus, of which approximately $&#8195;&#8195;&#8195; was related to vested options and approximately $&#8195;&#8195;&#8195; was related to unvested options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Determination of Fair Value of Our Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the absence of a public trading market to date, the fair value of our common stock has been determined by our board of
directors at the time of each option grant, with input from management, considering contemporaneous independent third-party valuations of common stock, and our board of directors&#146; assessment of additional objective and subjective factors that
it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant, including: the prices at which we sold shares of our redeemable convertible preferred stock to outside investors in
arms-length transactions, and the superior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
rights, preferences, and privileges of the redeemable convertible preferred stock relative to the common stock at the time of each grant; the progress of our company&#146;s R&amp;D programs,
including their stages of development, and our company&#146;s business strategy; operating and financial performance; the lack of liquidity of the common stock and trends in the broader economy and biotechnology industry also impact the
determination of the fair value of the common stock; the likelihood of achieving a liquidity event for our company&#146;s securityholders, such as an initial public offering or a sale of the company, taking into consideration prevailing market
conditions; the hiring of key personnel and the experience of management; and the analysis of initial public offerings and the market performance of peer companies in the biopharmaceutical industry, as well as completed mergers and acquisitions of
public peer companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These independent third-party valuations were performed in accordance with the guidance outlined
in the American Institute of Certified Public Accountants&#146; Auditing and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I> (the Guide). The methodology to determine the fair value of our common
stock included estimating the fair value of the enterprise using a market approach, which estimates the fair value of a company by including an estimation of the value of the business based on guideline public companies under a number of different
scenarios. The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the Guide, we considered the following methods: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Current Value Method</I>. Under the current value method, once the fair value of the enterprise is
established, the value is allocated to the various series of preferred and common stock based on their respective seniority, liquidation preferences or conversion values, whichever is greatest. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Option Pricing Method (OPM)</I>. Under the OPM, shares are valued by creating a series of call options with
exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the redeemable convertible preferred stock and common stock are inferred by analyzing these options. This method is
appropriate to use when the range of possible future outcomes is so difficult to predict that estimates would be highly speculative, and dissolution or liquidation is not imminent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Probability-Weighted Expected Return Method (PWERM)</I>. The PWERM is a scenario-based analysis that
estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on our early stage of development, the difficulty in predicting the range of specific outcomes
(and their likelihood), and other relevant factors, a hybrid method computing the probability-weighted value across two scenarios: the Current Value Method scenario and the OPM scenario, was considered most appropriate for valuations prior to April
2023. For options granted after April&nbsp;30, 2023, a hybrid method between the PWERM and OPM was used, where the equity value was probability-weighted across multiple scenarios but using the OPM to estimate the allocation of value within one or
more of those scenarios, and in certain cases taking into account secondary sale transactions. This method was determined to be the most appropriate valuation methodology based on our stage of development and other relevant factors. In determining
the estimated fair value of our common stock, our board of directors also considered the fact that our stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability
of our common stock based on the weighted-average expected time to liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are significant judgments and
estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions regarding our future operating performance, the time to complete an initial public offering or other liquidity event,
and the determination of the appropriate valuation methods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once a public trading market for our common stock has been established in
connection with the completion of this offering, it will no longer be necessary for our board of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options or for any other such awards we may
grant, as the fair value of our common stock will be determined based on the closing price of our common stock as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We did not have, during the periods presented, and we do not currently have, any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting
Standards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A description of recently issued accounting standards that may potentially impact our financial position,
cash flows, and results of operations is included in Note 2 to our financial statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company
Status and Smaller Reporting Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are an emerging growth company, as defined in the JOBS Act. The JOBS
Act permits an emerging growth company such as us to take advantage of an extended transition period to comply with new or revised accounting standards. We have elected to avail ourselves of such extended transition period, which means that when a
standard is issued or revised and it has different application dates for public or private companies, we can adopt the new or revised standard at the time private companies adopt the new or revised standard and may do so until such time that we
either (i)&nbsp;irrevocably elect to opt out of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company. We may choose to early adopt any new or revised accounting standards whenever such early adoption is
permitted for private companies. We will continue to remain an emerging growth company until the earliest of the following: (1)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of the completion of this offering;
(2)&nbsp;the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.235&nbsp;billion; (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in nonconvertible debt during the previous three
years; or (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are
also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to
smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risks </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our cash, cash equivalents, and marketable securities consist of cash held in readily available checking and money market
accounts, as well as short-term debt securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments
in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under our investment policy, we invest in highly rated securities, issued by the U.S. government or liquid money market funds.
We do not invest in financial instruments for trading or speculative purposes, nor do we use </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
leveraged financial instruments. We do not believe a hypothetical 10% increase or decrease in interest rates during any of the periods presented would have had a material impact on our financial
statements included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Exchange Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates. As we continue
to develop our business, our results of operations and cash flows will likely be more affected by fluctuations in foreign currency exchange rates, including the Euro and other currencies, which could adversely affect our results of operations. All
of our employees and operations are currently located in the United States and our expenses are generally denominated in U.S. dollar. To date, we have not entered into any foreign currency hedging contracts to mitigate our exposure to foreign
currency exchange risk. We do not believe that a hypothetical 10% increase or decrease in exchange rates during any of the periods presented would have had a material impact on our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Effects of Inflation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Inflation could affect us by increasing our cost of labor and R&amp;D costs. We do not believe inflation has had a material
effect on our business, financial condition or results of operations, or on our financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are a
late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Our product candidate, cretostimogene, is initially in clinical
development for the treatment of patients with high-risk <FONT STYLE="white-space:nowrap">Non-Muscle</FONT> Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for high-risk NMIBC. There is significant unmet need for treatments in these patients given the limitations of currently approved therapies and patient reluctance to undergo radical
cystectomy, or the complete removal of the bladder. We are evaluating the safety and efficacy of cretostimogene as monotherapy in <FONT STYLE="white-space:nowrap">BOND-003,</FONT> our ongoing Phase 3 clinical trial in high-risk <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients. We have completed enrollment for this trial and expect to report topline data by&#8195;&#8195;&#8195;&#8195;&#8195;. If successful, we believe that this trial could serve as the
basis for a Biologics License Application (BLA) submission to the U.S.&nbsp;Food and Drug Administration (FDA). We are also evaluating the use of cretostimogene when administered to this same patient population in combination with <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> pembrolizumab in <FONT STYLE="white-space:nowrap">CORE-001,</FONT> our ongoing Phase 2 clinical trial. Moreover, we intend to assess the safety and efficacy of cretostimogene in treating a range of
other bladder cancer indications as an alternative to BCG therapy and in patients who are not categorized as <FONT STYLE="white-space:nowrap">BCG-unresponsive,</FONT> including our second Phase 3 clinical trial,
<FONT STYLE="white-space:nowrap">PIVOT-006,</FONT> evaluating adjuvant cretostimogene in intermediate-risk NMIBC patients following transurethral resection of the bladder tumor (TURBT). We believe cretostimogene, if approved, has the potential to
serve as first-line therapy, thereby alleviating the current need to prioritize treatment recipients and ration administration of BCG given its significant market shortage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cretostimogene has shown clinical benefit and has been generally well-tolerated as both a monotherapy and in combination with
other therapies in clinical trials to date. In <FONT STYLE="white-space:nowrap">BOND-002,</FONT> our completed open-label Phase 2 clinical trial which evaluated the use of cretostimogene as monotherapy to treat patients with high-risk NMIBC who had
failed BCG therapy with a specific high-risk bladder cancer profile designated as carcinoma <I>in situ</I> (CIS), 65% of the 46 patients with <FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC achieved a complete response (CR), meaning no
detectable tumor lesions, at any time after the administration of cretostimogene. The duration of response (DOR) was also notable, with 44% and 28% of patients maintaining a CR at six months and 12 months, respectively. Cretostimogene was generally
well-tolerated in this trial, with two Grade 3 (dysuria and hypotension) and no Grade 4 or 5 treatment-related adverse effects (TRAEs) observed or patient discontinuations due to TRAEs. We have also observed encouraging interim results in our
ongoing open-label Phase 2 <FONT STYLE="white-space:nowrap">CORE-001</FONT> clinical trial of cretostimogene in combination with pembrolizumab in high-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients. In this trial, 29 of
the 34 (85%) patients evaluable as of the March&nbsp;3, 2023 data cutoff achieved a CR after an initial induction course of therapy, with 82% (n=27/33) of patients maintaining a CR at six months, and 68% (n=17/25) of patients maintaining a CR at 12
months. Cretostimogene was generally well-tolerated in this trial as of the January 31, 2023 safety data cutoff, with one TRAE leading to a patient discontinuation of pembrolizumab. We intend to evaluate cretostimogene for use in a variety of
bladder cancer treatment settings, as shown in our pipeline below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Our Cretostimogene Pipeline </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g89m10.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Planned clinical trials to be conducted under existing Investigational New Drug application (IND) previously
cleared by the FDA. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strengths </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe our product candidate is differentiated by several strengths that support our vision of cretostimogene as a
potential backbone therapy in bladder cancer, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Demonstrated monotherapy clinical utility and durability of response, with a 65% CR at any time, in addition
to 44% and 28% CR at six months and 12 months, respectively, in our completed Phase 2 <FONT STYLE="white-space:nowrap">BOND-002</FONT> cretostimogene monotherapy trial. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Observed tolerability, with two Grade 3 TRAEs and no Grade 4 or 5 TRAEs or patient discontinuations due to
TRAEs in our completed <FONT STYLE="white-space:nowrap">BOND-002</FONT> cretostimogene monotherapy trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cretostimogene is administered intravesically and uses a similar route of administration as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> BCG therapy which urology practices perform regularly. This is unlike some treatment procedures that require a urologist to perform a cystoscopic examination
that involves local anesthesia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The potential for deploying cretostimogene in combination with other therapies due to its observed
tolerability and novel mechanism of action, supported by 85% of patients having shown a CR at any time in our ongoing Phase 2 <FONT STYLE="white-space:nowrap">CORE-001</FONT> clinical trial of cretostimogene in combination with the checkpoint
inhibitor (CPI) pembrolizumab as of March&nbsp;3, 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Cretostimogene&#146;s potential broad applicability across bladder cancer indications, beginning with
high-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC, and expanding into intermediate-risk and BCG-exposed and BCG-na&iuml;ve high-risk NMIBC, with potential incremental opportunity in muscle invasive bladder cancer (MIBC).
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bladder Cancer Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Bladder cancer is a heterogeneous disease and involves several different cancer
<FONT STYLE="white-space:nowrap">sub-types,</FONT> which can be segmented into NMIBC or MIBC. The American Cancer Society estimates that in 2023, more than 82,000 people will be diagnosed with bladder cancer and that the disease will result in
nearly 17,000 deaths. An estimated 725,000 people in the United States are currently living with the disease. NMIBC, which accounts for approximately 75% of newly diagnosed patients, describes earlier-stage bladder cancer that has not spread to the
muscle wall. NMIBC can be further stratified by its specific risk profile, with high-risk NMIBC patients, who make up approximately 40% of the NMIBC patient population, at an elevated probability of disease progression to more aggressive MIBC within
five years of initial diagnosis. Patients with intermediate-risk disease account for approximately 30% of total NMIBC diagnoses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Current treatment for high-risk NMIBC typically involves TURBT followed by the intravesical (IVE) delivery of BCG therapy to
induce a <FONT STYLE="white-space:nowrap">non-specific</FONT> anti-tumor immune response. This treatment protocol has demonstrated therapeutic benefit with nearly 70% of patients achieving a CR following an initial induction course of therapy.
However, approximately 50% of these patients will experience a recurrence of the tumor and few treatment options are available for patients who become unresponsive to BCG treatment. While radical cystectomy is the current <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care,</FONT></FONT> only approximately 6% of NMIBC patients elect to undergo the procedure in light of the significant social, functional and emotional burden associated with
it. Further complicating the treatment options available to NMIBC patients is the ongoing shortage of BCG which has restricted patient eligibility to high-risk <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> patients only. Even among these
patients a significant number of newly-diagnosed, <FONT STYLE="white-space:nowrap">BCG-eligible,</FONT> <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> patients in the United States may not receive sufficient BCG therapy, if at all.
Moreover, patients with intermediate-risk NMIBC may not have access to BCG due to the shortage, despite the likely therapeutic benefit of earlier adjuvant BCG therapy, because high-risk patients are prioritized in line with guidance published by the
National Comprehensive Care Network (NCCN) and guidance published jointly by the American Urological Association (AUA) and the Society of Urologic Oncology (SUO). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Instances of refractory and recurrence disease, patient aversion to cystectomy and the ongoing BCG supply constraints, have
created a sizeable unmet medical need for alternative NMIBC therapeutics that are both safe and efficacious. Beyond our ongoing clinical trials in NMIBC, we also intend to initiate <FONT STYLE="white-space:nowrap">CORE-008,</FONT> an open-label
multi-cohort Phase 2 clinical trial designed to assess the safety and efficacy of cretostimogene when administered as monotherapy and in combination with a CPI in high-risk NMIBC patients including <FONT STYLE="white-space:nowrap">BCG-exposed</FONT>
and BCG-na&iuml;ve NMIBC patients. <FONT STYLE="white-space:nowrap">BCG-exposed</FONT> patients are classified as those NMIBC patients with persistent, recurrent or progressive disease after BCG treatment but who do not meet the specific disease
classification criteria requisite to be designated as <FONT STYLE="white-space:nowrap">BCG-unresponsive.</FONT> BCG-na&iuml;ve patients are classified as those NMIBC patients who have not received any prior BCG therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to NMIBC, we are also evaluating cretostimogene as a potential therapeutic to treat patients with MIBC. MIBC is a
more aggressive form of bladder cancer than NMIBC and is associated with significantly higher mortality. In <FONT STYLE="white-space:nowrap">CORE-002,</FONT> an ongoing <FONT STYLE="white-space:nowrap">single-arm</FONT> exploratory
investigator-sponsored clinical trial, cretostimogene is being evaluated in combination with the CPI nivolumab in MIBC patients ineligible for cisplatin chemotherapy prior to radical cystectomy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team and Investors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our management team includes industry executives with extensive biopharmaceutical experience. Arthur Kuan, our Chief Executive
Officer, was a founding member of the Ally Bridge Group, a global healthcare-focused investment platform. Previously, Arthur was a member of Themes Investment Partners, a healthcare and life sciences-focused private equity fund. Our President and
Chief Operating Officer, Ambaw Bellete, has over 30 years of industry experience, including serving as Chief Operating Officer for FerGene, the Ferring Pharmaceuticals subsidiary responsible for the development and commercialization of its bladder
cancer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
treatment, nadofaragene. Ambaw was also the President of Photocure, a company focused on the diagnosis and treatment of bladder cancer and has also held several global leadership positions with
biotech and medical device companies. Our Chief Medical Officer, Vijay Kasturi, M.D., previously served as Vice President, Clinical Development and Medical Affairs with AVEO Pharmaceuticals and SVP of Scientific Affairs at FerGene where he led
Medical Affairs, Clinical Operations, Regulatory and Clinical Development in connection with the nadofaragene program. Earlier, he led U.S.&nbsp;Medical Affairs, Oncology for EMD Serono, where he had broad leadership responsibilities including
developing and managing the global medical strategy and launch plan for an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> agent in bladder and kidney cancers. Our Chief Technical Officer, Swapnil Bhargava,
Ph.D., has supported multiple INDs and BLAs and has contributed to bringing multiple modalities to the clinic and market. He was previously a Senior Vice President of CMC Development and GMP Manufacturing for Abcellera, leading Tech Ops. Prior to
that, he was the VP for Drug Substance Process Development at Seagen, where he was responsible for leading cell line development, upstream, downstream and conjugation process development and analytical sciences departments for early and late-stage
drug development. We believe the breadth and depth of experience amongst our management team will enable us to bolster the cretostimogene development strategy and, if approved, its commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the strength and experience of our leadership team, we believe we have a world class Chemistry, Manufacturing
and Control (CMC) Advisory Board. The advisory board is chaired by Rick Rutter, Ph.D., who was previously the Executive Vice President of Biotherapeutics Pharmaceutical Sciences at Pfizer, responsible for Drug Substance and Drug Product Development
for all macromolecules and vaccines in the Pfizer portfolio. Dan Takefman, Ph.D. was formerly the chief of the Gene Therapy Branch at the FDA. Dr.&nbsp;Takefman also headed regulatory activities at Spark Therapeutics from 2014 until its acquisition
by Roche and oversaw the submission through regulatory approval of Luxturna (voretigene neparvovec). Richard Peluso, Ph.D. was the former Vice President of Biologics, Vaccines and Bioprocess R&amp;D at Merck&nbsp;&amp; Co (Merck), responsible for
research and development for biologics and vaccines across the Merck portfolio. Victoria Sluzky, Ph.D., was the Senior Vice President of Technical Development at BioMarin, leading Global Quality and Process Sciences and facilitating implementation
of global regulatory CMC strategy. We believe our CMC Advisory Board provides differentiated expertise in production and potential commercialization of cretostimogene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are backed by a strong set of healthcare-specific investors, including our 5% or greater stockholders, ORI Capital, Decheng
Capital, Longitude Capital, Kissei Pharmaceutical Co., Foresite Capital Management and TCGX. Prospective investors should not rely on the investment decisions of our existing investors, as these investors may have different risk tolerances and
strategies and have purchased their shares in prior offerings at prices lower than the price offered to the public in this offering. In addition, some of these investors may not be subject to reporting requirements under Section&nbsp;16 of the
Securities Exchange Act of 1934 (the Exchange Act), and, thus, prospective investors may not necessarily know the total amount of investment by each of the prior investors and if and when some of the prior investors decide to sell any of their
shares. See the sections titled &#147;Certain Relationships and Related Person Transactions&#148; and &#147;Principal Stockholders&#148; for more information on prior purchases by and current holdings of these stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend
to become a leading company in the development and commercialization of innovative therapeutics to treat cancer, with an initial focus on bladder cancer. Key elements of our strategy to accomplish this objective include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Complete the ongoing BOND-003 Phase 3 trial of cretostimogene as monotherapy in high-risk <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC and pursue FDA approval</B><B><I>.</I></B><I> </I>We are evaluating the safety and efficacy of cretostimogene in <FONT STYLE="white-space:nowrap">BOND-003,</FONT> our ongoing Phase 3 clinical
trial. We have completed enrollment for this trial and expect to report topline data in &#8195;&#8195;&#8195;&#8195;. Given the significant unmet need in this indication, the FDA published guidance in 2018 that stated a <FONT
STYLE="white-space:nowrap">single-arm</FONT> clinical trial in patients with <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC that assess CR rate as the primary endpoint, taking DOR into account, may be appropriate for full approval.
Based on this guidance, we believe that, if successful, our <FONT STYLE="white-space:nowrap">BOND-003</FONT> trial could serve as the basis for a BLA submission to the FDA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand the development of cretostimogene monotherapy as a potential backbone therapy across NMIBC
indications</B><I>. </I>In addition to evaluating cretostimogene in patients with high-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC, and in light of the significant and ongoing global shortage of BCG, we intend to evaluate the
safety and efficacy of cretostimogene as an alternative to BCG therapy in additional bladder cancer indications, including: (1)&nbsp;patients diagnosed with intermediate-risk NMIBC, who would likely benefit from earlier therapeutic intervention but
are currently lacking access to BCG therapy, in our <FONT STYLE="white-space:nowrap">PIVOT-006</FONT> Phase 3 clinical trial; and (2)&nbsp;patients with high-risk <FONT STYLE="white-space:nowrap">BCG-exposed</FONT> and BCG-na&iuml;ve NMIBC in the
monotherapy portion of our planned <FONT STYLE="white-space:nowrap">CORE-008</FONT> open-label multi-cohort Phase 2 clinical trial. Through expanding the clinical evaluation of cretostimogene across NMIBC indications, we will attempt to address the
significant unmet need in treatment of bladder cancer, with over 82,000 new U.S. diagnoses per year and over 725,000 patients living with bladder cancer in the United States, according to the American Cancer Society. We believe cretostimogene, if
approved, has the potential to serve as first-line therapy, thereby alleviating the current need to prioritize treatment recipients and ration administration of BCG given its significant market shortage. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to evaluate cretostimogene in combination with other therapies, such as CPIs, to potentially
further enhance its clinical utility across various stages of bladder cancer</B><B><I>.</I></B><I> </I>As of September&nbsp;30, 2023, cretostimogene had been administered in over 270 patients with a broad range of NMIBC risk profiles across multiple
clinical trials and has been generally well tolerated with no Grade 4 or 5 TRAEs observed and one TRAE resulting in a patient discontinuation of pembrolizumab in the <FONT STYLE="white-space:nowrap">CORE-001</FONT> trial. Based on observed
tolerability data to date, we plan to evaluate the safety and efficacy of cretostimogene in combination with other therapies in addition to our monotherapy trials. These include our ongoing Phase 2 <FONT STYLE="white-space:nowrap">CORE-001</FONT>
trial in combination with pembrolizumab for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC, the combination portion of our planned <FONT STYLE="white-space:nowrap">CORE-008</FONT> multi-cohort trial in combination with a CPI in <FONT
STYLE="white-space:nowrap">BCG-exposed</FONT> and BCG-na&iuml;ve NMIBC, and <FONT STYLE="white-space:nowrap">CORE-002,</FONT> an ongoing exploratory investigator-sponsored single arm clinical trial in combination with nivolumab in MIBC. We believe
our approach to combine cretostimogene with other therapeutics across several bladder cancer indications may potentially enhance the potential utility of our product candidate beyond our core strategy of targeting intermediate- and high-risk NMIBC
via cretostimogene monotherapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Build our operational capabilities to successfully commercialize cretostimogene</B><I>. </I>If we obtain
FDA regulatory approval for cretostimogene, we intend to build <FONT STYLE="white-space:nowrap">in-house</FONT> sales and marketing capabilities to commercialize cretostimogene in the United States. While the number of patients suffering from
bladder cancer is large and growing, a high volume of patients is concentrated in a small number of high value targets and a significant portion of large urology practices including academic urology practices that are concentrated in a relatively
small number of major metropolitan areas. We believe this concentration will potentially enable us to efficiently reach a large portion of our addressable market with a relatively small commercial footprint. Importantly, urology practices are
already deeply familiar with IVE delivery of BCG in NMIBC patients. Cretostimogene is similarly administered via IVE in the clinic setting by a nurse or medical assistant, and therefore does not require urologists nor anesthesia. We believe this
could drive increased physician adoption and improve patient experience versus alternative treatments that require urology practices to learn an entirely new and unfamiliar procedure or to transfer them to a medical oncologist for treatment and <FONT
STYLE="white-space:nowrap">follow-up.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage our CMC expertise and relationships to scale commercialization efforts</B><I>.</I> We have
established <FONT STYLE="white-space:nowrap">in-house</FONT> CMC expertise made up of individuals with oncolytic immunotherapy manufacturing experience, enhanced by an advisory board to help oversee our overall CMC strategic focus, while leveraging
third parties for product manufacturing. We believe this approach will drive a high-yield manufacturing process capable of rapidly scaling to meet demand should cretostimogene receive FDA approval. We have established a world class CMC Advisory
Board providing differentiated expertise in production and potential commercialization of cretostimogene. Our CMC Advisory Board represents former senior leadership from large pharmaceutical companies with deep experience in manufacturing at scale,
as well as former FDA leadership. We believe our strategic CMC </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
approach will potentially enable us to maintain an attractive cost of goods while rapidly achieving commercial scalability, if cretostimogene receives FDA approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bladder Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The human
bladder, which functions in the storage and elimination of urine, is a hollow muscular organ composed of multiple tissue layers. As shown below, the inner wall of the bladder is the urothelium, or transitional epithelium. The interior space where
urine collects is known as the bladder lumen. The internal side of the urothelium is lined by a glycosaminoglycan (GAG) membrane, which acts as a protective barrier from urine as well as infectious agents. Between the thick, detrusor muscular
portion of the bladder wall and the urothelium is the lamina propria, which consists of connective tissue, blood vessels and nerves. A fatty connective tissue layer makes up the organ&#146;s exterior surface, facing the rest of the body. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The Anatomy of the Bladder Wall </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g59q43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The American Cancer Society estimates that in 2023, more than 82,000 people will be
diagnosed with bladder cancer in the United States and that it will result in nearly 17,000 deaths. Notable is the disease prevalence with an estimated 725,000 people in the United States living with the disease. The relatively high prevalence rate
is driven in part by chances of recurrence, which can be very high for NMIBC. It is estimated that approximately 31% to 78% of people with NMIBC will develop recurrence or a secondary bladder cancer within five years following treatment, depending
on risk-factors. Bladder cancer is the sixth most common form of cancer in the United States, and men account for three-quarters of newly diagnosed cases. The global bladder cancer treatment market has been forecast to be approximately
$9.9&nbsp;billion by 2028, according to Evaluate Pharma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Bladder cancer is a heterogeneous disease and involves a number
of different cancer <FONT STYLE="white-space:nowrap">sub-types.</FONT> In the United States, the vast majority of patients with bladder cancer, accounting for approximately 90% of all diagnoses, have urothelial carcinoma (UC). UC is further
segmented into two subtypes, papillary and <FONT STYLE="white-space:nowrap">non-papillary.</FONT> Papillary UC involves tumors configured as finger-like projections extending from the transitional epithelium into the bladder lumen. <FONT
STYLE="white-space:nowrap">Non-papillary,</FONT> or flat, UC, which contains CIS, is restricted to the transitional epithelium, and is generally difficult to treat via resection. The 5% of bladder cancer that is not UC includes squamous cell
carcinomas and adenocarcinomas. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NMIBC is often used to describe earlier stage disease that has not reached
the muscle wall. NMIBC accounts for approximately 75% of newly diagnosed patients, and includes three stages: <FONT STYLE="white-space:nowrap">CIS-containing</FONT> tumors, Ta and T1. Ta and T1 are papillary UCs which have not spread beyond the
lamina propria. T2 through T4 stage make up MIBC, indicative of more aggressive locally advanced and metastatic disease. Bladder cancer has metastasized in an estimated 5% of patients with newly diagnosed disease. The graphic presented below
illustrates the differences in disease progression represented by these stages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Bladder Cancer is Classified as either NMIBC or MIBC.
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g12m13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NMIBC may be further differentiated by the risk of progression to MIBC. NMIBC patients with
high-grade Ta or T1 stage cancer, any cancer containing CIS (which can occur in any grade of NMIBC or MIBC), and large volume or recurrent Ta stage tumors are considered to be high-risk tumors. Approximately 40% of patients with NMIBC have high-risk
disease. Intermediate-risk NMIBC includes mostly <FONT STYLE="white-space:nowrap">low-grade</FONT> Ta tumors that reoccur within 12 months, solitary <FONT STYLE="white-space:nowrap">low-grade</FONT> Ta tumors greater than three centimeters,
multifocal <FONT STYLE="white-space:nowrap">low-grade</FONT> Ta tumors, or high-grade Ta tumors less than or equal to three centimeters. Intermediate-risk NMIBC accounts for an estimated 30% of patients with NMIBC.
<FONT STYLE="white-space:nowrap">Low-risk</FONT> NMIBC consists of <FONT STYLE="white-space:nowrap">low-grade</FONT> solitary Ta stage tumors and makes up the remaining 30% of NMIBC cases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Treatment for NMIBC and its Limitations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regardless of risk stratification, treatment of NMIBC generally involves TURBT, a surgical procedure enabling the visual
inspection and biopsy of the lesion along with removal of the cancerous cells allowing a patient with NMIBC to retain normal bladder function. Use of TURBT alone is associated with a five-year estimated recurrence rate of approximately 44% to 63%,
and remains a backbone of early NMIBC treatment regimen. <FONT STYLE="white-space:nowrap">CIS-containing</FONT> tumors cannot be resected using TURBT. Progression to a more advanced stage or grade subsequent to initial diagnosis is also commonly
encountered. As such, in both high-risk and intermediate-risk NMIBC patients, surgical removal of NMIBC tumors through TURBT is often accompanied by the delivery of adjuvant BCG therapy or chemotherapy, through IVE delivery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">BCG therapy involves the use of a live, attenuated mycobacterium to induce a
<FONT STYLE="white-space:nowrap">non-specific</FONT> anti-tumor immune response in the bladder mucosa and provides meaningful therapeutic utility in the treatment of NMIBC. The use of BCG therapy following TURBT has exhibited sustained anti-tumor
activity, with nearly 70% of patients experiencing a CR after an initial induction course of therapy. Despite BCG&#146;s effectiveness, there is a significant global shortage of BCG as described below. In addition, approximately 50% of these
patients will experience a recurrence of the tumor and few treatment options are available for patients who become unresponsive to BCG treatment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patient Classification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">NMIBC is a heterogeneous disease with significant variation in individual risk of recurrence and progression to MIBC. In
clinical practice, patients fall on a spectrum of high-risk NMIBC extending from <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> NMIBC, which refers to patients who haven&#146;t received BCG treatment, at one end to <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC at the other. Numerous iterations of guidelines on disease classification have evolved over time, primarily from medical industry groups such as the AUA. In February 2018, the FDA published
guidance titled <FONT STYLE="white-space:nowrap">&#147;BCG-Unresponsive</FONT> Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment,&#148; in order to assist sponsors in the development of drugs, including biologics, for
the treatment of <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients. The FDA guidance provides disease-state definitions and advice on patient selection, risk stratification, and clinical trial design in the <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patient population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">According to the 2018 FDA guidance, <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC is defined as being at least one of the following: (1)&nbsp;persistent or recurrent CIS alone or with recurrent Ta/T1 disease within 12 months of completion of adequate BCG therapy;
(2)&nbsp;recurrent high-grade Ta/T1 disease within six months of completion of adequate BCG therapy; or (3)&nbsp;T1 high-grade disease at the first evaluation following an induction BCG course. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In this context, adequate BCG therapy is defined as at least one of the following: (1)&nbsp;at least five of six doses of an
initial induction course plus at least two of three doses of maintenance therapy, or (2)&nbsp;at least five of six doses of an initial induction course plus at least two of six doses of a second induction course. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In between <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> and <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT>
NMIBC lies a disease state where patients do not meet the criteria for either definition called <FONT STYLE="white-space:nowrap">BCG-exposed,</FONT> which describes a combination of disease states related to prior BCG treatment that are neither <FONT
STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> nor <FONT STYLE="white-space:nowrap">BCG-unresponsive.</FONT> The chart below shows the various treatment pathways leading patients to be classified as
<FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> or <FONT STYLE="white-space:nowrap">BCG-exposed.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g08o97.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Patients will be classified as
<FONT STYLE="white-space:nowrap">BCG-exposed</FONT> in many cases including: (1)&nbsp;persistent or recurrent high-grade Ta or <FONT STYLE="white-space:nowrap">CIS-containing</FONT> disease within three months of completion of adequate BCG therapy;
(2)&nbsp;any high-risk recurrence after completion of adequate BCG therapy outside of the <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> window; or (3)&nbsp;any high-risk recurrence after completion of inadequate BCG therapy within a <FONT
STYLE="white-space:nowrap">24-month</FONT> window. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">According to AUA risk stratification guidelines, intermediate-risk
NMIBC is defined as at least one of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Low-grade</FONT> urothelial carcinoma </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Low-grade</FONT> T1 disease </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Solitary <FONT STYLE="white-space:nowrap">low-grade</FONT> Ta disease &gt; 3 cm </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Multifocal <FONT STYLE="white-space:nowrap">low-grade</FONT> Ta disease </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Recurrent <FONT STYLE="white-space:nowrap">low-grade</FONT> Ta disease within 1 year </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">High-grade urothelial carcinoma </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Solitary High-grade Ta &#8804; 3cm </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limited Treatment Options for High-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC Patients </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">While BCG has been the standard adjuvant therapy for high-risk NMIBC after TURBT, BCG is not without its limitations; it is
estimated that approximately 50% of patients eventually develop tumor recurrence. While a subset of these patients will respond to a second round of BCG induction therapy, few treatment options are available to those who are <FONT
STYLE="white-space:nowrap">BCG-unresponsive.</FONT> <FONT STYLE="white-space:nowrap">IVE-delivery</FONT> of chemotherapy has demonstrated limited benefit. The CR rate reported for valrubicin, the only approved chemotherapy for <FONT
STYLE="white-space:nowrap">BCG-refractory</FONT> patients, is 18% at six months. <FONT STYLE="white-space:nowrap">CIS-containing</FONT> tumors are typically not considered resectable, further limiting treatment options for <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> patients. Failure to achieve a CR is associated with an increased risk of death or a disease-worsening event. As such, the use of valrubicin in this setting has not been widely adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2020, pembrolizumab, sold by Merck, was approved by the FDA to treat high-risk
<FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC as monotherapy based on the results of the <FONT STYLE="white-space:nowrap">KEYNOTE-057</FONT> Phase 2 clinical trial. In the cohort of participants with
<FONT STYLE="white-space:nowrap">CIS-stage</FONT> tumors, with or without papillary tumors, 39 of 96 patients, or 41%, had a CR at 3 months, with the median duration of response being 16.2 months. The percentage of trial participants with a CR
declined to 19% at 12 months. Among the trial cohort involving <FONT STYLE="white-space:nowrap">BCG-unresponsive,</FONT> high-risk <FONT STYLE="white-space:nowrap">non-CIS</FONT> papillary tumors the <FONT STYLE="white-space:nowrap">12-month</FONT>
disease free survival (DFS) rate was 43.5% with a median DFS of 7.7 months. Patients in <FONT STYLE="white-space:nowrap">KEYNOTE-057</FONT> were administered systemic pembrolizumab by a medical oncologist by infusion every 3 weeks for up to 24
months or until disease persistence, recurrence, progression, unacceptable toxic effects, or withdrawal of consent. Across both trial cohorts, Grade 3 or 4 toxicities were observed in 13% of participants, of which the most common were hyponatremia
and arthralgia. Serious treatment-related adverse events were noted in 8% of patients, including but not limited to colitis, autoimmune nephritis, hyperthyroidism, lymphocyte count decrease, pulmonary embolism, and syncope. Seven percent of patients
discontinued due to TRAEs (cholestatic hepatitis, hyponatremia, nephritis, and type 1 diabetes mellitus). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Nadofaragene
firadenovec (nadofaragene), a <FONT STYLE="white-space:nowrap">non-replicating</FONT> adenoviral-based gene therapy produced by Ferring that activates interferon <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>2b, was approved by the FDA in December
2022 to treat high-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC <FONT STYLE="white-space:nowrap">CIS-stage,</FONT> with or without papillary tumors. In a Phase 3 clinical trial evaluating nadofaragene for the treatment
BCG-unresponsive NMIBC, 51% of patients achieved a CR and 24% of patients maintained a CR at 12 months. Grade 3 or 4 treatment-related adverse events occurred in 4% of patients, including micturition urgency, bladder spasms, urinary incontinence,
syncope, and hypertension. Serious treatment-related adverse events were reported in 2% of patients (syncope, sepsis, and hematuria). In September 2023, Ferring announced that it dosed the first bladder cancer patient with commercially available
nadofaragene as part of their limited-release commercial launch as they increase manufacturing capacity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based in part on a retrospective analysis of high-risk NMIBC patients,
combination chemotherapy of gemcitabine and docetaxel are used in practice, although these drugs have not received FDA approval for this indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the significant unmet medical need, several additional potential treatments for NMIBC are in various stages of clinical
development and regulatory approval. There are multiple companies that have reported drug candidates in clinical development. For example, ImmunityBio Inc.&#146;s <FONT STYLE="white-space:nowrap">N-803</FONT> is an
<FONT STYLE="white-space:nowrap">IVE-delivered</FONT> <FONT STYLE="white-space:nowrap">IL-15</FONT> agonist delivered in combination with BCG. <FONT STYLE="white-space:nowrap">N-803&#146;s</FONT> regulatory application received a complete response
letter from the FDA due to deficiencies in <FONT STYLE="white-space:nowrap">pre-license</FONT> inspections of the company&#146;s third-party manufacturers. In addition, Urogen Pharma, Inc.&#146;s <FONT STYLE="white-space:nowrap">UGN-102</FONT> is an
<FONT STYLE="white-space:nowrap">IVE-delivered</FONT> DNA synthesis inhibitor, mitomycin, in gel formulation for treatment of <FONT STYLE="white-space:nowrap">low-grade</FONT> intermediate-risk <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT>
NMIBC. Janssen Pharmaceuticals, Inc.&#146;s <FONT STYLE="white-space:nowrap">TAR-200</FONT> is a drug delivery system administered via cystoscopic procedure every three weeks for the first 24 weeks (administered by a urologist in a procedure room
under local anesthesia) with a continuous controlled-release dose of gemcitabine for treatment of <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC. enGene, Inc.&#146;s <FONT STYLE="white-space:nowrap">EG-70</FONT> is an <FONT
STYLE="white-space:nowrap">IVE-delivered</FONT> <FONT STYLE="white-space:nowrap">IL-2</FONT> and <FONT STYLE="white-space:nowrap">RIG-I</FONT> dual-agonist. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patient Aversion to Complete Removal of the Bladder as well as Underlying Mortality Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Radical cystectomy, or the complete removal of the bladder, remains the standard of care for high-risk <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients, but commonly requires an ostomy appliance for urinary diversion. Despite being the standard of care, only approximately 6% of high-risk
<FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC patients elect to have a radical cystectomy. This hesitancy is associated with significant social, functional and emotional burden. Cystectomy and the radical change in daily routine
required often results in diminished body image perception. While the physical and functional trauma may subside, the psychological and emotional burden associated with the consequences of the surgery, which may extend to a patient&#146;s caregivers
and healthcare providers, remain. In addition, the procedure is associated with high degrees of morbidity and mortality. Approximately 64% of patients undergoing a radical cystectomy experience complications, with approximately 26% of patients
requiring readmission for surgery-related complications and an overall readmission rate estimated to be between 20% and 29%. Moreover, the mortality rate within 90 days of the procedure is between 2% and 5%, likely associated with the more advanced
age of many bladder cancer patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Chronic Short Supply of BCG is Expected to Persist for Years </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A key current issue with BCG is that continual production shortages have left many urological practices in need of an effective
and readily available alternative first-line treatment. The production of BCG therapy involves a lengthy and complex manufacturing process and is produced for both the United States and most international markets by a single manufacturer, Merck. In
2017, Sanofi discontinued production of Connaught BCG after a history in challenges producing the product, including a shutdown following a 2011 FDA inspection of documented nonconformances including isolation of mold within the BCG aseptic
processing areas, which further exacerbated the overall availability of BCG in the United States. While there are other options globally for BCG, none of the options are available in the United States, except for the TICE BCG strain manufactured by
Merck. A randomized controlled, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trial may be needed to fully examine the impact of different BCG strains on clinical outcomes for bladder cancer patients.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">BCG has been in short supply for over ten years as demand has outpaced available production capacity. In light of these
supply constraints, the use of BCG therapy as induction therapy has been restricted to BCG-na&iuml;ve, high-grade T1 or <FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC patients only, with maintenance therapy limited to 12 months. The
NCCN and AUC/SOC guidelines no longer recommend BCG therapy for intermediate-risk NMIBC, instead indicating that BCG should be prioritized for high-risk NMIBC patients only. Moreover, even among <FONT STYLE="white-space:nowrap">BCG-eligible</FONT>
patients, drug shortages have in some cases necessitated a reduction from a full-dose course of treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October&nbsp;2020, Merck announced plans to build an additional BCG
manufacturing site and has stated that construction is underway, and the new facility is on track to be completed between late 2025 and late 2026. The current market is only producing 69% of the estimated BCG need based on 2018 baseline volume; even
with additional supply, the annual supply gap could be significant. We believe that disease recurrence after BCG therapy, together with current and anticipated ongoing supply shortages, highlights a significant unmet medical need for alternative
NMIBC therapeutics which are both safe and efficacious, particularly in the intermediate- and high-risk NMIBC patient populations for whom BCG therapy is not available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant Barriers Exist in Development and Adoption of New Treatments for NMIBC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Treatments that require administrative methods differing from BCG, such as requirements for operating/procedure room time under
anesthesia or intravenous (IV)&nbsp;administration, may limit physician adoption, particularly in community urology practices. Further, we believe any treatment seeking to replace or compete with TURBT in intermediate-risk NMIBC will face slow
adoption given TURBT&#146;s place as a cornerstone treatment for urology practices, driving a significant portion of providers&#146; economics. In addition, treatments leveraging chemotherapies have demonstrated tolerability challenges and adverse
events that limit their potential to be combined with other therapeutic agents to further enhance the efficacy profile. Cretostimogene&#146;s administration, which is similar to BCG, could offer convenience for urology practice adoption that will
potentially allow cretostimogene to become a backbone therapy across several bladder cancer indications, if successfully developed and approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cretostimogene: Our Product Candidate for Intermediate- and High-Risk NMIBC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cretostimogene is an investigational engineered oncolytic immunotherapy that has been designed both to eliminate cancer cells
directly by selective replication within cancer cells and indirectly activating an anti-tumor immune response. Our ongoing open-label Phase 3 clinical trial, <FONT STYLE="white-space:nowrap">BOND-003,</FONT> is designed to assess the safety and
efficacy of cretostimogene in high-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC when administered as a monotherapy. We have completed patient enrollment in the <FONT STYLE="white-space:nowrap">116-patient</FONT> <FONT
STYLE="white-space:nowrap">BOND-003</FONT> trial and expect to report topline data by&#8195;&#8195;&#8195;&#8195;. We are also evaluating the safety and efficacy of cretostimogene when used in combination with pembrolizumab in <FONT
STYLE="white-space:nowrap">CORE-001,</FONT> our open-label Phase 2 clinical trial in this same patient population. We believe the clinical trial results observed to date reflect the differentiated therapeutic potential of cretostimogene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cretostimogene has shown clinical benefit and has been generally well-tolerated as both a monotherapy and in combination in
clinical trials to date. In <FONT STYLE="white-space:nowrap">BOND-002,</FONT> our completed Phase 2 clinical trial which evaluated the use of cretostimogene as monotherapy to treat patients with high-risk NMIBC who had failed BCG therapy, 65% of the
46 patients with <FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC achieved a CR at any time after the administration of cretostimogene. Cretostimogene has also demonstrated clinical activity when administered in combination with
pembrolizumab to patients with high risk, <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC in our ongoing Phase 2 <FONT STYLE="white-space:nowrap">CORE-001</FONT> open-label clinical trial. In this trial, 29 of the 34 (85%) patients
evaluable as of the March&nbsp;3, 2023 data cutoff achieved a CR after an initial induction therapy, with 82% (n=27/33) of evaluable patients maintain a CR at six months, and 68% (n=17/25) of evaluable patients maintaining a CR at 12 months. As of
September&nbsp;30,&nbsp;2023, cretostimogene has been administered in over 270 patients during clinical trial investigations, and has been generally well tolerated with no Grade 4 or 5 TRAEs observed and no treatment-related study discontinuations.
Only one TRAE has led to a patient discontinuation of pembrolizumab in the <FONT STYLE="white-space:nowrap">CORE-001</FONT> trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We initiated <FONT STYLE="white-space:nowrap">PIVOT-006</FONT> in&#8195;&#8195;&#8195;&#8195;, which is a randomized Phase 3
clinical trial designed to assess the safety and efficacy of adjuvant cretostimogene in intermediate-risk NMIBC patients following TURBT. We also intend to initiate <FONT STYLE="white-space:nowrap">CORE-008,</FONT> which is an open-label
multi-cohort Phase 2 clinical trial designed to assess the safety and efficacy of cretostimogene when administered as monotherapy and in combination with a CPI including (1)&nbsp;high-risk NMIBC patients categorized as
<FONT STYLE="white-space:nowrap">BCG-exposed</FONT> but not yet designated unresponsive, and (2)&nbsp;high-risk NMIBC patients categorized as BCG-na&iuml;ve. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our ongoing and planned clinical trials and the specific NMIBC patient
population to be evaluated are presented in the following chart. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Clinical Trials are Ongoing or Planned to Evaluate Cretostimogene in a
Range of NMIBC Patient Populations </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g13p01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We believe NMIBC patients with <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT>
disease are unlikely to benefit from further BCG therapy. Additionally, given the patient burden and mortality associated with cystectomy, bladder preservation through the avoidance or delay of cystectomy is an intended outcome of new therapeutic
product candidates for bladder cancer. We believe our approach is supported by the February 2018 FDA guidance regarding clinical trial design targeting a <FONT STYLE="white-space:nowrap">BCG-unresponsive,</FONT>
<FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC patients states that a <FONT STYLE="white-space:nowrap">single-arm</FONT> trial that assesses CR rate as the primary endpoint, taking DOR into account, may be appropriate for full
approval, or may require a confirmatory trial after accelerated approval. As of September&nbsp;30, 2023, there were two products that have received full FDA approval based on data from <FONT STYLE="white-space:nowrap">single-arm</FONT> clinical
trials following the issuance of the guidance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cretostimogene Grenadenorepvec </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cretostimogene is an investigational engineered, conditionally replicating oncolytic immunotherapy that has been designed to
preferentially replicate in retinoblastoma (Rb) gene pathway defective cells present in the majority of urothelial carcinomas and trigger an anti-tumor immune response. Cretostimogene enters the tumor by binding to Coxsackievirus and Adenovirus
Receptors (CAR) present in specialized intracellular junctions and tight junctions of polarized epithelial cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There
are two modifications made to cretostimogene for tumor selectivity and potency. The first modification is the insertion of an <FONT STYLE="white-space:nowrap">E2F-1</FONT> promoter in cretostimogene which acts as a safety mechanism to selectively
replicate and lyse <FONT STYLE="white-space:nowrap">Rb-defective</FONT> tumor cells rather than healthy cells which have intact Rb pathways. The second modification is the insertion of the gene for the cytokine granulocyte-macrophage colony
stimulation factor <FONT STYLE="white-space:nowrap">(GM-CSF).</FONT> <FONT STYLE="white-space:nowrap">GM-CSF</FONT> is widely recognized as a potent stimulator of longer-term anti-tumor activity and we believe its addition to the viral construct may
both prime the immune system and induce tumor-specific immunity. Replication and lysis of <FONT STYLE="white-space:nowrap">Rb-defective</FONT> tumor cells by cretostimogene may trigger an immunogenic cell death that stimulates an anti-tumor immune
response. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Comparison of Wild-Type Adenovirus and Our Cretostimogene Constructs </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g78c79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Overview of Cretostimogene&#146;s Replication Selectivity in Healthy Versus Cancerous Cells with
Defective <FONT STYLE="white-space:nowrap">Rb-Pathway</FONT> </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g15m15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cretostimogene Administration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to the administration of cretostimogene, patients undergo a saline wash and are then pretreated with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">n-Dodecyl-&szlig;-D-maltoside</FONT></FONT></FONT> (DDM) through IVE delivery. DDM is a mild detergent and solubilizing agent used to attenuate the GAG
lining of the transitional epithelium and enhance transduction efficiency of adenovirus by urothelial cells. Following DDM wash/dwell and GAG layer attenuation, cretostimogene is <FONT STYLE="white-space:nowrap">IVE-delivered</FONT> via a catheter.
This administration process does not require operating room time nor placement of the patient under anesthesia. Furthermore, this is a similar route of administration as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> BCG therapy, which urology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
practices perform regularly and, thus, we believe will require limited provider <FONT STYLE="white-space:nowrap">re-training</FONT> versus other NMIBC treatment approaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Overview of Cretostimogene&#146;s IVE Administration into the Bladder </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g19a20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cretostimogene Clinical Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cretostimogene Monotherapy for High-risk <FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC after BCG Failure </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of <FONT STYLE="white-space:nowrap">BOND-002</FONT> Trial Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">BOND-002</FONT> trial was a Phase 2, open-label,
<FONT STYLE="white-space:nowrap">single-arm</FONT> clinical trial of cretostimogene in patients with high-risk NMIBC after BCG failure. Cretostimogene was administered intravesically at 1 x 10<SUP STYLE="font-size:75%; vertical-align:top">12</SUP>
viral particles (VPs) per milliliter to high-risk <FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC patients, with or without Ta/T1 tumors, and a group of patients with only Ta/T1, that were categorized as having failed BCG therapy and
refused radical cystectomy. The trial included a heterogenous mixture of <FONT STYLE="white-space:nowrap">BCG-exposed</FONT> and <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In this study, 46 CIS patients, with or without Ta/T1 disease, and 19 patients with Ta/T1 disease were enrolled. Patients
received an initial induction course of six weekly administrations. Patients who achieved a CR at month six received six weekly maintenance doses of cretostimogene using the same concentration. Patients that did not respond to the first induction
course were provided a second induction course at month three with no maintenance doses provided at month six. Six weekly follow up doses were then administered at months 12 and 18. In this trial, CR rates were evaluated at various timepoints
throughout the study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of Response Data in <FONT STYLE="white-space:nowrap">BOND-002</FONT> Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Among the 46 patients with high-risk <FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC, 30 (65%) patients displayed
a CR at any time subsequent to administration of cretostimogene. Four out of 10 (40.0%) patients who did not achieve CR at three months, and who were subsequently reinduced with cretostimogene at three months demonstrated CR at six months. The DOR
to treatment was also notable, with 44% and 28% of patients demonstrating a CR at six months and 12 months, respectively. The results of <FONT STYLE="white-space:nowrap">BOND-002</FONT> are summarized below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>CR Data from <FONT STYLE="white-space:nowrap">BOND-002</FONT> Trial </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g22a22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of Safety Data in <FONT STYLE="white-space:nowrap">BOND-002</FONT> Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Safety and Tolerability Data from <FONT STYLE="white-space:nowrap">BOND-002</FONT> Trial </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g23a23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to the 65 patients enrolled per the trial protocol, the safety results above
included three additional patients, two who were dosed with cretostimogene for compassionate, <FONT STYLE="white-space:nowrap">single-use</FONT> patient INDs and one more determined not to have baseline NMIBC retrospectively. Cretostimogene was
generally well-tolerated and most TRAEs were limited to Grade 1 to 2, only two Grade 3 TRAEs involving dysuria and hypotension (both of which were resolved), and no Grade 4 or 5 TRAEs. Furthermore, eight severe adverse events were reported but were
determined not related to cretostimogene. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of <FONT STYLE="white-space:nowrap">BOND-003</FONT> Trial Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">BOND-003</FONT> is a global, open-label, <FONT STYLE="white-space:nowrap">single-arm</FONT>
Phase 3 clinical trial enrolling 116 patients designed to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients that have received adequate BCG therapy with high-risk
<FONT STYLE="white-space:nowrap">BCG-unresponsive,</FONT> <FONT STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC and BCG-unresponsive Ta or T1 papillary tumors. We designed this trial in light of the 2018 FDA guidance which defines <FONT
STYLE="white-space:nowrap">BCG-unresponsive</FONT> disease states and says that <FONT STYLE="white-space:nowrap">single-arm</FONT> trials that assess CR rate as the primary endpoint, taking DOR into account, may be appropriate for full approval or
may require a confirmatory trial following accelerated approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial induction course of therapy is six weekly
doses of cretostimogene containing 1 x 10<SUP STYLE="font-size:75%; vertical-align:top">12</SUP> VPs per milliliter. Patients who achieve a CR at month three receive maintenance treatments, involving three weekly cretostimogene doses administered at
the same concentration every three months for the first 12 months with a fifth and final course of therapy administered at 18 months. Patients who do not achieve a CR after the first induction course may receive a second induction course of six
weekly cretostimogene treatments at month 3, rather than the maintenance course involving three weekly treatments. The primary endpoint of the <FONT STYLE="white-space:nowrap">BOND-003</FONT> trial is CR at any time subsequent to induction. We have
completed enrollment for this trial and expect to report topline data by&#8195;&#8195;&#8195;&#8195;&#8195;. We intend to enroll an additional cohort to evaluate the safety and efficacy of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cretostimogene as a monotherapy in the treatment of patients with high-risk BCG-unresponsive NMIBC, high-grade Ta or T1 without CIS that have received adequate BCG therapy. The primary endpoint
of this cohort is overall DFS, with secondary endpoints including DFS at 12-months, progression-free survival (PFS) to worsening of grade, stage or death, and PFS to muscle invasion, metastasis or death. DFS is based on time from treatment until
disease relapse. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Combination of Cretostimogene Plus Pembrolizumab for High-risk <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> <FONT
STYLE="white-space:nowrap">CIS-containing</FONT> NMIBC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of <FONT STYLE="white-space:nowrap">CORE-001</FONT> Trial
Design </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">CORE-001</FONT> is a Phase 2
<FONT STYLE="white-space:nowrap">single-arm,</FONT> open-label clinical trial of cretostimogene administered in up to 35 patients with high risk, <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> NMIBC that have
<FONT STYLE="white-space:nowrap">CIS-containing</FONT> tumors, in combination with pembrolizumab. Patients that demonstrate a CR after an initial <FONT STYLE="white-space:nowrap">six-week</FONT> induction phase of weekly cretostimogene
administrations, dosed at a concentration of 1 x 10<SUP STYLE="font-size:75%; vertical-align:top">12</SUP> VP per milliliter, who also receive two, 400 mg doses of pembrolizumab over three months, are given a maintenance course of three weekly doses
of cretostimogene at an equivalent VP concentration, along with two doses of pembrolizumab for three months. Trial participants that do not respond to an initial induction course are eligible to receive a second induction course of six weekly
administrations over the following three-month period. During the following six months, patients are provided three weekly doses of cretostimogene every three months for six months, in addition to pembrolizumab every six weeks, with longer-term
follow up administration of three weekly doses every six months for 12 months, along with pembrolizumab every 6 weeks. The primary endpoints of the <FONT STYLE="white-space:nowrap">CORE-001</FONT> trial is CR at 12 months, with a secondary endpoint
of CR any time. We have entered into a clinical trial collaboration and supply agreement with Merck providing at <FONT STYLE="white-space:nowrap">no-cost</FONT> supply of pembrolizumab for use in <FONT STYLE="white-space:nowrap">CORE-001</FONT>
(which agreement also provides for the joint ownership of clinical trial data but has no additional financial obligations and terminates upon conclusion of the trial). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The dosing schedule of cretostimogene in <FONT STYLE="white-space:nowrap">CORE-001</FONT> is similar to <FONT
STYLE="white-space:nowrap">BOND-003,</FONT> while pembrolizumab is administered pursuant to its approved dosing schedule. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of
Interim Clinical Results in Our Ongoing <FONT STYLE="white-space:nowrap">CORE-001</FONT> Trial </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Interim results from
the <FONT STYLE="white-space:nowrap">CORE-001</FONT> demonstrated that, as of the March&nbsp;3, 2023 data cutoff, 29 of the 34 (85%) evaluable patients displayed a CR at any time subsequent to completion of induction therapy. Moreover,
administration of cretostimogene has also resulted in durable responses, with 82% (n=27/33) of the evaluable patients maintaining a CR at six months and 68% (n=17/25) of evaluable patients maintaining a CR at 12 months, each as of the cutoff date.
In the chart below is presented a summary of the interim results observed in patients enrolled in the <FONT STYLE="white-space:nowrap">CORE-001</FONT> trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of Interim Results from <FONT STYLE="white-space:nowrap">CORE-001</FONT> Trial </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g24a25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We anticipate reporting additional durability data in &#8195;&#8195;&#8195;&#8195;&#8195;.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview of Interim Safety Data from Ongoing
<FONT STYLE="white-space:nowrap">CORE-001</FONT> Trial </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Similar to the results achieved in the <FONT
STYLE="white-space:nowrap">BOND-002</FONT> trial, cretostimogene was observed to be generally well tolerated with transient, localized Grade 1 or 2 local urinary tract related issues as of the January&nbsp;31, 2023 safety data cutoff. Subsequent to
the data cutoff, one Grade 2 serious adverse event (urinary retention) was reported and resolved. In addition, Grade 3 immune-related adverse safety events consistent with prior <FONT STYLE="white-space:nowrap">anti-PD1</FONT> CPI trials were
observed in certain trial participants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cretostimogene Monotherapy for Intermediate-risk NMIBC following TURBT </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 3 <FONT STYLE="white-space:nowrap">PIVOT-006</FONT> Clinical Trial </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We initiated <FONT STYLE="white-space:nowrap">PIVOT-006</FONT> in &#8195;&#8195;&#8195;&#8195;&#8195;&#8195;, which is a
randomized Phase 3 trial intended to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following TURBT. This is a <FONT STYLE="white-space:nowrap">two-arm</FONT> trial
enrolling up to 426 intermediate-risk NMIBC patients, one arm to be administered cretostimogene in combination with the standard of care TURBT with the second arm receiving the standard of care only. The primary endpoint of this trial is overall
recurrence free survival (RFS), with secondary endpoints including RFS at 12 and 24 months. RFS is based on time to last cystoscopic evaluation or time to disease relapse where relapse is defined as any grade bladder cancer recurrence. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Planned Clinical Trial </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2
<FONT STYLE="white-space:nowrap">CORE-008</FONT> Clinical Trial </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The planned study is an open-label multi-cohort Phase
2 trial intended to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC including <FONT STYLE="white-space:nowrap">BCG-exposed</FONT> and <FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> NMIBC
patients. <FONT STYLE="white-space:nowrap">BCG-exposed</FONT> patients are classified as those NMIBC patients with persistent, recurrent or progressive disease after BCG treatment but do not meet the specific disease classification criteria to be
designated <FONT STYLE="white-space:nowrap">BCG-unresponsive.</FONT> BCG-na&iuml;ve patients are classified as those NMIBC patients who have not received any prior BCG therapy. After an induction course of therapy, we expect that patients who
achieve a CR will receive a maintenance course every three months for one year. The targeted efficacy endpoints of this trial are expected to include CR at any time following induction, CR at 12 months, DOR and progression free survival (PFS). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Clinical Trial Evaluations in MIBC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">MIBC is associated with significantly higher mortality than NMIBC, the five-year mortality rate for patients with MIBC ranging
from approximately 66% to 95% depending on disease stage. As such, the delay of disease progression is of particular significance to the estimated 20% to 25% of newly diagnosed bladder cancer patients with MIBC as well as those high-risk NMIBC
patients that progress to MIBC. Moreover, the annual cost of care for patients with MIBC is estimated to be approximately 2.5 times the annual cost of care for patients with NMIBC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Systemic administration of cisplatin is often used as neoadjuvant chemotherapy in the treatment of MIBC. However, as many as
50% of patients are ineligible to receive cisplatin because of existing <FONT STYLE="white-space:nowrap">co-morbidities</FONT> such as decreased renal function or neuropathy in which case CPIs are the default standard of care. We are currently
evaluating the use of cretostimogene in combination with the CPI nivolumab as a treatment for MIBC, including by our support of <FONT STYLE="white-space:nowrap">CORE-002,</FONT> a <FONT STYLE="white-space:nowrap">single-arm</FONT> exploratory
investigator-sponsored clinical trial of 30 cisplatin-ineligible patients with no evidence of distant metastases prior to radical cystectomy. Cretostimogene induction therapy is accompanied by IV nivolumab dosed week 2 and week 6 followed by TURBT
or cystectomy. Endpoints of this clinical trial are pathological CR (pCR) at any time, pCR at 12 months and DOR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of
the March&nbsp;31, 2023 <FONT STYLE="white-space:nowrap">CORE-002</FONT> data cutoff, among the 15 evaluable patients, the combination of cretostimogene and nivolumab had produced a pCR in eight patients, or a pCR rate of 53% (n=8/15). An
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
additional patient had a negative post-treatment biopsy but refused radical cystectomy. Cretostimogene has been generally well tolerated among trial participants as of the data cutoff. Immune
related AE was seen in one patient, who had Grade 2 autoimmune thyroiditis. There was no delay in time to radical cystectomy and no unexpected surgical complications from treatment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We
leverage third-party manufacturers to support the manufacturing of cretostimogene for clinical trials and, if we receive regulatory approval, we intend to rely on such third parties for commercial manufacture. We do not own or operate, and currently
have no plans to establish, any manufacturing facilities. We believe this strategy will enable us to maintain a nimble, efficient and effective working model without making significant internal capital investments. We are currently focused on
developing high-yield and scalable processes and analytical methods for the manufacture of cretostimogene. We work with a third-party manufacturer for the production of cretostimogene and a third-party manufacturer for the production of DDM. We
currently obtain our supplies from these manufacturers on a purchase order basis and do not have any long-term supply agreements in place. In order to <FONT STYLE="white-space:nowrap">de-risk</FONT> our supply chain, and as we advance toward
potential commercialization, we intend to enter into long-term supply agreements as well as evaluate additional product manufacturing sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have established strong <FONT STYLE="white-space:nowrap">in-house</FONT> CMC capabilities consisting of expertise in
process and analytical development and manufacturing, spanning across different modalities including viruses. To complement our <FONT STYLE="white-space:nowrap">in-house</FONT> CMC capabilities, we have established a CMC Advisory Board, consisting
of some of the most respected names in the industry. This advisory group is chaired by Dr.&nbsp;Richard Rutter, Ph.D., formerly Executive Vice President of Biotherapeutics Pharmaceuticals Sciences at Pfizer, and includes Dr.&nbsp;Daniel Takefman,
Ph.D., formerly chief of the gene therapy branch at the FDA; Dr.&nbsp;Richard Peluso, Ph.D., formerly Vice President, Biologics and Vaccines, Bioprocess R&amp;D at Merck; and Dr.&nbsp;Victoria Sluzky, Ph.D., formerly Senior Vice President, Technical
Development for BioMarin Pharmaceuticals. In combination with the CMC Advisory Board&#146;s experience and strong internal capabilities, we strive to build a sustainable and effective CMC organization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We face
substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions. In addition, many
biotechnology companies have formed collaborations with large, established companies to (i)&nbsp;obtain support for their research, development and commercialization of products or (ii)&nbsp;combine several treatment approaches to develop longer
lasting or more efficacious treatments that may potentially directly compete with our current or future product candidates. We anticipate that we will continue to face increasing competition as new therapies, technologies, and data emerge within the
field of oncology and, furthermore, within the treatment of bladder cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We will continue to face competition from
current standard of care treatments, including BCG. To the extent Merck or another manufacturer increases the supply of BCG, there may be less demand for alternative treatments such as cretostimogene in
<FONT STYLE="white-space:nowrap">BCG-na&iuml;ve</FONT> or <FONT STYLE="white-space:nowrap">BCG-exposed</FONT> patients. In addition, there are numerous companies that have commercialized or are developing treatments for NMIBC, including Bristol
Meyers Squibb, enGene Inc., Gilead Sciences, Inc., <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche AG (Roche), ImmunityBio Inc., Johnson&nbsp;&amp; Johnson Inc., Merck, Protara Therapeutics, Inc., Pfizer, Inc., and UroGen Pharma, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Many of our competitors, either alone or in combination with their respective strategic partners, have significantly greater
financial resources and expertise in research and development, manufacturing, regulatory processes, and marketing than we do. Mergers and acquisitions activity in the pharmaceutical, biopharmaceutical and biotechnology sector is likely to result in
greater resource concentration among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
sizeable collaborative arrangements with established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial opportunity could be reduced or eliminated if one or more of our competitors successfully develop and
commercialize products that are safer, more effective, better-tolerated, or of greater convenience or economic benefit than our proposed product offering. Our competitors also may be in a position to obtain FDA or other regulatory approval for their
products more rapidly, resulting in a stronger or dominant market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be product safety, efficacy, convenience and
treatment cost. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. If we
obtain FDA approval for cretostimogene, we intend to build <FONT STYLE="white-space:nowrap">in-house</FONT> sales and marketing capabilities to commercialize cretostimogene in the United States, and potentially other regions, and expect to rely on
third parties for distribution. While the number of patients suffering from bladder cancer is large and growing, a significant portion of large urology practices are concentrated in a relatively small number of major metropolitan areas and urology
physician groups. We believe this concentration will potentially enable us to efficiently reach a large portion of our estimated addressable market with a relatively small commercial footprint. Importantly, urology practices are already deeply
familiar with the administration of TURBT followed by intravesical administration of BCG in NMIBC patients. Cretostimogene is similarly designed to be administered intravesically and we believe will not require urology practices to retrain or learn
a new administrative method. Outside of the United States, we may, where appropriate, pursue development and commercialization relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners, to
maximize the commercial potential of cretostimogene in such countries, such as with our agreements with Kissei Pharmaceutical Co., Ltd. and Lepu Biotech Co., Ltd. described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License and Collaboration Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kissei
Pharmaceutical Co., Ltd. License and Collaboration Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, and as amended September 2022, we
entered into a license and collaboration agreement (the Kissei Agreement) with Kissei Pharmaceutical Co., Ltd. (Kissei), under which we granted to Kissei an exclusive license to certain intellectual property rights in Bangladesh, Bhutan, Brunei,
Cambodia, India, Indonesia, Japan, South Korea, Laos, Malaysia, Myanmar, Nepal, Pakistan, Palau, Philippines, Singapore, Sri Lanka, Taiwan, Thailand and Vietnam (the Kissei Territory), for Kissei to develop and commercialize, but not manufacture,
cretostimogene in combination with DDM (the Licensed Product) for all uses in oncology indications for which marketing approval is being sought. Under the Kissei Agreement, we and Kissei agreed to use commercially reasonable efforts to collaborate
on clinical development activities in the Kissei Territory and each party is responsible for conducting the applicable activities pursuant to an agreed development plan. Kissei is responsible for the costs of developing the Licensed Product in the
Kissei Territory, and we are responsible for the costs of developing the Licensed Product outside the Kissei Territory, provided that Kissei is responsible for a <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentage and we are
responsible for a high-double digit percentage of the cost of development activities that cannot be attributed solely to the Kissei Territory or outside the Kissei Territory. We are obligated to supply and Kissei will exclusively purchase its
clinical and commercial requirements of Licensed Product from us. Kissei is responsible for commercializing the Licensed Product in the Kissei Territory and is obligated to use commercially reasonable efforts to seek regulatory approval for and
commercialize at least one Licensed Product in a specified indication. Until a certain period of time has passed after the first regulatory approval of the Licensed Product, we are prohibited from commercializing certain competing products worldwide
and Kissei is prohibited from researching, developing or commercializing certain competing products worldwide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Kissei paid to us a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront
payment of $10.0&nbsp;million and, in connection with the entry into the Kissei Agreement, purchased $30.0&nbsp;million worth of shares of our Series D redeemable convertible preferred stock as part of our Series D financing. Kissei is obligated to
make development, regulatory and commercial milestone payments of up to $100.0&nbsp;million. We have also agreed to pay Kissei a royalty on net sales of Licensed Product outside the Kissei Territory and outside the Lepu Territory (as described
below), including on any U.S. sales, in a <FONT STYLE="white-space:nowrap">low-single</FONT> digit percentage, subject to certain reductions. We are entitled to receive a royalty on net sales of Licensed Product in the Kissei Territory in the <FONT
STYLE="white-space:nowrap">mid-twenties</FONT> percentage, subject to certain capped reductions. Also, Kissei has the right to offset the royalty payments due to us with respect to the cost for the supply of Licensed Product sold by us to Kissei,
and to indefinitely carry forward credits for any excess supply amounts paid over royalty amounts owed in a given quarter. We are entitled to receive a specified minimum percentage of royalties on net sales of a given Licensed Product in a given
country and a given quarter, unless, if for such Licensed Product in such country and such quarter, Kissei has taken the maximum allowable reductions and the ratio of the cost for the supply of Licensed Product to the sales price for Licensed
Product exceeds a <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentage threshold, then we shall receive no royalties on the net sales of such Licensed Product in such country and such quarter. Kissei&#146;s and our royalty obligations
will expire on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis on the
later of twelve years from the date of first commercial sale of such Licensed Product in such country or when there is no longer a valid patent claim covering such Licensed Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Kissei Agreement will expire on a Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis when there is no remaining
royalty or milestone payment obligation due to a party with respect to such Licensed Product in such country. Following expiration of the Kissei Agreement in its entirety, the licenses we granted to Kissei will become non-exclusive, fully-paid
royalty-free and irrevocable and Kissei will have the right to negotiate directly with our product suppliers for the direct supply of Licensed Product to Kissei. The Kissei Agreement may be terminated either by Kissei or by us in the event of an
uncured material breach by the other party or in the event the other party becomes subject to specified bankruptcy, insolvency or similar circumstances. In addition, we have the right to terminate the Kissei Agreement in the event that Kissei
commences a legal action challenging the validity, enforceability or scope of any licensed patents under the Kissei Agreement. Kissei may terminate the Kissei Agreement at will upon specified written notice. Additionally, Kissei may terminate the
Kissei Agreement for our willful and malicious misconduct that results in substantial and irreparable harm to the commercial value of the Licensed Products in the Kissei Territory and upon any such termination, the licenses we granted to Kissei will
become royalty-free and fully <FONT STYLE="white-space:nowrap">paid-up</FONT> and Kissei will have the right to negotiate directly with our contract manufacturing organizations for the supply of Licensed Product. Upon termination of the Kissei
Agreement for any other reason all rights and licenses granted to Kissei to develop and commercialize the product under the Kissei Agreement will terminate, subject to certain rights to sell existing inventory of Licensed Products by Kissei and its
sublicensees. Upon termination of the Kissei Agreement for Kissei&#146;s breach, any sublicenses granted by Kissei may, upon our discretion, continue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lepu Biotech Co., Ltd. Development and License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2019, we entered into a development and license agreement (the Lepu Agreement) with Lepu Biotech Co., Ltd. (Lepu),
under which we granted an exclusive license to Lepu to develop, manufacture and commercialize cretostimogene and/or DDM to treat and/or prevent cancer in mainland China, including Hong Kong and Macau (the Lepu Territory). Under the Lepu Agreement,
Lepu is responsible for using commercially reasonable efforts to develop cretostimogene and DDM in the Lepu Territory, including by performing clinical development activities pursuant to an agreed development plan, and we are obligated to provide
Lepu with reasonably requested information, <FONT STYLE="white-space:nowrap">know-how</FONT> and assistance at Lepu&#146;s cost and expense. Additionally, Lepu is obligated to meet a certain clinical diligence milestone by a specified date in 2024.
We are also obligated to use commercially reasonable efforts to supply Lepu with its requirements of cretostimogene and DDM for its development activities at Lepu&#146;s cost and to periodically provide Lepu with manufacturing documentation and, at
Lepu&#146;s cost, reasonably requested assistance related to the manufacture of clinical and, if applicable, commercial supplies of cretostimogene and DDM. Lepu is obligated to use commercially reasonable efforts to commercialize
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
at least one of cretostimogene and/or DDM and achieve the first commercial sale of such product in the Lepu Territory within specified time periods after receipt of marketing authorization
approval therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lepu paid to us a <FONT STYLE="white-space:nowrap">one-time</FONT> upfront payment of
$4.5&nbsp;million, and Lepu is obligated to make regulatory milestone payments of up to $2.5&nbsp;million and commercial milestone payments of up to $57.5&nbsp;million. We are entitled to receive a high single-digit royalty on net sales of
cretostimogene and/or DDM sold in the Lepu Territory, subject to a specified reduction. Lepu&#146;s royalty obligations will expire upon termination of the Lepu Agreement. Lepu may terminate the Lepu Agreement for any reason upon specified prior
written notice. The agreement may be terminated either by Lepu or by us in the event of an uncured material breach by the other party. In addition, we have the right to terminate the agreement in the event that Lepu commences or requests a legal
action challenging the validity, enforceability or scope of any licensed patents. Upon termination of the agreement for any reason, all rights and licenses granted to Lepu to develop and commercialize cretostimogene and DDM under the agreement will
terminate, and Lepu will be obligated to provide to us all data and results pertaining to cretostimogene and DDM products and assign and transfer to us all regulatory filings, manufacturing documentation and marketing authorization approvals for
cretostimogene and DDM. In the event that Lepu has any ongoing clinical trials with respect to cretostimogene and/or DDM as of the effective date of termination, at our request, Lepu is obligated to either promptly transition such clinical trials to
us or continue to conduct and complete such clinical trials, at our expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The proprietary nature of, and protection for, our product candidates and their methods of use are an important part of our
strategy to develop and commercialize novel medicines, as described in more detail below. We have obtained patents and filed patent applications in the United States and other countries relating to certain of our proprietary technology, inventions,
improvements, and product candidates, and are pursuing additional patent protection for them. We endeavor to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent protection
intended to cover cretostimogene, its methods of use, related technologies, and other inventions that are important to our business. In addition to patent protection, we also rely on trade secret to protect aspects of our business that are not
amenable to, or that we do not consider appropriate for, patent protection, including our proprietary method of manufacturing cretostimogene. We will also seek to rely on regulatory protection afforded through inclusion in expedited development and
review, data exclusivity, market exclusivity and patent term extensions where available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of October&nbsp;19, 2023, we
own five patent families comprising five issued U.S. patents, five issued foreign patents in Australia, New Zealand, Japan, and Singapore, 3 pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, and 18 pending
patent applications in jurisdictions outside of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With regard to cretostimogene, we own three issued
U.S. patents and three issued patents in Japan and Singapore with claims covering methods of use using cretostimogene, including claims covering treatment schedules and combination therapy. These issued patents are expected to expire between 2036
and 2038, without accounting for potentially available patent term adjustments or extensions. We also own three pending U.S. applications and 18 related pending applications in Australia, New Zealand, Japan, South Korea, China, Singapore, Hong Kong,
and before the European Patent Office, and any patents that issue from these applications are expected to expire between 2036 and 2038, without accounting for potentially available patent term adjustments or extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We expect to file additional patent applications in support of current and new product candidates as well as new platform and
core technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our commercial success will depend in part on obtaining and maintaining patent protection and trade
secret protection of cretostimogene, our future product candidates, and their methods of use, as well as successfully </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
defending any such patents against third-party challenges, preserving the confidentiality of our trade secrets, and operating without infringing on the proprietary rights of others. Our ability
to stop third parties from making, using, selling, offering to sell or importing our product candidates will depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We cannot be
sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any patents that may be granted to us in the future will be
commercially useful in protecting our product candidates, discovery programs and processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The terms of individual
patents depend upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing
a&nbsp;non-provisional&nbsp;patent application. In the United States, a patent&#146;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO, in
examining and granting a patent, or may be shortened if a patent is terminally disclaimed over another patent of ours. In the United States, the term of a patent that covers <FONT STYLE="white-space:nowrap">an&nbsp;FDA-approved&nbsp;drug</FONT> may
also be eligible for extension, which permits patent term restoration as compensation for a portion of the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the
expiration of the patent. The length of the patent term extension is related to the length of time the subject drug candidate is under regulatory review. Patent term extension cannot extend the remaining term of a patent beyond a total of 14 years
from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions to extend
the term of a patent that covers an approved drug are available in Europe, Japan and other foreign jurisdictions. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those
products. We plan to seek patent term extensions to any issued patents we may obtain in any jurisdiction where such patent term extensions are available, however there is no guarantee that the applicable authorities, including the FDA in the United
States, will agree with our assessment that such extensions should be granted, and if granted, the length of such extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The actual protection afforded by a patent varies on a claim by claim and country by country basis and depends upon many
factors, including the type of patent, the scope of its coverage, the availability of any patent term extensions or adjustments, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to patent protection, we also rely on trade secret protection for our proprietary information that is not amenable
to, or that we do not consider appropriate for, patent protection, including, for example, aspects of our manufacturing processes for cretostimogene. However, trade secret can be difficult to protect. Although we take steps to protect our
proprietary information, including restriction to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors, and potential collaborators, such individuals may breach such agreements
and disclose our proprietary information including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In addition, third parties may independently develop the same or similar proprietary information or may
otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For more information regarding the risks related to our intellectual property, please see the section titled &#147;Risk
Factors&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively
regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
advertising, promotion, marketing, post-approval monitoring, and post-approval reporting of biological product candidates such as those we are developing. The process of obtaining regulatory
approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Biologics Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, the Public
Health Service Act, and other federal, state, local and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with Good
Laboratory Practice regulations (GLPs), and other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board (IRB) or ethics committee at each clinical site before
each trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice
regulations (GCPs), to evaluate the safety, purity and potency of the product candidate for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of a BLA, after completion of all pivotal trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the biologic
is produced to assess compliance with current Good Manufacturing Practice requirements (cGMPs), to assure that the facilities, methods and controls are adequate to preserve the biologic&#146;s identity, strength, quality and purity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of potential inspection of selected clinical investigation sites to assess compliance
with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications
for use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Once a product candidate is identified for development, it enters the
preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing
information and analytical data, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans. An IND will also include a protocol detailing, among other things, the objectives
of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the trial includes an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND
automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, places the IND on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with FDA
requirements, in which case clinical trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Clinical trials involve the administration of the investigational product to human subjects, and must be conducted under the
supervision of one or more qualified investigators in accordance with GCPs, which include, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
among other things, the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials must be conducted under
protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND, and a separate
submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials
and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected
suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs or biologics, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically
important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Furthermore, an independent IRB or ethics committee at each institution participating in the clinical trial must review and
approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the
study until completed and otherwise comply with IRB regulations. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable
health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the biologic has been associated with
unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may
determine whether a trial may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries,
including clinicaltrials.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Human clinical trials are typically conducted in three sequential phases that may overlap
or be combined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 1</I></B>:&#8195;The product candidate is initially introduced into healthy human subjects and
tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 2</I></B>:&#8195;The product candidate is administered to a limited patient population with a
specified disease or condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance and appropriate dosage.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 3</I></B>:&#8195;The product candidate is administered to an expanded patient population to
further evaluate dosage, to provide substantial evidence of efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio
of the product candidate and provide an adequate basis for product labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Post-approval trials,
sometimes referred to as Phase 4 studies, may be conducted after BLA approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the
performance of Phase 4 clinical trials as a condition of approval of a BLA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Concurrent with clinical trials, companies
usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the biologic and finalize a process for manufacturing the product in commercial quantities in accordance with
cGMPs. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final
product. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>BLA Review and Approval Process </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Assuming successful completion of all required testing in accordance with applicable regulatory requirements, the results of
product development, including among other things, results, from nonclinical studies and clinical trials, are submitted to the FDA as part of a BLA requesting approval to market the product candidate for one or more indications. The BLA must include
all relevant data available from preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and
proposed labeling, among other things. Data can come from company-sponsored clinical studies, or from a number of alternative sources, such as studies initiated by investigators or other third parties. The submission of a BLA requires payment of a
substantial user fee to FDA, and the sponsor of an approved BLA is also subject to an annual program fee. A waiver of user fees may be obtained under certain limited circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA conducts a preliminary review of all BLAs within the first 60 days after submission, before accepting them for filing,
to determine whether they are sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event,
the BLA must be resubmitted with the additional information before FDA will review the application. Once filed, the FDA reviews a BLA to determine, among other things, whether the biologic is safe, pure and potent and the facility in which it is
manufactured, processed, packed, or held meets standards designed to assure the product&#146;s continued safety, purity and potency. Under the Prescription Drug User Fee Act (PDUFA), guidelines that are currently in effect, the FDA has a goal of ten
months from the date of &#147;filing&#148; of an original BLA to review and act on the submission. This review typically takes twelve months from the date the BLA is submitted to the FDA because the FDA has approximately two months to make a
&#147;filing&#148; decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may refer an application for a novel biologic to an advisory committee. An advisory
committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by
the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured.
Additionally, before approving a BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCPs. After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or
its substance will be produced, the FDA may issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the biologic with prescribing information for specific indications. A CRL indicates that
the review cycle for the application is complete, and the application will not be approved in its present form. A CRL usually describes the specific deficiencies in the BLA identified by the FDA and may include requirements to conduct additional
clinical trials, or other significant and time-consuming requirements related to clinical data, nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the BLA, addressing all of the deficiencies identified in the letter,
or withdraw the application. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a product receives regulatory approval, referred to as &#147;licensure&#148; by the FDA, such approval may be significantly
limited to specific diseases and dosages, or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor of an approved BLA to conduct post-marketing clinical
trials designed to further assess a biologic&#146;s safety, purity or potency, and may also require testing and surveillance programs to monitor the safety of the product, once commercialized, and may limit further marketing of the product based on
the results of these post-marketing studies. The FDA may also place other conditions on BLA approval. Including the requirement for a risk evaluation and mitigation strategy (REMS) to assure the safe use of the product. If the FDA concludes a REMS
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
is needed, the sponsor of the BLA must submit a proposed REMS in connection with the application. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include
medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the
commercial promotion, distribution, prescription or dispensing of commercial products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the Pediatric
Research Equity Act (PREA), requires a sponsor to conduct pediatric clinical trials for most biologics, as well as for new indications, new dosage forms, new dosing regimens or new route of administrations. Under PREA, original BLAs and supplements
must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and
support dosing and administration for each pediatric subpopulation for which the product is deemed safe, pure and potent. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A
deferral may be granted for several reasons, including a finding that the biologic is ready for approval for use in adults before pediatric clinical trials are complete or that additional data need to be collected before the pediatric clinical
trials begin. The FDA must send a <FONT STYLE="white-space:nowrap">non-compliance</FONT> letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric
formulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan Designation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the Orphan Drug Act, the FDA may grant orphan designation to a biologic intended to treat a rare disease or condition,
which is a disease or condition that affects fewer than 200,000 individuals in the United States or where, if the disease or condition affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of
developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan
designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which
it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same biologic for the same disease or condition for seven years, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such biologic also entitles a party to financial incentives such as
opportunities for grant funding towards clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. However, competitors, may receive approval of different products for the disease or condition for which the
orphan product has exclusivity, or obtain approval for the same product but for a different disease or condition for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of a competing product for seven years if
a competitor obtains approval of the &#147;same drug,&#148; as defined by the FDA, or if a the biologic is determined to be contained within the competitor&#146;s product for the same disease or condition. In addition, if an orphan-designated
product receives approval for a disease or condition broader than covered in the orphan designation, the product may not be entitled to orphan exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expedited Development and Review Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA has a number of programs intended to expedite the development or review of a marketing application for an
investigational biologic. For example, the fast track designation program is intended to expedite or facilitate the process for developing and reviewing product candidates that meet certain criteria. Specifically, investigational biologics are
eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The sponsor of a fast track product
candidate has opportunities for more frequent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
interactions with the applicable FDA review team during product development and, once a BLA is submitted, the application may be eligible for priority review. With regard to a fast track product
candidate, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of
the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough
therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs
or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast
track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any product candidate submitted to the FDA for approval, including a product candidate with a fast track designation or
breakthrough designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A BLA is eligible for priority review if the product candidate is designed
to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of a BLA designated for priority
review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of original BLAs under its current PDUFA review goals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, a product candidate may be eligible for accelerated approval. A biological product candidate intended to
treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a
clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or
prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a sponsor of a biologic receiving accelerated approval perform adequate and well-controlled confirmatory
clinical trials, and may require that such confirmatory trials be underway prior to granting accelerated approval. Biologics receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the
required confirmatory trials in a timely manner or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition of accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of
promotional materials, which could adversely impact the timing of the commercial launch of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fast track
designation, breakthrough therapy designation, priority review, and accelerated approval do not change the standards for approval, but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these
programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Post-approval Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Biologics are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating
to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other
labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and
certain state agencies, and are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our
third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and
correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and
quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The FDA may withdraw
approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of requirements for post-market studies or clinical
studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical holds on ongoing or planned clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, the FDA closely regulates the marketing, labeling, advertising and promotion of biological products. A company
can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting
the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal
penalties. Physicians may prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT>
uses are common across medical specialties. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of
physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Biosimilars and Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Affordable Care Act, signed into law in 2010, includes a subtitle called the BPCIA, which created an abbreviated approval
pathway for biological products that are biosimilar to or interchangeable with an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product
and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the
product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may
be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date
that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#146;s own preclinical
data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture,
it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted,
adds six months to existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary
completion of a pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by
authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, pricing reporting, and physician payment
transparency laws and regulations regarding drug pricing and payments or other transfers of value made to physicians and other licensed healthcare professionals as well as similar foreign laws in the jurisdictions outside the United States.
Violation of any of such laws or any other governmental regulations that apply may result in significant penalties, including, without limitation, administrative civil and criminal penalties, damages, disgorgement fines, additional reporting
requirements and oversight obligations, contractual damages, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and/ or imprisonment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Successful sales of our drug candidates in the U.S. market, if approved, will depend, in part, on the extent to which our drugs
will be covered by third-party payors, such as government health programs or private health insurance (including managed care plans). Patients generally rely on such third-party payors to reimburse all or part of the costs associated with their
prescriptions and therefore adequate coverage and reimbursement from such third-party payors are critical to new and ongoing product acceptance. Coverage and reimbursement policies for drug products can differ significantly from payor to payor as
there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and
reimbursement is often time consuming and costly. Further, third-party payors are increasingly reducing reimbursements for medical drugs and services and implementing measures to control utilization of drugs (such as requiring prior authorization
for coverage). For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate
reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Additionally, the containment of healthcare costs has become a priority of
federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price
controls, restrictions on reimbursement and requirements for substitution of generic drugs. Adoption or expansion of price controls and cost-containment measures could further limit our net revenue and results. Decreases in third-party reimbursement
for our drug candidates, if approved, or a decision by a third-party payor to not cover our drug candidates could have a material adverse effect on our sales, results of operations and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">General legislative cost control measures may also affect reimbursement for our products. If we obtain approval to market a
drug candidate in the United States, we may be subject to spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs and/or any significant taxes or fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost
containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For example, in March 2010, the Affordable Care Act (ACA), was enacted in the United States and substantially changed the way
healthcare is financed by both the government and private insurers. The ACA contains provisions that may reduce the profitability of drug products. Among other things, the ACA established an annual, nondeductible fee on any entity that manufactures
or imports specified branded prescription drugs and biologic agents; extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded eligibility
criteria for Medicaid programs; expanded the entities eligible for discounts under the 340B drug pricing program; and increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program. Since its enactment, there
have been executive, judicial and Congressional challenges to certain aspects of the ACA. On June&nbsp;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on
the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, other legislative
changes have been proposed and adopted since the ACA was enacted. On March&nbsp;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a
drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&nbsp;1, 2024. Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in
light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries, presidential executive orders and proposed and enacted federal and state legislation designed to, among other things,
bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Most recently, on August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. Among other
things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize
price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS)
to implement many of these provisions through guidance, as opposed to regulation, for the initial years. On August&nbsp;29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug
price negotiation program is currently subject to legal challenges. In addition, in response to the Biden administration&#146;s October 2022 executive order, on February&nbsp;14, 2023, HHS released a report outlining three new models for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear
whether the models will be utilized in any health reform measures in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or reimbursement constraints, discounts, restrictions on certain product access and marketing cost
disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to
determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Existing healthcare reform measures, as well as the implementation of additional cost containment measures or other reforms
may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and
Security Laws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Numerous state, federal, and foreign laws, regulations and standards govern the collection, use,
access to, confidentiality, and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and
regulations, including data breach notification laws, health information privacy and security laws, and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information.
In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate
compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2023, we had 58 employees, all of whom were full-time and 44 of whom were engaged in research and
development activities. Thirteen of our employees hold Ph.D. or M.D. degrees. All laboratory personnel and our administrative team are based in and around Irvine, CA. None of our employees are represented by a labor union or covered under a
collective bargaining agreement. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our human capital resources
objectives include, as applicable: identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and
reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our
objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We currently lease approximately 1,249 square feet of laboratory and office space in and around Irvine, CA. We believe these
facilities will be adequate for the foreseeable future and that suitable additional or substitute space will be available as and when needed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal
Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any
proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense
and settlement costs, diversion of management resources, and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the name, age and position of each of our executive officers and directors as of
October&nbsp;24, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers and Employee Directors</I></B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B><I>&nbsp;</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Kuan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ambaw Bellete</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Operating Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen DiPalma</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vijay Kasturi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors</I></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Liu, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James J. Mul&eacute;, IPh.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leonard Post, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hong Fang &#147;Simone&#148;
Song<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Victor Tong, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Arthur Kuan</I></B> has served as our Chief Executive Officer and as a member of our board of directors since our
inception in 2017. Mr.&nbsp;Kuan is also a founding member of Ally Bridge Group, a global healthcare-focused investment platform, and serves on the IP Commercialization Strategy Committee at Moffit Cancer Center. Previously, Mr.&nbsp;Kuan was a
member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. Mr.&nbsp;Kuan began his career in an
operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Mr.&nbsp;Kuan received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology
from the University of Pennsylvania. Mr.&nbsp;Kuan&#146;s knowledge of our business and experience investing in a number of biopharmaceutical companies contributed to our board of directors&#146; conclusion that he should serve as a director of our
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Ambaw Bellete</I></B> has served as our President and Chief Operating Officer since July 2023. Previously,
Mr.&nbsp;Bellete served as Chief Executive Officer of Lion Healthcare Strategies, a strategic advisory firm, from April 2021 to August 2023, and Chief Operating Officer of FerGene, a gene therapy company dedicated to revolutionizing the treatment of
bladder cancer, from March 2020 to March 2021. Prior to FerGene, Mr.&nbsp;Bellete served as the president of Photocure, a company focused on developing and commercializing pharmaceutical products based on photodynamic technology to treat bladder
cancer, and also held several global leadership positions with biopharma, biotech and medical device companies, including President of Medical Compression Systems from January 2012 to July 2019. Mr.&nbsp;Bellete started his biopharma career at the
Upjohn Company (now Pfizer) and then Sanofi, where he held diverse leadership roles in business development, managed care, marketing and sales positions in specialty, oncology and urology. Mr.&nbsp;Bellete currently serves on the board of directors
The Axiom REACH Foundation and OncoSTING. Mr.&nbsp;Bellete holds a B.S. in Biology and Chemistry from Murray State University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Stephen DiPalma</I></B><I> </I>has served as our Chief Financial Officer since March 2023 and has worked with us as a
consultant and senior advisor regarding our finance operations since March 2021. Mr.&nbsp;DiPalma is a Managing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Director of Danforth Advisors, a professional consultancy that specializes in working with life sciences companies. Prior to and during his tenure at Danforth, Mr.&nbsp;DiPalma has served as
Chief Financial Officer to several public and emerging companies in various stages of development. Mr.&nbsp;DiPalma served as Chief Financial Officer at Forum Pharmaceuticals from 2009 to 2014. Mr.&nbsp;DiPalma holds a B.S. from the University of
Massachusetts and M.B.A. from Babson College. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Vijay Kasturi</I></B> has served as our Chief Medical Officer since
September 2023. Previously, Dr.&nbsp;Kasturi was Vice President of Clinical Development and Medical Affairs of AVEO Pharmaceuticals, a cancer therapeutics company, from April 2021 to August 2023. Prior to AVEO Pharmaceuticals, Dr.&nbsp;Kasturi was
Senior Vice President of Scientific Affairs at FerGene from March 2020 to March 2021. Prior to FerGene, Dr.&nbsp;Kasturi was head of U.S. Medical Affairs, Oncology for EMD Serono, a pharmaceutical company focused on reproductive health, multiple
sclerosis and cancer, from November 2015 to March 2020, where he had responsibility for developing global and regional strategies that brought new therapies to patients in immunology, hematology and oncology. Earlier in his career, Dr.&nbsp;Kasturi
treated patients with cancer and served as an assistant professor of medicine, Division of Hematology-Oncology at the University of Massachusetts Medical School and as the program leader for genitourinary oncology at UMass Memorial Cancer Center.
Dr.&nbsp;Kasturi trained in Hematology-Oncology at the National Cancer Institute (NCI) and worked as an investigator and physician at the NCI and Dartmouth Hitchcock Medical Center. Dr.&nbsp;Kasturi holds an M.D. from Rush Medical College of Rush
University and a B.S. in Biology from University of Illinois, Chicago. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Brian Liu, M.D.</I></B> has served as a member of our board of directors since September 2022. Dr.&nbsp;Liu is a Managing
Director at Longitude Capital, a healthcare venture capital firm, where he has been employed since 2018. Prior to joining Longitude Capital, Dr.&nbsp;Liu was an Engagement Manager in the pharmaceuticals practice of McKinsey&nbsp;&amp; Company from
January 2016 to July 2018. Dr.&nbsp;Liu currently serves on the board of directors of Lassen Therapeutics and as a board observer at Quanta Therapeutics., Rivus Pharmaceuticals and Zenas BioPharma. Dr.&nbsp;Liu previously served as a board observer
at Endeavor Biomedicines, Inflazome (acquired by Roche Holding), Descena Lab, Talaris Therapeutics, and Vera Therapeutics. Dr.&nbsp;Liu holds an M.D. from Stanford School of Medicine and a B.S. in Biomedical Engineering from Johns Hopkins
University. Dr.&nbsp;Liu&#146;s investment experience in the pharmaceutical industry and prior board experience contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>James J. Mul</I></B><B><I>&eacute;</I></B><B><I>, IPh.D.</I></B> has served as a member of our board of directors since
2018. Dr.&nbsp;Mul&eacute; has served as Associate Center Director for Translational Science and the Michael McGillicuddy (U.S. Senator Connie Mack (ret.) &amp; Family) Endowed Chair for Melanoma Research and Treatment since 2003 and is the
Associate Center Director of the Moffitt Cancer Center, Tampa, Florida, where he has served as a Director since 2003. Since 1993, Dr.&nbsp;Mul&eacute; has served multiple tenures as a special government employee to the FDA at the Center for Drug
Evaluation and Research and at the Center for Biologics Evaluation and Research and to the National Cancer Institute (NCI). Dr.&nbsp;Mul&eacute; also served on the board of directors of publicly-traded company Fulgent Genetics from 2016 to 2020.
Dr.&nbsp;Mul&eacute; serves on the advisory boards of numerous biotechnology companies, pharmaceutical companies, <FONT STYLE="white-space:nowrap">NCI-designated</FONT> cancer centers and investment funds, including Buffett Cancer Center, Omaha;
Masonic Cancer Center, Minneapolis; Affyimmune Therapeutics; Aleta Biotherapeutics; OncoPep; Turnstone Biologics; UbiVac; Vault Pharma; Vycellix; and Noble Life Science Partners. Dr.&nbsp;Mul&eacute; holds an Interdisciplinary Ph.D. in Tumor
Immunology, Immunocytology, and Immunopathology from the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, Washington, a M.S. in Cellular Immunology from the University of Washington School of Medicine and a B.A. from
New Jersey City University. Dr.&nbsp;Mul&eacute; received his formal postgraduate training at the Surgery Branch, Division of Cancer Treatment, NCI, National Institutes of Health (NIH), Bethesda, Maryland. Dr.&nbsp;Mul&eacute; has held tenured
senior positions at the NCI/NIH and the University of Michigan, Ann Arbor. Dr.&nbsp;Mul&eacute;&#146;s extensive regulatory, basic, translational and clinical research as well as administration leadership experience in both <FONT
STYLE="white-space:nowrap">non-profit</FONT> and <FONT STYLE="white-space:nowrap">for-profit</FONT> entities and the biopharmaceutical industry contributed to our board of directors&#146; conclusion that he should serve as a director of our company.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Leonard Post, Ph.D</I></B><B>. </B>has served as a member of our board
of directors since 2018. Dr.&nbsp;Post has over three decades of pharmaceutical R&amp;D experience. Since July 2016, Dr.&nbsp;Post has served as Chief Scientific Officer of Vivace Therapeutics, an oncology company working on small molecules
targeting the hippo pathway, and is also Chief Scientific Officer of its sister company Virtuoso Therapeutics, a company working on bispecific antibodies for oncology. From February 2010 until June 2016, Dr.&nbsp;Post worked at BioMarin, in various
positions including Chief Scientific Officer. During that time, he oversaw the initiation of BioMarin&#146;s first gene therapy project for hemophilia A. Prior to that, Dr.&nbsp;Post served as Chief Scientific Officer of LEAD Therapeutics, Senior
Vice President of Research&nbsp;&amp; Development at Onyx Pharmaceuticals, and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. Dr.&nbsp;Post is also currently an advisor to Canaan Partners. Mr.&nbsp;Post currently serves on the
board of directors of uniQure, a publicly-traded biopharmaceutical company, and privately-held biopharmaceutical companies, AceLink Therapeutics, Aniko Pharmaceuticals, Vivace Therapeutics, Orphagen Pharmaceuticals, Fedora Pharma and Oxyrane UK.
Dr.&nbsp;Post also previously served on the board of directors of publicly-traded genetic diagnostics company Fulgent Genetics from August 2022 to October 2022. Dr.&nbsp;Post is a virologist by training and did early work on engineering of herpes
simplex virus as a postdoctoral fellow. Dr.&nbsp;Post has a B.S. in Chemistry from the University of Michigan, and a Ph.D. in Biochemistry from the University of Wisconsin. Dr.&nbsp;Post&#146;s extensive experience in the biotechnology industry, and
specifically in oncolytic viruses, contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Simone Song</I></B> has served as a member of our board of directors since November 2015. Ms.&nbsp;Song is the Founder
and has been a Senior Partner of ORI Capital Limited, a venture capital firm, since July 2015. Prior to ORI Capital, Ms.&nbsp;Song served as the Head of Healthcare Investment Banking for Greater China for Goldman Sachs. Prior to Goldman Sachs,
Ms.&nbsp;Song was a Managing Director of Cowen, a member of the advisory board of AXA Investment Managers, a global investment management firm, and an executive board advisor to AXA Asia Pacific Holdings Limited. Ms.&nbsp;Hong holds a B.A. in
Economics from Fudan University and an M.A. in Economics from Claremont Graduate School. Ms.&nbsp;Song&#146;s extensive experience in the healthcare sector contributed to our board of directors&#146; conclusion that she should serve as a director of
our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Victor Tong, Jr.</I></B> has served as a member of our board of directors since July 2023.
Mr.&nbsp;Tong is a Managing Director at Decheng Capital (Decheng), an investment firm, where he has worked since its inception in 2012 and focuses on investments in biotechnology and medical technology companies in China and the United States.
Before joining Decheng, Mr.&nbsp;Tong was a Principal at Bay City Capital, a life sciences investment firm, and a member of the healthcare investment banking division at Morgan Stanley. Mr.&nbsp;Tong serves on the board of directors of multiple
privately held biotechnology and biopharmaceutical companies including Cellares Corp., EpimAb Biotherapeutics, Harton Therapeutics, Hummingbird Bioscience, LevitasBio, Nalu Medical, Take2, and Watchmaker Genomics. Mr.&nbsp;Tong holds a B.A. in
Molecular and Cell Biology and B.S. in Business Administration from the University of California, Berkeley. Mr.&nbsp;Tong&#146;s investment and board experience in the biopharmaceutical industry contributed to our board of directors&#146; conclusion
that he should serve as a director of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors currently consists of six members. Our board of directors has determined that all of our directors,
other than Mr.&nbsp;Kuan are independent directors in accordance with the listing requirements of the Nasdaq Stock Market (Nasdaq). The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has
not been for at least three years, one of our employees and that neither </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
the director nor any of his or her family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective
determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of the director. In making
these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as they may relate to us and our management.
There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In accordance with the terms of our amended and restated certificate of incorporation that will go into effect immediately
prior to the closing of this offering, our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the directors whose terms then expire will be eligible for reelection until
the third annual meeting following reelection. Effective upon the closing of this offering, our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will be&#8195;&#8195;&#8195;&#8195;, and their terms will expire at our first
annual meeting of stockholders following this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will be&#8195;&#8195;&#8195;&#8195;, and their terms will expire at our second
annual meeting of stockholders following this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will be&#8195;&#8195;&#8195;&#8195;, and their terms will expire at our third
annual meeting of stockholders following this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of
incorporation that will go into effect immediately prior to the closing of this offering will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an
increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors
into three classes with staggered three-year terms may delay or prevent a change of our board of directors or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding voting stock then entitled to vote in an election of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership
Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors is currently chaired by &#8195;&#8195;&#8195;&#8195;&#8195;. Our board of directors
recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as the Company continues to grow. We separate the roles of chief executive officer and chairman of the board of
directors in recognition of the differences between the two roles. The chief executive officer is responsible for setting the strategic direction for our company and the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> leadership and performance of our company, while the chairman of the board of directors provides guidance to the chief executive officer and presides over
meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to managing the board of directors and overseeing our company. Our board of directors has concluded that our current leadership
structure is appropriate at this time. However, our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has responsibility for the oversight of our risk management processes and, either as a whole or through
its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and
members of senior management to enable our board of directors to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory,
strategic and reputational risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The audit committee reviews information regarding liquidity and operations,
and oversees our management of financial risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct
communication with our external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing
whether any of our compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the board of directors, corporate
disclosure practices and potential conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors is regularly informed through committee reports
about such risks. Matters of significant strategic risk are considered by our board of directors as a whole. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees and Independence
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors has established three standing committees &#150; audit, compensation and nominating and
corporate governance &#150; each of which operates under a charter that has been approved by our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The audit committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our
financial statements. This committee&#146;s responsibilities include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the qualifications, independence and performance of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our
independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our
critical accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing with management and the independent registered public accounting firm the results of our annual
audit and the review of our quarterly unaudited financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal
and regulatory requirements as they relate to financial statements or accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board of
directors any changes to such investment policy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and our auditors any earnings announcements and other public announcements regarding
our results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code
of conduct and ethics; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating, at least annually, the performance of the audit committee and its members including
compliance of the audit committee with its charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The members of our audit committee are
Dr.&nbsp;Liu, Ms.&nbsp;Song and&#8195;&#8195;&#8195;&#8195; .&#8195;&#8195;&#8195;&#8195;serves as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and
regulations of the SEC and Nasdaq. Our board of directors has determined that&#8195;&#8195;&#8195;&#8195; is an &#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
financial sophistication as defined under the applicable Nasdaq listing standards. Our board of directors has determined that each of Mr.&nbsp;Kuan, Mr.&nbsp;Liu and Ms.&nbsp;Song is independent
under the applicable rules of the SEC and Nasdaq. Upon the listing of our common stock on Nasdaq, the audit committee will operate under a written charter that satisfies the applicable standards of the SEC and Nasdaq. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our compensation committee approves policies relating to compensation and benefits of our officers and employees. The
compensation committee approves corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives and approves
the compensation of these officers based on such evaluations. The compensation committee also approves the issuance of stock options and other awards under our equity plans. The compensation committee will review and evaluate, at least annually, the
performance of the compensation committee and its members, including compliance by the compensation committee with its charter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The members of our compensation committee are Dr.&nbsp;Liu, Dr.&nbsp;Post and Ms.&nbsp;Song. Ms.&nbsp;Song serves as the
chairperson of the committee. Our board of directors has determined that each of Dr.&nbsp;Liu, Dr.&nbsp;Post and Ms.&nbsp;Song is independent under the applicable Nasdaq listing standards and is a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Upon the listing of our common stock on Nasdaq, the compensation committee
will operate under a written charter, which the compensation committee will review and evaluate at least annually. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate
Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The nominating and corporate governance committee is responsible for assisting our board of
directors in discharging the board of directors&#146; responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or
special meetings of stockholders at which directors are to be elected), and the selection of candidates to fill any vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is
responsible for overseeing our corporate governance policies, reporting and making recommendations to our board of directors concerning governance matters, reviewing and assisting the Board with oversight of matters relating to environmental, social
and governance matters affecting the Company and oversight of the evaluation of our board of directors. The members of our nominating and corporate governance committee are&#8195;&#8195;&#8195;&#8195;.&#8195;&#8195;&#8195;&#8195;serves as the
chairperson of the committee. Our board of directors has determined that each of&#8195;&#8195;&#8195;&#8195;is independent under the applicable Nasdaq listing standards. Upon the listing of our common stock on Nasdaq, the nominating and corporate
governance committee will operate under a written charter, which the nominating and corporate governance committee will review and evaluate at least annually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the members of our compensation committee has ever been one of our officers or employees. None of our executive
officers currently serves, or has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the
closing of this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors
as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for election or appointment, the nominating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
and corporate governance committee and the board of directors will take into account many factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personal and professional integrity, ethics and values; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience in corporate management, such as serving as an officer or former officer of a publicly-held
company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience as a board member or executive officer of another publicly-held company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strong finance experience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversity of expertise and experience in substantive matters pertaining to our business relative to other
board members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversity of background and perspective, including, but not limited to, with respect to age, gender, race,
place of residence and specialized experience; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience relevant to our business industry and with relevant social policy concerns; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relevant academic expertise or other proficiency in an area of our business operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Currently, our board of directors evaluates, and following the closing of this offering will evaluate, each individual in the
context of the board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in
these various areas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We plan to adopt a written code of business conduct and ethics that applies to our directors, officers and employees, including
our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, which will be effective upon the closing of this offering. Upon the closing of this offering, our code
of business conduct and ethics will be available under the Corporate Governance section of our website at https://cgoncology.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of
Nasdaq concerning any amendments to, or waivers from, any provision of the code. We have included our website address in this prospectus solely as an inactive textual reference. The reference to our website address does not constitute incorporation
by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_12"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named
executive officers for 2022, which consist of our principal executive officer during 2022 and our two next most highly compensated executive officers during 2022, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arthur Kuan, Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">James Burke, M.D., Senior Clinical and Medical Advisor and former Chief Medical Officer; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Georg Roth, Ph.D., former Chief Technical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective August&nbsp;14, 2023, Dr.&nbsp;Burke transitioned from the role of Chief Medical Officer to Senior Clinical and
Medical Advisor. Effective August&nbsp;9, 2023, Dr.&nbsp;Roth separated from the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This discussion may contain
forward-looking statements that are based on our current plans, considerations, expectations, and determinations regarding future compensation programs. Actual compensation programs that we adopt following the closing of this offering may differ
materially from the currently planned programs summarized in this discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information
regarding compensation earned with respect to the fiscal year ended December&nbsp;31, 2022 by our named executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022
Summary Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Arthur Kuan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">694,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,229,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">James Burke, M.D.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">344,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Senior Clinical and Medical Advisor and former Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Georg Roth, Ph.D.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">516,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><I>Former Chief Technical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The amounts reported in the &#147;Option Awards&#148; column represent the aggregate grant date fair value of
the stock options awarded to our named executive officers during fiscal year 2022, calculated in accordance with Financial Accounting Standards Board (FASB), Accounting Standards Codification (ASC) Topic 718. The assumptions used in calculating the
grant date fair value of the awards reported in this column are set forth in Note 9 to our audited financial statements included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for the stock options and
do not reflect the actual economic value that will be realized by the individual upon the vesting of the stock options, the exercise of the stock options or the sale of the common stock underlying such awards. See the subsection
&#147;&#151;Narrative to Summary Compensation Table&#151;Equity-Based Incentive Awards&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Amounts reflect performance bonuses earned by each executive in 2022, which were paid in early 2023.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Amounts reflect $8,432 and $8,393 in 401(k) matching contributions for Dr.&nbsp;Burke and Dr.&nbsp;Roth,
respectively, and $760 in Company-paid premiums for long-term disability insurance and $370 in Company-paid premiums for life insurance for each of Mr.&nbsp;Kuan, Dr.&nbsp;Burke, and Dr.&nbsp;Roth. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Amount reflects a <FONT STYLE="white-space:nowrap">one-time</FONT> referral bonus paid to Dr.&nbsp;Roth.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Base Salary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The compensation of our named executive officers is generally determined and approved by our board of directors. The 2022 base
salaries of each of our named executive officers are described below under the subsection titled &#147;&#151;Employment Arrangements with our Named Executive Officers&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Bonus </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash bonuses, which
are designed to provide appropriate incentives to our executives to achieve annual corporate goals and to reward our executives for individual achievement towards these goals. The annual performance-based bonus each named executive officer is
eligible to receive is based on the extent to which we achieve the corporate goals that our board of directors establishes each year. At the end of the year, our board of directors reviews our performance against each corporate goal and determines
the extent to which we achieved each of our corporate goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For 2022, Mr.&nbsp;Kuan, Dr.&nbsp;Burke, and Dr.&nbsp;Roth
were each eligible to earn a target annual bonus equal to 40%, 35%, and 35% of their respective annual base salaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
corporate goals the board of directors established for 2022 related to regulatory, clinical and development goals, as well as operational objectives. In February 2023, our board of directors determined that the 2022 goals were achieved at 100% of
targeted levels. The board of directors awarded cash bonuses to Mr.&nbsp;Kuan, Dr.&nbsp;Burke, and Dr.&nbsp;Roth in the amounts of $140,000, $133,000, and $124,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective January&nbsp;1, 2023, the target annual bonuses for Dr.&nbsp;Burke and Dr.&nbsp;Roth were each increased to 40% of
such executive&#146;s respective annual base salary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Incentive Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our equity-based incentive awards are designed to align our interests and those of our stockholders with those of our
employees, including our executive officers. The board of directors or an authorized committee thereof is responsible for approving equity grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, we have granted stock options pursuant to our 2015 Equity Incentive Plan (2015 Plan) and our 2022
Incentive Award Plan (2022 Plan). Following this offering, we will grant equity awards under the terms of our 2024 Incentive Award Plan (2024 Plan). The terms of our equity plans are described below under the subsection titled &#147;&#151;Equity
Incentive Plans&#148; below. All options are granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant of such award as determined by our board of directors based on an independent
third-party valuation. Our stock option grants generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. In addition, from time to time our board
of directors has also granted performance-based stock options, the vesting of which is tied to key clinical or regulatory milestones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2022, Mr.&nbsp;Kuan was granted an option to purchase 114,343 shares of our common stock pursuant to our 2015
Plan. The option has an exercise price of $0.19 per share, the fair market value on the date of grant as determined by our board of directors based on an independent third-party valuation. The option was fully vested as of the date of grant. In
addition, in October 2022, Mr.&nbsp;Kuan was granted an option to purchase 3,900,000 shares of our common stock pursuant to our 2022 Plan. The option has an exercise price of $0.24 per share, the fair market value on the date of grant as determined
by our board of directors based on an independent third-party valuation. The option vests over a period of four years, with 1/48<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the shares underlying the option vesting monthly, subject to
Mr.&nbsp;Kuan&#146;s continuous service with us as of each such vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In February 2022, Dr.&nbsp;Burke and
Dr.&nbsp;Roth were each granted an option to purchase 38,229 shares and 47,285 shares of our common stock, respectively, pursuant to our 2015 Plan. The options have an exercise price of $0.19 per share, the fair market value on the date of grant as
determined by our board of directors based on an independent third-party valuation. The options were fully vested as of the date of grant. In October 2023, Mr.&nbsp;Kuan was granted an option to purchase 5,000,000 shares of our common stock pursuant
to our 2022 Plan. The option has an exercise price of $0.70 per share, the fair market value on the date of grant as determined by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
our board of directors based on an independent third-party valuation, and vests over a period of four years, with 1/48th of the shares underlying the option vesting monthly, subject to
Mr.&nbsp;Kuan&#146;s continuous service with us as of each such vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, pursuant to the Burke
Transition Agreement (defined below), on August&nbsp;15, 2023, Dr.&nbsp;Burke was granted an option to purchase 300,000 shares of our common stock pursuant to our 2022 Plan. The option has an exercise price of $0.53 per share, the fair market value
on the date of grant as determined by our board of directors based on an independent third-party valuation, and vests as follows: (i) 150,000 shares vest upon the filing with the FDA of the Company&#146;s BLA with respect to cretostimogene, and (ii)
150,000 shares vest upon approval of such BLA by the FDA prior to December&nbsp;31, 2026, in each case subject to Dr.&nbsp;Burke&#146;s continued service with the Company through such date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2022 Fiscal Year End</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table presents information regarding the outstanding stock options held by each of our named executive officers
as of December&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant</B><br><B>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underlying</B><br><B>Unexercised</B><br><B>Options</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Securities</B><br><B>Underling</B><br><B>Unexercised</B><br><B>Options</B><br><B>Unexercisable<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Exercise<BR>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Kuan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">05/25/16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,701,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">05/25/26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/12/19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/12/29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/23/31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/19/21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,764,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/18/31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/28/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/28/32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/19/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,737,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/19/32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Burke, M.D.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/12/19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/12/29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/13/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/13/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/22/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/22/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/22/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/22/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/16/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,722,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944,404</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/16/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/16/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666,638</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/16/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Georg Roth, Ph.D.,<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/13/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">01/13/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/22/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">04/22/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/22/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">07/22/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/16/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,148,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">629,603</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/16/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/16/20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444,425</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/16/30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/24/32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">These awards are subject to potential acceleration of vesting in connection with a qualifying termination of
employment following a change in control, as described below under the subsection titled &#147;&#151;Employment Arrangements with our Named Executive Officers&#148; below. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The options vest over a period of four years, with 1/48th of the shares underlying the option vesting on the
monthly anniversary of the vesting commencement date (December 19, 2022), subject to Mr.&nbsp;Kuan&#146;s continuous service with us through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">The options vest over a period of four years, with 25% of the shares subject to the options vesting on the
first anniversary of the vesting commencement date (May 1, 2020), and the remaining shares vesting in equal monthly installments thereafter over the subsequent three-year period, subject, respectively, to Dr.&nbsp;Burke and Dr.&nbsp;Roth&#146;s
continuous services with us through each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Half of the shares subject to the options vested upon the Company&#146;s closing of our Series E capital
financing by December&nbsp;31, 2022, and the remaining half of the shares subject to the options vest upon the completion of the Company&#146;s initial public offering or a change in control. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">In connection with Dr.&nbsp;Roth&#146;s separation from the Company on August&nbsp;9, 2023, all of his
unvested stock options were forfeited effective as of the separation date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements with Our Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into employment agreements with each of our named executive officers which governs the terms of their
employment with us. Pursuant to their employment agreements, Mr.&nbsp;Kuan, Dr.&nbsp;Burke and Dr.&nbsp;Roth are each entitled to an annual base salary of $450,000, $368,567, and $346,698, respectively (Dr.&nbsp;Burke and Dr.&nbsp;Roth&#146;s base
salaries were increased to $402,401 and $367,777, respectively, effective as of January&nbsp;1, 2023). In addition, in accordance with their employment agreements, Mr.&nbsp;Kuan, Dr.&nbsp;Burke and Dr.&nbsp;Roth are eligible to earn an annual bonus
at a target amount of 40%, 35%, and 35%, respectively, (which target amounts for Dr.&nbsp;Burke and Dr.&nbsp;Roth were increased to 40% effective January&nbsp;1, 2023) of their base salaries actually paid for the year to which such annual bonus
relates, subject to the achievement of performance objectives as determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Regardless of the
manner in which our named executive officers&#146; employment terminates, they are entitled to receive certain accrued amounts previously earned during their employment, including unpaid salary, reimbursement of expenses owed, and accrued but unpaid
paid time off and any continuation of benefits required by applicable law. In addition, our named executive officers are entitled to certain severance benefits under their employment agreements, subject to their execution of a release of claims and
compliance with post-termination obligations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Arthur Kuan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Mr.&nbsp;Kuan&#146;s employment agreement provides for severance benefits for certain terminations that arise during and
outside a change in control period. Upon a termination without cause or a resignation for good reason outside of the period commencing upon a change in control and continuing until 18 months after such change in control (such period, the
&#147;change in control period&#148;), Mr.&nbsp;Kuan is entitled to (i)&nbsp;an amount in cash equal to his annual base salary, payable in a lump sum, (ii)&nbsp;payment or reimbursement of the COBRA premiums for Mr.&nbsp;Kuan and his eligible
dependents, or if COBRA is not available under our group health plan, a cash amount equal to such payments or reimbursements, for a maximum period of up to 12 months from the date of Mr.&nbsp;Kuan&#146;s termination of employment, (iii)&nbsp;an
amount in cash equal to his target annual bonus, prorated for the portion of the year that elapsed prior to the date of Mr.&nbsp;Kuan&#146;s termination of employment, payable in a lump sum, and (iv)&nbsp;accelerated vesting of the unvested portion
of Company equity awards that would have vested during the 12 months following the date of Mr.&nbsp;Kuan&#146;s termination of employment had he continued in employment with the Company during such period; provided, however, that any
performance-based equity awards shall remain subject to attainment of the relevant performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon a termination
without cause or a resignation for good reason within the change in control period, Mr.&nbsp;Kuan is entitled to (i)&nbsp;an amount in cash equal to his annual base salary, payable in a lump sum, (ii)&nbsp;payment or reimbursement of the COBRA
premiums for Mr.&nbsp;Kuan and his eligible dependents, or if COBRA is not available under our group health plan, a cash amount equal to such payments or reimbursements, for a maximum period of up to 12 months from the date of Mr.&nbsp;Kuan&#146;s
termination of employment, (iii)&nbsp;an amount in cash equal to his target annual bonus, payable in a lump sum, and (iv)&nbsp;full accelerated vesting of all unvested Company equity awards; provided, however, that any performance-based equity
awards shall remain subject to attainment of the relevant performance goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>James Burke, M.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Burke&#146;s employment agreement provided for severance benefits for certain terminations that arise during and
outside a change in control period. Upon a termination without cause or a resignation for good reason outside of a change in control period (as such terms are defined below), Dr.&nbsp;Burke was entitled to (i)&nbsp;an amount in cash equal to 0.5
times his annual base salary, payable in a lump sum, and (ii)&nbsp;payment or reimbursement of the COBRA premiums for Dr.&nbsp;Burke and his eligible dependents, or if COBRA was not available under our group health plan, a cash amount equal to such
payments or reimbursements, for a maximum period of up to 6 months from the date of Dr.&nbsp;Burke&#146;s termination of employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon a termination without cause or a resignation for good reason within 18
months after a change in control (such period, the &#147;change in control period&#148;), Dr.&nbsp;Burke was entitled to (i)&nbsp;an amount in cash equal to 0.75 times his annual base salary, payable in a lump sum, (ii)&nbsp;payment or reimbursement
of the COBRA premiums for Dr.&nbsp;Burke and his eligible dependents, or if COBRA was not available under our group health plan, a cash amount equal to such payments or reimbursements, for a maximum period of up to 9 months from the date of
Dr.&nbsp;Burke&#146;s termination of employment, (iii)&nbsp;an amount in cash equal to his target annual bonus, payable in a lump sum, and (iv)&nbsp;full accelerated vesting of all unvested Company equity awards; provided, however, that any
performance-based equity awards would remain subject to attainment of the relevant performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Burke&#146;s employment agreement was superseded by his transition agreement, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Transition Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;21, 2023, the Company and Dr.&nbsp;Burke entered into a transition agreement, which was subsequently amended and
restated effective August&nbsp;9, 2023 (as amended, the Burke Transition Agreement). The Burke Transition Agreement provides that Mr.&nbsp;Burke will continue to be employed by the Company until December&nbsp;31, 2023 (the Burke Role Conversion
Date). Prior to the Burke Role Conversion Date, Dr.&nbsp;Burke continued to serve as Chief Medical Officer of the Company until his replacement commenced employment with the Company on August&nbsp;14, 2023, after which Dr.&nbsp;Burke serves as
Senior Clinical and Scientific Advisor of the Company. In addition, prior to the Burke Role Conversion Date, Dr.&nbsp;Burke will continue to receive his base salary, remain eligible to participate in the Company&#146;s annual incentive program and
health and welfare benefit plans, and his outstanding equity awards will continue to vest in accordance with their terms. Pursuant to the Burke Transition Agreement, Dr.&nbsp;Burke was also granted an option to purchase 300,000 shares of the
Company&#146;s common stock. For additional details regarding the terms of this option award, see the subsection titled &#147;&#151;Narrative to Summary Compensation Table&#151;Equity-Based Incentive Awards&#148; above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the Burke Role Conversion Date, Dr.&nbsp;Burke will transition to a consulting position with the Company, serving as
Scientific Advisor to the Chief Executive Officer. Dr.&nbsp;Burke&#146;s consulting services will terminate on the earliest of (i)&nbsp;the date the FDA approves the Company&#146;s BLA with respect to cretostimogene, (ii)&nbsp;December&nbsp;31,
2026, (iii) the date of a Change in Control (as defined in the Burke Transition Agreement), or (iv)&nbsp;such earlier date on which the Burke Consulting Agreement terminates pursuant to its terms. In the event that Dr.&nbsp;Burke&#146;s employment
with the Company terminates prior to the Burke Role Conversion Date by reason of (i)&nbsp;his discharge by the Company without cause, or (ii)&nbsp;his resignation for good reason (as such terms are defined in the Burke Transition Agreement), there
will be no consulting period, but Dr.&nbsp;Burke will be entitled to receive the severance benefits pursuant to his employment agreement. In addition, if the Company terminates Dr.&nbsp;Burke&#146;s employment without cause prior to the Burke Role
Conversion Date, then (i)&nbsp;all of Dr.&nbsp;Burke&#146;s unvested stock options will accelerate and vest in their entirety, except for the Second Milestone Option (as defined below) and the Third Milestone Option (as defined below), (ii) all of
Dr.&nbsp;Burke&#146;s vested stock options, including the stock options that vest pursuant to clause (i)&nbsp;above, will remain exercisable until the earlier of December&nbsp;31, 2026 or the original expiration date of such stock options, and
(iii)&nbsp;the Second Milestone Option will remain outstanding until December&nbsp;31, 2026 as if Dr.&nbsp;Burke remained a service provider to the Company during such period, and shall remain eligible to vest if the vesting conditions are satisfied
prior to such date (and if it does so vest, it shall remain exercisable until the earlier of December&nbsp;31, 2026 and the original expiration date of the Second Milestone Options). The &#147;Second Milestone Option&#148; means the stock option to
purchase 666,638 shares of the Company&#146;s common stock granted to Dr.&nbsp;Burke on November&nbsp;16, 2020 that is eligible to vest upon the occurrence of this initial public offering or a change in control. The &#147;Third Milestone
Option&#148; means the stock option to purchase 300,000 shares of the Company&#146;s common stock granted to Dr.&nbsp;Burke on August&nbsp;15, 2023, 50% of which is eligible to vest upon the submission of certain FDA filings on or before
December&nbsp;31, 2025 and 50% of which is eligible to vest upon the approval of certain FDA filings on or before December&nbsp;31, 2026. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Georg Roth, Ph.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Roth&#146;s employment agreement provided for severance benefits for certain terminations that arise during and
outside a change in control period. Upon a termination without cause or a resignation for good reason outside of a change in control period (as such terms are defined below), Dr.&nbsp;Roth was entitled to (i)&nbsp;an amount in cash equal to 0.5
times his annual base salary, payable in a lump sum, and (ii)&nbsp;payment or reimbursement of the COBRA premiums for Dr.&nbsp;Roth and his eligible dependents, or if COBRA was not available under our group health plan, a cash amount equal to such
payments or reimbursements, for a maximum period of up to 6 months from the date of Dr.&nbsp;Roth&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon a termination without cause or a resignation for good reason within 18 months after a change in control (such period, the
&#147;change in control period&#148;), Dr.&nbsp;Roth was entitled to (i)&nbsp;an amount in cash equal to 0.75 times his annual base salary, payable in a lump sum, (ii)&nbsp;payment or reimbursement of the COBRA premiums for Dr.&nbsp;Roth and his
eligible dependents, or if COBRA was not available under our group health plan, a cash amount equal to such payments or reimbursements, a maximum period of up to 9 months from the date of Dr.&nbsp;Roth&#146;s termination of employment, (iii)&nbsp;an
amount in cash equal to his target annual bonus, payable in a lump sum, and (iv)&nbsp;full accelerated vesting of all unvested Company equity awards; provided, however, that any performance-based equity awards would remain subject to attainment of
the relevant performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Dr.&nbsp;Roth&#146;s employment agreement was superseded by his transition agreement, as
described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Transition Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On June&nbsp;26, 2023, the Company and Dr.&nbsp;Roth entered into a transition agreement (the Roth Transition Agreement), which
provided that Dr.&nbsp;Roth would continue in his position with the Company as Chief Technical Officer until the earlier of (i)&nbsp;September&nbsp;1, 2023, and (ii)&nbsp;the date a successor to his position was appointed or commenced employment
with the Company (the Roth Role Conversion Date). Prior to the Roth Role Conversion Date, Dr.&nbsp;Roth would continue to receive his base salary, remain eligible to participate in the Company&#146;s annual incentive program and health and welfare
benefit plans, and his outstanding equity awards would continue to vest in accordance with their terms. Upon the Roth Role Conversion Date, Dr.&nbsp;Roth would transition to a consulting position with the Company, serving as CMC Advisor to the Chief
Executive Officer. In the event that Dr.&nbsp;Roth&#146;s employment with the Company terminated prior to the Roth Role Conversion Date by reason of (i)&nbsp;his discharge by the Company without cause, or (ii)&nbsp;his resignation for good reason
(as such terms are defined in the Roth Transition Agreement), there would be no consulting term, but Dr.&nbsp;Roth would be entitled to receive the severance benefits pursuant to his employment agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective August&nbsp;9, 2023, Dr.&nbsp;Roth&#146;s employment with the Company terminated and Dr.&nbsp;Roth and the Company
entered into a separation agreement and general release executed on August&nbsp;16, 2023 (the Roth Separation Agreement), as further described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Separation Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the Roth Separation Agreement, in exchange for Dr.&nbsp;Roth&#146;s release of claims against the Company,
Dr.&nbsp;Roth received, or will receive, the following severance benefits: (i)&nbsp;an amount in cash equal to 0.5 times his annual base salary, paid in a lump sum, (ii)&nbsp;payment or reimbursement of the COBRA premiums for Dr.&nbsp;Roth and his
eligible dependents, or if COBRA is not available under our group health plan, a cash amount equal to such payments or reimbursements, until the earlier of February&nbsp;29, 2024 or the date that he is eligible for comparable coverage from a
subsequent employer, (iii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rated</FONT> annual bonus for 2023 based on the portion of the year that elapsed prior to his termination of employment and upon our actual performance relative to corporate
objectives for the 2023 year, payable when annual bonuses are paid to Company employees generally but no later than March&nbsp;15, 2024, and (iv)&nbsp;an extension of the final exercise dates of certain of Dr.&nbsp;Roth&#146;s vested Company stock
options that were granted to him in 2020 and 2022. Dr.&nbsp;Roth&#146;s receipt of these severance benefits is subject to and conditioned upon his continued compliance with certain restrictive covenants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Health and Welfare Benefits; Perquisites </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of our current named executive officers are eligible to participate in our employee benefit plans, including our medical,
dental, vision, disability, and life insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. Our
board of directors may elect to adopt qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> benefit plans in the future if it determines that doing so is in our best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our named
executive officers are eligible to participate in a defined contribution retirement plan that provides eligible employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees may defer eligible compensation on a <FONT
STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) basis, up to the statutorily prescribed annual limits on contributions under the Code. Contributions are allocated to each participant&#146;s
individual account and are then invested in selected investment alternatives according to the participants&#146; directions. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code with the 401(k) plan&#146;s related trust
intended to be tax exempt under Section&nbsp;501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, contributions to the 401(k) plan (except for Roth contributions) and earnings on those contributions are not
taxable to the employees until distributed from the 401(k) plan. Under the 401(k) plan, we provide matching contributions equal to 100% of the first 4% of eligible compensation deferred by our employees, not to exceed 1% of an employee&#146;s
eligible compensation. Our board of directors may elect to adopt qualified or nonqualified retirement plans in the future, if it determines that doing so is in our best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clawback Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In
connection with this offering, we intend to adopt a compensation recovery policy that is compliant with the Nasdaq Listing Rules, as required by the Dodd-Frank Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The principal features of our equity incentive plans are summarized below. These summaries are qualified in their entirety by
reference to the actual text of the applicable plan, each of which is or will be filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2024 Incentive Award Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, we intend to adopt and ask our stockholders to approve the 2024 Plan, which would become effective in
connection with this offering. Under the 2024 Plan, we may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent for which we compete. The material terms of the 2024 Plan, as it is
currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving, and implementing the 2024 Plan and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility and administration.</I> Our employees, consultants and directors, and employees and consultants of our
subsidiaries, will be eligible to receive awards under the 2024 Plan. Following our initial public offering, the 2024 Plan will generally be administered by our board of directors with respect to awards to
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and by our compensation committee with respect to other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred
to collectively as the plan administrator below), subject to certain limitations that may be imposed under the 2024 Plan, Section&nbsp;16 of the Exchange Act and/or stock exchange rules, as applicable. The plan administrator will have the authority
to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the administration of, the 2024 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and
conditions of all awards under the 2024 Plan, including any vesting and vesting acceleration conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Limitation on awards and shares available. </I>The number of shares
initially available for issuance under awards granted pursuant to the 2024 Plan will be the sum of (1)&nbsp;approximately&#8195;&#8195;&#8195;&#8195;% of the shares of our common stock outstanding upon the closing of this offering, plus (2)&nbsp;any
shares of our common stock which, as of the effective date of the 2024 Plan, remain available for issuance under the 2022 Plan, plus (3)&nbsp;any shares subject to outstanding awards under the 2015 Plan and 2022 Plan as of the effective date of the
2024 Plan that become available for issuance under the 2024 Plan thereafter in accordance with its terms. The number of shares initially available for issuance will be increased on January&nbsp;1 of each calendar year beginning in 2025 and ending in
2034, by an amount equal to the lesser of (a)&#8195;&#8195;&#8195;&#8195;% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b)&nbsp;such smaller number of shares as determined by our board of
directors. No more than&#8195;&#8195;&#8195;&#8195;shares of common stock may be issued upon the exercise of incentive stock options under the 2024 Plan. Shares issued under the 2024 Plan may be authorized but unissued shares, shares purchased on
the open market or treasury shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an award under the 2024 Plan or the 2022 Plan expires, lapses or is terminated,
exchanged for or settled in cash, surrendered, repurchased, cancelled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring shares covered by the award at a price not greater than the price
paid by the participant for such shares or not issuing any shares covered by the award, any shares subject to such award will, as applicable, become or again be available for new grants under the 2024 Plan. Awards granted under the 2024 Plan upon
the assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant
under the 2024 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards. </I>The 2024 Plan provides for the grant of stock options, including incentive stock
options (ISOs) within the meaning of Section&nbsp;422 of the Code, and nonqualified stock options (NSOs); restricted stock; dividend equivalents; restricted stock units (RSUs); stock appreciation rights (SARs); and other stock or cash-based awards.
Certain awards under the 2024 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2024
Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be
settled in shares of our common stock, but the plan administrator may provide for cash settlement of any award. A brief description of each award type follows. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock options. </I>Stock options provide for the purchase of shares of our common stock in the future at an
exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. The
exercise price of a stock option will not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute
options granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined by the plan
administrator may apply to stock options and may include continued service, performance and/or other conditions. ISOs generally may be granted only to our employees and employees of our parent or subsidiary corporations, if any.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>SARs.</I> SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation
of the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR will not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain substitute
SARs granted in connection with a corporate transaction), and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance and/or other
conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted stock and RSUs.</I> Restricted stock is an award of nontransferable shares of our common stock
that remain forfeitable unless and until specified conditions are met, and which may be subject to a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified conditions are met. Delivery of the
shares underlying RSUs may be deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on continuing service, the
attainment of performance goals and/or such other conditions as the plan administrator may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other stock or cash-based awards.</I> Other stock or cash-based awards are awards of cash, fully vested
shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash-based awards may be granted to participants and may also be available as a payment form in
the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees, or other cash compensation otherwise payable to any individual who is eligible to receive awards. The plan administrator will determine the
terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service, performance and/or other conditions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend equivalents.</I> RSUs or other stock and cash-based awards may be accompanied by the right to
receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Such dividend equivalents will only be paid out to the extent that any vesting conditions are subsequently satisfied, unless
otherwise determined by the plan administrator. No dividend equivalents will be payable on stock options or SARs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Performance awards</I>. Performance awards include any of the foregoing awards that are granted subject to vesting and/or
payment based on the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively determinable. Performance criteria upon which performance goals are established by the plan
administrator may include: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization and <FONT STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or
revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including, but not limited to, gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios
or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on
assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per
share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating
to research, development, regulatory, commercial or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service;
employee satisfaction; recruitment and maintenance of personnel; human capital management (including diversity and inclusion); supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including
those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing
initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to our performance or the performance of a subsidiary, division,
business segment or business unit, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Director compensation</I>. The 2024 Plan provides that the plan administrator may establish compensation for <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors from time to time subject to the 2024 Plan&#146;s limitations. Prior to this offering, our stockholders will approve the initial terms of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, which is described below under the subsection titled &#147;&#151;Director Compensation.&#148; Our board of directors or its authorized committee may modify the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the exercise of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
business judgment, taking into account such factors, circumstances and considerations as it deems relevant from time to time, provided that the sum of any cash compensation or other compensation
and the grant date fair value (as determined in accordance with FASB ASC 718, or any successor thereto) of any equity awards granted as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any calendar
year may not exceed $&#8195;&#8195;&#8195;&#8195;, increased to $&#8195;&#8195;&#8195;&#8195;in the calendar year of a <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial service as a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director or during which a <FONT STYLE="white-space:nowrap">non-employee</FONT> director serves as chair of our board of directors or lead independent director (which limits will not apply to the
compensation for any <FONT STYLE="white-space:nowrap">non-employee</FONT> director who serves in any capacity in addition to that of a <FONT STYLE="white-space:nowrap">non-employee</FONT> director for which he or she receives additional compensation
or any compensation paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director prior to the calendar year following the calendar year in which this offering occurs). The plan administrator may make exceptions to this limit for
individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in such circumstances as the plan administrator may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such
additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Certain transactions</I>. In connection with certain transactions and events affecting our common stock, including a change
in control (as defined below), or change in any applicable laws or accounting principles, the plan administrator has broad discretion to act under the 2024 Plan to prevent the dilution or enlargement of intended benefits, facilitate such transaction
or event, or give effect to such change in applicable laws or accounting principles. This includes canceling awards in exchange for either an amount in cash or other property with a value equal to the amount that would have been obtained upon
exercise or settlement of the vested portion of such award or realization of the participant&#146;s rights under the vested portion of such award, accelerating the vesting of awards, providing for the assumption or substitution of awards by a
successor entity, adjusting the number and type of shares available, replacing awards with other rights or property or terminating awards under the 2024 Plan. In the event of a change in control where the acquirer does not assume awards granted
under the 2024 Plan, awards issued under the 2024 Plan will be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as applicable. In addition, in the event of certain <FONT
STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders (an equity restructuring) the plan administrator will make equitable adjustments to the 2024 Plan and outstanding awards as it deems appropriate to reflect the
equity restructuring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of the 2024 Plan, a &#147;change in control&#148; means and includes each of the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a transaction or series of transactions whereby any &#147;person&#148; or related &#147;group&#148; of
&#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than our company or our subsidiaries or any employee benefit plan maintained by us or any of our subsidiaries or a &#147;person&#148; that, prior
to such transaction, directly or indirectly controls, is controlled by, or is under common control with, us) directly or indirectly acquires beneficial ownership (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the
Exchange Act) of our securities possessing more than 50% of the total combined voting power of our securities outstanding immediately after such acquisition; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">during any period of two consecutive years, individuals who, at the beginning of such period, constitute our
board of directors together with any new directors (other than a director designated by a person who has entered into an agreement with us to effect a change in control transaction) whose election by our board of directors or nomination for election
by our stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in office who either were directors at the beginning of the <FONT STYLE="white-space:nowrap">two-year</FONT> period
or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the consummation by us (whether directly or indirectly) of (x)&nbsp;a merger, consolidation, reorganization,
or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of our assets in any single transaction or series of related transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case
other than a transaction: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">which results in our voting securities outstanding immediately before the transaction continuing to represent
either by remaining outstanding or by being converted into voting securities of the company </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
or the person that, as a result of the transaction, controls, directly or indirectly, the company or owns, directly or indirectly, all or substantially all of our assets or otherwise succeeds to
our business, directly or indirectly, at least a majority of the combined voting power of the successor entity&#146;s outstanding voting securities immediately after the transaction, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after which no person or group beneficially owns voting securities representing 50% or more of the combined
voting power of the successor entity; provided, however, that no person or group will be treated as beneficially owning 50% or more of the combined voting power of the successor entity solely as a result of the voting power held in our company prior
to the consummation of the transaction. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Foreign participants, clawback provisions, transferability,
and participant payments. </I>With respect to foreign participants, the plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above. All awards will be
subject to the provisions of any clawback policy implemented by our company and to the extent set forth in such clawback policy or in the applicable award agreement. With limited exceptions for estate planning, domestic relations orders, certain
beneficiary designations and the laws of descent and distribution, awards under the 2024 Plan are generally nontransferable prior to vesting and are exercisable only by the participant. With regard to tax withholding obligations arising in
connection with awards under the 2024 Plan and exercise price obligations arising in connection with the exercise of stock options under the 2024 Plan, the plan administrator may, in its discretion, accept cash, wire transfer, or check, shares of
our common stock that meet specified conditions (a market sell order) or such other consideration as it deems suitable or any combination of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan amendment and termination. </I>Our board of directors may amend, suspend, or terminate the 2024 Plan at any time;
however, except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2024 Plan. The plan administrator will have the authority,
without the approval of our stockholders, to amend any outstanding stock option or SAR to reduce its exercise price per share. No award may be granted pursuant to the 2024 Plan after the tenth anniversary of the date on which our board of directors
adopts the 2024 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2022 Incentive Award Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors and our stockholders have adopted and approved the 2022 Plan, effective as of September&nbsp;30, 2022.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2023, a total of&#8195;&#8195;&#8195;&#8195;shares are subject to issued and outstanding stock
options granted under the 2022 Plan and a total of&#8195;&#8195;&#8195;&#8195;shares remain available for issuance under the 2022 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an award under the 2022 Plan or the 2015 Plan expires, lapses or is terminated, exchanged for or settled in cash,
surrendered, repurchased, cancelled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring shares covered by the award at a price not greater than the price paid by the participant for such
shares or not issuing any shares covered by the award, any shares subject to such award will, as applicable, become or again be available for new grants under the 2022 Plan. Awards granted under the 2022 Plan upon the assumption of, or in
substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the 2022 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the effective date of the 2024 Plan, no additional awards will be granted under the 2022 Plan. However, the 2022 Plan
will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of our common stock subject to awards granted under the 2022 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased,
or forfeited following the effective date of the 2022 Plan will be available for issuance under the 2024 Plan in accordance with its terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility and administration.</I> Our employees, consultants and
directors, and employees and consultants of our subsidiaries, are eligible to receive awards under the 2022 Plan. The 2022 Plan is administered by our compensation committee, which may delegate its duties and responsibilities to committees of our
directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be imposed under the 2022 Plan. The plan administrator will have the authority to make all determinations and
interpretations under, prescribe all forms for use with, and adopt rules for the administration of, the 2022 Plan, subject to its express terms and conditions. The plan administrator also sets the terms and conditions of all awards under the 2022
Plan, including any vesting and vesting acceleration conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards. </I>The 2022 Plan provides for the grant of
stock options, including incentive stock options (ISOs) within the meaning of Section&nbsp;422 of the Code, and nonqualified stock options (NSOs); restricted stock; dividend equivalents; restricted stock units (RSUs); stock appreciation rights
(SARs); and other stock or cash-based awards. Certain awards under the 2022 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose additional requirements on the terms and conditions
of such awards. All awards under the 2022 Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. Awards
other than cash awards generally will be settled in shares of our common stock, but the plan administrator may provide for cash settlement of any award. A brief description of each award type follows. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock options. </I>Stock options provide for the purchase of shares of our common stock in the future at an
exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. The
exercise price of a stock option will not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute
options granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined by the plan
administrator may apply to stock options and may include continued service, performance and/or other conditions. ISOs generally may be granted only to our employees and employees of our parent or subsidiary corporations, if any.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>SARs.</I> SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation
of the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR will not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain substitute
SARs granted in connection with a corporate transaction), and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance and/or other
conditions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted stock and RSUs.</I> Restricted stock is an award of nontransferable shares of our common stock
that remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and
until specified conditions are met. Delivery of the shares underlying RSUs may be deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted
stock and RSUs may be based on continuing service, the attainment of performance goals and/or such other conditions as the plan administrator may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other stock or cash-based awards.</I> Other stock or cash-based awards are awards of cash, fully vested
shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash-based awards may be granted to participants and may also be available as a payment form in
the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees, or other cash compensation otherwise payable to any individual who is eligible to receive awards. The plan administrator will
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
determine the terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service, performance and/or other conditions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend equivalents.</I> RSUs or other stock and cash-based awards may be accompanied by the right to
receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Such dividend equivalents will only be paid out to the extent that any vesting conditions are subsequently satisfied, unless
otherwise determined by the plan administrator. No dividend equivalents will be payable on stock options or SARs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Performance awards</I>. Performance awards include any of the foregoing awards that are granted subject to vesting and/or
payment based on the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively determinable. Performance criteria upon which performance goals are established by the plan
administrator may include: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization and <FONT STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or
revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including, but not limited to, gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios
or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on
assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per
share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating
to research, development, regulatory, commercial or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service;
employee satisfaction; recruitment and maintenance of personnel; human capital management (including diversity and inclusion); supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including
those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing
initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to our performance or the performance of a subsidiary, division,
business segment or business unit, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Director compensation</I>. The 2022 Plan provides that the plan administrator may establish compensation for <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors from time to time subject to the 2022 Plan&#146;s limitations. Our board of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it deems relevant from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Certain transactions</I>. In connection with certain transactions and events affecting our common stock, including a change
in control (as defined below), or change in any applicable laws or accounting principles, the plan administrator has broad discretion to act under the 2022 Plan to prevent the dilution or enlargement of intended benefits, facilitate such transaction
or event, or give effect to such change in applicable laws or accounting principles. This includes canceling awards in exchange for either an amount in cash or other property with a value equal to the amount that would have been obtained upon
exercise or settlement of the vested portion of such award or realization of the participant&#146;s rights under the vested portion of such award, accelerating the vesting of awards, providing for the assumption or substitution of awards by a
successor entity, adjusting the number and type of shares available, replacing awards with other rights or property or terminating awards under the 2022 Plan. In the event of a change in control where the acquirer does not assume awards granted
under the 2022 Plan, awards issued under the 2022 Plan will be subject to accelerated vesting such that 100% of the awards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
will become vested and exercisable or payable, as applicable. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders (an
equity restructuring) the plan administrator will make equitable adjustments to the 2022 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of the 2022 Plan, a &#147;change in control&#148; means and includes each of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a transaction or series of transactions whereby any &#147;person&#148; or related &#147;group&#148; of
&#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than our company or our subsidiaries or any employee benefit plan maintained by us or any of our subsidiaries or a &#147;person&#148; that, prior
to such transaction, directly or indirectly controls, is controlled by, or is under common control with, us) directly or indirectly acquires beneficial ownership (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the
Exchange Act) of our securities possessing more than 50% of the total combined voting power of our securities outstanding immediately after such acquisition; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">during any period of two consecutive years, individuals who, at the beginning of such period, constitute our
board of directors together with any new directors (other than a director designated by a person who has entered into an agreement with us to effect a change in control transaction) whose election by our board of directors or nomination for election
by our stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in office who either were directors at the beginning of the <FONT STYLE="white-space:nowrap">two-year</FONT> period
or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the consummation by us (whether directly or indirectly) of (x)&nbsp;a merger, consolidation, reorganization,
or business combination or (y)&nbsp;a sale or other disposition of all or substantially all of our assets in any single transaction or series of related transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case
other than a transaction: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">which results in our voting securities outstanding immediately before the transaction continuing to represent
either by remaining outstanding or by being converted into voting securities of the company or the person that, as a result of the transaction, controls, directly or indirectly, the company or owns, directly or indirectly, all or substantially all
of our assets or otherwise succeeds to our business, directly or indirectly, at least a majority of the combined voting power of the successor entity&#146;s outstanding voting securities immediately after the transaction, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after which no person or group beneficially owns voting securities representing 50% or more of the combined
voting power of the successor entity; provided, however, that no person or group will be treated as beneficially owning 50% or more of the combined voting power of the successor entity solely as a result of the voting power held in our company prior
to the consummation of the transaction. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Foreign participants, clawback provisions, transferability,
and participant payments. </I>With respect to foreign participants, the plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above. All awards will be
subject to the provisions of any clawback policy implemented by our company and to the extent set forth in such clawback policy or in the applicable award agreement. With limited exceptions for estate planning, domestic relations orders, certain
beneficiary designations and the laws of descent and distribution, awards under the 2022 Plan are generally nontransferable prior to vesting and are exercisable only by the participant. With regard to tax withholding obligations arising in
connection with awards under the 2022 Plan and exercise price obligations arising in connection with the exercise of stock options under the 2022 Plan, the plan administrator may, in its discretion, accept cash, wire transfer, or check, shares of
our common stock that meet specified conditions (a market sell order) or such other consideration as it deems suitable or any combination of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan amendment and termination. </I>Our board of directors may amend, suspend, or terminate the 2022 Plan at any time;
however, except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2022 Plan. The plan
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
administrator will have the authority, without the approval of our stockholders, to amend any outstanding stock option or SAR to reduce its exercise price per share. After the effective date of
the 2024 Plan, no additional awards will be granted under the 2022 Plan. However, the 2022 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors and our stockholders have adopted and approved the 2015 Equity Incentive Plan, effective as of
July&nbsp;28, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2023, a total of&#8195;&#8195;&#8195;&#8195;shares are subject to issued and
outstanding stock options granted under the 2015 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After the effective date of the 2022 Plan, no additional awards
were granted under the 2015 Plan and the 2015 Plan was terminated. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of our common stock subject to awards granted under the
2015 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased, or forfeited following the effective date of the 2015 Plan will be available for issuance under the 2022 Plan in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Administration.</I> Our compensation committee administers the 2015 Plan unless it delegates authority for administration
of the plan. Subject to the terms and conditions of the 2015 Plan, the administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each person, determine the number
of awards to grant, determine the number of shares to be subject to such awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other actions necessary or advisable for the administration
of the 2015 Plan. The plan administrator is also authorized to establish, adopt, amend, or revise rules relating to administration of the 2015 Plan, subject to certain restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility.</I> Awards under the 2015 Plan may be granted to individuals who are then our employees, consultants, and
members of our board of directors and our subsidiaries. Only employees may be granted ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Awards.</I> The 2015 Plan
provides that our administrator may grant or issue stock options (including NSOs and ISOs) and restricted stock. The administrator considers each award grant subjectively, considering factors such as the individual performance of the recipient and
the anticipated contribution of the recipient to the attainment of our long-term goals. Each award is set forth in a separate agreement with the person receiving the award and indicates the type, terms, and conditions of the award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Certain Transactions; Change in Control.</I> The plan administrator has broad discretion to equitably adjust the provisions
of the 2015 Plan and the terms and conditions of existing and future awards, including with respect to aggregate number and type of shares subject to the 2015 Plan and awards granted pursuant to the 2015 Plan, to prevent the dilution or enlargement
of intended benefits and/or facilitate necessary or desirable changes in the event of certain transactions and events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate
transactions. The plan administrator may also provide for the acceleration, <FONT STYLE="white-space:nowrap">cash-out,</FONT> termination, assumption, substitution, or conversion of awards in the event of a change in control, a merger of the Company
with or into another corporation or other entity occurs or certain other unusual or nonrecurring events or transactions. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders,
or an &#147;equity restructuring,&#148; the plan administrator will make equitable adjustments to the 2015 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Termination</I>. Upon the effectiveness of our 2022 Plan, our board of directors terminated the 2015 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2024 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Effective the day prior to the first public trading date of our common stock, we intend to adopt and ask our stockholders to
approve the CG Oncology, Inc. 2024 Employee Stock Purchase Program (the ESPP), the material terms of which, as it is currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving, and
implementing the ESPP and, accordingly, this summary is subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP is comprised of two distinct
components in order to provide increased flexibility to grant options to purchase shares under the ESPP to U.S. and to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> employees. Specifically, the ESPP authorizes (1)&nbsp;the grant of options to
U.S. employees that are intended to qualify for favorable U.S. federal tax treatment under Section&nbsp;423 of the Code, (the Section&nbsp;423 Component), and (2)&nbsp;the grant of options that are not intended to be
<FONT STYLE="white-space:nowrap">tax-qualified</FONT> under Section&nbsp;423 of the Code to facilitate participation for employees located outside of the U.S. who do not benefit from favorable U.S. federal tax treatment and to provide flexibility to
comply with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> law and other considerations (the <FONT STYLE="white-space:nowrap">Non-Section</FONT> 423 Component). Where permitted under local law and custom, we expect that the <FONT
STYLE="white-space:nowrap">Non-Section</FONT> 423 Component will generally be operated and administered on terms and conditions similar to the Section&nbsp;423 Component. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Shares available for awards; administration. </I>A total of&#8195;&#8195;&#8195;&#8195;shares of our common stock will
initially be reserved for issuance under the ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 2025 and ending in and including 2034, by an
amount equal to the lesser of (A)&#8195;&#8195;&#8195;&#8195;% of the shares outstanding on the final day of the immediately preceding calendar year and (B)&nbsp;such smaller number of shares as is determined by our board of directors, provided that
no more than&#8195;&#8195;&#8195;&#8195;shares of our common stock may be issued under the Section&nbsp;423 Component. Our board of directors or a committee of our board of directors will administer and will have authority to interpret the terms of
the ESPP and determine eligibility of participants. We expect that the compensation committee will be the initial administrator of the ESPP (referred to as the plan administrator below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Eligibility.</I><B><I> </I></B>We expect that all of our employees will be eligible to participate in the ESPP. However, an
employee may not be granted rights to purchase stock under the ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of
our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Grant of rights.</I><B><I></I></B>&nbsp;Stock will be offered under the ESPP during offering periods. The
length of the offering periods under the ESPP will be determined by the plan administrator and may be up to twenty-seven months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The
purchase dates for each offering period will be the final trading day in the offering period. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of
future offering periods. In <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions where participation in the ESPP through payroll deductions is prohibited, the plan administrator may provide that an eligible employee may elect to
participate through contributions to the participant&#146;s account under the ESPP in a form acceptable to the plan administrator in lieu of or in addition to payroll deductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ESPP permits participants to purchase common stock through payroll deductions of up to a specified percentage of their
eligible compensation. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period. In addition, no employee will be permitted to accrue the right to purchase stock under the
Section&nbsp;423 Component at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the offering
period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On the first trading day of each offering period, each participant will automatically be granted an option to
purchase shares of our common stock. The option will expire at the end of the applicable offering period and will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
be exercised at that time to the extent of the payroll deductions accumulated during the offering period. The purchase price of the shares, in the absence of a contrary designation, will be 85%
of the lower of the fair market value of our common stock on the first trading day of the offering period or on the purchase date. Participants may voluntarily end their participation in the ESPP at any time during a specified period prior to the
end of the applicable offering period and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation ends automatically upon a participant&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A participant may not transfer rights granted under the ESPP other than by will or the laws of descent and distribution, and
such rights are generally exercisable only by the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Certain transactions.</I><B><I> </I></B>In the event of
certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions or events affecting our common stock, the plan administrator will make equitable adjustments to the ESPP and outstanding rights. In the event of certain unusual or <FONT
STYLE="white-space:nowrap">non-recurring</FONT> events or transactions, including a change in control, the plan administrator may provide for (1)&nbsp;either the replacement of outstanding rights with other rights or property or termination of
outstanding rights in exchange for cash, (2)&nbsp;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (3)&nbsp;the adjustment in the number and type of shares of
stock subject to outstanding rights, (4)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering
periods or (5)&nbsp;the termination of all outstanding rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Plan amendment.</I><B><I></I></B>&nbsp;The plan
administrator may amend, suspend, or terminate the ESPP at any time. However, stockholder approval will be obtained for any amendment that increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the
ESPP or changes the corporations or classes of corporations whose employees are eligible to participate in the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We provide a $36,000 cash retainer, paid in quarterly installments, to certain directors for their service on our board. We
also have a policy of reimbursing all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in connection
with attending board of directors and committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, we also from time to time provide equity
compensation to certain directors for their service on our board. On June&nbsp;14, 2023, Drs. Mul&eacute; and Post were granted options to purchase 75,000 shares and 150,000 shares, respectively, of our common stock. The options have an exercise
price of $0.39 per share, the fair market value on the date of grant as determined by our board based on an independent third-party valuation. The options vest over a period of three years in equal monthly installments beginning on the first monthly
anniversary of the vesting commencement date (June 14, 2023), subject to Dr.&nbsp;Mul&eacute; and Dr.&nbsp;Post&#146;s continuous service with us as of each such vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the year ended December&nbsp;31, 2022, we did not provide any equity compensation to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Liu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James J. Mul&eacute;, IPh.D.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osamu Nakanishi, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leonard Post, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jue Pu<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simone Song</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Victor Tong, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">As of December&nbsp;31, 2022, Drs. Mul&eacute; and Post each held options to purchase 257,593 shares and
1,287,964 shares, respectively, of the Company&#146;s common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Dr.&nbsp;Nakanishi ceased serving as a director in October 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Ms.&nbsp;Pu ceased serving as a director in October 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Post-IPO</FONT> Director Compensation Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with this offering, we intend to adopt and ask our stockholders to approve the initial terms of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation program. The material terms of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, as it is currently contemplated, are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program will provide for annual retainer fees
and/or long-term equity awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. We expect each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual retainer of $&#8195;&#8195;&#8195;&#8195;,
with the <FONT STYLE="white-space:nowrap">non-employee</FONT> director serving as chair of the board or lead independent director receiving an additional annual retainer of $&#8195;&#8195;&#8195;&#8195;. The
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors serving as the chairs of the audit, compensation and nominating and corporate governance committees will receive additional annual retainers of $&#8195;&#8195;&#8195;&#8195;,
$&#8195;&#8195;&#8195;&#8195;and $&#8195;&#8195;&#8195;&#8195;, respectively. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors serving as members of the audit, compensation and nominating and corporate governance committees will
receive additional annual retainers of $&#8195;&#8195;&#8195;&#8195;, $&#8195;&#8195;&#8195;&#8195;and $&#8195;&#8195;&#8195;&#8195;respectively. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors commencing service following this
offering will also receive initial grants of options to purchase&#8195;&#8195;&#8195;&#8195;shares of our common stock, vesting over three years, upon election or appointment to the board of directors. Each year on the date of each annual meeting,
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual grant of options to purchase&#8195;&#8195;&#8195;&#8195;shares of our common stock, vesting in substantially equal monthly installments over the 12 months
following the date of grant (or, in the event the next annual meeting of our stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the annual award will vest on the date of such annual meeting of
our stockholders). Awards to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will also vest in the event of a change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Compensation under our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program will be subject to
the annual limits on non-employee director compensation set forth in the 2024 Plan, as described above. Our board of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation
program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, subject to the annual limit on
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2024 Plan (which limits will not apply to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director that serves in any additional capacity with the
company for which he or she receives compensation or any compensation paid to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director prior to the calendar year following the calendar year in which this offering occurs). As provided in the
2024 Plan, our board of directors or its authorized committee may make exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the board of directors or its authorized
committee may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the decision to award such compensation or in other compensation
decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our
directors and officers to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is
amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This
limitation of liability does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that we shall have the
power to indemnify our employees and agents to the fullest extent permitted by law. Our amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his
or her actions in this capacity, regardless of whether our amended and restated bylaws would permit indemnification. We have obtained directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into separate indemnification agreements with our directors and executive officers, in addition to
indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments,
fines and settlement amounts incurred by this person in any action or proceeding arising out of this person&#146;s services as a director or executive officer or at our request. We believe that these provisions in our amended and restated
certificate of incorporation and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The above description of the indemnification provisions of our amended and restated certificate of incorporation, our amended
and restated bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and
amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an
action, if successful, might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is
against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any
pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_13"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following includes a summary of transactions since January&nbsp;1, 2020 to which we have been a party in which the amount
involved exceeded or will exceed the lesser of $120,000 and one percent of the average of our total assets as of December&nbsp;31, 2021 and 2022, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more
than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other
arrangements, which are described in the section titled &#147;Executive and Director Compensation.&#148; We also describe below certain other transactions with our directors, executive officers and stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redeemable Convertible Preferred Stock Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Series D Redeemable Convertible Preferred Stock Financing. </I>In March 2020 we entered into a Series D redeemable
convertible preferred stock purchase agreement, as amended in June 2020, pursuant to which in closings between April 2020 and October 2020 we sold to investors, in private placements, an aggregate of 53,271,754 shares of Series D redeemable
convertible preferred stock. The per share purchase price was $0.8879, and we received gross proceeds of approximately $47&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Series E Redeemable Convertible Preferred Stock Financing. </I>In September 2022, we entered into a Series E redeemable
convertible preferred stock purchase agreement, pursuant to which in closings in September 2022 and October 2022 we sold to investors, in private placements, an aggregate of 112,422,700 shares of Series E redeemable convertible preferred stock. The
per share purchase price was $1.0674, and we received gross proceeds of approximately $120&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Series F
Redeemable Convertible Preferred Stock Financing. </I>In July 2023, we entered into a Series F redeemable convertible preferred stock purchase agreement, pursuant to which in July 2023 we sold to investors, in private placements, an aggregate of
81,587,937 shares of Series F redeemable convertible preferred stock. The per share purchase price was $1.2872, and we received gross proceeds of approximately $105&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth the aggregate number of shares acquired by the listed directors, executive officers or holders
of more than 5% of our capital stock, or their affiliates. Each outstanding share of redeemable convertible preferred stock identified in the table below will convert into shares of common stock at a ratio of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> immediately prior to the closing of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series F<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or greater stockholders<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with ORI
Capital<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,378,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,474,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decheng Capital Global Life Sciences Fund IV,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,547,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,402,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Foresite
Capital<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,306,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kissei Pharmaceutical Co., Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,787,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Longitude Venture
Partners<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,547,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,402,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCG Crossover Fund I, L.P.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,306,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Additional details regarding these stockholders and their equity holdings are provided in the section titled
&#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Represents securities acquired by Abundant Supply Global Limited and Charming Jade Limited. Simone Song is a
Founder and Senior Partner at ORI Capital and a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Victor Tong, Jr. is a Managing Director at Decheng and a member of our board of directors.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Represents securities acquired by Foresite Capital Fund V, L.P., Foresite Capital Fund VI, L.P. and Foresite
Capital Opportunity Fund V, L.P. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Represents securities acquired by Longitude Prime Fund, L.P. and Longitude Venture Partners IV, L.P. Brian
Liu, M.D. is a Managing Director at Longitude Capital Management and a member of our board of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Secondary Stock Sales
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In October 2023, Abundant Supply Global Limited, an entity affiliated with ORI Capital, a greater than 5% stockholder
of our company, entered into stock transfer agreements with certain other holders of our capital stock pursuant to which Abundant Supply Global Limited sold an aggregate of 27,190,800 shares of Series C redeemable convertible preferred stock at a
purchase price of $1.2872 per share for an aggregate purchase price of $34,999,997.84 (the ASGL Secondary Sales). In connection with these transactions, Abundant Supply Global Limited sold 3,107,520 shares of Series C redeemable convertible
preferred stock to Decheng Capital Global Life Sciences Fund IV, L.P., a greater than 5% stockholder of our company (Decheng Capital Global), 3,107,520 shares of Series C redeemable convertible preferred stock to TCG Crossover Fund I, L.P.,
3,107,520 shares of Series C redeemable convertible preferred stock to Longitude Prime Fund, L.P., an entity affiliated with Longitude Venture Partners, a greater than 5% stockholder of our company, (Longitude Prime), an affiliate of Longitude
Venture Partners, and an aggregate of 3,107,520 shares of Series C redeemable convertible preferred stock to entities affiliated with Foresite Capital. In connection with the ASGL Secondary Sales, we entered into a stock transfer agreement with
Abundant Supply Global Limited and each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2023, Longitude Prime entered into a stock transfer
agreement with an entity affiliated with a holder of our capital stock pursuant to which Longitude Prime sold 1,756,323 shares of Series C redeemable convertible preferred stock at a purchase price of $0.9073 per share for an aggregate purchase
price of $1,593,511.86 (the August 2023 Longitude Secondary Transaction). In July 2023, Longitude Prime entered into a stock transfer agreement with Lepu Holdings Limited pursuant to which Longitude Prime purchased 3,512,646 shares of Series C
redeemable convertible preferred stock from Lepu Holdings Limited at a purchase price of $0.9073 per share for an aggregate purchase price of $3,187,023.72 (the July 2023 Longitude Secondary Transaction). Jue Pu, our then-director, was an affiliate
of Lepu Holdings Limited at the time of the July 2023 Longitude Secondary Transaction. In connection with the August 2023 Longitude Secondary Transaction and the July 2023 Longitude Secondary Transaction, we entered into stock transfer agreements
with Longitude Prime and each counterparty. In May 2023, Longitude Venture Partners IV, L.P, an entity affiliated with Longitude Venture Partners, entered into a common stock transfer agreement with various holders of capital stock pursuant to which
Longitude Venture Partners IV, L.P. purchased 8,873,500 shares of common stock at a purchase price of $0.80055 per share for an aggregate purchase price of $7,103,680.43 (the May 2023 Longitude Secondary Transaction). In connection with the May 2023
Longitude Secondary Transaction, we entered into a common stock transfer agreement with Longitude Venture Partners IV, L.P. and each seller pursuant to which, among other things, we waived our right of first refusal to purchase the shares of common
stock sold in the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In July 2023, Decheng Capital Global entered into a stock transfer agreement with Lepu
Holdings Limited pursuant to which Decheng Capital Global purchased 3,512,646 shares of Series C redeemable convertible preferred stock from Lepu Holdings Limited at a purchase price of $0.9073 per share for an aggregate purchase price of
$3,187,023.72 (the July 2023 Decheng Secondary Transaction). Jue Pu, our then-director, was an affiliate of Lepu Holdings Limited at the time of the July 2023 Decheng Secondary Transaction. In June 2023, Decheng Capital Global entered into a stock
transfer agreement with a holder of our capital stock pursuant to which Decheng Capital Global purchased 2,024,725 shares of Series C redeemable convertible preferred stock at a purchase price of $0.91 per share for an aggregate purchase price of
$1,842,499.75 (the June 2023 Decheng Secondary Transaction). In connection with the July 2023 Decheng Secondary Transaction and the June 2023 Decheng Secondary Transaction, we entered into stock transfer agreements with Decheng Capital Global and
each seller. In May 2023, Decheng Capital Global entered into common stock transfer agreements with various holders of capital stock pursuant to which Decheng Capital Global purchased 8,873,500 shares of common stock at a purchase price of $0.80055
per share for an aggregate purchase price of $7,103,680.44 (the May 2023 Decheng Secondary Transaction). In connection with the May 2023 Decheng Secondary Transaction, we entered into a common stock transfer agreement with Decheng Capital Global and
each seller pursuant to which, among other things, we waived our right of first refusal to purchase the shares of common stock sold in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License and Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;11, 2019, we entered into the Development and License Agreement with Lepu. Jue Pu, a former member of our board
of directors, is an affiliate of Lepu. On March&nbsp;26, 2020, and as amended September&nbsp;15, 2022, we entered into the License and Collaboration Agreement with Kissei. Osamu Nakanishi, a former member of our board of directors, is an affiliate
of Kissei. Please see the section titled &#147;Business&#151;Collaboration and License Agreements&#148; for a description of each of these agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We entered into an investors&#146; rights agreement in July 2014, as last amended and restated in July 2023 (the
Investors&#146; Rights Agreement), with the holders of our redeemable convertible preferred stock and certain holders of our common stock, including the holders of more than 5% of our capital stock listed above as well as entities with which certain
of our directors are affiliated. This agreement provides for certain rights relating to the registration of their shares of common stock issuable upon conversion of their redeemable convertible preferred stock and certain additional covenants made
by us. Except for the registration rights (including the related provisions pursuant to which we have agreed to indemnify the parties to the Investors&#146; Rights Agreement), all rights under this agreement will terminate upon closing of this
offering. The registration rights will continue following this offering and will terminate five years after the closing of this offering or earlier for certain holders. See the section titled &#147;Description of Capital Stock&#151;Registration
Rights&#148; for more information regarding these registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We entered into a voting agreement in July 2014, as last amended and restated in July 2023 (the Voting Agreement), with the
holders of our redeemable convertible preferred stock and certain holders of our common stock, including the holders of more than 5% of our capital stock listed above as well as entities with which certain of our directors are affiliated, pursuant
to which the following directors were each elected to serve as members on our board of directors and, as of the date of this prospectus, continue to so serve: Brian Liu, M.D., Simone Song, James J. Mul&eacute;, IPh.D., Arthur Kuan, Leonard Post,
Ph.D. and Victor Tong, Jr. Pursuant to the Voting Agreement, Mr.&nbsp;Kuan, as our Chief Executive Officer, serves on our board of directors as the CEO director. Mr.&nbsp;Tong was selected to serve on our board of directors as representative of the
holders of our common stock and holders of our redeemable convertible preferred stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, Dr.&nbsp;Post was selected to serve on our board of directors
as representative of the holders of our common stock, Mr.&nbsp;Kuan was selected to serve on our board of directors as representative of the holders of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock,
Dr.&nbsp;Mul&eacute; was selected to serve on our board of directors as representative of the holders of our Series B redeemable convertible preferred stock, Ms.&nbsp;Song was selected to serve on our board of directors as representative of the
holders of our Series C redeemable convertible preferred stock, and Dr.&nbsp;Liu was selected to serve on our board of directors as a representative of the holders of our Series E redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Voting Agreement will terminate upon the closing of this offering, and members previously elected to our board of
directors pursuant to this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected by holders of our common stock. The composition of our board of directors after this offering is described
in more detail in the section titled &#147;Management&#151;Board Composition and Election of Directors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right of Refusal <FONT
STYLE="white-space:nowrap">and&nbsp;Co-Sale&nbsp;Agreement</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We entered into a right of first refusal and <FONT
STYLE="white-space:nowrap">co-sale</FONT> agreement in July 2014, as last amended and restated in July 2023 (the ROFR Agreement), with holders of our common stock affiliated with our executive officers, which entities are referred to in the ROFR
Agreement as key holders, and certain other holders of redeemable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
convertible preferred stock, including the holders of more than 5% of our capital stock listed above. Pursuant to the ROFR Agreement, we have a right of first refusal on certain transfers of our
shares by the key holders, holders of our redeemable convertible preferred stock have a secondary right of first refusal on such transfers, and such redeemable convertible preferred stockholders have a right of
<FONT STYLE="white-space:nowrap">co-sale</FONT> in respect of such transfers. The ROFR Agreement will terminate upon the closing of this offering.<B> </B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consulting Agreement with Danforth Advisors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;16, 2021, we entered into a consulting agreement with Danforth Advisors, LLC (Danforth) to provide us with
resources to assist with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> finance and accounting functions. Services provided under the agreement with Danforth are billed at hourly rates.
Mr.&nbsp;DiPalma, a managing director at Danforth, currently serves as our Chief Financial Officer and is compensated through his position at Danforth.&nbsp;The agreement does not have a specified term and can be terminated without cause upon 30
days&#146; notice by either party.&nbsp;During the years ended December&nbsp;31, 2021 and 2022 and during the nine-month period ended September&nbsp;30, 2023, we made payments to Danforth for such services of $57,875, $38,392 and
$&#8195;&#8195;&#8195;&#8195;, respectively.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consulting Agreement with Lion Healthcare Strategies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On April&nbsp;15, 2021, we entered into a consulting agreement with Lion Healthcare Strategies to provide us with corporate and
strategic consulting services. Services provided under the agreement with Lion Healthcare Strategies are billed at daily or hourly rates. Mr.&nbsp;Bellete is the sole owner of Lion Healthcare Strategies, served as Chief Executive Officer of Lion
Healthcare Strategies, from April 2021 to August 2023, and has served as our President and Chief Operating Officer since July 2023. The agreement was terminated when Mr.&nbsp;Bellete joined our company. During the years ended December&nbsp;31, 2021
and 2022 and during the nine-month period ended September&nbsp;30, 2023, we made payments to Lion Healthcare Strategies for such services of $204,000, $433,269 and $&#8195;&#8195;&#8195;&#8195;, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Officer Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among
other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as
attorneys&#146; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director
or executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws provide
that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General Corporation Law. Further, we have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our
directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. For further information, see the section titled &#147;Executive and Director Compensation&#151;Limitations of Liability and
Indemnification Matters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors will adopt a written related person transaction policy, to be effective upon the closing of this
offering, setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount
involved exceeds the lesser of $120,000 or one percent of the average of our total assets at <FONT STYLE="white-space:nowrap">year-end</FONT> for the last two completed fiscal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
years, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in
which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee will be tasked to consider all relevant facts
and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the
transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table sets forth information with respect to the beneficial ownership of our common stock as of October&nbsp;24,
2023, and as adjusted to reflect the sale of shares of common stock in this offering, by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person<B> </B>or group of affiliated persons known by us to beneficially own more than 5% of our common
stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The number of shares beneficially owned by each stockholder is determined under rules issued by
the SEC. Under these rules, beneficial ownership includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based on 414,611,809 shares of common stock outstanding on
October&nbsp;24, 2023, which gives effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 366,277,131 shares of our common stock immediately prior to the closing of this offering. In computing
the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options or other rights held by such person that are currently exercisable or that will become exercisable or
otherwise vest within 60 days of October&nbsp;24, 2023 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. The table below excludes any potential
purchases in this offering by the beneficial owners identified in the table below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless otherwise indicated, the
address of each beneficial owner listed below is c/o CG Oncology, Inc., 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618. We believe, based on information provided to us, that each of the stockholders listed below has sole voting and
investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially</B><br><B>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% or Greater Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with ORI
Capital<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,115,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decheng Capital Global Life Sciences Fund IV,
L.P.<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,468,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Longitude Venture
Partners<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,687,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kissei Pharmaceutical Co., Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,787,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Foresite
Capital<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,413,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCG Crossover Fund I, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,413,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arthur Kuan<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,153,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Burke, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,515,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Georg Roth, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,583,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Liu, M.D.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James J. Mul&eacute;, IPh.D.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">542,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leonard Post, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,312,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Simone Song<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,460,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Victor Tong, Jr.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (9 persons)<SUP
STYLE="font-size:75%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,590,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Less than 1%. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i)&nbsp;9,641,725&nbsp;shares of common stock held by Abundant Supply Global Limited and (ii)
37,474,236 shares of common stock held by Charming Jade Limited. Abundant Supply Global Limited is a wholly-owned subsidiary of ORI Healthcare Fund, L.P. ORI Capital Inc. is the general partner of ORI Healthcare Fund, L.P. and may be deemed to have
voting, investment and dispositive power with respect to these securities. ORI Capital Inc. is a wholly-owned subsidiary of ORI Capital Holding Inc, which is a wholly-owned subsidiary of Healthcare Seed Limited. Charming Jade Limited is a
wholly-owned subsidiary of ORI Healthcare Fund II, L.P. ORI Capital II Inc. is the general partner of ORI Healthcare Fund II, L.P. and may be deemed to have voting, investment and dispositive power with respect to these securities. ORI Capital II
Inc. is a wholly-owned subsidiary of ORI Capital Holding Inc, which is a wholly-owned Subsidiary of Healthcare Seed Limited. Ms.&nbsp;Song is the sole owner of Healthcare Seed Limited. The business address for Ms.&nbsp;Song and these entities is C/O
Room Nos. 4727-4734, 47/F, Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hong Kong. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 43,468,396&nbsp;shares of common stock held by Decheng Capital Global Life Sciences Fund IV, L.P.
Decheng Capital Management IV (Cayman), LLC (the Decheng GP) is the general partner of the Fund. Xiangmin Cui is the manager of the Decheng GP. Each of the Fund, the Decheng GP and Dr.&nbsp;Cui may be deemed to beneficially own the securities held
by the Fund. Each of the Fund, the Decheng GP and Dr.&nbsp;Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. The business address for Decheng is 3000 Sand Hill Road, Building
2, Suite 110, Menlo Park, California 94025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i) 30,421,185 shares of common stock held by Longitude Venture Partners IV, L.P. (LVPIV) and
(ii)&nbsp;9,266,163 shares of common stock held by Longitude Prime Fund, L.P. (LPF). Longitude Capital Partners IV, LLC (LCPIV) is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these
securities. Longitude Prime Partners, LLC (LPP) is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright are the
managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LPP, LCPIV, Ms.&nbsp;Tammenoms Bakker and Mr.&nbsp;Enright disclaim beneficial ownership of such
shares except to the extent of their respective pecuniary interests therein. The business address for these individuals and entities is 2740 Sand Hill Road, 2nd Floor, Menlo Park, California 94025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 33,787,589 shares of common stock held by Kissei Pharmaceutical Co., Ltd. (Tokyo Stock Exchange,
stock code: 4547). The business address for Kissei is <FONT STYLE="white-space:nowrap">19-48</FONT> Yoshino, Matsumoto City, Nagano, Japan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i)&nbsp;6,603,480&nbsp;shares of common stock held by Foresite Capital Fund V, L.P. (Fund V),
(ii)&nbsp;13,206,961&nbsp;shares of common stock held by Foresite Capital Fund VI, L.P. (Fund VI) and (iii)&nbsp;6,603,480 shares of common stock held by Foresite Capital Opportunity Fund V, L.P. (Opportunity Fund V, and, together with Fund V and
Fund VI, Foresite). Foresite Capital Management V LLC (FCM V) is the general partner of Fund V. Foresite Capital Management VI, LLC (FCM VI) is the general partner of Fund VI. Foresite Capital Opportunity Management V, LLC (FCOM V) is the general
partner of Opportunity Fund V. FCM V, FCM VI and FCOM V may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum is the sole managing member of FCM V, FCM VI and FCOM V and may be deemed to have sole voting and
dispositive power over these shares. Each of FCM V, FCM VI, FCOM V and Dr.&nbsp;Tananbaum disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. The address of Foresite, FCM VI, FCM
V, FCOM V and Dr.&nbsp;Tananbaum is 900 Larkspur Landing Circle, Suite 150 Larkspur, CA 94939. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 26,413,921&nbsp;shares of common stock held by TCG Crossover Fund I, L.P. TCG Crossover GP I, LLC
(TCG Crossover GP I) is the general partner of TCG Crossover Fund I, L.P. (TCG Crossover I) and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP
I and may be deemed to share voting, investment and dispositive power with respect to these securities. The business address for TCG Crossover GP I, TCG Crossover I and Mr.&nbsp;Yu is 705 High St., Palo Alto, CA 94301. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 10,596,951&nbsp;shares of common stock held directly and 2,556,250&nbsp;shares of common stock
underlying options held by Mr.&nbsp;Kuan that are exercisable as of October&nbsp;24, 2023 or that will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 3,515,878&nbsp;shares of common stock underlying options held by Dr.&nbsp;Burke that are
exercisable as of October&nbsp;24, 2023 or that will become exercisable within 60 days after such date. Dr.&nbsp;Burke transitioned out of the role of Chief Medical Officer on August&nbsp;14, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,000,382 shares of common stock held directly and 583,021 shares of common stock underlying
options held by Dr.&nbsp;Roth that are exercisable as of October&nbsp;24, 2023 or that will become exercisable within 60 days after such date. Dr.&nbsp;Roth&#146;s employment with us terminated on August&nbsp;9, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 542,321&nbsp;shares of common stock underlying options held by Dr.&nbsp;Mul&eacute; that are
exercisable as of October&nbsp;24, 2023 or that will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of 1,312,964&nbsp;shares of common stock underlying options held by Dr.&nbsp;Post that are
exercisable as of October&nbsp;24, 2023 or that will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Consists of (i)&nbsp;9,641,725&nbsp;shares of common stock held by Abundant Supply Global Limited,
(ii)&nbsp;37,474,236 shares of common stock held by Charming Jade Limited and (iii)&nbsp;3,344,608 shares of common stock held directly by Ms.&nbsp;Song. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Includes the shares described in footnotes&nbsp;7, 10, 11 and 12 above and an additional 237,500 shares of
common stock underlying options exercisable as of October&nbsp;24, 2023 or that will become exercisable within 60 days after such date held by our other executive officers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following
description summarizes some of the terms of our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect upon the closing of this offering, our investors&#146; rights agreement and of the Delaware
General Corporation Law. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description you should refer to our amended and restated certificate of incorporation, amended and restated
bylaws and our investors&#146; rights agreement, copies of which have been filed as exhibits to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of this offering, our authorized capital stock will consist of&#8195;&#8195;&#8195;&#8195; shares of
common stock, $0.0001 par value per share, and&#8195;&#8195;&#8195;&#8195;shares of preferred stock, $0.0001 par value per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2023, there were &#8195;&#8195;&#8195;&#8195;shares of our common stock outstanding and held
of record by 100 stockholders, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 366,277,131 shares of common stock, which will automatically occur immediately prior to the
closing of this offering. Based on the number of shares of common stock outstanding as of September&nbsp;30, 2023, and further assuming the issuance by us of&#8195;&#8195;&#8195;&#8195;shares of common stock in this offering, there will
be&#8195;&#8195;&#8195;&#8195; &#8195;&#8195;&#8195;&#8195;shares of common stock outstanding upon the closing of this offering. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of
stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the
directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters shall be decided by the
affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also
provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote
thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt
any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See the subsection titled &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and
Bylaws-Amendment of Charter Provisions&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to preferences that may be applicable to any then outstanding
preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of
common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then
outstanding. Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the
common stock to be outstanding upon the closing of this offering will be, duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected
by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, all of our previously outstanding shares of redeemable convertible preferred stock will have
been converted into common stock, there will be no authorized shares of our previously </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
outstanding redeemable convertible preferred stock, and we will have no shares of preferred stock outstanding. Under the terms of our amended and restated certificate of incorporation, which will
become effective immediately prior to the closing of this offering, our board of directors has the authority, without further action by our stockholders, to issue up to &#8195;&#8195;&#8195;&#8195;shares of preferred stock in one or more series, to
establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or
restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely
affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the
effect of delaying, deterring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of
preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of September&nbsp;30, 2023, options to purchase&#8195;&#8195;&#8195;&#8195;shares of our common stock were outstanding, of
which&#8195;&#8195;&#8195;&#8195;were vested and exercisable as of that date. For additional information regarding the terms of our 2015 Plan and 2022 Plan, see the sections titled &#147;Executive and Director Compensation&#151;Equity Incentive
Plans&#151;2015 Equity Incentive Plan&#148; and &#147;Executive and Director Compensation&#151;Equity Incentive Plans&#151;2022 Incentive Award Plan.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As
of September&nbsp;30, 2023, upon the closing of this offering holders of 366,277,131 shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion redeemable convertible preferred stock
immediately prior to the closing of this offering, will be entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to an investors&#146; rights agreement by and among us
and certain investors. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement
is declared effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Form <FONT STYLE="white-space:nowrap">S-1.</FONT> </I>If at any time beginning six months following the closing of this
offering, the holders of at least 25% of the registrable securities then-outstanding request in writing that we effect a registration, we may be required to provide notice of such request to all holders of registrable securities and offer them the
opportunity to participate in such registration, and to use best efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, among other things, we have already effected either one
registration in the last twelve months or three registrations in total for the holders of registrable securities in response to these demand registration rights, or the anticipated aggregate proceeds of the registration (after deduction for
underwriter&#146;s discounts and expenses related to the issuance) are less than $5&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Form S-</I>3. If at
any time beginning six months following the closing of this offering, any holder of registrable securities then-outstanding requests in writing that we effect a registration with respect to all or a part of the registrable securities then
outstanding, we may be required to provide notice of such request to all holders of registrable securities and offer them the opportunity to participate in such registration, and to use best efforts to effect such registration; provided, however,
that we will not be required to effect such a registration if, among other things, Form <FONT STYLE="white-space:nowrap">S-3</FONT> is not available for such offering or the anticipated aggregate offering price to the public is less than
$1&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the holders requesting registration intend to distribute their shares by
means of an underwritten offering, the underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares in accordance with the
<FONT STYLE="white-space:nowrap">cut-back</FONT> provisions of the investors&#146; rights agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If at any time following the closing of this offering we propose to register any shares of our common stock under the
Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an
underwritten offering, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares in accordance with the
<FONT STYLE="white-space:nowrap">cut-back</FONT> provisions of the investors&#146; rights agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our investors&#146; rights agreement contains customary cross indemnification provisions, under which we are obligated to
indemnify holders of registrable securities in the event of material misstatements or omissions in a registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Other
than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing
fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders, blue sky fees and expenses and the expenses of any special audits incident to the registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The registration rights terminate upon the earlier of (i)&nbsp;five years after the closing of this offering or (ii)&nbsp;with
respect to a particular holder, such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all shares by such holder without limitation during a three-month period without registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws
contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It
is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that provide for payment
of a premium over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These provisions, summarized below, are intended to discourage
coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased
protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result
in an improvement of their terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The ability of our board of directors, without action by the stockholders, to issue up to &#8195; shares of undesignated
preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or
delaying changes in control or management of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board
of directors, chief executive officer or president, or by a resolution adopted by a majority of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for Advance
Notification of Stockholder Nominations and Proposals </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws establish advance notice
procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of
the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to
act by written consent without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated bylaws provide that our board of directors will be divided into three classes. The directors in each
class will serve for a three-year term, with one class being elected each year by our stockholders. For more information on the classified board of directors, see the section titled &#147;Management&#151;Board Composition and Election of
Directors.&#148; This system of electing directors may tend to discourage a third party from attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from
office except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of
directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders
of our preferred stock may be entitled to elect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be
&#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an
&#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock.
Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect
to transactions not approved in advance by the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an
alternative form, the Court of Chancery of the State of Delaware (the Court of Chancery) (or, in the event the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State
of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of
breach of a fiduciary duty by any of our directors, officers or stockholders to us or our stockholders; (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our amended and
restated certificate of incorporation or amended and restated bylaws; or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law. The provision would not apply to suits
brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, our amended and restated certificate of incorporation will also provide that unless we
consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including
all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such
complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. In any case, stockholders will not be
deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in
legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our amended and restated certificate of incorporation also provides that any person or entity purchasing or otherwise
acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue
preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws
could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover
attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may
otherwise deem to be in their best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The transfer agent and registrar for our common stock will be&#8195;&#8195;&#8195;&#8195;. The transfer agent and
registrar&#146;s address is&#8195;&#8195;&#8195;&#8195;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Nasdaq Global Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have applied to have our common stock listed on the Nasdaq Global Market under the symbol &#147;CGON,&#148; and this
offering is contingent upon obtaining such approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For a discussion of liability and indemnification, see the section titled &#147;Executive and Director
Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of
common stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although we have applied to have our common stock listed on Nasdaq, we cannot assure you that there will be
an active public market for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Based on the number of shares of our common stock outstanding as of
September&nbsp;30, 2023, and assuming (i)&nbsp;the issuance of&#8195;&#8195;&#8195;&#8195;&#8195;shares in this offering, (ii)&nbsp;the automatic conversion of all of our outstanding shares of redeemable convertible preferred stock into 366,277,131
shares of common stock and the related reclassification of the carrying value of the redeemable convertible preferred stock to permanent equity upon the closing of this offering, (iii)&nbsp;no exercise of the underwriters&#146; option to purchase
additional shares of common stock and (iv)&nbsp;no exercise of outstanding options, we will have outstanding an aggregate of&#8195;&#8195;&#8195;&#8195;shares of common stock following the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under
the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below,
other than the holding period requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The remaining &#8195;&#8195;&#8195;&#8195; shares of common stock will be
&#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from
registration under Rule 144 or Rule 701 under the Securities Act, each of which is summarized below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, our officers, directors and substantially all of our
securityholders, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, among other things and subject to certain exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sell, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of
common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership
of the common stock, or publicly declare an intention to do any of the foregoing. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, certain of our stockholders will have the right to require us to register their shares
under the Securities Act. See the subsection titled &#147;&#151;Registration Rights&#148; below and the section titled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan Stanley&nbsp;&amp; Co. LLC and Goldman Sachs&nbsp;&amp; Co. LLC may, in their sole discretion and at any time or from
time to time before the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, in certain cases without public notice, release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements. There are no existing agreements between the underwriters and any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement providing consent to the sale of shares prior to the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the closing of this offering, certain of our officers, directors and significant stockholders may adopt written
plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, in which they will contract with a broker to buy or sell </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
shares of our common stock on a periodic basis to diversify their assets and investments. Under these <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a broker may execute trades
pursuant to parameters established by the officer, director or stockholder when entering into the plan, without further direction from such officer, director or stockholder. Such sales would not commence until the expiration of the applicable <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by such officer, director or stockholder in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 144 as currently in effect, beginning 90 days after the effective date of the registration statement of
which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, and who has beneficially owned shares of our common stock for at least six months would be entitled to sell
in &#147;broker&#146;s transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal
approximately&#8195;&#8195;&#8195;&#8195; shares immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in our common stock on Nasdaq during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">An &#147;affiliate&#148; is a person that
directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with an issuer. Affiliate resales under Rule 144 are also subject to the availability of current public information about us. In
addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form 144 with the SEC and Nasdaq
concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 144 as
currently in effect, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of ours at the time of sale, and has not been an affiliate at any time during the
three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell such shares subject only to the availability of current public information about us. If such
person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the <FONT STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public
information requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of
sale, volume limitation or notice filing provisions of Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In general, under Rule 701 as currently in effect, any of an issuer&#146;s employees, directors, officers, consultants or
advisors who purchase shares from the issuer in connection with a compensatory stock or option plan or other written agreement before the effective date of a registration statement under the Securities Act are entitled to sell such shares 90 days
after such effective date in reliance on Rule 144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the
issuer can resell shares in reliance on Rule 144 without having to comply with the current public information and holding period requirements. However, substantially all Rule 701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements as described above and will become eligible for sale in compliance with Rule 144 only upon the expiration of the restrictions set forth in those agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The SEC has indicated that Rule 701 will apply to typical options granted by
an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange
Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities
Act to register all shares of common stock subject to outstanding stock options and common stock issued or issuable under our equity incentive plans and employee stock purchase plan. We expect to file the registration statement covering shares
offered pursuant to these stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the
sale by affiliates in the public market subject to compliance with the resale provisions of Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Upon the closing of this offering, holders of 366,277,131 shares of our common stock, which includes all of the shares of
common stock issuable upon the automatic conversion of our redeemable convertible preferred stock into shares of our common stock immediately prior to the closing of this offering, will be entitled to various rights with respect to the registration
of these shares under the Securities Act upon the closing of this offering. Registration of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon the
effectiveness of the registration, except for shares purchased by our affiliates. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration statement will be
eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_17"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following discussion is a summary of the material U.S. federal
income tax consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of
all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the
U.S. Internal Revenue Code of 1986, as amended (the Code), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the IRS), in each case in
effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that
discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This
discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This
discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the Medicare contribution tax on net investment
income and the alternative minimum tax provisions of the Code. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a
conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes
(and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or
otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all
of the interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If an entity or arrangement
treated as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at
the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE
APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>
SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE,
LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For purposes of this discussion, a
<FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is
any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof, or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
&#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As
described in the section titled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying cash dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common
stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as
dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero.
Any excess will be treated as capital gain and will be treated as described in the subsection titled &#147;&#151;Sale or Other Taxable Disposition&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussion below on effectively connected income, dividends paid to a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable
documentation) certifying qualification for the lower treaty rate). If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds the stock through a financial institution or other intermediary, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to the intermediary, which then will be required to provide certification to the applicable withholding agent, either directly or through
other intermediaries. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely
filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent
establishment or fixed base in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any
such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax
at a rate of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable
Disposition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the discussion below of backup withholding and withholding under FATCA (defined below), a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment or fixed base in the United States to which
such gain is attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest (USRPI) by reason of our status as a U.S. real
property holding corporation (USRPHC) for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Gain described in the first
bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate
of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in the second bullet point above will be subject to U.S.
federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our common stock, which may be offset by U.S. source capital losses of the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns
with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to the third bullet point above, we believe we currently are not, and do not
anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property
interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition of our common
stock by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities
market, and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or
the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding potentially applicable
income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent
does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information
returns are required to be filed with the IRS in connection with any distributions on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether such distributions constitute dividends or whether any
tax was actually withheld. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will be subject to backup
withholding or information reporting unless the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise
establishes an exemption. Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup
withholding or information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Copies of information returns that are filed with the IRS may also be made
available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a
refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections are commonly referred to as the Foreign
Account Tax Compliance Act (FATCA)) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30%
withholding tax may be imposed on dividends on, or subject to the proposed Treasury Regulations discussed below, gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT
STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to
the diligence and reporting requirements in clause (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United
States persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to
<FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing
FATCA may be subject to different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the applicable Treasury Regulations and administrative guidance,
withholding under FATCA generally applies to payments of dividends on our common stock. While withholding under FATCA would also have applied to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019,
proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers (including applicable withholding agents) generally may rely on these proposed Treasury Regulations until final Treasury Regulations are
issued. There can be no assurance that final Treasury Regulations would provide an exemption from FATCA withholding for gross proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to
their investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters
named below, for whom Morgan Stanley&nbsp;&amp; Co. LLC, Goldman Sachs&nbsp;&amp; Co. LLC and Cantor Fitzgerald&nbsp;&amp; Co. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the
number of shares of common stock indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>&#8195;&#8195;Shares&#8195;&#8195;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeSci Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and the representatives are collectively referred to as the
&#147;underwriters&#148; and the &#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides
that the obligations of the several underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The
underwriters are obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146;
over-allotment option described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters initially propose to offer part of the shares of common stock
directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $&#8195;&#8195;&#8195;&#8195;per share under the public offering price.
After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to
&#8195;&#8195;&#8195;&#8195;additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of
covering over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to
purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common stock listed next to the names of all
underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table shows the per share and total public offering price,
underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional &#8195;&#8195;&#8195;&#8195;shares of
our common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The estimated offering expenses payable by us, exclusive of the underwriting discounts and
commissions, are approximately $&#8195;&#8195;&#8195;&#8195;. We have also agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to $&#8195;&#8195;&#8195;&#8195;.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters have informed us that they do not intend sales to
discretionary accounts to exceed 5% of the total number of shares of common stock offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have applied to
list our common stock on the Nasdaq Global Market under the trading symbol&nbsp;&#147;CGON,&#148; and this offering is contingent upon obtaining approval of such listing </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and all of our directors and officers and the holders of substantially all of our outstanding securities directly or
indirectly convertible into or exchangeable or exercisable for shares of our common stock have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters agreeing that, subject to certain exceptions, without the
prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC and Goldman Sachs&nbsp;&amp; Co. LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 180 days after the date of
this prospectus (the restricted period): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any hedging, swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of our common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submit or file any registration statement with the SEC relating to the offering of any shares of common stock
or any securities convertible into or exercisable or exchangeable for common stock; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">whether any such transaction
described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such person have agreed that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC and Goldman
Sachs&nbsp;&amp; Co. LLC on behalf of the underwriters, we or such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security
convertible into or exercisable or exchangeable for common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to us, the restrictions described in the
immediately preceding paragraph do not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares to be sold in this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance by us of shares of common stock upon the exercise of an option or warrant or the conversion of a
security outstanding on the date of this prospectus as described in the registration statement and this prospectus; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(3)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment of a trading plan on behalf of any of our shareholders, officers or directors
pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of our common stock, provided that (a)&nbsp;such plan does not provide for the transfer of common stock during the restricted period
and (b)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no
transfer of common stock may be made under such plan during the restricted period. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">With respect to our
directors, officers and securityholders, the restrictions described above do not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions relating to shares of common stock or other securities acquired in this offering or in open
market transactions after the completion of this offering, provided that no filing under Section&nbsp;16(a) of the Exchange Act or other public announcement shall be required or shall be voluntarily made during the restricted period in connection
with subsequent sales of common stock or other securities acquired in this offering or in such open market transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares of common stock or any security convertible into common stock (i)&nbsp;as a bona fide
gift, (ii)&nbsp;to an immediate family member or to any trust for the direct or indirect benefit of the holder or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
an immediate family member of the holder, (iii)&nbsp;to any corporation, partnership, limited liability company, investment fund, trust or other entity of which the holder and the immediate
family of the holder are the legal and beneficial owner of all of the outstanding equity securities or similar interests, or (iv)&nbsp;by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or an
immediate family member of the holder; provided that in the case of any transfer or distribution pursuant to this clause (2), (A) such transfer shall not involve a disposition for value, (B)&nbsp;each donee, distributee or transferee shall sign and
deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement and (C)&nbsp;no public disclosure or filing shall be made voluntarily during the restricted period, and to the extent a filing under Section&nbsp;16(a) of the Exchange Act is
required during the restricted period as a result of transfers made pursuant to this clause (2), it shall clearly indicate that the filing relates to the circumstances described in this clause (2), including that the securities remain subject to the
terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(3)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the holder is a corporation, partnership, limited liability company, trust or other business entity,
(i)&nbsp;transfers or distributions of shares of common stock or any security convertible into shares of common stock to current or former general or limited partners, managers or members, stockholders, other equityholders or direct or indirect
affiliates (within the meaning of Rule 405 under the Securities Act) of the holder, or to the estates of any of the foregoing or (ii)&nbsp;transfers or distributions to any investment fund or other entity controlling, controlled by, managing or
managed by or under common control with the holder or affiliates of the holder (including, for the avoidance of doubt, where the holder is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such
partnership); <I>provided</I> that, in the case of any transfer or distribution pursuant to this clause (3), (A) each transferee, donee or distributee shall sign and deliver a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, (B)&nbsp;no
filing under Section&nbsp;16(a) of the Exchange Act or other public announcement reporting a reduction in beneficial ownership of shares of common stock shall be required or shall be voluntarily made during the restricted period (other than a
required filing on Schedule 13D, 13F or 13G) and (C)&nbsp;such transfer shall not involve a disposition for value; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(4)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilitating the establishment or amendment of a trading plan on behalf of any of our stockholders, officers,
or directors pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares of common stock, provided that (i)&nbsp;such plan does not provide for the transfer of shares of our common stock during
the restricted period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the holder or us regarding the establishment or amendment of such plan during the
restricted period, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the restricted period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(5)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transfer of shares of common stock or any other securities to us to satisfy any tax, including estimated
tax, remittance, or other payment obligations of the holder arising in connection with a vesting event of our securities, upon the settlement of restricted stock units or the payment due for the exercise of options (including a transfer to us for
the &#147;net&#148; or &#147;cashless&#148; exercise of options) or other rights to purchase our securities, in all such cases pursuant to equity awards granted under our equity incentive plan or other equity award plan described in this prospectus;
<I>provided</I>, that any remaining shares of common stock or other securities received upon such vesting, settlement or exercise shall be subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; and <I>provided
</I>further, that no public disclosure or filing shall be made voluntarily during the restricted period and, to the extent a filing under Section&nbsp;16(a) of the Exchange Act is required during the restricted period as a result of transfers made
pursuant to this clause (5), it shall clearly indicate that the filing relates to the circumstances described in this clause (5), including that the securities remain subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(6)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transfer of shares of common stock or any other securities that occurs by operation of law pursuant to a
qualified domestic order or other court order in connection with a divorce settlement, provided that (i)&nbsp;the transferee shall sign and deliver a lock- up agreement, (ii)&nbsp;no public disclosure or filing shall be voluntarily made during the
restricted period and (iii)&nbsp;any filing required under Section&nbsp;16(a) of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Exchange Act during the restricted period shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (6); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(7)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers to us (A)&nbsp;from any of our employees upon death, disability or termination of employment, in
each case, of such employee or (B)&nbsp;pursuant to any contractual arrangement described in this prospectus or in an exhibit filed with the registration statement related to this offering and disclosed to the Representatives that provides for the
repurchase of shares of common stock in connection with the termination of the holder&#146;s employment with or service to us; provided that in the case of clause (B), no public disclosure or filing under Section&nbsp;16(a) of the Exchange Act shall
be required or shall be voluntarily made during the restricted period within the first 75 days after the date of this prospectus, and after such 75th day, to the extent a filing under Section&nbsp;16(a) of the Exchange Act is required during the
restricted period as a result of transfers made pursuant to this clause (7), it shall clearly indicate that the filing relates to the circumstances described in this clause (7)&nbsp;and no public disclosure or filing shall be voluntarily made;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(8)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of shares of our redeemable convertible preferred stock into shares of common stock as
described in this prospectus, provided that, in each case such shares shall continue to be subject to the restrictions on transfer set forth in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(9)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transfer of shares of common stock or any other securities pursuant to a bona fide third- party tender
offer, merger, consolidation or other similar transaction that is approved by our board of directors, made to all holders of common stock involving a change of control, provided that, in the event that the tender offer, merger, consolidation or
other such transaction is not completed, the common stock owned by the holder shall remain subject to the restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Morgan Stanley&nbsp;&amp; Co. LLC and Goldman Sachs&nbsp;&amp; Co. LLC, in their sole discretion, may release the common stock
and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain
or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is
no greater than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open market. In
determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may also sell
shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters
are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the
underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or
retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A prospectus in electronic format may be made available on websites maintained by one or more
underwriters, or selling group members, if any, participating in this offering. The representatives may agree to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters
that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which
may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective
affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may
make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any
time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or
publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Prior to this offering, there has been no public market for our common stock. The initial public offering price will be
determined by negotiations between us and the representatives. Among the factors to be considered in determining the initial public offering price will be our future prospects and those of our industry in general, our sales, earnings and certain
other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106</FONT><I></I><I>&nbsp;Prospectus Exemptions</I>&nbsp;or subsection 73.3(1) of the<I></I><I>&nbsp;Securities Act</I>&nbsp;(Ontario), and are permitted clients, as defined
in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103</FONT><I></I><I>&nbsp;Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in
a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Securities legislation in
certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are
exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s
province or territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to section 3A.3 of
National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105</FONT><I></I><I>&nbsp;Underwriting Conflicts</I><FONT STYLE="white-space:nowrap">&nbsp;(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure
requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In relation to each Member State of the European Economic Area (each, a Relevant State), no shares have been offered or will be
offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in
another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the EU Prospectus Regulation (as defined below), except that offers of shares may be made to the public in that Relevant State at any time
under the following exemptions under the EU Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any legal entity which is a qualified investor as defined under the EU Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to fewer than 150 natural or legal persons (other than qualified investors as defined under the
EU&nbsp;Prospectus Regulation), subject to obtaining the prior consent of the representatives; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other circumstances falling within Article 1(4) of the EU Prospectus Regulation,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus
pursuant to Article 3 of the EU Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the EU Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in any
Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase any shares, and the expression &#147;EU Prospectus
Regulation&#148; means Regulation (EU) 2017/1129 (as amended). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">it has only communicated or caused to be communicated and will only communicate or cause to be communicated
an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (the FSMA)) received by it in connection with the issue or sale of the shares in circumstances in
which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by
it in relation to the shares in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No shares have been
offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be
offered to the public in the United Kingdom at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation
(as defined below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">in any other circumstances falling within Section&nbsp;86 of the FSMA, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Section&nbsp;85
of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus is only for distribution to and directed at: (i)&nbsp;in the United Kingdom, persons having professional
experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the Order), and high net worth entities falling within Article 49(2)(a) to
(d)&nbsp;of the Order; (ii)&nbsp;persons who are outside the United Kingdom; and (iii)&nbsp;any other person to whom it can otherwise be lawfully distributed (all such persons together, Relevant Persons). Any investment or investment activity to
which this prospectus relates is available only to and will be engaged in only with Relevant Persons, and any person who is not a Relevant Person should not rely on it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of
Hong Kong and any rules made under that Ordinance or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer
to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in
Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of common
stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares
of common stock have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the
benefit of any Japanese Person (as defined below) or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to any Japanese Person, except in compliance with all applicable laws, regulations
and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; means any person resident in Japan, including any
corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares of
common stock were not offered or sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus
or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or
indirectly, to any person in Singapore other than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore (as modified or amended from time to time, the SFA)) pursuant to
Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions
specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Where the shares of common stock are subscribed or purchased under
Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(i)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(ii)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">securities or securities-based derivatives
contracts (each term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust
has acquired the securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(d)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the SIX) or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the
disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock
exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Neither this prospectus nor any other offering or marketing material relating to us, the offering, or the shares have been or
will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offering of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offering
of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (the CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to
acquirers of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services
Authority (the DFSA). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the
Australian Securities and Investments Commission, in relation to the offering. This prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations Act), and does not purport to include the information
required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Any
offer in Australia of the shares may only be made to persons (Exempt Investors) who are &#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of
section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of
12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or
otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring the shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This prospectus contains general information only and does not take account of the investment objectives, financial situation
or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate
to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under
the Israeli Securities Law, 5728 - 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728 - 1968, including
if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the Addressed Investors); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the
First Addendum of the Israeli Securities Law, 5728 - 1968, subject to certain conditions (the Qualified Investors). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase shares
of common stock in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 - 1968. We have not and will
not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Qualified Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the
Israeli Securities Law, 5728 - 1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an
investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 - 1968; (ii)&nbsp;which of the categories listed in the First Addendum to the Israeli Securities Law, 5728 - 1968 regarding Qualified
Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728 - 1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that the
shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 - 1968: (a)&nbsp;for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale
within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 - 1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit
written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, San
Diego, California. The underwriters are being represented by Cooley LLP, San Diego, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_20"></A>EXPERTS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our financial statements at December
31, 2021 and 2022, and for each of the two years in the period ended December 31, 2022, as set forth in their report. We&#146;ve included our financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst
&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc551455_21"></A>WHERE YOU CAN
FIND MORE INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have filed with the SEC a registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the shares of our common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set
forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed therewith.
Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by
reference to the full text of such contract or other document filed as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We are
not currently subject to the information and periodic and current reporting requirements of the Exchange Act. Upon the closing of this offering, we will become subject to the information and periodic and current reporting requirements of the
Exchange Act and, in accordance therewith, will file periodic reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy statements and other information regarding companies
that file electronically with it. Our periodic and current reports, proxy statements and other information will be available at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We also maintain a website at https://cgoncology.com. Upon the closing of this offering, you may access our proxy statements,
annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed
or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our
website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock. We have included
our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A><A NAME="toc551455_22"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin551455_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">F-2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin551455_2">Balance Sheets as of December&nbsp;31, 2021 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">F-3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin551455_3">Statements of Operations and Comprehensive Loss for the years ended December&nbsp;31,
 2021 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">F-4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin551455_4">Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit for the years ended December&nbsp;31, 2021 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">F-5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin551455_5">Statements of Cash Flows for the years ended December&nbsp;
31, 2021 and 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">F-6</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin551455_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">F-7</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin551455_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">To the Stockholders and the Board of Directors of CG Oncology, Inc.<B><SUP STYLE="font-size:75%; vertical-align:top">&nbsp;</SUP></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have audited the accompanying balance sheets of CG Oncology, Inc. (the Company) as of December&nbsp;31, 2021 and 2022, the
related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#146; deficit and cash flows for the years then ended and the related notes (collectively referred to as the &#147;financial
statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2021 and 2022, and the results of its operations and its cash flows for the years then
ended in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion
on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.<B></B><B><SUP STYLE="font-size:75%; vertical-align:top">&nbsp;</SUP></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We conducted our audits in accordance with the standards of the PCAOB<B></B>&nbsp;and in accordance with auditing standards
generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have served as the Company&#146;s auditor since 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">/s/ Ernst &amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;27, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin551455_2"></A>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2021&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;2022&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;58,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;147,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Long-term debt, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Success fee liability, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Operating lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock,
$0.0001 par value per share; 5,075,000 shares authorized, issued and outstanding as of December&nbsp;31, 2021 and 2022; liquidation value of $3,570 as of December&nbsp;31, 2021 and 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Series B redeemable convertible preferred stock, $0.0001 par value per share; 11,973,000 shares
authorized, issued and outstanding as of December&nbsp;31, 2021 and 2022; liquidation value of $10,000 as of December&nbsp;31, 2021 and 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Series C redeemable convertible preferred stock, $0.0001 par value per share; 73,598,283 shares
authorized, issued and outstanding of December&nbsp;31, 2021 and 2022; liquidation value of $22,000 as of December&nbsp;31, 2021 and 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Series D redeemable convertible preferred stock, $0.0001 par value per share; 53,271,754 shares
authorized, issued and outstanding as of December&nbsp;31, 2021 and 2022; liquidation value of $47,300 as of December&nbsp;31, 2021 and 2022.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Series E redeemable convertible preferred stock, $0.0001 par value per share; zero and
112,422,700 shares authorized, issued and outstanding as of December&nbsp;31, 2021 and 2022, respectively; liquidation value of zero and $120,000 as of December&nbsp;31, 2021 and 2022, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Common stock, $0.001 par value per share; 263,000,000 and 393,500,000 shares authorized as of
December&nbsp;31, 2021 and 2022, respectively; 35,408,988 and 36,640,092 shares issued and outstanding at December&nbsp;31, 2021 and 2022, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin551455_3"></A>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense) income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(196</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (expense) income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend on redeemable convertible preferred stock issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative redeemable convertible preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;34,807,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;35,669,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an
integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin551455_4"></A>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<B>In thousands, except share amounts)</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-1</FONT><BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,075,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,598,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,271,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,346,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,053</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,075,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,598,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,271,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,408,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42,618</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series E redeemable<B> </B>convertible<B> </B>preferred stock (inclusive of deemed
dividend of $474k to accrete to redemption value)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,422,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Common Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,231,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,075,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,598,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,271,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,422,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,640,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(81,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(77,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin551455_5"></A>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2021&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Amortization of loan fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Final payment amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Mark to market on success fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Success fee amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Forgiveness of PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> lease expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.80em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Prepaid and current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.80em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.80em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.80em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Investing Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Purchase of securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Financing Activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from issuance of Series E redeemable convertible preferred stock, net of issuance
costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from issuance of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net increase in cash, cash equivalent and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;53,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;88,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Supplemental Disclosure of Cash Flow Information:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash paid for taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Supplemental&nbsp;Schedule&nbsp;of&nbsp;Noncash&nbsp;Investing&nbsp;And&nbsp;Financing&nbsp;Activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Forgiveness of PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset obtained in exchange for lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral
part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin551455_6"></A>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
Description of Business and Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Cold Genesys Inc. was incorporated in California in September 2010, reincorporated in Delaware in November 2017 and is
headquartered in Irvine, California. Cold Genesys, Inc. changed its name to CG Oncology, Inc. (the Company), in March 2020. The Company is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product
candidate, cretostimogene, for patients with bladder cancer. The Company is at a clinical stage and does not project to generate significant revenues if and until the U.S. Food and Drug Administration (FDA) approves its primary asset,
cretostimogene. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The accompanying financial statements are prepared in conformity with U.S. generally accepted accounting principles (GAAP). Any
reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Management&#146;s Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2022, the Company had approximately $143.5&nbsp;million of cash, cash equivalents and marketable
securities and working capital of approximately $131.8&nbsp;million. The revenue and income potential of the Company&#146;s business and market are unproven. The Company has experienced net losses and negative cash flows from operations since its
inception and, as of December&nbsp;31, 2022, the Company had an accumulated deficit of $81.3&nbsp;million. During the year ended December&nbsp;31, 2022, the Company incurred a net loss of $35.4&nbsp;million and negative cash flows from operations of
$29.8&nbsp;million. The Company will continue to incur significant costs and expenses related to its ongoing operations until it successfully develops, obtains regulatory approval and gains market acceptance of cretostimogene and achieves a level of
revenues adequate to support the Company&#146;s operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From inception to December&nbsp;31, 2022, the Company has
funded its operations through the issuance of shares of its redeemable convertible preferred stock and long-term debt. The Company believes that its current capital resources, which consist of cash, cash equivalents and marketable securities, will
be sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on its expected cash needs. As the Company continues to pursue its business plan, it expects to finance its
operations through equity offerings, debt financings, or other capital sources, including current or potential future collaborations, licenses, and other similar arrangements. However, there can be no assurance that any additional financing or
strategic arrangements will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it may be necessary to significantly reduce its scope of operations to
reduce the current rate of spending through actions such as reductions in staff and the need to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market product candidates
that it would otherwise prefer to develop and market itself, which could have a material adverse effect on the Company&#146;s business, results of operations or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use
of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The preparation of financial statements in conformity with GAAP requires management to make
estimates, assumptions, and judgements that affect the reported amounts of assets, liabilities, expenses, and related </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
disclosures in the accompanying notes. The Company bases its estimates, assumptions and judgements on historical experience when available and on various factors that it believes to be reasonable
under the circumstances as of the date of the accompanying financial statements including the fair value of common stock, stock-based compensation expense, accrued expenses, lease accounting, and the recoverability of the Company&#146;s net deferred
tax assets and related valuation allowance. In addition, other factors may affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions used in developing estimates, and
whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within
that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying financial statements under different assumptions or conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents and Marketable Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company considers all highly liquid investments and instruments with original maturities of 90 days or less that can be
liquidated without prior notice or penalty to be cash equivalents. Cash equivalents consisted primarily of demand deposit accounts, insurance deposits and short-term U.S. Treasury money market funds as of December&nbsp;31, 2021 and 2022. Marketable
securities represent fixed income securities which consists of U.S. Treasury bills with maturities greater than 90 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit
Risks </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments that subject the Company to significant concentrations of credit risk consist
primarily of cash and cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions in the United States. These deposits are held in checking and money market accounts and may, from time to time,
exceed the federally insured amounts. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant risk in its cash and cash equivalents. The primary objectives of the Company&#146;s
investment portfolio are the preservation of capital and maintenance of liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is subject to risks common
to companies in the biopharmaceutical industry, including, but not limited to, risks related to the successful development and commercialization of product candidates, fluctuations in operating results and financial risks, the ability to
successfully raise additional funds when needed, protection of proprietary rights and patent risks, patent litigation, compliance with government regulations, dependence on key personnel and collaboration partners, and competition from competing
products in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company applies fair value measurements to record fair value adjustments to certain assets and liabilities and to determine
fair value disclosures. The Company&#146;s financial instruments consist principally of cash, cash equivalents, marketable securities, accounts payable and operating lease liabilities. Fair value is measured as the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal
market for the asset or liability or, in the absence of a principal market, the most advantageous market. A framework is used for measuring fair value utilizing a three-tier hierarchy that prioritizes the inputs to valuation techniques used to
measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The three levels of the fair value hierarchy are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Level</I></B><B> 1</B>&#151;Observable inputs such as unadjusted quoted prices in active markets that are accessible at
the measurement date for identical unrestricted assets or liabilities the Company has the ability to access; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Level</I></B><B> 2</B>&#151;Inputs (other than quoted prices included within Level&nbsp;1) that are observable for the
asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or
liabilities in markets that are not active; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>Level</I></B><B> 3</B>&#151;Unobservable inputs that are significant
to the fair value measurement and reflect the reporting entity&#146;s use of significant management judgment and assumptions when there is little or no market data. Level&nbsp;3 assets and liabilities include those whose fair value measurements are
determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Financial instruments are categorized in their entirety based on the lowest level of input that is significant to the fair
value measurement. The assessment of the significance of a particular input to the fair value measurement requires judgment and considers factors specific to the investment. To the extent that the valuation is based on models or inputs that are less
observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. The
Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The
Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no differences between net loss and comprehensive loss presented in the statements of operations for the years ended
December&nbsp;31, 2021 and 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over five years, which
equals the estimated useful lives of the respective assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The initial cost of property and equipment consists of its
purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the assets have been put into operation, such as repairs and maintenance, are charged to
expense in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluates its long-lived assets, which consist of property and equipment and operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, for impairment at least annually and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.
Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or
planned changes in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
use of the assets. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The
Company recognized no impairment losses for the years ended December&nbsp;31, 2021 and 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On March&nbsp;27, 2020, President Trump signed into law the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The
Company entered into a loan agreement (the PPP Loan) with Silicon Valley Bank (SVB) under the Paycheck Protection Program (the PPP), which is part of the CARES Act administered by the U.S. Small Business Administration (SBA). As part of the
application for these funds, the Company, in good faith, certified that the then current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. The certification further required the Company to take
into account its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that was not significantly detrimental to the business. The Company recorded the entire amount of
the PPP Loan as debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company applied for forgiveness of the PPP Loan of $0.4&nbsp;million in 2021. In 2021, the
Company received a confirmation notice from SVB that the forgiveness of the PPP Loan was approved by the SBA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets represent the
Company&#146;s right to use an underlying asset for the lease term, and lease liabilities represent the Company&#146;s obligation to make lease payments arising from the lease. Operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities are recognized when the Company takes possession of the leased property (the Commencement Date) based on the present value of lease payments over the lease term. At the
inception of a contract, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. The Company had no finance leases as of December&nbsp;31, 2021 and 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets also
include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and
related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elects the practical expedient to exclude short-term agreements of less than 12 months
from capitalization. The Company enters into various operating leases for office space. The leases expire at various dates, have various options to renew, and may contain escalation provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Rent expense on cancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over
the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets on the accompanying balance sheets. Landlord improvement allowances and other such lease incentives are recorded as property and equipment and as a
reduction of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> leased assets and are amortized on a straight-line basis as a reduction to operating lease costs. The key estimates for the Company&#146;s
leases include the incremental borrowing rate used to determine the present value of lease payments and the lease term. The Company&#146;s leases generally do not include an implicit rate. Management determines the incremental borrowing rate based
on the information available at lease commencement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct
costs incurred less any lease incentives received. Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are subsequently measured </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease
incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Collaboration Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company entered into development and license agreements with Lepu Biotech Co., Ltd. (Lepu) and Kissei Pharmaceutical Co.,
Ltd. (Kissei), collectively referred to as the License and Collaboration Agreements. See Note 6 for a description of the License and Collaboration Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint
operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of ASC 808,
<I>Collaborative Arrangements</I> (ASC 808). This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808
that contain multiple units of account, the Company first determines which components of the collaboration are deemed to be within the scope of ASC 808 and which components of the collaboration are more reflective of a vendor-customer relationship
and therefore within the scope of ASC 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For units of account of collaboration arrangements that are accounted for
pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to authoritative accounting literature or by applying a reasonable and rational policy election. The Company evaluates the income
statement classification for presentation of amounts due from or owed to other participants associated with multiple activities in a collaboration arrangement based on the nature of each separate activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For units of account accounted within scope of ASC 606, to determine the appropriate amount of revenue to be recognized for
the arrangements, the Company performs the following steps: (i)&nbsp;identification of the promised goods or services in the contract; (ii)&nbsp;determination of whether the promised goods or services are performance obligations including whether
they are distinct in the context of the contract; (iii)&nbsp;measurement of the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocation of the transaction price to the performance obligations; and
(v)&nbsp;recognition of revenue when (or as) the Company satisfies each performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s
performance obligations under the terms of these agreements include a license grant, research and development services or customer options, depending on the terms of the License and Collaboration Agreement. Payments to the Company include a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront payment, payments based upon the achievement of development and commercial milestones, and royalties on product sales under the License and Collaboration agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Development milestones </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The License and Collaboration Agreements include milestone payments that are triggered by the achievement of development
milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price. Revenue from milestones will be recognized at the time the specified milestone events have been achieved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Sales milestones and royalty payments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The License and Collaboration Agreements also include certain sales-based milestone and royalty payments upon successful
commercialization of a licensed product. In accordance with ASC 606, the Company recognizes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
revenue from sales-based milestone and royalty payments at the later of: (i)&nbsp;the occurrence of the subsequent sale; or (ii)&nbsp;the performance obligation to which some or all of the
sales-based milestone or royalty payments has been allocated or has been satisfied. The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Research and development (R&amp;D) expenses consist of costs incurred for R&amp;D of its product candidate and are recorded to
operating expenses when incurred. The Company&#146;s R&amp;D expenses consist primarily of costs incurred in performing R&amp;D activities, including personnel-related expenses such as salaries, stock-based compensation and benefits, as well as
allocated facilities costs, dues and subscriptions and external costs of outside vendors engaged as contract research organization (CRO), contract manufacturers, consultants and other third parties to conduct and support our clinical trials and
preclinical studies. The Company accrues expenses related to development activities performed by third parties based on an evaluation of services received and efforts expended pursuant to the terms of the contractual arrangements. Payments under
some of these contracts depend on clinical trial milestones. There may be instances in which payments made to the Company&#146;s vendors will exceed the level of services provided and result in a prepayment of expenses. In accruing service fees, the
Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will
adjust the accrual or prepaid expense accordingly. Costs to acquire technologies to be used in R&amp;D that have not reached technological feasibility and have no alternative future use are also expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021 and 2022, the Company had two stock-based compensation plans, the 2015 Equity Incentive Plan (the
2015 Plan) and 2022 Incentive Award Plan (the 2022 Plan), which are more fully described in Note 9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company
periodically grants equity-based payment awards in the form of stock options to employees, directors and <FONT STYLE="white-space:nowrap">non-employees</FONT> and records stock-based compensation expenses for awards of stock-based payments based on
their estimated fair value at the grant date. The Company recognizes stock-based compensation expense for all equity-based payments, including stock options. Stock-based compensation costs are calculated based on the estimated fair value of the
underlying option using the Black-Scholes option pricing model on the date of grant for stock options and are recognized as expense in the accompanying statement of operations and comprehensive loss on a straight-line basis over the requisite
service period, which is the vesting period. Determining the appropriate fair value model and related input assumptions requires judgment, including estimating the fair value of the Company&#146;s common stock, stock price volatility, and expected
term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Given the absence of a public trading market, the fair value of the Company&#146;s common stock is determined by
the Company&#146;s Board of Directors (the Board) at the time of each option grant by considering a number of objective and subjective factors. These factors include the valuation of a select group of public peer companies within the industry that
focus on biotechnology that the Board believes is comparable to the Company&#146;s operations; operating and financial performance; the lack of liquidity of the common stock and trends in the broader economy and medical device industry also impact
the determination of the fair value of the common stock. In addition, the Company regularly engages a third-party valuation specialist to assist with estimates related to the valuation of the Company&#146;s common stock; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in
effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant&#146;s expected term; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The dividend yield is zero as the Company has not paid dividends and does not anticipate paying a cash
dividend in the foreseeable future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected term for options granted is calculated using the simplified method and represents the average
time that options are expected to be outstanding based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term of the award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expected volatility is derived from the historical volatilities of a select group of comparable peer
companies, for a look-back period commensurate with the expected term of the stock options, as the Company has no trading history of common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company recognizes forfeitures related to stock-based compensation awards as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award
recipients&#146; payroll costs are classified or in which the award recipients&#146; service payments are classified. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company accounts for income taxes in accordance with ASC 740, <I>Income Taxes</I> (ASC 740). ASC 740 requires the use of
the asset and liability method of accounting for income taxes. The current or deferred tax consequences of a transaction are measured by applying the provisions of enacted tax laws to determine the amount of taxes payable currently or in future
years. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities and expected future tax consequences of events that have been included in the financial
statements or tax returns using enacted tax rates in effect for the year in which the differences are expected to reverse. Under this method, a valuation allowance is used to offset deferred tax assets if, based upon the available evidence, it is
more likely than not that some or all of the deferred tax assets may not be realized. Management annually evaluates the recoverability of deferred taxes and the adequacy of the valuation allowance. See Note 10 for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company follows the provisions of ASC 740 relative to accounting for uncertain tax positions. These provisions provide
guidance on the recognition, <FONT STYLE="white-space:nowrap">de-recognition</FONT> and measurement of potential tax benefits associated with tax positions. For those benefits to be recognized, a tax position must be more likely than not to be
sustained upon examination by taxing authorities. As applicable, the Company recognizes accrued penalties and interest related to unrecognized tax benefits in the provision for income taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Significant judgment is required in determining the Company&#146;s provision for income taxes, deferred tax assets and
liabilities and the valuation allowance recorded against net deferred tax assets. The Company assesses the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The evaluation of the need for a valuation
allowance is performed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis and includes a review of all available positive and negative evidence. Factors reviewed include
projections of <FONT STYLE="white-space:nowrap">pre-tax</FONT> book income for the foreseeable future, determination of cumulative <FONT STYLE="white-space:nowrap">pre-tax</FONT> book income after permanent differences, earnings history and
reliability of forecasting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company is required to file federal and state income tax returns in the U.S. The
preparation of state tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s income tax returns are based on calculations and assumptions that are subject to examination by the
Internal Revenue Service and other tax authorities. In addition, the calculation of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Company&#146;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a <FONT
STYLE="white-space:nowrap">two-step</FONT> process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on
audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes it has
appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses
the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company follows the accounting guidance on accounting for uncertainty in income taxes. The guidance prescribes a
recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classification of Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Classification of the Company&#146;s Series <FONT STYLE="white-space:nowrap">A-1,</FONT> B, C, D and E redeemable convertible
preferred stock is being treated as mezzanine equity and not as part of stockholders&#146; deficit because the holders of such shares have liquidation rights in the event of a deemed liquidation that, in certain situations, are not solely within the
control of the Company and would require the redemption of the then-outstanding redeemable convertible preferred stock. In addition, all of the Company&#146;s redeemable convertible preferred stock are redeemable with the passage of time on or after
September&nbsp;30, 2027, by class and if requested by a requisite majority of each class. See Note 7 for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The carrying values of the Series <FONT STYLE="white-space:nowrap">A-1,</FONT> B, C, D and E redeemable convertible preferred
stock are reported at their respective redemption values. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined all of its redeemable convertible preferred stock qualifies as participating securities, as defined in
ASC 260. Under ASC 260, securities are considered participating securities if the securities may participate in undistributed earnings with common stock. In accordance with ASC 260, a company is required to use the
<FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net income (loss) per share when a company has securities that qualify as participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method is an earnings
allocation formula that determines net income (loss) per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. Under the two-class method,
the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the preferred stockholders do not have a contractual obligation to share in the Company&#146;s losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment and Geographic Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs
expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company&#146;s chief operating decision maker is
its Chief Executive Officer. The chief operating decision maker reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire company. The Company views its operations and manages its
business as one operating segment. All of the Company&#146;s assets are located in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Accounting standards not listed below were assessed and determined not to be applicable or are expected to have minimal impact
on the Company&#146;s financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In December 2019, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2019-12,</FONT> <I>Simplifying the Accounting for Income Taxes</I>. The guidance eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in
an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. The guidance was effective for fiscal years beginning after
December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022. Early adoption was permitted. The adoption of the guidance did not have a material impact on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In August 2020, the FASB <FONT STYLE="white-space:nowrap">issued&nbsp;ASU&nbsp;2020-06,</FONT><I>&nbsp;Debt &#151; Debt with
Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging &#151; Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40)</FONT></I>. The guidance simplifies
the accounting for certain financial instruments, eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments, and simplifies the derivative scope exception guidance
pertaining to equity classification of contracts in an entity&#146;s own equity. It also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#146;s own equity and amends
the diluted earnings per share guidance, including the requirement to use the <FONT STYLE="white-space:nowrap">if-converted</FONT> method for all convertible instruments. The guidance is effective for public business entities that meet the
definition of a Securities and Exchange Commission filer, excluding entities eligible to be smaller reporting companies as defined by the Securities and Exchange Commission, for fiscal years beginning after December&nbsp;15, 2021, including interim
periods within those fiscal years. For all other entities, the guidance is effective for fiscal years beginning after December&nbsp;15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than
fiscal years beginning after December&nbsp;15, 2020, including interim periods within those fiscal years. The Board specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company early-adopted the
guidance as of January&nbsp;1, 2021. The adoption of the guidance did not have a material impact on the Company&#146;s financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair
Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following tables present the financial instruments carried at fair value on a recurring basis
as of December&nbsp;31, 2021 and 2022 in accordance with the ASC 820 hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;53,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;53,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success fee liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;55,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Success fee liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s cash equivalents represent deposits in a short-term U.S.
Treasury money market fund quoted in an active market and were classified as a Level&nbsp;1 fair value measurement. Marketable securities represent fixed income securities (U.S. treasury bills) with original maturities greater than 90 days and were
classified as a level 2 fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The success fee liability associated with the Loan and Security Agreement
(the Loan Agreement) the Company entered into in January 2021 was classified as a Level&nbsp;3 fair value measurement, due to the use of unobservable inputs. See Note 11 for additional information on the Loan Agreement and success fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">There were no transfers between Level&nbsp;1 and Level&nbsp;2 of the fair value hierarchy during the years ended
December&nbsp;31, 2021 and 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides a summary of the changes in the Company&#146;s Level&nbsp;3
fair value measurement (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement of success fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in fair value of success fee recorded in earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in fair value of success fee recorded in earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8194;352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued Expenses and Other Current Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The components of accrued expenses and other current liabilities for the years ended December&nbsp;31, 2021 and 2022 were as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;1,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;5,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On January&nbsp;1, 2019, the Company adopted ASC 842, <I>Leases</I>. As of December&nbsp;31, 2021, the Company had one
operating lease, in which the Company was the lessee for office space. As of December&nbsp;31, 2022, the Company had two operating leases, in which the Company is the lessee for office space. As of December&nbsp;31, 2022, the lease terms were
through 2023 and 2025. The Company had no finance leases as of December&nbsp;31, 2021 and 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The components of lease expense for the years ended December&nbsp;31, 2021
and 2022 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2021&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;2022&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lease cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset obtained in exchange for new operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities, included in operating
cash flows</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average remaining lease term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Maturities of lease liabilities as of December&nbsp;31, 2022 were as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: amount representing imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A liability for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources is
recorded in the financial statements if it is determined that it is probable that a loss has been incurred, and that the amount (or range) of the loss can be reasonably estimated. There are no matters currently outstanding for which any liabilities
have been accrued or require disclosure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors,
business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has
entered into indemnification agreements with officers and members of the Board that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or
officers. As of December&nbsp;31, 2021 and 2022, the Company had not experienced any losses related to these indemnification obligations, and no claims with respect thereto were outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. License and Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lepu Biotech Co., Ltd. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2019, the Company entered into a development and license agreement with Lepu for cretostimogene (the Lepu License
Agreement). Under the terms of the Lepu License Agreement, the Company granted to Lepu an exclusive license to develop, manufacture and commercialize cretostimogene and/or DDM to treat and/or prevent cancer in mainland China, including Hong Kong and
Macau (the Lepu Territory). The Company is obligated to use commercially reasonable efforts to supply Lepu with its requirements of cretostimogene and DDM for its development activities at Lepu&#146;s cost and to periodically provide Lepu with
manufacturing documentation and, at Lepu&#146;s cost, reasonably requested assistance related to the manufacture of clinical and, if applicable, commercial supplies of cretostimogene and DDM. The Company determined that control of the license was
transferred to Lepu on March 2019 upon execution of the contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Lepu paid to the Company a one-time upfront payment of
$4.5&nbsp;million, and Lepu is obligated to make regulatory milestone payments of up to $2.5&nbsp;million and commercial milestone payments of up to $57.5 million. The Company is entitled to receive a high single-digit royalty on net sales of
cretostimogene and/or DDM sold in the Lepu Territory, subject to a specified reduction. Lepu&#146;s royalty obligations will expire upon termination of the Lepu License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company assessed the Lepu License Agreement in accordance with ASC 606 and determined that the performance obligation is
comprised solely of the license grant to Lepu. The Company determined the transaction price was $4.5&nbsp;million and recorded the entire amount upon transfer of control of the functional intellectual property license rights in 2019. The Company
evaluated the provision of manufacturing activities related to clinical and commercial supply of the licensed products and concluded that the manufacturing activities were not performance obligations as the terms do not provide a material right to
Lepu. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Future milestone payments are fully contingent as the risk of significant revenue reversal will only be resolved
depending on future regulatory approval and sales level outcomes. The Company will re-evaluate the likelihood of achieving future milestones at the end of each reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The sales-based royalty fee is considered variable consideration and will be recognized as revenue as such sales occur. The
sales-based royalty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the years ended December&nbsp;31, 2021 and 2022, no development or commercial milestones were met and, as a result, no
revenue was recorded related to the Lepu License Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kissei Pharmaceutical Co., Ltd. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In March 2020, and amended as of September 2022, the Company entered into a license and collaboration agreement with Kissei
(the Kissei License Agreement). Under the terms of the Kissei License Agreement, the Company granted to Kissei an exclusive license to certain intellectual property rights in Bangladesh, Bhutan, Brunei, Cambodia, India, Indonesia, Japan, South
Korea, Laos, Malaysia, Myanmar, Nepal, Pakistan, Palau, Philippines, Singapore, Sri Lanka, Taiwan, Thailand and Vietnam (the Kissei Territory), for Kissei to develop and commercialize, but not manufacture, cretostimogene in combination with DDM (the
Licensed Product) for all uses in oncology indications for which marketing approval is being sought. Under the Kissei Agreement, the Company and Kissei agree to use commercially reasonable efforts to collaborate on clinical development activities in
the Kissei Territory and each party is responsible for conducting the applicable activities pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
an agreed development plan. Kissei is responsible for the costs of developing the Licensed Product in the Kissei Territory, and the Company is responsible for the costs of developing the Licensed
Product outside the Kissei Territory (Global Development), provided that Kissei is responsible for a low-double digit percentage and the Company is responsible for a high-double digit percentage of the cost of development activities that cannot be
attributed solely to the Kissei Territory or outside the Kissei Territory. The Company is obligated to supply and Kissei will exclusively purchase its clinical and commercial requirements of Licensed Product from the Company. Kissei is responsible
for commercializing the Licensed Product in the Kissei Territory and is obligated to use commercially reasonable efforts to seek regulatory approval for and commercialize at least one Licensed Product in a specified indication. Until a certain
period of time has passed after the first regulatory approval of the Licensed Product, the Company is prohibited from commercializing certain competing products worldwide and Kissei is prohibited from researching, developing or commercializing
certain competing products worldwide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the Kissei License Agreement, the Company received a
$10.0&nbsp;million one-time upfront payment and, in connection with entry into this agreement, Kissei purchased $30.0&nbsp;million worth of Series&nbsp;D redeemable convertible preferred stock as part of the Company&#146;s Series D financing. Kissei
is obligated to make development and regulatory milestone payments to the Company of up to $33.0&nbsp;million and commercial milestone payments of up to $67.0&nbsp;million. The Company has agreed to pay Kissei a royalty on net sales of Licensed
Product outside the Kissei Territory and outside the Lepu Territory (as described above), including on any U.S. sales, in a low-single digit percentage, subject to certain capped reductions. We are entitled to receive a royalty on net sales of
Licensed Product in the Kissei Territory in the mid-twenties percentage, subject to certain capped reductions. Also, Kissei has the right to offset the royalty payments due to the Company with respect to the cost for the supply of Licensed Product
sold by the Company to Kissei, and to indefinitely carryforward credits for any excess supply amounts paid over royalty amounts owed in a given quarter. The Company is entitled to receive a specified minimum percentage of royalties on net sales of a
given Licensed Product in a given country and a given quarter, unless, if for such Licensed Product in such country and such quarter, Kissei has taken the maximum allowable reductions and the ratio of the cost for the supply of Licensed Product to
the sales price for Licensed Product exceeds a low-double digit percentage threshold, then the Company shall receive no royalties on the net sales of such Licensed Product in such country and such quarter. Kissei&#146;s and the Company&#146;s
royalty obligations will expire on a Licensed Product-by-Licensed Product and country-by-country basis on the later of twelve years from the date of first commercial sale of such Licensed Product in such country or when there is no longer a valid
patent claim covering such Licensed Product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Kissei Agreement will expire on a Licensed
Product-by-Licensed Product and country-by-country basis when there is no remaining royalty or milestone payment obligation due to a party with respect to such Licensed Product in such country. Following expiration of the Kissei Agreement in its
entirety, the licenses the Company granted to Kissei will become non-exclusive, fully-paid royalty-free and irrevocable and Kissei will have the right to negotiate directly with our product suppliers for the direct supply of Licensed Product to
Kissei. The Kissei Agreement may be terminated either by Kissei or by the Company in the event of an uncured material breach by the other party or in the event the other party becomes subject to specified bankruptcy, insolvency or similar
circumstances. In addition, the Company have the right to terminate the Kissei Agreement in the event that Kissei commences a legal action challenging the validity, enforceability or scope of any licensed patents under the Kissei Agreement. Kissei
may terminate the Kissei Agreement at will upon specified written notice. Additionally, Kissei may terminate the Kissei Agreement for our willful and malicious misconduct that results in substantial and irreparable harm to the commercial value of
the Licensed Products in the Kissei Territory and upon any such termination, the licenses the Company granted to Kissei will become royalty-free and fully paid-up and Kissei will have the right to negotiate directly with our contract manufacturing
organizations for the supply of Licensed Product. Upon termination of the Kissei Agreement for any other reason all rights and licenses granted to Kissei to develop and commercialize the product under the Kissei Agreement will terminate,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
subject to certain rights to sell existing inventory of Licensed Products by Kissei and its sublicensees. Upon termination of the Kissei Agreement for Kissei&#146;s breach, any sublicenses
granted by Kissei may, upon the Company&#146;s discretion, continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluated the Kissei Agreement to
determine whether it is a collaborative arrangement in the scope of ASC 808, <I>Collaborative Arrangements</I> (ASC 808). The Company concluded the Kissei Agreement is a collaborative agreement under ASC 808, as the Kissei Agreement involves a joint
operating activity, each party is an active participant in the activities related to the Kissei Agreement, and both parties are exposed to significant risks and rewards dependent upon the commercial success of the activities related to the Kissei
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company determined the Kissei Agreement contained&nbsp;two&nbsp;material components: (i)&nbsp;an exclusive
license granted to Kissei to certain intellectual property rights in the Kissei Territory, for Kissei to develop and commercialize, but not manufacture, the Licensed Product for all uses in oncology; and (ii)&nbsp;the parties&#146; participation in
the Global Development of the Licensed Product. The Company used the criteria specified in ASC 606&nbsp;to determine which of the components of the Kissei Agreement are performance obligations with a customer&nbsp;and concluded Kissei is the
Company&#146;s customer for the license and related activities in the Kissei Territory under ASC 606. The Global Development activities under the agreement does not present a transaction with a customer and the payments received by the Company for
Global Development activities, including manufacturing, will be accounted for as a reduction of related expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company evaluated the Kissei Territory specific license and related activities under ASC 606, as these transactions are considered transactions with a customer, and identified&nbsp;two material promises at the outset of the Kissei License Agreement,
which consists of the following: (1)&nbsp;the exclusive license and (2)&nbsp;the manufacturing activities related to development and commercial supply of the Licensed Product in the Kissei Territory. The Company further evaluated the material
promise associated with manufacturing activities related to development and commercial supply of the Licensed Products in the Kissei Territory. Given Kissei is not obligated to purchase any minimum amount or quantities of the development and
commercial supply from the Company, the Company concluded, for the purpose of ASC 606, the provision of manufacturing activities related to development and commercial supply of the Licensed Product in the Kissei Territory was an option but not a
performance obligation of the Company at the inception of the Kissei Agreement and will be accounted for if and when exercised. The Company also concluded there is no separate material right in connection with the development and commercial supply
of the licensed product, as the expected pricing was not issued at a significant and incremental discount. Therefore, the manufacturing activities were excluded as performance obligation at the outset of the arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluated the license under ASC 606 and concluded the license is a functional intellectual property license. The
Company determined Kissei benefited from the license at the time of grant and, therefore, the related performance obligation was satisfied at a point in time. Additionally, the Company is entitled to development and regulatory milestones as well as
sales milestones and royalties from Kissei upon future sales of the Licensed Product in the Kissei Territory. Future milestone payments are fully contingent as the risk of significant reversal will only be resolved depending on future development
milestones, regulatory approval and sales level outcomes. The Company re-evaluates the likelihood of achieving future milestones at the end of each reporting period. The royalties are considered variable consideration and will be recognized as
revenue as such sales occur. The sales-based royalties qualify for the royalty constrain exception and do not require an estimate of the future transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As the sale of $30.0 million of the Company&#146;s Series D redeemable convertible preferred stock and the Kissei License
Agreement were entered into concurrently and negotiated as a package with a single commercial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
objective, the Company accounted for the two agreements as a single arrangement for accounting purposes. The total upfront payments of $40.0&nbsp;million were comprised of $30.0&nbsp;million
attributed to the Series&nbsp;D redeemable convertible preferred stock sold to Kissei and $10.0&nbsp;million attributed to the functional intellectual property license granted to Kissei. The Company determined that the sale of the Series&nbsp;D
redeemable convertible preferred stock of $30.0&nbsp;million was at fair value and did not include a premium or discount. As a result, $10.0&nbsp;million of the total upfront payments was allocated to the transaction price of the exclusive license.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For the purposes of ASC 606, the transaction price of the Kissei Agreement as of the outset of the arrangement was
determined to be $10.0&nbsp;million, which consisted of the one-time upfront payment. The other potential milestone payments the Company is eligible to receive were excluded from the transaction price, as all milestone amounts were fully constrained
based on the probability of achievement. The Company satisfied the performance obligation upon delivery of the license and recognized the upfront payment of $10.0&nbsp;million as revenue during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2021, the Company recognized milestone revenue of $10&nbsp;million for cash
consideration received associated with an achieved development milestone and $0.4&nbsp;million in development income related to the Kissei License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">During the year ended December&nbsp;31, 2022, the Company recorded $0.2&nbsp;million in development income related to the
Kissei License Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Redeemable convertible preferred stock consisted of the following as of December&nbsp;31, 2022 (in thousands, except share
amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation&nbsp;&amp;<BR>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,075,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,075,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,942,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,973,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,454,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,598,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,598,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,598,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,271,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,271,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,271,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,422,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,422,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,422,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series E Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2022, the Company entered into a securities purchase agreement (the Series E Agreement) with certain investors to sell
shares of Series E redeemable convertible preferred stock (Series E) at $1.0674 per share. From September through October 2022, the Company issued 112,422,700 shares of Series E redeemable convertible preferred stock to existing and new investors at
a price of $1.0674 per share for gross cash proceeds of $120.0&nbsp;million, less issuance costs of $0.5&nbsp;million, resulting in net proceeds of $119.5&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences and Privileges </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each preferred stockholder is entitled to cast the number of votes equal to the number of whole shares of common stock into
which the shares of preferred stock held by such holder are convertible at the time of such vote<B>. </B>All preferred stockholders are entitled to vote on all matters upon which holders of common stock have the right to vote, other than matters
that must by law be voted by class or series vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Conversion Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each share of redeemable convertible preferred stock is convertible at the option of the holder at any time into a share of
common stock. Each share of convertible preferred stock is convertible into that number of common shares as is determined by dividing the applicable Initial Purchase Price (the Initial Purchase Price) of such share by the applicable conversion
price. The conversion rate is subject to adjustment upon the occurrence of certain events, including diluting issues of shares, stock splits, stock combinations, certain dividends and distributions, a merger and a reorganization. The conversion
rates for each series of redeemable convertible preferred stock as of December&nbsp;31, 2022 were as follows: Series <FONT STYLE="white-space:nowrap">A-1</FONT> 2.3531:1, Series B 2.7942:1, and Series C, D and E 1:1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All shares of the redeemable convertible preferred stock shall automatically be converted into shares of common stock, based
on the then-effective applicable conversion rate (i)&nbsp;upon the closing of the sale of shares of common stock to the public at a price of at least $1.33 per share (subject to the appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to the common stock), in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the
offer and sale of common stock for the account of the Company (1)&nbsp;which results in at least $75.0&nbsp;million of gross proceeds to the Company and (2)&nbsp;in which the <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of the Company
immediately prior to such public offering is at least $400.0&nbsp;million or (ii)&nbsp;upon the written consent of the holders of at least 75% of the then-outstanding shares of redeemable convertible preferred stock voting together as a single class
and not as separate series, and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Holders of Series E Preferred Stock shall be entitled to receive, prior and in preference to any other class or series
of capital stock, cumulative cash dividends, when, as and if declared by the Board, out of any funds that are legally available, at the rate of 8% of the Series E Initial Purchase Price of $1.0674 per annum on each outstanding share of Series E
Preferred Stock, subject to adjustment for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the issuance and distribution of dividends to holders of Series E Preferred Stock, holders of Series D Preferred
Stock and Series C Preferred Stock (together, the Senior Preferred Stock) shall be entitled to receive, on a pari passu basis and prior and in preference to the holders of Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preferred Stock and common stock, cumulative cash dividends, when, as and if declared by the Board, out of any funds that are legally available, at the rate of (i)&nbsp;with respect to the Series D Preferred Stock, 8% of the Series D Initial
Purchase Price per annum on each outstanding share of Series D Preferred Stock, subject to adjustment for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares and (ii)&nbsp;with respect to the Series
C Preferred Stock, 8% of the Series C Initial Purchase Price per annum on each outstanding share of Series C Preferred Stock, subject to adjustment for any stock dividends, combinations, splits, recapitalizations and the like with respect to such
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Following the issuance and distribution of dividends to holders of Series E Preferred Stock and Senior Preferred
Stock, holders of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall be entitled to receive, on a pari passu basis and prior and in preference to the holders of common stock, noncumulative cash
dividends, when, as and if declared by the Board, out of any funds that are legally available, at the rate of (i)&nbsp;with respect to the Series B Preferred Stock, 8% of the Series B Initial Purchase Price per annum on each outstanding share of
Series B Preferred Stock, subject to adjustment for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares and (ii)&nbsp;with respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred
Stock, 8% of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial Purchase Price per annum on each outstanding share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, subject to adjustment for any stock dividends,
combinations, splits, recapitalizations and the like with respect to such shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No distributions shall be made with respect to the common stock unless
dividends on the redeemable convertible preferred stock have been declared and all declared dividends on the redeemable convertible preferred stock have been paid or set aside for payment to the redeemable convertible preferred stockholders. The
right to receive dividends on shares of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall not be cumulative, and no right to dividends shall accrue to holders of Series B Preferred Stock and Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by reason of the fact that dividends on said shares are not declared or paid. Payment of any dividends to the holders of Series B Preferred Stock and Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall be on a pro rata, pari passu basis in proportion to the dividend rate for the Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, as
applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After payment of the full amount of any dividends to holders of redeemable convertible preferred stock, any
additional dividends shall be distributed among all holders of common stock and all holders of redeemable convertible preferred stock in proportion to the number of shares of common stock which would be held by each such holder if all such shares of
redeemable convertible preferred stock were converted to common stock at the then-effective applicable conversion rate. The Company has not declared or paid any dividends for the years ended December&nbsp;31, 2021 and 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In the event of any voluntary or involuntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of
the Company, or a deemed liquidation event of the Company (which includes certain mergers, acquisitions, and asset transfers), before any distribution or payment shall be made to the holders of common stock: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">The holders of Series E Preferred Stock shall be entitled to be paid out of the assets of the Company, prior
and in preference to any distribution of the proceeds of such liquidation, dissolution or winding up to the holders of Senior Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock or common
stock, an amount per share of Series E Preferred Stock equal to the Series E Initial Purchase Price, plus all declared but unpaid dividends on the Series E Preferred Stock, for each share of Series E Preferred Stock then held. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the distribution pursuant to holders of Series E Preferred Stock, the holders of each series of
Senior Preferred Stock shall be entitled to be paid out of the assets of the Company, on a pari passu basis and prior and in preference to any distribution of the proceeds of such liquidation, dissolution or winding up to the holders of Series B
Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock or common stock, (i)&nbsp;with respect to the Series D Preferred Stock, an amount per share of Series D Preferred Stock equal to the Series D Initial Purchase Price,
plus all declared but unpaid dividends on the Series D Preferred Stock, for each share of Series D Preferred Stock then held and (ii)&nbsp;with respect to the Series C Preferred Stock, an amount per share of Series C Preferred Stock equal to the
Series C Initial Purchase Price, plus all declared but unpaid dividends on the Series C Preferred Stock, for each share of Series C Preferred Stock then held. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Following the distributions pursuant to holders of Series E Preferred Stock and Senior Preferred Stock, the
holders of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall be entitled to be paid out of the assets of this Corporation, on a pari passu basis (i)&nbsp;with respect to the Series B Preferred
Stock, an amount per share of Series B Preferred Stock equal to the Series B Initial Purchase Price, plus all declared but unpaid dividends on the Series B Preferred Stock, for each share of Series B Preferred Stock then held; and (ii)&nbsp;with
respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, an amount per share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock equal to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial
Purchase Price, plus all declared but unpaid dividends on the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, for each share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then held by them.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If, upon any such liquidation, dissolution or winding up, the assets of the Company shall be insufficient to
make payment in full of the liquidation preferences described in (i), (ii), and (iii)&nbsp;above, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
then such assets shall be distributed in the following order of priority: (a)&nbsp;to the holders of Series E Preferred Stock in preference and ratably in proportion to the full amounts to which
they would otherwise be respectively entitled pursuant to in (i)&nbsp;above, (b) any remaining assets then to the holders of each series of Senior Preferred Stock in preference and ratably in proportion to the full amounts to which they would
otherwise be respectively entitled pursuant to (ii)&nbsp;above, and (c)&nbsp;any remaining assets then to the holders of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock ratably in proportion to the
full amounts to which they would otherwise be respectively entitled pursuant to (iii)&nbsp;above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After
the payment of the full liquidation preferences as set out above, the remaining assets of the Company legally available for distribution, if any, shall be distributed ratably to the holders of the common stock, Series E Preferred Stock on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> to common stock basis, Senior Preferred Stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock on
an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis; provided, however, that if the aggregate amount which a holder of a share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock is entitled to receive
exceeds the sum of three times the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial Purchase Price plus declared but unpaid dividends thereon, such holder of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall cease
participating in such distribution as to such Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, and the balance shall be distributed ratably to the holders of common stock, Series E Preferred Stock on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> to common stock basis and Senior Preferred Stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to common stock basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Redemption Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">At any time, following September&nbsp;30, 2027, all shares of convertible preferred shares are redeemable as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If requested in writing by holders of a majority of the then-outstanding shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock, all of the outstanding Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock shall be redeemed by paying in cash in exchange for the
shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock to be redeemed an amount equal to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial Purchase Price per share of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares), plus any and all declared but unpaid dividends with
respect to such shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> redeemable convertible preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If requested in writing by holders of a majority of the then-outstanding shares of Series B redeemable
convertible preferred stock, all of the outstanding Series B Preferred Stock shall be redeemed by paying in cash in exchange for the shares of Series B redeemable convertible preferred stock to be redeemed an amount equal to the Series B Initial
Purchase Price per share of Series B redeemable convertible preferred stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares), plus any and all declared but unpaid dividends with
respect to such shares of Series B redeemable convertible preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If requested in writing by holders of 66.67% of the then-outstanding shares of Series C redeemable
convertible preferred stock and to the extent affirmatively elected by a holder not to redeem, shares of the outstanding Series C redeemable convertible preferred stock shall be redeemed by paying in cash in exchange for the shares of Series C
redeemable convertible preferred stock to be redeemed an amount equal to the Series C Initial Purchase Price per share of Series C redeemable convertible preferred stock (as adjusted for any stock dividends, combinations, splits, recapitalizations
and the like with respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series C redeemable convertible preferred stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If requested in writing by holders of a majority of the then-outstanding shares of Series D redeemable
convertible preferred stock and to the extent affirmatively elected by a holder not to redeem, shares of the outstanding Series D redeemable convertible preferred stock shall be redeemed by paying in cash in exchange for the shares of Series D
redeemable convertible preferred stock to be redeemed an amount equal to the Series D Initial Purchase Price per share of Series D redeemable convertible preferred stock (as adjusted for any stock dividends, combinations, splits, recapitalizations
and the like with respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series D redeemable convertible preferred stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">If requested in writing by holders of a majority of the then-outstanding shares of Series E redeemable
convertible preferred stock and to the extent affirmatively elected by a holder not to redeem, all of the outstanding Series E Preferred Stock shall be redeemed by paying in cash in exchange for the shares of Series E Preferred Stock to be redeemed
(other than those holders of Series E Preferred Stock that affirmatively choose to not participate in such redemption) an amount equal to: the Series E Initial Purchase Price per share of Series E Preferred Stock (as adjusted for any stock
dividends, combinations, splits, recapitalizations and the like with respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series E Preferred Stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
Company is authorized to issue up to 263,000,000 and 393,500,000 shares of common stock as of December&nbsp;31, 2021 and 2022, respectively, of which 35,408,988 and 36,640,092 shares were issued and outstanding as of December&nbsp;31, 2021 and 2022,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by
the rights, preferences and privileges of the holders of the redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each holder of outstanding shares of common stock shall be entitled to one vote in respect of each share. The holders of
outstanding shares of common stock, voting together as a single class, shall be entitled to elect one director. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding
shares of common stock and preferred stock voting together as a single class. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Subject to the payment in full of all preferential dividends to which the holders of the preferred stock are entitled, the
holders of common stock shall be entitled to receive dividends out of funds legally available therefor at such times and in such amounts as the Board may determine in its sole discretion, with holders of preferred stock and common stock sharing pari
passu in such dividends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">After payment in full of all preferential amounts to which the holders of preferred stock are entitled upon any voluntary or
involuntary liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company or deemed liquidation event of the Company, all of the remaining assets of the Company available for distribution to the stockholders shall be
distributed among the holders of the preferred stock and common stock, pro rata based on the number of shares held by each such holder on an as converted to common stock basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reserved Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2022, the Company reserved the following shares of common stock for issuance upon conversion of the
outstanding redeemable convertible preferred stock and exercise of stock options: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,689,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options available for issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,505,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,900,921</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,095,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2015, the Company established the 2015 Plan, under which the Company was able to grant options and restricted stock to its
employees and certain <FONT STYLE="white-space:nowrap">non-employees.</FONT> As of December&nbsp;31, 2021 and 2022, the maximum number of shares of common stock reserved for issuance under the 2015 Plan were 32,808,386 and 30,093,877&nbsp;shares,
respectively. Following the establishment of the 2022 Plan, the maximum number of shares reserved for issuance under the 2015 Plan will be equal to the number of shares subject to issued and outstanding stock options and shares of restricted stock
granted under the 2015 Plan. As of December&nbsp;31, 2021, there were 28,971,871&nbsp;shares of common stock subject to outstanding awards and 13,583,907&nbsp;shares of common stock available for future issuance under the 2015 Plan. As of
December&nbsp;31, 2022, there were 30,093,877&nbsp;shares of common stock subject to outstanding awards and 0 shares of common stock available for future issuance under the 2015 Plan. In 2022, the Company established the 2022 Plan, under which the
Company may grant options, restricted stock units, restricted stock, stock appreciation rights, dividend equivalents and other stock and cash-based awards to its employees and certain <FONT STYLE="white-space:nowrap">non-employees.</FONT> As of
December&nbsp;31, 2022, the maximum number of shares of common stock reserved for issuance under the 2022 Plan was 23,501,942 shares. As of December&nbsp;31, 2022, there were 5,807,044&nbsp;shares of common stock subject to outstanding awards and
17,505,315&nbsp;shares of common stock available for future issuance under the 2022 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company may grant options
to purchase authorized but unissued shares of the Company&#146;s common stock. Options granted under the 2015 Plan and 2022 Plan include incentive stock options that can be granted only to the Company&#146;s employees and <FONT
STYLE="white-space:nowrap">non-statutory</FONT> stock options that can be granted to the Company&#146;s employees, consultants, advisors and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The exercise prices, vesting and other restrictions of the awards to be granted under the 2015 Plan and 2022 Plan are
determined by the Board, except that no stock option may be issued with an exercise price less than the fair market value of the common stock at the date of the grant or have a term in excess of ten years. Options granted under the 2015 Plan and
2022 Plan are exercisable in whole or in part at any time subsequent to vesting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table provides the assumptions used in determining the fair value of option awards for the years ended
December&nbsp;31, 2021 and 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2022</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70.0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">81.8%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.60%&nbsp;-&nbsp;1.10%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.60%&nbsp;-&#8201;4.35%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.95</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The weighted-average grant-date fair value of the options granted was $0.12
and $0.16 per share for the years ended December&nbsp;31, 2021 and 2022, respectively. The fair value of shares vested during the years ended December&nbsp;31, 2021 and 2022 was $0.18 and $0.18 per share, respectively. The fair value of shares
exercised during the years ended December&nbsp;31, 2021 and 2022 was $0.12 and $0.17 per share, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The
following table summarizes stock option activity for the year ended December&nbsp;31, 2022 (in thousands, except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,971,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,411,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,231,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(251,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,900,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,900,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,641,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;2,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has recorded stock-based compensation expense related to stock options of $1.1
million and $0.7&nbsp;million for December 31, 2021 and 2022, respectively. The Company had an aggregate $1.7&nbsp;million of gross unrecognized stock-based compensation expense as of December&nbsp;31, 2022 remaining to be amortized over a
weighted-average period of 3.0 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Stock-based compensation expense related to stock options recorded in the
accompanying statements of operations for the years ended December&nbsp;31, 2021 and 2022 was as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has not recognized and does not expect to recognize in the near future, any tax
benefit related to employee stock-based compensation expense as a result of the full valuation allowance related to its net deferred tax assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.
Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A reconciliation of the expected income tax benefit computed using the federal statutory income tax rate
to the Company&#146;s effective income tax rate was as follows for the years ended December&nbsp;31, 2021 and 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2021&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2022&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax computed at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22.32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s deferred tax assets as of December&nbsp;31, 2021 and 2022,
consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2021&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2022&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign tax credit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;174</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Deferred tax assets are reduced by a valuation allowance if, based on the weight of available
positive and negative evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. For the year ended December&nbsp;31, 2022, the valuation allowance for deferred tax assets increased by
$8.0&nbsp;million. This increase was primarily related to the establishment of a valuation allowance against additional net operating loss, Section&nbsp;174 capitalized research and experimental (R&amp;E) costs and research credits generated in the
current year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2022, the Company calculated $62.5&nbsp;million and $0.2&nbsp;million of federal
and state net operating loss carryforwards (NOL), respectively. These amounts are subject to certain return-to-provision adjustments. Of the $62.5 million in federal NOL carryforwards, $50.3&nbsp;million is not subject to expiration and the other
$12.2&nbsp;million begin to expire in 2030. The state NOL carryforwards begin to expire in 2040. In addition, as of December&nbsp;31, 2022, the Company had $3.7&nbsp;million of federal R&amp;D credit carryovers which begin to expire in 2032 and
$0.9&nbsp;million of state credit carryovers, which can be carried forward indefinitely, and $0.4&nbsp;million of foreign tax credit carryover which will expire in 2029. These loss and credit carryforwards are subject to review and possible
adjustment by the appropriate taxing authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Utilization of the Company&#146;s NOL carryforwards and R&amp;D credit
carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section&nbsp;382 of the Internal Revenue Code of 1986 (Section
382) as well as similar state provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change as
defined by Section&nbsp;382 results from transactions increasing the ownership of certain shareholders or public companies in the stock of a corporation by more than 50% over a three-year period. Since its formation, the Company has raised capital
through the issuance of capital stock on several occasions. The Company believes one or more of these financings resulted in an ownership change as defined by Section&nbsp;382, and consequently the Company&#146;s ability to fully utilize its NOL
carryforwards will likely be limited. As a current analysis has not been performed, the amount of such limitations, if any, cannot be accurately estimated at this time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2021 and 2022, the Company recorded $0.6&nbsp;million
and $0.7&nbsp;million unrecognized tax benefits on R&amp;D credits. The Company&#146;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of income.
For the years ended December&nbsp;31, 2021 and 2022, no estimated interest or penalties were recognized on uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following reconciliation of the beginning and ending amount of gross unrecognized tax benefits, excluding interest and
penalties, is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2021&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8194;2022&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance of unrecognized tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance of unrecognized tax benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">None of the unrecognized tax benefits, if recognized, would impact the annual effective tax
rate, due to the valuation allowance. The Company&#146;s unrecognized tax benefits are recorded as a reduction in deferred tax assets. The Company does not expect any significant increases or decreases to the Company&#146;s unrecognized tax benefits
within the next 12 months. Due to the valuation allowance, future changes in the Company&#146;s unrecognized tax benefits will not impact the Company&#146;s effective tax rate. The Company has not incurred any material interest or penalties as of
the current reporting date with respect to income tax matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tax Cuts and Jobs Act&#146;s (TCJA) amendment to
Section&nbsp;174 required Research and Experimental (R&amp;E) expenditures to be capitalized in the year the amounts are incurred for amounts paid in tax years starting after December&nbsp;31, 2021. The capitalized amounts are then amortized over a
period of five years, if the research is performed within the U.S., or 15 years, with respect to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> based research. The amended statute specifies that amortization will begin with the midpoint of the
taxable year in which expenses are paid or incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PPP Loan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In April
2020, the Company entered into the PPP Loan with SVB under the PPP, which is part of the CARES Act administered by the SBA. As part of the application for these funds, the Company in good faith, certified that the current economic uncertainty made
the loan request necessary to support the ongoing operations of the Company. This certification further required the Company to take into account its current business activity and its ability to access other sources of liquidity sufficient to
support ongoing operations in a manner that is not significantly detrimental to the business. Under the PPP, the Company received proceeds of $0.2&nbsp;million from the PPP Loan. In accordance with the requirements of the PPP, the Company used the
proceeds from the PPP Loan primarily for payroll costs. The PPP Loan had a 1.00% interest rate per annum, was scheduled to mature in April 2022, and was subject to the terms and conditions applicable to loans administered by the SBA under the PPP.
Under the terms of PPP, all or certain amounts of the PPP Loan may have been forgiven if they were used for qualifying expenses, as described in the CARES Act. Further, if, despite the good-faith belief that, given the Company&#146;s circumstances
all eligibility requirements for the PPP Loan were satisfied, it was later determined the Company had violated any applicable laws or regulations or it was otherwise determined the Company was ineligible to receive the PPP Loan, it may have been
required to repay the PPP Loan in its entirety and/or be subject to additional penalties. The Company recorded the entire amount of the PPP Loan as debt. Under the terms of the PPP Loan, monthly payments of principal and interest were due to
commence in November 2020, however, the SBA deferred loan payments for borrowers who applied for loan forgiveness until the SBA remitted the borrower&#146;s loan forgiveness amount to the lender. No payments were made in 2020. In January 2021, the
Company completed an application for forgiveness of the PPP Loan. In January 2021, the SBA approved the forgiveness of the PPP Loan, plus accrued interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, the Company entered into a second loan agreement (the Second
PPP Loan) with SVB under the PPP and received proceeds of $0.2&nbsp;million from the Second PPP Loan. The Second PPP Loan had a 1.00% interest rate per annum, was scheduled to mature in January 2026, and was subject to similar certifications, terms
and conditions as applicable to the PPP Loan. The Company recorded the entire amount of the Second PPP Loan as debt. Under the terms of the Second PPP Loan, monthly payments of principal and interest were due to commence in June 2022, however, the
SBA deferred loan payments for borrowers who applied for loan forgiveness until the SBA remitted the borrower&#146;s loan forgiveness amount to the lender. No payments were made in 2021. In June 2021, the SBA approved the forgiveness of the Second
PPP Loan, plus accrued interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SVB Term Loan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In January 2021, the Company entered into the Loan Agreement with SVB for a term loan in three tranches. The Company drew down
Tranche A funds in January 2021 for an original principal amount of $5.0&nbsp;million, in increments of $2.5&nbsp;million each. The Company drew down Tranche B funds in December 2021 for an original principal amount of $10.0&nbsp;million, in
increments of $5.0&nbsp;million each, following the achievement of certain milestones. The Tranche C funds, for which the original principal amounts are not to exceed $5.0&nbsp;million, in increments of $2.5&nbsp;million each, were not drawn upon in
2021 or in 2022 and are only available on the achievement of certain milestones. In addition, at any time during the term of the Loan Agreement, the Company may request that SVB make one additional term loan available to the Company in an original
principal amount equal to $10.0&nbsp;million. SVB, in its sole and absolute discretion, may grant or deny any such request from the Company for this term loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Funds received under the Loan Agreement (the Term Loan Advances) shall be interest-only during an interest-only period (the
Interest-Only Period), with interest due and payable monthly on the first calendar day of each month. The Interest-Only Period, which was from January&nbsp;8, 2021 through January&nbsp;31, 2022, was able to be extended through July&nbsp;31, 2022 if
the Company achieved certain milestones (the Interest-Only Extension Milestones). The Interest-Only Period was extended to July&nbsp;31, 2022 upon the draw down of Tranche B funds in December 2021. In August and September 2022, the Company entered
into amendments to the Loan Agreement (the Loan Agreement Amendments). Per the Loan Agreement Amendments, the Interest-Only Period was extended from July&nbsp;31, 2022 until October&nbsp;31, 2022 and the net cash proceeds related to one of the
Interest-Only Extension Milestones (Interest-Only Extension Milestone 1) were increased from $50&nbsp;million to $80&nbsp;million. In addition, if Interest-Only Extension Milestone 1 was achieved, the Interest-Only Period would be extended until
January&nbsp;31, 2023. Interest-Only Extension Milestone 1 was achieved in September 2022 as a result of the sale of Series E. Thereafter, the Term Loan Advances are payable in thirty, twenty-four, or eighteen equal monthly installments (dependent
on the achievement of the Interest-Only Extension Milestones) of principal plus accrued and unpaid interest (each a Term Loan Payment) beginning on the first day of the next month following the end of the Interest-Only Period and continuing on the
first day of each month thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Term Loan Advances accrue interest at a floating per annum rate equal to the
greater of 3.25% above the Prime Rate or 6.50%, provided however, the interest rate shall not exceed 7.50% at any time. Immediately upon the occurrence and during the continuance of an event of default, obligations bear interest at a rate per annum
which is 5.0% above the rate that is otherwise applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s final Term Loan Payment, due on
July&nbsp;1, 2024, shall include all outstanding principal and accrued and unpaid interest on the Term Loan Advances, a final payment (the Final Payment), and all other outstanding obligations with respect to the Term Loan Advances. The Final
Payment shall equal the aggregate original amount of all Term Loan Advances made by SVB to the Company multiplied by 8.50%. The Final Payment is in addition to, and not a substitution for, the regular monthly payments of principal plus accrued
interest. After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company has the option to prepay all, but not less than all, of the Term
Loan Advances advanced by SVB under the Loan Agreement, provided the Company delivers written notice to SVB of its election to prepay such Term Loan Advances at least thirty days prior to such prepayment and pays, on the date of such prepayment, all
outstanding principal due in connection with the Term Loan Advances, plus accrued and unpaid interest thereon, a prepayment fee (the Prepayment Fee), the Final Payment, and all other sums, if any, that have become due and payable in connection with
the Term Loan Advances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If the Term Loan Advances are accelerated following the occurrence of an event of default, the
Company shall immediately pay to SVB an amount equal to the sum of all outstanding principal, due in connection with the Term Loan Advances, plus accrued and unpaid interest thereon, a prepayment fee, the Final Payment, and all other sums, if any,
that have become due and payable hereunder in connection with the Term Loan Advances. The prepayment fee equals 2.00% of the outstanding principal balance of the Term Loan Advances, if such prepayment occurs prior to January&nbsp;8, 2022, or 1.00%
of the outstanding principal balance of the Term Loan Advances if such prepayment occurs on or after January&nbsp;8, 2022, but prior to January&nbsp;8, 2023. The following situations constitutes an event of default; payment default, covenant
default, material adverse change, attachment, levy, insolvency, judgements, penalties, misrepresentations, subordinated debt, guaranty, lien priority and governmental approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In connection with the Loan Agreement, the Company entered into a Success Fee Agreement (the Success Fee Agreement) with SVB
in January 2021. In accordance with the Success Fee Agreement, the Company agreed to pay to SVB an amount equal to (a)&nbsp;the quotient of (i)&nbsp;the aggregate original principal amount of all Term Loan Advances made by SVB to the Company divided
by (ii) $5&nbsp;million, multiplied by (b) $125,000 (the Success Fee), upon the closing of a success fee event (the Success Fee Event) and, in the event of an initial public offering (an IPO), within five business days of closing such IPO. The
Success Fee Event means the earliest to occur of any one of the following after January&nbsp;8, 2021: (a) any sale, license, transfer or other disposition of all or substantially all of the assets of the Company or any of its subsidiaries; or
(b)&nbsp;any reorganization, consolidation, or merger of the Company (or a subsidiary, but only if such subsidiary is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> to the Company&#146;s
business) where the holders of the Company&#146;s securities (or such subsidiary&#146;s securities) before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction, or
(c)&nbsp;an IPO by the Company or such subsidiary of its capital stock. The Company&#146;s obligation to pay SVB the Success Fee terminates on January&nbsp;8, 2031. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">As of December&nbsp;31, 2022, the principal amounts of long-term debt maturities for each of the following fiscal years were
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Fiscal year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future principal payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8194;16,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: unamortized debt discount and issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(777</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying value of long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Basic and diluted net loss per share was calculated as follows (in thousands, except share and per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,839</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend on redeemable convertible preferred stock issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative redeemable convertible preferred stock dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,544</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,871</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,383</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(43,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,807,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,669,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company&#146;s potentially dilutive securities, which include redeemable convertible
preferred stock and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Basic and diluted net loss per share attributable to common stockholders is computed in
conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. The Company considers all series of its convertible preferred stock to be participating securities as the holders of such stock have
the right to receive dividends on a pari passu basis in the event that a dividend is paid on common stock. Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, the net loss attributable to common stockholders is not allocated to the
convertible preferred stock as the preferred stockholders do not have a contractual obligation to share in the Company&#146;s losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company excluded the following from the computation of diluted net loss per share attributable to common stockholders as
of December&nbsp;31, 2021 and 2022 because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,266,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,689,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,971,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,900,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,238,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,590,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In 2022, the Company entered into an agreement with an outside consulting firm for the provision of interim Chief Financial
Officer (CFO) services. The Company paid the consulting firm for the provision of the interim CFO services rendered less than $0.1&nbsp;million for services rendered for the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Company evaluated subsequent events through October&nbsp;27, 2023, the date on which the December&nbsp;31, 2022 financial
statements were issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On May&nbsp;12, 2023, the Company repaid&nbsp;all outstanding principal and accrued and unpaid
interest on the Term Loan Advances under the Loan Agreement and all other outstanding obligations with respect to the Term Loan Advances under the Loan Agreement and made the Final Payment. The Company&#146;s obligation to pay SVB the Success Fee
remains outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG Oncology, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">On July&nbsp;28, 2023, the Company entered into a securities purchase
agreement (the Series F Agreement) with certain investors to sell shares of Series F redeemable convertible preferred stock (Series F) at a price of $1.2872 per share. In July 2023, the Company issued 81,587,937 shares of Series F redeemable
convertible preferred stock to existing and new investors at a price of $1.2872 per share for gross cash proceeds of $105.0&nbsp;million, less issuance costs of $0.4&nbsp;million, resulting in net proceeds of $104.6&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195; Shares </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g551455g03p01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Morgan Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>LifeSci Capital </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#8195;&#8195;&#8195;&#8195;, 2023 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>Through and including&#8195;&#8195;&#8195;&#8195; , 2023 (the 25th day after the date of this prospectus), all dealers effecting
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an
unsold allotment or subscription. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The following table indicates the expenses to be incurred in connection with the offering described in this registration
statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc. (FINRA) filing fee and the Nasdaq Global
Market listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;Paid&nbsp;or<BR>to Be Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">To be provided by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal
liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in
intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that
no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the
General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to
indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses
(including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to
any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any
criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or
matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of
the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Our amended and restated certificate of incorporation and our amended and restated bylaws, each of which will become effective
immediately prior to the closing of this offering, will provide that we will indemnify each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the
fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation,
partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she
reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated certificate of
incorporation and our amended and restated bylaws, each as currently in effect, provide that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the
fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another
corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts
paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our
best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all
of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all
expenses (including attorneys&#146; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may
require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or
her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation
arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">In any underwriting
agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the
Securities Act, against certain liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Set forth below is information regarding unregistered securities issued by us since October&nbsp;1, 2020 to the date of this
registration statement. Also included is the consideration received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issuances of Securities </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In October 2020, we issued to investors an aggregate of 3,040,881 shares of Series D redeemable convertible
preferred stock at a purchase price of $0.8879 per share, for aggregate consideration of approximately $2.7&nbsp;million </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In September 2022 and October 2022, we issued to investors an aggregate of 112,422,700 shares of Series E
redeemable convertible preferred stock at a purchase price of $1.0674 per share, for aggregate consideration of approximately $120&nbsp;million. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">In July 2023, we issued to investors an aggregate of 81,587,937 shares of Series F redeemable convertible
preferred stock at a purchase price of $1.2872 per share, for aggregate consideration of approximately $105&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (a)&nbsp;of
Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder, for transactions by an
issuer not involving any public offering, to the extent an exemption from such registration was required. All holders of securities described above represented to us in connection with their purchase or issuance that they were accredited investors
and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities
for an indefinite period of time. The holders received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such
registration. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Grants of Stock Options </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">From October&nbsp;1, 2020 through the date of this registration statement, we granted stock options to
purchase an aggregate of 52,741,148 shares of our common stock at a weighted-average exercise price of $0.367 per share, to certain of our employees, consultants and directors in connection with services provided to us by such persons. 13,987,828 of
these options have been exercised and 3,050,968 have been cancelled through the date of this registration statement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The stock options and common stock issuable upon exercise of such options as described in this section (b)&nbsp;of Item 15
were issued pursuant to written compensatory plans or arrangements with our employees and directors, in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities Act or
the exemption set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering. All recipients either received adequate information about us or
had access, through employment or other relationships, to such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">All of the foregoing securities are deemed
restricted securities for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item 15 included appropriate legends setting forth that the securities had not been registered and the
applicable restrictions on transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Exhibits.</B> See Exhibit Index attached to this registration statement, which is incorporated by reference
herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(d)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Financial Statement Schedules. </B>Schedules not listed above have been omitted because the information
required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item 17. Undertakings.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned registrant hereby undertakes to provide to the underwriters, at the closing specified in the
underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant
will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The undersigned hereby undertakes that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description of
Exhibit</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;1.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation, as amended (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;3.3*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation (to be effective immediately prior to the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;3.4*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws (to be effective immediately prior to the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;4.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen stock certificate evidencing the shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#146; Rights Agreement, dated July&nbsp;28, 2023, by and among the Registrant and certain of its stockholders</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;5.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CG Oncology, Inc. 2015 Equity Incentive Plan, as amended, and form of stock grant agreement and form of stock option agreement thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CG Oncology, Inc. 2022 Incentive Award Plan and form of stock option agreement, form of stock option agreement (early exercise) and restricted stock unit agreement thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3#*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CG Oncology, Inc. 2024 Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4#*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CG Oncology, Inc. 2024 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5#*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Development and License Agreement, dated March&nbsp;11, 2019, between the Lepu Biotech Co., Ltd. and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License and Collaboration Agreement, dated March&nbsp;26, 2020, between Kissei Pharmaceutical Co., Ltd. and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to the License and Collaboration Agreement, dated September&nbsp;15, 2022, between Kissei Pharmaceutical Co., Ltd. and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement, effective March&nbsp;15, 2023 between Arthur Kuan and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, effective July&nbsp;9, 2023, between Ambaw Bellete and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11#</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, effective August&nbsp;14, 2023, between Vijay Kasturi and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.12#*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement for Directors and Officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.13#*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Policy for the Recovery of Erroneously Awarded Compensation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.2*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">107*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Filing Fee Table</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="justify">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601 of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> because it is both not material and is the type that the registrant treats as private or confidential. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City of Irvine, State of California, on this&#8195;&#8195;&#8195;&#8195;day of &#8195;&#8195;&#8195;&#8195;, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">CG ONCOLOGY, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Arthur Kuan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We, the undersigned officers and directors of CG Oncology, Inc., hereby severally constitute and appoint Arthur Kuan and
Stephen DiPalma, and each of them singly (with full power to each of them to act alone), our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of
substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other
registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and
thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following
persons in the capacities held on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Arthur Kuan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(principal
executive officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;,&nbsp;2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stephen DiPalma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(principal financial
and accounting officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brian Liu, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">James J. Mul&eacute;, IPh.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Leonard Post, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Simone Song</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Victor Tong, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#8195;&#8195;&#8195;, 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Sections 242 and 245 of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CG Oncology, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of
Delaware (the &#147;<U>General Corporation Law</U>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FIRST</B>: That the name of this corporation is CG Oncology, Inc. and that this corporation was originally incorporated pursuant to the
General Corporation Law on November&nbsp;30, 2017 under the name Cold Genesys, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>SECOND</B>: That the Board of Directors of this
corporation (the &#147;<U>Board of Directors</U>&#148;) duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests
of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Certificate of Incorporation of this corporation be amended and restated in its entirety as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of
this corporation is <B>CG Oncology, Inc. </B>(the &#147;<U>Corporation</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the registered office of this Corporation in the State of Delaware is 3500 South DuPont Highway, in the City of Dover, County
of Kent, 19901. The name of its registered agent at such address is Incorporating Services, Ltd. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be
organized under the General Corporation Law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <U>Classes of Stock</U>. This Corporation is authorized to issue two classes of stock to be designated, respectively, Common Stock and
Preferred Stock. The total number of shares which this Corporation is authorized to issue is 831,458,674 shares. 493,530,000 shares shall be Common Stock, par value $0.0001 per share (the &#147;<U>Common Stock</U>&#148;) and 337,928,674 shares shall
be Preferred Stock, par value $0.0001 per share (the &#147;<U>Preferred Stock</U>&#148;). Of the Preferred Stock, 81,587,937 shares shall be designated Series F Preferred Stock (the &#147;<U>Series F Preferred Stock</U>&#148;), 112,422,700 shares
shall be designated Series E Preferred Stock (the &#147;<U>Series E Preferred Stock</U>&#148;), 53,271,754 shares shall be designated Series D Preferred Stock (the &#147;<U>Series D Preferred Stock</U>&#148;), 73,598,283 shares shall be designated
Series C Preferred Stock (the &#147;<U>Series C Preferred Stock</U>&#148;), 11,973,000 shares shall be designated Series B Preferred Stock (the &#147;<U>Series B Preferred Stock</U>&#148;) and 5,075,000 shares shall be designated Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock</U>&#148;). The Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, the Series B Preferred Stock,
the Series C Preferred Stock, the Series D Preferred Stock, the Series E Preferred Stock and the Series F Preferred Stock shall be collectively referred to herein as the &#147;<U>Preferred Stock</U>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <U>Rights, Preferences and Restrictions of Preferred Stock</U>. The rights, preferences, privileges, and restrictions granted to and
imposed on the Preferred Stock are as set forth below in this Article IV.B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividend Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Holders of Series F Preferred Stock shall be entitled to receive, prior and in preference to any other class or series of capital stock
of this corporation, cumulative cash dividends, when, as and if declared by the Board of Directors, out of any funds that are legally available therefor, at the rate of eight percent (8%) of the Series F Initial Purchase Price (as defined below) per
annum on each outstanding share of Series F Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Following the issuance and distribution of dividends pursuant to subsection 1(a) above, holders of Series E Preferred Stock shall be
entitled to receive, prior and in preference to any other class or series of capital stock of this corporation, cumulative cash dividends, when, as and if declared by the Board of Directors, out of any funds that are legally available therefor, at
the rate of eight percent (8%) of the Series E Initial Purchase Price (as defined below) per annum on each outstanding share of Series E Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with
respect to such shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Following the issuance and distribution of dividends pursuant to subsections 1(a) and 1(b) above, holders
of Series D Preferred Stock and Series C Preferred Stock (together, the &#147;<U>Senior Preferred Stock</U>&#148;) shall be entitled to receive, on a pari passu basis and prior and in preference to the holders of Series B Preferred Stock, Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock and Common Stock, cumulative cash dividends, when, as and if declared by the Board of Directors, out of any funds that are legally available therefor, at the rate of (i)&nbsp;with respect to the
Series D Preferred Stock, eight percent (8%) of the Series D Initial Purchase Price (as defined below) per annum on each outstanding share of Series D Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and
the like with respect to such shares) and (ii)&nbsp;with respect to the Series C Preferred Stock, eight percent (8%) of the Series C Initial Purchase Price (as defined below) per annum on each outstanding share of Series C Preferred Stock (as
adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Following the issuance and distribution of dividends pursuant to subsections 1(a), 1(b)
and 1(c) above, holders of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall be entitled to receive, on a pari passu basis and prior and in preference to the holders of Common Stock, noncumulative
cash dividends, when, as and if declared by the Board of Directors, out of any funds that are legally available therefor, at the rate of (i)&nbsp;with respect to the Series B Preferred Stock, eight percent (8%) of the Series B Initial Purchase Price
(as defined below) per annum on each outstanding share of Series B Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares) and (ii)&nbsp;with respect to the Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, eight percent (8%) of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial Purchase Price (as defined below) per annum on each outstanding share of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">As used herein, the &#147;<U>Series F Initial Purchase Price</U>&#148; shall be $1.2872 per share of Series F Preferred Stock (as adjusted
for any stock dividends, combinations, splits, recapitalizations and the like, as described herein). As used herein, the &#147;<U>Series E Initial Purchase Price</U>&#148; shall be $1.0674 per share of Series E Preferred Stock (as adjusted for any
stock dividends, combinations, splits, recapitalizations and the like, as described herein). As used herein, the &#147;<U>Series D Initial Purchase Price</U>&#148; shall be $0.8879 per share of Series D Preferred Stock (as adjusted for any stock
dividends, combinations, splits, recapitalizations and the like, as described herein). As used herein, the &#147;<U>Series C Initial Purchase Price</U>&#148; shall be $0.29892 per share of Series C Preferred Stock (as adjusted for any stock
dividends, combinations, splits, recapitalizations and the like, as described herein). As used herein, the &#147;<U>Series B Initial Purchase Price</U>&#148; shall be $0.83523 per share of Series B Preferred Stock (as adjusted for any stock
dividends, combinations, splits, recapitalizations and the like, as described herein). As used herein, the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial Purchase Price</U>&#148; shall be $0.70339 per share of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like, as described herein). For the avoidance of doubt, &#147;fully-diluted,
<FONT STYLE="white-space:nowrap">as-converted</FONT> and <FONT STYLE="white-space:nowrap">as-exercised</FONT> basis&#148; means all issued and outstanding Common Stock, all outstanding options under employee stock option plans or similar plans, all
shares of outstanding Preferred Stock or convertible securities or instruments on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, and all outstanding warrants, options or similar rights to purchase the capital stock of the Corporation
on an <FONT STYLE="white-space:nowrap">as-exercised</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No distributions shall be made with respect to the Common Stock
unless dividends on the Preferred Stock have been declared in accordance with the preferences stated herein and all declared dividends on the Preferred Stock have been paid or set aside for payment to the Preferred Stock holders. The right to
receive dividends on shares of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall not be cumulative, and no right to dividends shall accrue to holders of Series B Preferred Stock and Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock by reason of the fact that dividends on said shares are not declared or paid. Payment of any dividends to the holders of Series B Preferred Stock and Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall be on a pro rata, pari passu basis in proportion to the dividend rate for the Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, as
applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) After payment of the full amount of any dividends pursuant to Articles IV.B.1(a),
IV.B.1(b), IV.B.1(c) and IV.B.1(d), any additional dividends shall be distributed among all holders of Common Stock and all holders of Preferred Stock in proportion to the number of shares of Common Stock which would be held by each such holder if
all such shares of Preferred Stock were converted to Common Stock at the then-effective applicable conversion rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Distributions
can be made without regard to any preferential rights amount or preferential dividends arrears amount with respect to distributions made by this Corporation in connection with (i)&nbsp;repurchases of Common Stock issued to or held by employees,
officers, directors or consultants of the Corporation or its subsidiaries upon termination of their employment or services pursuant to agreements providing for the right of said repurchase, (ii)&nbsp;repurchases of Common Stock issued to or held by
employees, officers, directors or consultants of the Corporation or its subsidiaries pursuant to rights of first refusal contained in agreements providing for such right, (iii)&nbsp;repurchases of Common Stock or Preferred Stock in connection with
the settlement of disputes with any stockholder, or (iv)&nbsp;any other repurchase or redemption of Common Stock or Preferred Stock that are approved by the holders of at least 75% of the then outstanding shares of Preferred Stock (voting together
as a single class and not as separate series, and on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) (the &#147;<U>Requisite Holders</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation Preference</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Upon any liquidation, dissolution or winding up of this Corporation, whether voluntary or involuntary, and subject to Article IV.B.2(f),
before any distribution or payment shall be made to the holders of Common Stock: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) The holders of Series F Preferred Stock shall be
entitled to be paid out of the assets of this Corporation, prior and in preference to any distribution of the proceeds of such liquidation, dissolution or winding up to the holders of Series E Preferred Stock, Senior Preferred Stock, Series B
Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock or Common Stock by reason of their ownership thereof, an amount per share of Series F Preferred Stock equal to the Series F Initial Purchase Price, plus all declared
but unpaid dividends on the Series F Preferred Stock, for each share of Series F Preferred Stock then held (the &#147;<U>Series F Preference</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) Following the distribution pursuant to Article IV.B.2(a)(i) above, the holders of Series E Preferred Stock shall be entitled to be paid
out of the assets of this Corporation, prior and in preference to any distribution of the proceeds of such liquidation, dissolution or winding up to the holders of Senior Preferred Stock, Series B Preferred Stock, Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock or Common Stock by reason of their ownership thereof, an amount per share of Series E Preferred Stock equal to the Series E Initial Purchase Price, plus all declared but unpaid dividends on the
Series E Preferred Stock, for each share of Series E Preferred Stock then held (the &#147;<U>Series E Preference</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)
Following the distributions pursuant to Articles IV.B.2(a)(i) and Article IV.B.2(a)(ii) above, the holders of each series of Senior Preferred Stock shall be entitled to be paid out of the assets of this Corporation, on a pari passu basis and prior
and in preference to any distribution of the proceeds of such liquidation, dissolution or winding up to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holders of Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock or Common Stock by reason of their ownership thereof, (i)&nbsp;with respect to the Series D
Preferred Stock, an amount per share of Series D Preferred Stock equal to the Series D Initial Purchase Price, plus all declared but unpaid dividends on the Series D Preferred Stock, for each share of Series D Preferred Stock then held (the
&#147;<U>Series D Preference</U>&#148;) and (ii)&nbsp;with respect to the Series C Preferred Stock, an amount per share of Series C Preferred Stock equal to the Series C Initial Purchase Price, plus all declared but unpaid dividends on the Series C
Preferred Stock, for each share of Series C Preferred Stock then held (the &#147;<U>Series C Preference</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv) Following the
distributions pursuant to Article IV.B.2(a)(i),Article IV.B.2(a)(ii) and Article IV.B.2(a)(iii) above, the holders of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall be entitled to be paid out of
the assets of this Corporation, on a pari passu basis (i)&nbsp;with respect to the Series B Preferred Stock, an amount per share of Series B Preferred Stock equal to the Series B Initial Purchase Price, plus all declared but unpaid dividends on the
Series B Preferred Stock, for each share of Series B Preferred Stock then held (the &#147;<U>Series B Preference</U>&#148;); and (ii)&nbsp;with respect to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, an amount per share of
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock equal to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial Purchase Price, plus all declared but unpaid dividends on the Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, for each share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock then held by them (the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preference</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v) The Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preference, Series B Preference, Series C Preference,
Series D Preference, Series E Preference and Series F Preference are hereinafter collectively referred to as the &#147;<U>Liquidation Preferences</U>.&#148; Notwithstanding the foregoing provisions in Article IV.B.2(a)(i), Article IV.B.2(a)(ii),
Article IV.B.2(a)(iii) and Article IV.B.2(a)(iv) above, if, upon any such liquidation, dissolution or winding up, the assets of this Corporation shall be insufficient to make payment in full of the Liquidation Preferences, then such assets shall be
distributed in the following order of priority: (a)&nbsp;to the holders of Series F Preferred Stock in preference and ratably in proportion to the full amounts to which they would otherwise be respectively entitled pursuant to Article IV.B.2(a)(i),
(b) any remaining assets then to the holders of Series E Preferred Stock in preference and ratably in proportion to the full amounts to which they would otherwise be respectively entitled pursuant to Article IV.B.2(a)(ii), (c) any remaining assets
then to the holders of each series of Senior Preferred Stock in preference and ratably in proportion to the full amounts to which they would otherwise be respectively entitled pursuant to Article IV.B.2(a)(iii), and (d)&nbsp;any remaining assets
then to the holders of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock ratably in proportion to the full amounts to which they would otherwise be respectively entitled pursuant to Article
IV.B.2(a)(iv). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) After the payment of the full Liquidation Preferences as set forth in Article IV.B.2(a), the remaining assets of this
Corporation legally available for distribution, if any, shall be distributed ratably to the holders of the Common Stock, Series F Preferred Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), Series E Preferred
Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), Senior Preferred Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) and Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis); provided, however, that if the aggregate amount which a holder of a share of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock is entitled to receive under Article IV.B.2(a) and this Article IV.B.2(b) exceeds the sum of (i)&nbsp;three (3) times the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial Purchase Price
plus (ii)&nbsp;declared but unpaid dividends thereon, such holder of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall cease participating in such distribution as to such Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock, and the balance shall be distributed ratably to the holders of Common Stock, Series F Preferred Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis),
Series E Preferred Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis) and Senior Preferred Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis). The aggregate amount that a
holder of a share of Preferred Stock is entitled to receive under Articles IV.B.2(a) and IV.B.2(b) is hereinafter referred to as the &#147;<U>Liquidation Amount</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Any Acquisition or Asset Transfer (each as defined below) shall be deemed a liquidation under this Article IV.B.2; <U>provided</U>,
<U>however</U>, <U>that</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) This Corporation and, as applicable, its stockholders shall not have the power to effect such an
Acquisition unless the agreement or plan of merger, or consolidation for such transaction provides that the consideration payable to the stockholders of this Corporation shall be allocated among the holders of capital stock of this Corporation in
accordance with Articles IV.B.2(a) and IV.B.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) In the event of an Asset Transfer, if this Corporation does not effect a
dissolution of this Corporation within 90 days after such Asset Transfer, then (A)&nbsp;this Corporation shall send a written notice to each holder of shares of Preferred Stock no later than the 90th day after such Asset Transfer, advising such
holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause (B)&nbsp;to require the redemption of such shares of Preferred Stock, and (B)&nbsp;if the Requisite Holders so request in a
written instrument delivered to this Corporation not later than 120 days after such Asset Transfer, this Corporation shall use the consideration received by this Corporation for such Asset Transfer, net of any retained liabilities associated with
the assets sold or technology licensed, as determined in good faith by the Board of Directors of this Corporation and approved by the Requisite Holders, together with any other assets of this Corporation available for distribution to its
stockholders, all to the extent permitted by the General Corporation Law governing distributions to stockholders (the &#147;<U>Available Proceeds</U>&#148;), on the 150th day after such Asset Transfer, to redeem all outstanding shares of Preferred
Stock at a price per share equal to the applicable Liquidation Amounts. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of
Preferred Stock in accordance with the Liquidation Preferences and priorities of payment set forth in Articles IV.B.2(a) and IV.B.2(b), this Corporation shall ratably redeem each holder&#146;s shares of Preferred Stock in accordance with such
Liquidation Preferences and priorities of payment to the fullest extent of such Available Proceeds, and shall redeem the remaining shares as soon as it may lawfully do so under the General Corporation Law governing distributions to stockholders. The
provisions of Article IV.B.3 shall apply, with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred Stock pursuant to this Article IV.B.2(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) If the consideration received by this Corporation or the stockholders, as the case may
be, in connection with an Acquisition or Asset Transfer is other than cash, its value will be deemed its fair market value as determined in good faith by the Board of Directors of this Corporation and approved by the Requisite Holders. Any
securities shall be valued as follows received as consideration in connection with such Acquisition or Asset Transfer shall be valued as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) The value of securities not subject to investment letter or other similar restrictions on free marketability (other than restrictions
arising solely by virtue of a stockholder&#146;s status as an affiliate or former affiliate) shall be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A) if traded on a securities
exchange or through the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market, the value shall be deemed to be the average of the closing prices of the securities on such exchange or system over the thirty (30)&nbsp;day
period (or portion thereof) ending three (3)&nbsp;days prior to the closing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B) if actively traded <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> the value shall be deemed to be the average of the closing bid or sale prices (whichever is applicable) over the thirty (30)&nbsp;day period (or portion thereof) ending three (3)&nbsp;days
prior to the closing; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C) if there is no active public market, the value shall be the fair market value thereof, as determined by
the Board of Directors of this Corporation. The Requisite Holders shall each have the right to challenge any determination by the Board of Directors of fair market value pursuant to this Article IV.B.2(d)(i)(C), in which case the determination of
fair market value shall be made by an independent appraiser selected jointly by the Board of Directors and the challenging parties, the cost of such appraisal to be borne equally by this Corporation and the challenging parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) The method of valuation of securities subject to investment letter or other restrictions on free marketability (other than restrictions
arising solely by virtue of a stockholder&#146;s status as an affiliate or former affiliate) shall be adjusted to make an appropriate discount from the value determined as above in Article IV.B.2(d)(i) to reflect the approximate fair market value
thereof, as determined in good faith by the Board of Directors, or by a liquidator if one is appointed. The Requisite Holders, voting together as a single class, shall have the right to challenge any determination by the Board of Directors of fair
market value pursuant to this Article IV.B.2(d)(ii), in which case the determination of fair market value shall be made by an independent appraiser selected jointly by the Board of Directors and the challenging parties, the cost of such appraisal to
be borne equally by the Corporation and the challenging parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) In the event of a liquidation in connection with an Acquisition
under Article IV.B.2(c), then the &#147;assets of this Corporation&#148; available for distribution shall be deemed to be the aggregate consideration to be paid to all stockholders participating in such Acquisition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) In the event of an Acquisition or Asset Transfer that is deemed a liquidation in accordance with Article IV.B.2(c), if any portion of the
consideration payable to the stockholders of this Corporation is placed into escrow and/or is payable to the stockholders of this Corporation subject to contingencies, the definitive agreement(s) relating to such Acquisition or Asset Transfer shall
provide that: (i)&nbsp;the portion of such consideration that is not placed in escrow and not subject to any contingencies (the &#147;<U>Initial Consideration</U>&#148;) shall be allocated among the holders of capital stock of this Corporation in
accordance with Articles IV.B.2(a) and IV.B.2(b) as if the Initial Consideration were the only consideration payable in connection with such Acquisition or Asset Transfer; and (ii)&nbsp;any additional consideration which becomes payable to the
stockholders of this Corporation upon release from escrow or satisfaction of contingencies shall be allocated among the holders of capital stock of this Corporation in accordance with Articles IV.B.2(a) and IV.B.2(b) after taking into account the
previous payment of the Initial Consideration as part of the same transaction. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding the foregoing provisions of this Article IV.B.2, upon any liquidation,
dissolution, winding up, Acquisition or Asset Transfer (each, a &#147;<U>Liquidation Event</U>&#148;), each holder of shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock or Series B Preferred Stock shall be entitled to
receive, for each share of such series of Preferred Stock then held, out of the proceeds available for distribution, the greater of (i)&nbsp;the amount of cash, securities or other property to which such holder would be entitled to receive with
respect to such shares in a Liquidation Event pursuant to Articles IV.B.2(a), IV.B.2(b) and IV.B.2(c) (without giving effect to this Article IV.B.2(f)) or (ii)&nbsp;the amount of cash, securities or other property to which such holder would be
entitled to receive in a Liquidation Event with respect to such shares if such shares had been converted to Common Stock immediately prior to such Liquidation Event, giving effect to this Article IV.B.2(f) with respect to all shares of Preferred
Stock simultaneously; <U>provided</U> that, so long as any shares of Series F Preferred Stock are outstanding, the Company shall not, without the approval of the holders of a majority of the then outstanding shares of Series F Preferred Stock,
voting as a separate series (the &#147;<U>Series F Majority</U>&#148;), enter into any Liquidation Event where the proceeds per share of Series F Preferred Stock the holders of Series F Preferred Stock are entitled to receive pursuant to this
Article IV.B.2 are less than two (2)&nbsp;times the Series F Initial Purchase Price; and <U>provided further</U>, that, so long as any shares of Series E Preferred Stock are outstanding, the Company shall not, without the approval of the holders of
a majority of the then outstanding shares of Series E Preferred Stock, voting as a separate series (the &#147;<U>Series E Majority</U>&#148;), enter into any Liquidation Event where the proceeds per share of Series E Preferred Stock the holders of
Series E Preferred Stock are entitled to receive pursuant to this Article IV.B.2 are less than two and a half (2.5) times the Series E Initial Purchase Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Redemption</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At
any time following the fifth anniversary date of July&nbsp;28, 2023 (the &#147;<U>Series F Original Issue Date</U>&#148;), if requested in writing by holders of a majority of the then-outstanding shares of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, this Corporation shall, to the extent not prohibited by Delaware law governing distributions to stockholders, redeem all of the outstanding Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock sixty (60)&nbsp;days following the date of such written request (the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redemption Date</U>&#148;). This Corporation shall effect
such redemptions on the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redemption Date by paying in cash in exchange for the shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock to be redeemed an amount equal to: the
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Initial Purchase Price per share of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with
respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (collectively, the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Redemption Price</U>&#148;). The number of shares redeemable pursuant to this Article IV.B.3(a) shall be limited to (y)&nbsp;the number that may be redeemed with the then-maximum amount of funds to the extent not prohibited by Delaware law governing
distributions to stockholders (the &#147;<U>Legally Available Funds</U>&#148;); and (z)&nbsp;any further restrictions pursuant to Article IV.B.3(g). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) At any time following the fifth anniversary date of the Series F Original Issue Date,
if requested in writing by holders of a majority of the then-outstanding shares of Series B Preferred Stock, this Corporation shall, to the extent not prohibited by Delaware law governing distributions to stockholders, redeem all of the outstanding
Series B Preferred Stock sixty (60)&nbsp;days following the date of such written request (the &#147;<U>Series B Redemption Date</U>&#148;). This Corporation shall effect such redemptions on the Series B Redemption Date by paying in cash in exchange
for the shares of Series B Preferred Stock to be redeemed an amount equal to the Series B Initial Purchase Price per share of Series B Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with
respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series B Preferred Stock (collectively, the &#147;<U>Series B Redemption Price</U>&#148;). The number of shares redeemable pursuant to this
Article IV.B.3(b) shall be limited to (x)&nbsp;the number that may be redeemed with the Legally Available Funds; and (y)&nbsp;any further restrictions pursuant to Article IV.B.3(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) At any time following the fifth anniversary date of the Series F Original Issue Date, if requested in writing by holders of at least
66.67% of the then-outstanding shares of Series C Preferred Stock, this Corporation shall, to the extent not prohibited by Delaware law governing distributions to stockholders, redeem all of the outstanding Series C Preferred Stock sixty
(60)&nbsp;days following the date of such written request (the &#147;<U>Series C Redemption Date</U>&#148;). This Corporation shall effect such redemptions on the Series C Redemption Date by paying in cash in exchange for the shares of Series C
Preferred Stock to be redeemed (other than those holders of Series C Preferred Stock that affirmatively choose to not participate in such redemption) an amount equal to: the Series C Initial Purchase Price per share of Series C Preferred Stock (as
adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series C Preferred Stock (collectively, the
&#147;<U>Series C Redemption Price</U>&#148;). The number of shares redeemable pursuant to this Article IV.B.3(c) shall be limited to (y)&nbsp;the number that may be redeemed with the Legally Available Funds; and (z)&nbsp;any further restrictions
pursuant to Article IV.B.3(g). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) At any time following the fifth anniversary date of the Series F Original Issue Date, if requested in
writing by holders of a majority of the then-outstanding shares of Series D Preferred Stock, this Corporation shall, to the extent not prohibited by Delaware law governing distributions to stockholders, redeem all of the outstanding Series D
Preferred Stock sixty (60)&nbsp;days following the date of such written request (the &#147;<U>Series D Redemption Date</U>&#148;). This Corporation shall effect such redemptions on the Series D Redemption Date by paying in cash in exchange for the
shares of Series D Preferred Stock to be redeemed (other than those holders of Series D Preferred Stock that affirmatively choose to not participate in such redemption) an amount equal to: the Series D Initial Purchase Price per share of Series D
Preferred Stock (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series D Preferred Stock
(collectively, the &#147;<U>Series D Redemption Price</U>&#148;). The number of shares redeemable pursuant to this Article IV.B.3(d) shall be limited to (y)&nbsp;the number that may be redeemed with the Legally Available Funds; and (z)&nbsp;any
further restrictions pursuant to Article IV.B.3(g). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) At any time following the fifth anniversary date of the Series F Original Issue Date,
if requested in writing by the Series E Majority, this Corporation shall, to the extent not prohibited by Delaware law governing distributions to stockholders, redeem all of the outstanding Series E Preferred Stock (other than the Series E Preferred
Stock held by holders that affirmatively choose to not participate in such redemption) sixty (60)&nbsp;days following the date of such written request (the &#147;<U>Series E Redemption Date</U>&#148;). This Corporation shall effect such redemptions
on the Series E Redemption Date by paying in cash in exchange for the shares of Series E Preferred Stock to be redeemed an amount equal to: the Series E Initial Purchase Price per share of Series E Preferred Stock (as adjusted for any stock
dividends, combinations, splits, recapitalizations and the like with respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series E Preferred Stock (collectively, the &#147;<U>Series E Redemption
Price</U>&#148;). The number of shares redeemable pursuant to this Article IV.B.3(e) shall be limited to (y)&nbsp;the number that may be redeemed with the Legally Available Funds; and (z)&nbsp;any further restrictions pursuant to Article IV.B.3(g).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) At any time following the fifth anniversary date of the Series F Original Issue Date, if requested in writing by the Series F
Majority, this Corporation shall, to the extent not prohibited by Delaware law governing distributions to stockholders, redeem all of the outstanding Series F Preferred Stock (other than the Series F Preferred Stock held by holders that
affirmatively choose to not participate in such redemption) sixty (60)&nbsp;days following the date of such written request (the &#147;<U>Series F Redemption Date</U>&#148;). This Corporation shall effect such redemptions on the Series F Redemption
Date by paying in cash in exchange for the shares of Series F Preferred Stock to be redeemed an amount equal to: the Series F Initial Purchase Price per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like
with respect to such shares), plus any and all declared but unpaid dividends with respect to such shares of Series F Preferred Stock (collectively, the &#147;<U>Series F Redemption Price</U>&#148;). The number of shares redeemable pursuant to this
Article IV.B.3(f) shall be limited to (y)&nbsp;the number that may be redeemed with the Legally Available Funds; and (z)&nbsp;any further restrictions pursuant to Article IV.B.3(g). The Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redemption
Price, the Series B Redemption Price, the Series C Redemption Price, the Series D Redemption Price, the Series E Redemption Price and the Series F Redemption Price shall be referred to hereinafter as a &#147;<U>Redemption Price</U>&#148; for their
applicable shares of Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Should the Legally Available Funds be an amount less than the amount necessary to effect a
redemption as requested pursuant to Article IV.B.3(a), Article IV.B.3(b), Article IV.B.3(c), Article IV.B.3(d), Article IV.B.3(e), Article IV.B.3(f), or any of the foregoing (should more than one redemption be requested simultaneously, pursuant to
Article IV.B.3(h)), up to two separate redemptions (each, a &#147;<U>Senior Redemption</U>&#148;) shall be effected in accordance with this Article IV.B.3(g) prior to a single, partial redemption (a &#147;<U>Partial Redemption</U>&#148;). First, a
Senior Redemption shall be paid by this Corporation to redeem shares from the holders of the Series F Preferred Stock ratably in proportion to the aggregate Redemption Price that would be payable to each holder of the Series F Preferred Stock. After
the full Redemption Price of the Series F Preferred Stock has been paid, a second Senior Redemption shall be paid to the holders of the Series E Preferred Stock ratably in proportion to the aggregate Redemption Price that would be payable to each
holder of the Series E Preferred Stock. After the full Redemption Price of the Series F Preferred Stock and Series E Preferred Stock to be redeemed has been paid, a Partial Redemption shall be paid by this Corporation, such that each Eligible
Redeemer (as defined below) shall be able to redeem only its Redeemable Shares (as defined below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) Subject to Article IV.B.3(g), an &#147;<U>Eligible Redeemer</U>&#148; shall be any
holder of shares of Preferred Stock from whom this Corporation has received a request for redemption under this Article IV.B.3. Notwithstanding anything to the contrary in this Article IV.B.3, however, in the event any holder of shares of Preferred
Stock, regardless of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redemption Date, the Series B Redemption Date, the Series C Redemption Date, the Series D Redemption Date, the Series E Redemption Date or the Series F Redemption Date,
receives a Redemption Notice (as defined in Article IV.B.3(h)), which states that this Corporation shall effect a Partial Redemption in accordance with this Article IV.B.3(g), such holder may become an Eligible Redeemer, only if this Corporation
receives written notice that such holder of shares of Preferred Stock also requests redemption of its shares of Preferred Stock such that its request is deemed a Simultaneous Redemption under Article IV.B.3(h). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>Redeemable Shares</U>&#148; shall be a certain amount of shares of Preferred Stock that is less than the total number of shares
of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock requested to be redeemed by an Eligible Redeemer in accordance with Article IV.3(g) (the
&#147;<U>Total Requested Shares</U>&#148;). The Redeemable Shares for each Eligible Redeemer shall be determined in good faith by this Corporation by first multiplying the Legally Available Funds by a fraction: the numerator of which is the Total
Requested Shares held by such Eligible Redeemer on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, and the denominator of which is the sum of all Total Requested Shares of all Eligible Redeemers under the Redemption
Notice, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis (such figure shall be referred to herein as the &#147;<U>Maximum Payout Proportion</U>&#148;). The Redeemable Shares shall be those shares of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock out of the Total Requested Shares that may be redeemed without exceeding the Maximum Payout Proportion. Redeemable
Shares may only be a whole number of shares, and may consist of shares of multiple series of Preferred Stock, should the Total Requested Shares comprise more than one series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Within ten (10)&nbsp;calendar days of receiving a redemption request contemplated by Article IV.B.3(a), Article IV.B.3(b), Article
IV.B.3(c), Article IV.B.3(d), Article IV.B.3(e) or Article IV.B.3(f), this Corporation shall send a notice (a &#147;<U>Redemption Notice</U>&#148;) to all holders of shares of Preferred Stock setting forth: (i)&nbsp;which series (or <FONT
STYLE="white-space:nowrap">sub-series,</FONT> as applicable) of Preferred Stock requested a redemption and the number of shares of subject to such redemption; (ii)&nbsp;the then-current Redemption Price for such series (or <FONT
STYLE="white-space:nowrap">sub-series,</FONT> as applicable) of Preferred Stock to be redeemed; (iii)&nbsp;the place at which the applicable holders may obtain payment of such Redemption Price upon surrender of their share certificates; and
(iv)&nbsp;what provisions of Article IV.B.3(g), if any, apply. Any additional requests for redemption, pursuant to any provision of Article IV.B.3, received by this Corporation within ten (10)&nbsp;calendar days of the date of a Redemption Notice
shall be grouped together as a single request, such that all such requests shall be deemed to have been made simultaneously with the redemption request that triggered the original Redemption Notice (a &#147;<U>Simultaneous Redemption</U>&#148;), and
the original Redemption Notice shall be promptly amended and restated and sent to all holders of shares of Preferred Stock in order to notify them of such Simultaneous Redemption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) If there has been a failure for any reason in payment of the Series F Redemption Price
on the Series F Redemption Date, notwithstanding anything herein to the contrary, the Series F Redemption Price shall be automatically increased at the rate of 8% of the Series F Initial Purchase Price per annum on each outstanding share of Series F
Preferred Stock, compounding from the Series F Redemption Date until the date that the Series F Redemption Price is paid in full. If there has been a failure for any reason in payment of the Series E Redemption Price on the Series E Redemption Date,
notwithstanding anything herein to the contrary, the Series E Redemption Price shall be automatically increased at the rate of 8% of the Series E Initial Purchase Price per annum on each outstanding share of Series E Preferred Stock, compounding
from the Series E Redemption Date until the date that the Series E Redemption Price is paid in full. If there has been a failure for any reason in payment of the Series D Redemption Price on the Series D Redemption Date, notwithstanding anything
herein to the contrary, the Series D Redemption Price shall be automatically increased at the rate of 8% of the Series D Initial Purchase Price per annum on each outstanding share of Series D Preferred Stock, compounding from the Series D Redemption
Date until the date that the Series D Redemption Price is paid in full. If there has been a failure for any reason in payment of the Series C Redemption Price on the Series C Redemption Date, notwithstanding anything herein to the contrary, the
Series C Redemption Price shall be automatically increased at the rate of 8% of the Series C Initial Purchase Price per annum on each outstanding share of Series C Preferred Stock, compounding from the Series C Redemption Date until the date that
the Series C Redemption Price is paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) On or prior to the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redemption
Date, the Series B Redemption Date, the Series C Redemption Date, the Series D Redemption Date, the Series E Redemption Date or the Series F Redemption Date, as the case may be, this Corporation shall deposit the appropriate Redemption Price of all
shares of Preferred Stock to be redeemed with a bank or trust company having aggregate capital and surplus in excess of $100,000,000, as a trust fund, with irrevocable instructions and authority to the bank or trust company to pay, on and after the
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redemption Date, Series B Redemption Date, Series C Redemption Date, Series D Redemption Date, Series E Redemption Date or the Series F Redemption Date, as the case may be, such Redemption Price of
the shares to their respective holders upon the surrender of their share certificates (or, if such holder alleges that such certificate or certificates have been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably
acceptable to this Corporation to indemnify this Corporation against any claim that may be made against this Corporation on account of the alleged loss, theft or destruction of such certificate). Any funds deposited by this Corporation pursuant to
this Article IV.B.3(j) for the redemption of shares of Preferred Stock thereafter converted into shares of Common Stock pursuant to Article IV.B.4 hereof shall be returned to this Corporation forthwith upon such conversion. The balance of any funds
deposited by this Corporation pursuant to this Article IV.B.3(j) remaining unclaimed at the expiration of one (1)&nbsp;year following the date this Corporation first deposited the funds shall be returned to this Corporation promptly upon its written
request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Subject to the provisions of Article IV.B.3(g), on or after the Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Redemption Date, Series B Redemption Date, Series C Redemption Date, Series D Redemption Date, Series E Redemption Date or Series F Redemption Date, as the case may be, each holder of shares of Preferred Stock to be redeemed shall surrender such
holder&#146;s certificates representing such shares to this Corporation in the manner and at the place designated in the Redemption Notice, and thereupon the appropriate Redemption Price of such shares shall be payable to the order of the person
whose name appears on such certificate or certificates as the owner thereof and each surrendered certificate shall be canceled. In the event less than all the shares of Preferred Stock represented by such certificates are redeemed, a new certificate
shall be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued representing the unredeemed shares of Preferred Stock. From and after the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Redemption Date, Series B Redemption Date, Series C Redemption
Date, Series D Redemption Date, Series E Redemption Date or Series F Redemption Date, as the case may be, unless there shall have been a failure in payment for any reason of the appropriate Redemption Price or this Corporation is unable to pay such
Redemption Price due to not having sufficient Legally Available Funds, all rights of the holder of such shares as holder of Preferred Stock (except the right to receive the Redemption Price upon surrender of their certificates), shall cease and
terminate with respect to such shares; <U>provided</U>, <U>however</U>, that in the event that shares of Preferred Stock are not redeemed for the Redemption Price in accordance with this Article IV.B.3 (including Article IV.B.3(i)), such shares of
Preferred Stock shall remain outstanding and shall be entitled to all of the rights and preferences provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.
<U>Conversion</U>. The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<U>Conversion Rights</U>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Optional Conversion</U>. Subject to and in compliance with the provisions of this Article IV.B.4, any shares of Preferred Stock may, at
the option of the holder, be converted at any time into fully paid and nonassessable shares of Common Stock. The number of shares of Common Stock to which a holder of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock,
Series C Preferred Stock, Series B Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock shall be entitled upon conversion shall be the product obtained by multiplying the Series F Conversion Rate, Series E Conversion
Rate, Series D Conversion Rate, Series C Conversion Rate, Series B Conversion Rate or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Rate (each as defined in and determined as provided in Article IV.B.4(c) and collectively, as
applicable, the &#147;<U>Conversion Rate</U>&#148;), as applicable, then in effect, by the number of shares of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock or Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock being converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Each holder of Preferred Stock who desires to convert
shares into shares of Common Stock pursuant to this Article IV.B.4(a) shall surrender the certificate or certificates representing the shares being converted (or, if such holder alleges that such certificate or certificates have been lost, stolen or
destroyed, a lost certificate affidavit and agreement reasonably acceptable to this Corporation to indemnify this Corporation against any claim that may be made against this Corporation on account of the alleged loss, theft or destruction of such
certificate), duly endorsed, at the office of this Corporation or any transfer agent for such shares and shall give written notice to this Corporation at such office that such holder elects to convert such shares. Such notice shall state the number
of shares of Preferred Stock being converted and, optionally, the preferred form of payment of declared and unpaid dividends. Thereupon, this Corporation shall promptly issue and deliver at such office to such holder a certificate or certificates
for the number of shares of Common Stock to which such holder is entitled and shall promptly pay in cash, or, at this Corporation&#146;s option (unless otherwise indicated prior to conversion by the notice of conversion provided by such holder), in
shares of Common Stock (at the Common Stock&#146;s fair market value determined in good faith by the Board of Directors as of the date of such conversion), any declared and unpaid dividends on the shares of Preferred Stock being converted. Such
conversion shall be deemed to have been made at the close of business on the date of such surrender of the certificates representing the shares of Preferred Stock to be converted, and the person entitled to receive the shares of Common Stock
issuable upon such conversion shall be treated for all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purposes as the record holder of such shares of Common Stock on such date. The Requisite Holders shall have the right to challenge any determination by the Board of Directors of fair market value
pursuant to this Article IV.B.4(a), in which case the determination of fair market value shall be made by an independent appraiser selected jointly by the Board of Directors and the challenging parties, the cost of such appraisal to be borne equally
by the Corporation and the challenging parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Automatic Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) Each share of Preferred Stock shall automatically be converted into shares of Common Stock, based on the then-effective applicable
Conversion Rate: (x)&nbsp;upon the closing of the sale of shares of Common Stock to the public at a price of at least $1.33 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Common Stock), in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock for the
account of this Corporation (1)&nbsp;which results in at least $100,000,000 of gross proceeds to the Corporation and (2)&nbsp;in which the <FONT STYLE="white-space:nowrap">pre-money</FONT> valuation of the Corporation immediately prior to such
public offering is at least $700,000,000 (a &#147;<U>QIPO</U>&#148;) or (y)&nbsp;upon the written consent of the Requisite Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)
Upon the occurrence of an event giving rise to the conversion specified by Article IV.B.4(b)(i), the outstanding shares of Preferred Stock shall be converted automatically into shares of Common Stock without any further action by the holders of such
shares and whether or not the certificates representing such shares are surrendered to this Corporation or its transfer agent; <U>provided</U>, <U>however</U>, that this Corporation shall not be obligated to issue certificates evidencing the shares
of Common Stock issuable upon such conversion unless the certificates evidencing such shares of Preferred Stock are either delivered to this Corporation or its transfer agent as provided below, or the holder notifies this Corporation or its transfer
agent that such certificates have been lost, stolen or destroyed and executes an agreement reasonably satisfactory to this Corporation to indemnify this Corporation from any loss incurred by it in connection with such certificates. Upon the
occurrence of such automatic conversion of any shares of Preferred Stock, this Corporation shall provide a notice of the automatic conversion to the holders of Preferred Stock, and the holders of such shares shall surrender the certificates
representing such shares at the office of this Corporation or any transfer agent for such shares. Thereupon, there shall be issued and delivered to such holders promptly at such office and in the holders&#146; names as shown on such surrendered
certificate or certificates, a certificate or certificates for the number of shares of Common Stock into which the shares of Preferred Stock were convertible on the date on which such automatic conversion occurred, and any declared and unpaid
dividends shall be paid in accordance with the provisions of Article IV.B.4(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Conversion Rate</U>. The conversion rate in
effect at any time for conversion of each share of Series F Preferred Stock (the &#147;<U>Series F Conversion Rate</U>&#148;) shall be the quotient obtained by dividing the Series F Initial Purchase Price by the Series F Conversion Price (as defined
in and calculated as provided in Article IV.B.4(d)). The conversion rate in effect at any time for conversion of each share of Series E Preferred Stock (the &#147;<U>Series E Conversion Rate</U>&#148;) shall be the quotient obtained by dividing the
Series E Initial Purchase Price by the Series E </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Conversion Price (as defined in and calculated as provided in Article IV.B.4(d)). The conversion rate in effect at any time for conversion of each share of Series D Preferred Stock (the
&#147;<U>Series D Conversion Rate</U>&#148;) shall be the quotient obtained by dividing the Series D Initial Purchase Price by the Series D Conversion Price (as defined in and calculated as provided in Article IV.B.4(d)). The conversion rate in
effect at any time for conversion of each share of Series C Preferred Stock (the &#147;<U>Series C Conversion Rate</U>&#148;) shall be the quotient obtained by dividing the Series C Initial Purchase Price by the Series C Conversion Price (as defined
in and calculated as provided in Article IV.B.4(d)). The conversion rate in effect at any time for conversion of each share of Series B Preferred Stock (the &#147;<U>Series B Conversion Rate</U>&#148;) shall be the quotient obtained by dividing the
Series B Initial Purchase Price by the Series B Conversion Price (as defined in and calculated as provided in Article IV.B.4(d)). The conversion rate in effect at any time for conversion of each share of Series
<FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Rate</U>&#148;) shall be the quotient obtained by dividing the Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Initial Purchase Price by the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price (as defined in and calculated as provided in Article IV.B.4(d)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Conversion Price</U>. The conversion price for the Series F Preferred Stock (the &#147;<U>Series F Conversion Price</U>&#148;) as of
the date upon which this Restated Certificate of Incorporation is accepted for filing by the Secretary of State of the State of Delaware (the &#147;<U>Filing Date</U>&#148;) shall initially be the Series F Initial Purchase Price, the conversion
price for the Series E Preferred Stock (the &#147;<U>Series E Conversion Price</U>&#148;) as of the Filing Date shall initially be the Series E Initial Purchase Price, the conversion price for the Series D Preferred Stock (the &#147;<U>Series D
Conversion Price</U>&#148;) as of the Filing Date shall initially be the Series D Initial Purchase Price, the conversion price for the Series C Preferred Stock (the &#147;<U>Series C Conversion Price</U>&#148;) as of the Filing Date shall initially
be the Series C Initial Purchase Price, the conversion price for the Series B Preferred Stock (the &#147;<U>Series B Conversion Price</U>&#148;) as of the Filing Date shall initially be the Series C Initial Purchase Price and the conversion price
for the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock (the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price</U>&#148;) as of the Filing Date shall initially be the Series C Initial Purchase Price. The
Series <FONT STYLE="white-space:nowrap">A-1</FONT> Conversion Price, the Series B Conversion Price, the Series C Conversion Price, the Series D Conversion Price, the Series E Conversion Price and the Series F Conversion Price shall be adjusted from
time to time in accordance with this Article IV.B.4, and all references herein shall mean the Series F Conversion Price, Series E Conversion Price, Series D Conversion Price, Series C Conversion Price, Series B Conversion Price and Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Conversion Price as so adjusted (sometimes referred to hereinafter as the &#147;<U>Conversion Price</U>&#148; of the applicable Preferred Stock). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Adjustment for Stock Splits and Combinations</U>. If this Corporation shall, on or after the Filing Date, effect a subdivision of the
outstanding Common Stock without a corresponding subdivision of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock or Series
F Preferred Stock, then the applicable Conversion Price in effect for such series of Preferred Stock immediately before such respective subdivision shall be proportionately decreased. Conversely, if this Corporation shall at any time or from time to
time after the Filing Date combine the outstanding shares of Common Stock into a lower number of shares without a corresponding combination of the Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, Series B Preferred Stock, Series C
Preferred Stock, Series D Preferred Stock, Series E Preferred Stock or Series F Preferred Stock, then the applicable Conversion Price in effect for such series of Preferred Stock immediately before such combination shall be proportionately
increased. Any adjustment under this Article IV.B.4(e) shall become effective at the close of business on the date such subdivision or combination becomes effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <U>Adjustment for Common Stock Dividends and Distributions</U>. If this Corporation at
any time or from time to time after the Filing Date makes, or fixes a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in shares of Common Stock, in each such event the
applicable Conversion Price then in effect for shares of Preferred Stock shall be decreased as of the time of such issuance or, in the event such record date is fixed, as of the close of business on such record date, by multiplying the Conversion
Price for such share of Preferred Stock then in effect by a fraction: (i)&nbsp;the numerator of which is the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on
such record date; and (ii)&nbsp;the denominator of which is the sum of (x)&nbsp;the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and
(y)&nbsp;the number of shares of Common Stock issuable in payment of such dividend or distribution; <U>provided</U>, <U>however</U>, that if such record date is fixed and such dividend is not fully paid or if such distribution is not fully made on
the date fixed therefor, such Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter such Conversion Price shall be adjusted pursuant to this Article IV.B.4(f) to reflect the actual payment of
such dividend or distribution; and, <U>provided</U> <U>further</U>, that no such adjustment shall be made if the holders of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the
number of shares of Common Stock as they would have received if all outstanding shares of such Preferred Stock had been converted into Common Stock on the date of such event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <U>Adjustments for Other Dividends and Distributions</U>. If this Corporation at any time or from time to time after the Filing Date
makes or issues, or fixes a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of this Corporation (other than a distribution of shares of Common Stock in respect
of outstanding shares of Common Stock) or in other property and the provisions of Article IV.B.1 do not apply to such dividend or distribution, then and in each such event the holders of shares of Preferred Stock shall receive, simultaneously with
the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of
such Preferred Stock had been converted into Common Stock on the date of such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) <U>Adjustment for Reclassification, Exchange
and Substitution</U>. If at any time or from time to time after the Filing Date the Common Stock issuable upon the conversion of any share of Preferred Stock is changed into the same or a different number of shares of any class or classes of stock,
whether by recapitalization, reclassification or otherwise (other than an Acquisition or Asset Transfer, each as defined below, or a subdivision or combination of shares, stock dividend or reorganization, merger, consolidation or sale of assets
provided for elsewhere in this Article IV.B.4), then in each such event, provision shall be made so that the holders of shares of Preferred Stock shall thereafter be entitled to receive, upon the conversion of such Preferred Stock, that number of
shares of stock or other securities or property of this Corporation upon such recapitalization, reclassification or other change to which a holder of that number of shares of Common Stock deliverable upon conversion of such share of Preferred Stock
would have been entitled as a result of such recapitalization, reclassification or other change, all subject to further adjustment as provided herein or with respect to such other securities or property by the terms thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Reorganizations, Mergers or Consolidations</U>. If at any time or from time to time
after the Filing Date there is a capital reorganization of the Common Stock or a merger or consolidation of this Corporation with or into another corporation or another entity or person (other than an Acquisition or Asset Transfer that is deemed a
liquidation, or a subdivision or combination of shares, stock dividend or reorganization, merger, consolidation or sale of assets provided for elsewhere in this Article IV.B.4), then as a part of such capital reorganization, provision shall be made
so that the holders of shares of Preferred Stock shall thereafter be entitled to receive, upon the conversion of such shares of Preferred Stock, that number of shares of stock or other securities or property of this Corporation to which a holder of
that number of shares of Common Stock deliverable upon conversion of such Preferred Stock would have been entitled as a result of such capital reorganization, merger or consolidation. In any such case, appropriate adjustment shall be made in the
application of the provisions of this Article IV.B.4 with respect to the rights of the holders of Preferred Stock after the capital reorganization such that the provisions of this Article IV.B.4 (including adjustment of the applicable Conversion
Price for such Preferred Stock then in effect and the number of shares issuable upon conversion of such Preferred Stock) shall be applicable after that event and be as nearly equivalent as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) <U>Sale of Shares Below Conversion Price</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(A) <U>Anti-Dilution Adjustment</U>. If at any time or from time to time after the Filing Date, this Corporation issues or sells, or is
deemed by the express provisions of this Article IV.B.4(j) to have issued or sold, Additional Shares of Common Stock (as defined below), other than as a dividend or other distribution on any class of stock as provided in Article IV.B.4(f) above, and
other than a subdivision or combination of shares of Common Stock as provided in Article IV.B.4(e) above, for an Effective Price (as defined below) less than the then-effective applicable Conversion Price in effect immediately prior to such issuance
or at no Effective Price, then, and in each such case, such then-existing applicable Conversion Price shall be reduced, as of the opening of business on the date of such issue or sale, to a price (calculated to the nearest <FONT
STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB
STYLE="font-size:75%; vertical-align:bottom">2</SUB> = CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB>* (A + B) &divide; (A + C). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
purposes of the foregoing formula, the following definitions shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">i.
&#147;CP<SUB STYLE="font-size:75%; vertical-align:bottom">2</SUB>&#148; shall mean the applicable Conversion Price in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">ii. &#147;CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB>&#148; shall mean the applicable Conversion Price in effect immediately
prior to such issuance or deemed issuance of Additional Shares of Common Stock; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iii. &#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately
prior to such issuance or deemed issuance of Additional Shares of Common Stock on a fully-diluted, <FONT STYLE="white-space:nowrap">as-converted</FONT> and <FONT STYLE="white-space:nowrap">as-exercised</FONT> basis; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">iv. &#147;B&#148; shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had
been issued or deemed issued at a price per share equal to CP<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">v. &#147;C&#148; shall mean the number of such Additional Shares of Common
Stock issued in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(B) For the purpose of making any adjustment required under this Article IV.B.4(j), the consideration
received by this Corporation for any issue or sale of Additional Shares of Common Stock shall: (i)&nbsp;to the extent it consists of cash, be computed at the net amount of cash received by this Corporation after deduction of any underwriting or
similar commissions, compensation or concessions paid or allowed by this Corporation in connection with such issue or sale but without deduction of any expenses payable by this Corporation; and (ii)&nbsp;to the extent it consists of property other
than cash, be computed at the fair value of that property as determined in good faith by the Board of Directors. In the event that Additional Shares of Common Stock are issued or sold together with other stock or securities or other assets of this
Corporation for a consideration which covers both, the consideration received by this Corporation for any issue or sale of securities shall be computed as the portion of the consideration so received that may be reasonably determined in good faith
by the Board of Directors to be allocatable to such Additional Shares of Common Stock. In each event, the Requisite Holders, voting together as a single class, shall have the right to challenge any determination by the Board of Directors, in which
case the determination shall be made by an independent appraiser selected jointly by the Board of Directors and the challenging parties, the cost of such appraisal to be borne equally by the Corporation and the challenging parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(C) For the purpose of the adjustments required under this Article IV.B.4(j), if this Corporation issues or sells: (i)&nbsp;stock or other
securities convertible into, Additional Shares of Common Stock (such convertible stock or securities being herein referred to as &#147;<U>Convertible Securities</U>&#148;); or (ii)&nbsp;rights or options for the purchase of Additional Shares of
Common Stock or Convertible Securities, this Corporation shall be deemed to have issued at the time of the issuance of such rights or options or Convertible Securities the maximum number of Additional Shares of Common Stock issuable upon exercise or
conversion thereof and to have received as consideration for the issuance of such shares an amount equal to the total amount of the consideration, if any, received by this Corporation for the issuance of such rights or options or Convertible
Securities, plus, in the case of such rights or options, the minimum amounts of consideration, if any, payable to this Corporation upon the exercise of such rights or options, plus, in the case of Convertible Securities, the minimum amounts of
consideration, if any, payable to this Corporation (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) upon the conversion thereof; <U>provided</U>, <U>however</U>, that if in the case of Convertible
Securities the minimum amounts of such consideration cannot be ascertained but are a function of anti-dilution or similar protective clauses, this Corporation shall be deemed to have received the minimum amounts of consideration without reference to
such clauses; and, <U>provided</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>further</U>, <U>that</U>: (i)&nbsp;if the minimum amount of consideration payable to this Corporation upon the exercise or conversion of rights, options or Convertible Securities is reduced
over time or based on the occurrence or <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of specified events other than by reason of anti-dilution adjustments, the Effective Price shall be recalculated using the figure to which such minimum
amount of consideration is reduced; and (ii)&nbsp;if the minimum amount of consideration payable to this Corporation upon the exercise or conversion of such rights, options or Convertible Securities is subsequently increased, the Effective Price
shall be again recalculated using the increased minimum amount of consideration payable to this Corporation upon the exercise or conversion of such rights, options or Convertible Securities. No further adjustment of such Conversion Price as adjusted
upon the issuance of such rights, options or Convertible Securities, shall be made as a result of the actual issuance of Additional Shares of Common Stock on the exercise of any such rights or options or the conversion of any such Convertible
Securities. If any such rights or options or the conversion privilege represented by any such Convertible Securities shall expire without having been exercised, the applicable Conversion Price for each share of Preferred Stock, as adjusted upon the
issuance of such rights, options or Convertible Securities shall be readjusted to the applicable Conversion Price that would have been in effect had an adjustment been made on the basis that the only Additional Shares of Common Stock so issued were
the Additional Shares of Common Stock, if any, actually issued or sold on the exercise of such rights or options or rights of conversion of such Convertible Securities, and such Additional Shares of Common Stock, if any, were issued or sold for the
consideration actually received by this Corporation upon such exercise, plus the consideration, if any, actually received by this Corporation for the granting of all such rights or options, whether or not exercised, plus the consideration received
for issuing or selling the Convertible Securities actually converted, plus the consideration, if any, actually received by this Corporation (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) on the
conversion of such Convertible Securities; provided, however, that such readjustment shall not apply to prior conversions of Preferred Stock. Notwithstanding the foregoing, no readjustment pursuant to this clause (C)&nbsp;shall have the effect of
increasing the Conversion Price for a share of Preferred Stock to an amount that exceeds the lower of (i)&nbsp;the applicable Conversion Price for such series in effect immediately prior to the original adjustment made as a result of the issuance of
such Convertible Securities or options or rights, or (ii)&nbsp;the Conversion Price for such series that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as
a result of the issuance of such Convertible Securities) between the original adjustment date and such readjustment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(D) As used
herein, &#147;<U>Additional Shares of Common Stock</U>&#148; shall mean all shares of Common Stock issued by this Corporation or deemed to be issued pursuant to this Article IV.B.4(j), other than: (i)&nbsp;any shares of Common Stock issued upon any
conversion of shares of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock; (ii)&nbsp;any shares of
Common Stock issued as a dividend or distribution on shares of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preferred Stock, or upon a stock split, stock dividend or any other subdivision of the number of shares of Common Stock; (iii)&nbsp;any shares of Common Stock (or options or rights to purchase shares of Common Stock) issued on or after the Filing
Date to employees, officers or directors of, or consultants or advisors to, this Corporation pursuant to current stock purchase plans or current stock option plans, or pursuant to similar plans that are approved by the Requisite
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holders pursuant to Article IV.B.6(p); and (iv)&nbsp;any shares of Series F Preferred Stock issued pursuant to that certain Series F Preferred Stock Purchase Agreement, by and between the
Corporation and certain other investors thereto, dated on or about the Filing Date (the &#147;<U>Series F Stock Purchase Agreement</U>&#148;). The &#147;<U>Effective Price</U>&#148; of Additional Shares of Common Stock shall mean the quotient
determined by dividing the aggregate consideration received, or deemed to have been received by this Corporation for such issue under this Article IV.B.4(j), for such Additional Shares of Common Stock, by the total number of Additional Shares of
Common Stock issued or sold, or deemed to have been issued or sold by this Corporation under this Article IV.B.4(j). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) <U>Certificate
of Adjustment</U>. Upon the request of any holder of shares of Preferred Stock, and in each case of an adjustment or readjustment of the Conversion Price for any share of Preferred Stock pursuant to this Article IV.B.4, this Corporation, at its
expense, shall compute such adjustment or readjustment in accordance with the provisions hereof and prepare a certificate showing such adjustment or readjustment and shall mail such certificate, by first-class mail, postage prepaid, to each
registered holder of such share of the applicable Preferred Stock at the holder&#146;s address as shown in this Corporation&#146;s books. The certificate shall set forth such adjustment or readjustment, showing in detail the facts upon which such
adjustment or readjustment is based. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) <U>Notices of Record Date</U>. Upon: (i)&nbsp;any taking by this Corporation of a record of the
holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution; or (ii)&nbsp;any Acquisition or other capital reorganization of this Corporation, any
reclassification or recapitalization of the capital stock of this Corporation, any merger or consolidation of this Corporation with or into any other corporation, any Asset Transfer, or any voluntary or involuntary dissolution, liquidation or
winding up of this Corporation, this Corporation shall mail a notice to each holder of Preferred Stock, at least fifteen (15)&nbsp;business days prior to, and specifying the earliest of: (A)&nbsp;the date on which any such record is to be taken for
the purpose of such dividend or distribution and a description of such dividend or distribution; (B)&nbsp;the date on which any such Acquisition, reorganization, reclassification, transfer, consolidation, merger, Asset Transfer, dissolution,
liquidation or winding up is expected to become effective; and (C)&nbsp;the date, if any, that is to be fixed as to when the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other
securities) for securities or other property deliverable upon such Acquisition, reorganization, reclassification, transfer, consolidation, merger, Asset Transfer, dissolution, liquidation or winding up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) <U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of any shares of Preferred Stock. All
shares of Common Stock (including fractions thereof) issuable upon conversion of more than one share of Preferred Stock by a holder thereof shall be aggregated for purposes of determining whether the conversion would result in the issuance of any
fractional share. If, after the aforementioned aggregation, the conversion would result in the issuance of any fractional share, this Corporation shall, in lieu of issuing any fractional share, pay cash in an amount equal to the product of such
fraction multiplied by the fair market value of a share of Common Stock, as determined in good faith by the Board of Directors, on the date of conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) <U>Reservation of Stock Issuable Upon Conversion</U>. This Corporation shall at all
times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of the Preferred Stock, such number of shares of Common Stock as shall from time to time be
sufficient to effect the conversion of all then-outstanding shares of Preferred Stock. If at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then-outstanding shares of
Preferred Stock, the Corporation will take such corporate action as is, in the opinion of its counsel, necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) <U>Notices</U>. Any notice required by the provisions of this Article IV.B.4 shall be in writing and shall be deemed effectively given:
(i)&nbsp;upon personal delivery to the party to be notified; (ii)&nbsp;when sent by electronic mail or confirmed facsimile, if sent during normal business hours of the recipient or, if not, then on the next business day; (iii)&nbsp;five (5) days
after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv)&nbsp;one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with verification of receipt. All
notices shall be addressed to each holder of record at the address of such holder appearing on the books of this Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p)
<U>Payment of Taxes</U>. This Corporation will pay all taxes (other than taxes based upon income) and other governmental charges that may be imposed with respect to the issue or delivery of shares of Common Stock upon conversion of shares of
Preferred Stock, excluding any tax or other charge imposed in connection with any transfer involved in the issue and delivery of shares of Common Stock in a name other than that in which such shares of Preferred Stock so converted were registered.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) <U>No Impairment</U>. This Corporation will not, without the appropriate vote of the stockholders under the General Corporation Law
or Section&nbsp;6 of this Article IV(B), by amendment of its Certificate of Incorporation or through any reorganization, recapitalization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by this Corporation, but will at all times in good faith assist in the carrying out of all the provisions of this Section&nbsp;4
and in the taking of all such action as may be necessary or appropriate in order to protect the Conversion Rights of the holders of the Preferred Stock against impairment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(r) <U>Waiver of Adjustment to Conversion Price</U>. Notwithstanding anything herein to the contrary, any downward adjustment of the
Conversion Price of any series of Preferred Stock may be waived, either prospectively or retroactively and either generally or in a particular instance, by the consent or vote of the holders of at least a majority of the outstanding shares of such
series of Preferred Stock (each voting as a separate class); <U>provided</U>, <U>however</U>, that any amendment to the Series C Conversion Price shall require the consent or vote of the holders of at least 66.67% of the then outstanding shares of
Series C Preferred Stock, voting as a separate class. Any such waiver shall bind all future holders of shares of such series of Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Voting Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>General Rights</U>. Except as otherwise provided herein or as required by law, shares of Preferred Stock shall be voted together with
the shares of the Common Stock of the Corporation and not as a separate class, at any annual or special meeting of stockholders of this Corporation, and may act by written consent in the same manner as the Common Stock. In the event of any such vote
or action by written consent, each holder of shares of Preferred Stock shall be entitled to that number of votes equal to the whole number of shares of Common Stock into which such holder&#146;s aggregate number of shares of Preferred Stock are
convertible (pursuant to Article IV.B.4 hereof) as of the close of business on the record date fixed for such vote or the effective date of such written consent. Any fractional shares shall be disregarded for purposes of such voting rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Election of Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) The size of the Board of Directors shall be nine (9)&nbsp;persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii) So long as any shares of Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock are outstanding, the holders of Series <FONT
STYLE="white-space:nowrap">A-1</FONT> Preferred Stock, voting as a separate class, shall be entitled to elect one (1)&nbsp;member of the Board of Directors (the &#147;<U>Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director</U>&#148;) at each
meeting or pursuant to each consent of this Corporation&#146;s stockholders for the election of directors. So long as holders of outstanding Series B Preferred Stock hold at least nine percent (9%) of the outstanding shares of Common Stock on a
fully diluted and <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, holders of outstanding Series B Preferred Stock shall be entitled to elect one (1)&nbsp;member of the Board of Directors (the &#147;<U>Series B Director</U>&#148;) at each
meeting or pursuant to each consent of this Corporation&#146;s stockholders for the election of directors. So long as any shares of Series C Preferred Stock remain outstanding, the holders of Series C Preferred Stock, voting as a separate class,
shall be entitled to elect two (2)&nbsp;members of the Board of Directors (each, a &#147;<U>Series C Director</U>&#148; and together, the &#147;<U>Series C Directors</U>&#148;) at each meeting or pursuant to each consent of this Corporation&#146;s
stockholders for the election of directors. So long as at least twenty percent (20%) of the shares of Series D Preferred Stock originally issued on March&nbsp;26, 2020 are outstanding, the holders of Series D Preferred Stock, voting as a separate
class, shall be entitled to elect one (1)&nbsp;member of the Board of Directors (the &#147;<U>Series D Director</U>&#148;) at each meeting or pursuant to each consent of this Corporation&#146;s stockholders for the election of directors. So long as
at least twenty percent (20%) of shares of Series E Preferred Stock originally issued on September&nbsp;30, 2022 are outstanding, the holders of Series E Preferred Stock, voting as a separate class, shall be entitled to elect two (2)&nbsp;members of
the Board of Directors (the &#147;<U>Series E Directors</U>&#148;) at each meeting or pursuant to each consent of this Corporation&#146;s stockholders for the election of directors. The Series <FONT STYLE="white-space:nowrap">A-1</FONT> Director,
the Series B Director, the Series C Directors, the Series D Director and the Series E Directors are together referred to as the &#147;<U>Preferred Directors</U>.&#148; The holders of Common Stock, voting as a separate class, shall be entitled to
elect one (1)&nbsp;member of the Board of Directors at each meeting or pursuant to each consent of this Corporation&#146;s stockholders for the election of directors. The holders of a majority in voting power of the Preferred Stock and the Common
Stock, voting as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis, shall be entitled to elect the remaining members of the Board of Directors at each meeting or pursuant to each consent of this
Corporation&#146;s stockholders for the election of directors. Any directors elected as provided in this Article IV.B.5(b)(ii) may be removed, and any vacancy or vacancies caused by the resignation, death or removal of such directors may be filled,
by, and only by, the affirmative vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii) To the extent that Section&nbsp;2115 of the California General Corporation Law makes
Section&nbsp;708 subdivisions (a), (b) and (c)&nbsp;of the California General Corporation Law applicable to the Corporation, the Corporation&#146;s stockholders shall have the right to cumulate their votes in connection with the election of
directors as provided by Section&nbsp;708 subdivisions (a), (b) and (c)&nbsp;of the California General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding
the provisions of Section&nbsp;223(a)(1) and 223(a)(2) of the General Corporation Law, any vacancy, including newly created directorships resulting from any increase in the authorized number of directors or amendment of this Certificate of
Incorporation, and vacancies created by removal or resignation of a director, may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office
until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced; provided, however, that where such vacancy occurs among the directors elected by the holders of a class or series of stock, the
holders of shares of such class or series may override the Board of Directors&#146; action to fill such vacancy by (i)&nbsp;voting for their own designee to fill such vacancy at a meeting of this Corporation&#146;s stockholders or (ii)&nbsp;written
consent, if the consenting stockholders hold a sufficient number of shares to elect their designee at a meeting of the stockholders. Any director may be removed during his or her term of office, either with or without cause, by, and only by, the
affirmative vote of the holders of the shares of the class or series of stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of
stockholders, and any vacancy thereby created may be filled by the holders of that class or series of stock represented at the meeting or pursuant to written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Preferred Stock Protective Provisions</U>. So long as any shares of Preferred Stock are outstanding, this Corporation shall not (by
amendment, merger, consolidation or otherwise) without first obtaining the approval (by vote or written consent, as provided by law) of the Requisite Holders: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) alter or change, whether by merger, consolidation, conversion or otherwise, the rights, preferences or privileges of the shares of
Preferred Stock so as to affect adversely such shares; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) increase or decrease the aggregate number of authorized shares of any class
or series of the capital stock of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) amend or waive any provision of this Certificate of Incorporation or the Bylaws
of the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) authorize or issue, or obligate itself to issue, whether by merger, consolidation, conversion or otherwise, any
equity security, including any other security convertible into or exercisable for any equity security, other than any shares of Common Stock (or options or rights to purchase shares of Common Stock) issued on or after the Filing Date to employees,
officers or directors of, or consultants or advisors to, this Corporation pursuant to current stock purchase plans or current stock option plans, or pursuant to similar plans that are approved by the Requisite Holders pursuant to Article IV.B.6(p);
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) incur aggregate indebtedness in excess of $250,000; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) effect any reclassification or recapitalization of the Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) effect a Liquidation Event; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) effect any consolidation, conversion or merger of this Corporation with or into any other corporation or other entity or person, share
transfer or any other corporate reorganization, in which the stockholders of this Corporation immediately prior to such consolidation, conversion, merger or reorganization, own less than 50% of this Corporation&#146;s voting power immediately after
such consolidation, conversion, merger or reorganization (excluding any merger effected exclusively for the purpose of changing the domicile of the Corporation and any transaction or series of related transactions the sole purpose of which is to
create a holding company that is owned in substantially the same proportions by the persons who held the Corporation&#146;s securities immediately prior to such transaction or series of related transactions) (an &#147;<U>Acquisition</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) effect any sale, lease, license, transfer or other disposition, in a single transaction or a series of related transactions, of all or
substantially all of the assets, technology or intellectual property of this Corporation, other than <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses granted in the ordinary course of this Corporation&#146;s business, or the sale or
disposition (whether by merger or otherwise) of one or more subsidiaries of this Corporation if substantially all the assets of this Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such
sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of this Corporation (an &#147;<U>Asset Transfer</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) increase or decrease the authorized number of directors of the Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) declare or pay dividends or make other distributions on the capital stock of the Corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) redeem, purchase or otherwise acquire (or pay into or set aside for a sinking fund for such purpose) any share or shares of Preferred
Stock or Common Stock; <U>provided</U>, <U>however</U>, that this restriction shall not apply to (i)&nbsp;the repurchase of shares of Common Stock from employees, officers, directors, consultants or other persons performing services for this
Corporation or any subsidiary pursuant to agreements under which this Corporation has the option to repurchase such shares at cost upon the occurrence of certain events, such as the termination of employment or other provision of services to the
Corporation or (ii)&nbsp;the redemption of any share or shares of Preferred Stock in accordance with Article IV.B.3; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) do any act or
thing which would result in taxation of the holders of shares of the Preferred Stock under Section&nbsp;305 of the Internal Revenue Code of 1986, as amended (or any comparable provision of the Internal Revenue Code as hereafter from time to time
amended); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) incur any indebtedness in excess of US$100,000 individually, or in the event of
indebtedness individually less than US$100,000, in excess of US$250,000 in the aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) consummate a public offering pursuant to a
registration statement under the Act or otherwise become subject to the periodic reporting requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) adopt or amend, or increase or decrease the aggregate number of shares of Common Stock reserved for issuance pursuant to, any stock
option plans or restricted stock purchase plans; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;(i) materially change the principal business of this Corporation from the
business in which this Corporation is engaged on the date of filing of this Restated Certificate of Incorporation, (ii)&nbsp;enter into a material new line of business in which this Corporation is not engaged on the date of filing of this
Certificate of Incorporation, or (iii)&nbsp;cease any material line of business in which the Corporation is engaged on the date of filing of this Certificate of Incorporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(r) form any subsidiary (except for a wholly-owned subsidiary), joint venture, partnership or similar business entity or make loans to or
investments in any such entity; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(s) enter into any related party transactions, except as those disclosed in the Series F Stock Purchase
Agreement or any schedule attached thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(t) allow any subsidiary of the Corporation to issue shares of capital stock of such
subsidiary other than to the Corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(u) acquire a material amount of assets through a merger or purchase of all or substantially
all of the assets or capital stock of another entity; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) amend this Article IV.B.6; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(w) cause any entity over which the Corporation has, directly or indirectly, a majority of the voting power to take any of the actions set
forth in this Article IV.B.6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;6 and Section&nbsp;7 below, the term conversion refers to the conversion
of the Corporation into a different entity type pursuant to Section&nbsp;266 of the General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Series E Preferred Stock Protective Provisions</U>. So long as any shares of Series E
Preferred Stock are outstanding, this Corporation shall not (by amendment, merger, consolidation or otherwise) without first obtaining the approval (by vote or written consent, as provided by law) of the Series E Majority: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) increase or decrease the aggregate number of authorized shares of Series E Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) amend or waive the final proviso in Article IV.B.2(f) hereof with respect to the Series E Preferred Stock; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) amend this Article IV.B.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Series F Preferred Stock Protective Provisions</U>. So long as any shares of Series F Preferred Stock are outstanding, this Corporation
shall not (by amendment, merger, consolidation or otherwise) without first obtaining the approval (by vote or written consent, as provided by law) of the Series F Majority: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) increase or decrease the aggregate number of authorized shares of Series F Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) amend or waive the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">second-to-final</FONT></FONT> proviso in Article
IV.B.2(f) hereof with respect to the Series F Preferred Stock; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) amend this Article IV.B.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Status of Redeemed or Converted Stock</U>. In the event any shares of the Preferred Stock shall be redeemed or converted pursuant to
Article IV.B.3 or Article IV.B.4, the shares so redeemed or converted shall be cancelled and shall not be issuable by this Corporation. This Certificate of Incorporation shall be appropriately amended to effect the corresponding reduction in this
Corporation&#146;s authorized capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. <U>Common Stock</U>. The rights, preferences, privileges and restrictions granted to and
imposed on the Common Stock are as set forth below in this Article IV.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividend Rights</U>. Subject to the prior rights of
holders of all classes of stock at the time outstanding having prior rights as to dividends, the holders of the Common Stock shall be entitled to receive, when and as declared by the Board of Directors, out of any assets of this Corporation legally
available therefor, such dividends as may be declared from time to time by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation Rights</U>. Upon a
Liquidation Event, the assets of this Corporation shall be distributed as provided in Article IV.B.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Redemption</U>. Neither the
Corporation nor the holders of Common Stock shall have the unilateral right to call or redeem or cause to have called or redeemed any shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Voting Rights</U>. The holder of each share of Common Stock shall have the right to one vote for each such share, and shall be entitled
to notice of any stockholders&#146; meeting in accordance with the Bylaws of this Corporation, and shall be entitled to vote upon such matters and in such manner as may be provided by law; <U>provided</U>, <U>however</U>, <U>that</U>, except as
otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or
together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation or pursuant to the General Corporation Law. The number of authorized shares of Common Stock may be increased or decreased (but
not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of this Corporation entitled to vote, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except
as otherwise provided in this Certificate of Incorporation, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of
this Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the requirements of Section&nbsp;5 of Article IV(B) hereof,&nbsp;the number of directors of this Corporation shall be determined in
the manner set forth in the Bylaws of this Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Elections of directors need not be by written ballot unless the Bylaws of this Corporation shall so provide. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Meetings
of stockholders may be held within or without the State of Delaware, as the Bylaws of this Corporation may provide. The books of this Corporation may be kept (subject to any provision contained in the statutes) outside the State of Delaware at such
place or places as may be designated from time to time by the Board of Directors or in the Bylaws of this Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the fullest extent permitted by law, a director or officer of this Corporation shall not be personally liable to this Corporation
or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the General Corporation Law is amended after approval by the stockholders of this Article&nbsp;IX to authorize corporate action further eliminating or
limiting the personal liability of directors or officers, then the liability of a director or officer of this Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions of this Article IX by the stockholders of this Corporation shall not
adversely affect any right or protection of a director or officer of this Corporation existing at the time of, or increase the liability of any director or officer of this Corporation with respect to any acts or omissions of such director or officer
occurring prior to, such amendment, repeal or modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the
manner now or hereafter prescribed by statute, and, subject to the requirements of Section&nbsp;6 of Article IV(B) hereof, all rights conferred upon stockholders herein are granted subject to this reservation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the
fullest extent permitted by applicable law, this Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers, employees and agents of this Corporation (and any other persons to which General
Corporation Law permits this Corporation to provide indemnification) through Bylaw provisions, agreements with such persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise
permitted by Section&nbsp;145 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions of this
Article&nbsp;XI shall not adversely affect any right or protection of a director, officer, employee, agent or other person existing at the time of, or increase the liability of any such person with respect to any acts or omissions of such person
occurring prior to, such amendment, repeal or modification. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of this Corporation in, or in being offered an
opportunity to participate in, any Excluded Opportunity. An &#147;<U>Excluded Opportunity</U>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of
(i)&nbsp;any director of this Corporation who is not an employee of this Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or agent of any such
holder, other than someone who is an employee of this Corporation or any of its subsidiaries (collectively, the persons referred to in <U>clauses (i)</U>&nbsp;and <U>(ii)</U> are &#147;<U>Covered Persons</U>&#148;), unless such matter, transaction
or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of this Corporation while such Covered Person is
performing services in such capacity. Any repeal or modification of this Article XII will only be prospective and will not affect the rights under this Article XII in effect at the time of the occurrence of any actions or omissions to act giving
rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Amended and Restated Certificate of Incorporation, the affirmative vote of the Requisite Holders will be required to amend or repeal, or to adopt any provisions
inconsistent with this Article XII. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIII. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with repurchases by this Corporation of its Common Stock from employees, officers, directors, advisors, consultants or other
persons performing services for this Corporation or any subsidiary pursuant to agreements under which this Corporation has the option to repurchase such shares at cost upon the occurrence of certain events, such as the termination of employment,
Section&nbsp;500 of the California Corporations Code shall not apply in all or in part with respect to such repurchases. In the case of any such repurchases, distributions by the corporation may be made without regard to the &#147;preferential
dividends arrears amount&#148; or any &#147;preferential rights amount,&#148; as such terms are defined in Section&nbsp;500(b) of the California Corporations Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XIV. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <U>Forum Selection</U>. Unless this Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the
State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or
proceeding brought on behalf of this Corporation, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of this Corporation to this Corporation or this Corporation&#146;s stockholders,
(iii)&nbsp;any action arising pursuant to any provision of the General Corporation Law or this Certificate of Incorporation or the Bylaws (as either may be amended from time to time), or (iv)&nbsp;any action asserting a claim governed by the
internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the
indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten (10)&nbsp;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery,
or for which the Court of Chancery does not have subject matter jurisdiction. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of this Corporation shall be deemed to have notice of and
consented to the provisions of this Article XIV. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. <U>Personal Jurisdiction</U>. If any action the subject matter of which is within the
scope of Article XIV(A) is filed in a court other than a court located within the State of Delaware (a &#147;<U>Foreign Action</U>&#148;) in the name of any stockholder, such stockholder shall be deemed to have consented to (i)&nbsp;the personal
jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce Article XIV(A) (an &#147;<U>FSC Enforcement Action</U>&#148;) and (ii)&nbsp;having service of
process made upon such stockholder in any such FSC Enforcement Action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. <U>Savings</U>. If any provision or provisions of this Article XIV shall be held to be invalid, illegal or unenforceable as applied to any
person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article XIV
(including, without limitation, each portion of any sentence of this Article XIV containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such
provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&#8195;*&#8195;* </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of Incorporation has been
executed by a duly authorized officer of this corporation on this 27<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of July, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arthur Kuan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arthur Kuan, Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLD
GENESYS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(A DELAWARE CORPORATION) </B></P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5">ARTICLE I OFFICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registered Office</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offices</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5">ARTICLE II MEETINGS OF STOCKHOLDERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Location</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; Records</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice of Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Business Transacted at Special Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quorum; Meeting Adjournment; Presence by Remote Means</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Voting Thresholds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Votes Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Action by Written Consent of Stockholders; Electronic Consent; Notice of Action</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5">ARTICLE III DIRECTORS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorized Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vacancies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Authority</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Location of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regular Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Special Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quorum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Action Without a Meeting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Telephonic Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minutes of Meetings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Removal of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5">ARTICLE IV NOTICES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver of Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Electronic Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5">ARTICLE V OFFICERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Required and Permitted Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment of Required Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appointment of Permitted Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8195;&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Officer Compensation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term of Office; Vacancies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chairman Presides</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Chairman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Powers of Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer&#146;s Signature Authority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Powers of President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Duties of Secretary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Duties of Assistant Secretary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Duties of Treasurer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disbursements and Financial Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treasurer&#146;s Bond</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Duties of Assistant Treasurer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VI CERTIFICATE OF STOCK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Stock Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Facsimile Signatures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Lost Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transfer of Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fixing a Record Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registered Stockholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5">ARTICLE VII GENERAL PROVISIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reserve for Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Checks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Fiscal Year</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Corporate Seal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conflicts with Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE VIII AMENDMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE IX RESTRICTIONS ON TRANSFER </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE X LOANS TO OFFICERS </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE XI RECORDS AND REPORTS </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED BYLAWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLD GENESYS, INC.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1 <B>Registered
Office</B>. The registered office shall be in the City of Dover, County of Kent, State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2 <B>Offices</B>. The corporation
may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the corporation may require. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEETINGS OF
STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <B>Location</B>. All meetings of the stockholders for the election of directors shall be held in the City of Santa
Ana, State of California, at such place as may be fixed from time to time by the Board of Directors, or at such other place either within or without the State of Delaware as shall be designated from time to time by the Board of Directors and stated
in the notice of the meeting; provided, however, that the Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as authorized by
Section&nbsp;211 of the Delaware General Corporations Law (&#147;<U>DGCL</U>&#148;). Meetings of stockholders for any other purpose may be held at such time and place, if any, within or without the State of Delaware, as shall be stated in the notice
of the meeting or in a duly executed waiver of notice thereof, or a waiver by electronic transmission by the person entitled to notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <B>Timing</B>. Annual meetings of stockholders, commencing with the year 2017, shall be held at such date and time as shall be designated
from time to time by the Board of Directors and stated in the notice of the meeting, at which they shall elect by a plurality vote a Board of Directors, and transact such other business as may properly be brought before the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3 <B>Notice of Meeting</B>. Written notice of any stockholder meeting stating the place, if any, date and hour of the meeting, the means of
remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, shall be given to each stockholder entitled to vote at such meeting not fewer than ten (10)&nbsp;nor more than sixty
(60)&nbsp;days before the date of the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4 <B>Stockholders</B><B>&#146;</B><B> Records</B>. The officer who has charge of the
stock ledger of the corporation shall prepare and make, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address
(but not the electronic address or other electronic contact information) of each stockholder and the number of shares registered in the name of each stockholder. Such list </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least 10 days prior to the meeting: (i)&nbsp;on a reasonably accessible electronic
network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii)&nbsp;during ordinary business hours, at the principal place of business of the corporation. In the event that the
corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. If the meeting is to be held at a place, then
the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall
also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.5 <B>Special Meetings</B>. Special meetings of the stockholders, for any purpose or purposes, unless otherwise prescribed by statute or by
the certificate of incorporation, may be called by the Chief Executive Officer and shall be called by the Chief Executive Officer or secretary at the request in writing of a majority of the Board of Directors, or at the request in writing of
stockholders owning at least fifty percent (50%) in amount of the entire capital stock of the corporation issued and outstanding and entitled to vote. Such request shall state the purpose or purposes of the proposed meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.6 <B>Notice of Meeting</B>. Written notice of a special meeting stating the place, date and hour of the meeting and the purpose or purposes
for which the meeting is called, shall be given not fewer than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting, to each stockholder entitled to vote at such meeting. The means of remote communication, if any, by which
stockholders and proxyholders may be deemed to be present in person and vote at such meeting shall also be provided in the notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.7
<B>Business Transacted at Special Meeting</B>. Business transacted at any special meeting of stockholders shall be limited to the purposes stated in the notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8 <B>Quorum; Meeting Adjournment; Presence by Remote Means</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>Quorum; Meeting Adjournment</I>. The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present
in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by statute or by the certificate of incorporation. If, however, such quorum shall not be
present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at the
meeting, until a quorum shall be present or represented. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted that might have been transacted at the meeting as originally notified. If the
adjournment is for more than thirty (30)&nbsp;days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I>Presence by Remote Means</I>. If authorized by the Board of Directors in its sole
discretion, and subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxyholders not physically present at a meeting of stockholders may, by means of remote communication: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) participate in a meeting of stockholders; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) be deemed present in person and vote at a meeting of stockholders whether such meeting is to be held at a designated place or solely by
means of remote communication, provided that (i)&nbsp;the corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a stockholder or
proxyholder, (ii)&nbsp;the corporation shall implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an
opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (iii)&nbsp;if any stockholder or proxyholder votes or takes other action at the meeting by means of remote communication, a record of
such vote or other action shall be maintained by the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.9 <B>Voting Thresholds</B>. When a quorum is present at any meeting,
the vote of the holders of a majority of the stock having voting power present in person or represented by proxy shall decide any question brought before such meeting, unless the question is one upon which by express provision of the statutes or of
the certificate of incorporation, a different vote is required, in which case such express provision shall govern and control the decision of such question. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10 <B>Number of Votes Per Share</B>. Unless otherwise provided in the certificate of incorporation, each stockholder shall at every meeting
of the stockholders be entitled to one vote by such stockholder or by proxy for each share of the capital stock having voting power held by such stockholder, but no proxy shall be voted on after three years from its date, unless the proxy provides
for a longer period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.11 <B>Action by Written Consent of Stockholders; Electronic Consent; Notice of Action</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>Action by Written Consent of Stockholders</I>. Unless otherwise provided by the certificate of incorporation, any action required or
permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing setting forth the action so taken, is signed in a manner permitted by law by
the holders of outstanding stock having not less than the number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Written stockholder consents shall
bear the date of signature of each stockholder who signs the consent in the manner permitted by law and shall be delivered to the corporation as provided in subsection (b)&nbsp;below. No written consent shall be effective to take the action set
forth therein unless, within sixty (60)&nbsp;days of the earliest dated consent delivered to the corporation in the manner provided above, written consents signed by a sufficient number of stockholders to take the action set forth therein are
delivered to the corporation in the manner provided above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I>Electronic Consent</I>. A telegram, cablegram or other electronic transmission
consenting to an action to be taken and transmitted by a stockholder or proxyholder, or a person or persons authorized to act for a stockholder or proxyholder, shall be deemed to be written, signed and dated for the purposes of this section,
provided that any such telegram, cablegram or other electronic transmission sets forth or is delivered with information from which the corporation can determine (1)&nbsp;that the telegram, cablegram or other electronic transmission was transmitted
by the stockholder or proxyholder or by a person or persons authorized to act for the stockholder or proxyholder and (2)&nbsp;the date on which such stockholder or proxyholder or authorized person or persons transmitted such telegram, cablegram or
electronic transmission. The date on which such telegram, cablegram or electronic transmission is transmitted shall be deemed to be the date on which such consent was signed. No consent given by telegram, cablegram or other electronic transmission
shall be deemed to have been delivered until such consent is reproduced in paper form and until such paper form is delivered to the corporation by delivery to its registered office in the State of Delaware, its principal place of business or an
officer or agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to a corporation&#146;s registered office shall be made by hand or by certified or registered mail, return
receipt requested. Notwithstanding the foregoing limitations on delivery, consents given by telegram, cablegram or other electronic transmission may be otherwise delivered to the principal place of business of the corporation or to an officer or
agent of the corporation having custody of the book in which proceedings of meetings of stockholders are recorded if, to the extent and in the manner provided by resolution of the Board of Directors of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice of Action</I>. Prompt notice of any action taken pursuant to this Section&nbsp;2.11 shall be provided to the stockholders in
accordance with Section&nbsp;228(e) of the DGCL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1
<B>Authorized Directors</B>. The number of directors that shall constitute the whole Board of Directors shall be determined by resolution of the Board of Directors or by the stockholders at the annual meeting of the stockholders, except as provided
in Section&nbsp;3.2 of this Article, and each director elected shall hold office until his or her successor is elected and qualified. Directors need not be stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <B>Vacancies</B>. Unless otherwise provided in the corporation&#146;s certificate of incorporation, as it may be amended, vacancies and
newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall
hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute. If,
at the time of filling any vacancy or any newly created directorship, the directors then in office shall constitute less than a majority of the whole Board of Directors (as constituted immediately prior to any such increase), the Court of Chancery
may, upon application of any stockholder or stockholders holding at least ten percent (10%) of the total number of the shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any
such vacancies or newly created directorships, or to replace the directors chosen by the directors then in office. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <B>Board Authority</B>. The business of the corporation shall be managed by or under the
direction of its Board of Directors, which may exercise all such powers of the corporation and do all such lawful acts and things as are not by statute or by the certificate of incorporation or by these bylaws directed or required to be exercised or
done by the stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <B>Location of Meetings</B>. The Board of Directors of the corporation may hold meetings, both regular and
special, either within or without the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5 <B>First Meeting</B>. The first meeting of each newly elected Board of
Directors shall be held at such time and place as shall be fixed by the vote of the stockholders at the annual meeting and no notice of such meeting shall be necessary to the newly elected directors in order to legally constitute the meeting,
provided a quorum shall be present. In the event of the failure of the stockholders to fix the time or place of such first meeting of the newly elected Board of Directors, or in the event such meeting is not held at the time and place so fixed by
the stockholders, the meeting may be held at such time and place as shall be specified in a notice given as hereinafter provided for special meetings of the Board of Directors, or as shall be specified in a written waiver signed by all of the
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6 <B>Regular Meetings</B>. Regular meetings of the Board of Directors may be held without notice at such time and at such
place as shall from time to time be determined by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7 <B>Special Meetings</B>. Special meetings of the Board of
Directors may be called by the Chief Executive Officer upon notice to each director; special meetings shall be called by the Chief Executive Officer or secretary in like manner and on like notice on the written request of two (2)&nbsp;directors
unless the Board of Directors consists of only one director, in which case special meetings shall be called by the Chief Executive Officer or secretary in like manner and on like notice on the written request of the sole director. Notice of any
special meeting shall be given to each director at his or her business or residence in writing, or by telegram, facsimile transmission, telephone communication or electronic transmission (provided, with respect to electronic transmission, that the
director has consented to receive the form of transmission at the address to which it is directed). If mailed, such notice shall be deemed adequately delivered when deposited in the United States mails so addressed, with postage thereon prepaid, at
least five (5)&nbsp;days before such meeting. If by telegram, such notice shall be deemed adequately delivered when the telegram is delivered to the telegraph company at least twenty-four (24)&nbsp;hours before such meeting. If by facsimile
transmission or other electronic transmission, such notice shall be transmitted at least twenty-four (24)&nbsp;hours before such meeting. If by telephone, the notice shall be given at least twelve (12)&nbsp;hours prior to the time set for the
meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in the notice of such meeting, except for amendments to these Amended and Restated Bylaws as provided
under Section&nbsp;8.1 of Article VIII hereof. A meeting may be held at any time without notice if all the directors are present (except as otherwise provided by law) or if those not present waive notice of the meeting in writing, either before or
after such meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.8 <B>Quorum</B>. At all meetings of the Board of Directors a majority of the directors
shall constitute a quorum for the transaction of business and any act of a majority of the directors present at any meeting at which there is a quorum shall be an act of the Board of Directors, except as may be otherwise specifically provided by
statute or by the certificate of incorporation. If a quorum is not present at any meeting of the Board of Directors, the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting,
until a quorum shall be present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.9 <B>Action Without a Meeting</B>. Unless otherwise restricted by the certificate of incorporation or
these bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all members of the Board of Directors or committee, as the case may be, consent thereto
in writing or by electronic transmission, and the writing, writings, electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10 <B>Telephonic Meetings</B>. Unless otherwise restricted by the certificate of incorporation or these bylaws, members of the Board of
Directors or any committee designated by the Board of Directors may participate in a meeting of the Board of Directors or any committee, by means of conference telephone or other means of communication by which all persons participating in the
meeting can hear each other, and such participation shall constitute presence in person at the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.11 <B>Committees</B>. The Board
of Directors may designate one or more committees, each committee to consist of one or more of the directors of the corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any
absent or disqualified member at any meeting of the committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the absence or disqualification of a member of a committee, the member
or members thereof present at any meeting and not disqualified from voting, whether or not he or she or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent
or disqualified member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any such committee, to the extent provided in the resolution of the Board of Directors, shall have and may
exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it, but no such committee
shall have the power or authority in reference to the following matters: (i)&nbsp;approving or adopting, or recommending to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval or
(ii)&nbsp;adopting, amending or repealing any provision of these bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.12 <B>Minutes of Meetings</B>. Each committee shall keep
regular minutes of its meetings and report the same to the Board of Directors when required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.13 <B>Compensation of Directors</B>. Unless otherwise restricted by the certificate of
incorporation or these bylaws, the Board of Directors shall have the authority to fix the compensation of directors. The directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid a fixed
sum for attendance at each meeting of the Board of Directors or a stated salary as director. No such payment shall preclude any director from serving the corporation in any other capacity and receiving compensation therefor. Members of special or
standing committees may be allowed like compensation for attending committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.14 <B>Removal of Directors</B>. Unless otherwise
provided by the certificate of incorporation or these bylaws, any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority of shares entitled to vote at an election of directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <B>Notice</B>. Unless otherwise provided in these bylaws, whenever, under the provisions of the statutes or of the certificate of
incorporation or of these bylaws, notice is required to be given to any director or stockholder, it shall not be construed to mean personal notice, but such notice may be given in writing, by mail, addressed to such director or stockholder, at his
or her address as it appears on the records of the corporation, with postage thereon prepaid, and such notice shall be deemed to be given at the time when the same shall be deposited in the United States mail. Notice to directors may also be given
by telegram. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 <B>Waiver of Notice</B>. Whenever any notice is required to be given under the provisions of the statutes or of the
certificate of incorporation or of these bylaws, a waiver thereof in writing, signed by the person or persons entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <B>Electronic Notice</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>Electronic Transmission</I>. Without limiting the manner by which notice otherwise may be given effectively to stockholders and
directors, any notice to stockholders or directors given by the corporation under any provision of the DGCL, the certificate of incorporation or these bylaws shall be effective if given by a form of electronic transmission consented to by the
stockholder or director to whom the notice is given. Any such consent shall be revocable by the stockholder or director by written notice to the corporation. Any such consent shall be deemed revoked if (1)&nbsp;the corporation is unable to deliver
by electronic transmission two consecutive notices given by the corporation in accordance with such consent and (2)&nbsp;such inability becomes known to the secretary or an assistant secretary of the corporation or to the transfer agent, or other
person responsible for the giving of notice; provided, however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I>Effective Date of Notice</I>. Notice given pursuant to subsection (a)&nbsp;of this section shall be deemed given: (1)&nbsp;if by
facsimile telecommunication, when directed to a number at which the stockholder or director has consented to receive notice; (2)&nbsp;if by electronic mail, when directed to an electronic mail address at which the stockholder or director has
consented to receive notice; (3)&nbsp;if by a posting on an electronic network together with separate notice to the stockholder or director of such specific posting, upon the later of (i)&nbsp;such posting and (ii)&nbsp;the giving of such separate
notice; and (4)&nbsp;if by any other form of electronic transmission, when directed to the stockholder or director. An affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the corporation that the notice
has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <I>Form of Electronic Transmission</I>. For purposes of these bylaws,
&#147;<U>electronic transmission</U>&#148; means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be
directly reproduced in paper form by such a recipient through an automated process. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <B>Required
and Permitted Officers</B>. The officers of the corporation shall be chosen by the Board of Directors and shall be a Chief Executive Officer and/or a president, a treasurer and a secretary. The Board of Directors may elect from among its members a
Chairman of the Board and a Vice-Chairman of the Board. The Board of Directors may also choose one or more vice-presidents, assistant secretaries and assistant treasurers. Any number of offices may be held by the same person, unless the certificate
of incorporation or these bylaws otherwise provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <B>Appointment of Required Officers</B>. The Board of Directors at its first
meeting after each annual meeting of stockholders shall choose a Chief Executive Officer and/or a president, a treasurer, and a secretary and may choose vice-presidents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <B>Appointment of Permitted Officers</B>. The Board of Directors may appoint such other officers and agents as it shall deem necessary who
shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined from time to time by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <B>Officer Compensation</B>. The salaries of all officers and agents of the corporation shall be fixed by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5 <B>Term of Office; Vacancies</B>. The officers of the corporation shall hold office until their successors are chosen and qualify. Any
officer elected or appointed by the Board of Directors may be removed at any time by the affirmative vote of a majority of the Board of Directors. Any vacancy occurring in any office of the corporation shall be filled by the Board of Directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THE CHAIRMAN OF THE BOARD </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6 <B>Chairman Presides</B>. Unless the Board of Directors appoints a Chairman of the Board, the Chief Executive Officer shall be the
Chairman of the Board, so long as the Chief Executive Officer is a director of the corporation. The Chairman of the Board shall preside at all meetings of the Board of Directors and of the stockholders at which he or she shall be present. He or she
shall have and may exercise such powers as are, from time to time, assigned to him or her by the Board of Directors and as may be provided by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7 <B>Absence of Chairman</B>. In the absence of the Chairman of the Board, the
Vice-Chairman of the Board, if any, shall preside at all meetings of the Board of Directors and of the stockholders at which he or she shall be present. He or she shall have and may exercise such powers as are, from time to time, assigned to him or
her by the Board of Directors and as may be provided by law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THE CHIEF EXECUTIVE OFFICER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8 <B>Powers of Chief Executive Officer</B>. The Chief Executive Officer shall have general and active management of the business of the
corporation and shall see that all orders and resolutions of the Board of Directors are carried into effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9 <B>Chief Executive
Officer&#146;s Signature Authority</B>. The Chief Executive Officer shall execute bonds, mortgages and other contracts requiring a seal, under the seal of the corporation, except where required or permitted by law to be otherwise signed and executed
and except where the signing and execution thereof shall be expressly delegated by the Board of Directors to some other officer or agent of the corporation. The Chief Executive Officer may sign certificates for shares of stock of the corporation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10 <B>Absence of Chief Executive Officer</B>. In the absence of the Chief Executive Officer or in the event of his or her inability or
refusal to act, the president shall perform the duties of the Chief Executive Officer, and when so acting, shall have all the powers of and be subject to all the restrictions upon the Chief Executive Officer. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THE PRESIDENT AND VICE-PRESIDENTS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11 <B>Powers of President</B>. Unless the Board of Directors appoints a president of the corporation, the Chief Executive Officer shall be
the president of the corporation. The president of the corporation shall have such powers as required by law and shall perform such other duties and have such other powers as the Board of Directors may from time to time prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12 <B>Absence of President</B>. In the absence of the president or in the event of his or her inability or refusal to act, the
vice-president, if any, (or in the event there be more than one vice-president, the vice-presidents in the order designated by the directors, or in the absence of any designation, then in the order of their election) shall perform the duties of the
president, and when so acting, shall have all the powers of and be subject to all the restrictions upon the president. The vice-presidents shall perform such other duties and have such other powers as the Board of Directors may from time to time
prescribe. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THE SECRETARY AND ASSISTANT SECRETARY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.13 <B>Duties of Secretary</B>. The secretary shall attend all meetings of the Board of Directors and all meetings of the stockholders and
record all the proceedings of the meetings of the corporation and of the Board of Directors in a book to be kept for that purpose and shall perform like duties for the standing committees when required. He or she shall give, or cause to be given,
notice of all meetings of the stockholders and special meetings of the Board of Directors, and shall perform such other duties as may be prescribed by the Board of Directors or the Chief Executive Officer, under whose supervision he or she shall be.
He or she shall have custody of the corporate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seal of the corporation and he or she, or an assistant secretary, shall have authority to affix the same to any instrument requiring it and when so affixed, it may be attested by his or her
signature or by the signature of such assistant secretary. The Board of Directors may give general authority to any other officer to affix the seal of the corporation and to attest the affixing by his or her signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.14 <B>Duties of Assistant Secretary</B>. The assistant secretary, or if there be more than one, the assistant secretaries in the order
determined by the Board of Directors (or if there be no such determination, then in the order of their election) shall, in the absence of the secretary or in the event of his or her inability or refusal to act, perform the duties and exercise the
powers of the secretary and shall perform such other duties and have such other powers as the Board of Directors may from time to time prescribe. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THE TREASURER AND ASSISTANT TREASURERS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.15 <B>Duties of Treasurer</B>. The treasurer shall have the custody of the corporate funds and securities and shall keep full and accurate
accounts of receipts and disbursements in books belonging to the corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the corporation in such depositories as may be designated by the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.16 <B>Disbursements and Financial Reports</B>. He or she shall disburse the funds of the corporation as may be ordered by
the Board of Directors, taking proper vouchers for such disbursements, and shall render to the Chief Executive Officer and the Board of Directors, at its regular meetings or when the Board of Directors so requires, an account of all his or her
transactions as treasurer and of the financial condition of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.17 <B>Treasurer</B><B>&#146;</B><B>s Bond</B>. If required
by the Board of Directors, the treasurer shall give the corporation a bond (which shall be renewed every six years) in such sum and with such surety or sureties as shall be satisfactory to the Board of Directors for the faithful performance of the
duties of his or her office and for the restoration to the corporation, in case of his or her death, resignation, retirement or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his or her possession
or under his or her control belonging to the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.18 <B>Duties of Assistant Treasurer</B>. The assistant treasurer, or if there
shall be more than one, the assistant treasurers in the order determined by the Board of Directors (or if there be no such determination, then in the order of their election) shall, in the absence of the treasurer or in the event of the
treasurer&#146;s inability or refusal to act, perform the duties and exercise the powers of the treasurer and shall perform such other duties and have such other powers as the Board of Directors may from time to time prescribe. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE
OF STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <B>Stock Certificates</B>. Every holder of stock in the corporation shall be entitled to have a certificate, signed by
or in the name of the corporation by, the Chairman or <FONT STYLE="white-space:nowrap">Vice-Chairman</FONT> of the Board of Directors, or the president or a vice-president and the treasurer or an assistant treasurer, or the secretary or an assistant
secretary of the corporation, certifying the number of shares owned by him or her in the corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Certificates may be issued for partly paid shares and in such case upon the face or back of
the certificates issued to represent any such partly paid shares, the total amount of the consideration to be paid therefor, and the amount paid thereon shall be specified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the corporation shall be authorized to issue more than one class of stock or more than one series of any class, the powers, designations,
preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualification, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the
face or back of the certificate which the corporation shall issue to represent such class or series of stock, provided that, except as otherwise provided in Section&nbsp;202 of the DGCL, in lieu of the foregoing requirements, there may be set forth
on the face or back of the certificate which the corporation shall issue to represent such class or series of stock, a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations,
preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <B>Facsimile Signatures</B>. Any or all of the signatures on the certificate may be facsimile. In the event that any officer, transfer
agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, the certificate may be issued by the corporation
with the same effect as if such officer, transfer agent or registrar were still acting as such at the date of issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3 <B>Lost
Certificates</B>. The Board of Directors may direct a new certificate or certificates to be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen or destroyed upon the making of an
affidavit of that fact by the person claiming the certificate to be lost, stolen or destroyed. When authorizing such issuance of a new certificate or certificates, the Board of Directors may, in its discretion and as a condition precedent to the
issuance, require the owner of such lost, stolen or destroyed certificate or certificates, or his or her legal representative, to advertise the same in such manner as it shall require and/or to give the corporation a bond in such sum as it may
direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen or destroyed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.4 <B>Transfer of Stock</B>. Upon surrender to the corporation or the transfer agent of the corporation of a certificate for shares duly
endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, it shall be the duty of the corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction
upon its books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.5 <B>Fixing a Record Date</B>. In order that the corporation may determine the stockholders entitled to notice of or to
vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to
exercise any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date which shall not be more than sixty
(60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting, nor more than sixty (60)&nbsp;days prior to any other action. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall
apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.6 <B>Registered Stockholders</B>. The corporation shall be entitled to recognize the exclusive right of a person registered on its books as
the owner of shares to receive dividends, to vote as such owner, to hold liable for calls and assessments a person registered on its books as the owner of shares and shall not be bound to recognize any equitable or other claim to or interest in such
share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL
PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1 <B>Dividends</B>. Dividends upon the capital stock of the corporation, if any, subject to the provisions of the
certificate of incorporation, may be declared by the Board of Directors at any regular or special meeting, pursuant to law. Dividends may be paid in cash, in property or in shares of the capital stock, subject to the provisions of the certificate of
incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2 <B>Reserve for Dividends</B>. Before payment of any dividend, there may be set aside out of any funds of the
corporation available for dividends such sum or sums as the directors from time to time, in their sole discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property
of the corporation, or for such other purposes as the directors think conducive to the interests of the corporation, and the directors may modify or abolish any such reserve in the manner in which it was created. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3 <B>Checks</B>. All checks or demands for money and notes of the corporation shall be signed by such officer or officers or such other
person or persons as the Board of Directors may from time to time designate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.4 <B>Fiscal Year</B>. The fiscal year of the corporation
shall be fixed by resolution of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5 <B>Corporate Seal</B>. The Board of Directors may adopt a corporate seal
having inscribed thereon the name of the corporation, the year of its organization and the words &#147;Corporate Seal, Delaware.&#148; The seal may be used by causing it or a facsimile thereof to be impressed or affixed or otherwise reproduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.6 <B>Indemnification</B>. The corporation shall, to the fullest extent authorized under the laws of the State of Delaware, as those laws may
be amended and supplemented from time to time, indemnify any director made, or threatened to be made, a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of being a director of the corporation or a
predecessor corporation or a director or officer of another corporation, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such person served in such position at the request of the corporation; provided, however, that the corporation shall indemnify any such director or officer in connection with a proceeding
initiated by such director or officer only if such proceeding was authorized by the Board of Directors of the corporation. The indemnification provided for in this Section&nbsp;7.6 shall: (i)&nbsp;not be deemed exclusive of any other rights to which
those indemnified may be entitled under these bylaws, agreement or vote of stockholders or disinterested directors or otherwise, both as to action in their official capacities and as to action in another capacity while holding such office,
(ii)&nbsp;continue as to a person who has ceased to be a director, and (iii)&nbsp;inure to the benefit of the heirs, executors and administrators of a person who has ceased to be a director. The corporation&#146;s obligation to provide
indemnification under this Section&nbsp;7.6 shall be offset to the extent of any other source of indemnification or any otherwise applicable insurance coverage under a policy maintained by the corporation or any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Expenses incurred by a director of the corporation in defending a civil or criminal action, suit or proceeding by reason of the fact that he
or she is or was a director of the corporation (or was serving at the corporation&#146;s request as a director or officer of another corporation) shall be paid by the corporation in advance of the final disposition of such action, suit or proceeding
upon receipt of an undertaking by or on behalf of such director to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the corporation as authorized by relevant sections of the DGCL.
Notwithstanding the foregoing, the corporation shall not be required to advance such expenses to an agent who is a party to an action, suit or proceeding brought by the corporation and approved by a majority of the Board of Directors of the
corporation that alleges willful misappropriation of corporate assets by such agent, disclosure of confidential information in violation of such agent&#146;s fiduciary or contractual obligations to the corporation or any other willful and deliberate
breach in bad faith of such agent&#146;s duty to the corporation or its stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The foregoing provisions of this Section&nbsp;7.6
shall be deemed to be a contract between the corporation and each director who serves in such capacity at any time while this bylaw is in effect, and any repeal or modification thereof shall not affect any rights or obligations then existing with
respect to any state of facts then or theretofore existing or any action, suit or proceeding theretofore or thereafter brought based in whole or in part upon any such state of facts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Board of Directors in its sole discretion shall have power on behalf of the corporation to indemnify any person, other than a director,
made a party to any action, suit or proceeding by reason of the fact that he or she, his or her testator or intestate, is or was an officer or employee of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">To assure indemnification under this Section&nbsp;7.6 of all directors, officers and employees who are determined by the corporation or
otherwise to be or to have been &#147;fiduciaries&#148; of any employee benefit plan of the corporation that may exist from time to time, Section&nbsp;145 of the DGCL shall, for the purposes of this Section&nbsp;7.6, be interpreted as follows: an
&#147;other enterprise&#148; shall be deemed to include such an employee benefit plan, including without limitation, any plan of the corporation that is governed by the Act of Congress entitled &#147;Employee Retirement Income Security Act of
1974,&#148; as amended from time to time; the corporation shall be deemed to have requested a person to serve the corporation for purposes of Section&nbsp;145 of the DGCL, as administrator of an employee benefit plan where the performance by such
person of his or her duties to the corporation also imposes duties on, or otherwise involves services by, such person to the plan or participants or beneficiaries of the plan; excise taxes assessed on a person with respect to an employee benefit
plan pursuant to such Act of Congress shall be deemed &#147;fines.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CERTIFICATE OF INCORPORATION GOVERNS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.7 <B>Conflicts with Certificate of Incorporation</B>. In the event of any conflict between the provisions of the corporation&#146;s
certificate of incorporation and these bylaws, the provisions of the certificate of incorporation shall govern. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1 These
bylaws may be altered, amended or repealed, or new bylaws may be adopted by the stockholders or by the Board of Directors, when such power is conferred upon the Board of Directors by the certificate of incorporation at any regular meeting of the
stockholders or of the Board of Directors or at any special meeting of the stockholders or of the Board of Directors if notice of such alteration, amendment, repeal or adoption of new bylaws be contained in the notice of such special meeting. If the
power to adopt, amend or repeal bylaws is conferred upon the Board of Directors by the certificate of incorporation, it shall not divest or limit the power of the stockholders to adopt, amend or repeal bylaws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTIONS
ON TRANSFER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1 In addition to any other restrictions on transfer created by law or contract with any stockholder, no stockholder
shall sell, assign, pledge, or in any manner transfer any of the shares of Common Stock of the corporation or any right or interest therein, whether voluntarily or by operation of law, or by gift or otherwise (&#147;<U>Transfer</U>&#148;), except by
a Transfer which meets the requirements hereinafter set forth in this Article IX: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <I>Notice of Proposed Transfer</I>. If the
stockholder desires to sell or otherwise Transfer any of his or her shares of Common Stock, then the stockholder shall first give written notice thereof to the corporation. The notice shall name the proposed transferee and state the number of shares
to be transferred, the proposed consideration and all other terms and conditions of the proposed Transfer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <I>No Transfers Without Consent</I>. Subject to this Article IX, no stockholder may
Transfer shares of Common Stock of the corporation without the approval of the Board of Directors or any committee provided with the power and authority in a resolution of the Board of Directors to consent to such Transfer thereof. In the case of
any Transfer consented to by the corporation, the transferee, assignee or other recipient shall receive and hold such stock subject to the provisions of this bylaw, and there shall be no further Transfer of such shares except in accord with this
bylaw. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <I>Corporate Option to Purchase</I>. In addition to and without limiting the effect of subsection (b)&nbsp;above, for fifteen
(15)&nbsp;days following receipt of such notice, the corporation shall have the option to purchase all or any part of the shares specified in the notice at the price and upon the terms set forth in such notice. In the event the corporation elects to
purchase all the shares, it shall give written notice to the selling stockholder of its election and settlement for said shares shall be made as provided below in paragraph (e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The corporation may assign its rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <I>Closing of Corporate Purchase</I>. In the event the corporation elects to acquire any of the shares of the selling stockholder as
specified in said selling stockholder&#146;s notice, the corporation shall so notify the selling stockholder and settlement thereof shall be made in cash within thirty (30)&nbsp;days after the corporation receives said selling stockholder&#146;s
notice; provided that if the terms of payment set forth in said selling stockholder&#146;s notice were other than cash against delivery, the corporation shall pay for said shares on the same terms and conditions set forth in said selling
stockholder&#146;s notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) <I>Sale by Selling Stockholder</I>. In the event the corporation does not elect to acquire all of the
shares specified in the selling stockholder&#146;s notice, said selling stockholder may, within the sixty (60)&nbsp;day period following the expiration of the option rights granted to the corporation, sell elsewhere the shares specified in said
selling stockholder&#146;s notice which were not acquired by the corporation, in accordance with the provisions of paragraph (e)&nbsp;of this Section&nbsp;9.1, provided that said sale shall not be on terms and conditions more favorable to the
purchaser than those contained in said selling stockholder&#146;s notice. All shares so sold by said selling stockholder shall continue to be subject to the provisions of this bylaw in the same manner as before said Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) <I>Permitted Transactions</I>. Anything to the contrary contained herein notwithstanding, the following transactions shall be exempt from
the provisions of this bylaw: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) A Transfer of shares of Common Stock of the corporation issued upon conversion of shares of any series
of Preferred Stock of the corporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) A stockholder&#146;s Transfer of any or all shares held either during such stockholder&#146;s
lifetime or on death by will or intestacy to such stockholder&#146;s immediate family or to any custodian or trustee for the account of such stockholder or such stockholder&#146;s immediate family. &#147;Immediate family&#148; as used herein shall
mean spouse, lineal descendant, father, mother, brother, or sister of the stockholder making such Transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3) A stockholder&#146;s
bona fide pledge or mortgage of any shares with a commercial lending institution, provided that any subsequent Transfer of said shares by said institution shall be conducted in the manner set forth in this bylaw; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(4) A stockholder&#146;s Transfer of any or all of such stockholder&#146;s shares to the corporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(5) A corporate stockholder&#146;s Transfer of any or all of its shares pursuant to and in accordance with the terms of any merger,
consolidation, reclassification of shares or capital reorganization of the corporate stockholder or pursuant to a sale of all or substantially all of the stock or assets of a corporate stockholder; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(6) An entity stockholder&#146;s Transfer of any or all of its shares to any or all of its
(i)&nbsp;equity holders if such Transfer constitutes a distribution by the stockholder entity or (ii)&nbsp;a partner, member or affiliate (defined as a person or entity controlling, controlled by or under common control) of such stockholder entity;
or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(7) A Transfer by a stockholder which is a limited or general partnership to any or all of its partners or former partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In any such case, the transferee, assignee or other recipient shall receive and hold such stock subject to the provisions of this bylaw, and
there shall be no further Transfer of such stock except in accord with this bylaw. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) <I>Waiver of Restrictions on Transfer</I>. The
provisions of this bylaw may be waived with respect to any Transfer by the corporation upon duly authorized action of the Board of Directors or any committee provided with the power and authority in a resolution of the Board of Directors, including
consent of the Series C Director, as such term is defined in the Restated Certificate of Incorporation of the corporation (as amended and/or restated from time to time), or by the stockholders, upon the express written consent of the owners of a
majority of the voting power of the corporation (excluding the votes represented by those shares to be transferred by the transferring stockholder), to waive such restrictions on Transfers. This bylaw may be amended or repealed by a duly authorized
action of the Board of Directors (including consent of the Series C Director) or by the stockholders, upon the express written consent of the owners of a majority of the voting power of the corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <I>Void Transfers</I>. Any sale or Transfer, or purported sale or Transfer, of securities of the corporation shall be null and void ab
initio unless the terms, conditions and provisions of this bylaw are strictly observed and followed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) <I>Termination of Restrictions
on Transfer</I>. The foregoing restrictions on Transfer contained in this Article IX shall terminate on either of the following dates, whichever shall first occur: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the closing of a Liquidation Event, as such term is defined in the Restated Certificate of Incorporation of the corporation (as amended
and/or restated from time to time); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the first sale of Common Stock of the corporation to the general public pursuant to a
registration statement filed with and declared effective by the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) <I>Legends</I>. The certificates representing shares of stock of the corporation shall bear on their face the following legend so long as
the foregoing restrictions on transfer remain in effect: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE TRANSFERRED ONLY IN
ACCORDANCE WITH THE BYLAWS OF THE CORPORATION, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE CORPORATION.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOANS TO OFFICERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1
The corporation may lend money to, or guarantee any obligation of or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a director of the corporation or its
subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured
or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing in these bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty
of the corporation at common law or under any statute. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECORDS AND REPORTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1
The application and requirements of Section&nbsp;1501 of the California General Corporation Law are hereby expressly waived to the fullest extent permitted thereunder </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF SECRETARY OF </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLD GENESYS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
undersigned, <B>Arthur Kuan</B>, hereby certifies that they are the duly elected and acting Secretary of <B>Cold Genesys, Inc.</B>, a Delaware corporation (the &#147;<U>Corporation</U>&#148;), and that the Amended and Restated Bylaws attached hereto
constitute the bylaws of said Corporation as duly adopted by Action by Written Consent of the Board of Directors on December&nbsp;5, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned has hereunto subscribed their name this December&nbsp;5, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Arthur Kuan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arthur Kuan, Secretary</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED: July&nbsp;28, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS&#146; RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS AMENDED AND RESTATED INVESTORS&#146; RIGHTS AGREEMENT (this &#147;<U>Agreement</U>&#148;) is made as of July&nbsp;28, 2023 by and among
<B>CG ONCOLOGY, INC.</B>, a Delaware corporation (the &#147;<U>Company</U>&#148;), and the investors listed on <U>Schedule A</U> hereto (each an &#147;<U>Investor</U>&#148; and collectively the &#147;<U>Investors</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
certain of the Investors (the &#147;<U>Existing Investors</U>&#148;) hold shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> Preferred Stock of the Company (the
&#147;<U>Series</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;A-1</FONT> Preferred Stock</U>&#148;), shares of Series&nbsp;B Preferred Stock of the Company (the &#147;<U>Series</U><U></U><U>&nbsp;B Preferred Stock</U>&#148;), shares of
Series&nbsp;C Preferred Stock of the Company (the &#147;<U>Series</U><U></U><U>&nbsp;C Preferred Stock</U>&#148;), shares of Series D Preferred stock of the Company (the &#147;<U>Series D Preferred Stock</U>&#148;), shares of Series E Preferred
stock of the Company (the &#147;<U>Series E Preferred Stock</U>&#148;) and/or shares of Common Stock of the Company (the &#147;<U>Common Stock</U>&#148;) issued upon conversion thereof and possess registration rights, information rights, rights of
first offer and other rights pursuant to that certain Amended and Restated Investors&#146; Rights Agreement dated as of September&nbsp;30, 2022 by and among the Company and such Existing Investors (the &#147;<U>Prior Agreement</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Prior Agreement may be amended, and any provision therein waived, with the consent of the Company and the holders of at
least 75% of the Registrable Securities then outstanding (as such term is defined in the Prior Agreement); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Existing
Investors as holders of at least 75% of the Registrable Securities outstanding desire to terminate the Prior Agreement and to accept the rights created pursuant hereto in lieu of the rights granted to them under the Prior Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, certain Investors are parties to that certain Series F Preferred Stock Purchase Agreement of even date herewith by and among
the Company and certain of the Investors (the &#147;<U>Series F Stock Purchase Agreement</U>&#148;), which provides that as a condition to the closing of the sale of the Series F Preferred Stock of the Company (the &#147;<U>Series F Preferred
Stock</U>&#148; and collectively with the <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> Preferred Stock, Series B Preferred Stock, the Series C Preferred Stock, Series D Preferred Stock and the Series E Preferred Stock, the
&#147;<U>Preferred Stock</U>&#148;), this Agreement must be executed and delivered by such Investors, Existing Investors holding at least 75% of the Registrable Securities outstanding, and the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual promises and covenants set forth
herein, the Company and the Existing Investors hereby agree that the Prior Agreement shall be superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Rights</U>. The Company covenants and agrees as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.1 <U>Definitions</U>. For purposes of this Section&nbsp;1: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) The term &#147;<U>Act</U>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) The term &#147;<U>Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>&#148; means such form under the Act as in effect on the date
hereof or any registration form under the Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) The term &#147;<U>Holder</U>&#148; means any person owning or having the right to acquire Registrable Securities or any assignee thereof
in accordance with Section&nbsp;1.11 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) The term &#147;<U>Initial Public Offering</U>&#148; means the first firm commitment
underwritten public offering of securities of the Company pursuant to an effective registration statement under the Act (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock
option, stock purchase or similar plan or an SEC Rule 145 transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(e) The term &#147;<U>1934 Act</U>&#148; means the Securities
Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(f) The term &#147;<U>register,</U>&#148; &#147;<U>registered,</U>&#148; and
&#147;<U>registration</U>&#148; refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or
document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(g) The term &#147;<U>Registrable Securities</U>&#148; means the Common Stock issuable or issued upon conversion of the
Company&#146;s Preferred Stock and any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange
for, or in replacement of, the shares referenced above, excluding in all cases, however, any Registrable Securities sold by a person (x)&nbsp;in a transaction in which his, her or its rights under this Section&nbsp;1 are not assigned,
(y)&nbsp;pursuant to a registration statement under the Act that has been declared effective and such Registrable Securities have been disposed of pursuant to such effective registration statement, or (z)&nbsp;in a transaction in which such
Registrable Securities are sold pursuant to Rule 144 (or any similar provision then in force) under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(h) The number of shares of
&#147;<U>Registrable Securities then outstanding</U>&#148; shall be determined by the number of shares of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities
that are, Registrable Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i) The term &#147;<U>Restated Certificate</U>&#148; shall mean the Company&#146;s current
Amended and Restated Certificate of Incorporation, as duly filed with the Delaware Secretary of State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(j) The term
&#147;<U>SEC</U>&#148; shall mean the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2 <U>Request for Registration.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) Subject to the conditions of this Section&nbsp;1.2, if the Company shall receive at any time after the earlier of (i)&nbsp;five
(5)&nbsp;years after the date of this Agreement or (ii)&nbsp;six (6)&nbsp;months after the effective date of the Initial Public Offering, a written request from the Holders of twenty-five percent (25%) or more of the Registrable Securities then
outstanding (the &#147;<U>Initiating Holders</U>&#148;) that the Company file a registration statement under the Act covering the registration of Registrable Securities, then the Company shall, within twenty (20)&nbsp;days of the receipt thereof,
give written notice of such request to all Holders, and subject to the limitations of this Section&nbsp;1.2, use best efforts to effect, as soon as practicable, the registration under the Act of all Registrable Securities that the Holders request to
be registered in a written request received by the Company within twenty (20)&nbsp;days of the mailing of the Company&#146;s notice pursuant to this Section&nbsp;1.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they
shall so advise the Company as a part of their request made pursuant to this Section&nbsp;1.2 and the Company shall include such information in the written notice referred to in this Section&nbsp;1.2(a). In such event the right of any Holder to
include its Registrable Securities in such registration shall be conditioned upon such Holder&#146;s participation in such underwriting and the inclusion of such Holder&#146;s Registrable Securities in the underwriting (unless otherwise mutually
agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form
with the underwriter or underwriters selected for such underwriting by a majority in interest of the Initiating Holders. Notwithstanding any other provision of this Section&nbsp;1.2, if the underwriter advises the Company that marketing factors
require a limitation of the number of securities underwritten (including Registrable Securities), then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares
that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities on a pro rata basis (as nearly as practicable) based on the number of Registrable Securities held by all such Holders (including the Initiating
Holders), provided that no Registrable Securities shall be excluded unless and until all other securities of the Company have been excluded; and provided further that at least 33% of the Registrable Securities requested to be included in such
underwriting are in fact so included. Any Registrable Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) In addition, the Company shall not be required to effect a registration pursuant to
this Section&nbsp;1.2: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(i) after the Company has effected three (3)&nbsp;registrations pursuant to this Section&nbsp;1.2, and such
registrations have been declared or ordered effective; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(ii) If the Company has effected a registration pursuant to this Section&nbsp;1.2
within the preceding twelve (12)&nbsp;months, and such registration has been declared or ordered effective; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(iii) If the Initiating
Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration statement, propose to sell Registrable Securities and such other securities (if any) and the aggregate proceeds of which (after
deduction for underwriter&#146;s discounts and expenses related to the issuance) are less than US$5,000,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(iv) during the period
starting with the date sixty (60)&nbsp;says prior to the Company&#146;s good faith estimate of the date of filing of, and ending on a date one hundred eighty (180)&nbsp;days following the effective date of, a Company-initiated registration subject
to Section&nbsp;1.3, provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(v) if the Initiating Holders propose to dispose of Registrable Securities that may be registered on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> pursuant to Section&nbsp;1.4; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(vi) if the Company shall furnish to Holders requesting a
registration pursuant to this Section&nbsp;1.2, a certificate signed by the Company&#146;s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously
detrimental to the Company and its stockholders for such registration to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90)&nbsp;days after receipt of the request
of the Initiating Holders, provided that such right to delay a request shall be exercised by the Company not more than once in any twelve (12)-month period and provided further, that the Company shall not register any other of its shares during such
ninety (90)&nbsp;days; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(vii) in any particular jurisdiction in which the Company would be required to execute a general consent to
service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3 <U>Company Registration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the
Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with the public offering of such securities (other than a registration relating solely to the sale of securities to participants in a
Company stock plan, a registration relating to a corporate reorganization or other transaction under Rule 145 of the Act, a registration on any form that does not include substantially the same information as would be required to be included in a
registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within ten (10)&nbsp;days
after mailing of such notice by the Company, the Company shall, subject to the provisions of Section&nbsp;1.5(e), use commercially reasonable efforts to cause to be registered under the Act all of the Registrable Securities that each such Holder has
requested to be registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) <U>Right to Terminate Registration</U>. The Company shall have the right to terminate or withdraw any
registration initiated by it under this Section&nbsp;1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall be borne by
the Company in accordance with Section&nbsp;1.7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.4 <U>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration</U>. In
case the Company shall receive from any Holder of the Registrable Securities then outstanding a written request or requests that the Company effect a registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and any related qualification or
compliance with respect to all or a part of the Registrable Securities owned by such Holder, the Company shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) promptly give written
notice of the proposed registration, and any related qualification or compliance, to all other Holders; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) use best efforts to
effect, as soon as practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders&#146; Registrable Securities as
are specified in such request, together with all or such portion of the Registrable Securities of any other Holders joining in such request as are specified in a written request given within twenty (20)&nbsp;days after receipt of such written notice
from the Company, provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section&nbsp;1.4: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(i) if Form <FONT STYLE="white-space:nowrap">S-3</FONT> is not available for such offering by the Holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to
sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than US$1,000,000; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(iii) in
the circumstances described in Sections 1.2(c)(iv) and 1.2(c)(vi); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(iv) prior to the earlier of (A)&nbsp;the five (5)&nbsp;year
anniversary of the date of this Agreement or (B)&nbsp;six (6)&nbsp;months after the effective date of the Initial Public Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c)
Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders;
provided, however, the provisions of Section&nbsp;1.2(c)(vi) shall apply to any registration pursuant to this Section&nbsp;1.4. Registrations effected pursuant to this Section&nbsp;1.4 shall not be counted as requests for registration effected
pursuant to Section&nbsp;1.2 or Section&nbsp;1.3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.5 <U>Obligations of the Company</U>. Whenever required under this Section&nbsp;1 to
effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) prepare and file
with the SEC a registration statement with respect to such Registrable Securities and use best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred eighty (180)&nbsp;days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that
(i)&nbsp;such <FONT STYLE="white-space:nowrap">180-day</FONT> period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common
Stock (or other securities) of the Company; and (ii)&nbsp;in the case of any registration of Registrable Securities on Form <FONT STYLE="white-space:nowrap">S-3</FONT> which are intended to be offered on a continuous or delayed basis, such <FONT
STYLE="white-space:nowrap">180-day</FONT> period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an
offering on a continuous or delayed basis, and provided further that applicable rules under the Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which (I)&nbsp;includes any
prospectus required by Section&nbsp;10(a)(3) of the Act or (II)&nbsp;reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information
required to be included in (I)&nbsp;and (II)&nbsp;above to be contained in periodic reports filed pursuant to Section&nbsp;13 or 15(d) of the 1934 Act in the registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with
such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) furnish to each Holder (i)&nbsp;a draft copy of the registration statement, and (ii)&nbsp;such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as it may reasonably request in order to facilitate the disposition of Registrable Securities owned by it; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) use best efforts to register and qualify the securities covered by such registration statement under such other securities or
&#147;<U>blue sky</U>&#148; laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business, where not otherwise
required, or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Act; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(e) in the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. In
connection with any offering involving an underwriting of shares of the Company&#146;s capital stock, the Company shall not be required to include any of the Holders&#146; securities in such underwriting unless they accept the terms of the
underwriting as agreed upon between the Company and the underwriters selected by a majority of the Holders and enter into an underwriting agreement in customary form with the underwriters. If the total amount of securities, including Registrable
Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then
subject to Section&nbsp;1.2 above, the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, that the underwriters determine in their sole discretion will not jeopardize the
success of the offering (the securities so included to be apportioned pro rata among the selling stockholders according to the total amount of securities entitled to be included therein owned by each selling stockholder or in such other proportions
as shall mutually be agreed to by such selling stockholders, except that no Registrable Securities of Holders shall be excluded until all Common Stock held by directors, officers and employees of the Company have been excluded), but in no event
shall the amount of securities of the selling Holders included in the offering be reduced below thirty-three percent (33%) of the total amount of securities included in such offering, unless such offering is the Initial Public Offering of the
Company&#146;s securities, in which case the selling stockholders may be excluded if the underwriters make the determination described above and no other stockholder&#146;s securities are included. For purposes of the preceding parenthetical
concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a partnership, limited liability company or corporation, the partners, retired partners, members, retired members and stockholders of such
Holder, or the estates and family members of any such partners, retired partners, members, retired members, and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single &#147;<U>selling stockholder,</U>&#148; and any
pro rata reduction with respect to such &#147;<U>selling stockholder</U>&#148; shall be based upon the aggregate amount of Registrable Securities owned by all entities and individuals included in such &#147;<U>selling stockholder,</U>&#148; as
defined in this sentence; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(f) notify each Holder of Registrable Securities covered by such registration statement, at any time when a
prospectus relating thereto is required to be delivered under the Act, of (i)&nbsp;the issuance of any stop order by the SEC in respect of such registration statement, or (ii)&nbsp;the happening of any event as a result of which the prospectus
included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of
the circumstances then existing; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(g) cause all such Registrable Securities registered pursuant hereunder to be listed on each securities
exchange on which similar securities issued by the Company are then listed; provided that in the case of a registration effected pursuant to Section&nbsp;1.2 above, which registration constitutes the Initial Public Offering, the Registrable
Securities shall be listed on a national securities exchange or the NASDAQ Global Market system; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(h) provide a transfer agent and
registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.6 <U>Information from Holder</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section&nbsp;1 with respect to
the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be reasonably
required to effect the registration of such Holder&#146;s Registrable Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) The Company shall have no obligation with respect
to any registration requested pursuant to Section&nbsp;1.2 if, due to the operation of subsection 1.6(a), the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not
equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company&#146;s obligation to initiate such registration as specified in subsection 1.2(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.7 <U>Expenses of Registration</U>. All expenses other than underwriting discounts and commissions incurred in connection with
registrations, filings or qualifications pursuant to Sections 1.2 and 1.3, including, without limitation, all registration, filing and qualification fees (including &#147;<U>blue sky</U>&#148; fees), printers&#146; and accounting fees, fees and
disbursements of counsel for the Company (including fees and disbursements of counsel for the Company in its capacity as counsel to the selling Holders hereunder; if Company counsel does not make itself available for this purpose, the Company will
pay the reasonable fees and disbursements of one counsel for the selling Holders not to exceed US$50,000) shall be borne by the Company. Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any registration
proceeding begun pursuant to Sections 1.2 and 1.4 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear
such expenses pro rata based upon the number of Registrable Securities that were to be registered in the withdrawn registration), provided, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the
condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the
Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section&nbsp;1.2 or 1.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.8
<U>Delay of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or
implementation of this Section&nbsp;1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.9 <U>Indemnification</U>. In the event any Registrable Securities are included in a
registration statement under this Section&nbsp;1: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) To the extent permitted by law, the Company will indemnify and hold harmless each
Holder, the partners or officers, directors and stockholders of each Holder, legal counsel and accountants for each Holder, any underwriter (as defined in the Act) for such Holder and each person, if any, who controls such Holder or underwriter,
within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act or any state securities laws, insofar as such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a
&#147;<U>Violation</U>&#148;): (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii)&nbsp;the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii)&nbsp;any violation or alleged violation by the
Company of the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state securities laws; and the Company will reimburse each such Holder, partner, officer, director, stockholder,
counsel, accountant, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action as such expenses are incurred;
provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission based upon written information furnished to the Company
by such Holder, any of such Holder&#146;s officers, directors, partners, legal counsel or accountants, any person controlling such Holder, such underwriter or any person who controls any such underwriter, and stated to be specifically for use
therein; and provided, further that the indemnity agreement contained in this Section&nbsp;1.9(a)&nbsp;shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the
consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that
occurs in reliance upon and in conformity with information furnished expressly for use in connection with such registration by any such Holder, partner, officer, director, stockholder, counsel, accountant, underwriter or controlling person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, each selling Holder, on a several and not joint basis, will indemnify and hold harmless the Company, each
of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, any underwriter, any other stockholder selling securities in such registration statement
and any controlling person of any such underwriter or other stockholder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act or any state
securities laws, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation (but excluding clause (iii)&nbsp;of the definition thereof), in each case to the extent (and only to
the extent) that such Violation occurs in reliance upon and in conformity with information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any person intended to be indemnified
pursuant to this Section&nbsp;1.9(b) for any legal or other expenses reasonably incurred by such person in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement
contained in this Section&nbsp;1.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, provided that in no event shall any indemnity
under this Section&nbsp;1.9(b) exceed the net proceeds from the offering received by such Holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this Section&nbsp;1.9 of actual
knowledge of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section&nbsp;1.9, deliver to the indemnifying party a
written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense
thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate
counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between
such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability
to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section&nbsp;1.9 to the extent of such prejudice, but the omission to so deliver written notice to the indemnifying party will not
relieve it of any liability that it may have to any indemnified party otherwise than under this Section&nbsp;1.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) If the
indemnification provided for in this Section&nbsp;1.9 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying
party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect
the relative fault of and the relative benefits received by the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or
expense, as well as any other relevant equitable considerations, provided that no person guilty of fraud shall be entitled to contribution. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties&#146; relative
intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. The relative benefits received by the indemnifying party and the indemnified party shall be determined by reference to the net proceeds and
underwriting discounts and commissions from the offering received by each such party. In no event shall any contribution under this Section&nbsp;1.9(d) exceed the net proceeds from the offering received by such Holder, less any amounts paid under
subsection 1.9(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(f) The obligations of the Company and Holders under this Section&nbsp;1.9 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section&nbsp;1, and otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.10 <U>Reports Under Securities Exchange Act of
1934</U>. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the Company agrees to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) make and keep
public information available, as those terms are understood and defined in SEC Rule 144, at all times and after ninety (90)&nbsp;days following the effective date of the Initial Public Offering; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) take such action, including the voluntary registration of its Common Stock under
Section&nbsp;12 of the 1934 Act, as is necessary to enable the Holders to utilize Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the
fiscal year in which the first registration statement filed by the Company for the offering of its securities to the general public is declared effective; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon written request (i)&nbsp;a written statement
by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90)&nbsp;days after the effective date of the Initial Public Offering), the Act and the 1934 Act (at any time after it has become subject
to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form <FONT STYLE="white-space:nowrap">S-3</FONT> (at any time after it so qualifies), (ii)&nbsp;a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by the Company, and (iii)&nbsp;such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling
of any such securities without registration or pursuant to such form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.11 <U>Assignment of Registration Rights</U>. The rights to cause
the Company to register Registrable Securities pursuant to this Section&nbsp;1 may be assigned (but only with all related obligations) by a Holder to a transferee, member, retired member or assignee of such securities that (i)&nbsp;is a subsidiary,
affiliate, parent, partner, limited partner, retired partner, member, retired member, or stockholder of a Holder, (ii)&nbsp;is a Holder&#146;s immediate family member (spouse or child) or trust for the benefit of an individual Holder, or
(iii)&nbsp;after such assignment or transfer, holds at least 500 shares of Registrable Securities (subject to appropriate adjustment for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares),
provided: (a)&nbsp;the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being
assigned; (b)&nbsp;such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including without limitation the provisions of Section&nbsp;1.13 below; and (c)&nbsp;such assignment shall be
effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act. For the purposes of determining the number of shares of Registrable Securities held by a
transferee or assignee, the holdings of transferees and assignees of a partnership who are partners or retired partners of such partnership (including spouses and ancestors, lineal descendants and siblings of such partners or spouses who acquire
Registrable Securities by gift, will or intestate succession) shall be aggregated together and with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the partnership, and the holdings of transferees and assignees of a limited liability company who are members or retired members of such limited liability company (including spouses and
ancestors, lineal descendants and siblings of such members or spouses who acquire Registrable Securities by gift, will or intestate succession) shall be aggregated together and with the limited liability company; provided that all assignees and
transferees who would not qualify individually for assignment of registration rights shall have a single <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for the purpose of exercising any rights,
receiving notices or taking any action under this Section&nbsp;1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.12 <U>Limitations on Subsequent Registration Rights</U>. From and
after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least 75% of the outstanding Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of
the Company that would allow such holder or prospective holder (a)&nbsp;to include such securities in any registration filed under Section&nbsp;1.3 hereof, unless under the terms of such agreement, such holder or prospective holder may include such
securities in any such registration only to the extent that the inclusion of such securities will not reduce the amount of the Registrable Securities of the Holders that are included or (b)&nbsp;to make a demand registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.13 &#147;<U>Market <FONT STYLE="white-space:nowrap">Stand-Off&#148;</FONT> Agreement</U>. Each Holder hereby agrees that it will not,
directly or indirectly, without the prior written consent of the Company and the managing underwriter, during the period commencing on the date of the final prospectus relating to the initial public offering by the Company and ending on the date
specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180)&nbsp;days) (i)&nbsp;lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock held immediately before
the effective date of the registration statement for such offering, or (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any
such transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise; provided, however, that if and to the extent that Rule 2241 of the Financial Industry
Regulatory Authority, Inc. (&#147;<U>FINRA</U>&#148;) would apply to a FINRA member publishing or otherwise distributing a research report, or making a public appearance, concerning the Company, if (1)&nbsp;during the last 17 days of such <FONT
STYLE="white-space:nowrap">180-day</FONT> period, the Company releases earnings results or announces material news or a material event or (2)&nbsp;prior to the expiration of such <FONT STYLE="white-space:nowrap">180-day</FONT> period, the Company
announces that it will release earnings results during the <FONT STYLE="white-space:nowrap">15-day</FONT> period following the last day of the initial <FONT STYLE="white-space:nowrap">180-day</FONT> period, then in each case such <FONT
STYLE="white-space:nowrap">180-day</FONT> period will be automatically extended until the expiration of the <FONT STYLE="white-space:nowrap">18-day</FONT> period beginning on the date of release of the earnings results or the announcement of the
material news or material event, as applicable, unless the managing underwriter waives, in writing, such extension. The foregoing provisions of this Section&nbsp;1.13 shall not apply to the sale of any shares to an underwriter pursuant to an
underwriting agreement, and shall only be applicable to the Holders if all officers and directors and greater than one percent (1%) stockholders of the Company enter into similar agreements. The underwriters in connection with the initial public
offering by the Company are intended third party beneficiaries of this Section&nbsp;1.13 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto; further, each Holder hereby agrees to enter
into written agreement with such underwriters containing terms substantially equivalent to the terms of this Section&nbsp;1.13, and each Holder hereby agrees that such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underwriters shall be entitled to require each such Holder to enter into such a written agreement. Any discretionary waiver or termination of the restrictions of any or all of such agreements by
the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of
each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.14
<U>Termination of Registration Rights</U>. No Holder shall be entitled to exercise any right provided for in this Section&nbsp;1 after five (5)&nbsp;years following the consummation of a QIPO, as defined in the Restated Certificate or, as to any
Holder, such earlier time at which all Registrable Securities held by such Holder (and any affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144) can be sold in any ninety (90)&nbsp;day period without registration in
compliance with Rule 144 of the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Covenants of the Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Delivery of Financial Statements</U>. The Company shall deliver to each Investor: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) as soon as practicable, but in any event within one hundred eighty (180)&nbsp;days after the end of each fiscal year of the Company,
audited consolidated financial statements of the Company for the preceding fiscal year, including balance sheet of the Company and statement of stockholder&#146;s equity as of the end of such year, and a statement of cash flows of the Company and
its subsidiaries for such year, such <FONT STYLE="white-space:nowrap">year-end</FONT> financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles (&#147;<U>GAAP</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) as soon as practicable, but in any event within forty-five (45)&nbsp;days after the end of each quarter, unaudited consolidated financial
statements of the Company for the preceding quarter, including a consolidated income statement, a statement of cash flows, and a balance sheet as of the end of such quarter, all in reasonable detail; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) as soon as practicable, but in any event within thirty (30)&nbsp;days after the end of each calendar month, unaudited consolidated
financial statements of the Company for the preceding calendar month, including a consolidated income statement, a statement of cash flows, and a balance sheet as of the end of such calendar month, all in reasonable detail; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) as soon as practicable, but in any event at least thirty (30)&nbsp;days prior to the end of each fiscal year, a budget for the next
fiscal year, prepared on a monthly basis, including balance sheets, income statements and statements of cash flows for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(e) with respect to the financial statements called for in Sections 2.1(b) and 2.1(c), an instrument executed by the Chief Financial Officer
or President of the Company certifying that such financials were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the exception of footnotes and <FONT STYLE="white-space:nowrap">year-end</FONT>
adjustments that may be required by GAAP) and fairly present the financial condition of the Company and its results of operation for the period specified, subject to <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustment; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(f) such other information relating to the financial condition, business, prospects or
corporate affairs of the Company as such Investor or any assignee of such Investor may from time to time reasonably request, or promptly after transmission or occurrence (but in any event within 10 days), other reports, including any <FONT
STYLE="white-space:nowrap">non-routine</FONT> communications with stockholders or the financial community, the Company&#146;s accountants and business consultants, governmental agencies and authorities, any reports filed by the Company or its
officers, directors and representatives with any securities exchange or the SEC, to the extent not publicly available, and notice of any event which would have a significant effect on the Company&#146;s business prospects or financial condition or
on the Investors&#146; investments, provided, however, that the Company shall not be obligated under this Section&nbsp;2.1 to provide information that it deems in good faith to be a trade secret or similar confidential information, and provided
further that the Company may require the Investor to execute a confidentiality and nondisclosure agreement prior to disclosure of any such information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Inspection</U>. The Company shall permit each Investor, at such Investor&#146;s expense, to visit and inspect the Company&#146;s
properties, to examine its books of account and records and to discuss the Company&#146;s affairs, finances and accounts with its officers, all at such reasonable times as may be reasonably requested by the Investor; provided, however, that the
Company shall not be obligated pursuant to this Section&nbsp;2.2 to provide access to any information that it reasonably considers to be a trade secret or similar confidential information, and provided further that the Company may require the
Investor to execute a confidentiality and nondisclosure agreement prior to any such visit and inspection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Right of First
Offer</U>. Subject to the terms and conditions specified in this Section&nbsp;2.3, the Company hereby grants to each Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined). An Investor
shall be entitled to apportion the right of first offer hereby granted it among itself and its partners, members and affiliates in such proportions as it deems appropriate. Each time the Company proposes to offer any shares of, or securities
convertible into or exchangeable or exercisable for any shares of, any class of its capital stock (the &#147;<U>Shares</U>&#148;), the Company shall first make an offering of such Shares to each Investor in accordance with the following provisions:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) The Company shall deliver a notice in accordance with Section&nbsp;3.6 (the &#147;<U>Notice</U>&#148;) to each Investor stating
(i)&nbsp;its bona fide intention to offer such Shares, (ii)&nbsp;the number of such Shares to be offered, and (iii)&nbsp;the price and general terms upon which it proposes to offer such Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) By written notification received by the Company, within thirty (30)&nbsp;calendar days after receipt of the Notice, each Investor may
elect to purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred
Stock then held, by such Investor bears to the total number of shares of Common Stock of the Company issued or held, or issuable upon conversion of the Preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock then outstanding. The Company shall promptly, in writing, inform each Investor which purchases all the shares available to it (&#147;<U>Fully-Exercising Investor</U>&#148;) of any other
Investor&#146;s failure to do likewise. During the ten (10)&nbsp;day period commencing after receipt of such information, each Fully-Exercising Investor shall be entitled to obtain that portion of the Shares for which all Investors were entitled to
subscribe but which were not subscribed for by the Investors which is equal to the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of Preferred Stock then held, by such Fully-Exercising Investor
bears to the total number of shares of Common Stock issued and held, or issuable upon conversion of Preferred Stock then held, by all Fully-Exercising Investors who wish to purchase some of the unsubscribed shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) If all Shares that the Investors are entitled to obtain pursuant to Section&nbsp;2.3(b) are not elected to be obtained as provided in
Section&nbsp;2.3(b) hereof, the Company may, during the ninety (90)&nbsp;day period following the expiration of the period provided in Section&nbsp;2.3(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a
price not less than, and upon terms no more favorable to the offeree than those specified in the Notice. If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within
ninety (90)&nbsp;days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Investors in accordance herewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) The right of first offer in this Section&nbsp;2.3 shall not be applicable to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(i) the issuance of shares of securities pursuant to a split or subdivision of the outstanding shares of Common Stock or the determination of
holders of Common Stock entitled to receive a dividend or other distribution payable in additional shares of Common Stock or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly, additional
shares of Common Stock (hereinafter referred to as &#147;<U>Common Stock Equivalents</U>&#148;) without payment of any consideration by such holder for the additional shares of Common Stock or the Common Stock Equivalents (including the additional
shares of Common Stock issuable upon conversion or exercise thereof); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(ii) the issuance of any shares of Common Stock (or options or
rights to purchase shares of Common Stock) after the Series F Original Issue Date (as defined in the Restated Certificate), to employees, officers or directors of, or consultants or advisors to, the Company pursuant to current stock purchase plans
or current stock option plans, or pursuant to similar plans that are approved by the Requisite Holders pursuant to Article IV.B.6(p) of the Restated Certificate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(iii) any Common Stock Equivalents issued upon any conversion of shares of Series F Preferred Stock, Series E Preferred Stock, Series D
Preferred Stock, Series C Preferred Stock, Series B Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(iv) any Common Stock Equivalents issued as a dividend or distribution on shares of Series F Preferred Stock, Series E Preferred Stock,
Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock or Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Stock; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(v) the issuance of shares of Common Stock (A)&nbsp;in a QIPO, or (B)&nbsp;upon exercise of
warrants or rights granted to underwriters in connection with such a QIPO; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(vi) the issuance of shares of Series F Preferred Stock
pursuant to the Series F Stock Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, the right of first offer in this Section&nbsp;2.3 shall
not be applicable with respect to any Investor and any subsequent securities issuance, if (i)&nbsp;at the time of such subsequent securities issuance, the Investor is not an &#147;<U>accredited investor,</U>&#148; as that term is then defined in
Rule 501(a) under the Act, and (ii)&nbsp;such subsequent securities issuance is otherwise being offered only to accredited investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.4 <U>Board of Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) The Board of Directors shall meet at least quarterly, unless otherwise approved by a majority of the directors then serving on the Board
of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) Each of the Series E Preferred Directors, Series D Preferred Director and the Series C Preferred Directors (as defined
in that certain Amended and Restated Voting Agreement, dated on or about the date hereof) shall have the right to serve on any committee of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) The Company shall reimburse all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
expenses incurred by directors of the Board of Directors for attending meetings of the Board of Directors and performing their duties as directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.5 <U>Notice of Litigation</U>. The Company shall provide notice to the Holders promptly upon the filing of any material action, suit or
proceeding by or against the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.6 <U>No Investment Company</U>. The Company shall not become an &#147;<U>investment
company</U>&#148; or a company &#147;<U>controlled</U>&#148; by an &#147;<U>investment company,</U>&#148; within the meaning of the Investment Company Act of 1940, as amended. In the event the Company breaches the foregoing, the Company shall
forthwith notify the Investors and shall take immediate corrective action to remedy such breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.7 <U>Directors&#146; and
Officers&#146; Insurance</U>. The Company shall maintain from financially sound and reputable insurers directors and officers liability insurance in an amount and on terms and conditions satisfactory to the Board of Directors, and will use its
commercially reasonable efforts to cause such insurance policy to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.8 <U>Proprietary Information and Inventions Agreements</U>. The Company shall require all employees and consultants with access to
confidential information to execute and deliver a Proprietary Information and Inventions Agreement in substantially the form approved by the Board of Directors or a consulting agreement containing substantially similar proprietary rights assignment
and confidentiality provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.9 <U>Expenses of Counsel</U>. In the event of a transaction which is a Deemed Liquidation
Event (as defined in the Amended and Restated Voting Agreement of even date herewith among the Investors, the Company and the other parties named therein), the reasonable fees and disbursements, not to exceed $75,000, of one counsel for the
Investors (&#147;<U>Investor Counsel</U>&#148;), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would constitute a Deemed Liquidation Event, the Company
shall obtain the ability to share with the Investor Counsel (and such counsel&#146;s clients) and shall share the confidential information (including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters
of intent and other transaction documents and related noncompete, employment, consulting and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or when aggregated with others would
constitute the Deemed Liquidation Event. The Company shall be obligated to share (and cause the Company&#146;s counsel and investment bankers to share) such materials when distributed to the Company&#146;s executives and/or any one or more of the
other parties to such transaction(s). In the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense (or common interest) agreement or other arrangement to enhance the ability of the parties to
protect their communications and other reviewed materials under the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance
reasonably acceptable to Investor Counsel and the Company&#146;s counsel. In the event that one or more of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint
defense (or common interest) agreement in order to receive such information, then the Company shall share whatever information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable
Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the clients of Investor Counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.10 <U>Right to Conduct Activities</U>. The Company hereby agrees and acknowledges that ABG-ColdGen Limited, ABG II-ColdGen Limited, ABG <FONT
STYLE="white-space:nowrap">WTT-CG</FONT> Limited, Acorn Bioventures, L.P., Acorn Bioventures 2, L.P., Longitude Venture Partners IV, L.P., Decheng Capital Global Life Sciences Fund IV, L.P., RA Capital Management, L.P., Foresite Capital Fund VI,
L.P., BVF Partners L.P. and Avidity Private Master Fund I LP (together with their respective Affiliates) (collectively, the &#147;<U>Funds</U>&#148;) are professional investment organizations, and as such review business plans and related
proprietary information of many enterprises, some of which may compete directly or indirectly with the Company&#146;s business (as currently conducted or as currently proposed to be conducted). Nothing in this Agreement shall preclude or in any way
restrict the Investors from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating in any particular enterprise whether or not such enterprise has products or services
which compete with those of the Company; and the Company hereby agrees that, to the extent permitted under applicable law, the Funds (and their Affiliates) shall not be liable to the Company for any claim arising out of, or based upon, (i)&nbsp;the
investment by the Funds (or their Affiliates) in any entity competitive with the Company, or (ii)&nbsp;actions taken by any partner, officer, employee or other representative of the Funds (or their Affiliates) to assist any such competitive company,
whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve
(x)&nbsp;any of the Investors from liability associated with the unauthorized disclosure of the Company&#146;s confidential information obtained pursuant to this Agreement, or (y)&nbsp;any director or officer of the Company from any liability
associated with his or her fiduciary duties to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.11 <U>Confidentiality</U>. Each Investor agrees that such Investor will keep confidential
and will not disclose, divulge, or use for any purpose (other than to monitor or make decisions with respect to its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including
notice of the Company&#146;s intention to file a registration statement), unless such confidential information (a)&nbsp;is known or becomes known to the public in general (other than as a result of a breach of this Section&nbsp;2.11 by such
Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company&#146;s confidential information, or (c)&nbsp;is or has been made known or disclosed to such Investor by a third party without a breach of
any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i)&nbsp;to its attorneys, accountants, consultants, and other professionals to the extent
reasonably necessary to obtain their services in connection with monitoring its investment in the Company; (ii)&nbsp;to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by
the provisions of this Section&nbsp;2.11; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such person that such information is
confidential and directs such person to maintain the confidentiality of such information; or (iv)&nbsp;as may otherwise be required by law, regulation, rule, court order or subpoena, provided that such Investor promptly notifies the Company of such
disclosure and takes reasonable steps to minimize the extent of any such required disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.12 <U>Termination of Certain
Covenants</U>. The covenants set forth in this Section&nbsp;2, except for Section&nbsp;2.9, shall terminate and be of no further force or effect upon the consummation of a QIPO or at such time as the Company is required to file reports pursuant to
Section&nbsp;13 or 15(d)&nbsp;of the 1934 Act. This Agreement shall terminate and be of no further force or effect upon the consummation of a transaction or series of related transactions which are deemed to be a Liquidation Event of the Company
pursuant to the Restated Certificate, as such Restated Certificate may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>Subsequent Closing Investors</U>. Upon the sale of shares of Series F Preferred Stock to new Investors in accordance with the
subsequent closing provisions of Section&nbsp;1.3 of the Series F Purchase Agreement, the Company, without prior action on the part of any Investor, shall require each such Investor to execute and deliver this Agreement. Each such Investor, upon
execution and delivery of this Agreement, shall be deemed an &#147;Investor&#148; hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Successors and Assigns</U>. Except
as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing
in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Governing Law; Venue</U>. This Agreement is to be construed in accordance with and
governed by the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of
the parties. In the event of any dispute arising out of or relating to this Agreement, such dispute shall be resolved solely and exclusively by confidential binding arbitration with the Irvine, California branch of JAMS (&#147;<U>JAMS</U>&#148;) to
be governed by JAMS&#146; Commercial Rules of Arbitration applicable at the time of the commencement of the arbitration (the &#147;<U>JAMS Rules</U>&#148;) and heard before on arbitrator. The parties shall attempt to mutually select the arbitrator.
In the event they are unable to mutually agree, the arbitrator shall be selected by the procedures prescribed by the JAMS Rules. Each party shall bear its own attorneys&#146; fees, expert witness fees, and costs incurred in connection with any
arbitration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5 <U>Titles and Subtitles</U>. The titles and
subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.6 <U>Notices</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) All
notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i)&nbsp;personal delivery to the party to be notified; (ii)&nbsp;when sent, if
sent by electronic mail during the recipient&#146;s normal business hours, and if not sent during normal business hours, then on the recipient&#146;s next business day; (iii)&nbsp;five (5) days after having been sent by registered or certified mail,
return receipt requested, postage prepaid; or (iv)&nbsp;one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying <FONT STYLE="white-space:nowrap">next-day</FONT> delivery,
with written verification of receipt. All communications shall be sent to the respective parties at their email address or address as set forth on the signature page or <U>Schedule A</U> hereto, or in any case to such email address or address as
subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;3.6</U>. If notice is given to the Company, a copy (which copy shall not constitute notice) shall also be sent to Latham&nbsp;&amp; Watkins LLP,
12670 High Bluff Drive, San Diego, CA 92130, Attention: Cheston J. Larson and Cheston.larson@lw.com, and if notice is given to the Investors, a copy (which copy shall not constitute notice) shall also be sent to Gunderson Dettmer Stough Villeneuve
Franklin&nbsp;&amp; Hachigian, LLP, 3570 Carmel Mountain Rd, San Diego, CA 92130, Attention: Jonathan Spencer and jspencer@gunder.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) <U>Consent to Electronic Notice</U>. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General
Corporation Law (the &#147;<U>DGCL</U>&#148;), as amended or superseded from time to time, by electronic transmission pursuant to Section&nbsp;232 of the DGCL (or any successor thereto) at the electronic mail address set forth below
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Investor&#146;s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of
electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted electronic notice shall be
ineffective and deemed to not have been given. Each Investor agrees to promptly notify the Company of any change in such stockholder&#146;s electronic mail address, and that failure to do so shall not affect the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.7 <U>Expenses</U>. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party
shall be entitled to reasonable attorney&#146;s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.8 <U>Amendments and Waivers</U>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of (a)&nbsp;the Company and (b)&nbsp;the holders of at least 75% of the Registrable Securities then outstanding; provided,
however, that no amendment or waiver which adversely affects the holders of less than a majority of the Registrable Securities in a manner different than the holders of a majority of the Registrable Securities shall be affected without the prior
written consent of at a majority of the holders in interest of such Registrable Securities so affected. Notwithstanding the foregoing, in the event that (a)&nbsp;the provisions of Section&nbsp;2.3 are waived in accordance with this Section&nbsp;3.8
in respect of a future sale by the Company of its Shares, and (b)&nbsp;one or more Investors or its affiliates purchases securities in such offering, then any other Investor who did not consent to such waiver shall be permitted to purchase up to the
same percentage (not to exceed 100%) of its pro rata share of the Shares in such offering as the percentage of the pro rata share of the Shares so purchased by the Investor purchasing the largest portion of such Investor&#146;s pro rata share in
such offering. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities, each future holder of all such Registrable Securities and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.9 <U>Severability</U>. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall
be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.10 <U>Aggregation of Stock</U>. All shares of Registrable Securities held or acquired by entities advised by the same investment adviser
and affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such affiliated entities or persons may apportion such rights among themselves in any manner they
deem appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.11 <U>Entire Agreement</U>. This Agreement and the documents referred to herein constitute the entire agreement
among the parties with respect to the subject matter hereof and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein or therein. Upon the
effectiveness of this Agreement, the Prior Agreement shall be superseded and replaced in its entirety by this Agreement and shall be of no further force or effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&#8195;*&#8195;* </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arthur Kuan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Arthur Kuan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">400 Spectrum Center Drive, Suite 2040</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Irvine, CA 92618 U.S.A.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FORESITE CAPITAL FUND V, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: Foresite Capital Management V, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dennis D. Ryan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Dennis D. Ryan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FORESITE CAPITAL OPPORTUNITY FUND V, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: Foresite Capital Opportunity Management V, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dennis D. Ryan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Dennis D. Ryan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FORESITE CAPITAL FUND VI, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: Foresite Capital Management VI, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dennis D. Ryan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Dennis D. Ryan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">900 Larkspur Landing Circle, Suite 150</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Larkspur, CA 94939</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>TCG CROSSOVER FUND I, L.P.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: TCG Crossover GP I, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Its General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Chen Yu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Chen Yu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Managing Member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">TCG Crossover Management, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">705 High Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Palo Alto, CA 94301</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: Craig Skaling</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE FUND, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE FUND II, L.P</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Lampert</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOTECHNOLOGY VALUE TRADING FUND OS LP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MSI BVF SPV, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Lampert</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS LP</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: President BVF Inc., General Partner of BVF Partners L.P., itself <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for MSI BVF SPV, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BVF Partners LP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">44 Montgomery
Street 40th FL</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">San Francisco CA 94104</TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>AVIDITY PRIVATE MASTER FUND I LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: Avidity Capital Partners Fund (GP) LP, its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: Avidity Capital Partners (GP) LLC, its general partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Gregory</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Michael Gregory</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Managing Member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">c/o Avidity Partners Management LP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2828 N. Harwood St., Suite 1220</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dallas, TX 75201</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Michael Gregory; Andrew So</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>JANUS HENDERSON HORIZON FUND&#151;BIOTECHNOLOGY FUND</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: Janus Henderson Investors US LLC, its investment advisor</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew Acker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Andrew Acker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: Janus Henderson Investors US LLC, its investment advisor</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andrew Acker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Andrew Acker</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">151 Detroit Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denver, Colorado 80206 USA</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">With a copy to (which shall not constitute notice):</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stradley Ronon Stevens&nbsp;&amp; Young, LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2005 Market Street, Suite 2600</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philadelphia, PA 19103</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Kevin Kundra</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">kkundra@stradley.com</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B><FONT STYLE="white-space:nowrap">ABG-COLDGEN</FONT> LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ YEH Shan-ju</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: YEH Shan-ju</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ABG <FONT STYLE="white-space:nowrap">II-COLDGEN</FONT> LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ YEH Shan-ju</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: YEH Shan-ju</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ABG <FONT STYLE="white-space:nowrap">WTT-CG</FONT> LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ YEH Shan-ju</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: YEH Shan-ju</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">c/o Unit 3002-3004</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">30/F, Gloucester Tower</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Landmark</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">15 Queen&#146;s
Road</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Central, Hong Kong</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ABUNDANT SUPPLY GLOBAL LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Hong Fang Song</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Hong Fang Song</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Vistra Corporate Services Centre</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Wickhams Cay II, Road Town</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tortola, VG1110</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">British Virgin Islands</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTOR:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ACORN BIOVENTURES, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: ACORN CAPITAL ADVISORS GP, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anders Hove</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Anders Hove</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ACORN BIOVENTURES 2, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By: ACORN CAPITAL ADVISORS 2 GP, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Its: General Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Anders Hove</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Anders Hove</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Member</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contact information:</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acorn Bioventures, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acorn Bioventures 2, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">C/O Acorn Capital Advisors, LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Att: Anders Hove</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">420 Lexington Avenue, Suite 2626</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10170</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">With a copy (which shall not constitute notice) to:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schulte Roth&nbsp;&amp; Zabel LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">919 Third Avenue</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10022</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attn: Michael Flynn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> michael.flynn@srz.com</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>AMPLEWOOD RESOURCES LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Chan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Marc Chan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unit 21E, 21F, United Centre, 95 Queensway,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Admiralty, Hong Kong, CHN</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ANGELES DIRECT EQUITY FUND 1, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By: its General Partner,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Angeles Direct Equity Fund 1, LP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Rosen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Michael Rosen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">429 Santa Monica Blvd, Suite 650</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Santa Monica, CA, 90401</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>CHARMING JADE LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Hong Fang Song</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Hong Fang Song</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Ritter House</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Wickhams Cay II</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">PO Box 3170</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Road Town, Tortola VG1110</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">British Virgin Islands</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By its General Partner,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decheng Capital Management IV (Cayman), LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Xiangmin Cui</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Xiangmin Cui</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3000 Sand Hill Road</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Building 2, Suite 110</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ERCT LIFE SCIENCES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sibel Oz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Sibel Oz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">PO Box 1200, Montclair NJ, 07042</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>GAVIN RESOURCES LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ LEE King Yue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>LEE King Yue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">72/76F., Two International Finance Centre,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">8 Finance Street, Central, Hong Kong</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>KISSEI PHARMACEUTICAL CO., LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mutsuo Kanzawa</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mutsuo Kanzawa</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="white-space:nowrap">19-48</FONT> Yoshino, Matsumoto-City</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Nagano-Prefecture, <FONT STYLE="white-space:nowrap">399-8710,</FONT> Japan</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LEPU HOLDINGS LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Xia Zhang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Xia Zhang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director and Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Vistra Corporate Services Centre</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Wickhams Cay II, Road Town</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tortola, VG1110, British Virgin Islands</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LONGITUDE VENTURE PARTNERS IV, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>By: Longitude Capital Partners IV, LLC, its</B> <B>General Partner</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Patrick Enright</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patrick Enright</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LONGITUDE PRIME FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By: Longitude Prime Partners, LLC, its General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Patrick Enright</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patrick Enright</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">2740 Sand Hill Rd, Second Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Menlo Park, CA 94025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With a copy (which shall not itself constitute</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">notice) to:</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3175 Hanover Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94304</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Mark P. Tanoury</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email:
tanourymp@cooley.com</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MALIN LIFE SCIENCES HOLDINGS LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Darragh Lyons</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Darragh Lyons</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">The Lennox Building</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">50 Richmond Street South</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dublin 2</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D02 FK02</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ireland</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PALM DRIVE CAPITAL II LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By: Palm Drive Capital II GP LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>its General Partner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By: Palm Drive Capital LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>its Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Seamon Chan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Seamon Chan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">54 W. 21st St Suite 807</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">New York, NY, 10010</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PEI MIN LIU</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Pei Min Liu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Pei Min Liu</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">30C Tower 3, Larvotto, 8 Apleichau Praya Road, Apleichau, Hong Kong</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PERSEVERANCE CG LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ben Shyong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Ben Shyong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PERSEVERANCE CAPITAL MANAGEMENT LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ben Shyong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Ben Shyong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">600 N Broad St Ste 5 #2122</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Middletown, DE 19709</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PERSEVERANCE FUND LLC&#151;SERIES 1</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>By: Perseverance Investments LLC, its<BR>Managing member</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ben Shyong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Ben Shyong</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Title: Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Perseverance Fund LLC&#151;Series 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Canopy</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">8 The Green, Suite
#13283</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Dover, Delaware, 19901, United States</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL HEALTHCARE FUND, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By: RA Capital Healthcare Fund GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Its: General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL NEXUS FUND III, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By: RA Capital Nexus Fund III GP, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Its: General Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Rajeev Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">RA Capital Management, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 Berkeley Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">18<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> Floor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, MA 02116</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Attn: General Counsel</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>SHINY CROWN LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Yulan Su</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name: Yulan Su</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6F, No.&nbsp;11, Lane 186, <FONT STYLE="white-space:nowrap">Ren-Ai</FONT> Road,
<FONT STYLE="white-space:nowrap">Yong-He</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">District, New Taipei City, TWN</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INVESTOR</B>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>SLEEPING BEAUTY LIMITED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Cheng Ying Pin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Name: Cheng Ying Pin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title: Sole Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">10F, No.337, Fuxing North Road</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Song-shan&nbsp;Dist. Taipei City, Taiwan 10544</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTOR</B>:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SONG HONG FANG</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Song Hong Fang</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTOR</B>:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SUPER STRATEGY LIMITED</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ KaiYuan Kuo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KaiYuan Kuo</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16F, 325 JenAi Road, Section&nbsp;4</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taipei, TWN</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors&#146;
Rights Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INVESTOR</B>:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>WELLCHAMP FUND LIMITED</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Ronald Yan Tak Angus Cheng</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ronald Yan Tak Angus Cheng</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">804A, 81F, Worldwide House,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">19 Des Voeux Road Central, Hong Kong</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Central Hong Kong, CHN</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> CG O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> I<SMALL>NVESTORS</SMALL>&#146; R<SMALL>IGHTS</SMALL>
A<SMALL>GREEMENT</SMALL> </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE OF INVESTORS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>Investor Names</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Aaron <FONT STYLE="white-space:nowrap">Chi-Yu</FONT> Ni</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ABG II-ColdGen Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ABG <FONT STYLE="white-space:nowrap">WTT-CG</FONT> Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ABG-ColdGen Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abundant Supply Global Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Acorn Bioventures 2, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Acorn Bioventures, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aestas Capital LLC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">AIG DECO Fund II, LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alex Wah Hin Yeung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amazing Key Investments Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">American Estate&nbsp;&amp; Trust, LC FBO Philip Bendler&#146;s IRA</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amplewood Resources Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Angeles Direct Equity Fund 1 LP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Avidity Private Master Fund I LP</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Best Prosper Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Biotechnology Value Fund, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Biotechnology Value Fund II, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Biotechnology Value Trading Fund OS LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">MSI BVF SPV, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charming Jade Limited</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Chih-Wei Wu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Danhua Capital II LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Decheng Capital Global Life Sciences Fund IV, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">ERCT Life Sciences LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Focus Way Developments Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Focus Way Developments Limited</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foresite
Capital Fund V, L.P.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foresite Capital Opportunity Fund V, L.P.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Foresite Capital Fund VI, L.P.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Fortress International Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Freedom Enterprises Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Gavin Resources Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Hank CK Wuh</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><U>Investor Names</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Ipolis Commercial Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Janus Henderson Horizon Fund&#151;Biotechnology Fund</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Janus Henderson Biotech Innovation Master Fund Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Jason Kung Yi Koo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Jennifer <FONT STYLE="white-space:nowrap">Cho-Chun</FONT> Lee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Jordon Wang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Keen Browne</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Kissei Pharmaceutical Co., Ltd.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Kuang-Hui Pai</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Lepu Holdings Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Longitude Venture Partners IV, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Longitude Prime Fund, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Longling Capital Ltd</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Lyra Capital Management Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Malin Life Sciences Holdings Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Noble Eagle Holdings Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Palm Drive Capital II LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Panlabs Biologics Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Pei Min Liu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Pentepebble Holdings Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Perseverance Capital Management LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Perseverance CG LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Perseverance Fund LLC&#151;Series 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">PRSS Capital Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">RA Capital Healthcare Fund, LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">RA Capital Nexus Fund III, LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Rick Delamarter</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Shiny Crown Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Shu Fai So</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Sleeping Beauty Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Song Hong Fang</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Spring Investments Holding LP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Super Strategy Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Tanya Marie Lee</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">TCG Crossover Fund I, L.P.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Visual Systems International Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">War Capital LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Wellchamp Fund Limited</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Zen Spirit Limited</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015
EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Purposes of the Plan</U>. The purposes of this Plan are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to attract and retain the best available personnel for positions of substantial responsibility,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide additional incentive to Employees, Directors and Consultants, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to promote the success of the Company&#146;s business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options and Restricted Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Definitions</U>. As used herein, the following definitions will apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Administrator</U>&#148; means the Board or any of its Committees as will be administering the Plan, in accordance with
Section&nbsp;4 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Applicable Laws</U>&#148; means the requirements relating to the administration of equity-based
awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where
Awards are, or will be, granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Award</U>&#148; means, individually or collectively, a grant of Options or
Restricted Stock under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Award Agreement</U>&#148; means the written or electronic agreement setting forth the terms
and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Board</U>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Change in Control</U>&#148; means the occurrence of any of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Change in Ownership of the Company</U>. A change in the ownership of the Company which occurs on the date that any one person, or more
than one person acting as a group (&#147;Person&#148;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than 50% of the total voting power of the stock of the Company, except that
any change in the ownership of the stock of the Company as a result of a private financing of the Company that is approved by the Board will not be considered a Change in Control; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Change in Effective Control of the Company</U>. If the Company has a class of securities registered pursuant to Section&nbsp;12 of
the Exchange Act, a change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12)&nbsp;month period by Directors whose appointment or election is not endorsed by a
majority of the members of the Board prior to the date of the appointment or election. For purposes of this clause (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by
the same Person will not be considered a Change in Control; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Change in Ownership of a Substantial Portion of the
Company&#146;s Assets</U>. A change in the ownership of a substantial portion of the Company&#146;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12)&nbsp;month period ending on the date of the most
recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition
or acquisitions. For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For purposes of this definition, persons will be considered to be acting as a group if they are owners of a corporation that enters into
a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless
the transaction qualifies as a change in control event within the meaning of Code Section&nbsp;409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has
been promulgated or may be promulgated thereunder from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Further and for the avoidance of doubt, a transaction will not
constitute a Change in Control if: (i)&nbsp;its sole purpose is to change the state of the Company&#146;s incorporation, or (ii)&nbsp;its sole purpose is to create a holding company that will be owned in substantially the same proportions by the
persons who held the Company&#146;s securities immediately before such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Code</U>&#148; means the Internal
Revenue Code of 1986, as amended. Reference to a specific section of the Code or regulation thereunder will include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future
legislation or regulation amending, supplementing or superseding such section or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Committee</U>&#148; means a
committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or a duly authorized committee of the Board, in accordance with Section&nbsp;4 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Common Stock</U>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#147;<U>Company</U>&#148; means CG Oncology, Inc., a Delaware corporation, or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<U>Consultant</U>&#148; means any natural person, including an advisor, engaged by the Company or a Parent or Subsidiary to render
bona fide services to such entity, provided the services (i)&nbsp;are not in connection with the offer or sale of securities in a capital-raising transaction, and (ii)&nbsp;do not directly promote or maintain a market for the Company&#146;s
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<U>Director</U>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) &#147;<U>Disability</U>&#148; means total and permanent disability as defined in Section&nbsp;22(e)(3) of the Code, provided that in the
case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> standards
adopted by the Administrator from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) &#147;<U>Employee</U>&#148; means any person who is a
<FONT STYLE="white-space:nowrap">common-law</FONT> employee of the Company or any Parent or Subsidiary of the Company. Neither service as a Director nor payment of a director&#146;s fee by the Company will be sufficient to constitute
&#147;employment&#148; by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) &#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) &#147;<U>Exchange Program</U>&#148; means a program under which (i)&nbsp;outstanding Awards are surrendered or cancelled in exchange for
awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash, (ii)&nbsp;Participants would have the opportunity to transfer any outstanding Awards to a financial institution or
other person or entity selected by the Administrator, and/or (iii)&nbsp;the exercise price of an outstanding Award is increased or reduced. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) &#147;<U>Exercise Price</U>&#148; means the amount for which one Share may be purchased upon exercise of an Option, as specified by
the Board in the applicable Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) &#147;<U>Fair Market Value</U>&#148; means, as of any date, the value of Common Stock
determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) If the Common Stock is listed on any established stock exchange or a national market system, including without
limitation the New York Stock Exchange, the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market of The NASDAQ Stock Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if
no sales were reported) as quoted on such exchange or system on the day of determination, as reported in <I>The Wall Street Journal</I> or such other source as the Administrator deems reliable; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the Common Stock is regularly quoted by a recognized securities dealer but selling
prices are not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for the Common Stock on the day of determination (or, if no bids and asks were reported on that date, as applicable, on the last
trading date such bids and asks were reported), as reported in <I>The Wall Street Journal </I>or such other source as the Administrator deems reliable; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the
Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if the determination date for the Fair Market Value occurs on a weekend or holiday, the
Fair Market Value will be the price as determined in accordance with subsections (i)&nbsp;through (iii) above (as applicable) on the next business day, unless otherwise determined by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) &#147;<U>Incentive Stock Option</U>&#148; means an Option that by its terms qualifies and is otherwise intended to qualify as an incentive
stock option within the meaning of Section&nbsp;422 of the Code and the regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) &#147;<U>Nonstatutory
Stock Option</U>&#148; means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u)
&#147;<U>Option</U>&#148; means a stock option granted pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) &#147;<U>Parent</U>&#148; means a &#147;parent
corporation,&#148; whether now or hereafter existing, as defined in Code Section&nbsp;424(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(w) &#147;<U>Participant</U>&#148; means
the holder of an outstanding Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) &#147;Period of Restriction&#148; means the period during which the transfer of Shares of
Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of
other events as determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(y) &#147;<U>Plan</U>&#148; means this 2015 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(z) &#147;<U>Restricted Stock</U>&#148; means Shares issued pursuant to an Award of Restricted Stock under Section&nbsp;7 of the Plan, or
issued pursuant to the early exercise of an Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<U>Service Provider</U>&#148; means an Employee, Director or Consultant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<U>Service End Date</U>&#148; means date Participant is no longer actively providing services to the Company or any Parent or
Subsidiary (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#146;s engagement
agreement, if any). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<U>Share</U>&#148; means a share of the Common Stock, as adjusted in accordance with Section&nbsp;10 of
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<U>Subsidiary</U>&#148; means a &#147;subsidiary corporation,&#148; whether now or hereafter existing, as defined in
Section&nbsp;424(f) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Stock Subject to the Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Subject to the Plan</U>. Subject to the provisions of Section&nbsp;10 of the Plan, the maximum aggregate number of Shares that
may be issued under the Plan is 44,128,766. The Shares may be authorized, but unissued, or reacquired Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Lapsed
Awards</U>. If an Award expires or becomes unexercisable without having been exercised in full, or if it is surrendered pursuant to an Exchange Program or, with respect to Restricted Stock, if it is forfeited to or repurchased by the Company due to
the failure to vest, then the unpurchased Shares (or, for Awards other than Options, the forfeited or repurchased Shares) which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated).
Shares that actually have been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution under the Plan; <I>provided, however,</I> that if Shares issued pursuant
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Awards of Restricted Stock are repurchased by the Company or are forfeited to the Company, such Shares will become available for future grant under the Plan. Shares used to pay the exercise
price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan. To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will
not result in reducing the number of Shares available for issuance under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Share Reserve</U>. The Company, during the term
of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Administration of the Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Procedure</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)
<U>Multiple Administrative Bodies</U>. Subject to specific delegation by the Board, different Committees with respect to different groups of Service Providers may administer the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Other Administration</U>. Other than as provided above, the Plan will be administered by (A)&nbsp;the Board or (B)&nbsp;a Committee,
which committee shall have been constituted to satisfy Applicable Laws and shall have been specifically delegated duties by the Board as an Administrator of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Powers of the Administrator</U>. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties
delegated by the Board to such Committee, the Administrator will have the authority, in its discretion: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to determine the Fair Market
Value; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to select the Service Providers to whom Awards may be granted hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to determine the number of Shares to be covered by each Award granted hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) to approve forms of Award Agreements for use under the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or
limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) to institute and determine the terms and conditions of an Exchange Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to <FONT
STYLE="white-space:nowrap">sub-plans</FONT> established for the purpose of satisfying applicable foreign laws or for qualifying for favorable tax treatment under applicable foreign laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) to modify or amend each Award, including but not limited to the discretionary authority to extend the post-termination exercisability
period of Awards and to extend the maximum term of an Option (subject to Section&nbsp;6(d) of the Plan regarding Incentive Stock Options); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) to allow Participants to satisfy tax withholding obligations in such manner as prescribed in Section&nbsp;12 of the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xi) to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted
by the Administrator; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xii) to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise
would be due to such Participant under an Award; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(xiii) to make all other determinations deemed necessary or advisable for
administering the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Effect of Administrator&#146;s Decision</U>. The Administrator&#146;s decisions, determinations and
interpretations will be final and binding on all Participants and any other holders of Awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Eligibility</U>. Nonstatutory Stock Options and Restricted Stock may be granted to
Service Providers. Incentive Stock Options may be granted only to Employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Stock Options</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Grant of Options</U>. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant
Options in such amounts as the Administrator, in its sole discretion, will determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Option Agreement</U>. Each Award of an
Option will be evidenced by an Award Agreement that will specify the exercise price, the term of the Option, the number of Shares subject to the Option, the exercise restrictions, if any, applicable to the Option, and such other terms and conditions
as the Administrator, in its sole discretion, will determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Limitations</U>. Each Option will be designated in the Award
Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. However, notwithstanding such designation, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable
for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be treated as Nonstatutory Stock Options. For purposes of
this Section&nbsp;6(c), Incentive Stock Options will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted, and
calculation will be performed in accordance with Code Section&nbsp;422 and Treasury Regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Term of
Option</U>. The term of each Option will be stated in the Award Agreement. In the case of an Incentive Stock Option, the term will be ten (10)&nbsp;years from the date of grant or such shorter term as may be provided in the Award Agreement.
Moreover, in the case of an Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%) of the total combined voting power of all classes of stock of the
Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five (5)&nbsp;years from the date of grant or such shorter term as may be provided in the Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Option Exercise Price and Consideration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Exercise Price</U>. The per share exercise price for the Shares to be issued pursuant to exercise of an Option will be determined by
the Administrator, subject to the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) In the case of an Incentive Stock Option </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) granted to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing more than ten
percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than one hundred ten percent (110%) of the Fair Market Value per Share on the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) granted to any Employee other than an Employee described in paragraph (A)&nbsp;immediately above, the per Share exercise
price will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) In the case of a
Nonstatutory Stock Option, the per Share exercise price will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding the foregoing, Options may be granted with a per Share exercise price of less than one hundred percent (100%) of the Fair
Market Value per Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Waiting Period and Exercise Dates</U>. At the time an Option is granted, the Administrator will fix the period within which the
Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Form of Consideration</U>. The Administrator will determine the acceptable form of
consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time of grant. Such consideration may consist entirely
of: (1)&nbsp;cash; (2) check; (3)&nbsp;promissory note, to the extent permitted by Applicable Laws; (4)&nbsp;other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the
Shares as to which such Option will be exercised and provided that accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (5)&nbsp;consideration received
by the Company under cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan; (6)&nbsp;by net exercise; (7)&nbsp;such other consideration and method of payment for the issuance of
Shares to the extent permitted by Applicable Laws; or (8)&nbsp;any combination of the foregoing methods of payment. In making its determination as to the type of consideration to accept, the Administrator will consider if acceptance of such
consideration may be reasonably expected to benefit the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Exercise of Option</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) <U>Procedure for Exercise; Rights as a Stockholder</U>. Any Option granted hereunder will be exercisable according to the terms of the
Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">An Option will be deemed exercised when the Company receives: (i)&nbsp;a notice of exercise (in such form as the Administrator may specify
from time to time) from the person entitled to exercise the Option, and (ii)&nbsp;full payment for the Shares with respect to which the Option is exercised (together with applicable withholding taxes). Full payment may consist of any consideration
and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the
Participant and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a
stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a
dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&nbsp;10 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under
the Option, by the number of Shares as to which the Option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) <U>Termination of Relationship as a Service Provider</U>.
If a Participant ceases to be a Service Provider, other than upon the Participant&#146;s termination as the result of the Participant&#146;s death or Disability, the Participant may exercise his or her Option within such period of time as is
specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the
Award Agreement, the Option will remain exercisable for three (3)&nbsp;months following the Participant&#146;s termination (but in no event shall the right to exercise terminate earlier than 30 days after the Participant&#146;s termination as a
Service Provider). Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. If after
termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by such Option will revert to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) <U>Disability of Participant</U>. If a Participant ceases to be a Service Provider as a result of the Participant&#146;s Disability,
the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as
set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12)&nbsp;months following the Participant&#146;s termination (but in no event shall the right to exercise
terminate earlier than six (6)&nbsp;months after the Participant&#146;s termination as a Service Provider). Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option,
the Shares covered by the unvested portion of the Option will revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such
Option will revert to the Plan. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) <U>Death of Participant</U>. If a Participant dies while a Service Provider, the
Option may be exercised following the Participant&#146;s death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the
expiration of the term of such Option as set forth in the Award Agreement), by the Participant&#146;s designated beneficiary, provided such beneficiary has been designated prior to Participant&#146;s death in a form acceptable to the Administrator.
If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant&#146;s estate or by the person(s) to whom the Option is transferred pursuant to the Participant&#146;s
will or in accordance with the laws of descent or distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12)&nbsp;months following Participant&#146;s death (but in no event shall the
right to exercise terminate earlier than six (6)&nbsp;months following the Participant&#146;s death). Unless otherwise provided by the Administrator, if at the time of death Participant is not vested as to his or her entire Option, the Shares
covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Restricted Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Grant of Restricted Stock</U>. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time,
may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Restricted Stock Agreement</U>. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of
Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine. Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted
Stock until the restrictions on such Shares have lapsed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Transferability</U>. Except as provided in this Section&nbsp;7 or the
Award Agreement, Shares of Restricted Stock may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated until the end of the applicable Period of Restriction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Restrictions</U>. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as
it may deem advisable or appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Removal of Restrictions</U>. Except as otherwise provided in this Section&nbsp;7, Shares of
Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine. The
Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Voting Rights</U>.
During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Dividends and Other Distributions</U>. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be
entitled to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions
on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Return of Restricted
Stock to Company</U>. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed with revert to the Company and again will become available for grant under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Leaves of Absence/Transfer Between Locations</U>. Unless required by applicable law or the Administrator provides otherwise, vesting of
Awards granted hereunder will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i)&nbsp;any leave of absence approved by the Company or (ii)&nbsp;transfers between locations of the
Company or between the Company, its Parent, or any Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed three (3)&nbsp;months, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If
reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six (6)&nbsp;months following the first (1st) day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an
Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Limited Transferability of Awards</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless determined otherwise by the Administrator, Awards may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in
any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award may only be transferred
(i)&nbsp;by will, (ii)&nbsp;by the laws of descent or distribution, or (iii)&nbsp;as permitted by Rule 701 of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Further, during the period the Company is relying upon the exemption from registration provided in Rule
<FONT STYLE="white-space:nowrap">12h-1(f)(1)</FONT> promulgated under the Exchange Act (the &#147;Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT> Exemption&#148;) until the Company either (i)&nbsp;becomes subject to the reporting requirements
of Section&nbsp;13 or 15(d) of the Exchange Act or (ii)&nbsp;is no longer relying upon the Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT> Exemption, an Option, or prior to exercise, the Shares subject to the Option, may not be pledged,
hypothecated or otherwise transferred or disposed of, in any manner, including by entering into any short position, any &#147;put equivalent position&#148; or any &#147;call equivalent position&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">16a-1(h)</FONT> and Rule <FONT STYLE="white-space:nowrap">16a-1(b)</FONT> of the Exchange Act, respectively), other than to (x)&nbsp;persons who are &#147;family members&#148; (as defined in Rule 701(c)(3) of the
Securities Act) through gifts or domestic relations orders, or (y)&nbsp;to an executor or guardian of the Participant upon the death or disability of the Participant, in each case, to the extent required for continued reliance on the Rule <FONT
STYLE="white-space:nowrap">12h-1(f)</FONT> Exemption. Notwithstanding the foregoing sentence, the Administrator, in its sole discretion, may determine to permit transfers to the Company or in connection with a Change in Control or other acquisition
transactions involving the Company to the extent permitted by Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT> or, if the Company is not relying on the Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT> Exemption, to the extent permitted by
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Adjustments Upon Changes in Capitalization; Dissolution or Liquidation</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Adjustments Upon Changes in Capitalization</U>. Subject to any required action by the stockholders of the Company and Section&nbsp;11
below, the number of Shares covered by each outstanding Award, and the number of Shares which have been authorized for issuance under the Plan but as to which no Awards have yet been granted or which have been returned to the Plan, the exercise or
purchase price of each such outstanding Award, the maximum number of Shares with respect to which Awards may be granted to any Participant in any calendar year, as well as any other terms that the Administrator determines require adjustment shall be
proportionately adjusted for: (i)&nbsp;any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, recapitalization, combination or reclassification of the Shares, or similar transaction
affecting the Shares; (ii)&nbsp;any other increase or decrease in the number of issued Shares effected without receipt of consideration by the Company; or (iii)&nbsp;any other transaction with respect to Common Stock including a corporate merger,
consolidation, acquisition of property or stock, separation (including a <FONT STYLE="white-space:nowrap">spin-off</FONT> or other distribution of stock or property), reorganization, liquidation (whether partial or complete) or any similar
transaction; <I>provided, however,</I> that (i)&nbsp;conversion of any convertible securities of the Company shall not be deemed to have been &#147;effected without receipt of consideration&#148; and (ii)&nbsp;the Administrator will make such
adjustments to an Award required by Section&nbsp;25102(o) of the California Corporations Code to the extent the Company is relying upon the exemption afforded thereby with respect to the Award. In the event of any distribution of cash or other
assets to shareholders other than a normal cash dividend, the Administrator shall also make such adjustments as provided in this Section&nbsp;10 or substitute, exchange or grant Awards to effect such adjustments (collectively
&#147;adjustments&#148;). Any such adjustments to outstanding Awards will be effected in a manner that precludes the enlargement of rights and benefits under such Awards. In connection with the foregoing adjustments, the Administrator may, in its
discretion, prohibit the exercise of Awards or other issuance of Shares, cash or other consideration pursuant to Awards during certain periods of time. Except as the Administrator determines, no issuance by the Company of shares of any class, or
securities convertible into shares of any class, shall affect, and no adjustment by reason hereof shall be made with respect to, the number or price of Shares subject to an Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Dissolution or Liquidation</U>. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify
each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it previously has not been exercised, an Award will terminate immediately prior to the consummation of such proposed action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Change in Control</U>. If a Change in Control or a merger of the Company with or into
another corporation or other entity occurs, all Shares acquired under the Plan and all Options and other Awards outstanding on the effective date of the transaction shall be treated in the manner described in the definitive transaction agreement
(or, in the event the transaction does not entail a definitive agreement to which the Company is a party, in the manner determined by the Board in its capacity as the Administrator, with such determination having final and binding effect on all
parties), which agreement or determination need not treat all Options and other Awards (or all portions of an Option or other Award) in an identical manner. The treatment specified in the transaction agreement or as determined by the Board may
include (without limitation) one or more of the following with respect to each outstanding Option or Award: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Continuation of the
Option or Award by the Company (if the Company is the surviving corporation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Assumption of the Option by the surviving corporation
or its parent in a manner that complies with Code Section&nbsp;424(a) (whether or not the Option is an Incentive Stock Option). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
Substitution by the surviving corporation or its parent of a new option for the Option in a manner that complies with Code Section&nbsp;424(a) (whether or not the Option is an Incentive Stock Option). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Cancellation of the Option and a payment to the Participant with respect to each Share subject to the portion of the Option that is vested
as of the transaction date equal to the excess of (A)&nbsp;the value, as determined by the Board&nbsp;in its absolute discretion, of the property (including cash) received by the holder of a share of Common Stock as a result of the transaction, over
(B)&nbsp;the <FONT STYLE="white-space:nowrap">per-Share</FONT> Exercise Price of the Option (such excess, the &#147;Spread&#148;).&nbsp;Such payment shall be made in the form of cash, cash equivalents, or securities of the surviving corporation or
its parent having a value equal to the Spread.&nbsp;In addition, any escrow, holdback, <FONT STYLE="white-space:nowrap">earn-out</FONT> or similar provisions in the transaction agreement may apply to such payment to the same extent and in the same
manner as such provisions apply to the holders of Common Stock. If the&nbsp;Spread applicable to an Option is zero or a negative number, then the Option may be cancelled without making a payment to the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Cancellation of the Option without the payment of any consideration; provided that the Participant shall be notified of such treatment and
given an opportunity to exercise the Option (to the extent the Option is vested or becomes vested as of the effective date of the transaction) during a period of not less than five (5)&nbsp;business days preceding the effective date of the
transaction, unless (A)&nbsp;a shorter period is required to permit a timely closing of the transaction and (B)&nbsp;such shorter period still offers the Participant a reasonable opportunity to exercise the Option. Any exercise of the Option during
such period may be contingent upon the closing of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Suspension of the Participant&#146;s right to exercise the Option
during a limited period of time preceding the closing of the transaction if such suspension is administratively necessary to permit the closing of the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Termination of any right the Participant has to exercise the Option prior to vesting in the Shares subject to the Option (i.e.,
&#147;early exercise&#148;), such that following the closing of the transaction the Option may only be exercised to the extent it is vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the Board has discretion to accelerate, in whole or part, the vesting and exercisability of an Option or other
Award in connection with a transaction covered by this Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Tax</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Withholding Requirements</U>. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof) or such earlier
time as any tax withholding obligations are due, the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes
(including the Participant&#146;s FICA obligation) required to be withheld with respect to such Award (or exercise thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Withholding Arrangements</U>. The Administrator, in its sole discretion and pursuant
to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation)&nbsp;(i) paying cash, (ii)&nbsp;electing to have the Company withhold otherwise
deliverable Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld, (iii)&nbsp;delivering to the Company already-owned Shares having a Fair Market Value equal to the statutory amount required to be withheld,
provided the delivery of such Shares will not result in any adverse accounting consequences, as the Administrator determines in its sole discretion, or (iv)&nbsp;selling a sufficient number of Shares otherwise deliverable to the Participant through
such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld. The amount of the withholding requirement will be deemed to include any amount which the
Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the date
that the amount of tax to be withheld is to be determined. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Compliance With Code Section</U><U></U><U>&nbsp;409A</U>. Awards will be designed and operated in such a manner that they are either
exempt from the application of, or comply with, the requirements of Code Section&nbsp;409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section&nbsp;409A, except as
otherwise determined in the sole discretion of the Administrator. The Plan and each Award Agreement under the Plan is intended to meet the requirements of Code Section&nbsp;409A and will be construed and interpreted in accordance with such intent,
except as otherwise determined in the sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section&nbsp;409A, the Award will be granted, paid, settled or deferred in
a manner that will meet the requirements of Code Section&nbsp;409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>No Effect on Employment or Service</U>. Neither the Plan nor any Award will confer upon a Participant any right with respect to
continuing the Participant&#146;s relationship as a Service Provider with the Company, nor will they interfere in any way with the Participant&#146;s right or the Company&#146;s right to terminate such relationship at any time, with or without
cause, to the extent permitted by Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Date of Grant</U>. The date of grant of an Award will be, for all purposes, the
date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant within a reasonable time after the date of
such grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Term of Plan</U>. Subject to Section&nbsp;19 of the Plan, the Plan will become effective upon its adoption by the
Board. It will continue in effect for a term of ten (10)&nbsp;years from the date adopted by the Board, unless terminated earlier under Section&nbsp;16 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Amendment and Termination of the Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendment and Termination</U>. The Administrator may at any time amend, alter, or suspend the Plan. The Company may at any time
terminate the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stockholder Approval</U>. The Company will obtain stockholder approval of any Plan amendment to the extent
necessary and desirable to comply with Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Effect of Amendment or Termination</U>. No amendment, alteration,
suspension of termination of the Plan will materially impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the
Company. Termination of the Plan will not affect the Administrator&#146;s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Conditions Upon Issuance of Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Legal Compliance</U>. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance
and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Investment Representations</U>. As a condition to the exercise of an Award, the Company may require the person exercising such Award to
represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation
is required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Inability to Obtain Authority</U>. The inability of the Company to obtain authority from any regulatory body having
jurisdiction or to complete or comply with the requirements of any registration or other qualification of the Shares under any state, federal or foreign law or under the rules and regulations of the Securities and Exchange Commission, the stock
exchange on which Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed by the Company&#146;s counsel to be necessary or advisable for the
issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration, qualification or rule compliance will not have been
obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Stockholder Approval</U>. The Plan will be subject to approval by the stockholders of the Company within twelve
(12)&nbsp;months after the date the Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Information to Participants</U>. If and as required (i)&nbsp;pursuant to Rule 701 of the Securities Act, if the Company is relying on
the exemption from registration provided pursuant to Rule 701 of the Securities Act with respect to the applicable Award, and/or (ii)&nbsp;pursuant to Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT> of the Exchange Act, to the extent the
Company is relying on the Rule <FONT STYLE="white-space:nowrap">12h-(1)(f)</FONT> Exemption, then during the period of reliance on the applicable exemption and in each case of (i)&nbsp;and (ii) until such time as the Company becomes subject to the
reporting requirements of Section&nbsp;13 or 15(d) of the Exchange Act,, the Company shall provide to each Participant the information described in paragraphs (e)(3), (4), and (5)&nbsp;of Rule 701 under the Securities Act not less frequently than
every six (6)&nbsp;months with the financial statements being not more than 180 days old and with such information provided either by physical or electronic delivery to the Participants or by written notice to the Participants of the availability of
the information on an Internet site that may be password-protected and of any password needed to access the information. The Company may request that Participants agree to keep the information to be provided pursuant to this section confidential. If
a Participant does not agree to keep the information to be provided pursuant to this section confidential, then the Company will not be required to provide the information unless otherwise required pursuant to Rule
<FONT STYLE="white-space:nowrap">12h-1(f)(1)</FONT> under the Exchange Act (if the Company is relying on the Rule <FONT STYLE="white-space:nowrap">12h-1(f)</FONT> Exemption) or Rule 701 of the Securities Act (if the Company is relying on the
exemption pursuant to Rule 701 of the Securities Act). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. 2015 EQUITY INCENTIVE PLAN: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF STOCK GRANT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">The Purchaser is acquiring shares of the Common Stock of CG Oncology, Inc. on the following terms:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name of Purchaser:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Total Number of Purchased Shares:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Purchase Price per Share: $</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date of Offer:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date of Purchase:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vesting Commencement Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Vesting Schedule:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">The Right of Repurchase shall lapse with respect to the first ____% of the Purchased Shares when the Purchaser completes ___ months of continuous Service beginning with the Vesting Commencement Date set forth above. The Right of
Repurchase shall lapse with respect to an additional ___% of the Purchased Shares when the Purchaser completes each month of continuous Service thereafter.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Purchase Price must be paid on or before the Date of Purchase set forth above. If the Purchaser fails to make payment
before the Date of Purchase, this offer automatically terminates. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing below, the Purchaser and the Company agree that the acquisition of the
Purchased Shares is governed by the terms and conditions of the 2015 Equity Incentive Plan and the Restricted Stock Purchase Agreement. Both of these documents are attached to, and made a part of, this Summary of Stock Purchase. The Purchaser agrees
to accept by email all documents relating to the Company, the Plan or this purchase and all other documents that the Company is required to deliver to its security holders (including, without limitation, disclosures that may be required by the
Securities and Exchange Commission). The Purchaser also agrees that the Company may deliver these documents by posting them on a website maintained by the Company or by a third party under contract with the Company. If the Company posts these
documents on a website, it shall notify the Purchaser by email of their availability. The Purchaser acknowledges that he or she may incur costs in connection with electronic delivery, including the cost of accessing the internet and printing fees,
and that an interruption of internet access may interfere with his or her ability to access the documents. This consent shall remain in effect until the Purchaser gives the Company written notice that it should deliver paper documents. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">PURCHASER:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">CG ONCOLOGY, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Address for Mailing Stock Certificate:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary of Stock
Purchase, page 1 </B></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CG ONCOLOGY, INC. 2015 EQUITY INCENTIVE PLAN: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">RESTRICTED STOCK PURCHASE AGREEMENT </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION
1.&#8195;ACQUISITION OF SHARES. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Issuance. On the terms and conditions set forth in the Summary of Stock Purchase and this
Agreement, the Company agrees to issue to the Purchaser the number of Shares set forth in the Summary of Stock Purchase. The issuance shall occur at the offices of the Company on the date of purchase set forth in the Summary of Stock Purchase or at
such other place and time as the parties may agree. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Consideration. The Purchaser agrees to pay the Purchase Price set forth in
the Summary of Stock Purchase for each Purchased Share. The Purchase Price is agreed to be not less than 100% of the Fair Market Value of the Purchased Shares. Payment shall be made in cash or cash equivalents on the date of purchase set forth in
the Summary of Stock Purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Stock Plan and Defined Terms. The transfer of the Purchased Shares is subject to the Plan, a copy
of which the Purchaser acknowledges having received. The provisions of the Plan are incorporated into this Agreement by this reference. Except as otherwise defined in this Agreement (including without limitation Section&nbsp;11 hereof), capitalized
terms shall have the meaning ascribed to such terms in the Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 2.&#8195;RIGHT OF REPURCHASE. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Scope of Repurchase Right. Until they vest in accordance with the Summary of Stock Purchase and Subsection (b)&nbsp;below, the
Purchased Shares acquired under this Agreement shall be Restricted Shares and shall be subject to the Company&#146;s Right of Repurchase. The Company, however, may decline to exercise its Right of Repurchase or may exercise its Right of Repurchase
only with respect to a portion of the Restricted Shares. The Company may exercise its Right of Repurchase only during the Repurchase Period following the termination of the Purchaser&#146;s Service, but the Right of Repurchase may be exercised
automatically under Subsection (d)&nbsp;below. If the Right of Repurchase is exercised, the Company shall pay the Purchaser an amount equal to the lower of (i)&nbsp;the Purchase Price of each Restricted Share being repurchased or (ii)&nbsp;the Fair
Market Value of such Restricted Share at the time the Right of Repurchase is exercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Lapse of Repurchase Right. The Right of
Repurchase shall lapse with respect to the Restricted Shares in accordance with the vesting schedule set forth in the Summary of Stock Purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Escrow. Upon issuance, the certificate(s) for Restricted Shares shall be deposited in escrow with the Company to be held in
accordance with the provisions of this Agreement. Any additional or exchanged securities or other property described in Subsection (f)&nbsp;below shall immediately be delivered to the Company to be held in escrow. All ordinary cash dividends on
Restricted Shares (or on other securities held in escrow) shall be paid directly to the Purchaser and shall not be held in escrow. Restricted Shares, together with any other assets held in escrow under this Agreement, shall be (i)&nbsp;surrendered
to the Company for repurchase upon exercise of the Right of Repurchase or the Right of First Refusal or (ii)&nbsp;released to the Purchaser upon his or her request to the extent that the Shares have ceased to be Restricted Shares (but not more
frequently than once every six months). In any event, all Purchased Shares that have ceased to be Restricted Shares, together with any other vested assets held in escrow under this Agreement, shall be released within 90 days after the earlier of
(i)&nbsp;the termination of the Purchaser&#146;s Service or (ii)&nbsp;the lapse of the Right of First Refusal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Exercise of
Repurchase Right. The Company shall be deemed to have exercised its Right of Repurchase automatically for all Restricted Shares as of the commencement of the Repurchase Period, unless the Company during the Repurchase Period notifies the holder of
the Restricted Shares pursuant to Section&nbsp;9 that it will not exercise its Right of Repurchase for some or all of the Restricted Shares. The Company shall pay to the holder of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">the Restricted Shares the purchase price determined under Subsection (a)&nbsp;above for the
Restricted Shares being repurchased. Payment shall be made in cash or cash equivalents and/or by canceling indebtedness to the Company incurred by the Purchaser in the purchase of the Restricted Shares. The certificate(s) representing the Restricted
Shares being repurchased shall be delivered to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;Termination of Rights as Stockholder. If the Right of Repurchase is
exercised in accordance with this Section&nbsp;2 and the Company makes available the consideration for the Restricted Shares being repurchased, then the person from whom the Restricted Shares are repurchased shall no longer have any rights as a
holder of the Restricted Shares (other than the right to receive payment of such consideration). Such Restricted Shares shall be deemed to have been repurchased pursuant to this Section&nbsp;2, whether or not the certificate(s) for such Restricted
Shares have been delivered to the Company or the consideration for such Restricted Shares has been accepted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;Additional or
Exchanged Securities and Property. In the event of a merger or consolidation of the Company, a sale of all or substantially all of the Company&#146;s stock or assets, any other corporate reorganization, the declaration of a stock dividend, the
declaration of an extraordinary dividend payable in a form other than stock, a spin off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#146;s outstanding securities, any
securities or other property (including cash or cash equivalents) that are by reason of such transaction exchanged for, or distributed with respect to, any Restricted Shares or into which such Restricted Shares thereby become convertible shall
immediately be subject to the Right of Repurchase. Appropriate adjustments to reflect the exchange or distribution of such securities or property shall be made to the number and/or class of the Restricted Shares. Appropriate adjustments shall also
be made to the price per share to be paid upon the exercise of the Right of Repurchase, provided that the aggregate purchase price payable for the Restricted Shares shall remain the same. In the event of any transaction described in Section&nbsp;11
of the Plan or any other corporate reorganization, the Right of Repurchase may be exercised by the Company&#146;s successor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;Transfer of Restricted Shares. The Purchaser shall not transfer, assign, encumber or otherwise dispose of any Restricted Shares
without the Company&#146;s written consent, except as provided in the following sentence. The Purchaser may transfer Restricted Shares to one or more members of the Purchaser&#146;s Immediate Family or to a trust established by the Purchaser for the
benefit of the Purchaser and/or one or more members of the Purchaser&#146;s Immediate Family, provided in either case that the Transferee agrees in writing on a form prescribed by the Company to be bound by all provisions of this Agreement. If the
Purchaser transfers any Restricted Shares, then this Agreement shall apply to the Transferee to the same extent as to the Purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;Assignment of Repurchase Right. The Board of Directors may freely assign the Company&#146;s Right of Repurchase, in whole or in part.
Any person who accepts an assignment of the Right of Repurchase from the Company shall assume all of the Company&#146;s rights and obligations under this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;Part-Time Employment and Leaves of Absence. If the Purchaser commences working on a part-time basis, then the Company may adjust the
vesting schedule set forth in the Summary of Stock Purchase. If the Purchaser goes on a leave of absence, then the Company may adjust the vesting schedule set forth in the Summary of Stock Purchase in accordance with the Company&#146;s leave of
absence policy or the terms of such leave. Except as provided in the preceding sentence, Service shall be deemed to continue while the Purchaser is on a bona fide leave of absence, if (i)&nbsp;such leave was approved by the Company in writing and
(ii)&nbsp;continued crediting of Service is expressly required by the terms of such leave or by applicable law (as determined by the Company). Service shall be deemed to terminate when such leave ends, unless the Purchaser immediately returns to
active work. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 3.&#8195;RIGHT OF FIRST REFUSAL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Right of First Refusal. In the event that the Purchaser proposes to sell, pledge or otherwise transfer to a third party any Purchased
Shares, or any interest in Purchased Shares, the Company shall have the Right of First Refusal with respect to all (and not less than all) of such Purchased Shares. If the Purchaser desires to transfer Purchased Shares, the Purchaser shall give a
written Transfer Notice to the Company describing fully the proposed transfer, including the number of Purchased Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed Transferee and proof satisfactory
to the Company that the proposed sale or transfer will not violate any applicable federal, State or foreign securities laws. The Transfer Notice shall be signed both by the Purchaser and by the proposed Transferee and must constitute a binding
commitment of both parties to the transfer of the Purchased Shares. The Company shall have the right to purchase all, and not less than all, of the Purchased Shares on the terms of the proposal described in the Transfer Notice (subject, however, to
any change in such terms permitted under Subsection (b)&nbsp;below) by delivery of a notice of exercise of the Right of First Refusal within 30 days after the date when the Transfer Notice was received by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Transfer of Shares. If the Company fails to exercise its Right of First Refusal within 30 days after receiving the Transfer Notice,
the Purchaser may, not later than 90 days after the Company received the Transfer Notice, conclude a transfer of the Purchased Shares subject to the Transfer Notice on the terms and conditions described in the Transfer Notice, provided that any such
sale is made in compliance with applicable federal, State and foreign securities laws and not in violation of any other contractual restrictions to which the Purchaser is bound. Any proposed transfer on terms and conditions different from those
described in the Transfer Notice, as well as any subsequent proposed transfer by the Purchaser, shall again be subject to the Right of First Refusal and shall require compliance with the procedure described in Subsection (a)&nbsp;above. If the
Company exercises its Right of First Refusal, the parties shall consummate the sale of the Purchased Shares on the terms set forth in the Transfer Notice within 60 days after the Company received the Transfer Notice (or within such longer period as
may have been specified in the Transfer Notice); provided, however, that in the event the Transfer Notice provided that payment for the Purchased Shares was to be made in a form other than cash or cash equivalents paid at the time of transfer, the
Company shall have the option of paying for the Purchased Shares with cash or cash equivalents equal to the present value of the consideration described in the Transfer Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Additional or Exchanged Securities and Property. In the event of a merger or consolidation of the Company, a sale of all or
substantially all of the Company&#146;s stock or assets, any other corporate reorganization, a stock split, the declaration of a stock dividend, the declaration of an extraordinary dividend payable in a form other than stock, a spin off, an
adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#146;s outstanding securities, any securities or other property (including cash or cash equivalents) that are by reason of such transaction exchanged
for, or distributed with respect to, any Purchased Shares subject to this Section&nbsp;3 shall immediately be subject to the Right of First Refusal. Appropriate adjustments to reflect the exchange or distribution of such securities or property shall
be made to the number and/or class of the Purchased Shares subject to this Section&nbsp;3. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Termination of Right of First
Refusal. Any other provision of this Section&nbsp;3 notwithstanding, in the event that the Stock is readily tradable on an established securities market when the Purchaser desires to transfer Purchased Shares, the Company shall have no Right of
First Refusal, and the Purchaser shall have no obligation to comply with the procedures prescribed by Subsections (a)&nbsp;and (b) above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;Permitted Transfers. This Section&nbsp;3 shall not apply to (i)&nbsp;a transfer by beneficiary designation, will or intestate
succession or (ii)&nbsp;a transfer to one or more members of the Purchaser&#146;s Immediate Family or to a trust established by the Purchaser for the benefit of the Purchaser and/or one or more members of the Purchaser&#146;s Immediate Family,
provided in either case that the Transferee agrees in writing on a form prescribed by the Company to be bound by all provisions of this Agreement. If the Purchaser transfers any Purchased Shares, either under this Subsection (e)&nbsp;or after the
Company has failed to exercise the Right of First Refusal, then this Agreement shall apply to the Transferee to the same extent as to the Purchaser. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;Termination of Rights as Stockholder. If the Company makes available, at the time
and place and in the amount and form provided in this Agreement, the consideration for the Shares to be purchased in accordance with this Section&nbsp;3, then after such time the person from whom such Shares are to be purchased shall no longer have
any rights as a holder of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such Shares shall be deemed to have been purchased in accordance with the applicable provisions hereof, whether
or not the certificate(s) therefor have been delivered as required by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;Assignment of Right of First Refusal. The
Board of Directors may freely assign the Company&#146;s Right of First Refusal, in whole or in part. Any person who accepts an assignment of the Right of First Refusal from the Company shall assume all of the Company&#146;s rights and obligations
under this Section&nbsp;3. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 4.&#8195;OTHER RESTRICTIONS ON TRANSFER. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Purchaser Representations. In connection with the issuance and acquisition of Shares under this Agreement, the Purchaser hereby
represents and warrants to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;The Purchaser is acquiring and will hold the Purchased Shares for investment
for his or her account only and not with a view to, or for resale in connection with, any &#147;distribution&#148; thereof within the meaning of the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;The Purchaser understands that the Purchased Shares have not been registered under the Securities Act by reason of a specific
exemption therefrom and that the Purchased Shares must be held indefinitely, unless their sale or other transfer is subsequently registered under the Securities Act or the Purchaser obtains an opinion of counsel, in form and substance satisfactory
to the Company and its counsel, that such registration is not required. The Purchaser further acknowledges and understands that the Company is under no obligation to register the Purchased Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;The Purchaser is aware of Rule 144 under the Securities Act, which permits limited public resales of securities acquired in a <FONT
STYLE="white-space:nowrap">non-public</FONT> offering, subject to the satisfaction of certain conditions. These conditions may include (without limitation) that certain current public information about the issuer be available, that the resale occur
only after a holding period required by Rule 144 has been satisfied, that the sale occur through an unsolicited &#147;broker&#146;s transaction,&#148; and that the amount of securities being sold during any three month period not exceed specified
limitations. The Purchaser acknowledges and understands that the conditions for resale set forth in Rule 144 have not been satisfied as of either the Date of Offer or the Date of Purchase and that the Company is not required to take action to
satisfy any such conditions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;The Purchaser will not sell, transfer or otherwise dispose of the Purchased Shares in violation of
the Securities Act, the Securities Exchange Act of 1934, or the rules promulgated thereunder, including Rule 144 under the Securities Act. The Purchaser agrees that he or she will not dispose of the Purchased Shares unless and until he or she has
complied with all requirements of this Agreement applicable to the disposition of Purchased Shares and he or she has provided the Company with written assurances, in substance and form satisfactory to the Company, that (A)&nbsp;the proposed
disposition does not require registration of the Purchased Shares under the Securities Act or all appropriate action necessary for compliance with the registration requirements of the Securities Act or with any exemption from registration available
under the Securities Act (including Rule 144) has been taken and (B)&nbsp;the proposed disposition will not result in the contravention of any transfer restrictions applicable to the Purchased Shares under applicable state law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(v)&#8195;The Purchaser has received and has had access to such information as he or she considers necessary or appropriate for deciding
whether to invest in the Purchased Shares, and the Purchaser has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the issuance of the Purchased Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(vi)&#8195;The Purchaser is aware that his or her investment in the Company is a speculative
investment that has limited liquidity and is subject to the risk of complete loss. The Purchaser is able, without impairing his or her financial condition, to hold the Purchased Shares for an indefinite period and to suffer a complete loss of his or
her investment in the Purchased Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Securities Law Restrictions. Regardless of whether the offer and sale of Shares under
the Plan have been registered under the Securities Act or have been registered or qualified under the securities laws of any State or other relevant jurisdiction, the Company at its discretion may impose restrictions upon the sale, pledge or other
transfer of the Purchased Shares (including the placement of appropriate legends on the stock certificates (or electronic equivalent) or the imposition of stop transfer instructions) and may refuse (or may be required to refuse) to transfer Shares
acquired hereunder (or Shares proposed to be transferred in a subsequent transfer) if, in the judgment of the Company, such restrictions, legends or refusal are necessary or appropriate to achieve compliance with the Securities Act or other relevant
securities or other laws, including without limitation under Regulation S of the Securities Act or pursuant to another available exemption from registration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Market <FONT STYLE="white-space:nowrap">Stand-Off.</FONT> In connection with any underwritten public offering by the Company of its
equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company&#146;s initial public offering, the Purchaser or a Transferee shall not directly or indirectly sell, make any short sale of,
loan, hypothecate, pledge, offer, grant or sell any option or other contract for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in any of the foregoing transactions
with respect to, any Purchased Shares without the prior written consent of the Company or its managing underwriter. Such restriction (the &#147;Market <FONT STYLE="white-space:nowrap">Stand-Off&#148;)</FONT> shall be in effect for such period of
time following the date of the final prospectus for the offering as may be requested by the Company or such underwriter. In no event, however, shall such period exceed 180 days plus such additional period as may reasonably be requested by the
Company or such underwriter to accommodate regulatory restrictions on (i)&nbsp;the publication or other distribution of research reports or (ii)&nbsp;analyst recommendations and opinions, including (without limitation) the restrictions set forth in
Rule 2711(f)(4) of the National Association of Securities Dealers and Rule 472(f)(4) of the New York Stock Exchange, as amended, or any similar successor rules. The Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT> shall in any event
terminate two years after the date of the Company&#146;s initial public offering. In the event of the declaration of a stock dividend, a spin off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction
affecting the Company&#146;s outstanding securities without receipt of consideration, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market <FONT
STYLE="white-space:nowrap">Stand-Off,</FONT> or into which such Shares thereby become convertible, shall immediately be subject to the Market <FONT STYLE="white-space:nowrap">Stand-Off.</FONT> In order to enforce the Market <FONT
STYLE="white-space:nowrap">Stand-Off,</FONT> the Company may impose stop-transfer instructions with respect to the Purchased Shares until the end of the applicable <FONT STYLE="white-space:nowrap">stand-off</FONT> period. The Company&#146;s
underwriters shall be beneficiaries of the agreement set forth in this Subsection (c). This Subsection (c)&nbsp;shall not apply to Shares registered in the public offering under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Rights of the Company. The Company shall not be required to (i)&nbsp;transfer on its books any Purchased Shares that have been sold
or transferred in contravention of this Agreement or (ii)&nbsp;treat as the owner of Purchased Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom Purchased Shares have been transferred in contravention
of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 5.&#8195;SUCCESSORS AND ASSIGNS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly provided to the contrary, the provisions of this Agreement shall inure to the benefit of, and be binding upon,
the Company and its successors and assigns and be binding upon the Purchaser and the Purchaser&#146;s legal representatives, heirs, legatees, distributees, assigns and transferees by operation of law, whether or not any such person has become a
party to this Agreement or has agreed in writing to join herein and to be bound by the terms, conditions and restrictions hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 6.&#8195;NO RETENTION RIGHTS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Nothing in this Agreement or in the Plan shall confer upon the Purchaser any right to continue providing services to the Company for any period
of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining the Purchaser) or of the Purchaser, which rights are hereby expressly reserved by each, to
terminate his or her Service at any time and for any reason, with or without cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 7.&#8195;TAX ELECTION. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The acquisition of the Purchased Shares may result in adverse tax consequences that may be avoided or mitigated by filing an election under
Code Section&nbsp;83(b). Such election may be filed only within 30 days after the date of purchase set forth in the Summary of Stock Purchase. The form for making the Code Section&nbsp;83(b) election is attached to this Agreement as Exhibit 1. The
Purchaser should consult with his or her tax advisor to determine the tax consequences of acquiring the Purchased Shares and the advantages and disadvantages of filing the Code Section&nbsp;83(b) election. The Purchaser acknowledges that it is his
or her sole responsibility, and not the Company&#146;s, to file a timely election under Code Section&nbsp;83(b), even if the Purchaser requests the Company or its representatives to make this filing on his or her behalf. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 8.&#8195;LEGENDS. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All certificates
evidencing Purchased Shares shall bear the following legends: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED HEREBY MAY NOT BE SOLD, ASSIGNED, TRANSFERRED,
ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF A WRITTEN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER OF THE SHARES (OR THE PREDECESSOR IN INTEREST TO THE SHARES). SUCH AGREEMENT GRANTS TO THE COMPANY
CERTAIN RIGHTS OF FIRST REFUSAL UPON AN ATTEMPTED TRANSFER OF THE SHARES AND CERTAIN REPURCHASE RIGHTS UPON TERMINATION OF SERVICE WITH THE COMPANY. IN ADDITION, THE SHARES ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A LIMITED PERIOD FOLLOWING THE
EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY&#146;S SECURITIES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER. THE SECRETARY OF THE COMPANY WILL UPON
WRITTEN REQUEST FURNISH A COPY OF SUCH AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All certificates evidencing the Purchased
Shares acquired under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are required or deemed advisable under the provisions of any applicable law): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;) OR ANY
SECURITIES LAWS OF ANY U.S. STATE, AND MAY NOT BE SOLD, REOFFERED, PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND
ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED. IN THE ABSENCE OF REGISTRATION OR THE AVAILABILITY (CONFIRMED BY OPINION OF COUNSEL) OF AN ALTERNATIVE EXEMPTION FROM REGISTRATION UNDER THE ACT (INCLUDING WITHOUT LIMITATION IN ACCORDANCE WITH
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">REGULATION S UNDER THE ACT), THESE SHARES MAY NOT BE SOLD, REOFFERED, PLEDGED, ASSIGNED,
ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED OF. HEDGING TRANSACTIONS INVOLVING THESE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If required by the authorities of any State in connection with the issuance of the Purchased Shares, the legend or legends required by such
State authorities shall also be endorsed on all such certificates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 9.&#8195;MISCELLANEOUS PROVISIONS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Choice of Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, as such laws
are applied to contracts entered into and performed in such State. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Notice. Any notice required by the terms of this Agreement
shall be given in writing. It shall be deemed effective upon (i)&nbsp;personal delivery, (ii)&nbsp;deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, (iii)&nbsp;deposit with Federal Express
Corporation, with shipping charges prepaid or (iv)&nbsp;deposit with any internationally recognized express mail courier service. Notice shall be addressed to the Company at its principal executive office and to the Purchaser at the address that he
or she most recently provided to the Company in accordance with this Subsection (b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Entire Agreement. The Summary of Stock
Purchase, this Agreement and the Plan constitute the entire contract between the parties hereto with regard to the subject matter hereof. They supersede any other agreements, representations or understandings (whether oral or written and whether
express or implied) that relate to the subject matter hereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 10.&#8195;ACKNOWLEDGEMENTS OF THE PURCHASER. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition to the other terms, conditions and restrictions imposed on the Shares acquired pursuant to this Agreement, the Purchaser expressly
acknowledges being subject to Sections 2 (Right of Repurchase), 3 (Right of First Refusal) and 4 (Other Restrictions on Transfer, including without limitation the Market <FONT STYLE="white-space:nowrap">Stand-Off),</FONT> as well as the following
provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Plan Discretionary. The Purchaser understands and acknowledges that (i)&nbsp;the Plan is entirely discretionary,
(ii)&nbsp;the Company and the Purchaser&#146;s employer have reserved the right to amend, suspend or terminate the Plan at any time, (iii)&nbsp;the transfer of the Purchased Shares does not in any way create any contractual or other right to receive
additional awards under the Plan at any time or in any amount and (iv)&nbsp;all determinations with respect to any additional awards, including (without limitation) the times when awards will be granted, the number of Shares offered and the vesting
schedule, will be at the sole discretion of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;Termination of Service. The Purchaser understands and acknowledges that
participation in the Plan ceases upon termination of his or her Service for any reason, except as may explicitly be provided otherwise in the Plan or this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;Extraordinary Compensation. The value of the Purchased Shares shall be an extraordinary item of compensation outside the scope of the
Purchaser&#146;s employment contract, if any, and shall not be considered a part of his or her normal or expected compensation for purposes of calculating severance, resignation, redundancy or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-of-service</FONT></FONT> payments, bonuses, long-service awards, pension or retirement benefits or similar payments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Authorization to Disclose. The Purchaser hereby authorizes and directs the Purchaser&#146;s employer to disclose to the Company or
any Subsidiary any information regarding the Purchaser&#146;s employment, the nature and amount of the Purchaser&#146;s compensation and the fact and conditions of the Purchaser&#146;s participation in the Plan, as the Purchaser&#146;s employer
deems necessary or appropriate to facilitate the administration of the Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;Personal Data Authorization. The Purchaser consents to the collection, use and
transfer of personal data as described in this Subsection (e). The Purchaser understands and acknowledges that the Company, the Purchaser&#146;s employer and the Company&#146;s other Subsidiaries hold certain personal information regarding the
Purchaser for the purpose of managing and administering the Plan, including (without limitation) the Purchaser&#146;s name, home address, telephone number, date of birth, social insurance number, salary, nationality, job title, any Shares or
directorships held in the Company and details of all options or any other entitlements to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Purchaser&#146;s favor (the &#147;Data&#148;). The Purchaser further understands
and acknowledges that the Company and/or its Subsidiaries will transfer Data among themselves as necessary for the purpose of implementation, administration and management of the Purchaser&#146;s participation in the Plan and that the Company and/or
any Subsidiary may each further transfer Data to any third party assisting the Company in the implementation, administration and management of the Plan. The Purchaser understands and acknowledges that the recipients of Data may be located in the
United States or elsewhere. The Purchaser authorizes such recipients to receive, possess, use, retain and transfer Data, in electronic or other form, for the purpose of administering the Purchaser&#146;s participation in the Plan, including a
transfer to any broker or other third party with whom the Purchaser elects to deposit Shares acquired under the Plan of such Data as may be required for the administration of the Plan and/or the subsequent holding of Shares on the Purchaser&#146;s
behalf. The Purchaser may, at any time, view the Data, require any necessary modifications of Data or withdraw the consents set forth in this Subsection (e)&nbsp;by contacting the Company in writing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SECTION 11.&#8195;DEFINITIONS. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;&#147;Agreement&#148; shall mean this Stock Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;&#147;Board of Directors&#148; shall mean the Board of Directors of the Company, as constituted from time to time or, if a Committee
has been appointed, such Committee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;&#147;Company&#148; shall mean CG Oncology, Inc., a Delaware corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;&#147;Immediate Family&#148; shall mean any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">brother-in-law</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law</FONT></FONT> and shall include adoptive relationships. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;&#147;Plan&#148; shall mean the CG Oncology, Inc. 2015 Equity Incentive Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;&#147;Purchased Shares&#148; shall mean the Shares purchased by the Purchaser pursuant to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;&#147;Purchase Price&#148; shall mean the amount for which one Share may be purchased pursuant to this Agreement, as specified in the
Summary of Stock Purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;&#147;Purchaser&#148; shall mean the person named in the Summary of Stock Purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;&#147;Repurchase Period&#148; shall mean a period of 90 consecutive days commencing on the date when the Purchaser&#146;s Service
terminates for any reason, including (without limitation) death or disability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(j)&#8195;&#147;Restricted Share&#148; shall mean a
Purchased Share that is subject to the Right of Repurchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(k)&#8195;&#147;Right of First Refusal&#148; shall mean the Company&#146;s
right of first refusal described in Section&nbsp;3. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(l)&#8195;&#147;Right of Repurchase&#148; shall mean the Company&#146;s right of
repurchase described in Section&nbsp;2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(m)&#8195;&#147;Service&#148; means service as an Employee, Outside Director or Consultant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(n)&#8195;&#147;Transferee&#148; shall mean any person to whom the Purchaser has directly or indirectly transferred any Purchased Share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(o)&#8195;&#147;Transfer Notice&#148; shall mean the notice of a proposed transfer of Purchased Shares described in Section&nbsp;3. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SECTION 83(b) ELECTION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned taxpayer
hereby elects, pursuant to Section&nbsp;83(b) of the Internal Revenue Code of 1986, as amended, and pursuant to Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.83-2,</FONT> to include in gross income as compensation for services
the excess (if any) of the fair market value of the shares described below over an amount paid for those shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;The taxpayer
who performed the services is: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Name: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Address: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Social Security No.:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;The property with respect to which the election is made is &#8195;&#8195;&#8195;&#8195; shares of the common stock of CG
Oncology, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;The property was transferred to the taxpayer on &#8195;&#8195;&#8195;, &#8195;&#8195;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;The taxable year for which the election is made is the calendar year &#8195;&#8195;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(e)&#8195;The property is subject to a repurchase right pursuant to which the issuer has the right to acquire the property if for any reason
taxpayer&#146;s service with the issuer terminates. The issuer&#146;s repurchase right lapses in a series of installments over a &#8195;&#8195;&#8195;-year period ending on &#8195;&#8195;&#8195;, &#8195;&#8195;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f)&#8195;The fair market value of such property at the time of transfer (determined without regard to any restriction other than a restriction
that by its terms will never lapse) is $&#8195;&#8195; per share x&#8195;&#8195; shares = $&#8195;&#8195;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g)&#8195;For the property
transferred, the taxpayer paid $&#8195;&#8195; per share &times;&#8195;&#8195; shares = $&#8195;&#8195;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(h)&#8195;The amount to include
in gross income is $&#8195;&#8195;. [The amount in Item f less the amount in Item g] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i)&#8195;A copy of this statement was furnished to
CG Oncology, Inc., for whom taxpayer rendered the services underlying the transfer of such property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(j) This statement is executed on
&#8195;&#8195;&#8195;, &#8195;&#8195;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#8195;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature of Spouse (if any)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature of Taxpayer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Within 30 days after the date of transfer of the property, this election must be filed with the Internal Revenue Service
office where the taxpayer files his or her annual federal income tax return. The filing should be made by registered or certified mail, return receipt requested. The taxpayer must (a)&nbsp;include a copy of the completed form with his or her federal
income tax return for the taxable year in which the property is transferred and (b)&nbsp;deliver an additional copy to the Company. </I></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, the terms defined in the CG Oncology, Inc. 2015 Equity Incentive Plan (the &#147;Plan&#148;) will have the
same defined meanings in this Stock Option Agreement (the &#147;Agreement&#148;), including the Notice of Stock Option Grant (the &#147;Notice of Grant&#148;) and Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>NOTICE OF STOCK OPTION GRANT </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Participant: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Address:
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participant has been granted an Option to purchase Common Stock of CG Oncology, Inc. (the &#147;Company&#148;), subject to the terms and conditions
of the Plan and this Agreement, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Grant Number: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Date of Grant: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Vesting
Commencement Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Number of Shares Granted: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Exercise Price per Share: $ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total Exercise Price: $ </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Type of
Option: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">___ Incentive Stock Option </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">___ Nonstatutory Stock Option </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Term/Expiration Date: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Vesting Schedule:
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to accelerated vesting as set forth below or in the Plan, this Option will be exercisable, in whole or in part, in
accordance with the following schedule: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Twenty-five percent (25%) of the Shares subject to the Option shall vest twelve (12)&nbsp;months
after the Vesting Commencement Date, and thereafter 1/36 of the remaining unvested Shares subject to the Option shall vest on each of the next <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;monthly anniversaries of the Vesting
Commencement Date (and if there is no corresponding day, on the last day of the month), subject to Participant continuing to be a Service Provider through each such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the vesting of the Shares subject to the Option shall be subject to any vesting acceleration provisions
applicable to this Option contained in the Plan and/or any employment or service agreement, offer letter, change in control severance agreement or policy, or any other agreement or policy that, prior to and effective as of the date of this
Agreement, has been entered into or agreed upon, as the case may be, between Participant and the Company or any parent or subsidiary corporation of the Company (such agreement or policy, a &#147;Separate Agreement&#148;) to the extent not otherwise
duplicative of the vesting terms described above (by way of example, if a Separate Agreement provides for different acceleration of vesting provisions for all of Participant&#146;s stock options upon a termination of Participant as a Service
Provider for &#147;good reason&#148; that is defined differently, and the Participant&#146;s status as a Service Provider terminates in a manner that would trigger &#147;good reason&#148; under the Separate Agreement but not under this Agreement,
the Participant would remain entitled to the acceleration of vesting under the Separate Agreement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stock Option Agreement,
page 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Termination Period: </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided in a Separate Agreement, this Option will be exercisable for thirty (30)&nbsp;calendar days after Participant ceases to be a
Service Provider, unless such termination is due to Participant&#146;s death or Disability, in which case this Option will be exercisable for twelve (12)&nbsp;months after Participant ceases to be a Service Provider. Notwithstanding the foregoing
sentence, if the exercise of the Option within the applicable time periods set forth in the preceding sentence is prevented by Section&nbsp;18 of the Plan, the Option shall remain exercisable until thirty (30)&nbsp;days (or such longer period of
time as determined by the Administrator, in its discretion) after the date Participant is notified by the Company that the Option is exercisable, but in any event no later than the expiration of the term of the Option as set forth in the Notice of
Grant. Notwithstanding anything herein to the contrary, in no event may this Option be exercised after the Term/Expiration Date as provided above and may be subject to earlier termination as provided in Section&nbsp;11 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By Participant&#146;s signature and the signature of the Company&#146;s representative below, Participant and the Company agree that this
Option is granted under and governed by the terms and conditions of the Plan and this Agreement, including exhibits hereto, all of which are made a part of this document. Participant has reviewed the Plan and this Agreement in their entirety, has
had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of the Plan and Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or
interpretations of the Administrator upon any questions relating to the Plan and Agreement. Participant further agrees to notify the Company upon any change in the residence address indicated below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PARTICIPANT </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">CG ONCOLOGY, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Signature:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Print&nbsp;Name:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Address:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stock Option Agreement,
page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMS AND CONDITIONS OF STOCK OPTION GRANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Grant of Option</U>. The Company hereby grants to the Participant named in the Notice of Grant (the &#147;Participant&#148;) an option
(the &#147;Option&#148;) to purchase the number of Shares, as set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the &#147;Exercise Price&#148;), subject to all of the terms and conditions in this
Agreement, the Plan, and the Separate Agreement (as applicable), which are incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Agreement, the terms and
conditions of the Plan will prevail. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Option will be designated as either an Incentive Stock Option
(&#147;ISO&#148;) or a Nonstatutory Stock Option (&#147;NSO&#148;). If designated in the Notice of Grant as an ISO, this Option is intended to qualify as an ISO under Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;). However, if this Option is intended to be an Incentive Stock Option, to the extent that it exceeds the $100,000 rule of Code Section&nbsp;422(d) it will be treated as an NSO. Further, if for any reason this Option (or portion
thereof) will not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a NSO granted under the Plan. In no event will the Administrator, the Company or any Parent or Subsidiary or any
of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify for any reason as an ISO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) For <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxpayers and Participants not subject to U.S. taxation, the Option
will be designated as an NSO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Vesting Schedule</U>. Except as provided in Section&nbsp;3, the Option awarded by this Agreement will
vest in accordance with the vesting provisions set forth in the Notice of Grant. Shares scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in Participant in accordance with any of the provisions of this
Agreement, unless Participant will have been continuously a Service Provider from the Date of Grant until the date such vesting occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Administrator Discretion</U>. The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of
the balance, of the unvested Option at any time, subject to the terms of the Plan. If so accelerated, such Option will be considered as having vested as of the date specified by the Administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Exercise of Option</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Right to Exercise</U>. This Option may be exercised only within the term set out in the Notice of Grant, and may be
exercised during such term only in accordance with the Plan and the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Method of
Exercise</U>. This Option is exercisable by delivery of an exercise notice, in the form attached as Exhibit B (the &#147;Exercise Notice&#148;) or in a manner and pursuant to such procedures as the Administrator may determine, which will state the
election to exercise the Option, the number of Shares in respect of which the Option is being exercised (the &#147;Exercised Shares&#148;), and such other representations and agreements as may be required by the Company pursuant to the provisions of
the Plan. The Exercise Notice will be completed by Participant and delivered to the Company. The Exercise Notice will be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares together and of any <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items (as defined in Section&nbsp;6(a)). This Option will be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Method of Payment</U>. Payment of the aggregate Exercise Price will be by any of the following, or a combination thereof, at the
election of Participant: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) cash; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B>1</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) check; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with
the Plan; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) if Participant is a U.S. employee, surrender of other Shares which have a Fair Market Value on the date
of surrender equal to the aggregate Exercise Price of the Exercised Shares, provided that accepting such Shares, in the sole discretion of the Administrator, will not result in any adverse accounting consequences to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Tax Obligations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Responsibility for Taxes</U>. Notwithstanding any contrary provision of this Agreement, no certificate representing the
Shares will be issued to Participant, unless and until satisfactory arrangements (as determined by the Administrator) will have been made by Participant with respect to the payment of income, employment, social insurance, payroll tax, fringe benefit
tax, payment on account or other <FONT STYLE="white-space:nowrap">tax-related</FONT> items related to Participant&#146;s participation in the Plan and legally applicable to Participant including, without limitation, in connection with the grant,
vesting or exercise of the Option, the subsequent sale of Shares acquired under the Plan and/or the receipt of any dividends on such Shares which the Company determines must be withheld <FONT STYLE="white-space:nowrap">(&#147;Tax-Related</FONT>
Items&#148;). To the extent determined appropriate by the Company in its discretion, it will have the right (but not the obligation) to satisfy any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by reducing the number of Shares otherwise
deliverable to Participant. If Participant fails to make satisfactory arrangements for the payment of any required <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items hereunder at the time of the Option exercise, Participant acknowledges and
agrees that the Company may refuse to honor the exercise and refuse to deliver the Shares if such amounts are not delivered at the time of exercise. Participant authorizes the Company and/or the Employer to withhold any <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items legally payable by Participant from his or her wages or other cash compensation paid to Participant by the Company and/or the Employer or from proceeds of the sale of Shares. Further, if
Participant is subject to tax in more than one jurisdiction between the Date of Grant and the date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges and agrees that the Company and/or Participant&#146;s
employer (the &#147;Employer&#148;), or former employer, as applicable, may be required to withhold or account for tax in more than one jurisdiction. Regardless of any action of the Company or the Employer, Participant acknowledges that the ultimate
liability for all <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items is and remains Participant&#146;s responsibility and may exceed the amount actually withheld by the Company or the Employer. Participant further acknowledges that the
Company and the Employer (1)&nbsp;make no representations or undertakings regarding the treatment of any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in connection with any aspect of the Option; and (2)&nbsp;do not commit to and are
under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate Participant&#146;s liability for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items or achieve any particular tax result. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of Disqualifying Disposition of ISO Shares</U>. If the Option granted to Participant herein is an ISO, and if
Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i)&nbsp;the date two (2)&nbsp;years after the Date of Grant, or (ii)&nbsp;the date one (1)&nbsp;year after the date of exercise,
Participant will immediately notify the Company in writing of such disposition. Participant agrees that Participant may be subject to income tax withholding by the Company on the compensation income recognized by Participant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Code Section</U><U></U><U>&nbsp;409A</U>. Under Code Section&nbsp;409A, an option that vests after December&nbsp;31,
2004 (or that vested on or prior to such date but which was materially modified after October&nbsp;3, 2004) that was granted with a per share exercise price that is determined by the Internal Revenue Service (the &#147;IRS&#148;) to be less than the
fair market value of a share on the date of grant (a &#147;Discount Option&#148;) may be considered &#147;deferred compensation.&#148; A Discount Option may result in (i)&nbsp;income recognition by Participant prior to the exercise of the option,
(ii)&nbsp;an additional twenty percent (20%) federal income tax, and (iii)&nbsp;potential penalty and interest charges. The Discount Option may also result in additional state income, penalty and interest charges to Participant. Participant
acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share Exercise Price of this Option equals or exceeds the Fair Market Value of a Share on the Date of Grant in a later examination. Participant agrees
that if the IRS determines that the Option was granted with a per Share Exercise Price that was less than the Fair Market Value of a Share on the Date of Grant, Participant will be solely responsible for Participant&#146;s costs related to such a
determination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B></B><B>2</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Rights as Stockholder</U>. Neither Participant nor any person claiming under or
through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares will have been issued, recorded on the records of the
Company or its transfer agents or registrars, and delivered to Participant. After such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of
dividends and distributions on such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Right of First Refusal</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Right of First Refusal</U>. In the event that the Participant proposes to sell, pledge or otherwise transfer to a third
party any Shares acquired under this Agreement, or any interest in such Shares, the Company shall have a right of first refusal with respect to all (and not less than all) of such Shares (the &#147;Right of First Refusal&#148;). If the Participant
desires to transfer Shares acquired under this Agreement, the Participant shall give a written notice (the &#147;Transfer Notice&#148;) of a proposed transfer of the Shares to the Company describing fully the proposed transfer, including the number
of Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed person to whom the Participant wants to transfer the Shares to (whether directly or indirectly, such person, the &#147;Transferee&#148;) and
proof satisfactory to the Company that the proposed sale or transfer will not violate any applicable federal, State or foreign securities laws. The Transfer Notice shall be signed both by the Participant and by the proposed Transferee and must
constitute a binding commitment of both parties to the transfer of the Shares. The Company shall have the right to purchase all, and not less than all, of the Shares on the terms of the proposal described in the Transfer Notice (subject, however, to
any change in such terms permitted under Subsection (b)&nbsp;below) by delivery of a notice of exercise of the Right of First Refusal within 30 days after the date when the Transfer Notice was received by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Transfer of Shares</U>. If the Company fails to exercise its Right of First Refusal within 30 days after the date when
it received the Transfer Notice, the Participant may, not later than 90 days following receipt of the Transfer Notice by the Company, conclude a transfer of the Shares subject to the Transfer Notice on the terms and conditions described in the
Transfer Notice, provided that any such sale is made in compliance with applicable federal, State and foreign securities laws and not in violation of any other contractual restrictions to which the Participant is bound. Any proposed transfer on
terms and conditions different from those described in the Transfer Notice, as well as any subsequent proposed transfer by the Participant, shall again be subject to the Right of First Refusal and shall require compliance with the procedure
described in Subsection (a)&nbsp;above. If the Company exercises its Right of First Refusal, the parties shall consummate the sale of the Shares on the terms set forth in the Transfer Notice within 60 days after the date when the Company received
the Transfer Notice (or within such longer period as may have been specified in the Transfer Notice); provided, however, that in the event the Transfer Notice provided that payment for the Shares was to be made in a form other than cash or cash
equivalents paid at the time of transfer, the Company shall have the option of paying for the Shares with cash or cash equivalents equal to the present value of the consideration described in the Transfer Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Additional or Exchanged Securities and Property</U>. In the event of a Change in Control or a merger of the Company with
or into another corporation or other entity, any other corporate reorganization, a stock split, the declaration of a stock dividend, the declaration of an extraordinary dividend payable in a form other than stock, a
<FONT STYLE="white-space:nowrap">spin-off,</FONT> an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#146;s outstanding securities, any securities or other property (including cash or cash
equivalents) that are by reason of such transaction exchanged for, or distributed with respect to, any Shares subject to this Section&nbsp;8 shall immediately be subject to the Right of First Refusal. Appropriate adjustments to reflect the exchange
or distribution of such securities or property shall be made to the number and/or class of the Shares subject to this Section&nbsp;8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B>3</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Termination of Right of First Refusal</U>. Any other provision of
this Section&nbsp;8 notwithstanding, in the event that the Common Stock is readily tradable on an established securities market when the Participant desires to transfer Shares, the Company shall have no Right of First Refusal, and the Participant
shall have no obligation to comply with the procedures prescribed by Subsections (a)&nbsp;and (b) above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Permitted
Transfers</U>. This Section&nbsp;8 shall not apply to (i)&nbsp;a transfer by beneficiary designation, will or intestate succession or (ii)&nbsp;a transfer to one or more members of the Participant&#146;s Immediate Family or to a trust established by
the Participant for the benefit of the Participant and/or one or more members of the Participant&#146;s Immediate Family, provided in either case that the Transferee agrees in writing on a form prescribed by the Company to be bound by all provisions
of this Agreement. If the Participant transfers any Shares acquired under this Agreement, either under this Subsection (e)&nbsp;or after the Company has failed to exercise the Right of First Refusal, then this Agreement shall apply to the Transferee
to the same extent as to the Participant. For purposes of this Agreement, &#147;Immediate Family&#148; shall mean any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">sister-in-law</FONT></FONT> and shall include adoptive relationships. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Termination of
Rights as Stockholder</U>. If the Company makes available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be purchased in accordance with this Section&nbsp;8, then after such time the
person from whom such Shares are to be purchased shall no longer have any rights as a holder of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such Shares shall be deemed to have been
purchased in accordance with the applicable provisions hereof, whether or not the certificate(s) therefor have been delivered as required by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Assignment of Right of First Refusal</U>. The Board may freely assign the Company&#146;s Right of First Refusal, in
whole or in part. Any person who accepts an assignment of the Right of First Refusal from the Company shall assume all of the Company&#146;s rights and obligations under this Section&nbsp;8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>No Guarantee of Continued Service</U>. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE
HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER.
PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE
VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#146;S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT&#146;S RELATIONSHIP AS A
SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE, SUBJECT TO APPLICABLE LAWS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Service Acknowledgments</U>. In accepting the
Option, Participant acknowledges, understands and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Plan is established voluntarily by the Company, it
is discretionary in nature, and may be amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future
grants of options, or benefits in lieu of options, even if options have been granted in the past; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) all decisions with
respect to future option or other grants, if any, will be at the sole discretion of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Participant is
voluntarily participating in the Plan; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B>4</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the Option and any Shares acquired under the Plan are not intended to
replace any pension rights or compensation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the Option and Shares acquired under the Plan and the income and value of
same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-service</FONT></FONT>
payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the future
value of the Shares underlying the Option is unknown, indeterminable, and cannot be predicted with certainty; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) if the
underlying Shares do not increase in value, the Option will have no value; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) if Participant exercises the Option and
acquires Shares, the value of such Shares may increase or decrease in value, even below the Exercise Price; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) for
purposes of the Option, Participant&#146;s engagement as a Service Provider will be considered terminated as of the Service End Date, and unless otherwise expressly provided in this Agreement or determined by the Administrator,
(i)&nbsp;Participant&#146;s right to vest in the Option under the Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., Participant&#146;s period of service would not include any contractual notice period
or any period of &#147;garden leave&#148; or similar period mandated under employment laws in the jurisdiction where Participant is a Service Provider or Participant&#146;s engagement agreement, if any, unless Participant is providing bona fide
services during such time); and (ii)&nbsp;the period (if any) during which Participant may exercise the Option after such termination of Participant&#146;s engagement as a Service Provider will commence on the Service End Date and will not be
extended by any notice period mandated under employment laws in the jurisdiction where Participant is employed or terms of Participant&#146;s engagement agreement, if any; the Administrator shall have the exclusive discretion to determine the
Service End Date (including the determination whether Participant may still be considered to be providing services while on a leave of absence); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) unless otherwise provided in the Plan or by the Company in its discretion, the Option and the benefits evidenced by this
Agreement do not create any entitlement to have the Option or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) the following provisions apply only if Participant is providing services outside the United States: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Option and the Shares subject to the Option are not part of normal or expected compensation or salary for any purpose;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Participant acknowledges and agrees that none of the Company, the Employer, or any Parent or Subsidiary shall be
liable for any foreign exchange rate fluctuation between Participant&#146;s local currency and the United States Dollar that may affect the value of the Option or of any amounts due to Participant pursuant to the exercise of the Option or the
subsequent sale of any Shares acquired upon exercise; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) no claim or entitlement to compensation or damages shall
arise from forfeiture of the Option resulting from the termination of Participant&#146;s engagement as a Service Provider (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where
Participant is a Service Provider or the terms of Participant&#146;s engagement agreement, if any), and in consideration of the grant of the Option to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any
claim against the Company, any Parent, any Subsidiary or the Employer, waives his or her ability, if any, to bring any such claim, and releases the Company, any Subsidiary and the Employer from any such claim; if, notwithstanding the foregoing, any
such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request
dismissal or withdrawal of such claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B>5</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) The Participant consents to the collection, use and transfer of personal
data as described in this Subsection (m). The Participant understands and acknowledges that the Company, the Participant&#146;s employer and the Company&#146;s other Subsidiaries hold certain personal information regarding the Participant for the
purpose of managing and administering the Plan, including (without limitation) the Participant&#146;s name, home address, telephone number, date of birth, social insurance number, salary, nationality, job title, any Shares or directorships held in
the Company and details of all options or any other entitlements to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Participant&#146;s favor (the &#147;Data&#148;). The Participant further understands and acknowledges
that the Company and/or its Subsidiaries will transfer Data among themselves as necessary for the purpose of implementation, administration and management of the Participant&#146;s participation in the Plan and that the Company and/or any Subsidiary
may each further transfer Data to any third party assisting the Company in the implementation, administration and management of the Plan. The Participant understands and acknowledges that the recipients of Data may be located in the United States or
elsewhere. The Participant authorizes such recipients to receive, possess, use, retain and transfer Data, in electronic or other form, for the purpose of administering the Participant&#146;s participation in the Plan, including a transfer to any
broker or other third party with whom the Participant elects to deposit Shares acquired under the Plan of such Data as may be required for the administration of the Plan and/or the subsequent holding of Shares on the Participant&#146;s behalf. The
Participant may, at any time, view the Data, require any necessary modifications of Data or withdraw the consents set forth in this Subsection (m)&nbsp;by contacting the Company in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>No Advice Regarding Grant</U>. The Company is not providing any tax, legal or financial advice, nor is the Company making any
recommendations or assessments regarding Participant&#146;s participation in the Plan, or Participant&#146;s acquisition or sale of the underlying Shares. Participant is hereby advised to consult with his or her own personal tax, legal and financial
advisors regarding his or her participation in the Plan before taking any action related to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Address for Notices</U>. Any
notice to be given to the Company under the terms of this Agreement will be addressed to the Company at CG Oncology, Inc., 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618, or at such other address as the Company may hereafter designate in
writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Option</U>. This Option may not be transferred in any
manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Participant only by Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Restrictions on Transfer of Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Securities Law Restrictions</U>. Regardless of whether the offer and sale of Shares under the Plan have been registered
under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) or have been registered or qualified under the securities laws of any State or other relevant jurisdiction, the Company at its discretion may impose restrictions upon the
sale, pledge or other transfer of such Shares (including the placement of appropriate legends on the stock certificates (or electronic equivalent) or the imposition of stop-transfer instructions) and may refuse (or may be required to refuse) to
transfer Shares acquired hereunder (or Shares proposed to be transferred in a subsequent transfer) if, in the judgment of the Company, such restrictions, legends or refusal are necessary or appropriate to achieve compliance with the Securities Act
or other relevant securities or other laws, including without limitation under Regulation S of the Securities Act or pursuant to another available exemption from registration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT></U>. In connection with any underwritten public offering by the
Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company&#146;s initial public offering, the Participant or a Transferee shall not directly or indirectly sell, make any
short sale of, loan, hypothecate, pledge, offer, grant or sell any option or other contract for the purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B>6</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in any of the foregoing transactions with respect to, any Shares acquired under
this Agreement without the prior written consent of the Company or its managing underwriter. Such restriction (the &#147;Market <FONT STYLE="white-space:nowrap">Stand-Off&#148;)</FONT> shall be in effect for such period of time following the date of
the final prospectus for the offering as may be requested by the Company or such underwriter. In no event, however, shall such period exceed 180 days plus such additional period as may reasonably be requested by the Company or such underwriter to
accommodate regulatory restrictions on (i)&nbsp;the publication or other distribution of research reports or (ii)&nbsp;analyst recommendations and opinions, including (without limitation) the restrictions set forth in Rule 2711(f)(4) of the National
Association of Securities Dealers and Rule 472(f)(4) of the New York Stock Exchange, as amended, or any similar successor rules. The Market <FONT STYLE="white-space:nowrap">Stand-Off</FONT> shall in any event terminate two years after the date of
the Company&#146;s initial public offering. In the event of the declaration of a stock dividend, a <FONT STYLE="white-space:nowrap">spin-off,</FONT> a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction
affecting the Company&#146;s outstanding securities without receipt of consideration, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market <FONT
STYLE="white-space:nowrap">Stand-Off,</FONT> or into which such Shares thereby become convertible, shall immediately be subject to the Market <FONT STYLE="white-space:nowrap">Stand-Off.</FONT> In order to enforce the Market <FONT
STYLE="white-space:nowrap">Stand-Off,</FONT> the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable <FONT STYLE="white-space:nowrap">stand-off</FONT> period. The
Company&#146;s underwriters shall be beneficiaries of the agreement set forth in this Subsection (b). This Subsection (b)&nbsp;shall not apply to Shares registered in the public offering under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Investment Intent at Grant</U>. The Participant represents and agrees that the Shares to be acquired upon exercising
this Option will be acquired for investment, and not with a view to the sale or distribution thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Investment
Intent at Exercise</U>. In the event that the sale of Shares under the Plan is not registered under the Securities Act but an exemption is available that requires an investment representation or other representation, the Participant shall represent
and agree at the time of exercise that the Shares being acquired upon exercising this option are being acquired for investment, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed
necessary or appropriate by the Company and its counsel, including (if applicable because the Company is relying on Regulation S under the Securities Act) that as of the date of exercise the Participant is (i)&nbsp;not a U.S.&nbsp;Person;
(ii)&nbsp;not acquiring the Shares on behalf, or for the account or benefit, of a U.S. Person; and (iii)&nbsp;is not exercising the option in the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Legends</U>. All certificates evidencing Shares purchased under this Agreement shall bear the following legend: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED HEREBY MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH
THE TERMS OF A WRITTEN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER OF THE SHARES (OR THE PREDECESSOR IN INTEREST TO THE SHARES). SUCH AGREEMENT GRANTS TO THE COMPANY CERTAIN RIGHTS OF FIRST REFUSAL UPON AN ATTEMPTED TRANSFER OF THE
SHARES. IN ADDITION, THE SHARES ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A LIMITED PERIOD FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY&#146;S SECURITIES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER
WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER. THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY OF SUCH AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B>7</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All certificates evidencing Shares purchased under this Agreement in an unregistered transaction shall bear
the following legend (and such other restrictive legends as are required or deemed advisable under the provisions of any applicable law): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;) OR ANY
SECURITIES LAWS OF ANY U.S.&nbsp;STATE, AND MAY NOT BE SOLD, REOFFERED, PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY
AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED. IN THE ABSENCE OF REGISTRATION OR THE AVAILABILITY (CONFIRMED BY OPINION OF COUNSEL) OF AN ALTERNATIVE EXEMPTION FROM REGISTRATION UNDER THE ACT (INCLUDING WITHOUT LIMITATION IN ACCORDANCE
WITH REGULATION S UNDER THE ACT), THESE SHARES MAY NOT BE SOLD, REOFFERED, PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED OF. HEDGING TRANSACTIONS INVOLVING THESE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE
ACT.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Removal of Legends</U>. If, in the opinion of the Company and its counsel, any legend placed on a stock
certificate representing Shares sold under this Agreement is no longer required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Administration</U>. Any determination by the Company and its counsel in connection with any of the matters set forth in
this Section&nbsp;14 shall be conclusive and binding on the Participant and all other persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Binding Agreement</U>. Subject to
the limitation on the transferability of this grant contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Additional Conditions to Issuance of Stock</U>. If at any time the Company will determine, in its discretion, that the listing,
registration, qualification or rule compliance of the Shares upon any securities exchange or under any state, federal or foreign law, the tax code and related regulations or the consent or approval of any governmental regulatory authority is
necessary or desirable as a condition to the purchase by, or issuance of Shares to, Participant (or his or her estate) hereunder, such purchase or issuance will not occur unless and until such listing, registration, qualification, rule compliance,
consent or approval will have been completed, effected or obtained free of any conditions not acceptable to the Company. The Company will make all reasonable efforts to meet the requirements of any such state, federal or foreign law or securities
exchange and to obtain any such consent or approval of any such governmental authority or securities exchange. Assuming such compliance, for income tax purposes the Exercised Shares will be considered transferred to Participant on the date the
Option is exercised with respect to such Exercised Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>Plan Governs</U>. This Agreement is subject to all terms and provisions
of the Plan. In the event of a conflict between one or more provisions of this Agreement and one or more provisions of the Plan, the provisions of the Plan will govern. Capitalized terms used and not defined in this Agreement will have the meaning
set forth in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>Administrator Authority</U>. The Administrator will have the power to interpret the Plan and this Agreement
and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Shares subject
to the Option have vested). All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant and all other interested persons or entities (other than the Company). No
member of the Administrator will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B>8</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>Electronic Delivery and Acceptance</U>. The Company may, in its sole discretion,
decide to deliver any documents related to Options awarded under the Plan or future options that may be awarded under the Plan by electronic means or request Participant&#146;s consent to participate in the Plan by electronic means. Participant
hereby consents to receive such documents by such means of electronic delivery and agrees to participate in the Plan through any online or electronic system established and maintained by the Company which may, but do not necessarily, include the
delivery of a link to a Company intranet or the Internet site of a third party involved in administering the Plan, the delivery of the document via <FONT STYLE="white-space:nowrap">e-mail</FONT> or such other means of electronic delivery specified
by the Company. Participant consents to the electronic delivery of the Plan documents and this Agreement. Participant acknowledges that he or she may receive from the Company a paper copy of any documents delivered electronically at no cost to
Participant by contacting the Company by telephone or in writing. Participant further acknowledges that Participant will be provided with a paper copy of any documents if the attempted electronic delivery of such documents fails. Similarly,
Participant understands that Participant must provide the Company or any designated third party administrator with a paper copy of any documents if the attempted electronic delivery of such documents fails. Participant may revoke his or her consent
to the electronic delivery of documents or may change the electronic mail address to which such documents are to be delivered (if Participant has provided an electronic mail address) at any time by notifying the Company of such revoked consent or
revised <FONT STYLE="white-space:nowrap">e-mail</FONT> address by telephone, postal service or electronic mail. Finally, Participant understands that he or she is not required to consent to electronic delivery of documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>Captions</U>. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>Language</U>. If Participant has received this Agreement, or any other document related to the Option and/or the
Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control, subject to Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>Agreement Severable</U>. In the event that any provision in this Agreement will be held invalid or unenforceable, such provision will
be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>Amendment, Suspension or Termination of the Plan</U>. By accepting this Award, Participant expressly warrants that he or she has
received an Option under the Plan, and has received, read and understood a description of the Plan. Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Company at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>Governing Law and Venue</U>. This Agreement will be governed by the laws of California, without giving effect to the conflict of law
principles thereof. For purposes of litigating any dispute that arises under this Option or this Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree that such litigation will be conducted in
the courts of Orange County, California, or the federal courts for the United States for the Central District of California, and no other courts, where this Option is made and/or to be performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>Modifications to the Agreement</U>. This Agreement constitutes the entire understanding of the parties on the subjects covered.
Participant expressly warrants that he or she is not accepting this Agreement in reliance on any promises, representations, or inducements other than those contained herein. Modifications to this Agreement or the Plan can be made only in an express
written contract executed by a duly authorized officer of the Company. Notwithstanding anything to the contrary in the Plan or this Agreement, the Company reserves the right to revise this Agreement as it deems necessary or advisable, in its sole
discretion and without the consent of Participant, to comply with Code Section&nbsp;409A or to otherwise avoid imposition of any additional tax or income recognition under Section&nbsp;409A of the Code in connection with the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>Waiver</U>. Participant acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be
construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Participant or any other Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit A to Stock Option
Agreement, page <B>9</B> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015
EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CG Oncology, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">400 Spectrum Center Drive, Suite 2040 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, CA 92618 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Attention</U>: Stock Administration </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercise of Option</U>. Effective as of today, ______________, 20___, the undersigned (&#147;Purchaser&#148;) hereby elects to purchase
__________ shares (the &#147;Shares&#148;) of the Common Stock of CG Oncology, Inc. (the &#147;Company&#148;) under and pursuant to the 2015 Equity Incentive Plan (the &#147;Plan&#148;) and the Stock Option Agreement
dated&#8195;&#8195;&#8195;&#8195;(the &#147;Agreement&#148;). The purchase price for the Shares will be $__________, as required by the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Delivery of Payment</U>. Purchaser herewith delivers to the Company the full purchase price of the Shares and any required tax
withholding to be paid in connection with the exercise of the Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations of Purchaser</U>. Purchaser acknowledges that
Purchaser has received, read and understood the Plan and the Agreement and agrees to abide by and be bound by their terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Rights as Stockholder</U>. Until the issuance (as evidenced by the appropriate entry on the books of the Company or of a duly authorized
transfer agent of the Company) of the Shares, no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to the Option, notwithstanding the exercise of the Option. The Shares so acquired
will be issued to Purchaser as soon as practicable after exercise of the Option. No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance, except as provided in Section&nbsp;10 of the Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Tax Consultation</U>. Purchaser understands that Purchaser may suffer adverse tax consequences as a result of Purchaser&#146;s
purchase or disposition of the Shares. Purchaser represents that Purchaser has consulted with any tax consultants Purchaser deems advisable in connection with the purchase or disposition of the Shares and that Purchaser is not relying on the Company
for any tax advice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Entire Agreement; Governing Law</U>. The Plan and Agreement are incorporated herein by reference. This Exercise
Notice, the Plan and the Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Purchaser with respect to the
subject matter hereof, and may not be modified adversely to the Purchaser&#146;s interest except by means of a writing signed by the Company and Purchaser. This agreement is governed by the internal substantive laws, but not the choice of law rules,
of California. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Submitted by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Accepted by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">PURCHASER</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">CG ONCOLOGY, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Print Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name: </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Date Received: </P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Exhibit B to Stock Option
Agreement, page <B>1</B> </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022
INCENTIVE AWARD PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURPOSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan&#146;s
purpose is to enhance the Company&#146;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or
equity-linked compensatory opportunities. Capitalized terms used in the Plan are defined in Article&nbsp;XI. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELIGIBILITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Service
Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADMINISTRATION AND DELEGATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Administration</U>. The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers
receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan
and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any
Award Agreement as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#146;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any
interest in the Plan or any Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Appointment of Committees</U>. To the extent Applicable Laws permit, the Board or the
Administrator may delegate any or all of its powers under the Plan to one or more Committees or committees of officers of the Company or any of its Subsidiaries. The Board or the Administrator, as applicable, may rescind any such delegation, abolish
any such committee or Committee and/or <FONT STYLE="white-space:nowrap">re-vest</FONT> in itself any previously delegated authority at any time. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK
AVAILABLE FOR AWARDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Number of Shares</U>. Subject to adjustment under Article&nbsp;VIII and the terms of this
Article&nbsp;IV, Awards may be made under the Plan covering up to the Overall Share Limit. As of the Plan&#146;s effective date, the Company will cease granting awards under the Prior Plan; however, the Prior Plan Awards will remain subject to the
terms of the Prior Plan. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Share Recycling</U>. If all or any part of an Award or a Prior Plan Award expires, lapses or is terminated, exchanged for or settled in
cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award or Prior Plan Award at a price not greater than the price (as
adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or again be available for Award grants under the Plan. Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or
purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation with respect to an Award or Prior Plan Award (including Shares retained by the Company from the Award or Prior Plan Award being exercised or
purchased and/or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards shall not count against the
Overall Share Limit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Incentive Stock Option Limitations</U>. Notwithstanding anything to the contrary herein, no more than
54,505,146 Shares may be issued pursuant to the exercise of Incentive Stock Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Substitute Awards</U>. In connection with an
entity&#146;s merger or consolidation with the Company or the Company&#146;s acquisition of an entity&#146;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before
such merger or consolidation by such entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the
Overall Share Limit (nor shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the
maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines
has shares available under a <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such <FONT
STYLE="white-space:nowrap">pre-existing</FONT> plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to
the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not be added to
the Shares available for Awards under the Plan as provided above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the
<FONT STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees, Consultants or Directors prior to such acquisition or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5 <U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation</U>. The Administrator may establish compensation for <FONT
STYLE="white-space:nowrap">non-employee</FONT> Directors from time to time, subject to the limitations in the Plan. The Administrator will from time to time determine the terms, conditions and amounts of all such
<FONT STYLE="white-space:nowrap">non-employee</FONT> Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from
time to time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTIONS AND STOCK APPRECIATION RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>General</U>. The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the
Plan, including any limitations in the Plan that apply to Incentive Stock Options. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise
of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the
number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the
Administrator may determine or provide in the Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Exercise Price</U>. The Administrator will establish each Option&#146;s and Stock
Appreciation Right&#146;s exercise price and specify the exercise price in the Award Agreement. Unless otherwise determined by the Administrator, the exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option
(subject to Section&nbsp;5.6) or Stock Appreciation Right. Notwithstanding the foregoing, in the case of an Option or a Stock Appreciation Right that is a Substitute Award, the exercise price per share of the Shares subject to such Option or Stock
Appreciation Right, as applicable, may be less than the Fair Market Value per share on the date of grant; provided that the exercise price of any Substitute Award shall be determined in accordance with the applicable requirements of Sections 424 and
409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Duration</U>. Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the
Award Agreement, provided that, unless otherwise determined by the Administrator, the term of an Option or Stock Appreciation Right will not exceed ten (10)&nbsp;years (subject to Section&nbsp;5.6). Notwithstanding the foregoing and unless
determined otherwise by the Company, to the extent permitted under Applicable Laws, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT
STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company
or any of its Subsidiaries, the right of the Participant and the Participant&#146;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company
otherwise determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Exercise</U>. Options and Stock Appreciation Rights may be exercised by delivering to the Company a written
notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i)&nbsp;as specified in
Section&nbsp;5.5 for the number of Shares for which the Award is exercised and (ii)&nbsp;as specified in Section&nbsp;9.5 for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be
exercised for a fraction of a Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Payment Upon Exercise</U>. Subject to Section&nbsp;10.8, any Company insider trading policy
(including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) cash, wire transfer of immediately
available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A)&nbsp;delivery (including
electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or
(B)&nbsp;the Participant&#146;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided
that such amount is paid to the Company at such time as may be required by the Administrator; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) to the extent permitted by the
Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their fair market value; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#146;s exercise valued at their fair
market value on the exercise date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) to the extent permitted by the Administrator, delivery of a promissory note or any other
property that the Administrator determines is good and valuable consideration; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) to the extent permitted by the Company, any
combination of the above payment forms approved by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Additional Terms of Incentive Stock Options</U>. The
Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections&nbsp;424(e) or (f)&nbsp;of the Code, respectively, and any other entities the
employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value on the Option&#146;s
grant date, and the term of the Option will not exceed five (5)&nbsp;years. All Incentive Stock Options will be subject to and construed consistently with Section&nbsp;422 of the Code. By accepting an Incentive Stock Option, the Participant agrees
to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i)&nbsp;two (2) years from the grant date of the Option or (ii)&nbsp;one (1)
year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other consideration, in such
disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of
the Code. Any Incentive Stock Option or portion thereof that fails to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Code for any reason, including becoming exercisable with respect to Shares having a fair market
value exceeding the $100,000 limitation under Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.422-4,</FONT> will be a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. The foregoing terms shall be incorporated
into any Award Agreement evidencing an Option intended to be an Incentive Stock Option to the extent necessary to cause such Award to so qualify. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED
STOCK; RESTRICTED STOCK UNITS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>General</U>. The Administrator may grant Restricted Stock, or the right to purchase Restricted
Stock, to any Service Provider, subject to the Company&#146;s right to repurchase all or part of such Shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such Shares) if conditions the
Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant to Service Providers
Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Restricted Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Dividends</U>. Participants holding Shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to
such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to holders of
Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stock Certificates</U>. The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock
certificates issued in respect of Shares of Restricted Stock, together with a stock power endorsed in blank. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Restricted Stock Units.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Settlement</U>. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably
practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#146;s election, in a manner intended to comply with Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stockholder Rights</U>. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit
unless and until the Shares are delivered in settlement of the Restricted Stock Unit. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER STOCK OR CASH BASED AWARDS; DIVIDEND EQUIVALENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Other Stock or Cash Based Awards</U>. Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling
Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations
in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock or
Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Dividend Equivalents</U>. A
grant of Restricted Stock Units or Other Stock or Cash Based Award may provide a Participant with the right to receive Dividend Equivalents, and no Dividend Equivalents shall be payable with respect to Options or Stock Appreciation Rights. Dividend
Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Award with to which the Dividend Equivalents are paid and
subject to other terms and conditions as set forth in the Award Agreement. Notwithstanding anything to the contrary herein, unless otherwise determined by the Administrator, Dividend Equivalents with respect to an Award shall only be paid out to a
Participant to the extent that the vesting conditions are subsequently satisfied. All such Dividend Equivalent payments will be made no later than March&nbsp;15 of the calendar year following the calendar year in which the right to the Dividend
Equivalent payment becomes nonforfeitable, unless determined otherwise by the Administrator or unless deferred in a manner intended to comply with Section&nbsp;409A. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VIII. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADJUSTMENTS FOR CHANGES IN COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND CERTAIN OTHER EVENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Equity Restructuring</U>(a) . In connection with any Equity Restructuring, notwithstanding anything to the contrary in this
Article&nbsp;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the
Award&#146;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section&nbsp;8.1 will be nondiscretionary and final and binding on the
affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>Corporate Transactions</U>. In the event of any dividend or other distribution
(whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other
disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the
Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such
terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be
made within a reasonable period of time after such change), is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x)&nbsp;prevent dilution or
enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y)&nbsp;to facilitate such transaction or event or (z)&nbsp;give effect to
such changes in Applicable Laws or accounting principles: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) To provide for the cancellation of any such Award in exchange for either an
amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#146;s rights under the vested portion of such
Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#146;s rights, in any case, is equal to or less than zero, then
the Award may be terminated without payment; provided, further, that Awards held by members of the Board will be settled in Shares on or immediately prior to the applicable event if the Administrator takes action under this clause (a); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To provide that such Award shall vest and, to the extent applicable, be exercisable as to all Shares covered thereby, notwithstanding
anything to the contrary in the Plan or the provisions of such Award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To provide that such Award be assumed by the successor or
survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of
shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) To make adjustments in the
number and type of Shares (or other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&nbsp;IV on the
maximum number and kind of shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price or applicable performance goals), and the criteria included in, outstanding Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) To replace such Award with other rights or property selected by the Administrator; and/or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <U>Effect of <FONT STYLE="white-space:nowrap">Non-Assumption</FONT> in a Change in Control</U>. Notwithstanding the provisions of
Section&nbsp;8.2, if a Change in Control occurs and a Participant&#146;s Awards are not continued, converted, assumed, or replaced with a substantially similar award by (a)&nbsp;the Company, or (b)&nbsp;a successor entity or its parent or subsidiary
(an &#147;<B><I>Assumption</I></B>&#148;), and provided that the Participant has not had a Termination of Service, then the Administrator may provide that, immediately prior to the Change in Control, such Awards
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall become fully vested, exercisable and/or payable, as applicable, and all forfeiture, repurchase and other restrictions on such Awards shall lapse, in which case, such Awards shall be
canceled upon the consummation of the Change in Control in exchange for the right to receive the Change in Control consideration payable to other holders of Common Stock (i)&nbsp;which may be on such terms and conditions as apply generally to
holders of Common Stock under the Change in Control documents (including, without limitation, any escrow, <FONT STYLE="white-space:nowrap">earn-out</FONT> or other deferred consideration provisions) or such other terms and conditions as the
Administrator may provide, and (ii)&nbsp;determined by reference to the number of Shares subject to such Awards and net of any applicable exercise price; <I>provided that</I> to the extent that any Awards constitute &#147;nonqualified deferred
compensation&#148; that may not be paid upon the Change in Control under Section&nbsp;409A without the imposition of taxes thereon under Section&nbsp;409A, the timing of such payments shall be governed by the applicable Award Agreement (subject to
any deferred consideration provisions applicable under the Change in Control documents); and <I>provided, further</I>, that if the amount to which a Participant would be entitled upon the settlement or exercise of such Award at the time of the
Change in Control is equal to or less than zero, then such Award may be terminated without payment. An Award will be considered replaced with a comparable award if the Award is exchanged for an amount of cash or other property with a value equal to
the amount that could have been obtained upon the settlement of such Award in such Change in Control (as determined by the Administrator), even if such cash or other property payable with respect to the unvested portion of such Award remains subject
to similar vesting provisions following such Change in Control. Notwithstanding the foregoing, the Administrator will have full and final authority to determine whether an Assumption of an Award has occurred in connection with a Change in Control.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 <U>Administrative Stand Still</U>. In the event of any pending stock dividend, stock split, combination or exchange of shares,
merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the Share price, including any Equity Restructuring or any
securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty (60)&nbsp;days before or after such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5 <U>General</U>. Except as expressly provided in the Plan or the Administrator&#146;s action under the Plan, no Participant will have any
rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as
expressly provided with respect to an Equity Restructuring under Section&nbsp;8.1 or the Administrator&#146;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect,
and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#146;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way
the Company&#146;s right or power to make or authorize (i)&nbsp;any adjustment, recapitalization, reorganization or other change in the Company&#146;s capital structure or its business, (ii)&nbsp;any merger, consolidation dissolution or liquidation
of the Company or sale of Company assets or (iii)&nbsp;any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may treat
Participants and Awards (or portions thereof) differently under this Article&nbsp;VIII. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS APPLICABLE TO AWARDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.1 <U>Transferability</U>. Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards other than
Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except for certain Designated Beneficiary designations, by will or the laws of descent and
distribution, or, subject to the Administrator&#146;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be exercisable only by the Participant. Any permitted transfer of an Award hereunder shall be without consideration, except as required by Applicable Law. References to a Participant, to the
extent relevant in the context, will include references to a Participant&#146;s authorized transferee that the Administrator specifically approves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.2 <U>Documentation</U>. Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator
determines. Each Award may contain terms and conditions in addition to those set forth in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.3 <U>Discretion</U>. Except as the
Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof)
uniformly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.4 <U>Termination of Status</U>. The Administrator will determine how the disability, death, retirement, an authorized leave
of absence or any other change or purported change in a Participant&#146;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#146;s legal representative, conservator,
guardian or Designated Beneficiary may exercise rights under the Award, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.5 <U>Withholding</U>. Each Participant must pay
the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by Applicable Law to be withheld in connection with such Participant&#146;s Awards by the date of the event creating the tax liability. The Company
may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of
any kind otherwise due to a Participant. In the absence of a contrary determination by the Company (or, with respect to withholding pursuant to clause (ii)&nbsp;below with respect to Awards held by individuals subject to Section&nbsp;16 of the
Exchange Act, a contrary determination by the Administrator), all tax withholding obligations will be calculated based on the minimum applicable statutory withholding rates. Subject to Section&nbsp;10.8 and any Company insider trading policy
(including blackout periods), Participants may satisfy such tax obligations (i)&nbsp;in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the
foregoing payment forms if one or more of the payment forms below is permitted, (ii)&nbsp;to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares delivered by attestation and Shares retained from the
Award creating the tax obligation, valued at their fair market value, (iii)&nbsp;if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A)&nbsp;delivery (including
electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or
(B)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding; provided
that such amount is paid to the Company at such time as may be required by the Administrator, or (iv)&nbsp;to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator. Notwithstanding any
other provision of the Plan, the number of Shares which may be so delivered or retained pursuant to clause (ii)&nbsp;of the immediately preceding sentence shall be limited to the number of Shares which have a fair market value on the date of
delivery or retention no greater than the aggregate amount of such liabilities based on the maximum individual statutory tax rate in the applicable jurisdiction at the time of such withholding (or such other rate as may be required to avoid the
liability classification of the applicable award under generally accepted accounting principles in the United States of America); provided, however, to the extent such Shares were acquired by Participant from the Company as compensation, the Shares
must have been held for the minimum period required by applicable accounting rules to avoid a charge to the Company&#146;s earnings for financial reporting purposes; provided, further, that, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such Shares delivered or retained shall be rounded up to the nearest whole Share to the extent rounding up to the nearest whole Share does not result in the liability classification of the
applicable Award under generally accepted accounting principles in the United States of America. If any tax withholding obligation will be satisfied under clause (ii)&nbsp;above by the Company&#146;s retention of Shares from the Award creating the
tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable
Participant&#146;s behalf some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#146;s acceptance of an Award under the Plan will constitute the Participant&#146;s authorization
to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.6
<U>Amendment of Award</U><U>; Repricing</U>. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an
Incentive Stock Option to a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. The Participant&#146;s consent to such action will be required unless (i)&nbsp;the action, taking into account any related action, does not materially
and adversely affect the Participant&#146;s rights under the Award, or (ii)&nbsp;the change is permitted under Article&nbsp;VIII or pursuant to Section&nbsp;10.6. Notwithstanding the foregoing or anything in the Plan to the contrary, the
Administrator may, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights that have an exercise
price in excess of Fair Market Value in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.7 <U>Conditions on Delivery of Stock</U>. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions
from Shares previously delivered under the Plan until (i)&nbsp;all Award conditions have been met or removed to the Company&#146;s satisfaction, (ii)&nbsp;as determined by the Company, all other legal matters regarding the issuance and delivery of
such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant has executed and delivered to the Company such representations or agreements as the
Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#146;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and
sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.8 <U>Acceleration</U>. The Administrator may at any time provide that any Award will become immediately vested and fully or partially
exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.9 <U>Cash Settlement</U>.
Without limiting the generality of any other provision of the Plan, the Administrator may provide, in an Award Agreement or subsequent to the grant of an Award, in its discretion, that any Award may be settled in cash, Shares or a combination
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.10 <U>Broker-Assisted Sales</U>9.11 . In the event of a broker-assisted sale of Shares in connection with the payment of
amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&nbsp;9.5: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment
first becomes due, or as soon thereafter as practicable; (b)&nbsp;such Shares may be sold as part of a block trade with other Participants in the Plan in which all Participants receive an average price; (c)&nbsp;the applicable Participant will be
responsible for all broker&#146;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d)&nbsp;to the
extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e)&nbsp;the Company and its designees are under no obligation to arrange for such sale at any
particular price; and (f)&nbsp;in the event the proceeds of such sale are insufficient to satisfy the Participant&#146;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount
in cash sufficient to satisfy any remaining portion of the Participant&#146;s obligation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>No
Right to Employment or Other Status</U>. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the
Company or any of its Subsidiaries. The Company and its Subsidiaries expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except
as expressly provided in an Award Agreement or in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>No Rights as Stockholder; Certificates</U>. Subject to the Award
Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan,
unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in
the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable
Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Effective Date and Term of Plan</U>. Unless earlier terminated by the Board, the Plan will become effective on the date it
is adopted and approved by the Board (the &#147;<B><I>Effective Date</I></B>&#148;). The Plan will remain in effect until the tenth anniversary of the earlier of (a)&nbsp;the date the Board adopted the Plan or (b)&nbsp;the date the Company&#146;s
stockholders approved the Plan, but Awards previously granted may extend beyond that date in accordance with the Plan. The Plan will be submitted for the approval of the Company&#146;s stockholders within twelve (12)&nbsp;months after the date of
the Board&#146;s adoption of the Plan. Awards may be granted or awarded prior to such stockholder approval; provided that no Award shall become exercisable, vested or realizable, as applicable to such Award, unless the Plan has been approved by the
Company&#146;s stockholders within twelve&nbsp;(12) months before or after the date the Plan was adopted by the Board; and provided, further, that if such approval has not been obtained at the end of said twelve-month period, all Awards previously
granted or awarded under the Plan shall thereupon be canceled and become null and void. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 <U>Amendment of Plan</U>. The Administrator
may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected
Participant&#146;s consent. No Awards may be granted under the Plan during any suspension period or after the Plan&#146;s termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and
the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5 <U>Provisions for Foreign Participants</U>. The Administrator may modify Awards granted to Participants who are foreign nationals or
employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other
matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6 <U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. The Company intends that all Awards be structured to comply with, or be exempt from, Section&nbsp;409A, such that no
adverse tax consequences, interest, or penalties under Section&nbsp;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#146;s consent, amend this Plan or Awards,
adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to
(A)&nbsp;exempt this Plan or any Award from Section&nbsp;409A, or (B)&nbsp;comply with Section&nbsp;409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#146;s grant date.
The Company makes no representations or warranties as to an Award&#146;s tax treatment under Section&nbsp;409A or otherwise. The Company will have no obligation under this Section&nbsp;10.6 or otherwise to avoid the taxes, penalties or interest
under Section&nbsp;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#147;nonqualified deferred
compensation&#148; subject to taxes, penalties or interest under Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Separation from Service</U>. If an Award
constitutes &#147;nonqualified deferred compensation&#148; under Section&nbsp;409A, any payment or settlement of such Award upon a termination of a Participant&#146;s Service Provider relationship will, to the extent necessary to avoid taxes under
Section&nbsp;409A, be made only upon the Participant&#146;s &#147;separation from service&#148; (within the meaning of Section&nbsp;409A), whether such &#147;separation from service&#148; occurs upon or after the termination of the
Participant&#146;s Service Provider relationship. For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#147;termination,&#148; &#147;termination of employment&#148; or like terms means a
&#147;separation from service.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Payments to Specified Employees</U>. Notwithstanding any contrary provision in the Plan or
any Award Agreement, any payment(s) of &#147;nonqualified deferred compensation&#148; required to be made under an Award to a &#147;specified employee&#148; (as defined under Section&nbsp;409A and as the Administrator determines) due to his or her
&#147;separation from service&#148; will, to the extent necessary to avoid taxes under Section&nbsp;409A(a)(2)(B)(i) of the Code, be delayed for the six (6)-month period immediately following such &#147;separation from service&#148; (or, if earlier,
until the specified employee&#146;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six (6)-month period or as soon as administratively practicable thereafter (without interest). Any
payments of &#147;nonqualified deferred compensation&#148; under such Award payable more than six (6)&nbsp;months following the Participant&#146;s &#147;separation from service&#148; will be paid at the time or times the payments are otherwise
scheduled to be made. Furthermore, notwithstanding any contrary provision of the Plan or any Award Agreement, any payment of &#147;nonqualified deferred compensation&#148; under the Plan that may be made in installments shall be treated as a right
to receive a series of separate and distinct payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.7 <U>Limitations on Liability</U>. Notwithstanding any other provisions of the
Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense
incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other
employee or agent of the Company or any Subsidiary. The Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power
relating to the Plan&#146;s administration or interpretation, against any cost or expense (including attorneys&#146; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#146;s approval) arising from any act or
omission concerning this Plan unless arising from such person&#146;s own fraud or bad faith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.8 <U><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</U>. The Company may, at the
request of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares
or other Company securities during a period of up to one hundred eighty (180)&nbsp;days following the effective date of a Company registration statement filed under the Securities Act, or such longer period as determined by the underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.9 <U>Right of First Refusal</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Before any shares of Common Stock held by a Participant or any permitted transferee (each, a &#147;<B><I>Holder</I></B>&#148;) may be
sold, pledged, assigned, hypothecated, transferred, or otherwise disposed of (each, a &#147;<B><I>Transfer</I></B>&#148;), the Company or its assignee(s) shall have a right of first refusal to purchase the shares of Common Stock proposed to be
Transferred on the terms and conditions set forth in this Section&nbsp;10.9 (the &#147;<B><I>Right of First Refusal</I></B>&#148;). In the event that the Company&#146;s charter, bylaws and/or a stockholders&#146; agreement applicable to the shares
of Common Stock contain a right of first refusal with respect to the shares of Common Stock, such right of first refusal shall apply to the shares of Common Stock to the extent such provisions are more restrictive than the Right of First Refusal set
forth in this Section&nbsp;10.9 and the Right of First Refusal set forth in this Section&nbsp;10.9 shall not in any way restrict the operation of the Company&#146;s charter, bylaws or the operation of any applicable stockholders&#146; agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In the event any Holder desires to Transfer any shares of Common Stock, the Holder shall deliver to the Company a written notice (the
&#147;<B><I>Notice</I></B>&#148;) stating: (i)&nbsp;the Holder&#146;s bona fide intention to sell or otherwise Transfer such shares of Common Stock; (ii)&nbsp;the name of each proposed purchaser or other transferee (&#147;<B><I>Proposed
Transferee</I></B>&#148;); (iii)&nbsp;the number of shares of Common Stock to be Transferred to each Proposed Transferee; and (iv)&nbsp;the price for which the Holder proposes to Transfer the shares of Common Stock (the &#147;<B><I>Offered
Price</I></B>&#148;), and the Holder shall offer such shares of Common Stock at the Offered Price to the Company or its assignee(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
Within twenty-five days after receipt of the Notice, the Company and/or its assignee(s) may elect in writing to purchase all, but not less than all, of the shares of Common Stock proposed to be Transferred to any one or more of the Proposed
Transferees by delivery of a written exercise notice to the Holder (a &#147;<B><I>Company Notice</I></B>&#148;). The purchase price (&#147;<B><I>Purchase Price</I></B>&#148;) for the shares of Common Stock repurchased under this Section&nbsp;10.9
shall be the Offered Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by
check or wire transfer), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or by any combination thereof, within five days after delivery
of the Company Notice or in the manner and at the times mutually agreed to by the Company and the Holder. Should the Offered Price specified in the Notice be payable in property other than cash, the Company or its assignee shall have the right to
pay the purchase price in the form of cash equal in amount to the value of such property, as determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) If all
or a portion of the shares of Common Stock proposed in the Notice to be Transferred are not purchased by the Company and/or its assignee(s) as provided in this Section&nbsp;10.9, then the Holder may sell or otherwise Transfer such shares of Common
Stock to that Proposed Transferee at the Offered Price or at a higher price; provided that such sale or other Transfer is consummated within sixty days after the date of the Notice; and provided, further, that any such sale or other Transfer is
effected in accordance with any Applicable Laws and the Proposed Transferee agrees in writing that the provisions of this Plan and the applicable Award Agreement and any other applicable agreements governing the shares of Common Stock to be
Transferred shall continue to apply to the shares of Common Stock in the hands of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Proposed Transferee. If the shares of Common Stock described in the Notice are not Transferred to the Proposed Transferee within such <FONT STYLE="white-space:nowrap">sixty-day</FONT>
period, a new Notice shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal, as provided herein, before any shares of Common Stock held by the Holder may be sold or otherwise
Transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Anything to the contrary contained in this Section&nbsp;10.9 notwithstanding and to the extent permitted by the
Administrator, the Transfer of any or all of the shares of Common Stock during a Participant&#146;s lifetime or upon a Participant&#146;s death by will or intestacy to the Participant&#146;s Immediate Family or a trust for the benefit of the
Participant&#146;s Immediate Family shall be exempt from the Right of First Refusal. As used herein, &#147;<B><I>Immediate Family</I></B>&#148; shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister or stepchild
(whether or not adopted). In such case, the transferee or other recipient shall receive and hold the shares of Common Stock so Transferred subject to the provisions of this Plan (including the Right of First Refusal), the applicable Award Agreement
and any other applicable agreements governing the shares of Common Stock to be Transferred, and there shall be no further Transfer of such shares of Common Stock except in accordance with the terms of this Section&nbsp;10.9 (or otherwise as
expressly provided under the Plan). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Right of First Refusal shall terminate as to all shares of Common Stock upon the occurrence
of a Change in Control or the Public Trading Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.10 <U>Data Privacy</U>. As a condition for receiving any Award, each Participant
explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing,
administering and managing the Participant&#146;s participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#146;s name, address and telephone
number; birthdate; social security number, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer
the Plan and Awards (the &#147;<B><I>Data</I></B>&#148;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#146;s participation in the Plan, and
the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#146;s country, or elsewhere,
and the Participant&#146;s country may have different data privacy laws and protections than the recipients&#146; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in
electronic or other form, to implement, administer and manage the Participant&#146;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any
Shares. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#146;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding
such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this
Section&nbsp;10.10 in writing, without cost, by contacting the local human resources representative. If the Participant refuses or withdraws the consents in this Section&nbsp;10.10, the Company may cancel Participant&#146;s ability to participate in
the Plan and, in the Administrator&#146;s discretion, the Participant may forfeit any outstanding Awards. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources
representative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.11 <U>Severability</U>. If any portion of the Plan or any action taken under it is held illegal or invalid for any
reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.12 <U>Governing Documents</U>. If any contradiction occurs between the Plan and any Award
Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a
specific provision of the Plan will not apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.13 <U>Governing Law; Venue; Waiver of Jury Trial</U>. The Plan and all Awards will be
governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles requiring the application of a
jurisdiction&#146;s laws other than the State of Delaware. By accepting an Award, each Participant irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of Delaware and of the United States of
America, in each case located in the State of Delaware, for any action arising out of or relating to the Plan (and agrees not to commence any litigation relating thereto except in such courts), and further agrees that service of any process,
summons, notice or document by U.S. registered mail to the address contained in the records of the Company shall be effective service of process for any litigation brought against it in any such court. By accepting an Award, each Participant
irrevocably and unconditionally waives any objection to the laying of venue of any litigation arising out of the Plan or any Award hereunder in the courts of the State of Delaware or the United States of America, in each case located in the State of
Delaware, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such litigation brought in any such court has been brought in an inconvenient forum. By accepting an Award, each Participant
irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any and all rights to trial by jury in connection with any litigation arising out of or relating to the Plan or any Award hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.14 <U>Restrictions on Shares; Claw-Back Provisions</U>. Awards and shares of Common Stock acquired in respect of Awards shall be subject to
such terms and conditions as the Administrator shall determine, including, without limitation, restrictions on the transferability of shares of Common Stock, the right of the Company to repurchase shares of Common Stock, the right of the Company to
require that shares of Common Stock be transferred in the event of certain transactions, <FONT STYLE="white-space:nowrap">tag-along</FONT> rights, bring-along rights, redemption and <FONT STYLE="white-space:nowrap">co-sale</FONT> rights and voting
requirements. Such terms and conditions may be additional to those contained in the Plan and may, as determined by the Administrator, be contained in the applicable Award Agreement or in an exercise notice, stockholders&#146; agreement or in such
other agreement as the Administrator shall determine, in each case in a form determined by the Administrator. The issuance of such shares of Common Stock shall be conditioned on the Participant&#146;s consent to such terms and conditions and the
Participant&#146;s entering into such agreement or agreements. All Awards (including any proceeds, gains or other economic benefit actually or constructively received by Participant upon any receipt or exercise of any Award or upon the receipt or
resale of any shares of Common Stock underlying the Award) shall be subject to the provisions of any claw-back policy implemented by the Company, including, without limitation, any claw-back policy adopted to comply with Applicable Laws (including
the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder), to the extent set forth in such claw-back policy and/or in the applicable Award Agreement. A Participant shall, as a condition to
receiving an Award, agree to execute such further instruments and to take such further action as the Company requests to carry out the purposes and intent of this Section&nbsp;10.14. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.15 <U>Titles and Headings</U>. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the
Plan&#146;s text, rather than such titles or headings, will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.16 <U>Conformity to Securities Laws</U>. Participant acknowledges
that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent Applicable Laws
permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.17 <U>Relationship to Other Benefits</U>. No payment under the Plan will be taken into
account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.18 <U>Plan Language</U>. The official language of the Plan shall be English. To the extent that the Plan or any Award
Agreements are translated from English into another language, the English version of the Plan and Award Agreements will always govern, in the event that there are inconsistencies or ambiguities which may arise due to such translation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.19 <U>Applicable Currency</U>. The Award Agreement shall specify the currency applicable to such Award. The Administrator may determine, in
its sole discretion, that an Award denominated in one currency may be paid in any other currency based on the prevailing exchange rate as the Administrator deems appropriate. A Participant may be required to provide evidence that any currency used
to pay the exercise price of any Award were acquired and taken out of the jurisdiction in which the Participant resides in accordance with Applicable Laws, including foreign exchange control laws and regulations. In the absence of a designation in
an Award Agreement, the currency applicable to an Award shall be U.S. Dollars. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in
the Plan, the following words and phrases will have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 &#147;<B><I>Administrator</I></B>&#148; means the Board
or a Committee to the extent that the Board&#146;s powers or authority under the Plan have been delegated to such Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2
&#147;<B><I>Applicable Laws</I></B>&#148; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any
stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 &#147;<B><I>Award</I></B>&#148; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights,
Restricted Stock, Restricted Stock Units, Dividend Equivalents, or Other Stock or Cash Based Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4 &#147;<B><I>Award
Agreement</I></B>&#148; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5 &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6 &#147;<B><I>Cause</I></B>&#148; means (a)&nbsp;if a Participant is a party to a written employment, severance or consulting agreement
with the Company or any of its Subsidiaries or an Award Agreement in which the term &#147;cause&#148; is defined (a &#147;<B><I>Relevant Agreement</I></B>&#148;), &#147;Cause&#148; as defined in the Relevant Agreement, and (b)&nbsp;if no Relevant
Agreement exists, (i)&nbsp;the Administrator&#146;s determination that the Participant failed to substantially perform the Participant&#146;s duties (other than a failure resulting from the Participant&#146;s Disability); (ii) the
Administrator&#146;s determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participant&#146;s immediate supervisor; (iii)&nbsp;the Participant&#146;s unauthorized use or
disclosure of confidential information or trade secrets of the Company or any of its Subsidiaries or any material breach of a written agreement between the Participant and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company; (iv)&nbsp;the occurrence of any act or omission by the Participant that could reasonably be expected to result in (or has resulted in) the Participant&#146;s conviction, plea of no
contest, plea of nolo contendere, or imposition of <FONT STYLE="white-space:nowrap">un-adjudicated</FONT> probation for any felony or indictable offense or crime involving moral turpitude; (v)&nbsp;the Participant&#146;s unlawful use (including
being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&#146;s duties and responsibilities for the Company or any of its Subsidiaries; or (vi)&nbsp;the
Participant&#146;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.7 &#147;<B><I>Change in Control</I></B>&#148; means and includes each of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement
filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i)&nbsp;and (ii) of subsection&nbsp;(c) below) whereby any &#147;person&#148; or related &#147;group&#148; of
&#147;persons&#148; (as such terms are used in Sections&nbsp;13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a
&#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#146;s securities outstanding immediately after such acquisition; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) During any period of two (2)&nbsp;consecutive years, individuals who, at the beginning of such period, constitute the Board together with
any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a)&nbsp;or (c)) whose election by the Board or nomination for election by
the Company&#146;s stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the Directors then still in office who either were Directors at the beginning of the two (2)-year period or whose election or
nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The consummation by the
Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&nbsp;a merger, consolidation, reorganization, or business combination or (y)&nbsp;a sale or other disposition of all or
substantially all of the Company&#146;s assets in any single transaction or series of related transactions or (z)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) which results in the Company&#146;s voting securities outstanding immediately before the transaction continuing to represent (either by
remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the
Company&#146;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#147;<B><I>Successor Entity</I></B>&#148;)) directly or indirectly, at least a majority of the combined voting power of the Successor
Entity&#146;s outstanding voting securities immediately after the transaction, and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) after which no person or group beneficially owns
voting securities representing 50% or more of the combined voting power of the Successor Entity; <U>provided</U>, <U>however</U>, that no person or group shall be treated for purposes of this clause (ii)&nbsp;as beneficially owning 50% or more of
the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the following events shall not constitute a &#147;Change in
Control&#148;: (x) an initial public offering of any of the Company&#146;s securities; (y)&nbsp;a reincorporation of the Company solely to change its jurisdiction; or (z)&nbsp;a transaction undertaken for the primary purpose of creating a holding
company that will be owned in substantially the same proportion by the persons who held the Company&#146;s securities immediately before such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that
provides for the deferral of compensation that is subject to Section&nbsp;409A, to the extent required to avoid the imposition of additional taxes under Section&nbsp;409A, the transaction or event described in subsection&nbsp;(a), (b) or
(c)&nbsp;with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#147;change in control event,&#148; as defined in Treasury
Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator shall have full and final authority,
which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto;
provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#147;change in control event&#148; as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT>
shall be consistent with such regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.8 &#147;<B><I>Code</I></B>&#148; means the U.S. Internal Revenue Code of 1986, as amended,
and the regulations issued thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.9 &#147;<B><I>Committee</I></B>&#148; means one or more committees or subcommittees of the
Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> it is intended that each
member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148;
within the meaning of Rule <FONT STYLE="white-space:nowrap">16b-3;</FONT> however, a Committee member&#146;s failure to qualify as a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; within the meaning of Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.10 &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.11 &#147;<B><I>Company</I></B>&#148; means CG Oncology, Inc., a Delaware corporation, or any successor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.12 &#147;<B><I>Consultant</I></B>&#148; means any consultant or advisor (whether an entity or natural person) engaged by the Company or any
of its Subsidiaries to render services to such entity if the consultant or advisor is eligible to be offered securities registrable on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.13 &#147;<B><I>Designated Beneficiary</I></B>&#148; means the beneficiary or beneficiaries the Participant designates, in a manner the
Administrator determines, to receive amounts due or exercise the Participant&#146;s rights if the Participant dies or becomes incapacitated. Without a Participant&#146;s effective designation, &#147;Designated Beneficiary&#148; will mean the
Participant&#146;s estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.14 &#147;<B><I>Director</I></B>&#148; means a Board member. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.15 &#147;<B><I>Disability</I></B>&#148; means a permanent and total disability under Section&nbsp;22(e)(3) of the Code, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.16 &#147;<B><I>Dividend Equivalents</I></B>&#148; means a right granted to a Participant
under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.17 &#147;<B><I>Employee</I></B>&#148;
means any employee of the Company or its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.18 &#147;<B><I>Equity Restructuring</I></B>&#148; means a <FONT
STYLE="white-space:nowrap">non-reciprocal</FONT> transaction between the Company and its stockholders, such as a stock dividend, stock split, <FONT STYLE="white-space:nowrap">spin-off</FONT> or recapitalization through a large, nonrecurring cash
dividend that affects the number or kind of Shares (or other securities of the Company) or the share price of Common Stock (or other securities of the Company) and causes a change in the per share value of the Common Stock underlying outstanding
Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.19 &#147;<B><I>Exchange Act</I></B>&#148; means the U.S. Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.20 &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a Share of Common Stock determined as follows:
(a)&nbsp;if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day
preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal</I> or another source the Administrator deems reliable; (b)&nbsp;if the Common Stock is not traded on a stock exchange but is quoted on a national market or
other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in <I>The Wall Street Journal </I>or another source the
Administrator deems reliable; or (c)&nbsp;in the absence of an established market for the Common Stock, the Administrator may determine the Fair Market Value in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.21 &#147;<B><I>Good Reason</I></B>&#148; means (a)&nbsp;if a Participant is a party to a Relevant Agreement, &#147;Good Reason&#148; as
defined in the Relevant Agreement, and (b)&nbsp;if no Relevant Agreement exists, (i)&nbsp;a material diminution in the Participant&#146;s level of base compensation, except in connection with a general reduction in the base compensation of the
Company&#146;s personnel with similar status and responsibilities or (ii)&nbsp;a relocation of the Participant&#146;s place of employment by more than fifty (50)&nbsp;miles, provided that such change, reduction or relocation is effected by the
Company (or its subsidiary employing the Participant) without the Participant&#146;s consent. Notwithstanding the foregoing, Good Reason shall only exist if Participant shall have provided the Company with written notice within sixty (60)&nbsp;days
of the initial occurrence of any of the foregoing events or conditions, and the Company or any successor or affiliate fails to eliminate the conditions constituting Good Reason within thirty (30)&nbsp;days after receipt of written notice of such
event or condition from Participant. Participant&#146;s resignation from employment with the Company for &#147;Good Reason&#148; must occur within six (6)&nbsp;months following the initial occurrence of one of the foregoing events or conditions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.22 &#147;<B><I>Greater Than 10% Stockholder</I></B>&#148; means an individual then owning (within the meaning of Section&nbsp;424(d)
of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporation, as defined in Section&nbsp;424(e) and (f)&nbsp;of the Code, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.23 &#147;<B><I>Incentive Stock Option</I></B>&#148; means an Option intended to qualify as an &#147;incentive stock option&#148; as defined
in Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.24 &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</I></B>&#148; means
an Option, or portion thereof, not intended or not qualifying as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.25 &#147;<B><I>Option</I></B>&#148; means
an option to purchase Shares, which will either be an Incentive Stock Option or a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.26 &#147;<B><I>Other Stock or Cash Based Awards</I></B>&#148; means cash awards, awards
of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property awarded to a Participant under Article&nbsp;VII. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.27 &#147;<B><I>Overall Share Limit</I></B>&#148; means the sum of (i) 12,081,562 Shares; plus (ii)&nbsp;such number of Shares as remain
available for issuance under the Prior Plan as of the Effective Date, which number is 11,320,380 Shares; plus (iii)&nbsp;any shares of Common Stock which are subject to Prior Plan Awards which become available for issuance under the Plan pursuant to
Article IV, which number of Shares shall not exceed 31,103,204 Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.28 &#147;<B><I>Participant</I></B>&#148; means a Service
Provider who has been granted an Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.29 &#147;<B><I>Performance Criteria</I></B>&#148; means the criteria (and adjustments) that
the Administrator may select for an Award to establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and <FONT
STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross
profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash
flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs,
reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends);
regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added
models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human capital management (including diversity and inclusion); supervision of
litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital
raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may
be based solely by reference to the Company&#146;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or
upon comparisons of any of the indicators of performance relative to performance of other companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.30 &#147;<B><I>Plan</I></B>&#148;
means this 2022 Incentive Award Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.31 &#147;<B><I>Prior Plan</I></B>&#148; means the CG Oncology, Inc. 2015 Equity Incentive Plan,
as may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.32 &#147;<B><I>Prior Plan Award</I></B>&#148; means an award outstanding under the Prior Plan as
of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.33 &#147;<B><I>Public Trading Date</I></B>&#148; means the first date upon which the Common Stock is listed (or
approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system, or, if earlier, the date on which the
Company becomes a &#147;publicly held corporation&#148; for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.162-27(c)(1).</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.34 &#147;<B><I>Restricted Stock</I></B>&#148; means Shares awarded to a Participant under
Article&nbsp;VI subject to certain vesting conditions and other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.35 &#147;<B><I>Restricted Stock Unit</I></B>&#148; means
an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date awarded to a Participant under
Article&nbsp;VI subject to certain vesting conditions and other restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.36 &#147;<B><I>Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.37 &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148; means Section&nbsp;409A of the Code and all regulations,
guidance, compliance programs and other interpretative authority thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.38 &#147;<B><I>Securities Act</I></B>&#148; means the
U.S. Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.39 &#147;<B><I>Service Provider</I></B>&#148; means an Employee, Consultant or Director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.40 &#147;<B><I>Shares</I></B>&#148; means shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.41 &#147;<B><I>Stock Appreciation Right</I></B>&#148; means a stock appreciation right granted under Article&nbsp;V. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.42 &#147;<B><I>Subsidiary</I></B>&#148; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of
entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of
all classes of securities or interests in one of the other entities in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.43 &#147;<B><I>Substitute Awards</I></B>&#148;
means Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any
Subsidiary or with which the Company or any Subsidiary combines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.44 &#147;<B><I>Termination of Service</I></B>&#148; means the date
the Participant ceases to be a Service Provider. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 INCENTIVE AWARD PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALIFORNIA SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Administrator has adopted this supplement for purposes of satisfying the requirements of Section&nbsp;25102(o) of the California
Corporations Code and the regulations issued thereunder (&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;25102(o)</I></B>&#148;). Notwithstanding anything to the contrary contained in the Plan and except as otherwise determined by the
Administrator, the provisions set forth in this supplement shall apply to all Awards granted under the Plan to a Participant who is a resident of the State of California on the date of grant (a &#147;<B><I>California Participant</I></B>&#148;) and
which are intended to be exempt from registration in California pursuant to Section&nbsp;25102(o). This supplement shall not apply to Awards granted to California Participants on or after the Public Trading Date. Definitions in the Plan are
applicable to this supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Limitation on Securities Issuable Under the Plan</U><I>. </I>The amount of securities issued
pursuant to the Plan shall not exceed the amounts permitted under Section&nbsp;260.140.45 of the California Code of Regulations to the extent applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.<I> </I><U>Additional Limitations On Options</U><I>. </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <I>Maximum Duration of Options.</I>&nbsp;No Options granted to California Participants will be granted for a term in excess of
ten&nbsp;(10) years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <I>Minimum Exercise Period Following Termination.</I>&nbsp;Unless a California Participant&#146;s Service
Provider relationship is terminated for Cause, in the event of termination of such Participant&#146;s Service Provider relationship, to the extent required by Applicable Laws, he or she shall have the right to exercise an Option, to the extent that
he or she was otherwise entitled to exercise such Option on the date employment terminated, as follows: (i)&nbsp;at least six (6)&nbsp;months from the date of termination, if termination was caused by such Participant&#146;s death or Disability and
(ii)&nbsp;at least thirty&nbsp;(30) days from the date of termination, if termination was caused other than by such Participant&#146;s death or Disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Additional Limitations for Restricted Stock Awards, Restricted Stock Units and Other Stock-Based Awards</U><I>.</I>&nbsp;The terms of
all Awards granted to California Participants shall comply, to the extent applicable, with Section&nbsp;260.140.41 and Section&nbsp;260.140.42 of the California Code of Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Adjustments</U>. The Administrator will make such adjustments to an Award held by a California Participant as may be required by
Section&nbsp;260.140.41 or Section&nbsp;260.140.42 of the California Code of Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Additional Requirement to Provide
Information to California Participants</U><I>.</I>&nbsp;To the extent required by Section&nbsp;260.140.46 of the California Code of Regulations, the Company shall provide to each California Participant and to each California Participant who acquires
Common Stock pursuant to the Plan, not less frequently than annually, copies of annual financial statements (which need not be audited). The Company shall not be required to provide such statements to key persons whose duties in connection with the
Company assure their access to equivalent information. In addition, this information requirement shall not apply to the Plan to the extent that it complies with all conditions of Rule 701 of the Securities Act (&#147;<B><I>Rule 701</I></B>&#148;) as
determined by the Administrator; provided that for purposes of determining such compliance, any registered domestic partner shall be considered a &#147;family member&#148; as that term is defined in Rule 701. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Stockholder Approval; Additional Limitations On Timing Of Awards</U><I>.</I>&nbsp;The
Plan will be submitted for the approval of the Company&#146;s stockholders within twelve (12)&nbsp;months after the date of the Board&#146;s adoption of the Plan. Awards may be granted or awarded prior to such stockholder approval; provided that no
Award granted to a California Participant shall become exercisable, vested or realizable, as applicable to such Award, unless the Plan has been approved by the Company&#146;s stockholders within twelve&nbsp;(12) months before or after the date the
Plan was adopted by the Administrator; and provided, further, that if such approval has not been obtained at the end of said twelve (12)-month period, all Awards previously granted or awarded under the Plan to California Participants shall thereupon
be canceled and become null and void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 INCENTIVE AWARD PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT GRANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;) have the
meanings given to them in the 2022 Incentive Award Plan (as amended from time to time, the &#147;<B><I>Plan</I></B>&#148;) of CG Oncology, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the participant listed below (&#147;<B><I>Participant</I></B>&#148;) the Restricted Stock Units described in this
Grant Notice (the &#147;<B><I>RSUs</I></B>&#148;), subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement attached hereto as <B>Exhibit A</B> (the &#147;<B><I>Agreement</I></B>&#148;), both of which are incorporated
into this Grant Notice by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>[Insert Participant Name]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>[Insert Grant Date]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Commencement Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>[Insert Vesting Commencement Date]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of RSUs:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>[Insert Number of RSUs]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting and Distribution Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Insert Vesting Schedule]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, in the event a Participant experiences a Termination of Service as a result of (a)&nbsp;Participant&#146;s termination by the Company other than
for Cause (and excluding a Termination of Service as a result of Participant&#146;s death or Disability), or (b)&nbsp;Participant&#146;s resignation for Good Reason, in each case within eighteen (18)&nbsp;months following a Change in Control, then
any remaining unvested RSUs shall become fully vested on the date of such Termination of Service.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company uses an electronic capitalization table system (such as E*Trade, Shareworks or Carta) and the
fields in this Grant Notice are blank or the information is otherwise provided in a different format electronically, the blank fields and other information shall be deemed to come from the electronic capitalization system and is considered part of
this Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By accepting (whether in writing, electronically or otherwise, including an acceptance through an electronic
capitalization table system used by the Company) the RSUs, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has
had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all
decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>CG ONCOLOGY, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>PARTICIPANT</B></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Print&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Print&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED STOCK UNIT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant
Notice, in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Award of
RSUs</U>. The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#147;<B><I>Grant Date</I></B>&#148;). Each RSU represents the right to receive one Share, as set forth in this Agreement.
Participant will have no right to the distribution of any Shares until the time (if ever) the RSUs have vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Incorporation of
Terms of Plan</U>. The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan
will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Unsecured Promise</U>. The RSUs will at all times prior to settlement represent an unsecured Company obligation
payable only from the Company&#146;s general assets. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VESTING; FORFEITURE AND SETTLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Vesting; Forfeiture</U>. The RSUs will vest according to the vesting schedule in the Grant Notice (the &#147;<B><I>Vesting
Schedule</I></B>&#148;), except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. Except as provided in the Grant Notice, in the event of Participant&#146;s
Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Settlement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) RSUs will be paid in Shares as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than
sixty days after the applicable vesting date. Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably
determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(7)(ii)),</FONT> provided the Company reasonably believes the delay will not result
in the imposition of excise taxes under Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) All distributions shall be made by the Company in the form of whole shares
of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Neither the time nor form of distribution of Shares with respect to the RSUs may be changed, except as may be
permitted by the Administrator in accordance with the Plan and Section&nbsp;409A of the Code and the Treasury Regulations thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAXATION AND TAX WITHHOLDING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Taxes; Tax Withholding. </U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the RSUs to Participant or his
or her legal representative unless and until Participant or his or her legal representative shall have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes required by Applicable Law to be withheld in
connection with the vesting or settlement of the RSUs, the distribution of the Shares issuable with respect thereto, or any other taxable event related to the RSUs (the &#147;<B><I>Tax Withholding Obligation</I></B>&#148;). The Company shall have
the authority and the right to deduct or withhold, or require Participant to remit to the Company, an amount sufficient to satisfy any Tax Withholding Obligation, including, without limitation, the authority to deduct such amounts from other
compensation payable to Participant by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Unless Participant elects to satisfy the Tax Withholding Obligation by some other
means in accordance with Section&nbsp;9.5 of the Plan, the Company shall have the right, but not the obligation, with respect to the Tax Withholding Obligation arising as a result of the vesting or distribution of the RSUs, to treat
Participant&#146;s failure to provide timely payment in accordance with Section&nbsp;9.5 of the Plan as Participant&#146;s election to satisfy the Tax Withholding Obligation by requesting the Company to withhold a net number of vested Shares
otherwise issuable pursuant to the RSUs having a then-current fair market value not exceeding the amount necessary to satisfy the Tax Withholding Obligation (provided that if Participant is subject to Section&nbsp;16 of the Exchange Act, any such
action by the Company shall require the approval of the Administrator). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Participant acknowledges that Participant is ultimately
liable and responsible for all taxes owed in connection with the RSUs, regardless of any action the Company or any Subsidiary takes with respect to any Tax Withholding Obligations that arise in connection with the RSUs. Neither the Company nor any
Subsidiary makes any representation or undertaking regarding the tax treatment to Participant in connection with the awarding, vesting or payment of the RSUs or the subsequent sale of Shares. The Company and its Subsidiaries do not commit and are
under no obligation to structure the RSUs to reduce or eliminate Participant&#146;s tax liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Participant represents to the
Company that Participant has reviewed with Participant&#146;s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any
statements or representations of the Company or any of its agents. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PARTICIPANT REPRESENTATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the award of the RSUs, Participant represents to the Company the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Participant is aware of the Company&#146;s business affairs and financial condition and has acquired sufficient information about the
Company to reach an informed and knowledgeable decision to acquire the Shares issuable upon settlement of the RSUs. Participant is acquiring these Shares for investment for Participant&#146;s own account only and not with a view to, or for resale in
connection with, any &#147;distribution&#148; thereof within the meaning of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Participant acknowledges and understands that the Shares constitute &#147;restricted
securities&#148; under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Participant&#146;s investment
intent as expressed herein. Participant further understands that the Shares must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further
acknowledges and understands that the Company is under no obligation to register the Shares. Participant understands that the certificate evidencing the Shares may be imprinted with a legend which prohibits the transfer of the Shares unless they are
registered or such registration is not required in the opinion of counsel satisfactory to the Company and any other legend required under Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Participant is familiar with the provisions of Rule&nbsp;701 and Rule&nbsp;144, each promulgated under the Securities Act, which, in
substance, permit limited public resale of &#147;restricted securities&#148; acquired, directly or indirectly from the issuer thereof, in a <FONT STYLE="white-space:nowrap">non-public</FONT> offering subject to the satisfaction of certain
conditions. In the event the Company becomes subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Exchange Act, ninety (90)&nbsp;days thereafter (or such longer period as any market
<FONT STYLE="white-space:nowrap">stand-off</FONT> agreement may require) the Shares exempt under Rule&nbsp;701 may under present law be resold, subject to the satisfaction of certain of the conditions specified by Rule&nbsp;144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In the event that the Company does not qualify under Rule&nbsp;701 at the time of purchase of the Shares, then the Shares may be resold in
certain limited circumstances subject to the provisions of Rule&nbsp;144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Participant further understands that in the event all of
the applicable requirements of Rule&nbsp;701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rules 144 and
701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 will
have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk.
Participant understands that no assurances can be given that any such other registration exemption will be available in such event. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Award Not Transferable; Other Restrictions</U>. Without limiting the generality of any other provision hereof, the
Award shall be subject to the restrictions on transferability set forth in Section&nbsp;9.1 of the Plan. Without limiting the generality of any other provision hereof, the Participant hereby expressly acknowledges that Section&nbsp;10.8 (&#147;<I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</I>&#148;), Section&nbsp;10.9 (&#147;<I>Right of First Refusal</I>&#148;) and Section&nbsp;10.14 (&#147;<I>Restrictions on Shares; Claw-Back Provisions</I>&#148;) of the Plan are expressly
incorporated into this Agreement and are applicable to the Shares issued pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Restrictive Legends and
Stop</U><U><FONT STYLE="white-space:nowrap">-Transfer</FONT> Orders.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Legends</U>. The Participant understands and agrees that
the Company shall cause the legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by state or federal
securities laws: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION
WITH, THE SALE OR DISTRIBUTION THEREOF. THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#147;ACT&#148;) OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED,
PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT AND SUCH LAWS OR, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN
COMPLIANCE THEREWITH. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN REPURCHASE RIGHTS,
FORFEITURE PROVISIONS, TRANSFER RESTRICTIONS AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEE(S), AS SET FORTH IN A RESTRICTED STOCK UNIT AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, COPIES OF WHICH MAY BE
OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH REPURCHASE RIGHTS, FORFEITURE PROVISIONS, TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stop</U><U><FONT STYLE="white-space:nowrap">-Transfer</FONT> Notices</U>. The Participant agrees that, in order to ensure compliance
with the restrictions referred to herein, the Company may issue appropriate &#147;stop transfer&#148; instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to&nbsp;the
same effect in its own records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Refusal to Transfer</U>. The Company shall not be required (i)&nbsp;to transfer on its books any
Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii)&nbsp;to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom
such Shares shall have been so transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Restrictions on Transfer</U>. In addition to the limitations contained in
Section&nbsp;5.1 above and this Section&nbsp;5.2, the Participant agrees and acknowledges that Participant will not transfer in any manner the Shares issued pursuant to this Agreement unless (i)&nbsp;the transfer is pursuant to an effective
registration statement under the Securities Act or the rules and regulations in effect thereunder, or (ii)&nbsp;counsel for the Company shall have reasonably concluded that no such registration is required because of the availability of an exemption
from registration under the Securities Act. To the extent permitted by Applicable Laws, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Adjustments</U>. Participant acknowledges that the RSUs and the Shares issuable with respect thereto are subject to adjustment,
modification and termination in certain events as provided in this Agreement and the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Notices</U>. Any notice to be given
under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#146;s Secretary at the Company&#146;s principal office or the Secretary&#146;s then-current email address or facsimile number.
Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#146;s last known mailing address, email address or facsimile number in the Company&#146;s personnel files. By a
notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt
requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile
transmission confirmation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Titles</U>. Titles are provided herein for convenience only and are not to serve as a
basis for interpretation or construction of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Conformity to Securities Laws</U>. Notwithstanding any other provision
of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the RSUs will be subject to any additional limitations set forth in any applicable exemptive rule under
Section&nbsp;16 of the Exchange Act (including any amendment to Rule <FONT STYLE="white-space:nowrap">16b-3)</FONT> that are requirements for the application of such exemptive rule. Participant acknowledges that the Plan, the Grant Notice and this
Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended to the extent necessary to conform to such Applicable Laws or any such exemptive rule described in
the preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Successors and Assigns</U>. The Company may assign any of its rights under this Agreement to single or
multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in the Plan, this Agreement shall be binding upon and inure to the benefit of
the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Entire Agreement</U>. The Plan, the
Grant Notice and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. Participant hereby agrees
to execute such further instruments and to take such further action as the Company requests to carry out the purposes and intent of this Agreement and the Plan, including, without limitation, restrictions on the transferability of the Shares, the
right of the Company to repurchase the Shares pursuant to Section&nbsp;10.9 of the Plan, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions,
<FONT STYLE="white-space:nowrap">tag-along</FONT> rights, bring-along rights, redemption and <FONT STYLE="white-space:nowrap">co-sale</FONT> rights and voting requirements in accordance with the Plan. This Agreement may be amended by the Company in
accordance with Section&nbsp;9.6 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Agreement Severable</U>. In the event that any provision of the Grant Notice or this
Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Limitation on Participant&#146;s Rights</U>. Participation in the Plan confers no rights or interests other than as herein provided.
This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have
only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Shares as a general unsecured creditor with
respect to the RSUs, as and when settled pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Rights as a Stockholder</U>. Neither Participant nor any
person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book-entry
form) will have been issued and recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account). Except as otherwise provided herein, after such
issuance, recordation and delivery, Participant will have all the rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares. The issuance of Shares under this
Award to Participant shall be subject to Participant&#146;s satisfaction of the conditions under Section&nbsp;10.14 of the Plan and execution of a counterpart signature page or joinder agreeing to be subject to any stockholders agreement as the
Administrator shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Not a Contract of Employment</U>. Nothing in the Plan, the Grant Notice or this Agreement confers
upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or
terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>Counterparts</U>. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject
to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14
<U>Section</U><U></U><U>&nbsp;409A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any other provision of the Plan, this Agreement or the Grant Notice, the
Plan, this Agreement and the Grant Notice shall be interpreted in accordance with, and incorporate the terms and conditions required by, Section&nbsp;409A of the Code (together with any Department of Treasury regulations and other interpretive
guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date, &#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;). The Administrator may, in its
discretion, adopt such amendments to the Plan, this Agreement or the Grant Notice or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator
determines are necessary or appropriate to comply with the requirements of Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Agreement is not intended to
provide for any deferral of compensation subject to Section&nbsp;409A, and, accordingly, the Shares issuable pursuant to the RSUs shall be distributed to Participant no later than the later of: (A)&nbsp;the fifteenth (15<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>) day of the third month following Participant&#146;s first taxable year in which such RSUs are no longer subject to a substantial risk of forfeiture, and (B)&nbsp;the fifteenth (15<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP>) day of the third month following first taxable year of the Company in which such RSUs are no longer subject to substantial risk of forfeiture, as determined in accordance with Section&nbsp;409A.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For purposes of Section&nbsp;409A (including, without limitation, for purposes of Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> each payment that Participant may be eligible to receive under this Agreement shall be treated as a separate and distinct payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.15 <U>Governing Law</U>. The provisions of the Plan and all Awards made thereunder, including the RSUs, shall be governed by and interpreted
in accordance with the laws of the State of Delaware, disregarding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles of the law of any state that would require the application of the laws of a
jurisdiction other than such state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 INCENTIVE AWARD PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION GRANT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Stock Option Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;) have the meanings
given to them in the 2022 Incentive Award Plan (as amended from time to time, the &#147;<B><I>Plan</I></B>&#148;) of CG Oncology, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the participant listed below (&#147;<B><I>Participant</I></B>&#148;) the stock option described in this Grant
Notice (the &#147;<B><I>Option</I></B>&#148;), subject to the terms and conditions of the Plan and the Stock Option Agreement attached hereto as <B>Exhibit A</B> (the &#147;<B><I>Agreement</I></B>&#148;), both of which are incorporated into this
Grant Notice by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Participant Name]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Grant Date]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Exercise Price]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shares Subject to the Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Number of Options]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Final Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Tenth Anniversary of Grant Date]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Commencement Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Vesting Commencement Date]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>[Insert Vesting Schedule]</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, in the event a Participant experiences a Termination of Service as a result of (a)&nbsp;Participant&#146;s termination by the Company other than
for Cause (and excluding a Termination of Service as a result of Participant&#146;s death or Disability), or (b)&nbsp;Participant&#146;s resignation for Good Reason, in each case within eighteen (18)&nbsp;months following a Change in Control, then
any remaining unvested portion of the Option shall become fully vested and exercisable on the date of such Termination of Service.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Option </B><B><I>(select one)</I></B><B>:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Incentive Stock Option</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#9744; <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company uses an electronic capitalization table system (such as E*Trade, Shareworks or Carta) and the
fields in this Grant Notice are blank or the information is otherwise provided in a different format electronically, the blank fields and other information shall be deemed to come from the electronic capitalization system and is considered part of
this Grant Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By accepting (whether in writing, electronically or otherwise, including an acceptance through an electronic
capitalization table system used by the Company) the Option, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has
had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all
decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PARTICIPANT</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant
Notice, in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Grant of
Option</U>. The Company has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#147;<B><I>Grant Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Incorporation of Terms of Plan</U>. The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which
is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PERIOD OF
EXERCISABILITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Commencement of Exercisability</U>. The Option will vest and become exercisable according to the vesting
schedule in the Grant Notice (the &#147;<B><I>Vesting Schedule</I></B>&#148;), except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable only when a whole Share
has accumulated. The Option shall not be exercisable with respect to fractional Shares. Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, the Option will immediately expire and be forfeited as to any portion
that is not vested and exercisable as of Participant&#146;s Termination of Service for any reason, except as may be otherwise provided by the Administrator or as set forth in another written agreement between the Company or any Subsidiary and
Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Duration of Exercisability</U>. The Vesting Schedule is cumulative. Any portion of the Option which vests and becomes
exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Expiration of Option</U>. Subject to Section&nbsp;5.3 of the Plan, the Option may not be exercised to any extent by anyone after, and
will expire on, the first of the following to occur: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The final expiration date in the Grant Notice, which shall in no event be more
than ten (10)&nbsp;years from the Grant Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If this Option is designated as an Incentive Stock Option and the Participant, at the
time the Option was granted, was a Greater Than 10% Stockholder, the expiration of five (5)&nbsp;years from the Grant Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as
the Administrator may otherwise approve, the expiration of three (3)&nbsp;months from the date of Participant&#146;s Termination of Service, unless Participant&#146;s Termination of Service is for Cause or by reason of Participant&#146;s death or
Disability; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as the Administrator may otherwise approve, the expiration of one (1)&nbsp;year from the date of
Participant&#146;s Termination of Service by reason of Participant&#146;s death or Disability; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as the Administrator may otherwise approve, the date of Participant&#146;s
Termination of Service for Cause; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as otherwise provided in clauses (c)&nbsp;or (d) above, with respect to any unvested
portion of the Option, the date that is thirty (30)&nbsp;days following Participant&#146;s Termination of Service by reason of Participant&#146;s death or Disability, or such shorter period as may be determined by the Administrator. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE
OF OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Person Eligible to Exercise</U>. During Participant&#146;s lifetime, only Participant may exercise the Option,
unless it has been disposed of, with the consent of the Administrator, pursuant to a domestic relations order. After Participant&#146;s death, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under
Section&nbsp;2.3 hereof, be exercised by the Participant&#146;s Designated Beneficiary or by any person empowered to do so under the deceased Participant&#146;s will or under the then Applicable Laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Manner of Exercise</U>. The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the
Company or the Secretary&#146;s office, or such other place as may be determined by the Administrator, of all of the following prior to the time when the Option or such portion thereof becomes unexercisable under Section&nbsp;2.3, except that the
Option may only be exercised for whole Shares: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) An exercise notice in substantially in the form attached as <B>Exhibit B</B> to the
Grant Notice (or such other form as is prescribed by the Administrator, which may be an electronic form) (the &#147;<B><I>Exercise Notice</I></B>&#148;) signed by Participant or any other person then entitled to exercise the Option or portion
thereof, stating that the Option or portion thereof is thereby exercised, such Exercise Notice complying with all applicable rules established by the Administrator; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to Section&nbsp;5.5 of the Plan, full payment for the Shares with respect to which the Option or portion thereof is exercised,
which payment may be made by Participant, by: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Cash, wire transfer of immediately available funds or check, payable to
the order of the Company; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) With the consent of the Administrator, surrender to or withholding by the Company of a
net number of vested Shares issuable upon the exercise of the Option valued at their fair market value; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) With the
consent of the Administrator, delivery (either by actual delivery or attestation) of Shares owned by Participant valued at their fair market value; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) If there is a public market for the Shares at the time of exercise, unless the Company or the Administrator otherwise
determines, through the (A)&nbsp;delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company
sufficient funds to pay the exercise price, or (B)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check
sufficient to pay the exercise price, provided in either case, that such amount is paid to the Company at such time as may be required by the Administrator; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) With the consent of the Administrator, any other form of payment
permitted under Section&nbsp;5.5 of the Plan; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) Any combination of the above permitted forms of payment; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to Section&nbsp;9.5 of the Plan, full payment for any applicable Tax Withholding Obligation (as defined below) in such form as
permitted by the Plan; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the event the Option or portion thereof shall be exercised pursuant to Section&nbsp;3.1 by any person
or persons other than Participant, appropriate proof of the right of such person or persons to exercise the Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Taxes; Tax
Withholding</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the
Option to Participant or his or her legal representative unless and until Participant or his or her legal representative shall have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes required by Applicable
Law to be withheld in connection with the vesting, exercise or settlement of the Option, the distribution of the Shares issuable with respect thereto, or any other taxable event related to the Option (the &#147;<B><I>Tax Withholding
Obligation</I></B>&#148;). The Company shall have the authority and the right to deduct or withhold, or require Participant to remit to the Company, an amount sufficient to satisfy any Tax Withholding Obligation, including, without limitation, the
authority to deduct such amounts from other compensation payable to Participant by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Participant acknowledges that
Participant is ultimately liable and responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any Tax Withholding Obligations that arise in connection with the Option.
Neither the Company nor any Subsidiary makes any representation or undertaking regarding the tax treatment to Participant in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and its
Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate Participant&#146;s tax liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Participant represents to the Company that Participant has reviewed with Participant&#146;s own tax advisors the tax consequences of this
Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company and/or any of its agents. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PARTICIPANT
REPRESENTATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the award of the Option, Participant represents to the Company the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Participant is aware of the Company&#146;s business affairs and financial condition and has acquired sufficient information about the
Company to reach an informed and knowledgeable decision to acquire the Shares issuable upon exercise of the Options. Participant is acquiring these Shares for investment for Participant&#146;s own account only and not with a view to, or for resale
in connection with, any &#147;distribution&#148; thereof within the meaning of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Participant acknowledges and understands that the Shares constitute &#147;restricted
securities&#148; under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Participant&#146;s investment
intent as expressed herein. Participant further understands that the Shares must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further
acknowledges and understands that the Company is under no obligation to register the Shares. Participant understands that the certificate evidencing the Shares may be imprinted with a legend which prohibits the transfer of the Shares unless they are
registered or such registration is not required in the opinion of counsel satisfactory to the Company and any other legend required under Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Participant is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance,
permit limited public resale of &#147;restricted securities&#148; acquired, directly or indirectly from the issuer thereof, in a <FONT STYLE="white-space:nowrap">non-public</FONT> offering subject to the satisfaction of certain conditions. In the
event the Company becomes subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Exchange Act, ninety (90)&nbsp;days thereafter (or such longer period as any market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreement may
require) the Shares exempt under Rule 701 may under present law be resold, subject to the satisfaction of certain of the conditions specified by Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the event that the Company does not qualify under Rule 701 at the time of purchase of the Shares, then the Shares may be resold in
certain limited circumstances subject to the provisions of Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Participant further understands that in the event all of the
applicable requirements of Rule 701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rules 144 and 701 are
not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 will have a
substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. Participant
understands that no assurances can be given that any such other registration exemption will be available in such event. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Award Not Transferable; Other Restrictions</U>. Without limiting the generality of any other provision hereof, the Award shall be
subject to the restrictions on transferability set forth in Section&nbsp;9.1 of the Plan. Without limiting the generality of any other provision hereof, the Participant hereby expressly acknowledges that Section&nbsp;10.8 (&#147;<I><FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Period</I>&#148;), Section&nbsp;10.9 (&#147;<I>Right of First Refusal</I>&#148;) and Section&nbsp;10.14 (&#147;<I>Restrictions on Shares; Claw-Back Provisions</I>&#148;) of the Plan are expressly
incorporated into this Agreement and are applicable to the Shares issued pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Restrictive Legends and Stop Transfer Orders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Legends</U>. The Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially
equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by state or federal securities laws: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR
DISTRIBUTION THEREOF. THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#147;ACT&#148;) OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT AND SUCH LAWS OR, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE
THEREWITH. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN REPURCHASE RIGHTS, FORFEITURE PROVISIONS, TRANSFER
RESTRICTIONS AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEE(S), AS SET FORTH IN A STOCK OPTION AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE
ISSUER. SUCH REPURCHASE RIGHTS, FORFEITURE PROVISIONS, TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stop Transfer Notices</U>. The Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the
Company may issue appropriate &#147;stop transfer&#148; instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Refusal to Transfer</U>. The Company shall not be required (i)&nbsp;to transfer on its books any Shares that have been sold or
otherwise transferred in violation of any of the provisions of this Agreement or (ii)&nbsp;to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so
transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Restrictions on Transfer</U>. In addition to the limitations contained in Section&nbsp;5.1 above and this
Section&nbsp;5.2, the Participant agrees and acknowledges that Participant will not transfer in any manner the Shares issued pursuant to this Agreement unless (i)&nbsp;the transfer is pursuant to an effective registration statement under the
Securities Act or the rules and regulations in effect thereunder, or (ii)&nbsp;counsel for the Company shall have reasonably concluded that no such registration is required because of the availability of an exemption from registration under the
Securities Act. To the extent permitted by Applicable Laws, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Adjustments</U>. Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as
provided in this Agreement and the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Notices</U>. Any notice to be given under the terms of this Agreement to the Company
must be in writing and addressed to the Company in care of the Company&#146;s Secretary at the Company&#146;s principal office or the Secretary&#146;s then-current email address or facsimile number. Any notice to be given under the terms of this
Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#146;s last known mailing address, email address or facsimile number in the
Company&#146;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when
sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company
or upon receipt of a facsimile transmission confirmation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Titles</U>. Titles are provided herein for convenience only and are not
to serve as a basis for interpretation or construction of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Conformity to Securities Laws</U>.<B> </B>.
Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations set forth in
any applicable exemptive rule under Section&nbsp;16 of the Exchange Act (including any amendment to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3)</FONT> that are requirements for the application of such exemptive rule. Participant acknowledges
that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended to the extent necessary to conform to such Applicable Laws
or any such exemptive rule described in the preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Successors and Assigns</U>. The Company may assign any of its
rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in the Plan, this Agreement shall be
binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8
<U>Entire Agreement</U>. The Plan, the Grant Notice and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject
matter hereof. Participant hereby agrees to execute such further instruments and to take such further action as the Company requests to carry out the purposes and intent of this Agreement and the Plan, including, without limitation, restrictions on
the transferability of the Shares, the right of the Company to repurchase the Shares pursuant to Section&nbsp;10.9 of the Plan, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, <FONT
STYLE="white-space:nowrap">tag-along</FONT> rights, bring-along rights, redemption and <FONT STYLE="white-space:nowrap">co-sale</FONT> rights and voting requirements in accordance with the Plan. This Agreement may be amended by the Company in
accordance with Section&nbsp;9.6 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Agreement Severable</U>. In the event that any provision of the Grant Notice or this
Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Limitation on Participant&#146;s Rights</U>. Participation in the Plan confers no rights or interests other than as herein provided.
This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have
only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general unsecured creditor with
respect to the Option, as and when exercised pursuant to the terms hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Rights as a Stockholder</U>. Neither Participant nor any person claiming under or
through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book-entry form) will have been
issued and recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account). Except as otherwise provided herein, after such issuance,
recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares. The issuance of Shares
under this Award to Participant shall be subject to Participant&#146;s satisfaction of the conditions under Section&nbsp;10.14 of the Plan and execution of a counterpart signature page or joinder agreeing to be subject to any stockholders agreement
as the Administrator shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Not a Contract of Employment</U>. Nothing in the Plan, the Grant Notice or this Agreement
confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to
discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>Counterparts</U>. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject
to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14 <U>Governing
Law</U>. The provisions of the Plan and all Awards made thereunder, including the Option, shall be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles of the law of any state that would require the application of the laws of a jurisdiction other than such state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.15 <U>Incentive Stock Options</U>. If the Option is designated as an Incentive Stock Option, the following provisions, in addition to the
terms set forth in Section&nbsp;5.6 of the Plan, shall apply to the Option: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Participant acknowledges that to the extent the aggregate
fair market value of shares (determined as of the time the option with respect to the shares is granted) with respect to which stock options intended to qualify as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, including the
Option, are exercisable for the first time by Participant during any calendar year exceeds $100,000 or if for any other reason such stock options do not qualify or cease to qualify for treatment as &#147;incentive stock options&#148; under
Section&nbsp;422 of the Code, such stock options (including the Option) will be treated as <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options. Participant further acknowledges that the rule set forth in the preceding sentence will
be applied by taking the Option and other stock options into account in the order in which they were granted, as determined under Section&nbsp;422(d) of the Code. Participant acknowledges that amendments or modifications made to the Option pursuant
to the Plan that would cause the Option to become a Non-Qualified Stock Option will not materially or adversely affect Participant&#146;s rights under the Option, and that any such amendment or modification shall not require Participant&#146;s
consent. Participant also acknowledges that if the Option is exercised more than three (3)&nbsp;months after Participant&#146;s Termination of Service as an Employee, other than by reason of death or Disability, the Option will be taxed as a <FONT
STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. If the Option is an Incentive Stock Option and Participant is a Greater Than 10% Stockholder as of the Grant Date, the term of the Option will not exceed five (5)&nbsp;years from the
Grant Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Participant will give prompt written notice to the Company of any disposition or other
transfer of any Shares acquired under this Agreement if such disposition or other transfer is made (a)&nbsp;within two (2)&nbsp;years from the Grant Date or (b)&nbsp;within one (1)&nbsp;year after the transfer of such Shares to Participant. Such
notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of
today, <U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U>, <U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U>, the undersigned <I>(</I>&#147;<B><I>Participant</I></B>&#148;) hereby elects to exercise Participant&#146;s option to purchase
<U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U> Shares of CG Oncology, Inc. (the &#147;<B><I>Company</I></B>&#148;)<B><I> </I></B>under and pursuant to the CG Oncology, Inc.<B> </B>2022 Incentive Award Plan (the
&#147;<B><I>Plan</I></B>&#148;) and the Stock Option Grant Notice and Stock Option Agreement dated <U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U>, ____ (the &#147;<B><I>Agreement</I></B>&#148;).<B><I> </I></B>Capitalized terms used herein
without definition shall have the meanings given in the Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Grant Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number of Shares as to which Option is Exercised:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exercise Price per Share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$____________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Exercise Price:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$____________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Certificate to be issued in name of:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Payment delivered herewith (if applicable):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$______________ (Representing the full Exercise Price for the Shares, as well as any applicable withholding tax)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Type of Option (select one): </B>&#8195;&#8195;&#9744;&#8195;Incentive Stock
<FONT STYLE="white-space:nowrap">Option&#8195;&#8195;&#9744;&#8195;Non-Qualified</FONT> Stock Option </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><I>Representations of
Participant</I></B>. Participant acknowledges that Participant has received, read and understood the Plan and the Agreement. Participant agrees to abide by and be bound by their terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><I>Tax Consultation</I></B>. Participant understands that Participant may suffer adverse tax consequences as a result of
Participant&#146;s purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection with the purchase or disposition of the Shares and that Participant is
not relying on the Company for any tax advice. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Participant understands that Participant (and not the Company) shall be
responsible for Participant&#146;s tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><I>Participant Representations</I></B>. Participant hereby reaffirms the representations in Article IV of the Agreement as of the date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><I>Further Instruments</I></B>. Participant hereby agrees to execute such further instruments and to take such further
action as the Company requests to carry out the purposes and intent of this Agreement and the Plan, including, without limitation, restrictions on the transferability of the Shares, the right of the Company to exercise its repurchase rights pursuant
to Section&nbsp;10.9 of the Plan, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, <FONT STYLE="white-space:nowrap">tag-along</FONT> rights, bring-along rights, redemption and <FONT
STYLE="white-space:nowrap">co-sale</FONT> rights and voting requirements in accordance with the Plan. The issuance of Shares shall be further subject to Participant&#146;s satisfaction of the conditions under Section&nbsp;10.14 of the Plan and
execution of a counterpart signature page or joinder agreeing to be subject to any stockholders agreement as the Administrator shall determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><I>Notices</I></B>. Any notice required or permitted hereunder shall be given in
accordance with the provisions set forth in Section&nbsp;5.4 of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><I>Entire Agreement</I></B>. The Plan and Agreement
are incorporated herein by reference. This Notice, the Plan and the Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the
subject matter hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PARTICIPANT:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2022 INCENTIVE AWARD PLAN </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION GRANT NOTICE (EARLY EXERCIZE) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Stock Option Grant Notice (the &#147;<B><I>Grant Notice</I></B>&#148;) have the meanings
given to them in the 2022 Incentive Award Plan (as amended from time to time, the &#147;<B><I>Plan</I></B>&#148;) of CG Oncology, Inc. (the &#147;<B><I>Company</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby grants to the participant listed below (&#147;<B><I>Participant</I></B>&#148;) the stock option described in this Grant
Notice (the &#147;<B><I>Option</I></B>&#148;), subject to the terms and conditions of the Plan and the Stock Option Agreement attached hereto as <B>Exhibit A</B> (the &#147;<B><I>Agreement</I></B>&#148;), both of which are incorporated into this
Grant Notice by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Participant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Participant Name]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Grant Date]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Exercise Price]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Shares Subject to the Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Number of Options]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Final Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Tenth Anniversary of Grant Date]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Commencement Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>[Insert Vesting Commencement Date]</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&yacute; Early Exercise Permitted</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Option is exercisable immediately, in whole or in part, at such times as are established by the Administrator. The shares subject to
this Option shall vest and/or be released from the Company Repurchase Right, as set forth in Section&nbsp;5.1 of the Agreement, according to the following schedule:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>[Insert Vesting Schedule]</I></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, in the event a Participant experiences a Termination of Service as a result of (a)&nbsp;Participant&#146;s termination by the Company other than
for Cause (and excluding a Termination of Service as a result of Participant&#146;s death or Disability), or (b)&nbsp;Participant&#146;s resignation for Good Reason, in each case within eighteen (18)&nbsp;months following a Change in Control, then
any remaining unvested portion of the Option shall become fully vested and and/or be released from the Company Repurchase Right on the date of such Termination of Service.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Option </B><B><I>(select one)</I></B><B>:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&#8194;&#8201;&#8201;Incentive Stock Option</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#9744;&#8194;&#8201;&#8201;Non-Qualified</FONT> Stock Option</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company uses an electronic capitalization table system (such as E*Trade, Shareworks or Carta) and the
fields in this Grant Notice are blank or the information is otherwise provided in a different format electronically, the blank fields and other information shall be deemed to come from the electronic capitalization system and is considered part of
this Grant Notice. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By accepting (whether in writing, electronically or otherwise, including an acceptance
through an electronic capitalization table system used by the Company) the Option, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement
in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding,
conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>PARTICIPANT</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant
Notice, in the Plan. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Grant of
Option</U>. The Company has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#147;<B><I>Grant Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Incorporation of Terms of Plan</U>. The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which
is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISABILITY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1
<U>Vesting</U>. The Option will vest according to the vesting schedule in the Grant Notice (the &#147;<B><I>Vesting Schedule</I></B>&#148;), except that any fraction of a Share as to which the Option would be vested will be accumulated and will vest
only when a whole Share has accumulated. The Option shall not be exercisable with respect to fractional Shares. The Vesting Schedule is cumulative. Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, any portion
of the Option that has not become vested on or prior to the date of Participant&#146;s Termination of Service for any reason shall not thereafter become vested, except as may be otherwise provided by the Administrator or as set forth in another
written agreement with the Company and Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Exercisability</U>. Any portion of the Option or the entire Option may be
exericised in whole or in part at any time prior to the time when the Option or portion thereof becomes unexercisable under Section&nbsp;2.3, provided that each unvested Share with respect to which the Option is exercised (each a
&#147;<B><I>Restricted Share</I></B>&#148;) shall be subject to the Company Repurchase Right (as defined in Section&nbsp;5.1 below) for so long as the Option shall remain unvested with respect to such Share under the terms of this Agreement. The
Restricted Shares shall be released from the Company Repurchase Right as set forth in Section&nbsp;5.1. For the avoidance of doubt, all Shares with respect to which the Option is exercised shall at all times be assumed to be Restricted Shares to the
fullest extent possible under the terms of this Agreement, unless otherwise provided by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Expiration of
Option</U>. Subject to Section&nbsp;5.3 of the Plan, the Option may not be exercised to any extent by anyone after, and will expire on, the first of the following to occur: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The final expiration date in the Grant Notice, which shall in no event be more than ten (10)&nbsp;years from the Grant Date; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If this Option is designated as an Incentive Stock Option and the Participant, at the time the Option was granted, was a Greater Than 10%
Stockholder, the expiration of five (5)&nbsp;years from the Grant Date; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as the Administrator may otherwise approve, the expiration of three
(3)&nbsp;months from the date of Participant&#146;s Termination of Service, unless Participant&#146;s Termination of Service is for Cause or by reason of Participant&#146;s death or Disability; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Except as the Administrator may otherwise approve, the expiration of one (1)&nbsp;year from the date of Participant&#146;s Termination of
Service by reason of Participant&#146;s death or Disability; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as the Administrator may otherwise approve, the date of
Participant&#146;s Termination of Service for Cause; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Except as otherwise provided in clauses (c)&nbsp;or (d) above, with respect
to any unvested portion of the Option, the date that is thirty (30)&nbsp;days following Participant&#146;s Termination of Service by reason of Participant&#146;s death or Disability, or such shorter period as may be determined by the Administrator.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE OF OPTION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1
<U>Person Eligible to Exercise</U>. During Participant&#146;s lifetime, only Participant may exercise the Option, unless it has been disposed of, with the consent of the Administrator, pursuant to a domestic relations order. After Participant&#146;s
death, any exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section&nbsp;2.3 hereof, be exercised by the Participant&#146;s Designated Beneficiary or by any person empowered to do so under the
deceased Participant&#146;s will or under the then Applicable Laws of descent and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Manner of Exercise</U>. The
Option, or any portion thereof, may be exercised solely by delivery to the Secretary of the Company or the Secretary&#146;s office, or such other place as may be determined by the Administrator, of all of the following prior to the time when the
Option or such portion thereof becomes unexercisable under Section&nbsp;2.3, except that the Option may only be exercised for whole Shares: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) An exercise notice in substantially in the form attached as <B>Exhibit B</B> to the Grant Notice (or such other form as is prescribed by
the Administrator, which may be an electronic form) (the &#147;<B><I>Exercise Notice</I></B>&#148;) signed by Participant or any other person then entitled to exercise the Option or portion thereof, stating that the Option or portion thereof is
thereby exercised, such Exercise Notice complying with all applicable rules established by the Administrator; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to
Section&nbsp;5.5 of the Plan, full payment for the Shares with respect to which the Option or portion thereof is exercised, which payment may be made by Participant, by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Cash, wire transfer of immediately available funds or check, payable to the order of the Company; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) With the consent of the Administrator, surrender to or withholding by the Company of a net number of vested Shares
issuable upon the exercise of the Option valued at their fair market value; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) With the consent of the
Administrator, delivery (either by actual delivery or attestation) of Shares owned by Participant valued at their fair market value; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) If there is a public market for the Shares at the time of exercise, unless the Company or the Administrator otherwise
determines, through the (A)&nbsp;delivery (including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company
sufficient funds to pay the exercise price, or (B)&nbsp;delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check
sufficient to pay the exercise price, provided in either case, that such amount is paid to the Company at such time as may be required by the Administrator; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) With the consent of the Administrator, any other form of payment permitted under Section&nbsp;5.5 of the Plan; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) Any combination of the above permitted forms of payment; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to Section&nbsp;9.5 of the Plan, full payment for any applicable Tax Withholding Obligation (as defined below) in such form as
permitted by the Plan; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the event the Option or portion thereof shall be exercised pursuant to Section&nbsp;3.1 by any person
or persons other than Participant, appropriate proof of the right of such person or persons to exercise the Option; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) In the event
the Option or portion thereof shall be exercised as to Restricted Shares, the following (collectively, the &#147;<B><I>Additional Documents</I></B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The stock assignment duly endorsed in blank, attached as <B>Exhibit C</B> to the Grant Notice (the &#147;<B><I>Stock
Assignment</I></B>&#148;), executed by Participant; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If Participant has a spouse of Participant, the Consent of Spouse attached
as <B>Exhibit</B><B></B><B>&nbsp;D</B> to the Grant Notice, executed by Participant&#146;s spouse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Taxes; Tax Withholding</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall not be obligated to deliver any certificate representing Shares issuable with respect to the Option to Participant
or his or her legal representative unless and until Participant or his or her legal representative shall have paid or otherwise satisfied in full the amount of all federal, state, local and foreign taxes required by Applicable Law to be withheld in
connection with the vesting, exercise or settlement of the Option, the distribution of the Shares issuable with respect thereto, or any other taxable event related to the Option (the &#147;<B><I>Tax Withholding Obligation</I></B>&#148;). The Company
shall have the authority and the right to deduct or withhold, or require Participant to remit to the Company, an amount sufficient to satisfy any Tax Withholding Obligation, including, without limitation, the authority to deduct such amounts from
other compensation payable to Participant by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Participant acknowledges that Participant is ultimately liable and
responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any Tax Withholding Obligations that arise in connection with the Option. Neither the Company nor any
Subsidiary makes any representation or undertaking regarding the tax treatment to Participant in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and its Subsidiaries do not commit and are
under no obligation to structure the Option to reduce or eliminate Participant&#146;s tax liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Participant represents to the Company that Participant has reviewed with
Participant&#146;s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the
Company and/or any of its agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Section</U><U></U><U>&nbsp;83(b)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Election for Restricted Shares Purchased Pursuant to a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</U>.
Participant acknowledges that, with respect to the exercise of a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option for Restricted Shares, unless an election is filed by Participant with the Internal Revenue Service and, if
necessary, the proper state taxing authorities, within thirty days of the purchase of the Shares, electing pursuant to Section&nbsp;83(b) of the Code (and similar state tax provisions if applicable) to be taxed currently on any difference between
the purchase price of the Shares and their Fair Market Value on the date of purchase, there will be a recognition of taxable income to Participant, measured by the excess, if any, of the Fair Market Value of the Shares, at the time the Company
Repurchase Right lapses over the purchase price for the Shares. Participant represents that Participant has consulted any tax consultant(s) Participant deems advisable in connection with the purchase of the Shares or the filing of the election under
Section&nbsp;83(b) of the Code and similar tax provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Section</U><U></U><U>&nbsp;83(b) Election for Restricted Shares
Purchased Pursuant to an Incentive Stock Option</U>. Participant hereby acknowledges that he or she has been informed that, with respect to the exercise of an Incentive Stock Option for Restricted Shares, unless an election is filed by Participant
with the Internal Revenue Service and, if necessary, the proper state taxing authorities, within thirty days of the purchase of the Shares, electing pursuant to Section&nbsp;83(b) of the Code (and similar state tax provisions if applicable) to be
taxed currently on any difference between the purchase price of the Shares and their Fair Market Value on the date of purchase, there will be a recognition of income to the Participant, for alternative minimum tax purposes measured by the excess, if
any, of the Fair Market Value of the Shares at the time the Company&#146;s Repurchase Option lapses over the purchase price for the Shares. Participant further acknowledges that if an election is filed under Section&nbsp;83(b) of the Code for the
Unvested Shares and such shares are sold or transferred prior to the date two years following the Grant Date and one year following the purchase date of such shares, there will be a recognition of income to the Participant, for ordinary income,
measured by the excess, if any, of the Fair Market Value of the Shares at the time the Company&#146;s Repurchase Option lapses over the purchase price for the Shares. Participant represents that Participant has consulted any tax consultant(s)
Participant deems advisable in connection with the purchase of the Shares or the filing of the election under Section&nbsp;83(b) and similar tax provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">PARTICIPANT ACKNOWLEDGES THAT IT IS PARTICIPANT&#146;S SOLE RESPONSIBILITY AND NOT THE COMPANY&#146;S TO TIMELY FILE THE ELECTION UNDER
SECTION 83(B) OF THE CODE, AND THE COMPANY AND ITS REPRESENTATIVES SHALL HAVE NO OBLIGATION OR AUTHORITY TO MAKE THIS FILING ON PARTICIPANT&#146;S BEHALF. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PARTICIPANT
REPRESENTATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the award of the Option, Participant represents to the Company the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Participant is aware of the Company&#146;s business affairs and financial condition and has acquired sufficient information about the
Company to reach an informed and knowledgeable decision to acquire the Shares issuable upon exercise of the Options. Participant is acquiring these Shares for investment for Participant&#146;s own account only and not with a view to, or for resale
in connection with, any &#147;distribution&#148; thereof within the meaning of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Participant acknowledges and understands that the Shares constitute &#147;restricted
securities&#148; under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Participant&#146;s investment
intent as expressed herein. Participant further understands that the Shares must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further
acknowledges and understands that the Company is under no obligation to register the Shares. Participant understands that the certificate evidencing the Shares may be imprinted with a legend which prohibits the transfer of the Shares unless they are
registered or such registration is not required in the opinion of counsel satisfactory to the Company and any other legend required under Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Participant is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance,
permit limited public resale of &#147;restricted securities&#148; acquired, directly or indirectly from the issuer thereof, in a <FONT STYLE="white-space:nowrap">non-public</FONT> offering subject to the satisfaction of certain conditions. In the
event the Company becomes subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Exchange Act, ninety (90)&nbsp;days thereafter (or such longer period as any market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreement may
require) the Shares exempt under Rule 701 may under present law be resold, subject to the satisfaction of certain of the conditions specified by Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In the event that the Company does not qualify under Rule 701 at the time of purchase of the Shares, then the Shares may be resold in
certain limited circumstances subject to the provisions of Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Participant further understands that in the event all of the
applicable requirements of Rule 701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rules 144 and 701 are
not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 will have a
substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. Participant
understands that no assurances can be given that any such other registration exemption will be available in such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPURCHASE AND TRANSFER RESTRICTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Company Repurchase Right</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Company Repurchase Right</U>. Upon Participant&#146;s Termination of Service for any reason, the Company shall have the right and
option to repurchase all of the Restricted Shares from Participant, or Participant&#146;s transferee or legal representative, as the case may be, for a purchase price equal to the price per Share paid for such Restricted Shares (the
&#147;<B><I>Company Repurchase Right</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise of Company Repurchase Right</U>. The Company may exercise the
Company Repurchase Right by delivering to Participant (or his or her transferee or legal representative, as the case may be), within ninety days of the date of Participant&#146;s Termination of Service, a written notice indicating the Company&#146;s
intention to exercise the Company Repurchase Right and setting forth a date for closing not later than thirty days from the issuance of such notice. The closing shall take place at the Company&#146;s office. At the closing, the holder of the
certificates for the Restricted Shares shall deliver the stock certificate or certificates evidencing the Restricted Shares, and the Company shall deliver the purchase price therefore. At its option, the Company may elect to make payment for the
Restricted Shares to a bank selected by the Company. The Company shall avail itself of this option by a written notice to Participant stating the name and address of the bank, date of closing, and waiving the closing at the Company&#146;s office. If
the Company does not elect to exercise the Company Repurchase Right by giving the requisite notice within ninety days following the date of Participant&#146;s Termination of Service, the Company Repurchase Right shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Release of Restricted Shares</U>. The Restricted Shares shall be released from the Company Repurchase Right upon vesting of the Option
with respect to such Shares in accordance with the terms of this Agreement. For the avoidance of doubt, all Shares with respect to which the Option is exercised shall at all times be assumed to be Restricted Shares to the fullest extent possible
under the terms of this Agreement, unless otherwise provided by the Administrator. Fractional Shares shall be rounded down to the nearest whole share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Award Not Transferable; Other Restrictions</U>. Without limiting the generality of any other provision hereof, the Option and the
Restricted Shares, as applicable, shall be subject to the restrictions on transferability set forth in Section&nbsp;9.1 of the Plan. Without limiting the generality of any other provision hereof, the Participant hereby expressly acknowledges that
Section&nbsp;10.8 (&#147;<I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period</I>&#148;), Section&nbsp;10.9 (&#147;<I>Right of First Refusal</I>&#148;) and Section&nbsp;10.14 (&#147;<I>Restrictions on Shares; Claw-Back Provisions</I>&#148;) of
the Plan are expressly incorporated into this Agreement and are applicable to the Shares issued pursuant to this Agreement. Any transferee of the Shares shall hold such Shares subject to all of the provisions hereof and the Plan and the Exercise
Notice and Additional Documents executed by Participant with respect to such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Restricted Shares; Rights as a
Stockholder</U>. Except as otherwise provided herein, upon exercise of the Option and the issuance of the Shares to Participant (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the
Company), Participant shall have all the rights of a stockholder with respect to the Restricted Shares, including the right to receive any cash or stock dividends or other distributions paid to or made with respect to the Restricted Shares, subject
to the restrictions described in the following sentence, which restrictions shall lapse when the Restricted Shares are released from the Company Repurchase Right as set forth in Section&nbsp;5.1. Unless otherwise provided by the Administrator, if
any dividends or distributions are paid in shares, or consist of a dividend or distribution to holders of Common Stock of property, the shares or other property will be retained in custody by the Company (without interest) (the &#147;<B><I>Retained
Distributions</I></B>&#148;) and subject to the same repurchase and transferability restrictions as the Restricted Shares with respect to which they were paid and shall automatically be forfeited to the Company for no consideration in the event the
Company exercises the Company Repurchase Right for the Restricted Shares with respect to which they were paid. In no event shall a Retained Distribution be paid with respect to Restricted Shares later than the end of the calendar year in which the
corresponding dividends or distributions are paid to holders of Common Stock or, if later, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the 15th day of the third month following the later of (a)&nbsp;the date the corresponding dividends or distributions are paid to holders of Common Stock and (b)&nbsp;the date the Restricted
Shares with respect to which the Retained Distributions are paid vest. Participant shall enjoy rights as a stockholder until such time as Participant disposes of the Shares or the Company and/or its assignee(s) exercises the Right of First Refusal
under the Plan. Upon such exercise, Participant shall have no further rights as a holder of the Shares so purchased except the right to receive payment for the Shares so purchased in accordance with the provisions of the Plan and this Agreement, and
Participant shall forthwith cause the certificate(s), if any issued, evidencing the Shares so purchased to be surrendered to the Company for transfer or cancellation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Restrictive Legends and Stop Transfer Orders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Legends</U>. The Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially
equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by state or federal securities laws: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR
DISTRIBUTION THEREOF. THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE &#147;ACT&#148;) OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT AND SUCH LAWS OR, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE
THEREWITH. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN REPURCHASE RIGHTS, FORFEITURE PROVISIONS, TRANSFER
RESTRICTIONS AND A RIGHT OF FIRST REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEE(S), AS SET FORTH IN A STOCK OPTION AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE
ISSUER. SUCH REPURCHASE RIGHTS, FORFEITURE PROVISIONS, TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Stop Transfer Notices</U>. The Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the
Company may issue appropriate &#147;stop transfer&#148; instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same effect in its own records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Refusal to Transfer</U>. The Company shall not be required (i)&nbsp;to transfer on its books any Shares that have been sold or
otherwise transferred in violation of any of the provisions of this Agreement or (ii)&nbsp;to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so
transferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Restrictions on Transfer</U>. In addition to the limitations contained in
Section&nbsp;5.2 above and this Section&nbsp;5.4, the Participant agrees and acknowledges that Participant will not transfer in any manner the Shares issued pursuant to this Agreement unless (i)&nbsp;the transfer is pursuant to an effective
registration statement under the Securities Act or the rules and regulations in effect thereunder, or (ii)&nbsp;counsel for the Company shall have reasonably concluded that no such registration is required because of the availability of an exemption
from registration under the Securities Act. To the extent permitted by Applicable Laws, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Escrow</U>. To insure the availability for delivery of the Restricted Shares upon repurchase by the Company pursuant to the Company
Repurchase Right, Participant appoints the Secretary of the Company, or such other person designated by the Administrator from time to time as escrow agent, as its
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to sell, assign and transfer unto the Company, such Restricted Shares, if any, repurchased by the Company pursuant to the Company Repurchase Right,
together with and any Retained Distributions paid thereon pursuant to Section&nbsp;5.3 and held by the Company, and shall, upon execution of the applicable Exercise Notice, deliver and deposit with the Secretary of the Company, or such other person
designated by the Administrator from time to time, the share certificate(s) representing the Restricted Shares, together with the Stock Assignment. The Restricted Shares and Stock Assignment (and any Retained Distributions) shall be held by the
Secretary, or such other person designated by the Administrator from time to time, in escrow, until the Company exercises the Company Repurchase Right, until such Restricted Shares are released from the Company Repurchase Right as set forth in
Article V or until such time as this Agreement no longer is in effect. Upon release of the Restricted Shares from the Company&#146;s Repurchase Right, the escrow agent shall as soon as reasonably practicable deliver to Participant the certificate or
certificates representing such Shares in the escrow agent&#146;s possession belonging to Participant, and the escrow agent shall be discharged of all further obligations hereunder. The Company, or its designee, shall not be liable for any act it may
do or omit to do with respect to holding the Restricted Shares (or any Retained Distributions) in escrow and while acting in good faith and in the exercise of its judgment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
PROVISIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Adjustments</U><B>B. </B>. Participant acknowledges that the Option is subject to adjustment, modification and
termination in certain events as provided in this Agreement and the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Notices</U>. Any notice to be given under the terms of
this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#146;s Secretary at the Company&#146;s principal office or the Secretary&#146;s then-current email address or facsimile number. Any notice to be
given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#146;s last known mailing address, email
address or facsimile number in the Company&#146;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually
received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally
recognized express shipping company or upon receipt of a facsimile transmission confirmation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Titles</U>. Titles are provided
herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Conformity to
Securities Laws</U><B>C. </B>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&nbsp;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any
additional limitations set forth in any applicable exemptive rule under Section&nbsp;16 of the Exchange Act (including any amendment to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3)</FONT> that are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements for the application of such exemptive rule. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all
Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended to the extent necessary to conform to such Applicable Laws or any such exemptive rule described in the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Successors and Assigns</U>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this
Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in the Plan, this Agreement shall be binding upon and inure to the benefit of the heirs, legatees, legal
representatives, successors and assigns of the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Entire Agreement</U>. The Plan, the Grant Notice and this Agreement
constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. Participant hereby agrees to execute such further
instruments and to take such further action as the Company requests to carry out the purposes and intent of this Agreement and the Plan, including, without limitation, restrictions on the transferability of the Shares, the right of the Company to
repurchase the Shares pursuant to Section&nbsp;10.9 of the Plan, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, <FONT STYLE="white-space:nowrap">tag-along</FONT> rights,
bring-along rights, redemption and <FONT STYLE="white-space:nowrap">co-sale</FONT> rights and voting requirements in accordance with the Plan. This Agreement may be amended by the Company in accordance with Section&nbsp;9.6 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Agreement Severable</U>. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the
provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Limitation on Participant&#146;s Rights</U>. Participation in the Plan confers no rights or interests other than as herein provided.
This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have
only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general unsecured creditor with
respect to the Option, as and when exercised pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Rights as a Stockholder</U>. Neither Participant nor
any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in
book-entry form) will have been issued and recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account). Except as otherwise provided herein,
after such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to such Shares, including, without limitation, the right to receipt of dividends and distributions on such Shares. The
issuance of Shares under this Award to Participant shall be subject to Participant&#146;s satisfaction of the conditions under Section&nbsp;10.14 of the Plan and execution of a counterpart signature page or joinder agreeing to be subject to any
stockholders agreement as the Administrator shall determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Not a Contract of Employment</U>. Nothing in the Plan, the Grant
Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby
expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and
Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Counterparts</U>. The Grant Notice may be executed in one or more counterparts,
including by way of any electronic signature, subject to Applicable Laws, each of which will be deemed an original and all of which together will constitute one instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Governing Law</U>. The provisions of the Plan and all Awards made thereunder, including the Option, shall be governed by and
interpreted in accordance with the laws of the State of Delaware, disregarding <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">choice-of-law</FONT></FONT> principles of the law of any state that would require the application of the
laws of a jurisdiction other than such state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.13 <U>Incentive Stock Options</U>. If the Option is designated as an Incentive Stock
Option, the following provisions, in addition to the terms set forth in Section&nbsp;5.6 of the Plan, shall apply to the Option: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Participant acknowledges that to the extent the aggregate fair market value of shares (determined as of the time the option with respect to the shares is granted) with respect to which stock options intended to qualify as &#147;incentive stock
options&#148; under Section&nbsp;422 of the Code, including the Option, are exercisable for the first time by Participant during any calendar year exceeds $100,000 or if for any other reason such stock options do not qualify or cease to qualify for
treatment as &#147;incentive stock options&#148; under Section&nbsp;422 of the Code, such stock options (including the Option) will be treated as <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options. Participant further acknowledges
that the rule set forth in the preceding sentence will be applied by taking the Option and other stock options into account in the order in which they were granted, as determined under Section&nbsp;422(d) of the Code. Participant acknowledges that
amendments or modifications made to the Option pursuant to the Plan that would cause the Option to become a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option will not materially or adversely affect Participant&#146;s rights under
the Option, and that any such amendment or modification shall not require Participant&#146;s consent. Participant also acknowledges that if the Option is exercised more than three (3)&nbsp;months after Participant&#146;s Termination of Service as an
Employee, other than by reason of death or Disability, the Option will be taxed as a <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option. If the Option is an Incentive Stock Option and Participant is a Greater Than 10% Stockholder as
of the Grant Date, the term of the Option will not exceed five (5)&nbsp;years from the Grant Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Participant will give prompt
written notice to the Company of any disposition or other transfer of any Shares acquired under this Agreement if such disposition or other transfer is made (a)&nbsp;within two (2)&nbsp;years from the Grant Date or (b)&nbsp;within one (1)&nbsp;year
after the transfer of such Shares to Participant. Such notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such
disposition or other transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>*&nbsp;*&nbsp;*&nbsp;*&nbsp;* </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of
today, <U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U>, <U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U>, the undersigned <I>(</I>&#147;<B><I>Participant</I></B>&#148;) hereby elects to exercise Participant&#146;s option to purchase
<U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U> Shares of CG Oncology, Inc. (the &#147;<B><I>Company</I></B>&#148;)<B><I> </I></B>under and pursuant to the CG Oncology, Inc.<B> </B>2022 Incentive Award Plan (the
&#147;<B><I>Plan</I></B>&#148;) and the Stock Option Grant Notice and Stock Option Agreement dated <U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U>, ____ (the &#147;<B><I>Agreement</I></B>&#148;).<B><I> </I></B>Capitalized terms used herein
without definition shall have the meanings given in the Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Grant Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number of Shares as to which Option is Exercised:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Exercise Price per Share:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Exercise Price:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Certificate to be issued in name of:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Payment delivered herewith (if applicable):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<U>&#8195;&#8195;&#8195;&#8195;&#8195;</U> (Representing the full Exercise Price for the Shares, as well as any applicable withholding tax)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Type of Option (select one): </B>&#9744;&#8194;Incentive Stock
<FONT STYLE="white-space:nowrap">Option&#8195;&#9744;&#8194;Non-Qualified</FONT> Stock Option </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><I>Representations of
Participant</I></B>. Participant acknowledges that Participant has received, read and understood the Plan and the Agreement. Participant agrees to abide by and be bound by their terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><I>Tax Consultation</I></B>. Participant understands that Participant may suffer adverse tax consequences as a result of
Participant&#146;s purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection with the purchase or disposition of the Shares and that Participant is
not relying on the Company for any tax advice. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Participant understands that Participant (and not the Company) shall be
responsible for Participant&#146;s tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><I>Participant Representations</I></B>. Participant hereby reaffirms the representations in Article IV of the Agreement as of the date
hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><I>Further Instruments</I></B>. Participant hereby agrees to execute such further instruments and to take such further
action as the Company requests to carry out the purposes and intent of this Agreement and the Plan, including, without limitation, restrictions on the transferability of the Shares, the right of the Company to exercise its repurchase rights pursuant
to Section&nbsp;10.9 of the Plan, the right of the Company to require that shares of Common Stock be transferred in the event of certain transactions, <FONT STYLE="white-space:nowrap">tag-along</FONT> rights, bring-along rights, redemption and <FONT
STYLE="white-space:nowrap">co-sale</FONT> rights and voting requirements in accordance with the Plan. The issuance of Shares shall be further subject to Participant&#146;s satisfaction of the conditions under Section&nbsp;10.14 of the Plan and
execution of a counterpart signature page or joinder agreeing to be subject to any stockholders agreement as the Administrator shall determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><I>Notices</I></B>. Any notice required or permitted hereunder shall be given in
accordance with the provisions set forth in Section&nbsp;6.2 of the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><I>Entire Agreement</I></B>. The Plan and Agreement
are incorporated herein by reference. This Notice, the Plan and the Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the
subject matter hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>CG ONCOLOGY, INC.</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:11pt"><B>PARTICIPANT:</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK ASSIGNMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>See
instructions below</I>] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED I, <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, hereby sell, assign and transfer
unto _____________________ the shares of the Common Stock of CG Oncology, Inc. registered in my name on the books of said corporation represented by Certificate No. _____ and do hereby irrevocably constitute and appoint
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> to transfer the said stock on the books of the within named corporation with full power of substitution in the premises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Assignment Separate from Certificate may be used only in accordance with the Stock Option Grant Notice and Stock Option Agreement between
CG Oncology, Inc. and the undersigned dated
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, <U>&#8195;&#8195;</U></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>[Name]</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>INSTRUCTIONS:</U></B><U> Please do not fill in any blanks other than the signature line. The purpose of this
assignment is to enable the Company to exercise the Company Repurchase Right, as set forth in the Stock Option Grant Notice and Stock Option Agreement, without requiring additional signatures on the part of Participant</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF SPOUSE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I,
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, spouse of <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U>, have read and approve the Stock Option Grant Notice and Stock Option Agreement dated
<U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U>&#8195;</U><U> </U>, between my spouse and CG Oncology, Inc. In consideration of granting of the right to my spouse to purchase shares of CG Oncology, Inc. set forth in the Stock Option Grant Notice and
Stock Option Agreement, I hereby appoint my spouse as my <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> in respect to the exercise of any rights under the Stock Option Grant Notice and Stock Option
Agreement and agree to be bound by the provisions of the Stock Option Grant Notice and Stock Option Agreement insofar as I may have any rights in said Stock Option Grant Notice and Stock Option Agreement or any shares issued pursuant thereto under
the community property laws or similar laws relating to marital property in effect in the state of our residence as of the date of the signing of the Stock Option Grant Notice and Stock Option Agreement or the exercise of the option granted
thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><U>&#8195;&#8195;&#8195;&#8195;&#8195;</U>, <U>&#8195;&#8195;</U></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature of Spouse</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>INSTRUCTIONS:</B> Please do not fill in the blanks other than the signature line. The purpose of this
assignment is to enable the Company to exercise its &#147;Repurchase Option,&#148; as set forth in the Stock Option Grant Notice and Stock Option Agreement, without requiring additional signatures on the part of Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF 83(B) ELECTION AND INSTRUCTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These instructions are provided to assist you if you choose to make an election under Section&nbsp;83(b) of the Internal Revenue Code, as
amended, with respect to the shares of common stock of CG Oncology, Inc. transferred to you. <B>Please consult with your personal tax advisor as to whether an election of this nature will be in your best interests in light of your personal tax
situation.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The executed original of the Section&nbsp;83(b) election must be filed with the Internal Revenue Service not later than 30
days after the date the shares were transferred to you. <B>There is no remedy for failure to file on time.</B> The steps outlined below should be followed to ensure the election is mailed and filed correctly and in a timely manner. <B>If you make
the Section</B><B></B><B>&nbsp;83(b) election, the election is irrevocable.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complete the Section&nbsp;83(b) election form (attached
as <U>Attachment 1</U>) and make four (4)&nbsp;copies of the signed election form. Your spouse, if any, should sign the Section&nbsp;83(b) election form as well. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepare the cover letter to the Internal Revenue Service (sample letter attached as <U>Attachment 2</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Send the cover letter with the originally executed Section&nbsp;83(b) election form and one (1)&nbsp;copy via certified mail, return receipt
requested to the Internal Revenue Service at the address of the Internal Revenue Service where you file your personal tax returns. We suggest that you have the package date-stamped at the post office. The post office will provide you with a
certified receipt that includes a dated postmark. Enclose a self-addressed, stamped envelope so that the Internal Revenue Service may return a date-stamped copy to you. However, your postmarked receipt is your proof of having timely filed the
Section&nbsp;83(b) election if you do not receive confirmation from the Internal Revenue Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One (1)&nbsp;copy must be sent to CG
Oncology, Inc. for its records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Retain the Internal Revenue Service file stamped copy (when returned) for your records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please consult your personal tax advisor for the address of the office of the Internal Revenue Service to which you should mail your election
form. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ATTACHMENT 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION UNDER INTERNAL REVENUE CODE SECTION 83(B) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned taxpayer hereby elects, pursuant to Section&nbsp;83(b) of the Internal Revenue Code of 1986, as amended, to include in
taxpayer&#146;s gross income for the current taxable year the amount of any compensation taxable to taxpayer in connection with taxpayer&#146;s receipt of shares (the &#147;<B><I>Shares</I></B>&#148;) of Common Stock of CG Oncology, Inc., a Delaware
corporation (the &#147;<B><I>Company</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The name, address and taxpayer identification number of the undersigned taxpayer are: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">SSN: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The name, address and taxpayer identification number of the Taxpayer&#146;s spouse are (complete if
applicable): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">SSN: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Description of the property with respect to which the election is being made: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">__________________ (_____) shares of Common Stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The date on which the property was transferred was ______________. The taxable year to which this election relates is calendar year ____. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nature of restrictions to which the property is subject: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Shares are subject to repurchase by the Company or its assignee upon the occurrence of certain events. This repurchase right lapses based
upon the continued performance of services by the taxpayer over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair market value at the time of transfer (determined without regard to any
lapse restrictions, as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.83-3(i))</FONT> of the Shares was $___________ per Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount paid by the taxpayer for the Shares was <U></U>per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of this statement has been furnished to the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: _____________, ____</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Taxpayer Signature ________________________</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CG ONCOLOGY, INC. HAS DETERMINED THE INFORMATION
(I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;WOULD LIKELY CAUSE COMPETITIVE HARM TO CG ONCOLOGY, INC. IF PUBLICLY DISCLOSED. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT AND
LICENSE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This DEVELOPMENT AND LICENSE AGREEMENT (&#147;<B><I>Agreement</I></B>&#148;) effective as of March&nbsp;11, 2019
(&#147;<B><I>Effective Date</I></B>&#148;), is entered into by and between Cold Genesys, Inc. (&#147;<B><I>CG</I></B>&#148;), with offices at Santa Ana, CA 92707, and Lepu Biotech Co., Ltd. (&#147;<B><I>Lepu</I></B>&#148;), with offices at <FONT
STYLE="white-space:nowrap">1-C280,</FONT> No.&nbsp;1628 Suzhao Road, Minhang, Shanghai. CG and Lepu may each be referred to as a &#147;<B><I>Party</I></B>&#148; or together as the &#147;<B><I>Parties.</I></B>&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, CG owns or controls
certain intellectual property assets, including, but not limited to, patents, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and scientific and technical information relating to CG&#146;s CG0070 recombinant adenovirus; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Lepu possesses expertise and resources relating to the development, manufacture and commercialization of pharmaceutical products and wishes to obtain
an exclusive license under CG&#146;s patents, proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> and scientific and technical information relating to CG&#146;s CG0070 recombinant adenovirus to develop, manufacture and commercialize
products for China; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, CG and Lepu desire to enter into a collaboration for the development and commercialization of such products as set forth
in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties and covenants contained herein, CG and
Lepu, intending to be legally bound, hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&#8195;<B>CERTAIN DEFINITIONS</B>. For purposes of this Agreement, the following capitalized terms, whether used in the singular or plural,
shall have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1&#8195;&#147;<B><I>Adverse Event</I></B>&#148; means any undesirable event or experience associated
with the use of a medicinal product, whether or not expected, including, but not limited to, an event or experience that occurs: in the course of the use of the product in professional practice; from overdose whether accidental or intentional; from
abuse; from withdrawal; or from a failure of expected pharmacological or biological therapeutic action of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2&#8195;&#147;<B><I>Affiliate</I></B>&#148; means any Person that, directly or indirectly, controls, is controlled by or is under common
control with a Party for so long as such control exists, where &#147;control&#148; means the decision-making authority as to such Person and, further, where such control </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be presumed to exist where a Person owns more than fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) entitled to vote regarding composition of the board of directors or other body entitled to direct the affairs of the entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3&#8195;&#147;<B><I>Approval Request</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;9.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.4&#8195;&#147;<B><I>Business Day</I></B>&#148; means any day other than (a)&nbsp;Saturday or Sunday or (b)&nbsp;any other day on which banks
in New York, New York, United States are permitted or required to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.5&#8195;&#147;<B><I>CG0070 Patents</I></B>&#148; means the
following: (a)&nbsp;the patents and patent applications set forth in Exhibit&nbsp;1 attached hereto; (b)&nbsp;all other patents and patent applications owned or Controlled by CG as of the Effective Date or during the Term with at least one pending
or issued claim that would be infringed by the manufacture, use, and/or sale of a Product; (c)&nbsp;all patent applications claiming priority from a patent or patent application described in (a)&nbsp;or (b), including, without limitation,
continuations, divisionals, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> and foreign patent applications; (d)&nbsp;all patents and patent applications from which any patent or patent
application described in (a), (b), or (c)&nbsp;claims priority; and (e)&nbsp;all patents issuing from a patent application described in (a), (b), (c), or (d), including, without limitation, all reissues, reexaminations and extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.6&#8195;&#147;<B><I>Change in Control</I></B>&#148; means a transaction or series of related transactions pursuant to which an entity that
directly or indirectly obtains ownership of more than fifty percent (50%) of the voting securities of CG, provided that (i)&nbsp;CG is the surviving or continuing entity in the event of any merger, combination, conversion, reorganization, or similar
transaction that constitutes all or part of such Change in Control and (ii)&nbsp;no assets of CG relating to the Licensed IP are assigned, transferred or sold in connection with such transaction or series of related transactions constituting such
Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.7&#8195;&#147;<B><I>Claim</I></B>&#148; means any charge, complaint, action, suit, proceeding, hearing,
investigation, claim or demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.8&#8195;&#147;<B><I>Combination Product</I></B>&#148; means a Product(s) and Other Product(s) sold in
combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.9&#8195;&#147;<B><I>Commercially Reasonable Efforts</I></B>&#148; means efforts at least consistent with the efforts a
party would be expected to devote to a product of similar market potential, profit potential (determined without taking into account payments under this Agreement) or strategic value resulting from its own research efforts, based on conditions then
prevailing. In all cases, the level of efforts required of a party in connection with its Development and/or Commercialization efforts (as applicable) shall be determined without reference to any product other than Products or any other drug
development program owned by that Party, its Affiliates or any Sublicensee, or to which any of them have any rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.10&#8195;&#147;<B><I>Commercialization</I></B>&#148;, &#147;<B><I>Commercialize</I></B>&#148; or &#147;<B><I>Commercializing</I></B>&#148;
means engaging in any and all activities directed to manufacturing of commercial supplies, marketing, promoting, distributing, offering for sale, selling, importing, exporting or exploiting a product, and conducting post Marketing Authorization
Approval studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.11&#8195;&#147;<B><I>Confidential Information</I></B>&#148; shall have the meaning
assigned thereto in Section&nbsp;10.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.12&#8195;&#147;<B><I>Control</I></B>&#148; or &#147;<B><I>Controlled</I></B>&#148; means, with
respect to any item of or right under CG0070 Patents or Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> the possession of such item or right (whether by ownership or license, other than pursuant to this Agreement) or the ability of a
Party to grant a license or sublicense of such item or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other
Party such license or sublicense and without payment of additional consideration to such Third Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.13&#8195;&#147;<B><I>Cover</I></B>&#148; or &#147;<B><I>Covering</I></B>&#148; means, (a)&nbsp;with respect to a patent or patent
application, that at least one Valid Claim of such patent or patent application would be infringed by the product, method, use, or device, as applicable, and (b)&nbsp;with respect to any other intellectual property right, that the product, method,
use or device would infringe or misappropriate such rights unless a license were granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.14&#8195;&#147;<B><I>Development</I></B>&#148;, &#147;<B><I>Develop</I></B>&#148; or &#147;<B><I>Developing</I></B>&#148; means engaging in
preclinical and clinical drug development activities, including, but not limited to, test method development, stability testing, toxicology, formulation, process development, manufacturing <FONT STYLE="white-space:nowrap">scale-up,</FONT>
development-stage manufacturing, analytical method validation, manufacturing process validation, cleaning validation, post-approval changes, quality assurance/quality control, statistical analysis, report writing, preclinical and Clinical studies,
regulatory filing submission and approval and regulatory affairs, but expressly excluding Research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.15&#8195;&#147;<B><I>Development
Activities</I></B>&#148; means activities undertaken in performance of the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.16&#8195;&#147;<B><I>Development
Plan</I></B>&#148; means the comprehensive plan for the Development of Products for the purpose of obtaining Marketing Authorization Approval for the Products in the Field of Use in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.17&#8195;&#147;<B><I>Disclosing Party</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.18&#8195;&#147;<B><I>FDA</I></B>&#148; means the United States Food and Drug Administration and any successor agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.19&#8195;&#147;<B><I>FDCA</I></B>&#148; means the Federal Food, Drug and Cosmetics Act, as amended from time to time, and the rules,
regulations and guidelines promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.20&#8195;&#147;<B><I>Field of Use</I></B>&#148; means the use of the CG0070
recombinant adenovirus and/or <FONT STYLE="white-space:nowrap">n-Dodecyl-beta-Maltoside</FONT> (&#147;<B><I>DDM</I></B>&#148;) to treat and/or prevent cancer (in each case, including in a combination therapy). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.21&#8195;&#147;<B><I>First Commercial Sale</I></B>&#148; means the first transfer for
value of commercial quantities of any Product by Lepu or any of its Affiliates or Sublicensees after receipt of Marketing Authorization Approval. Sales for test marketing, sampling and promotional uses, clinical study purposes or compassionate or
similar uses shall not be considered to constitute a First Commercial Sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.22&#8195;&#147;<B><I>Good Manufacturing
Practices</I></B>&#148; means, with respect to the United States, the minimum then-current good manufacturing practices for methods, facilities, and controls to be used for the manufacture, processing, packing, or holding of a drug to assure that it
meets the requirements of the FDCA for safety and has the identity and strength and meets the quality and purity characteristics, specified in 21 C.F.R. Parts 210 and 211, as may be amended, and, with respect to any other country or jurisdiction,
the equivalent regulations in such other country or jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.23&#8195;&#147;<B><I>Governmental Authority</I></B>&#148; means any
court, tribunal, arbitrator, agency, legislative body, commission, official or other instrumentality of (a)&nbsp;any government of any country, (b)&nbsp;a federal, state, province, county, city or other political subdivision thereof or (c)&nbsp;any
supranational body, including, but not limited to, the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.24&#8195;&#147;<B><I>Intellectual Property Rights</I></B>&#148; means any
and all patent rights, copyright rights, trade secret rights, <I>sui generis</I> database rights and all other intellectual and industrial property rights of any sort throughout the world (including, but not limited to, any application therefor)
whether now known or hereafter existing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.25&#8195;&#147;<B><I>Laws</I></B>&#148; means all laws, statutes, rules, regulations,
ordinances and other pronouncements having the binding effect of law of any Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.26&#8195;&#147;<B><I>Licensed
IP</I></B>&#148; means the Licensed Patents and Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.27&#8195;&#147;<B><I>Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></I></B>&#148; means all
<FONT STYLE="white-space:nowrap">know-how</FONT> and technical information Controlled and possessed by CG during the Term that relates to the CG0070 recombinant adenovirus and/or DDM and is reasonably necessary or useful to develop, use, sell, offer
to sell, market or promote the CG0070 recombinant adenovirus and/or DDM in the Field of Use in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.28&#8195;&#147;<B><I>Licensed Patents</I></B>&#148; means CG0070 Patents held in a jurisdiction within the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.29&#8195;&#147;<B><I>Manufacturing Documentation</I></B>&#148; means, with respect to a Product, the documentation that is in CG&#146;s
possession and relevant to the manufacture of such Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.30&#8195;&#147;<B><I>Marketing Authorization Approval</I></B>&#148; shall
mean approval by the applicable Regulatory Authority for sale of a Product in the Field of Use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.31&#8195;&#147;<B><I>Materials</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;7.1.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.32&#8195;&#147;<B><I>Net Sales</I></B>&#148; means with respect to a given period, the
gross amounts invoiced for Products sold or otherwise disposed of by Lepu, an Affiliate of Lepu, or a Sublicensee, to Third Party customers, less the following amounts: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&#8195;[***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;[***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;[***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;[***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&#8195;[***]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi)&#8195;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.33&#8195;&#147;<B><I>Other Product</I></B>&#148; means an active ingredient, other than the Product, consisting of a separate and distinct
molecular entity having a clearly defined therapeutic activity other than as an adjuvant, <FONT STYLE="white-space:nowrap">bio-availability</FONT> enhancer, formulation excipient, stabilizer, antioxidant, device, carrier or the like. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.34&#8195;&#147;<B><I>Party</I></B>&#148; or &#147;<B><I>Parties</I></B>&#148; shall have the meaning assigned thereto in the first paragraph
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.35&#8195;&#147;<B><I>Patent Costs</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;13.1.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.36&#8195;&#147;<B><I>Person</I></B>&#148; means any natural person, corporation, general partnership, limited partnership, limited liability
company, joint venture, proprietorship or other <I>de jure </I>entity organized under the Laws of any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.37&#8195;&#147;<B><I>Personnel Costs</I></B>&#148; shall mean CG&#146;s internal and external costs for personnel to the extent directed to
work under this Agreement (e.g. assisting in Development and/or manufacturing of Products), excluding any such costs related to participation of CG&#146;s employees on the JDC. External costs for consultants will be equivalent to the amount CG is
required to pay such consultants, but only if such consultants are approved in advance by Lepu. Costs for CG personnel will be calculated on an hourly basis based on such personnel&#146;s base salary (excluding bonuses, benefits, and other
perquisites). For clarity, costs and expenses for CG&#146;s consultants to engage in JDC activities shall be deemed Personnel Costs, but only if such consultants are approved in advance by Lepu. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.38&#8195;&#147;<B><I>Product</I></B>&#148; means CG0070 recombinant adenovirus and/or DDM, the Development, manufacture, Commercialization
or use of which (i)&nbsp;is Covered by a Valid Claim of at least one (1)&nbsp;Licensed Patent or; (ii)&nbsp;uses or incorporates all or any part of the Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.39&#8195;&#147;<B><I>Regulatory Authority</I></B>&#148; means a federal, national, multinational or other regulatory agency or governmental
entity involved in the granting of marketing approval for a pharmaceutical product in a country (e.g., the FDA). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.40&#8195;&#147;<B><I>Regulatory Exclusivity</I></B>&#148; means, with respect to a
Product, any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to such Product, other than patent rights, that prohibits a third party from (a)&nbsp;relying on data generated by or on behalf of
the Parties with respect to such Product in an application for regulatory approval, or (b)&nbsp;commercializing such Product (for example, any Data Exclusivity rules released by the CFDA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.41&#8195;&#147;<B><I>Regulatory Filings</I></B>&#148; means any written application, submission, notice or other filing made to an
applicable Regulatory Authority in the Territory: (a)&nbsp;seeking approval for the commercial manufacture, use, storage, import, export, transport, distribution, marketing or sale of a Product, including, without limitation, any Marketing
Authorization Approval; or (b)&nbsp;that is required to be filed with the applicable Regulatory Authority before beginning clinical testing of a Product in human subjects, including, without limitation, any successor application or procedure, <FONT
STYLE="white-space:nowrap">non-U.S.&nbsp;equivalents</FONT> to any of the foregoing and all supplements and amendments that may be filed with respect to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.42&#8195;&#147;<B><I>Research</I></B>&#148; means activities to (i)&nbsp;develop a virus other than CG0070 recombinant adenovirus or
(ii)&nbsp;develop applications for CG0070 recombinant adenovirus and/or DDM outside the Field of Use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.43&#8195;&#147;<B><I>Senior
Executives</I></B>&#148; shall mean the Chairman or Chief Executive Officer of CG and the Chief Executive Officer or other &#147;<B><I><FONT STYLE="white-space:nowrap">C-Level</FONT></I></B>&#148; Management of Lepu. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.44&#8195;&#147;<B><I>Sublicensee</I></B>&#148; means a sublicensee to whom Lepu has sublicensed any of its rights to Develop and/or
Commercialize (e.g., without limitation, the right to sell or offer to sell) Products pursuant to Section&nbsp;3.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.45&#8195;&#147;<B><I>Term</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;14.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.46&#8195;&#147;<B><I>Territory</I></B>&#148; means mainland China (including Hong Kong and Macau). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.47&#8195;&#147;<B><I>Third Party</I></B>&#148; means a Person who is not a Party or an Affiliate of a Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.48&#8195;&#147;<B><I>United States</I></B>&#148; means the United States of America and its territories and possessions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.49&#8195;&#147;<B><I>Upfront Payment</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;9.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.50&#8195;&#147;<B><I>Valid Claim</I></B>&#148; means a claim in an issued, unexpired patent that (i)&nbsp;has not been finally cancelled,
withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (ii)&nbsp;has not been revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent
jurisdiction that is unappealable or unappealed within the time allowed for appeal, (iii)&nbsp;has not been rendered unenforceable through disclaimer or otherwise, and (iv)&nbsp;is not lost through an interference proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&#8195;<B>[Intentionally omitted]</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&#8195;<B>LICENSE GRANTS, OWNERSHIP AND EXCLUSIVITY</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1&#8195;<U>License Grant</U>. Subject to the terms and conditions of this Agreement, CG grants to Lepu and its Affiliates (but only to the
extent those Affiliates agree in writing provided to CG and for CG&#146;s benefit to be bound by all the restrictions in this Agreement in the same manner in which Lepu is bound) an exclusive, royalty-bearing,
<FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as expressly set forth in Section&nbsp;15.8) license under the Licensed IP, to manufacture (but not have manufactured), Commercialize and Develop Products in the Field of Use in the
Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2&#8195;<U>Sublicenses</U>. Lepu may not sublicense any of the rights granted under Section&nbsp;2.1 without CG&#146;s prior
written consent, which shall not be unreasonably withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3&#8195;<U>Research</U>. For clarity, Section&nbsp;3.1 does not grant Lepu
any rights to conduct (and Lepu agrees not to conduct) Research with respect to the Licensed IP. Without limiting any remedies of CG, CG shall own (and Lepu hereby assigns) all right, title and interest in and to any inventions conceived or reduced
to practice during the Term that are improvements or modifications to any Licensed IP or otherwise resulting from Research using the Licensed IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4&#8195;<U>No Implied Rights</U>. Nothing contained in this Agreement confers or will be construed to confer any rights by implication,
estoppel or otherwise, under any Intellectual Property Rights, other than the rights expressly granted in this Agreement. All rights not expressly granted by a Party under this Agreement are reserved to such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5&#8195;<U>Ownership of Licensed IP</U>. Other than through a license outside the Field of Use or outside the Territory, CG shall not sell,
convey, assign, license, or otherwise transfer all or part of its right, title, or interest in the Licensed IP unless, prior to or contemporaneously with such transaction, the transferee delivers to Lepu an instrument by which the transferee assumes
CG&#146;s obligations under this Agreement and agrees that such Licensed IP is being transferred subject to the license grant in Section&nbsp;3.1. For the avoidance of doubt, a Change in Control, by itself, is not a sale, conveyance, assignment,
license or transfer of Licensed IP subject to this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&#8195;<B>JOINT DEVELOPMENT COMMITTEE</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1&#8195;<U>General</U>. The parties shall establish a joint development committee (the &#147;<B><I>Joint Development Committee</I></B>&#148;
or &#147;<B><I>JDC</I></B>&#148;) consisting of [***] from each Party, which committee shall oversee, guide, and monitor the Development (including the conducting of clinical trials) and regulatory approval efforts for the Products in the Field of
Use in the Territory by (a)&nbsp;reviewing and discussing the progress of the Development Activities, including any significant difficulties encountered or anticipated to be encountered in connection therewith, and (b)&nbsp;reviewing and approving
any amendments to the then-current Development Plan. The Parties acknowledge that one goal of the JDC&#146;s efforts will be to maximize the commercial potential of Products in the Territory for the Field of Use while harmonizing such efforts with
the development and commercialization of the same or other Products outside the Territory in the Field of Use. Notwithstanding the foregoing sentence, the JDC will not oversee, guide, or monitor the Commercialization of Products. The JDC shall meet
on a [***] basis. JDC decisions shall be made by consensus, with each party having a single vote regardless of the number of the representatives of such Party; provided, however, that Lepu shall cast the deciding vote for each matter where the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
JDC cannot reach consensus after escalation to each Party&#146;s Senior Executives, so long as such JDC decision would not reasonably be expected to result in (i)&nbsp;any direct, material
impairment to the Licensed IP or the Development of any Products outside of the Territory or (ii)&nbsp;any direct, material conflict with the rights of other CG licensees of the Licensed IP. In the case of clause (i)&nbsp;or (ii) above, CG shall
cast the deciding vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2&#8195;<U>Product Development</U>. Lepu agrees not to research, develop, use, sell, market and promote any
Products without informing the JDC. In addition, Lepu will not undertake any Development efforts (including conducting any preclinical studies or clinical trials) for any Product (other than pursuant to the Development Plan) without informing the
JDC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&#8195;<B>DEVELOPMENT OF PRODUCTS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1&#8195;<U>Approval of Development Plan; Annual Updates</U>. An initial Development Plan shall be prepared by Lepu and submitted to the JDC
for approval within [***] of the Effective Date. Lepu shall submit to the JDC updates to the Development Plan by [***] of each calendar year in which Lepu anticipates conducting Development Activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2&#8195;<U>Lepu Responsibilities; CG Assistance</U>. Lepu shall use Commercially Reasonable Efforts to Develop Products in the Field of Use
in the Territory, including by performing Development Activities in accordance with the corresponding timelines set forth in Development Plan, all at Lepu&#146;s sole cost and expense. Without limiting the foregoing, Lepu shall achieve the following
clinical and regulatory milestones on or before the following dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target<BR>Completion<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CG shall provide all reasonably requested information, Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> and
assistance to Lepu in connection with the Development Activities, at Lepu&#146;s cost and expense (which CG may reasonably require in advance). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3&#8195;<U>CG Development Costs</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.3.1&#8195;The Parties acknowledge and agree that their intent is for Lepu to be responsible for all of the internal and external costs and
expenses incurred by CG in its performance of all Development Activities it is required to perform, including, without limitation, Personnel Costs, but excluding costs related to participation of CG&#146;s employees on the JDC (the &#147;<B><I>CG
Development Costs</I></B>&#148;). Accordingly, Lepu shall pay CG for the CG Development Costs within [***] after receipt of CG&#146;s written invoice(s), supported by reasonable documentation for the amounts charged in such invoice(s). However, to
the extent CG must pay its approved consultants prior to such time period, then Lepu shall pay CG such CG Development Costs within the later of (i) [***] after invoice, or (ii)&nbsp;the date such consultant requires payment after invoice. For the
avoidance of doubt, unless otherwise agreed to by the Parties in writing, CG will not be required to perform any activities under the Development Plan for which funding by Lepu is not provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&#8195;<B>COMMERCIALIZATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1&#8195;<U>Commercialization Plan</U>. No later than [***] prior to the estimated date of Marketing Authorization Approval in the Territory,
Lepu shall provide CG with a written plan for the Commercialization of Products in the Field of Use in the Territory (the &#147;<B><I>Commercialization Plan</I></B>&#148;) including a corresponding budget, which shall include reasonable detail
regarding the activities Lepu expects to undertake, and the amounts it expects to expend in connection with such activities over the [***] period immediately following Marketing Authorization Approval in the Territory. The Commercialization Plan
shall be updated [***] and shall include revenue projections for the first [***] covered by the Commercialization Plan. The Commercialization Plan shall, at a minimum, contain reasonably sufficient detail to demonstrate to CG how Lepu intends to
meet its obligations under Section&nbsp;6.2. Lepu shall provide CG with a reasonable opportunity to review and comment on the initial Commercialization Plan and each update thereto, and Lepu shall consider all such comments in good faith. Lepu shall
be responsible to use Commercially Reasonable Efforts to Commercialize Products in accordance with the Commercialization Plan and otherwise as expressly provided under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2&#8195;<U>Diligence</U>. Lepu shall use Commercially Reasonable Efforts to Commercialize Products in the Field of Use in the Territory, at
its sole expense. Without limiting the generality of the foregoing, Lepu shall use Commercially Reasonable Efforts to Commercialize at least one (1)&nbsp;Product and achieve the First Commercial Sale in the Territory within [***] after receipt of
Marketing Authorization Approval therefor, and to Commercialize at least one (1)&nbsp;Product and achieve the First Commercial Sale in the Territory within [***] after receipt of Marketing Authorization Approval in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3&#8195;<U>Samples and Labeling</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3.1&#8195;<U>Markings</U>. To the extent permitted or required by applicable Law, Lepu shall (and shall require that its Affiliates and
Sublicensees) indicate that the Product is licensed by CG in the package insert for all Products distributed in the Field of Use in the Territory. Subject to the Parties&#146; agreement as to which Licensed Patents Cover any Product, Lepu shall, and
shall require its Affiliates and Sublicensees to, mark all Products and all associated packaging and documentation, with the appropriate marking and notices associated with the applicable Licensed Patents in accordance with the laws and customs of
each country or jurisdiction in which such Products are manufactured, used or sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3.2&#8195;<U>Statements Consistent with
Labeling</U>. Lepu shall ensure that its employees, independent contractors and other agents market and sell Products consistent with the requirements of all applicable Laws. Lepu shall ensure that all samples provided under this Agreement are
labeled and distributed in accordance with applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&#8195;<B>MANUFACTURING; TECHNOLOGY TRANSFER</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1&#8195;<U>Manufacturing by CG</U>. CG shall use Commercially Reasonable Efforts to manufacture or otherwise supply Lepu of its requirements
of CG&#146;s CG0070 recombinant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adenovirus and DDM (the &#147;<B><I>Materials</I></B>&#148;) for Development Activities. Lepu shall pay CG its fully burdened cost of such Materials plus (a) [***] thereof, and (b)&nbsp;actual
freight and other Third Party transportation and handling expenses and within [***] after acceptance of Materials. Lepu may (as its sole and exclusive remedy for any <FONT STYLE="white-space:nowrap">non-conformance</FONT> of Materials) only reject
any Materials that do not conform in all material respects to specifications agreed upon in writing between Lepu and CG, and CG shall promptly upon such rejection provide Lepu with conforming replacement Materials in accordance with this Section.
Materials that Lepu does not reject by notifying CG within [***] after delivery to Lepu shall be deemed accepted. Furthermore, the timing of delivery of the Materials shall be as reasonably specified by Lepu (but always subject to CG&#146;s then
current lead time), provided that the parties shall resolve any disputes regarding such timing through the JDC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2&#8195;<U>Manufacturing by Lepu; Technology Transfer</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.1&#8195;At least [***] every [***] during the Term or at Lepu&#146;s request, CG will provide Lepu with copies of all Manufacturing
Documentation in its possession and necessary for Lepu to manufacture clinical and commercial supplies of CG&#146;s CG0070 recombinant adenovirus and DDM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.2&#8195;With respect to the manufacture of CG&#146;s CG0070 recombinant adenovirus and DDM, CG shall provide all reasonably requested
information (including, without limitation, Licensed <FONT STYLE="white-space:nowrap">Know-How)</FONT> and assistance to Lepu, at Lepu&#146;s cost and expense, necessary to enable the manufacture of CG&#146;s CG0070 recombinant adenovirus and DDM at
a manufacturing facility designated by Lepu. Such assistance shall include, if requested by Lepu and at Lepu&#146;s expense (including, without limitation CG&#146;s Personnel Costs), provision of reasonable access to and consultation with persons
knowledgeable of the manufacture of CG&#146;s CG0070 recombinant adenovirus and DDM. Prior to the start of the validation process of a Third Party facility, CG shall have the right to require that the Third Party facility enter into a reasonable
agreement with CG and/or its Third Party manufacturer that includes confidentiality obligations that are at least as protective of CG&#146;s Confidential Information as those set forth in Article&nbsp;9. CG shall use Commercially Reasonably Efforts
to provide reasonably requested information and assistance under this Section&nbsp;7.2.2, at Lepu&#146;s cost and expense, on an ongoing basis with the intent that Products can be manufactured to meet then-current demand with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">batch-to-batch</FONT></FONT> stability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.3&#8195;Lepu acknowledges that
CG&#146;s obligations in Sections&nbsp;7.2.1 and 7.2.2 are conditioned on Lepu providing certain documentation reasonably necessary to enable CG to perform its obligations and Lepu agrees to provide CG with such documentation and otherwise
reasonably cooperate with CG in the performance of its obligations under this Section&nbsp;7.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3&#8195;<U>Compliance with Laws</U>.
Each Party shall conduct, or have conducted, all manufacturing of Product for which it is responsible in accordance with this Agreement and Laws, including, without limitation, all Good Manufacturing Practices, to the extent applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&#8195;<B>REGULATORY MATTERS</B><B>. </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1&#8195;<U>Responsibility</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.1.1&#8195;Lepu shall be the holder and owner of all the Marketing Authorization Approvals in the Territory for Products in the Field of Use
during the Term, and shall be responsible for all associated legal obligations with respect to all of the foregoing. Lepu shall use Commercially Reasonable Efforts to maintain all the Marketing Authorization Approvals for Products in the Territory,
including submitting any supplemental applications, annual reports, variations or renewals thereof that are required by applicable Law to be obtained in order to maintain the Marketing Authorization Approval(s) in the Territory. Lepu shall use
Commercially Reasonable Efforts, and bear its own costs and expenses, in connection with the foregoing and all other regulatory-related activities Lepu undertakes or is required to undertake in the Territory. Lepu shall not assign or transfer any
Marketing Authorization Approvals in the Territory to any Third Party without the prior written consent of CG, except in connection with a permitted assignment of this Agreement pursuant to Section&nbsp;15.8. At Lepu&#146;s request and expense
(which CG may reasonably request in advance), CG shall provide reasonable assistance with Lepu&#146;s pursuit of Marketing Authorization Approvals and other regulatory activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2&#8195;<U>Communication</U>. Lepu shall keep CG informed of all significant matters arising from Lepu&#146;s regulatory-related activities
with respect to Products and shall provide CG with a copy or a summary of any material correspondence that it receives from a Regulatory Authority regarding any Product, with such copy or summary to be provided no later than [***] after receipt of
the correspondence to which it relates. Lepu shall provide CG reasonable advance written notice of any meetings, conferences, or calls with Regulatory Authority(ies) in the Territory concerning Products and an opportunity participate in any such
meetings, conferences or calls, and to review and comment on any materials or correspondence proposed to be submitted to any Regulatory Authority. Lepu shall give reasonable consideration to CG&#146;s comments and suggestions regarding all
regulatory matters related. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3&#8195;<U>Right of Reference</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.3.1&#8195;Lepu hereby grants CG a right of reference, subject to applicable Law, to all data and information contained or referenced in any
submissions to Regulatory Authorities for Products in the Territory that are reasonably necessary or useful for any regulatory filings CG decides to make with respect to Products outside the Territory and/or Field of Use. Lepu shall provide the
applicable Regulatory Authority(ies) a letter confirming this right of reference at any time within [***] after CG&#146;s request and shall take such other actions and execute such other documents as CG may reasonably request to further confirm and
give effect to this right of reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.3.2&#8195;CG hereby grants Lepu a right of reference, subject to applicable Law, to all data
and information contained or referenced in any submissions to Regulatory Authorities for Products outside the Territory that are reasonably necessary or useful for any regulatory filings Lepu decides to make with respect to Products in the Territory
in the Field of Use. CG shall provide the applicable Regulatory Authority(ies) a letter confirming this right of reference at any time within [***] after Lepu&#146;s request and shall take such other actions and execute such other documents as Lepu
may reasonably request to further confirm and give effect to this right of reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4&#8195;<U>Drug Safety Information</U>. Lepu shall comply fully with all applicable
Adverse Event reporting recommendations and requirements in all countries in the Territory where Lepu intends to Commercialize the Product and the Parties agree to exchange with one another such information as may be necessary to achieve that end
and to ensure that the Parties are completely informed regarding Adverse Events with respect to the Products. This includes single case reports, together with an appropriate medical evaluation, as well as aggregate data, such as Periodic Safety
Update Reports (PSURs) required by applicable Regulatory Authorities. Within [***] after the Effective Date of this Agreement, the Parties shall commence good faith negotiations on a mutually acceptable pharmacovigilance agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&#8195;<B>UPFRONT PAYMENTS; MILESTONE PAYMENTS; ROYALTY PAYMENTS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As partial consideration for the contributions and activities of CG under this Agreement and the rights granted by CG to Lepu hereunder, Lepu
shall make the following payments to CG as set forth in this Article&nbsp;9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1&#8195;<U>Upfront Payment</U>. Lepu shall pay CG four
million five hundred thousand United States Dollars (USD$4,500,000) (the &#147;<B><I>Upfront Payment</I></B>&#148;) in accordance with the terms of this Section&nbsp;9.1. Within [***] after the Effective Date, and with CG&#146;s assistance at
Lepu&#146;s reasonable request, Lepu shall seek approval from the China State Tax Administration (an &#147;<B><I>Approval Request</I></B>&#148;) and shall provide CG with written verification of such Approval Request. Lepu shall pay CG the Upfront
Payment within [***] after the Approval Request is granted, which grant Lepu expects will occur approximately [***] after submission of the Approval Request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2&#8195;<U>Milestone Payments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.2.1&#8195;In the event CG or Lepu achieves a regulatory or commercial milestone specified below with respect to any Product (including
achievement of any milestone by any Affiliate or Sublicensee of Lepu), then CG or Lepu, as applicable, shall promptly notify the other Party in writing of such achievement. Within [***] after such achievement, and with CG&#146;s assistance at
Lepu&#146;s reasonable request, Lepu shall file an Approval Request to pay to CG the corresponding <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payments specified in the
table below, and shall provide CG with written verification of such Approval Request. Lepu shall pay CG the applicable milestone payment within [***] after the Approval Request is granted. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Milestone Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone&nbsp;Payment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[</TD>
<TD NOWRAP VALIGN="bottom">***]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.2.2&#8195;All milestones are intended to be cumulative, such that if a later milestone is achieved prior to
the achievement of one or more earlier milestones, the earlier milestone(s) will be deemed to have been achieved at the time the later milestone is achieved, and the corresponding milestone payment(s) shall be due and payable in accordance with this
Section&nbsp;9.2. Each milestone payment shall be made by Lepu only once. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3&#8195;<U>Royalties</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.1&#8195;<U>Net Sales Royalties</U>. From and after the date of the First Commercial Sale of a Product until termination of this Agreement
for any reason, Lepu will pay royalties to CG in an amount equal to seven percent (7%) of annual Net Sales. Royalty payments shall be payable on a calendar quarterly basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.2&#8195;<U>Timing of Royalty Payments</U>. Within [***] after the end of each calendar quarter Lepu shall file an Approval Request to
make the royalty payment to CG for Net Sales during such calendar quarter, and shall provide CG with written verification of such Approval Request. Lepu shall pay CG the applicable royalty payment within [***] after the Approval Request is granted.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.3&#8195;<U>Discounts</U>. To the extent permitted by applicable Laws, Lepu shall not, and shall ensure that its Affiliates and
Sublicensees do not, sell a Product to any Third Party at a discount greater than customary industry standards in the Territory with respect to products similar to the Product (and Lepu shall not be entitled to deduct the excess portion of such
discount in the calculation of Net Sales in respect of such sale). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.4&#8195;<U>Calculation of Net Sales for Combination Products</U>.
With respect to Combination Products, if Products are sold in the form of Combination Products containing one or more Other Products, Net Sales for the Combination Product will be calculated by multiplying actual Net Sales of such Combination
Product by the fraction A/(A+B) where A is the invoice price of a Product as the only therapeutically active ingredient if sold separately, and B is the total invoice price of any Other Products in such Combination Product, if sold separately. If
the Other Products in the combination are not sold separately, Net Sales for the purpose of determining royalties of the Combination Product shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/C where A
is the invoice price of the Product as the only therapeutically active ingredient, if sold separately, and C is the invoice price of the Other Product. If neither such Product nor the other active component or components of the Combination Product
is sold separately, Net Sales for the purposes of determining royalties of the Combination Product shall be determined by the Parties in good faith based on the relative value of the Product and the additional active ingredients that are included in
the Combination Product (an &#147;<B><I>Unprecedented Combination Product</I></B>&#148;). Neither Lepu, its Affiliates nor its Sublicensees shall sell any Unprecedented Combination Product until the Parties have made the determination required by
the previous sentence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.3.5&#8195;<U>Royalty Reduction Upon Loss of Patent Coverage</U>. The royalty rate
applicable to Net Sales of each Product shall be reduced to [***] when both (a)&nbsp;the sale of such Product is not Covered by at least one Valid Claim within the Licensed Patents; and (b)&nbsp;there is no Regulatory Exclusivity for such Product.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.4&#8195;<U>Net Sales</U>. Within [***] following the end of each calendar quarter, Lepu shall submit to CG a written statement
reporting Net Sales on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis during such calendar quarter, total royalty payments due CG in respect of such Net Sales, and information supporting
the calculation of such Net Sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.5&#8195;[<U>Intentionally omitted</U>.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.6&#8195;<U>Payment Terms</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.6.1&#8195;All sums due to CG shall be payable in United States dollars by bank wire transfer in immediately available funds to such bank
account(s) as CG shall designate. Lepu shall pay CG for Personnel Costs within [***] following receipt of CG&#146;s invoice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.6.2&#8195;When Products are sold for monies other than United States dollars, the Net Sales of such Products will first be determined in
the foreign currency of the country in which such Products were sold and then converted into equivalent United States funds. The exchange rate will be the applicable rate published by the Wall Street Journal on the last Business Day of the calendar
quarter in which such royalties accrued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.6.3&#8195;Where royalties are due for Net Sales where by reason of currency regulations of
any kind it is impossible to make royalty payments for that country&#146;s Net Sales in accordance with Section&nbsp;9.6.1, said royalties shall be deposited in whatever currency is allowable for the benefit or credit of CG in an account designated
by CG in an accredited bank in that country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.6.4&#8195;In case of any delay in payment by Lepu to CG, interest on the overdue payment
shall accrue at an annual interest rate, compounded monthly, equal to the prime rate as reported in [***], [***], as determined for each month on the last business day of that month plus [***], or if lower, the maximum rate allowed by applicable
Laws, assessed from the day payment was initially due. The foregoing interest shall be due from Lepu without any special notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.7&#8195;<U>Tax Withholding, Financial Records and Audits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.7.1&#8195;Each Party shall be responsible for, and shall pay, any taxes imposed on it by applicable Law resulting or arising from the
transactions contemplated herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.7.2&#8195;If laws or regulations require Lepu to withhold any taxes from royalty or advance payments
made to CG under this Agreement, then such taxes shall be deducted by Lepu as required by law from such remittable royalty, milestone or similar payments and shall be paid by Lepu to the proper tax authorities. Official receipts of payment of any
withholding tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be secured and sent to CG as evidence of such payment. All amounts required to be withheld by Lepu and remitted to a taxing authority shall be treated as if they were paid to CG under this
Agreement. Notwithstanding the foregoing, any payments by Lepu for Materials provided by CG or pursuant to Sections&nbsp;5.2, 5.3, 7.2.2 and 13.1.2 shall be net of any withholding and any amounts remitted to a taxing authority in connection
therewith shall not be treated as if they were paid to CG. For the avoidance of doubt, the foregoing sentence shall not apply to any other payments under this Agreement (including, without limitation, the Upfront Payment, any royalty payments or any
milestone payments) to the extent tax withholding may be required with respect to such amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.7.3&#8195;[Intentionally omitted.]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.7.4&#8195;CG shall have the right, at its own expense, to nominate an independent certified public accountant acceptable to and
approved by Lepu, said approval not to be unreasonably withheld, who shall have access to Lepu&#146;s records during reasonable business hours for the purpose of verifying the amounts payable by Lepu under this Agreement for any period within the
preceding [***] period, but this right may not be exercised more than once in any [***] except for <FONT STYLE="white-space:nowrap">re-audits</FONT> performed by CG following a deficiency of any payment to CG by [***] or more. The accountant shall
disclose to CG only information relating solely to the accuracy of the amounts payable by Lepu under this Agreement. If any audit or examination shall reveal a deficiency of any payment due hereunder, Lepu shall make payment to CG of such deficiency
plus interest at the prevailing prime rate reported in United States dollars in the money rate section&nbsp;of Wall Street Journal, New York edition on the date of communication to Lepu of such deficiency plus [***] for the period of such
deficiency. Payment shall be made within [***] following notification of Lepu by CG of such deficiency. In addition, in the event that such an audit or examination shall reveal a deficiency of any royalty payment due in an amount equaling or
exceeding [***] of Lepu&#146;s accounting of the undisputed amounts due hereunder, Lepu shall also reimburse CG for the reasonable costs of such audit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&#8195;<B>CONFIDENTIAL INFORMATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1&#8195;<U>Definition</U>. &#147;<B><I>Confidential Information</I></B>&#148; means confidential or proprietary information, data or <FONT
STYLE="white-space:nowrap">know-how,</FONT> whether provided in written, oral, visual or other form, provided by one Party (the &#147;<B><I>Disclosing Party</I></B>&#148;) to the other Party (the &#147;<B><I>Receiving Party</I></B>&#148;) in
connection with this Agreement, including, but not limited to, the terms of this Agreement and information relating to the Disclosing Party&#146;s existing or proposed research, development efforts, patent applications, business or products,
including, but not limited to Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> Confidential Information shall not include any such information that: (a)&nbsp;is already rightfully known to the Receiving Party or its Affiliates (other than
under an obligation of confidentiality at least as stringent as required in this Agreement) at the time of disclosure (as evidenced by written records of the Receiving Party); (b) is or becomes generally available to the public other than through
any act or omission of the Receiving Party or its Affiliates; (c)&nbsp;is disclosed to the Receiving Party or its Affiliates without an obligation of confidentiality by a Third Party who had no separate nondisclosure obligation in respect of such
information; or (d)&nbsp;is independently discovered or developed by or on behalf of the Receiving Party or its Affiliates without the use of or reference to the Confidential Information of the Disclosing Party (as evidenced by written records of
the Receiving Party). The Parties agree that with respect to the Licensed IP, CG shall be deemed the Disclosing Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2&#8195;<U>Confidentiality</U>. The Receiving Party shall keep in confidence all
Confidential Information of the Disclosing Party with the same degree of care it employs to maintain the confidentiality of its own Confidential Information, but no less than a reasonable degree of care. The Receiving Party shall not use such
Confidential Information for any purpose other than in performance of this Agreement or disclose the same to any other Person other than to such of its Affiliates and Sublicensees and its and their employees, agents and subcontractors who have a
need to know such Confidential Information to implement the terms of this Agreement. A Receiving Party shall advise any such Affiliate, employee, agent, and subcontractor who receives Confidential Information of such obligations, and the Receiving
Party shall ensure (through enforcement of written agreements or otherwise) that all such Affiliates, employees, agents, and subcontractors comply with such obligations as if they had been a Party hereto. The Receiving Party will be liable for
breach of confidentiality by any of its Affiliates or Sublicensees its or their employees, agents, or subcontractors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.3&#8195;<U>Permitted Disclosure and Use</U>. The Receiving Party shall have the right to disclose Confidential Information if, (a)&nbsp;in
the reasonable opinion of the Receiving Party&#146;s legal counsel, such disclosure is required by any applicable Laws (including, but not limited to, the rules of any stock exchange), provided that the Receiving Party gives adequate prior notice of
such disclosure to the Disclosing Party and the Receiving Party seeks confidential treatment of such Confidential Information to the maximum extent permitted by the relevant Governmental Authority; or (b)&nbsp;a court, tribunal, administrative
agency or other Governmental Authority orders such disclosure, provided that the Receiving Party gives adequate prior notice of such disclosure to the Disclosing Party to permit the Disclosing Party to intervene and to request protective orders or
other confidential treatment. The Receiving Party will cooperate reasonably with any such efforts by the Disclosing Party. Without limiting Section&nbsp;10.2, each Party may disclose Confidential Information of the other Party to Third Parties under
appropriate terms and conditions, including, without limitation, confidentiality provisions substantially equivalent to these in this Agreement only (a)&nbsp;for sublicensing (if approved by CG), consulting, manufacturing permitted under this
Agreement, development, external testing and marketing studies with respect to the Products covered by this Agreement or (b)&nbsp;to the extent such disclosure is reasonably necessary in filing or prosecuting patent, copyright and trademark
applications, prosecuting or defending litigation, complying with applicable governmental regulations, conducting preclinical or Clinical studies, engaging in regulatory activities for the purpose of obtaining Marketing Authorization Approval, and
developing and marketing Products pursuant to this Agreement. The disclosing Party shall be responsible for any breaches of confidentiality by such Third Parties to whom it has disclosed the other Party&#146;s Confidential Information. Furthermore,
notwithstanding any other provision of this Agreement, each Party may disclose: (i)&nbsp;the terms of this Agreement as necessary in connection with any proposed financing, merger or similar transaction, subject to confidentiality; or
(ii)&nbsp;Confidential Information to the extent necessary to obtain legal or financial advice from its attorneys or accountants. The Parties shall also be permitted to make disclosures consistent with, and pursuant to, Sections&nbsp;15.1
(Publications) and 14.2 (Public Announcements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.4&#8195;<U>Return</U>. Upon termination of this Agreement, the Receiving Party shall
return or destroy all documents or other media containing Confidential Information of the Disclosing Party with the exception of one (1)&nbsp;copy for the sole purpose of monitoring and documenting the confidentiality obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.5&#8195;<U>Remedies</U>. Money damages may not be an adequate remedy if this
Article&nbsp;9 is breached and, therefore, either Party may, in addition to any other legal or equitable remedies, seek an injunction or other equitable relief in any court of competent jurisdiction against such breach or threatened breach without
the necessity of posting any bond or surety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&#8195;<B>REPRESENTATIONS AND WARRANTIES</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.1&#8195;<U>Mutual Representations and Warranties</U>. CG and Lepu each represents and warrants to the other as of the Effective Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.1&#8195;Such Party: (a)&nbsp;is a company duly organized, validly existing and in good standing under the Laws of the jurisdiction of
its organization; and (b)&nbsp;has the requisite corporate power and authority and the legal right to conduct its business as now conducted and hereafter contemplated to be conducted; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.2&#8195;The execution, delivery and performance of this Agreement by such Party: (a)&nbsp;are within the corporate power of such Party;
(b)&nbsp;have been duly authorized by all necessary or proper corporate action; (c)&nbsp;do not conflict with any provision of the organizational documents of such Party; (d)&nbsp;will not, to the Party&#146;s knowledge, violate any Laws or any
order or decree of any court or Governmental Authority applicable to such Party; and (e)&nbsp;will not violate or conflict with any terms of any indenture, mortgage, deed of trust, lease, agreement or other instrument to which such Party is a party,
or by which such Party is bound; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.3&#8195;This Agreement has been duly executed and delivered by such Party and constitutes a legal,
valid and binding obligation of such Party, enforceable against such Party in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium and other similar Laws of general application relating to or affecting
creditors&#146; rights and to general equity principles; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.4&#8195;No governmental authorization, consent, approval (except Marketing
Authorization Approvals), license, registration, filing or exemption therefrom with any court or other Governmental Authority applicable to such Party is or will be necessary for, or in connection with, the performance of the transaction
contemplated by this Agreement or any other agreement or instrument executed in connection therewith; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.1.5&#8195;Neither such
Party nor, to either Party&#146;s knowledge, any of its employees has been debarred by the FDA (or similar action by any other Regulatory Authority), or subject to an FDA debarment investigation or proceeding (or similar investigation or proceeding
by any other Regulatory Authority) for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.2&#8195;<U>CG Representations and Warranties</U>. CG represents and warrants to
Lepu as of the Effective Date: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.2.1&#8195;CG is the sole and exclusive owner of the entire right, title and interest in
and to the CG0070 Patents, and is not aware of any dispute or challenge to inventorship or ownership of the CG0070 Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.2.2&#8195;CG has not granted any licenses under the CG0070 Patents in the Field of Use in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.2.3&#8195;Aside from statements by patent examiners in the course of prosecution of the CG0070 Patents, CG has not received any express
written claim that a CG0070 Patent is invalid or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.2.4&#8195;CG has not received any express written notice of any
substantial and continuing infringement by a Third Party of any Valid Claim of a CG0070 Patent in the Field of Use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">11.2.5&#8195;To
CG&#146;s actual knowledge (without any search or special investigation) as of the Effective Date, neither CG0070 recombinant adenovirus nor DDM infringe Third Party intellectual property rights in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.3&#8195;<U>Disclaimer of Warranty</U>. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION&nbsp;11, NEITHER PARTY MAKES ANY REPRESENTATION
OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY, AND EACH PARTY HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
<FONT STYLE="white-space:nowrap">NON-INFRINGEMENT.</FONT> EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF THE PRODUCTS PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL OR THAT ANY
PARTICULAR SALES LEVEL WITH RESPECT TO THE PRODUCTS WILL BE ACHIEVED. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&#8195;<B>INDEMNIFICATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.1&#8195;<U>Indemnification by Lepu</U>. Subject to Section&nbsp;12.3, Lepu shall indemnify and defend CG and its Affiliates and each of
their officers, directors, employees, successors and assigns from and against all Claims of Third Parties to the extent arising out of (a)&nbsp;Lepu&#146;s negligence or willful misconduct in performing any of its obligations under this Agreement,
(b)&nbsp;breach by Lepu of any of its representations or warranties under this Agreement, or (c)&nbsp;the Development, Commercialization, use, handling, storage, marketing, sale, distribution or other disposition of Products by Lepu, its Affiliates,
agents or subcontractors, except to the extent arising from CG&#146;s negligence or willful misconduct or breach of CG&#146;s representations or warranties in Section&nbsp;11 and except as to infringement of Third Party intellectual property by Lepu
based on Lepu&#146;s use of the Licensed IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.2&#8195;<U>Indemnification by CG</U>. Subject to Section&nbsp;12.3, CG shall indemnify
and defend Lepu and its Affiliates and each of their officers, directors, employees, successors and assigns from and against all Claims of Third Parties to the extent arising out of (a)&nbsp;CG&#146;s negligence or willful misconduct in performing
any of its obligations under this Agreement; (b)&nbsp;breach by CG of any of its representations or warranties in Section&nbsp;11; or (c)&nbsp;infringement of Third Party intellectual property by Lepu based on Lepu&#146;s use of the Licensed IP.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12.3&#8195;<U>Procedure for Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">12.3.1&#8195;<U>Notice</U>. Each Party (the &#147;<B><I>Indemnified Party</I></B>&#148;) will notify promptly the other Party (the
&#147;<B><I>Indemnifying Party</I></B>&#148;) in writing if it becomes aware of a Claim (actual or potential) by any Third Party or any proceeding (including, but not limited to, any investigation by a Governmental Authority) for which
indemnification may be sought and will give such related information as the Indemnifying Party shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">12.3.2&#8195;<U>Defense of Claim</U>. The Indemnifying Party shall have sole control over the defense and/or settlement of any such Claims
and shall be responsible for satisfying and discharging any award made to or settlement reached with the Third Party pursuant to the terms of this Agreement; provided that the Indemnified Party may assume control over the defense and settlement of
such Claims to the extent the Indemnifying Party fails to assume such control. The Indemnifying Party shall retain counsel to represent the Indemnified Party and shall pay the reasonable fees and expenses of such counsel related to such proceeding.
In any such proceeding, the Indemnified Party, at its sole expense, shall have the right to retain its own counsel at its own expense, provided that the Indemnifying Party shall reimburse such reasonable expenses to the extent that a conflict of
interest arises between the Indemnified Party and the Indemnifying Party. The Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall not be unreasonably withheld, refused, conditioned or delayed),
effect any settlement of any such Third Party Claim, unless such settlement (a)&nbsp;provides only for recovery of monetary damages that are paid in full by the Indemnifying Party and (b)&nbsp;includes an unconditional release of the Indemnified
Party from all liability on such Claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&#8195;<B>PROSECUTION; LITIGATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.1&#8195;<U>Prosecution and Maintenance of Patents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">13.1.1&#8195;Subject to Section&nbsp;13.1.3, CG shall have the sole right (but not the obligation) to prepare, file, prosecute and maintain
the Licensed Patents. In connection therewith, CG shall have the authority to select patent counsel, to determine the form and content of such filing, prosecution and maintenance documents and to make all decisions regarding whether to file,
prosecute and maintain such Licensed Patents, and in which countries to do so. CG shall provide Lepu with copies of all official correspondence (including, without limitation, applications, office actions and responses) relating to filing,
prosecution and/or maintenance of Licensed Patents in the Territory. Lepu may provide comments on such correspondence, and CG will give good faith consideration thereto. In order to facilitate Lepu&#146;s rights to comment, CG shall provide to Lepu
copies of all such official correspondence and any proposed responses by CG at least [***] prior to any filing or response deadlines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">13.1.2&#8195;Lepu shall be responsible for [***] of all costs incurred by CG after the Effective Date in connection with the filing,
prosecution or maintenance of the Licensed Patents, including, but not limited to, (a)&nbsp;filing fees, (b)&nbsp;attorneys&#146; fees and other expenses associated with application preparation, prosecution, and maintenance, (c)&nbsp;all costs
associated with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reexamination, oppositions and interference proceedings, (d)&nbsp;maintenance fees and annuities, including, without limitation, any service fees paid to an annuity payment service provider and
(e)&nbsp;attorneys&#146; fees and filing fees associated with protest or appeal proceedings (collectively, &#147;<B><I>Patent Costs</I></B>&#148;). Lepu shall pay CG Lepu&#146;s share of Patent Costs within [***] after receipt of an invoice from CG
for such amounts that are supported with reasonable documentation for the amounts charged in such invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">13.1.3&#8195;CG shall not
abandon prosecution or maintenance of any Licensed Patents without notifying Lepu in a timely manner of CG&#146;s intention and reason therefor and providing Lepu with reasonable opportunity to comment upon such abandonment and to assume
responsibility for prosecution or maintenance of such Licensed Patents as set forth below. In the event that CG abandons prosecution or maintenance of Licensed Patents in the Territory at any time during the Term, Lepu may assume prosecution
responsibility therefor in the name of CG, and the costs associated with such prosecution shall be paid by Lepu at its sole discretion. No such action by Lepu will change the ownership or license provisions with respect to the applicable Licensed
Patent unless agreed by the Parties in writing. CG will execute all documents that Lepu may reasonably request for such purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13.2&#8195;<U>Patent Infringement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">13.2.1&#8195;<U>Notice of Infringement</U>. Each Party shall promptly notify the other in writing (a)&nbsp;of any actual or suspected
infringement of any Licensed Patents in the Territory (including, without limitation, unauthorized importation into the Territory for sale in the Territory), of which it becomes aware or (b)&nbsp;upon receiving notification that a Licensed Patent is
subject to a declaratory judgment action alleging <FONT STYLE="white-space:nowrap">non-infringement,</FONT> invalidity or unenforceability in the Territory, which notification shall specify in reasonable detail the nature of such actual or suspected
infringement or judicial action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">13.2.2&#8195;<U>Right to Enforce</U>. Lepu shall have the initial right, using counsel of its choice,
to enforce the applicable Licensed Patent(s) in the Territory with respect to infringement in the Field of Use, at its expense, and CG shall give reasonable assistance (excluding financial assistance) to Lepu in such action, at Lepu&#146;s expense.
Lepu shall provide CG with an opportunity to make suggestions and comments regarding such enforcement or defense, and Lepu shall consider all such suggestions and comments in good faith. Lepu shall keep CG reasonably informed of the status and
progress of the litigation. Prior to initiating any action to enforce or defend any Licensed Patent(s) under this Section&nbsp;13.2.2, Lepu and CG shall confer to determine a reasonable course of action which fairly balances the interests of both
Parties to minimize risks of validity challenges to the applicable Licensed Patent(s), inside and outside the Field of Use, to minimize risks of lost sales of Products due to infringement and to minimize any potential adverse consequences to
CG&#146;s other licensees of the Licensed Patent(s). Without limiting the foregoing, if Lepu is authorized hereunder to initiate an action against a Third Party under this Section&nbsp;13.2.2, but Lepu is not recognized by the applicable court or
other relevant body as having the requisite standing to pursue such action, then at Lepu&#146;s request, CG shall join in as party-plaintiff or commence such action in its own name and, in either event, cooperate with Lepu, at Lepu&#146;s expense.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">13.2.3&#8195;<U>Distribution of Remedies</U>. Any damages, royalties, settlement fees or
other consideration for infringement resulting from such suit shall be distributed as follows: (a)&nbsp;first, each Party shall be reimbursed for its reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs paid in connection with the proceeding; and (b)&nbsp;thereafter, shall be paid [***] and [***]; provided, however, that, if the nature of the
infringement by a Third Party of the Licensed Patent(s) extends to any Other Products, and the amounts recovered by the Party prosecuting the infringement includes damages, royalties, fees or other consideration associated with such Other Products,
then Lepu shall only be entitled to receive (or, if it is the prosecuting Party, to retain) the <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of any such recovery which is associated with the infringement of the Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">13.2.4&#8195;<U>Settlement</U>. In no case may Lepu enter into any settlement or consent judgment or other voluntary final disposition with
respect to any infringement action referenced in this Section&nbsp;that: (a)&nbsp;extends, or purports to exercise, Lepu&#146;s rights under the Licensed IP beyond the rights granted pursuant to this Agreement; (b)&nbsp;makes any admission regarding
wrongdoing by CG or the invalidity, unenforceability or absence of infringement of any Licensed Patents; (c)&nbsp;subjects CG to an injunction or other equitable relief; or (d)&nbsp;obligates CG to make a monetary payment; in all cases without the
prior written consent of CG, which consent will not be unreasonably withheld or delayed. Similarly, in no case may CG enter into any settlement or consent judgment or other voluntary final disposition with respect to any infringement action
referenced in this Section&nbsp;that: (i)&nbsp;limits Lepu&#146;s rights under the Licensed IP or under this Agreement other than as expressly stated herein; (ii)&nbsp;subjects Lepu to an injunction or other equitable relief; or (iii)&nbsp;obligates
Lepu to make a monetary payment; in all cases without the prior written consent of Lepu, which consent shall not be unreasonably withheld or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&#8195;<B>TERM AND TERMINATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.1&#8195;<U>Term</U>. This Agreement shall commence on the Effective Date and shall remain in effect until the termination of this Agreement
as provided in this Article&nbsp;14 (the &#147;<B><I>Term</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.2&#8195;<U>Termination of this Agreement by Lepu for
Convenience</U>. Lepu may terminate this Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis for any reason upon [***] prior written notice to CG. For clarity, Lepu is not licensed
to use any Confidential Information (and Section&nbsp;10 restricts Lepu from using Confidential Information) to manufacture, Develop or Commercialize any Product for which Lepu terminates this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.3&#8195;<U>Termination for Breach</U>. The failure by a Party to comply with any of the material obligations contained in this Agreement
shall entitle the other Party to give notice to have the default cured. If such default is not cured within (a) [***] after the receipt of such notice for all defaults other than payment or (b) [***] after the receipt of such notice for defaults on
payment, the notifying Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies that may be available to it, to terminate this Agreement; provided, however, to the
extent a Party disputes the grounds for termination hereunder in good faith, this Agreement may not be terminated until a determination has been made by an arbitrator pursuant to Section&nbsp;15.5 that grounds for such termination exist hereunder.
The proviso in the foregoing sentence shall not apply to any failure to pay the amount set forth in Section&nbsp;9.1. In addition, CG shall have the right to terminate this Agreement in its entirety, immediately upon the issuance of written notice
to Lepu, if at any time Lepu or any of its Affiliates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or Sublicensees challenges, or causes to be challenged, in any way, the validity, enforceability or scope of the Licensed Patents in any court or before any Governmental Authority with authority
to determine the validity, enforceability or scope of such Licensed Patents, or cause or request, without the prior written approval of CG, a review by any such court or Governmental Authority of the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.4&#8195;[<U>Intentionally omitted</U>.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.5&#8195;<U>Effects of Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">14.5.1&#8195;On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, in the event of
termination of this Agreement, (a)&nbsp;all rights and licenses on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis granted to Lepu herein shall terminate and revert to CG on termination, if
any; (b)&nbsp;in the event that Lepu has any <FONT STYLE="white-space:nowrap">on-going</FONT> Clinical studies with respect to the applicable Product as of the effective date of termination, Lepu agrees, at CG&#146;s request, to either promptly
transition such Clinical studies to CG or continue to conduct and complete such Clinical studies, at CG&#146;s expense; (c)&nbsp;Lepu shall, at its own expense, promptly provide CG with all data and results pertaining, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, to the applicable Products; (d)&nbsp;Lepu will, at its own expense, promptly assign or transfer, or cause to be assigned and transferred to CG (or if
not so assignable, Lepu shall take all reasonable actions to make available to CG the benefits of), all Regulatory Filings, Manufacturing Documentation and Marketing Authorization Approvals concerning the applicable Products; and (e)&nbsp;all rights
granted by Lepu to CG under this Agreement will survive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">14.5.2&#8195;Except as otherwise provided herein, upon termination of this
Agreement, all remaining records and materials in a Party&#146;s possession or control containing the other Party&#146;s Confidential Information and to which the former Party does not retain rights hereunder, shall promptly be returned or destroyed
at the request of the disclosing Party. Notwithstanding the foregoing, one copy of such records may be retained by legal counsel for the former Party solely for archival purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.6&#8195;<U>Survival of Obligations</U>. The termination or expiration of this Agreement shall not relieve the Parties of any liability
(including, without limitation, any payment obligations) accruing prior to such termination, and any such termination shall be without prejudice to the rights of either Party against the other. The provisions of Sections&nbsp;3.3, 8.3.1, 9.6, 9.7,
10, 12, 14 and 15 shall survive any termination or expiration of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.7&#8195;<U>Termination Not Sole Remedy</U>.
Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies will remain available except as expressly agreed to otherwise herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&#8195;<B>MISCELLANEOUS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.1&#8195;<U>Publications</U>. Lepu will notify CG of any planned abstracts, oral presentations and manuscripts relating to the publication
of clinical data and other scientific data generated in the course of Development of the relevant Product by Lepu. The Parties shall discuss whether a planned submission might contain information which compromises the patentability or
confidentiality of the Licensed IP. Lepu shall provide a draft of the planned submission or presentation at least [***] prior to publication or presentation (as the case may be) to allow for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filing of patent applications and shall take such measures as necessary to preserve proprietary rights in and the confidentiality of the information in the material being submitted for
publication or presentation (including, but not limited to, withholding such publication). The review period may be extended for an additional [***] if CG can demonstrate a reasonable need for such extension, including, but not limited to, the
preparation and filing of patent applications. By mutual agreement of the Parties, this period may be further extended. The Parties will each comply with standard academic practice regarding authorship of scientific publications and recognition of
contribution of other parties in any such publications or presentations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.2&#8195;<U>Public Announcements</U>. Except as may be
expressly permitted under this Section&nbsp;15.2 or mandated by applicable Laws or the rules of any stock exchange, neither Party will make any public announcement of any information regarding this Agreement without the prior written consent of the
other Party. Once any statement is approved for disclosure by the Parties, either Party may make a subsequent public disclosure containing the same information disclosed in such prior public announcement without further approval of the other Party.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.3&#8195;<U>Relationship of the Parties</U>. This Agreement is not a partnership agreement and nothing in this Agreement shall be
construed to establish a relationship of partners or joint venturers between the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.4&#8195;<U>Force Majeure</U>. The occurrence
of an event which materially interferes with the ability of a Party to perform its obligations or duties hereunder which is not within the reasonable control of the Party affected, and which could not with the exercise of Commercially Reasonable
Efforts have been avoided (&#147;<B><I>Force Majeure Event</I></B>&#148;), including, but not limited to, war, rebellion, earthquake, fire, accident, strike, riot, civil commotion, act of God, inability to obtain raw materials, delay or errors by
shipping companies or change in Law, shall not excuse such Party from the performance of its obligations or duties under this Agreement, but shall merely suspend such performance (other than performance of payment obligations) during the Force
Majeure Event. The Party subject to a Force Majeure Event shall promptly notify the other Party of the occurrence and particulars of such Force Majeure Event and shall provide the other Party, from time to time, with its best estimate of the
duration of such Force Majeure Event and with notice of the termination thereof. The Party so affected shall use Commercially Reasonable Efforts to avoid or remove such causes of <FONT STYLE="white-space:nowrap">non-performance</FONT> as soon as is
reasonably practicable. Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty shall without delay recommence. The Party subject to the Force Majeure Event shall not be liable to the other Party for any
damages arising out of or relating to the suspension or termination of any of its obligations or duties under this Agreement by reason of the occurrence of a Force Majeure Event, provided such Party complies in all material respects with its
obligations under this Section&nbsp;15.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.5&#8195;<U>Dispute Resolution</U>. The prevailing Party may enforce any arbitration decision
or award, and either Party may seek injunctive, equitable or similar relief (without the requirement of arbitration), in any court having competent jurisdiction. Any and all disputes arising out of or in connection with this Agreement, including its
interpretation, shall be finally settled in the English language and under the Rules of Arbitration of the International Chamber of Commerce (&#147;<B><I>ICC</I></B>&#148;), in effect at the time of filing a notice of arbitration. The arbitration is
to take place in the City and State of New York and is to be decided by a tribunal comprised of three arbitrators. Each Party shall select an arbitrator, to be confirmed by the ICC according to its Rules,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the two arbitrators shall then agree on a third arbitrator who shall be the president of the tribunal; the president shall also be subject to confirmation by the ICC in accordance with its
Rules. A final decision by the majority of the tribunal shall be final and <FONT STYLE="white-space:nowrap">non-appealable.</FONT> After the filing of the notice of arbitration, the ICC and/or the tribunal designated for this dispute, shall decide
all matters pertaining to this Agreement. The issue of &#147;arbitrability&#148; of any and all disputes between the Parties, shall be decided solely by the ICC and/or the tribunal designated for this dispute. Notwithstanding any of the foregoing,
any Party may seek injunctive, equitable or similar relief (without the requirement of arbitration), in any court having competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.6&#8195;<U>Governing Law</U>. This Agreement shall be construed, and the respective rights of the Parties determined, according to the
substantive law of the State of New York without regard to the provisions governing conflict of laws, except matters of intellectual property law, which shall be determined in accordance with the intellectual property laws relevant to the
intellectual property in question. The United Nations Convention on the International Sale of Goods shall not apply to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.7&#8195;<U>Attorneys&#146; Fees and Related Costs</U>. If there should occur any legal proceeding related to this Agreement, then the <FONT
STYLE="white-space:nowrap">non-prevailing</FONT> Party shall pay all reasonable costs and fees (including reasonable attorneys&#146; fees and expenses) of the prevailing Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.8&#8195;<U>Assignment</U>. This Agreement may not be assigned by either Party, in whole or in part, whether voluntarily or by operation of
law, without the prior written consent of the other Party; provided that, without prior written consent, either Party may assign this Agreement, in whole or in part, to (a)&nbsp;any of its Affiliates if such Party guarantees the performance of this
Agreement by such Affiliate, or (b)&nbsp;to a successor to all or substantially all of the assets of such Party to which this Agreement relates; provided that prior to or contemporaneously with a transaction under
<FONT STYLE="white-space:nowrap">sub-section&nbsp;(b),</FONT> any such successor of CG delivers to Lepu an instrument by which such successor assumes CG&#146;s obligations under this Agreement. For the avoidance of doubt, a Change in Control, by
itself, is not an assignment of this Agreement subject to this Section, and the Parties hereby agree that this Agreement shall continue in full force and effect in accordance with its terms following any Change in Control. Any assignment in
violation of this provision is void and without effect. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their permitted successors, legal representatives and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.9&#8195;<U>Notices</U>. All demands, notices, consents, approvals, reports, requests and other communications hereunder must be in writing,
in English, and will be deemed to have been duly given only if delivered personally, by mail (first class, postage prepaid), or by overnight delivery using a globally-recognized carrier, to the Parties at the following addresses: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>CG</B>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Lepu</B>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cold Genesys, Inc. <BR>6 Hutton Centre Drive, Suite 1220 <BR>Santa Ana, CA 92707 <BR>Attn: Arthur Kuan, CEO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lepu Biotech Co., Ltd. <BR><FONT STYLE="white-space:nowrap">1-C280,</FONT> No.&nbsp;1628 Suzhao Road <BR>Minhang, Shanghai <BR>Attn: CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>with a copy to:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>with a copy to:</I></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gunderson Dettmer Stough, Villeneuve, <BR>Franklin and Hachigian, LLP <BR>3570 Carmel Mountain Rd Suite 200 <BR>San Diego, CA 92130 <BR>Attn: Brendan C. McCarthy, Esq.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Akerman LLP <BR>350 East Las Olas Blvd., Suite 1600 <BR>Fort Lauderdale, FL 33301 <BR>Attn: Mary V. Carroll, Esq.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the addressee shall have last furnished in writing in accord with this provision. All
notices shall be deemed effective upon receipt by the addressee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.10&#8195;<U>Severability</U>. If any provision of this Agreement is
held to be invalid, illegal or unenforceable in any respect, that provision shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.11&#8195;<U>Headings</U>. The headings used in this Agreement have been inserted for convenience of reference only and do not define or
limit the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.12&#8195;<U>Waiver</U>. No waiver of any term or condition of this Agreement shall be effective unless
set forth in a written instrument duly executed by or on behalf of the waiving Party. No waiver by any Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any
other term or condition of this Agreement on any prior, concurrent or future occasion. Except as expressly set forth in this Agreement, all rights and remedies available to a Party, whether under this Agreement or afforded by Law or otherwise, will
be cumulative and not in the alternative to any other rights or remedies that may be available to such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.13&#8195;<U>Entire
Agreement</U>. This Agreement (including, but not limited to, the exhibits and schedules hereto) constitutes the entire agreement between the Parties hereto with respect to the subject matter hereof and supersedes all previous agreements and
understandings between the Parties, whether written or oral, including, but not limited, to all proposals, negotiations, conversations, letters of intent, memoranda of understanding or discussions, between Parties relating to the subject matter of
this Agreement and all past dealing or industry custom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.14&#8195;<U>Modification</U>. This Agreement may be altered, amended or
changed only by a writing making specific reference to this Agreement and the clause to be modified, which amendment is signed by duly authorized representatives of CG and Lepu. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.15&#8195;<U>No Third Party Beneficiaries</U>. None of the provisions of this Agreement shall be for the benefit of or enforceable by any
Third Party, including, but not limited to, any creditor of either Party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.16&#8195;<U>Ambiguities</U>. This Agreement shall be
deemed to have been drafted jointly by both Parties; and ambiguities, if any, shall not be construed against either Party, irrespective of which Party may have actually drafted the ambiguous provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15.17&#8195;<U>Counterparts</U>. This Agreement may be executed in counterparts, each of which, when executed, shall be deemed to be an
original and all of which together shall constitute one and the same document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature Page Follows] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, CG and Lepu, by their duly authorized officers, have executed this Agreement as of the
Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COLD GENESYS, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>LEPU BIOTECH CO., LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arthur Kuan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Zhongjie Pu</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Arthur Kuan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Zhongjie Pu</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CG ONCOLOGY, INC. HAS DETERMINED THE INFORMATION
(I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;WOULD LIKELY CAUSE COMPETITIVE HARM TO CG ONCOLOGY, INC. IF PUBLICLY DISCLOSED. </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AND COLLABORATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BETWEEN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CG ONCOLOGY,
INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KISSEI PHARMACEUTICAL CO., LTD. </B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE&nbsp;1 DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Accounting Standard&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Affiliate&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Anti-Corruption Laws&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Applicable Law&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Biosimilar&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Biosimilar Application&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Business Day&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG Collaboration IP&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG Collaboration <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG Collaboration Patents&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG IP&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG Patents&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.14</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG Territory&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.15</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG Territory Activities&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.16</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CG Trademark&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.17</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Change of Control&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.18</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Clinical Trial&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.19</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CMC&#148; or &#147;Chemistry Manufacturing and Controls&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.20</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CMO&#148; or &#147;Contract Manufacturing Organization&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.21</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Collaboration Compound&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.22</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Collaboration IP&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.23</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Collaboration <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.24</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Collaboration Patents&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.25</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Commercially Reasonable Efforts&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.26</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Companion Diagnostic&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.27</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Competing Product&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.28</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Compulsory Competing Product&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.29</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Compulsory Sublicense&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.30</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Confidential Information&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Control&#148; or &#147;Controlled by&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.32</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Covers&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.33</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;CRO&#148; or &#147;Contract Research Organization&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.34</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Development Program&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.35</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Encumbrance&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.36</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Existing <FONT STYLE="white-space:nowrap">In-License&#148;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.37</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Export Control Laws&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.38</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;FDA&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.39</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Field&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.40</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;First Commercial Sale&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.41</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;FTE&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.42</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;GMP&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.43</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;IND&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.44</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Indication&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.45</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Initial Indication&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.46</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Inventor&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.47</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Joint Collaboration IP&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.48</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Joint Collaboration <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.49</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Joint Collaboration Patents&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Kissei Collaboration IP&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.51</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Kissei Collaboration <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.52</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Kissei Collaboration Patents&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.53</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Kissei IP&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.54</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Kissei <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.55</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Kissei Patents&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.56</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">&#147;Know-How&#148;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.57</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Lepu Territory&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.58</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Licensed Intellectual Property&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.59</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Marketing Approval&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.60</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Marketing Approval Application&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.61</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;MHLW&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.62</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Net Sales&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.63</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Other Indication&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.64</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;P3 Trial&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.65</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Patent(s)&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.66</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Peer Pharmaceutical Company&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.67</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Person&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.68</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Pharmacology Study(s)&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.69</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Phase I Clinical Trial&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.70</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Phase II Clinical Trial&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.71</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Phase III Clinical Trial&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.72</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;PHSA&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.73</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;PMDA&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.74</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">&#147;Pre-Approved</FONT> Subcontractor&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.75</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Product&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.76</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Prosecution and Maintenance&#148; or &#147;Prosecute and Maintain&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.77</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Public Official or Entity&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.78</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Regulatory Authority&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.79</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Regulatory Materials&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.80</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Residuals&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.81</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Series D Preferred Stock&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.82</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Territory&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.83</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Third Party&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.84</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;US&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.85</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;Valid Claim&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.86</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&#147;VAT&#148;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 2 DEVELOPMENT PROGRAM</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subcontractors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports; Records; and Inspections</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development Efforts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Dispatch</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 3 GOVERNANCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joint Development Committee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joint Patent Working Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Joint Manufacturing Working Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Working Groups; Other Committees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Meetings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>JDC Decision-Making</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limits on Authority; Dissolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Alliance Managers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Change of Control</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 4 LICENSES AND RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>License Grants to Kissei</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>License Grants to CG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusivity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Rights, Retained Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 5 MANUFACTURING AND SUPPLY; REGULATORY MATTERS; DELIVERABLES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Manufacturing and Supply</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Regulatory Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Deliverables</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 6 DILIGENCE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development and Commercialization of Products</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Progress Reports</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 7 FINANCIAL TERMS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Initial License Fees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Equity Investment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Development and Commercial Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Royalty Payments for Products by Kissei</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Royalty Payments for Products by CG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 8 PAYMENT TERMS; REPORTS; AUDITS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Timing of Royalty Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Royalty Report</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mode of Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Currency of Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Blocked Currency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Late Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Records; Inspection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acknowledgement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 9 INTELLECTUAL PROPERTY; OWNERSHIP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Kissei</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Inventorship; CREATE Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ownership; Collaboration IP; Rights of Joint Owners</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights of Joint Owners</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Filing, Prosecution, Maintenance and Strategy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Enforcement and Defense</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third Party Infringement Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Extensions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Patent Listings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Common Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trademarks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third Party Technologies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 10 CONFIDENTIALITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-use</FONT> and <FONT STYLE="white-space:nowrap">Non-disclosure</FONT> of Confidential Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Exclusions Regarding Confidential Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorized Uses and Disclosures of Confidential Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Terms of this Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Prior Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No License</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 11 PUBLICITY; PUBLICATIONS; USE OF NAME</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Initial Press Release</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Releases</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Right to Use Names</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 12 REPRESENTATIONS AND WARRANTIES; DISCLAIMERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mutual Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CG Covenants and Additional Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disclaimers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 13 INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Procedure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">13.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limitation of Damages</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 14 TERM; TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Either Party for Material Breach</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination by Either Party for Insolvency or Bankruptcy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination for Patent Challenge</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination at Will</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination for Catastrophic Breach</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">14.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effects of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 15 DISPUTE RESOLUTION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disputes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Arbitration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subject Matter Exclusions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Continued Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">ARTICLE 16 MISCELLANEOUS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Applicable Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Independent Contractors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Integration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.6</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment; Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.7</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Assurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.8</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.9</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third Party Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.10</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Construction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.11</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Original Text</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.12</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interpretation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">16.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; "><B>Schedules</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;1.13</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CG Patents</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;1.35</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Encumbrance Exceptions</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;1.36</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Existing <FONT STYLE="white-space:nowrap">In-License</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;1.74</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Pre-Approved</FONT> Subcontractor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;2.1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Initial Development Plan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;7.4.3(c)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Royalty Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule&nbsp;12.3(g)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Schedule&nbsp;of Exceptions</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AND COLLABORATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS LICENSE AND COLLABORATION AGREEMENT </B>(&#147;<B>Agreement</B>&#148;) is made and entered into, as of March&nbsp;26, 2020
(&#147;<B>Effective Date</B>&#148;), by and between Kissei Pharmaceutical Co., Ltd., a corporation duly organized and existing under the laws of Japan and having its registered office at <FONT STYLE="white-space:nowrap">19-48,</FONT> Yoshino,
Matsumoto, Nagano Prefecture, Japan (&#147;<B>Kissei</B>&#148;) and CG Oncology, Inc. (formerly known as Cold Genesys, Inc.), a company organized and existing under the laws of the state of Delaware, United States, located at 400 Spectrum Center
Drive, Suite #2040 Irvine, CA 92618 (&#147;<B>CG</B>&#148;). Kissei and CG are each referred to individually as a &#147;<B>Party</B>&#148; and together as the &#147;<B>Parties</B>.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, CG owns or controls the CG Patents and CG <FONT STYLE="white-space:nowrap">Know-How</FONT> (each as defined below) relating to
the Products (each as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Kissei wishes to obtain, and CG wishes to grant, rights to the Products in the
Field in the Territory (each as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Kissei will have the right, among other things, to develop and
commercialize Products in the Territory in the Field, subject to paying CG the royalty and milestone payments set out herein, all as set forth in more detail in the Agreement below; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, contemporaneously with the execution of this Agreement, the Parties have executed a separate Series D Preferred Stock Purchase
Agreement of even date herewith (&#147;<B>Stock Purchase Agreement</B>&#148;) pursuant to which Kissei shall purchase share of Series D Preferred Stock of CG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B>, in consideration of the mutual covenants and agreements herein contained below, the Parties agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used in this Agreement, whether used in the singular or plural, shall have the meanings set forth below, unless
otherwise specifically indicated herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&#8195;<B>&#147;</B><B>Accounting Standard</B><B>&#148;</B><B> </B>means either
(a)&nbsp;International Financial Reporting Standards (&#147;<B>IFRS</B>&#148;), (b) United States generally accepted accounting principles or (c)&nbsp;Japan generally accepted accounting principles, in each case, which standards or principles (as
applicable) are currently used at the applicable time, and as consistently applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&#8195;<B>&#147;</B><B>Affiliate</B><B>&#148;</B><B> </B>means, with respect to a Person, any Person that, directly or indirectly
(through one or more intermediaries) controls, is controlled by, or is under common control with such first Person. For purposes of this definition only, &#147;<B>control</B>&#148; means: (a)&nbsp;the direct or indirect ownership of more than fifty
percent (50%) of the voting stock or other voting interests or interest in the profits of the Party; or (b)&nbsp;the ability to otherwise control or direct the decisions of the board of directors or equivalent governing body thereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&#8195;<B>&#147;</B><B>Anti-Corruption Laws</B><B>&#148;</B><B> </B>means the
United States Foreign Corrupt Practices Act, the United Kingdom Bribery Act and any other applicable anti-corruption or anti-bribery laws, in each case as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B>&#8195;<B>&#147;</B><B>Applicable Law</B><B>&#148;</B><B> </B>means any and all laws, ordinances, orders, rules, rulings, directives
and regulations of any kind whatsoever of any Regulatory Authority or other governmental authority within the applicable jurisdiction applicable to a Party&#146;s activities under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B>&#8195;<B>&#147;</B><B>Biosimilar</B><B>&#148;</B><B> </B>means, with respect to a Product, any drug or biological product that is
subject to review under an abbreviated approval pathway as a biosimilar, <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic or generic biological product, as those terms are commonly understood under the U.S.&nbsp;Federal Food, Drug and
Cosmetics Act (as amended from time to time) or the PHSA and related rules and regulations, or the corresponding or similar laws, rules and regulations of any other jurisdiction, including, without limitation, those promulgated by the MHLW and PMDA
in Japan, which drug or biological product is sold by a Third Party that is not a sublicensee of Kissei (or any of its Affiliates) and that has not otherwise been authorized, directly or indirectly, by Kissei (or any of its Affiliates) to market and
sell such product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B>&#8195;<B>&#147;</B><B>Biosimilar Application</B><B>&#148;</B><B> </B>means an application submitted to the
FDA under subsection&nbsp;(k) of Section&nbsp;351 of the PHSA, or any analogous application submitted to a Regulatory Authority in the United States or in another country in the world, including, without limitation, the MHLW and PMDA in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B>&#8195;<B>&#147;</B><B>Business Day</B><B>&#148;</B><B> </B>means any day that is not a Saturday, Sunday or other days on which
commercial banks in New York and/or Japan are authorized or required to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B>&#8195;<B>&#147;</B><B>CG Collaboration
IP</B><B>&#148;</B><B> </B>means CG Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> and CG Collaboration Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B>&#8195;<B>&#147;</B><B>CG Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT></B><B>&#148;</B><B> </B>means Collaboration
<FONT STYLE="white-space:nowrap">Know-How</FONT> that is generated, discovered or obtained during the Term of this Agreement by or on behalf of CG and its Affiliates as of the Effective Date, without the inventive contribution of any employee,
consultant or agent of Kissei. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B>&#8195;<B>&#147;</B><B>CG Collaboration Patents</B><B>&#148;</B><B> </B>means Patents claiming
CG Collaboration <FONT STYLE="white-space:nowrap">Know-How.</FONT> CG Collaboration Patents exclude Joint Collaboration Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B>&#8195;<B>&#147;</B><B>CG IP</B><B>&#148;</B><B> </B>means the CG <FONT STYLE="white-space:nowrap">Know-How,</FONT> the CG Patents
and the CG Trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B>&#8195;<B>&#147;</B><B>CG <FONT STYLE="white-space:nowrap">Know-How</FONT></B><B>&#148;</B><B>
</B>means all <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by CG or any of its Affiliates as of the Effective Date or during the Term of this Agreement. For clarity, CG <FONT STYLE="white-space:nowrap">Know-How</FONT>
(a)&nbsp;includes CG Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> and (b)&nbsp;excludes Joint Collaboration <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B>&#8195;<B>&#147;</B><B>CG Patents</B><B>&#148;</B><B> </B>means all Patents
Controlled by CG or any of its Affiliates as of the Effective Date or during the Term of this Agreement, including Patents claiming CG Collaboration <FONT STYLE="white-space:nowrap">Know-How.</FONT> CG Patents exclude Joint Collaboration Patents.
The CG Patents existing as of the Effective Date are identified on <B>Schedule</B><B></B><B>&nbsp;1.13</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B>&#8195;<B>&#147;</B><B>CG Territory</B><B>&#148;</B><B> </B>means all territories other than (i)&nbsp;the Territory, and
(ii)&nbsp;the Lepu Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B>&#8195;<B>&#147;</B><B>CG Territory Activities</B><B>&#148;</B><B> </B>means certain material
activities conducted by or on behalf of CG in the CG Territory for the CG Territory including Clinical Trials, CMC activities, and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies,
in each case that are agreed to be included in the Initial development Plan by the Parties prior to formation of the JDC and by the JDC thereafter. The material activities which are required or reasonably necessary to develop and commercialize
Products in the Territory will be included in the CG Territory Activities by the JDC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B>&#8195;<B>&#147;</B><B>CG
Trademark</B><B>&#148;</B><B> </B>means any and all trademark or service mark rights that are Controlled by CG or any of its Affiliates as of the Effective Date or during the Term. CG Trademark includes trademarks that are specific to the Product
but excludes (i)&nbsp;CG&#146;s and its Affiliates&#146; corporate names and logos, together with any derivative marks of any such name or logo, and (ii)&nbsp;any trademarks used by CG where such trademarks are specific to CG products for
indications other than Indications selected by the JDC under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B>&#8195;<B>&#147;</B><B>Change of
Control</B><B>&#148;</B><B> </B>means any of the following events: (a)&nbsp;any Third Party (or group of Third Parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting
power of the equity securities then outstanding of a Party normally entitled to vote in elections of directors; (b)&nbsp;a Party consolidates with or merges into another corporation or entity, or any corporation or entity consolidates with or merges
into a Party, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting power of the equity securities outstanding of the surviving entity normally entitled to vote in elections of directors is not held by
the Persons holding at least fifty percent (50%) of the outstanding shares of a Party preceding such consolidation or merger; or (c)&nbsp;a Party conveys, transfers or sells all or substantially all of its assets to any Third Party, except in each
case (a) &#150; (c), (i) in connection with the issuance of equity securities for financing purposes that does not result in a <FONT STYLE="white-space:nowrap">non-financial</FONT> investor (e.g., a pharmaceutical company or biotechnology company)
becoming (as a result of such issuance of equity securities) the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting power of the equity securities then outstanding of a Party normally entitled to vote in
election of directors, or (ii)&nbsp;to change the domicile of a Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B>&#8195;<B>&#147;</B><B>Clinical
Trial</B><B>&#148;</B><B> </B>means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-approval or other human clinical trial, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B>&#8195;<B>&#147;</B><B>CMC</B><B>&#148;</B><B> or </B><B>&#147;</B><B>Chemistry Manufacturing and Controls</B><B>&#148;</B><B>
</B>means the chemistry, manufacturing and controls (or their biologic equivalents) of the Product, as specified by the FDA, or other applicable Regulatory Authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B>&#8195;<B>&#147;</B><B>CMO</B><B>&#148;</B><B> or </B><B>&#147;</B><B>Contract
Manufacturing Organization</B><B>&#148;</B><B> </B>means a Third Party with which a Party has contracted to conduct manufacturing (including process development and <FONT STYLE="white-space:nowrap">scale-up)</FONT> of one or more Products,
Collaboration Compound and DDM on behalf of such Party, other than a bona fide collaborator of such Party (e.g., a Third Party with whom such Party can jointly develop any other product). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B>&#8195;<B>&#147;</B><B>Collaboration Compound</B><B>&#148;</B><B> </B>means CG0070 recombinant oncolytic adenovirus, which contains
an oncolytic-specific E2F transcription factor promoter and a granulocyte-macrophage colony stimulating factor <FONT STYLE="white-space:nowrap">(GM-CSF)</FONT> transgene. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B>&#8195;<B>&#147;</B><B>Collaboration IP</B><B>&#148;</B><B> </B>means the Collaboration
<FONT STYLE="white-space:nowrap">Know-How</FONT> and the Collaboration Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B>&#8195;<B>&#147;</B><B>Collaboration <FONT
STYLE="white-space:nowrap">Know-How</FONT></B><B>&#148;</B><B> </B>means <FONT STYLE="white-space:nowrap">Know-How</FONT> that is generated, discovered or obtained by or on behalf of a Party or its Affiliates, or jointly by or on behalf of both
Parties or their respective Affiliates in the conduct of activities, under the Development Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B>&#8195;<B>&#147;</B><B>Collaboration Patents</B><B>&#148;</B><B> </B>means Patents claiming Collaboration <FONT
STYLE="white-space:nowrap">Know-How.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B>&#8195;<B>&#147;</B><B>Commercially Reasonable Efforts</B><B>&#148;</B><B>
</B>shall mean that level of efforts and resources consistent with the usual practice followed by Kissei or a Peer Pharmaceutical Company or CG or a similarly sized and situated biopharmaceutical company in the exercise of reasonable business
discretion relating to other pharmaceutical products owned by it or to which it has exclusive rights, which is of similar market potential and at a similar stage in development or product life, taking into account issues of patent coverage, safety
and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the compound or product, the regulatory structure involved, the profitability of the products (including, without limitation, pricing and
reimbursement status achieved), and other relevant factors, including without limitation technical, legal, scientific, and/or medical factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B>&#8195;<B>&#147;</B><B>Companion Diagnostic</B><B>&#148;</B><B> </B>means any product or service, the development of which is
initiated or continued as part of the conduct of activities under the Development Program, that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;identified a person
having a disease or condition, or a molecular genotype or phenotype that predisposes a person to such disease or condition, for which a Product could be used to treat and/or prevent such disease or condition; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;defines the prognosis or monitors the progress of a disease or condition in a person for which a Product could be used to
treat and/or prevent such disease or condition; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;is used to select a therapeutic or prophylactic regimen, wherein at
least one (1)&nbsp;potential therapeutic or prophylactic regimen involves a Product, and where the selected regimen is determined, based on the use of such product or service, to likely be effective and/or to be safe for a person; and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;is used to confirm a Product&#146;s biological activity and/or to optimize
dosing or the scheduled administration of a Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B>&#8195;<B>&#147;</B><B>Competing Product</B><B>&#148;</B><B> </B>means
any product comprising an adenovirus-backbone oncolytic virus with the E2F promoter and <FONT STYLE="white-space:nowrap">GM-CSF</FONT> transgene other than the Collaboration Compound and a Product developed, manufactured or commercialized under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B>&#8195;<B>&#147;</B><B>Compulsory Competing Product</B><B>&#148;</B><B> </B>means a Competing Product sold under a
license (or sublicense) granted (other than by Kissei or any of its Affiliates or sublicensees) to a Third Party through (or, to implement) the order, decree or grant of a governmental authority having competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B>&#8195;<B>&#147;</B><B>Compulsory Sublicense</B><B>&#148;</B><B> </B>means a sublicense granted to a Third Party through (or, to
implement) the order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to manufacture, use, sale, offer for sale, import or export a Product in any country in the Territory or in the CG
Territory with a royalty rate lower than the applicable royalty rates provided in <B>Section</B><B></B><B>&nbsp;7.4 (Royalty Payments for Products by Kissei) and Section</B><B></B><B>&nbsp;7.5 (Royalty Payments for Products by CG)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B>&#8195;<B>&#147;</B><B>Confidential Information</B><B>&#148;</B><B> </B>means proprietary
<FONT STYLE="white-space:nowrap">Know-How</FONT> (of whatever kind and in whatever form or medium, including copies thereof), tangible materials or other deliverables (a)&nbsp;disclosed by or on behalf of a Party in connection with this Agreement,
whether prior to or during the Term and whether disclosed orally, electronically, by observation or in writing, or (b)&nbsp;created by, or on behalf of, either Party and provided to the other Party or its Affiliate, or created jointly by the Parties
or their Affiliates, in the course of this Agreement. For the avoidance of doubt, &#147;Confidential Information&#148; of a Party includes <FONT STYLE="white-space:nowrap">(i)&nbsp;Know-How</FONT> regarding such Party&#146;s research, development
plans, clinical trial designs, preclinical and clinical data, technology, products, business information or objectives and other information of the type that is customarily considered to be confidential information by entities engaged in activities
that are substantially similar to the activities being engaged in by the Parties pursuant to this Agreement and (ii)&nbsp;any tangible materials or other deliverables provided by one Party to the other Party pursuant to
<B>Article</B><B></B><B>&nbsp;5 (Manufacturing and Supply; Regulatory Matters; Deliverables)</B>. Notwithstanding the foregoing, subject to the terms of <B>Section</B><B></B><B>&nbsp;9.5 (Rights of Joint Owners), </B>the Joint Collaboration IP shall
be the Confidential Information of both CG and Kissei, and both CG and Kissei shall be deemed to be the disclosing Party with respect thereto. For clarity, (a)&nbsp;the Kissei IP shall be the Confidential Information of Kissei, and Kissei shall be
deemed to be the disclosing Party with respect thereto, and (b)&nbsp;the CG IP shall be the Confidential Information of CG, and CG shall be deemed to be the disclosing Party with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B>&#8195;<B>&#147;</B><B>Control</B><B>&#148;</B><B> or </B><B>&#147;</B><B>Controlled by</B><B>&#148;</B><B> </B>means, when used in
reference to intellectual property rights, other intangible property or materials, the rightful possession by a Party of the contractual, legal or regulatory right or ability, as of the Effective Date or during the Term, to grant access, title, a
license, sublicense or other right to exploit such right, property or material without violating the terms of any agreement with any Third Party, court order or other legal obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B>&#8195;<B>&#147;</B><B>Covers</B><B>&#148;</B><B> </B>(including variations such
as &#147;<B>Covered</B>&#148;, &#147;<B>Covering</B>&#148; and the like) means, with respect to a particular Patent in a particular country and in reference to a particular compound or product (whether alone or in combination with one or more other
ingredients) that the manufacture, use, sale, offer for sale or importation of such compound or product in a country would infringe (including direct infringement, contributory infringement or any inducement to infringe) a Valid Claim of such Patent
in that country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B>&#8195;<B>&#147;</B><B>CRO</B><B>&#148;</B><B> or </B><B>&#147;</B><B>Contract Research
Organization</B><B>&#148;</B><B> </B>means a Third Party with which a Party has contracted to conduct, organize, monitor, and/or oversee Clinical Trials of one or more Products on behalf of such Party, other than a bona fide collaborator of such
Party (e.g., a Third Party with whom such Party can jointly develop any other product). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B>&#8195;<B>&#147;</B><B>Development
Program</B><B>&#148;</B><B> </B>means the development activities conducted by the Parties pursuant to <B>Article</B><B></B><B>&nbsp;2 (Development Program) </B>and one or more Development Plan(s) solely in and for the Territory. For the avoidance of
doubt the Development Program excludes those activities conducted in the Lepu Territory and the CG Territory, except with respect to (i)&nbsp;P3 Trial activities in the Territory and in the CG Territory and (ii)&nbsp;information exchange with
respect to CG Territory Activities, in both cases of (i)&nbsp;and (ii) above, solely to the extent included in the Initial Development Plan by the Parties prior to formation of the JDC and by the JDC thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B>&#8195;<B>&#147;</B><B>Encumbrance</B><B>&#148;</B><B> </B>means any claim, charge, equitable interest, hypothecation, lien,
mortgage, pledge, option, license, lease, assignment, power of sale, retention of title, right of <FONT STYLE="white-space:nowrap">pre-emption,</FONT> right of first refusal, security interest or any other encumbrance of any kind, other than
(a)&nbsp;the terms and conditions of the Development and License Agreement between CG, Inc. and Lepu Biotech Co., Ltd. or (b)&nbsp;as identified on <B>Schedule</B><B></B><B>&nbsp;1.35</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B>&#8195;<B>&#147;</B><B>Existing <FONT STYLE="white-space:nowrap">In-License</FONT></B><B>&#148;</B><B> </B>means, individually,
each of the license agreements listed on <B>Schedule</B><B></B><B>&nbsp;1.36 </B>between CG and the Third Party(ies) identified on such Schedule&nbsp;in effect as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B>&#8195;<B>&#147;</B><B>Export Control Laws</B><B>&#148;</B><B> </B>means all Applicable Laws relating to (a)&nbsp;sanctions and
embargoes imposed by the Office of Foreign Assets Control of the U.S.&nbsp;Department of Treasury or (b)&nbsp;the export or <FONT STYLE="white-space:nowrap">re-export</FONT> of commodities, technologies, or services, including the Export
Administration Act of 1979, 24 U.S.C. &#167;&#167;&nbsp;2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. &#167;&#167;&nbsp;1701-1706, the Trading with the Enemy Act, 50 U.S.C. &#167;&#167;&nbsp;1 et. seq., the Arms Export
Control Act, 22 U.S.C. &#167;&#167;&nbsp;2778 and 2779, and the International Boycott Provisions of Section&nbsp;999 of the U.S.&nbsp;Internal Revenue Code of 1986, in each case, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B>&#8195;<B>&#147;</B><B>FDA</B><B>&#148;</B><B> </B>means the United States Food and Drug Administration, or any successor entity
thereto performing similar functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B>&#8195;<B>&#147;</B><B>Field</B><B>&#148;</B><B> </B>means all uses for an oncology
Indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B>&#8195;<B>&#147;</B><B>First Commercial Sale</B><B>&#148;</B><B> </B>means, with respect to a particular Product
in a given country, the first bona fide commercial sale to a Third Party of such Product following Marketing Approval in such country by or under authority of a Party or any of its Affiliates (or any of its or their sublicensees hereunder). For
clarity, sales or other dispositions under Compulsory Sublicenses, for Clinical Trial or other scientific testing purposes, as free samples, under named patient use, patient assistance, charitable purposes, early access or compassionate use
programs, or similar uses, programs, or studies, shall not constitute a First Commercial Sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B>&#8195;<B>&#147;</B><B>FTE</B><B>&#148;</B><B> </B>means the equivalent of the
work of one employee full time for a twelve (12)&nbsp;month period of work directly related to the Development Program, including experimental laboratory work, recording and writing up results, reviewing literature and references, holding scientific
discussions, managing and leading scientific staff, carrying out management duties related to the Development Program, writing up results for publications or presentation and attending or presenting appropriate education programs, seminars and
symposia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B>&#8195;<B>&#147;</B><B>GMP</B><B>&#148;</B><B> </B>means, applicable good manufacturing practices in effect in the
United States, respectively, during the Term and, with respect to any other jurisdiction, manufacturing practices equivalent to good manufacturing practices then in effect in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B>&#8195;<B>&#147;</B><B>IND</B><B>&#148;</B><B> </B>means an investigational new drug application filed with the FDA pursuant to 21
CFR Part 312 before the commencement of clinical trials of a product, or any comparable filing with any relevant regulatory authority in any other jurisdiction including under MHLW and PMDA regulations in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B>&#8195;<B>&#147;</B><B>Indication</B><B>&#148;</B><B> </B>means the intended use of a Product for therapeutic treatment of a
distinct disease or medical condition, regardless of the size of the patient class, for which any Marketing Approval is being sought and which will be referenced in detail on such Product labeling. All variants, including histological variants, of a
single disease or medical condition (whether classified by severity or otherwise), regardless of the patient population, shall be treated as the distinct Indications, provided there are distinct labels in the Marketing Approval Application approved
by the applicable Regulatory Authority. By way of example, but not limitation, (i)&nbsp;the treatment of a disease or medical condition in a particular patient population and the treatment of the same disease or medical condition in another
population (e.g., adult population and pediatric population) shall be treated as a distinct Indication if more than one label is approved by the applicable Regulatory Authority, (ii)&nbsp;label extensions (including front line, second line, third
line, metastatic, adjuvant, etc.) shall be treated as distinct additional Indications if a label is extended by the applicable Regulatory Authority (e.g., an MAA approval for <FONT STYLE="white-space:nowrap">BCG-unresponsive</FONT> patients is a
distinct indication from a label extension adding front line BCG na&iuml;ve patients), and (iii)&nbsp;combination therapy or combination Products containing more than one active moiety (other than the Collaboration Compound plus DDM) that contain
different labels (for example, additional patient subtypes) than monotherapy shall be treated as distinct indications. For clarity, and subject to the foregoing, (a)&nbsp;label expansions shall not be deemed to be separate Indications (e.g., an MAA
approval for BCG unresponsive CIS patients is not a separate indication from a label expansion to add BCG unresponsive Ta/T1 patients); (b) dosing changes shall not be deemed to be separate Indications; and (c)&nbsp;Indication includes the intended
evaluation of a Collaboration Compound or a Product for therapeutic treatment of a distinct disease or medical condition in the relevant preclinical study or Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B>&#8195;<B>&#147;</B><B>Initial Indication</B><B>&#148;</B><B> </B>means bacillus Calmette-Guerin (BCG) unresponsive urothelial
carcinoma in situ (CIS) subtype of <FONT STYLE="white-space:nowrap">non-muscle-invasive</FONT> bladder cancer (NMIBC), or any replacement initial Indication identified by the JDC, including in response to input by the applicable Regulatory
Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B>&#8195;<B>&#147;</B><B>Inventor</B><B>&#148;</B><B> </B>means an individual that
discovered or made, in whole or in part, <FONT STYLE="white-space:nowrap">Know-How</FONT> or subject matter disclosed in a Patent and that such individual&#146;s contribution to such <FONT STYLE="white-space:nowrap">Know-How</FONT> or subject matter
meets the legal standard of inventorship in accordance with United States patent laws for determining inventorship, irrespective of the jurisdiction where such <FONT STYLE="white-space:nowrap">Know-How</FONT> or subject matter was conceived or made.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B>&#8195;<B>&#147;</B><B>Joint Collaboration IP</B><B>&#148;</B><B> </B>means the Joint Collaboration <FONT
STYLE="white-space:nowrap">Know-How</FONT> and the Joint Collaboration Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B>&#8195;<B>&#147;</B><B>Joint Collaboration <FONT
STYLE="white-space:nowrap">Know-How</FONT></B><B>&#148;</B><B> </B>means Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> (a)&nbsp;generated, discovered or obtained by (i)&nbsp;at least one employee, consultant or agent of Kissei or
its Affiliates, and (ii)&nbsp;at least one employee, consultant or agent of CG or its Affiliates and (b)&nbsp;without use of any Kissei IP that is not Kissei Collaboration IP (other than incidental use of such Kissei IP, as determined pursuant to
<B>Section</B><B></B><B>&nbsp;3.2.2(c) (JPWG Responsibilities)</B>). For clarity, Joint Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> includes any <FONT STYLE="white-space:nowrap">Know-How</FONT> that is deemed Joint Collaboration <FONT
STYLE="white-space:nowrap">Know-How</FONT> pursuant to <B>Section</B><B></B><B>&nbsp;3.2.2(c) (JPWG Responsibilities)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B>&#8195;<B>&#147;</B><B>Joint Collaboration Patents</B><B>&#148;</B><B> </B>means Patents claiming Joint Collaboration <FONT
STYLE="white-space:nowrap">Know-How</FONT> and which name (a)&nbsp;one employee, consultant or agent of Kissei or its Affiliates as an Inventor and (b)&nbsp;one employee, consultant or agent of CG or its Affiliates as an Inventor. For purposes of
clarity, Patents that claim Joint Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> shall constitute Joint Collaboration Patents (and shall not constitute Kissei Patents even if such Patents also claim Kissei <FONT
STYLE="white-space:nowrap">Know-How</FONT> nor CG Patents even if such Patents also claim CG <FONT STYLE="white-space:nowrap">Know-How).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B>&#8195;<B>&#147;</B><B>Kissei Collaboration IP</B><B>&#148;</B><B> </B>means Kissei Collaboration
<FONT STYLE="white-space:nowrap">Know-How</FONT> and Kissei Collaboration Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B>&#8195;<B>&#147;</B><B>Kissei Collaboration
<FONT STYLE="white-space:nowrap">Know-How</FONT></B><B>&#148;</B><B> </B>means Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> that is generated, discovered or obtained by or on behalf of Kissei or its Affiliates during the Term of
this Agreement, without the inventive contribution of any employee, consultant or agent of CG or its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B>&#8195;<B>&#147;</B><B>Kissei Collaboration Patents</B><B>&#148;</B><B> </B>means (a)&nbsp;Patents claiming Kissei Collaboration <FONT
STYLE="white-space:nowrap">Know-How</FONT> and (b)&nbsp;Patents claiming <FONT STYLE="white-space:nowrap">Know-How</FONT> generated, discovered or obtained by or on behalf of Kissei or its sublicensees in the course of clinical development of a
Product during the Development Program for such Product and ending on the Marketing Approval of such Product anywhere in the Territory. Kissei Collaboration Patents exclude Joint Collaboration Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B>&#8195;<B>&#147;</B><B>Kissei IP</B><B>&#148;</B><B> </B>means the Kissei <FONT STYLE="white-space:nowrap">Know-How</FONT> and
Kissei Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B>&#8195;<B>&#147;</B><B>Kissei <FONT STYLE="white-space:nowrap">Know-How</FONT></B><B>&#148;</B><B> </B>means <FONT
STYLE="white-space:nowrap">Know-How</FONT> (a)&nbsp;Controlled by Kissei as of the Effective Date or during the Term of this Agreement and (b)(i) the Parties agree to the use in the conduct of the Development Program pursuant to
<B>Sections</B><B></B><B>&nbsp;2.1 (General) </B>or <B>4.2.3 (Other Kissei IP) </B>or (ii)&nbsp;Kissei incorporates into or uses for the purposes of a Product hereunder. For clarity, Kissei <FONT STYLE="white-space:nowrap">Know-How</FONT>
(a)&nbsp;includes Kissei Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT> and (b)&nbsp;excludes Joint Collaboration <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B>&#8195;<B>&#147;</B><B>Kissei Patents</B><B>&#148;</B><B> </B>means all Patents (a)&nbsp;Controlled by Kissei as of the Effective
Date or during the Term of this Agreement and (b)&nbsp;claiming Kissei <FONT STYLE="white-space:nowrap">Know-How.</FONT> Kissei Patents exclude Joint Collaboration Patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B>&#8195;<B>&#147;</B><B><FONT STYLE="white-space:nowrap">Know-How</FONT></B><B>&#148;</B><B> </B>means all information, inventions
(whether or not patentable), improvements, practices, formula, trade secrets, techniques, methods, procedures, knowledge, results, test data (including pharmacological, toxicological, pharmacokinetic and
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical information and test data, related reports, structure-activity relationship data and statistical analysis), analytical and quality control data, protocols, processes, models, designs,
and other information regarding discovery, development, marketing, pricing, distribution, cost, sales and manufacturing. <FONT STYLE="white-space:nowrap">Know-How</FONT> excludes any Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B>&#8195;<B>&#147;</B><B>Lepu Territory</B><B>&#148;</B><B> </B>means mainland China, Hong Kong and Macau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B>&#8195;<B>&#147;</B><B>Licensed Intellectual Property</B><B>&#148;</B><B> </B>means CG IP and CG&#146;s interest in the Joint
Collaboration IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B>&#8195;<B>&#147;</B><B>Marketing Approval</B><B>&#148;</B><B> </B>means all approvals, licenses,
registrations or authorizations of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport and sale of Products in a country or regulatory
jurisdiction. For countries where governmental approval is required for pricing or reimbursement for a Product, &#147;Marketing Approval&#148; shall not be deemed to occur until such pricing or reimbursement approval is obtained for such Product.
For clarity, for the United States no governmental approval is required, and shall not be deemed required, for pricing or reimbursement for a Product unless and until the U.S.&nbsp;federal governmental approval is required for pricing or
reimbursement for such Product under the federal Medicare or Medicaid program or any successor programs thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B>&#8195;<B>&#147;</B><B>Marketing Approval Application</B><B>&#148;</B><B> </B>means BLA, sBLA, NDA, sNDA and any equivalent thereof
in the United States or any other country or jurisdiction in the world including Japan pursuant to MHLW and PMDA regulations. As used herein: &#147;<B>BLA</B>&#148; means a Biologics License Application and amendments thereto filed pursuant to the
requirements of the FDA, as defined in 21 C.F.R. &#167;&nbsp;600 et seq., for FDA approval of a Product and &#147;<B>sBLA</B>&#148; means a supplemental BLA; and &#147;NDA&#148; means a New Drug Application and amendments thereto filed pursuant to
the requirements of the FDA, as defined in 21 C.F.R. &#167;&nbsp;314 et seq., for FDA approval of a Product and &#147;<B>sNDA</B>&#148; means a supplemental NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B>&#8195;<B>&#147;</B><B>MHLW</B><B>&#148;</B><B> </B>means the Ministry of Health, Labour, and Welfare of Japan or any successor
entity thereto performing similar functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B>&#8195;<B>&#147;</B><B>Net Sales</B><B>&#148;</B><B> </B>means, with respect to
any Product, the gross amounts invoiced by each Party, its Affiliates or sublicensees to Third Party customers for sales or other transfers or disposition of a Product, less: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;[***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;[***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;[***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;[***]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net Sales shall be calculated on an accrual basis in accordance with the then-currently used Accounting
Standard. In no event shall Net Sales be deemed to occur in the case of transfers of samples, product development, clinical research or similar transfers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event a Product is sold for a single price in combination (in the same package, including as a <FONT STYLE="white-space:nowrap">co-formulation,</FONT>
or under the same label) with one or more additional active ingredients that are not Products (each such additional active ingredient, an &#147;<B>Additional Active</B>&#148; and any such combination, a &#147;<B>Combination</B>&#148;), then Net
Sales for that Product shall be calculated using the gross invoiced price for such Combination multiplied by the fraction A/(A+B), where &#147;A&#148; is the gross invoiced price for the Product sold separately and &#147;B&#148; is the gross
invoiced price for the Additional Active(s) sold as a separate pharmaceutical product. In the event that an Additional Active(s) is not sold as a separate pharmaceutical product, then Net Sales for that Product shall be calculated using the gross
invoiced price for the Combination multiplied by the fraction A/C, where &#147;A&#148; is the gross invoiced price for the Product, if sold separately, and &#147;C&#148; is the gross invoiced price for the Combination. In the event that no such
separate sales are made, Net Sales of the Product in the Combination for royalty determination under this Agreement shall be determined by the Parties in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B>&#8195;<B>&#147;</B><B>Other Indication</B><B>&#148;</B><B> </B>means an Indication for a distinct disease or medical condition
that is not an Initial Indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B>&#8195;<B>&#147;</B><B>P3 Trial</B><B>&#148;</B><B> </B>means that Phase III Clinical Trial
of a monotherapy Product incorporating the Collaboration Compound for the Initial Indication to be conducted within the Territory and CG Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B>&#8195;<B>&#147;</B><B>Patent(s)</B><B>&#148;</B><B> </B>means any and all patents and patent applications (including provisional
and converted provisional applications) and any patents issuing therefrom or claiming priority thereto, worldwide, together with any extensions (including patent term extensions and supplementary protection certificates), renewals, reissues,
reexaminations, substitutions, confirmation patents, registration patents, invention certificates, patents of addition, renewals, divisionals, continuations, and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66</B>&#8195;<B>&#147;</B><B>Peer Pharmaceutical Company</B><B>&#148;</B><B> </B>means a Person that is [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67</B>&#8195;<B>&#147;</B><B>Person</B><B>&#148;</B><B> </B>means any individual, corporation, company, partnership, association,
joint-stock company, trust, unincorporated organization or government or political subdivision thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B>&#8195;<B>&#147;</B><B>Pharmacology Study(s)</B><B>&#148;</B><B> </B>means <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or <FONT
STYLE="white-space:nowrap">non-clinical</FONT> <FONT STYLE="white-space:nowrap">in-vitro</FONT> or <FONT STYLE="white-space:nowrap">non-human</FONT> animal studies of a Collaboration Compound or a Product comprising (i)&nbsp;pharmacokinetics (i.e.
absorption, distribution, metabolism, and excretion), (ii) toxicology, and/or (iii)&nbsp;pharmacodynamics studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B>&#8195;<B>&#147;</B><B>Phase I Clinical Trial</B><B>&#148;</B><B> </B>means a human clinical trial, the principal purpose of which
is preliminary determination of safety of a Product in healthy individuals or patients or as otherwise described in 21 C.F.R. &#167;312.21(a), or similar clinical study in a country other than the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B>&#8195;<B>&#147;Phase II Clinical Trial&#148;</B><B> </B>means a human clinical
trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy of a Product in patients being studied or as otherwise described in 21 C.F.R. &#167;312.21(b), or similar clinical study in
a country other than the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B>&#8195;<B>&#147;</B><B>Phase III Clinical Trial</B><B>&#148;</B><B> </B>means a human
clinical trial, the principal purpose of which is to demonstrate clinically and statistically the efficacy and safety of a Product for one or more indications in order to obtain Marketing Approval of such Product for such indication(s), or as
otherwise described in 21 C.F.R. &#167;312.21(c) or a similar clinical study in a country other than the United States. The term &#147;Phase III Clinical Trial&#148; also includes any human clinical trial that is intended to serve as a pivotal
clinical trial for the Marketing Approval of the applicable Product, even if officially designated as a Phase II Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B>&#8195;<B>&#147;</B><B>PHSA</B><B>&#148;</B><B> </B>means the Public Health Services Act (Title 42, U.S.C., Chapter 6A), as amended
from time to time. As used herein the PHSA shall refer, more specifically, to 42 USC &#167;&nbsp;262, which governs the regulation of biological products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B>&#8195;<B>&#147;</B><B>PMDA</B><B>&#148;</B><B> </B>means the Pharmaceuticals and Medical Devices Agency of Japan or any successor
entity thereto performing similar functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B>&#8195;<B>&#147;</B><B><FONT STYLE="white-space:nowrap">Pre-Approved</FONT>
Subcontractor</B><B>&#148;</B> means a Person listed on <B>Schedule</B><B></B><B>&nbsp;1.74</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B>&#8195;<B>&#147;</B><B>Product</B><B>&#148;</B><B> </B>means a finished dosage pharmaceutical formulation comprising the
Collaboration Compound in combination with CG&#146;s permeabilization agent
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">N-Dodecyl-3-D-maltoside</FONT></FONT></FONT></FONT> (&#147;<B>DDM</B>&#148;), which is developed, manufactured or
commercialized under this Agreement including all other formulations and modes of administration thereof. For the avoidance of doubt, any combination Products containing additional active pharmaceutical moieties in addition to the Collaboration
Compound plus DDM, will be considered distinct Products (e.g., monotherapy, adjuvant combination chemotherapy with two active moieties, and adjuvant combination chemotherapy with three active moieties etc. are three or more distinct Products). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B>&#8195;<B>&#147;</B><B>Prosecution and Maintenance</B><B>&#148;</B><B> </B><B>or </B><B>&#147;</B><B>Prosecute and
Maintain</B><B>&#148;</B> means, with respect to a particular Patent, all activities associated with the preparation, filing, prosecution and maintenance of such Patent (and patent application(s) derived from or claiming priority to such Patent)
including final decision making authority on whether to <FONT STYLE="white-space:nowrap">opt-in</FONT> or <FONT STYLE="white-space:nowrap">opt-out</FONT> of the European Unified Patent Court, as well as supplemental examinations, <FONT
STYLE="white-space:nowrap">re-examinations,</FONT> reissues, applications for patent term adjustments and extensions, supplementary protection certificates and the like with respect to that Patent, together with the conduct of interferences,
derivation proceedings, inter partes review, post-grant review, the defense of oppositions and other similar proceedings with respect to that Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B>&#8195;<B>&#147;</B><B>Public Official or Entity</B><B>&#148;</B><B> </B>means (a)&nbsp;any officer, employee (including
physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality, or subdivision of any government, military, or international
organization, including any ministry or department of health or any state-owned or affiliated company or hospital, or (b)&nbsp;any candidate for political office, any political party, or any official of a political party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B>&#8195;<B>&#147;</B><B>Regulatory Authority</B><B>&#148;</B><B> </B>means any
federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the research, development, use, manufacture or commercialization (including the granting of Marketing
Approval) of a Collaboration Compound, Product in any jurisdiction, including the FDA, MHLW, and PMDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B>&#8195;<B>&#147;</B><B>Regulatory Materials</B><B>&#148;</B><B> </B>means regulatory applications (including Marketing Approval
Applications), submissions, notifications, communications, correspondence, registrations, Marketing Approvals or other filings made to, received from or otherwise conducted with the FDA or other relevant Regulatory Authority (including minutes of
any meeting with a Regulatory Authority) that are necessary for or relate to the research, development, manufacture or commercialization (including the granting of Marketing Approval) of a Product, in each case, in the Field in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B>&#8195;<B>&#147;</B><B>Residuals</B><B>&#148;</B><B> </B>means information retained in the unaided memory of an individual. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B>&#8195;<B>&#147;</B><B>Series D Preferred Stock</B><B>&#148;</B><B> </B>means the Series D Preferred Stock, $0.0001 per share par
value, of CG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B>&#8195;<B>&#147;</B><B>Territory</B><B>&#148;</B><B> </B>means Bangladesh, Bhutan, Brunei, Cambodia, India,
Indonesia, Japan, South Korea, Laos, Malaysia, Myanmar, Nepal, Pakistan, Palau, Philippines, Singapore, Sri Lanka, Taiwan, Thailand and Vietnam. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B>&#8195;<B>&#147;</B><B>Third Party</B><B>&#148;</B><B> </B>means any entity other than CG or Kissei or an Affiliate of either. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84</B>&#8195;<B>&#147;</B><B>US</B><B>&#148;</B><B> </B>means the United States of America and its territories and possessions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B>&#8195;<B>&#147;</B><B>Valid Claim</B><B>&#148;</B><B> </B>means, with respect to a particular country, an issued, unexpired claim
contained in a CG Patent, CG Collaboration Patent, Kissei Collaboration Patent or Joint Collaboration Patent, in each instance that is directed to the composition of matter or method of use of or method of treatment using a Collaboration Compound in
such country that has not been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that
has not been admitted to be invalid or unenforceable through <FONT STYLE="white-space:nowrap">re-examination,</FONT> <FONT STYLE="white-space:nowrap">re-issue,</FONT> disclaimer or otherwise, or lost in an interference proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B>&#8195;<B>&#147;</B><B>VAT</B><B>&#148;</B><B> </B>means, any value added tax calculated in accordance with Applicable Law in a
particular country inside or outside the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional Definitions. Each of the following terms has the meaning ascribed to them
in the corresponding Section&nbsp;or Schedule&nbsp;of this Agreement indicated below: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section/Schedule:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section/Schedule:</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Active</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnitee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnitor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alliance Manager</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insolvency Proceedings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average Net Sales per</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4.3(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>JDC</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bankrupt Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.3(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>JMWG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>JPWG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.5.7(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Kissei</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.5.7(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Kissei Indemnitees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carry-Forward Amount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4.3(a)(ii)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Loss or Losses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Catastrophic Breach</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>NDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.60</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Net Sales Report</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.2.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CG Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Party or Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CG Indemnitees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Pharmacovigilance Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.2.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Product Royalty Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4.5</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CG Product Royalty Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.5.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Project <FONT STYLE="white-space:nowrap">Co-Leader</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>3.1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Challenge</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Releases</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.3.1(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Requesting Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.2.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Supply Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Required Release</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.2.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CMC Information</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reviewing Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.2.4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.62</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rules</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>15.2.1</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section/Schedule:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Definition:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Section/Schedule:</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial Supply Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>sBLA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.60</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Competitive Infringement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>sNDA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>1.60</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CPA Firm</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>8.8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Specified Marks</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CREATE Act</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defending Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Stock Purchase Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Background</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deliverables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Subcontractor Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Supply and Sales Fraction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Supply Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4.3(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosing Party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>11.2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Supply Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.1.2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dispute</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>15.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Introduction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third Party Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.1.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Royalty Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.4.3(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third Party Infringement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.7.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Election Notice</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.5.7(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third Party Infringement Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>9.8.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Japan Approval Milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.3.1(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title 11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>14.3(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First <FONT STYLE="white-space:nowrap">Non-Japan</FONT> Approval Milestone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.3.1(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transacting Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Development Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transacting Party Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.3.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indemnify</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>13.1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Valuation Firm</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>7.5.7(c)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT PROGRAM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B>&#8195;<B>General</B>. The Parties agree to undertake, using Commercially Reasonable Efforts, the Development Program to develop
Products in the Field in accordance with one or more work plans (the &#147;<B>Development Plan(s)</B>&#148;). The Development Plan for the Initial Indication is set forth in <B>Schedule</B><B></B><B>&nbsp;2.1 </B>(the &#147;<B>Initial Development
Plan</B>&#148;) and will include (i)&nbsp;P3 Trial activities in the Territory and (ii)&nbsp;information exchange with respect to CG Territory Activities. Each Development Plan, together with <B>Schedule</B><B></B><B>&nbsp;2.1</B>, may be amended by
the Parties from time to time during the Development Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B>&#8195;<B>Certain Activities</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.1</B>&#8195;Each Party shall be responsible for conducting the activities assigned to it in the Development Plan. Each Party shall make
available to the Development Program the number and types of dedicated FTEs reasonably needed to complete the activities described in the Development Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.2</B>&#8195;Except as mutually agreed otherwise, neither Party will provide Product to support any investigator-initiated study of such
Product in the Territory; provided that CG shall reasonably notify Kissei of any such studies in the CG Territory. For clarity, after the Development Term, Kissei at its sole discretion will be able to provide Product to support any
investigator-initiated study of such Product in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.3</B>&#8195;Except as set forth in
<B>Section</B><B></B><B>&nbsp;2.2.1 (Certain Activities) </B>and <B>Section</B><B></B><B>&nbsp;2.6.2 (Additional Efforts) </B>or as mutually agreed through the JDC, which shall not be unreasonably delayed or withheld, Kissei may not, directly or
indirectly, (a)&nbsp;conduct activities directed to the research or development of Collaboration Compounds or Products in the Field, including any Other Indication or (b)&nbsp;appoint, license or otherwise authorize or facilitate any Affiliate or
Third Party, whether pursuant to such appointment, license or otherwise, to perform any of the activities set forth in the foregoing clause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B>&#8195;<B>Subcontractors</B>. Subject to the terms and conditions of this Agreement (including <B>Section</B><B></B><B>&nbsp;2.2.3
(Certain Activities)</B>), either Party may subcontract portions of its work under the Development Program to its Affiliates or <FONT STYLE="white-space:nowrap">Pre-Approved</FONT> Subcontractors; provided, such subcontract is consistent with the
terms and conditions of this Agreement. A Party may not subcontract portions of its work under the Development Program to any other Third Parties other than pursuant to the following procedure: (a)&nbsp;such Party shall notify the other Party (which
notice may be provided via <FONT STYLE="white-space:nowrap">e-mail)</FONT> of any proposed subcontractor and the scope of work proposed to be subcontracted (such notice, a &#147;<B>Subcontractor Notice</B>&#148;); (b) the other Party shall notify
the requesting Party if it wishes to audit the proposed subcontractor or of any other reasonable concerns with respect to such proposed subcontractor, if any, within [***] of receipt of such Subcontractor Notice; (c)&nbsp;the requesting Party shall
consider any such concerns in good faith; and (d)&nbsp;the matter shall be referred to the JDC for discussion. In the event a Party indicates its desire to audit a proposed subcontractor, the Parties shall cooperate with the each other and the
proposed subcontractor to organize and conduct an audit subject to mutually agreeable conditions including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
timing, duration, subject matter and confidentiality restrictions, provided that each Party shall bear its own costs and expenses incurred in such audit. In the event a proposed subcontractor
refuses to participate in an audit, the requesting Party shall not subcontract any portions of its work to the proposed subcontractor without the other Party&#146;s express written consent. In the event the other Party does not respond to any such
Subcontractor Notice within [***] period, the requesting Party may subcontract the work described in such Subcontractor Notice to the proposed subcontractor identified therein. The requesting Party shall remain responsible (at its cost) for and
shall ensure that each subcontractor (including Affiliates to whom the requesting Party has subcontracted) complies with the terms and conditions of this Agreement. For clarity, the foregoing in this <B>Section</B><B></B><B>&nbsp;2.3
(Subcontractors) </B>shall not be applicable to any Third Party consultant that provides advisory services to the requesting Party, but does not undertake any of the activities in the Development Program. Notwithstanding the above, the above
Subcontractor Notice process will not be applied to subcontractors for <FONT STYLE="white-space:nowrap">non-major</FONT> activities including, by way of example, the measurement of general clinical examinations and setting up the interactive web
response system (IWRS), provided, however, that information regarding such subcontractors for such <FONT STYLE="white-space:nowrap">non-major</FONT> activities will be shared through the JDC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B>&#8195;<B>Development Term</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4.1</B>&#8195;The term of each Development Plan shall be determined by the JDC (the &#147;<B>Development Term</B>&#148;), except that the
Development Term for the Initial Development Plan shall commence on the Effective Date and shall continue, unless extended by Kissei as set forth in this <B>Section</B><B></B><B>&nbsp;2.4 (Development Term) </B>or this Agreement is earlier
terminated in accordance with <B>Article</B><B></B><B>&nbsp;14 (Term; Termination)</B>, until the [***] of the IND in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4.2</B>&#8195;At any time prior to the expiration of the Development Term, on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Indication-by-Indication</FONT></FONT> basis, if the activities set forth in the Development Plan for such Indication have not been completed by the then-current Development Term, Kissei may elect to extend the Development
Term by [***] by written notice to CG; provided, that either (a)&nbsp;the scope of the Development Plan with respect to the Initial Indication does not change in any material manner, or (b)&nbsp;the Parties mutually consent to an amended Development
Plan. CG shall not unreasonably withhold its consent to an amended Development Plan if Kissei&#146;s amended Development Plan includes appropriate provisions providing that Kissei shall be responsible for all costs including cost reimbursement to CG
that reasonably account for additional activities not contemplated in the then-existing Development Plan (including patient recruitment). For clarity, the Development Term shall not be extended more than [***] under this
<B>Section</B><B></B><B>&nbsp;2.4 (Development Term)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.4.3</B>&#8195;For the purposes of this <B>Section</B><B></B><B>&nbsp;2.4
(Development Term)</B>, if either Party is experiencing patient recruitment challenges not previously contemplated by the JDC at the commencement of the Development Term, the Development Plan shall be amended to reflect such recruitment challenge
and appropriate provisions providing that Kissei shall be responsible for all costs including cost reimbursement to CG that reasonably accounts for any additional activities necessary to address such challenge (e.g., engaging new clinical sites).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5</B>&#8195;<B>Reports; Records; and Inspections</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.5.1</B>&#8195;<B>Progress Reports</B>. Each Party shall keep the other Party informed of its activities under the Development Program and
shall provide to the other Party&#146;s representatives on the JDC, summary updates of the same at each meeting of the JDC. Further, as requested by the JDC, CG shall provide to the JDC summary updates of CG Territory Activities. If reasonably
necessary for a Party to perform its work under the Development Program, that Party may request that the other Party provide more detailed information and data regarding the updates it earlier provided, and the other Party shall promptly provide the
requesting Party with information and data as is reasonably available and reasonably necessary to conduct the Development Program, and such other information as the Parties agree. Neither Party is required to generate additional data or prepare
additional reports to comply with the foregoing obligation. Subject to <B>Article</B><B></B><B>&nbsp;10 (Confidentiality)</B>, all such reports, information and data provided by a Party shall be considered the providing Party&#146;s Confidential
Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.5.2</B>&#8195;<B>Development Records</B>. Each Party shall maintain records of the Development Program (or cause such
records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of the Development Program. All laboratory notebooks shall be
maintained for no less than the [***]. All other records shall be maintained by each Party during the Term and for [***] thereafter. All such records of a Party shall be considered such Party&#146;s Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6</B>&#8195;<B>Development Efforts</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.6.1</B>&#8195;<B>Commercially Reasonable Efforts</B>. The Parties shall use Commercially Reasonable Efforts to conduct their respective
tasks under the Development Program. Each Party shall devote such numbers of scientists and clinical professionals, with the requisite qualifications, as the Development Program may require to meet such Commercially Reasonable Efforts requirement.
Such FTEs shall be provided by the employing-Party&#146;s cost. Without limiting the foregoing, it is understood and agreed that each Party will ensure that the Development Program will have sufficient staffing at all times. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.6.2</B>&#8195;<B>Additional Efforts</B>. Notwithstanding any Commercially Reasonable Efforts applied by a Party to the Development
Program, each Party shall have the right, by mutual agreement of the Parties, at its sole cost, to apply additional FTEs to conduct activities under the Development Program. CG shall use Commercially Reasonable Efforts to avoid the situations where
the development of the Products by its other licensees causes a negative impact on the development of the Products in and outside the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.7</B>&#8195;<B>Development Costs</B>. The Parties acknowledge and agree as follows: (a)&nbsp;Kissei shall be responsible for (i)&nbsp;all
of the internal and external costs and expenses for those portions of Clinical Trials (e.g., patient recruitment in the Territory, study sites in the Territory, data collection, analysis and reporting from and for the Territory etc.) conducted
solely in or for the Territory, with the exception of the P3 Trial for which Kissei shall be responsible for costs and expenses for Clinical Trials conducted in or for Japan and <FONT STYLE="white-space:nowrap">(ii)&nbsp;non-clinical</FONT> studies
and CMC development reasonably necessary for the Territory and not necessary for the CG Territory, (b) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CG shall be responsible for (i)&nbsp;all of the internal and external costs and expenses for Clinical Trials conducted solely in the CG Territory, [***], (ii) other
<FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and CMC development reasonably necessary for the CG Territory and not necessary for the Territory, and (iii)&nbsp;CG Territory Activities, and (c)&nbsp;Kissei shall be responsible for
[***] and CG shall be responsible for [***] of external costs and expenses for Clinical Trials conducted within both the Territory and CG Territory that cannot be attributed solely to the Territory or to the CG Territory, as the case may be, [***],
as the case may be Subject to the forgoing, the Parties shall discuss through the JDC which Party shall be the sponsor of and how costs and expenses will be allocated amongst the Parties for, any Clinical Trials with study subjects within and
outside of Territory, including the P3 Trial, that, with respect to the Territory, the Parties agree to conduct pursuant to any agreed amendment to the Development Plan, provided that, as between the Parties, CG shall have the deciding vote for all
matters outside the Territory relating to Clinical Trials with study subjects outside of the Territory, [***]. On a [***] basis, or such other period as agreed by the JDC, each Party shall provide to the other Party a written invoice for development
costs incurred by such Party in the prior [***] for which such other Party is responsible, supported by reasonable documentation for the amounts charged in such invoice(s). Each Party shall remit payment to the other Party within [***] of the date
of invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.8</B>&#8195;<B>Cooperation</B>. The Parties shall reasonably cooperate with each other for the preparation of documents
necessary for the development including investigator&#146;s brochure and for obtaining Marketing Approval in their respective territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.9</B>&#8195;<B>Dispatch</B>. If Kissei wishes to dispatch its personnel to CG&#146;s facilities for purposes of training or information
sharing, the Parties shall discuss the details. In addition, if Kissei requests access to the facilities of CG&#146;s CMO or CRO under contract with CG with respect to the Product, CG shall use reasonable efforts to obtain such Third Party&#146;s
consent to accommodate such requests, provided that Kissei acknowledges CG does not guarantee such access. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&#8195;<B>Joint Development Committee</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.1.1</B>&#8195;<B>Formation and Composition</B>. Within thirty (30)&nbsp;days after the Effective Date, the Parties shall establish a
joint development committee (the &#147;<B>JDC</B>&#148;) to (i)&nbsp;manage the activities under, and facilitate communications between the Parties with respect to, the Development Program, and (ii)&nbsp;discuss CG Territory Activities. The
JDC&#146;s authority shall be strictly limited to development activities for and within the Territory. The JDC shall be composed of [***] designated by each Party. Representatives must be appropriate for the tasks then being undertaken and the stage
of research or <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as
its primary JDC contact (each, a &#147;<B>Project <FONT STYLE="white-space:nowrap">Co-Leader</FONT></B>&#148;). Each Party may replace its representatives from time to time upon written notice to the other Party; <I>provided, however</I>, if a
Party&#146;s representative is unable to attend a meeting, such Party may designate a knowledgeable alternate to attend such meeting and perform the functions of such representative. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.1.2</B>&#8195;<B>JDC Responsibilities</B>. In addition to its overall responsibility
for managing the Development Program, the JDC shall, in particular: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;prepare and approve amendments to the Development
Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;oversee implementation of the Development Plan in and for the Territory, ensuring that activities thereunder are
performed in accordance with the approved timelines and budgets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;request from CG as needed, information or reports
regarding CG Territory Activities and discuss such CG Territory Activities as appropriate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;ensure that each Party keeps
the JDC informed regarding all material activities performed by such Party under this Agreement that are within the purview of the JDC; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;generate and maintain a list of all Products identified under the Development Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&#8195;work to resolve any scientific, clinical, or technical disputes, controversy or claim within its scope of authority; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&#8195;determine whether Kissei may conduct (or appoint, license, or otherwise authorize or facilitate any Affiliate or Third Party
to conduct) activities directed to the development of any Collaboration Compound or Product for another Indication in the Territory as set forth in <B>Section</B><B></B><B>&nbsp;2.2.3 (Certain Activities)</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&#8195;determine whether to provide Product to support any proposal for an investigator-initiated study of such Product as set
forth in <B>Section</B><B></B><B>&nbsp;2.2.2 (Certain Activities)</B>; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&#8195;perform such other functions as may be
allocated to the JDC under this Agreement or by mutual written agreement of the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B>&#8195;<B>Joint Patent Working
Group</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.2.1</B>&#8195;As soon as reasonably possible and in any event within sixty (60)&nbsp;days after the Effective Date, the
Parties shall establish a joint patent working group (&#147;<B>JPWG</B>&#148;), which shall consist of at least [***] of each Party, unless otherwise agreed by the Parties. The JPWG shall provide a forum for the exchange of information between the
Parties, and shall undertake a decision-making role with respect to the intellectual property matters arising under the collaboration, including with respect to the protection of the Collaboration IP and the Prosecution and Maintenance of the CG
Collaboration Patents and Kissei Collaboration Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.2.2</B>&#8195;<B>JPWG Responsibilities</B>. In addition to its overall
responsibility for overseeing and coordinating the Parties&#146; efforts in the protection of the Collaboration IP and the Prosecution and Maintenance of the CG Collaboration Patents and Kissei Collaboration Patents, the JPWG shall, in particular:
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;establish strategies for Prosecuting and Maintaining the CG Collaboration
Patents and the Kissei Collaboration Patents; review and recommend to the Parties assessments of inventorship pursuant to <B>Section</B><B></B><B>&nbsp;9.3 (Inventorship; CREATE Act)</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;oversee and coordinate the conduct of enforcement and defense of the CG Collaboration Patents and Kissei Collaboration
Patents pursuant to <B>Article</B><B></B><B>&nbsp;9 (Intellectual Property; Ownership)</B>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;determine whether any use
of Kissei IP in the Development Program constitutes incidental use, in which case the <FONT STYLE="white-space:nowrap">Know-How</FONT> generated, discovered or obtained by either Party resulting from such incidental use of Kissei IP will be Joint
Collaboration <FONT STYLE="white-space:nowrap">Know-How,</FONT> otherwise the <FONT STYLE="white-space:nowrap">Know-How</FONT> will be Kissei Collaboration <FONT STYLE="white-space:nowrap">Know-How;</FONT> and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;serve as an information exchange with respect to filing and prosecution of CG Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;perform such other functions as specified in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B>&#8195;<B>Joint Manufacturing Working Group</B>. As soon as reasonably possible and in any event within [***] after the Effective
Date, the Parties shall establish a joint manufacturing working group (&#147;<B>JMWG</B>&#148;), which shall consist of at least [***] of each Party, unless otherwise agreed by the Parties. The JMWG shall provide a forum for the exchange of
information between the Parties with respect to the CMC matters, including visit of Kissei&#146;s experts to CMO&#146;s site during manufacturing the Collaboration Compound and Product, securing close communication among CG, its CMOs and Kissei,
discussing the CMC regulatory strategies in and outside the Territory, and other CMC matters agreed by the JMWG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B>&#8195;<B>Working Groups; Other Committees</B>. From time to time, the Parties may also establish and delegate duties to directed
teams or committees on an <FONT STYLE="white-space:nowrap">&#147;as-needed&#148;</FONT> basis to oversee particular projects or activities, and such teams shall be constituted and shall operate as the Parties determine. Each such team and its
activities shall be subject to the oversight, review and approval of, and shall report to, the JDC. In no event shall the authority of a team exceed that specified for the JDC in this <B>Article</B><B></B><B>&nbsp;3 (Governance)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B>&#8195;<B>Meetings</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.5.1</B>&#8195;<B>JDC</B>. The JDC shall meet at least [***], or at such other frequency as agreed by the JDC by audio or video
teleconference or as otherwise agreed by the JDC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.5.2</B>&#8195;<B>JPWG</B>. The JPWG shall meet at least [***], or at such other
frequency as agreed by the JPWG by audio or video teleconference or as otherwise agreed by the JPWG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.5.3</B>&#8195;<B>JMWG</B>. The
JMWG shall meet at least [***], or at such other frequency as agreed by the JMWG by audio or video teleconference or as otherwise agreed by the JMWG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.5.4</B>&#8195;<B>Meeting Agendas and Minutes</B>. Not later than [***] after the JDC, JPWG and JMWG are formed, the respective committees
or working group, as applicable, shall each hold an organizational meeting by video- or tele-conference to establish their respective operating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
procedures, including establishment of agendas, and preparation and approvals of minutes. Kissei shall be responsible for keeping the minutes for the initial meetings of the JDC, JPWG and JMWG.
Thereafter, the Parties shall take turns with such responsibility. Meeting minutes shall be sent to both Parties promptly after a meeting for review, comment and approval by each Party. A decision that is made at the JDC, JPWG or JMWG meeting shall
be recorded in minutes, and decisions that are made by the JDC, JPWG or JMWG outside of a meeting should be documented in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.5.5</B>&#8195;<B>General</B>. Employees of each Party other than its JDC, JPWG or JMWG representatives may attend meetings of the JDC,
JPWG or JMWG as nonvoting participants, and, with the consent of the other Party, a Party&#146;s consultants and advisors involved in the Development Program may attend meetings of the JDC, JPWG or JMWG as nonvoting observers; provided, that such
Third Party consultants and advisors are under written obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as protective of the other Party and the Confidential Information of the other Party as the terms of
<B>Article</B><B></B><B>&nbsp;10 (Confidentiality) </B>of this Agreement. Subject to <B>Section</B><B></B><B>&nbsp;2.7 (Development Costs)</B>, Each Party shall be responsible for all of its own expenses of participating in the JDC, JPWG or JMWG.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B>&#8195;<B>JDC Decision-Making</B>. Each Party shall discuss and attempt to resolve any potential or evolving disagreement
related to the Development Program through its respective Project <FONT STYLE="white-space:nowrap">Co-Leaders</FONT> before it is brought before the JDC. The JDC shall operate as to matters within its responsibility by unanimous Party vote, with
each Party having one vote. If the JDC is unable to achieve unanimous Party vote within [***] after the dispute matter is brought to a vote before the JDC then the following will apply: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;CG shall cast the deciding vote for: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;[***] and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;[***], </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;Kissei shall cast the deciding vote for [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;Notwithstanding the forgoing and for the avoidance of doubt: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;neither the JDC nor either Party shall have the authority to (1)&nbsp;impose any financial obligations on either Party or its
Affiliates other than those explicitly required by this Agreement, (2)&nbsp;resolve any dispute regarding the existence of amounts of any payment owed under this Agreement, (3)&nbsp;impose on either Party or its Affiliates, an obligation to allocate
such Party&#146;s or its Affiliate&#146;s tangible or intangible resources or assets in a certain manner (except as contemplated in the Development Plan) or (4)&nbsp;amend or modify, or waive its own compliance with, this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;neither the JDC nor Kissei shall have the right to increase the level of CG&#146;s FTEs dedicated to conducting research under the
Development Plan; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;neither the JDC nor Kissei shall have any authority over CG Territory
Activities other than to discuss and exchange information with respect to CG Territory Activities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;Kissei shall not have the
right to (1)&nbsp;change the scope of, or otherwise amend, the Development Plan, (2)&nbsp;approve any proposal to substitute the Initial Indication with an Other Indication in the Development Plan, (3)&nbsp;approve any addition or replacement of any
Product, (4)&nbsp;determine whether Kissei may conduct (or appoint, license, or otherwise authorize or facilitate any Affiliate or Third Party to conduct) activities directed to the research or development of any Collaboration Compound or Product
for an Other Indication as set forth in <B>Section</B><B></B><B>&nbsp;2.2 (Certain Activities) </B>or (5)&nbsp;determine whether to provide Product to support any investigator-initiated study of such Product as set forth in
<B>Section</B><B></B><B>&nbsp;2.2.2 (Certain Activities)</B>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v)&#8195;<U STYLE="border-bottom:1pt double; padding-bottom:1pt">Further,</U> if the JDC is unable to achieve a unanimous agreement within
[***] after any of the following matters are brought to vote before the JDC, then such matter(s) shall be submitted for resolution pursuant to <B>Article</B><B></B><B>&nbsp;15 (Dispute Resolution):
</B><U STYLE="border-bottom:1pt double; padding-bottom:1pt">(1)</U> any matter set forth in subparagraph <B>3.6(c)(iv) </B>above, (2)&nbsp;any dispute within the JDC regarding <B>Section</B><B></B><B>&nbsp;7.4.3 (Royalty Payment Offsets)</B>,
<U>including, without limitation</U> and by way of example, any dispute under <B>Section</B><B></B><B>&nbsp;7.4.3(a)(iii) (Royalty Payment Offsets; Third Party Payments) </B>whether a license from a Third Party is reasonably necessary in or for the
Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.6.1</B>&#8195;<B>Working Group</B>. Each Party shall use Commercially Reasonable Efforts to perform its responsibilities
under any working group and provide reasonable support to the other Party in connection with the same. Unless otherwise agreed in connection with the formation of any working group (other than the JDC, which is addressed in
<B>Section</B><B></B><B>&nbsp;3.5.1 (JDC)</B>), each Party will discuss and attempt to resolve any potential or evolving disagreement related to the subject matter of a given working group at the working group level prior to escalation to the JDC
(for any scientific or technical matters) or to the Alliance Managers (for any <FONT STYLE="white-space:nowrap">non-scientific</FONT> or <FONT STYLE="white-space:nowrap">non-technical</FONT> matters). With respect to the decisions of any working
group (other than the JDC, which is addressed in <B>Section</B><B></B><B>&nbsp;3.5.1 (JDC)</B>), each Party shall have [***] in all decisions, and the Parties shall attempt to make decisions by reaching unanimous agreement. If the relevant working
group is unable to achieve a unanimous vote within [***] after a matter is brought to vote before such working group then either Party may refer the relevant dispute to the JDC (for any scientific or technical matters) or the Alliance Managers (for <FONT
STYLE="white-space:nowrap">non-scientific</FONT> or <FONT STYLE="white-space:nowrap">non-technical</FONT> matters) for resolution (or, in the case of the JPWG, resolution subject to <B>Section</B><B></B><B>&nbsp;15.3 (Subject Matter Exclusions)</B>,
if applicable). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.6.2</B>&#8195;<B>Escalation</B>. Each Party shall discuss and attempt to resolve any potential or evolving
disagreement related to the Development Program in and for the Territory through the JDC, or the Parties&#146; other activities in and for the Territory under a given working group at the working group level, in accordance with
<B>Sections</B><B></B><B>&nbsp;3.5.1 (JDC) </B>and <B>3.6.1 (Working Group)</B>, as applicable. If the Parties are unable to resolve a potential or evolving disagreement for any matter under this Agreement, but outside the scope of the JDC&#146;s or
a working group&#146;s decision-making authority, the Parties shall submit such disagreement to the process set forth in <B>Article</B><B></B><B>&nbsp;15 (Dispute Resolution)</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7</B>&#8195;<B>Limits on Authority; Dissolution</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.7.1</B>&#8195;On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, upon
Marketing Approval for a Product, the working groups and the JDC will have no further responsibilities or authority under this Agreement with respect to such Product. On an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Indication-by-Indication</FONT></FONT> basis, upon the earlier of expiration or termination of the Development Program with respect to such Indication, the working groups and the JDC
will have no further responsibilities or authority under this Agreement with respect to such Indication. Upon the earlier of expiration or termination of the Development Program with respect to the last Indication, the working groups and the JDC
will have no further responsibilities or authority under this Agreement and the working groups and the JDC will be deemed dissolved by the Parties. Notwithstanding the foregoing, the JPWG and JMWG shall remain in effect during the Term, unless
earlier dissolved with the consent of the Parties. Notwithstanding anything to the contrary in this <B>Section</B><B></B><B>&nbsp;3.7.1 (Limits on Authority; Dissolution)</B>, for a period of [***] (or such other period as agreed to by the Parties)
following Marketing Approval for any Product, each relevant working group (other than the JPWG, the term of which is addressed in the preceding sentence), the JDC shall continue to exist solely for the purpose of facilitating the transition of
responsibilities with respect to such Product from CG to Kissei, but without any responsibility or authority ascribed to such relevant working group and the JDC with respect to such Product under this <B>Article</B><B></B><B>&nbsp;3
(Governance)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8</B>&#8195;<B>Alliance Managers</B>. Promptly following the Effective Date, each Party shall designate an
individual to act as the primary business contact for such Party for matters related to this Agreement (such Party&#146;s &#147;<B>Alliance Manager</B>&#148;), unless another contact is expressly specified in the Agreement or designated by the
Parties for a particular purpose. The Alliance Managers shall facilitate the flow of information and collaboration between the Parties, including information concerning nonbinding forecasts for sales of a Product in the Territory or CG Territory and
the P3 Trial activities in the Territory and CG Territory, and assist in the resolution of potential and pending issues and potential disputes in a timely manner to enable the working groups and the JDC, and Parties to reach consensus and avert
escalation of such issues or potential disputes, including in accordance with <B>Section</B><B></B><B>&nbsp;15.1 (Disputes)</B>. Either Party may replace its Alliance Manager at any time upon prior written notice (including by email) to the other
Party&#146;s Alliance Manager. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.9</B>&#8195;<B>Change of Control</B>. In the event of a Change of Control of CG in which the
Transacting Party is either (a)&nbsp;engaged in the research, development, manufacture or commercialization of any Competing Product (as of the effective date of such Change of Control or at any time during the Term) or (b)&nbsp;a Peer
Pharmaceutical Company, Kissei may (without limiting Kissei&#146;s rights under this Agreement, including under <B>Section</B><B></B><B>&nbsp;14.5 (Termination at Will)</B>) elect to take any or all of the following actions set forth in
<B>Sections</B><B></B><B>&nbsp;3.9.1 (Change of Control) </B>and/or <B>3.9.2 (Change of Control)</B>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.1</B>&#8195;provide written
notice to CG (or its successor entity) terminating the provisions of this <B>Article</B><B></B><B>&nbsp;3 (Governance) </B>in whole or in part, and upon such notice (a)&nbsp;neither Party will be obligated under the terminated provisions of this
<B>Article</B><B></B><B>&nbsp;3 (Governance) </B>for the remainder of the Term, (b)&nbsp;any information, documents or reports that a Party is otherwise required to provide to the working groups or JDC pursuant to the terminated provisions of this
<B>Article</B><B></B><B>&nbsp;3 (Governance)</B>, as applicable, shall be provided directly to the other Party, (c)&nbsp;Kissei&#146;s obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to provide the annual progress reports under <B>Section</B><B></B><B>&nbsp;6.2 (Progress Reports) </B>shall be limited to high-level information regarding the status of Products (including
Marketing Approvals) and commercialization as of the end of the preceding calendar year, and (d)&nbsp;any matters delegated to the working groups or JDC pursuant to the terminated provisions of this <B>Article</B><B></B><B>&nbsp;3 (Governance)</B>,
as applicable, shall be made by mutual agreement of the Parties, subject to the decision-making and dispute resolution provisions of <B>Section</B><B></B><B>&nbsp;3.6 (JDC Decision-Making) </B>and <B>Article</B><B></B><B>&nbsp;15 (Dispute
Resolution)</B>; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.2</B>&#8195;provide written notice to CG (or its successor entity) terminating the provisions of
<B>Sections</B><B></B><B>&nbsp;2.1 (General) </B>and/or <B>2.2 (Certain Activities)</B>, in whole or in part, without relieving either Party of any obligation that accrued under any such section&nbsp;prior to such termination. If Kissei provides a
notice to CG under this <B>Section</B><B></B><B>&nbsp;3.9.2 (Change of Control)</B>, CG shall as soon as reasonably practicable transfer and assign to Kissei all data, Marketing Approvals and regulatory documentation with respect to the Products in
the Territory and a copy of all of the data with respect to the Products in the Territory, including all data comprising the global safety database for the Products and any related Companion Diagnostics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.3</B>&#8195;Notwithstanding the foregoing, Kissei shall not have the right to take any of the actions set forth in
<B>Section</B><B></B><B>&nbsp;3.9.1 (Change of Control) </B>or <B>Section</B><B></B><B>&nbsp;3.9.2 (Change of Control) </B>so long as (a)&nbsp;no unpublished CG Patents, unpublished CG <FONT STYLE="white-space:nowrap">Know-How,</FONT> Kissei IP,
Confidential Information, or any Collaboration IP are used by such Transacting Party Group, (b)&nbsp;such Transacting Party Group segregates the CG Group&#146;s personnel from all programs of such Transacting Party Group directed to the
(i)&nbsp;research, development, manufacture, sale, marketing, promotion or distribution of any Competing Product or (ii)&nbsp;research, development, manufacture, sale, marketing, promotion or distribution of any product for the diagnosis,
prevention, or treatment of any of the Indications covered by any Development Plan under this Agreement, and (c)&nbsp;if such Transacting Party is a Peer Pharmaceutical Company, CG&#146;s JDC, JPWG and other working group representatives remain
employees or contractors solely of the CG Group (and not such Transacting Party). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSES AND RIGHTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&#8195;<B>License Grants to Kissei</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1.1</B>&#8195;<B>Products</B>. Subject to the terms and conditions of this Agreement, CG hereby grants to Kissei (a)&nbsp;an exclusive
(even as to CG and its Affiliates, except for activities conducted by or on behalf of CG under the Development Plan), <FONT STYLE="white-space:nowrap">non-sublicensable</FONT> (except as permitted by <B>Section</B><B></B><B>&nbsp;4.1.4
(Sublicenses)</B>), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as set forth in <B>Section</B><B></B><B>&nbsp;16.3 (Assignment)</B>), royalty-bearing license under the CG IP and CG&#146;s interest in the Joint Collaboration IP
to use, import, offer for sale, sell, have sold, and promote, but not the right to make or have made, Products and (b)&nbsp;a limited semi-exclusive, <FONT STYLE="white-space:nowrap">non-sublicensable,</FONT>
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> royalty-bearing license under the CG IP to develop (subject to <B>Article</B><B></B><B>&nbsp;2 (Development Program)</B>), excluding the right to make or have made, Products, in each case of
(a)&nbsp;and (b) in the Field in the Territory. For clarity, the license granted to Kissei in <B>Section</B><B></B><B>&nbsp;4.1.1(b) (License Grants to Kissei; Products) </B>includes the right to conduct Pharmacology Studies in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved in writing by CG through the JDC. For purposes of this Agreement, &#147;semi-exclusive&#148; means that CG hereby may grant to a Third Party agreed between the Parties in the Development
Program, a license under the CG IP to develop the Products in the Territory to the extent agreed between the Parties in the Development Program. Notwithstanding anything to the contrary herein, the license granted in this
<B>Section</B><B></B><B>&nbsp;4.1.1 (Products) </B>shall exclude: (a)&nbsp;the right to offer for sale, sell, have sold, conduct medical affairs with respect to, and otherwise commercialize any Collaboration Compound that is not incorporated into a
Product and <FONT STYLE="white-space:nowrap">(b)&nbsp;Know-How</FONT> and Patents (i)&nbsp;owned or controlled by any member of any Transacting Party Group that was not licensed to CG prior to a Change of Control and (ii)&nbsp;with respect to any
Additional Active or other component incorporated into a Product that is not a Collaboration Compound or a component of a Collaboration Compound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1.2</B>&#8195;<B>Companion Diagnostics</B>. The Parties agree and understand that the JDC may amend the Development Plan to include one
or more Companion Diagnostics for one or more Products as appropriate for a given Indication. In such case, CG hereby grants to Kissei an exclusive (even as to CG and its Affiliates, except for activities conducted by or on behalf of CG under the
Development Plan), <FONT STYLE="white-space:nowrap">non-sublicensable</FONT> (except as permitted by <B>Section</B><B></B><B>&nbsp;4.1.4 (Sublicenses)</B>), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except pursuant to
<B>Section</B><B></B><B>&nbsp;16.3 (Assignment)</B>), fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free license under the CG IP and CG&#146;s interest in the Joint Collaboration IP to use, import, offer for sale, sell, have sold,
conduct medical affairs with respect to, and otherwise commercialize Companion Diagnostics in the Territory solely for purposes of, in connection with and in support of the research, development, manufacture, commercialization or therapeutic use of
Products. Notwithstanding anything to the contrary herein, the license granted in this <B>Section</B><B></B><B>&nbsp;4.1.2 (Companion Diagnostics) </B>shall exclude <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents owned or controlled by
any member of any Transacting Party Group that was not licensed to CG prior to a Change of Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1.3</B>&#8195;<B>Collaboration
IP</B>. CG hereby grants to Kissei a semi-exclusive, fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, <FONT STYLE="white-space:nowrap">non-sublicensable</FONT> (except as permitted by <B>Section</B><B></B><B>&nbsp;4.1.4
(Sublicenses)</B>), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except pursuant to <B>Section</B><B></B><B>&nbsp;16.3 (Assignment)</B>) license under CG&#146;s interest in the Collaboration IP solely to conduct research activities in
the Field in the Territory, other than to research Products, Companion Diagnostics and Competing Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1.4</B>&#8195;<B>Sublicenses</B>. Kissei shall have the right to sublicense the rights granted under this
<B>Section</B><B></B><B>&nbsp;4.1 (License Grants to Kissei) </B>to its Affiliates or Third Parties though multiple tiers; provided, that (i)&nbsp;prior to granting any such sublicense, Kissei first obtains CG&#146;s prior written consent, not to be
unreasonably withheld, (ii)&nbsp;each such sublicense is subordinate to and consistent with the terms and conditions of this Agreement, and (iii)&nbsp;Kissei shall remain responsible for such Affiliate&#146;s or Third Party&#146;s compliance with
all obligations under this Agreement applicable to such Affiliate or Third Party. For clarity, no grant of any sublicense to a Third Party or an Affiliate shall relieve Kissei of its obligations hereunder. For further clarity, any Kissei Affiliate
sublicensee hereunder and any Kissei Affiliate acting on behalf of, under the authority of or in lieu of Kissei hereunder shall be a &#147;sublicensee&#148; of Kissei for purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&#8195;<B>License Grants to CG</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2.1&#8195;Collaboration IP</B>. Kissei hereby grants to CG a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> sublicensable (subject to <B>Section&nbsp;4.2.5 (Sublicenses)</B>), transferable (subject to <B>Section&nbsp;16.3</B> <B>(Assignment)</B>), license, under Kissei&#146;s interest in the Joint Collaboration
IP, for any and all uses and products (a)&nbsp;in the CG Territory, and (b)&nbsp;other than to use, import, offer for sale, sell, have sold and otherwise commercialize Products, Companion Diagnostics and Competing Products in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2.2</B>&#8195;<B>Kissei Collaboration IP</B>. Kissei hereby grants to CG a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> royalty-bearing, sublicensable (subject to <B>Section</B><B></B><B>&nbsp;4.2.5 (Sublicenses)</B>), transferable (subject to
<B>Section</B><B></B><B>&nbsp;16.3 (Assignment)</B>), license, under Kissei&#146;s interest in the Kissei Collaboration IP for all uses and products (a)&nbsp;in the CG Territory, and (b)&nbsp;other than to use, import, offer for sale, sell, have
sold and otherwise commercialize Products, Companion Diagnostics and Competing Products in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2.3</B>&#8195;<B>Other
Kissei IP</B>. Prior to using any Kissei IP (other than Kissei Collaboration IP) in the Development Program, Kissei shall provide CG a general description of the proposed Kissei IP and the intended use thereof in the Development Program, without
disclosing any Confidential Information with respect thereto. By mutual agreement of the Parties, CG may use such Kissei IP in the Development Program solely for the limited, agreed upon purpose, which shall be in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2.4</B>&#8195;<B>Residuals</B>. CG may use for any purpose Residuals resulting pursuant to this Agreement from CG and its Affiliates
employees&#146;, consultants&#146; and agents&#146; access to or work with any Kissei IP or other Confidential Information of Kissei. Kissei may use for any purpose Residuals resulting pursuant to this Agreement from Kissei and its Affiliates
employees&#146;, consultants&#146; and agents&#146; access to or work with any CG IP or other Confidential Information of CG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2.5</B>&#8195;<B>Sublicenses</B>. CG shall have the right to sublicense the rights granted under this <B>Section</B><B></B><B>&nbsp;4.2
(License Grants to CG) </B>to its Affiliates or Third Parties though multiple tiers; provided, that such sublicense is consistent with the terms and conditions of this Agreement, and provided further that CG shall remain responsible for such
Affiliate&#146;s or Third Party&#146;s compliance with all obligations under this Agreement applicable to such Affiliate or Third Party. For clarity, no grant of any sublicense to a Third Party or an Affiliate shall relieve CG of its obligations
hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B>&#8195;<B>Exclusivity</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.3.1</B>&#8195;For a period beginning on the Effective Date and concluding [***] following first Marketing Approval for a Product, neither
CG nor any of its Affiliates shall: (a)&nbsp;promote, market, distribute, sell or otherwise commercialize a Competing Product; or (b)&nbsp;either directly or indirectly, appoint, license, or otherwise authorize or facilitate any Third Party, whether
pursuant to such appointment, license or otherwise, to perform any of the activities set forth in the foregoing clause (a). Notwithstanding anything to the contrary in this Agreement, in the event of any Change of Control of CG (or successor entity
thereto, applying the definition of Change of Control to such successor in place of CG), the Person engaged in the Change of Control event with CG (the &#147;<B>Transacting Party</B>&#148;) and its Affiliates other than the CG Group (collectively,
the &#147;<B>Transacting Party Group</B>&#148;) will not be deemed to be Affiliates of CG for purposes of this <B>Section</B><B></B><B>&nbsp;4.3.1 (Exclusivity)</B>, provided, that, and only so long as (a)&nbsp;no unpublished CG Patents,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unpublished CG <FONT STYLE="white-space:nowrap">Know-How,</FONT> Kissei IP or Confidential Information, or any Collaboration IP are used by such Transacting Party Group, and (b)&nbsp;the
Transacting Party Group segregates the CG Group&#146;s personnel from all programs of the Transacting Party Group directed to the (1)&nbsp;research, development, manufacture, sale, marketing, promotion or distribution of any Collaboration Compound
or Product, other than as a research tool as permitted by the JDC, which may include use as a positive control or (2)&nbsp;research, development, manufacture, or commercialization of any product for the diagnosis, prevention, or treatment of any of
the Indications which are actively under development under this Agreement as of the date hereof. For the purposes hereof, the &#147;<B>CG Group</B>&#148; means CG and its Affiliates as in existence immediately prior to consummation of the Change of
Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.3.2</B>&#8195;For a period beginning on the Effective Date and concluding [***] following first Marketing Approval for a
Product, Kissei shall not: (a)&nbsp;conduct or participate in, either directly or indirectly, any activities directed toward the (i)&nbsp;research, development, manufacture, sale, marketing, promotion or distribution of any Competing Product; or
(b)&nbsp;either directly or indirectly, appoint, license, or otherwise authorize or facilitate any Affiliate or Third Party, whether pursuant to such appointment, license or otherwise, to perform any of the activities set forth in the foregoing
clause (a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B>&#8195;<B>No Other Rights, Retained Rights</B>. Except as expressly provided in this Agreement, nothing in this
Agreement shall grant either Party any right, title or interest in and to the <FONT STYLE="white-space:nowrap">Know-How,</FONT> Patents or other intellectual property rights of the other Party (either expressly or by implication or estoppel). Any
intellectual property right of a Party not expressly licensed to the other Party by such Party under this Agreement is expressly retained by such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B>&#8195;<B>Interpretation</B>. As used in this <B>Article</B><B></B><B>&nbsp;4 (Licenses and Rights)</B>, the word
&#147;commercialization&#148; (including its cognates, e.g., commercializing) includes any and all of the following activities: selling, offering for sale, promoting, marketing, conducting details, and performing such other activities as are typical
in support of any of the foregoing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANUFACTURING AND SUPPLY; REGULATORY MATTERS; DELIVERABLES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&#8195;<B>Manufacturing and Supply</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.1</B>&#8195;<B>Generally</B>. CG (itself or through designees) shall manufacture and supply to Kissei Products for the Field in the
Territory, in each case in accordance with <B>Section</B><B></B><B>&nbsp;5.2 (Regulatory Matters) </B>and separate written agreements, one for supply in Clinical Trials (&#147;<B>Clinical Supply Agreement</B>&#148;), and another for commercial
supply (the &#147;<B>Commercial Supply Agreement</B>&#148;) each to be negotiated in good faith between the Parties pursuant to <B>Section</B><B></B><B>&nbsp;5.1.2 (Supply Agreements)</B>. CG shall supply to Kissei and Kissei shall (and shall cause
its Affiliates and sublicensees to) exclusively purchase from CG all requirements of Product, and CG shall have the exclusive right to manufacture Product. CG shall report generally regarding the status of activities of CMOs and suppliers related to
Product for supply to Kissei. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.2</B>&#8195;<B>Supply Agreements</B>. The Parties shall negotiate in good faith and
execute a Clinical Supply Agreement and a Commercial Supply Agreement for the supply by CG, or a CMO designated by CG, to Kissei of Product for Kissei&#146;s, its Affiliates&#146; and sublicensees&#146; exercise of the rights and licenses in
accordance herewith including the conduct of Clinical Trials and commercialization in the Territory. The Clinical Supply Agreement shall include (a)&nbsp;supply of sufficient quantities of such Products to enable a Clinical Trials of such Product in
the Territory as provided by the Development Plan; (b)&nbsp;payment by Kissei of an amount [***]; and (c)&nbsp;other terms customary in the pharmaceutical industry to agreements of this nature. The Commercial Supply Agreement shall include
(x)&nbsp;at least [***] supply based on Kissei&#146;s then-current forecasts under such agreement (depending on the final shelf life and stability of the Product and other relevant factors) of Products at all times for the development and
commercialization of such Products under this Agreement, (y)&nbsp;payment by Kissei of an amount equal to [***], and (z)&nbsp;other terms customary in the pharmaceutical industry to agreements of this nature. The Parties shall negotiate the Clinical
Supply Agreement immediately following the Effective Date and use commercially reasonable efforts to execute the Clinical Supply Agreement within [***] of the Effective Date but in no event later than [***]. The Parties shall, through the JDC, agree
upon a timeline for negotiating and executing the Commercial Supply Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.3</B>&#8195;<B>Quality Agreement</B>. CG and Kissei
shall execute a mutually acceptable quality agreement that allocates roles and responsibilities to each Party with respect to quality control and regulatory compliance with respect to the manufacture and supply of Products hereunder and under the
Clinical Supply Agreement and Commercial Supply Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.4</B>&#8195;<B>CMC Information</B>. Subject to
<B>Section</B><B></B><B>&nbsp;2.7 (Development Costs)</B>, as long as CG is manufacturing (or having manufactured through a CMO) Product for Kissei pursuant to the Clinical Supply Agreement or Commercial Supply Agreement, CG shall provide to Kissei
CG&#146;s then-current CMC Information, to the extent reasonably necessary for Kissei to file and maintain a Marketing Approval Application for Product in the Territory. CG shall permit Kissei to cross-reference such CMC Information in its
Regulatory Materials for Product for the Field in the Territory in accordance with this Agreement. &#147;<B>CMC Information</B>&#148; means all technical information regarding a Party&#146;s (or its CMO&#146;s) CMC filed or required to be filed with
the FDA or PMDA in connection with the development or commercialization of Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.5</B>&#8195;<B>CMO Agreements</B>. In each
agreement with a CMO, CG shall use commercially reasonable efforts to obtain the following: (i) [***]; (ii) [***]; and (iii) [***]. At Kissei&#146;s request, CG shall use commercially reasonable efforts, at Kissei&#146;s cost, to facilitate any
inspection or audit of a CMO and permit Kissei to observe the CMO during the manufacturing of Collaboration Compound and Product, including a <FONT STYLE="white-space:nowrap">three-way</FONT> confidentiality agreement with such CMO if such
inspection or audit requires disclosure of any confidential information of such CMO with respect to its processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B>&#8195;<B>Regulatory Matters</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.2.1</B>&#8195;<B>Regulatory Approval Application</B>. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, (i)&nbsp;CG or its designee shall be responsible for preparing and submitting in its own name, and shall own, the IND, Marketing Approval
Application or equivalent for such Product in the CG Territory and Kissei or its designee shall be responsible for preparing and submitting in its own name, and shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
own, the IND, Marketing Approval Application or equivalent for such Product in the Territory, (ii)&nbsp;each Party shall be responsible for liaising and managing interactions with Regulatory
Authorities with respect thereto in its respective territory and (iii)&nbsp;each Party shall support the other Party in the other Party&#146;s territory, as may be reasonably necessary and as reasonably requested by such Party, in preparing and
submitting such IND and Marketing Approval Application, and in the activities in support thereof, including providing information, documents or other materials required by Applicable Law for inclusion in or in support of such IND and Marketing
Approval Application, in each case in accordance with the terms and conditions of this Agreement and the Development Plan. In addition, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis,
the following shall apply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;<B>Regulatory Correspondence</B>. To the extent permitted by agreements with Third Parties
and Applicable Laws, Kissei shall provide to CG summaries or copies in English or original language of the following with respect to Regulatory Authorities in the Territory, and CG shall provide to Kissei summaries or copies of the following with
respect to the FDA and European Medicines Agency (&#147;<B>EMA</B>&#148;) in English or original language: any material documents, information or other correspondence received from such Regulatory Authority pertaining to the Development Plan or such
Product in the US, Europe or Territory, including, but not limited to, any IND, all IND amendments, Regulatory Authority meeting requests, and Regulatory Authority advice (including scientific advisory packages). To the extent reasonably feasible
and based on timelines required by such Regulatory Authority, each Party shall provide the other Party with access to a draft of all material Regulatory Materials in English or original language pertaining to such Product to be submitted by such
Party to such Regulatory Authority, sufficiently in advance of the intended submission dates via the access methods (such as secure databases) established by the JDC, to enable the receiving Party to review and provide comments to the disclosing
Party concerning the content thereof. Each Party shall consider in good faith any such comments of the other Party provided sufficiently in advance of any deadlines required by such Regulatory Authority. The Parties acknowledge and agree that a
Regulatory Authority may require submissions of, or responses containing, Regulatory Materials, the timeline for which would not reasonably allow the Parties to share information and deliberate responses through the JDC. In such case, the Parties
will make reasonable attempts to notify the JDC of the circumstances of such scenarios in advance of the deadline required by the Regulatory Authority, but a Party&#146;s failure to notify the JDC or to consider comments of the other Party will not
constitute a breach of this Agreement; provided that in all instances the Party will notify the JDC as soon as reasonably practicable, even if after the Regulatory Materials have been submitted to the Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;<B>Regulatory Correspondence Related to Manufacturing</B>. CG shall immediately and within [***] of receipt by CG notify
Kissei in writing of, and shall provide Kissei with copies of, any correspondence and other documentation received or prepared by CG, or received by CG and prepared by its CMO, in connection with any of the following events: (a)&nbsp;receipt of a
regulatory letter, warning letter, Form 483 (Inspectional Observations) or similar item, from the FDA or any other Regulatory Authority directed to the manufacture of such Product or in connection with any general cGMP inspections applicable to the
manufacturing facility for such Product; and (b)&nbsp;receipt of a regulatory letter, warning letter or similar item from the FDA or any other Regulatory Authority directed to or any regulatory comments related to such Product where the comments
relate or are attributable to any manufacturing, testing, packaging, storage or distribution activities by CG or on behalf of CG through its designated CMO. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;<B>Meetings with Regulatory Authorities in the Territory</B>. Kissei shall
provide to the JDC, with respect to Regulatory Authorities in Japan, South Korea and Taiwan, and CG shall provide to the JDC, with respect to the FDA and EMA, to the extent reasonably possible, prior written notice of any substantive meeting,
conference, or discussion (including any advisory committee meeting) with such Regulatory Authority relating to such Product, within [***] after such Party first receives notice of the scheduling of such meeting or within such shorter period as may
be necessary in order to give the JDC a reasonable opportunity to determine whether such meeting is material to the Party&#146;s responsibilities in the Territory and it is appropriate for up to [***] of the other Party to attend such meeting. If
the JDC determines that attendance by representatives of the other Party is appropriate, (i)&nbsp;such other Party shall have the right to attend and participate in all such meetings, to the extent permitted by Applicable Law, and (ii), such other
Party may participate in any substantive preparatory <FONT STYLE="white-space:nowrap">pre-meetings</FONT> held prior to such Regulatory Authority meeting. If such Regulatory Authority initiates a meeting, conference or discussion in such a manner
that does not permit a Party to notify the other Party, then the Party discussing with the Regulatory Authority shall, as soon as reasonably practicable and permitted, provide a written summary of the contents of the discussion to the JDC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;<B>Adverse Event Reports</B>. CG shall be responsible managing and controlling a global database for adverse events for any
Product. Subject to <B>Section</B><B></B><B>&nbsp;5.2.2 (Safety Data Exchange) </B>each Party shall be responsible for investigating adverse events and other required safety information associated with the use of such Product in such Party&#146;s
territory and such Party shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events in accordance with Applicable Laws and shall keep the other Party informed with respect to the same.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;<B>Third Party Information</B>. CG shall use Commercially Reasonable Efforts to obtain from Third Parties that become
licensees or Affiliates of CG after the Effective Date and who have rights to develop and commercialize the Collaboration Compound or a Product, for the benefit of Kissei, with respect to the CG Territory: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;a right of reference from such Third Parties who control Marketing Approval Applications pertaining to the Collaboration Compound
and Product, except as otherwise set forth in <B>Section</B><B></B><B>&nbsp;5.2.3 (Right of Reference)</B>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;access to data
regarding Clinical Trials pertaining to the Collaboration Compound or the Product under such Third Parties&#146; Control; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;use and access to all information and data (including CMC Information) contained within Regulatory Materials of such Third
Parties who control Marketing Approval Applications pertaining to the Collaboration Compound and Product; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;copies or summaries
of material regulatory correspondence such Third Parties receive from the FDA or EMA pertaining to Collaboration Compound or Product; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v)&#8195;similar rights as to meetings with Regulatory Authorities as CG provides to
Kissei in <B>Section</B><B></B><B>&nbsp;5.2.1(c) (Meetings with Regulatory Authorities in the Territory)</B>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>provided, however</I>,
that Kissei shall grant reciprocal rights to such CG licensee or Affiliate. Kissei will be under no obligation to grant such CG licensee or Affiliate any of the above rights if such CG licensee or Affiliate does not also grant Kissei the same
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.2.2</B>&#8195;<B>Safety Data Exchange</B>. Beginning on or about the date on which the Parties begin negotiating the
Clinical Supply Agreement, the Parties will negotiate and enter into a pharmacovigilance agreement that defines the Parties&#146; responsibilities and obligations with respect to the procedures and timeframes for compliance with Applicable Law
pertaining to safety reporting for such Product (&#147;<B>Pharmacovigilance Agreement</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.2.3</B>&#8195;<B>Right of
Reference</B>. To the extent permitted by Applicable Law each Party hereby grants the other Party a right of reference and full use and access to all information and data (including CMC Information) within Regulatory Materials Controlled by the
granting Party and its Affiliates and directly relating to any Collaboration Compound, Product or Companion Diagnostics for the purpose of and to the extent necessary or useful to support a Marketing Approval Application for any Collaboration
Compound, Product or Companion Diagnostics in the other Party&#146;s territory. In addition, CG shall obtain from Third Parties that become licensees or Affiliates of CG after the Effective Date and who have rights to develop and commercialize the
Collaboration Compound or a Product, for the benefit of Kissei, a right of reference and full use and access to all information and data (including CMC Information) within Regulatory Materials for a monotherapy Product for the Initial Indication,
for monotherapy Products for all bladder cancer Indications, and for a combination therapy Product for a BCG Indication, to the extent necessary or useful to support a Marketing Approval Application for any Collaboration Compound, Product or
Companion Diagnostics in the Territory; provided that Kissei shall grant reciprocal rights to each such CG licensee or Affiliate. The granting Party shall, at the other Party&#146;s request and expense, take actions reasonably necessary to effect
such grant of right of reference and use to the other Party, including by making such filings as may be required with Regulatory Authorities in the such other Party&#146;s territory that may be necessary to record such grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B>&#8195;<B>Deliverables</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.3.1</B>&#8195;<B>Generally</B>. Each Party shall use Commercially Reasonable Efforts to provide the other Party with the tangible
materials and other deliverables specified under the Development Plan to be provided by such Party (collectively, the &#147;<B>Deliverables</B>&#148;). The JDC shall determine the specific format and timeline for the transfer of such Deliverables,
consistent with the Development Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.3.2</B>&#8195;<B>Rights of Use</B>. With respect to the Deliverables provided by one Party to
another Party pursuant to <B>Section</B><B></B><B>&nbsp;5.1 (Manufacturing and Supply)</B>, each Party shall have the right to use such Deliverables solely for the performance of activities under the Development Program and to exercise the rights
granted to such Party pursuant to <B>Article</B><B></B><B>&nbsp;4 (Licenses and Rights)</B>. Subject to the foregoing, all such Deliverables (i)&nbsp;shall be used by a Party only in accordance with the terms and conditions of this Agreement;
(ii)&nbsp;shall not be used or delivered by a Party to or for the benefit of any Third Party except as expressly provided for herein; and (iii)&nbsp;shall be used by a Party in compliance with all Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.3.3</B>&#8195;<B>Care in Use of Deliverables</B>. Each Party acknowledges that certain
Deliverables provided by the other Party may be experimental in nature and may have unknown characteristics and therefore agrees to use prudence and all reasonable care in the use, handling, storage, containment, transportation and disposition of
such Deliverables. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.3.4</B>&#8195;<B>NO WARRANTY</B>. EACH PARTY ACKNOWLEDGES AND AGREES THAT THE DELIVERABLES PROVIDED BY THE OTHER
PARTY ARE PROVIDED <FONT STYLE="white-space:nowrap">&#147;AS-IS&#148;</FONT> AND THE PROVIDING PARTY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO SUCH DELIVERABLES, AND EXPRESSLY DISCLAIMS ANY WARRANTY OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT OR VIOLATION OF ANY INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DILIGENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B>&#8195;<B>Development and Commercialization of Products</B>. Except with respect to the activities being conducted by the
Parties under the Development Programs, as between Kissei and CG (a)&nbsp;Kissei shall have sole responsibility for, and bear all costs for commercializing Products in the Territory; and (b)&nbsp;Kissei shall have the sole right and authority to
control all decisions related to the commercialization of Products in the Territory. Kissei agrees to use Commercially Reasonable Efforts to commercialize (including seek Marketing Approval for) at least one Product for the Initial Indication. For
the avoidance of doubt, with respect to the CG&#146;s manufacturing obligations, as between Kissei and CG (i)&nbsp;CG shall have sole responsibility therefor, and bear all costs therefor (subject to payments to be made by Kissei to CG under the
Clinical Supply Agreement and Commercial Supply Agreement); and (ii)&nbsp;CG shall have the sole right and authority to control all decisions related thereto; provided that CG will reasonably consult with Kissei for any matters that are reasonably
likely to have a material and detrimental impact on the development, Marketing Approval or sales of the Product in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B>&#8195;<B>Progress Reports</B>. On an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Indication-by-Indication</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis, following the expiration (or
earlier termination) of the Development Term and up until the First Commercial Sale of such Product for the relevant Indication, Kissei shall provide to the JDC at each of its regularly-scheduled meetings during such period a written report
summarizing Kissei&#146;s progress in the development of such Product for the relevant Indication or otherwise in the Field. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL TERMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&#8195;<B>Initial License Fees</B>. In consideration of the rights granted by CG to Kissei under <B>Article</B><B></B><B>&nbsp;4
(Licenses and Rights) </B>to the Licensed Intellectual Property, Kissei shall pay to CG a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-time-non-refundable-non-creditable-license-fee</FONT></FONT></FONT></FONT></FONT></FONT> in the amount of Ten Million US Dollars </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
($10,000,000). Such payment shall be made within fifteen (15)&nbsp;Business Days after Kissei receives electronic notice from CG of completion of the dosing of the first patient of a full six
(6)&nbsp;week treatment in a Phase III Clinical Trial in the United States for a Product and an invoice to Kissei for such payment with bank information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&#8195;<B>Equity Investment</B>. Kissei shall purchase shares of Series D Preferred Stock of CG in accordance with and subject to
the terms and conditions of the Stock Purchase Agreement. Kissei shall pay CG an aggregate amount of [***], which shall be paid as set forth in the Stock Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B>&#8195;<B>Development and Commercial Milestone Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3.1</B>&#8195;<B>Milestones</B>. Subject to the terms of <B>Section</B><B></B><B>&nbsp;7.3.2 (Notice of Achievement; Timing of
Payment)</B>, Kissei shall pay CG the following <FONT STYLE="white-space:nowrap">one-time</FONT> milestone payments upon the first Product achieving the following milestones in rows (a)&nbsp;through (j): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Product Event</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Payment Amount</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a) [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(b) [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(c) [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(d) [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(e) [***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(f) [***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(g) [***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(h) [***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(i) [***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(j) [***].</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Potential Milestone Payments:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3.2</B>&#8195;<B>Notice of Achievement; Timing of Payments</B>. With respect to each milestone referred
to in <B>Section</B><B></B><B>&nbsp;7.3 (Development and Commercial Milestone Payments)</B>, Kissei (or its sublicensee, if applicable) shall promptly, and in any event within [***], inform CG of the achievement of such event. The corresponding
milestone payment shall be due within [***] after achievement of a milestone in <B>Section</B><B></B><B>&nbsp;7.3.1(a) </B>through <B>(e) (Milestones) </B>or within [***] after the end of quarter of achieving the milestone in
<B>Section</B><B></B><B>&nbsp;7.3.1(f) through (j) (Milestones)</B>. Upon written request by Kissei, CG shall issue an invoice for each such milestone payment, provided that Kissei&#146;s obligation to remit payment is not contingent upon CG&#146;s
issuance of an invoice. For the avoidance of doubt, if more than one milestone is achieved in any calendar year, a milestone payment for each such milestone will be due in such calendar year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B>&#8195;<B>Royalty Payments for Products by Kissei</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4.1</B>&#8195;<B>Products in Territory</B>. Subject to the terms of <B>Sections</B><B></B><B>&nbsp;7.4.2 (Products not Covered by a Valid
Claim) </B>through <B>7.4.6 (Other Indications)</B>, Kissei shall pay CG, on a quarterly basis, [***] of Net Sales in the Territory of the applicable Product by Kissei (or its Affiliate or sublicensee hereunder) during the Product Royalty Term: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4.2</B>&#8195;<B>Products not Covered by a Valid Claim</B>. Subject to the terms of <B>Section</B><B></B><B>&nbsp;7.4.3 (Royalty Payment
Offsets)</B> through <B>7.4.6 (Other Indications)</B>, the royalty amounts payable in accordance with <B>Section</B><B></B><B>&nbsp;7.4.1 (Products in Territory)</B> shall be reduced on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis by [***] of the amounts otherwise payable pursuant to
<B>Section</B><B></B><B>&nbsp;7.4.1 (Products in Territory)</B>, as applicable, during any portion of the Product Royalty Term, in which there is not at least one Valid Claim that Covers the sale of such Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4.3</B>&#8195;<B>Royalty Payment Offsets</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;<B>Third Party Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<B>CG</B>. CG shall have the obligation to make payments owed under written agreements entered into by CG with Third Parties, as of
the Effective Date or during the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<B>Supply Payments</B>. On a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">quarter-by-quarter</FONT></FONT> basis, Kissei shall have the right to offset <FONT STYLE="white-space:nowrap">one-hundred</FONT> percent (100%) of royalty payments due and payable by Kissei (or its Affiliates or
sublicensees) to CG with respect to the supply of Product under the Commercial Supply Agreement in a calendar quarter. In the event the amounts paid by Kissei for supply of Product in the Commercial Supply Agreement exceed the royalty amounts owed
by Kissei in this Agreement, such excess amount (&#147;<B>Carry-Forward Amount</B>&#148;) shall carry forward and be deducted from the royalty payments due under the next quarter, and for each subsequent quarter, until Kissei has offset <FONT
STYLE="white-space:nowrap">one-hundred</FONT> percent (100%) of payments paid for the supply of Product under the Commercial Supply Agreement. For clarity, in no event shall CG be obligated to pay or refund the Carry-Forward Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;<B>Kissei</B>. If, after the Effective Date, the JDC determines that a license to a Patent owned or Controlled by a Third Party
in the Territory is reasonably necessary for the making, using, selling, offering for sale or importing of a Product in or for the Territory and Kissei (or its sublicensee) obtains a right or license under such Patent of a Third Party, then Kissei
may offset the royalty payments due and payable by Kissei to CG with respect to the Product in a calendar quarter by [***] of the amount of royalty payments paid by Kissei (or its sublicensee) to such Third Party for such right or license; provided,
that (a)&nbsp;no such reduction may be taken with respect to any amounts paid for any Additional Active in a Combination and (b)&nbsp;in no event shall such reductions reduce a royalty payment owed to CG for such Product by more than [***] of what
would otherwise be owed by Kissei to CG hereunder. For clarity, any such amount that would otherwise be offset if not for such [***] floor shall be applied to the subsequent royalty payment periods until such amount is fully offset, subject to the
applicable floor in each such subsequent royalty payment period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;<B>Biosimilar/Compulsory Competing Product</B>. If following the first
commercial sale of a Biosimilar or a Compulsory Competing Product in a country, and, in each case, Net Sales of the Product incorporating the same reference product with the same active moiety as such Biosimilar or Compulsory Competing Product in
such country in a given [***] period fall by [***] from the Net Sales of such Product in the [***] immediately preceding the [***] in which such launch of the Biosimilar or Compulsory Competing Product occurred, the royalties due and payable by
Kissei under <B>Section</B><B></B><B>&nbsp;7.4.1 (Products in Territory) </B>for such Product shall be reduced by [***] in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;<B>Royalty Floor</B>. Except as expressly set forth in this <B>Section</B><B></B><B>&nbsp;7.4.3(c) (Royalty Floor)</B>, in
no event shall the royalties payable to CG in accordance with the provisions of <B>Section</B><B></B><B>&nbsp;7.4.1 (Products in Territory) </B>for any Product in any country in any calendar quarter be reduced, pursuant to
<B>Section</B><B></B><B>&nbsp;7.4.2 (Products not Covered by a Valid Claim) </B>or this <B>Section</B><B></B><B>&nbsp;7.4.3 (Royalty Payment Offsets)</B>, to less than [***] of the amount that would otherwise be payable to CG in accordance with the
provisions of <B>Section</B><B></B><B>&nbsp;7.4.1 (Products in Territory)</B>, for such Product in such country in such calendar quarter. For clarity, any such amount that would otherwise be offset if not for such quarterly [***] floor shall be
applied to the subsequent royalty payment periods until such amount is fully offset, subject to the applicable floor in each such subsequent royalty payment period; provided, however, that no offsetting shall be allowed at any time subsequent to the
expiration of the Product Royalty Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, if in any calendar quarter that Kissei owes a royalty payment to
CG, Kissei has actually taken sufficient deductions permitted by the first paragraph of this <B>Section</B><B></B><B>&nbsp;7.4.3(d) (Royalty Floor) </B>to reach the [***] floor, and the Supply and Sales Fraction exceeds [***], Kissei shall have the
right to reduce the Effective Royalty Rate by a ratio of [***]. If the Supply and Sales Fraction equals or exceeds 35% in such quarter, then the Effective Royalty Rate shall equal [***], but CG will have no obligation to pay, refund or reimburse
Kissei as a result of any such reduction. If the Supply and Sales Fraction equals or exceeds [***] in such quarter, the Parties shall meet and discuss a reasonable reduction to the calculation of payments owed to CG for supply of Products for
commercial use in <B>Section</B><B></B><B>&nbsp;7.4.3(a)(ii) (Supply Payment)</B>. For any such quarter that the Supply and Sales Fraction exceeds [***], the Effective Royalty Rate for such quarter shall replace the [***] royalty rate set forth in
<B>Section</B><B></B><B>&nbsp;7.4.1 (Products in Territory) </B>for purposes of calculating the royalty payment owed to CG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes
of this Section, the following terms shall mean: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Average Net Sales per Product</B>&#148; means the total Net Sales for a Product
in a calendar quarter divided by the total units of Products accounted for in Net Sales in the same quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effective Royalty
Rate</B>&#148; means a percentage calculated by the formula [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Supply and Sales Fraction</B>&#148; means the Supply Payment
in a given a calendar quarter divided by the Average Net Sales per Product in the same quarter, expressed as a percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Supply Payment</B>&#148; means the total amount paid by Kissei pursuant to <B>Section</B><B></B><B>&nbsp;7.4.3 (a)(ii)(Supply
Payment) </B>in a calendar quarter divided by the total units of Products purchased by Kissei in the same quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schedule</B><B></B><B>&nbsp;7.4.3(d) </B>provides (i)&nbsp;a table showing the relationship between the
Supply and Sales Fraction and the Effective Royalty Rate, and (ii)&nbsp;an example to demonstrate the calculations of this <B>Section</B><B></B><B>&nbsp;7.4.3(d) (Royalty Floor)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4.4</B>&#8195;<B>Single Royalty</B>. No more than one royalty payment shall be due under this <B>Section</B><B></B><B>&nbsp;7.4 (Royalty
Payments for Products by Kissei) </B>with respect to a sale of a particular Product. For the avoidance of doubt, multiple royalties shall not be payable because the sale of a particular Product is Covered by more than one (1)&nbsp;Valid Claim in the
country in which such Product is sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4.5</B>&#8195;<B>Royalty Term</B>. For any Product, the royalty obligations set forth in
<B>Section</B><B></B><B>&nbsp;7.4.1 (Products in Territory) </B>will commence on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the First Commercial Sale of such Product in such
country by or under the authority of Kissei, its Affiliates or any of their sublicensees, and expire on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of (i)&nbsp;the
expiration of the last to expire Valid Claim Covering such Product in such country, and (ii)&nbsp;the twelve (12th) anniversary of the date of First Commercial Sale of such Product in such country (the &#147;<B>Product Royalty Term</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4.6</B>&#8195;<B>Other Indications</B>. For clarity, the applicable royalties in this <B>Section</B><B></B><B>&nbsp;7.4 (Royalty Payments
for Products by Kissei) </B>will apply to each Product for the Field whether for the Initial Indication or any Other Indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4.7</B>&#8195;<B>Certain Net Sales</B>. Notwithstanding anything to the contrary in this Agreement, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, all Net Sales of a Product in a
country prior to obtaining required governmental pricing and reimbursement approval in such country shall be accrued and Kissei shall make royalty payment on such Net Sales of such Product within [***] after the end of the first calendar quarter
following obtaining such required governmental pricing and reimbursement approval in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.4.8</B>&#8195;<B>Rights Following
Expiration of Royalty Term</B>. Upon expiry of its payment obligation hereunder with respect to a Product in a country, the license in <B>Section</B><B></B><B>&nbsp;4.1 (License Grants to Kissei) </B>shall be
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> and fully <FONT STYLE="white-space:nowrap">paid-up</FONT> in respect of such Product in that country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B>&#8195;<B>Royalty Payments for Products by CG</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5.1</B>&#8195;<B>Products in CG Territory</B>. Subject to the terms of <B>Sections</B><B></B><B>&nbsp;7.5.2 (Products</B> <B>not Covered
by a Valid Claim) </B>through <B>7.5.6 (Other Indications)</B>, CG shall pay Kissei, on a quarterly basis, [***] of Net Sales of the applicable Product in the CG Territory, excluding the Lepu Territory, by CG (or its Affiliate or sublicensee
hereunder). For avoidance of doubt, no payment shall be due under this <B>Section</B><B></B><B>&nbsp;7.5.1 (Products in CG Territory)</B> for sales of the Product made in the CG Territory and intended for distribution outside of the CG Territory.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5.2</B>&#8195;<B>Products not Covered by a Valid Claim</B>. Subject to the terms of <B>Section</B><B></B><B>&nbsp;7.5.3 (Royalty
Payment Offsets) </B>through <B>7.5.6 (Other Indications)</B>, the royalty amounts payable in accordance with <B>Section</B><B></B><B>&nbsp;7.5.1 (Products in CG Territory) </B>shall be reduced on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis by [***] of the amounts otherwise payable pursuant to
<B>Section</B><B></B><B>&nbsp;7.5.1 (Products in CG Territory)</B>, as applicable, during any portion of the Product Royalty Term, in which there is not at least one Valid Claim that Covers the sale of such Product in such country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5.3&#8195;Royalty Payment Offsets.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;<B>Third Party Payments</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;<B>Kissei</B>. Kissei shall have the obligation to make payments owed under written agreements entered into by Kissei with Third
Parties, as of the Effective Date or during the Term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;<B>CG</B>. If, after the Effective Date, CG (or its sublicensee)
obtains a right or license under any Patent of a Third Party (which right or license includes one or more Patents), where CG (or its sublicensee) determines that such Patent is reasonably necessary for the making, using, selling, offering for sale
or importing of a Product, then CG may offset the payments due and payable by CG to Kissei with respect to the Product in a calendar quarter by [***] of the amount of payments paid by CG (or its sublicensee) to such Third Party for such right or
license; provided, that (a)&nbsp;no such reduction may be taken with respect to any amounts paid for any Additional Active in a Combination and (b)&nbsp;in no event shall such reductions reduce a payment owed to Kissei for such Product by more than
[***] of what would otherwise be owed by CG to Kissei hereunder. For clarity, any such amount that would otherwise be offset if not for such quarterly [***] floor shall be applied to the subsequent royalty payment periods until such amount is fully
offset, subject to the applicable floor in each such subsequent royalty payment period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;<B>Biosimilar/Compulsory
Competing Product</B>. If following the first commercial sale of a Biosimilar or a Compulsory Competing Product in a country, and, in eachcase, Net Sales of the Product incorporating the same reference product with the same active moiety as such
Biosimilar or Compulsory Competing Product in such country in a given [***] period fall by [***] from the Net Sales of such Product in the [***] immediately preceding the [***] in which such launch of the Biosimilar or Compulsory Competing Product
occurred, the royalties due and payable by Kissei under <B>Section</B><B></B><B>&nbsp;7.5.1 (Products in CG Territory) </B>for such Product shall be reduced by [***] in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;<B>Royalty Floor</B>. Notwithstanding anything to the contrary in this Agreement, in no event shall the royalties payable to
Kissei in accordance with the provisions of <B>Section</B><B></B><B>&nbsp;7.5.1 (Products in CG Territory) </B>for any Product in any country in any calendar quarter be reduced, pursuant to <B>Section</B><B></B><B>&nbsp;7.5.2 (Products not Covered
by a Valid Claim) </B>or this <B>Section</B><B></B><B>&nbsp;7.5.3 (Royalty Payment Offsets)</B>, to less than [***] of the amount that would otherwise be payable to Kissei in accordance with the provisions of <B>Section</B><B></B><B>&nbsp;7.5.1
(Products in CG Territory)</B>, for such Product in such country in such calendar quarter. For clarity, any such amount that would otherwise be offset if not for such quarterly [***] floor shall be applied to the subsequent royalty payment periods
until such amount is fully offset, subject to the applicable floor in each such subsequent royalty payment period; provided, however, that no offsetting shall be allowed at any time subsequent to the expiration of the CG Product Royalty Term (as
defined in <B>Section</B><B></B><B>&nbsp;7.5.5 (CG Royalty Term) </B>below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5.4</B>&#8195;<B>Single Royalty</B>. No more than one royalty payment shall be due
under this <B>Section</B><B></B><B>&nbsp;7.5 (Royalty Payments for Products by CG) </B>with respect to a sale of a particular Product. For the avoidance of doubt, multiple royalties shall not be payable because the sale of a particular Product is
Covered by more than one (1)&nbsp;Valid Claim in the country in which such Product is sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5.5</B>&#8195;<B>CG Royalty Term</B>.
For any Product, the royalty obligations set forth in <B>Section</B><B></B><B>&nbsp;7.5.1 (Products in CG Territory) </B>will commence on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon
the First Commercial Sale of such Product in such country in the CG Territory by or under the authority of CG, its Affiliates or any of their sublicensees, and expire on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of (i)&nbsp;the expiration of the last to expire Valid Claim Covering such Product in such country, and (ii)&nbsp;the twelve
(12th) anniversary of the date of First Commercial Sale of such Product in such country (the &#147;<B>CG Product Royalty Term</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5.6</B>&#8195;<B>Other Indications</B>. For clarity, the applicable royalties in this <B>Section</B><B></B><B>&nbsp;7.5 (Royalty Payments
for Products by CG ) </B>will apply to each Product for the Field whether for the Initial Indication or any Other Indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5.7&#8195;Royalty <FONT STYLE="white-space:nowrap">Buy-Out.</FONT></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;<B>Change of Control</B>. In the event of a Change of Control of CG during the Term, CG shall have the right to pay Kissei a
single <FONT STYLE="white-space:nowrap">lump-sum</FONT> in order to terminate CG&#146;s obligation to pay Kissei royalties pursuant to <B>Section</B><B></B><B>&nbsp;7.5.1 (Products in CG Territory) </B>and convert all licenses in
<B>Section</B><B></B><B>&nbsp;4.2 (License Grants to CG) </B>into fully-paid licenses (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;<B>Exercise</B>. CG, itself or through a member of the Transacting Party Group, shall notify Kissei in writing if CG wishes
to exercise its <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option (&#147;Election Notice&#148;). If CG provides an Election Notice to Kissei, the amount payable by CG to Kissei in consideration for the
<FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option, which shall be the fair market value, shall be determined by a Valuation Firm in accordance with <B>Section</B><B></B><B>&nbsp;7.5.7(c) (Valuation Firm) (the
<FONT STYLE="white-space:nowrap">&#147;Buy-Out</FONT> Option Price&#148;)</B>. Following payment of the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option Price, which shall be within [***] from the date when the amount of the <FONT
STYLE="white-space:nowrap">Buy-Out</FONT> Option Price is so determined, CG&#146;s obligations under <B>Section</B><B></B><B>&nbsp;7.5 (Royalty Payments for Products by CG) </B>shall be terminated. CG may exercise the
<FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option right only once during the Term, but CG&#146;s <FONT STYLE="white-space:nowrap">non-exercise</FONT> of the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option for any particular Change of
Control does not waive the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option for any subsequent Change of Control. CG must exercise the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option within [***] after the Change of Control occurs or
the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option will be deemed waived solely with respect to that Change of Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;<B>Valuation Firm</B>. The <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option Price shall be finally determined by a
reputable, independent third-party valuation firm (&#147;<B>Valuation Firm</B>&#148;), at CG&#146;s expense. The Parties shall mutually agree upon a list of no more than [***] valuation firms, and CG shall have the sole right to choose the Valuation
Firm from such list; provided that if the Parties, using good faith efforts, cannot agree on a list within [***] of the Election Notice, CG shall choose the Valuation Firm. Prior to disclosing any Confidential Information to the Valuation Firm, CG,
alone or in a <FONT STYLE="white-space:nowrap">three-way</FONT> agreement with Kissei, at Kissei&#146;s reasonable option, shall enter into a confidentiality agreement consistent with <B>Article</B><B></B><B>&nbsp;10 (Confidentiality) </B>to
facilitate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure of information to the Valuation Firm. The Valuation Firm shall develop and deliver a report of evidencing its calculations of the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option
Price, in accordance with <B>Section</B><B></B><B>&nbsp;7.5.7(b)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;<B>No Obligation</B>. CG and the Transacting
Party Group shall have no obligation to exercise the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option, and any solicitation of information or pricing from a Valuation Firm shall not constitute the Election Notice. CG and the Transacting Party
Group shall only have the obligation to pay the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option Price to Kissei once CG or the Transacting Party Group provides the Election Notice to Kissei. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAYMENT
TERMS; REPORTS; AUDITS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B>&#8195;<B>Timing of Royalty Payment</B>. All royalty payments shall be made by each Party within
[***] of the end of each calendar quarter in which the sale was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B>&#8195;<B>Royalty Report</B>. For each calendar quarter
for which a Party has an obligation to make royalty payments, such payments shall be accompanied by a report that specifies for such calendar quarter the following information on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, in sufficient detail to allow such the other Party to verify the amount of royalties paid with respect to such calendar quarter (&#147;<B>Net
Sales Report</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;[***]; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;[***]; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B>&#8195;<B>Mode of Payment</B>. <B>If a Party is reporting Net Sales for more than one Product, the foregoing information shall be
reported on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis</B>. All payments hereunder shall be made in immediately available funds to such account as CG or Kissei, as applicable, shall
designate from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B>&#8195;<B>Currency of Payments</B>. All payments under this Agreement shall be made in US dollars.
The portion of Net Sales outside of the US shall be first determined in the currency in which they are earned and shall then be converted into an amount in US dollars as follows: (i)&nbsp;with respect to sales by or on behalf of a Party or its
Affiliates, using the selling-Party&#146;s customary and usual conversion procedures, to the extent consistent with the then-current Accounting Standard and consistently applied, and (ii)&nbsp;with respect to sales of a Product by or on behalf of a
given sublicensee, using the conversion procedures applicable to payments by such sublicensee to Kissei or CG, as applicable, for such sales, provided, that such procedures are reasonable and consistent with industry standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5</B>&#8195;<B>Blocked Currency</B>. If, at any time, legal restrictions prevent a Party from remitting part or all of royalty payments
when due with respect to any country where Products are sold, such Party shall continue to provide Net Sales Reports for such royalty payments, and such royalty payments shall continue to accrue in such country, but such Party shall not be obligated
to make such royalty payments until such time as payment may be made through reasonable, lawful means or methods that may be available, as the Parties mutually agree. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6</B>&#8195;<B>Late Payment</B>. Any payments or portions thereof due hereunder which
are not paid when due shall bear interest equal to the lesser of (a)&nbsp;the rate equal to the Effective Federal Funds Rate (EFFR) effective for the date that payment was due, as published by The Wall Street Journal on its website at www.wsj.com on
the date such payment was due, plus an additional [***], or (b)&nbsp;the maximum rate permitted by Applicable Law, calculated on the number of days such payment is delinquent. This <B>Section</B><B></B><B>&nbsp;8.6 (Late Payment) </B>shall in no way
limit any other remedies available to either Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.7</B>&#8195;<B>Taxes</B>. Each Party shall comply with Applicable Laws and
regulations regarding filing and reporting for tax purposes. Neither Party shall treat their relationship under this Agreement as a pass through entity for tax purposes. All payments made under this Agreement shall be made free and clear of any and
all taxes, duties, levies, fees or other charges, except for withholding taxes and VAT. Each Party, as the Party making royalty payments, shall be entitled to deduct from those royalty payments made under this Agreement the amount of any withholding
taxes required to be withheld, to the extent paid to the appropriate governmental authority on behalf of the other Party (and not refunded or reimbursed). Official receipts of payment of any withholding tax shall be secured and sent to the recipient
of royalty payments as evidence of such tax payment. The Parties will exercise Commercially Reasonable Efforts to ensure that any withholding taxes imposed are reduced as far as possible under the provisions of any applicable tax treaty. Each Party
shall provide reasonable assistance to the other Party in seeking any benefits available to it with respect to government tax withholdings by any relevant law, regulation or double tax treaty. Both Parties agree that under the applicable tax treaty
as of the Effective Date, no withholding taxes are due between the US and Japan on any amounts due hereunder, provided that the appropriate procedures are taken by the Parties. All payments made under this Agreement shall be exclusive of VAT (if
applicable) and such VAT shall be paid promptly by the Party making the payment on receipt of a valid VAT invoice. Notwithstanding the foregoing, if as a result of either Party assigning this Agreement or changing its domicile, additional taxes
become due that would not have otherwise been due hereunder with respect to payments hereunder, such Party shall be responsible for all such additional taxes and shall pay the other Party such amounts as are necessary to ensure that the other Party
receives the same amount as it would have received had no such assignment or change in domicile been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.8</B>&#8195;<B>Records;
Inspection</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.8.1</B>&#8195;<B>Records</B>. Each Party agrees to keep, and to cause its Affiliates and sublicensees to keep, for
[***] from the year of creation, complete and accurate records of all sales of Products for each reporting period in which royalty payments are due, showing sales of Products by such Person and applicable deductions in sufficient detail to enable
the report provided under <B>Section</B><B></B><B>&nbsp;8.2 (Royalty Report) </B>to be verified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.8.2</B>&#8195;<B>Audits</B>. Each
Party shall have the right to request that the other Party&#146;s report be verified by an independent, certified and internationally recognized public accounting firm selected by the auditing-Party and acceptable to the other Party (the
&#147;<B>CPA Firm</B>&#148;). Such right to request a verified report shall (i)&nbsp;be limited to the [***] during which the Party or its Affiliate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or sublicensee is required to maintain records with respect to the same, (ii)&nbsp;not be exercised more than [***], (iii) be exercised only up [***], and (iv)&nbsp;be exercised only for a full
calendar year(s), not portions thereof. Subject to <B>Section</B><B></B><B>&nbsp;8.8.3 (Confidentiality)</B>, a Party shall, upon timely request and at least [***] advance notice from the auditing-Party and at a mutually agreeable time during its
regular business hours, make its and its Affiliates&#146; and sublicensees&#146; records available for inspection by such CPA Firm at such place or places where such records are customarily kept, solely to verify the accuracy of the reports provided
under <B>Section</B><B></B><B>&nbsp;8.2 (Royalty Report) </B>and related payments due under this Agreement. The CPA Firm shall only state factual findings in the audit reports. The CPA Firm shall share all draft audit reports with the audited-Party
before the draft audit report is shared with the auditing-Party and before the final document is issued. The final audit report shall be shared with the audited-Party at the same time that it is shared with auditing-Party. Absent clear error, the
findings of any such inspection, including the final audit report, shall be binding on both Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.8.3</B>&#8195;<B>Confidentiality</B>. Prior to any audit under <B>Section</B><B></B><B>&nbsp;8.8.2 (Audits)</B>, the CPA Firm shall enter
into a written confidentiality agreement with the audited-Party that (i)&nbsp;limits the CPA Firm&#146;s use of the audited-Party&#146;s records to the verification purpose described in <B>Section</B><B></B><B>&nbsp;8.8.2 (Audits)</B>; (ii) limits
the information that the CPA Firm may disclose to the auditing-Party to the numerical summary of payments due and paid, whether the payments subject to such audit are correct or incorrect and the specific details concerning any discrepancies; and
(iii)&nbsp;prohibits the disclosure of any information contained in such records to any Third Party for any purpose. The Parties agree that all information subject to review under <B>Section</B><B></B><B>&nbsp;8.8.2 (Audits) </B>and/or provided by
the CPA Firm to the auditing-Party is the audited-Party&#146;s Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.8.4</B>&#8195;<B>Underpayment;
Overpayment</B>. After reviewing the CPA Firm&#146;s audit report, the audited-Party shall promptly pay any uncontested, understated amounts due to the auditing-Party, together with interest thereon, calculated as set forth in
<B>Section</B><B></B><B>&nbsp;8.6 (Late Payment)</B>. Any overpayment made by the audited-Party shall be promptly refunded or fully creditable against amounts payable in subsequent payment periods, at the audited-Party&#146;s election. Any audit
under <B>Section</B><B></B><B>&nbsp;8.8.2 (Audits) </B>shall be at the auditing-Party&#146;s expense; provided, however, the audited-Party shall reimburse reasonable audit fees and other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs actually incurred by the auditing Party for a given audit if the results of such audit reveal that the audited-Party underpaid the auditing-Party, as applicable, with respect to the
royalty payments, by [***] or more of the aggregate amount of such payments due for the audited calendar year(s) (for the avoidance of doubt, such audit calendar year shall consist of four (4)&nbsp;full fiscal quarters); provided, that such amount
exceeds [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.8.5</B>&#8195;<B>Duration</B>. If a Party does not request an audit of a Net Sales Report within the period during
which corresponding records must be maintained by the other Party under <B>Section</B><B></B><B>&nbsp;8.8.1 (Records)</B>, then the Party in receipt of royalty payments shall be conclusively deemed to have accepted such Net Sales Report and the
corresponding royalty payments as final and accurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.9</B>&#8195;<B>Acknowledgement</B>. The Parties acknowledge that the economic
terms and conditions set forth herein were negotiated and agreed to and represent a fair and equitable allocation of the value of the Product(s) for the Field in the Territory and the CG Territory. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parties further acknowledge that there is considerable value in the CG IP and CG&#146;s interest in Joint Collaboration IP (including any <FONT STYLE="white-space:nowrap">Know-How</FONT> in any
of the foregoing) that is consistent with the economic terms and conditions herein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY; OWNERSHIP </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B>&#8195;<B>CG</B>. As between the Parties, CG will own the entire right, title and interest in, to and under the CG IP (including, as
set forth in <B>Section</B><B></B><B>&nbsp;9.4.1 (Ownership)</B>) and CG Collaboration IP, subject to the licenses granted to Kissei herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B>&#8195;<B>Kissei</B>. As between the Parties, Kissei will own the entire right, title and interest in, to and under the Kissei IP
(including, as set forth in <B>Section</B><B></B><B>&nbsp;9.4.1 (Ownership)</B>) and Kissei Collaboration IP, subject to the licenses granted to CG herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B>&#8195;<B>Inventorship; CREATE Act</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.1</B>&#8195;Inventorship of inventions and discoveries (including <FONT STYLE="white-space:nowrap">Know-How)</FONT> first conceived or
made in the conduct of activities under the Development Program or otherwise under this Agreement will be determined in accordance with United States patent laws for determining inventorship, irrespective of whether such invention or discovery is
patentable or incorporated into a patent application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.2</B>&#8195;Notwithstanding anything to the contrary in this Agreement, each
Party will have the right to invoke the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. &#167;&nbsp;103(c)(2)-(c)(3) (as amended from time to time, the &#147;<B>CREATE Act</B>&#148;) when exercising its rights under this
Agreement. If a Party intends to invoke the CREATE Act, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with respect to filings or other activities in support thereof. The Parties
acknowledge and agree that this Agreement is a &#147;joint research agreement&#148; as defined in the CREATE Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4</B>&#8195;<B>Ownership; Collaboration IP; Rights of Joint Owners</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.4.1</B>&#8195;<B>Ownership</B>. Ownership of Collaboration IP will follow inventorship, where (a)&nbsp;CG will own the entire right,
title and interest in, to and under the CG Collaboration IP, subject to the licenses granted to Kissei herein; (b)&nbsp;Kissei will own the entire right, title and interest in, to and under the Kissei Collaboration IP, subject to the licenses
granted to CG herein; and (c)&nbsp;subject to <B>Section</B><B></B><B>&nbsp;9.5 (Rights of Joint Owners)</B>, the Parties will jointly own the entire right, title and interest in, to and under the Joint Collaboration IP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.4.2</B>&#8195;<B>Cooperation</B>. Each Party agrees to cooperate with the other Party, including executing documents and making its
employees, consultants and agents available, as necessary to accomplish the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.4.3</B>&#8195;Each employee, agent or
consultant working on behalf of a Party in the performance of activities under this Agreement is, or shall be prior to the performance of any such activities under this Agreement, contractually bound to (i)&nbsp;assign to such Party all of its, his
or her </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
right, title and interest in and to any intellectual property, Patents and/or <FONT STYLE="white-space:nowrap">Know-How</FONT> arising from activities performed by such employee, agent or
consultant under this Agreement, and (ii)&nbsp;comply with written confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations that are at least as protective of the other Party and the Confidential Information of the other Party
as those set forth in <B>Article</B><B></B><B>&nbsp;10 (Confidentiality)</B>. Each Party shall use commercially reasonable efforts to obtain from any other Third Party working on behalf of a Party in the performance of activities under this
Agreement (e.g., any subcontractor, sublicensee, collaborator or service provider) written obligations with respect to assignment of intellectual property rights, confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> substantially
similar to those set forth in the preceding sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5</B>&#8195;<B>Rights of Joint Owners</B>. Subject to the rights and licenses
granted pursuant to, and the obligations of each Party under, this Agreement, including the exclusivity obligations under <B>Section</B><B></B><B>&nbsp;4.3 (Exclusivity)</B>, each Party has the right to practice, license, sublicense, assign,
transfer and otherwise exploit such Party&#146;s interest in the Joint Collaboration IP for any and all purposes on a worldwide basis without restriction, and without a duty of accounting to the other Party, but with the consent the other Party in
case of license, sublicense, assignment, or transfer, provided that such consent shall not be unreasonable withheld or delayed. Each Party will grant and hereby does grant all permissions, consents and waivers with respect to, and all licenses
under, such Party&#146;s interest in the Joint Collaboration IP, throughout the world, necessary to provide the other Party with the foregoing rights, and will execute documents and make its employees, consultants and agents available, as may be
reasonably requested by the other Party and as necessary to accomplish the foregoing grant of rights set forth in this <B>Section</B><B></B><B>&nbsp;9.5 (Rights of Joint Owners)</B>. In the event of any conflict between the terms of this
<B>Section</B><B></B><B>&nbsp;9.5 (Rights of Joint Owners) </B>and the terms of <B>Article</B><B></B><B>&nbsp;10 (Confidentiality)</B>, the terms of this <B>Section</B><B></B><B>&nbsp;9.5 (Rights of Joint Owners) </B>shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6</B>&#8195;<B>Patent Filing, Prosecution, Maintenance and Strategy</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.6.1</B>&#8195;<B>Joint Patent Working Group</B>. The Prosecution and Maintenance of the Kissei Collaboration Patents, the CG
Collaboration Patents and the Joint Collaboration Patents shall be coordinated by the JPWG as set forth in <B>Article</B><B></B><B>&nbsp;3 (Governance)</B>. In no event shall the authority of the JPWG exceed that of the JDC or include CG Patents.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.6.2&#8195;CG Patents.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;To the extent permitted by CG agreements with Third Parties with respect to CG Patents, as between the Parties, CG shall at
its sole discretion (subject to its information sharing obligations under the JPWG), and at its sole expense, have the right (but not the obligation) to Prosecute and Maintain CG Patents inside and outside of the Territory. CG, through the JPWG,
will keep Kissei reasonably informed of the status of each CG Patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;CG will notify Kissei of any decision by CG or
its designee not to Prosecute and Maintain, or to cease the Prosecution and Maintenance of, or not to continue to pay the expenses of Prosecution and Maintenance of, any CG Patent. CG will provide such notice at least thirty (30)&nbsp;days prior to
any filing or payment due date, or any other due date that requires action, in connection with such CG Patent. In such event, CG shall discuss in good faith through the JPWG with Kissei, subject to CG agreements with Third Parties with respect to
such CG </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Patents, whether at upon CG express consent, which shall not be unreasonably withheld, and at Kissei&#146;s discretion and expense, Kissei can file or to continue to Prosecute and Maintain such
CG Patent. Should Kissei continue the Prosecution and Maintenance of any such CG Patent, such Patent shall cease to be a CG Patent and shall thereafter be a Kissei Collaboration Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.6.3&#8195;CG Collaboration Patents.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;As between the Parties, CG shall at its sole discretion (subject to its obligations under the JPWG), and at its sole
expense, have the right (but not the obligation) to Prosecute and Maintain CG Collaboration Patents inside and outside of the Territory. Kissei will fully cooperate with CG in connection with the Prosecution and Maintenance of the CG Collaboration
Patents, including by providing access to relevant persons and executing all documentation reasonably requested by CG. CG, through the JPWG, will keep Kissei reasonably informed of the status of each CG Collaboration Patent, and will provide Kissei
with copies of any substantive filings relating to the CG Collaboration Patents with any patent office at least [***] prior to the submission of such filing. CG will consult with Kissei, including through the JPWG, on its strategy for the
Prosecution and Maintenance of the CG Collaboration Patents, and will consider in good faith any timely comments received from or on behalf of Kissei on such filings prior to submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;CG will notify Kissei of any decision by CG or its designee not to Prosecute and Maintain, or to cease the Prosecution and
Maintenance of, or not to continue to pay the expenses of Prosecution and Maintenance of, any CG Collaboration Patent. CG will provide such notice at least [***] prior to any filing or payment due date, or any other due date that requires action, in
connection with such CG Collaboration Patent. In such event, unless otherwise recommended by the JPWG due to double patenting (including &#147;obviousness-type&#148; double patenting) or other like concerns that could adversely impact the CG
Collaboration Patents, CG shall permit Kissei, at its sole discretion and expense, to file or to continue to Prosecute and Maintain such CG Collaboration Patent. Should Kissei continue the Prosecution and Maintenance of any such CG Collaboration
Patent, such Patent shall cease to be a CG Collaboration Patent and shall thereafter be a Kissei Collaboration Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.6.4</B>&#8195;<B>Kissei Collaboration Patents</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;As between the Parties, Kissei shall, at its sole discretion (subject to its obligations under the JPWG), and sole expense,
have the right (but not the obligation) to Prosecute and Maintain Kissei Collaboration Patents. CG will fully cooperate with Kissei in connection with the Prosecution and Maintenance of the Kissei Collaboration Patents, including by providing access
to relevant persons and executing all documentation reasonably requested by Kissei. Kissei, through the JPWG, will keep CG reasonably informed of the status of each Kissei Collaboration Patent, and will provide CG with copies of any substantive
filings relating to the Kissei Collaboration Patents with any patent office at least [***] prior to the submission of such filing. Kissei, through the JPWG, will consult with CG, on its strategy for the Prosecution and Maintenance of the Kissei
Collaboration Patents, and will consider and incorporate in good faith any timely comments received from CG regarding such filings prior to submission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;Kissei will notify CG and the JPWG of any decision by Kissei or its
designee not to file applications for, or to cease the Prosecution and Maintenance of, or not to continue to pay the expenses of Prosecution and Maintenance of, any Kissei Collaboration Patent. Kissei will provide such notice at least [***] prior to
any filing or payment due date, or any other due date that requires action, in connection with such Kissei Collaboration Patent. In such event, unless otherwise recommended by the JPWG due to double patenting (including &#147;obviousness-type&#148;
double patenting) or other like concerns that could adversely impact the Kissei Collaboration Patents, Kissei shall permit CG, at its sole discretion and expense, to file or to conduct or continue the Prosecution and Maintenance of such Kissei
Collaboration Patent. Should CG continue the Prosecution and Maintenance of any such Kissei Collaboration Patent, such Patent shall cease to be a Kissei Collaboration Patent and shall thereafter be a CG Collaboration Patent and Kissei shall
nevertheless retain the licenses under such Kissei Collaboration Patent granted to Kissei under this Agreement, including under <B>Article</B><B></B><B>&nbsp;4 (Licenses and Rights) </B>of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.6.5</B>&#8195;<B>Cooperation</B>. Each Party hereby agrees to: (i)&nbsp;use reasonable efforts to make its employees, agents and
consultants reasonably available to the JPWG and to the other Party (or to the other Party&#146;s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable such other Party to undertake any Prosecution and
Maintenance described herein; and (ii)&nbsp;reasonably cooperate in any such Prosecution and Maintenance by the other Party at the requesting Party&#146;s reasonable request and cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7</B>&#8195;<B>Enforcement and Defense</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.7.1</B>&#8195;<B>Notices</B>. Each Party will promptly (and in any event within [***] after becoming aware thereof) notify the other
Party and the JPWG of any infringement or misappropriation by a Third Party of any Collaboration IP or the CG IP in the Territory of which it becomes aware, including the filing of a Biosimilar Application, the filing of a &#147;patent
certification&#148; filed in the United States under 21 U.S.C. &#167;355(b)(2) or 21 U.S.C. &#167;355(j)(2) or similar provisions in other jurisdictions in and outside the Territory and of any request for declaratory judgment, opposition, nullity
action, interference, <FONT STYLE="white-space:nowrap">ex-partes</FONT> and inter-partes reexaminations, <FONT STYLE="white-space:nowrap">ex-partes</FONT> and inter-partes review, post-grant review, derivation proceeding, or similar action alleging
the invalidity, unenforceability or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any Collaboration Patent or CG Patent (collectively &#147;<B>Third Party Infringement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.7.2</B>&#8195;<B>Kissei Enforcement Rights</B>. Kissei will have the sole right (but not the obligation) to bring and control any legal
action (including deciding on any litigation strategy) in connection with a Third Party Infringement of a Kissei Collaboration Patent, Joint Collaboration Patent, CG Patent, and CG Collaboration Patent relating to Products or Companion Diagnostics
in the Field in the Territory (&#147;<B>Competitive Infringement</B>&#148;), at its own expense as it reasonably determines appropriate (including selecting counsel of its choice and deciding on any litigation strategy), provided, that Kissei will
consult with CG prior to initiating any such action and consider in good faith any input received from CG. CG shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. At Kissei&#146;s request and
cost, CG shall provide assistance in connection therewith, including by executing reasonably appropriate documents, providing reasonable access to CG&#146;s premises and employees, cooperating reasonably in discovery and joining as a party to the
action if required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.7.3</B>&#8195;<B>CG Enforcement Rights</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;As between the Parties, CG or its designee will have the sole right (but not the obligation) to bring and control any legal
action (including deciding on any litigation strategy) in connection with a Third Party Infringement of a Kissei Collaboration Patent, Joint Collaboration Patent, CG Patent, and CG Collaboration Patent in the Territory other than a Competitive
Infringement and with a Third Party Infringement of a Kissei Collaboration Patent, Joint Collaboration Patent, CG Patent, and CG Collaboration Patent outside the Territory, at its own expense as it reasonably determines appropriate (including
selecting counsel of its choice and deciding on any litigation strategy), and Kissei shall have the right, at its own expense, to be represented in any such action in the Territory by counsel of its own choice. At the request and cost of CG, Kissei
shall provide assistance in connection therewith, including by executing reasonably appropriate documents, providing reasonable access to Kissei&#146;s premises and employees, cooperating reasonably in discovery and joining as a party to the action
if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;Without limiting <B>Section</B><B></B><B>&nbsp;9.7.3(a) (CG Enforcement Rights) </B>and at the written
request of Kissei, CG shall consider in good faith, subject to any agreements between CG and a Third Party relating to the Products or Companion Diagnostics, the possibility of Kissei bringing and controlling any legal action (including deciding on
any litigation strategy) in connection with a Third Party Infringement of a CG Patent relating to Products or Companion Diagnostics. If CG so agrees, then Kissei may bring and control such legal action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.7.4</B>&#8195;<B>Biosimilar Application</B>. Notwithstanding <B>Sections</B><B></B><B>&nbsp;9.7.2 (Kissei Enforcement Rights) </B>and
<B>9.7.3 (CG Enforcement Rights)</B>, if either Party or its Affiliates receives a copy of a Biosimilar Application naming a Collaboration Compound, Product or Companion Diagnostic as a reference product or otherwise becomes aware that such a
Biosimilar Application has been filed (such as in an instance described in Section&nbsp;351(1)(9)(c) of the PHSA or an equivalent rule or law in the Territory), such Party will promptly (and in any event within ten (10)&nbsp;Business Days after
receipt thereof) notify the other Party and the JPWG. If either Party receives any equivalent or similar certification or notice in the United States, Japan, or any other jurisdiction, such Party will promptly (and in any event within [***] after
receipt thereof) notify the other Party and the JPWG, and provide the other Party with copies of such communication. Regardless of the Party, or Affiliate or sublicensee of such Party, as the case may be, that is the &#147;reference product
sponsor&#148; for purposes of such Biosimilar Application, with respect to a Biosimilar Application in the Territory: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;Kissei will have the right, after consulting with CG, (A)&nbsp;to identify Patents for which the enforcement rights in
<B>Section</B><B></B><B>&nbsp;9.7.2 (Kissei Enforcement Rights) </B>are applicable, or (b)&nbsp;respond to relevant communications under any equivalent or similar listing to those described in the preceding <B>Section</B><B></B><B>&nbsp;9.7.4
(Biosimilar Application) </B>in the Territory. If required pursuant to Applicable Law, upon Kissei&#146;s request, CG will assist in the preparation of such list and make such response after consulting with Kissei. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;CG shall: (a)&nbsp;within [***] after Kissei&#146;s written request, provide Kissei with all information in its possession
and Control, including a list of Patents Controlled by CG for which the enforcement rights in <B>Section</B><B></B><B>&nbsp;9.7.2 (Kissei Enforcement Rights) </B>are applicable, that is necessary or reasonably useful to enable Kissei to make any
lists or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
communications with respect to such Patents that are described in the foregoing <B>Section</B><B></B><B>&nbsp;9.7.4 (Biosimilar Application) </B>or <B>Section</B><B></B><B>&nbsp;9.7.4(d)
(Biosimilar Application)</B>, and (b)&nbsp;cooperate with Kissei&#146;s reasonable requests in connection therewith to the extent not prohibited by law. Kissei will consult with CG prior to identifying any Patents Controlled by CG as contemplated by
this <B>Section</B><B></B><B>&nbsp;9.7.4 (Biosimilar Application). </B>Kissei will consider in good faith advice and suggestions with respect thereto received from CG, and will notify CG of any such lists or communications promptly after they are
made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;For the avoidance of doubt, the Parties recognize that procedures other than those set forth above in this
<B>Section</B><B></B><B>&nbsp;9.7.4 (Biosimilar Application) </B>may be applicable to Biosimilar Applications that are not governed by the PHSA or equivalent rule or law in Japan. As a result, if the Parties, acting in good faith, mutually determine
that certain provisions of law in the United States or in any other country or jurisdiction are applicable to actions taken by the Parties with respect to Biosimilar Applications under this <B>Section</B><B></B><B>&nbsp;9.7.4 (Biosimilar
Application) </B>in such country or jurisdiction, the Parties will comply with any such law in such country or jurisdiction (and any relevant and reasonable procedures established by the applicable governing body in such jurisdiction) in exercising
their respective rights and obligations with respect to Biosimilar Applications under this <B>Section</B><B></B><B>&nbsp;9.7.4 (Biosimilar Application)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.7.5</B>&#8195;<B>Defense</B>. As between the Parties, the Party controlling the Prosecution and Maintenance of any Patent under
<B>Section</B><B></B><B>&nbsp;9.6 (Patent Filing, Prosecution, Maintenance and Strategy) </B>will have the first right (but not the obligation), at its sole discretion, to defend against a declaratory judgment action or other action challenging any
such Patent, including, e.g., opposition or inter-partes review proceedings, other than with respect to (i)&nbsp;any counter-claims in any enforcement action brought by the other Party pursuant to <B>Section</B><B></B><B>&nbsp;9.7.2 (Kissei
Enforcement Rights)</B>, <B>Section</B><B></B><B>&nbsp;9.7.3 (CG Enforcement Rights) </B>or <B>Section</B><B></B><B>&nbsp;9.7.4 (Biosimilar Application) </B>or (ii)&nbsp;any action by a Third Party in response to such an enforcement action brought
by the other Party, which in both cases ((i) and (ii)) will be controlled by such other Party. If the Party controlling such Prosecution and Maintenance of such Patent under <B>Section</B><B></B><B>&nbsp;9.6 (Patent Filing, Prosecution, Maintenance
and Strategy) </B>does not defend such Patent under this <B>Section</B><B></B><B>&nbsp;9.7.5 (Defense) </B>within [***] (or such shorter period of time as is required to comply with other Applicable Law in the Territory to not waive any statutory
rights), or elects not to continue any such defense (in which case it will promptly provide notice thereof to the other Party), then the other Party will have the right (but not the obligation), at its sole discretion, to defend any such Patent in
the Territory, after consultation and good faith consideration of any input received from the Party controlling such Prosecution and Maintenance of such Patents under <B>Section</B><B></B><B>&nbsp;9.6 (Patent Filing, Prosecution, Maintenance and
Strategy)</B>; provided that, (a)&nbsp;CG shall have no right to defend any Kissei Patent and (b)&nbsp;except as set forth in the first sentence of this <B>Section</B><B></B><B>&nbsp;9.7.5 (Defense)</B>, Kissei shall have no right to defend any CG
Patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.7.6</B>&#8195;<B>Withdrawal, Cooperation and Participation; Recoveries. </B>With respect to any pending action initiated
pursuant to <B>Section</B><B></B><B>&nbsp;9.7 (Enforcement and Defense)</B>, and subject to the terms of this <B>Section</B><B></B><B>&nbsp;9.7.6 (Withdrawal, Cooperation and Participation; Recoveries)</B>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;The <FONT STYLE="white-space:nowrap">non-controlling</FONT> Party will cooperate with the Party controlling any such action
(as may be reasonably requested by the controlling Party), including, at the controlling Party&#146;s sole cost and expense, (a)&nbsp;by providing reasonable access to relevant documents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other evidence, (b)&nbsp;using reasonable efforts to make its and its Affiliates and licensees and sublicensees and their respective employees, subcontractors, consultants and agents
available at reasonable business hours and for reasonable periods of time, but only to the extent relevant to such action, and (c)&nbsp;if reasonably necessary, by being joined as a party. The Party controlling any such action will keep the other
Party reasonably updated with respect to any such action, including providing copies of all materials and documents received or filed in connection with any such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;Each Party will have the right to consult with the other Party regarding any such action controlled by such other Party, in
each case at such first Party&#146;s sole cost and expense. If a Party elects to so be involved, the Party shall have the right to be represented by its own counsel at its own expense and the controlling Party will provide the other Party and its
counsel with an opportunity to consult with the controlling Party and its counsel regarding the prosecution of such action (including reviewing the contents of any correspondence or other documents related thereto), and the controlling Party will
take into account reasonable and timely requests of the other Party regarding such enforcement or defense. Except as expressly set forth herein, nothing in this <B>Section</B><B></B><B>&nbsp;9.7.6 (Withdrawal, Cooperation and Participation;
Recoveries) </B>will limit the controlling Party&#146;s ability to conduct any such action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;Any recovery obtained by a
Party in connection with or as a result of any action with respect to any Competitive Infringement, whether by settlement or otherwise, shall be shared in order as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;the controlling Party shall recoup all of its costs and expenses incurred in connection with such action; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;the other Party shall then, to the extent possible, recover its costs and expenses incurred in connection with such action; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;any remaining recovery from such action shall be shared by the Parties, [***] in favor of the controlling Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.8</B>&#8195;<B>Third Party Infringement Claims</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.8.1</B>&#8195;<B>Notice</B>. In the event that a Third Party shall make any claim, give notice, or bring any suit or other inter parties
proceeding against Kissei or CG, or any of their respective Affiliates or licensees or customers, for infringement or misappropriation of any intellectual property rights with respect to the research, development, making, using, selling, offering
for sale, import or export of any Collaboration Compounds or Products (&#147;<B>Third Party Infringement Claim</B>&#148;), in each case, the Party receiving notice of a Third Party Infringement Claim shall promptly notify the other Party within
[***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.8.2</B>&#8195;<B>Defense in the Territory</B>. The Parties shall consult as to potential strategies to defend against any
Third Party Infringement Claim in the Territory, including by initiating any opposition proceeding against the relevant Third Party&#146;s Patent, consistent with the overall goals of this Agreement, including by being joined as a Party. If the
Parties fail to agree on such strategies in the Territory, or if a Party is a named defendant outside of the Territory, and subject to the respective indemnity obligations of the Parties set forth in <B>Article</B><B></B><B>&nbsp;13
(Indemnification)</B>, each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party shall have the right to defend itself against a suit that names it as a defendant (the &#147;<B>Defending Party</B>&#148;) in its Territory. The Defending Party shall keep the other Party
reasonably informed with respect to the defense of such claim and shall consider and take into account the other Party&#146;s reasonable interests and comments regarding the defense of such claim. The other Party shall reasonably assist the
Defending Party and cooperate in any such litigation at the Defending Party&#146;s request and expense. In addition, the other Party shall have the right to be represented by its own counsel at its own expense and the Defending Party will provide
the other Party and its counsel with an opportunity to consult with the Defending Party and its counsel regarding the defense of such claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.8.3</B>&#8195;<B>Costs and Expenses</B>. The Defending Party shall bear all costs and expenses, including but not limited to litigation
expenses to defend against any Third Party Infringement Claim; provided, however, that if the <FONT STYLE="white-space:nowrap">non-Defending</FONT> Party is obligated to Indemnify the Defending Party in respect of such claims in accordance with
<B>Article</B><B></B><B>&nbsp;13 (Indemnification)</B>, then the <FONT STYLE="white-space:nowrap">non-Defending</FONT> Party shall reimburse the Defending Party&#146;s actual, documented cost and expenses. Any damages or settlement amounts paid by
Kissei under this <B>Section</B><B></B><B>&nbsp;9.8 (Third Party Infringement Claims) </B>with respect to a Product, including any amounts paid to a Third Party to the extent attributable to a right or license under any intellectual property of such
Third Party in settlement of such Third Party Infringement Claim, may be treated by Kissei as royalties paid to a Third Party under <B>Section</B><B></B><B>&nbsp;7.4.3(a)(iii) (Kissei) </B>and subject to the credit therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.8.4</B>&#8195;<B>Settlement</B>. With respect to any Competitive Infringement, Third Party Infringement Claim or defensive action
identified in <B>Section</B><B></B><B>&nbsp;9.7 (Enforcement and Defense) </B>or this <B>Section</B><B></B><B>&nbsp;9.8 (Third Party Infringement Claims)</B>, the Party controlling such action or the Defending Party, as applicable, will have the
right to settle or otherwise dispose of such action on such terms as such Party will determine in its sole discretion, including by granting a license or sublicense to a Third Party under the rights granted to such Party in
<B>Article</B><B></B><B>&nbsp;4 (Licenses and Rights)</B>; provided, that any such settlement that results in a sublicense will be subject to the terms and conditions of this Agreement pertaining to sublicenses and, if any such settlement would
adversely affect the other Party&#146;s rights under this Agreement or impose a financial obligation upon the other Party or affect the validity or enforceability, of the other Party&#146;s Patents, then any settlement, consent judgment or other
voluntary final disposition of such action shall not be entered into without the consent of the other Party (such consent not to be unreasonably withheld, delayed or conditioned). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.9</B>&#8195;<B>Patent Extensions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.9.1</B>&#8195;If requested by Kissei, CG shall cooperate in obtaining patent term restoration (including equivalents to the Drug Price
Competition and Patent Term Restoration Act under Applicable Law in the Territory), supplemental protection certificates or their equivalents, and patent term extensions with respect to the Kissei Collaboration Patents and Joint Collaboration
Patents in any country or region in the Territory, where applicable. CG shall provide all reasonable assistance requested by Kissei, including permitting Kissei to proceed with applications for such in the name of CG, if deemed appropriate by
Kissei, and executing documents and providing any relevant information (including, for example, all correspondence with any Regulatory Authority regarding the approved Product, Collaboration Compound or Companion Diagnostic) to Kissei. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.9.2</B>&#8195;Kissei shall in its sole discretion determine which, if any, Kissei
Collaboration Patents or Joint Collaboration Patents it will apply to extend; provided that Kissei will consider in good faith any timely comments received from or on behalf of CG with respect to such extensions prior to making any application
therefor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.9.3</B>&#8195;CG shall make decisions regarding whether to apply for patent term extensions, including supplementary
protection certificates and any other similar extensions that are now or become available in the future, wherever applicable, for the CG Patents and CG Collaboration Patents in any country worldwide. However, at the written request of Kissei, CG
shall consider in good faith the possibility of Kissei determining which, if any, CG Patent or CG Collaboration Patents it will apply to extend in the Territory. If CG so agrees, then Kissei may make such determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.10&#8195;Patent Listings. </B>With respect to any filings made to Regulatory Authorities with respect to Collaboration Compounds,
Products or Companion Diagnostics, including, as required or allowed under Applicable Laws in the Territory equivalent to the FDA&#146;s Orange or Purple Book, if applicable, the Parties will jointly have the right to make any such decision whether
to list Patents within the CG IP or the Collaboration IP. The Parties will reasonably cooperate in the implementation of any decision made under this <B>Section&nbsp;9.10 (Patent Listings)</B>. Any dispute under this <B>Section&nbsp;9.10 (Patent
Listings)</B> will be resolved pursuant to the dispute resolution provisions of <B>Article&nbsp;15 (Dispute Resolution)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.11</B>&#8195;<B>Common Interest</B>. All information exchanged between the Parties regarding the Prosecution and Maintenance, and
enforcement and defense, of Patents under this <B>Article</B><B></B><B>&nbsp;9 (Intellectual Property; Ownership) </B>will be deemed Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard
to such Prosecution and Maintenance, and enforcement and defense, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature. The
Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Patents under this <B>Article</B><B></B><B>&nbsp;9 (Intellectual Property; Ownership)</B>, including
privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary contained herein, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to
the other Party under this <B>Article</B><B></B><B>&nbsp;9 (Intellectual Property; Ownership) </B>is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such
information and the Parties shall in good faith cooperate to agree upon a procedure (including entering into a specific common interest agreement, disclosing such information on a &#147;for counsel eyes only&#148; basis or similar procedure) under
which such information may be disclosed without waiving or breaching such privilege or immunity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.12</B>&#8195;<B>Trademarks</B>.
Kissei shall have the right to brand the Products and Companion Diagnostics in the Territory using Kissei related trademarks and any other trademarks and trade names it determines appropriate for the Products or Companion Diagnostics, which may vary
by country or within a country (other than the CG Trademark, the &#147;<B>Specified Marks</B>&#148;). Kissei shall own all rights in, to and under the Specified Marks, including all goodwill associated therewith, and may register and maintain the
Specified Marks in the countries and regions it determines reasonably necessary, and no rights are granted to CG or its Affiliates, under this Agreement or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise, to use the Specified Marks. CG shall have the right to brand the Products and Companion Diagnostics outside of the Territory using CG related trademarks, including the CG Trademark,
and any other trademarks and trade names it determines appropriate for the Products or Companion Diagnostics, which may vary by country or within a country. Notwithstanding anything to the contrary in this Agreement, but subject to the licenses
granted to Kissei under <B>Sections</B><B></B><B>&nbsp;4.1.1 (Products) </B>and <B>4.1.2 (Companion Diagnostics)</B>, the Parties agree and acknowledge that, as between the Parties, CG owns and will own the entire right, title, and interest in, to
and under the CG Trademarks as well as CG&#146;s corporate name and any trademarks used by CG, including all registrations and applications for registrations of the foregoing and all goodwill associated therewith; provided, that, Kissei will own
goodwill associated with the Specified Marks and with Kissei&#146;s business, generally or as it relates to the Collaboration Compounds, Products or Companion Diagnostics in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.13</B>&#8195;<B>Third Party Technologies</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.13.1</B>&#8195;<B>Generally</B>. With respect to the Prosecution and Maintenance, and enforcement, of CG Patents licensed by CG from a
Third Party, to the extent CG has the right to do so, CG shall cooperate with Kissei to Prosecute and Maintain, and to enforce, such CG Patents in the Territory in the same manner as set forth in this <B>Article</B><B></B><B>&nbsp;9 (Intellectual
Property; Ownership)</B>. As between CG and Kissei, any recoveries from enforcement of such CG Patents licensed from a Third Party (including any amounts that CG receives from the Third Party licensor as a result of such enforcement) shall be shared
in accordance with <B>Section</B><B></B><B>&nbsp;9.7.6 (Withdrawal, Cooperation and Participation; Recoveries)</B>, after deducting from such recoveries any amounts owed to the Third Party licensor for such enforcement; provided, that any actions
with respect to Competitive Infringement initiated by the Third Party licensor shall be deemed initiated by CG for purposes of <B>Section</B><B></B><B>&nbsp;9.7.6 (Withdrawal, Cooperation and Participation; Recoveries)</B>, and the costs and
expenses incurred by CG in such action shall include the costs and expenses reimbursed or required to be reimbursed by CG to the Third Party licensor in such action. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B>&#8195;<B><FONT STYLE="white-space:nowrap">Non-use</FONT> and <FONT STYLE="white-space:nowrap">Non-disclosure</FONT> of
Confidential Information</B>. During the Term, and for a period of [***] thereafter, each Party shall (i)&nbsp;except to the extent expressly permitted by this Agreement or otherwise agreed to in writing, keep confidential and not disclose to any
Third Party any Confidential Information of the other Party; (ii)&nbsp;except to the extent expressly permitted by this Agreement or reasonably necessary for the performance of its obligations or the exercise of its rights under this Agreement or
otherwise agreed to in writing, not use for any purpose any Confidential Information of the other Party; and (iii)&nbsp;take all reasonable precautions to protect the Confidential Information of the other Party, including all precautions a Party
employs with respect to its own confidential information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2</B>&#8195;<B>Exclusions Regarding Confidential Information</B>.
Notwithstanding anything set forth in this <B>Article</B><B></B><B>&nbsp;10 (Confidentiality)</B> to the contrary, the obligations of <B>Section</B><B></B><B>&nbsp;10.1 <FONT STYLE="white-space:nowrap">(Non-use</FONT> and <FONT
STYLE="white-space:nowrap">Non-disclosure</FONT> of Confidential Information)</B> above shall not apply to the extent that the Party seeking the benefit of the exclusion can demonstrate that the Confidential Information of the other Party: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;was already known to the receiving Party, other than under an obligation
of confidentiality, at the time of receipt by the receiving Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;was generally available to the public or otherwise
part of the public domain at the time of its receipt by the receiving Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;became generally available to the public
or otherwise part of the public domain after its receipt by the receiving Party other than through any act or omission of the receiving Party in breach of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;was received by the receiving Party without an obligation of confidentiality from a Third Party having the right to disclose
such information without restriction; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;was independently developed by or for the receiving Party without use of or
reference to the Confidential Information of the other Party; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&#8195;was released from the restrictions set forth in this
Agreement by express prior written consent of the Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B>&#8195;<B>Authorized Uses and Disclosures of Confidential
Information</B>. Notwithstanding the provisions of <B>Sections</B><B></B><B>&nbsp;10.1 <FONT STYLE="white-space:nowrap">(Non-use</FONT> and <FONT STYLE="white-space:nowrap">Non-disclosure</FONT> of Confidential Information)</B> and <B>10.2
(Exclusions Regarding Confidential Information)</B> and subject to this <B>Section</B><B></B><B>&nbsp;10.3 (Authorized Uses and Disclosures of Confidential Information)</B>, each Party may use or disclose the Confidential Information of the other
Party as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;to the extent required by any Applicable Law, rule or governmental regulation, including as may be
required in connection with any filings made with, or by the disclosure requirements of a major stock exchange; provided, that the Party seeking to disclose the Confidential Information of the other Party (i)&nbsp;inform the other Party prior to
making any such disclosures and cooperate with the other Party, upon request, in seeking a protective order or other appropriate remedy (including redaction) and (ii)&nbsp;whenever possible, request confidential treatment of such information;
provided that any Confidential Information that is disclosed as permitted by this <B>Section</B><B></B><B>&nbsp;10.3(a) (Authorized Uses and Disclosures of Confidential Information) </B>shall remain otherwise subject to the confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> provisions of this <B>Article</B><B></B><B>&nbsp;10 (Confidentiality)</B>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;to
the extent such use or disclosure is reasonably required in the Prosecution and Maintenance of a Patent in accordance with this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;as reasonably necessary to obtain or maintain any regulatory approval, including to conduct preclinical studies and clinical
trials and for pricing approvals, for any Products, provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential Information outside such regulatory agency and to otherwise maintain the confidentiality
of the Confidential Information; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;to the extent reasonably necessary to file or pursue any legal action that
it deems necessary to protect its interest under, or to enforce compliance with the terms and conditions of, this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;to the extent reasonably necessary, to permitted sublicensees, licensees, collaborators, vendors, consultants, agents,
attorneys, contractors and clinicians under written agreements of confidentiality at least as restrictive on those set forth in this Agreement, who have a need to know such information for such Party to perform its obligations or exercise its rights
under this Agreement. Further, the receiving Party may disclose Confidential Information of the disclosing Party to existing or potential acquirers, merger partners, collaborators, licensees, sublicensees and sources of financing or to professional
advisors (e.g., attorneys, accountants and prospective investment bankers) involved in such activities, for the limited purpose of evaluating such transaction, collaboration, or license or sublicense and under appropriate conditions of
confidentiality, only to the extent necessary and with the agreement by those permitted individuals to maintain such Confidential Information in strict confidence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B>&#8195;<B>Terms of this Agreement</B>. The Parties agree that this Agreement and the terms hereof will be considered Confidential
Information of both Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5</B>&#8195;<B>Prior Agreements</B>. As of the Effective Date, as between the Parties, (a)&nbsp;all
&#147;<B>Confidential Information</B>&#148; or &#147;<B>Information</B>&#148; (as defined in the Mutual Confidentiality Agreement effective as of November&nbsp;15th, 2018 and as amended as of November&nbsp;6th, 2019 by and between CG and Kissei (the
&#147;<B>CDA</B>&#148;) ) and all other information exchanged between the Parties thereunder relating to the subject matter of this Agreement shall be deemed Confidential Information hereunder and shall be subject to the provisions of this
<B>Article</B><B></B><B>&nbsp;10 (Confidentiality)</B>, and (b)&nbsp;without limiting the provisions of <B>Section</B><B></B><B>&nbsp;16.5 (Integration)</B>, the confidentiality provisions of the CDA shall be superseded by the provisions of this
<B>Article</B><B></B><B>&nbsp;10 (Confidentiality)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6</B>&#8195;<B>No License</B>. As between the Parties, Confidential
Information disclosed hereunder shall remain the property of the disclosing Party. Disclosure of Confidential Information to the other Party shall not constitute any grant, option or license to the other Party, beyond those licenses expressly
granted under <B>Article</B><B></B><B>&nbsp;4 (Licenses and Rights)</B>, under any patent, trade secret or other rights held by the disclosing Party. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PUBLICITY;
PUBLICATIONS; USE OF NAME </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B>&#8195;<B>Initial Press Release</B>. The Parties shall have the right to make a public
announcement of the execution of this Agreement in the form of the press release, to be mutually agreed upon by the Parties, on or shortly following the Effective Date, and thereafter each Party shall be entitled to make or publish any public
statement consistent with the contents thereof upon [***] prior notice to the other Party, but only to the extent such subsequent publication or public statement only discloses information that has previously been approved for disclosure by the
other Party. For the avoidance of doubt, each Party may make subsequent public disclosure of the all or a portion of the contents of the initial press release without the further approval of the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B>&#8195;<B>Releases</B>. Except as provided in <B>Section</B><B></B><B>&nbsp;11.1
(Initial Press Release)</B>, the text of any other press releases or other public statements or announcement concerning this Agreement, the subject matter hereof, or the research, development or commercial results of products hereunder (a
&#147;<B>Release</B>&#148;) shall be addressed pursuant to this <B>Section</B><B></B><B>&nbsp;11.2 (Releases)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.2.1</B>&#8195;<B>Releases Reporting the Activities of the Development Program</B>. Subject to <B>Section</B><B></B><B>&nbsp;11.2.4
(Releases Requires by Law or Regulation)</B>, neither Party may issue a Release reporting on the activities under the Development Program without the prior written consent of the other, which consent shall not be unreasonably withheld, conditioned
or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.2.2</B>&#8195;<B>Releases Reporting on the Development or Commercialization of Collaboration Compounds, Products and
Companion Diagnostics. </B>Subject to <B>Section</B><B></B><B>&nbsp;11.2.4 (Releases Requires by Law or Regulation)</B>, in connection with the development (outside the Development Program) or commercialization of Collaboration Compound, Products
and Companion Diagnostics: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;CG may not issue a Release without Kissei&#146;s prior written consent; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;Kissei may not issue a Release without CG&#146;s prior written consent if it includes reference to CG by name, which, in each
case, consent shall not be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.2.3</B>&#8195;<B>Approved Releases</B>. If a Release
requires consent pursuant to this <B>Section</B><B></B><B>&nbsp;11.2 (Releases)</B>, (a) the Party reviewing such Release shall notify the Party seeking to issue such Release of any such consent (together with any associated comments) or denial
(together the rationale therefor) within [***] of receipt of a draft of the proposed Release and (b)&nbsp;once consent has been given both Parties may make subsequent public disclosure of the contents of such statement without the further approval
of the Party whose consent was required; provided, such content is not presented with any new data or information or conclusions and/or in a form or manner that materially alters the understanding of the subject matter therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.2.4</B>&#8195;<B>Releases Required by Law or Regulation</B>. Each Party may issue any Release it is required to issue by Applicable Law
or regulation or rules of any stock exchange on which it or its Affiliate&#146;s equity securities is traded (such a Release, a &#147;<B>Required Release</B>&#148;) in accordance with the following procedure: the Party proposed to issue a Required
Release (the &#147;<B>Requesting Party</B>&#148;) shall provide the other Party (the &#147;<B>Reviewing Party</B>&#148;) with a draft of the Required Release at least [***] in advance of the issuance thereof, to the extent practicable under the
circumstances. The Reviewing Party may notify the Requesting Party of any reasonable objections or suggestions that such Party may have regarding the content in the draft Required Release provided for review under this
<B>Section</B><B></B><B>&nbsp;11.2.4 (Releases Requires by Law or Regulation)</B>, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided within [***]. The principles to be observed with respect to
disclosures of Required Release shall include accuracy, compliance with Applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of a Regulatory Authority, reasonable sensitivity to commercial
information of value to competitors, the need to keep investors informed regarding the Requesting Party&#146;s business. The Requesting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party may disclose the Confidential Information of the Reviewing Party solely as permitted under <B>Article</B><B></B><B>&nbsp;10 (Confidentiality)</B>, including
<B>Section</B><B></B><B>&nbsp;10.3(a) (Authorized Uses and Disclosures of Confidential Information)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.2.5</B>&#8195;<B>Publications. </B>Notwithstanding <B>Sections</B><B></B><B>&nbsp;11.2.1 (Releases Reporting the Activities of the
Development Program)</B> to <B>11.2.4 (Releases Require by Law or Regulation)</B>, both Parties recognize that the publication or disclosure of papers, presentations, abstracts or any other written or oral presentations regarding results of and
other information regarding the Products or Products obtained by or on behalf of the Parties in the performance of their obligations under this Agreement for the Territory including the P3 Trial may be beneficial to both Parties, provided, that such
publications or presentations are subject to reasonable controls to protect Confidential Information, the patentability of inventions and other commercial considerations. Accordingly, the following shall apply with respect to any such papers and
presentations proposed for disclosure by either Party (the &#147;<B>Disclosing Party</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The other
<FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party shall have the right to review and approve any such proposed paper or presentation. The Disclosing Party shall submit to the <FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party
the proposed publication or presentation (including posters, slides, abstracts, manuscripts, marketing materials and written descriptions of oral presentations) at least [***] prior to the date of submission for publication or the date of
presentation, whichever is earlier, of any of such submitted materials. The <FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party shall review such submitted materials and respond to the Disclosing Party as soon as reasonably possible, but in
any case within [***] ([***] for abstracts) of receipt thereof. At the option of the <FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party, the Disclosing Party shall (a)&nbsp;delete from such proposed publication or presentation any
Confidential Information of the <FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party, and/or (b)&nbsp;delay the date of such submission for publication or the date of such presentation for a period of time sufficiently long (but in no event
longer than an additional [***]) to permit the <FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party to prepare and file a patent application for any patentable subject matter in accordance with <B>Section</B><B></B><B>&nbsp;9.6 (Patent
Filing, Prosecutions, Maintenance and Strategy)</B>, and/or (c)&nbsp;in the case of proposed publication or presentation under clause (ii)&nbsp;above, delete from such proposed publication or presentation any information described in such clause
(ii)&nbsp;the disclosure of which information could have an adverse effect on the further research, development, manufacture or commercialization of the relevant Collaboration Compound, Product or Companion Diagnostic as reasonably determined by <FONT
STYLE="white-space:nowrap">Non-Disclosing</FONT> Party. Once a publication has been approved by the <FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party, the Disclosing Party may make subsequent public disclosure of the contents of such
publication without the further approval of the <FONT STYLE="white-space:nowrap">Non-Disclosing</FONT> Party; provided, such content is not presented with any new data or information or conclusions and/or in a form or manner that materially alters
the understanding of the subject matter therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, CG will submit to Kissei the proposed publications or presentations (including posters,
slides, abstracts, manuscripts, marketing materials and written descriptions of oral presentations) for CG Territory Activities prior to the date of submission for publication or the date of presentation, whichever is earlier, of any of such
submitted materials for Kissei&#146;s review to the extent possible under agreements with Third Parties existing at the time of such submission. In the case that such prior submission is not possible due to such agreements with Third Parties, CG
will submit the materials to Kissei immediately after the publication or presentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B>&#8195;<B>No Right to Use Names</B>. Except as expressly provided herein, no
right, express or implied, is granted by the Agreement to Kissei to use in any manner the name of &#147;CG Oncology&#148; or any other trade name, symbol, logo or trademark or derivative thereof of CG or its Affiliates, or to CG to use in any manner
the name of &#147;Kissei&#148; or any other trade name, symbol, logo or trademark or derivative thereof of Kissei or its Affiliates, in connection with the performance of this Agreement or otherwise. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS AND WARRANTIES; DISCLAIMERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1</B>&#8195;<B>Mutual Representations and Warranties</B>. Each Party represents and warrants to the other Party that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;it is validly organized under the laws of its jurisdiction of incorporation; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;it has obtained all necessary consents, approvals and authorizations of all governmental authorities and other persons or
entities required to be obtained by it in connection with this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;the execution, delivery and performance of
this Agreement have been duly authorized by all necessary corporate action on its part; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;it has the legal right and
power to enter into this Agreement and to fully perform its obligations hereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;the performance of its obligations
will not conflict with such Party&#146;s charter documents or any agreement, contract or other arrangement to which such Party is a party; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&#8195;it follows reasonable commercial practices common in the industry to protect its proprietary and confidential information,
including requiring its employees, consultants and agents to be bound in writing by obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> and requiring its employees, consultants and agents to assign to it any
and all inventions and discoveries discovered by such employees, consultants or agents made within the scope of, and during their employment, and only disclosing proprietary and confidential information to Third Parties pursuant to written
confidentiality and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&#8195;neither it nor anyone
employed by it has been debarred under 21 USC &#167;&nbsp;335a, disqualified under 21 USC &#167;&nbsp;312.70 or &#167;&nbsp;812.119, sanctioned by a Federal Health Care Program (as defined in 42 USC
<FONT STYLE="white-space:nowrap">&#167;&nbsp;1320a-7b(f)),</FONT> including the federal Medicare or a state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar regional, national, federal or
state agency or program. If a Party receives notice of debarment, suspension, sanction, exclusion, ineligibility or disqualification under the foregoing-referenced statutes, such Party shall notify the other Party within two (2)&nbsp;Business Days
of its becoming aware of this fact, and the Parties shall agree upon appropriate action to address the matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2</B>&#8195;<B>Compliance</B>. Each Party covenants as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.1</B>&#8195;In the performance of its obligations under this Agreement, each Party shall comply and shall cause its and its
Affiliates&#146; employees, licensees, sublicensees, and contractors to comply with all Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.2</B>&#8195;Each Party
and its and its Affiliates&#146; employees, licensees, sublicensees, and contractors shall not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise, or
offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or Entity or other person for purpose of obtaining or retaining business for or with, or
directing business to, any person, including, each Party (and each Party represents and warrants that as of the Effective Date, such Party, and to its knowledge, its and its Affiliates&#146; employees, licensees, sublicensees, and contractors, have
not directly or indirectly promised, offered, or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift, or hospitality or other illegal or unethical benefit to a Public Official or Entity or any other person in connection
with the performance of such Party&#146;s obligations under this Agreement, and such Party covenants that it and its Affiliates&#146; employees, licensees, sublicensees, and contractors shall not, directly or indirectly, engage in any of the
foregoing) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.3</B>&#8195;Each Party and its Affiliates, and their respective employees, licensees, sublicensees, and contractors,
in connection with the performance of their respective obligations under this Agreement, shall not violate or cause the violation of the Anti-Corruption Laws, Export Control Laws, or any other Applicable Laws, or otherwise cause any reputational
harm to the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.4</B>&#8195;Each Party shall immediately notify the other Party if it has any information or suspicion
that there may be a violation of the Anti-Corruption Laws, Export Control Laws, or any other Applicable Laws in connection with the performance of this Agreement or the development or commercialization of any Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.5</B>&#8195;Each Party will have the right, upon reasonable prior written notice and during the other Party&#146;s regular business
hours, to conduct at its own cost and expenses inspections of and to audit the other Party&#146;s books and records in the event of a suspected violation or to ensure compliance with the representations, warranties, and covenants of this
<B>Section</B><B></B><B>&nbsp;12.2 (Compliance) </B>provided, however, that in the absence of good cause for such inspections and audits, each Party exercise this right no more than annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.6</B>&#8195;In the event that one Party has violated or been suspected of violating any of the representations, warranties, or
covenants in this <B>Section</B><B></B><B>&nbsp;12.2 (Compliance)</B>, such Party will cause its or its Affiliates&#146; personnel or others working under its direction or control to submit to periodic training that it will provide on
Anti-Corruption Law compliance or other relevant compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.7</B>&#8195;Each Party will, at the other&#146;s request, annually
certify to the other Party in writing its compliance, in connection with the performance of its obligations under this Agreement, with the representations, warranties, or covenants in <B>Section</B><B></B><B>&nbsp;12.2 (Compliance)</B>, which
certification shall be issued by its appropriate executive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.8</B>&#8195;Each Party shall have the right to suspend or terminate this Agreement
in its entirety where there is a credible finding, after a reasonable investigation, that the other Party or its Affiliates, licensees, or sublicensees in connection with the performance of such other Party&#146;s obligations under this Agreement,
has engaged in chronic or material violations of the Anti-Corruption Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3</B>&#8195;<B>CG Covenants and Additional
Representations and Warranties</B>. CG also covenants that CG will not, and will cause its Affiliates to not, grant during the term of this Agreement, any right, license or interest in or to the Licensed Intellectual Property or any portion thereof,
inconsistent with the rights granted to Kissei herein; and CG represents and warrants to Kissei that </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;to its actual
knowledge, CG owns the entire right, title and interest in, or otherwise Controls the CG IP and it has the legal right and power to extend the rights and licenses granted to Kissei hereunder free and clear of all Encumbrances; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;as of the Effective Date, (i)&nbsp;CG has not been notified of any action, lawsuit, claim or arbitration proceeding
contesting the validity, ownership or enforceability of the Licensed Intellectual Property, and (ii)&nbsp;to its actual knowledge, there is no reasonable threat of any actions, lawsuits, claims or arbitration proceedings contesting the validity,
ownership or enforceability of the Licensed Intellectual Property; provided, however, that nothing in this <B>Section</B><B></B><B>&nbsp;12.3 (CG Covenants and Additional Representations and Warranties) </B>shall be interpreted as requiring CG to
have undertaken any inquiries or to have obtained any freedom to operate opinion; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;to its actual knowledge, as of the
Effective Date, no activities of any Third Parties are infringing or threatening to infringe or misappropriating or threatening to misappropriate any CG IP (including any pending Patent applications and registrations within the CG IP as if such
applications or registrations were to issue or become registered); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;to its actual knowledge, as of the Effective Date
(i)&nbsp;the conception, reduction to practice or creation of the CG IP did not infringe or misappropriate or otherwise violate any intellectual property right of any Third Party under the Applicable Laws of any jurisdiction where there is a Valid
Claim; (ii)&nbsp;the research, development, manufacture or commercialization of Products based upon the CG IP does not infringe or misappropriate or otherwise violate any intellectual property right of any Third Party under the Applicable Laws of
any jurisdiction where there is a Valid Claim; and (iii)&nbsp;the CG Patents are not dominated by any Patent of any Third Party and not Controlled by CG; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;as of the Effective Date, (i)&nbsp;to its actual knowledge, none of the CG Patents has ever been, or now are subject to any
pending or threatened, <FONT STYLE="white-space:nowrap">re-examination,</FONT> opposition, interference or litigation proceedings; and (ii)&nbsp;there are no acts or omissions of CG that would reasonably (a)&nbsp;constitute inequitable conduct,
fraud or misrepresentation with respect to any Patent application included within CG Patents or (b)&nbsp;render any Patent within the CG Patents invalid or unenforceable in whole or in part; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&#8195;as of the Effective Date, neither CG nor any of its Affiliates has
(i)&nbsp;granted any Third Party the right to control the Prosecution and Maintenance of any of the CG Patents in the Territory, (ii)&nbsp;granted any Third Party the right to bring infringement actions with respect to, or otherwise to enforce
rights with respect to, any of the CG Patents in the Territory, or (iii)&nbsp;expressly agreed not to sue or to indemnify any Third Party against any charge of infringement of any of CG Patents in the Territory; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&#8195;except as set forth on <B>Schedule</B><B></B><B>&nbsp;12.3(g)</B>, as of the Effective Date, there are no agreements between
CG or its Affiliates with any Third Parties (i)&nbsp;pursuant to which a Third Party has obtained, or has a right to obtain, a license, right, or interest in, or to use, any CG IP in the Territory or (ii)&nbsp;pursuant to which CG or its Affiliate
otherwise owes, or would otherwise owe, payments to a Third Party as a result of the activities conducted hereunder (whether by CG or Kissei or their respective Affiliates or (sub)licensees), including the grant of rights, interests, and licenses
under this Agreement or the transfer or sale of Products; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(h)</B>&#8195;CG has made available to Kissei true and complete copies of
the Existing <FONT STYLE="white-space:nowrap">In-License;</FONT> and the agreement referenced in <B>Schedule</B><B></B><B>&nbsp;12.3(g)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.4</B>&#8195;<B>Disclaimers</B>. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR
WARRANTY OF ANY KIND WITH RESPECT TO PATENTS, <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> MATERIALS OR CONFIDENTIAL INFORMATION SUPPLIED BY IT TO THE OTHER PARTY HEREUNDER, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING
BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON INFRINGEMENT. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1</B>&#8195;<B>Indemnification</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.1.1</B>&#8195;Subject to <B>Section&nbsp;13.2 (Procedure)</B>, CG shall indemnify, defend and hold harmless
(&#147;<B>Indemnify</B>&#148;) Kissei, its Affiliates and their respective directors, officers, and employees and the successors and assigns of any of the foregoing (&#147;<B>Kissei Indemnitees</B>&#148;) harmless from and against any and all
liabilities, damages, settlements, penalties, fines, costs or expenses (including reasonable attorneys&#146; fees and other expenses of litigation) (collectively, &#147;<B>Loss</B>&#148; or &#147;<B>Losses</B>&#148;) resulting from any Third Party
claims, suits, actions, demands or judgments (&#147;<B>Third Party Claims</B>&#148;) arising out of (a)&nbsp;breach by CG of this Agreement, including any of the representations and warranties made by CG under <B>Article&nbsp;12 (Representations and
Warranties</B><B>; Disclaimers)</B>, (b) any CG Indemnitee&#146;s gross negligence or willful misconduct, or (c)&nbsp;the activities performed by or on behalf of CG or any of its Affiliates or its or their licensees (i)&nbsp;in connection with the
exercise of its licenses and rights hereunder, including product liability claims and infringement claims (including the costs and expenses described in <B>Section&nbsp;9.8.3 (Costs and</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>Expenses)</B>) or (ii)&nbsp;unrelated to the Development Program, Collaboration Compound, Product or Companion Diagnostic, except, in each case (a)&nbsp;through (c), that CG&#146;s obligation
to Indemnify the Kissei Indemnitees pursuant to this <B>Section</B><B></B><B>&nbsp;13.1.1 (Indemnification) </B>shall not apply to the extent that any such Losses are Losses for which Kissei is obligated to Indemnify the CG Indemnitees pursuant to
<B>Section</B><B></B><B>&nbsp;13.1.2 (Indemnification)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.1.2</B>&#8195;Subject to <B>Section</B><B></B><B>&nbsp;13.2
(Procedure)</B>, Kissei shall Indemnify CG, its Affiliates and their respective directors, officers, and employees and the successors and assigns of any of the foregoing (&#147;<B>CG Indemnitees</B>&#148;) harmless from and against any and all
Losses resulting from any Third Party Claims arising out of (a)&nbsp;breach by Kissei of this Agreement, including any of the representations and warranties made by Kissei under <B>Article</B><B></B><B>&nbsp;12 (Representations and Warranties;
Disclaimers)</B>, (b) any Kissei Indemnitee&#146;s gross negligence or willful misconduct, or (c)&nbsp;the activities performed by or on behalf of Kissei or any of its Affiliates or its or their sublicensees (i)&nbsp;in connection with the exercise
of its licenses and rights hereunder, including, product liability and infringement claims (including the costs and expenses described in <B>Section</B><B></B><B>&nbsp;9.8.3 (Costs and Expenses)</B>) or (ii)&nbsp;unrelated to the Development
Program, Collaboration Compound, Product or Companion Diagnostic, except, in each case (a)&nbsp;through (c), that Kissei&#146;s obligation to Indemnify the CG Indemnitees pursuant to this <B>Section</B><B></B><B>&nbsp;13.1.2 (Indemnification)
</B>shall not apply to the extent that any such Losses are Losses for which CG is obligated to Indemnify the Kissei Indemnitees pursuant to <B>Section</B><B></B><B>&nbsp;13.1.1 (Indemnification)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2</B>&#8195;<B>Procedure</B>. In order for a Party to be eligible to claim indemnification under this Agreement (the
&#147;<B>Indemnitee</B>&#148;), it shall promptly notify the other Party (the &#147;<B>Indemnitor</B>&#148;) in writing of such alleged Loss. Except as provided in <B>Section</B><B></B><B>&nbsp;9.8.2 (Defense in the Territory)</B>, the Indemnitor
shall have the exclusive right to control the defense or settlement thereof with counsel of its choice as long as such counsel is reasonably acceptable to Indemnitee; provided, however, that the Indemnitor shall not enter into any settlement that
admits fault, wrongdoing or damages without the Indemnitee&#146;s written consent, such consent not to be unreasonably withheld, conditioned or delayed. Any Indemnitee shall have the right to retain its own counsel at its own expense for any reason,
provided, however, that if the Indemnitee shall have reasonably concluded, based upon a written opinion from outside legal counsel, that there is a conflict of interest between the Indemnitor and the Indemnitee in the defense of such action by the
Indemnitor&#146;s selected counsel, the Indemnitor shall pay the fees and expenses of one law firm serving as counsel for the Indemnitee. In any event, the Indemnitor shall have no obligations with respect to any Losses resulting from the
Indemnitee&#146;s admission, settlement or other communication without the prior written consent of the Indemnitor. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the
investigation of any Third Party Claims covered by this Agreement. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such
action, shall relieve the Indemnitor of any obligation to the Indemnitee under this <B>Section</B><B></B><B>&nbsp;13.2 (Procedure)</B>. It is understood that only Kissei or CG may claim indemnity under this Agreement (on its own behalf or on behalf
of its Indemnitees), and other Indemnitees may not directly claim indemnity hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.3</B>&#8195;<B>Insurance</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.3.1</B>&#8195;<B>Insurance Coverage</B>. Subject to <B>Section</B><B></B><B>&nbsp;13.3.4 (Election to Self-Insure)</B>, each Party shall
obtain and maintain comprehensive general liability insurance customary in the industry for companies of similar size conducting similar business, and in any case sufficient to cover its obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.3.2</B>&#8195;<B>Evidence of Insurance</B>. Within [***] of signing this Agreement, each Party shall provide the other Party with its
certificate of insurance evidencing the insurance coverage set forth <B>Section</B><B></B><B>&nbsp;13.3.1 (Insurance Coverage)</B>. Each Party shall provide to the other Party at least thirty (30)&nbsp;days prior written notice of any cancellation, <FONT
STYLE="white-space:nowrap">non-renewal</FONT> or material change in any of such insurance coverage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.3.3</B>&#8195;<B>Product /
Clinical Trial Liability Insurance</B>. Commencing not later than [***] prior to the a Clinical Trial pursuant to the Development Plan under this Agreement with respect to a Collaboration Compound, Product or Companion Diagnostic by a Party or any
of its Affiliates or sublicensees, such Party and such Affiliate or sublicensee shall have and maintain such type and amounts of Products / Clinical Trial Liability insurance covering the development, manufacture, use and sale of Products, Products
and Companion Diagnostics as is normal and customary in the industry generally for parties similarly situated, but, in any event, with a minimum combined single limit per occurrence for products / clinical trials liability as follows: (a)&nbsp;a
minimum limit of [***] for any period during which such Party or any of its sublicensees is conducting a Clinical Trial with any Collaboration Compound(s), Product(s) or Companion Diagnostic(s); and (b)&nbsp;a minimum limit of [***] for any period
during which Kissei or any of its Affiliates or sublicensees is selling any Product(s) or Companion Diagnostic(s) in the Territory. Each of the above insurance policies shall be primary insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.3.4</B>&#8195;<B>Election to Self-Insure</B>. In the event that either Party is or becomes an entity which, by Change of Control or
otherwise, together with its Affiliates, has worldwide revenues from pharmaceutical sales in excess of [***] per year, the obligations set forth in <B>Section</B><B></B><B>&nbsp;13.3.3 (Product / Clinical Trial Liability Insurance)</B>,
<B>Section</B><B></B><B>&nbsp;13.3.1 (Insurance Coverage) </B>and <B>Section</B><B></B><B>&nbsp;13.3.2 (Evidence of Insurance) </B>above shall not apply with respect to such Party, if such Party notifies the other Party in writing that it elects to
provide coverage through a commercially reasonable program of self-insurance; provided, however, that the obligations set forth in <B>Section</B><B></B><B>&nbsp;13.3.1 (Insurance Coverage)</B>, <B>Section</B><B></B><B>&nbsp;13.3.2 (Evidence of
Insurance) </B>and <B>Section</B><B></B><B>&nbsp;13.3.3 (Product / Clinical Trial Liability Insurance) </B>above shall resume with respect to such Party and its Affiliates, or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> and its Affiliates, if such program of self-insurance is terminated or discontinued for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.4</B>&#8195;<B>Limitation of Damages</B>. NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL,
EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT IN RESPECT OF ANY BREACH OF A PARTY&#146;S OBLIGATIONS UNDER <B>SECTION 4.3 (EXCLUSIVITY) </B>OR
<B>ARTICLE 10 (CONFIDENTIALITY</B>) OR INDEMNIFICATION OBLIGATIONS UNDER THIS <B>ARTICLE 13 (INDEMNIFICATION) </B>FOR CLAIMS OF THIRD PARTIES. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM; TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1</B>&#8195;<B>Term</B>. The term of this Agreement (the &#147;<B>Term</B>&#148;) shall commence on the Effective Date and, unless
sooner terminated as provided in this <B>Article</B><B></B><B>&nbsp;14 (Term; Termination)</B>, shall continue in full force and effect, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis until there is no remaining royalty payment or other payment obligation in such country with respect to such Product, at which time this Agreement
shall expire with respect to such Product in such country. Subject to <B>Section</B><B></B><B>&nbsp;7.4.8 (Rights Following Expiration of Royalty Term) </B>the Term shall expire on the date this Agreement has expired in its entirety with respect to
all Products in all countries in the world. Following the expiration of the Term, (i)&nbsp;the grants in <B>Section</B><B></B><B>&nbsp;4.1.1 (Products) </B>and <B>Section</B><B></B><B>&nbsp;4.1.2 (Companion Diagnostics) </B>shall become <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> fully-paid, royalty-free and irrevocable and (ii)&nbsp;Kissei shall have the right to negotiate directly with CG&#146;s then-existing CMO(s), including Fuji Film, an agreement for the manufacture and
supply of the Collaboration Compound and Product independent of, and without any financial obligation to, CG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2</B>&#8195;<B>Termination by Either Party for Material Breach</B>. Either Party may terminate this Agreement (a)&nbsp;on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Product</FONT></FONT> basis by written notice to the other Party for any material breach of this Agreement by the other Party specific to a particular Product or (b)&nbsp;in its
entirety by written notice to the other Party for any material breach of this Agreement by the other Party that is not specific to a particular Product, if, in the case of remediable breach, such material breach is not cured within [***] ([***] for
payment defaults) after the breaching Party receives written notice of such breach from the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party; provided, that if such breach is not capable of being cured within such [***] ([***]) period,
the cure period shall be extended for such amount of time that the Parties may agree in writing is reasonably necessary to cure such breach, so long as (1)&nbsp;the breaching Party is making Commercially Reasonable Efforts to do so, and (2)&nbsp;the
Parties agree on an extension within such [***] ([***]) period. Notwithstanding anything to the contrary herein, if the allegedly breaching Party in good faith either disputes (i)&nbsp;whether a breach is material or has occurred or (ii)&nbsp;the
alleged failure to cure or remedy such material breach, and provides written notice of that dispute to the other Party within the above time periods, then the matter will be addressed under the dispute resolution provisions in
<B>Article</B><B></B><B>&nbsp;15 (Dispute Resolution)</B>, and the notifying Party may not so terminate this Agreement until it has been determined under <B>Article</B><B></B><B>&nbsp;15 (Dispute Resolution) </B>that the allegedly breaching Party is
in material breach of this Agreement, and such breaching Party further fails to cure such breach within [***] ([***] for payment defaults) (or such longer period as determined by the arbiter of such dispute resolution) after the conclusion of that
dispute resolution procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.3</B>&#8195;<B>Termination by Either Party for Insolvency or Bankruptcy</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;Either Party may terminate this Agreement, effective on written notice to the other Party, upon (i)&nbsp;the liquidation,
dissolution, winding up, adjudication of insolvency or bankruptcy, (ii)&nbsp;the filing of any petition therefor, appointment of a receiver, custodian or trustee with respect to all or substantially all of such other Party&#146;s (the
&#147;<B>Bankrupt Party</B>&#148;) assessor (iii)&nbsp;any other similar proceeding (the proceedings referred to in (i)&nbsp;through (iii), the &#147;<B>Insolvency Proceedings</B>&#148;), by or of the Bankrupt Party where such Insolvency Proceeding
is not dismissed or vacated within [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;All rights and licenses granted pursuant to this Agreement are for
purposes of Section&nbsp;365(n) of Title 11 of the United States Code or any equivalents thereof in any other countries (&#147;<B>Title 11</B>&#148;), licenses of rights to &#147;intellectual property&#148; as defined in Title 11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;The Parties recognize that this Agreement is personal to the Parties and that intellectual property law excuses a Party from
accepting the performance from or rendering performance to anyone other than the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.4</B>&#8195;<B>Termination for Patent
Challenge</B>. If, without the prior consent of CG and except as provided below, Kissei or any of its Affiliates or its or their sublicensees voluntarily challenges under any court action or proceeding, or before any patent office, the validity,
patentability, enforceability, scope or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any CG Patent, or voluntarily initiates a reexamination of any such Patent, or voluntarily assists any Third Party to conduct any of the foregoing
activities (each, a &#147;<B>Challenge</B>&#148;), then either (a)&nbsp;Kissei or its Affiliate or sublicensee shall withdraw (or cause to be withdrawn) such Challenge within [***] after being requested to do so by CG in writing and CG shall have no
right to terminate this Agreement pursuant to this <B>Section</B><B></B><B>&nbsp;14.4 (Termination for Patent Challenge) </B>with respect to such Challenge; or (b)&nbsp;if such challenge is maintained or is not capable of being withdrawn and
terminated, CG shall have the right to terminate this Agreement on [***] written notice to Kissei; such termination to be effective immediately. However the foregoing shall not apply: (i)&nbsp;to any such action or proceeding brought in response to
an action brought by or under the authority of CG or its Affiliate against Kissei, its Affiliate or sublicensee for infringement of any CG Patent, (ii)&nbsp;to any ordinary course Prosecution and Maintenance matters (i.e., those intended to cause a
Patent to issue or strengthen an already issued Patent or that are approved by CG) controlled by Kissei in accordance with <B>Section</B><B></B><B>&nbsp;9.6 (Patent Filing, Prosecution, Maintenance and Strategy) </B>above, or (iii)&nbsp;if Kissei
acquires or is acquired by a Third Party already engaged in a Challenge at the time of such acquisition; provided, that neither Kissei nor any of its Affiliates (as in existence immediately prior to such acquisition), directly or indirectly, assists
or supports such Third Party in any manner with respect to such Challenge. Further, for the avoidance of doubt, CG may not terminate the Agreement if Kissei or its Affiliate or sublicensee is required by legal process to be joined as a party in such
proceedings by a Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.5</B>&#8195;<B>Termination at Will</B>. Kissei shall also have the right to terminate this Agreement
at will in its entirety, or with respect to a particular Product, in its sole discretion, any time after the [***] of the Effective Date by providing [***] written notice to CG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.6</B>&#8195;<B>Termination for Catastrophic Breach</B>. If CG commits an incurable Catastrophic Breach of this Agreement, Kissei shall
have the right to terminate the entire Agreement on [***] written notice. If Kissei fails to provide such written termination notice within [***] from the date when Kissei learns of the Catastrophic Breach, then Kissei&#146;s termination under this
<B>Section</B><B></B><B>&nbsp;14.6 (Termination for Catastrophic Breach) </B>will be deemed waived for such Catastrophic Breach. For purposes of this Agreement, &#147;<B>Catastrophic Breach</B>&#148; means a material breach of this Agreement by CG
caused solely by CG&#146;s willful and malicious misconduct that results in substantial and irreparable harm to the commercial value of the Product in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.7</B>&#8195;<B>Effects of Termination</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.7.1</B>&#8195;<B>Effects of Termination in General</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;<B>Accrued Rights and Obligations</B>. Expiration or termination of this Agreement in its entirety, or with respect to a
particular Product, for any reason shall not release either Party hereto from any liability which, as of the effective date of such expiration or termination, had already accrued to the other Party or which is attributable to a period prior to such
termination, nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to the effective date of such expiration or termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;<B>Termination of Licenses. Upon termination of this Agreement</B>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&#8195;with respect to a particular Product by either Party pursuant to <B>Section</B><B></B><B>&nbsp;14.2 (Termination by Either Party
for Material Breach) </B>or by Kissei pursuant to <B>Section</B><B></B><B>&nbsp;14.5 (Termination at Will) </B>all licenses under this Agreement with respect to such Product, the Collaboration Compound contained therein and the Companion Diagnostic
thereto (other than the licenses set forth in <B>Sections</B><B></B><B>&nbsp;4.1.3 (Collaboration IP)</B>, <B>4.1.2 (Companion Diagnostics)</B>, <B>4.2.1 (Collaboration IP) </B>and <B>4.2.4 (Residuals)</B>) shall terminate, and the provisions of
<B>Section</B><B></B><B>&nbsp;4.3 (Exclusivity) </B>shall terminate solely with respect to such Product, the Collaboration Compound contained therein, the Companion Diagnostic thereto or the Indication to which such Product is directed (if there are
no other exclusive licenses to any Product directed to such Indication is then in effect), in each case, as of the effective date of such termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&#8195;in its entirety by either Party pursuant to <B>Section</B><B></B><B>&nbsp;14.2 (Termination by Either Party for Material
Breach)</B>, <B>14.3 (Termination by Either Party for Insolvency or Bankruptcy)</B> or <B>14.4 (Termination for Patent Challenge)</B> all licenses under this Agreement (other than the licenses set forth in <B>Sections</B><B></B><B>&nbsp;4.1.3
(Collaboration IP), 4.1.2 (Companion Diagnostics), 4.2.1 (Collaboration IP)</B> and <B>4.2.4 (Residuals)</B>) shall terminate as of the effective date of such termination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&#8195;in its entirety by Kissei pursuant to <B>Section</B><B></B><B>&nbsp;14.6 (Termination for Catastrophic Breach) </B>all licenses
granted to Kissei under <B>Section</B><B></B><B>&nbsp;4.1 (License Grants to Kissei) </B>shall become royalty-free, fully <FONT STYLE="white-space:nowrap">paid-up</FONT> licenses, and Kissei shall have the right to negotiate directly with CG&#146;s
then-existing CMO(s), including Fuji Film, an agreement for the manufacture or and supply of the Collaboration Compound and Product independent of, and without any financial obligation to, CG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv)&#8195;with respect to the last Product by Kissei pursuant to <B>Section</B><B></B><B>&nbsp;14.5 (Termination at Will) </B>(i.e., there
are no other exclusive licenses to any Product in effect), or in its entirety pursuant to <B>Section</B><B></B><B>&nbsp;14.2 (Termination by Either Party for Material Breach) </B>or <B>14.3 (Termination by Either Party for Insolvency or
Bankruptcy)</B>, all licenses under this Agreement (other than the licenses set forth in <B>Sections</B><B></B><B>&nbsp;4.1.3 (Collaboration IP), 4.1.2 (Companion Diagnostics), 4.2.1 (Collaboration IP) </B>and <B>4.2.4 (Residuals)</B>) shall
terminate as of the effective date of such termination; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v)&#8195;for clarity, from and after the effective date of termination of this Agreement
with respect to a Product, such Product shall be excluded from the definition of Product for all purposes of this Agreement (except as required to implement the provisions of this <B>Article</B><B></B><B>&nbsp;14 (Term; Termination) </B>with respect
to such Product). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;<B>Continuation of Sublicenses</B>. Upon termination by CG of this Agreement with respect to a
particular Product under <B>Section</B><B></B><B>&nbsp;14.2 (Termination by Either Party for Material Breach)</B>, any existing, permitted sublicense granted by Kissei under this Agreement with respect to such Product may, in CG&#146;s sole
discretion, continue in full force and effect, provided, that the permitted sublicensee did not cause the breach that gave rise to a termination under <B>Section</B><B></B><B>&nbsp;14.2 (Termination by Either Party for Material Breach) </B>and
agrees to be bound by all the terms and conditions of this Agreement that are applicable to such permitted sublicensee including rendering directly to CG all payments and other obligations due to CG related to such sublicense (including all event
payments and royalty payments) that would have been owed by Kissei if not for such termination and granting rights and licenses to CG of the same scope as set forth in <B>Section</B><B></B><B>&nbsp;4.2 (License Grants to CG) </B>with respect to the
intellectual property rights of such sublicensee; provided further CG is not obligated to assume any obligations under such sublicense that are greater or more adverse to CG than the obligations contained within this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;<B>Return of Confidential Information</B>. It is understood and agreed, that each Party shall have a continuing right to use
Confidential Information of the other Party under any surviving licenses pursuant to <B>Article</B><B></B><B>&nbsp;4 (Licenses and Rights) </B>and/or <B>Section</B><B></B><B>&nbsp;14.7 (Effects of Termination)</B>. Subject to the foregoing,
following expiry or any early termination of this Agreement, the Party that has Confidential Information of the other Party shall destroy (at such Party&#146;s written request) all such Confidential Information in its possession as of the effective
date of expiration or termination (with the exception of one copy of such Confidential Information, which may be retained by the legal department of the Party that received such Confidential Information to confirm compliance with the <FONT
STYLE="white-space:nowrap">non-use</FONT> and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> provisions of this Agreement), and any Confidential Information of the other Party contained in its laboratory notebooks or databases, provided,
that notwithstanding the foregoing, each Party may retain and continue to use the Confidential Information of the other Party solely to the extent necessary to exercise any surviving rights, licenses or obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&#8195;<B>Inventory at Termination</B>. Upon termination of this Agreement after Marketing Approval is obtained for one or more
Products, Kissei and its permitted sublicensee shall have the right to sell all inventory of any such approved Products in all countries in the Territory then in its stock (or dispose of all inventory of any Product then in its stock that may not be
sold as reasonably determined by Kissei, including for expired shelf-life), subject to the applicable royalty payments due under this Agreement, and any other applicable provisions of this Agreement, and CG covenants not to sue Kissei or its
permitted sublicensee for infringement under any of the Patents that were licensed by CG to Kissei immediately prior to such termination with respect to such activities conducted by Kissei or its permitted sublicensee pursuant to this
<B>Section</B><B></B><B>&nbsp;14.7.1(e) (Inventory at Termination)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(f)&#8195;Survival</B>. In addition to any provisions
specified in this Agreement as surviving under the applicable circumstances, the provisions of <B>Article&nbsp;1 (Definitions), 10 (Confidentiality), 11 (Publicity; Publications; Use of Name), 15 (Dispute Resolution)</B> and <B>16</B>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>(Miscellaneous) </B>and <B>Sections</B><B></B><B>&nbsp;2.5.2 (Development Records)</B>, <B>4.1.3 (Collaboration IP)</B>, <B>4.1.4 (Sublicenses)</B>, <B>4.2.1 (Collaboration IP)</B>, <B>4.2.4
(Residuals)</B>, <B>4.2.5 (Sublicenses)</B>, <B>4.4 (No Other Rights, Retained Rights)</B>, <B>4.5 (Interpretation)</B>, <B>5.3.4 (No Warranty)</B>, <B>9.1 (Intellectual Property; Ownership)</B>, <B>9.2 (Kissei)</B>, <B>9.3.2 (Inventorship; CREATE
Act)</B>, <B>9.4 (Ownership; Collaboration IP; Rights of Joint Owners)</B>, <B>9.5 (Rights of Joint Owners)</B>, <B>12.1 (Mutual Representations and Warranties)</B>, <B>12.3 (CG Covenants and Additional Representations and Warranties)</B>, <B>12.4
(Disclaimers)</B>, <B>13.1 (Indemnification)</B>, <B>13.2 (Procedure)</B>, <B>13.4 (Limitation of Damages)</B>, <B>14.1 (Term) </B>(solely with respect to the last sentence thereof) and <B>14.7 (Effects of Termination) </B>shall survive any
termination or expiration of this Agreement; provided, that, with respect to <B>Sections</B><B></B><B>&nbsp;12.1 (Mutual Representations and Warranties)</B>, <B>12.3 (CG Additional Representations and Warranties)</B>, <B>12.4 (Disclaimers)</B>,
<B>13.1 (Indemnification)</B>, <B>13.2 (Procedure)</B>, <B>13.4 (Limitation of Damages)</B>, <B>14.1 (Term)</B>, only with respect to those claims that arise from the acts or omissions of a Party prior to the effective date of termination or
expiration. In addition, the applicable provisions of <B>Articles </B>7 <B>(Financial Terms) </B>and <B>8 (Payment Terms; Reports; Audits) </B>shall survive with respect to any outstanding unpaid amounts that accrued prior to the effective date of
any termination or expiration of this Agreement (or any amounts owed as a result of the continuing payment obligations addressed in <B>Section</B><B></B><B>&nbsp;14.7.1(b) (Accrued Rights and Obligations) </B>or <B>14.7.1(f) (Inventory at
Termination)</B>, if and as applicable). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISPUTE RESOLUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.1</B>&#8195;<B>Disputes</B>. CG and Kissei recognize that a dispute, controversy or claim of any nature whatsoever arising out of or
relating to this Agreement, or the breach, termination or invalidity thereof, (each, a &#147;<B>Dispute</B>&#148;) may from time to time arise during the Term. Unless otherwise specifically recited in this Agreement (including
<B>Section</B><B></B><B>&nbsp;3.6 (JDC Decision-Making)</B>), such Disputes between CG and Kissei will be resolved as recited in this <B>Article</B><B></B><B>&nbsp;15 (Dispute Resolution)</B>. In the event of the occurrence of such a Dispute, the
Parties shall first refer such Dispute to their respective Alliance Managers for attempted resolution by such Alliance Managers within [***] after such referral. If such Dispute is not resolved within such [***] period by the Alliance Managers,
either CG and Kissei may, by written notice to the other, have such Dispute referred to their respective officers designated below, or their respective designees, for attempted resolution by within [***] after such notice is received. Such
designated officers are as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[For Kissei:&#8195;President, Chief Operating Officer] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[For CG:&#8195;Chief Executive Officer] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event the designated officers, or their respective designees, are not able to resolve such dispute within [***] of such other
Party&#146;s receipt of such written notice, then, unless otherwise expressly set forth herein (including in the subsequent paragraph of this <B>Section</B><B></B><B>&nbsp;15.1 (Disputes) </B>or in <B>Section</B><B></B><B>&nbsp;3.6.2
(Escalation)</B>) either Party may initiate the dispute resolution procedures set forth in <B>Section</B><B></B><B>&nbsp;15.2 (Arbitration)</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Disputes shall not include any disagreements solely about
decisions for which one Party has final decision-making authority under this Agreement, including under <B>Article</B><B></B><B>&nbsp;3 (Governance)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.2</B>&#8195;<B>Arbitration</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>15.2.1</B>&#8195;<B>Rules</B>. Except as otherwise expressly provided in this Agreement (including under <B>Section</B><B></B><B>&nbsp;15.3
(Subject Matter Exclusions)</B>), the Parties agree that any Dispute not resolved internally by the Parties pursuant to <B>Section</B><B></B><B>&nbsp;15.1 (Disputes) </B>shall be resolved through binding arbitration administered by International
Chamber of Commerce (ICC) in accordance with its ICC Rules of Arbitration (for purposes of this <B>Article</B><B></B><B>&nbsp;15 (Dispute Resolution)</B>, the &#147;<B>Rules</B>&#148;), except as modified in this Agreement, applying the substantive
law specified in <B>Section</B><B></B><B>&nbsp;16.1 (Applicable Law)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>15.2.2</B>&#8195;<B>Arbitrators; Location</B>. Arbitration
proceedings will be held in Singapore. Each Party shall select one (1)&nbsp;arbitrator, and the two (2)&nbsp;arbitrators so selected shall choose a third arbitrator. All three (3)&nbsp;arbitrators shall serve as neutrals and have at least [***] of
(a)&nbsp;dispute resolution experience (including judicial experience) and/or (b)&nbsp;legal or business experience in the biotech or pharmaceutical industry. In any event, at least one (1)&nbsp;arbitrator shall satisfy the foregoing experience
requirement under clause (b). If a Party fails to nominate its arbitrator, or if the Parties&#146; arbitrators cannot agree on the third, the necessary appointments shall be made in accordance with the Rules. Once appointed by a Party, such Party
shall have no ex parte communication with its appointed arbitrator. The arbitration proceedings and all pleadings and written evidence shall be in the English language. Any written evidence originally in another language shall be submitted in
English translation accompanied by the original or a true copy thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>15.2.3</B>&#8195;<B>Procedures; Awards</B>. Each Party agrees
to use reasonable efforts to make all of its current employees available, if reasonably needed, and agrees that the arbitrators may determine any person as necessary. The arbitrators shall be instructed and required to render a written, binding, <FONT
STYLE="white-space:nowrap">non-appealable</FONT> resolution and award on each issue that clearly states the basis upon which such resolution and award is made. The written resolution and award shall be delivered to the Parties as expeditiously as
possible, but in no event more than [***] after conclusion of the hearing, unless otherwise agreed by the Parties. Judgment upon such award may be entered in any competent court or application may be made to any competent court for judicial
acceptance of such an award and order for enforcement. Each Party agrees that, notwithstanding any provision of Applicable Law or of this Agreement, it will not request, and the arbitrators shall have no authority to award, punitive or exemplary
damages against any Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>15.2.4</B>&#8195;<B>Costs</B>. The prevailing Party, as determined by the arbitrators, shall be entitled to
(a)&nbsp;its share of fees and expenses of the arbitrators and (b)&nbsp;its attorneys&#146; fees and any and all associated costs and expenses. In determining which Party &#147;prevailed,&#148; the arbitrators shall consider (i)&nbsp;the
significance, including the financial impact, of the claims prevailed upon and (ii)&nbsp;the scope of claims prevailed upon, in comparison to the total scope of the claims at issue. If the arbitrators determine that, given the scope of the
arbitration, neither Party &#147;prevailed,&#148; the arbitrators shall order that the Parties (1)&nbsp;share equally the fees and expenses of the arbitrators and (2)&nbsp;bear their own attorneys&#146; fees and associated costs and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>15.2.5</B>&#8195;<B>Interim Equitable Relief</B>. Notwithstanding anything to the
contrary in this <B>Section</B><B></B><B>&nbsp;15.2 (Arbitration)</B>, in the event that a Party reasonably requires relief on a more expedited basis than would be possible pursuant to the procedure set forth in this <B>Article</B><B></B><B>&nbsp;15
(Dispute Resolution)</B>, such Party may seek a temporary injunction or other interim equitable relief in a court of competent jurisdiction pending the ability of the arbitrators to review the decision under this <B>Section</B><B></B><B>&nbsp;15.2
(Arbitration)</B>. Such court shall have no jurisdiction or ability to resolve Disputes beyond the specific issue of temporary injunction or other interim equitable relief. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>15.2.6</B>&#8195;<B>Protective Orders; Arbitrability</B>. At the request of either Party, the arbitrator shall enter an appropriate
protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings. The arbitrators shall have the power to decide all questions of arbitrability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.3</B>&#8195;<B>Subject Matter Exclusions</B>. Notwithstanding the provisions of <B>Section</B><B></B><B>&nbsp;15.2 (Arbitration)</B>,
any Dispute not resolved internally by the Parties pursuant to <B>Section</B><B></B><B>&nbsp;15.1 (Disputes) </B>that involves the validity, infringement or enforceability of a Patent included in a license granted in this Agreement (a)&nbsp;that is
issued in the United States shall be subject to actions before the United States Patent and Trademark Office and/or submitted exclusively to the federal court located in the jurisdiction of the district where any of the defendants resides; and
(b)&nbsp;that is issued in any other country shall be brought before an appropriate regulatory or administrative body or court in that country, and the Parties hereby consent to the jurisdiction and venue of such courts and bodies solely for such
purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.4</B>&#8195;<B>Continued Performance</B>. Provided that this Agreement has not terminated, the Parties agree to continue
performing under this Agreement in accordance with its provisions, pending the final resolution of any Dispute. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 16 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.1</B>&#8195;<B>Applicable Law</B>. This Agreement (including the arbitration provisions of <B>Section</B><B></B><B>&nbsp;15.2
(Arbitration)</B>) shall be governed by and interpreted in accordance with the laws of the State of Delaware, without reference to the principles of conflicts of laws. The United Nations Convention on Contracts for the International Sale of Goods
shall not apply to the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.2</B>&#8195;<B>Notices</B>. Except as otherwise expressly
provided in the Agreement, any notice required under this Agreement shall be in writing and shall specifically refer to this Agreement. Notices shall be sent via one of the following means and will be effective (a)&nbsp;on the date of delivery, if
delivered in person; (b)&nbsp;on the date of receipt, if sent by a facsimile (with delivery confirmed); or (c)&nbsp;on the date of receipt, if sent by private express courier or by first class certified mail, return receipt requested. Any notice
sent via facsimile shall be followed by a copy of such notice by private express courier or by first class mail. Notices shall be sent to the other Party at the addresses set forth below. Either Party may change its addresses for purposes of this
<B>Section</B><B></B><B>&nbsp;16.2 (Notices) </B>by sending written notice to the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to Kissei: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Senior Director, Business Development&nbsp;&amp; Licensing </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kissei Pharmaceutical Co., Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-8-9</FONT></FONT> Nihonbashi, Muromachi, <FONT STYLE="white-space:nowrap">Chuo-Ku,</FONT> Tokyo <FONT STYLE="white-space:nowrap">103-0022,</FONT> Japan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with required copies (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Senior Director, Legal </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Kissei
Pharmaceutical Co., Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">19-48,</FONT> Yoshino, Matsumoto-City, Nagano-Prefecture <FONT
STYLE="white-space:nowrap">399-8710,</FONT> Japan </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to CG: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Vice President, Business Development </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">400 Irvine Spectrum Center Dr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Suite 2040 Irvine, CA 92618 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with required copies (which shall not constitute notice) to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn: John E. Wehrli, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">12235
El Camino Real, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">California, U.S.A. 92130 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.3</B>&#8195;<B>Assignment</B>. Neither Party may assign or otherwise transfer, in whole or in part, this Agreement without the prior
written consent of the <FONT STYLE="white-space:nowrap">non-assigning</FONT> Party, such approval not to be unreasonably withheld or delayed. Notwithstanding the foregoing, either Party may assign this Agreement to (i)&nbsp;an Affiliate; provided
that, unless such Affiliate controls (as defined in <B>Section</B><B></B><B>&nbsp;1.2 (Affiliate)</B>) such Party, such Party shall remain responsible for such Affiliate&#146;s performance hereunder or (ii)&nbsp;any purchaser of all or substantially
all of the business or assets of such Party to which this Agreement applies, or of all of its capital stock, or to any successor corporation or entity resulting from any merger or consolidation of such Party with or into such corporation or entity,
provided, that the party to which this Agreement is assigned expressly agrees in writing to assume and be bound by all obligations of the assigning Party under this Agreement. A copy of such written agreement by such assignee shall be provided to
the <FONT STYLE="white-space:nowrap">non-assigning</FONT> Party within [***] of execution of such written agreement. Subject to the foregoing, this Agreement will benefit and bind the Parties&#146; successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.4</B>&#8195;<B>Independent Contractors</B>. The Parties hereto are independent contractors and nothing contained in this Agreement shall
be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.5</B>&#8195;<B>Integration</B>. This Agreement, together with the Clinical Supply Agreement, Commercial Supply Agreement, Quality
Agreement, Pharmacovigilance Agreement, and Stock Purchase Agreement, constitutes the entire agreement between the Parties relating to the subject matter of this Agreement and supersedes all previous oral and written communications between the
Parties with respect to the subject matter of this Agreement (including term sheets exchanged by and between CG and Kissei with respect to this Agreement) and the CDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.6</B>&#8195;<B>Amendment; Waiver</B>. Except as otherwise expressly provided herein,
no alteration of or modification to this Agreement shall be effective unless made in writing and executed by an authorized representative of both Parties. No course of dealing or failing of either Party to strictly enforce any term, right or
condition of this Agreement in any instance shall be construed as a general waiver or relinquishment of such term, right or condition. The observance of any provision of this Agreement may be waived (either generally or any given instance and either
retroactively or prospectively) only with the written consent of the Party granting such waiver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.7</B>&#8195;<B>Further
Assurance</B>. Each Party shall and shall use all reasonable endeavors to procure that any necessary Third Party shall promptly execute and deliver such further documents and do such further acts as may be required for the purpose of giving full
effect to the express terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.8</B>&#8195;<B>Severability</B>. The Parties do not intend to violate any public
policy or statutory or common law. However, if any sentence, paragraph, clause or combination or part thereof of this Agreement is in violation of any law or is found to be otherwise invalid or unenforceable, such sentence, paragraph, clause or
combination or part of the same shall be deleted and the remainder of this Agreement shall remain binding and the Parties will negotiate a valid and enforceable replacement provision for such sentence, paragraph, clause or combination or part
thereof of this Agreement, which conforms as nearly as possible with the original intent of the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.9</B>&#8195;<B>No Third
Party Rights</B>. Except for the rights to indemnification provided for certain Third Parties as specified in <B>Article</B><B></B><B>&nbsp;13 (Indemnification) </B>and as otherwise expressly set forth herein, the Parties do not intend that any term
of this Agreement should be enforceable by any Person who is not a Party and all rights, benefits and remedies under this Agreement are solely intended for the benefit of CG and its Affiliates and Kissei and its Affiliates, and except for such
rights to indemnification expressly provided pursuant to <B>Article</B><B></B><B>&nbsp;13 (Indemnification)</B>, no Third Party shall have any rights whatsoever to (a)&nbsp;enforce any obligation contained in this Agreement, (b)&nbsp;seek a benefit
or remedy for any breach of this Agreement, or (c)&nbsp;take any other action relating to this Agreement under any legal theory, including, actions in contract, tort (including negligence, gross negligence and strict liability), or as a defense,
setoff or counterclaim to any action or claim brought or made by either Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.10</B>&#8195;<B>Construction</B>. The Parties
mutually acknowledge that they and their attorneys have participated in the negotiation and preparation of this Agreement. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to
have drafted this Agreement or authorized the ambiguous provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.11</B>&#8195;<B>Original Text</B>. This text of this Agreement
in the English language shall be the original text, and any text in another language, even if such a text is made by translation of the text in English language or prepared by any of the parties hereto for the purpose of its own convenience, shall
have no meaning for any purpose between the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.12</B>&#8195;<B>Interpretation</B>. The captions and headings to this
Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. To the extent there exists any discrepancy between any internal, alphabetical or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
numerical cross-reference to a Section, Article&nbsp;or Schedule&nbsp;of this Agreement and the parenthetical immediately following such cross-reference, the parenthetical shall govern. Unless
context otherwise clearly requires, whenever used in this Agreement: (a)&nbsp;the words &#147;include&#148; or &#147;including&#148; shall be construed as incorporating &#147;but not limited to&#148; or &#147;without limitation&#148;; (b) the words
&#147;hereof,&#148; &#147;herein,&#148; &#147;hereby&#148; and derivative or similar words refer to this Agreement, including the Schedules; (c)&nbsp;the word &#147;law&#148; or &#147;laws&#148; means any applicable, legally binding statute,
ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment, injunction, mandate or other legally binding requirement of a governmental authority (including a court, tribunal, agency, legislative body or other instrumentality
of any (i)&nbsp;government or country or territory, (ii)&nbsp;any state, province, county, city or other political subdivision thereof, or (iii)&nbsp;any supranational body); (d) all references to the word &#147;will&#148; are interchangeable with
the word &#147;shall&#148; and shall be understood to be imperative or mandatory in nature; (e)&nbsp;all references to &#147;sublicensees&#148; shall include all sublicensees of sublicensees through multiple tiers of sublicensing; (f)&nbsp;the
singular shall include the plural and vice versa; and (g)&nbsp;the word &#147;or&#148; has the inclusive meaning represented by the phrase &#147;and/or&#148;. All references to days, months, quarters or years are references to calendar days,
calendar months, calendar quarters, or calendar years. Unless otherwise provided herein, whenever any matter hereunder requires consent or approval, such consent shall not be unreasonably withheld or delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.13</B>&#8195;<B>Counterparts</B>. This Agreement may be executed in two or more counterparts, each of which will be deemed an original,
but all of which together will constitute one and the same instrument. For purposes hereof, a facsimile copy, or email with attached pdf copy, of this Agreement, including the signature pages hereto, will be deemed to be an original. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Signature page follows &#150; the rest of this page intentionally left blank.] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, CG and Kissei have executed this Agreement by their respective officers hereunto duly authorized, on the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>KISSEI PHARMACEUTICAL CO., LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arthur Kuan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mutsuo Kanzawa</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Arthur Kuan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mutsuo Kanzawa</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1.13 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1.35 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1.36 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1.74 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2.1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 7.4.3(C) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 12.3(G) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[***] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE CG ONCOLOGY, INC. HAS DETERMINED THE INFORMATION
(I)&nbsp;IS NOT MATERIAL AND (II)&nbsp;WOULD LIKELY CAUSE COMPETITIVE HARM TO CG ONCOLOGY, INC. IF PUBLICLY DISCLOSED. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIRST AMENDMENT
TO THE LICENSE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND COLLABORATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT</B> (&#147;<B>First Amendment</B>&#148;) is effective as of
September&nbsp;15, 2022 (the &#147;<B>First Amendment Effective Date</B>&#148;) by and between Kissei Pharmaceutical Co., Ltd., a corporation duly organized and existing under the lases of Japan and having its registered office at <FONT
STYLE="white-space:nowrap">19-48,</FONT> Yoshino, Matsumoto, Nagano Prefecture, Japan (&#147;<B>Kissei</B>&#148;), and CG Oncology, Inc. (formerly known as Cold Genesys, Inc.), a company organized and existing under the laws of the state of
Delaware, United States, located at 400 Spectrum Center Drive, Suite #2040 Irvine, CA 92618 (&#147;<B>CG</B>&#148;). Kissei and CG are each referred to herein by name or, individually, as a &#147;<B>Party</B>&#148; and together as the
&#147;<B>Parties</B>.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Kissei and CG are parties to that certain License and Collaboration Agreement, effective as of March&nbsp;26, 2020 (the
&#147;<B>Original Agreement,</B>&#148; and collectively with the First Amendment, the &#147;<B>Agreement</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, The
Parties desire to amend the Original Agreement as set forth below; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the mutual covenants
and agreements provided below and other consideration, the receipt and sufficiency of which is hereby acknowledged, Kissei and CG hereby agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&#8195;<B><U>Definitions</U></B>. Capitalized terms used in this First Amendment but not specifically defined below shall have the
meaning ascribed to them in the Original Agreement. The corresponding definitions in the Original Agreement are replaced in their entirety with the definitions below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.9</B>&#8195;&#147;<B>CG Collaboration <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means Collaboration <FONT
STYLE="white-space:nowrap">Know-How</FONT> that is generated, discovered or obtained during the Term of this Agreement by or on behalf of the CG Group without the inventive contribution of any employee, consultant or agent of Kissei. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.12</B>&#8195;&#147;<B>CG <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all
<FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by the CG Group as of the Effective Date or during the Term of this Agreement. For clarity, CG <FONT STYLE="white-space:nowrap">Know-How</FONT> (a)&nbsp;includes CG Collaboration <FONT
STYLE="white-space:nowrap">Know-How</FONT> and (b)&nbsp;excludes Joint Collaboration <FONT STYLE="white-space:nowrap">Know-How.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.13</B>&#8195;&#147;<B>CG Patents</B>&#148; means all Patents Controlled by the CG Group as of the Effective Date or during the Term of
this Agreement, including Patents claiming CG Collaboration <FONT STYLE="white-space:nowrap">Know-How.</FONT> CG Patents exclude Joint Collaboration Patents. The CG Patents existing as of the Effective Date are identified on <B>Schedule 1.13</B>.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&#8195;The following new definitions are hereby inserted out of alphabetical order
after the existing definitions in the Original Agreement to preserve the section numbering in the Original Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.87</B>&#8195;&#147;<B>CG Group</B>&#148; means CG and any of its Affiliates existing immediately prior to the consummation of a Change of
Control of CG. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.88</B>&#8195;&#147;<B>Transacting Party</B>&#148; means a Person engaged in the Change of Control event with CG
immediately prior to the consummation of the Change of Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.89</B>&#8195;&#147;<B>Transacting Party Group</B>&#148; means the
Transacting Party and its Affiliates in existence immediately prior to consummation of the Change of Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&#8195;<B>Section
3.9 (Change of Control)</B> of the Original Agreement is replaced in its entirety with the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.9</B>&#8195;<B>Change of Control</B>. In the event of a Change of Control of CG (or successor entity thereto, applying
the definition of Change of Control to such successor in place of CG), and the Transacting Party Group is either (a)&nbsp;engaged in the research, development, manufacture or commercialization of any Competing Product (as of the effective date of
such Change of Control or at any time during the Term) or (b)&nbsp;a Peer Pharmaceutical Company, Kissei may (without limiting Kissei&#146;s rights under this Agreement, including under <B>Section</B><B></B><B>&nbsp;14.5 (Termination at Will))</B>
elect to take any or all of the following actions set forth in <B>Sections 3.9.1 (Change of Control)</B> and/or <B>3.9.2 (Change of Control)</B>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.1</B>&#8195;provide written notice to CG (or its successor entity) terminating the provisions of this <B>Article 3
(Governance) </B>in whole or in part, and upon such notice (a)&nbsp;except with respect to <B>Section</B><B></B><B>&nbsp;3.6 (JDC Decision Making)</B> as discussed in this <B>Section</B><B></B><B>&nbsp;3.9.1</B>, neither Party will be obligated
under the terminated provisions of this <B>Article 3 (Governance)</B> for the remainder of the Term, (b)&nbsp;any information, documents or reports that a Party is otherwise required to provide to the working groups or JDC pursuant to the terminated
provisions of this <B>Article 3 (Governance)</B>, as applicable, shall be provided directly to the other Party, (c)&nbsp;Kissei&#146;s obligations to provide the annual progress reports under <B>Section</B><B></B><B>&nbsp;6.2</B> <B>(Progress
Reports)</B> shall be limited to high-level information regarding the status of Products (including Marketing Approvals) and commercialization as of the end of the preceding calendar year, and (d)&nbsp;any matters delegated to the working groups or
JDC pursuant to the terminated provisions of this <B>Article 3 (Governance)</B>, as applicable, shall be made by mutual agreement of the Parties, subject to the decision-making and dispute resolution provisions of <B>Section</B><B></B><B>&nbsp;3.6
(JDC Decision-Making)</B> and <B>Article 15 (Dispute Resolution)</B> with such disputes first being referred to the officers listed in <B>Section</B><B></B><B>&nbsp;15.1 (Disputes)</B>; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.2</B>&#8195;provide written notice to CG (or its successor entity) terminating the provisions of <B>Sections 2.1
(General)</B> and/<B>or 2.2 (Certain Activities)</B>, in whole or in part, without relieving either Party of any obligation that accrued under any such section prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to such termination. If Kissei provides a notice to CG under this <B>Section</B><B></B><B>&nbsp;3.9.2 (Change of Control)</B>, CG shall as soon as reasonably practicable transfer and assign to
Kissei all data, Marketing Approvals and regulatory documentation with respect to the Products in the Territory and a copy of all of the data with respect to the Products in the Territory, including all data comprising the global safety database for
the Products and any related Companion Diagnostics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.3</B>&#8195;Notwithstanding the foregoing, Kissei shall not
have the right to take any of the actions set forth in <B>Section</B><B></B><B>&nbsp;3.9.1 (Change of Control)</B> or <B>Section</B><B></B><B>&nbsp;3.9.2 (Change of Control)</B> so long as (a)&nbsp;no unpublished CG Patents or unpublished CG <FONT
STYLE="white-space:nowrap">Know-How</FONT> that is used in the conduct of activities under the Development Program, and no Kissei IP and Confidential Information, and no Collaboration IP is used by such Transacting Party Group in the research,
development, manufacture, sale, marketing, promotion or distribution of any Competing Product, (b)&nbsp;individual personnel of the CG Group do not remain employed by such Transacting Party Group following the closing of such Change of Control,
(c)&nbsp;such Transacting Party Group segregates any remaining CG Group personnel who remain employed by the Transacting Party Group for any period following closing of such Change of Control from all programs of such Transacting Party Group
directed to the (i)&nbsp;research, development, manufacture, sale, marketing, promotion or distribution of any Competing Product or (ii)&nbsp;research, development, manufacture, sale, marketing, promotion or distribution of any product for the
diagnosis, prevention, or treatment of any of the Indications covered by any Development Plan under this Agreement, and (d)&nbsp;if such Transacting Party Group is a Peer Pharmaceutical Company, CG&#146;s JDC, JPWG and other working group
representatives remain employees or contractors solely of the CG Group (and not such Transacting Party Group) or are otherwise no longer employed by the CG Group and not hired by the Transacting Party Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&#8195;<B>Section 4.3.1 (Exclusivity) of the Original Agreement</B> is replaced in its entirety with the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.3.1</B>&#8195;<B>CG Exclusivity</B>. For a period beginning on the Effective Date and concluding [***] following first
Marketing Approval for a Product, neither CG nor any of its Affiliates (which Affiliates shall not include a Transacting Party Group for so long as the conditions set forth in (a)&nbsp;through (d) of <B>Section</B><B></B><B>&nbsp;3.9.3 (Change of
Control) </B>remain satisfied) shall: (a)&nbsp;promote, market, distribute, sell or otherwise commercialize a Competing Product; or (b)&nbsp;either directly or indirectly, appoint, license, or otherwise authorize or facilitate any Third Party,
whether pursuant to such appointment, license or otherwise, to perform any of the activities set forth in the foregoing clause (a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&#8195;<B>Section 7.5.7 (Royalty <FONT STYLE="white-space:nowrap">Buy-Out)</FONT> of the Original Agreement</B> is replaced in its
entirety with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.5.7&#8195;Royalty <FONT STYLE="white-space:nowrap">Buy-Out.</FONT></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&#8195;<B>Change of Control</B>. In the event of a Change of Control of CG during the Term, CG shall have the right
to pay Kissei a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> in order to terminate CG&#146;s obligation to pay Kissei royalties pursuant to <B>Section</B><B></B><B>&nbsp;7.5.1 (Products in CG Territory) </B>and convert all licenses in
<B>Section</B><B></B><B>&nbsp;4.2 (License Grants to CG)</B> into fully-paid licenses (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&#8195;<B>Exercise</B>. Subject to
<B>Section</B><B></B><B>&nbsp;7.5.7(d) (No Obligation)</B>, CG, itself or through a member of the Transacting Party Group, shall notify Kissei in writing if CG wishes to exercise its <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option
(&#147;<B>Election Notice</B>&#148;). If CG provides an Election Notice to Kissei, the amount payable by CG to Kissei in consideration for the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option, which shall be the fair market value, shall be
determined by a Valuation Firm in accordance with <B>Section</B><B></B><B>&nbsp;7.5.7(c) (Valuation Firm)</B> (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option Price</B>&#148;). Following payment of the <FONT
STYLE="white-space:nowrap">Buy-Out</FONT> Option Price, which shall be within [***] from the date when the report described in <B>Section</B><B></B><B>&nbsp;7.5.7(c) (Valuation Firm)</B> indicating the amount of the
<FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option Price is received by Kissei, CG&#146;s obligations under <B>Section</B><B></B><B>&nbsp;7.5 (Royalty Payments for Products by CG)</B> shall be terminated. CG may exercise the <FONT
STYLE="white-space:nowrap">Buy-Out</FONT> Option right only once during the Term, but CG&#146;s <FONT STYLE="white-space:nowrap">non-exercise</FONT> of the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option for any particular Change of Control
does not waive the <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option for any subsequent Change of Control. CG must provide Kissei with the Election Notice within [***] after the Change of Control occurs or the
<FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option will be deemed waived solely with respect to that Change of Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&#8195;<B>Valuation Firm</B>. The <FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option Price shall be finally
determined by a reputable, independent third-party valuation firm (&#147;<B>Valuation Firm</B>&#148;), at CG&#146;s expense. Following Kissei&#146;s receipt of the Election Notice, the Parties shall mutually agree upon a list of no more than [***]
valuation firms, and CG shall have the sole right to choose the Valuation Firm from such list; provided that if the Parties, using good faith efforts, cannot agree on a list within [***] of the Election Notice, CG shall choose the Valuation Firm.
Prior to disclosing any Confidential Information to the Valuation Firm, CG, alone or in a <FONT STYLE="white-space:nowrap">three-way</FONT> agreement with Kissei, at Kissei&#146;s reasonable option, shall enter into a confidentiality agreement
consistent with <B>Article 10 (Confidentiality)</B> to facilitate disclosure of information to the Valuation Firm. The Valuation Firm shall develop and deliver a report of evidencing its calculations of the
<FONT STYLE="white-space:nowrap">Buy-Out</FONT> Option Price, in accordance with <B>Schedule 7.5.7</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&#8195;<B>No Obligation</B>. CG and the Transacting Party Group shall have no obligation to exercise the <FONT
STYLE="white-space:nowrap">Buy-Out</FONT> Option, and any solicitation of information or pricing from a Valuation Firm shall not constitute the Election Notice. CG and the Transacting Party Group shall only have the obligation to pay the <FONT
STYLE="white-space:nowrap">Buy-Out</FONT> Option Price to Kissei once CG or the Transacting Party Group provides the Election Notice to Kissei and completes the process described in <B>Section</B><B></B><B>&nbsp;7.5.7(c) (Valuation Firm)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B>&#8195;<B>Section 14.3 (Termination by Either Party for Insolvency or Bankruptcy)</B>. Replace &#147;<B>assessor</B>&#148; with
&#147;<B>assets</B>&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>The remainder of this page intentionally left blank; signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have caused their duly authorized representatives to
execute this First Amendment as of the First Amendment Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>KISSEI PHARMACEUTICAL CO., LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arthur Kwan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mutsuo Kanzawa</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Arthur Kuan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mutsuo Kanzawa</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amended and Restated Employment Agreement (this &#147;<U>Agreement</U>&#148;) is made by and between CG Oncology, Inc. (the
&#147;<U>Company</U>&#148;), and Arthur Kuan (&#147;<U>Executive</U>&#148;) (collectively referred to herein as the &#147;<U>Parties</U>&#148; or individually referred to as a &#147;<U>Party</U>&#148;), effective as of March&nbsp;15, 2023 (the
&#147;<U>Effective Date</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company currently employs Executive as its Chief Executive Officer pursuant to an Employment Agreement between Executive and the
Company dated July&nbsp;20, 2022 (the &#147;<U>Prior Agreement</U>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to amend and restate the Prior
Agreement on the terms and conditions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants
and agreements set forth below, the Parties hereto agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. <U>Employment</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>General</U>. Effective on the Effective Date, the Company shall employ Executive, and Executive shall be employed by the Company, for the period and in the positions set forth in this Section&nbsp;1, and subject to the other terms and conditions
herein provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment</U>. The Company and Executive acknowledge that
Executive&#146;s employment is and shall continue to be <FONT STYLE="white-space:nowrap">at-will,</FONT> as defined under applicable law, and that Executive&#146;s employment with the Company may be terminated by either Party at any time for any or
no reason (subject to the notice requirements of Section&nbsp;3(b)). This <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> nature of Executive&#146;s employment shall remain unchanged during Executive&#146;s tenure as an employee and may
not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. If Executive&#146;s employment terminates for any reason, Executive shall not be entitled to any severance payments, benefits, awards or
compensation other than as provided in this Agreement or otherwise agreed to in writing by the Company (including pursuant to the terms of any equity award agreement) or as provided by applicable law. The term of this Agreement (the
&#147;<U>Term</U>&#148;) shall commence on the Effective Date and end on the date this Agreement is terminated under Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Positions and Duties</U>. During the Term, Executive shall serve as Chief Executive Officer of the Company, with such responsibilities, duties and authority normally associated with such position and as may from time to time be reasonably
assigned to Executive by the Board of Directors (the &#147;<U>Board</U>&#148;). Executive shall report to the Board. Executive shall devote substantially all of Executive&#146;s working time and efforts to the business and affairs of the Company
(which shall include service to its affiliates, if applicable) and shall not engage in outside business activities (including serving on outside boards or committees) without the consent of the Board, <I>provided</I> that Executive shall be
permitted to (i)&nbsp;manage Executive&#146;s personal, financial and legal affairs, (ii)&nbsp;participate in trade associations, and (iii)&nbsp;serve on the board of directors of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> or <FONT STYLE="white-space:nowrap">tax-exempt</FONT> charitable organizations or, with the consent of the Board (not to be unreasonably withheld), the
board of directors of <FONT STYLE="white-space:nowrap">non-competitive</FONT> <FONT STYLE="white-space:nowrap">for-profit</FONT> businesses, in each case, subject to compliance with this Agreement and provided that such activities do not materially
interfere with Executive&#146;s performance of Executive&#146;s duties and responsibilities hereunder. Executive agrees to observe and comply with the reasonable rules and policies of the Company as adopted by the Company
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from time to time (to the extent they do not conflict with the terms of this Agreement), in each case, as amended from time to time, and as delivered or made available to Executive (each, a
&#147;<U>Policy</U>&#148;). The Company shall appoint Executive to the Board effective as of the Effective Date and shall renominate Executive to the Board upon expiration of his Board term during the Term. Executive&#146;s continued employment
shall not be a condition to continued service by Executive on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Principal Location</U>. During the Term, Executive shall
perform the services required by this Agreement at the Company&#146;s offices located in Irvine and/or Emeryville, California, <I>provided</I>, <I>however</I>, that the Parties acknowledge and agree that Executive may be required to travel to other
locations as may be necessary to fulfill Executive&#146;s duties and responsibilities hereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. <U>Compensation and Related Matters</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Annual Base Salary</U>. During the Term, Executive shall receive a base salary at a rate initially of $450,000 per annum, which shall be
paid in accordance with the customary payroll practices of the Company and shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for partial years of employment. Such annual base salary shall be reviewed (and may be adjusted for increase, but
not decrease) from time to time (such annual base salary, as it may be adjusted from time to time, the &#147;<U>Annual Base Salary</U>&#148;) by the Board or its compensation committee (&#147;<U>Compensation Committee</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Annual Cash Bonus</U><U> Opportunity</U>. During the Term, Executive will be eligible to participate in an annual incentive program
established by the Board or Compensation Committee with target level annual incentive compensation opportunities as may be determined by the Board or Compensation Committee from time to time, but with an annual &#147;target level&#148; incentive
bonus opportunity (the &#147;<U>Target Bonus</U>&#148;) that is not less than 40% of the Annual Base Salary. The annual bonus payable under the incentive program (&#147;<U>Annual Bonus</U>&#148;) shall be based on the achievement of performance
goals or such other criteria as may be determined by the Board or Compensation Committee. The payment of any Annual Bonus pursuant to the incentive program shall be subject to Executive&#146;s continued employment with the Company through the date
of payment, except as otherwise provided in Section&nbsp;4. The Annual Bonus shall be paid to Executive when paid generally to other senior executives of the Company, but in any event, to the extent determinable as of such time, not later than March
15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the year immediately following the applicable year for which such Annual Bonus is being paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Equity Awards</U>. During the Term, Executive will be eligible to participate and receive awards under the Company&#146;s equity plans
as in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Benefits</U>. During the Term, Executive (and Executive&#146;s spouse and/or eligible dependents
to the extent provided in the applicable plans and programs) shall be eligible to participate in and be covered under the health and welfare benefit plans and programs maintained by the Company for the benefit of its employees from time to time,
pursuant to the terms of such plans and programs including any medical, life, hospitalization, dental, disability, accidental death and dismemberment and travel accident insurance plans and programs on the same terms and conditions as those
applicable to similarly situated senior executives. In addition, during the Term, Executive shall be eligible to participate in any retirement, savings and other employee benefit plans and programs maintained from time to time by the Company for the
benefit of its senior executive officers. Nothing contained in this Section&nbsp;2(d) shall create or be deemed to create any obligation on the part of the Company to adopt or maintain any health, welfare, retirement or other benefit plan or program
at any time or to create any limitation on the Company&#146;s ability to modify or terminate any such plan or program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Vacation or
Paid Time Off</U>. During the Term, Executive shall be entitled to paid personal leave in accordance with the Company&#146;s Policies applicable to similarly situated executives. Any vacation or paid time off shall be taken in the reasonable
convenience of Executive. Through the Company&#146;s paid <FONT STYLE="white-space:nowrap">time-off</FONT> policies Executive will receive paid sick leave as required by state and any applicable local laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Business Expenses</U>. During the Term, the Company shall reimburse Executive for all
reasonable travel and other business expenses incurred by Executive in the performance of Executive&#146;s duties to the Company in accordance with the Company&#146;s Travel and Expense Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Indemnification and D&amp;O Insurance</U>. The Company shall indemnify Executive (and advance expenses to Executive) to the greatest
extent permitted by applicable state law and shall provide Executive with coverage under a directors&#146; and officers&#146; liability insurance policy to the same extent provided to other senior executives and directors of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. <U>Termination of Employment</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive&#146;s employment hereunder and the Term may be terminated by the Company or Executive, as applicable, without any breach of this
Agreement under the following circumstances and the Term will end on the Date of Termination: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Circumstances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Death</I>. Executive&#146;s employment hereunder shall terminate upon Executive&#146;s death. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Disability</I>. If Executive has incurred a Disability (as defined below), the Company may terminate Executive&#146;s
employment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Termination for Cause</I>. The Company may terminate Executive&#146;s employment for Cause (as
defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Termination without Cause</I>. The Company may terminate Executive&#146;s employment without
Cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Resignation from the Company with Good Reason. </I>Executive may resign Executive&#146;s employment with the
Company with Good Reason (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>Resignation from the Company without Good Reason</I>. Executive may
resign Executive&#146;s employment with the Company for any reason other than Good Reason or for no reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of
Termination</U>. Any termination of Executive&#146;s employment by the Company or by Executive under this <U>Section</U><U></U><U>&nbsp;3</U> (other than termination pursuant to Section&nbsp;3(a)(i)) shall be communicated by a written notice to the
other Party hereto (i)&nbsp;indicating the specific termination provision in this Agreement relied upon, (ii)&nbsp;setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#146;s
employment under the provision so indicated, if applicable, and (iii)&nbsp;specifying a Date of Termination which, if submitted by Executive, shall be at least thirty (30)&nbsp;days following the date of such notice (a &#147;<U>Notice of
Termination</U>&#148;); <I>provided, however</I>, that in the event that Executive delivers a Notice of Termination to the Company, the Company may, in its sole discretion, change the Date of Termination to any date that occurs following the date of
the Company&#146;s receipt of such Notice of Termination and is prior to the date specified in such Notice of Termination, but the termination will still be considered a resignation by Executive. A Notice of Termination submitted by the Company may
provide for a Date of Termination on the date Executive receives the Notice of Termination, or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date thereafter elected by the Company. The failure by either Party to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or Good Reason shall
not waive any right of the Party hereunder or preclude the Party from asserting such fact or circumstance in enforcing the Party&#146;s rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Company Obligations upon Termination</U>. Upon termination of Executive&#146;s employment pursuant to any of the circumstances listed
in this <U>Section</U><U></U><U>&nbsp;3</U>, Executive (or Executive&#146;s estate, if applicable) shall be entitled to receive the following (the &#147;<U>Accrued Obligations</U>&#148;): (i)&nbsp;the portion of Executive&#146;s Annual Base Salary
earned through the Date of Termination, but not yet paid to Executive (payable on the Company&#146;s next payroll date or such earlier date as required by applicable law); (ii) any expense reimbursements owed to Executive pursuant to
Section&nbsp;2(f), payable pursuant to the applicable policy; and (iii)&nbsp;any amount accrued and arising from Executive&#146;s participation in, or benefits accrued under any employee benefit plans, programs or arrangements, which amounts shall
be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the &#147;<U>Company Arrangements</U>&#148;). Except as otherwise expressly required by law (<U>e.g.</U>, COBRA) or
applicable Company Arrangement or as specifically provided herein, all of Executive&#146;s rights to salary, severance, benefits, bonuses, and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive&#146;s
employment hereunder. In the event that Executive&#146;s employment is terminated by the Company for any reason, Executive&#146;s sole and exclusive remedy for severance benefits shall be to receive the payments and benefits described in this
Section&nbsp;3(c) or Section&nbsp;4, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Deemed Resignation</U>. Upon termination of Executive&#146;s employment for
any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its subsidiaries, other than his position on the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Return of Property</U>. Upon termination of Executive&#146;s employment for any reason, unless otherwise specified in a written
agreement between Executive and the Company, Executive agrees to return to the Company all documents of the Company and its affiliates (and all copies thereof) and all other Company or Company affiliate property that Executive has in his or her
possession, custody, or control. Such property includes, without limitation: (i)&nbsp;any materials of any kind that Executive knows contain or embody any proprietary or confidential information of the Company or an affiliate of the Company (and all
reproductions thereof), (ii) computers (including, but not limited to, laptop computers, desktop computers and similar devices) and other portable electronic devices (including, but not limited to, tablet computers), cellular phones/smartphones,
credit cards, phone cards, entry cards, identification badges and keys, and (iii)&nbsp;any correspondence, drawings, manuals, letters, notes, notebooks, reports, programs, plans, proposals, financial documents, or any other documents concerning the
customers, business plans, marketing strategies, products and/or processes of the Company or any of its affiliates and any information received from the Company or any of its affiliates regarding third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. <U>Severance Payments</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Termination for Cause, or Termination Upon Death, Disability, Resignation from the Company Without Good Reason or Resignation from the Company for Good Reason Prior to a Change in Control or More Than Eighteen (18)</U><U></U><U>&nbsp;Months
Following a Change in Control</U>. If Executive&#146;s employment shall terminate as a result of Executive&#146;s death pursuant to Section&nbsp;3(a)(i) or Disability pursuant to Section&nbsp;3(a)(ii), pursuant to Section&nbsp;3(a)(iii) for Cause,
pursuant to Section&nbsp;3(a)(vi) for Executive&#146;s resignation from the Company without Good Reason, or pursuant to Section&nbsp;3(a)(v) for Executive&#146;s resignation from the Company without Good Reason, and such resignation for Good Reason
occurs prior to a Change in Control or more than eighteen (18)&nbsp;months following a Change in Control, then Executive shall not be entitled to any severance payments or benefits, except for the Accrued Obligations as provided in
Section&nbsp;3(c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination without Cause Prior to a Change in Control or More Than Eighteen
(18)</U><U></U><U>&nbsp;Months Following a Change in Control</U>. If Executive&#146;s employment terminates without Cause pursuant to Section&nbsp;3(a)(iv), and such termination without Cause occurs prior to a Change in Control or more than eighteen
(18)&nbsp;months following a Change in Control, then subject to Sections 3(e), 4(d) and 9(k), and Executive&#146;s continued compliance with the terms of this Agreement (including, without limitation, Section&nbsp;5), the Company shall pay Executive
in addition to the Accrued Obligations set forth in Section&nbsp;3(c), the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an amount in cash equal to
Executive&#146;s Annual Base Salary as in effect immediately prior to the Date of Termination, payable in a lump sum on the first regular payroll date following the effective date of Executive&#146;s Release (as defined below); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if Executive timely elects to receive continued medical, dental or vision coverage under one or more of the Company&#146;s
group medical, dental or vision plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), then the Company shall directly pay, or reimburse Executive for, the COBRA premiums for Executive
and Executive&#146;s covered dependents under such plans during the period commencing on Executive&#146;s Separation from Service and ending upon the earliest of (A)&nbsp;the last day of the twelve (12)&nbsp;month period following the Date of
Termination, (B)&nbsp;the date that Executive and/or Executive&#146;s covered dependents become no longer eligible for COBRA or (C)&nbsp;the date Executive becomes eligible to receive medical, dental or vision coverage, as applicable, from a
subsequent employer (and Executive agrees to promptly notify the Company of such eligibility) (the &#147;<U>COBRA Continuation Period</U>&#148;). Notwithstanding the foregoing, if the Company determines it cannot provide the foregoing benefit
without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide to Executive a taxable monthly payment in an
amount equal to the monthly COBRA premium that Executive would be required to pay to continue Executive&#146;s and Executive&#146;s covered dependents&#146; group health coverage in effect on the Date of Termination (which amount shall be based on
the premium for the first month of COBRA coverage), less the amount Executive would have had to pay to receive group health coverage as an active employee for Executive and his or her covered dependents based on the cost sharing levels in effect on
the Date of Termination, which payments shall for the remainder of the COBRA Continuation Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) an amount in
cash equal to the Target Bonus (and without regard to any reduction in the Target Bonus that resulted in Executive&#146;s resignation with Good Reason), prorated for the portion of the year in which Executive&#146;s Date of Termination occurs that
has elapsed through the Date of Termination, payable in a lump sum on the first regular payroll date following the effective date of Executive&#146;s Release (but in no event later than March&nbsp;15 of the calendar year following the year in which
Executive&#146;s Date of Termination occurs); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) such number of the outstanding, unvested Company equity awards held by
Executive under any Company equity compensation plans as would have vested during the twelve (12)&nbsp;months following the date of Executive&#146;s Separation from Service had Executive continued in employment or service with the Company during
such period shall immediately become vested on the effectiveness of the Release, <I>provided</I>, <I>however</I>, that any performance-based equity award will remain subject to attainment of the relevant performance goals unless a more favorable or
alternative provision is contained in an applicable award agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Change in Control</U>. In lieu of the payments and benefits set forth in
Section&nbsp;4(b), in the event Executive&#146;s employment terminates without Cause pursuant to Section&nbsp;3(a)(iv), or pursuant to Section&nbsp;3(a)(v) due to Executive&#146;s resignation with Good Reason, in either case, on or within eighteen
(18)&nbsp;months following the date of a Change in Control, then subject to Sections 3(e), 4(d) and 9(k), and Executive&#146;s continued compliance with the terms of this Agreement (including, without limitation, Section&nbsp;5), the Company shall
pay, Executive, in addition to the Accrued Obligations set forth in Section&nbsp;3(c), the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an amount in
cash equal to Executive&#146;s Annual Base Salary as in effect immediately prior to the Date of Termination (and without regard to any reduction in Annual Base Salary that resulted in Executive&#146;s resignation with Good Reason), payable in a lump
sum on the first regular payroll date following the effective date of Executive&#146;s Release; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) an amount in cash
equal to the Target Bonus (and without regard to any reduction in the Target Bonus that resulted in Executive&#146;s resignation with Good Reason), payable in a lump sum on the first regular payroll date following the effective date of
Executive&#146;s Release (but in no event later than March&nbsp;15 of the calendar year following the year in which Executive&#146;s Date of Termination occurs); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if Executive timely elects to receive continued medical, dental or vision coverage under one or more of the
Company&#146;s group medical, dental or vision plans pursuant to COBRA, then the Company shall directly pay, or reimburse Executive for, the COBRA premiums for Executive and Executive&#146;s covered dependents under such plans during the period
commencing on Executive&#146;s Separation from Service and ending upon the earliest of (A)&nbsp;the last day of the twelve (12)&nbsp;month period following the Date of Termination, (B)&nbsp;the date that Executive and/or Executive&#146;s covered
dependents become no longer eligible for COBRA or (C)&nbsp;the date Executive becomes eligible to receive medical, dental or vision coverage, as applicable, from a subsequent employer (and Executive agrees to promptly notify the Company of such
eligibility) (the &#147;<U>CIC COBRA Continuation Period</U>&#148;). Notwithstanding the foregoing, if the Company determines it cannot provide the foregoing benefit without potentially violating applicable law (including, without limitation,
Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay
to continue Executive&#146;s and Executive&#146;s covered dependents&#146; group health coverage in effect on the Date of Termination (which amount shall be based on the premium for the first month of COBRA coverage), less the amount Executive would
have had to pay to receive group health coverage as an active employee for Executive and his or her covered dependents based on the cost sharing levels in effect on the Date of Termination, which payments shall for the remainder of the CIC COBRA
Continuation Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) all outstanding, unvested Company equity awards held by Executive under any Company equity
compensation plans shall immediately become 100% vested on the effectiveness of the Release, <I>provided</I>, <I>however</I>, that any performance-based equity award will remain subject to attainment of the relevant performance goals unless a more
favorable or alternative provision is contained in an applicable award agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Release</U>. Notwithstanding the foregoing, it
shall be a condition to the Executive&#146;s right to receive the amounts provided for in Sections 4(b) and 4(c) hereof that the Executive execute and deliver to the Company an effective release of claims in substantially the form attached hereto as
<U>Exhibit A</U> (the &#147;<B><I>Release</I></B>&#148;) within 21 days (or, to the extent required by law, 45 days) following the Date of Termination and that the Executive not revoke such Release during any applicable revocation period. For the
avoidance of doubt, all equity awards eligible for accelerated vesting pursuant to this Section&nbsp;4 shall remain outstanding and eligible to vest following the Date of Termination and shall actually vest and become exercisable (if applicable) and
<FONT STYLE="white-space:nowrap">non-forfeitable</FONT> upon the effectiveness of the Release. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exclusive Remedy</U>. In the event of a termination of Executive&#146;s employment
with the Company, Executive&#146;s sole remedy shall be to receive the payments and benefits described in this Section&nbsp;4. In addition, Executive acknowledges and agrees that he or she is not entitled to any reimbursement by the Company for any
taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section&nbsp;4, including, without limitation, any excise tax imposed by Section&nbsp;4999 of the Code. Any payments made to Executive under
this Section&nbsp;4 shall be inclusive of any amounts or benefits to which Executive may be entitled pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations
thereunder, or any similar state statute. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. <U>Covenants</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Executive hereby acknowledges that Executive has previously entered into the Company&#146;s standard form of agreement containing
confidentiality, intellectual property assignment and other protective covenants (the &#147;<U>Restrictive Covenant Agreement</U>&#148;), a copy of which is attached hereto as <U>Exhibit B</U>, that Executive shall continue to be bound by the terms
and conditions of the Restrictive Covenant Agreement, and that such agreement shall be additional to, and not in limitation of, the covenants contained in this Section&nbsp;5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Executive shall hold in a fiduciary capacity for the benefit of the Company all secret or confidential information, knowledge or data
relating to the Company and its subsidiaries and affiliates, which shall have been obtained by Executive in connection with Executive&#146;s employment by the Company and which shall not be or become public knowledge (other than by acts by Executive
or representatives of Executive in violation of this Agreement). After termination of Executive&#146;s employment with the Company, Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal
process, communicate or divulge any such information, knowledge or data, to anyone other than the Company and those designated by it; <I>provided</I>, <I>however</I>, that if Executive receives actual notice that Executive is or may be required by
law or legal process to communicate or divulge any such information, knowledge or data, Executive shall promptly so notify the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) While employed by the Company, Executive shall not be engaged in any other business activity that would be competitive with the business
of the Company and its subsidiaries or affiliates. In addition, while employed by the Company and for a period of twelve (12)&nbsp;months after the Date of Termination, Executive shall not directly or indirectly solicit, induce, or encourage any
employee or consultant of the Company and/or its subsidiaries and affiliates to terminate their employment or other relationship with the Company and its subsidiaries and affiliates or to cease to render services to the Company and/or its
subsidiaries and affiliates and Executive shall not initiate discussion with any such person for any such purpose or authorize or knowingly cooperate with the taking of any such actions by any other individual or entity except, in each case, to the
extent the foregoing occurs as a result of general advertisements or other solicitations not specifically targeted to such employees and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Subject to Section&nbsp;5(f), during Executive&#146;s service with the Company and thereafter, excepting any litigation between the
Parties, (i)&nbsp;Executive agrees not to publish or disseminate, directly or indirectly, any statements, whether written or oral, that are or could be harmful to or reflect negatively on any of the Company or any of its subsidiaries or affiliates,
or that are otherwise disparaging of any policies, procedures, practices, decision-making, conduct, professionalism or compliance with standards of the Company, its affiliates or any of their past or present officers, directors, employees, advisors
or agents, and (ii) the Company agrees to instruct its directors and executive officers not to publish or disseminate, directly or indirectly, any statements, whether written or oral, that are or could be harmful to or reflect negatively on
Executive&#146;s personal or business reputation or business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) In recognition of the fact that irreparable injury will result to the Company in the
event of a breach by Executive of his or her obligations under Sections 5(a)-(d) hereof, that monetary damages for such breach would not be readily calculable, and that the Company would not have an adequate remedy at law therefor, Executive
acknowledges, consents and agrees that in the event of such breach, or the threat thereof, the Company shall be entitled, in addition to any other legal remedies and damages available, to specific performance thereof and to temporary and permanent
injunctive relief (without the necessity of posting a bond) to restrain the violation or threatened violation of such obligations by Executive and to cease the payment of any benefits under Section&nbsp;4(b) or (c)&nbsp;above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in this Agreement or the Restrictive Covenant Agreement or, if applicable, the Arbitration Agreement (as defined
below) to the contrary, nothing contained in this Agreement shall prohibit either party (or either party&#146;s attorney(s)) from (i)&nbsp;filing a charge with, reporting possible violations of federal law or regulation to, participating in any
investigation by, or cooperating with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority, the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health
Administration, the U.S. Commodity Futures Trading Commission, the U.S. Department of Justice or any other securities regulatory agency, self-regulatory authority or federal, state or local regulatory authority (collectively, &#147;<U>Government
Agencies</U>&#148;), or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation, (ii)&nbsp;communicating directly with, cooperating with, or providing information (including trade secrets) in
confidence to any Government Agencies for the purpose of reporting or investigating a suspected violation of law, or from providing such information to such party&#146;s attorney(s) or in a sealed complaint or other document filed in a lawsuit or
other governmental proceeding, and/or (iii)&nbsp;receiving an award for information provided to any Government Agency. Pursuant to 18 USC Section&nbsp;1833(b), Executive will not be held criminally or civilly liable under any federal or state trade
secret law for the disclosure of a trade secret that is made: (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a
suspected violation of law; or (y)&nbsp;in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, nothing in this Agreement is intended to or shall preclude either party from providing
truthful testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative or legal process or otherwise as required by law. If Executive is required to provide testimony, then unless otherwise directed or
requested by a Government Agency or law enforcement, Executive shall notify the Company as soon as reasonably practicable after receiving any such request of the anticipated testimony. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. <U>Assignment and Successors</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company may assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise). This Agreement shall be binding upon and inure to the benefit of
the Company, Executive and their respective successors, assigns, personal and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive&#146;s rights or obligations may be
assigned or transferred by Executive, other than Executive&#146;s rights to payments hereunder, which may be transferred only by will or operation of law. Notwithstanding the foregoing, Executive shall be entitled, to the extent permitted under
applicable law and applicable Company Arrangements, to select and change a beneficiary or beneficiaries to receive compensation hereunder following Executive&#146;s death by giving written notice thereof to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. <U>Certain Definitions</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Cause</U>. The Company shall have &#147;Cause&#148; to terminate Executive&#146;s employment hereunder upon: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the continued failure by Executive to substantially perform Executive&#146;s duties with the Company (other than any such failure resulting
from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to Executive by the Company or an affiliate that specifically identifies the alleged manner in which Executive has not substantially
performed Executive&#146;s duties and after Executive has been provided with a thirty (30)&nbsp;day cure period, or Executive&#146;s deliberate violation of a Company policy; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the engaging by Executive in illegal conduct or misconduct (including fraud, embezzlement, theft or dishonesty or material violation of
any Company policy), or gross negligence, in any case that has caused or is reasonably expected to result in injury to the Company or any affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Executive&#146;s commission of, or plea of no contest to, a felony or any misdemeanor crime involving fraud, moral turpitude or
dishonesty; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Executive&#146;s material breach of any written agreement or restrictive covenants with the Company; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Executive&#146;s violation of any law, rule or regulation relating in any way to the business or activities of the Company or any
affiliate, or other law, rule or regulation that is violated, during the course of Executive&#146;s performance of services hereunder that results in Executive&#146;s regulatory suspension or disqualification, including, without limitation, the
Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167; 335(a), or any similar legislation applicable in the United States or in any other country where the Company or any affiliate intends to develop its activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action or inaction based upon direction of the Board or advice of counsel to the Company shall constitute Cause. Poor performance shall
not, in and of itself, constitute Cause. No termination of Executive&#146;s employment for Cause shall occur absent a resolution of the Board and the reasonable opportunity for Executive (with Executive&#146;s counsel) to be heard before the Board.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Change in Control</U>. &#147;<U>Change in Control</U>&#148; shall have the meaning set forth in the Company&#146;s 2022 Incentive
Award Plan, as in effect on the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Code</U>. &#147;<U>Code</U>&#148; shall mean the Internal Revenue Code of 1986, as
amended, and the regulations and guidance promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Date of Termination</U>. &#147;<U>Date of Termination</U>&#148;
shall mean (i)&nbsp;if Executive&#146;s employment is terminated by Executive&#146;s death, the date of Executive&#146;s death; or (ii)&nbsp;if Executive&#146;s employment is terminated pursuant to Section&nbsp;3(a)(ii)-(vi) either the date
indicated in the Notice of Termination or the date specified by the Company pursuant to Section&nbsp;3(b), whichever is earlier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<U>Disability</U>. &#147;<U>Disability</U>&#148; shall mean, at any time the Company sponsors a long-term disability plan for the Company&#146;s employees, &#147;disability&#148; as defined in such long-term disability plan for the purpose of
determining a participant&#146;s eligibility for benefits, <I>provided, however</I>, if the long-term disability plan contains multiple definitions of disability, &#147;Disability&#148; shall refer to that definition of disability which, if
Executive qualified for such disability benefits, would provide coverage for the longest period of time. The determination of whether Executive has a Disability shall be made by the person or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
persons required to make disability determinations under the long-term disability plan. At any time the Company does not sponsor a long-term disability plan for its employees,
&#147;Disability&#148; shall mean Executive&#146;s inability to perform, with reasonable accommodation, the essential functions of Executive&#146;s positions hereunder for a total of<B> </B>180 days within a 12 month period as a result of incapacity
due to mental or physical illness as determined by a physician selected by the Company or its insurers and acceptable to Executive or Executive&#146;s legal representative, with such agreement as to acceptability not to be unreasonably withheld or
delayed. Any refusal by Executive to submit to a medical examination for the purpose of determining Disability shall be deemed to constitute conclusive evidence of Executive&#146;s Disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Good Reason</U>. For the sole purpose of determining Executive&#146;s right to severance payments and benefits as described above,
Executive&#146;s resignation will be with &#147;<U>Good Reason</U>&#148; if Executive resigns within one hundred twenty (120)&nbsp;days after any of the following events, unless Executive expressly consents in writing to the applicable event:
(i)&nbsp;a reduction in Executive&#146;s Annual Base Salary or Target Bonus, other than a reduction of less than ten percent (10%) (aggregating all prior reductions) that is implemented in connection with a contemporaneous reduction in annual base
salaries affecting other senior executives of the Company; (ii)&nbsp;a material decrease in Executive&#146;s authority or areas of responsibility as are commensurate with Executive&#146;s title or position with the Company (including the failure to
nominate Executive to the Board); (iii) the relocation of Executive&#146;s primary office to a location that increases Executive&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than fifty (50)&nbsp;miles from Executive&#146;s
commute to the location at which Executive is employed prior to such change; or (iv)&nbsp;the Company&#146;s breach of a material provision of this Agreement. Notwithstanding the foregoing, no Good Reason will have occurred unless and until:
(a)&nbsp;Executive has provided the Company, within sixty (60)&nbsp;days of Executive&#146;s knowledge of the occurrence of the facts and circumstances underlying the Good Reason event, written notice stating with specificity the applicable facts
and circumstances underlying such finding of Good Reason; (b)&nbsp;the Company has had an opportunity to cure the same within thirty (30)&nbsp;days after the receipt of such notice; and (c)&nbsp;the Company shall have failed to so cure within such
period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. <U>Parachute Payments</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Best Pay Provision</U>. In the event that any payment or benefit received or to be received by Executive pursuant to the terms of any
plan, arrangement or agreement (including any payment or benefit received in connection with a change in ownership or control or the termination of Executive&#146;s employment) (all such payments and benefits being hereinafter referred to as the
&#147;<U>Total Payments</U>&#148;) would be subject (in whole or part) to the excise tax (the &#147;<U>Excise Tax</U>&#148;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no
portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (after subtracting the
net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized
deductions and personal exemptions attributable to such unreduced Total Payments); <U>provided</U>, <U>however</U>, that this sentence shall not apply if, immediately before the change in ownership or control on which such Total Payments are
contingent or otherwise relate, no stock in the Company is readily tradeable on an established securities market or otherwise (as determined in accordance with Treasury Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.280G-1</FONT> Q&amp;A 6).
Except to the extent that an alternative reduction order would result in a greater economic benefit to Executive on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties intend that the Total Payments shall be reduced in the
following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to Executive that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or benefits otherwise payable to Executive that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from
Section&nbsp;409A of the Code, (y)&nbsp;reduction of any other payments or benefits otherwise payable to Executive on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but
excluding any payment attributable to the acceleration of vesting and payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or
payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the acceleration of vesting of Company
equity awards shall be first applied to equity awards with later vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies with and does not result in the
imposition of additional taxes on Executive under Section&nbsp;409A of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to Executive on an <FONT STYLE="white-space:nowrap">after-tax</FONT>
basis and, to the extent economically equivalent payments or benefits are subject to reduction, in a pro rata manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Determinations</U>. All determinations regarding the application of this Section&nbsp;8 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing
calculations regarding the applicability of Section&nbsp;280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#147;<U>280G Firm</U>&#148;). For purposes of determining
whether and the extent to which the Total Payments will be subject to the Excise Tax, (i)&nbsp;no portion of the Total Payments shall be taken into account which (x)&nbsp;does not constitute a &#147;parachute payment&#148; within the meaning of
Section&nbsp;280G(b)(2) of the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of
Section&nbsp;280G(b)(4)(B) of the Code, in excess of the &#147;base amount&#148; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of
which Executive shall have waived at such time and in such manner as not to constitute a &#147;payment&#148; within the meaning of Section&nbsp;280G(b) of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT
STYLE="white-space:nowrap">non-cash</FONT> benefit or any deferred payment or benefit included in the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All
determinations related to the calculations to be performed pursuant to this &#147;Section&nbsp;280G Treatment&#148; section shall be done by the 280G Firm. The 280G Firm will be directed to submit its determination and detailed supporting
calculations to both Executive and the Company within fifteen (15)&nbsp;days after notification from either the Company or Executive that Executive may receive payments which may be &#147;parachute payments.&#148; Executive and the Company will each
provide the 280G Firm access to and copies of any books, records, and documents as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and
calculations contemplated by this Agreement. The fees and expenses of the 280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be borne solely by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exception</U>. Notwithstanding the foregoing, if any portion of the Total Payments would not be subject to the Excise Tax if the
stockholder approval requirements of Section&nbsp;280G(b)(5) of the Code are satisfied, subject to Executive&#146;s waiver of the rights to such portion of the Total Payments above the safe harbor threshold in accordance with and to the extent
required by Section&nbsp;280G of the Code with respect to any portion of the Total Payments that would otherwise be subject to excise tax imposed by Section&nbsp;4999 of the Code (before giving effect to any reduction in the Total Payments
contemplated above), the Company shall use its reasonable best efforts to cause such payments to be submitted for such approval prior to the event giving rise to such payments. To the extent the Company submits any payment or benefit payable to
Executive under this Agreement or otherwise to the Company&#146;s stockholders for approval in accordance with Treasury Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.280G-1</FONT> Q&amp;A 7, the foregoing provisions under this Section&nbsp;8
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall not apply following such submission and such payments and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver above the safe harbor
threshold of, such payments or benefits required by such vote will be applied without any application of discretion by Executive and in the order prescribed in Section&nbsp;8(a). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. <U>Miscellaneous Provisions</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Governing Law and Venue</U>. This Agreement shall be governed, construed, interpreted and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the State of California without reference to the
principles of conflicts of law of the State of California or any other jurisdiction that would result in the application of the laws of a jurisdiction other than the State of California, and where applicable, the laws of the United States. Any suit
brought hereon shall be brought in the state or federal courts sitting in Orange County, California, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court
shall have in personam jurisdiction over it and consents to service of process in any manner authorized by California law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Validity</U>. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notices</U>. Any notice, request, claim, demand, document, and other communication hereunder to any Party shall be effective upon
receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile, email or certified or registered mail, postage prepaid, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If to the Company, to the Chairman of the Board of the Company at the Company&#146;s headquarters, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If to Executive, to the last address that the Company has in its personnel records for Executive, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) At any other address as any Party shall have specified by notice in writing to the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Counterparts</U>. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of
which together will constitute one and the same Agreement. Signatures delivered by facsimile or PDF shall be deemed effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Entire Agreement</U>. The terms of this Agreement, and the Restrictive Covenant Agreement incorporated herein by reference as set forth
in Section&nbsp;5, are intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof and supersede all prior understandings and agreements, whether written or oral, including any prior employment
offer letter or employment agreement between Executive and the Company (including the Prior Agreement). The Parties further intend that this Agreement shall constitute the complete and exclusive statement of their terms and that no extrinsic
evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Amendments; Waivers</U>. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a
duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party was or is obligated to comply with or perform; <I>provided</I>, <I>however</I>, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent
failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Construction</U>. This Agreement shall be deemed drafted equally by both the Parties. Its language shall be construed as a whole and
according to its fair meaning. Any presumption or principle that the language is to be construed against any Party shall not apply. The headings in this Agreement are only for convenience and are not intended to affect construction or
interpretation. Any references to paragraphs, subparagraphs, sections or subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary. Also, unless the context clearly indicates to the contrary, (i)&nbsp;the
plural includes the singular and the singular includes the plural; (ii) &#147;and&#148; and &#147;or&#148; are each used both conjunctively and disjunctively; (iii) &#147;any,&#148; &#147;all,&#148; &#147;each,&#148; or &#147;every&#148; means
&#147;any and all,&#148; and &#147;each and every&#148;; (iv) &#147;includes&#148; and &#147;including&#148; are each &#147;without limitation&#148;; (v) &#147;herein,&#148; &#147;hereof,&#148; &#147;hereunder&#148; and other similar compounds of
the word &#147;here&#148; refer to the entire Agreement and not to any particular paragraph, subparagraph, section or subsection; and (vi)&nbsp;all pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter,
singular or plural as the identity of the entities or persons referred to may require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Arbitration</U>. The Company offers a
voluntary arbitration program for California employees, which will be provided to Executive separately. The program is not a condition of employment. In the event Executive elects to participate in such voluntary arbitration program, such agreement
shall be referred to herein as the &#147;<U>Arbitration Agreement</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Enforcement</U>. If any provision of this Agreement
is held to be illegal, invalid or unenforceable under present or future laws effective during the Term, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision
had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from this
Agreement. Furthermore, in lieu of such illegal, invalid, or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible
and be legal, valid and enforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Withholding</U>. The Company shall be entitled to withhold from any amounts payable under
this Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on the advice of counsel if any questions as to the amount or requirement of
withholding shall arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>General.</I> The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt
from Section&nbsp;409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. If the Company and Executive agree in good faith that the payments and benefits under this Agreement would
not comply with Section&nbsp;409A, the Parties hereto shall reasonably and in good faith attempt to modify this Agreement to comply with Section&nbsp;409A while endeavoring to maintain the intended economic benefits hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Separation from Service. </I>Notwithstanding anything in this
Agreement to the contrary, (A)&nbsp;any compensation or benefits payable under this Agreement that is designated under this Agreement as payable upon Executive&#146;s termination of employment shall be payable only upon Executive&#146;s
&#147;separation from service&#148; with the Company within the meaning of Section&nbsp;409A (a &#147;<U>Separation from Service</U>&#148;) and (B)&nbsp;in the event that, with respect to the amounts payable under Sections 4(b) or 4(c), the timing
of the delivery of Executive&#146;s Release could cause such amounts to begin in one or another taxable year, to the extent such amounts are subject to Section&nbsp;409A, then notwithstanding the payment timing set forth in such Sections, such
amounts shall not be payable until the later of (1)&nbsp;the payment date specified in such Section or (2)&nbsp;the first business day of the taxable year following Executive&#146;s Separation from Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Specified Employee.</I> Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the
Company at the time of Executive&#146;s Separation from Service to be a &#147;specified employee&#148; for purposes of Section&nbsp;409A, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this
Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A, such portion of Executive&#146;s benefits shall not be provided to Executive prior to the earlier of (x)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap">six-month</FONT> period measured from the date of Executive&#146;s Separation from Service with the Company or (y)&nbsp;the date of Executive&#146;s death. Upon the first business day following the expiration of the
applicable Section&nbsp;409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive&#146;s estate or beneficiaries), and any remaining payments due to Executive under this Agreement
shall be paid as otherwise provided herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Expense Reimbursements. </I>To the extent that any reimbursements
under this Agreement are subject to Section&nbsp;409A, (A)&nbsp;any such reimbursements payable to Executive shall be paid to Executive no later than December&nbsp;31 of the year following the year in which the expense was incurred,
(B)&nbsp;Executive shall submit Executive&#146;s reimbursement request promptly following the date the expense is incurred, (C)&nbsp;the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any
subsequent year, other than medical expenses referred to in Section&nbsp;105(b) of the Code, and (D)&nbsp;Executive&#146;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Installments.</I> Executive&#146;s right to receive any installment payments under this Agreement, including without
limitation any continuation salary payments that are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate
and distinct payment as permitted under Section&nbsp;409A. Except as otherwise permitted under Section&nbsp;409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or
interest pursuant to Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Survival</U>. Notwithstanding anything to the contrary in this Agreement, the provisions
of Sections 5 through 9 will survive the termination of Executive&#146;s employment and the termination of the Term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. <U>Executive
Acknowledgement</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal
effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#146;s own judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement on the date and year first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Simone Song</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Simone Song</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; text-indent:-2.50em; font-size:10pt; font-family:Times New Roman">Title:&#8201;&#8202;Member of the Board of Directors&nbsp;&amp; Chairman of the Compensation
Committee</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Arthur Kuan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Print Name: Arthur Kuan</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Amended and Restated Employment Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#147;<U>Agreement</U>&#148;) is made by and between Arthur Kuan (&#147;<U>Executive</U>&#148;) and CG
Oncology, Inc. (the &#147;<U>Company</U>&#148;) (collectively referred to as the &#147;<U>Parties</U>&#148; or individually referred to as a &#147;<U>Party</U>&#148;). Capitalized terms used but not defined in this Agreement shall have the meanings
set forth in the Amended and Restated Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have previously entered into that
certain Amended and Restated Employment Agreement, dated as of March&nbsp;15, 2023 (the &#147;<U>Employment Agreement</U>&#148;) and that certain Restrictive Covenant Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#146;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[________], 20[__], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releases as defined below, including, but not
limited to, any and all claims arising out of or in any way related to Executive&#146;s employment with or separation from the Company or its subsidiaries or affiliates but, for the avoidance of doubt, nothing herein will be deemed to release any
rights or remedies in connection with Executive&#146;s ownership of vested equity securities of the Company, vested benefits or Executive&#146;s right to indemnification or liability insurance by the Company or any of its affiliates pursuant to
contract or applicable law (collectively, the &#147;<U>Retained Claims</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance
payments and benefits described in Section&nbsp;4 of the Employment Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Agreement,
and in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Severance Payments and Benefits; Salary
and Benefits</U>. The Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;4 of the Employment Agreement, payable at the times set forth in, and subject to the terms and conditions of, the Employment
Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive the Accrued Obligations described in Section&nbsp;3(c) of the Employment
Agreement, subject to and in accordance with the terms thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Release of Claims</U>. Executive agrees that, other than with respect to the
Retained Claims, the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries, and any of its or their current and former officers, directors,
equityholders, managers, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and successor corporations and assigns
(collectively, the &#147;<U>Releasees</U>&#148;) related to Executive&#146;s employment with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#146;s own behalf and on behalf of any of Executive&#146;s affiliated
companies or entities and any of their respective heirs, family members, executors, agents, and assigns, other than with respect to the Retained Claims, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any
manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive may possess against any
of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the date Executive signs this Agreement relating to Executive&#146;s employment with the Company or its subsidiaries or termination
therefrom, including, without limitation: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any and all claims relating to or arising from Executive&#146;s employment or service
relationship with the Company or any of its direct or indirect subsidiaries and the termination of that relationship; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any and all claims relating to, or arising from, Executive&#146;s right to purchase, or
actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state law,
and securities fraud under any state or federal law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any and all claims for wrongful discharge of employment; termination in
violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction
of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury;
assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any and all claims for violation of
any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the
Fair Labor Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining
Notification Act; the Family and Medical Leave Act; and the Sarbanes-Oxley Act of 2002; and the California Fair Employment and Housing Act, California Government Code Section&nbsp;12940, et seq.; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for violation of the federal or any state constitution; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the
<FONT STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has
provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#146; fees and costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL COUNSEL AND IS FAMILIAR WITH THE PROVISIONS
OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR
RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER
STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive agrees that the release set forth in this section shall be and remain in
effect in all respects as a complete general release as to the matters released. This release does not release claims that cannot be released as a matter of law, including, but not limited to, Executive&#146;s right to report possible violations of
federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the Sarbanes-Oxley Act of 2002, or any
other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, Executive&#146;s right to file a charge with or participate in a charge by the Equal Employment
Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company for discrimination (with the understanding that
Executive&#146;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment), claims for unemployment compensation or any state disability insurance benefits
pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#146;s group benefit plans pursuant to the terms and conditions of COBRA, claims for indemnity under the bylaws of the Company, as provided
for by California or Delaware law or under any applicable insurance policy with respect to Executive&#146;s liability as an employee, director or officer of the Company, claims to any benefit entitlements vested as the date of separation of
Executive&#146;s employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#146;s right under applicable law and any Retained Claims. This release further does not release claims for breach of
Section&nbsp;3(c) or Section&nbsp;4 of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive
understands and acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#147;<U>ADEA</U>&#148;), and that this waiver and release is knowing and voluntary. Executive
understands and agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the date Executive signs this Agreement. Executive understands and acknowledges that the consideration given for this
waiver and release is in addition to anything of value to which Executive was already entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a)&nbsp;Executive should consult with an attorney
prior to executing this Agreement; (b)&nbsp;Executive has <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] days within which to consider this Agreement, and the Parties agree that such time period to review this Agreement shall not be
extended upon any material or immaterial changes to this Agreement; (c)&nbsp;Executive has seven business days following Executive&#146;s execution of this Agreement to revoke this Agreement pursuant to written notice to the General Counsel of the
Company; (d)&nbsp;this Agreement shall not be effective until after the revocation period has expired; and (e)&nbsp;nothing in this Agreement prevents or precludes Executive from challenging or seeking a determination in good faith of the validity
of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Agreement and returns it to the Company in less than the <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)] day period identified above, Executive hereby acknowledges that Executive has freely and voluntarily chosen to waive the time period allotted for considering this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Severability</U>. In the event that any provision or any portion of any provision
hereof or any surviving agreement made a part hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or
portion of provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>No Oral Modification</U>. This Agreement may only be amended in a writing signed by Executive and a duly
authorized officer of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Governing Law; Dispute Resolution</U>. This Agreement shall be subject to the provisions of
Sections 9(a), 9(c), and 9(h) of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Effective Date</U>. Executive has seven business days after Executive
signs this Agreement to revoke it and this Agreement will become effective on the day immediately following the seventh business day after Executive signed this Agreement (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Voluntary Execution of Agreement</U>. Executive understands and agrees that Executive executed this Agreement voluntarily, without any
duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#146;s claims against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive
has read this Agreement; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement; (c)&nbsp;Executive has been represented in the preparation, negotiation, and
execution of this Agreement by legal counsel of Executive&#146;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands the terms and consequences of this Agreement and of the releases it contains; and
(e)&nbsp;Executive is fully aware of the legal and binding effect of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set
forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Print Name: Arthur Kuan</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>CG ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dated:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:0%; font-size:11pt; font-family:Times New Roman" ALIGN="center">RESTRICTIVE COVENANT AGREEMENT </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Attached</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>11
<FILENAME>filename11.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (this &#147;<U>Agreement</U>&#148;) is made by and between CG Oncology, Inc. (the &#147;<U>Company</U>&#148;), and
Ambaw Bellete (&#147;<U>Executive</U>&#148;) (collectively referred to herein as the &#147;<U>Parties</U>&#148; or individually referred to as a &#147;<U>Party</U>&#148;), effective as of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">09-Jul-2023</FONT></FONT> (the &#147;<U>Effective Date</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company seeks to employ Executive as its President and Chief Operating Officer; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to enter into an agreement setting forth the terms of such employment as of the Effective Date, which supersedes
any and all prior understandings and agreements, whether written or oral, including any prior employment offer letters, between Executive and the Company or any of its affiliates, subject to the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as
follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Employment</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Effective on the Effective Date, the Company shall employ Executive, and Executive shall be employed by the Company, for
the period and in the positions set forth in this Section&nbsp;1, and subject to the other terms and conditions herein provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U><FONT
STYLE="white-space:nowrap">At-Will</FONT> Employment</U>. The Company and Executive acknowledge that Executive&#146;s employment is and shall continue to be <FONT STYLE="white-space:nowrap">at-will,</FONT> as defined under applicable law, and that
Executive&#146;s employment with the Company may be terminated by either Party at any time for any or no reason (subject to the notice requirements of Section&nbsp;3(b)). This <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> nature of
Executive&#146;s employment shall remain unchanged during Executive&#146;s tenure as an employee and may not be changed, except in an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement (the
&#147;<U>Term</U>&#148;) shall commence on the Effective Date and end on the date this Agreement is terminated under Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Positions and Duties</U>. During the Term, Executive initially shall serve as President and Chief Operating Officer of the Company, with such responsibilities, duties and authority normally associated with such positions and as may from time to
time be reasonably assigned to Executive by the Chief Executive Officer of the Company (the &#147;<U>CEO</U>&#148;). Initial functional oversight will include Commercial, Sales, Marketing, Regulatory, Quality, Project Management, and Alliance
Management with an overall focus on working with the Board of Directors and CEO to exploit market opportunities and build relationships with investors, partners, industry contacts, and customers to create long term value for the organization;
defining the strategies and tactics across the organization that will help achieve the corporate strategic plan and goals to advance the product pipeline, marketing/sales, productivity, and profitability targets; working with every functional leader
to help them optimize productivity; increasing revenue/cash flow while also helping to manage operational costs; and developing strategies and tactics to operationalize corporate growth opportunities leveraging the organization&#146;s resources.
Executive shall report to the CEO. Executive shall devote substantially all of Executive&#146;s working time and efforts to the business and affairs of the Company (which shall include service to its affiliates, if applicable) and shall not engage
in outside business activities (including serving on outside boards or committees) without the consent of the CEO or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Board, <I>provided</I> that Executive shall be permitted to (i)&nbsp;manage Executive&#146;s personal, financial and legal affairs, (ii)&nbsp;participate in trade associations,
(iii)&nbsp;serve on the board of directors of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> or <FONT STYLE="white-space:nowrap">tax-exempt</FONT> charitable organizations or, with the consent of the
Board (not to be unreasonably withheld), the board of directors of <FONT STYLE="white-space:nowrap">non-competitive</FONT> <FONT STYLE="white-space:nowrap">for-profit</FONT> businesses, in each case, subject to compliance with this Agreement and
provided that such activities do not materially interfere with Executive&#146;s performance of Executive&#146;s duties and responsibilities hereunder, and (iv)&nbsp;provide consulting services to the
<FONT STYLE="white-space:nowrap">non-competitive</FONT> businesses listed on <U>Schedule 1</U> hereto, subject to compliance with this Agreement and provided that such consulting services are performed in a manner consistent with such services
performed prior to the Effective Date and do not materially interfere with Executive&#146;s performance of Executive&#146;s duties and responsibilities hereunder. Executive&#146;s engagement in outside business activities, including consulting
services for any additional <FONT STYLE="white-space:nowrap">non-competitive</FONT> businesses that are not listed on <U>Schedule 1</U>, shall be subject to the consent of the CEO or Board. Executive agrees to observe and comply with the reasonable
rules and policies of the Company as adopted by the Company from time to time (to the extent they do not conflict with the terms of this Agreement), in each case, as amended from time to time, and as delivered or made available to Executive (each, a
&#147;<U>Policy</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Principal Location</U>. During the Term, Executive shall perform the services required by this
Agreement at his home office in New Jersey, located at 2 Vail Lane, Flemington, NJ 08822 (the &#147;<U>Principal Location</U>&#148;) as of the Effective Date, <I>provided</I>, <I>however</I>, that the Parties acknowledge and agree that Executive may
be required to travel to other locations as may be necessary to fulfill Executive&#146;s duties and responsibilities hereunder. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Compensation and Related Matters</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Annual Base Salary</U>. During the Term, Executive shall receive a base salary at a rate initially of $430,000 per annum, which shall be
paid in accordance with the customary payroll practices of the Company and shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for partial years of employment. Such annual base salary shall be reviewed (and may be adjusted for increase, but
not decrease) from time to time (such annual base salary, as it may be adjusted from time to time, the &#147;<U>Annual Base Salary</U>&#148;) by the Board or its compensation committee (&#147;<U>Compensation Committee</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Annual Cash Bonus</U><U> Opportunity</U>. During the Term, Executive will be eligible to participate in an annual incentive program
established by the Board or Compensation Committee with target level annual incentive compensation opportunities as may be determined by the Board or Compensation Committee from time to time, but with an annual &#147;target level&#148; incentive
bonus opportunity (the &#147;<U>Target Bonus</U>&#148;) that is not less than 40% of the Annual Base Salary. The annual bonus payable under the incentive program (&#147;<U>Annual Bonus</U>&#148;) shall be based on the achievement of performance
goals or such other criteria as may be determined by the Board or Compensation Committee. The payment of any Annual Bonus pursuant to the incentive program shall be subject to Executive&#146;s continued employment with the Company through the date
of payment, except as otherwise provided in Section&nbsp;4. The Annual Bonus shall be paid to Executive when paid generally to other senior executives of the Company, but in any event, to the extent determinable as of such time, not later than March
15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of the year immediately following the applicable year for which such Annual Bonus is being paid. For the year ending December&nbsp;31, 2023, Executive&#146;s Annual Bonus shall not be <FONT
STYLE="white-space:nowrap">pro-rated</FONT> for the partial year of employment and Executive shall receive the full Annual Bonus for 2023 based on the level of achievement of performance goals or other such criteria as determined by the Board or
Compensation Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U><FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus</U>. Executive shall be entitled to a <FONT
STYLE="white-space:nowrap">one-time</FONT> signing bonus equal to the amount of $125,000, less any taxable withholdings (the &#147;<U><FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus</U>&#148;), which will be paid not later than 30 days
following Executive&#146;s start date. If Executive is terminated for Cause or voluntarily leaves the Company without Good Reason prior to completing twelve (12)&nbsp;months of service from Executive&#146;s start date, Executive shall be required to
repay to the Company, within thirty (30)&nbsp;days following Executive&#146;s last day of employment with the Company, 100% of the <FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Equity Awards</U>. During the Term, Executive will be eligible to participate and
receive awards under the Company&#146;s equity plans as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Initial Option</I>: On
June&nbsp;14, 2023, Executive was granted stock options to purchase 4,122,091 shares of the Company&#146;s common stock (the &#147;<U>Shares</U>&#148;) (the &#147;<U>Initial Option</U>&#148;). The Initial Option was granted in accordance with the
Company&#146;s 2022 Incentive Award Plan (the &#147;Plan&#148;) and related stock option documents. The Initial Option has an exercise price per share equal to the fair market value on the grant date, as determined by the Board. Subject to
Executive&#146;s continued employment with the Company, the Initial Option will vest over a four-year period starting on the Effective Date (the &#147;<U>Vesting Commencement Date</U>&#148;), with 25% of the shares fully vested twelve
(12)&nbsp;months after the Vesting Commencement Date and the remainder vesting in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;equal monthly installments over the subsequent three (3)&nbsp;year period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Milestone Option</I>: On June&nbsp;14, 2023, Executive was also granted stock options to purchase 1,161,680 Shares (the
&#147;<U>Milestone Option</U>&#148;). The Milestone Option was granted in accordance with the Plan and related stock option documents. The Milestone Option has an exercise price per share equal to the fair market value on the grant date, as
determined by the Board. The Milestone Option will vest as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) 280,000 Shares subject to the Milestone Option
(the &#147;<U>First Milestone Option</U>&#148;) will be eligible to vest upon successful completion of the initial public offering of the Company&#146;s common stock on a public exchange by December&nbsp;31, 2026, subject to Executive&#146;s
continued employment with the Company through such date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) 280,000 Shares subject to the Milestone Option (the
&#147;<U>Second Milestone Option</U>&#148;) will be eligible to vest upon the enrolment of the first patient in the IR trial by December&nbsp;31, 2026, subject to Executive&#146;s continued employment with the Company through such date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) 160,840 Shares subject to the Milestone Option (the &#147;<U>Third Milestone Option</U>&#148;) will be eligible to vest
upon the Company achieving commercial organization readiness by December&nbsp;31, 2026, as determined by the Board, subject to Executive&#146;s continued employment with the Company through such date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D) 280,000 Shares subject to the Milestone Option (the &#147;<U>Fourth Milestone Option</U>&#148;) will be eligible to vest
upon the approval by the Federal Drug Administration of the Company&#146;s Biologics License Application with respect to cretostimogene grenadenorepvec (CG0070) (&#147;<U>BLA Approval</U>&#148;), provided such BLA Approval occurs on or before
December&nbsp;31, 2026, subject to Executive&#146;s continued employment with the Company through such date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(E)
160,840 Shares subject to the Milestone Option (the &#147;<U>Fifth Milestone Option</U>&#148;) will be eligible to vest upon the Company&#146;s achievement of the first successful commercial sale by December&nbsp;31, 2026, subject to
Executive&#146;s continued employment with the Company through such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Benefits</U>. During the Term, Executive (and Executive&#146;s spouse and/or eligible
dependents to the extent provided in the applicable plans and programs) shall be eligible to participate in and be covered under the health and welfare benefit plans and programs maintained by the Company for the benefit of its employees from time
to time, pursuant to the terms of such plans and programs including any medical, life, hospitalization, dental, disability, accidental death and dismemberment and travel accident insurance plans and programs on the same terms and conditions as those
applicable to similarly situated senior executives. In addition, during the Term, Executive shall be eligible to participate in any retirement, savings and other employee benefit plans and programs maintained from time to time by the Company for the
benefit of its senior executive officers. Nothing contained in this Section&nbsp;2(e) shall create or be deemed to create any obligation on the part of the Company to adopt or maintain any health, welfare, retirement or other benefit plan or program
at any time or to create any limitation on the Company&#146;s ability to modify or terminate any such plan or program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Vacation or
Paid Time Off</U>. During the Term, Executive shall be entitled to paid personal leave in accordance with the Company&#146;s Policies applicable to similarly situated executives. Any vacation or paid time off shall be taken in the reasonable
convenience of Executive. Through the Company&#146;s paid <FONT STYLE="white-space:nowrap">time-off</FONT> policies Executive will receive paid sick leave as required by state and any applicable local laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Business Expenses</U>. During the Term, the Company shall reimburse Executive for all reasonable travel and other business expenses
incurred by Executive in the performance of Executive&#146;s duties to the Company in accordance with the Company&#146;s Travel and Expense Reimbursement Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Relocation Reimbursement</U>. If the Company should require Executive to relocate from the Principal Location to the Orange County,
California area in order to work from the Company&#146;s principal executive offices, the Company shall pay for or reimburse Executive for Executive&#146;s reasonable relocation expenses (the &#147;<U>Relocation Reimbursement</U>&#148;). In
addition, the Company shall pay to Executive a tax <FONT STYLE="white-space:nowrap">gross-up</FONT> (the &#147;<U>Tax <FONT STYLE="white-space:nowrap">Gross-Up</FONT></U>&#148;) for any federal and state income and employment taxes that Executive is
required to pay resulting from the Relocation Reimbursement and from the Tax <FONT STYLE="white-space:nowrap">Gross-Up,</FONT> which Tax <FONT STYLE="white-space:nowrap">Gross-Up</FONT> shall be paid in accordance with Treasury Regulation <FONT
STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(v).&nbsp;The</FONT> Relocation Reimbursement and any Tax <FONT STYLE="white-space:nowrap">Gross-Up</FONT> shall be subject to an aggregate cap of $90,000.&nbsp;All amounts eligible for the
Relocation Reimbursement must be incurred by and paid to Executive during the term of Executive&#146;s employment with the Company. The Relocation Reimbursement and the Tax <FONT STYLE="white-space:nowrap">Gross-Up</FONT> shall be paid to Executive
within thirty (30)&nbsp;days following the Company&#146;s receipt of a written request for such reimbursement, but subject to receipt by the Company of supporting receipts and/or documentation and/or receipts in form and substance reasonably
acceptable to the Company in a manner required by the Company&#146;s Travel and Expense Reimbursement Policy.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Indemnification and
D&amp;O Insurance</U>. The Company shall indemnify Executive (and advance expenses to Executive) to the greatest extent permitted by applicable state law and shall provide Executive with coverage under a directors&#146; and officers&#146; liability
insurance policy to the same extent provided to other senior executives and directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Termination of Employment</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive&#146;s employment hereunder and the Term may be terminated by the Company or Executive, as applicable, without any breach of this
Agreement under the following circumstances and the Term will end on the Date of Termination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Circumstances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Death</I>. Executive&#146;s employment hereunder shall terminate upon Executive&#146;s death. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Disability</I>. If Executive has incurred a Disability (as defined below), the Company may terminate Executive&#146;s
employment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Termination for Cause</I>. The Company may terminate Executive&#146;s employment for Cause (as
defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Termination without Cause</I>. The Company may terminate Executive&#146;s employment without
Cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Resignation from the Company with Good Reason. </I>Executive may resign Executive&#146;s employment with the
Company with Good Reason (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>Resignation from the Company without Good Reason</I>. Executive may
resign Executive&#146;s employment with the Company for any reason other than Good Reason or for no reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of
Termination</U>. Any termination of Executive&#146;s employment by the Company or by Executive under this <U>Section</U><U></U><U>&nbsp;3</U> (other than termination pursuant to Section&nbsp;3(a)(i)) shall be communicated by a written notice to the
other Party hereto (i)&nbsp;indicating the specific termination provision in this Agreement relied upon, (ii)&nbsp;setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#146;s
employment under the provision so indicated, if applicable, and (iii)&nbsp;specifying a Date of Termination which, if submitted by Executive, shall be at least thirty (30)&nbsp;days following the date of such notice (a &#147;<U>Notice of
Termination</U>&#148;); <I>provided, however</I>, that in the event that Executive delivers a Notice of Termination to the Company, the Company may, in its sole discretion, change the Date of Termination to any date that occurs following the date of
the Company&#146;s receipt of such Notice of Termination and is prior to the date specified in such Notice of Termination, but the termination will still be considered a resignation by Executive. A Notice of Termination submitted by the Company may
provide for a Date of Termination on the date Executive receives the Notice of Termination, or any date thereafter elected by the Company. The failure by either Party to set forth in the Notice of Termination any fact or circumstance which
contributes to a showing of Cause or Good Reason shall not waive any right of the Party hereunder or preclude the Party from asserting such fact or circumstance in enforcing the Party&#146;s rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Company Obligations upon Termination</U>. Upon termination of Executive&#146;s employment pursuant to any of the circumstances listed
in this <U>Section</U><U></U><U>&nbsp;3</U>, Executive (or Executive&#146;s estate, if applicable) shall be entitled to receive, at a minimum, the following (the &#147;<U>Accrued Obligations</U>&#148;): (i)&nbsp;the portion of Executive&#146;s
Annual Base Salary earned through the Date of Termination, but not yet paid to Executive (payable on the Company&#146;s next payroll date or such earlier date as required by applicable law); (ii) any expense reimbursements owed to Executive pursuant
to Section&nbsp;2(g), payable pursuant to the applicable policy; and (iii)&nbsp;any amount accrued and arising from Executive&#146;s participation in, or benefits accrued under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements
(collectively, the &#147;<U>Company Arrangements</U>&#148;). Except as otherwise expressly required by law (<U>e.g.</U>, COBRA) or applicable Company Arrangement or as specifically provided herein, all of Executive&#146;s rights to salary,
severance, benefits, bonuses, and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive&#146;s employment hereunder. In the event that Executive&#146;s employment is terminated by the Company for any reason,
Executive&#146;s sole and exclusive remedy for severance benefits shall be to receive the payments and benefits described in this Section&nbsp;3(c) or Section&nbsp;4, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Deemed Resignation</U>. Upon termination of Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from
all offices and directorships, if any, then held with the Company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Return of Property</U>. Upon
termination of Executive&#146;s employment for any reason, unless otherwise specified in a written agreement between Executive and the Company, Executive agrees to return to the Company all documents of the Company and its affiliates (and all copies
thereof) and all other Company or Company affiliate property that Executive has in his possession, custody, or control. Such property includes, without limitation: (i)&nbsp;any materials of any kind that Executive knows contain or embody any
proprietary or confidential information of the Company or an affiliate of the Company (and all reproductions thereof), (ii) computers (including, but not limited to, laptop computers, desktop computers and similar devices) and other portable
electronic devices (including, but not limited to, tablet computers), cellular phones/smartphones, credit cards, phone cards, entry cards, identification badges and keys, and (iii)&nbsp;any correspondence, drawings, manuals, letters, notes,
notebooks, reports, programs, plans, proposals, financial documents, or any other documents concerning the customers, business plans, marketing strategies, products and/or processes of the Company or any of its affiliates and any information
received from the Company or any of its affiliates regarding third parties. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Severance Payments</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination for Cause, or Termination Upon Death, Disability, Resignation from the Company Without Good Reason or Resignation from the
Company for Good Reason Prior to a Change in Control or More Than Eighteen (18)</U><U></U><U>&nbsp;Months Following a Change in Control</U>. If Executive&#146;s employment shall terminate as a result of Executive&#146;s death pursuant to
Section&nbsp;3(a)(i) or Disability pursuant to Section&nbsp;3(a)(ii), pursuant to Section&nbsp;3(a)(iii) for Cause, pursuant to Section&nbsp;3(a)(vi) for Executive&#146;s resignation from the Company without Good Reason, or pursuant to
Section&nbsp;3(a)(v) for Executive&#146;s resignation from the Company with Good Reason, and such resignation for Good Reason occurs prior to a Change in Control or more than eighteen (18)&nbsp;months following a Change in Control, then Executive
shall not be entitled to any severance payments or benefits, except for the Accrued Obligations as provided in Section&nbsp;3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Termination without Cause Prior to a Change in Control or More Than Eighteen (18)</U><U></U><U>&nbsp;Months Following a Change in Control</U>. If Executive&#146;s employment terminates without Cause pursuant to Section&nbsp;3(a)(iv), and such
termination without Cause occurs prior to a Change in Control or more than eighteen (18)&nbsp;months following a Change in Control, then subject to Sections 3(e), 4(d) and 9(k), and Executive&#146;s continued compliance with the terms of this
Agreement (including, without limitation, Section&nbsp;5), the Company shall pay Executive in addition to the Accrued Obligations set forth in Section&nbsp;3(c), the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an amount in cash equal to Executive&#146;s Annual Base Salary as in effect immediately prior to the Date of Termination,
payable in a lump sum on the first regular payroll date following the effective date of Executive&#146;s Release (as defined below); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if Executive timely elects to receive continued medical, dental or
vision coverage under one or more of the Company&#146;s group medical, dental or vision plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), then the Company shall directly pay, or
reimburse Executive for, the COBRA premiums for Executive and Executive&#146;s covered dependents under such plans during the period commencing on Executive&#146;s Separation from Service and ending upon the earliest of (A)&nbsp;the last day of the
twelve (12)&nbsp;month period following the Date of Termination, (B)&nbsp;the date that Executive and/or Executive&#146;s covered dependents become no longer eligible for COBRA or (C)&nbsp;the date Executive becomes eligible to receive medical,
dental or vision coverage, as applicable, from a subsequent employer (and Executive agrees to promptly notify the Company of such eligibility) (the &#147;<U>COBRA Continuation Period</U>&#148;). Notwithstanding the foregoing, if the Company
determines it cannot provide the foregoing benefit without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide
to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that Executive would be required to pay to continue Executive&#146;s and Executive&#146;s covered dependents&#146; group health coverage in effect on the Date of
Termination (which amount shall be based on the premium for the first month of COBRA coverage), less the amount Executive would have had to pay to receive group health coverage as an active employee for Executive and his covered dependents based on
the cost sharing levels in effect on the Date of Termination, which payments shall for the remainder of the COBRA Continuation Period; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) an amount in cash equal to the Target Bonus (and without regard to any reduction in the Target Bonus that resulted in
Executive&#146;s resignation with Good Reason), prorated for the portion of the year in which Executive&#146;s Date of Termination occurs that has elapsed through the Date of Termination, payable in a lump sum on the first regular payroll date
following the effective date of Executive&#146;s Release (but in no event later than March&nbsp;15 of the calendar year following the year in which Executive&#146;s Date of Termination occurs); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) (A) with respect to Company equity awards held by Executive other than the Initial Option, such number of the outstanding,
unvested Company equity awards held by Executive under any Company equity compensation plans as would have vested during the twelve (12)&nbsp;months following the date of Executive&#146;s Separation from Service had Executive continued in employment
or service with the Company during such period shall immediately become vested on the effectiveness of the Release; <I>provided</I>, <I>however</I>, that, with respect to this clause (A), any performance-based equity award will remain subject to
attainment of the relevant performance goals unless a more favorable or alternative provision is contained in an applicable award agreement; and (B)&nbsp;with respect to the Initial Option only, (1)&nbsp;to the extent such termination occurs prior
to the first (1<SUP STYLE="font-size:75%; vertical-align:top">st</SUP>) anniversary of the Effective Date, such portion of the Initial Option as would have vested during the twelve (12)&nbsp;months following the date of Executive&#146;s Separation
from Service had Executive continued in employment or service with the Company during such period shall immediately become vested on the effectiveness of the Release; (2)&nbsp;to the extent such termination occurs on or after the first (1<SUP
STYLE="font-size:75%; vertical-align:top">st</SUP>) anniversary of the Effective Date but prior to the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) anniversary of the Effective Date, such portion of the Initial Option as would
have vested during the eighteen (18)&nbsp;months following the date of Executive&#146;s Separation from Service had Executive continued in employment or service with the Company during such period shall immediately become vested on the effectiveness
of the Release; and (3)&nbsp;to the extent such termination occurs on or after the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) anniversary of the Effective Date, any remaining unvested portion of the Initial Option shall
immediately become vested on the effectiveness of the Release; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) outplacement services by a nationally or industry-recognized
outplacement services organization of the Executive&#146;s choosing, subject to the written consent of the Company (not to be unreasonably withheld), for the cost of twelve (12)&nbsp;months of professional outplacement services for the Executive up
to a maximum cost of $20,000, <I>provided</I> that the Executive commences the use of such services no later than the ninetieth (90th) day following the Date of Termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Change in Control</U>. In lieu of the payments and benefits set forth in Section&nbsp;4(b), in the event Executive&#146;s employment
terminates without Cause pursuant to Section&nbsp;3(a)(iv), or pursuant to Section&nbsp;3(a)(v) due to Executive&#146;s resignation with Good Reason, in either case, on or within eighteen (18)&nbsp;months following the date of a Change in Control,
then subject to Sections 3(e), 4(d) and 9(k), and Executive&#146;s continued compliance with the terms of this Agreement (including, without limitation, Section&nbsp;5), the Company shall pay Executive, in addition to the Accrued Obligations set
forth in Section&nbsp;3(c), the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an amount in cash equal to Executive&#146;s Annual Base Salary as in effect
immediately prior to the Date of Termination (and without regard to any reduction in Annual Base Salary that resulted in Executive&#146;s resignation with Good Reason), payable in a lump sum on the first regular payroll date following the effective
date of Executive&#146;s Release; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) an amount in cash equal to the Target Bonus (and without regard to any reduction in
the Target Bonus that resulted in Executive&#146;s resignation with Good Reason), payable in a lump sum on the first regular payroll date following the effective date of Executive&#146;s Release (but in no event later than March&nbsp;15 of the
calendar year following the year in which Executive&#146;s Date of Termination occurs); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if Executive timely elects
to receive continued medical, dental or vision coverage under one or more of the Company&#146;s group medical, dental or vision plans pursuant to COBRA, then the Company shall directly pay, or reimburse Executive for, the COBRA premiums for
Executive and Executive&#146;s covered dependents under such plans during the period commencing on Executive&#146;s Separation from Service and ending upon the earliest of (A)&nbsp;the last day of the twelve (12)&nbsp;month period following the Date
of Termination, (B)&nbsp;the date that Executive and/or Executive&#146;s covered dependents become no longer eligible for COBRA or (C)&nbsp;the date Executive becomes eligible to receive medical, dental or vision coverage, as applicable, from a
subsequent employer (and Executive agrees to promptly notify the Company of such eligibility) (the &#147;<U>CIC COBRA Continuation Period</U>&#148;). Notwithstanding the foregoing, if the Company determines it cannot provide the foregoing benefit
without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide to Executive a taxable monthly payment in an
amount equal to the monthly COBRA premium that Executive would be required to pay to continue Executive&#146;s and Executive&#146;s covered dependents&#146; group health coverage in effect on the Date of Termination (which amount shall be based on
the premium for the first month of COBRA coverage), less the amount Executive would have had to pay to receive group health coverage as an active employee for Executive and his covered dependents based on the cost sharing levels in effect on the
Date of Termination, which payments shall for the remainder of the CIC COBRA Continuation Period; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) all outstanding,
unvested Company equity awards held by Executive under any Company equity compensation plans shall immediately become 100% vested on the effectiveness of the Release, <I>provided</I>, <I>however</I>, that any performance-based equity award will
remain subject to attainment of the relevant performance goals unless a more favorable or alternative provision is contained in an applicable award agreement; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) outplacement services by a nationally or industry-recognized
outplacement services organization of the Executive&#146;s choosing, subject to the written consent of the Company (not to be unreasonably withheld), for the cost of eighteen (18)&nbsp;months of professional outplacement services for the Executive
up to a maximum cost of $20,000, <I>provided</I> that the Executive commences the use of such services no later than the ninetieth (90th) day following the Date of Termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Release</U>. Notwithstanding the foregoing, it shall be a condition to the Executive&#146;s right to receive the amounts provided for
in Sections 4(b) and 4(c) hereof that the Executive execute and deliver to the Company an effective release of claims in substantially the form attached hereto as <U>Exhibit A</U> (the &#147;<B><I>Release</I></B>&#148;) within 21 days (or, to the
extent required by law, 45 days) following the Date of Termination and that the Executive not revoke such Release during any applicable revocation period. For the avoidance of doubt, all equity awards eligible for accelerated vesting pursuant to
this Section&nbsp;4 shall remain outstanding and eligible to vest following the Date of Termination and shall actually vest and become exercisable (if applicable) and <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> upon the effectiveness of
the Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exclusive Remedy</U>. In addition, Executive acknowledges and agrees that he is not entitled to any reimbursement by
the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section&nbsp;4, including, without limitation, any excise tax imposed by Section&nbsp;4999 of the Code. Any payments made
to Executive under this Section&nbsp;4 shall be inclusive of any amounts or benefits to which Executive may be entitled pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor
regulations thereunder, or any similar state statute. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Covenants</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In connection with his commencement of employment, Executive has entered into the form of agreement containing confidentiality,
intellectual property assignment and other protective covenants (the &#147;<U>Restrictive Covenant Agreement</U>&#148;), which is attached hereto as <U>Exhibit B</U>. Executive shall be bound by the terms and conditions of the Restrictive Covenant
Agreement, and hereby agrees that such agreement shall be additional to, and not in limitation of, the covenants contained in this Section&nbsp;5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Executive shall hold in a fiduciary capacity for the benefit of the Company all secret or confidential information, knowledge or data
relating to the Company and its subsidiaries and affiliates, which shall have been obtained by Executive in connection with Executive&#146;s employment by the Company and which shall not be or become public knowledge (other than by acts by Executive
or representatives of Executive in violation of this Agreement). After termination of Executive&#146;s employment with the Company, Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal
process, communicate or divulge any such information, knowledge or data, to anyone other than the Company and those designated by it; <I>provided</I>, <I>however</I>, that if Executive receives actual notice that Executive is or may be required by
law or legal process to communicate or divulge any such information, knowledge or data, Executive shall promptly so notify the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) While employed by the Company, Executive shall not be engaged in any other business activity that would be competitive with the business
of the Company and its subsidiaries or affiliates. In addition, while employed by the Company and for a period of twelve (12)&nbsp;months after the Date of Termination, Executive shall not directly or indirectly solicit, induce, or encourage any
employee or consultant of the Company and/or its subsidiaries and affiliates to terminate their employment or other relationship with the Company and its subsidiaries and affiliates or to cease to render services to the Company and/or its
subsidiaries and affiliates and Executive shall not initiate discussion with any such person for any such purpose or authorize or knowingly cooperate with the taking of any such actions by any other individual or entity except, in each case, to the
extent the foregoing occurs as a result of general advertisements or other solicitations not specifically targeted to such employees and consultants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Subject to Section&nbsp;5(f), during Executive&#146;s service with the Company and
thereafter, excepting any litigation between the Parties, (i)&nbsp;Executive agrees not to publish or disseminate, directly or indirectly, any statements, whether written or oral, that are or could be harmful to or reflect negatively on any of the
Company or any of its subsidiaries or affiliates, or that are otherwise disparaging of any policies, procedures, practices, decision-making, conduct, professionalism or compliance with standards of the Company, its affiliates or any of their past or
present officers, directors, employees, advisors or agents, and (ii)&nbsp;the Company agrees to instruct its directors and executive officers not to publish or disseminate, directly or indirectly, any statements, whether written or oral, that are or
could be harmful to or reflect negatively on Executive&#146;s personal or business reputation or business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) In recognition of the fact
that irreparable injury will result to the Company in the event of a breach by Executive of his obligations under Sections 5(a)-(d) hereof, that monetary damages for such breach would not be readily calculable, and that the Company would not have an
adequate remedy at law therefor, Executive acknowledges, consents and agrees that in the event of such breach, the Company shall be entitled, in addition to any other legal remedies and damages available, to specific performance thereof and to
temporary and permanent injunctive relief (without the necessity of posting a bond) to restrain the violation of such obligations by Executive and to cease the payment of any benefits under Section&nbsp;4(b) or (c)&nbsp;above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in this Agreement or the Restrictive Covenant Agreement or, if applicable, the Arbitration Agreement (as defined
below) to the contrary, nothing contained in this Agreement shall prohibit either party (or either party&#146;s attorney(s)) from (i)&nbsp;communicating directly with, filing a charge with, reporting possible violations of federal law or regulation
to, participating in any investigation by, or cooperating with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority, the Equal Employment Opportunity Commission, the National Labor Relations Board (the
&#147;<U>NLRB</U>&#148;), the Occupational Safety and Health Administration, the U.S. Commodity Futures Trading Commission, the U.S. Department of Justice or any other securities regulatory agency, self-regulatory authority or federal, state or
local regulatory authority (collectively, &#147;<U>Government Agencies</U>&#148;), or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation, (ii)&nbsp;communicating directly with, cooperating
with, or providing information (including trade secrets) in confidence to any Government Agencies for the purpose of reporting or investigating a suspected violation of law, or from providing such information to such party&#146;s attorney(s) or in a
sealed complaint or other document filed in a lawsuit or other governmental proceeding, and/or (iii)&nbsp;receiving an award for information provided to any Government Agency. Further, nothing herein will prevent Executive from participating in
activity permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. Pursuant to 18 USC Section&nbsp;1833(b), Executive will not be held criminally or civilly liable under any federal
or state trade secret law for the disclosure of a trade secret that is made: (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or
investigating a suspected violation of law; or (y)&nbsp;in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, nothing in this Agreement is intended to or shall preclude either party from
providing truthful testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative, or legal process or otherwise as required by law. If Executive is required to provide testimony, then unless otherwise
directed or requested by a Government Agency or law enforcement, Executive shall notify the Company as soon as reasonably practicable after receiving any such request of the anticipated testimony.<B> </B>Further, nothing in this Agreement prevents
Executive from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Executive has reason to believe is unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Assignment and Successors</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the
assets of the Company (by merger or otherwise). The Company will require any such successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and
to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; <U>provided</U>, <U>however</U>, that no such assumption shall relieve the Company
of its obligations hereunder. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personal and legal representatives, executors, administrators, heirs, distributees,
devisees, and legatees, as applicable. None of Executive&#146;s rights or obligations may be assigned or transferred by Executive, other than Executive&#146;s rights to payments hereunder, which may be transferred only by will or operation of law.
Notwithstanding the foregoing, Executive shall be entitled, to the extent permitted under applicable law and applicable Company Arrangements, to select and change a beneficiary or beneficiaries to receive compensation hereunder following
Executive&#146;s death by giving written notice thereof to the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Certain Definitions</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Cause</U>. The Company shall have &#147;Cause&#148; to terminate Executive&#146;s employment hereunder upon: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the continued failure by Executive to substantially perform Executive&#146;s duties with the Company (other than any such failure resulting
from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to Executive by the Company or an affiliate that specifically identifies the alleged manner in which Executive has not substantially
performed Executive&#146;s duties and after Executive has been provided with a thirty (30)&nbsp;day cure period, or Executive&#146;s deliberate violation of a Company policy; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the engaging by Executive in illegal conduct or misconduct (including fraud, embezzlement, theft or dishonesty or material violation of
any Company policy), or gross negligence, in any case that has caused or is reasonably expected to result in injury to the Company or any affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Executive&#146;s commission of, or plea of no contest to, a felony or any misdemeanor crime involving fraud, moral turpitude or
dishonesty; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Executive&#146;s material breach of any written agreement or restrictive covenants with the Company; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Executive&#146;s violation of any law, rule or regulation relating in any way to the business or activities of the Company or any
affiliate, or other law, rule or regulation that is violated, during the course of Executive&#146;s performance of services hereunder that results in Executive&#146;s regulatory suspension or disqualification, including, without limitation, the
Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167; 335(a), or any similar legislation applicable in the United States or in any other country where the Company or any affiliate intends to develop its activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action or inaction based upon direction of the Board or advice of counsel to the Company shall constitute Cause. Poor performance shall
not, in and of itself, constitute Cause. No termination of Executive&#146;s employment for Cause shall occur absent a resolution of the Board and the reasonable opportunity for Executive (with Executive&#146;s counsel) to be heard before the Board.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Change in Control</U>. &#147;<U>Change in Control</U>&#148; shall have the meaning
set forth in the Plan, as in effect on the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Code</U>. &#147;<U>Code</U>&#148; shall mean the Internal Revenue Code
of 1986, as amended, and the regulations and guidance promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Date of Termination</U>. &#147;<U>Date of
Termination</U>&#148; shall mean (i)&nbsp;if Executive&#146;s employment is terminated by Executive&#146;s death, the date of Executive&#146;s death; or (ii)&nbsp;if Executive&#146;s employment is terminated pursuant to Sections 3(a)(ii)-(vi) either
the date indicated in the Notice of Termination or the date specified by the Company pursuant to Section&nbsp;3(b), whichever is earlier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Disability</U>. &#147;<U>Disability</U>&#148; shall mean, at any time the Company sponsors a long-term disability plan for the
Company&#146;s employees, &#147;disability&#148; as defined in such long-term disability plan for the purpose of determining a participant&#146;s eligibility for benefits, <I>provided, however</I>, if the long-term disability plan contains multiple
definitions of disability, &#147;Disability&#148; shall refer to that definition of disability which, if Executive qualified for such disability benefits, would provide coverage for the longest period of time. The determination of whether Executive
has a Disability shall be made by the person or persons required to make disability determinations under the long-term disability plan. At any time the Company does not sponsor a long-term disability plan for its employees, &#147;Disability&#148;
shall mean Executive&#146;s inability to perform, with reasonable accommodation, the essential functions of Executive&#146;s positions hereunder for a total of<B> </B>180 days within a 12 month period as a result of incapacity due to mental or
physical illness as determined by a physician selected by the Company or its insurers and acceptable to Executive or Executive&#146;s legal representative, with such agreement as to acceptability not to be unreasonably withheld or delayed. Any
refusal by Executive to submit to a medical examination for the purpose of determining Disability shall be deemed to constitute conclusive evidence of Executive&#146;s Disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Good Reason</U>. For the sole purpose of determining Executive&#146;s right to severance payments and benefits as described above,
Executive&#146;s resignation will be with &#147;<U>Good Reason</U>&#148; if Executive resigns within one hundred twenty (120)&nbsp;days after any of the following events, unless Executive expressly consents in writing to the applicable event: (i) a
reduction in Executive&#146;s Annual Base Salary or Target Bonus, other than a reduction of less than ten percent (10%) (aggregating all prior reductions) that is implemented in connection with a contemporaneous reduction in annual base salaries
affecting other senior executives of the Company; (ii)&nbsp;a material decrease in Executive&#146;s authority or areas of responsibility as are commensurate with Executive&#146;s title or position with the Company; (iii)&nbsp;the relocation of
Executive&#146;s primary working location to a location that is more than fifty (50)&nbsp;miles from Executive&#146;s home office in New Jersey as of the Effective Date, provided, that, prior to the occurrence of a Change in Control, the
Company&#146;s requirement that Executive relocate pursuant to Section&nbsp;2(h) will not constitute &#147;Good Reason&#148; so long as Executive has been provided with the Relocation Reimbursement; or (iv)&nbsp;the Company&#146;s breach of a
material provision of this Agreement.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Notwithstanding the foregoing, no Good Reason will have occurred unless and until: (a)&nbsp;Executive has provided the Company, within sixty (60)&nbsp;days
of Executive&#146;s knowledge of the occurrence of the facts and circumstances underlying the Good Reason event, written notice stating with specificity the applicable facts and circumstances underlying such finding of Good Reason; (b)&nbsp;the
Company has had an opportunity to cure the same within thirty (30)&nbsp;days after the receipt of such notice; and (c)&nbsp;the Company shall have failed to so cure within such period. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">NTD: Section&nbsp;6 provides that this agreement shall be binding upon the Company&#146;s successors.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Parachute Payments</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Best Pay Provision</U>. In the event that any payment or benefit received or to be received by Executive pursuant to the terms of any
plan, arrangement or agreement (including any payment or benefit received in connection with a change in ownership or control or the termination of Executive&#146;s employment) (all such payments and benefits being hereinafter referred to as the
&#147;<U>Total Payments</U>&#148;) would be subject (in whole or part) to the excise tax (the &#147;<U>Excise Tax</U>&#148;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent necessary so that no
portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total Payments and after
taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction (after subtracting the
net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized
deductions and personal exemptions attributable to such unreduced Total Payments); <U>provided</U>, <U>however</U>, that this sentence shall not apply if, immediately before the change in ownership or control on which such Total Payments are
contingent or otherwise relate, no stock in the Company is readily tradeable on an established securities market or otherwise (as determined in accordance with Treasury Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.280G-1</FONT> Q&amp;A 6).
Except to the extent that an alternative reduction order would result in a greater economic benefit to Executive on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties intend that the Total Payments shall be reduced in the
following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to Executive that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or benefits otherwise payable to Executive that are
exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, (y)&nbsp;reduction of any other payments
or benefits otherwise payable to Executive on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting and
payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from
Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the acceleration of vesting of Company equity awards shall be first applied to equity awards with later
vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies with and does not result in the imposition of additional taxes on Executive under Section&nbsp;409A
of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to Executive on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis and, to the extent economically equivalent payments or benefits
are subject to reduction, in a pro rata manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Determinations</U>. All determinations regarding the application of this
Section&nbsp;8 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability of Section&nbsp;280G of the Code
and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#147;<U>280G Firm</U>&#148;). For purposes of determining whether and the extent to which the Total Payments will be subject to the
Excise Tax, (i)&nbsp;no portion of the Total Payments shall be taken into account which (x)&nbsp;does not constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G(b)(2) of the Code (including by reason of
Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or (y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the Code, in excess of the &#147;base
amount&#148; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of which Executive shall have waived at such time and in such manner as
not to constitute a &#147;payment&#148; within the meaning of Section&nbsp;280G(b) of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> benefit or any deferred payment or benefit
included in the Total Payments shall be determined by the 280G Firm in accordance with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determinations related to the calculations to be performed pursuant to this &#147;Section&nbsp;280G Treatment&#148; section shall be done by the 280G Firm. The 280G Firm will be directed to
submit its determination and detailed supporting calculations to both Executive and the Company within fifteen (15)&nbsp;days after notification from either the Company or Executive that Executive may receive payments which may be &#147;parachute
payments.&#148; Executive and the Company will each provide the 280G Firm access to and copies of any books, records, and documents as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the
preparation and issuance of the determinations and calculations contemplated by this Agreement. The fees and expenses of the 280G Firm for its services in connection with the determinations and calculations contemplated by this Agreement will be
borne solely by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exception</U>. Notwithstanding the foregoing, if any portion of the Total Payments would not be
subject to the Excise Tax if the stockholder approval requirements of Section&nbsp;280G(b)(5) of the Code are satisfied, subject to Executive&#146;s waiver of the rights to such portion of the Total Payments above the safe harbor threshold in
accordance with and to the extent required by Section&nbsp;280G of the Code with respect to any portion of the Total Payments that would otherwise be subject to excise tax imposed by Section&nbsp;4999 of the Code (before giving effect to any
reduction in the Total Payments contemplated above), the Company shall use its reasonable best efforts to cause such payments to be submitted for such approval prior to the event giving rise to such payments. To the extent the Company submits any
payment or benefit payable to Executive under this Agreement or otherwise to the Company&#146;s stockholders for approval in accordance with Treasury Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.280G-1</FONT> Q&amp;A 7, the foregoing
provisions under this Section&nbsp;8 shall not apply following such submission and such payments and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver above the safe harbor threshold of,
such payments or benefits required by such vote will be applied without any application of discretion by Executive and in the order prescribed in Section&nbsp;8(a). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous Provisions</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Governing Law and Venue</U>. This Agreement shall be governed, construed, interpreted and enforced in accordance with its express terms,
and otherwise in accordance with the substantive laws of the State of New Jersey without reference to the principles of conflicts of law of the State of New Jersey or any other jurisdiction that would result in the application of the laws of a
jurisdiction other than the State of New Jersey, and where applicable, the laws of the United States. Any suit brought hereon shall be brought in the state or federal courts sitting in the State of New Jersey, the parties hereto hereby waiving any
claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by New Jersey law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Validity</U>. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or
enforceability of any other provision of this Agreement, which shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notices</U>. Any notice,
request, claim, demand, document, and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile, email or certified or registered mail,
postage prepaid, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If to the Company, to the Chief Executive Officer of the Company at the Company&#146;s
headquarters, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If to Executive, to the last address that the Company has in its personnel records for Executive, or
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) At any other address as any Party shall have specified by notice in writing to the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Counterparts</U>. This Agreement may be executed in several counterparts, each of
which shall be deemed to be an original, but all of which together will constitute one and the same Agreement. Signatures delivered by facsimile or PDF shall be deemed effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Entire Agreement</U>. The terms of this Agreement, and the Restrictive Covenant Agreement incorporated herein by reference as set forth
in Section&nbsp;5, are intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof and supersede all prior understandings and agreements, whether written or oral, including that certain employment
offer letter dated June&nbsp;14, 2023, between Executive and the Company. The Parties further intend that this Agreement shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced
in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Amendments; Waivers</U>. This
Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the
Company may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; <I>provided</I>, <I>however</I>, that such waiver shall not operate as
a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power
provided herein or by law or in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Construction</U>. This Agreement shall be deemed drafted equally by both the Parties. Its
language shall be construed as a whole and according to its fair meaning. Any presumption or principle that the language is to be construed against any Party shall not apply. The headings in this Agreement are only for convenience and are not
intended to affect construction or interpretation. Any references to paragraphs, subparagraphs, sections, or subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary. Also, unless the context clearly
indicates to the contrary, (i)&nbsp;the plural includes the singular and the singular includes the plural; (ii) &#147;and&#148; and &#147;or&#148; are each used both conjunctively and disjunctively; (iii) &#147;any,&#148; &#147;all,&#148;
&#147;each,&#148; or &#147;every&#148; means &#147;any and all,&#148; and &#147;each and every&#148;; (iv) &#147;includes&#148; and &#147;including&#148; are each &#147;without limitation&#148;; (v) &#147;herein,&#148; &#147;hereof,&#148;
&#147;hereunder&#148; and other similar compounds of the word &#147;here&#148; refer to the entire Agreement and not to any particular paragraph, subparagraph, section or subsection; and (vi)&nbsp;all pronouns and any variations thereof shall be
deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the entities or persons referred to may require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Arbitration</U>. In the event of any dispute or claim relating to, or arising out of Executive&#146;s employment relationship with the
Company or its affiliates, including, but not limited, claims of wrongful termination, age, race, gender, disability or other discrimination&#151;but not including claims for sexual harassment or sexual assault&#151;Executive and the Company agree
that all such disputes shall be fully and finally resolved by binding arbitration conducted before a single neutral arbitrator pursuant to the rules for arbitration of employment disputes by the American Arbitration Association (available at
www.adr.org) in the State of New Jersey. The arbitrator shall permit adequate discovery and is empowered to award all remedies otherwise available in a court of competent jurisdiction, and any judgment rendered by the arbitrator may be entered by
any court of competent jurisdiction. The arbitrator shall issue an award in writing and state the essential findings and conclusions of law on which the award is based. By executing this Agreement, the Parties are both waiving the right to a jury
trial with respect to any such disputes. The Company shall bear the costs of the arbitrator, forum and filing fees. Each Party shall bear its own respective attorney fees and all other costs, unless provided by law and awarded by the arbitrator.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Enforcement</U>. If any provision of this Agreement is held to be illegal, invalid or
unenforceable under present or future laws effective during the Term, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a portion of
this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from this Agreement. Furthermore, in lieu of such
illegal, invalid, or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and be legal, valid and enforceable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Withholding</U>. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local
or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on the advice of counsel if any questions as to the amount or requirement of withholding shall arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Section 409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>General.</I> The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt
from Section&nbsp;409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. If the Company and Executive agree in good faith that the payments and benefits under this Agreement would
not comply with Section&nbsp;409A, the Parties hereto shall reasonably and in good faith attempt to modify this Agreement to comply with Section&nbsp;409A while endeavoring to maintain the intended economic benefits hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Separation from Service. </I>Notwithstanding anything in this Agreement to the contrary, (A)&nbsp;any compensation or
benefits payable under this Agreement that is designated under this Agreement as payable upon Executive&#146;s termination of employment shall be payable only upon Executive&#146;s &#147;separation from service&#148; with the Company within the
meaning of Section&nbsp;409A (a &#147;<U>Separation from Service</U>&#148;) and (B)&nbsp;in the event that, with respect to the amounts payable under Sections 4(b) or 4(c), the timing of the delivery of Executive&#146;s Release could cause such
amounts to begin in one or another taxable year, to the extent such amounts are subject to Section&nbsp;409A, then notwithstanding the payment timing set forth in such Sections, such amounts shall not be payable until the later of (1)&nbsp;the
payment date specified in such Section or (2)&nbsp;the first business day of the taxable year following Executive&#146;s Separation from Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Specified Employee.</I> Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the
Company at the time of Executive&#146;s Separation from Service to be a &#147;specified employee&#148; for purposes of Section&nbsp;409A, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this
Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A, such portion of Executive&#146;s benefits shall not be provided to Executive prior to the earlier of (x)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap">six-month</FONT> period measured from the date of Executive&#146;s Separation from Service with the Company or (y)&nbsp;the date of Executive&#146;s death. Upon the first business day following the expiration of the
applicable Section&nbsp;409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive&#146;s estate or beneficiaries), and any remaining payments due to Executive under this Agreement
shall be paid as otherwise provided herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Expense Reimbursements. </I>To the extent that any reimbursements
under this Agreement are subject to Section&nbsp;409A, (A)&nbsp;any such reimbursements payable to Executive shall be paid to Executive no later than December&nbsp;31 of the year following the year in which the expense was incurred,
(B)&nbsp;Executive shall submit Executive&#146;s reimbursement request promptly following the date the expense is incurred, (C)&nbsp;the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any
subsequent year, other than medical expenses referred to in Section&nbsp;105(b) of the Code, and (D)&nbsp;Executive&#146;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Installments.</I> Executive&#146;s right to receive any installment payments under this Agreement, including without
limitation any continuation salary payments that are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate
and distinct payment as permitted under Section&nbsp;409A. Except as otherwise permitted under Section&nbsp;409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or
interest pursuant to Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Survival</U>. Notwithstanding anything to the contrary in this Agreement, the provisions
of Sections 5 through 9 will survive the termination of Executive&#146;s employment and the termination of the Term. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Executive Acknowledgement</U>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance
upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#146;s own judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement on the date and year first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Arthur Kuan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Arthur Kuan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ambaw Bellete</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name: Ambaw Bellete</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#147;<U>Agreement</U>&#148;) is made by and between Ambaw Bellete (&#147;<U>Executive</U>&#148;) and
CG Oncology, Inc. (the &#147;<U>Company</U>&#148;) (collectively referred to as the &#147;<U>Parties</U>&#148; or individually referred to as a &#147;<U>Party</U>&#148;). Capitalized terms used but not defined in this Agreement shall have the
meanings set forth in the Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have previously entered into that certain
Employment Agreement, dated as of [_____], 2023 (the &#147;<U>Employment Agreement</U>&#148;) and that certain Restrictive Covenant Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#146;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[________], 20[__], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releases as defined below, including, but not
limited to, any and all claims arising out of or in any way related to Executive&#146;s employment with or separation from the Company or its subsidiaries or affiliates but, for the avoidance of doubt, nothing herein will be deemed to release any
rights or remedies in connection with Executive&#146;s ownership of vested equity securities of the Company, vested benefits or Executive&#146;s right to indemnification or liability insurance by the Company or any of its affiliates pursuant to
contract or applicable law (collectively, the &#147;<U>Retained Claims</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance
payments and benefits described in Section&nbsp;4 of the Employment Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Agreement,
and in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Severance Payments and
Benefits; Salary and Benefits</U>. The Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;4 of the Employment Agreement, payable at the times set forth in, and subject to the terms and conditions
of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive the Accrued Obligations described in Section&nbsp;3(c) of
the Employment Agreement, subject to and in accordance with the terms thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Release of Claims</U>. Executive agrees that, other
than with respect to the Retained Claims, the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries, and any of its or their current and
former officers, directors, equity holders, managers, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and
successor corporations and assigns (collectively, the &#147;<U>Releasees</U>&#148;) related to Executive&#146;s employment with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#146;s own behalf and on behalf of any
of Executive&#146;s affiliated companies or entities and any of their respective heirs, family members, executors, agents, and assigns, other than with respect to the Retained Claims, hereby and forever releases the Releasees from, and agrees not to
sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive
may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the date Executive signs this Agreement relating to Executive&#146;s employment with the Company or its
subsidiaries or termination therefrom, including, without limitation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any and all claims relating to or arising from Executive&#146;s
employment or service relationship with the Company or any of its direct or indirect subsidiaries and the termination of that relationship; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any and all claims relating to, or arising from, Executive&#146;s right to purchase, or
actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state law,
and securities fraud under any state or federal law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any and all claims for wrongful discharge of employment; termination in
violation of public policy; discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction
of emotional distress; fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury;
assault; battery; invasion of privacy; false imprisonment; conversion; and disability benefits; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any and all claims for violation of
any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the
Fair Labor Standards Act; the Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining
Notification Act; the Family and Medical Leave Act; and the Sarbanes-Oxley Act of 2002; New Jersey&#146;s Conscientious Employee Protection Act; the New Jersey Soldiers&#146; and Sailors&#146; Civil Relief Act; the Millville Dallas Airmotive Plant
Job Loss Notification Act; the New Jersey Family Leave Act; the New Jersey Law Against Discrimination; the New Jersey Security and Financial Empowerment Act; the New Jersey State Wage and Hour Law; the New Jersey Paid Sick Leave Law; and the New
Jersey State Wage Payment Law; or any similar state law; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for violation of the federal or any state constitution;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any and all claims arising out of any other laws and regulations relating to employment or employment discrimination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the
<FONT STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has
provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#146; fees and costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL COUNSEL AND IS FAMILIAR WITH
THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT
THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED
PARTY.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS
UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive agrees that the release set forth in this section shall be
and remain in effect in all respects as a complete general release as to the matters released. This release does not release claims that cannot be released as a matter of law, including, but not limited to, Executive&#146;s right to report possible
violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or Section&nbsp;806 of the Sarbanes-Oxley Act of
2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, Executive&#146;s right to file a charge with or participate in a charge by the Equal
Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the Company for discrimination (with the understanding
that Executive&#146;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment), claims for unemployment compensation or any state disability insurance
benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#146;s group benefit plans pursuant to the terms and conditions of COBRA, claims for indemnity under the bylaws of the Company, as
provided for by New Jersey or Delaware law or under any applicable insurance policy with respect to Executive&#146;s liability as an employee, director or officer of the Company, claims to any benefit entitlements vested as the date of separation of
Executive&#146;s employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#146;s right under applicable law and any Retained Claims. This release further does not release claims for breach of
Section&nbsp;3(c) or Section&nbsp;4 of the Employment Agreement. This release does not prevent Executive from cooperating with an investigation conducted by any such governmental agencies, including without limitation the National Labor Relations
Board (the &#147;NLRB&#148;). Nothing herein will prevent Executive from participating in an activity permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that Executive is waiving and releasing any
rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#147;<U>ADEA</U>&#148;), and that this waiver and release is knowing and voluntary. Executive understands and agrees that this waiver and release does not apply to
any rights or claims that may arise under the ADEA after the date Executive signs this Agreement. Executive understands and acknowledges that the consideration given for this waiver and release is in addition to anything of value to which Executive
was already entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a)&nbsp;Executive should consult with an attorney prior to executing this Agreement; (b)&nbsp;Executive has <FONT
STYLE="white-space:nowrap">[twenty-one</FONT> (21)] days within which to consider this Agreement, and the Parties agree that such time period to review this Agreement shall not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extended upon any material or immaterial changes to this Agreement; (c)&nbsp;Executive has seven business days following Executive&#146;s execution of this Agreement to revoke this Agreement
pursuant to written notice to the General Counsel of the Company; (d)&nbsp;this Agreement shall not be effective until after the revocation period has expired; and (e)&nbsp;nothing in this Agreement prevents or precludes Executive from challenging
or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this
Agreement and returns it to the Company in less than the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] day period identified above, Executive hereby acknowledges that Executive has freely and voluntarily chosen to waive the time period
allotted for considering this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Acknowledgment</U>. Executive acknowledges his ongoing obligations under Section&nbsp;5 of
the Employment Agreement. Sections 5(e) and 5(f) of the Employment Agreement are hereby incorporated by reference and will apply to this Agreement as if set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Severability</U>. In the event that any provision or any portion of any provision hereof or any surviving agreement made a part hereof
becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Oral Modification</U>. This Agreement may only be amended in a writing signed by Executive and a duly authorized officer of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Governing Law; Dispute Resolution</U>. This Agreement shall be subject to the provisions of Sections 9(a), 9(c), and 9(h)
of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effective Date</U>. Executive has seven business days after Executive signs this Agreement to revoke
it and this Agreement will become effective on the day immediately following the seventh business day after Executive signed this Agreement (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Voluntary Execution of Agreement</U>. Executive understands and agrees that Executive executed this Agreement voluntarily, without any
duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#146;s claims against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive
has read this Agreement; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement; (c)&nbsp;Executive has been represented in the preparation, negotiation, and
execution of this Agreement by legal counsel of Executive&#146;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands the terms and consequences of this Agreement and of the releases it contains; and
(e)&nbsp;Executive is fully aware of the legal and binding effect of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set
forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Print Name: Ambaw Bellete</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>CG ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated:<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:0%; font-size:11pt; font-family:Times New Roman" ALIGN="center">RESTRICTIVE COVENANT AGREEMENT </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Attached</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE 1 </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:0%; font-size:11pt; font-family:Times New Roman" ALIGN="center">PERMITTED OUTSIDE ACTIVITIES </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>12
<FILENAME>filename12.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (this &#147;<U>Agreement</U>&#148;) is made by and between CG Oncology, Inc. (the &#147;<U>Company</U>&#148;), and
Vijay Kasturi, M.D. (&#147;<U>Executive</U>&#148;) (collectively referred to herein as the &#147;<U>Parties</U>&#148; or individually referred to as a &#147;<U>Party</U>&#148;), effective as of August&nbsp;14, 2023 (the &#147;<U>Effective
Date</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company seeks to employ Executive as its Chief Medical Officer; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to enter into an agreement setting forth the terms of such employment as of the Effective Date, which supersedes
any and all prior understandings and agreements, whether written or oral, including any prior employment offer letters, between Executive and the Company or any of its affiliates, subject to the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as
follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.
<U>Employment</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General</U>. Effective on the Effective Date, the Company shall employ Executive, and Executive shall be
employed by the Company, for the period and in the positions set forth in this Section&nbsp;1, and subject to the other terms and conditions herein provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment</U>. The Company and Executive acknowledge that Executive&#146;s employment
is and shall continue to be <FONT STYLE="white-space:nowrap">at-will,</FONT> as defined under applicable law, and that Executive&#146;s employment with the Company may be terminated by either Party at any time for any or no reason (subject to the
notice requirements of Section&nbsp;3(b)). This <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> nature of Executive&#146;s employment shall remain unchanged during Executive&#146;s tenure as an employee and may not be changed, except in
an express writing signed by Executive and a duly authorized officer of the Company. The term of this Agreement (the &#147;<U>Term</U>&#148;) shall commence on the Effective Date and end on the date this Agreement is terminated under Section&nbsp;3.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Positions and Duties</U>. During the Term, Executive shall serve as Chief Medical Officer of the Company, with such
responsibilities, duties and authority normally associated with such position and as may from time to time be reasonably assigned to Executive by the Chief Executive Officer of the Company (the &#147;<U>CEO</U>&#148;). Executive shall report to the
CEO. Executive shall devote substantially all of Executive&#146;s working time and efforts to the business and affairs of the Company (which shall include service to its affiliates, if applicable) and shall not engage in outside business activities
(including serving on outside boards or committees) without the consent of the CEO or the Board of Directors (the &#147;<U>Board</U>&#148;) of the Company, <I>provided</I> that Executive shall be permitted to (i)&nbsp;manage Executive&#146;s
personal, financial and legal affairs, (ii)&nbsp;participate in trade associations, and (iii)&nbsp;serve on the board of directors of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> or <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> charitable organizations or, with the consent of the Board (not to be unreasonably withheld), the board of directors of <FONT STYLE="white-space:nowrap">non-competitive</FONT> <FONT
STYLE="white-space:nowrap">for-profit</FONT> businesses, in each case, subject to compliance with this Agreement and provided that such activities do not materially interfere with Executive&#146;s performance of Executive&#146;s duties and
responsibilities hereunder. Executive agrees to observe and comply with the reasonable rules and policies of the Company as adopted by the Company from time to time (to the extent they do not conflict with the terms of this Agreement), in each case,
as amended from time to time, and as delivered or made available to Executive (each, a &#147;<U>Policy</U>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Principal Location</U>. During the Term, Executive shall perform the services
required by this Agreement remotely from his residence in Worcester, Massachusetts, <I>provided</I>, <I>however</I>, that the Parties acknowledge and agree that Executive may be required to travel to other locations as may be necessary to fulfill
Executive&#146;s duties and responsibilities hereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. <U>Compensation and Related Matters</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Annual Base Salary</U>. During the Term, Executive shall receive a base salary at a rate initially of $415,000 per annum, which shall be
paid in accordance with the customary payroll practices of the Company and shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> for partial years of employment. Such annual base salary shall be reviewed (and may be adjusted for increase, but
not decrease) from time to time (such annual base salary, as it may be adjusted from time to time, the &#147;<U>Annual Base Salary</U>&#148;) by the Board or its compensation committee (&#147;<U>Compensation Committee</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Annual Cash Bonus</U><U> Opportunity</U>. During the Term, Executive will be eligible to participate in an annual incentive program
established by the Board or Compensation Committee with target level annual incentive compensation opportunities as may be determined by the Board or Compensation Committee from time to time, but with an annual &#147;target level&#148; incentive
bonus opportunity (the &#147;<U>Target Bonus</U>&#148;) of 40% of the Annual Base Salary. The annual bonus payable under the incentive program (&#147;<U>Annual Bonus</U>&#148;) shall be based on the achievement of performance goals or such other
criteria as may be determined by the Board or Compensation Committee. The payment of any Annual Bonus pursuant to the incentive program shall be subject to Executive&#146;s continued employment with the Company through the date of payment, except as
otherwise provided in Section&nbsp;4. The Annual Bonus shall be paid to Executive when paid generally to other senior executives of the Company, but in any event, to the extent determinable as of such time, not later than March 15<SUP
STYLE="font-size:75%; vertical-align:top">th</SUP> of the year immediately following the applicable year for which such Annual Bonus is being paid. The Executive&#146;s annual Bonus for 2023 shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT>
to reflect the portion of such year following the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U><FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus</U>.
Executive shall be entitled to a <FONT STYLE="white-space:nowrap">one-time</FONT> signing bonus equal to the amount of $50,000, less any taxable withholdings (the &#147;<U><FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus</U>&#148;), which will
be paid not later than thirty (30)&nbsp;days following the Effective Date. If Executive is terminated for Cause or voluntarily leaves the Company without Good Reason prior to completing twenty-four (24)&nbsp;months of service from the Effective
Date, Executive shall be required to repay to the Company, within thirty (30)&nbsp;days following Executive&#146;s last day of employment with the Company, 100% of the <FONT STYLE="white-space:nowrap">Sign-On</FONT> Bonus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Equity Awards</U>. During the Term, Executive will be eligible to participate and receive awards under the Company&#146;s equity plans
as in effect from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Initial Option</I>: As soon as practicable after the Effective Date, the
Compensation Committee of the Board shall approve a grant of stock options to purchase 4,230,000 shares of the Company&#146;s common stock (the &#147;<U>Shares</U>&#148;) (the &#147;<U>Initial Option</U>&#148;). The Initial Option shall be granted
in accordance with the Company&#146;s 2022 Incentive Award Plan (the &#147;<U>Plan</U>&#148;) and related stock option documents. The Initial Option shall have an exercise price per share equal to the fair market value on the grant date, as
determined by the Board. Subject to Executive&#146;s continued employment with the Company, the Initial Option will vest over a four (4)&nbsp;year period starting on the Effective Date (the &#147;<U>Vesting Commencement Date</U>&#148;), with 25% of
the shares vesting on the date that is twelve (12)&nbsp;months after the Vesting Commencement Date and the remainder vesting in <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;equal monthly installments over the subsequent three
(3)&nbsp;year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Milestone Option</I>: As soon as practicable after the Effective
Date, the Compensation Committee of the Board shall approve a grant of stock options to purchase 470,000 Shares (the &#147;<U>Milestone Option</U>&#148;). The Milestone Option shall be granted in accordance with the Plan and related stock option
documents. The Milestone Option shall have an exercise price per share equal to the fair market value on the grant date, as determined by the Board. The Milestone Option will vest as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) 235,000 Shares subject to the Milestone Option (the &#147;<U>First Milestone Option</U>&#148;) will be eligible to vest
upon the filing with the Federal Drug Administration of the Company&#146;s Biologics License Application (&#147;<U>BLA</U>&#148;) with respect to cretostimogene grenadenorepvec (CG0070), provided such BLA filing occurs on or before December&nbsp;31,
2025, subject to Executive&#146;s continued employment with the Company through such date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) 235,000 Shares subject
to the Milestone Option (the &#147;<U>Second Milestone Option</U>&#148;) will be eligible to vest upon the approval by the Federal Drug Administration of the Company&#146;s BLA with respect to cretostimogene grenadenorepvec (CG0070) (&#147;<U>BLA
Approval</U>&#148;), provided such BLA Approval occurs on or before December&nbsp;31, 2026, subject to Executive&#146;s continued employment with the Company through such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Benefits</U>. During the Term, Executive (and Executive&#146;s spouse and/or eligible dependents to the extent provided in the
applicable plans and programs) shall be eligible to participate in and be covered under the health and welfare benefit plans and programs maintained by the Company for the benefit of its employees from time to time, pursuant to the terms of such
plans and programs including any medical, life, hospitalization, dental, disability, accidental death and dismemberment and travel accident insurance plans and programs on the same terms and conditions as those applicable to similarly situated
senior executives. In addition, during the Term, Executive shall be eligible to participate in any retirement, savings and other employee benefit plans and programs maintained from time to time by the Company for the benefit of its senior executive
officers. Nothing contained in this Section&nbsp;2(d) shall create or be deemed to create any obligation on the part of the Company to adopt or maintain any health, welfare, retirement or other benefit plan or program at any time or to create any
limitation on the Company&#146;s ability to modify or terminate any such plan or program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Vacation or Paid Time Off</U>. During
the Term, Executive shall be entitled to paid personal leave in accordance with the Company&#146;s Policies applicable to similarly situated executives. Any vacation or paid time off shall be taken in the reasonable convenience of Executive. Through
the Company&#146;s paid <FONT STYLE="white-space:nowrap">time-off</FONT> policies Executive will receive paid sick leave as required by state and any applicable local laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Business Expenses</U>. During the Term, the Company shall reimburse Executive for all reasonable travel and other business expenses
incurred by Executive in the performance of Executive&#146;s duties to the Company in accordance with the Company&#146;s Travel and Expense Reimbursement Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Indemnification and D&amp;O Insurance</U>. The Company shall indemnify Executive (and advance expenses to Executive) to the greatest
extent permitted by applicable state law and shall provide Executive with coverage under a directors&#146; and officers&#146; liability insurance policy to the same extent provided to other senior executives and directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. <U>Termination of Employment</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive&#146;s employment hereunder and the Term may be terminated by the Company or Executive, as applicable, without any breach of this
Agreement under the following circumstances and the Term will end on the Date of Termination: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Circumstances</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Death</I>. Executive&#146;s employment hereunder shall terminate upon Executive&#146;s death. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Disability</I>. If Executive has incurred a Disability (as defined below), the Company may terminate Executive&#146;s
employment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Termination for Cause</I>. The Company may terminate Executive&#146;s employment for Cause (as
defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Termination without Cause</I>. The Company may terminate Executive&#146;s employment without
Cause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Resignation from the Company with Good Reason. </I>Executive may resign Executive&#146;s employment with the
Company with Good Reason (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <I>Resignation from the Company without Good Reason</I>. Executive may
resign Executive&#146;s employment with the Company for any reason other than Good Reason or for no reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of
Termination</U>. Any termination of Executive&#146;s employment by the Company or by Executive under this <U>Section</U><U></U><U>&nbsp;3</U> (other than termination pursuant to Section&nbsp;3(a)(i)) shall be communicated by a written notice to the
other Party hereto (i)&nbsp;indicating the specific termination provision in this Agreement relied upon, (ii)&nbsp;setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#146;s
employment under the provision so indicated, if applicable, and (iii)&nbsp;specifying a Date of Termination which, if submitted by Executive, shall be at least thirty (30)&nbsp;days following the date of such notice (a &#147;<U>Notice of
Termination</U>&#148;); <I>provided, however</I>, that in the event that Executive delivers a Notice of Termination to the Company, the Company may, in its sole discretion, change the Date of Termination to any date that occurs following the date of
the Company&#146;s receipt of such Notice of Termination and is prior to the date specified in such Notice of Termination, but the termination will still be considered a resignation by Executive. A Notice of Termination submitted by the Company may
provide for a Date of Termination on the date Executive receives the Notice of Termination, or any date thereafter elected by the Company. The failure by either Party to set forth in the Notice of Termination any fact or circumstance which
contributes to a showing of Cause or Good Reason shall not waive any right of the Party hereunder or preclude the Party from asserting such fact or circumstance in enforcing the Party&#146;s rights hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Company Obligations upon Termination</U>. Upon termination of Executive&#146;s employment pursuant to any of the circumstances listed
in this <U>Section</U><U></U><U>&nbsp;3</U>, Executive (or Executive&#146;s estate, if applicable) shall be entitled to receive the following (the &#147;<U>Accrued Obligations</U>&#148;): (i)&nbsp;the portion of Executive&#146;s Annual Base Salary
earned through the Date of Termination, but not yet paid to Executive (payable on the Company&#146;s next payroll date or such earlier date as required by applicable law); (ii) any expense reimbursements owed to Executive pursuant to
Section&nbsp;2(f), payable pursuant to the applicable policy; and (iii)&nbsp;any amount accrued and arising from Executive&#146;s participation in, or benefits accrued under any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements
(collectively, the &#147;<U>Company Arrangements</U>&#148;). Except as otherwise expressly required by law (<U>e.g.</U>, COBRA) or applicable Company Arrangement or as specifically provided herein, all of Executive&#146;s rights to salary,
severance, benefits, bonuses, and other compensatory amounts hereunder (if any) shall cease upon the termination of Executive&#146;s employment hereunder. In the event that Executive&#146;s employment is terminated by the Company for any reason,
Executive&#146;s sole and exclusive remedy for severance benefits shall be to receive the payments and benefits described in this Section&nbsp;3(c) or Section&nbsp;4, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Deemed Resignation</U>. Upon termination of Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from
all offices and directorships, if any, then held with the Company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Return of Property</U>. Upon
termination of Executive&#146;s employment for any reason, unless otherwise specified in a written agreement between Executive and the Company, Executive agrees to return to the Company all documents of the Company and its affiliates (and all copies
thereof) and all other Company or Company affiliate property that Executive has in his possession, custody, or control. Such property includes, without limitation: (i)&nbsp;any materials of any kind that Executive knows contain or embody any
proprietary or confidential information of the Company or an affiliate of the Company (and all reproductions thereof), (ii) computers (including, but not limited to, laptop computers, desktop computers and similar devices) and other portable
electronic devices (including, but not limited to, tablet computers), cellular phones/smartphones, credit cards, phone cards, entry cards, identification badges and keys, and (iii)&nbsp;any correspondence, drawings, manuals, letters, notes,
notebooks, reports, programs, plans, proposals, financial documents, or any other documents concerning the customers, business plans, marketing strategies, products and/or processes of the Company or any of its affiliates and any information
received from the Company or any of its affiliates regarding third parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. <U>Severance Payments</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Termination for Cause, or Termination Upon Death, Disability, Resignation from the Company Without Good Reason or Resignation from the
Company for Good Reason Prior to a Change in Control or More Than Eighteen (18)</U><U></U><U>&nbsp;Months Following a Change in Control</U>. If Executive&#146;s employment shall terminate as a result of Executive&#146;s death pursuant to
Section&nbsp;3(a)(i) or Disability pursuant to Section&nbsp;3(a)(ii), pursuant to Section&nbsp;3(a)(iii) for Cause, pursuant to Section&nbsp;3(a)(vi) for Executive&#146;s resignation from the Company without Good Reason, or pursuant to
Section&nbsp;3(a)(v) for Executive&#146;s resignation from the Company with Good Reason (if such resignation for Good Reason occurs prior to a Change in Control or more than eighteen (18)&nbsp;months following a Change in Control), then Executive
shall not be entitled to any severance payments or benefits, except for the Accrued Obligations as provided in Section&nbsp;3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Termination without Cause Prior to a Change in Control or More Than Eighteen (18)</U><U></U><U>&nbsp;Months Following a Change in Control</U>. If Executive&#146;s employment terminates without Cause pursuant to Section&nbsp;3(a)(iv), and such
termination without Cause occurs prior to a Change in Control or more than eighteen (18)&nbsp;months following a Change in Control, then subject to Sections 3(e), 4(d) and 9(k), and Executive&#146;s continued compliance with the terms of this
Agreement (including, without limitation, Section&nbsp;5), the Company shall pay Executive in addition to the Accrued Obligations set forth in Section&nbsp;3(c), the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an amount in cash equal to 0.75 times Executive&#146;s Annual Base Salary as in effect immediately prior to the Date of
Termination, payable in a lump sum on the first regular payroll date following the effective date of Executive&#146;s Release (as defined below); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) an amount in cash equal to the Target Bonus (and without regard to any
reduction in the Target Bonus that resulted in Executive&#146;s resignation with Good Reason), prorated to reflect the portion of the year in which the Date of Termination occurs that has elapsed prior to the Date of Termination, payable in a lump
sum on the first regular payroll date following the effective date of Executive&#146;s Release (but in no event later than March&nbsp;15 of the calendar year following the year in which Executive&#146;s Date of Termination occurs); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if Executive timely elects to receive continued medical, dental or vision coverage under one or more of the
Company&#146;s group medical, dental or vision plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), then the Company shall directly pay, or reimburse Executive for, the COBRA premiums
for Executive and Executive&#146;s covered dependents under such plans during the period commencing on Executive&#146;s Separation from Service and ending upon the earliest of (A)&nbsp;the last day of the nine (9)&nbsp;month period following the
Date of Termination, (B)&nbsp;the date that Executive and/or Executive&#146;s covered dependents become no longer eligible for COBRA or (C)&nbsp;the date Executive becomes eligible to receive medical, dental or vision coverage, as applicable, from a
subsequent employer (and Executive agrees to promptly notify the Company of such eligibility) (the &#147;<U>COBRA Continuation Period</U>&#148;). Notwithstanding the foregoing, if the Company determines it cannot provide the foregoing benefit
without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide to Executive a taxable monthly payment in an
amount equal to the monthly COBRA premium that Executive would be required to pay to continue Executive&#146;s and Executive&#146;s covered dependents&#146; group health coverage in effect on the Date of Termination (which amount shall be based on
the premium for the first month of COBRA coverage), less the amount Executive would have had to pay to receive group health coverage as an active employee for Executive and his covered dependents based on the cost sharing levels in effect on the
Date of Termination, which payments shall for the remainder of the COBRA Continuation Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) such number of the
outstanding, unvested Company equity awards held by Executive under any Company equity compensation plans as would have vested during the nine (9)&nbsp;months following the date of Executive&#146;s Separation from Service had Executive continued in
employment or service with the Company during such period shall immediately become vested on the effectiveness of the Release; <I>provided</I>, <I>however</I>, that any performance-based equity award will remain subject to attainment of the relevant
performance goals during such nine (9)&nbsp;months following the date of Executive&#146;s Separation from Service unless a more favorable or alternative provision is contained in an applicable award agreement, and to the extent such performance
goals are not attained prior to such deadline, such performance-based equity awards shall not vest pursuant to this clause (iv)&nbsp;and shall be forfeited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Change in Control</U>. In lieu of the payments and benefits set forth in Section&nbsp;4(b), in the event Executive&#146;s employment
terminates without Cause pursuant to Section&nbsp;3(a)(iv), or pursuant to Section&nbsp;3(a)(v) due to Executive&#146;s resignation with Good Reason, in either case, on or within eighteen (18)&nbsp;months following the date of a Change in Control,
then subject to Sections 3(e), 4(d) and 9(k), and Executive&#146;s continued compliance with the terms of this Agreement (including, without limitation, Section&nbsp;5), the Company shall pay Executive, in addition to the Accrued Obligations set
forth in Section&nbsp;3(c), the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) an amount in cash equal to 0.75 times Executive&#146;s Annual Base Salary
as in effect immediately prior to the Date of Termination (and without regard to any reduction in Annual Base Salary that resulted in Executive&#146;s resignation with Good Reason), payable in a lump sum on the first regular payroll date following
the effective date of Executive&#146;s Release; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) an amount in cash equal to the Target Bonus (and without regard to any
reduction in the Target Bonus that resulted in Executive&#146;s resignation with Good Reason), payable in a lump sum on the first regular payroll date following the effective date of Executive&#146;s Release (but in no event later than March&nbsp;15
of the calendar year following the year in which Executive&#146;s Date of Termination occurs); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) if Executive timely
elects to receive continued medical, dental or vision coverage under one or more of the Company&#146;s group medical, dental or vision plans pursuant to COBRA, then the Company shall directly pay, or reimburse Executive for, the COBRA premiums for
Executive and Executive&#146;s covered dependents under such plans during the period commencing on Executive&#146;s Separation from Service and ending upon the earliest of (A)&nbsp;the last day of the nine (9)&nbsp;month period following the Date of
Termination, (B)&nbsp;the date that Executive and/or Executive&#146;s covered dependents become no longer eligible for COBRA or (C)&nbsp;the date Executive becomes eligible to receive medical, dental or vision coverage, as applicable, from a
subsequent employer (and Executive agrees to promptly notify the Company of such eligibility) (the &#147;<U>CIC COBRA Continuation Period</U>&#148;). Notwithstanding the foregoing, if the Company determines it cannot provide the foregoing benefit
without potentially violating applicable law (including, without limitation, Section&nbsp;2716 of the Public Health Service Act) or incurring an excise tax, the Company shall in lieu thereof provide to Executive a taxable monthly payment in an
amount equal to the monthly COBRA premium that Executive would be required to pay to continue Executive&#146;s and Executive&#146;s covered dependents&#146; group health coverage in effect on the Date of Termination (which amount shall be based on
the premium for the first month of COBRA coverage), less the amount Executive would have had to pay to receive group health coverage as an active employee for Executive and his covered dependents based on the cost sharing levels in effect on the
Date of Termination, which payments shall for the remainder of the CIC COBRA Continuation Period; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) all
outstanding, unvested Company equity awards held by Executive under any Company equity compensation plans shall immediately become 100% vested on the effectiveness of the Release, <I>provided</I>, <I>however</I>, that any performance-based equity
award will remain subject to attainment of the relevant performance goals on or prior to the deadline for attainment of such goals as set forth in the applicable award agreement unless a more favorable or alternative provision is contained in an
applicable award agreement, and to the extent such performance goals are not attained prior to such deadline, such performance-based equity awards shall not vest pursuant to this clause (iv)&nbsp;and shall be forfeited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Release</U>. Notwithstanding the foregoing, it shall be a condition to the Executive&#146;s right to receive the amounts provided for
in Sections 4(b) and 4(c) hereof that the Executive execute and deliver to the Company an effective release of claims in substantially the form attached hereto as <U>Exhibit A</U> (the &#147;<U>Release</U>&#148;) within <FONT
STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days (or, to the extent required by law, forty-five (45)&nbsp;days) following the Date of Termination and that the Executive not revoke such Release during any applicable revocation period. For
the avoidance of doubt, all equity awards eligible for accelerated vesting pursuant to this Section&nbsp;4 shall remain outstanding and eligible to vest following the Date of Termination and shall actually vest and become exercisable (if applicable)
and <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> upon the effectiveness of the Release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exclusive Remedy</U>. In the
event of a termination of Executive&#146;s employment with the Company, Executive&#146;s sole remedy shall be to receive the payments and benefits described in this Section&nbsp;4. In addition, Executive acknowledges and agrees that he is not
entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section&nbsp;4, including, without limitation, any excise tax imposed by
Section&nbsp;4999 of the Code. Any payments made to Executive under this Section&nbsp;4 shall be inclusive of any amounts or benefits to which Executive may be entitled pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C.
Sections 2101 et seq., and the Department of Labor regulations thereunder, or any similar state statute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. <U>Covenants</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In connection with his commencement of employment, Executive shall enter into the Company&#146;s standard form of agreement containing
confidentiality, intellectual property assignment and other protective covenants (the &#147;<U>Restrictive Covenant Agreement</U>&#148;), which is attached hereto as <U>Exhibit B</U>. Executive shall be bound by the terms and conditions of the
Restrictive Covenant Agreement, and hereby agrees that such agreement shall be additional to, and not in limitation of, the covenants contained in this Section&nbsp;5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Executive shall hold in a fiduciary capacity for the benefit of the Company all secret or confidential information, knowledge or data
relating to the Company and its subsidiaries and affiliates, which shall have been obtained by Executive in connection with Executive&#146;s employment by the Company and which shall not be or become public knowledge (other than by acts by Executive
or representatives of Executive in violation of this Agreement). After termination of Executive&#146;s employment with the Company, Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal
process, communicate or divulge any such information, knowledge or data, to anyone other than the Company and those designated by it; <I>provided</I>, <I>however</I>, that if Executive receives actual notice that Executive is or may be required by
law or legal process to communicate or divulge any such information, knowledge or data, Executive shall promptly so notify the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) While employed by the Company, Executive shall not be engaged in any other business activity that would be competitive with the business
of the Company and its subsidiaries or affiliates. In addition, while employed by the Company and for a period of twelve (12)&nbsp;months after the Date of Termination, Executive shall not directly or indirectly solicit, induce, or encourage any
employee or consultant of the Company and/or its subsidiaries and affiliates to terminate their employment or other relationship with the Company and its subsidiaries and affiliates or to cease to render services to the Company and/or its
subsidiaries and affiliates and Executive shall not initiate discussion with any such person for any such purpose or authorize or knowingly cooperate with the taking of any such actions by any other individual or entity except, in each case, to the
extent the foregoing occurs as a result of general advertisements or other solicitations not specifically targeted to such employees and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Subject to Section&nbsp;5(f), during Executive&#146;s service with the Company and thereafter, excepting any litigation between the
Parties, (i)&nbsp;Executive agrees not to publish or disseminate, directly or indirectly, any statements, whether written or oral, that are or could be harmful to or reflect negatively on any of the Company or any of its subsidiaries or affiliates,
or that are otherwise disparaging of any policies, procedures, practices, decision-making, conduct, professionalism or compliance with standards of the Company, its affiliates or any of their past or present officers, directors, employees, advisors
or agents, and (ii)&nbsp;the Company agrees to instruct its directors and executive officers not to publish or disseminate, directly or indirectly, any statements, whether written or oral, that are or could be harmful to or reflect negatively on
Executive&#146;s personal or business reputation or business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) In recognition of the fact that irreparable injury will result to the
Company in the event of a breach by Executive of his obligations under Sections 5(a)-(d) hereof, that monetary damages for such breach would not be readily calculable, and that the Company would not have an adequate remedy at law therefor, Executive
acknowledges, consents and agrees that in the event of such breach, or the threat thereof, the Company shall be entitled, in addition to any other legal remedies and damages available, to specific performance thereof and to temporary and permanent
injunctive relief (without the necessity of posting a bond) to restrain the violation or threatened violation of such obligations by Executive and to cease the payment of any benefits under Section&nbsp;4(b) or (c)&nbsp;above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Notwithstanding anything in this Agreement or the Restrictive Covenant Agreement or, if
applicable, the Arbitration Agreement (as defined below) to the contrary, nothing contained in this Agreement shall prohibit either party (or either party&#146;s attorney(s)) from (i)&nbsp;communicating directly with, filing a charge with, reporting
possible violations of federal law or regulation to, participating in any investigation by, or cooperating with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority, the Equal Employment Opportunity Commission,
the National Labor Relations Board (the &#147;<U>NLRB</U>&#148;), the Occupational Safety and Health Administration, the U.S. Commodity Futures Trading Commission, the U.S. Department of Justice or any other securities regulatory agency,
self-regulatory authority or federal, state or local regulatory authority (collectively, &#147;<U>Government Agencies</U>&#148;), or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation,
(ii)&nbsp;communicating directly with, cooperating with, or providing information (including trade secrets) in confidence to any Government Agencies for the purpose of reporting or investigating a suspected violation of law, or from providing such
information to such party&#146;s attorney(s) or in a sealed complaint or other document filed in a lawsuit or other governmental proceeding, and/or (iii)&nbsp;receiving an award for information provided to any Government Agency. Further, nothing
herein will prevent Executive from participating in activity permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair labor practice charge with the NLRB. Pursuant to 18 USC Section&nbsp;1833(b), Executive will not be
held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an
attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (y)&nbsp;in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Further, nothing in this
Agreement is intended to or shall preclude either party from providing truthful testimony in response to a valid subpoena, court order, regulatory request or other judicial, administrative, or legal process or otherwise as required by law. If
Executive is required to provide testimony, then unless otherwise directed or requested by a Government Agency or law enforcement, Executive shall notify the Company as soon as reasonably practicable after receiving any such request of the
anticipated testimony. Further, nothing in this Agreement prevents Executive from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Executive has reason to
believe is unlawful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. <U>Assignment and Successors</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the
assets of the Company (by merger or otherwise). This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personal and legal representatives, executors, administrators, heirs,
distributees, devisees, and legatees, as applicable. None of Executive&#146;s rights or obligations may be assigned or transferred by Executive, other than Executive&#146;s rights to payments hereunder, which may be transferred only by will or
operation of law. Notwithstanding the foregoing, Executive shall be entitled, to the extent permitted under applicable law and applicable Company Arrangements, to select and change a beneficiary or beneficiaries to receive compensation hereunder
following Executive&#146;s death by giving written notice thereof to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. <U>Certain Definitions</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Cause</U>. The Company shall have &#147;Cause&#148; to terminate Executive&#146;s employment hereunder upon: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the continued failure by Executive to substantially perform Executive&#146;s duties with the Company (other than any such failure resulting
from incapacity due to physical or mental illness), after a written demand for substantial performance is delivered to Executive by the Company or an affiliate that specifically identifies the alleged manner in which Executive has not substantially
performed Executive&#146;s duties and after Executive has been provided with a thirty (30)&nbsp;day cure period, or Executive&#146;s deliberate violation of a Company policy; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the engaging by Executive in illegal conduct or misconduct (including fraud, embezzlement, theft or dishonesty or material violation of
any Company policy), or gross negligence, in any case that has caused or is reasonably expected to result in injury to the Company or any affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Executive&#146;s commission of, or plea of no contest to, a felony or any misdemeanor crime involving fraud, moral turpitude or
dishonesty; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Executive&#146;s material breach of any written agreement or restrictive covenants with the Company; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Executive&#146;s violation of any law, rule or regulation relating in any way to the business or activities of the Company or any
affiliate, or other law, rule or regulation that is violated, during the course of Executive&#146;s performance of services hereunder that results in Executive&#146;s regulatory suspension or disqualification, including, without limitation, the
Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167; 335(a), or any similar legislation applicable in the United States or in any other country where the Company or any affiliate intends to develop its activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No action or inaction based upon direction of the Board or advice of counsel to the Company shall constitute Cause. Poor performance shall
not, in and of itself, constitute Cause. No termination of Executive&#146;s employment for Cause shall occur absent a resolution of the Board and the reasonable opportunity for Executive (with Executive&#146;s counsel) to be heard before the Board.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Change in Control</U>. &#147;<U>Change in Control</U>&#148; shall have the meaning set forth in the Plan, as in effect on the
Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Code</U>. &#147;<U>Code</U>&#148; shall mean the Internal Revenue Code of 1986, as amended, and the regulations
and guidance promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Date of Termination</U>. &#147;<U>Date of Termination</U>&#148; shall mean (i)&nbsp;if
Executive&#146;s employment is terminated by Executive&#146;s death, the date of Executive&#146;s death; or (ii)&nbsp;if Executive&#146;s employment is terminated pursuant to Sections 3(a)(ii)-(vi) either the date indicated in the Notice of
Termination or the date specified by the Company pursuant to Section&nbsp;3(b), whichever is earlier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Disability</U>.
&#147;<U>Disability</U>&#148; shall mean, at any time the Company sponsors a long-term disability plan for the Company&#146;s employees, &#147;disability&#148; as defined in such long-term disability plan for the purpose of determining a
participant&#146;s eligibility for benefits, <I>provided, however</I>, if the long-term disability plan contains multiple definitions of disability, &#147;Disability&#148; shall refer to that definition of disability which, if Executive qualified
for such disability benefits, would provide coverage for the longest period of time. The determination of whether Executive has a Disability shall be made by the person or persons required to make disability determinations under the long-term
disability plan. At any time the Company does not sponsor a long-term disability plan for its employees, &#147;Disability&#148; shall mean Executive&#146;s inability to perform, with reasonable accommodation, the essential functions of
Executive&#146;s positions hereunder for a total of<B> </B>one hundred eighty (180)&nbsp;days within a twelve (12)&nbsp;month period as a result of incapacity due to mental or physical illness as determined by a physician selected by the Company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or its insurers and acceptable to Executive or Executive&#146;s legal representative, with such agreement as to acceptability not to be unreasonably withheld or delayed. Any refusal by Executive
to submit to a medical examination for the purpose of determining Disability shall be deemed to constitute conclusive evidence of Executive&#146;s Disability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Good Reason</U>. For the sole purpose of determining Executive&#146;s right to severance payments and benefits as described above,
Executive&#146;s resignation will be with &#147;<U>Good Reason</U>&#148; if Executive resigns within one hundred twenty (120)&nbsp;days after any of the following events, unless Executive expressly consents in writing to the applicable event:
(i)&nbsp;a reduction in Executive&#146;s Annual Base Salary or Target Bonus, other than a reduction of less than ten percent (10%) (aggregating all prior reductions) that is implemented in connection with a contemporaneous reduction in annual base
salaries affecting other senior executives of the Company; (ii)&nbsp;a material decrease in Executive&#146;s authority or areas of responsibility as are commensurate with Executive&#146;s title or position with the Company; (iii)&nbsp;the relocation
of Executive&#146;s primary working location to a location that is more than fifty (50)&nbsp;miles from Executive&#146;s home office in Worcester, Massachusetts as of the Effective Date; or (iv)&nbsp;the Company&#146;s breach of a material provision
of this Agreement. Notwithstanding the foregoing, no Good Reason will have occurred unless and until: (a)&nbsp;Executive has provided the Company, within sixty (60)&nbsp;days of Executive&#146;s knowledge of the occurrence of the facts and
circumstances underlying the Good Reason event, written notice stating with specificity the applicable facts and circumstances underlying such finding of Good Reason; (b)&nbsp;the Company has had an opportunity to cure the same within thirty
(30)&nbsp;days after the receipt of such notice; and (c)&nbsp;the Company shall have failed to so cure within such period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. <U>Parachute
Payments</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Best Pay Provision</U>. In the event that any payment or benefit received or to be received by Executive pursuant
to the terms of any plan, arrangement or agreement (including any payment or benefit received in connection with a change in ownership or control or the termination of Executive&#146;s employment) (all such payments and benefits being hereinafter
referred to as the &#147;<U>Total Payments</U>&#148;) would be subject (in whole or part) to the excise tax (the &#147;<U>Excise Tax</U>&#148;) imposed under Section&nbsp;4999 of the Code, then the Total Payments shall be reduced to the extent
necessary so that no portion of the Total Payments is subject to the Excise Tax but only if (i)&nbsp;the net amount of such Total Payments, as so reduced (after subtracting the amount of federal, state and local income taxes on such reduced Total
Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii)&nbsp;the net amount of such Total Payments without such reduction
(after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase
out of itemized deductions and personal exemptions attributable to such unreduced Total Payments); <U>provided</U>, <U>however</U>, that this sentence shall not apply if, immediately before the change in ownership or control on which such Total
Payments are contingent or otherwise relate, no stock in the Company is readily tradeable on an established securities market or otherwise (as determined in accordance with Treasury Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.280G-1</FONT>
Q&amp;A 6). Except to the extent that an alternative reduction order would result in a greater economic benefit to Executive on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, the Parties intend that the Total Payments shall be reduced
in the following order: (w)&nbsp;reduction of any cash severance payments otherwise payable to Executive that are exempt from Section&nbsp;409A of the Code, (x)&nbsp;reduction of any other cash payments or benefits otherwise payable to Executive
that are exempt from Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, (y)&nbsp;reduction of any other
payments or benefits otherwise payable to Executive on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis or such other manner that complies with Section&nbsp;409A of the Code, but excluding any payment attributable to the acceleration of
vesting and payment with respect to any equity award that is exempt from Section&nbsp;409A of the Code, and (z)&nbsp;reduction of any payments attributable to the acceleration of vesting or payment with
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to any equity award that is exempt from Section&nbsp;409A of the Code; <I>provided</I>, in case of clauses (x), (y) and (z), that reduction of any payments or benefits attributable to the
acceleration of vesting of Company equity awards shall be first applied to equity awards with later vesting dates; <I>provided</I>, <I>further</I>, that, notwithstanding the foregoing, any such reduction shall be undertaken in a manner that complies
with and does not result in the imposition of additional taxes on Executive under Section&nbsp;409A of the Code. The foregoing reductions shall be made in a manner that results in the maximum economic benefit to Executive on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis and, to the extent economically equivalent payments or benefits are subject to reduction, in a pro rata manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Determinations</U>. All determinations regarding the application of this Section&nbsp;8 shall be made by an independent accounting firm
or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability of Section&nbsp;280G of the Code and the Excise Tax retained by the Company prior to the date of
the applicable change in ownership or control (the &#147;<U>280G Firm</U>&#148;). For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (i)&nbsp;no portion of the Total Payments shall be
taken into account which (x)&nbsp;does not constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G(b)(2) of the Code (including by reason of Section&nbsp;280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, or
(y)&nbsp;constitutes reasonable compensation for services actually rendered, within the meaning of Section&nbsp;280G(b)(4)(B) of the Code, in excess of the &#147;base amount&#148; (as defined in Section&nbsp;280G(b)(3) of the Code) allocable to such
reasonable compensation, (ii)&nbsp;no portion of the Total Payments the receipt or enjoyment of which Executive shall have waived at such time and in such manner as not to constitute a &#147;payment&#148; within the meaning of Section&nbsp;280G(b)
of the Code shall be taken into account, and (iii)&nbsp;the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> benefit or any deferred payment or benefit included in the Total Payments shall be determined by the 280G Firm in accordance
with the principles of Sections 280G(d)(3) and (4)&nbsp;of the Code. All determinations related to the calculations to be performed pursuant to this &#147;Section&nbsp;280G Treatment&#148; section shall be done by the 280G Firm. The 280G Firm will
be directed to submit its determination and detailed supporting calculations to both Executive and the Company within fifteen (15)&nbsp;days after notification from either the Company or Executive that Executive may receive payments which may be
&#147;parachute payments.&#148; Executive and the Company will each provide the 280G Firm access to and copies of any books, records, and documents as may be reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in
connection with the preparation and issuance of the determinations and calculations contemplated by this Agreement. The fees and expenses of the 280G Firm for its services in connection with the determinations and calculations contemplated by this
Agreement will be borne solely by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exception</U>. Notwithstanding the foregoing, if any portion of the Total Payments
would not be subject to the Excise Tax if the stockholder approval requirements of Section&nbsp;280G(b)(5) of the Code are satisfied, subject to Executive&#146;s waiver of the rights to such portion of the Total Payments above the safe harbor
threshold in accordance with and to the extent required by Section&nbsp;280G of the Code with respect to any portion of the Total Payments that would otherwise be subject to excise tax imposed by Section&nbsp;4999 of the Code (before giving effect
to any reduction in the Total Payments contemplated above), the Company shall use its reasonable best efforts to cause such payments to be submitted for such approval prior to the event giving rise to such payments. To the extent the Company submits
any payment or benefit payable to Executive under this Agreement or otherwise to the Company&#146;s stockholders for approval in accordance with Treasury Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.280G-1</FONT> Q&amp;A 7, the foregoing
provisions under this Section&nbsp;8 shall not apply following such submission and such payments and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver above the safe harbor threshold of,
such payments or benefits required by such vote will be applied without any application of discretion by Executive and in the order prescribed in Section&nbsp;8(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. <U>Miscellaneous Provisions</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Governing Law and Venue</U>. This Agreement shall be governed, construed, interpreted and enforced in accordance with its express terms,
and otherwise in accordance with the substantive laws of the Commonwealth of Massachusetts without reference to the principles of conflicts of law of the Commonwealth of Massachusetts or any other jurisdiction that would result in the application of
the laws of a jurisdiction other than the Commonwealth of Massachusetts, and where applicable, the laws of the United States. Any suit brought hereon shall be brought in the state or federal courts sitting in the Commonwealth of Massachusetts, the
parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by
Massachusetts law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Validity</U>. The invalidity or unenforceability of any provision or provisions of this Agreement shall not
affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Notices</U>. Any notice, request, claim, demand, document, and other communication hereunder to any Party shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile, email or
certified or registered mail, postage prepaid, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If to the Company, to the CEO of the Company at the
Company&#146;s headquarters, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If to Executive, to the last address that the Company has in its personnel records for
Executive, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) At any other address as any Party shall have specified by notice in writing to the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Counterparts</U>. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of
which together will constitute one and the same Agreement. Signatures delivered by facsimile or PDF shall be deemed effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Entire Agreement</U>. The terms of this Agreement, the Restrictive Covenant Agreement incorporated herein by reference as set forth in
Section&nbsp;5, and any Release are intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof and supersede all prior understandings and agreements, whether written or oral, including any prior
employment offer letter or employment agreement, between Executive and the Company. The Parties further intend that this Agreement, the Restrictive Covenant Agreement incorporated herein by reference as set forth in Section&nbsp;5, and any Release
shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of such agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Amendments; Waivers</U>. This Agreement may not be modified, amended, or terminated except by an instrument in writing, signed by
Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified provision of this
Agreement that such other Party was or is obligated to comply with or perform; <I>provided</I>, <I>however</I>, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No failure to exercise
and no delay in exercising any right, remedy, or power hereunder will preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Construction</U>. This Agreement shall be deemed drafted equally by both the Parties.
Its language shall be construed as a whole and according to its fair meaning. Any presumption or principle that the language is to be construed against any Party shall not apply. The headings in this Agreement are only for convenience and are not
intended to affect construction or interpretation. Any references to paragraphs, subparagraphs, sections, or subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary. Also, unless the context clearly
indicates to the contrary, (i)&nbsp;the plural includes the singular and the singular includes the plural; (ii) &#147;and&#148; and &#147;or&#148; are each used both conjunctively and disjunctively; (iii) &#147;any,&#148; &#147;all,&#148;
&#147;each,&#148; or &#147;every&#148; means &#147;any and all,&#148; and &#147;each and every&#148;; (iv) &#147;includes&#148; and &#147;including&#148; are each &#147;without limitation&#148;; (v) &#147;herein,&#148; &#147;hereof,&#148;
&#147;hereunder&#148; and other similar compounds of the word &#147;here&#148; refer to the entire Agreement and not to any particular paragraph, subparagraph, section or subsection; and (vi)&nbsp;all pronouns and any variations thereof shall be
deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the entities or persons referred to may require. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Arbitration</U>. In the event of any dispute or claim relating to, or arising out of Executive&#146;s employment relationship with the
Company or its affiliates, including, but not limited, claims of wrongful termination, age, race, gender, disability or other discrimination&#151;but not including claims for sexual harassment or sexual assault&#151;Executive and the Company agree
that all such disputes shall be fully and finally resolved by binding arbitration conducted before a single neutral arbitrator pursuant to the rules for arbitration of employment disputes by the American Arbitration Association (available at
www.adr.org) in the Commonwealth of Massachusetts. The arbitrator shall permit adequate discovery and is empowered to award all remedies otherwise available in a court of competent jurisdiction, and any judgment rendered by the arbitrator may be
entered by any court of competent jurisdiction. The arbitrator shall issue an award in writing and state the essential findings and conclusions of law on which the award is based. By executing this Agreement, the Parties are both waiving the right
to a jury trial with respect to any such disputes. The Company shall bear the costs of the arbitrator, forum and filing fees. Each Party shall bear its own respective attorney fees and all other costs, unless provided by law and awarded by the
arbitrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Enforcement</U>. If any provision of this Agreement is held to be illegal, invalid or unenforceable under present or
future laws effective during the Term, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a portion of this Agreement; and the remaining
provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance from this Agreement. Furthermore, in lieu of such illegal, invalid, or unenforceable
provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and be legal, valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Withholding</U>. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local or
foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on the advice of counsel if any questions as to the amount or requirement of withholding shall arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Section 409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>General.</I> The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt
from Section&nbsp;409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. If the Company and Executive agree in good faith that the payments and benefits under this Agreement would
not comply with Section&nbsp;409A, the Parties hereto shall reasonably and in good faith attempt to modify this Agreement to comply with Section&nbsp;409A while endeavoring to maintain the intended economic benefits hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Separation from Service. </I>Notwithstanding anything in this
Agreement to the contrary, (A)&nbsp;any compensation or benefits payable under this Agreement that is designated under this Agreement as payable upon Executive&#146;s termination of employment shall be payable only upon Executive&#146;s
&#147;separation from service&#148; with the Company within the meaning of Section&nbsp;409A (a &#147;<U>Separation from Service</U>&#148;) and (B)&nbsp;in the event that, with respect to the amounts payable under Sections 4(b) or 4(c), the timing
of the delivery of Executive&#146;s Release could cause such amounts to begin in one or another taxable year, to the extent such amounts are subject to Section&nbsp;409A, then notwithstanding the payment timing set forth in such Sections, such
amounts shall not be payable until the later of (1)&nbsp;the payment date specified in such Section or (2)&nbsp;the first business day of the taxable year following Executive&#146;s Separation from Service. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <I>Specified Employee.</I> Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the
Company at the time of Executive&#146;s Separation from Service to be a &#147;specified employee&#148; for purposes of Section&nbsp;409A, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this
Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A, such portion of Executive&#146;s benefits shall not be provided to Executive prior to the earlier of (x)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap">six-month</FONT> period measured from the date of Executive&#146;s Separation from Service with the Company or (y)&nbsp;the date of Executive&#146;s death. Upon the first business day following the expiration of the
applicable Section&nbsp;409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive&#146;s estate or beneficiaries), and any remaining payments due to Executive under this Agreement
shall be paid as otherwise provided herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <I>Expense Reimbursements. </I>To the extent that any reimbursements
under this Agreement are subject to Section&nbsp;409A, (A)&nbsp;any such reimbursements payable to Executive shall be paid to Executive no later than December&nbsp;31 of the year following the year in which the expense was incurred,
(B)&nbsp;Executive shall submit Executive&#146;s reimbursement request promptly following the date the expense is incurred, (C)&nbsp;the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any
subsequent year, other than medical expenses referred to in Section&nbsp;105(b) of the Code, and (D)&nbsp;Executive&#146;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Installments.</I> Executive&#146;s right to receive any installment payments under this Agreement, including without
limitation any continuation salary payments that are payable on Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate
and distinct payment as permitted under Section&nbsp;409A. Except as otherwise permitted under Section&nbsp;409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or
interest pursuant to Section&nbsp;409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Survival</U>. Notwithstanding anything to the contrary in this Agreement, the provisions
of Sections 5 through 9 will survive the termination of Executive&#146;s employment and the termination of the Term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. <U>Executive
Acknowledgement</U>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal
effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#146;s own judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement on the date and year first
above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CG ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/Arthur Kuan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Arthur Kuan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Chief Executive Officer</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/Vijay Kasturi, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Print&nbsp;Name: Vijay Kasturi, M.D.</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Employment Agreement]</I> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION AGREEMENT AND RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement and Release (&#147;<U>Agreement</U>&#148;) is made by and between Vijay Kasturi, M.D. (&#147;<U>Executive</U>&#148;)
and CG Oncology, Inc. (the &#147;<U>Company</U>&#148;) (collectively referred to as the &#147;<U>Parties</U>&#148; or individually referred to as a &#147;<U>Party</U>&#148;). Capitalized terms used but not defined in this Agreement shall have the
meanings set forth in the Employment Agreement (as defined below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have previously entered into that certain
Employment Agreement, dated as of August&nbsp;14, 2023 (the &#147;<U>Employment Agreement</U>&#148;) and that certain Restrictive Covenant Agreement (as defined in the Employment Agreement); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in connection with Executive&#146;s termination of employment with the Company or a subsidiary or affiliate of the Company effective
[________], 20[__], the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that Executive may have against the Company and any of the Releases as defined below, including, but not
limited to, any and all claims arising out of or in any way related to Executive&#146;s employment with or separation from the Company or its subsidiaries or affiliates but, for the avoidance of doubt, nothing herein will be deemed to release any
rights or remedies in connection with Executive&#146;s ownership of vested equity securities of the Company, vested benefits or Executive&#146;s right to indemnification or liability insurance by the Company or any of its affiliates pursuant to
contract or applicable law (collectively, the &#147;<U>Retained Claims</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the severance
payments and benefits described in Section&nbsp;4 of the Employment Agreement, which, pursuant to the Employment Agreement, are conditioned on Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of this Agreement,
and in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Severance Payments and
Benefits; Salary and Benefits</U>. The Company agrees to provide Executive with the severance payments and benefits described in Section&nbsp;4 of the Employment Agreement, payable at the times set forth in, and subject to the terms and conditions
of, the Employment Agreement. In addition, to the extent not already paid, and subject to the terms and conditions of the Employment Agreement, the Company shall pay or provide to Executive the Accrued Obligations described in Section&nbsp;3(c) of
the Employment Agreement, subject to and in accordance with the terms thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Release of Claims</U>. Executive agrees that, other
than with respect to the Retained Claims, the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries, and any of its or their current and
former officers, directors, equity holders, managers, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor and
successor corporations and assigns (collectively, the &#147;<U>Releasees</U>&#148;) related to Executive&#146;s employment with the Company or its subsidiaries or termination therefrom. Executive, on Executive&#146;s own behalf and on behalf of any
of Executive&#146;s affiliated companies or entities and any of their respective heirs, family members, executors, agents, and assigns, other than with respect to the Retained Claims, hereby and forever releases the Releasees from, and agrees not to
sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge, duty, obligation, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive
may possess against any of the Releasees arising from any omissions, acts, facts, or damages that have occurred up until and including the date Executive signs this Agreement relating to Executive&#146;s employment with the Company or its
subsidiaries or termination therefrom, including, without limitation: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any and all claims relating to or arising from Executive&#146;s employment or service
relationship with the Company or any of its direct or indirect subsidiaries and the termination of that relationship; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any and all
claims relating to, or arising from, Executive&#146;s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates, including, without limitation, any claims for fraud,
misrepresentation, breach of fiduciary duty, breach of duty under applicable state law, and securities fraud under any state or federal law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) any and all claims for wrongful discharge of employment; termination in violation of public policy; discrimination; harassment;
retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress; fraud; negligent or intentional
misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion of privacy; false imprisonment;
conversion; and disability benefits; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) any and all claims for violation of any federal, state, or municipal statute, including, but not
limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the Fair Labor Standards Act; the Fair Credit Reporting Act; the Age
Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical Leave Act; the Sarbanes-Oxley Act
of 2002; the Massachusetts Fair Employment Practices Act; the Massachusetts Equal Rights Act; the Massachusetts Labor and Industry Code (Mass. Gen. Laws c. 149) (including without limitation the Massachusetts Payment of Wages Law (Mass. Gen. Laws c.
149, &#167; 148) and the Massachusetts <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Agreement Act (Mass. Gen. Laws c. 149, &#167; 24L)); the Massachusetts Minimum Fair Wages Law (Mass. Gen. Laws c. 151); and the Massachusetts Family and
Medical Leave Act, each as amended, or any other federal, state or local statute or ordinance; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) any and all claims for violation of
the federal or any state constitution; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) any and all claims arising out of any other laws and regulations relating to employment or
employment discrimination; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) any claim for any loss, cost, damage, or expense arising out of any dispute over the <FONT
STYLE="white-space:nowrap">non-withholding</FONT> or other tax treatment of any of the proceeds received by Executive as a result of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) any and all claims arising out of the wage and hour and wage payments laws and regulations of the state or states in which Executive has
provided service to the Company or any of its affiliates; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) any and all claims for attorneys&#146; fees and costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED BY LEGAL COUNSEL AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION
1542, WHICH PROVIDES AS FOLLOWS: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR
SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTIVE, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE
MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive agrees that the release
set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does not release claims that cannot be released as a matter of law, including, but not limited to,
Executive&#146;s right to report possible violations of federal law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated under Section&nbsp;21F of the Securities Exchange Act of 1934 or
Section&nbsp;806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation and any right to receive an award for information provided thereunder, Executive&#146;s right to file a charge
with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative body or government agency that is authorized to enforce or administer laws related to employment, against the
Company for discrimination (with the understanding that Executive&#146;s release of claims herein bars Executive from recovering such monetary relief from the Company or any Releasee for any alleged discriminatory treatment), claims for unemployment
compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company&#146;s group benefit plans pursuant to the terms and conditions of COBRA, claims for
indemnity under the bylaws of the Company, as provided for by Massachusetts or Delaware law or under any applicable insurance policy with respect to Executive&#146;s liability as an employee, director or officer of the Company, claims to any benefit
entitlements vested as the date of separation of Executive&#146;s employment, pursuant to written terms of any employee benefit plan of the Company or its affiliates and Executive&#146;s right under applicable law and any Retained Claims. This
release further does not release claims for breach of Section&nbsp;3(c) or Section&nbsp;4 of the Employment Agreement. This release does not prevent Executive from cooperating with an investigation conducted by any such governmental agencies,
including without limitation the National Labor Relations Board (the &#147;NLRB&#148;). Nothing herein will prevent Executive from participating in an activity permitted by Section&nbsp;7 of the National Labor Relations Act or from filing an unfair
labor practice charge with the NLRB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Acknowledgment of Waiver of Claims under ADEA</U>. Executive understands and acknowledges that
Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (&#147;<U>ADEA</U>&#148;), and that this waiver and release is knowing and voluntary. Executive understands and agrees that this
waiver and release does not apply to any rights or claims that may arise under the ADEA after the date Executive signs this Agreement. Executive understands and acknowledges that the consideration given for this waiver and release is in addition to
anything of value to which Executive was already entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a)&nbsp;Executive has the right to and should consult with an attorney prior to
executing this Agreement; (b)&nbsp;Executive has <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] days within which to consider this Agreement, and the Parties agree that such time period to review this Agreement shall not be extended upon
any material or immaterial changes to this Agreement; (c)&nbsp;Executive has seven (7)&nbsp;business days following Executive&#146;s execution of this Agreement to revoke this Agreement pursuant to written notice to the General Counsel of the
Company; (d)&nbsp;this Agreement shall not be effective until after the revocation period has expired without revocation; and (e)&nbsp;nothing in this Agreement prevents or precludes Executive from challenging or seeking a determination in good
faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this Agreement and returns it to the
Company in less than the <FONT STYLE="white-space:nowrap">[twenty-one</FONT> (21)] day period identified above, Executive hereby acknowledges </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that Executive has freely and voluntarily chosen to waive the time period allotted for considering this Agreement. To revoke this Agreement, Executive must notify the Company in writing sent to
the Chief Executive Officer of the Company, and such revocation must be received no later than the seventh (7<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) business day after Executive signs this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Restrictive Covenants</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Executive acknowledges his ongoing obligations under Section&nbsp;5 of the Employment Agreement. Sections 5(e) and 5(f) of the Employment
Agreement are hereby incorporated by reference and will apply to this Agreement as if set forth herein. The enforcement terms set forth therein shall apply to this Section&nbsp;4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Executive acknowledges that during the course of his employment with the Company, he became become familiar with the trade secrets of the
Company and with other Confidential Information (as defined in the Restrictive Covenant Agreement) concerning the Company and its predecessors and that Executive&#146;s services were of special, unique and extraordinary value to the Company.
Therefore, Executive agrees that, during the period of one year immediately following the termination of Executive&#146;s employment (the &#147;<U><FONT STYLE="white-space:nowrap">Non-Competition</FONT> Restricted Period</U>&#148;), Executive shall
not directly or indirectly own any interest in, manage, control, participate in, consult with, render services for, be employed in an executive, managerial, administrative or other capacity by, or in any manner engage in, any business or entity
competing with the Business (as defined in the Restrictive Covenant Agreement) in any country in which Executive had a material presence or the Company conducts business during the last two years of Executive&#146;s employment or in which the
Company has material plans to conduct business as of the termination of Executive&#146;s employment. Nothing herein shall prohibit Executive from being a passive owner of not more than 2% of the outstanding stock of any class of a corporation which
is publicly traded, so long as Executive has no active participation in the business of such corporation. In the event Executive breaches his fiduciary duty to the Company or unlawfully takes, physically or electronically, property belonging to the
Company as reasonably determined by the Company, the <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Restricted Period as defined above shall be extended for one additional year, for a maximum period of two years immediately following his
termination of employment from the Company. Further, in the event Executive breaches this Section&nbsp;4(b), the <FONT STYLE="white-space:nowrap">Non-Competition</FONT> Restricted Period shall extend for each day of Executive&#146;s <FONT
STYLE="white-space:nowrap">non-compliance,</FONT> so as to give the Company the bargained for benefit of Executive&#146;s <FONT STYLE="white-space:nowrap">non-competition</FONT> covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If, at the time of enforcement of this Section&nbsp;4, a court shall hold that the duration, scope or area restrictions stated herein are
unreasonable under circumstances then existing, the parties agree that the maximum duration, scope or area reasonable under such circumstances shall be substituted for the stated duration, scope or area and that the court shall be allowed to revise
the restrictions contained herein to cover the maximum period, scope and area permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Executive acknowledges that the
restrictions contained in this Section&nbsp;4 are reasonable and that Executive has been provided an opportunity to review the provisions of this Agreement with his legal counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Severability</U>. In the event that any provision or any portion of any provision hereof or any surviving agreement made a part hereof
becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>No Oral Modification</U>. This Agreement may only be amended in a writing signed by Executive and a duly authorized officer of the
Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Governing Law; Dispute Resolution</U>. This Agreement shall be subject to the
provisions of Sections 9(a), 9(c), and 9(h) of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effective Date</U>. Executive has seven (7)&nbsp;business
days after Executive signs this Agreement to revoke it and this Agreement will become effective on the day immediately following the seventh business day after Executive signed this Agreement (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Voluntary Execution of Agreement</U>. Executive understands and agrees that Executive executed this Agreement voluntarily, without any
duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive&#146;s claims against the Company and any of the other Releasees. Executive acknowledges that: (a)&nbsp;Executive
has read this Agreement; (b)&nbsp;Executive has not relied upon any representations or statements made by the Company that are not specifically set forth in this Agreement; (c)&nbsp;Executive has been represented in the preparation, negotiation, and
execution of this Agreement by legal counsel of Executive&#146;s own choice or has elected not to retain legal counsel; (d)&nbsp;Executive understands the terms and consequences of this Agreement and of the releases it contains; and
(e)&nbsp;Executive is fully aware of the legal and binding effect of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Entire Agreement</U>. The terms of this
Agreement, the Employment Agreement and the Restrictive Covenant Agreement are intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof and supersede all prior understandings and agreements,
whether written or oral, including any prior employment offer letter or employment agreement, between Executive and the Company. The Parties further intend that this Agreement, the Employment Agreement and the Restrictive Covenant Agreement shall
constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of such agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set
forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>EXECUTIVE</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Print Name: Vijay Kasturi, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5"><B>CG ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:0%; font-size:11pt; font-family:Times New Roman" ALIGN="center">RESTRICTIVE COVENANT AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Attached</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g551455g03p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g03p01.jpg
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M 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ 3\# 1$  A$! Q$!_\0 '@ !  ,
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M7&T+PI.(I(CQ2/%(O:\;LCJ=$JZ$JRD@D'1!'@D?D>+P0P# [! (/Y@C8/\
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MA?6+U'L6L;(6Z;P"R8S"@,&295<">TI4E621D7L(+H9#8F@D,-A0/T??P/\
M\/D_H7Z6++GJ_L]9=9O6RV;B="DV/JQQN<=CI58=\=A5GEGM(1'(GN5JEF(3
MT6)CQYK)S=+FMC;VBYW2_JE/:*#LI?L.R.+@8.ILK4E+;MT:U8))TI#JE92E
M+"K7 #X?5G./M9^_.,XSC&?.K7I7?7%XCT^R#G4=7#=-23'\H/Z.IK/K7W]I
MGU^O/SY^KT1G]1?4V(?S/UQUD%^WU?YP9$K_ (=P&^>9/SUM^R\Q]$:AW<('
MO9LNDMJ5&]?T.;AR"Y-D4VQPR)*N$4N-_FBME6(<L(10MO#S3,J0C*4K3\8W
M7R5*+*XV[0=A[5ZI-7]Q=,%$\3*DJ_(;L+*ZGX) Y1$,C031R@?5%(KZ^-]K
M E3^^M']^>L[H?>&MND]0:_WEJ*PQ;1KS9-<@V2NE(ZV\NH9E(RF6**1VW'<
MCCP*>W*#6 0^K$L0:@3ALM")$5U.-0LA0LXRY9H7(S%9JRM%*AWK:GPZGQW1
MR+IXW'TNC*RD@CD_BE2:-)8SW)(H93^A^Q'V(.P1]B".=M^(^9.?/VRV5FAU
M>Q7:Z'1=7J-2"D['9K&;F,CPX($&AO3RI8G.D+0Q$@P(3#TF2^ZM*&VFU*SG
M^/,D,,MB6.""-Y9IG6***-2SR2.P5$11LLS,0 !Y)//+,J*SL0JJ"S,3H!0-
MDDGX 'DGF +HGZEGNPIO+:DSG:WTJK:+S=#4?5 8_JRK%SJ*/!DJ@@2!F<7A
MO$,E3D.,@X0B2'7,#99%X<RM3$1K.=AL;Z88!*%1<E#/+D/80VWCMRI'[[#N
MD5%1@O9&3[:L .\*'/ECR)S9JT99#"RK%W'VP8U)[ =*22"=L/J(^Q.O@<G#
M[?-;],]*>DWC7KCH54<]O.B66!LO9ZQ5:@UB*#UAT#DA#K*E@A;#30Z4+8=T
MR*+L.-(>P0FDY,W+#C.6$L/1MG%XOKK-X?';CH6(GJ5 \IE,EK'=K2ZD<DN'
M(NNA!([0H78.^*<@D\^,K6)M-*C!WTO;J.;87P/ (_J@?'R3\:\U-_3^=L5/
MCCNL=#V:9BU_5/0=6>T[9[ 2?1%$56Q33 PS0+26DN*0U%&L6 ?FM$2$IUJ
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M8CK1(DD?<E="#:N$M&DS-(7:(=K]HBC8+W,[,6!18U]7&UZ+RS*SL2&T7/\
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M'7Q]2>Y.D^,F:*O&TCK$N,M(TA502%#R(I/YL!]^8L;-%!D;#S2+&I6=0SD
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JX<./#AQX<./#AQX<./#AQX<./#AQX<./#AQX<./#AQX<./#AQX<.?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g551455g08o97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g08o97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X7IL:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @
M(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P
M9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM
M;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]G+R(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T
M;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N,# \
M+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'!D9CI+97EW;W)D<SY#1R!/;F-O
M;&]G>3PO<&1F.DME>7=O<F1S/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/D%D;V)E($EL;'5S=')A=&]R(#(U+C @*%=I;F1O=W,I/"]X;7 Z0W)E871O
M<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(S+3$P+3(V5#(S
M.C,U.C0R*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-
M;V1I9GE$871E/C(P,C,M,3 M,C94,C,Z,S4Z-#,K,#4Z,S \+WAM<#I-;V1I
M9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(S+3$P+3(V
M5#(S.C,U.C0S*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \
M>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I
M9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,3(P/"]X
M;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z9F]R
M;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!
M<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!
M)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!
M0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-
M1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(
M=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&8O.$%!15%G065!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%1
M14)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"05%%
M04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C
M1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!"
M)B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&15
M6DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P
M6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/
M16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7
M;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%1$)#
M15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$
M4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95
M,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:
M;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO
M)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A
M04%W1$%104-%44U2040X03=,*V)L.$Y.;CAL=D<Q>D5T>C5J)B-X03MS<E-5
M5V1W,7)Z4U98;W-T039Y4CAL57-J3'5T44-T831Q>5AZ;G)$-D9O175O,C!%
M57-S8GAQ<5-,.%!X348O6DE09D9"3E!/=CA!)B-X03ML8T]T9CE7*WDO-$=4
M+VUV1FAX="]W1$LT9&(O04]R9EIF.$%!>68X,31R>'1F.$%+-&1A+W=#<F1:
M9CA$2B]Z6&EV1S,O>75(5R\K)B-X03MR9EIF.$1*+WI8:79'-R]L8T]T+SE7
M*WDO=T-":R\U<GA8:F$O=T-6=S8Q+S%B-TPO9UI0*V$X5C0P6&-F;71Q.%9H
M85A!<TQ-=&-E)B-X03MP>D)6-D1G,4)4-'9F1F5*0V8X04LT9&$O=T-R9EIF
M.$1*+WI8:79'-R]L8T]T9CE7*WDO-$=4+T%*<GA8:F0O>75(5W8K<F9:9CA!
M)B-X03M!>69,*V9&94XS+TLT9&$O-G0Y;"]W041*+WI8:79',R]W07)H,78O
M04MT.6PO=TUN+TYE2SAB6"]+-&1A+S9T.6PO=TUN+TYE2SAB)B-X03MF+TLT
M9&(O-G0Y;"]W36YZ+VYX6&IA+S581')8+U9V<W8K0FLK9CA!4&EV1S,O>75(
M5R\K<F9:9CA$2B]Z6&EV1S<O;&-/="\Y5RMY)B-X03LO=T-":R\U<GA8:F$O
M=T-6=S8Q+S%B<DPO9UI0*V$X5C0R+RM6=S8S+W="5RMY+S1'5#5F>C1R>'1F
M.$%+-&1A+W=#<F1:9CA$2B]Z)B-X03M8:79'-R]L8T]T9CE7*WDS-B]$2B]W
M03$T<GAP:F4O;6AQ<T=K86)E<EDR:&MV9E@Y4E-R.%(V5&A25#1U+V9&4$5L
M,R]+-&1A+S9T)B-X03LY;"]W36YZ+T%*.%5C8F8O04-U2%<O.$%Q,S)8+T%Y
M9E K9D9E3G(O04I81')8+U9V<W8K0FLO-7)X6&ID+WEU2%=V*W)F6F8X1$HO
M)B-X03MZ6&EV1S<O;&-/=&8Y5RMY+W=#0FLO-7)X6&ID+W=!<F@Q<B]!2W0Y
M;"]W36YY+VYX6&ID+W=!<F@Q<B]!2W0Y;"]W36XO3F5+.&%F)B-X03ME4R]Z
M0S%(6'1E5%0W<7IT;S1N:F1Y.&%T>7%O<BLP>$=+67ET5R].92]7>79F2F-I
M2VHS36YM1S!G55!C5%%C635W.&-K:7)&4&)C)B-X03LR05!%0G<V-VQ3<$15
M2WI42#@Q9BM5375F*TUK4"]%>&EX;'EE2$EX4C%99%9)27(W65=P4&)J>FYQ
M5GA,8U-V1$%'=4-F54,K;W$Q)B-X03M+8U!S:#96<#-.9G4R>%IC4T=G.'=Y
M4E(K;6)',&Q5:%9B;D5A<T5R4W!6;$HS4#9S55=V+W=!4U-B+S=J<D1V>$)G
M1$)A:VY935-/)B-X03LY358T;7)F>D8V24-(5#=1;U4Y3G%2,%IQ02]A87!R
M53=N>'A7,&]X46U..2]W06-F5% K92\X07A-67!02DQS54]X5C)+=7A6,DMP
M)B-X03MP66592F)+>DYQ;'!B4VER:U-Y;WI/1$EV1FE$>4%',W1I:T968GI)
M<$Q-3DMS1DQ&:5%)9FA(3&Q12T]7,TAN=#AH-%ER87!&-79V)B-X03M99G)1
M:'1,5T9,=C O55-*2&I!35%)1$E58T9383=M=4ME2DQD4C%/92]A2G!L5E1$
M1TDQ-#AT=T-4=GE,9GID='-516]41D1S5F1I)B-X03MR<U9D:7%D-G0O>6I/
M9R\Y2&8X07ED1TM4>5-41D-P8E1V8GIP36="84TQ06)C67%M-F5A6D993BMJ
M3E!0=W%J:C9V>$1H6E!5*TE+)B-X03MY:F8W2CA2:6YI53$X>$MO;W5M,EA)
M<'=,1TEK.4%/42M,63=F:6-6=%98>F)E<&%Y,G-6=&)245-Z3E!W:E8P-&QW
M0598:30K2&(W)B-X03M**VUO>%AI4WI58BM7+W5M=5I65EA92W!#.&E09U5+
M4'1&:C(X8U5%;V)&5UDO;% O=T%P:D0O>&AL+S1J:7EH>F5Q95ET3#AS551Z
M)B-X03M"-6=T<D]584A(2F-X6'0Q0TI48DMN1U8U22M83&EW35-K1E)Y,C)W
M3G%)2&U(4VIO;'9R;C$R26%68WAX5%%86E9G<E)Z04=.<44Q)B-X03M(3&M/
M;WEE4$A+6G%)<W1E6$Q(2$AI:V%#02]X.353+S9V1G0Y>F8Q>DDO235V-7!C
M6"M5=% X07HT+TYJ,VQJ>G!O54]S96%:<G$X)B-X03MG=%ER>E4P;G1*1V8Q
M0DY'=&AA,B]Q2T9O5D993V@S<EA(.&IM+VUL4#AP868K9D@U<VMH.#@K5C5P
M:VAI,6$S95=69VMA04Y5<WAO)B-X03M",7=(4EIG3$U3;5!A1T%M:$].;# S
M;G)Y<D1-.$UU<E<V4WA->5-)43%1>6UH2#!:<6IR<TE.1U1V23EK-FU10D5$
M4E-$>D0U.#!*)B-X03MT53AU=F%8:T8Q1D1Q1%-88W%T=T5-8E=L>$8V:D)T
M,D@W,FQ",WA'=G<O>F=K.6MA<B]5-4HU+WES1'EJ+S%E3&(W;7=F;CA0.#50
M)B-X03LX:C9R*UE6-RME=DMY4G!),G)7-%-517AT4G1W0U%F>'<O;G-0.#5I
M3WED4U-2=TA:1#-(-6@K5F\W95-33%9,96%614Q2=VEQ;#)!)B-X03M*0SAJ
M<T]2,G%C2#4O1"]/6F9Y4'%V.$%5>6QN:R]Z>C5C="]+96I7.35Q149P9%%7
M5G9&3F)/4S=2<VM3<59:;"M%:U4S<&A/=G<O)B-X03MZ9V=D:V%R+T%&3U-E
M4F5E4$Q%<5102'$Q=7E12C9K>D%..$M&;&I"3R\X04\V:C9C23%U13-5=5-*
M9&QA:T5!=T\K=RM6+V-&4#A!)B-X03LU5T(U4B\V=D9T.7I:2#@O:"]N378U
M2#%8.'=S93AV*V1T0VHX>&5:<#=M.6=T-V4U=6]'<S5Y,TU42VQP1D=75E(X
M4VA3=$1Y-S1F)B-X03MZ*T@K8T5$<VI69C9N2FM59FYZ>7!*27-C97(R-T\U
M0W%O1%9*2F]":4YF:% X4VYS;E9!5UE&4VLO369Y6$9).&-M=%=Y=6I&6%5Q
M)B-X03LK>$)O4FTQ1VIY;BM%=6]/;WAJ<49N+TMY+TI0+U8X='8K0F9(.&QM
M+VUL2#5N2"]!1&<S+W=!<DPX:V8Y6'4R+W=#0F9(.&QM+VUL)B-X03MF>D]0
M*V-(9CAR3#AK9CA!5C=T=BM"9D@X;&TO;6QF>D]0.$%N0DDO2C,U:V57;SE)
M;%A53"M#>&YA*W8U4D%Z1U%L2G)Y5U9(-4IT)B-X03M29SE2-UDO:W-V.$%.
M2R]M8V8X04]#968X<DPX:V8X058W='8K0F9(.&QM+VUL9GI/4#A!;D)R+T%*
M5U@U2B\V=FQT+W=,-"]K<S,X)B-X03LP<BM:>"]Z9S,O>7-V>5(O,69,8C(K
M1CAF>5=B*V%6+TTT+S5W9"]Y<W9Y4B]W0EAU,B\T1CAF>5=B*V%6+TTT+W=#
M8T=V.$%L6F9K)B-X03MN+W$K5S,O079J*U-Z9GI3=C5N2"]/1&8O2WDO2D@O
M5C=T=BM"9D@X;&TO;6QF>D]0*V-'=BM6;"M39BMR-6)F.$,K4#5,3B].2R]M
M)B-X03MC9CA!3T-36'8U:BM7=CA!1U=K>E(S.$5T9W1L97A81C9'2W)%.&ML
M<S9+55!X3GHY2&%N=EA(.&QL+VUL9GI/4"MC13@O-5=8-4DO)B-X03LV=FQT
M+W=!0RM0-4Q.+TY++VUC9C@T3F8X<DPX:R\X058X='8K0F9(.&QM+VUL9GI/
M4#A!;D)V+T%*5U@U22\V=FQT+W=,-"]K<S,X)B-X03LP<BM:>"]Z9VDY2S@V
M95<Y5W9"6C9B<6M&>F-S1UI9:U9Q,%562C-P,'E'5%1:24,U0V=Y:&UH23!#
M.#@X.3-M;7 U<3@V5SEH<6PR)B-X03LK;VYY:F1Y,W5L<&-*.5135E9#3$MY
M;6-T1D])>6Q"-D%(13AU6'A53D1A;5=S=DA**U(R:W9%2%=*<D14:D=S<W%Z
M=49+>#!$5$ES)B-X03MA>4=N5FQ502M!>EDY;"\S-"M0,T]P-V,O=T%6;#A0
M=D1"9$XX<'<V9VMB439P8G(K-CEE-D0Q2&]O0E9U5D]64U X05!F8DXY:S%2
M)B-X03MH>FEE9$1Z95AW.6Y$24%23U!+>C5+9BM%6GAB4C-,-FI9>'=Z1U@P
M5V5:;$0K:E=P5W%D-F)F,7<O;7AD8TUR,C9D-T@K5%I#26M:)B-X03MW04XQ
M=GIR-$XR=6QP<"]M4%-64SAT-WA*3&U%:#=D=SE/36]5:&=/;2]4>$<K37-V
M2&IL<U)S969U5T=N1U!00W!2;&-H>3DV,C@P)B-X03LV,G9.9#%J,7)Y3S!A
M3S9L.4Y:4#)Y,')B1&-D33AE;D%'8W0V,V9O,TAM;$1$:G%*;&-2>39B0EAN
M.&I88V0P8E9D47,R;FIG3GAD)B-X03M,>F-E:T9!3D=*6'5R1"M.36MD2U%A
M<UA6*S5H2'132FIX8TTV37%',U W549C95A%9W1*6B\P<%EY=D5!-&AI;4):
M;$E5+T1506QV)B-X03MJ*WI4<V9$25-W,$PT;R].=6AR1$M12$)-6#%)+T<R
M,U S3$1"2&-7*VM1>7I,8GAY0U)7;F8W2T%Y='5C:E8P1UA'66Y)44Q)<F(T
M)B-X03M+.3,U6E-#,&MU:S%+,FQH-4UT=5%31$M5<'I#.6%(-'1V2#)/,E-L
M:&]865E9.6%:4T540U%06'E6<'9*:VQV4$Q$9#9R65%V0VEU)B-X03LV1UEH
M-G5R37%H5U9+;C126'=Q36UD3E8S2T\S;3%X-U-%9T1'17I:-W9X*T%O5TYV
M.5=G.'E7+W%2>F5J6G%N<7=T>FIB:F8R=S5))B-X03LS9%0R3T-%845X-68W
M-DQ:;&YX2$1+:4QN,34O,V,K85-!1FE&559*,D%(56Y-9'II561C-DIQ9'1B
M3F-Z4DM)15E)>G)*1S0U1W4S)B-X03MW<V8U5%AW>6-S8V=,3%)$5EDU4S11
M9"]C5E!3=BM/<%HO.$%'95 O04EM3450<41,4#A!,V-V8U5L,6(O:G$S=B]'
M95@O:5IZ,F)()B-X03LY23EZ-$AK*V\K.4,U3F<W1EA9<3=&6$%%;6<S2C9$
M1E5Y9GEZ-6=3-BMQ=' X-&Y04F5";V1Y0GAB-TIQ4E%53S4R>7)X;U9D:'0X
M)B-X03M'9#%3,R]$=74P0BMO5&YL27-#9U)S4S!J:VA&54%64$EQ44M99D=H
M,VA(9WHW;')A1')A>E)W;7=N33!O<DA'<V)->D1B8TM!5%-J)B-X03M!+TEJ
M>'@X5TY8654T<&1Z8V5G83=+<71(<#$Q24A&54MW>4Y557)554AG8U1L9T]O
M6'=P.7A7,T=H83-B27HS1VXS34M)3U1.2D1))B-X03MG0V<P<5-13G%N0TUS
M5'E)46-C:'I"45=464]X5C)+=7A6,DMS."]*4"]L4$E0.$%J0E O04U2>D$W
M4R]U5#=W-75G+W909WDW>F5D)B-X03M85'HS-7$Q:S9F3VUN-F0U574W4DQL
M>&-*0DTT2UA+1DIK;'0P,TQY25)'-&1E1F53,4=C,C=P1V%X8UA6>BM2=6M8
M3C-+,#DQ4%EA)B-X03MB2E!->FU6;FMD23)::DE78W95;C=263%Z63EL+W="
M*U!J.7IQ93-0.%=L.%!V1'I(4V16=4Y-=2]R14-O-4MM3U-+445O-DXY<%A!
M)B-X03M+,54Y>&Y3-6-1;4M,>&5N,45S575)565M-EE1*V-.4VEI94I);U)'
M-FQ!;T1Q1E5X*VY12W)Q=7DY>4LK.4UQ3VMI5&1L>6\Y<5I!)B-X03M+06I8
M>#=Q-S!&-64O=T-/+W!V+T%$1E%F.&Y&>7I0+T%(8W9C6$<P9CDY1"MS4'97
M*UE0*T\Y<5@O3590+WEC8E!&<S,Q;C-L*VYT)B-X03M*+V-W+W%J-VQU;C9X
M93)%53A50DAP,T905E4Q;V%+>6I9140Y<S1)-41%141Q;DYP;S5#0V59+UHK
M<$):0G92.3DO>'I.3B\Q2F8K)B-X03M4<EI/6$E/4&DO=DHK.&9C=3!F6&)N
M4R]65T]+2S1H;C1M4T,T5FYJ2E%.>%!%374V;'%J,W<T.'!H-6\Q3VQJ;'%Y
M45(Q2$Y:<4=T)B-X03LS.2]"1$1D4#9I=S T36528EI1;E5K+WDT2EI$26)S
M<T]M:&I*365Q=F\S+T%">F1E+S5G52\V:G)83$U0,'HO04MV*RMI,39N-CA8
M)B-X03LY8R\W:6%66E$U84EM,4Q56C1Z2%!D5%-X=%%S:GE->6MR<W115#(W
M6DEZ2C5L<FIH:$4R26=(,TQT2R\T-FQN+W=!6C0O.$%I67AH)B-X03LY45)N
M+W4U931P3'$S+TA6=F8X06I03"]!351/97I9+W!(=69!.&XQ2#-O6$IS2%EQ
M-T9867$R:G5J<39-5F131U9L3D-#3G=14FE1)B-X03MO2T]L.'=A-4MJ3$YF
M>GDX=4Y795)M8C1!5E5C:5-W04(V5G!L67A12$E"<SA79F57<FI8=%IU16I3
M83EL6EEH4F9I25 R:3E723-9)B-X03LX;4IQ9#A2:6E/454U6DAQ-SE/-C,V
M:V-N-E%U9E5I24U4*W1*>55G041I83=50TPP.$)J-%5E-$DX5UAE6$189&-"
M46I58FM'2G55)B-X03M:13!N=W-!0E9D.6I11$AW;V1W6'A:9#5A;3%Z5W!L
M;%=B54QM4EHV*W5R>E--2#5%13@V;C1Q:T$W-%)I:4]10VY*23E39W-M=V1I
M)B-X03MR<U9D:7)S5EHU*U-F+TME468X04=#9B]!26IM0C)L+V-N,VAZ9$(O
M969".456;"]L6"]G:B]43V)D,&@W-GAG=C=:<F$Y=&]R:3-9)B-X03MG=$9)
M95-K:F-B1F5X>6--:V]'-&UI=WE9-'I(1$E717(O=U8U5R\V<W1N+T%-05 K
M86-U+T]:=C5X*V)J9GEF<"\U:V9K1T\K5G9,)B-X03MF;'DW,6YZ6$4K:U)T
M2&$V;VM6=7,X2E9%46%F859317-#0VAK-79T,V%V97!F>FUB*V1,-7(O2BMN
M+VU2*U%:3$8U4#AT=WEP3$9O)B-X03LY;6MS6D1X=49!25I4545F1&ED6&Q)
M;WE+639$0419:$<O8S%,-4XX<WI3=DQ,;SEO.'-J1C-C;T-3>$Y35#A09DYA
M9$AI2G-X1'59)B-X03LY<&%G0VA/5D1Z4T1Z2#5D.'(R5W$K6$E2;S!)5SDQ
M0F](14U*9%=8-FYC349L2W)13'E#=G8X07DK,E U3$0O0411;BM63E0O<6MV
M)B-X03MM;G8K0U!+=B]6;',O=T1G0B]Z5&<O2EEF-6]8*U9.5"]Q:W9M=6)Y
M8C5:6D52=$AT0VM925)3;V]+;7!P.%!J:"]*-'8U;U%/,'11)B-X03M$9DA,
M9GI58FIY:#54=#=E5V0Y17174TI$27EP2'I9:%%347%H87-D=&=/=40X;&@O
M;6A0.'%A;B]62F9.2W9*;FQB>7IF955D1G9*)B-X03M.270U2DQI>'1P2&MN
M:C1Y<WI22U-Z:&QR5FIV:$]I=R]W03!+3S%.5"]Q:W9M;FMF:R]Y,T=K<5(V
M4F%+<WDX2E9#9T)L1$LT0BM()B-X03MP>E%(-DU2<$U1+VA'-T4Y<&%G:T5Z
M;'1Y,RM(-E9N*T-02W8O5FQS+W=$9T(O>E1G+TI99C5O6F9Y<'%F.55L.#)/
M*UAF3&9L=38X)B-X03MX*V%,6CE(:4U6;&17.&-+>7=L63%$5VM415)%<E%G
M:SAJ5'AW+VMS4#@P22]L5%4O=T-Q4RMB23 X;65723-6,#!A>E8P4$I70VEO
M)B-X03M)3E%F<S1J4C1F-6]5.7 V:VEJ3UAZ535025AL0U-2<$@P3WE:,TI:
M;4M#<$I.4V9S-7-2<3AO+VE,<D1G:#-"8B]Y<B]W06YF.5=+)B-X03MY+S1!
M9C@P-"]M.'8X-&\O3#0O-6]D+WER+WEB+W="5TMY+S1!9CA!3D]0-79,+T]+
M+VPX9C@P3R]W0U9F*U1F*W)&6F8X05 K86-F)B-X03MZ95@K8U8O3#0O-6]3
M3'E:-54X;C9N;SAT>3)H=T=L+W%%44YX0UDS0W@S:WEQ;T1R6&EI9TM0;&HK
M8GDO=T$T<BM8>"]W03!*-R]Y)B-X03MR+WEB+W="5TMY+S1!9CA!3D]0-79,
M+T]++VPX9C@P3R]W0U9F*U1V*W)&6F8X05 K86-0-79,+T%$:78U9D@O0411
M-R]L6"]!2D\O)B-X03LV<U9L-V9!4"MA8T@U=DPO041I=C5F2"]!1%$W+VQ8
M+T%*3B\V<U9L+W=!05 K86-F>F58*V-6+TPT+S5O9"]Y<B]Y9"]W0E=+>2\T
M)B-X03M!9CA!3D]0-79,+T]++VPX9C@P3R]W0U9F*U1F*W)&6F8X05 K86-F
M>F58*V-6+TPT+S5O9"]Y<B]W06YF.5=+>2\T068X,#0O;3AV)B-X03LX-'(K
M6'@O>E%K5C<U5#AN=RMD3DDP-#9(0C9D,UDS>FQ5:$Q1;#1P3%EQ>G5&-&=Q
M<%E#=C@S=FHK8GDO=T$T<BM8>"]W03!*-R]Y)B-X03MR+WED+W="5TMY+S1!
M9CA!3D]0-79,+T]++VPX9C@P3R]W0U9F*U1V*W)&6F8X05 K86-F>F58*V-6
M+TPT+S5O9"]Y<B]W06YF.5=+)B-X03MY+S1!9C@P-"]M.'8X-'(K6'@O>E%I
M=$\X<"M8=$UU:&1A9G!6<F$S2V=Q<S!A.%=O4G5+:&4K4FYQ36MH56E31U5C
M55EM=T%'3RM:)B-X03MV>D1U3D@X>6%V<#A*=$QH9$LP0U17;3 K5F)I0S1D
M;W!+1FAC.%AG.4QH='-P8FPQ,G)3;'-5+U!7<%,V<"M6:U=P4WA2=WDS<U9N
M)B-X03MC4$1&36QZ1VI3;$A+<%!(.$5Q:75Z<G,S55IS97DO-SAF2#=N53EU
M9C1R3#1F94AL,FUE53E3,4LP:75R95-%2DMZ2T9K66]2=UI&)B-X03M:=#%P
M4F95-4=H-D$K1V1$:S%564=J8GEE1',W2FQI2E)),V1"-4\Q-EIP5D5+<4EG
M<$Q--F=%=7!:1D<O5G=.=GAW2%8T>#$U<&HR)B-X03M:;4I)<FPU+VIM-G@P
M=2LP>GI4<#EP9E(K:F-*9%%C;RM3<U(K.4$S-&QH,G=Z>7AN:6M9.'%0,TUC
M5T-E3%51:DU594M0,W).43 V)B-X03MA+SA!36UR4E%S<71&3&1Z<U<U531X
M37IS2V=.=E%B5GIX=6-$2V-Q.#,V5'<U:&IW44HV:4DK9$PW;GE8<C!,44MS
M851'-#1#4#!P)B-X03M&3SAP25)4>4LP2C0O=T)C2C P>%AM>&@R;&AL935(
M1&9-9#-.4C%$>71R3FAA:3=N:5@V<596:$]R;U8S0TAI0E5.565O05)427IW
M)B-X03M3:4Q03#AF<F)-3W5X6DIC25!Q-W$Y+S9L<C)S.3-B-E!A,C8X-34K
M8V-3,4%Q>GI%059.04XX2$-4=V=C>BMT4FM%2EI*2&M.+SA!)B-X03M9;SEF
M24AM07IM,UI9635W1DIJ:VM#1VI">7 K2V<S369(+U=)0GDP85-D,3%C8SER
M66$T='E0264W.60K-$5O83 X;F$O9&\W4E%,)B-X03MY4U5W2VI34FAN;%9L
M4FM11G1Y0S1R:UDV96-U438P,C5/,&--2W,Y3#5(64Y79'9.8F%F<FM-=T-Y
M2D)$>55%3E-T>$=E<6MJ0D55)B-X03M*1'DO4T4U2FE5.%I(2WHO04QK<6HK
M5&18:EHP;4UC57-A<7IX:W5X6&U50V=L1EID+U95.6-*,#AH>B]!0BM,66IT
M3$=D>%I(.79N)B-X03LU3E0K5$YE:6U725)*2U=*54Y(26A8:W%'46EP239)
M<% Y=4HP,'=A5TAA5T5I-TDK0CDS,W$Y=#5A,6)39&0P>#=Y3E)#,35!2355
M)B-X03MD1U8V>6)&441Y<#A"-UI+3T=52GAV=D184%<T.#)'66ED*T-85&QS
M;$=R9CAD5S@O=T--.'8X07A--3=.:2MG934K8714+V5Y+W)()B-X03LW,$IL
M:E,W1EA9<3)A,3,V-'%7<U9D:7)S5E1$>E@O>6I(;'(U6'8O04-F1UE%9C<R
M9CA!;2]C.4YP9CA7>"\U,S-S57DY<V1I<G-6)B-X03MD=FER<U9D:7)S5EHU
M*U-F+TME468X64HO=T1I3UE(85@Y>69E2$XP2#DU.$=7*V%F3%!N<EA04#-M
M=35T=$YA4%(S.')83V@V8E!0)B-X03M.15EB;3AL2WI)=VA9,4%R2U4U36Y(
M-&5U8S(W<$YF32MN,V5M+VLQ<"MN6'-343-L;F%7149Z1$=155-335)Q-G%6
M,F]'1D)43FHR)B-X03M8+V9J-"]C-FYT>B]!0E=8=RLX4$YW,VLP4C=P9FU1
M2V]P5T=H66]E6E!S2"MY4$1R;E$Q;2]O+V$X;41P8354*WA7<S=R>5)%0W1X
M)B-X03M:,V,O-W!V:EIG1#9P-%4R4C!(155B-SAH3T]C.&I%9FHS3FU02G!"
M>FI-+W(K0DAM,UIZ-DI*<D=J:E0T2&EM5SEJ.5IM0D-S<&M4)B-X03MJ44=7
M6#,O<65U331Z14IC4C(T9G@P0S0U-%1K>#A!25!'3"M9.'HK3SE4=D1O03%Z
M5FAQ:3-263-R:4TR>&IO<65Q+W%%:"MR9$]0)B-X03MB<EA024IC2$A,:78V
M=6XR=C!8:CAB=V]E2'<O44]D.#9&8W9T54),-515>4U)8GAZ=S1X23=2:&58
M16=S>%=H*S%19T1)6&HX,GIH)B-X03LQ0G)E2#)O=31V9DI$4S-"9W-*,&EA
M=C%D5S5->2]"46(K=4)4;#1G+U!T;&MP67).02]J-'1-35=R;UA+3CEF;B]6
M-W9D*VQ!;C9N)B-X03LY6#!F-C<V;C%3:VYR*VIX.51H-GI6-&-V:'(X.'$R
M.4XX=C)T+W%V2G=6>&)69DQL,5A-,VQ).$M,9D-P0FQ&679H*TDQ0V50=S V
M)B-X03LY.% W=GI10G%D+V\K,S=F:6EL=E!*67,R43)-+W="835$:$E35U5O
M23%"<4)-;$=,:&HP3DLY*VU417-81'E.+VIZ86IJ,5A&9D9()B-X03MH+V(O
M0494,'(Y;DYA2DY0:W1.8V)4-#)I=%1B,B]&2'%$>44X6$QQ.&@S878W5T-X
M57$U55!V0V%M2EDK33-,:6PO=5IE42LU4E)V)B-X03M*+V]R>5,O37=203%$
M1'AA46]F55!I04@K>5!$<F<O9#$O1F9W*TQ-:E4S>FA6;G8U6'0Y;E!Z5C=/
M-CAK>$%R8U=D,U K-F(T,EE!)B-X03LK<65(2%I(46-6;S,S-4M%<U$U9SAV
M=&$X;5!62#9:4D<O,F(K4C,U3C)%*VE387)P2S)-1'@S079O>DDU0D-L1$EV
M14%'4U=N>2]%)B-X03LT=TUE2TYF>G9X,5A,2$M-8RM-,D]!+V0W:"M/9U,S
M54I7:3%Q-6Q4-U5D>3=,.'A)4TTY;7AI-$%E5#@Q6C5'3V%22%-2*SE--'9/
M)B-X03LR<%)43$U,94)P1E%2+T8V>DM65U@Q44-P:S1N-'9B2T1O;VM66BMZ
M=7)U8W-D<35!8G%.+TAV=G956G9.9#5.6FDP;'1,4C1L46]P)B-X03MA2W)!
M:U4U.'$O84A9.7-K3DM"2W=:9DYH4'1'8V\X2FI'=F0K3C%39GIF4%!:>3)R
M-F)P,T(P84]'5#9U0SA+=7AC:45L:G@S63 V)B-X03LP=U(P9T5R-'!F4&XW
M,6XR:DM5945W:#5E;FPW;$]F>E1,3D9':C9D63AL4$HU=E)*:VLO94Q*4U)I
M>#5$-$]0*W)565DV54$O5DPU)B-X03MO;C)G6D1E15!L>C-V9F8X0F1E*V$U
M3'A,;U-A6'!Y=F1"45I59S1U:%%K.&\R-6)%,6]F2$=';#1A<55T=DYC=F%"
M;F1W>#-,<G<W)B-X03LO97%*-3$Q0T\S;'0T<E,P:6=L84YV5&IJ6D%P:5ES
M0W9&:%%K;F,O9%1);E)X2G-M5G-X,G)-1&A%64%B9$\W-'!F<D]U6%=R4$4Y
M)B-X03MW:4E95DMR=S5M;TIR=5A:>FPR2$%-9# T*W$Q8W,Q8U%',W8O4U,Q
M-7(O-5)J>3$X<C,O04I0:DUA4#DW4#A!>F9U9#5P9CA7>"\U)B-X03LS,W!*
M;S)T,T]K>FUE,VII:V-L4T1)1%5&1%5C6%%O-C$W9TY1.3AN:WA#66]U4FIY
M;4)S2FEV;F)51E9K*W R8E)U23%A3F]E4SA9)B-X03MK5TU$9'%G348K3'AY
M=CA!3$1V3&(K6FPS0E-T4$YK,71:3EIJ5&)#5T9W,U Q24-X6FE82W54>4AX
M2C9H0RLQ34US04IU-69.:4TU)B-X03M!<6<U9DYK-&I:1S V=V1I2%9:6'1W
M5U):1U9I<6(X5D$T:TQ18D%N2'=",WDK82]M1#-$-4MK2&Y&-#!62#!F5$QG
M2TDQ6#%R8W-1)B-X03MS5$LQ0659<'DT+T8T,5!J9T]N=BM+42M+9GI(.4=0
M>61P;FY3+S Q-%=T3$]Z5#!35%0P:CA:2W5L6$E91G%,2U(Q>&YP:$QM4W-D
M)B-X03M363AG14YQ6&UA*S%#,&4Q;6IJ5TXU5FU,2UI347EQ5F]/8G5+9D8T
M97<R04=3:&A%5%E9>GIM46]S;"]*4#A!-51Y1"]J0E O=T%2)B-X03MZ1S=3
M+W54-W<S-D0K."M$-DDU="]V='8K1B]R;DYU-E,O6$Y)<SEA,#4Y4'9O<$1B
M>49764EY<6%Q95$S<C1J3&-/85=/6$9(;3!A)B-X03MJ5'AZ44U*9E-732\X
M<6LX;B\X04Q08R\X:F@O6$TS*U9S,VPX;EAF>49P=30O37!*;T@U92M5=%$Q
M5'I(86M35$IP96]*87=,1DU/)B-X03M326)',FU+>65,97),2BMR<41J+T%#
M<FTW>#AL+VM,5&1X*UI:0F$O;%HU571B;4<U:70W;C%92%=73W-O235)47<W
M*TEW4S=5>E-")B-X03M"<F9Y6E$W1C X6D-10G-B.#)R<CAQ=DMD,6146$US
M1GE:6C-A4U-K;T$U33%45#<X-3)86F5):VYD-TA(-U%A;45216-.059Y4UA7
M)B-X03MV>34X;5=';V%*8G-*66AQ3C8Q<WEY5'%'8T,Q;FM#<%4O83E33E Q
M9#A(.&LT9E U<VHW4C9R=FHX:S$O=T-64F54+T%0;&YU9CA!)B-X03MK8TU(
M.&LT9DY0.$%O:C%8.4@U2W-V-58K535)65EM9W5E14%):B]E:71'67-F>$]%
M.6Q9=DYH2#)G,4E*4' S.&Q#5#AP+TI556)3)B-X03MY>%A%8U-!=$I),#9H
M5E5#<$I*3W=(9D(O2D](>EHO-DDY5B]2*U-895=0>3 X;S9P-6(P<E5N4V%A
M4SAT24IP2EEP:'=,=D='9FHW)B-X03MC<314,E1H."]M9V4P97$W-"]*3UEF
M>74X<7=W6$5#45A0<#-+<6MT6E)7:7-*0E1F*UIC23=,>$%%8C=S2F1V-FU2
M0DYE;GDX<55F)B-X03LK5E)E5"\X06QN=68K4G=Y4#AK-&9.<R\P4C9R*VHX
M:VPP6#AV4$M..7)M=C)*16MI-EAC47A2<$A-3V%#4S)J:TEK,S9L,F%M13EL
M)B-X03M99E U;TAT1G%U.&9*4#=8.'$O2V1R9%$S355&>C9S1')*1U1+0T]3
M14561F9B1$AS=D5#1'5X>64P1W!L17A01%)&8VUP+WEP.'!4)B-X03M44U10
M8C-03U9I-U5L04973E0S>F]O.7%:9TLR*U1X,"MX3E!):VM'>C5R4"M64V54
M+SA!;&YU9BM2=R]R:"]L8DXU9DIJ+TE7;3=J)B-X03LX>3<O04I62#50.$$K
M5V4U+W=#4G=X+VQB3C5F2F8U0S S8V9M6&8X<6HX;B]W1$Q08R\X:FAJ+T%#
M=&TX=FMV.&AA8G50>DM5*U=F)B-X03MY-SAM-G1P<VPP;VMU070S95%,2D1/
M<%AH0F134E)I;U!89VDQ*R](*U9C,V50:W8X:#9B=5!Z2V)F.$%+;R]*+W=$
M>7HS4"]!0T]')B-X03M0.'):=DPU3"])5VTW:CAY-R]L56YK+R]!2EHW;B]K
M8U V-"]Y=&TX=FMV.&AA8G50>DQV*U92*U0O.$%L;G5F*U)W+W)J+TLR8GDK
M)B-X03M3+WE&<'4T+TUQ;"\K5F9L4SES-T]Z;6=U9E)S9E5%05=502]V5T1.
M53DY.')(84]54TUT<DQL=S!'2TU"04199G!14"]+:W9*2"LK)B-X03M,=CA!
M-4A,:W8U5'DK4V9Y3U!U9"]W07%3.&MF-S1U+RM2=W@O;%!,-4PK4G@Y>G8K
M5DIE4U X069&,R]!36IL>"]L4$PU3"M2>#EY)B-X03M5,U U5F52;V9-*VXV
M4U)-;C%Y,'4U+U)A-%@Q5V5#4T)6-&IW-'E06"MW-"]W07 U9DPU3"M2>#EY
M8F8X<5,X:V8W-'4O.$%K8W50)B-X03LX<#5F2F9Y3U!U9"]Y<$QY4B]V:3<O
M-4A,:B]+95AY6#AJ:C=N9CA!2VMV2D@K*TQV+VMC=5 X04ME6'E8.&IJ-VMZ
M.'4O;' U6CAV)B-X03MA;W5P861$8T,U4E=25$I+<DQ2:%$W8EI6;3%U5$I(
M:&Q63FU05%%G8D1,.'A(25EV*UID+V4R2&Q'-75B2V0W9316-&=S<UI+<T%:
M)B-X03M!1'508DTW<S=(1V590U%S8G5T-UAY>7@V955O;6IT.3=X9B]!0G0U
M=2\V=D8S+WE.8BMU9$@K4W<O>E$X9"]+96\O;GE5;V9.9FU3)B-X03M#4V53
M1%5P-'!,;"]6=4A2>7!K:T-Q;DYY4'1.=U)6<65W1U U3$0O0411=CAQ86HK
M9DI-.44X-"MA<'1A<TEP9%9U;FIK=5E59$1))B-X03MX0E9P04-$=C-Y=DYP
M35%H26E)-49V,#-A3V]L;&E$33!:1#<Q;70K8V9.55=T6#A55W)84U)X,TUY
M;VEY<T%&5U%G06(Y<SAL>39R)B-X03M+2FXQ4S4Y-SE#85AS,U1N1D5M16)-
M4C X:W-U4$Y8;4\T94-3-#%'95HW5U0Q<EIN8W-9-4],2GI1;C=,8UA95DA9
M-40X,VPO;E,K)B-X03MB9CA!>5AP=CE4:CAL8B]',VTO+T%+=D8S+WE.8BMU
M1#@S;"]N4RMA+W=!;6%B+U4T+THS*TYV3B]W1#%E3'8O04I'="]82#@S;"]N
M)B-X03M3*V$O>5IP=CE4:CAM;3@V96)(57$R<C-42W=O>6U6:4-$,4)&8V9Z
M95@K9$PU<B]!0UIP=CE4:CAL3S$X,F5:8E,R:71B6%4W:4,R)B-X03MG4EDT
M24DU0VE):4-I<7%I9T%!1D%":"].-68U,'9M;S=,,#,K<'@K4W(O:F)Z9B]!
M3EAI-R\U1W0O6$(K8GDO>G!F3F8U33 S*W!X)B-X03LK5'8X8F5B+T%0<3A8
M9CA!>4YB*W50-79,+T]L.#$O:WI49C9N2#5+35!M<GI(1%!04$1Q53AC.3!Y
M=F-Y<35$4TUI:$9,<TXR2591)B-X03M"6'1H+TXU9C4P=FUV.&PV8B]5-"]*
M33E%.#0K87!D87-)<&17=6YJ:W595F1';%EG<3!G0D(S-S501G%S<&U05DQN
M,W1'<3=.,#1X)B-X03M326A'>$4Y4$IB<5AN4'I:2'%.,4=M<EA3;VLP:7%O
M;&%G05EG1')N<F504C1J165K8VXU-7HY<&%G6DI!5$Y754XO:F)Z9"\Q94QV
M)B-X03LO:V$S.6-N*U-W+WI1,69Y;G%0-3AN9C0R.#-F.5AI-R]W0U)R9C%X
M+TI99C5O6"M5.5(O4&LW+T%"=#5U+S9V1C,O>4YB*W50-4Q$)B-X03LO3D,O
M>6YQ4#4X;$<P.#%E63=/2#!B5%5:-V5(:SAN<'A/55AN27AD,F]T0E9N67-4
M,T]0-4Q$+T%$478X<6%N*V568B]',VTW+W$X)B-X03M89CA!>4YB*W50-4Q$
M+TY#+W=!<#9J*V9*,RM.=DXS+T%&94QV+VMA,SEC9GE72"MA1B]L4%5F>C5/
M+WAT-74O-G9&,R]W06I7+W)J)B-X03LK4W<O>E%V.' V:BMF2D<K6F9/2&UQ
M1'DY;T4X3W)856,Q=TQV,35&;%E&*T5W0SAI1'916FAX,#)0>$IJ:$9#=G5E
M9S K<7E(0D-2)B-X03MK8E!&.3='=CAE*V1F*W(U92\X04DY+S8U9"M6>&9Z
M4CAM9C5N2B]/3'8X04AV;E@O<2M8=B]).2]W0W50-5A&+TY(>5@X>FLO;D8S
M)B-X03LK4&9/=B]6.'9F.$%K92\Y8V9Y=4PK85!K=C5N2B]/2VDO;DAZ53DQ
M1F1V<71Y,3%!<GAW,T)K67E):VA5=7%S9'='-$Q51')162]L)B-X03M-6#@P
M3"M:>69Z:7)F-#DX-B\X058X=F8K4C<O04YC9GEU3"MA4&MV-6Y*+T],=CAE
M*V1F*W(U92]W1$DY+S8T+VQC6#@P9DIF>D]4)B-X03LK8UAF-#DX-B]W1%8X
M=F8K4C<O,7@O2S1V-6\K4R]M8VXX-'-Z+TM0>E8U;#%,>FY$83,K<#-.,6).
M1$UX:&QL6C%*0S%";U0R>D,W)B-X03M1=U%J:7-!0756;S@P-51O;#=R;6AD
M<WA0.#!:1FDX;U1Y3V=K4DIR9&UJ4%)G2E9*53EE=5HO6F=V34(U2#=N5CES
M4T$P-4I&,%DO)B-X03LW;U!)<G)Z2F\Q=W-Y:E));VQL2DE%8E),=T)91VES
M2651,C(V+TQB8D]G:G!P:7979G0O5SAR4%A9<$%J=V=,.3,O17%C3W1E5V\P
M)B-X03M.9$%6,U!D<G%5<E=R:V)5<E0T:S<O<R\U4G=N1&Q0.&8R1'DO8C@R
M16169T@K4R\R4C@O,F9,>E9T3#%(4C5D5G-)<EA3;'1P5W4W)B-X03M5:68Q
M<$I'0E8Q-55";W1',S=:2$IJ;4E32FQE>#9.;410:4]326IJ-%1X4C-S;G%%
M<#AW9CAD-U5V.$%M2VXO04]4:EHT-VTK<RLX)B-X03MV,&QP4#=M2#E59F-G
M37)C:%!03%!M9CE"<&1R.557-BMS;45G3S564C9,.#9-=$1Z1&1+2#4U:UE-
M+V@S=&0Q.6IG83=1*T]9*W)H)B-X03LT8BLP5CA&.#-M94=7>'5B5C=A95EZ
M0VE04&1/,WA643@U5E)9+U=D949&-6)!53(R,U1N0D)&2&9Z+T9O:F]32FE1
M249D,%(U-T,W)B-X03LT4G9V6&YV=6E'.#)A27-Q;41Y.6),06A4:$9)56MA
M;E!L2T=C>$%T>E5C4E@W4&)*+VU)6'1!5BM,-F8R3E$W4'DQ=FQL9FQ9.3(S
M)B-X03M&,#4K9E9D8V5A.4-L:F1K,$M',VM*:4-P1TE3=$5E5C-A<GA/450V
M:6EG1E!H,W%0:'AL<4E(*T5$;#-E9FPK2RM#26%$341V;$I')B-X03LO3RLV
M2393.&HX.70Y,3AF;DQ21CEF;C5C=&U%;T-X8U=336]V8U932E-E5E=Q9'1J
M5&]":$=P:'9C0BM09V<Y;35D<7EY,BM.+TTK)B-X03LW-65A5#9X<3%H9E<Y
M<D9A-F)&64<S37!E4TTX;6M%:D%Q1TY"6&=.:%A+36U14T%!1E4U=6TP.#A:
M:UI433=R-%8K=$LX<6-P2"M8)B-X03LO=T1J=F%B+T%->%5(+TIX8W-W+U=0
M94A(,68Y>E X07%N-VQ3-6YH9SAW5'I446EE2DQM479#4T)Y2$TW5DE99FAN
M=$U9:S1W06$R)B-X03MF;5!*35)Z:VMC431J=#A695164$QZ4FA5,%AI>3AA
M36)M43%O<$1C<4MT951'=G0P>4%X6E U+S).:#%'0W8W=B]:1D5P<F9L479Y
M)B-X03MM.'8X,%-O:FE7-FM7<3AG47)-;T(R2$PT=7!R-UI!-&-V4V8R3G8U
M<E1N;FDU9C!I;U%A>#5F:6M:>&]G8TUQ<G=E-&1G4#-:4U%I)B-X03MQ.5=9
M.'@O3#)Y4G<U0U!R*WIZ830V;D-$9FAF-TDY,S10:S905B],:5A:;2]164U)
M9%=J9TYZ25%!0S5+<U-0:7)Y5610,F9C-&Y&)B-X03MK27)J,SEY>#%/05-V
M=W1U-VE0;BMZ-4LX,G,K55AL5U)03#=)=DEL-&9R8VA"0G K,7@R+V$V1'<X
M36E-3V%V<B\R3$TV;E1(9G=V)B-X03LY:U9S978V1D9Z365H4C%K:E97.5-8
M,4%(5U1N>E%/:#0Q6#1A1$-C1U$X-2]:*S%9-GI#3')%3B]/+S!)2%9.5',W
M>4='3T-Y5S)E)B-X03M.;EHU1CE/<FAQ54(Y3T],<%0K9T$R>3-&:4U38DXO
M:C-L>#E2<4E404%J=S$W="]K070X,2\X04M-95=V;&4O.&YX;4Y(*SEN+VTO
M)B-X03MC-WI3+W=#3%DO.$%/*SE,>G$O;'AO<%$R:59L:T5L2F9R3$QX6F]W
M<4965D97:5!6<60K:'@X3V8X-S=(3$]32#@S-U974%=V2S-P)B-X03M24E-A
M0CA+0W-J3&135EHK65!,8U9!2T1J4W10,G9B06-E5"MD.6E2:W@X=4@W5D5A
M=#5C171U-#!084E.-GEF5W!#2D=-4TMR1W%M)B-X03MN1U)796YF;'@W669$
M;G8V=G-2-&M0-78R<G)J5W9,.&MI>5(V0VM:25!R<CE9:TMS>&-T.$E!6&=T
M3G%$-SA2:FU0-'9S53599GIF)B-X03MT8D=S*U=21#98-D%R.6<X+W)5;DQK
M;U%-83AA,&)I*S,K5C=$0C1C-RMR-T8X4T9F5#EQ<2MS*U1X3$HV9FPU>D,P
M:V))2'9(-4-.)B-X03M(3$]L46XW83!7=E590FIY5CE8,DI/5$@O3BLQ=3,X
M>C901D)B4DYO:TQ.0D=S8VMN-V]M56AI,TIU8TUM.414.61E;4IW4TI0<2](
M)B-X03MZ4TTX45!P2#0K0V0O:W<V=BM9351Q=D)7:'5#14A107(P>6IT3"LU
M*U1B;U0K.5IF-34X>F%T<$@U:6%Y,7!Q;W1)-U1Y9DYE47<S)B-X03M5<S5S
M-')H8GIG='DX0U)Y4G,T0F]+07-F<S S>FY(8W-R9S V6'IH*UA/;'@S;6]*
M3%!Q1FYA6$4K;S(X8D-/5GEI4TY*2$A)<TQ")B-X03M83S1$2W!(9T]M6D=M
M>BM&35-Q,T8Q;6Q'9D=913%B2'8K5D<R;B]6,VLO-45R+WI8;7HO04IA4#@S
M-UA3+S9'-&9Z>CAK<C!J.'!R)B-X03MB54Y1,74P3W!01TY)=E5S=R]P02MO
M2'-R83<U,#5$:B]V5GAP=C!R,W@O;'%8.#!F3E0W3G<O;FXU2C-99FMX83)D
M.6)863%6,TYV)B-X03M+:V]1=V=6-$U'<%AN-UI'9F)";$5J:#4K8E!&-U!W
M:$U3-'IS8C5,8B\X04IA,G4W-C5U>G%R;V)I5C53;F]G,#5S5W!8;C<U>',K
M)B-X03MY0DEK.%A0>2]A*VLT=F%A54E#4$%.9T)Z+UEO9CAQ371F.$%Q-W8O
M04UI0B]W03$U2"M2:"]/*WHY<EHO;W%L+W%9+S S-TAF.'%-)B-X03MT9CA!
M<3=V+T%-:4(O=T$Q-"]Y35 U,S)F=%@O04564R]W0E1(*VTO63<O;%)L<B]!
M3EAD+W=$:U%0.$%M=D@K4F@O3RMZ.7$O=T-I)B-X03MQ6"MP:B]49G-D+WEO
M>3$O-G4W+T%026=F.#$T+W=!:D0K9#EN-U8O,%93+S%-9C9B.6IV*U9'5W8O
M5C-F+VM14"MA.&8U1T@X-S=0)B-X03LR<B]O<6PO<5DO,#,W2&8X<4UT9BMR
M=2\O26=F.#$T+WE-4#4S,F9T6"]25DPO57@O<'8R3R\U55IA+SE89"\K4D$O
M-7)X+VM99GIV)B-X03MS+V%V*VEQ6"MP:B]!13,W2&8X04MJ3%@O<3=V+W=!
M:4(O>EAJ+TEW+VYF6BLQ9CE&578Y5$@K;2]9<C)(-4Q7,7!F5S$R3E9D>F)Y
M)B-X03MP2T4Y14-V0F<Q2S@O8DI1-TE%4T1X8W9,.7)8;#EP<%1G63A!,T)(
M4#EJ5C$K4VQR8UA5,#4Q5C%-<G,U6#!186-I5%0W961N2'1G)B-X03MG06-0
M,G9M=50R96A+4FQX;F,Y>6XO>6\R,"\V=3AN+T%#2E@O;79$+TQ2+VTO87@O
M=T)$8U U-2M4=BM61S)N+U8S:R]W0U)++SA!)B-X03M.95 X=$@K8CEQ+S9'
M-&9Z>CAN9CAQ3G10*W)V2B]Y2E@O;79(*U=J+TXK,68Y1&-0-34K4T(P9CAN
M-UA53%-3-$]P=DAW=6)Q,C0K)B-X03MK1%@V<F-Y5R],-U$K,3983$@K5W!F
M>F9T6"]1,T0K969K:G8K5D<R;B]6,VLO-45R+WI8:B],4B]M+V%V*VAU2#@X
M+THS+TMJ8E0O)B-X03M!2W4X;B]);&8K83AF-6%0.#,W5B]W0D1C4#4U*U1V
M*U9',FXO5C-K+W=#4DLO.$%.95 X=$@K8CEQ+S9'-&9Z>CAL8E9F>5AT<B]4
M)B-X03MD3W-4<7)X:E1X34$O;VAI+W)/2#9C>%-L37!(86A%:DQH*W%U=F,W
M2$@R6D='3TU,*VTO=%-R+T%+1C9T9CA!<3EY9CE)-"\V<5I0)B-X03LK5GHO
M041F=%0O2G<W,V8Y0SE7=B]6-VLO=T-K8V8X05942"M6>B].*S%F-4](93<O
M;UAQ,2\V=F-N+U-/4#A!<7!J+T%#=68U=C)R)B-X03LO2G<W,$9.*U)L<DAR
M5G)P=C998VDU=')M-3E8,$(X4#%E4T)/4$AN=GDK<U9R6'1J+TLU+VTO86XK
M5&\Y-DXO-D8V=&8K<C-*+S!J)B-X03MJ+W%P:B]+-2]M+V%J*U1H,W4O-D8V
M=&8K<C-*+W="230O-G%9+WEU9C5V,G(O2G<W,V8Y0SE7=B]6-VLO=T-K8V8X
M05942"M6>B].)B-X03LK,68U3TAE;G9K>CAO-%!,1W52-G%M<'1D36E02#9*
M:$-!.'A3=DE/,S9S;S%084)Y=S1A<'5W84U9-5AA1C%R.'%R,WI"-3,Q<E5T
M)B-X03M8=6U84F13<UDW1T0V=&1Y:31J4TM3,VU656AA2# T+S-S57!::$DQ
M47=O<6UP3W5C>$YV3C$Q9&539GDW:&HP855L=$QJ=&)/,VQN)B-X03M#=7AJ
M5&I&5F=!<3%+:G-O2&=";59O.%5C;5%2;'EA3E1K34E%:#56+W=!<G,X*V8W
M+V<O-45,;38O:S-$,T@U=7,O4#502D%A8BMA)B-X03M(;6Y48G958G5Z84-/
M9E9:>&18>F5K1S5Y:4Y)9W="2D,O0D=.:&<O:WI&-2].9GHK5'E2+W=$>75Z
M>C4O=CA!9R\U14QH+VLS1#-()B-X03LU<BMF>654=BM6,F5F4#A!9CA(+T%#
M25A(*U1C4&-F;78U+THU3R\U6%HU."]W0B]W9CA!26AC9C5.=SEX*V$O;CAN
M:S<O;&1N;GHO)B-X03M!2"]"+W=!:49X+VLS1#-(-7(K9GEE5'8K5C)E9E X
M068X2"]!0TE82"M48U!C9FUV-2]*-4\O-5A:-3@O=T(O=V8X04EH8V8U3G<Y
M)B-X03MX*V$O;CAN:S<O;&1N;GHO04@O0B]W06E&>"]K,T0S2#5R*V9Y951V
M*U8R9690.$%F.$@O04-)6$@K5&-08V9M=C4O2C5/+S586C4X)B-X03LO=T(O
M=V8X04EH8V8U3G<Y>"MA+VXX;FLW+VQD;FYZ+T%(+T(O=T%I1G@O:S-$,T@U
M<BMF>654=BM6,F5F4#A!9CA(+T%#25A(*U1C)B-X03M08V9M=C4O2C5/+S58
M6C4X+W="+W=F.$%):&-F-4YW.7@K82]N.&YK-R]L9&YN>B]!2"]"+W=!:49X
M+VLS1#-(-7(K9GEE5'8K5C)E)B-X03MF4#A!9CA(+T%#25A(*U1C4&-F;78U
M+THU3R\U6%HU."]W0B]W9CA!26AC9C5.=SEX*V$O;CAN:V=D1B].2'I6;W1K
M8DQ4;FAH='I,)B-X03M,3U9-9DTX-35';&,X;DQ(-U1M;F@P=V9Y6FDX+VUV
M-2]*-4DW+VQD;FYZ+T%(+T(O=T%I1G<O>6)H-VHX,2]0-5!*,R]+-U!0;BLO
M)B-X03LT4#A!:U%U4#AM-&4T+TYF>BM4>60O>75Z>C4O=BM$+T%*14QJ+TIU
M2'50>E@X+VLX;F8X<G,X*V8W+V<O=T-20S0O>6)H-VHX,2]0)B-X03LU4$HS
M+TLW4%!N*R\T4#A!:U%U4#AM-&4T+TYF>BM4>60O>75Z>C4O=BM$+T%*14QJ
M+TIU2'50>E@X+VLX;F8X<G,X*V8W+V<O=T-2)B-X03M#-"]Y8F@W:C@Q+U U
M4$I!>B]M:C5Q;C%I,#%I5C14<49L1DQ"8GDK;E%+:S55>4%Q1'AB*S=&2VIB
M=&<O:WI&-2].9GHK5'E2,R]+)B-X03LW4%!N*R\T4"M20S1F-4YW.7@K82]N
M.&YK-R]L9&YN>B]F.$%"+WE)6$@K5&-08V9M=C4O2C5/+S586C4X+S,O04%F
M.&E&>"]K,T0S)B-X03M(-7(K9GEE5$MV>3 O379Z5G(O;7%,5'12;&EE,65+
M5GE%:59$5D9Q3GAM2G)D1FIX-"M+4$YY3DQQ<'IN4F5W6G!N6DU'+T]N+VQ!
M)B-X03M,>B]J3$(O>6-'6B]:=CA!9D0T=4IR9C=O=FY,3VMD1S=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1E5:;W1Z6E=U<U=6>F92;6%Z)B-X03MH;FIE
M-6E#;S5A3E="6E%J+T$Q4C)B8DE:26MX24A/;65-9U-"4$IK>BM9=DHW>E97
M>F5#2&]65WIS-4AR-C5C>3AN4$AK,$HY4# K)B-X03M004@T:#!P;4M-3U-U
M9C)N=2]8=F9.>51L>#DS,D)$,G0U*UAB:3%J=4Q'.&IK0F8V>F-&=W=9;5-Q
M5E=->#!52C$T<E5F-5=3;$A.)B-X03MV4D1'37-054968E5F>3$Y658P>35A
M24MG8FAZ:DI94V]866-R;5=G84E-<6IS5#,W1&=Z,7I(-"M#95!$,T@X9D9,
M3F9V.$%Y,U!:)B-X03MW46%085-7>%-E95=1>7(X6'!Y0D)'<&LY4U1L>#1N
M.6QA935Q8W1X46U#5$DS<U!X>6$X<S1%5D5*2&PW43=&6%EQ-T9867$W1EA9
M)B-X03MQ-T9867$W1EA9<3=&5V5F:VXO>6YK2"]!0F=N+W=#235G9'!F,THY
M-&,S468S;G=F4DAR4F9Z<CDT>FTS9$U9+TUB4DQR>D(U5G5.)B-X03M-<TI)
M:&-Y=D5Y*W$O1F%)-%DW9TAS37ET2&U'4$E*2&LP86Y'6G=)1'E(+T%*56HU
M>"\S-UIF.&IZ+WI4;30O;%1&-75T+TE:4$IV)B-X03LO;%-0;DPO9FQL+WE0
M4#A!>E1J+T%#<&DX,2]K+THU3F8X<5,X-"\W.7-V*U(U+S5P>"]L5$8U<BM1
M>6549CA!>7!(>FPO=GEY+S5()B-X03MN+VUN2"M635AM=CAN-5!*,R]+:V9/
M4"LO8DPO04I(;B]M;D@K5DU8;78X04HK5'ED+WEP2'IJ+T%,.7-V*U(U+W=#
M86-F-55X96$O)B-X03MY9FLX;F8X04MK9D]0*R]B3"]K968K86-F-55X96$O
M:TUN:S$O=T%Q4C@T+S<Y<W8K4C4O-7!X+VQ41C5R+THK5'EB+T%/5DDK8V8Y
M)B-X03LK,E@O04-04"].3U X<5EV3F8U4'EE5%@O2VMF3U X078R>2\U2&XU
M+W=!=5 X<5EV3F8U4'EE5&8O2VMF3U K+V),+T%*2&XO;6Y()B-X03LK5DU8
M;78X04HK5'ED+WEP2'IL+W9Y>2\U2&XO04IP>"]L5$8U<B]**U1Y82]W0U9)
M*V-F.2LR6"])."\X,#0O>7!I.#$O25I02G8O)B-X03M!2E5J-7DO,S5:9CAJ
M>CAV-6-F-55X96$O=T%N-5!*<B]L4U!N2"]F=&PO>5!0>2]L>"]L5$8U<B]*
M*U1Y8B\U56HU>2]W0BM76"]))B-X03LX+SA!3D]0.'%9=DYF-5!Y951V*U9)
M*V-V.2M76"])."]W1$Y/4#A!2VU,>E@K5#AN:S$O>7!,>FHO=C)Y+S5(;B]M
M;D@K5DU8;78U)B-X03M$2C5.+W=$2VMF3U@K+TQ,+VME9FXO3&HO2VU,>E@K
M5#AN:S$O=T%Q4S@T+S<Y<W8K4C4O-7!X+VQ41C5R*U%Y951F+T%#<$AZ:B]V
M)B-X03LR>3(V+W9Z+T%-,#0O=T%Q679.9C50>654=CA!;%-0;DPO9FQL+WE0
M4"].3U X<5EV3F8U4'EE5%@O2VMF3U K+V),+T%*2&XU9GDT)B-X03LO=T%Q
M679.9C50>6549CA!>7!(>FPO=GEY+S5(;C5F>30O>7!I.#$O:R]*-4YF.$%+
M:V9/4"LO8DPO:V5F*V%C9C55>&5A+VM-;FLS)B-X03LO=T%Q4C@T+S<Y<W8K
M4C4O-7!X+VQ41C5R+THK5'ED+WEP2'IJ+W8R>2\U2&XO;6Y(*U9-6&UV.&XU
M4$IR+VQ34&Y(+T%(-UIF.&IZ)B-X03LX+S5C9C55>&5A+WEF:SAM+W=$;%-0
M;D@O9G1L+W=!:GHO>E1J+TMM3'I8*U0X;FMY:CAU4'DP.'<K6&9.15=P86A*
M82]6:VEL4FA()B-X03M,>6%R3%%B1E)M3').9&IY62M'3C(U1VPP<V]4<S O
M+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB
M;F%I;',^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z96,P
M.65B-SDM-S!E-2UC-S1A+3@P8F0M,F9C8S S,&$T968R/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.F5C
M,#EE8C<Y+3<P934M8S<T82TX,&)D+3)F8V,P,S!A-&5F,CPO>&UP34TZ26YS
M=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU
M=6ED.C-".3=%0S$Q+3E%0S$M-$%",2TY0C4U+3DQ,3 U-T$R.#,T1#PO>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET
M:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @
M(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-38T
M,V%E,&,M,#9B-BTV,#1C+6)B-C M8C S9#8Q-F%D93AA/"]S=%)E9CII;G-T
M86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED
M.C4V-#-A93!C+3 V8C8M-C T8RUB8C8P+6(P,V0V,39A9&4X83PO<W12968Z
M9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#YU=6ED.C-".3=%0S$Q+3E%0S$M-$%",2TY0C4U+3DQ,3 U-T$R.#,T
M1#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12
M968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA
M<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX
M;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#I&-$0T.#0W.#0Q-S)%13$Q0C$P,48R148X.$9#,#4V03PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTQ
M,"TR-%0Q-3HR-SHU-"LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@
M0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z96,P.65B-SDM-S!E
M-2UC-S1A+3@P8F0M,F9C8S S,&$T968R/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3$P+3(V5#(S.C,U
M.C0S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD
M;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T
M:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I=&QE
M/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL
M:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG,#AO.3<\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.
M86UE.B @(" @(" @(" @(" @(&<P.&\Y-RYA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C8P,C4W-28C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,C0M3V-T+3(P,C,@,34Z,S Z,S4F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,C0M3V-T+3(P,C,@,#8Z,# Z,S4F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,C4N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C
M>$$[XH"B(#4Q(&)L86-K('1E>'0@8VAA<F%C=&5R<R!C:&%N9V5D('1O(&]V
M97)P<FEN="XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @079E;FER3F5X
M=$Q44')O+4)O;&0F(WA!.R @(" @(" @("!!=F5N:7).97AT3%10<F\M4F5G
M=6QA<B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @
M(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @
M(" @(" @(" @(&<P.&\Y-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C8Q,30T,28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,C8M3V-T
M+3(P,C,@,C,Z,S4Z,S<F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C8M
M3V-T+3(P,C,@,30Z,#4Z,S<F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,C4N,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE
M('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M
M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%V96YI<DYE>'1,5%!R;RU";VQD
M)B-X03L@(" @(" @(" @079E;FER3F5X=$Q44')O+5)E9W5L87(F(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU9
M2R8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(#QD
M8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y-;W)G86X@4W1A;FQE>3PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @
M/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^.#DW+C$R,# W-SPO
M<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-3 T+C P,# P,#PO<W1$
M:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU
M;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @
M/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^079E;FER3F5X=$Q44')O
M+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A;6EL>3Y!=F5N:7(@3F5X="!,5"!0<F\\+W-T1FYT.F9O;G1&
M86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD
M/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@,RXP,# \+W-T
M1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC
M;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y!=F5N:7).97AT3%10<F\M0F]L
M9"YO=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^
M079E;FER3F5X=$Q44')O+5)E9W5L87(\+W-T1FYT.F9O;G1.86UE/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!=F5N:7(@3F5X="!,
M5"!0<F\\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z
M9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R
M:6YG/E9E<G-I;VX@,BXQ.S(P,#<\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT
M.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE
M3F%M93Y!=F5N:7).97AT3%10<F\M4F5G=6QA<BYO=&8\+W-T1FYT.F9O;G1&
M:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @
M(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A
M=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U
M<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R
M;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^4$%.5$].12 R-S(W($,\+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y34$]4
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1I;G0^,3 P+C P,# P,#PO>&UP1SIT:6YT/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/DQ!0CPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SI,/C4Q+C<V-#<P,CPO>&UP1SI,
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SI!/C,\+WAM<$<Z
M03X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z0CXM-3D\+WAM
M<$<Z0CX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/E!!3E1/3D4@3W)A;F=E(# R,2!#/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4U!/5#PO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M:6YT/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6]D93Y,04(\+WAM<$<Z;6]D93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z3#XV,"XW.#0S,#(\+WAM<$<Z3#X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z03XV-CPO>&UP1SI!
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SI"/C@U/"]X;7!'
M.D(^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y004Y43TY%(#(V,#(@0SPO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E-03U0\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z=&EN=#XQ,# N
M,# P,# P/"]X;7!'.G1I;G0^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUO9&4^3$%"/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.DP^,S0N.3 R,# P/"]X;7!'.DP^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.D$^-3<\+WAM<$<Z03X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z0CXM-#4\+WAM<$<Z0CX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @(" @(" @/"]X;7!'.D-O
M;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@
M(" @(" @(" \:6QL=7-T<F%T;W(Z0W)E871O<E-U8E1O;VP^061O8F4@26QL
M=7-T<F%T;W(\+VEL;'5S=')A=&]R.D-R96%T;W)3=6)4;V]L/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M=_D( M=;2UI$(2C)!/%C^/!6:0A02" !S7(-6-;DUU:'(@-96$G35]:! &"
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MZ==,/1C_ .Q[CG_%&U_^DM1'Z^ 5W/II2FE*:4II2FE*:4J7/AG_ ,+GC?\
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MNA'&0L&1H':"/*R'*MDRX6Z4Q02@.WR)-D,&1SXQE'*!( *3_AG_ ,+GC?\
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M8_9TPEE<6N*G'@S#V\M< 0&T<;WJ^&[6"XXC,@P!8B3AD*5(9(!/F-=O-G!
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M+(%]E64^1%X[;!XC?6E?&,<\RKH,KGI;JR'97V;I00)V)5V:KT!&VL9HH+F
MLMPV#0<MHS&$IP1YA(<@=OE'"C"J0$2>^-),Q G51"<B /\ O3^-XNC7"98)
M@+8PYI#C6UYXL60V++G6L-TA&O5NB27ECM!+N5G'/@12NDQ$9(D#<LN+EP@6
M\J'+KJG?)-FN=8GF>9,OL))H7WV7.R:,6O"+RM\\1>:U[K$>M^>/&- GANYI
M,<,G$//95.'>D?*8EPDQE<ZYW2WW*Y)*MCXBRKAPU!B&:<Y[27,._,#ZHK2B
M>V4Y81'C,5(ZM7+Y]<;+!G(UEAP]>K%8UMM_%<4MUE2U.-*D!L[1/#8)*12R
MOW..8$D;[>-ET PT:.^8A&Z6E]VI02,U,("R.TR=9ZR@D./N,A&R^P%L_ @#
M+"FFRX(4$'*&TI+'UD5V")"$9&,WI7$0L861QJ_J)US(\4P\[3!$<8LF8RX%
M8?@PD-&=<!#$*<D9Z*%LD0VC(C$T%>U$(_GF#62!V$ I%KB6E!RKBV/&@VTM
MEC&B</D.C3F64YI$BTK/$K93X$@SS@<5=]03W."/6NM+7*::4J3WB/\ \%SA
MC_S-W7_O<0NO73T!/\"V[\ XF_M6"O /_2/_ ,;.*?PE@S^PT:H,M>DE>:=-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E=D]B<BVHPNOR&XW'L+263*2A<%DI:
M'$JC+K*/;\V/J-Q#V)<Y+BT.,W=D-)2T^'Y(&5:EB/7*'^"T<./,[B^((UXG
M$C M8Q(D1C[@AY$P\(2W$:Z-M&J@BRUE &]#FFQ2,$QZ<%3?51SFUOK.>VQ&
M&+.>15D.;#408PY+TA/3.:3(LB.@"O:HAQCL<1S521F-%1JUD=3A^R-G98_M
MZ(X2\R RSQS&/?=CMGDY<]Y>9-;YIBAEJ!3R\A9Z:@[W"<OKZD:K$M+'I" "
MCY1[EP=?C&FWX0I-Q>CX\9@Y,K@<H45C8\>*&#+8$AV^K:>3E/A$,XI!#TVD
M8-'!1Y+XHMI(\$)JM,=Q  X2 DASC&D$E1GD8-?4*(&<24P;1L(_1<QSU0JM
M'C>-76V6'9)O55*'79)B\^%4>&T<-E:7<(&76%/NKM)-<WT!-,776D,5W7XY
MDN85P4-@-#6QR0#2/-&"4(W)E!NLV+8C;X6++;.D3I#A! XD,1K3>$!&<P["
MB<X!),6$4CAN<54<]$8]^FS' 6WQ9%U'H#/&6***)"%*UDEXKA;E*9'!>PB(
M5@#R6,:1J#16M57-9HOW!M[MOLUFF18;0 SP9F&F:XEA-M-D%WE-2%5X;>[I
M;M#F'TEE0###IE\^+ 8?:UM:6PZ)![&UM \4OV,MY,:TMQN=[@Q9T@C70"+"
MF3PMC1XAB%FQ[39W,&<4A[G+#;+)-"4K%&NF,0GS(ZJ!LK:PH-JE'BB:K9;.
M%1HA'&-)&P44L^XH]X2!:C>$K'9&(,;M--%Y"-C&_=7!T?N7=;>Y%B0!-=$"
MS,J&EV)H8;$4ZWD)O (MJ[0+-HS@2IY*F'WK7M%BM0,^N%!G;*782%36K#!U
MK=_:@7*-,*TJD6#(/B"0HWC"C0$6["?!49&-0R\+CR)9G(1Y&JC!Z"!T7(33
MW L(\8:L1G"@AM 4(UY5<5B6\C)37L<JC3@Y@@&U6-8[-[U<I$<W>]@UPNP=
MID,5&SP4+C865Y6$% =DERE:76CT^+,K,PM$M,IQ)AA1TSKYK:\++\,C?'7
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M19,N59H1Y!RNTTTB&,1Y'KEK<Y5K5_P[^,/RB-S/MU?X.M)WTMT/G?>O*O\
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ML7<IWHAX!) A,?-.W#*]O-.?/7'\6[G^"X6%<33(N&[6"5$P_>9,8XP:) R
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MP@WM:]CVJUR(J*E<JFI;/(;&"IJ!5+.G85,V+O8!XHQ@1)SSS"BBI8! @:\
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M'CR8YV-* X#"<X9@F$YI!%&YS",<U['*U45>32TMGD-E!4TXJF'D-)E9%WL
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M *HRBWP3TTAD09F#(C"-5'C<YB(\;FD9FQS7+;=6:RJE>V<_PD.+?].6!?\
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M!5-E855B#7WXI!U$<8$2,'=!"6!=2694DS1,AL11K0 ZM(($?-%">&4'(]I
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M5V:E(9[V[D8772\11&!:Z&YYS%DP !1T.?O1!S9P87# N;'3A446^J_?XSG
M>Y0#4[.$A>[.C660\CDDHT0A@EF+HR8F^,?%BDD\&(BF7@\@B,T=[.UI6HA7
M[T[>"M;R<:V%?DNU;MPA+VT2QD$RHT6FBQRO(IUCQ4ZG#E'+OO?9%=P&V/A5
M7"('A=E7C/BCDM;*OK7'6=93*Q"D6[>EKXXMZ1\0;CK*(TV<L9WHYD=8:@<P
M6\Y/TYPB/1RH$1"H,19CV99%N6:TQ$>K9+FB0#'"RC/$U6O,DA"M>_??4Z,0
MC&Y(I",'ID'\9]HL,;EMS@XNX-W/>89-E;\[.DP02''0ZO J6]M,N.Q,Y,VE
MM<C(0JC6JQ8&WH\2;?2V 15H9C$'5-&EMYG<#!/=;0("<V(EO&EP>LEY;@>.
M*$.8-8+0QFJT^^RR!/,X.T9&B9+=H*^%MD3A)8C9I5-%62LQZQ&H!HX8BDDN
MC/24I#N1P5&!I11D,KV*]P$TLM<9SB8V,28^361YLZDR2BAO*FQS;"HL+EM!
MI3#!NJI(1LBR<2ZI5:/$L5R-8L9(4\H-16=&DY&SM\Q\I)+#+ 0\60L<PX,Y
MTYHG(,;] [GQHCP'S<N8'#548C'Z:Z>BW!F1FQU X:2U#("AA/EQ4BJ1JN<W
M2$C3R&E$NBF16OR5RN9HYLS7!=;"L.NR7!I_>_X4_P#,EL9_W/Q?7&,;>PS%
MWXL7_P#14NMYACV2X>_#EI_K\>O?]KSNKN96/9;EV*8#C5YFF=9/CV%X?C-<
M3<9)E>5W-=CN-X_4AL60NTN[RW)#K*JN%C19"#3BH!H6(KI)&I\>E*\^WN*5
M!0XWO=QA5B#;0+FK<HRTS)[+;PW@?R/(#8;7>O<2VK(\IS3A\WQW8XBL@>.$
M:/#V.)"OJ+2M,C(KFV-E="'NTJM^>3=JIEJSTN1.5,D__2JI\U;<W_W!)JO=
MA-BJ4+B'*VCK:S;3$'9)A\>%9[NQ6;JIEN<0X$#MH0N0UK=J]@[;(KS/,+D=
MG.WQMAGU\!X/%S1*6G3&I+)]OM]OYM<)EDNK/DXLNG;FOO9999]-3G:537A9
MWEBCGWUW5@F>Z.&;=K.8I9&N@8YD<F86C'O:\J8<9KFM57(X@B"!JISFFBC1
MSV^I^&G.;A3#[F(BN;AZU.:BH]45R6T"HBH-KR*BJB(J,8]Z_<M<[)%\,\9-
M8_'6*F$<K6/Q9?&O<BC16L=>)2.<BE>,2*B*JHI"#&BIZM[&YN3<YNSVV/>/
MIJR660WWR#DH>;N?51FC8J_%<BM8JD^NAV^=-!DUI88^\:N'#IK2(BQL:6M
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MBG#?HQV7R:6/%03KC&G@D%89S'7(X+@Q0-D@]Q!_&KOA^C['OVC=KXQZ*'^
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M0(GUK-X<QJIQ"AH\8<54W,V08W/+A^,JN)6\\\)3B,8ACK(AJH5A8\1H]/'
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ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2II_\ 2 O]GP?_ /+M[/\
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MGG5&(BD]4JN3NXN3X.SSDY\TTJ<UU:O?U[/FJD!]S(@7?4*CK.TQ3$\)B2]
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M('BF*RB2'4M@16EO%EESN"609Q TCH))((9'Q*USXHW*K$^\0/0[8[N,&%<
M3,-H"=$CS H2X3VD04H+#C0C6VI[6O1CT1Z-<Y$=FB.5-:]6;IZ+S<OM-SN-
MJE6[&3I-LG2[?(<&U6IX7'A2"1C*)SKZQSAJ03E8YS&.<W)58U55$L7CG^$[
MZ-;W>:&(_P!0-9?@U;H'NW#'6-P^J:P?#,W*/%N-NJ+3]?T\<_PG?1K>[S0Q
M'^H&G@U;H'NW#'6-P^J:>&9N4>+<;=46GZ_J+_W5??C@J]TQV1V_VOL2]_-O
M,AV_WFV_SZKS&MQ?'8BX<3@OZ\'="@8T7<!R2EVV$2GV>,I/$H\.?8]AI91
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MLGC3 77=Y_PY3QSW";]&][?-#$O;_3PC\!>XL3=7V_ZVIX"V[)XTP%UW>?\
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MR%<K1L>1R-<]6L:Y[D8QJO>Y4:BKHL:BN<[8UJ*Y51$5:X.KE44__O\ _?\
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MH0&Y9B UYQ3;PN@86O 5L%[PWB!L*].M=O\ 3XEJNC)DJU1!NN!D;,B""V;
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M95BK_B5A3_V^F5"_KTVKQ!K:F'SX^;@>;XM:Y53XK86F1X)=ULUX%DY09@U
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M1>U0 3\%LK^PQT8>0C;Z SHQ.=EEJD>E4: MB1)D44)LZ8Y]N5EU9'G0I%T
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M +GXOKC&-O89B[\6+_\ HJ76\PQ[)</?ART_U^/7O^UYW5W,II2H1/<Q=_\
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MB!WP\HBJ14'P(SA1)(<W&0\F)O;7B,I&#V,\>-+E$/&4<&26%)T'.<K9C"Z
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MTJ\BN_2#M<ADA1K42*ASW(C\EV:&6I/NDS7BXZ^V3;A9?7S;E-#M^Y;09!A
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M]RZ&:[6O5=2:U32RXNA*I3;BYD6-B,A%QWC[3 LVNCE\'U3._LZB6Z;7$\F
MM2+IT$'3N84C'E[OG/%*KW]J5_N3YT2I:]RZ.:[6O5=2;45<N*J";BYE*/6O
MDN.TXC9W(\JF7P?5)V[X"6X:(?R0%$;W311TZ5J-"D[OG(.]7/[4HB>IZ79+
M[VKZ:C3=JU_[I7;$VII:]G0FK96%YMNWN%4,PU:[(.G6UP>DN#_]54DO46)D
G]@P@GY^ME[KO&P1)W,/=P,[/-D35<Y5IJAQ7IED[:U%V)M^*O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g551455g12m13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g12m13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X85F:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B W.2XQ
M-C0U,3DL(#(P,C O,#@O,C4M,3<Z-30Z,# @(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @
M(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P
M9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM
M;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]G+R(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T
M;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @
M(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N,# \
M+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'!D9CI+97EW;W)D<SY#1R!/;F-O
M;&]G>3PO<&1F.DME>7=O<F1S/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/D%D;V)E($EL;'5S=')A=&]R(#(U+C @*%=I;F1O=W,I/"]X;7 Z0W)E871O
M<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(S+3$P+3(T5#$V
M.C$W.C(S*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-
M;V1I9GE$871E/C(P,C,M,3 M,C14,38Z,3<Z,C,K,#4Z,S \+WAM<#I-;V1I
M9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(S+3$P+3(T
M5#$V.C$W.C(S*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \
M>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG.G=I
M9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,3@X/"]X
M;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z9F]R
M;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!
M<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!
M)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!
M0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-
M1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(
M=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&8O.$%!15%G079!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%1
M14)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"05%%
M04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C
M1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1:5!"
M)B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&15
M6DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P
M6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/
M16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7
M;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%1$)#
M15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$
M4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95
M,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:
M;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO
M)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A
M04%W1$%104-%44U2040X031N;E)U1S=&6%EQ-T9867$W1EA9)B-X03MQ-T98
M67$W1EA9<3)#46%J<4U#56$V:WAM;S9Q9'9O>D9(3G502DQY2T%R-$=U6'1&
M<6-H*T9F2$%78U9U3$HR1EAD<U9B>%9S9'-7)B-X03LP1%I5:39T.'8T:D-/
M8D1*>5A:3F]D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-65%A3+TLS;4Q6<E9R<E,Y)B-X03M0;79O,6Y3,317-BMR2UIP235*5E99
M:W)),S=U1C)*0S!!1RM1;&MI1%),24%O>'9Y*S@X<&%,9'EA1&924E-44C)S
M26MG:U(U6G!1)B-X03LW2VM-8D%02V%23EAG<' S<%594$=H9%=&-%-O87HU
M3#@R-DI'.'5Q-E)D5VM-6FI75V532G934C5O,6Q33C5!0VEY8TA5;$-E439%
M)B-X03M!-'AY4FQY2VU*0W9(*U@S;EHY3G5D5"]!14ID>#)6;S!#5%-Y>&U+
M<EA426M+>')*>&%1=5I5,E%(6F=E:'@X5TXQ83A*5DY:+TQB)B-X03MZ-6\Q
M>&)7*V\V1F1X4S-K:E$R<7!'6E),2W)U;G!O67596FHV8D913C)7:D-Q:T5I
M3V%%=5)5>$Q(6DDU27!7:FM5<$I'>%8P645-)B-X03MR03!)25!1:DQ%2G%%
M1%)G.6E0,6I-1S9,96Q8141I5#!B-%=Z3&-646Q1:'50=F=,3TI753-X6EAS
M-&=94V=%=4DR>%5&;SEC0EI")B-X03MD=#AV1$$U5DQO>CA2*U=3:GIA<S-*
M4&9,;FQ$>D0U:F%D9$AT4D],8F@V.&IY>%%2<5I35FI5>5101VY*>41X5W14
M43!',D=E4TUE)B-X03MB44EK<3EJ*U@O;F4K=7!B4S$P2RMK=4E223!I96<T
M<#90<6AX5F=">357,&E+=E9M57%+='1G3U=!,W-,=VQ8<W9Y>C@O,W-K159T
M)B-X03MO3C0X<SAX='A(-EI6:V16:6,K<T=O658T,T5B0C5E2VM'=&%6=TA.
M0616-%-L0RM8.65A87IH6%1R<'!D44)/;GAR1$E7=4%#5DIH)B-X03M!2#=W
M5D90:')K*TUD-DM+8U)F;&HU+VQ7=TMA2&-L=%5H=4QI>&E+9U-Y4E=I<3!Z
M*VU32%559&50241N54)/4DEY2&IW,S,U2C13)B-X03MG3E8X;2MB3DIV8GEY
M,4138G%#-# Y4%9V05EM6EDT=5)14VPQ1$HV6EE516=013EJ:&IK:5)94$Y4
M17!.;&I&,DMU>%8R2W5X5C)+)B-X03MU>%8R2W5X5C)+=7A6-F(K6%=N969X
M-6)38E%)<DHY3S%05E!Q36QX3WII4S-U2F):<D):2$-%34EI=7$W37%T4G=+
M,#)$6759=S1T)B-X03LW<T0Y=C9',DXQ<WI32'I**V,O;7E45'!6,&)2;W)/
M.'51-'9M;4MX3V)I0U<S34UR;3=K;5=S3C1X14M5:T$S4E)L0FAI:F4U+TAW
M)B-X03M:6$EO1'I$9B]M-S5L.'!796U.-68P<%ED671G;&U,5E<K=DI95TIT
M<&\Q37,P,&Y'3U-35TEO<G-89&HP*TIA>6=-8UI86C(O86<X)B-X03M20U(V
M+V,O;7@U,G4P,%=B4S=782MV-V%W,6%/1S%E25-E9W)Y*VI+87IS13E2.5-A
M4U)8,T%)86EO37-G36-.-S=X*U!K9VU26DIE)B-X03MA-2MC.79F=U@Y.6]U
M;&%D2$5*9%(Y1U)J3$5X4S$Q0S=L17-+,T9X26AU;W)M-#)92T-604)8:6-Q
M16-654-4*T(K>&QC;FHO;EI.)B-X03M45'IL<G$V<3!4-FU,*S4K=DYB,3E%
M>BMS,W%'4&M!,T1L5VQ25VU:;4MU159Y<'%L>E(R;%<K;'9A<6(V-&YG4$90
M5#E#0DIQ-V(Q)B-X03LU4W<P+TA-2UHY4F)H>5%,5S-L5&=W+U-.+S%R+W9$
M1#<O.$%,,VU53TQU+TAY8U-X86YC5W9L3W-:+U-.*TMJ+VQH:"M8+TQ:9TIL
M)B-X03LK4#='8V$S52]Q,VQ,<BMK<BMV+T%$05$O=T1:6FI:-W9X.&U60F(Y
M5CAP9CE82R\O=T-K0T@O<W-W6$PX9C)-.6YF5G9+9&8K3VQF)B-X03LY4#A!
M;&=H+S=,34YY+T@Y:D=G-S9R-5-*+S0V5B\X03E)15 O6EII5$QU+TAY6C1X
M=75.<C54,THQ3%5$6&]F<4U0+T%'5UE,4#0O)B-X03MS8W5L0S1G,$9)>6)+
M.'5P-39J-$IR5T]&2V0O:E<T;5 O0S501U1B4FTU33,O3$,Q.#-3-EIQ<F%*
M66%B<3EP.5IS;'5.3#%*9W!E)B-X03LT<$TY=$Q"5U,S3$]N0GAW5C9T>2MW
M,V%'8WAS5U-/9DIP:&92;&MM<2]M,DHO,%1*<%=L-G4T,4\O<S=I.$0P3GA+
M=S%!5'AZ8UHW)B-X03MD;V]A6$XP-DU5:C)'>#)Y<FAX.#=),D@V4#)-<FMM
M<W5S9FY(8E18334P9E(W<V9P."]6-&<Q=V=L=C=71C1'=4EY8FE&+U)I6%18
M)B-X03M,4$]W0DI9;FQ1.%EC3TDY5'DO2#-P=51'2#%V.#)H<5AL0T)T2',O
M<BMM439H83926FHP>$YC<$)%8D\W5S1J5UE38VA(8D=*9G-&)B-X03MU3D5Q
M,E<X3T]P8C@V63-,6D=3-D8K8V(K861-,516.4=S63=H:F,V85)C>7 V3')Q
M=#501$\X.&1T3S O1#$Y45I/8UE!04LO5$AI)B-X03MX8TI!2C<O;"]9;7!7
M;$AM8C@Q9E!.:E!Q5FAF>#9D23)U-F)'2C)J:FQF:$)Q2WI8>4=.<$AQ<VE2
M-G!*2#-!6&)E;DEZ:&=G84EV)B-X03M9+V1T*VA";5AL,EIB53=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867%Y2%)F4"]M-U).35143DQV+T%+=%EX,V%8-GA#
M2T9J.5EJ84XQ)B-X03M9=39--4A+0TTX0V5*2VEO>7%72TUJ6D1)4TE43S(O
M3U X>&)A>7-,2U!614YP<&%O=6YW>5=L;DES4FI!0T]V3T9V:E=N=W5F:4<K
M)B-X03LK-7E*,#A#4V$U*SE01U9+>"].<CAW<D@V;#E5,61O5' X16QR87-S
M34A)47ER1W)+>D=/<B]$8GAG1C9L94EP4VU%-F5"-DQX;$Q,)B-X03M0>G0U
M<'-T6E17<E,O941623=:8DM/-E)51$-"24)B2V](1VQ216]!86Y,=EAL=FMJ
M:6E25F))-&EM*W$O;D0K62MR5WAT=%$Q9WIW)B-X03ML<&Y+;3-T;$YB:4-3
M,FLK2EEG9#1:,U%B-U8R<%%5:$A4=TA)2C1Y>&)5.5-V9%4Q2S8Q2RMK.6$Y
M=EI8=4QM6&EQ.'!*1TQ/,T91)B-X03MQ:7!0441,67A!1D)I4VYK0T57151E
M15E0+T,Q>EAY*V\K.75(2DEN:G!&>3=S840K3UIO8T)2=6QP-E$X4#0W-4=4
M6FHV<4)(6$$R)B-X03MR85EP='5M-'=R8FQ(>%E,8F-8,4)F=E%B.4]G=T]:
M5&Q"1'18<FLT8S)J541:4"]!0S,U,SAZ95<T<FE,4G)P8EI,<#0U6F55145X
M)B-X03LY4T5-23-2<&MK36)P-FI56DM(9DI4>%)L>F-54TE44G9Z9"]-3F]O
M-&IQ=%EO<G5B5494-G9B54YX8RMR-GI.*S8K24],:5%&1W%T)B-X03M$4VQ+
M6D@X=D1U5'AL<5 X,U!Z1&IL:6Q45GES<TXS2G%%56=G="M1=4IF5DQT6# V
M.%0Y86PO9"]9*TDO1&HK6&@S3'AL3$IF4%!M)B-X03MQ6%=R2%<U3#EM,514
M;F%3>G53:V1595-E4S59:V-E3%9M;61V:4(V,#9B6DQW;S!25WA2>$9/-69Z
M<R]-*V$S5S-M,7@U63!K=#52)B-X03LV:T9S-V,W4U)*64-884ES94UK871U
M9FE05W145T@U8D@S2C1Y>$Q5=%5V=%-U175,,E@Q6FMH:'0Q8FEQ,&ET;VQH
M:5=I:%(X36-A)B-X03MI=E4Y.3AT:D5$:WA*=$-:2D1S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7%P1$)03WA31TYP6$%,1E5"63!55DIO3W=W17!P
M)B-X03M/3D\X;&5:3E)S67(K,7163G!-5T55<VLP15A,9V5,8U)+-D4P3S)1
M;&QI1%)326MO:B]L6&YM>B]L;6@O=T-K=3 O-G$T4$=I;F=+)B-X03LK2#AT
M=DXX<F-5=')E=G9E,F$Y9FY-34)Z=TA64FI,2W!F>3<X>7<V8S-+1S-666]#
M0S,Q>7IO2TI4+V9U839/44=6*V)B3TI!25E3)B-X03LK:C-286=E,S1R<TLS
M3G8O04Y633)0131(0U5.9&%09"]".&1V,R\T*W)F+T%+<5I#8VTS1DAM<$YO
M,3-5+TAB9CE*5G8O,55W8U19)B-X03M!="]1,3$O4&)F.$%35F)F.59-94I.
M3R]1,3-8-V1T+S!L5S,O5E1(:5)4;#!A-T0O8G1V*VMQ,B]W0W%M07EB8T$Y
M4S@V3F162DPR)B-X03MW.6AD5S,O5E1">$]9=$=J,V9)+W9,8B]!2U-R8B]Q
M<&LX8W0R:E!Y6&9O:3<O,S5B9CA!4U9B9CE6378T9S1T3R]21C,O=GDR+S93
M)B-X03MR8B]Q<&IX0F%D*VE,=CA!,S5B9CE*5G0O=T)6365)3%1V,%)D+S<X
M='8X07!+='8K<6U0149P,S9)=2\Y*U<S+U-68F8Y5DUE24Q4)B-X03MV,%)D
M+W=#+TQB+W!+='8K<6U0149P,S9)=2\Y*U<S+T%%;%<S+U942&E#,#<Y15AF
M*R],8B]P2W1V.$%Q<&IX0F%D*VE,=B]!2#5B)B-X03MF.4I6="\Q57@T9W1/
M+U)&,R]V>3(O-E-R8B]Q<&IX0F%74S9:8WA2=$EZ=T961E-&=4E(8C9&5GE4
M.4=016EK2FMK3WA6,DMU>%8R)B-X03M+=7A6,DMU>%9%,F=0;UAM>#)H1F%+
M1"]!3'5J-FXY;C4O4C-Y2C9*1$IR<CE(+V]8>60K:U X0650,#=Z,69T57 Y
M8F5N3&@X9D=T)B-X03M/6$@T<59P=FQ1=356-4TY<49R9&10:VLK5V]L,#A7
M<38T<WI'9#=F.4E-2%)M24-O3&YJ1VMA2T%15%8R2F]A57%42&HT="M8=U%A
M)B-X03MP:G5L:70O0U!C;C=G5&QE=$Y96F4U=3!9=DQ(,W-T,5-K5VUY53=H
M5D90>"]6;41P0G5%87,O5C<R3TQ(=%4Y='IM,&1:849V16]K)B-X03MB2&]7
M24@S6EAK8CA05E-D0E-U2D-94W,P<#AC:3).53-X5F9W2$U%:C4T>D104WEU
M45AS:$<O1V=B-U!F=FM86E5P371#9'9M8W-X)B-X03MC,T<Q03E+,TUH=VY9
M<3=&53,X=39F<&0W3&1I*VPT3D1"-FQR0C8X5G(V.'9Q>&]9+UAM1%)P4TXS
M9F-B.&%D.&A-:V-M44-E>2M2)B-X03MF3'E1,EI8>E)A=E!C<$<X<UDK<CA9
M039X12MO+W="6B]985)W46],9D17;3=C82]&;"].+TAY6F-!-S!7;C5F951F
M6'4O53@U=TQ:)B-X03LR>74X8S9X44Y*2T5H36Y"269R65!Q1FAX07)X,TAX
M5G%!4$=L+TXO2'E89TAE:&XX:&58;W13=$QA8GI86F96-316:VYU6693;#E*
M)B-X03LS12]W544T53!-0U9Q=TE%9W%O4'<T9D9L6#!L94%D-FQP,VLO=T%V
M6#EH2$HK;3=E>79(=$,V45A&>&(P:W5U8C!5:W1'<TU:4E R)B-X03LR<E5G
M;6QA66Y*24AK=D-/.74P.&\K6#0Q='9R=7!*3CE996MK<V1Z0F)*1$-T,4QB
M=$UV<D)Z8T)H1'E!4VA8<61S5&ML,$-I25,O)B-X03MZ<#5F,#-2.5%J1VTS
M275,1S18;D)784LT64Q25'9,0BLV63%B:3-$6EA$3%4X95)L:6U:1&1%;S!X
M,TQ71'-69&ER<U9D:7)S5F1I)B-X03MR<U9D:7%)='%E:&0Q<%@P:%-T83$Y
M5U!P5"M/4E!2251Z>D(O=T%O;C57+S1W,VXO55<K46@Y579G>5!)36)Y,6=N
M,F<V1F5/<T]P)B-X03MY9W<R2'%E:W,U2$E&:CA*1D%E6&9R5$Y:<F16:DXT
M8B]E16-V>',W2%,V6$M!33%F=7=E9C0S6DQR,7)9:3!69G)D05A'+W!T-$A)
M)B-X03LV465P=W1345%K8E=E;FE%=#ED,TQC4BLV8C9F-%IS3%!C-%9$=E$R
M<#)M;F5L1T9V9&MO4#=P=7)$9CAC<GE85&)H<2MA1F$Q,"MR)B-X03MF-F)T
M+W=!66UW16QN1TE&8G)"86%F6"]!2'0O-4I.:V),36=D-VAA86159C9B+WE3
M8D1:56=5,SE8<T$Y4F4K,SDP,V9B0DEL;F=!)B-X03M%9W%F5DY.;TM8<#5D
M+S-46D-Y-TI9.6YP,W@O-F1866(K:R]I36YJ2C1M:E5$,'%0,5A4=BM7-R]K
M:S):5FYU8T=H,W4K<39D+WDS)B-X03MF.&MM>',Y>3!/.3,Q6%1V*U<W+T%*
M2DYJ6C=L;V0W=G%U;F8X=#,O04-38D=Z,TQ1-S-F5F1/+S5B=BM35%DR935A
M2&4W-G)P,R],)B-X03MD+WE38D=Z,TQ1-S-F5F1/+W=#5S<O:VLR3FYU5V@S
M=2MQ-F0O=T%T,R]*2G-B4&-T1'9D.58P-R]L=2\U2DYJ6C=L;V0W=G%U;F8X
M)B-X03MT,R]*2G-B4&-T1'974S(Y:7-B36PS>F-$6E!4658K:S0R935A0T9Y
M5$8R2W W-6$X;39X-6EG=C5D3CE*=C!D1TI:;VYF:3=+5F0O)B-X03LS83!0
M36=216ME1R]116EU95%2<2MR2TU3561:+VQJ-7=U<GDP=&MT;VPK=58Y2V8V
M>$1*14)X-4LP:G=V2G=2*VE/,49*,D(R3DEN)B-X03M014HT0W-U+WDR.#,R
M,30Q;V)-4$Q(0F)4>6YM<V%P.6(T<6MB1UEX+W9%:V8P,U@Y;&QB<T-C4FUI
M479!5VPO3&IZ669Q<"MQ<#96)B-X03LY-F=S-3%L:F5/5C1O1G5'4E=1<TML
M2$9$.6MN;V1J:#AA2SA"9$(K5W9N860U1FDP,&M2<VDK<5IO0D4O<5-,17)2
M>49W:VE&-49()B-X03M.0U8S1RLK2GI2-S$T0VAB<GE0-71T3$,X,4,V,'EA
M0WIS0D<Q,4Q)079&6FXY3TYQ13%:5V9A<6=J0TUS4V%T0FE5<G1E6&]8;$LP
M)B-X03LY16-Q14%5.6%0<40Q1F5W>5(V241+2EED4&XP=GE20G%436UN>6TT
M:G4U1619;5=*<C5G-T(S5C%79TYA;%1L5FTU5BM.;6912E(U)B-X03MN,&)4
M3DYL<VTP*RM3.&AV-U9B=&]L94]74S%:,V-#,VUE26Q79%964U125'9U<3E-
M;D-24$U-6D-M4RM39%-N:C!/95<T=59&<%IL)B-X03ML4S))-4\S4&IZ2V<O
M0T12<S5(=#=$1'AH45!&25@U9#,V2'-U=V,X=D%*:V9413$U.2\V5C-M3G)3
M5T(R9V5G:FY-87A%1W!#3%1M)B-X03M'-VAQ+V=C=3=(,6MH35%L=F96,3-B
M=EHK37=/6$@V84\T-R]!1$1(-6Q(0T%$;V%K+U!K9C9:,5%$>#%Q1W!X:FYC
M041:5S(K:&IK)B-X03M*:C!T=4TW<&%U-%!Y+VIL66-I5S%/56(T07-U5%%'
M-'A#5'EA,W%0;418-F-I5V50-F=I3U)$361N<E5C:G8Q-S<U1C(V:SE+154V
M)B-X03MG-R])5GE59G%$4FY&>$M'>DUD63=&6%EQ>41Y5"]H1#E-:V5A>$HK
M:D=124=I36Y*2D=L4F95<$=#>$-)5UER,T%O3C9:6&PT<3E0)B-X03M.;$=U
M<6%#>"]+,4):<V11=3-K3'AV9$M!>GAH0DEO94ER-DU$9W5J8W53>4AH>$E(
M<45J25AK-VU64F)44W9Y=&Q.;34Q<3=T=SA")B-X03LK=E).1WHX2GA!>F-O
M,U=(9%1.>%5)5C96*U!V:GA:3S5A:C-R,C!B.'!L82]B+T5&-E922G8P9D5L
M=7I&,E9Y2655:E)X+V%3:%!W)B-X03M,.'AG-'-N8W12-S)$-6M.8G-69&ER
M<U9D:7%F*U)4-59(;64Q4&UO2V1$0WI'-59H3U%Z0TIJ178K:D9:9#5/27%$
M=#,R<FQE6&DT)B-X03MF5'I:4G$Y,EAA46XU53).;$102#5G=EER,F1':G9B
M94HW;4I5-3(U:$UG-%=R8VUR3$HX4$UG2V4Y4VU5>3A1.5!X.#)9-%(Q8C%V
M)B-X03M64'DX:VPP-CA46#E8=G)L-3=E4%4T4%=M2U)7-F9U-5A35U=*2DI3
M,%)K+VLS9F]"5F-9>&YU2T-K:G97=RM99$)N<W)U9E903G5P)B-X03M286Q+
M.')X,C)N6$8X,758-'=V1DLS,7%.-4=*:U$X9UAQ4T%A<49&57=.-U)&9D)B
M2&5V5%5V>2MJ=F1&=7)J>DAQ="]+3#E$<6-C)B-X03MK.7HV54YU.&EI95):
M1FAH;6-T06Y!.$],9$0R-#1/1V1(66-L<V0W350U<"])>3)S8D).33%V5G)D
M=TY0*W511S0Q5E5):G5O1$U8)B-X03LY3F=05FIG5U0K-TA$*U0T=4]5*TAL
M2DYG9&4U;'A263$K6D]T+VQP8V%8<4U0;%!5;FYL;4U8<4QD4S9U4DEI4V@T
M>&),37I)6%%&)B-X03MV5BMS,5AV2%%K9U<T67I"2$50=2](>5EY27):-6IB
M,T9B0S9G6DEQ0TY74GEQ:5-O;%0W3&=C:G-4<U0P*U%Z2TDS64$W2G8U9R\U
M)B-X03M24'ET+W=!66)Z+W%,9DE1*W%8=U-E45DT3719<RMT-V)Y:F]/<$YC
M45A,,U!#0EI)175'6&=:4U-'1$E&5&Q19%!V>FM-=7 Q97%X)B-X03LX4$(Q
M;S!$*W8U=E@T9%!P3DQK-'5-.')&:V9Q2'=25CE"3&-A4$YD>6US.&EP27EJ
M-TMG16M+4&M'>D\W33 T=WE!-FPP6&$R<VQQ)B-X03M,2C5$:W@R-%0Y>&)U
M3V=Q1#AW>"]G,F1%2&Y!5D,O5G%81'-+1C!,52M93&9X>45H-E=C1'5%<'1X
M554Y:BMV2V-9='EC>'%V93-')B-X03MH2BM71T5B2TUK-D,P1&,K,E)!6FMU
M5#=9,G)496U23&)$-F@W,%-E4F(T1T%-;C)L6%E#<#9'=$UI-VQ49FM+250X
M24IQ3V\S,E!4)B-X03M!5%18:T9G:$$U;D]N9&ER<U94:GDS-6MU=$)M=EHW
M5D$P,3-A4U=966MG24I3=DIQ1#=8=W%2>$]X<G955D)H3TA%>6I+;5A84#5L
M)B-X03LK57AD,F0S66558F5"-$EN5U-/<T-J,4-Q;TA$4E<X6EEL57$S26-A
M;C166#1I.4EW>39Y6CA9-VMS,5!Z4C56,41262M':E$R3W!A)B-X03ME,70Y
M5T-#3G9R5#A55V0W:FA"14-N1T0W4$PW5#%O87-C;$A(24AN<V=Y2&-R42]M
M2&\V5S@T=4Y"1W!8<SDQ2$],-U5P;V)Y5DE5)B-X03M!5C=D1$IB5C1U2S!Q
M5'@R;TMI<$AG;G9R,V8R<GAJ=55J-3<X=CA!<$Y&+VAE,30K;'=J8VDS.50Q
M1V%S:G5W=&A8;495555,=S,Y)B-X03M0:'E/2'=J,R]J-7)X:G5796%03RMG
M-C%B,WE7,VQI,#!U5S9A13(X;'0V4T-!4E!)>D)22$1'5'I76&EF:39+3FI1
M54U-4FI7.6]-)B-X03MG96I$<W593WA6,DMU>%8R2W5X5C)+=7A6,DMU>%9%
M,F=F,$PS:GEO25)Z-&Q12V5T2#EQ=35&869:,W)4=%A);F]K2C,U9R\U4E!Y
M)B-X03MT+WAH=E X07%,9DE1*W%8=UI(:T=.-6%W6F@U6CAS86)06C(Q.658
M,%EJ=5I#:VQV-E%K9$97=$-#5T%Q9FQN4#8O=&E73$EC8UE8)B-X03M85R\P
M5BML-DA19&I1>31X3U4V=G K,SEJ3C4R95!46C1&=&]P2%9F46EG5E$X:F-L
M<6IC469!5DY-,2MM-U9I6G@T:%9K5V5G8F18)B-X03LR1$]-6FU*=7)O9%0K
M,6HP=&YQ2S96.5EE>71Z17I%:$%H3')X2E9U4R]S-79O9'%A95=8=WA,9G9S
M8THY>&1$4'-F5E)X1$M98F0Q)B-X03M(:4AV1F535EAE;T=3>%HO<7-"94I'
M5U$X3S%.=2\P6G-:4C)/-W$T5#E826,P:6DQ3VE';')B.7@Y:C,K95DP4G,U
M:VIF4EAK,55Q)B-X03M2>'1B64$W;CDS+V)L<VA82G!G8C5G3V951CE-<TQ7
M,T)A;&8S9CA!8FI+07$P4GE(:7%H<W!2-FA6=U!Q='8O04UI+S=C;TU83S K
M)B-X03LK44)%3G%"031F53=F:W!022MN+T%'.7-J=W4Q-%9/5%510CA.=&(P
M+W=#368Y=4-5545)3#E*+SAU='8O=T%I+W=#,TTS:&1.>$\O)B-X03M39CA!
M>38R+R])=BLS2&A8:60K:R]W1&PQ="\K4F8X06)J=W)X26UX+U-.*SAQ5T]L
M2F1V0D<P.'EW5S=31DEO+W1Y345R4D8W<V1H)B-X03MG3D1M56<K4T<O4V8O
M3')B+W=$278K,T1W;S1L-'9:5$4P=W-91$-R0D=K.4DX47I!;%9*<E-P0VUN
M>7=6-7)B8TXS4$]X4T=X9VM:)B-X03M685)G<U9316I5=3=D96EQ0U1I4C5R
M86XK:R\K6%<S+T%/4F8Y=4AH6&ED*VLO.$%L,70O*U)F.7500W9%-SE*+W=$
M3')B+SAI+S=C)B-X03ME1F5*6DQF*W!'>696-$4U0VY*56]2.&I82&A7,$QK
M;4QS5F1I<G-69&ER<U9D:7)S5E).<4%93'=K06M19V=L0S5".5=-8DU0<V8V
M)B-X03MX*UAF055H;$5T-V(R3VPK4TQY-6E7-'1R8S-%<SA$;VMQ=D=T.'AD
M5$A)0VI66&%J8EI45FU1+TA*;C!#438W<61R<4UL<DY$8G@R)B-X03LX<5%L
M3&]24E)W23AV<7E.>D-204M09UI2,$A43$E225EY3F]Z4V1/=6)0561/3W)X
M>E%A8D]F5T%$8V5104I5:F9A<$%Z5C9Z55%N)B-X03MJ;C181$Q*158U.7AD
M=&\Y3E!(:V@T=D9(2$DS*W(Y1%!R835T:VU.>$)"8V-J8W(Y5&-":5=T=V1I
M844W,'IK375+64%"1F)05C1-)B-X03LX1$M20DUJ9&9D*S%D4$Q(8E=-:V%Y
M:$I:65I*2C9K=7)5;7%&4&130E%';G9M4$576$YK945'>G9U=VY51U9&=3)H
M57A24TLU4TTW)B-X03MK231*04YA.7%:-DQP0E X=DAX4'%P.'(Q<W-:,4UV
M1"MJ:5DY1U S5F9F*W53:4YK>4\V<$PY;T1W04=4:W=X.&YC=C-64$$T3VDQ
M)B-X03LV<F)H549Q,39'=$\U-V)F9FQ:8R]24G9*9F-%5VEY8W!J8C%604<U
M06M6-$4P,WE,=#956D9K*W(X*U W=FM">7 S<#!R:U-X4$I,)B-X03MC>EA1
M=7A6,DMS9SAM,DTY>F0S-W=U=V%#>6PU47A1+U=:-59N2S)R3$1$>FDU<T9N
M3"]A,E939#9:5FM.5C<R8UAQ34QE9C<R1T=#)B-X03M#6%).3G-B>4Y*-'1.
M5#E)47=O24<U=$UG05EQ>E-&1DUI3G53<%$X5C5,:2MG9#4K5&(V:U!C5R]W
M0UDU3W-#83<P-G5S,G-.=DQ")B-X03M%8G%A4&A*0VMG9U(Q-5)O94XT6%E/
M>"M)33,R871H0FAT>C)24E)*,3=Z;&\P*VIF<&E04V)#,G5B939E,U=W:DXP
M>7)P>5!/5FUT)B-X03LP=6]95U9Z25%&6FET9"M)8D)W>$XQ9CEV=U=Y3V)'
M+TYV:S=Z-S5J:V@Q4S9I<S-U15@P=E%T4%=5.%HW=3=K6G%31# V239313A'
M)B-X03MO16]A8DU28FIY46IT*T]I2E)*65(U<#AS,R]L<E=*3DIV-4E*8FU*
M5EHR='!05FHK259P>6]..'9H35-&:')L1VMO>6)&,DMU>%8R)B-X03M+=7A6
M,DMU>%8R2W5X5C)+;W94=W)M94YK;&%/4T]K:G=G=7E+2%9I>%%&47<K1VQ'
M3DXV.7-J2FM'67HK5G(S5B]*,VQU5S-U<D,S)B-X03M72DQX1U<K=G)3>6-N
M-C U<7%816MB164T>6M406ME9E1O>4ES0DQ0*U9D-G8O,6-T12\W:D]M9CE6
M.&PT=S=J.&EJ:%0K-G1D86ES)B-X03MP6F)U.#!M5FMH.45E:')';E-U1DQ!
M<U5J5V)K5'0P1V,Y3'-74$8V0U%03THK.39%9'5%:C%I>E9C,"MT.4LQ6%5)
M,'9&=5E)23=L)B-X03LT2F]K5U=*-F-D=U134E)5,4A4=WI!:C)65S!J=4QC
M<DXR.5HY361T=79C>&953DYV;6QK3%,R-5!)-R]!1FTS1S%D+SDR6C%V6BMJ
M)B-X03MX-$E!06(Y.5!(9&\V+TQQ36A*3D1U<TEB6$Y,=69Q878V;'96;U98
M+V5M,TA1.&8Y*V5!>DMY5$A#6$1W45!%4#%H258P93=%2R]V)B-X03M,8F-N
M+VHV="]W1'%P;4]$<S5H2'%B:S!M-DQN.35B9&8K5W$S+S9Q651,9$5);6<P
M3DEU=4HO95<S568X9E9V-R\X049M4$9S;F@S)B-X03M68E!2<G=S4TIB645B
M9VTV="MW<B]V>DMU2C)M:$9!;%@O43 W<W9+84%C:BLX63-.=C-0+T=49D)9
M8RMW<'HV3F,X-DI,8DUG4#)V)B-X03MR3G5.:#,O=DU%:7=M44%L,S9)=2]W
M1&9L="\P;%<S+T%&57I,-&<V4VYF;VDW+S,U8F8Y2E9T+S%5>#1G=$\O4D8S
M+T%,.'1V*VMQ)B-X03LR+S9Q63A15VYF;VDW+S,U8F8X05-68F8Y5DUE24Q4
M=C!29"\W.'1V*VMQ,B]W0W%M4$5&<#,V274O.$%F;'0O,&Q7,R]65$AI0S W
M)B-X03LY15AF*R],8B]P2W1V*W%M4$5&<#,V274O=T1F;'0O,&Q7,R]!1E5X
M-&=T3R]21C,O=GDR+W=#:W$R+S9Q63A15VYF;VDW+S,U8F8Y)B-X03M*5G0O
M,55X-&=T3$ID3759;S)K6C1#<6EP0S-%1'0Y0W$U2BMJ2&E24T5Y4TA9<3=&
M6%EQ-T9867$W1EA9<6E,640P3'5O1E)%2U9")B-X03M*<C9S9E%J-THY>CAS
M:65I47EM5W=H,4A3+TI&:$Y-,79&9&TT9V5D545H45-8>DQY0T9O=S%+.4]1
M>7$V36HK3U1/<D%5=%HO3"LX)B-X03MS9$$O5#!%<VHV945H:TLS55%T-6I(
M8U-Y>%%U:4LX-FQ7.4=U-VAQ145!<CA71T]913!G=S)T:6EQ>G-&559::E%!
M94IY,&UH8D5#)B-X03LY;G-U:G!08C9.1$)Y5U-E>&<O,&A4<U8Y2DMI9W!V
M5$]*,79A6DUY364R+TXV+U%D:5)%95!.=G0Y3S1O*V%6,WEA1S5L.5=&0UAT
M)B-X03MK94)O;5E+=%-/5$AO4U1Y>79&,G1Q-#AP;FXQ05 S:'EC+UDR:&MB
M3TUF5#!*2#-%8C<Y5E<T=F1-:&-7:G!&23!-3#)R3TEW5E!W)B-X03M%<31Q
M93E->&IQ33@W2FQ,8S-Z+T%",W5534=N>#%%4FHV4EA)9FIP=6PK<#)7:5@Y
M<41+1$9,0DAB*VUS2W%G0WEI<$9+9%)3;2M8)B-X03LV6%A:.$UT:GA8,S=U
M4'$Y1G X.%!53TAH2%-G<#9V-6(X=4Y$9$YP,%9X.6%D+U1S-%90359J,V9K
M2W-D,2ME6E=M-UIZ.%%%>41()B-X03MR93(S-TA&,5A996XT5#1926QY04)*
M,T<O;60R1GE1=D=J3$EP5C%9<7EN66=J66<U,3AA34])8VDX4DMX:TU4<UDX
M,3EQ=G=+1'15)B-X03LY9FYL6D1U97IT-$@K="MG26HP<%@U4G!34DEU5$9L
M.$(Q3E11,#)W3W=1=# V,5IL6&=!;T9"6')3;&0X04<T8UA64W%"4R]-<#!Z
M)B-X03MS5F1I<5HV1$)O.#%Z8TIQ<&M725=T=SEU,&-Q43!U231Y.%%9=DA,
M>59M6&IX04).9&IK2FLY1U%P:S O=T-8+VQY,FIE3V)Z6EIV)B-X03MQ169P
M<UEB67=444US<CA11750<D-+6%914W=)04<Q5T934E5-<W8U<DQG2&5P4V54
M=DM34C9V1U!-,&(S3VYX2DIA3T5H.4\U:TMY)B-X03M-655P3S%F<V]/86LP
M2DDT;EDT9D5L='-V0T\Y34Q0.'0O2VY/15AN;D14>4HT=FEA1U-(:$1)+TY6
M6GDX>7E&14E5:TMN23%P4E(X)B-X03M74D]A6%-*5'=$=EEP-7 P4%1T2'9O
M-V5W,5=,5C184C-.>D)X0V=P4$Q%0E)8:U!X2D=S9S553D=',V,R=VM:1&-5
M=VM+4V),1TQS)B-X03M69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%*=%130S@S
M<%=%9G1C82]V;RLS-UAY*VYT:U0P4T4W.'=F.$%+2BM6=BM-3C4O,49V:TEF
M)B-X03M63#1-:GE$1SAT64EN5%I96611='!:>5)&2$ER3U(Q;T18=&U0<6]3
M;&EL1U!->$QK85-C65I9>6PY26M#.65H=6)H.4]K=7A!-6=L)B-X03M73U<Q
M63!:5FIK4599:F1Q:T55<6,T3V9:,E=*;VIL>F4V:#)X9VYD4SDQ+UEH<FY5
M9$Q74V%6>7,P541X4E=P.5 X065'3559=6TQ)B-X03M+.'1U;552=WHR074U
M3U1,530V2DY61W8P2T8S-7-T<F%6,CE3<6TW9%EW,GAA0GE/5&-!2V<P3UIK
M3W@X.'%Q2C-$:%0W9# X06)M)B-X03M,:69S6%=V;4Q315A4<FDU8C%'+V5X
M4U)K2T%I8VU+1E-2,31G1$EN<WI0>'EG26YI2% X9D9N2'1F5&Y(2$E:1&A0
M23DS-'%K:FXX)B-X03LS;3%J9VAS=W-A=VU3<3<O04)C:5)Y2C8Q2SED.#)U
M;#=";D]D-7941W9+,U1A=C)I:$-&65!5469/=FXK<&IL,'AU5V1Z.70R-4@V
M)B-X03MC-B](<#1W>&E%9551.%!K,55P-5I:2F,U17),6EEY2&HS32]-96U#
M449P,%!+=5DP>%)E:#=+3C1V:BMG2VIO1$Q,>DMX1F%N:4ML)B-X03MA,39+
M4GEY3',P=G5Y,41V=%5B9E(O6FAX.#-!,3,P+T9#6F4V<#)+=7A63V9,4&U&
M=$5L=C(T4WEX,SEN2EI3>'A496AY5U)K9C0R)B-X03M#=7A53D=#5E5Q5#0P
M<4183TA&5$M*<&Q-;C5G*U)O<D]30WDX;5%6;6A:04QQ4TM8,%I#5"LX4U51
M2DTU<"]--$$V04%J:V%V0FYE)B-X03LX;5A'3S5:4"M:;6E88W=E.#AR5VI2
M4GE+,$5-2719;%-)3'9%0CE68T)E6DPO0T)V<V%R<U--0DA)+VHU<GAJ=59D
M4"].97=S3&DY)B-X03ME,SAT,C8R.7A+2G)3,#E196YB=7-T>59:44EV:4MW
M6'-K4V1/3WID9TU",#506#AF9TI'5'E13"ME9DLX8W-45TAL84LQ:F=L37%"
M)B-X03MP65IN25!O;F<P:C(S27)Y:%DW54DU54)(>&-P949,<DPX9DY(1T\U
M:C-M9E8W2%8Y8W5D4G-D3F@P:3%M-&5N<#%U87A2.$DQ43A3)B-X03M14'1&
M95(R-FY,25))1D4R=TIS<%9K,$]X5C)+=7A6,DMU>%8R2W5X5C)+=7A613)T
M9E%V2V-Q96E+,$%)<#8P9C)Q.4(X=2M24%)))B-X03M4=GI"+W=!;VXU5R\T
M=S-N+U57*U%H.55V9WE024UB>3%G<C)J5V=C:31H:VUR44E)<$9J3F9F:VML
M8VE5:#=69C-&=6YL4T]&-U-D)B-X03M:2&IT,&5&6E9"6#1A<U W<F]V1VY4
M3EIP94AX:'50:7DQ35-C6DE"4'59:%!0<$-Y=$-K1GEY3%%%+U=%;U-/+W=$
M8S5V>FAS9VM2)B-X03MS951P234V:5%$2VIZ.5@W141R3FI!=C%/8S9896U&
M9WIH>$UP2$@T9FE.24119E!-1$IR35IY0T%N2&EI84DX+VTW4$@R9FQJ:4UZ
M)B-X03MJ;G=Y:EE0;#,X=&MU4V92;D1/=&QC;5)D<4,T42\X04UJ36MZ,G-K
M6"M03GA":3E19T%33V8T,E%P;3!9.6)7-4YF*UAH4"MQ1U5B)B-X03MU6'0S
M2WDS3VI,26XK:3-.3TY0.395.% K34=79WE"1R]W0U!M,%-H17A/,U@X9$<T
M6CE$95II,7)C:6]04S14<4]N*S9C<&Y:3G4R)B-X03LW3$EI5$%);' Y1EI9
M*U9H3T9467-,:$MT=EAC;4$W-5A29'I24RLK;3!-<WA7,'51=DE52#%L2SE$
M+WA2:D,K2G=.9'E&;U0Q9$8O)B-X03LU6F)N+W!*:B]W0W%'6%585S=/.5A2
M9BM75S4O-E-9+RMQ1TY&9&YE<F]V+T%#>3-0+U-42"\Q47AO<G,W,61&+W=#
M5U<U+S9362\K)B-X03MQ1TY&9&YE<F]V.$%Y>3-0+U-42"]W0E5-84LW3SE8
M4F8K5U<U+S9362\X07%H:E)86G=K,%EM9W1,:VYR=&-*,C,O,WAJ=75Z=E8P
M)B-X03M8+VQL=68X07!*:B]!3W%'3D9D;F5R;W8O3$QC+W=$4U1(+S%1>&]R
M<S<Q9$8O-5IB;B]P2FHO-F]9,%8R5U-Y8559,D56=D]K;%!H)B-X03M:<#!:
M469D4D-T9G9X,U)S:$UK:#)+=7A6,DMU>%8R2W5X5C)+;VDR0VU'-W)3;VE(
M1W1A,3E63VQ/.5!(055H;$US;6Y2-E@U2695)B-X03LT,6PP-51C1SAJ8C%!
M1V@K=DXV9U!P1EI0<S$K>6$U5'9C<34O<UHY074Q4E!Y*VLX<E13,C!K35AM
M07)B>7=7.7%,,$E'85=95%%T)B-X03LY6E=65S11;4UL:$EV>&)$;%%L;5!(
M>&(X=F=P<6MM.&Y7,7)C*UDW4T<V:DUS6DQ%4FAU1E=64U(X6&%L2S5I9'):
M<#0Y4$M53FIT)B-X03LY-VXY:UE96DY21TUX63,K-39D9#9I0D1C,C W9TY,
M1E!B>7AO+SA!=3)&96(Y:C%"<5 Q-7=L4TUU3'IV-UAU-V=)8T$W<2MZ;#AV
M)B-X03LR<4YP1D)W=5)(865K='A$0U960VQ/1$9D-FYU,EAA:E8U<VQ#8WI,
M:$HK8E1P9$AG>#)C8T)(:4$U9%)V*U!.1C)S:3)S6E)*2C!#)B-X03MY1T=/
M1GEH;WE-1$=J06=B8V@X4GI(>5--<$5N;61Y-4]/15EW06IY1D%F1&(W;&$X
M;G9%4U8W53AP22M6=D-#67='855&,T))4%-O)B-X03M.1&M"6%9M95<R-39*
M8D):27(S0U=-549V2&1S23=I1&EF:$59<5=,1&(T=6U:1U154VU!2D5N:#5.
M1U!4>&=:8T%!-'59*V%*=$Y/)B-X03M-0F1B2T\S="]54$1G<UI(-W@P-&E-
M;G@R-FY)-4Y24$HY6FQ,,VQN:C X35%004EX2&M%;4AK,U(U3#93-%=+-'5)
M0T]->#5O<%,T)B-X03MR5F=G54-Q.$17=6)'2&)/94]-4D9B9F,V,E!9,DAX
M-5I..3=36'I";TYN66,U3&4U2E%Y17A13E)I23)&5G%Y-U9Z8F1N9'-3>7E%
M)B-X03M*4BM)+U4P87924GAI=V9G>&955$I*5U9Q9%9886<V2E%B1#5:,$5/
M8GHS84@P:C-O1$Q8575X5C)+<VDX:B\T9T]Q6$U7:'AV3&,S)B-X03M&;E!A
M>7A*3W1V>6IU5CE!07-Z2GDO95-*4D]R3E%$9DMS=%9U>FIF4FQJ86LX<U%T
M=$\O3&U33WEN155L<E<S1GAC5E=S-W5T=SEO)B-X03M78U!'=%%P0E5+3VA"
M87181#-Z+T%".#)6*U-J8V%X97)O=7!A:"]H2S%44F1::&=J<U-O=&E)0R]W
M0F)I4U=-2D5'37!K9VU034MR)B-X03M+1G!52U9X15)92$9U4#),9FMM3VXV
M*TE8:4YN*U=Z1#!)5E-E24M7.6%*9U=D5TPR>E-L6&IU1DHT='DT,'%X5&))
M;4AF4#AF3DXK)B-X03M4>B]Z5')M;C9Z9E(S3FIP8T]K4F]J<3%T8CAE0DQZ
M>7EG:FEK9C)5;%=-8W%M:6IF<TUI151%8FTR=5)T2G-S675X5C)+=7A6,DMU
M)B-X03MX5FMN:V)14$PK<V%Y.6XU:#%184I9:48R5SEE;$)+:DM!:$1D86AJ
M<TXX<7EZ249X1G,T9TAM;6LO-68V16QV9%AI95IR1F]&;EI,)B-X03M',FIN
M=%I,:5-)06YM-&5A1&A19TPX44A,<71D9UE$2V4T<#1",W%X.&AE4S Q9S)4
M*V(W6G)74S!.>DAE>$)'16-V<4M&:&M$4TER)B-X03MT>$IR4GA4<E-N5CA7
M5EAW<G=$=E=A4BM83V=8=6U1,U9Z-7@P>7IU2F]*6G9Q>E!'4VI):75S5&QP
M63)$3E9L*W@Q07!Y<65,3$U1)B-X03MF<$MI03<P:SAW95=T33!R5&],:418
M8E15-W53-&MH;'1B4W)C23!J:F1:95IP54TP:DPY:V9:-S<P;D-:2C559WAR
M<6QL=$)/=&QD)B-X03M41DA71U-+:5-F6E9I2F\V9T4O87 T1#4U36YD04=Y
M8BM94"M55#AR9CA98GHO<4QF25$K<5AW4V5163-L<D)'-E)$<50S:V(V9DA+
M)B-X03LX,&)$-&]K3&QE5S(Y065U534T46Y!>&YU0S(T8VLT4T5O1W!"-TQQ
M=6=A<G Q=$AD5S!%:DI"3DA*-E-W<WI68T=T4V$X=6YF3U=X)B-X03LY:E)Y
M-4-"3&A"1#!".6]:63A9=4A%460O4#=%<VHQ1%=L*TTV5DLQ2B]6;S%U5#0P
M2%0S>DEL-TQN<&MI>$AT94]U2V8T+U0K3%-7)B-X03LK,7IZ4$)C26EA6&-C
M4WIY3%-.>'@Y4W12<W5-=EIY36%">6(Q,V9T5U!T5$]6:UDV1FYM9C).4'(S
M;45I5DI.275#-5965B]4879W)B-X03MM;R]9>4UV6GE)3S)4-U R=&MF86E:
M1FY(4CDO-T5:1#5K,6573U@Q.4IM:'5*<%DS86-1>49U0T5%<E952'=T43%'
M55IU=UI24&]K)B-X03M*1#5.*TPR:&I)97%*:$PU-V9*<30X=V%V*RLY3%1R
M<FLQ-38V1# U4V5)3WEK;&%%53(S>4U/=UIK:7I%0W0R5U0R:&=);6A):TA:
M)B-X03M,:G%8;4-#5D=T-TLW:EEY35IM.4M244)*.$QD0G5!37E).6AB;FEK
M2S95-'@Y;TPT94=*<VUZ9E)$6#ET<DYY;G!065A,0D-3<V]I)B-X03MK<35R
M<U1683!P;7<P=EHR4$10:45R,F)S=7$T>%)393@P3%=05&%T:F-L-D-G.48O
M2#5:<VA-5TXS5F$R:D)!9F]05W8K<F9C+SA!)B-X03M);50K;5AC63<S53A*
M9"MG.6$O-G0Y>B]!36E:4#99.%DW,313-SE"-C$O,6(W;B]!2D5Y9C!X-'@S
M<G=L2#9+9DXR:3-:=DY.=&)I)B-X03M#-$MH95IT=E5O07EU0T)):F=-<F]R
M2W<S0D92:UIC36A24T%1>4=(.'=0>EIJ:'0W9#5,<31T-U)':G1O2G)53VEC
M;VI&>6]9+VE+)B-X03MH<6IL6#1T*W56;D9J6F-5:TAP=FUR.'I.3G-B0W=T
M4')+,F5M4WE4,E9U.6UK<4I*2W))-4EK:69N54]D;7%"5V\S=VU'36MN=CA!
M)B-X03M.04UL,6XU=2]-,GEU>&57;VUH=7A%<T,S2S)-6'%,1VEO<7%R*VIY
M54%23# W,5!5;7%C94TW9G!7-4U:+U%M=&8X04Q"8R\X:5I0)B-X03LV6F)X
M:G99.$ID*V<Y82\V=#EZ+T%-:5I0-EDX63<Q-%,W.4(V,2\Q8C=N+T%*17EF
M,'@T>#-R=VQ:3'!/<7=X=$I,6E1X>'%+<S=2)B-X03M/<6=E-4EX-&@S;V]O
M5$I)9&ER,&959GI7,&)5;'5J92M725HU<"]1144X<WE3=D(V2WA+>%5Y=U-%
M.'924$9394%$8U-R2T%->&\V)B-X03MC:FM7,#5,-D]U4'I8,%=9>D=4>7!A
M5'1,9%1886DU345I;S P.$5P;V]T:S5(:F(X1TPQ0D1%04MN=T9';E X-SAF
M3F9%2&-K*VPK)B-X03ME3D]T<E-/,W8Y2"]!16Q(2$0V4U<P<WEI,5)X2VMN
M<E)11T9V5&1G<$1L5RM+=FA65$]723E$4T).17 K65=H3&(S;&9+;&<Y-V11
M)B-X03MX<$9C3VQV=V=M5&M8;&EH5S-64#-J='E+4'E!<'A7:3=#4&=N*V-6
M-'@S37$P-R]!2GE&4WHX=C)':VIY,T=8<UDY2FIA.%,U2U-3)B-X03MJ4TI)
M-4(V9SE&=G0K:U%0-6$O=%5Y<5=K<VLS,R]A:UI.;4UF;4@K6G%E8TQA2T9B
M0V94:$1+<G!#=#0P,75Y<7)Q2DIO,FE6<&)K)B-X03LX*TIN6C9L44%26&9,
M8T]$9U!/+W@K3FM3;F)$3%IJ.5AU;$Q$:C9A<T9*27%W:U%65419;6A06'18
M3&EW1$ED5G1,=3@X=6558E<P)B-X03MH:W5B<65/-U-'0TI3.&IU,3(T0W%Q
M9VQI9D%:6$5G4VQB23AG:T=O-E9Q96UZ3$)Q3FY06E1S=DY9<FE.-&Y+:VQE
M459W<'!64TLU)B-X03M92D$X;4I$=$U2<$Y3=%551FDP>4%+3W!Q=WE'85%J
M06LX9T-Z>%%-<$-),TI,,F958C)/-EHY3F%-1TU/1W5%:W%G84Y.>'A:9"M8
M)B-X03MT;D5Y-U=Y=VU:67I1-F)F<F5X=SEG-%I116-S8FQZ3S5R+UES96TP
M1S-K=5=70U@V=$-84F94=4MI4E-W2DHT:79W-V)B-75T2#=5)B-X03MM3T]S
M=TTU9#1R9C,O<T1P=&(W2'AN:W9$25%H,T=Z6'4O8550<5!K,U-*;6HO,'%:
M2C1L;5=2=VQ58WAD3TAE;2M9;50R:WEY;51W)B-X03MJ:#9/9&DY;&--24-0
M1DQI-FYV4'4V9DUO3652:VQE4&AE2GHY2#$U,6-&4&=5+UI3=E9I3VQC>40W
M4T%G*VEJ,#-V9GIC85!S<UDX)B-X03M)-#=(6&%T<C9*;G$O;$112$IS<DM"
M<DLY:UI*27!:,V-X<$-2,6-H;D$S0D@S6G)T3C(S;D5H3$I,:6@Q1D0Y461N
M<75W=%!+0FIJ)B-X03MJ=S5/:'52+U-F-U5,+V=05&]B5D=U<FED<FU15&5N
M-E%5>'4X67%/3F%K:G8X<WE**S!E47E01$5C4&YZ8V5(<WAI14%*4VQX5C!R
M)B-X03LY6#EV:S=49DIU;D]F5'5F.4QN=3142F)P0WA!47%#5'DK>G9T6$1R
M=F%#8S8X26-(9F4W1',W,F-X-"\W-#AF.#)T<2]B>59B;GET)B-X03M$8U$R
M9W1*>D@V54I13$]V.3=/=C)O-"M0*U98<6-J9S=F:T-F148Y,61!-V%F6C1O
M8TIR.4HO2$Y"-FXU2V=M=4I5=#=N,%9T-#9Z)B-X03MV8T-G.54Y14A!8DAF
M;V-L:#=F4$]C9F1W+W1C9E=D:T-9-%EY.35,0TQU>74W4U@P<G%&-%I#3U%7
M4E-P2VYO440R>G X3V5'4U!&)B-X03M!9V@T-TYG;FE.5$)I9DY1>3%P9&EQ
M66%.<$1A<%!00VQZ1&).1&)Z6$E-+W%K3TE%36I);G!*2V5:5E14;%%E*U)L
M2VMG5VUN+TMU)B-X03MV3TES,G9(<T)&0VQ0545S.79&26ES,T%/.%1Y3$EQ
M5G(X6EAJ<U179T]1.&%..#)8059Z9FPQ-7)71%5*1W0T9S)L>$Q097=I-&=,
M)B-X03MR17=D=5%!8V=M:UI004AM45%1<$)R:C0P9'9.94%Q.6XK5FYN931L
M:6EB5"]Q.&QW:&$R:FUK:5-34C9/5FE3371Z36I'32]$4V]()B-X03MX1VDW
M-$1N:C-R=T9).6,X=C9V;U8R='!Q='8Y5W571$XV6$Y(24-3=D,Q941.46E3
M2FA1-S=E1U=2;4I#=WA)<$QS:V@R2W5X5C)+)B-X03MU>%8R2W5X5C)+=7A6
M,DMU>%9&5VY,-G9E,')4,%)Y;U%"5#%O*W1E;RM8-G-I96E1>4Q53#)A=S!,
M>6)F46A43F%I-6YJ1$%L4S!D)B-X03LV>D-O0D<Q4FQ91FU1+TA*;51S16LQ
M6%=P=%)T-T-#4T-'1DY0:$U%4FE$07-R4TY+>D]76CEY.&I(86<Y<VY'3E=X
M2G1F-5AN:F<X)B-X03MW5TTP:D)54U5&;6)O3FE/*UEF86-$3%1Z034Q,&,O
M<W%9:G%91U9!6#%E<5,S54TP>G=I84HP;FQA6F962'A2;%=Q4GA"02M/=3)E
M)B-X03MF.$I!=6IB-D%*9VM!145)<U1,4$='2E-+4U%R4D1+;T-40E-&9%%A
M;F@V9E56-C5"<TAE<VQL;65-=6952652,7%:2V-K1D)C<TMG)B-X03M$-"]B
M1F5F-#9/5V%Z959L-6ET>D,W>4]:5DI-2T5"23EX<U(W665%;S1H9C0O2%92
M=6)7,$HY1FMK9SEE,G)C>5)S4S9)2VQ),T1!)B-X03LO86M&86Y#0U=-;V=N
M;#A63S=T=S%R0F)*2TE9;S%$,TQS=$96,$$T4F\O,E-7<&AI9#<V<DE':$AK
M0E<O=T%K3D9*67<V6D-0<DI#)B-X03M7>#EC,CAH04QL>GA.1RM';CAX>593
M37583G)U35EJ9EEC,4=#97AU-315=&IY94-D-41"2S1%84I886=(13AH.#AT
M>31-;4UE=4I&)B-X03LK5$A(3TTV-%1D1D-09%-88T4V4V-I:7A3339W1W!:
M,6QO<&-!3G-&*T=U,WIX14%.+W9A<%I$2W=E5R],,W!"*UI.>$)0<E5,45A"
M)B-X03MU145#9W5X0F%T5#%P;E1E>G-#36-R1F)V3F4P57=C:V%.-V9P66QN
M4E!/=7A63W9+,$]J4UA&."MR6&MT;D)&6E1.13!$:$I*2E=P)B-X03M'<UEQ
M<CAG=V,Q5&%O,DQ+2VM6-4PR<&Q'=7)-=&,P=5),*UHT+WI*6%5B;4I),VMV
M2'5*9TA#5DUA>'8V<W)U,&)+9&EO0S=%2&9+)B-X03M9>3(K:6UD96)6>#59
M='9R,3)K9FXY3'!,9VQ*<'A016I4:&)I4S-5=C8Q,T=P6#!L.5$X,C9.4F51
M,TM*-V94*U!K=&5B:$M)8G95)B-X03MD369Z<F54=F(R>DA4.5%I,4@P-UIN
M=#=Y4TU*=UEV>D5K4VE33E))=$-A,4EX-D$X4#),.%=R:GE$<"MP-FM%=2]0
M,6A08E<P5&QR)B-X03MY.'5);616.5=9:$E53GA)6#5S=D]G8CEU<'A'56=B
M4DMM4&TX-6YJ4T]E4TY*0DMI37ER2W111T%.07=R=E$U:VAR2VYH43=&6%EQ
M)B-X03LW1EA9<3=&6%EQ-T9867$W1E5486ES1C5T5VM)+UHU52]F4CDO=T)N
M-2]2,WE*-DI#9"M94"M55#AR9CA98GHO04MI,WE%4'%L.$=2)B-X03LU0FIE
M5W-&93)7>EET.5IL:VE!<'A-8V%Y5BMF2C0V641A43DV='IP8R]L5DQT<$I(
M639E:V=:;T5*0CE.5W)4,4]T9F9.2BM8:FMY)B-X03MC16AZ3D]4*V%N:4A(
M13%W-W-+-39C16%56&1W67EE3$PV16162C-(*S=F8F)-,R]!14]9941H+VDW
M-RMZ;%18+V]P>F-F1B]$6# Q)B-X03LY=#-A0S$O54QE06%F-D8O9%)W>3AG
M9CE(:EIU431H=V55,V5T9'9(25,W0W=1:U!49"\P:C@R8U!A3%5Z:DPQ5E@Y
M165E>51P9E=N)B-X03MQ37<Q0S9Q:45)5&)21V=*0C=Z6F-/>F-*0DA!2SDU
M87HR<&Y":65-,WDU0DA4*UIK=6)L-5=V<FUS:UEJ971T1V1K<5(O=31E3UE7
M)B-X03M(<TQ#0E)&.65B<TTO=$1N2G-(:'9B;#4O=%5$<C!B,B]W0E=K,4,U
M84YM0EEM,FIR='-/:SE/;5=$<V)!2FE1:GDV6',Q4S=C,4)X)B-X03MM0FQZ
M-C%U,DQA835U<E-Y:VXQ02]784-'2#9S:48P<G91;5ED;#9N04)P8V9&:T%H
M='I.,U@T.&UC5'$X:S19-4=E+TMX5FHS+W)6)B-X03LR9W-T375P:T5T,TA*
M5F\Q-5<V17%1,VE*-D5I;5A(=W1404AA565F4#A&,U W>DA):7%+=$A:6$U7
M;#--.71,9'!%<D9B:#)T;RM2)B-X03M,:6]!5G O<#)'83=59FLK2TU*5F94
M8R]E,D5A:UDU4VE++TAC;U=F:T=W<%I4,RMP3D)B6$QL6&I-87!.2%%6*TUC
M,S0O8V-D5#(Y)B-X03M%6$A'3TM1-B]W04QG-F9S0UIQ5U$X350P+VDK,%5L
M;6\K6&1*=$Q#3S@O4T1.-FLX:V)13$=':U9&2D-.=7E"=5<S8V9Q<EIO93$U
M)B-X03LU<V=G659T>G9Y871D,E9$1&I--'IV9FPU6#DV5BML;W8O3%9C+SA!
M4TY(+T%.5C@S9&PP;7E,,'I23$Q5-5IO<E,U;%HT24I,;5%3)B-X03M*8E$O
M=6]6-5-&5$QC;T=)6&9I=%=065I'56E/9C0K>%%!55)&-5-U-7)28GE'>C%A
M4S!D>$=T>6UN33!:8W-&0VAX3'@U8VU!<#1N)B-X03M"-&Y48C5P-%8W95,W
M.6)E-6YA>C%267).0DQD1G)#:&II4$UE<39M8FM)-GAS0SE/24EP6$AX0C5F
M3F5&,6PU379B,656=&$V;3AF)B-X03MP1V-39E5A25EX>6]W67I54$IO,E9A
M9%=&0G9I8VQD,WI8:%%..7!&=%E33$9F1RMT2DA5<VE4,EEJ67%'6D-11VU&
M4GI2;"M927E1)B-X03MK5'ER-6])0T@Y3%)F*U=Q-2\V4F\O.$%Q=FAS<G,W
M,'1&+S5A<FXO04M2;R]W1'%V:EI86EI,2'!1:EEX6$4W>54K1E=G4E9*.3)%
M)B-X03MZ52LW2&1'>45Y4TA9<3=&6%EQ-T9867$W1EA9<6E,67%)8G-%9T5X
M04M#>$)*.59$<T(Y;S W2#4Y<T)31U5Y=S9F4'!F:VE$56U:)B-X03M.4&Q.
M>$AD>4DV>$US5%AZ0C)$=7)Q=$%A,4MN2V).>7(X8DTK9U-Z>E1P1VE715=L
M4S969$,U5RMT5W5,<%!8:6YA1U%Z>4)95SE.)B-X03M56E=315(X=6%I<E9)
M*T=M5'AY2G4R36=!:SEP8G1C6%550T-R4W5Q059!-FUN53=933)146=:2&],
M6C1-4GE415(Q3E!93&4O<S=+)B-X03M"<D5-.%5E;G=W;3--<6QZ-FM3;6DQ
M030P67(Y3V5E86I,:WI3-'!B=F]7;7<T=%!%=VIT.34O2#8P1DI017)P8S-6
M:6Q'4F\W9U!X)B-X03M*.6%I>6)I=&%Q=5I'2%<U.&-01&AK26HU9D9X."MJ
M,#)79FDU36-42W0W<FY1-3DK=U%D,G9L>5<R:6ML<VI),%5&5W$U*T-34E-Y
M)B-X03MT461"=#!Z2FPR=')*5410;#5$<#A(16HR4&]96$E9*UDS,U!8>78S
M,5-N66583DEH=FMA0S%K=7=%36)1>D5&6&Y.1T-!9T%6-%90)B-X03MH-#1C
M=F)E<&Q'<D5B-FIN4V-8665K:D]W1$QH-E,U6# K>2]*3DQ74%9#=&Q.1TEV
M<E9N1DML=$=V2#13=&9T.'1T;WI48DY78W4X)B-X03MT+W$U+V8X064W8G=:
M5DAL-F51-W5N,TMC=&IQ9DLP=5)$8C-3,DM'9'EO1$AH33-.:7=*2C5!-TM&
M.7-N1%!135%42&DR*UA*<7E9)B-X03M4>%)K44I'3FXS6'5F=3)P4FEA*VMK
M=&55<&EM=4E:871*56E/2#%#-CA"5W4W>#=F,'E"04%09#DW3TI-:41E-78T
M0F1';#4V55DY)B-X03M/4F\O<E0S9%A)5D=I255L:DE11BM,:C!(>7A.9EES
M8B]W0FQF-%!*<35E,G4W,C9U;U$Q>$)(8DDP=DUJ:4=505)H959'26]X,BM7
M)B-X03M!5T%!9&IA6F-*:U1(8U8O6BML3"]-9&QO:VM6.4Q*<54P:WER2%!B
M1TU+26UA5%EG.&Q,-U4X8S)F6BM82D-5941'1'97.2]R<C=()B-X03M79&\T
M.&,T:WIY16)8,"M(4R]T965T23=!0FU*0R]:0DY12S<W6C(T041X4FM3='=S
M5U-E479,=7(V.7)%.6YP8W)1>G):,T1--GAM)B-X03M5:U-*-D-2.%(P.6%7
M6DEI+W=#>'DU9'-Q>7I%4EI:>$),4$QR4U!Z4S%,,&)O-G!"2S$W<'DS9#!'
M<RM%0FEG=5=I5TI&4S$T4R]B)B-X03LU9D-P16Q30GHR<FII5TUD3W8T-G1L
M4U%W.',O;4DU,4=A-#$V>&EB57)',W4W=$%P85-A1V%/5DE9>$A(8FMO-$5:
M57 X3$1K3FEE)B-X03MH-#1B8DA:1E-2;&Y.*UIE<7HR33)K*UE9-6I&1EIY
M2F-89&Y$2$I&4% V3S!F;W@S5&9".6111U%L4W<U0VTQ0T1W1&U0>"M!;C%(
M)B-X03MQ>$AZ=#5F.#A.<%58;5AZ3DY#+TLT87EI571'='=X;&%7-DUP4TY6
M-4DW3WI">C$U0VTQ375X5&AF1$9H24AM5T9:93%U>%8R2W5X)B-X03M6,DMU
M>%8R2W5X5C)+=7A6,DMO<3!$1S-V86,V0T5C=5!';%!7:BLS6&5L9C5D-C W
M5GE*-DI#9&594"M55#AR9CA98GHO<4QF25$K)B-X03MQ6'=:2&M'3C5A=UA2
M=3AB<39-5F145E=(545:1U52255D=U=56D=*<V)%4%I*2'8T9$-T.5)M36$P
M1G)+675!-6=L86AD>'949D]0)B-X03MX9&A'951H174Y-FY.-U1#14])=U!4
M<6PY-7)44GEG<D1%6'0W:WE.2558:U=C2#(S;T)M9$@R56Y:0GE$:'(X8D]$
M3#)Z>%5#35HT)B-X03MR,W8T-S,S+T%)=$HW;GI/8DQM>G=I5DQY-3EE4D-!
M0E%-1%-L3GA1.4UN;CEM945#<VTY9#,W5T]L.7)/3U5G8V9P2G9N,"M33B]X
M)B-X03MR<'%X;3E22UA(,6HQ5F@U1&EO-#A31FHW5C)Z5'DW1GHX66A7,V8P
M*V)V63EU-F9G.%,Y+W=#8C$W:W O=T%A6$U&>$<V<'E66E=N)B-X03M113=!
M3W9(:GA)23DX,F@Y;6%I3&YV6&0K,3%%4&%S>6M3265K4S9N>2](5E5F>FI.
M2#9D>D5P3&5P2DLV:VA19E9.94926%IC:U!:)B-X03MK,6-P:71Q,EEF-DMX
M>%9'17)S,UHR*TA.46HX=U<X.75X4'<S25IM67-35#AD94E",BM%13$K95EU
M5'-B3$1)0D4S2'8O5TA986)T)B-X03MF2&UJ=4MN=BM"-4HS8V59;TQX8FA6
M=49H=#1K:5-/,D)00GA'4T-%<58T:C9-=THY;#5S6D9X379-8G4Q+T]2:T12
M-%(S9#9"1V]A)B-X03M8=U=1>DMN<45X3D%N1D8T06XT:C$U9EE79W!K9GEE
M66,T4RM287IN>#%D,$\W:S8K=CA!>7)D,W-9=59H93-T-TY5:%97555K.3-3
M)B-X03MN27(P,WI*=UED6FEG5$1I1GDW=C!/3&UZ85!*34-F0U%).2]8,V]+
M3'DU-5)7-G-J8U@W:4,T9SE39%$P631Y2&HX2VYW1E1M9"]+)B-X03MM<DU3
M0FHY45!C9E!O-%$W3#!9;$5Y;G-15#E1.'5Q5BM92F1!97ES,3 V0EE:,%5R
M37EV>DQK16IK,VA837IS,#9O-4I(3#E0;BMH)B-X03MW=3!V>79H>$=)1&E(
M9"ML43AU5"M7-%IR,#8Y8GI834PR8S974W=F85<W6F%1>4UF56EO<71U9G1E
M2$AU3GA-4S9/;49D5U@S,VY0)B-X03LX=E1:,CEL<&UI=F)7851Z,TIH:VA7
M9C U<')74T%30G W:5EY<6HK:31I8FEV=T=P3F-P1T]D,E-Z-&<V=W90>79U
M<F$U=C<S4W93)B-X03M3,450<7%(2WI81&TX57E'2S-7.&@T8W)C<T-Q2558
M<%9307I*1U%B02]J-4PV56@X>39J-4)U9$]%96=A6%!9,W%V05!5;%HS1$EI
M)B-X03M3:5ES5VYK2$M2;6I/>54R3D]043)117=D>7AK4C!9=FQR0C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W(T6G!O6D9L:&1O-48K)B-X03MY-D5Q
M=RM21T%H2V-A9#4Q.#%A9%IP6E=7<%11,FM:6F\T45%6575E5%5Q1#%/*U%/
M2TI.:TI%>454+WES8GIV+W="6&5B+VA0*V%C)B-X03M(9W<W:SA:6'@O;5@U
M.&IR-F5T6$-6-CA3;R]5369!:#-,>&QD4#A!;6HK654X16M%=78S8E)3<55D
M961+<7=O4E5B.4U!=U%(4F5-)B-X03MP4V9-+VU1.617=D0O=T)(178X07I6
M;&Y!3S5J83%V369M0G9T86YD=%1P5V51+SAB64]#4&-T;'(O14=V9CA!5GEU
M=BM2,&XO3E=0)B-X03M"2'54>$9X.'=A.&5U<%A2+W=#93!N+TY74$)(=5AI
M3'8X438O4VXV5'5Q94AR>68X,5DX164U94EU2&U$6&AU3E-U:"]W03EP4#A!
M)B-X03MM<DAW-#EW6&E093)0369M159P<6PR2S=':SAN+TY74&AX-V=N>$ID
M-U(X=S8K4E$V;&1%9CA:-5 K87-F1&HS0F5/6&5T+U1M=&8Y)B-X03M80S4O
M-4A39C%W.$$W:V-29"MN3F$O-G5&>B]Y3VLO<FIW1'58:4QV,#5R6"]6=W5F
M*U(P;CEC94%D>3A29"MN3F$O-G5&>B]!36IP)B-X03M0-C0X03=L-&DW.4]A
M,2\Q8TQN+T%*2%-F,7@T0C-,>$8S-F,Q<B]Q-%A0+T%#3VLO<FIW1'58:4QV
M,#5R6"]6=W5F*U(P;CEC94%D)B-X03MY.%)D*VY.82]W0W)H8R\X:G!0-C0X
M03=L-&DW.4]A,2]W0EA#-2\U2%-F,7@T0C-,>$8S-F,Q<B]Q-%A0+TDV5"MU
M4$%/-65)<DID)B-X03M7,5=A3F\U8C)E4TYH4FMA5C)5:C-"3U!#3S5&;#EI
M+SE9-R]!4&9O+W=$8W-Z5"]!3#<K;#ER:V5N>60O=T)9-R\X069O+SEY>D@Y
M)B-X03LY+U,K,694-4\O-G@S+S<Y2"]U5UDO=G8V6#)R-F9*,R]73R\O9F\O
M.7EZ2#DY+U,K,694-4\O-G@S+S<Y2"]U5UDO=G8V6#)R-F9*)B-X03LS+U=/
M+W=$,S90.$$S3$UF,S,Y3#=6.5!K-R]R2&8X03<Y2"]!3&QM4#<W*VPY<2MN
M>60O,6IV+T%.*VHO=T)Y>D@Y.2]3*S%F5#5/)B-X03LO=T-S9"\X078P9BLU
M6FHK*R]P9F%V<#AN9CA!5T\O+T%(-E O8W-X+V9F,'9T6# K5'8K<V0O*R]2
M+S=L;5 W-RML.7$K;GED+S%J)B-X03MV+S,V4"]C<W@O9F8P=G18,"M4=BMS
M9"\K+U(O-VQM4#<W*VPY<2MN>60O,6IV.$$Y*VHO04YY>D@Y.2]3*S%F5#5/
M+S9X,R]!3R]2)B-X03LO=T,U6FHK*R]P9F%V<#AN9CE9-R]W1&9O+SA!8W-X
M+V9F,'9T6# K5'8X07)(9B]!3#E(+W5762]V=C98,G(V9DHS+T%&:G8O=T(K
M)B-X03MJ+S-,368S,SE,-U8Y4&LW+W)(9B]V,&8K-5IJ*RLO<&9A=G X;F8Y
M63<O.2MJ+S-,368S,SE,-U8Y4&LW+W)(9B]V,&8K-5IJ*RLO)B-X03MP9F%V
M<#AN9CE9-R]!4&9O+W=$8W-X+V9F,'9T6# K5'8K<V0O=T1V,&8X075762]V
M=C98,G(V9DHS+U=/+SA!,S90+T%(3$UF,S,Y)B-X03M,-U8Y4&LW+T%+>#,O
M=T,O4B\W;&U0-S<K;#EQ*VYY9"]W0EDW+SA!9F\O.7EZ2#DY+U,K,694-4\O
M-G@S+S<Y2"]U5UDO=G8V6#)R)B-X03LV9DHS+U=/+R]F;R\Y>7I(.3DO4RLQ
M9E0U3R\V>#,O-SE(+W5762]V=C98,G(V9DHS+U=/+W=$,S90.$$S3$UF,S,Y
M3#=6.5!K-R]R)B-X03M(9CA!-SE(+T%,;&U0-S<K;#EQ*VYY9"\Q:G8O04XK
M:B]W0GEZ2#DY+U,K,694-5 O.6L]/"]X;7!'26UG.FEM86=E/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YX;7 N9&ED.F0S8S@U,60S+6,U,#DM9C@T9"TY-#-C+3-C9F$P8F1E
M-C4V.#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A
M;F-E240^>&UP+FEI9#ID,V,X-3%D,RUC-3 Y+68X-&0M.30S8RTS8V9A,&)D
M938U-C@\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^=75I9#HP,41%1#0R02TX0S0W+31%1#(M.# P,BTU
M-#@U03(R1$5".3D\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I
M=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#YX;7 N:6ED.F$Y,F-F,3-A+3$P93 M,&4T-"UB,F4R+6(R-#0Q8SAE
M.&,X83PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O
M8W5M96YT240^>&UP+F1I9#IA.3)C9C$S82TQ,&4P+3!E-#0M8C)E,BUB,C0T
M,6,X93AC.&$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HP,41%1#0R02TX0S0W+31%1#(M
M.# P,BTU-#@U03(R1$5".3D\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T
M4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&
M<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z,3@W9F4P,&(M-3%C9"UF9C0Y+6(S8C4M.6$S
M9C5A,3AE,S8T/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(S+3$P+3(T5#$U.C$Y.C$X*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z9#-C.#4Q9#,M8S4P.2UF.#1D+3DT,V,M,V-F83!B9&4V-38X
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(S+3$P+3(T5#$V.C$W.C(S*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B R-2XP("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA
M=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*
M(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG
M,3)M,3,\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @
M(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @
M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM;#IL
M86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @(&<Q,FTQ
M,RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C@R.3DP,R8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,C0M3V-T+3(P,C,@,38Z,3<Z,30F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C0M3V-T+3(P,C,@,#8Z-#<Z
M,30F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,C4N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C
M:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R
M92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @($%V96YI<DYE>'1,5%!R;RU";VQD)B-X03L@(" @(" @(" @
M079E;FER3F5X=$Q44')O+5)E9W5L87(F(WA!.R8C>$$[5&AE(&9O;&QO=VEN
M9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @
M(" @(" @($)L86-K)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*
M(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/DUO<F=A;B!3=&%N;&5Y/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R
M/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@
M(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^5')U93PO
M>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!4
M4&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXX
M.3<N,3(P,#<W/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XU,#0N
M,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN
M=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE
M/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A
M9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!=F5N
M:7).97AT3%10<F\M0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%V96YI<B!.97AT($Q4(%!R;SPO
M<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO
M;B S+C P,#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/D%V96YI<DYE
M>'1,5%!R;RU";VQD+F]T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT3F%M93Y!=F5N:7).97AT3%10<F\M4F5G=6QA<CPO<W1&;G0Z9F]N
M=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%V
M96YI<B!.97AT($Q4(%!R;SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&
M86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4
M>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.G9E<G-I;VY3=')I;F<^5F5R<VEO;B R+C$[,C P-SPO<W1&;G0Z=F5R<VEO
M;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&
M86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9I;&5.86UE/D%V96YI<DYE>'1,5%!R;RU296=U;&%R+F]T9CPO
M<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT
M<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @
M/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@
M4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @
M(" @(" @(" @(" \>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y004Y43TY%(#(X,"!#/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4U!/5#PO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT:6YT/C$P,"XP,# P,# \+WAM<$<Z=&EN=#X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y,04(\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z3#XQ-2XR.30Q
M,# \+WAM<$<Z3#X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M03XQ-3PO>&UP1SI!/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SI"/BTT-CPO>&UP1SI"/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A
M=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E
M871O<E-U8E1O;VP^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!#
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $[ ;,# 1$  A$! Q$!_\0 '@ !
M  $$ P$!              8$!0<( @,) 0K_Q !F$   !@$# @($!P@,"0H"
M!@L! @,$!08'  @1$B$3,0D4%4$6&")15V&7%UAQ@9:8U=@C)#(Y5FAVD;?6
MU^4H.$)WE:&QMO 9)C-266+!T=3A)W(E-C=#4X(*-45&2&9S='6#L__$ !X!
M 0 !!0$! 0$            $ @,%!@<!" D*_\0 81$  @$# P("! 0-#PH$
M! 0' 0(#! 41 !(A!A,Q00<4(E$(%6%Q(S)35%6!D9*3E*'1TR0S-$)R<Y6Q
MM,'2U-7A\!8U-E)B8V6RL^,))72"0T56\1<F1&2#XAEUHJ.U_]H # ,!  (1
M Q$ /P#\Q^OM#7/]--------------------------------------------
M-------------3> 7%5D*0CR*)Q3'@.1 H_+(8W/81, F3('N*B/;L'.HW>+
MM5Q8 [:F,2@^7<C';D 'EA1&Q]YD^?&;H'WP;21F)MOR[6RRD_;W*/D7'EJL
MD&WCM7R8]RB@8W8...GJ$1\AY$/D\]OP?5#IGV3P>(.X#[OEGP\?=]L>^[4C
M=!4>:[>??X>_^/!\N=8F1**#XA%!\E0*8>XAYB41_!TF W;L)1\];<<LA*XY
M7( &"//QSY<^7CG6K[@4]V&(\1Y$^X^1X_)SJF4**:@E-V$IC$$/QB7CD?G$
M  !UZ#G!&.1GZ4CW>'..<\GYO'5:G.X9)^8CQ'!&>?'^+WZZY3@Z#=SP(CTB
M@H(!_EI@ !S\XF)T#R'S#WYU8D&-PX SD%LJ.?(?,<_DX.I%+RQ'L\X(!)SQ
MP?#WYYS]K&K*EP()\<#Y>?UB'[GW#[^??SVUX@R.,<D8P>?/Q^3W>6L@W&XX
M..3[//O//B?M>'CKF8P=8]_>/<![>_S#G_WU41SG \?$'^?'\_VSKQ%)5>!X
M#QX)X'(/E\G@!YYUS-T@( '/(@4>X#SR(=_Q<^?GQ\^O?#Q]P/W1G52G()(7
MAB/+P'ADX/(\/\8U\_X_X_V::J&./I<\8Q[OD^UX#\O.NY/CDP\!V*/D(^_Z
MNX^X?_+52C.> ?G/YN3JF0_2CWL!\GGX^?GY?=U\ 0$0 .W(_7R(_5P/^WS'
MCSUYYCP\OFY]_P#/JME !/LG /GR/'[?S 8QSKX?@PB(<#QSSSSS[Q]W;_W[
M?5H>/(#G'!_.?YM>+PJYP,CP!_P?R?-KO2$"@/441^2''2/D(AR4??R&O&(S
MC/D#]P#_ !]W63H5S$YP3F1E&!SD9/&>?+RX]_R<RB!AX,/2'/?GN''X..>W
MGQY_Z] ?,'P]W\W^/?J28VQSP?N$?X'Y#K@?CG@H@/?MP''EY?7W^L-&? YS
MYY.2?R9^U_@:ME#@@DGR)SD>/GXCCCP.<^[4ZD@$K]X4?,CA0@]N/W!A+Y!^
M#5=M_P WT61C-+ <>[,:G[OO^76N5YS75A'G55!X.?&5SXZHM3=1--------
M------------------------------------------------------------
M-----------------------------------------------3^ILQ,S<+=)OV
M18..?W)BIE$B9@^3_DF.X >_ ]N0#IY'3NH)B:V&,$8A@SX<AYGRP)S_ *L4
M9'NW'Q/AF;>FV%W\"\F,GPQ&O!^Z[9]^!J4F9@=10@!P!VJX" !P'( 7CGCN
M ]QY[ 'U>7&&24@JY^K+SQD8;YN0/R< 8U-*EE"_ZT3$^?E^;\GCK!3Y(Q2(
MN"\\@)T3B'N4;CT<_/R*(IF]_(AV#S#6^Q$D8^17''DXW?\ -N'R#'//&EY'
M>9,<#(/C[^/DSX9(Q\OD==<BD8XIN"E^2Z1!8H@'8% ^2H7D?,04*(\<<\#S
M[]51G@IGE&*GSX\0?=X?+Y:]CD 8C//R^_P/\?)^3YM69X<3-DR@(@0ZI#"'
M?]T4APZO/MYB A]0=^-6J@8"X'(8C(\.??QGQY\O//&2)M(2)7YSA,C@?ZPQ
MC/C\A_GU:F8<@D(=^"\_S!QW^KY_YM68B< 8\AX_)GR\^3J=4.55R?VQ X^4
M_=\,\<ZY"!N1$/(1$/P\C\P^?GJMF'SGQ'W?DY!^YJX2-H '@ !]K[O\WA]K
M7<J'<H@ < ''U=O_ #]_(\>?F/&KDG 4Y.-H''C_ (_+GS SJQ XPPS@Y) \
M,CY^1D'CPSX<@9UT]0<>\/P"/^H/P_/[N>_8 U;Y'(((\\^>.!D\Y^T.3Y<D
MZD^'M @C/B1S[O'Q^V/N')U5I@)2#W_=>8#W'CC@.?=Q^/WZD*/9^5A\OVO\
M8U%>;,BCQ"G&1X9SXCY_G\AY\:Z4Q'K#G@0#D>WN$.X /GY#[O/MYZMH<N![
MN?GX\M2)' 0^.3@#(\=QQD?:^37$QPY'CSY'_P _K_%]?GVU21D>&?\ 'SCS
M^7\N-7%/ ^8?FU5H]S?*,($\0"B(!R/ % .>X<#[_P '\VK;D;L>>W@?;//R
M_P",ZSUMC!I$8\!I&Y\^1QQ[QR,YP/XN1C%Y$H<B'(B _P"4)?(!$!YXY  Y
MX'ZM4G'&/M_W?/J48QSXC!\?/Y..<#P\O=SKXL4R0D 0$#&*4Q0$0'L(\@(\
M#Q_/W#\&O2Y )SP%)/ECCQ)Q[_<?N>&J3%[2@@')'B?#GS.  ,#G[FIU('%5
M^]4'S.Z<&'\:IQ_X^;4ZC7;24J^ZF@'_ /J3G[?CK2JEM]34-_K3S'[LC:H]
M2-6---------------------------------------------------------
M-------------------------------------<B$.H;I(0QS" B!2%$QA H"
M8P\  CP  (B/'8 $1[!IIKCIIIIIJJ48O4FC=^JS=)L7:BR+5ZHW5(T<K-NC
MUA)NX,0$5E&_BI^,1,YC)>(3K O67GP$$D @D8R 1D9SC(\1G!QGQP<::I^@
M_1XG0;P^KH\3I'HZ^.KHZN.GJZ0$>GGGCOQQKW37'3333365J$!UF#HG(B!%
MSE* ^0@!$S"4OX3+"(\AQR(:T7J7"7"(C]O2HQQQRLLJ[B<<G 4>/@-9NW9-
M.W/TLK#GW%4.!]O<?MZFP- \4G;@1 Z7/'[H!*8P\>\0Y#OYC_KXP"OAMN01
MD,![B,\^9!&/' /!^0&:00/$C@J,'G&/+W@CC^<9U@%RW ZDTS  Y0<K.4B!
MSSPDL=)8 ]__ $1^>WET=Q\M=#IF/8HY#GVX(U8GG.Y R^\^(Q]OSUH54QCJ
MY]O $K  <# 8^&./'/R:M[9/UF.<(>:K$XKDY\Q2.)2+AP//[D!24 ?<'7W[
MCJ2WLR*W.']EL>\<KGQ\1D<<^&-6WDP0V,;L$>'S$<8]WAX?:SJ.NT^E(0X_
M<N4^GW?),0P_[>_X U;J/&+DCEL@^' \?#/G_P#?61I7W29SXP2'[8*@?Q\?
M/SSJV-$NE,PB AP90A?+R*<P#P(>[W?B_#JW2JS1EL9 # 'Q\,_./F\?#CWZ
MF54HW1)GQ",WCYA<$YY\R3[S\VN)0$3 '(]Q$..W?OVX_%S[_=\VJ%.2,C'M
M8Y\^?\?E\M278*C,? *3^3C[NJL2F#W<_P"L/F[@/X?F_P#'61PC  CC[1'S
MX(/E[ON:QBR+P!D8/B/?[\'/'\XXUU^&3GGI+R'(\\  _P#OJ@K$#@$9SP#^
M3C//W-7#++@X=RON.<8S[\Y\?FSYZY:JU0)"#G _Q]W76D3I,H)O+OT_7\W^
MW_CC5E5(+$@@!2!Y<8'E[C\H\M3'E#J@!!'!/B0#QD8^[D>?E\E)\H5"EX\Q
M#L/N 1'W^\ []@#R 1U8+$G /V_#)X_*3GQXY\O'4QB-AP<8!\O$@>.![^.3
MG\NJWE(2)@F!P,8IA.(]/_2 8>1+QWZ>.  //CMVU:+98DXY.!Y\'D9SY?DX
MX&MPH8=E#2I@@F,N?(9SP?/RQS\F/(:[O#'P_%ZB\=0DZ>0ZP[<\]/GTCY"(
M?@^?3(X\1QY\#YOGX_-XZDF/C("^XG&">!G/S\G[6N"93*.$$R@)A.HF0 #S
M'J4*7@ ]_F';_P ]6ZDE:><CQ$,A&/'A#R/F\=4;#N7CD;?#G@$'^8C[>IN[
M[.W7_P#<+_\ _0VLO2_L:G_>(?\ IKKG4W,LI]\C_P#,=4^K^K>FFFFFFFFF
MN12',!C%(8Q2  G,4HB! $> $P@ @4!'L CP CV\]--<=-----53MB]8&2(^
M9NF9UVZ+M CMNJW,LT<DZV[I(JQ""HW7)\M%8@&35)\HAC!WUX&5L[2#@E3@
M@X8>(./ CS!Y&F"/$8\_M>_5.8AR@4QB&*4X")#&*( < '@1*(AP8 $! 1#D
M $.//7NFN.FFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF
MFFFFFFFFFI]BE%)QE'&R"Z2:Z"]^IR*R*Q"J)+)*6*.(HDJF<#$434(82'(<
MHE.41*8! 1#4>K)%+4D'!%/,01X@]MN=5)],O[H?QC7ZW,K^CJV3YKW=9AF\
MP5;++:=S/Z4^Z[*Z>RP]=*?CRFX^@T]K>/LKPMR5K;S'MD]KO(F??2S889F\
MAF+Y*1:N7"G1$+1TYR*DZCOE#9Z)*.6D,=%TI!>YFK8)JF>HD-UJ*-X!*M3%
ML5XU0[V#LNU@.7#1YV2DIY*B0R+(#)6-3KVV5%0=A) V"C9()/' .1GPYP5M
M-]&KBRK5S8=G^B,,W5G)9]U.#JYD3+ETE%J#ZE*7++=QK,,ZP?C7(>WBT8AS
M)531-7C)9G,P66[+8:\Y=*2]VH_P?<-&9LA=NIJN67J"W5!H9:86FOEIJ.%?
M6"R0T<,CBNJJ:Y0UE%+OE=2DE'%'( $@G[@+:LP4:!:65>ZKF>-7D8[,%I&4
M&)'A:.1<*"")&()RR[2-;";!MDF+<:7BF;D:U1,X9<N^1Z=Z0^6O&XJ*N=(9
M81PW8*ZTS1C)GARZT)C34Y)U;[#  6>.[;3]==DGW[%] 0+ZFHS",-CNH+Y5
M5-//;)9Z"D@IING4@MKP3M75D<IHJHUL%0T^T0QR9CV]J4=M66219BA>[24R
M(R3!979UJBTH9!&C 2((V0+DL1[60RG)&%*YQYQ[H/1D[5\*>CPA-PU<M649
MO(#O#>WG)\!E=A&Y0L^),BW3+DA'(W;&;MS';?V>'Z,PJC5](MJZ[2W 3]S1
ML-?+#WFOQ;NPQ[5#9+7U/=:[J.2W20TJ4PK+E2R4C-2Q5E-!1JQ@J@&N)K)V
MF*J90;=' 8I-\$C"-F,6:CACI!,'<OVX7#X<QNTF R9$/;3;SMQ,S;AM<#<-
M7':IZ+[;=F/9OC'+%JCLSRKW*N*MT&0\B[JZO?*;$X%V<V?!!+&>E8\RG2)"
ML2$O-N;X2&B7$J:2M-9E73>TQ1Z:@X8E>3#.F[=4W*BO-521-0JM)5VNGIK3
M+!.]PO45P,0GJ*2=952,4Y=PNV&5 87[QW%8V04<4E.DA$GMQSN\X=1%3M%N
MVHZE26WX!/M*<,-HQDB9;\;Q@23RGZ$3#;S'=\8;>&&US:]D:8QA.9=A75."
MK9LL2:3E%= F,XN+;77QH22>9:R.X8JIY.CUHII\'*>,*H\D;%@@KUI.N:U:
MF!KBUVNM,E5'1N)N[0QD@@FJ9S!B15HZ8,#2MO;NS;PJU53QE[=&480B"%RG
M<!7$C>[MXW<$R/CVQ@;5QD^B-OVI[4'D5F+:)D7;YF?%.&\C^G"I>*\>5"H7
MN#J3F'F+SMTN4=5LLU]:6QBLV##[Z$<O;'3*(PC5UDV;FO-C7B:CV3XTIKL-
MVNP:BO%+<:*KK:;H6HJZF::G>99$@N4#2TD@2JSZXKA8YIV8#<)3V(V9=LMH
M8,20/%*D;W-8T56 (+Q,%<93];()95P< @;F Y\ZI;T2^U&H;&;[FF8N^5;3
M=82B[E;,;*U/B,G66ET7(>%LDV&CTS%-NK%%P!<L?0+"RIPD>C=9N_YRI=HB
M7=@^$L#75JA#N'#G8TZNNTU^@H4IZ2*!Y[;%ZI,]+'//3UM-'//5Q2U%Q@J)
M&B[C&!*:WSQ.L?;DD[S@"*:&!:9Y"TC,%F.]0[*KQ.55"$A9%#!?:,DBL"V5
M&T''YL]=*UB-9/QL/6K))"8?W")B$]W)O$ZS?A_8TP_F^K6D]7#:U!(!C(J4
M+?,82H/EYN=9:VGV)U\PT9 ^0B0$^_R ^YK+0-P!P@!>1 3GX'CW>$KV[<\!
MV^OZM:AO/CY_.?E\L\^7^.=90#) /AX>?W,\<^[!\_GUKLN!$K.\ P?L:DF[
M04*/EX:ZRB1^>?J.(_[ UTND):VT_/*TL# C'B(U8>_ X'RCGYM<^KSMJZD>
M0GE4?,'8#Q(SX?XYU96P PE^A0/D"8Z"Q0#S3 3(+!W^<IN0^LI1]VIK_1(L
MCQVAESQ@\,"/=_>1GQU&+;HO([6(&1X!LG!\CCG_  =66?;G9&4(//"#GPS"
M''R@(8X%$/\ Y@X$.P>?EP':Q.Z]I) ,$[2#S@ C!XY\!CR\!XZREL*R2LAY
M/9<#YSM/')X\#X^(^75K0* I#]1U..?F%0X^[MVY\O?^ . KIQB,!3@>UQQD
MY)'GGR'/!TJ\I. / )'@#P^D7C/G\Y\-=*2/2J)AY "\F\N Y'R\OJ#G\'/O
MU;C5A(QVD*A)R<X))\3GCP'EX'CSU*GJE:%%3#-+A2 <X&!G(\0<G 'CK@HJ
M;D0(/!0'SX[_ (Q_\/GUZTY8[0<9'NP3]WD9^[@9U=@I5509 &<\X/@"/</,
MC[8_)KHY'S]_/_'GJWG!#9.<\$$^?&?'4PJ"NW'LXQCY-=Z@]/AB';D -[OP
M?\ (^>K[R$;"#X@$CP/NQ]OG!&#SJ!#'N[P(&02JGW'DC^;[FNWH >!#L AS
MQ[P[?\<_[=203MY\_''GD>>!S\WAX^.HHD*AACD-XCRYQ@_WCGW:HA(8J@FX
M[%*<1'CS$I1Z>//CW=_(!UCR"'8'@*1X^ &&/'OX92? X'EG64$BRH%#<N8Q
M@?[3 -GSP> /'D>&JL?!%-#PRF P) "HF$! QQ[B)0#R 0X#OW\]1]X)8>.6
M\@? <<Y!^[P/M<:Z9#$%A@"\;(57S\"HSY')S[_X]=?28  >1XY^;@!X]W.O
M<D8\?>/XO[M5E"?$9^3G\G'/AY$^\:[F?(23  $0$7+< [\#_P!.GW ?>/E^
M#S'4>J;Z#*,''8EW8\_8;G^+)/O^;5HIA@0/M^0&?#'R?E\L<ZF;H>ITY-\[
MA8?YU##K8H!B&$>Z*,?<0#7+I#F1S[W8_P#^1U[4^A@K,3.SV[V1Q_3\=9#W
MK5C;D\F]E=*R9%U>?C)"^HS[4+O,U"MW4#U>PY/K=2XD:5%R"#PZ@C+*^I+,
M$9(Z6F]:RO''9TJ)JFGLDMR5+W/2M+&R4YC/82:6#Z+%2RS>S.ZE<>P-P8KF
M;;U!,^U4:I$6:97"D%\Y8J&]DR*O* Y\_+.O4&Z[1VF[R.V-X]](-28/&_I#
MLFP.\*1EZYC&*QMB?+F1<>4#&$_:\&R&6*E381.M,+)(7N$3AJVW5KL3*SM8
M+--DO">-)(\?J\%W-G:^U'3T[U73E+)9E22J>JJZ.EJ:BJCAKUI)II.XT:T\
MF^4B1T24QDY4IOF-3B<4RU2".K<5!Q&$CD=$1FC,B*NT-OX4;02N>,AL8UJ_
MHV]N>%,-9EHE[VRY6RQN1F?158/W52-*=VZ(:Y$H64I;--OI>4H^@0:>-K!*
MU=U5BPD$^GQ52EWT1"QUFK$HDDZF4Y2&E2]2W*MK**H@N=)26Q.K*^T+.L+-
M33TB4,$](U1(:F-)1+W)%CP45Y&BE4D(5>E:2*-)%:&228T,4^PL ZN9&60(
M.V2I7 )SD@!@1DY$Q2]'+BS;FY>7+"K/.F+8*Z^C_P!]0S$YE.62BLLW.<Q_
M@.HS-CA+7@S+VVNO-Z77GLM8I>+5N6*;AD&N3<,=@2L7>N32(OG]C_*2JN86
M"N-!5R0=0V'9'2*7HX8ZBX3I$\5=1W25IY D:.(:N&GD1PW=@E0[5]%(D.7C
M[J TE3[3X$C%(E+!HI(!L!+$;HV<$$;65N=2*(V*X;VZ[+MZU?HM8RY#U#)N
MT+:(XDMZ=XNE4G,"YF+E+)F([;<)G&U2BZY#25>C<5R,PX8NR?"RQ&&,:G3L
M0QSM6#EK%;>_5MQO=DDGEHWFI;S> MDIX9H[A1>J4U9##'4S/+(LCU:J&4]F
M,;S]#W*)$B]%-'%3U 4.%>GISZRS*8I-[Q,Q10H("$_ZS' YQP6\[O2U^CDV
MT;*<9U.<Q&[RZRMOW9W^,F*EUCLH3=0S!CME1_A";+,1>K+M[Q#CEG/(3?L]
MFM7\97+)]/EX>RM'5=LCM6LV)8=BZ1ZDN=[JIHZQ:,P^HK5,(&I8YJ.I:?M^
MIO!'<JVJ,93>PDJH*69'B99(E$L>HU=20TZ*8S)N[A3V@Y61 N[N!S#&F<X&
MU'=2&R&)5M;9/_1;[.,/U6L9)FJ1G2=J>-)?8[9*SGZ<RI0TL([['^XNP4QM
M>,?8IKR>/I!W7/@ >P2,B@DQD+L^5@ZE.L[B@Q;/&=B/B5ZJO-;-)31ST$<M
M4E]BEMZ4E0:ZPK;8IC!45<GK*B4U';5266!1),A@)*M$+WJ5.BAV64JAI664
MNO;J>\5WH@[9QLR?-C@'=MR&U=9 N#MT?_Z1#FO&&=<7VK+U4:L=PF):=1[S
MD.*G(Q*[8RQQ=Y:OEK[!S1"-V]4.C"3$=CC'+5'UNHVJ8@+ -GLIX)Q$3]"^
MO6KT=4-50545'*6MU7//!3-&_8JJF!).XPJ,F8&1&J:DG$T221]J+N!X_3VY
M[K(DJ-(OT6-59P1N1&*X]CZ4X(1/%78'<V,&Z90VP;=\[[,L&XYO./,XXPRQ
M@WT=GI ]P&)FTC>H4Y,7DV][C+W(IXFRG7GV/(N4NEG?+N#5FU6%,](]EJ02
MZK*K-WTL?V)32W2XT%[KJF"HH*JCK^H^G;?5E8),U7QC;:=/6Z21:ETAB4 2
MPQGO[]X#2E4^B>O##+31JR2QR14E5-&"P]CM3,3'("H+,?I6/LX(/LY/&I/I
M'_1D[5]I>UAKD?&MJRC-6V-F,',*?E!S&90L>*-Q<?DZBN[3;Y**GW&W^FX?
MIZD&NB25I*-%SAE5)W6VLG"6]5E<?54M9;IOJBZW>ZM354-+'$R5[34H>EBJ
M[:]+4"&%&C%QGK9^X#LJ#44%&5E*R0@P9U8JZ."" .C.7S&%8ARDH=2S8/96
M-2O!7;*^5!##=@Z_/CKH>L7IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
MIIIIIIIIIIIIIIIIIK-FV[!]CW+9[Q'@&H3$-7[1EZ]U^AP,W83OTX.+E)]Z
MFR:/90\8T?R)&2"IRG7,S9.7 % 121.;@-0KE7Q6R@J[A,DDD5'!)42)$%,C
M+&I8J@=E7<?+<P'O.KD49FECB4@-(ZH"<X!8XR< G'S#6P&'MDN>\O;DG6VX
MLJK1+8G#Y@O$3:+VWN</6K''8>JMIL4Q8*\Y"'6DI-">CJB\8P,NV8G0<*K-
M$W3IL@"ITL?67NWT=L%RV>L0[Z.!HH#"\L;5DT4:12#>%0QO.K2(6R!N(5C@
M&['2RR3=GA&Q(X9@P5A&"2RG&2#MP#CGC6JC^"RK%T^MV24A\@QU ?2;DU0G
MW\?8V=/>3)_%.\-6Y5PBG"N),W@+'<C%KG=&\%4RO/AG$,JLE*\TL:/3O4*@
M$T:M&TP3P E0$N$Y&-XQSQXZL$.%4D,$)]DD';GSVGPS\VMD)3:)G^J[5XK<
MG+'FX""L6YTVW./Q0_876*R-(7QSBB,R0QM:%<<Q+=F\AINNV!*%C':#I:9D
M'BJS=%DHQ5*LIC5O%OENK6Q=DDD=K^,FJU:%Z9:=:QZ9H3('+*\<L9D=2 B
M EMV0+I@D6'ND%09NUL(8.6,8<-MQ@@J< YR3QC&N&4]GV?,887VJ7&<"8ET
M=T;O-2U#PS&QES6O55F\,W\V.+,VL%*>1"!6\W,/BF?QB4,G(.U(GDTAZJMR
MAI27BWU5;=H8]B&U+1>L5K- *>6.MI_68FCG5SF-%]EB^U0_TNX<Z]>"5(X&
M.2)S+LC&[>&B?8P*$##$^&,G'CCPUKJVI>6DVMI@&=3R*1E#O5DKK"-H*RE:
MQ4C!LG\JX3M,:DU!)B]AX^-DY)8DLBDO'LF#]X<$4&KA1/)&>DS%(9J?+J#
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MU^T'O]W/Y="DQ 43'PR 43\P/O\ X^1KZTW+[(RR+(A/1KTTISKH%*<=TNY
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M^"HAFIG,E"RQB1YEJ$<4D\1G3<T &,>"X0@Q ^L2A(JB)I9<&7Z,R$.,2Y.
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MYUD[8"7FP?VB\>_VCY_<^WK9$&IO6DBF)TAX:JP\!V$Q2B4!'D.._4(  <
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M9&/$@.OCD>'CY'S^?WY\H60/VN7_ +JJP?7^[[<]N_81'4>-CV$R?I6<#Y?
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M25^650.J^TZ;H&YDU/JUQIX56:>CMJ[I]M/T_7O<GKZ211"0:EFN ,1&Z/\
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M_P"ZI.$'S8&/DX^WCR'NP!KX"(B@IR'/RR#Y?48/K^KZ^/+5:L"K8)X*D^0
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MT&B3B)5S%!! DC0S5DYIX95C241NM//5LSH[*-IAI944^UB1DRI7)%:+G<Q
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MJJU0'H%0Y>#+&,J;GGL!^Y ]W[DG!> #Y_+76FP<XP0..,<X\?D\>>=<TD8
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MQ3% H<@0! 3''D3#P'(]@UCP0RXY4$XR<\L><#=Y\\ '^?7=I%9R0!G:"O
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MNV1\!SXJ\;%*.WJ*?JSCK41*7P%>?#-:J&E2"9X$$DR12-#&3@22JC&-"<C
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M=3_NF_Z;Z\^MR?\ C%Y]_P ]64_]^9W6PVO_ #;;O_0TG\GCU%F_79?WQ_\
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M[_%ZVO\ V3?W_I\5_P#$;I^-_P#;T[W^ZA^\_OT^,[_%ZVO_ &3?W_I\5_\
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MVBXR"D=&NY=];EZ;6T4A6<XX_;T@YJ],<MY,J%Z=UB]:C++W:)F6%F42[I5
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MDIJ=GAV&.5&:1:6N(,D+,S03"*5RJ"-+Q,R #.Y &8$*'3#N V<J<*7B^E8
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M1.[0.[-)4T-%4NSNS1=^",%%EV/0T%$J!0R.R+,'D[IP["2E*,!N  "2R(
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M4&NW3*1&(M2S0A2% OAH.BOBIDZ2_)(!"@D40+P4P](@''G]Q>C&98K[%3J
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MKP:55V3M@QDQ@FI4))=DU&3DWTNZBP66-:>".HFEDEBIZ>!G3LHH6GIY8%1
ML" HO>E*LR]PY4,VQ%1:FF)9BJ@!F=@#N)]MU8DDL>?94<''B<9))LK7>5>6
M$4NRCJ)B^.EGCU-\]M3"#G&EE>*MC20L3.91O9$UG"K$LJNW:*N!6]5:M8Y)
MF1J=)ZK(739X&<,T]4R*I5(6DC:)00H;"F+ #; 6 QEBQ.<J%\$S 8"H">2P
M!#$\^>[Y>/=@8\\QB?W"R29L J54GCNL,5UJ,B]L40@D2Y6YSZI$R7MN.;S$
MF1[7&.-J[C[#K5 KUA[:I]#:2CF,AI2=DVR=Q+<A^,!+PM;(=JQNWT&(9==C
M%%*R-4R5%:QVMVYJAD#.D:$^&4_0L<]L<E@/:)XP1DY4($C'AE4!P"3KY5-Q
M32AIVU.EX2Q)##;:W(5U=V\1O5CE(HDO 7.M2CN#E;%=Y)]%&<1-W>H>KLE4
M$%Q@ZP>5"5,REQG4MN,YB,U=6/VI%D !IXT<I)#*@=(Z=%?#P*<L"1OEV;-R
M=L)=N[;'&-RE3PQ(!5E.TLQ(R&/@?)<YP<U ;I[@M.M[1)5:GRT_%YKD<ZUY
M^[5N:2<#:IF7H,I+Q2#%C;VK.1K3M/&M7BD&$TE)/(Z-2=E92*+LS)VP\^*H
M0AC6698VH4H)%'8)DBC2H1'+-"665353.60JK,1N4KN5O1.VX,54L)3*"=W#
M$J< ;L;<(!@Y.,X(.,=!-T-Q<Q"E<GZW4[)7'=6A:=)1+\]M:>O0M>J>$*E%
M)A)1%JCY1@N@WV_8^D%%(UXT37=I2C-5$T&[;Q#+TVR'N=V.6:*43/.KKV3M
M>2:NF;V7A92"UQJ5PP)"E2") 7:GNMC:0I&T*0=W(58E&<,#G$*>&//RP!=)
M?>%E:;?-Y!\WK8JHW!I=%4$4)])F[D6EYSQD$6+EJ%A%(8=S.[B+T1PR3!,Q
MF3>$(FNFY3EW<Q0EGI$7:IEQV3 /:C)53!04^X$QYWB.W4_M'/)DR""@2IIW
M;DA<YSG!Y]J5^>?,S./FQ\N<>Y1S5)91@:16UZ;1*=%47VLI'MZ1#O(<D@\G
M(FHQ$D]E$5I-ZU4<*HTR,7!1LW:JJ.G$@X>JO%G!3I2*6B6EDGE$U1,]1LW&
M=U?:$>9U5"$4@ S,,$D !0H4#FEY"X5=JJ%SC:",DA02<D\G:#Y9.2?'6%]3
M=6]---------------------------------------------------9&I"=3
M/6<PFL<?87DNECF,4H;B%([-&Q-L'+>+4G<A;3-EDT4Z\I1U;G%MCOR.&@VJ
M2K*9$0?*,ET8T_>[M'VFC5/67]8#XW/#ZG586'()[G?[+':0>TLN3MW U+MV
MR;@2=@V8\ W<3EODV[@,_MB//&O2GT$G[[)LZ_E7D#^AK(^M9Z]_T2O/[U3?
MRVFU,MO[.I_W3?\ 3?7GUN3_ ,8O/O\ GJRG_OS.ZV&U_P";;=_Z&D_D\>HL
MWZ[+^^/_ ,QUA74[5O5TAIN6KS].3A9!S&OTBJ)E<M5!(<4E2B19%0H\D606
M((D606*=%4H]*A#!VUC+O9K5?Z">UWJWTMSM]0%[U)5Q++$Q4[D<!N4D1@&C
ME0K)&P#(RGG61M-WN=BKH;G9ZZIMU?3DF&JI9&BE7<,,I(X>-Q[+QN&C=<JZ
ML.-90IA7.3+(Z^&&<JCBE1G%+.&]HR CD]6/?J&7;-#PK(F(\<Y%FR/W#==1
MR)W\,RBS,V;E-63*Y,T:.L';ND>F.F:"6AL?2U(*.JJ$FJ:.EAI)!)*B^Q--
M\9U,:N(]BA!W&9&(9$'M,,K=.KNIK_6Q7"[7^NGK:>!H(*IYI(7CA9B7BC-&
MB%=Y=BYVC>.'8@*->NNT7;M$5BLV,DSN3PR[&;E&<O'.U*ENLC ?M7# @BY1
M5M6VN 6D$5$_V<CED5V@)#@8RQ>K7&.LNH;#=KU%16BJM[/;Z$4M1045PL]5
M+1/!55"-')!;*^L2E[;?0FBF[3HZ%2@QSGWZ;ZHM5OBN5]LU[HZ:YR]^EN-S
MMMSI8:]9X8I5DAJJZGA%5W8V$JO&T@=&#AB#K87*N%:-,8LNC4VX_!C(C*09
M3'K2D/N%,T9)E7: H=4C? SMYU'\-V7]K-7 AUEYZ0ZQU7TA6O0]0VRJC@FF
MD8=CLH8!O##83'W9XE# 9P9)$7/CK3>JJ2.KZ>KH))UB3<)S*XD(1E8,-PCB
ME?:<'(6-CS\QUI+5,,8TCY]GXV[C;NJS=%<QCM(D)NB*H=M(MU62H 97;4D@
M!B@N"@"JH1,!)U&.4 Y#Z/FK*SL;%L-WW*$92TMD)!B(8>%Y)(]G!P#X?*-<
M%-'2+('%YMN#D,#'=LX/! S:L9Y/VP,CDZC,E@"@1$SX2V[K;L@X8N5V*J:D
M'NG!0BQ%.4RF%/;*HEUE63'@P*"3@>2F,(@(UBY5;@,+!=BC("#W;)DAE!/C
M>1[_  QG'B-7HZ&F=)8C>;<?,X2ZY!48/C:\8'_N\,#C5_N^"L=.9!K9";M=
MNS9&81))"8\#NC,51?H]5EQ)ZOMJ7$J99!%RL!%034 IBF.F4HE,-F&OJPHA
M-ANS-"^S DLO"^*#)O Y,94$^\$<'QJ6DI2I0WJVX89Y2Z[B<@$D&V <L#CC
MW<#&M4;A@#&1[:\4'>CMC1'QVO4BK7MW8J@'J@_NA0VJK(<GZ2F+PL8.![F
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M.Y/ZL&\W;/R?DA2!7MVX <  >HORMK %Y$/(.KDWD'<>-7$O;3,8%LMS.05
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M;B/IRV2,#&2.:]>*LU/22=IZ5$J756GV,"'1CM7U=ZAOVF>0%X\<X!C/Q?\
M%_WZ^U_\G=X/ZI^MT]?JOL+<_P +9O[6US/M)]<0_>U'Z#3XO^+_ +]?:_\
MD[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JO
ML+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M
M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3X
MO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\
MD[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JO
ML+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M
M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3X
MO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\
MD[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JO
ML+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M
M)]<0_>U'Z#3XO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3X
MO^+_ +]?:_\ D[O!_5/T]?JOL+<_PMF_M;3M)]<0_>U'Z#3XO^+_ +]?:_\
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M1L-G<#[N1G/A]OY/FUM+#*[6P4*E67WY4\'Q^;^;62F"X.XY-P/ G IO$'@
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MN7CUXY52;M6K=)1=PNHFBBF=0Y2C2S*BL[LJ(BEG=B%554$LS,2 JJ 222
M"2<: $D  DDX '))/@ /,G5\MM%NU D$(F]TZU4J5=,R2#6,MM>EZW(.6"BR
MS=-\@RF6;)RLS47;.$".4TS(F6063*<3I'*6B&>"H4O3S13H&*EX9$E4, "5
M+(S , 02,YP0?,:]964X964XSA@0<>_!QQP=1;5W7FFFFJAXS=Q[MTP?M7#%
M\Q<+LWK)X@JV=LW;94R+EJZ;+%(LW<-UB'2705(15)4ADU"E.40#Q65E#*0R
ML RLI!5E(R""."".01P1R-/#QU3Z]TU6/HZ0C%R-I)B\CW"K..D4V[YLLT74
MCY>/;2T2^(DX(FH=G)Q;UG)1SDI11>Q[ML\;'5;KI*'\5E895E8!F4E2" R,
M4=<C(W(ZLK#Q5@5.""-""/$8\#S[B,@_;'(^35'KW3333333333333333333
M33333333333333333333333333333333333333333363J$A"K57-BDK29RUO
MFN,8I>MSL2W=+L,:S1LR8D;+W:SJ-W*"32#?5UQ/XY0</DGC4UDO]>:$;%>N
MF;MK&G+B6BV3QQ*:EQ+&Y4-4IZE6$01!@29%D$=20I#".GD;) *FM<;9,J6.
MP;2,X0]R/VFQX KE.<C<P'GD>D/H)/WV39U_*O(']#61]:SU[_HE>?WJF_EM
M-J7;?V=3_NF_Z;ZU;E*O2[UORN-$O[&SO:U>MT5GI;P:A8XJKSC$;3EQU"!)
MMI*9J=S8* P2>JK^I*PW[:4*F3UML4#"?*QRS4]@@GIS$)8+5#,O?C>6-NU1
MK)M*QS0-[14#<)..>#JR55ZHHV[#SE3M(!&Z3&<LK#C.<8Y]XUB&>JV.W6)%
MLA51G<XJ63RH-4/&6"P0D]&MZX]JZTO&H$<QU5KKI]--G<:\5?3)DXYBZ;2#
M9@WKS16,5E)::DM0*L4\I@9#2]W=%')&QE64(QP\TH6,JRA4R[!E9C*0X1+1
M"[-PW9WX]HJ1M()'@JY.1R>!C VY!)PEJ;JC4B2L=J=,6U=3GYM6+,)&K:'-
M*O/9Q?&5)THIM#N :ID.J"8B4"%)U%*)OW("&!J;#TS%6/U!4V2S?&-*KU+7
M=[71O<(A%&[/**P0-5;DC+X*N7P2%\<'.TU[ZDFI(^GZ:\W<V^J=*9+0ERJD
MH)6FD14B-(9UI=KR;.&0)D MC&1[9L<"S6!L TF:G\DJ2+689J-7[:&;M^N,
M8*BBXEF8(/%9 7B\4249$8K$;L3"V0.0J;@3H%0_*;K+KWI3TA>D^LO4/3LM
MHH+E5SQM6T]5'53U34JPT\%PDHVIZ5*62J[9FJD]8F+,XD&)%E,OZJ=.^C_K
M#T<^BEK'%U1\;7>QT%%5_%M?1R4-OB@N+5$\U%2U\<]9+4I2C?#2R""(*86C
M($3Q=G9'X#,,'63%3XEP<0K>SKL8Y.;0D?&!HK*/2Q3"0<)J"Y19G4G$D2.E
MVS1NFF19591N"2912Y]?KS9.J((J6Q]-2V6JI3/71U4EX-:E3 D1:1)831PB
M&=5@:4/'4!,LT;(P*,N]])]/]2="/<JSJKK2/JV@J&I['66R+I@6R6EJIF0Q
M/33M<ZL5M++Z[%"4EH^YA4D25&$B20. KK6VW+-=M>9#=A-4^4@9&&CT2()E
MGS33M9%%$73@C@)9ZH\:NB+1S9))PS;F;/@$2N1 ,!/.D=DHHC00[ZD5 >66
M:3O)AE6H[$0PZQE9HY>[([C(F0K@%AN%-2R'JVN,=SKG@I&H_5XZ:FA]3CVP
M2R4 KIV61'E,U'+2K%"D+*/5GWAI(XST9Q6D\EIP$9EZ.GZX4:&#BNF3&)0&
M*G8$[IZ1A+G;M?$?,9%DLJZ9.A*@_*BBDT>H *ZWJ&?Z#ZGK^A>I*#JOIZ6D
MKKGT[<*66&*KBG[-;0S;89(RD4D+!D,TD$S!BCJQ=781H)M?](W1EH](G2E?
MT7U/25]KLG6%%<34ST-93M+:[Y2,\HE#S)4QM!4BCBJ((0(YH9%[<D*O-*U/
MY<QKA1B^64:*&259O5%VJR)@Y*9)PJ G2.41 2 X1,HF(B B0Y>LI#<E+^W'
M1/4476?2EEZG6D>DBO=NBJGI)65V@D.4FBW# =$E1UC? +IM9E5B5'\]W7W2
M\G1'6'4G2DE7%7/8KA-0"LB!5*F.-E:&< _2,\+H9$YV/O568*&.K^0WP2M^
MG7Q6Z+7QI45#H-^01(L1(R2HI%$/V-,ZP*'*D'!4P'H*/24 #5:]=USE*G(6
M7:"V<^R-H)QXG'RG/F?(;O85*V*CW$?L8GP.,._<Q[_#Y/'[NJ8Y>(YL'8.M
M5P<?JX!-,!'YQ$2F\OF[ZR;)MI8?E:1ON!%_C#8!YX.//4='5KC4D<[(J=?+
MG<97(Y\_:7(\>?#C5>8W17TB>]61,(=NW0FD(=^?> C_ ./GY7__ )<B@X+3
MGQ\PH8_.??J"%[E^=QX14*#GR9Y >,?[(((X\<<C5A # ' B'X/,/_#^;RU!
M92,\9'VN?M:SS..#@\8\#SGY/+Q/CXZE]=<"+611$?\ HDSJE .WF02F]_\
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MZAE>5=X9EDEE!&]BF9)OHCL$*AV(4%PQ1$3:BV'*EB5R <8R%7R&?97@#.<
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MO! (-!2 @C((-/&""#P01XC467B:7'U1_P#F.L*^L+^ +7QE?5A5!P+?Q#^
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M9*=:FY"&*HMT=#/5RLQHJFM>F[-68G+(T.^$1R22PVS(F8:[1Z[>L1(-(Z6
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MD'_F39AX_84S\=HSS*)C //?D# /<-9NIJZ,/&!54YVQ1@@3Q8^E!\FX\?\
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MG_6\SC'Y/'4_89SSDU*F=;,&5RG6,X.4I\@6\3$(HLJHB(",N(@4R)BB40[
M \ /?@8M124L500*2GQ[('ZGBR,+XC"8P1S]S)YX^J_1Y1QQ]'].RU,*O,]K
MC>1YHU9RSC*LSN"Q+C&&))/D2"3J\PN;,O/95JA*9IRO'L57*2;EV%\MKA1N
MV,H'BKI(!,%%02 (B"?("80#L(CQJTM%1L6S24N[!V*T,*[L<@9*' .<9QQC
MS\]NCI*0O[5-"H/F88^,@DD#8<8^49&/?@:ZI3-&:$I!XC&9LRFX9HN5TVSH
M]\MR9G+1-0P(KG;^V %(RI.@XD$0$O(E-SP(:I>W4^[V:6E4X&1V8CC@<$!0
M"0<@$ 9SG'OK>DHR?9I8,Y/)@C.<>> H\<'PQ]O2>R]N&J2L8M)99RDDLLW9
MR;1%U?K,H1RT44.Z;KG33F3IF34Z!(9)0.KHZ2&X$!'5EZ*F1=_8II K%".S
M%C<N2RGV/$>!\<<<^&K=31T\"J32TX8<@&"+R8M@C:1D>!\QP,^[&5BW"YR=
M&:*AF/*2*JP.G:I$,@6Y$A3.'!OD%(68Z2ID,D<$R@(@4@@4/+69L-%0RI53
MFCI26DCAY@B(!B0NV!M.,F;GS.!GPUP'TASK\<P0P[8A#1H72("-0\LLCG(3
M SC'!Y QGRU&_N^9T^FG+/VC7#],ZS_J%#]94GXM#_0UH/<D^J/]\WY]/N^9
MT^FG+/VC7#],Z>H4/UE2?BT/]#3N2?5'^^;\^GW?,Z?33EG[1KA^F=/4*'ZR
MI/Q:'^AIW)/JC_?-^?3[OF=/IIRS]HUP_3.GJ%#]94GXM#_0T[DGU1_OF_/I
M]WS.GTTY9^T:X?IG3U"A^LJ3\6A_H:=R3ZH_WS?GT^[YG3Z:<L_:-</TSIZA
M0_65)^+0_P!#3N2?5'^^;\^GW?,Z?33EG[1KA^F=/4*'ZRI/Q:'^AIW)/JC_
M 'S?GT^[YG3Z:<L_:-</TSIZA0_65)^+0_T-.Y)]4?[YOSZ?=\SI]-.6?M&N
M'Z9T]0H?K*D_%H?Z&G<D^J/]\WY]/N^9T^FG+/VC7#],Z>H4/UE2?BT/]#3N
M2?5'^^;\^GW?,Z?33EG[1KA^F=/4*'ZRI/Q:'^AIW)/JC_?-^?3[OF=/IIRS
M]HUP_3.GJ%#]94GXM#_0T[DGU1_OF_/I]WS.GTTY9^T:X?IG3U"A^LJ3\6A_
MH:=R3ZH_WS?GT^[YG3Z:<L_:-</TSIZA0_65)^+0_P!#3N2?5'^^;\^GW?,Z
M?33EG[1KA^F=/4*'ZRI/Q:'^AIW)/JC_ 'S?GT^[YG3Z:<L_:-</TSIZA0_6
M5)^+0_T-.Y)]4?[YOSZ?=\SI]-.6?M&N'Z9T]0H?K*D_%H?Z&G<D^J/]\WY]
M/N^9T^FG+/VC7#],Z>H4/UE2?BT/]#3N2?5'^^;\^L4'.=0YCG,8YSF,<YSF
M$QSG,(B8QC"(B8QA$1,81$1$1$1YU+\/#5&N.FFFFFFFFFFFFFFFFFFFFFFF
MFFFFFFFFFFFFFFFFFFLC4@U3"LYA"QN+ A,'QS&%H2<,9V$<[M@9;Q:=XWMH
M-B&1-7RT8MS=-BOS)M M3:LF(<7Q629X\_>[M'VA&4]9?UC?C<(?5*K!BSSW
M._V0=N3VC+GV=Q%2[</N)SM&S'@6WIPWR;=V/]K;KTI]!)^^R;.OY5Y _H:R
M/K6.O?\ 1*\_O5-_+:;4RV_LZG_=-_TWUJ7:J+ 9/WN9$QS8K+,5%K>MR5TJ
M#*>A:NRMZ[*7LN4WT)'*NH9];*:F:.37?>,]<(S!G**27"#%T<_27+PSR4MC
MI:F.))C!;()FC>5H0R14BNP#K#.=Q"X4%,$GEAJP4#U+(6*[YF4$*&P6<@<%
MEXYYYU$H_!T!<*B%@QO<+-.R[Z]0E%KT';*-"T=I996<<2!4HF)G0R/8D7-H
MC(YO&S]@C$&*]=@H:;B_:=Q;S$G"P\O?:NDAF[=3#%&BT[SR20SR3F-(PN7>
M/U:,B)F+QQL6$DCQOLA**[I3VU*Y1B27" ,H7).> =Y]H#!(QM 898$J&PU=
MJ59L=6J9I5QC#P]D@')&LI''<-78(**MT7:!TW3%=RS=(.6CA!TV<M7"R"[=
M9)5-0Q3@.ID$\53$D\+[XI!N1L$9&2#D, P(((((!!!!&=4,K(Q5AAAP1P<?
M<R-1;5W5.O6S8=B9C5Z%.;AK'79!ZI[3;0T%) D!FT/!'?$CYB73#N<BCEQX
ML>#P2E*DD57P3E6$IR_%?PE?3-':IJSH3IFY'_*:DIZ>>9((%F2AJ9>U4@U4
MDT;4QJ!029IJ95G=7D,DR1'LL?KKX._H)J>IZJS=;=:6M$]'<U34QEJFM-+-
M>Q#WZ41T4-++'7>I4]Q1#75;/21,J&*GEG*5"1^H!WD=(GGLLXVM"T'$UFM1
M[4D7)+,"NGIQ5.W>KD*9PY!1)=X_,T1,W\1468D<N44Q,=)/\];K>[Q>*J$W
MJKKKG54DB,DE=5225$,-1VA)! &) 3N%W*( JD\*,<?I3T_TOTSTU;9:.QVF
MS6>BO*5<4D-DML4-MJ:FWFJEI:JL>)$<5#4L42++*=^Y"!)(P76M-EN](-MV
MBK;#6"96LD5)N'!HN0<.%R13V(7(D9 ZR94V0H.W,<NP()$RN%DDD')3' Z*
MI9$%JG:^-2-3IZO-+ME2.$!?5JN)7BFCD;>X?MRJS+G"LNV0$ J;%3U!3)TS
M\9+4MZS34:2TU5/4[IC<;7530U%!40)VT>!9H'[4A0]V.?N0R!B#K(TG>:-<
M\X5FNY'FW-AKS2DBZK;I,RBJ\5)LVR2S!(S9M[/+)I"236;(.3(^,BHB5;A0
M/#%K96AJH:*J>)I"T55ZB\Z1@BII7[@CVAPW;&^)<D/AXWY/LG?7\:44M=0*
MM+3H];0F^_%U14M&*.Y@P&LWM&4$CM3S2%!VP(ZB,-M!DW1X'MF6F3G'UY;1
MU>5<3E O#<U<M*#!)RNBQ>,A=M(AX@9HX!RXCY1LX([757.FZ8/VK5ZWZTCK
MN<O16-A+92Y5'K(Y8ZVEFGV),BNB[XTWJZ[T8D! -CQL\;9;"82[=5$Q]6F
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MPC9Z:,,[\=+@79"JG!(Z(B"IODE!4IB@!2@40, CVUK3Q@@N<$[8Y,$G)0*
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MD2+K/]0? ZZ?O/2E[FZ7O5UI[_6[#1I=:FD%L= \<DU-.]';$JP)8P8DEWN
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M1=J0HH6.- <1Q*JKPHQ)74FBV]6 _(E=G I#@8 $A3 3H.;W<@8P%'@..PB
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MW&! 6R7>K2<?ANLTEG P;.>OCYV+6QM991LV;'4:.!<N%13;'6%5!ST+G=D
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M++40RNKRA)3W&@3+.))(82R0ON=9)Z=75F1I#BE90K.=OL.H1E&%RH*[C@#
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MV7T:R6B6P'H>F%EJI%J:BU1^CB[14$U2$1/6)*6'IU86J-L:()]AE**J[RH
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MP ZP$M!T96R"Y5O3%+5W&*6!(;A4]%U=161"%6,2QUDMF>6,1;1VU64%, J
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M4NLCN)4RQJHZ6/:#%'MEES@,LD#$&<;CC</:]KPWH" -I(&PNV2&.0ORJW=
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MVOT.O07*S&E%75]17BRW..HJ[D)*F.2VTMOK9*-X::G@,!:>:G$DM09.VXA
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M2FHV@CJ8HT+U<*U#TE35)3TUP-,K.Z4\JR+, 7,BQACL]DZFVX393*42 @;
MSO$98I*XRL2NU@8JOF8()&EY<L2D@R!&:E%P32?+%(FB9L4Y6Y.!X$.H=&Z5
M^%];.J.H::TWKI-.FK16,T\E]DZA-P6ABIHG?NUE*MFIB$*1-W62<LA(.U@"
M=9SJKT)S6FUSW"AO<MUKZ.X4UM>UK9GI6J9ZZ2")31R"OJ7E^B549 [(#J"=
MZGG6D.:]MN7,-MHZ8O554B8I^0I4'I7L>[*!G#A=5L5PBU<JN&ICH*(D*#E)
M+DY3)A\HHAKZ"]'_ *:?1QUS=Z[IWIKJ%:VZ0S551!32T-PHO6J9<N\M$]93
M01U*IMDD81,S"("4KL.=?#WIC]#'I!Z)DEZKOEC$'3U=4Q4T5PIZ^WUJ15!C
M15AJXJ2IFGHW8XC45,<>9 8\[^#KGKLNN ::::::::::::::::::::::::::
M::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
M:::::::::::S+B\TZ6D[BPB+3#5^//AJ$+:(F40;+/KQ!?&"P4=O5JXHN8%6
MLRTLQ:[=%UV0&<FKU0GFIB^IN79BPZKM]^W;XGD;UR3M.I(6"3XOK\RR <%#
M%W(0&X[DT9\0-7$SMEPP4=L;@<98=V+V1GP.[:QQSA3KT*]!)^^R;.OY5Y _
MH:R/K7.O?]$KS^]4W\MIM2K;^SJ?]TW_ $WUJA9*36LE;X[]CNU34[7HV][E
MKA3D9FOQ$?./HZ1L^57L(R>*QLE+P:#ADV4?"X=%)()+F(D!$@$Q^HN6AGEI
MK%35$*1R/!:X)BDCM&K+%2*[+N5'()"X!VD<Y.K!4/4LA)&^9ER!G!9R <9'
MAG6-GN-J-(XGMF2J;9;([7J5QKT"Z@[!'51H]6B+(2<\&5-&PMPFK$Q9QBL9
M$H.[$_A&]5>2UE0K;>40F&#,MAE+4SK5Q4TT48$L,D@DC:4J'C,>4#/"D;,X
M=R(ED,JI$92I1CVZ"J["ZD\, 0<9P<\X#$X&!DD;26QD$>U@C4_5O3337Z3L
M84&.HVS.B0THR:-6%A1KC%_(A+"9S%R]@;DE)%15GX!BG>I/'AE&RZ:J2;4S
M0H)**"0IR?B]Z5NN;_U5Z0^L*PW:MK+:O4MU@MM'%55 MPH+54S042+;S(82
MDU+213.[H&DD9W92S'/[6>B3T>=)=)=#]'4(L=LMU\EZ/M-7>+A/;:,W>6MO
ML-*:JI^.^R*A)J*JK)H$AC<B.%8XXY$5/:OLPE/[=31TS5W+^UU6P5YA"I2E
MB!BH]];<BZ:'!ND^1BRNTA._(FU(BF=R5^991$J@F3*&B4T;]0U$<"B"&K43
MM!30P2)%44YC[CI%O[OT9"'+$@>R(]I.&.MVJGBZ7H9W=:NJH6GHHZJIGK8)
M:Z@KXJG922U+1=AC3U"-"ZQ+O)9IED ,B@2.1HD!#2&+4H!ZZI-SMEC,^=25
MG*==BZD7)44C-6_B/B-6ZLO'$.W(HF+!NDX:I"<5U!337QD4T]3$8'1IXH:9
M_H:=NG[0#_09UFV;Y(HI2'<2;L*S#"KEUV"ICIJ">HKTDA@>2NC,<Q,];+4-
MV#Z_0S4>_LPU4U.CQ0F#87.T%G?$<EP:S,O(V;-:]BNX1B$O&OVITV:*:+6R
M^K5QJT<-&8IM%F_#L6A6B#=N"P'>@=45P,LDD3QI QH^TACJ3')WF/MQNRU$
MA1=B%?%<2*S%1@@+P&9J11K3PU<<L?K5MBKJ-J",>Q44B24L"R5(EF+-F!W:
M-TC,C#VB^X,$6 *U&C)56A(,+38&T^2>%Q,N3$6.^@&J3'Q3'4%9([!LU=MU
MCM$"G3ZV_2*BH'/X?B7&K)V%7,U- 8)>Y'+3B'$1DW((V24$32.#E]J/AMC!
MD48PBMT*3TM&*JL2IIHZ:IH[DU47G,;1SFHIY:8CL01JJB+?+!E1-&RR.0PU
M.X^)IS;)-LL;#(,ZW4A(=HE!S"+E^5O)OFT>E)MC-G(H&>J2*B7AMFQ?$%/K
M('D!B'+1*U1V8:7LP[BS5-/,(729@BE F 0 C%2=S(&) 4L%SN1+2L9JYDJ'
MCE$5LN=M-3#)2P"IES//DJ5<J)%,B+*1VW+]LL?9BF'7%OAZUEJVO[/$1JDX
MG*&9P,@W!&3DJ^\XBVKQ)&44.NZ,Y\9)5%1HDH*/4F[(H"9Q00DW!Z9I:9:*
M%T:"FBCK@&!B,TK_ $5(-H;';W9+%@RN67:53>T"W4]3VYEO$G>6MNE16664
M0R+)!%0Q%J66M<NH9*E83&$""*2+&'WR"*/$JL_69K;:Y&!QW)$M23ATW/*,
M(U19R:5,*T>N$8<L8#EY)!(I(G178_L8HB0"D*0B90R9BJ4OB15-?'VO689P
M)JE$@FI&7NJLM/W=BC8WT0.V>""-Q)UB!-32]+RU5%:9C_Y944+I36Z6>NI+
MM%,:=YJ>M$/>E+R(5B:) "3&4]@A=7_X6$P)2<?S-.G%WUYR<PK\=DN*G4A>
MR#6=F4HZ'E8 GK28>J/H]-T8T<0QG(-2G2.H51<3J#>-.;Y=ZD LUOITN$5*
M]*BK&L$33M&<.A6;N*J-(RA&?/#I[.,=ZR.F>FH/6H$AN\U;9*JJ%PJ'>:>J
MDAHC)(#'(DE*:>>2:G2%S-'&4D$D4ZD[\RL<=J/,;W&AN81A$W6OBI+R=A%R
MF)T3G1]H.5D4!:MG9W(.G39<CCEH=L)#E(@H3I4+K#5&*LSA9'$;(5C<;-U%
M$IB[$J%F4Y"J",N&&XN022>@"GW4=-"U1"D%=#+3&:%#./CFJD2JBN%-4J$=
M%7=,"[)$4<*L0*CC6*6R- PHX2L-/D!')D3+-<?W5=PU=E:A8"O6L78%&P@=
MZX<LDD%F]G9.RB+D8]R1N[*B(O&R>TFURN*\%)TM,M!+=:(@0J\(B6>HIH]R
M]M6;<AI9 P"%\E VU&.@QWZ-3:UG-#)U#3WR'IFXH/6)8JN.K:DHJZ=XW6:1
M %G]?A,1:00 "8QB29$S+:I*I5+)50RM8;&RR,TM\0I(NVS (]1B5=R[14(Z
M;&;-E%VJQ#,GK=)$RBZ;0BPJ&*)BIF+BH4KYZ>HMT%*8VBG6K<;I%J>T1+'/
M!(YV* 0R22 1J"5# !2V[.RRV>EGI[I)7N%:EDLU,Y6GEH1/$M-/05],@,DD
MFS8\4#/,[?1'1W:4*RPAE(U%3<+.NKG#2U5Q?.Q/6T:'!1M&2@R$@59)9L(E
M:(R;E&(,<CE-)+AR<0%41,BF09922"UQK321U-6M>RRM3F.HJ:2C9&';.0^Q
M>\$PS,I4J0@ D8ZA"5JB\3M6PR4M*;!&U**U):&V7:\QR1MWUPT88O )2Z@2
M K*C2D]E<2&H75>U9,GZ.YCYZTX9J DFE(PA"'CXAX10Z'J@BL7P'2CQH"#P
M&*ZCDY!;)&!,&W)=0ZFB%!:::HF/8KWK7&SNE9I*9XV+31Q;R(L$!&F5$0D[
M2V\YUDJ*XM>.H[A3T:1S44=FB19C LE)%<(9D:&CFG"AJJ,AGECI'EDD &Y4
M,/LZ[@AJBXRQ#W:YOW\)A4LJX^"+H!:*)^WR2:[!FLNE'/#N4C,RH@0T6H8&
MZ<D1+H$JS84%4;R)0/:X82U5/([S2K$S5*V]XED8+O4(X<%-SQL7$1<C>K[E
MIJXVEKX^HIJB$0T-'!%3T;UB)0-U!',(QW'1C+3;'$HACGC2)YNP2L;QD-")
M1*E[F,OV3&V8[8]6QY6&D3ZB550S-4#BL^2:Q[UVQ0(^%%@+9N[ Z#@L@/K:
M)%' M4BHJ;)T_>+[T!/8NJ;*307^*IJH8JV:!:I8DBA148TTG<BD,J5$D#K)
M')$54^P7RZZGU):>GO2%_E5TE<X4NW3L=+071[12U#4)JJRIJ9VJ8Q5IVYHA
M$])'5((IHINY(JF18MJ-XZ;HL<TK&N3'D+03.BUY1,ZJ#-XY6=KLE$UE$CHB
MJYY="0Q2E.4'!SJE$1*)AX[?I?\ !N]*/4_I+Z8N<O5R4[W>SU=/":VFIDI%
MK*>KCE>,RT\1$*3Q-"ZNT"11LK)]##!BWYG_  E_1CTIZ-.L:*FZ,DF6R7:A
M>ICH:BJDK7H*BGD6.6..IF)GE@D$B,G>>217$@,A7:!KAKZ.U\X:::::::::
M:K8U^O%2+"4:ILE7,:]:OVZ4E&QTS'*+LUTW"*;^'F&KZ)E61U$RE=1LHR>1
MSY 5&KUJX;*JHGI90ZLA+ ,I4E69& 8$$JZ%71L'AD964\J00#H#@@\<'/(!
M''O!R"/D((/GK=*ZP6+<L3V0[(:W8XJ#6DUA \)$U1OBW&D;-%;X-N=N:DBX
M.&AH,]QFY+,,/!U"1+%-96:;(V1%@N+%DG&NXS"PR55(E/%V:F8SS$.\IJJE
MDS7PPDO([R""-*)WF7>40F(L,L6#R'".SMN10J\!0B XB9AA0!N)D 4X!/('
MNQW/<7;0W=F<5Z'R);HIBRL,BU+:IG(%*E8N:AHG-,+C] &K5GCZ&")<6NAR
MKO(K&8<2<G'UJ/B'2SMA8(PZKUGXM5>%B$CT\+LT:GM)3SHT;O125!+$U$A<
M0U"+3-&$1Y6<!6B;"D4@W%0Q #$;BZD$"0+QA !N0E@V2!CD$:Q7E*CX6J=2
M!W6)Z5D[V_D85!2L-\B4NZQ=)0/%J/9=&1LE4J[>)R"9X/J*S*6K+N!C8):3
M6KTB25EX&04<2Z6>MFEQ+&BP*KGNFGF@><[]J%8II2]-CD,DHD:0*)%*)(N*
M'6-1[))8D<;U8+QD@LHP^>,%< 9*G)!UEZ\T#:G-WRTM8.\+P 3MLO#^'EXJ
MTU<,=P+.8SCDK'M(A6T -:&1:P$#5&^/,H3,L%H=*K452::1T0U4?14PPAP5
M%V2"(O ).W# KH\4OK,C)0TU1.YD[NUI))34TJ)V@!.$9G(#H;CI 7(5L!F8
M@AAM4&21%&"/  (Y);.PG YW#B7!NV+X.,)%/+RC^75O$W!MF:61<>1B%G@H
M:!S A&*+H2\,WF,8/+E=J!14F-CL\?8:/6:?EBN2\K-23YC-,X_WUZY]UU-(
M$001N2::H<Q2/)1%\%'V5:P05-1NBA:.HEFHY51%5HRWG;BV@]S)W,,;E 8!
M9,>(S&69%&Y@R*L@))P=22T8MVI2R;Z85N+^'E&!<05DU7HV0L&/V<.@TQ+@
M=O89%S(RKVH1N0IFP7:9R=$SUKJ!VL)7YVLOK?9R.8YTN5S:BJKJA5!"KHWK
MDO=GIZ]&<FKN!C4*JS/3I' E*\<,P,DD<JPQ$.!BIDA/.2".VI"M%@8CBW')
M*AR7+@LN "I<Y4ZTURY6ZM4<A6"OTJ70G*PR]DJQ,BA9(FW"9*1A(V37:.[#
M 1L5!2$G&.WCB,EPA&[F(9RC-XPC9>?9-4)V1S-'++-3QR3H4E;>'4Q/#RLC
M*"(I'>148*&3>0[(RLR1L3&MAP%8A3D<8]H/X@'!90%)&<'' ((!.,G'&I.J
M----------------------------------------------------------91
MQ^C&JU/.)WU&DK:Z;XMB5H:>8I'4;8QDAS3B!!6\S!BJ$!&-?Q"\KC9)50JI
M!E\A1:()@=4BJ<6H+=ZA"SK"#5.'C8X-4OJ581 GO97"5../8IV/E@UKC;)E
M2WL#!&?8/<C&XX\B,ISQEQKT>]!)^^R;.OY5Y _H:R/K6NO?]$KS^]4W\MIM
M2[;^SJ?]TW_3?6A>>YB4KVZ'-$_!R#N)FX//>1IB'E6"ZC5_&2D;D.9>Q\@R
M<I&*JW=LG:"+ELNF8JB2R9%"& Q0'6?MR)):J&.10Z/;Z9'1@"K(U,BLK \$
M,"00>"#C4:4D32$$@B5R".""')!'R@ZQJMD*[.*<UQ\O9I52F,G)73:O&<#Z
M@FHF[D9!!(0  549-)&9FI-E'*JG8,92:FI-HV1?R\BX<RA3P"8U B3OL-ID
MQ[1&%4GW;BJ1HS ;F2.-&)5$ M[FV[<G;G./+Q)_C)/SDGQ)S#M7M>::::_1
M)1IG%MEP;CBL2,C)IS[]M5TIJ;(\0'U(RE>4>&DFZ2AE"M5_76X U;)-#,00
M<<=@Z2+_ (@]:4M;;>N^M)8*(TU/1=4WT+2F,F$T7QM5P)3DL!*Q6)@K.S[V
M"DELG7[F]&5ENN_0O1%'47*&J>X='6)/6^^5K(KM':J2H>I4Y:G6.26)F6)5
M$:/M!C=?&>,(N8R7,,L97'*$<A$4H[*8@)V/<.$&;QJJ8[ADU43GHIL1AXKA
MFDNZ7,1RB910R3=P0HJ+$P,S45%#!+30R2M5^LQ(M8)(U@C=5W*NQO:W[R%P
MRA6&6!]E3EH?C.NEKFK>U3/1&W556+08*BIKY()7C5Y Z\& 1!G*QR-(C;8N
M1D98JSRX6VLR,%.M&$HK955:Q1;1,2?2+".8+%725;L2&$A$#-72A#,E#,#%
M=.A>$$.I45<&PC1HB"THQ#&5RP-/.IW20AG 5@S*1EBR@XY8C;K9SE&GE5EH
MV22ON-2D44;_ !I12Q^KPUCI!F2.2/;$WLE93VV5T 82K62B<O-H-YHT;6$4
ML+>O-WHD*"QIITFL+ '[@#K$!D9-1T,<51))<PAT\#T*E4-0#B(QJK"3;%'*
M5P 8S,I7?R6FW';D#8HP"<."!(01+5]V:H+PU\\\] C!G,4ZV\B6*!@JBD"H
M)G3>9' :0!>W@FQQEK?S-/MEQ"OQ,<MD9P#>HP3QH_078*N#-2D22=#XK<0
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MP.)F"E1V:&<.S4V]\LQ,CQ2JH4!2SD,A=@VRVN2:YU$%TBJH$I*M5I8)6CD
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MLN-:+ 4>V+B"U1GFB[1A&O 543DFR MY%(0.S1545$J::S<3N4F#E AETE2
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M6DJ(TC:2)L_1/687,L:F1XO:Y_#.2Z#=\@3D61[=U5I 4S>!U>R&R<@^071
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M%33.S=Z(2QR!BNX,CET).-QBCARY>*F7=N%W2Y@ #+.%5%U3 4."@914QCB
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M7*_+NVK\S'7H/Z"3]]DV=?RKR!_0UD?6N]>_Z)7G]ZIOY;3:E6W]G4_[IO\
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M$9?;(5*1[=PPV'(!VJA@LMJB6WT=/2V]*ZV4=8/BH3R-))25'9>6&?;W*B.
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MHY(F"SL\3*)(I%4D.&#1KY9V&8=S\R_EWQ1(Z>K"JJ41$PE'I   3& IC#P
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M;M6RB2JR2B"_6]]8'K29'6,9'EGHU^"16=:W*YV66\VVW114D[1U06>L)J%
M>GA,9AIME.9 #+('9T3.V%V;C>_27\/&CZ-H;3?Z2P76OJ)*ZG]8I6%'0!Z=
ME:"><R)55:S5*0$+%$Z+&Q"AJB)5RT,:Y?OE<MB#OV^@XD;M 0#I/@95B,BQ
MG&1F/J;IXDXEEV\DZ24Z78G%1B<AE %T'20RNU7WX O7U-;J.KM-TZ>O-;%4
MU,%504=9+1%:<)'LG6JN5-115&\F59XF$#1A8S'ZP798M<Z:_P#$O]&U75W2
MFOMGZBLEJ>.DEHJZXVV&M7UV"9R8?4K/5W.:D:-DADII5[JN3*)#2]I3/A2-
MR]<H$EC9$E3<R\A*E=,^57$:HV="!$R' %F"RJ[55(JQ5EB*%64*F?PTC(D$
MVY0?^'[>*FV6.KGZHLM!>/4@MVMU3!45$%++W"\44%;2=Q*HK$4$Q[:1B8-V
M998]KG2)O_$RM--<^H*.#IB]7.QO<FGLETIZBFIJBIB:%8Y*B2AK1#+1=Q^Z
M8097E:"3$T4#LZ:B;;);S%>,7DDU<NG15["_CG[(R*+U!VO,QKZ4,_737<MQ
M07.=J[(B*2ATP%$@^"0Q14-LOI#^ [95%DN5BZG2GJ*6T4M#=(KA122PU571
MP2=ZOI)(9]T*U&U5-')&XBX9:A@_;CU3T5_^(3U%OZ@L5^Z:DJ::MO57=;54
M6VNB2>EI;G6PK'05L<\(2:2E:8N*Z.5>\H*/3*T8EDK:SO32DL2J4V5EGS9,
MYV:1X)090@$>()H"J_!5BS<,'+15L\=LFBBKMJ\*8JPKLFY 075^<;Q\$'K6
MFOE4UB6@N]ID9JBEK&KZ:C,4@#[14TE2Z3+., L*=*J';(JB9F#JGUQ9/AH]
M%5G3U .H/6[3?8J8T%5 M!65+S4SM$9A3UM)#) :9R/8]8EI)@\1=H47MN^S
M&3-QM(@*!C4E7C&-5<TLY&Q%HM,PF71,S*FR4!@!"HA'I)G4*55JL?UD 163
M*=0A/%^>>F_1MU1U-U(_3[6ZIJ+Q6U$U))%(9%J14B99&J*EI,=@P&-C/))A
M(H][-MQD?2'5/I:Z2Z/Z;7J"DNT$=DHX:*LI(8HH314]**.2F>BHUB7$T-4L
MJ-!$GM/*J!"X.#JA=MU,I;L@(91=.WTHO'12S<!3< 0SJ5.FFW.X=#(QY5%&
MBI"@51HFBAR4_P A8O!D]?971_P)K]6].WBJZEO5OL+]ZG]32(&]2U,D$D;R
M25(BJ*>.&/:.W$%GDE:3+-&D:#N_"/6_P]+);>L.G;7TGT_7WJ)*6J2I4D6.
MGHH*J&9$CIS-35$L[@YDE!@AB6,X65Y7/9Q=2-STO5K/;K 9LY2"QKMW(ILC
M)*@<6Q1038/D#+,TU&1DUW!BJ(+$.ER*/JS@BYSI;!??@>6JML=BI+;U"D5W
MM4E4:ZJJZ.04=<M4P;-/!%+(](T';C148S"<,[RRJ41#C>F_AH7BVWWJ:NN-
M@DDM=\2C]3IJ:JB:LHVHD9%6>66.*.J68332&5!#V&5%C@<.[K,5,Q)?<RGZ
MU'2CU96X3KJS/TG!WS863UVV0B7"*+ A%HM0HQK1H"3@C\RHHI$*L!%0%L7'
M4GP(NN*GJ:V/-=>GSTM2"G$=Y@FD[JTB@U,S+;'B]9];>5C3]MG$0D5"9^R#
M+JS7_#YZ"MW2'4$,-IZC3K6Y/4BKLU53(5>J+"CIX&NL3FD]0BA5:M)1OE,<
MDF*8U+=G4(<;CGDO!L:;9HITM!I/6ZDJ=K)IKD6;,ECE209,'+$KA%L9IT(N
M6JDVKXX^*HFX03.1NGG+S\#JS4M9=JSI7JB:FF=)Y+92W2WQ2]NJ8'8U1<J:
M:(B,29<-';-ZJ44B0@NUNT?#/O=PM]BM?6/325E,JTD=WJK7<Y(Q-2(5:2*G
MME33S>,6(W1[KLD/<;*!Q&FPLUGB,R,YK%T-9(TC"E1+QLPC6ZRZZ[Z4;Q"D
M.RBS1+UO'J0+5")>"<@BDJF<B"0(F5*J*H_)US]"'7'3E55V.HZ;O-;6UZTT
M7QC1TLUQHIHS/#,LB5E*)4D9BB(8W9&B);NJC)@?85@].72?6WQ9=K+>+5%3
M6J2NK$L2LM-<5FFAJJ1EDM\\<$E/"'GE<3*LBR$*(7965C+S[@K SV\P6))"
M0C%_:L>R<09B/XMR)3NE3L1;2BBJHRC,C%NJ1OZLH4B90:IG2ZD@#61O?P=_
M2%;K[<+E56*NJ*"G9[JU31=J:.014O?F>,QMWGED*.>T5$C3,!M)=2=@I/27
M2#IVCH%$2W8VXV9Y9YI"A@>HW0I(LK;0E,KQQAU3:L49C5RJ$+<KW&X[J,!B
M26B;!:KG)198J!5C+$K"*PI90R;9A+&BVC=J>0(FJW=K.V"\@NJXB79^MNL=
M=FB[URBAJ[G7SUJ04$5LBG%<TSQF5)P',KA#,LB?0F!$<ZX1:A&DC=.U(R-G
M[C16BPTULGJ[U/>JJC>V0V],Q&G:%8H*69WIY(I2*M09S3.'E]5*P3I*9XE9
M>R@V.B7YP9]>)F8=0=1F)=6OU]VY8HIS,S%L4'46ZDYTR:"@1C-\*3I*-(GZ
MTJJS;F%TH@L?F_<K1>K#3T*4]F>CEO=L-937 ;U"1333TDAIU*L6SZO(HDW@
MC=E0.'-=!<[5U'+-5W6_FIHK-=XXQ:ZR'>+C#1B*>.:64.BE1.PPG;VEZ<[B
MP8KJGQID"M*W+&4N^@V"ZA<@RS8CY$C8C\M1*V69J2)D#/63=.1;G55(VE%2
MH.7AFK9RY%\Z#UAQ8N%OKVIZJ*JGE]7:TQ]R&(X9[D9=T(W+&6(<K SKNV ,
MWM(&*BU:KU;%JZ&HM5)2FXIU)4&DJ:I2\<=B$(2IRCR[!VU:L2&7M"4L(F(E
M9 [5U,R[52;KIVV7%4UJ8UN).,?$2ZP/'":\D]01EG NE$W2IA1!J4A9 '!U
MD#OU0.)T#<$R(Z4ZBI_1Q%=Z*AK$BJ[Z;5>*JG[L5//#%3K50Q3RI(NXR-)]
M$1HF@)IH7<][;NL?Y8]+U7I4N%MJ;O3P^H=,M5].4\@@DDM]74S^KSS4T,D1
M5131TZ=HI,LR+552(1%D)<XC&^!,_P">\G6/)\"W6K4=5U&];4CWTFU:R-F%
M5=VW;E&#<1\@_5!HBW9)KJF.T;&<_LZ9>HIT\S8O2?Z2_1ITM36'IGJ6IMAK
M[A-7+$:&CN?9B2.11%3"ZTE=3TD%142,9A#&C22PJY9=L@;&7KT<^CCTJ=;7
M#J7J/I:CO5-;+;;;9/*]QK+2M1/+4QFHJIFM5505-;4T=%&&C[DK1K#*R!6D
M>("'[<<+[54+)F-"X55.QF0E7L=2FDN(RJ$>1.%:R+=FU:OE 2,)I%8[5R^<
MF7>-T4TB%7(47 +[7UIZ?O3)>;5TA30WNNL<JVJ=KA6V-([=/=[FE740)4U<
ML**8T6E2$-2TS0TS5#R3&G.85BUKH3T$>A>SW?KBH-DM%_CAZCI(:&AZD>6Y
M4]KL$M'1U-134$,SLLDXJ)IRM54I-5]B**!*@ SM-(([/%.AMO-XQFC6H-A%
M5JS3,97WB+%TCZ[ $:HK&C5%BD.Q.LW5DP]97<+ H*3=)58YU'!E-<_GZ?ZT
MZIZIM5]F>Z7*_P!Z:AN!KV61ZV>X"::D'J[QJH";J=63M*J1R"15"JF!NL'6
M71/2_2U^L<(H*+IRQQW6Q16A @MHM79I:Y99TDW%YT]:FIY"[,9HNR[EI&);
MQ%<BF+EP*( "(KJBD >0)BH82 '8.P%X]P?@#RU^PEB2XQV2SQW=]]VCM5O2
MZ/E&WW%:2%:U\QX0[JD2G*#8<Y7C&OQ[NST4EUN<EM79;GN%:] F&&RB:IE:
ME7#>T-L!C&&]H8YYSJZ5IG$2%CK["P2J<% OIN*9S<XJV>/4H:(<OT$9*549
MQR+B0=IQS,ZSL[9B@N\7*B*39%1<Y"&R4I=8Y&C3N2*CE(\JN]PI*IN8A5W-
MA<L0HSDD#4 8) )P"1D\\#/)XR>/'@$ZW,N%?V:QJA64-8G<FM-PEP6DY6(/
M:&S>D3,'CV0DJNRKL.^=V%O+*6;(<?%PCL\K<+3%EC967*TDV"+B)L,!AH9+
MRPW/&J"-X0JOVB9T>H596E=5C9!%3,[KLAA;<B91B'BEOL*<9 8DD-R P"D(
M2H YSN< 9+,,,>1P173DSMOK4]B&'AW%+D:G Y4S=+NW3=.VWB-;P<Y7,<0V
M&K?D-C8ZG&/9]BC)UY*TWJAQD;((O6K.R1B=7@G,\:F,J8X[E)'5NXF6:2DH
M4 )A@<R)+4O6PT[13,L3%)##3U#,NTF)^[((^^WK&(% -NU7D)(#,,,$$;/E
M06 VY9 O/M#:"VT6>Q3>(W]#4;Y5L-2R#EJ)8W)Y R^/6#B,9*,YRU86A:I#
M6&2A*[6&]L?UZLJ9BN%=B#/&", FC!P,Q.J("C2(NN..L6I!I(Y:>C=H%=*A
M@Y!CBKGF>-'DE,2RR>I0R. QDS)(D8.9WI8IM.\JS@-@H,#DQA02% 8JN]AR
M ,!2Q^E&:+!M\VQ4B;BD\HS1L9QLK/7^-:QDHQRV>Q/<>QTU0(VI7LL3;(&@
MS<-:QB7]O</7*D+8ZM)V9F[;1U$,6"GZM7(4=PN<\;^JIZTZ1T[LZM2"-:EH
MZAIJ??#)41R0[U@"@/'*D3 M4?1(YI;C11*1O)C!9QC$A;8"@5\,$8-@MY%2
MV?9&"JX9B8+:!+':-5IH:\9&KS[!U*2<C<9)N:82K.$Y"/M#N/;,XQ9T]^$,
MWF^*9Q4.[;MVK"MUAR:N7.1BCQF2ISO>$W,$$F98V5%6%3L,M>&B5RS!5[4=
M S,X)9Y)1W8%</2VP(#@9*^RV2=Q&0L9!( '[8R@ $<*OLL1A](-9K5C3333
M333333333333333333333333333333333333333333333333333333333336
M0*-D%]2H_($"FS1?0&4ZE$T.Z( H+65-5XW)F/<HG+79(R;MK$32\YC:#:DD
MG\3.,T(]Q($/$N%5454(\].LS4\A)62EF>>$^*=UZ6HI?HBY!= E2[;5="6"
M^V "#4K%0X'@ZA6]^T.C\'R.4 R0>,\9Y&_?HWMPVV_;7Z27;?GV=/><;8'H
M<].N+0^N$@7*=D@BS>.KA5SR*RF/Z#5W<O'DEIMB<6T13%9)!D"ZA4'JA 3'
M7^I;=<KGTU<K?'V*FOJ(XQ$L*^JQ2=NIAEVCUBHE"-LC;EY@I; RHU*I)8H:
MN&5MR1H26R=Y&489]E%SR1P%R/EUNID/;5Z"[(-_O-]<>ESR-&N+O<+-;UXY
M'9CG5PC'K66:>S*K))PI1TSKI-3O3()K'33.J1,#F(03"4,)37/KNFIX*<='
MT[""&*$,;W;P6$2*@8@3X!(7) \,ZD/#;G=F]?8;F9L>K2\;B3CP^74/^)YZ
M"C_M@<E_F5YR_J5J]\<]>?\ T=3?PW0?I]4^KV[[(-^+2_FT^)YZ"C_M@<E_
MF5YR_J5I\<]>?_1U-_#=!^GT]7MWV0;\6E_-I\3ST%'_ &P.2_S*\Y?U*T^.
M>O/_ *.IOX;H/T^GJ]N^R#?BTOYM;G;9WGH4=L-=L<#4_2E62=4M+\KR4DYK
M9IN(3='32;%;MF9$V5211!!OPHJ01*)Q464$3<" !I?45FZWZBKHZR;IY:?M
M4ZT\<,=UMCHH#O(6W-4@[F9^>/  9X&,A33VVFA[0JBQ+ERW9F!)( QC8<8
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M[3O7O['6K^&:O^PM-M/]5F_ )_6-/@GLN^G[=!^:'BC]=[3O7O['6K^&:O\
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6FFFFFFFFFFFFFFFFFFFFFFFFFFO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g551455g13p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g13p01.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M.2,;QG(]SG_%BM[XJE:1.;)@U:L1[^;R-B"T,$," ;-35R],2$M\E</]A4<
MC4'IR0DTQ[-Z16'A1[]VB-8OB*J.C)FY7254 GF_7W:S$7E,<FP ;*8D;&R*
M.F$=UQI@2Z2>,76B2RK5QKHLEMMC5=H[0<,WK93X#ED];N&;M)%TW62T52L_
MQ2G%*PYV0A(PPT*2 FT$CU2@((DZ>JX225,2<X.C4=&)9SY<JOC4@+C PUMI
MC95V1?M6J.NRJVFN5,9YO;/XAD_DK^A#P62L-B@ HR,#M2!D3L]'N$W+;4G'
MC#^/G&.54L[:X="38LB*?H^7X;=\R<MU,842VQA2N<B7%B-&BA4BR':/R+(0
MQV>N46VKPH26PW'CFV5M],+O7J^VJ+5LG\)9=3.-$]-MOS<4KI*R8$A)F,.5
M()Z24F"*R9B*RFOE5P"!D PLJ0U6PEEKJFS?R$,VW347T7WV?)[))*)IK;I*
M?K^OXJSO%*<4IQ2M'GMDP:KQ+0W/9(PC8X@1P)'*.\.%G!(E@>0,*LAK!DBZ
M($%V@0.8.D-6;5?YN AC!Q_EN)%$'C950">89K"IW=4BTN"05O848=RB2-1[
MH$.9DDGB1/4N&>20,V;$VOQPG8D;C0XC) 8G9]J4-1T>_/"V;L2S<O$E,'M5
MD'EL5P/GPZKGLQ"-I^6027'QA5SG#]?+AB7*LV?PL:9:I%" F/2$P,#KN$BI
M,/'CY8>S<C@I1RU4P<9Z.:M5:=CJ-( #DG867&GX2//08\@[8N%WBBSB5/-A
MT0R%8MVZA"2-IF0368PI]'6I5C,7C=RUC+@JNV<:)J;)!P0<_)S^YCISS=-9
MXO<]5 HE%9X3G<=2A\Y48HPV0(/</Q\I5)!2$D8Z -Q^KK<KLO'Q!4WKAGHM
M\ 6-?OE/@-FBZB:F#DC!R.<=/:YJW:/2$!+08F3Q8T*D<</,&Q0(>!D&I4.7
M&O$]5FC\:18JKM'K-PEMJHBX;K*)*:9QMKMG'%4K]M3H5\1<B618<\*,Q8@X
MZ'MGC==XW#'UBK8&56;I*;*ICRZX(TB->;:X0>J"B&C=139HOC12LKQ2N-)9
M)=/55!5-9+?R_!42WU43V^#MG7;X.^F<ZY\FV,ZY\F<^3;&<9_/C/%*CO:X*
MM36L)!6?Q5%6IQ>#EDX7,-$-84$RD85R8D"BRFB; 5I]'9$@J14W^1I/(^=8
M*K:/0Y%NV57!W;COYO;]S]>D=NI&3WU4TT4T\OP5--=]?A:[:;?!VQC;7X6F
M^-=],^3./+KOKKMKG\VV,9QG'%4K]<4K19[9L"J]B()6!*!D69'S6(X$6)J*
M:Y*'/F8S(MAC))%)99PZ3 QTZ96T33SA 8((/5LZ-VJRFJJ@$\PS6SA#8:2A
MA,BCI8:?CYX:Q,@S@9\U*!S(@FV2>C2HHDR579D!Q!FLB[9/6BRK9TV53705
MW2WUVRJG-SUD^*5@C$F! '\7&%R";)_-#RT9C#?=-??8L=;QN0RY8>CLBDHF
MBHG'(K("F5'6Z"&4AJJ6JN7*K=%93_I6=XI3BE.*5K<LE\<@P5>0RHFF(#-E
M6Z"[Y5!TXT35=*ZH-],I,T'*^<J*[:Z8SJEG7&<^7;.N/S\4J-D>R%%./HEE
MO:$47UG*J*,:42?;*(O%'<H5@[##Q?5+*(34I-T%H6(4.[C4R\O3VC S=V<Q
M\@XJNR=^X[N?^_\ NWGM#?6V1.U:]G1J11Z(2H=("\3(EQ$B:CL.5=!90 :>
M1PV/7=Y0U9[O!)X>^$$&Z#A55H09N6J^NBJ"FNJA!'.#T?E&1^2L%I?M,;JS
MI'ZR8HGM6K<F\FRBY)-NV!M 9-V#.N=G:^$VK] #(&#V-'5A:SY,-*&;F-$]
MFIU!0?JILG=NY^;\/-^/H[==1SV+I!D'C1][94:9BI<[.,@KEVY6;;[+Q8NA
M'Y;DJT60T>1UO#I"[9Q^9O)$W%-(@>>L0LD7%DWK5JJILG?NYOU_Z'';Z*SD
M]N>J:M?"1UC3Z,PIT;8%BP[$B))#$-Q %P*:FS#EXX^ S'!Q+DZ'0(E2*[0>
MS4)L]7#E/*^GE4 )Y@3[@SS\U22JLDAIE5=5-%/&=-<J*[ZIZ8V4WU3TUSOO
MG&N,[J;:Z:8SGR[;[:ZX\NV<8RJE=(:7%F4G*XDBR)(LR)$0[58N476C8H(>
M+#BHY?9'??"3T<_;KLWK93.JS9PDHDKIKOKG&%*[JRR3=)5==5-!!!/=999;
M?5-)%)/7.ZBJJF^==$TT]-<[[[[[8UTUQG;;.,8SGBE<G%*PX&0A)0.P6CY-
MH7&_+RXO9VR5PJDF3CY=\ .CEO\ 9LB_#G!A$03:*ZZ.&))B[9N4TW""B>JG
MZ_CYJS'%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4KS/0ZW]E4I&0M5](:Q('[,VNQA8T&'Q0P&DS&
M)W%&!PR*@2%DN+)+Q.8/:=^KRF8NT?#ZXB^7\=C\M>#'."$@?Z'57[2< 84<
M8P<[MQR<#&[.3TUN;[K]9..N7:6NTV3=:4VBS"?0]J,.,VJSM09UKHZLUT]2
MKK9NS$O=I7 9 W8N'BJ2&B.C$@JJD@XQG15,C:2>@')W?^8GF]RM-:T1?K-O
M)Y9&@VZ1UW9=C65$0EI6%H5FN"Q7J46ID%M.YM7[X<JDB]FK2-CQS>+RTB<C
M,.;-WC6:L5]&8>+*KD9&1NP =G^=G<#[7;W9Z.D\<4J/LF/T9[S1O:TN@B,J
MLE8-7XN^R\.L 9M)XC2*=?2*22]E:A)TK&8A*0-Z:E8IBUK V"IST"8 !9@X
M "&P13*>C&<#)V<])R,8[6-^!G'1DYUL%ULO<=$*6@TD#2:1/H00Z*O QH-=
M;T#6==1.A"5'$+<A\B@*!H<,F\C<R""6!*0![6!2366(R2/B7T@B"D,CF[55
M=I.5'//M\X&259 .<;A@C(Z,'=OK/16A^U;EE(!4RG\[1(/9!6C.6G0UG2@$
M,GHYKV#@DLG<I@SEO:DJ.P+16HA$W!8$14%2*:*$OWA38!(A0.*EP2F4]H<Q
MZ!N[' SNW[\'>3S9Z35H; ALNC%GU-;,)B3ZR!< KBQZJ+PMM(A:$YT&3LM5
M9H?*8N9GYL4#-D1[FKT!4G82F7!'ID<9T.MY X)@-@4F5:",$$XR01NW;LC&
M[FY]V.UC':B>81OM!,[GJ^9L8\[@4:#.J\?E1X>TB;T:F!Q,90G8T>G8=*;#
MH><D#B$OP"K!@%JF0LDRBA;.MLDUHK"?C%,I (Y\Y W#VL'MC?[?X-YK2(]0
M?8F)PJ,,'DKLN9)YK?JZI;<>VOJ9N9E.IY#E+(^OEO"YU()8W<0Y_(URM=E-
M\B9%#8Q-&<5WAKI]'!)1^1154E))P!SJQNY@<8R.;=O[9'MUGV54=A]KHB1U
M(E/0%<(.*V( &+FSSTE6@<5C@[3Z<U[8^2EOO!,XD$M>IE,+2=>OK;?$-)0D
MVUGT97@<.DC13(V<;L[^@#/-@@XW#\(Z=V\UM8JK)S!:3ZK,)-O,K!ET"G5,
MG[J2*2F4V>>DDH)1=6!R>1_.IX@9?.A,-L*3#+2<),MFH80*AKHB('L]6J+?
MBJ$@E6-P.<;L;LYQN]K=^2M!"=<;O&[REZE)Y(&<C#C.2UL)CUJRD%%TS9/N
M)>UM3-\>BX4LQCIK)ZIY7  Y1O(QA1J5:9(QER@HBV4QFIWD^V:9'Y.U_P"4
M <_:.>:MQCU:WFV<J(.<SYI,T+<:2"3V41N<V8@,S@NUI/C[=A#:VS,G#6-L
MVL$58C3L77AT/;L%6V8F((S00JO(W%*9'M<V ,#(.,9)P,_E[>XU!FG7WL\L
M*:D _P!,HY8X>E T$FLSEEZ2";*V1,4[:IN6VLZK5-&:MB,"!V7!X;.0T9+L
M3-/E6A,^(;K@JR;QT2:U57*<]&,Y   QN.,[CG>1D=ES'GS6ZK]?^Q1B"[Y^
MG%FB9&+J3L,K !"]Q2T&XCUN2*414S1^)3L$L>8MY4UC20DSG#673:RH\$'&
MWL26=FH[ALT24VDYYAC*<[AS ;^@<^>@#.,UL4NJSL,^%W$P J3I&QS4M+&@
MMG;7/(TZ_.U0YNN,2IC5D/KH;8D=S!YUI1S!_5V).P U_N,D;=Y)Q=H)$)K(
M)$BID;N;&!NP,Y .\G!R,[SG.>;&X5/M+P:Q1=-+1B7RZ;1Z4%"DH>#B;L@&
MDTSA <H<=.A U$C*B]QBGKM@RVPJV;'9)8[(-H\U"-2I$4*'I(JM)&=P',/:
M!W>UC^X9J)KSI.T3@.N&^LRMRV$HI84CDI0E#9!5]2W,.9%JMD]?@DXC)Q8N
MMXDFP9O3[LE+DUG(@P15+.7PARH*$,H&\54$9.X#(P,Y(YP?;/Z]NM;A4(N0
M*;I:,VA5/QE=T1 JX<M'U2/H3M#I+;0"J68"134M'52H.>N 4(6R1BE6U^"A
M3A-1TBTE[_YP>-88,A:F1OP=ZB<YSG&>WS;^DD^UV\_PO4UL3J2'FBD->12/
MW+<E+=CBLX5D$?P5J;$&J6L8N<K-<2D_R<(3960U2/'MR(1FXB2\<G$F<.SC
M!^"0$R55<@<QS@$<VX[S@[^C!YCOR!V]VAQ"B;O#%Z;L8A6K9L_Z[Q#K[ -Z
M["RB(9<6KFKX)V(KN8GH@]<&6L=9QH<C>0Z5U*TGA6''7KV.G&$F$0E5Z-?*
M*9!!&><DYZ!DI(_N(./:P>>I;:]>+ (PCK<&($G41*Q3L/;-VSU6'GVB!&$#
M+5A_9MZG$XL6<CG+8HG%Y%<D<@N%VX]--V 9OB+)-HEHE\4JA(R?< '.,XV1
MT=O&:P)FB;9"7%6@6M4)%'*/AGS$P=O!-LSIK@Y$RPZ>IV3K,4GEHY=&+!)2
M24,C; PTKS<PZ43Q,G]M[2L+'  E501@YYSGH'M8QNW >[C&[&*BJ/=>NT$1
MJ*K(5&B,N$@J^J[K?"Y?!<VD>.&Y6_K5#L0'M'$).)VU#'(YI(3LGI29A,N;
M0@&AN!Q$?7\@2#C1:D%354J223@9*E$'',#LXSN.=P4.8X)SS[ZE090E^?*(
MR;*V#8;HM'XYU,'CFZMQ3)H/;9CEZ38WV):'00^3+ I85(T@?!PQ:22K,K.2
M54&Q<IR)W(F>LD<*IE._<,=GT;]Z<)_+O]K?T5HD+I'L!4R=7(PB-6 =S %I
M>T(QN4WU('M=GT4Y?*S.II)SFV6IYD3E(4D'1C>LOBEIQY=RWU#R&#U;LD[F
MY!N_7M?K[OY-]24G/-OZ<;^;&_<0<>Z#OW$\PFLIU7T7SU:U=8;R C7DV,E;
MP/:.UPZ5AC9"!F-G25R3$Z*[)E61[M>,JRT-0.V?BQ[@:Y;([:QUR?$%E6[7
MV1[8&/:Q@#'N)R/<]O%1BG5/;4?*;O,9.F#[HHQO#2)X<3R5CX3)0LWG;<C5
M($&-872P(1J4UU7&-0>I2.QVA56DH&[HM;$+M929FK55<IW;NUGFR,#?T=)[
M>UNZ,[J[4(JB[HV-$R:U7MP2*+UU#.U!=O XW;TVWFT@7E,DK:05&%>-XI/7
MKB42\3%!ME (TR>S"6M(04,MQ,://44@1A%0D=&-^SO('0"#T;AS9W#.,U86
MY:@D%D..M: <Q(XNQK6V',PE10/*=M)4P ;]>;OKE))I("R!9Z9?+R2=QYD0
M=J[*$W;-9^5V>ZKH[K95:#C.X'(Z1[8/1[G_ $J"YEUKM".@9V.IB02P*'$K
MTE&:VB"=IV#NSQ3\*;0W-BQL&SWL2+-Q,XDRH1_MF5OI.!D$I7U6%FYZ#'2D
M^9PJX*!QD9._)P.<\W0=P[6-PYAN%92(5#V1&N*?:NIY*-HP674<W&G()\87
ME41&P&TI);%5@XK\5()<D\7EC ^A3EPKN)A*7I>O0@0:\ELP4%8-D%4)3OW>
MY@#'-@D_AWC &\GFYJBF!T;VZ(%PIJ4E,Q9^+. I8.P=FI:?"(98Z]!]JZZF
M<DB ^4S^T32\,Q+K$J/8&,)RAN].!!;PN5BT9*[%QNZJDIQN]OHP<93@'  S
MN.?=YS6RUA0781VG"6%CRNSA,:;V#&7=B $[IG2#PH,C],W2%/E \J86].YJ
M^CDMLR358[W%[R^((ETX<C(2%81 EL<S(%"4[]PSOQ@#I(W'<.89Z-V<9/1F
M %3=E![,6PD)><G)MBEH=$X%8[>X3&D/K"?@8C(1)T_:T&S*Q.EK/R,B<B)+
MI('<;L1W,E]_F63(1EG'F1<NJA*?:QDD[N<9W8[7:QNQ[><"4NL->W#%8_-D
M;)-3(2Y,M(\-#CSTL<SMT%.C!)!M))C'RDML.YGJK0Z\>C,LTBYX<Q([1U,T
M^K**EB\@^?E%$$[L=/1@<_-@ ?+OQG<*WXS#;FC=>6$PA]K2*Q)\=#H!:^*V
M**K48U@Y5^HZ'_2Y_K!H/"VT@3 [F-9 1%N6F<EA44& Q39L8>E"II5!C(R,
M#IQG?[6\GGYJB&9UA*Q16FZ4B=5G"_6R"1^MU#1>/R>#)R.4&(!(M58=$IHO
M+9)'Y!I"8>L&&3Z5+ FYXQ998DD!=+#@;:8@Y^JN1O.>R)/1N //C'2>8=KG
MY\$?V#1RPZPLJ32 %6M@1ZMBQJ3(2B&.;.4M 3,[-N"_ )1G;-;#'IT\^KJ#
M1<5)K'F-F#MQM?(90/H),X412AS<MNH3D#)&<<^,;@GF/-GF '/4*N^M]TOV
M\*&ZQ,>AGKPRD7S 0>28'EO>CE7MUUZ[&A/F?9JY=/8T[/Q+K_L#F3N<L0J;
M"?SO9,?I(HR(=29\JN4[^??T=KL2/P[SNQT#HS@<$PZ^7<<TN^3,:^;[O^T$
M![!5NK#B,GB>NU);V>.KV*PZ12==(PJ'* B@>'/Y;;[2 $I6:9R=<0(BXZ<-
M<O)"R?K^ONT"@,?^4I.<<^,DCW,[A[62<<U6>M[KOFX;6AKV2%)&G6#2CKAK
M*<#P4H7CKV6ZV#):A<Z1TTN-31-J!"X.(R-,FY"DP[U%39)+1ZGEUKY*] 'M
MG\N/DJ@5@'&,Y!!QO&,\U5?L.@.R-BR>V4R[:1MH*0;2YP,BX"Y)@"#29Y%[
MUJR8TUO#=-[7*NH\;=53&9B.DBV6=11D5-SN ;0,]BS0;*&]*N"DC';W<X!Q
MV)VNCMX[9P/QYRQJ8[8FT0J,?F$V9"EG][-V+478QK250DC,K&;EZBE9HQK:
MT18GPL-@^B@IRQ**6DG&G+9%D/K6=#SA7#!5 4](W[O<( WCF/.?<SOR160M
M;K!<L[A5O!T)=,7I2TPG;J*D!I*Z; 0B^8Y8"9I6B1S *B?W$QIL&=MXXW<[
M@1K1V+"/9$ =[O0)@L*>J)4 1D<Q2<X&=W/[>_?^0\]2]3\(M<!>LHD!0;8+
M*K3<$:_(FUEVF5FY*.GT1=8C@<8CK)E:\JCSM!LS"S%U-BL@AGTG;3)1P2!6
MK8 B<',#E4)&R.;(/0.?>3GF![73S= QOE"A0Y8<(L8D1$D(ZRE=U6G)(]'2
M;1<>['!%9(L)U)Y8N$TE6R,[*""EF-M%$TUU$)JFN[32>JN4M%45T>T #S<_
MX.US?@J=>*I3BE.*4XI3BE.*4XI3BE.*4XI3BE.*54/SB_AO>OUU7]KT']X.
M=)U':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::
M[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ
M_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA
M(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\
M-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K
M\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/
MSJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O
M!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::
M[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ
M_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA
M(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\
M-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K
M\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/
MSJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O
M!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::
M[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ
M_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA
M(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\
M-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K
M\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/
MSJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O
M!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::
M[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ
M_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA
M(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\
M-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K
M\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/
MSJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O
M!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::
M[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ
M_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA
M(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\
M-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K
M\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/
MSJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O
M!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::
M[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ
M_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA
M(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\
M-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K
M\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/
MSJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O
M!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::
M[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ
M_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA
M(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\
M-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K
M\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/
MSJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O
M!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::
M[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ
M_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA
M(\W3::[LW[Y/SJ><7\-[U^NJ_M>@_O!QU':K\';QXA(\W3::[LW[Y/SJ_P L
M/GV94/3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI7H7(O"\[?Q5E "QN% V@*S^I\N[FPF0?2<>H$,TU X0WL.7:)/
M],9T2FX**/Q))[#E<:$M-30G7&=L/4]N<PUJ^QO*DH;D.*<B7IBPR&N)4'&Y
M\F08K&4],=QY*TI?!*/K:_8XK*6'!@D#"D%P'/\ )2,G\(&-WMBI#'^#9WK*
MWM4_7AA 8PXGET4GMV A3S2:B?HEM7">VB2[PS)?_1B"S5T[#,G(9SI\M2=2
M..IYU^"6;;YU5Z[TZBW3;HJ2\(T"X>ICZ>3KX_E6"0&VOLEME*7%!P=B0TZ?
MY!J[D[NTE&!E2=L;]V/;/XOQBM'A/A>=FYJQ$F?EE/0V-EJ7D-_;2VQ;9C$'
MB8>M8Q;>U)%"TAD)U1L,"N-; QJ.;M'RZ>R[55%YKOA-777.Q(UA:(ZEM[,]
M]Y$]JVAB+"=D/N2W87J@A#33>5. QNR)2#A0*<9%6AE:O8@;)7E2@!LA13DD
M\V\=-90)X4/;)Q);D!3OZF:0#T7.PM73>QKQNVO:YJ]Q9$G M)7%X/$YN2+K
M"I?()!$R Z4,VP'+Q%D!(L'YMP*3>-\*6.:TL@9@NQC.N*[C&<F1XMNM\J5+
M$1EU3#TA^.E 6PTT^E;*E.[.TXA26PO9.*AA>5 [*=DA)*E #)&0 >8DC?NY
MNG%5AB_5ZQI2RMTP@5KL5&J2GD#K2;S(Q8,;1@_TQLF;$(3%1X&9LG;^,GF#
MS(&5RY60CRBD<2@,/DDMP6W',T,NYAZ[Q6506RB4MVX1I,N.PW&=,CB(L=,A
MY3L=80\TH<8RP&E(#IDOM,% 6H[-FPKLN;"5!).1C)) P>;&XG.<8!.:M4Y\
M)WLS]*NO\6!2WK?-TNS/US;U5,(#V!@,QK\@TH")/)G:I(K-0;UT"$BXJ'8/
M$WQ!=UNU1)MEAKA1!TGOIK#)UI:>)N;SC%UCFT<@Y:Q)MDEB4A5S?2Q"0B.X
MD.+6\M22E( )00L BK^(7E !0=O:V2%@I[ 95DC=N%1\CX<U^E6MPD(<?H^R
M1-,L%W98U6=U0:=!9F[%UE(;DDX&LBD?(O&4WD,,K2)R:4RH4-6T6')!78I+
M+H_NT%.=DZJMB%042&KC$<GJ"4-R[?)C.,!<MJ RY+0ZA*H[<B6\TRRM0(5M
MA9V6@I8IQ*^RP4$)Z0H$'L2HA..<A()(&_=44$.H]N#Y=?\  =M8LZFW6>OE
M;&M6,,I$BX*#A@<A$!<\""M-4-4"\JJU]+\(V*$;+XW!:Q>9+MUR+:/K+*[J
M;W"6Q;)/UY,>[2A%AO*:*4+6M+ZXSB\G:0S,2QF*X1]<XY@*""Z +=A65#=E
M RH9W[L CW4Y[(=&#T UM_7CH7V&[/+5 TJX/&U"-\V1-ZPJ<7(Y*SCY&8EZ
MR@:]B6.='-G>FVV(;!P6K!J?DZ^4AZ9XNP",MGKY$JF-P734EKM G*F..[-M
MB1Y<U;3*G41T3)(BQ&EE)_=$EPJ4TR,J+3:G%;*2@KJAI:]G9 RHE*03C.!D
MGW .<]O=6L3_ *8]AZSC\4-RJ"/$WLVMZY:.C</%Y4-SLC85!/ 0VT!R$4%H
M.B:K2/DY$/&Y>HIJIN7FKI-'7.K;??F:-?K7+=>;9DI*8\&!<'GUX;CHC7-+
MBX:B\LA 4ZAI2]DXPDI)^R JBFU) )'.I20.G*,!0QS]-0HRJVS23@RT'5S.
MW[N./7@V0M640D#IP"(CV;P@_8&44!ZB@MZQ8#B#YXU?:H+MF;!XY63T1:K[
MZ;ZIL- ;4N7&2EU*5M%3[20ZA2DH2ILE8"TJ4M"4J3D%2D@'*@#;@GF!..?<
M:FWJITTO;N<>LF-T0 %G2=4U:>MZ7:%S;0$@E%(\_%#7*(]=Y_$('GKPPT2%
M!4?(Y(9T<Y1SY&^_(^\WZW6%J(]<7%MHF3&X+);;4X2\ZE:P5A.]+:4MJ*W#
MN3NSSU<AM3A4$#)2DJ._&X=KVZS4VZ)=DZ]ZX4UVFDT*T;UC?3N1I5LW9OM2
M,U*#(JR)DS$G>P]DDL6$Q5$4+4+I''^B+1<.\&%],_-I%JZ4QQ]1VF3=9UG:
MD9EVU+1EJ4G8CH6\M#;;*7U$(6\7%ALMIR0X%M_9I*14M+"$N$=BK.-^3@<Y
MQS@;N>JYZ5I8Z@\P73K^;;BH\*%GCY/2*'=AX,&<0PZ"F3#W5AEL,%%VV<.!
M9%ZJ@S((9PLT663_ (W)7E<3:0CE,?;=6MII''-[3CC1V7&T)VLK6VK<M"05
M(.Y0!JS!W[CNP3N.X'F)]WHJ9:SZCW-9@6V)'H$Q! 50]?Y!V2,E;(82:+LI
M)7H&0Q.*I)0AQ]'7R<@.2 ]- ;".I?"9AGRBCC=<VS30SOMH2[W B.0FN,Y2
MY.N;5J;1$4R\IJ4XT^\3('&I+3;3<=Q3I[):0!AM1-7);4K:W8V4%9VLC(!
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M._IR,X&[RKQI8-.KECT^.4#,8_%0]9RTT0&P>SD1$FD'<>?QB%0.8]D9"[7
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MASXZ^+3GLH7D"^^GTZRCAP[R6KXRV?SE/-8^!/ZSW?7]57/X<^.OBTY[*%Y
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M'&&-B\&5HAQG6(\Z<VXEZ _;I:&+4W+MJ[;),N(4/MVY"YA#I =]4#)#K:4
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M7!W;H!BN,7">'HUV<NVV&K<TVZJ3;F[5.B*CLPFH[<:7#04*+3:)+:W%.MR
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M%HM\YY1M%TA7&U.7#9>$=N',2^F M3*&UN1A&+\1I2MIY#;B,K5Q8KMB>_\
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MW])TZZWA_P#NA2/B_I/Z!IYLOHYZ"&'[\6=[Z\>LIP8>"S7E2]_2=.NMX?\
M[H4CXOZ3^@:O?SU.OGFG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*J]
MW9_HB]C_ -#TY_Y&[YW7!C_&'HS^L5K_ #E%>7\-G\4?"/\ U/OGYB[7Q,<_
M3:OQ/J4Z.@+&U+FJJLRCYV,&V!8</AK\BPU1W?,&<C/,1+EVST<:[H;.6Z3O
M=5#5;3=+*FNN%-=M?+C,%JB[.V'3=^O;#3;[UHL]QN33+I4&G7(41V0AMPH(
M6$+4V$J*2% $X(-=3H>PL:IUEI334I]Z-&U!J&SV:1(CA!?89N4]B&X\R'$J
M;+C:'BM 6DI*@ H$9KT,E'A]UT%E8IWK/YT-K415UVVQ9"C@="Y=)V("DY )
M O!\..0HZ_@9L_*%CHU;0*Y*-RL+:*:NY:Q;[.6K/?Q^#PNWF3 ?;]2+4]>I
M-]TQI^RI0]<[?!=EZGB2)3;UQBW.*S=HT2"F(^DR41U1[DX.+M[JPA;H^AKG
M]3[IV%=HKOJ_?HNFHFE];:LU(IR/9;O=(\#1,^)!>CVB=9)TBPS9]T5.C.)A
M.26Y=F95QMV8;4XTR8?@G7[K=8+">VF%D]WI4_"G5:PU",/QU=-+1/V=9A<N
M,&B&YY4OK!!$4'HC4G[R3G$F'E^5;L]66FS7+E;HKKJ[6EH=M-AE0=+JU%<V
M[U<ESF7KRY8H=CLD>.^_(7$3&-UD7!Y3ZF6H,53H'%APND.!">/L/!_P;Z@C
MW[54.YZW1H^RNZ:L[=L?C:<:U1/U/J69+BQH:)ZY@L,2U1VXR)#UTG)CCZ\I
MD,A3)6YI!_IC;+Z\B%5P* SUJ&7EXF)!))8#$6D+8$S\3&30,(E4RA#R4P%H
M9>@"X\BW;#CSE1PR?CW&[5JHZV;(RD3A)T^UI9F_7:[6ER2FW2+A)A6EU\R'
MF(EP?MDF1 MMT;@79R,U+CO,K6]$0E#K+R XXEL+5!W#@9U6_KF3I6P6"_-0
MEW>):(5RU Q%3%8E7"TQ;U"B76\V-VZ6!J:_;YD>2VU&GNJ6Q(CK4VTIPMHY
M@O1:Y)!/05?""]<DB$J@(BQHN;%RER;C$ACYHZZC+3 TJ"#$U-G*)YB^'OU'
M+1L,'X:+/W9)(5\6_4LD\*FFXEIEWB3'O+#,"[R++.BR(+<6=#F1HK<YPOQY
M4E@!M41UIYH(<6^[QB6FV%/[32<D+@*UE<;]!L$.7IR2_=+!#U':YT6Z.SK7
M<+?-G.VUKDTN!"E*+J)T=^/(4ZTU&C\4M]Z2B+LOJV4_TND+^& 2%?@)'O-%
MA+8Z:C,AE4;(OG8QO-0M*2#8 &" FKGXT1<^DBU=9<E7232$OHPYWW<$-2:N
MVE$X2X;-RELW>7#%L3(7%C38<":RTV^NV2M30Q+DRI3C>S(TT891L,(4Y=&I
MR $,EA(DI_ O<)%F@/V"!<3?%Q&Y\VV7&ZVV0\]%;O4+15P5;X<*"T[MQ-9B
MXAT.RG4M61ZV.*+DCE*CJICHG?8>$3FP-F,<(Q^!KS[Y<L)*O'V2XRKC2\>G
MIX$[T%:B%Q,?+,BC;;YQ)C"170.5= AQ1HS47YOQ^%72<BZ6NT!V:S,NR+26
MDR([;7)W[[&1,M,24V7S(1(EQW6%_66'V(YD,-RWF''$HJ*F<!.O8=COFH2Q
M;9%OL2[_ ,>N)+>?Y7&TO-7;[_/@O)B"&N+;Y;,IHB3*BR98ARG8$:4TR5FF
MW/2*\;JUW1?^F#UT_2I&/_V^<#PI_P 76LOO#._RZ]7X"_XX.#K^M-L_S37V
M"#/Y\)M^BFK_ /-]O<_+!G^$UR^\5D_2&H*_=F7_   L/]<-6_H7152MR=KC
MZ<4IQ2ND2)#@PX@8,/V0H2*9.B10H2=(,1PT<Q04=/GY!\Z42;,V3-LDJX=.
MG"J:#=!-19931/3;;%R$+<6E"$J6M:DH0A"2I:UJ("4I2 2I2B0$I ))( &:
M<W/4?)793*[2.$$+;K)9A,)BSKR)/49Y%E6DHGY!@^*L(/'G*979$U+WHL62
M(M(T-W<F7+ >^=HLMV[5=1/9,"<%.I,*6%,,*DOI,9X*9C)4E"I#HV,ML)6M
M"5.K ;"EI2594 ;=I.[LD[S@;QO.,X';.-^.?%2=S4JZG%*P$HE<7A (A*9I
M) $0C(E+18K(I08'  0Q%15-!-4@7*N6@]DENNJDCHHY<):[*J)IZYSOOKKG
M(RR](<2RPTX^ZLD(:9;4XXL@$D)0@*4H@ D@ [@35"0!DD #G). /PFN\(+B
M9 +'G )0<;"EF;<@*,"'K8D+)L':>JS5\/(,U5FCUFY1WT5;N6RRB*R>VNZ>
M^VNV,YM6A;:U-N(4VXA12M"TE*T*!P4J2H I4#N((!!YZKS\U9'EM*<4IQ2H
M?LS^6G7K],!O_0&\><]>OWRTC_6&3_RIJ>NVTI^\7"7_ %)@?^X_!_4P<Z&N
M)IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*<4IQ2G%*_.RFFN?)MOIKGR>7R;;8QGR?_ '\F<X_-^;/%*?#TSCRXVU\G
MPO@^7X6/)\+_ /I_V_\ U?\ ]O\ ;Q2F-],XSG&^N<:__5G&V,XU_P#\Y\OY
MO_\ ?%*_F5$\8QMG?3&N?+Y-L[:^3/D_V^3/E\F?)_[^3BE?K&<;8\NN<;8S
M_LSC.,XS_P"W^W'YO]OYN*5_>*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*55[NS_ $1>Q_Z'IS_R-WSNN#'^,/1G]8K7^<HKR_AL_BCX
M1_ZGWS\Q=KXF.?IM7XGUL\*F!^O9A%YW%'F@^3PT^)D\>?J-6KY-D9!OD"(U
MUNS>HN&;K5!VW25V;ND%FZV-<IK);I[;:YT;G;HEXMTZU3VR]!N421!F-)<6
MT7(TII3+R XTI#C94VM20MM25ISE*@0#4G9;Q/T_>+7?;4\F/<[-<(ETM[ZF
MFGTLS8+[<F,ZIE]#C+H;>;0HMNH6VL#96E220;#/.['8YU*XI+T9L,#OH6G*
M$@8J.0:"1N)_$SC9#::)%X@#C;"-R'65[-6VQW8\,)*/=VZ"NV^JJ"*FG'M<
M&6C&X$^W*MC\EJY*@*E2)MTNLVX;5K"Q;%1[C*FNS89@!Q8BB(^R&@M:0"E2
M@?1'N&SA'=NUJO"+W%AOV9-T3"B6ZQV*VVDHOA;-Z3,M$*W,6ZX"ZEIHSC.C
M2%/*;;65!:$*3QMNY=X,Y,8D31U FS*0QL7$#T%0JJN$JR-1T(_>%@S I7VD
M9UC#]864(/GP\JY'JF6BKMPD@1T:J[M\W+X-]+N08T-QN[+=AS7[C$NJK]>5
M7R--E,MQY+S%W,TSFDOL,M-/,(=3&<2VA2F2XD+%K?#-KAJYS+BT[8&F;C;8
MMHGV-O2FFTZ:FVZ"^]+AL2K +8+;(7%E2'Y$>4ZPN8RMYQ")"65ELZLKV@NM
M6Y&]\_2U-&QF9$449O&H,"S M'(*.LXD%PA$6HU&+:(C(X/8BFJ61.V,(-$=
MU<JN,;+;;R=#:93IM>E/4]2K,XR^PXVY*EN2W&Y4URX2=NXN/*G%3\UYV0M7
M*/LW%!.RC"1$KX4-:KUDWKSU72C4;4J++9>:@P&8#3L&W,VF%L6AJ,BUA$6V
MQV(C23$/UMI"EE3F5G8(?W%ON#,0HP#)@F1T=B\3B(9B7A$+/-6 N"2LS-H@
MX31,@GVFYB/R60&"0XRKA0DDH]^#LXVU;,\-]2X\'&D[H[*?EP97'3)]PN,E
MV/=+E$<=?NL"-;+B@JC2FB(TN%$CLO1DX94&\[ *W-N1L_#'KZQL0HL"YP>3
M6ZUVFT0V)=CLL]IB+8KK,O5H<2B; ?"ID"Y7"9(CS%[4A"GL<80TSQ?]"]RN
MP\>F,7GH6<I,)/#A4T"@GR4<C6R*(RP),5F,G:NV"HG=@1U=R8R\+M=B#9SN
M-=:L]AVS;5@SU1I)X-]'3+;.M,FU*=@W%^V2932ILX*4]9X,>VP5MO)D!UDM
MP8S<=P-+0'VR[QVV77"I"X9>$.W7FUW^'?$,72SQ;U"@OIMML*$1M07.7>;F
MT['5$,>0';G->EM%]IQ49T,\G+88:"-20['6NE5SJGG!@,6AB^36&OS]$8J>
MD81"2E-#<C:1Z6EP[R2 VITPG@F13&DV^=WRCETCLBL\=[KR*]&6!5]1J-$>
M3'N2>2ESDEQN$2'*7"CF+"<F6^/);A2EQ8QXADO,+ :"$*"DMMA$2WPCZL3I
M9W1[DR',LR^6AHW"TVN?<H+=SE)G7)JW7:7$>N4%J?,3RF2F/)1M/K==04+>
M=4N"^=37"U:[HO\ TP>NGZ5(Q_\ M\X'A3_BZUE]X9W^77J_ 7_'!P=?UIMG
M^::^P09_/A-OT4U?_F^WN?E@S_":Y?>*R?I#4%?NS+_@!8?ZX:M_0NBJE;D[
M7'TXI3BE5=[PP666CTK[?UG @R\CG5B]7>P$%A<>:K-&[D]+)=4\MC\<#-W#
M]PT8H+E#!!FQ26>NFS1)1?7=RX11UW4UF-/2&8=_L<N2X&H\6\6V1(=(40VR
MQ-8==<(2%*(0VE2B$I*B!@ G=5C@*FW$@9)0L =LE) 'XZ\)!7@[6=7-?=32
ML6E,S0M"==I>E\V[!.*>B=1TDC0-?4GUVON$DS\:#!6A,$5GPL[9WS3+;+=Z
M2J628HX&&6;)ONQ6<Y]$7KF'*E7M#S3!AQ[/?H]L$YZ=<#<I5PNMLD(;>6M2
M'&XRVX?&,Q$\0PR@+;4H[0%:O)U -D$[16V5E(2C92E"QN W9[+!.\[\\U;
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MLC-1=:-I=/#$+)"5Q>F#<[^?%][7>'79-,6+T![M$])W4T=C4NE7D7QA*/\
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M+G1))R7!B2CA-#&^$$UW[!N[5T1PINHIA+117;5/&ZF^^-,8QMOMMY=LQKJ
MVZX@9(0XM )Y\)40,X &<#?@#W*N!R >V,UG.8ZK3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE>5_C*50\L/H1>,FB;:SU[:JR($);4
M6]432SHO)4)>NY'#-E- ]:R .I,\9&N'6J8.0L#XM/?.SQ(=HZ2T<:=AH6:(
MNI+<T\8@A3'T,3A-CPWFBP I>"Y+:<Y/V022XTII?\DKV20<+Z26E$;6TD93
MLE0.?<21GW#FJT65.>Y75(G?E6]/88YD%*=6^G\/N"NZ_FL0MN\)Y;-MVO)[
M<TDP=K;DPL0G,#S6O72;:QB$(:KR.4$V@P/ H^O&Q)9KHG+1(]BO2+;,OL@-
M7"\7M^#*DQWX-NC084-F#Q3BH+$1##9DI*HJ)"@TRA2ER70ZM"JL474%0;!*
M4-@I!"E%2E%6>R)R<<^!D[@!C-5QFOB1^(,(ZIAYI'0K@W8YBS+N;U_.0W5R
MQC,>G</JRL(K+ L3G@=ZRCCN)RN5S@Z;BT:?PJ(G0LX%QHD@T.PTU&).^WDX
M^EM-.7I<=UP-Q6XEO,J,Y>(K;L=^9,>8<>C.(4\EYEB.VV\ZF0^TY'6ZDJ;?
M;=935A>=#85_*VE8.P<*  (!&[&2<;@<XYP0<]*2=S?$8JX[V[E;=Q+I!DW:
MW4HU&X@;H*?%P% T%<M-Q6336QX*]2W*CC@R!2[=6I9"+^1EOD,Q6-V3+1#1
M%H2CS:YFQ:7F-V1DI8:#<*]-NO-W**V[<KE!GOM1XLE)XM3:Y+ $UI>TC:8X
MN(PX2I#IH7'DEP[R-I&!L'L4*3DJ&.< ]CT[^R/2*B[O'VS[[VWU$VK.;@E8
M4A<72&42U#ZN^JE\V&Z[%V:[MN8Q%6#B"+=L%)T$4#4R#A=M/-I.#^3H$I@]
M52V*Q 8UU<[FGK+IN%>A+8<$@P=0,L'E=YML5-KAIA,/B0X@EQ%R0Y.<D0TA
MEPDHCI!XN0LE-'%NJ;V2,;3>>Q;4=M6T1@'^2=D!7-SG(W"OJSB>BB<5C*:V
MFZ:J<?#:*Z*:[:J:*:CFVN^BFNV,;:[Z[8SC?7;&-L;8SC.,9QGGCCN]UTCF
MXQ?^(UNCF'N"M@YCJM.*5%(S^?";?HIJ_P#S?;W()G^$UR^\5D_2&H*["7_
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M\TFIE9;RSYM-W(IH\2^>\$7+2P+"</QL8*#FQ&-)HHR1@8%Q,-D35NZW -2
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MH64@G>0" 3OJ4@7N]6I#C=KN]TMK;J@MUN!<)<-#JTC9"W$QWFTK4$[@I0)
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MN2V6RGNGLP48N<AX9I9?9XF+I^1'$/2,M4<W&=%N]XZI71'?9T[;I,-+DMR
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MU5X,Z@\C7'T:GU36IZ-+ _<V1_9O'5!8>_=H\I0O/4ZD]5>#.H/(UQ]&J_\
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MYXNNRUI^Z-._U-TO^C6ZEGD_7&TXI3BE07V![+4AU:B(2=7S.F\!BTDF N
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MR B,DOOAW:D(9>+QBH<DH0EI224I4-D:G)CQ:@2"L[83E2BA(6K.X8W$C )
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MX82ZT^MY!8;89MSJ4#,A]YY#:TT4RX5K5V.%!8[%925 XV0>P.",'))4,DX
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MI9<0B&ZT^["F6<O(?*@VA8<+@QW"%C*0"L* SG:QM9"U%&2-XP"%XQVL8]1
MW63L35?A_5OUAJH_7<OL>,18;#9GI<5A6NPC\BA1)P5VF$-B%S4T&KFQ:\=C
M!Q1('64Z#0+=Q% 848/Q$]7.J!0=R#EVM<W4LJ[S6Y3$5YY3[!@182G6GT!'
M$/OP)[DJ+*"U(+DN,Y)P\ZXM7'E.4+S!"TM!"=DD#!VE*P0<[0"DA*ASX2<;
MAC=4G^'IUNG'4CJ56-"6(?B<AE$-<SAXY5@R#_$6$-)=/I/,A\;%%33$;(Y7
MK'VA](8[FLJ9(2F8/V[N0R#&Y0@Y4WT]376/>KU+N45IYIE\1TI$@I+RRQ&9
M84ZM#:EM,\:IHK3'9466$E+36$( JYI!0VE*B"1GFYADDX!.\XSSG>><U=3D
M#62G%*CRW?YI[/\ T>37_+9/FU!_=L/^E1_\Y%6K^P5_-5_<:A0__0<-?V42
M/^D*W-]O^$+?WY3^?"K?_"_]/_XU86#?R)A__"T?_P"4M.1;_P"WO?[US_&J
MKT\P]P?W5M/,55KS(;=U>P]J=FK>IWK'UGA=AU=UMLF$U5>-JV->.]9$EY=)
MA@4_*&590YC74U5.(5I'#K,J<>2$F UD+K1P'CB"RNK9X[ZU5@MD.T09]VNT
MB+,NL61,M\*+;N5I##*W&F52WU2HX;,MUM2&TM(=XI)#CIQE*<(<6I:DH0"E
M"@E2E*V3D[SLC!SL@@[R,\PJ,NL'C$]=[-J>3R6^9"E3UC5\"N>>3D!F"6DG
M$]ZZK3L1(J,%FH!)B$:<CK++/7/T 9%0$")R4NC-)DA&&@_)1%R,8[5VT/=(
MDQEJW-&=%E.0(\=WE,,O"5+M;5Q6W)90\%Q$)3RE2'9*&4&.P7E*V"%JHA])
M22L[) 43N5C"5E&1N.3S9 ).3BI\W\4/IWF+Q&1,YA81HI-)S-JX$5I&J+NJ
M470A+JT%A3UCCS%.QZ!$[&#-H-'9+')'(RQ&.H"6P*0@"3=ZZ0-BLO(X:1OG
M'/-*8BMH8CQY3DMZXV]F 6):W&HJD3W9*(KBI+K3K+3:'2X7&G4%*2TYLW<<
MW@$$DDD!(0HJRG&T"D)*A@$$Y',0>D5$%-^+)1YUIV2:W48:0R3==K#[6J2H
M/#(E8<RUC%"=<K/+U\/LR?K!09M.+DI9\U*ZC ;]9D2DI9J3:Q0.^U'N]4-Z
M=HRX-FU*@-JD,W2+9N)<D/18_'7*ZPVY*HD8..-EY+.V-MQ(4EE"D%]:=M.;
M4OI.WM'!07,X"CA*%$ JP#@G'-TD' J6&_BF],7<5/29M-Y^H]!3B$5VG7>]
M$W>UN.22FSH^6EM9MH93CVOFUE2T?8,2 G91$C8*,O Q4 $+DM7Z;<:]V0TC
MH^_)>::,>,$NQY$KE7JC;S!:9B.H8EJD3DRC$85%?<;9?;=>2XAUQ"-@J6D&
M[CF\$Y5N4$XV5;1)&1A.-H@C)! W@&M)(>*OUJ%GUID[LF(*]:].M$.O?6<#
MX_<I*RD7\Q[(K=:F@Y_7[*KUVS,0SG^6\3+CE3>MD1^8(EF)^!C0HU<WKG1H
MZ[+;Y.F(_P"JWJJ_;S'4[ 1%*6+5ZK*4F2J8"IQ48*?;4&^2.L%"FI*W%I;-
MO'HSG:&QL!6<+VMZRCFV>;.['V0/.,;ZR<<\5CK9.KFZ^4W7P:Y9:0OV1W-"
MM#.M*VL 3K.<4D0""97$;+ R.&#)%%S#$@;0S(TR(]JE 1&XZ1SM2/@3H4@]
MM=T;=8\"YSI2X+";:U D%LSX3G*X]P2XME^(ZU(6T\A2&SQ6PM1DKVFHP==;
M<0FH?05(2 HE94/L5#9*.<*!&0>WVAO5@$&K2B[O)R/M5*J!C@)B]B]84S'Y
M]:,S4=./E0>=63*'C"KH"-;::X9JN',1AT^ETJRLKN[&,GE?[IHIH2#XU2'7
M;T-6=FY.N*2]+GNQHC 2-E<>(RE4N2LGLL!^1&89P-E:DR022U@7A1+A0!N2
MD%1[14>Q&/<!)_!VZL;R+J^JZ]HOYM(S_:*Z?_\ 5I27).T_NIW[V7K]#3ZL
M<^Q'\]O_ #$U8KD95].*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI5<+D_
MGAZD?I=GW_3E=').#^XKS_0H_P"DX%6JYT?SC_@55C^1E74XI7SJ>(;X@_9#
MICX@:AX05,3'JE7G5: F+(I,5&Q1%T^LBYSW96(5=,V15 5M)D-W5JU_5%?O
MV:9C4=LTENJVK1-75=SGT_3&FK5?M-<4XA#%YE7F2W$N"WEH2F) :M+\R.I!
M7Q1V84J;*2HM[>TQC:(V4UJ/.K;=R-Z V"I..<J*PDYY_L@D?A_#41T#XH/;
M:AJ,9P3L*2K"Y^QF.Q7>"$2:R[WLD%UZJ@*#Z=B8,\DT%'2*(UX<9$IS)WY]
M\/KL+@*AJZT:E29DKAB.SKG>N>D;)<;@9-K1,@6OU*T](:B6Z([=)KCE]<DI
M:D*:>E-J1'92TE4ISC#LE3:&T%2ZHEY:$@+V5+*W05*4$) ;(R!A)WGF2 /;
MZ*M7$_&)GDTMRM@XSK*,%TU,K#Z.UN<D!ZS2C2VP![O30K>Y(3AI7:-=J@B3
M2"O,/P,K7<38<Z((X%N@8U?+][@3#/:'CL09CB[LM<^/&U!*;::AH5"=;T[<
MC D$RC*#J5204N, 1E!)VPXL;*=N\2"I0 0 DEM))4=K+J-H;MG&!S'?[8Y]
MU9+ \<*^)5U]N6;5'5%(QB6M.O!'LO6SQM<#VT#-9P6,WO$Z=D42[(05K78M
M&!VZY1D>IX)&-"[X J@T/#GA]J0CZN[F6C<'UN9N<"/-FW!UE5T1:90,!,1$
MN2];GYS3]JD*E+,F""UQ;CQ;0X"II:6E)=&S89*BA12E((05I[+:*0%!)"QL
MC"CO(&<=!.1OD:O?$=[%53VRNH;:$4C%LTI/.SU*4VQ=5W<4@FRE:3*:=$0E
M[IA*$C[^O! Z>5:7,1*4/TI(^+PLO('4I$D&<4166>IZZLG2]KF66 N&\]"G
MQK1<)ZA*@-1Q,8CZD=MI<N3J)3BXTQM#["2TEN0VTEE:%/J 2:JEU:5JV@%)
M+B4]BHG!+05A(P,I.#@[B<\U=VLO&ZM*T:OUF\;ZKP]^=EM@]3XE6@M*Z2K6
M-+;=K)Z8@8:,3Z1/JQ2+1N7PQV.9/"1(5%CL2/HOR289_JYC!)NO27P?Q(<P
MQW;P^AMB->GI:S;T%X>HL9$EQZ,TF7Q;K$A*E!"%O-OM%*.,20\A0)DJ4G(;
M!)* !M;NS) !)3SC'0"/P@BLG8OC;2>KY]V$A!6FZNFGU,U/V$DHXG7MH6&H
MV>VGU><0P3:4!D>TXI>%[-12IZ1F1HJ2Q=*4,&SB-[MOCC&7JCIA9%T U,C6
MR0B?+CF?-MC2T28D7*8=X$AR%):$>X/Y6&FFUK:>+*E!X'#>SLJJJ3LE0V0K
M9"]X4?LD8"@<I'23O&1NYSG=LS/QGS4<C=@SRS*>J][6=)V]1$4NVT:%O)U<
M]=Q&M.RD",R2 3$1*-*[BZ)V10J8MH[7]JQM1J.;B',N!GA11ZP=X0UQ*T&V
MZ[%C1)TQ,NX0;B_;X=RMP@2GI=ID-M26%M<J>+;4A@O283H*RL,N-+0E2=HU
MY1@$E*2E*TA2D*VDA*QD'.!D@X"A[8P:]?NMEC3BX*"J"U[(@;:KYK9, C<Y
M-UXV,N#_ -#=I2/1-,8^[+.A85=T4'C'K)$QKN,:8;%M7K333=-#553A[K%C
MP;E.AQ9)F1XDEZ.W*+8:Y0&5ELNI0%N!*%J2HH[-64;)SOQ6="BI"5*&R5 $
MC.<9YM^[HY_;J;>:%7577M?_ #"S3_YT&_U"BG)2R_OE'_FR/S5ZK'/L#[J?
M\0JQ7(NKZ<4IQ2G%*<4IQ2G%*B:H_P#T,\_2S8W^85^0&G_VJZ_?^\_GBZ[+
M6G[HT[_4W2_Z-;J6>3]<;5+O$8LZ=4OT3[86Q6,@7BEA5]1T\E4.DK5J/?.
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M+! 4M78I2D)2+TI"2HC)*E;1)[>  .C<  !\M2]S1JZJZ]HOYM(S_:*Z?_\
M5I27).T_NIW[V7K]#3ZL<^Q'\]O_ #$U8KD95].*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI5<+D_GAZD?I=GW_3E=').#^XKS_0H_P"DX%6JYT?SC_@5
M5C^1E74XI6JE8+"#KUV2-PZ*F2)!H'8/WY6/""#UZPCICZ0Q]D[=.V:R[EH"
M/_\ G@=LLINB,,?^9LM$'O\ X_,R)$AM*4-OO(2DN*2E#JTI2IU'%.J2E*@
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MW8%#!)SDXNN !Q>W8LSD_P RIX,)GV>R\;).-(^1.,"ZF=WXOR C'XC7<?\
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M697))2[9&=F5P&B]+.B;X9-7 6)PV#3FBLJ68C]6$PJB 0J. 8.<,;SEZTE
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MY9! B!.,=QA9TD/GU<2N&OS 9RF*)L=C S15(4B?9BW:! FCJIM=5=D-GO\
M;7)$[%PMDH,"-&O,9;\UN%,8CPY#C#;"'H$M,QYJ1#FIDVQ]\Q'9\1]B,4B:
MTSHF^0M16RYRVX$,0G&EMR'Y6G[DRPI%PMT[CDM\N5-AR4&WI1'NEH=BW>%Q
MC@A2V..<77F^6ZQ35!8L)W!5U-U4WX^3O+0,U;(B4]O!TYF4%L$C3G8$^1F
M%Y8G7T4XA>]:L8P3!(K+U]M!M-1B>\(+#)K.:9UO8;9IW3]OGW6XF;;[);;9
M,0U&O"XS$J':_4]ZZ6TJM"EM7%]U:YIDE04J0I]2SM2$EB.U9HO4%YU3J:[V
MVT08UNNNH+Q=(#"[IIUIQN%/N;TV+"?::NZFD-,,+1'+#94VA*4H0HI;ROTP
M\/F"R2N8;O$)25P<,!*XA#8D]'US':RC M^3M/L-+,0Z-1R%QB*0E!C$0\G"
MC]L1H2U:*X40([,1>I) :UA'KO"ONL=07.VHD<B7:--QD//HN +KT9_4 >)>
MN20^\Z0XTZX"I:FP\V%J)(4I=[3-L6A=*VVY&*B>-3ZUF*C,3;=*<;BR;9H5
MJ.ZMNWR'TLM.NQ9+3*G @.JC/\6#Q:PGT2Y)5P]40HN]JWKF(RV'S5[*0,C&
MW[VF=.QKBMK*<9PS.=FK</A7J#IC$73)XQ+!"@XL->LW*[5Z/>MG3=91%;3?
M/0W&WRI3[+["67&EVZT!*A+B#LF[5";6DA3X4E2'$*0M*@%)4DI(!!%8DK2D
M$'(.VY_)5TK41S#I!S4R_E6T9_661>S&U/<KFCZCW#N37C</TBKN,3VS[U7R
M4_*MHS^LLB]F-J>Y7'J/<.Y->-P_2*<8GMGWJODI^5;1G]99%[,;4]RN/4>X
M=R:\;A^D4XQ/;/O5?)3\JVC/ZRR+V8VI[E<>H]P[DUXW#](IQB>V?>J^2GY5
MM&?UED7LQM3W*X]1[AW)KQN'Z13C$]L^]5\E/RK:,_K+(O9C:GN5QZCW#N37
MC</TBG&)[9]ZKY*?E6T9_661>S&U/<KCU'N'<FO&X?I%.,3VS[U7R4_*MHS^
MLLB]F-J>Y7'J/<.Y->-P_2*<8GMGWJODK@==I:)>-7+1242C1-TW6;J;MZWM
MENXTT73V2VW0<(PS19!;77;.4EDM]5$M\:[Z;:[:XSBY%IN*%I6&6"4*2H!4
MJ$I)*2" I*GRE221O2001N((-44I"DJ22H!0*24A:5 $8)"@ 4GM$$$'>#FO
M"XA2X",#G7T881^SQD9G#I8?4MW5 9G=56B)5=WD(#3*6QX7 :PU=R6,Q6>Q
M L-)S)](C;&0IR&,B$&<>:1DX(D(4"<WKF_WY;\R- O.G[1&$EN^%VX,W5-Z
MO=_NC;#DN5<)+<%N3>'8$)KC^):MK4.,PTRW%6B3U]^N]H?T#I'34#B94ZSW
M:?.D8LS%M98B.Z4T9IQB,XB((T)^2M[33\Z5)C16W)DIYVY3GGIMP=;B;+24
M,5K.PY;+2\E6P!:4A;,<R8QU\?$K@MN0S&/B! 6+S>SU0<VLQ>,PK8*@A7X-
MG*6H;6*C8. .-E#</>FICU$UWE3##26T\8;A#=V/5)"(<-IAU:UO,Q0Y'BAU
M_C"9+BF5+XU;[C9XMY*&?/F65MN%2CN#:P3Q8+CA4$@)4OLE[*,=@ K& E)W
MI*E^T!P.74Z9%X^F+(J'M^L1 /H$T8N=B^Y?:JEF6HO0;JEEYL1V>9PTU8X1
MRYRYSA#"65<_ YQ#;B!?4.E: T+LEPN%0V CE@5ME>=G8V>RVLXQOSBI/!XO
M&-^QC'3G9QBNA$.TE*,HG%V3N025NZ:1T(U<H*5?:FJB+AN-;)+(J8^A7YMT
MU--M-L?^VVN<<J]:)ZG75!MH@N+((EP\$%1(/[HZ15 M( WGF'\E7R5L7Y5M
M&?UED7LQM3W*YC]1[AW)KQN'Z15>,3VS[U7R4_*MHS^LLB]F-J>Y7'J/<.Y-
M>-P_2*<8GMGWJODJ$Q<FZ:A9>M-13VPV!%>2&YDH ;M>SFM<8ELD5?NI!)TJ
MCRWS5:$@-$RI4^4+H0U-^^DY0E*7#A21OW919ZCW#N37C</TBG&)[9]ZKY*Q
M$87Z.P]PQ6")SOX@((*@8D',L^STFC->AS0MP!?CZMB<F1+QFJD,QUVYC#+%
M<B8OL+BRZL9%[,P.^P[+U'N'<FO&X?I%.,3VS[U7S?\ [Z:YC[_I!(OFS=RC
M-!#D*.K\2'(PT5V5K\N+858QF@R H#S,%9QPJTVCHVPYB.070>:.'C SNS)*
MO6[(:FS>H]P[DUXW#](IQB=^\[^?L5?)6YE[2ZJR"N]:M/G;$.Q'384NEL9&
M=D"LM1( 3[.4Q\VWL5^/<6(WDD>D@T:<CTF0E*<@!%!@UZ)),UQ[/=!ZCW#N
M37C</TBG&)[9]ZKY*CUZET0(CXL+>CI<LPB24G;MF_S1V53Q)&LWD[":S9E9
MBB3316WV$SEPUM))<QM929LY.:W?$#B#]R4)J.WJ/<.Y->-P_2*KQJ>V>@_8
MJZ.;HZ*FMMV"ZV,Y6:G#8F>2E4BCT8BAHQBMK=V6?1^&DI<7C(W=#>(;-$TA
M1&=RUTDJ@W2<+;F5]72RZ:#31N]1[AW)KQN'Z15.,3VS[U7R5^I9V*H"8Q:2
MQ$E+IFT'2F/F8X_=B*]M<<6:LC@YR,=.!A!.$;*,2**#I11D\3UVW;.=4E],
M9VTQCFS#@W.%+BS6F(RW8DEB4VAZ1"=94Y'=2ZA+K9D .-J4@!Q!.%I)2>>L
M$EMJ5&D17%.);DL.L+4UMH<2AYM3:E-K"<H6$J)0H;TJ (YJ\-R5,,F$> IC
M1T0GN!HN20Q[6EO4H>G%9MS,K&#!I3L!&@4:BU0(-IS&M(\.:5T:*K.;&Q&I
M-/0AT^*>$AAAEGL5LE6S5&KY_*+@U:[L-,&VR57[E-V=-EMKL>2U-ES'[A+>
M;EID1XTI4M]]3C]J94T!;68,5'<ZTO=JNVGM'VNW)C2)=F=U6_,<:LK-GBLQ
M]071B?#@MP8G)X++MO=;FO;%KC1;<D7!3J$.W"1<93NZTY7IN/VVY,ZDGCMG
M)+1HQB/9MJ+U3LRT2!'OC5%RE)_=MO)QLK-I 5KB&,2T?;NC4Q2A?T1#MSC2
M/09T@3$ONIF/H<AA!2A):AW%2B;@#%B)1IZ9"1'@PRZAAM$I]2'"EMDO\<LM
MER0"E:?/&&5H=4H\RB!]@GC'"7TN;3KF"M10G*02K9V0#LI.X_1YSS.I2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2JQK=V.FC=95NX[;]8T'""BB*Z"U]56D
MLBLEMG15)5+>5Z[IJ)[Z[:*)[ZXVTVQG7;&,XSCDL+!?2 19;L00""+;,((.
M\$$,X((YC5G&-]T1[Y/RUQ_EO=+O6\ZO^WZJ/>SE>I^_=Y+OY-F^9IQC?=$>
M^3\M6/#F!$B$"I!'RHTZ!.C6)@(;#OFI,08$$VJ3T:5%$F2J[,@-(,UT7;%\
MT66:NVJR3ANJHDIIOF+<;6TM;3J%MN-K4VXVXDH6VM!*5H6A0"DK2H%*DJ *
M2"" 15X((R#D'>".8CMUD>64IQ2G%*<4IQ2G%*<4K\[[Z)Z;J*;ZIIIZ[;J*
M;[8TTTTTQG;;??;;.-====<9SMMG.,8QC.<YQC'*$@ DD  $DDX  WDDG< !
MO)/-54I4I24I25*40E*4@E2E$X"4@9)))   R3N%0[CL5U]SC&<7K3><9QC.
M,XLZ$YQG&?SXSC.#GDSC./\ 9GG/=5^DO"C3OENV>DUVQX,N$@$@\'VMP1N(
M.D[]D'M'_8*_N>Q77W&,YS>M-XQC'ESG-G0G&,8Q_MSG/SY^;&..J_27A1IW
MRW;/2:#@RX2"<#@^UN2=P TG?LD]K]P5+R"Z+E%%RV62<-W"2:[=P@IHJBNB
MKIA1)9%5/.R:J2NFVNZ:FFVVF^FV-M<YQG&>= E25I2M"DK0M(4A:2%)4E0!
M2I*@2%)4""""0000<5Q;C:VG%M.H6VZVM3;C;B2AQM:"4K0M"@%)6E0*5)4
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2XI3BE.*4XI3BE.*4XI3BE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g551455g15m15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g15m15.jpg
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M Q$!_\0 '@   00# 0$!            !@0%!P@" PD!  K_Q !R$  !! (
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M !DD?P\+0NWNKZ^Z-_PV\\+W_P#&?I_7'OZV91_RCOO_ $S9?]*\+0G^%?\
MA'\L+W_\9^G]<8_K5E&R3DE^=^QN;$@?A_2=_P ?"T)_A7_A'\L+W_\ &?I_
M7'OZU9/_ ,HKW_TQ9?\ 2O"T)_A7_A'\L+W_ /&?I_7'WZU9/_RBO?\ TQ9?
M]*\+0G^%?^$?RPO?_P 9^G]<??K7D_\ RBO?_3%E_P!*\+0G^%?^$?RPK?\
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M2T*R3( - I'VS9:WU"NT@?0_O^GAU5:(T@B[!H5V^8.)8R=+;7N"2:/;UO\
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MO^VLC2EM=>BE-[^[W);WKHV?"K5L+L;^E'D;_$\':\4W71)K%B)B 1I]T&P
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MW#R/#[-R30VTVFN+?'[23#5.I[!V*^E#5V%I7C!FC$;V055Q(" =F5A6S#<
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MXKX34%8NQ(-:15>]P<%MY"_6Q_$;]J  ^6)&IOT5K65>;+RX\#L7XTO*X/\
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M+JJL*N.VTW)G39C*$9A\PL&7S(F5 \>8 #(T8*AHY"DH"LM:UH&P"#Y'L22
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MD8FR\;K)I77*\BQH6:.%6HK&A:B0*O90 Q-;8)$9;4U9)(4<+>] G;Z "[K
MA_LB,)3^CBK/*DRQDS'%.#YX;7S&_:2($5&+-X/+X$4?#>*RS<(M!9#)F\CK
M7GS!%0B(W7>E*1:*D$Q42>&?MIG)4QG*B&M[U>*7-BJTZ35WSM5;X?PVUEJV
MT@<B[!)_CBW-MY[>!G$GS"?HZO.9Q&J\\B>93@7Q#X/)\X\^GQZFFU'&?&N!
MV9XU-PSB]03G<CA2IG%>XP*D1CV;5=M$JJRTM*VGEP+*%&;D!RJ,M)'#G<JA
M4P2I)]FLD&-I%8-&11J,,;4BR 38L[!H*AU!%'4%]+!!!] ?CR</^.<9OT7N
M&>9R3Y\*2Q\T%GF&.\6)_''!?)Y.X>X7"QMOBS"R9_-,5^T?,,UQ$E.JX30<
MN3 M%UBN%AS./4,)H9*[QQEZSL09,^\ RA$ 4QB)LP&)/AZ0IJ+0/WA6Q>L+
M>X"BAA%7*:?=K[I:SQ7^&N:_WJ^'&*!J\^'G-AGB1#Q;S'\9\!QCBMF>?9YF
MF"X!Q(R_$\%M,@XFV4RSS1]S%JFZ8JU-7;TYYF:V^R\J3$Y&)*WD)'B[]GRA
M$9>%&9%1%9H]3 ( %WTWM^?&'"KL2HL <@$[>M8)N.OF P7B1Y,O(AP H(N1
M-YQY:CYH3Q!E65?#C8_*_EDXITV:8I^K,]BSE2[+T*B ^W<_'5U7\'-+;,;X
MUI2GTA&C+FLW-MHF^SZ1WJ.,JVH$"@3QON.:(K#JH#.QOWM-5Z C?Y^6'O\
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M:WC;PL;X=\4'L:1%H,LL+>JR''[AVKJKAOD=<FQ$0-EFCDE(RV5S"S2-(#,
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M+LT/0;;L-P=@"#M0H6+YO\JQ4/CGB/D,QO!ICW #C!YCN*_$BZR:MF4<3/\
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M_C\15UMU]:E*![D@[Z ?(=_;O]>I\"6.^Y^OTY.)* JJX'Q^>WGZWC6(BBH
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M]_"V'._S_P \1G618LT*V(Y\_CO].QQ](CH0D.-@K;]UCM^?;7X'J?J->!)
M%G#(9-6YWH^ZU^8HT/T//?9(DMCJ6U*_ Z'X'OU_/^[P.L>1Q*2>+%^==O06
M;.VP[]N#6Y/KD I;4EHZ)2E)UKL2H#JHZV=G>^O0@^ +$G8D?/\ 7Z^F&->=
MD>?PJB3MOWXW/GC;RMD=4[/X#^\;'AK/F?J<.+X 4<7Z&O(<_47^.//33RDC
ME![:T-D?YWX<,;WLCR)YPS&S]X #G?>_AW_SPC(Y5#87KFUT![=M@]]?EO\
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MH20 IPI(7)T=[( ^ZR5?>2V?O*4.=P[(0$TG 6J':C_3GOSAX("&\6?>3_"
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MO:AH!2"H;!'[_<=B='^_K[^'UM54!V')V^?]<&!5['_BW/RV'^7SP\MPDK
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M[QR<'7,Q)G/'DD=Y)65FD<EB>:[@!06.R@*#]T4!BUEW,$BJE)&*5544OG=
M66J[)-MO9LDXEO*;"145=%?UM9%CRYRK+XN4PC^>4&I+;A4E77T@GXI25I:"
M4@J7S[4HE6]>T/M?U/,]+Z9&,UFXLH\<L#9<3.4E.4$4&MG!4RDE'D96+Z6U
M:BR\4EARN5SN;FC@@;,.RS>.D*QD+F&DF*(!7A@:@2!N;L[V<#CN>3Y<-34E
M"'T+6E:RL$K0-*#@2KF2-+"@5["ME*5#1V3J,OM'+-E1E<P4G$13P9I5+9B!
M$W\*.4$,822I,4FM%(#(J,6+3!E:4SC5&SAA*JT(YB=@\B"QX@%TZZ6()#$@
M#%B^$/#R!YELQKJO,+!;5O-FH<D9H)@_65V,&S)>5<B0TM&0(2S&>8;E2>2W
MC.OL%^PFU\9$!&<Z5EDZ_K;,A&DA17\:-DCS,BT5T,I&F954* Q4LE*ME36
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MCY>PZ]5$^WR/8^Q>/[RZ5L6+OGGT/'\\-H/G7?N-O6Q_7Y8N5P:LJW,\'O\
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MI;N]J^8%C>B.>?S',;+>Y&Y^/H2.WGS\]\-J*9YY9 04IZZ!"AU'Y#V/7O\
MA\G:0T3N:WY4T/+:_(? GZ@5)^Z-/%[_ ,K\^;[X=6,<65 *3]PJZCIWZ?\
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MZIM,R()+#+_H/A/.V'66UI!T1TWXH=0RQZ?G)LL9$F\&5XP\?O(=.Q - VK
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MW -ZY L<;#X'WR/@*/ O"5\8Y7 HB5QE.@?[]-4)*C^*#J/U(! 2SL=?O$=
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M1ZS:>4E;S?R&R#].^M@]M^#)'.H;>H\C^N_&&;4#1%CR(L^9_.AZ8P6J2>5
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MN.1?;BM]Q>WK6!4%3YV=B!8Y(WO!5'B0Y+8<94E8(WO9!'MU23L=?F.OR'8
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MG4EQB3%I^+:8OVE,?=Q.'5Y'(N5<(8F3L^ID.*,1$9%(QF:S&Y[ Z8<R]&,
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MLPK5L'50RUI*AA(#LMGWS>S+1!DIC!KUF$[*>F4L6VN%B9/@SK=A5G""@2S
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MO> ^\ 0.?(\57)&Y*.%" $C%L^Z=_P#=ECO<;_\  3^/_7XW7_0*3MU51_\
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MY/&D<ZXIV9;=J^ZZ:_=H@K:JH!(!:BHS4LK9'+1918V6&&%? =$*AHP6!$@
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M<8\<PSF7>1W=; ^\ Q_=C[Q54U,Q*/3)'>G00(7"D XS$;  40#9%FN:Y-4
M3=[_ (@[59XH3+1'$/)*Y%9(;K?65+K['[.B+C/29Q,QU"9<F*@R'&ICKB%J
M=<=*0.5?*TE(\<8]HWS.4ZXT8RH&78K(F8;*QVPFBB:51F'2W42*1IUE8ZJA
M0)Z[T&++9GI>2D?,'QS'X3PKFW#(L+/&E1++[MQZ#14$DD"A[H\SKS *PGA5
M2L658IM[XF31H^&"%.+?A)3\0Z&VV]!!0\Q\0XD)0MV3&+*%-?$OQ^U>R66R
MO6(HI\NXA5$4,DQCCTE+4 E*C]X R*$X0MJ(.E6Y[[4Y/,].ZG.DC&<YD+.C
MQ+*X*RC@AR\B:&3PRLI4DB]P;Q2[AKF]WE>6WN675D_C^/& Q5USZ:V*^[*F
MHD-ON/,O28[DPPXFG6W&X<E*')$STVUJ5'=:36_:CU_HWL_E.F=,*+F\\\LF
M;D99BARD/ALB E4D4/.:904O3$&)K3C(^Q/3LU-)FL^Q,&7.G+)')&K)F)E(
M=B SH;B%@G4-Y !9NI^AR+)Y#+DAAV00[,,9]##<82X+BVPF3-YI-@\794E+
MDDGG965/!;K:%M+5XX/[2];R'5>@>)%FF3./U*)FR68S1S&:F5,G+']LC<PQ
M 9>-#%!H+,\?A[D*R@[R<O)%G/!TQ'++D7"RY>$9>&)SFO%$!C#N#*3XDC2*
M%5A)&-RC6V6%;9L3D7#->984AN*J'&<;1))6XG^>;4ZX&2AKD)?+KK7(R%K4
M>5"N;EASQ3W5D8,"06W(/=A0'/PV'X8-8R&L#8<70LGMVW-DCSYWQE'MJV+S
MFZ18LSG T'8KU>[IA3: E1:99$E;*'B><^J\X7#]]"BC0!#,.PU.P-\'GCG8
M<=N1SA,"W JKL$@5Z6:!JN18[\$8$D8\.@*2?GLCW_$;_P [UXVBR>3?Z];Q
MF]+U8JOY<]S^7\\+&L>)4A"&EK4I24MH0"M:UJ4 E"4I22HJ)T$@=20!U/A[
M-<GZ_P J_A@#J4%F9%4 EB32A5%L22-@!N230Q+$BJ9X;TBXZ VO+;=D_:#P
MTI5/$/-JM86DD!]13N:ZE6E.)#"2I#86N?6(HP$;4S@VQNUL< \\&JX\[QKI
M8]6S&M]\AEV @0@JN9D)HROMNBG_ &=U8-T!OBNEO#D27'7%E2EN%U2M@D@*
M/,5'?=1))Z_OUXKVW%\DDUW&_.WG5U_#;-*NE0NU=@ *KRX&U;5OL-L!JJ-3
MSB=)/*LG70 JY1]XG0_ D=A[>^V#,?.CW)YVY('R_IQ@_/;Y^?X_F//TPOCX
MWISF2T24Z ) !Z]R ===^_37N/;PA)O1)^=BQY;_ ,M]P.1@E0\C3SO7^6Q]
M=_3L<."<=+K@*FE%/UY">_?OO>M_V^"#CMJ^5[_0"_J#ZC!4>^@4.]G\[H#L
M+KZUAU9QHI[(.AT]@=>^B>W3Z?+PP+4P.Y)-$\#R(Y^??ZWARR^0-CT/E5[_
M ,>V-IQM>]\IW[$D$Z^6]^!IO\?X##:E_P /QV V_P ZQX<96I2?N[T1W/7O
M^/;PAJ!^]MWVJQY;=C\<+4OEM>VP]-_CSA2G&EC9*=@'Z'I^[6_\CW\2A^?<
MKYC?Z?QP]H2-OH#^/G^.-IQQ)'1&B?GKIU^GT_CV\/K\A^/], *U-8)!X !_
MGM\@/7&G]6E[[;',/]']G?7\]?\ 5X6I>Z_ES],$VD@UL?A1![CCG"C]7&_]
M ].^@/\ $^%K&PT[#U(_+?\ '?$1!/I7//\  C&]6,)*1I( "20.FR=_,C73
M9';Z?/3ZU\C?;MO\C6_J#@PIL6":YY&VVU7] =^*P@7C3@6 $]#K6M;[_P -
M#\=]^G4>&U@\K?EW_A@K0'CXW^!W['"LXCS(2-<Q.B=@Z[CMT UKKX6I?(_'
M8'\*_AA+0)L V>+7SXJ_AY\8R1C349900 ._4==[_#Y#Z^WY+6!M1_C^)W[;
MWY=L.2!ROPXW^GQ)K&IVAYE%26^@&N@'76]?=UU'7V\1,SDV"0/+;;]<?'?U
M(^[N11]*(_$\>>W/'D,(SCBRG]C9'L #T_B-[/T^7@@DS;J21QMS??;OMOM^
M P2LMT-K)\OX>GI]3>,FJ!2%A:D$@ZWT&SUUU'0]/;Z]/$D)"2@3-M]T@U5\
MT=_*\&"-5>5$\T1MQ]>X\_3#ZS7-MIYO3C(4E7W26W'@.J]+4D*CD%7W"4)4
M0GE6 M7.DIWS*9WV:ACR['*YMYO#02ELW B/,OWJ5,GJ\(DB@'5R#5J=RR)F
M@[DYG):/$)B7[%.[JFVD,YZ@H+BO\&D>1&V(ZR7C[?\ #K/44$NO@8_6R(#,
MNOM:Z/:L,645+*&T+2[(N[6,F:BQ:7\07J:<PU)0PAVO7&D(4YWWV6S72>I=
M(A3*HT8BI1EW='6,L"3^\\)'=2#3'5&U&]0:BW'O;+I>9RW5\Q+FY),V^8 E
M@SC:0LT0I2 D:E8PA&D()&"T =1)I^N>,\7.*]R'7O+FVKA"6X[+HDRN9^5!
M;;7+Y5R5)<7->:2F277X86N.#;2'5QZ^-L+10Y5'E9E*HI!44-1"E=*J:M3L
MM4-R?< !=M6R.1S.8GBC@C;6\@$546U$@@BC>Q .QM !;"ULJ;]:NC-H$*B?
ML@TREZRG5:Y;WKI:2'RPQ)F.U[84\%K;=5!6\D:*5)4.G/V]G>A23M/FLL[.
MSF30DFF*FD9]T$9.X.Z^)I!X&^.RS9W-*D4)S<3&*&.*75 0698PK7(<R6>F
MOWO[U5>UAJ=Q'*,T?^.<7(E,1@EM^SLYA9JH">B@P)LQ3;#("=B/#8 ?> "(
M\9:RE!'-2](Z. D0ARR$6N7B0--*H-@^$@U2#:S=XQ9R\V:DC6,>))Q<:L03
M9!(%L5&_F;-[T3B6L8X:XU.9$2QLX4YVJC%V-(GMR8U2L+=6XMB)&*XUG.CM
MO!YT+=%:@/O+YHSX<4GQ<R\V;ZKE7ERH.45I#$)#&9I#I-,0"1&A(-#_ &CI
M6F@5WCZQU3)>ST\,&;RS9N:>)9Y(()H4,2[B%I&:.4H[A**-6P!/-X#\L81+
M8<@P_AWFZ]YZ*E42.(<=E)#2E-1H+:&F6&EZ0ZXOT?5</(%K5Z8YM&]M!/T^
M 9(+,9'B$SSR.S)*"'78$D,RMKM^0M)1"XW+V?S.7ZIT[^T,J$",\L1RP :3
M+2*$8JSLS.ON%*C!T'4S@@-I$1&L>BNI3HC:CU.B0 =ZW\^X]M'>_'&1F,Q#
M)[Q*$$;V03W/!![6?R&,E6FJVHWL!R3R;[#>_3OMA\;J8:VU*D,(*P I*_O+
M*R0@GF0 D)Y"%#_?%<_.@GD*"E>X9+.] 2"+[7E\U+F;/B.,U#'%IY30C96=
MP:W8EB"0:7G"=<TTC,F:RD<15-"2Y.6:93_>+.N;@!!-4 H*WN3O8MEW&2WX
M73L8C1Z:KATLYGX8W\6)=(6](9D+=G1[%364QFA(5"6RED-PPVJ,7GD-/KCN
MI;[?[#]0Z-GL@V7RL4N7=)#^Y,D<AE]P*LID.60L?=MJ0+8*KI4C'+_;SI>;
M7-9;/9F4YS+S9;PX)0JQ0Y>16O[.D2B3PP;M2TK.VKWW9KP7/>8"NRRN=B/3
MUS9[[4I3;9?3(FR7/LJ4I][TF8[?J14,-I6VB)"94RR'B[54;0>7(WE<O##[
MX9%1!; $@(%8,003=BSJ+$FZ.N6@%YPF5D>2D0[LI J[.J@JD KK+;*M#42J
MT"=Y:C85E]'C^/JR%,-IZUJVYK"'H#SY:9?47409#R9[25S(3#C;,I"$H]-P
M )VA(4K@/M1U+V>DZGF))<G/<DK$2PYN.)7.X8^&V3G4%C1O[W8GD8]"= 3.
MITK)923/0"?*PB.;+YK)R22Q ,3''XB9R%B%C*IJK;25T41A@E8ZXUKU4,**
ME**7(S:VVBD'2-)=4M25<HVI)<5RD\J5*"><\SZU/TV2<-TY)8X1'&-$\D<L
MOB43(=<4,":"2 G[I37(%UC,H',=3/#-*"X+0Q-%'I8DHNAGD<%0=[DDL_WJ
M%8S:KGXZ66X\)R2)3PC2'6G$(5$87H+>(6I)4 CGZH4E:2D<@6M24*VCV&FZ
M7EFS>>SN9$>9RD#S9"$KJ6;-E9(U#5;#PRT<JKW--8K%+J.4S>9@@RF5B5H\
MYF4BS\HD$<D.3#(TWA+8+/(@>.]^:(HG!?7UJC)0'$H0RZXB.HK4EML-O*],
MDE1 TV-* 'WN9(4C2T@^,K[-9?,]7ZO/%)K:*=)_'5@[B2.0$NLI4V"2;5S>
MF4J134</U[-Y?I/3)L_F458\L86RX1E1UD4JL*P@D [A49%*L8=0XU487N+T
M6*)C/*M6IIE+8;')'6RRA4A;81ZCX<=3RJ#S)"E! *7.B^9*DC>,G['1]+^T
MY[+F2:6.*5M.A5<*$<N8UU,I8)J12ZOI(+43MC1^F_M R_5LY!D9LBO3S/,J
M_:7S#9B/4"!&IC2++2Z#-H=P979UN$R(I+@1B8[,BJLFW)++T>3:2IE?%8AB
M(U6Q92P\8+:$NK2MMN0IU37*EI"&UH;0V.3?CFOMGULY\P>!E!!+%EUBS#AR
MYG>.E62F 90$ 4@DEB2S=QC>WAER<;Y<YB3,1ZV>%I*#QAS;JSJ 'MK86JZ!
M[J[8(*B@].8R^XC_ 'CG?V=:"F6EN-]P>S@3]/GXY;J+.+)+,;L^?KW[>6,1
MG=1B;2;+&-*WLZWH@F]E*['S!\N&O,X$:/=642 \N?*$M:I18*6H["D+4E$1
M+BP?5=2'"A1VVVT4E(4K]L;3[/9:27J< 9W17GC D12[+J= 75!NS 644"R^
MD+OBITXR+$I\,4D#/I=U1&98]8+N=A'8N1C8":BVUT>T_#.HL:MJ]LYZHDMQ
MIJ8^VTP92G5I+C7I.L#UU2')2FTEQ;#:5%_U5( 0 5^AH^A119ALPS?ZY+ T
M,DJJJ@22(JR9E58((I65=3ZKT,S;W>-&G]NQEY&RF3Z=%/E8,SXD)FEE5Y%6
M021Q$QDAX(WUI'7WH]&H;5@6F3X\&;,B8_,<5,BMI29<4KBNMLRFEMK3&*.5
M2O42'6'Y#+KC827HH<]0*]/%>T68E]F<E XB,XD,BP22QM(B.NEF>102LDQ)
M]U"4TII<@@ -L_2^JQ>T4.8EDCCR[AXI,SE$D,CLB%AEXEE:W&5CHN>&DF=W
M=:((&6</;L(LE-S1(L8TR9(G*D(?=BW+;\MQ3TA^/9 /<Q=<4IP,SXT^(A:E
M*:CH4M:CSA/;O/-+&%G,8C58Q',A:!XT.P>*P=2@@:U8/0O9JP^>3QRRA716
M=GH'W=1(MJ'P )H CRH !-IP:D.+4[BTPVJ@5*---;;K[YO1!"([2EF#<$;Y
M6TUDE5A((*_LEA/0;KTWVPR&;"IG4^R2.0K2$"3)M= D&C)$A%^[(K"_O2:;
M9<)+EF2F9=6XX]*H[T.?/R'R05MGF-*LU]@]*F0J]1:=J+Z(Y/1$*=\T=AF6
MVJ97N:2?N07(KH(&CL:\9Z3V9Z)U>IILIEK?>/,Y?PHF8'<,9H@58&PP.H@W
M8)WQ-E#*CASK5$U,5 LM790.3VWXO>CO@8R3A?PNXG6J)E_-R/$,J'.W'O:>
MSD*B?#*>4]&@/&9'M%Q&8KBW$PPY#FH92L-*D1FD+=5:DR_5>BQPIT)XW@A]
MV6!E197V%NK6%9A5"@'8@LP))Q=S$72^HNHZA$[2O01TE*^&A!TH]$ZR"2Y[
M+JT+85<37@/#^NHL;KZ]IB1-F2*V&BUO)>YHN9,$NUDI?VB&_@I);G0I9<9A
MJ+:7%F4XGU9BUN\]]O.N9]1E<W+FGCS$>N-LMK>&6!PB2"98P05BF21 &7]W
MXJ2*NX-93)Y3*=/R^8@RD-Q24[3LJ$S*+1HI'U:V,;AF"L*"L*L@C$C0L/BL
M,_S; 25$J(45*2C8  ;"U*#:0$I(;;Y&T[)"05'QQKJ76LSU9XVG<22)&D ?
M2 Q4';416ISW8V2>_DU(1H1-(U7Z:B>:W '?Y>>X\D8JE1WR#M]T :YAUZZ[
M]!W([]/?QC989X0OB!EU $#?CE2>.0;&&,1 UE01W;G?BO/L!Y<889&$./K(
M"UHUKJDJ3KZ$ []OE\_GX@$Y6QIU'@$CRVN_Z;X;0>VUCD"_2N#_ "\CA;&P
M7TBAQ7,M0 ZDG7L>Q/SZ]?X>!,S$<+OY4#_'?GU/Q&&" $:M_,DW]03] 1SV
M)VP^HHU)2!Z9&AHZ V=#OL$^(B[$D@\F]Z_E_#!@*. #5<FOS(V_]'?\</\
MC]06F\K7RG[O#WB("2/96%W:>FC_ ,[6]=_&>]E6)]H.EC?_ *03O_\ 4Y!W
MW]:\NW.,;UJO[,S6Q'N#D=]:T+/Y?QQ'N!\&&\[Q&UO(V4UM3<P\JK:2)46<
M2W^&>I6\8RC+,LR.38P*^<EF+B]+CJ[*1$CLRY\F(U,:C1';!VHA6?=,QFSE
MYDC:%VC:)G9U*:@YEBAAC",RV97DTAB0H:K(4.R\[2+6I8, =04 @\:69F)
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M[;!<F8QQ^'6&-.CV+TYVKEA4EQQM;,2(VI462@>H'W1M,YM:$_S"HSAE=?\
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MRZ]ZS<EPFXS4B0RGFD(.TLK4GGVI* .?27"E7)Z9=2@D@A2NA9W]G.;SN3R
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M>NE+@=_;'V3D<R2$22,-+2/T]V<KI*T7,9)73:T36FQQAA[/]:52OA@5NO\
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MM$627K/4^K0RY_K.>RX_L_.J\2+T_, 2*'\(BM$*M&8!%I6%H@4 ;?$V;Z1
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MV%9'<[<>E_K?"95:M(_WLI _YNQU_+P&I;JVH#\_7@#CXW6%A([ !&ONG?\
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MY8(\O+(&;WXH2S1H5U:5 9V)( )O>Z 'M;7KC.CF;4$+ 0H<IT.8D$["1U[
MG?MT^7C"PSM'()%)U63=BR:('>Q\AMSSOBN;^\"ONF]CVO8'^5[[BL3YPUE.
MT*(C,9L1822J I#+(989#AW'4EI*0A*4N!'37I[2A*@$+419GS^8S4K33RR2
M.227=R[,S;DDDF^:LBZKML*.8RZR(%I0(U#1JH"TJV"J   '2&4 ;&[N\6;R
M;"4\1\:%U6QT#*Z%I:9$9L*]2QC, JDQ>57WE.-IW,A$J4IUA;D<#^9;YHI
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M>K^'TY)&PQJL*5MJ.ZXH<J4)*E+) 2$)T25$\H2E(!*C[#9.NXL=)FD.:C5
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M0(P52,7I+$D,SD5I%:1JL8?H/[.IXEFS/7(P6%+ELO!(VE]6JY)#I5M.D4J
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M,&.-8E)!076U$ =!RGF)Z =.NO;V'T[^'(+-9(WV]:_ "^+\CAD;2-&Y(N[
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M:\P"./,GZ7PRBI8+"^695N*Z@>G9P2?F.BGD'??IH'IUT1KPP=2/O#>^6!Y
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MP'73S0UGT7@\ZQM+<AU7CDDY8%2& ]T>[?(H6#Y77/UYQN:*"6D M0[!R-P
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M:BD*J)5#$2G30$E!5K[I%GS4'4%JN+)/-$_ XWM<>(UF]'@Y73WTVA'#'(\
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M $GSQ//%#B#E-C&J>'L"H+!9J8V11KL0G7&784 2$O(96$AMU,-AU:Y1!*$
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M812QL'$1)$4I+:HRLQ632!1]PL:U8A^TY3.Q',9*6.:"O]K$]AGW+HFX.J,
M:MMBU=KQ5_S/0G'.--E%1C]A8.RHV(*]>M85\)7^E@F+GU)1=<$9"7"KD0A;
MB%!'J\NT*4E7I/\ 9O-,/9?I9BH#P9]1) 7_ *1F.": -$D$';S!._&/:+-0
M1]6SQEE1=,R,D;7J<LJ@'2 3V);@:11'O"Y'F\2N'RLD3/LL3F+IIS];F&1U
M<FNI)DJQXF9)G&#Y3Q4OA'?F"(B)9TM)>XOC[:9*W%PY#4B4S6NWUTF/:S.5
MZC%%X)S0$T:')PD22J$Z;ELKFH.FP$A26:.26',2D  ."JLXAAU4(\U!,1H2
MT9O$-*M&9Y4:<UL%NF47NUZF^\<"M/Q$X>26JZPR&G]7*FJ^+!L(C/#G$YF*
ME]KB;39+(NG8D;(\95*C?J- =PU&-1H-45I6XAJ]B1YSJVL5F(<X'E2&0#+D
MF0.^;G28)]DD@T:VBFTD9EQF/&9I#>FXF91B>-(R%+@%SL (UTZO$5SL"IHQ
M@IH &U@,+.$D[/L69S;,,IH*4J9GXZQ!Q=BVQG&%Q8>0.0Z*MGVLNC(FU,-A
MAEF_F4BA]M6<:4Y4NV$ZPM#.NU4V,[Y:'+R,=,<S-,8Y9BSQJ\KHOB^ZY/O1
M*ZCPT(#A41"L>+J1(K%]M3* H(4!20 :4;;T=Z)W%$D:L2LCB3PGLH<SX*CI
M\98Q[#);M4Z_P\Q>?>0;JPD8?B[<*N3;9?*@YS)CM3[S()$V="I+%IVM>R>+
M':G/3X[6,\+.*03+)*99UUC[3,J%%$TI9BL(: &DC"H76B(2:TDV-*?X0*&U
M ;$T"!O[U<V0-_>KD8#Y_%?AD\&(=E@TVZI/MF-93(2:''(#5HE=KP08R"U^
M C3FZVHL,FI>&N7R;2NKG$18LO,WJ:/.<KG)$XWDRN<6(NDH\1XRMZY7T!4Z
M@(T+%272)LY#I9]V$ =E#A5Q6=H]94BE7<TJBV9HF) VHD1L"1M;5Q@;;XJ\
M.*S'L]:D-3,CRV\KK6@IK2QX2X'11&&Y6/LQ<4E18F.WKHIY-'D4ZXE37WV;
M^/*KH&.)C-5:XKZ6".7S)DC96$"HT9I<WF9F/[QC*A$D5NLB"-0+BHF8L7!!
MPO<H @MJ#?W% ND .QVJVV]XBE (P27O&7AM?-YTXG'!+M\JR;(7(-I?\-<=
ME2VL6O*NDK\>@!55G=6U36& ANWD52HB+-JSM&:NQE26$R'XM=7@Z?G5;*W)
MH6)8-2KFI /%C=FE8AX7UK.=(>RNA2ZJ#0+R/-%ID'-AQN@W!%#<':N1N;VN
MN,1SG^0X[F7&7AW>8C6_9T&/GG#)*XS=!58U#3.;S6N^)-91U<RV^ JXR9#;
M<-BQO;RP;CQ %V*8J(D&%*D,D'3NJ)*Q=OL6<HEWE8KX=#5(Z)J:QJ8K'&O?
M3JLF&<@ME=(V^T0GL #JO[H) &Y %D]M\3QPFQ;[(K;F'4K48S#E-:0EI5R^
MLFQJXR5N\XWI;ZX3KG-S?M.)/?7CSC-)NA)\QQV H[?'Z\XZS"M!@NUZ31W!
ML>]=[=^./CBW2L(Q#B33T=GEV,T][)CQWDL+L(33ZHZWEH1+2T2G;:7'(J"I
M'1(4@: Z^*R32*6TNRV237?=MZWW.][\_4SK#%(B^*JL5M5+!2:%#DW?'.UX
MYY.+5,DN2%_UW0E'3IKH-'\!U.OD3[>-N^8^OI?Y8NC85Q8W^ \MQR.QY[<X
M;4MA04!T2E WTWTYSUV= DGKKYGZ^%@BHH*-KNAY#?L. ;W[["^#61CZ4I/7
M25%7T!"4^Y(&MCYZT?%B 1DL&-$UI]3O0-#?M9-"L1F_=K8=_E8X]>#?<DC"
M1U12E25*5LJV.A!T >@Z_>[#KO1/4>+J99GK0%8$UM7PX_/MMSSB9"K$#[IH
M[4.UDD'R/EV\[.&&_P V@\/,7O,VE.(,RM,>LQUI:$N)=R:R+K<)Q25 H(JX
MT:;<$*0ZT7H$:-)0IN6$KW7V?]FY>I9C+90*55R'E8;5&*+D F@3L ?EQQ1Z
MAU#+Y)#)I\4HMR;E;"D'2"+V)VU;CT[8I#4\36\GL)3H2ZU,4M;I:?>+STIL
M*"%2&WE(;+ZUN!1=2$EP*TH\WJ(4KJ_6?8)CE!-EZE*QIJ3W5=51 @I0-["@
M@<W9(%;8_P!G/;GI69>/I.=7[%*I*03%@^7F,CWX;2$ P2%GTQ^+43[*L@85
MB38DYI+:';)2D*<;YV82/NREI6G^;=="B!&;ZA:2Y]]PA/*TMHJ5XT-/9C)]
M.89GK$;RQTQ7(1,1+,2" 9I4U+ET#$%;;Q'/"JH)QL^;GGZB),OT1HE"$"3J
MTJZ\G#(K#]U I*G.R, 58I4$=G]X[* V8=]1!(&DJV>7?,0.NAS%(/;6SKJ1
MO0[#G75,O'%*XB%)K8@$ E5.X75Y#CMOV[8R,D6A0"!K -G36X%&N*!-[ _$
MFL(7.ZOP_N\8%_O'Y?D,56_N_P#:&&>3^V/P\&![E>A_&ZP6&I__ 'P?E_8?
M H3=;T+V[#Y>>V)5 (78<GMSSSA OL/Q_P ?$UGS/UP[;::V]X#;RWV^&$*D
ME2%=0.W4_4^'D8!@M;FC?IN,%A&L#L1M0Z$]-'N0>Q.^H&_D/ 'CB_3_ #PL
M:BA)'4=^_4_GW\0DMN"3ZB_G\,*[_+Z;8\],:Z$_3?\ ?X;"QJ+2][YM]=Z_
MNZD>'4D$&ZW!^AQ(&'9=]JJN?I],/5?(<0X&T.R6%* (7'DO,N-K2#R.,K:6
MGTW$J^\%C6E)2I1Z>-YZ#UZ7*R11QB"TE5UD:""1P=MR[Q,^D4*750WTT=\/
M)EH,T)(IQ(ZSQF%U\:94*,"I4HL@C]X&BS(;OWK Q"M%5<:(DHUF07-;*P=^
M8MM^U>L')&2-5LI]QMA3L%$=4),R,76Q,<1-7!8:^(=C/.-;*_1#^VV1H95H
MA_:'@J&95_=QS>'[Q8"BY!LZ%TDD#NH&.-Q?LTS!S(S:YC+KTT3,44S"+-G+
MI.I5670RJTL:D+(;#*2Q5=5">W)<>.4!@20$M^FGG?D+'*-#[S<AP_>VD:44
MA6NN]'KP3VEZU+#F,QE6&69A(=<D"9<ZCNW[N:%%)5]5L"19)L6#CL*P9;1&
M43,)&8@B1S29C5IKPR)(LPS^\ FS"Q0OSI$916HE3BM$?\[J?J!\AL?V^-!F
MS4DQ.IFW8D@DGSKD\[[FKOOAA'7""AL+"FAMMO\ #TVVQZE]9.FU=2?],#?U
M()'?^WQ$#7]\C;<;_"NX_#UP1U;;7MML"*^0KMAT9]0I'.0HZWL:^G3H3\^O
M\-=O '<[6?4]^P^M?P[8-;'-#Z"SOY?+RPN82YS@ +'R[@?NU^/7P@31HGMY
M\41SV' KOMY8370(.W/ZWH_#OB1L:I9-D\VVD*4-#8.R>Z1U[[(]O;?T\2*6
M9@"QTV:N](V/%\?7\L59Y B[GM=CL*-C:^=UKFL3Q X"\5K7[.N,0;D4<)E"
MI/ZR(M34*$E#JF@U&D17DSVUMEM1464)"E*2.<)!YLYT^/+@E\RK.J[A47<D
M=V&^U;V=K_#5\[U2&-GB55DD)"A2@?0K ^\5-ACV%@@$W6VZV6G)J.4[!SBG
MK,P<9?<;E6$O4+)$*!+;RV,F@MID3G^X:>R!F_;1T46"2H>)I,Q&E^&3&E$Z
M 6()[79JOEO7RQ1CRRYD*4=E)W)6@K'?8@@"_0:1Q8)WPK:H*3(NF,3'S-4%
M$XS=I8CW1.N;DK)+2A7Y$D;#;:(9BW,A25K31-L@+\5'SQ.RUL0;JA0_/<][
M.W.+T61\$J\J$*-BXLJ/+5=E;-7N1OMP!@273B,^I*VU)6API4"DA22"00KF
M (UV.P"-:/7Q5^UR&[(.YL;>=[_U\MN^,H,M&0:LWP;L"^*('<]^_EA4N, D
MZ)['>NP]]@$D]>G8ZT-:UT\"<RY%<<<&CZ<>>$<E?;D\ [7SML?U7?#+:6UC
MZ<=AQFGFIA,)B1E6..X_9R&8R5N.!A,NPK94HM(6ZXI#1>4AL+(0$IZ>)X>J
M=0@C\*#.YN&.V94BS,L: L;)"HP4$DDDU;&SYG%23HN0D<R3Y3+RR&@7>%68
ME %%D\["A\+K<X:H=O+]=*%UV,D$:ZX9B6NG_P!!.XZ[_#Z>!?K/5P=NJ=0X
MW_US,;\\_O-\).B=*NCT_*GO?@IY? _HX=E6+X6ZE57BX'+M)&&8@>56@._V
M'^>M]1KK\JC=;ZR&;_G7J( OC.3U6VW^T]#Z\;\8LCH?2*/_ #=E *)L0I\:
MX]3MMZ;8=&K1*PVARKQA)*4*2Y^IF)?UDGE4!]AZZJ!WVT!V T? GKG60"/[
M6ZB>"#]LS Y]/$]/\B<5FZ)TO_Z7Y04./!0<_*_H-C=V+!/<9R*+'=3%L:/$
M7BLH#3JL.Q)(4@IY 4'[$T%)6$A85S'T^902HHY?"'7^LT >J]1/_P!FY@^?
M8R5BM)T/IF[+D,JMG<"%0?6OC\3_  Q;?'Z?',ZQ&7%B8QA8OZQG[6JRG#,6
M2_+B-I(L*U873DK4@%*F$)*RT\CT0MPE;BYAUWK<T+K_ &MU$21+J2LYF-T%
MVM^)Y5M^?.,%F.E].Z=G(YWR.6.4G8QS@PIIC8C]W,"!J)!M23V.Y%#  *JJ
M<;YTXUB!+9 6/U+Q4$CIUT:<G\1WV3^6.;V@ZX!_]]^H@D[?Z[/_ /W./PQE
MVZ3TOG[#E2"!0\)2-Q=W6XHV=C5>AP)9WE>,\.L1M<D=QG"I%FEM%=CT!S#<
M5"9=[8@QXCJP*8GX6H2M=M-7KEU%9BDI7,:W)!UWKA8D]7ZC[FY)SDYWH\'7
MM7/GY\8QV=Z9TT!(8\AE=3M[Y$2;1BBPW! U<4=Q7<XU8LNDO+JROFJ3$Y->
M:;':V.VYA6*A+4N-30OM'[@I>CBY;3CSA'W0J40$_=YBV8]H>MV O5NI"@#?
MVR?C<5_M/UZ8KP])Z<%.K)Y8[L?]C&.3L* W(!WLGCRXE9BDI%@*_57#2%==
M_J9B9[Z( _VGZZ[ C\#KIXK?Z0]>_P#IQU+S/^N3U6_-R?KM=$8=^F]-07]A
MRU<"HD&^_I^M_2_45%&W("3BV' * Z'#,5^7M_M/\^O_ %> 'M%U\'?K/4J
ML_ZY.=O6GY]<0'IG3M)(R66/_P"Z3;ZC\^>W;!2R>:6AY]*.4I#:@AMIIMIM
M*$--(:::2AIEEI"$--M--I;:;2E+:$H0 ,1F9'E:25W9YI',DDC$M([N2SLS
M;LS,Q))/)-DXN1IX2JB+I10%15H*H'W0H' &P%4 /0;$JHS"DD% UH]1K?;O
MV'777\_EXJ@N"#; 6-[-?/<8EU$6;W&_-_,C;UV_'$9<4F8T.D#R^4J8(YB
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MTR(;ZFE-K4YZCK:W$*6$^M)E.*(9;9\>PN@=5Z)-TF.;+Y[+?9TA0,7D6(H
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MKN6K0B L23Y :C?GQZC<XG2W3$L>#U^U=<2D0<$GSX0O757T^;5VSU.^Z_\
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MK!'4;'8'\/'#NHP2P2,)4>)B**MJ1ZL;,I"FK .]W\,960:KD1U97%W&X96
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MN22E4H <S=[DDJ20 2)->+)YHGZAQHZ.]A6COIKQ)SYB_/U\_P!'&!(  V!
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M4R1LKH\6;CNV:3+T2JK[SJS+>]G ]4R$DT3-"0LR%ZU&E=7!+(6[$D KN#J
MVHG%><,XI0\3R=W#N(%G78MD%C#H+2NC39+<2ME,G&Z6'-9B2UMQJ]IQJSBS
M0U#26$J2'$PV/3CJ2C*^T'3US.:SG5LL1F<GU&27.G-+K"+)]IERQ1HV)=65
M(X6D9[8N[%CN+HY:2')9/+V@BDB\:#-6=0&8^T39AG>1?=)DCG4J12U2@;'%
M[:%]]3;(=2M'.TVZ@.(4DK:=0%H<3L';;B%!:%I'*I"@I!((\<_SN2>%J8%
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M>0.H WMQP?R^?QP,I)&_GYW5@X;;%OU8Z5:VI+BB3T!UT)/[]?\ 5X!3W\P
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M@F[.!S+ZIE!D].H;=(VD=TH/4D]^YZ>WU[>,\PT-MP31!\SP?Y^?Y:]$]K9
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MWO $-5!@3=_$<76WEY;8EQ7%BT+847&O7]/TQ*2VV)/+RZ*2_KU"D@ $%8!
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M5,%R+'>>0V^F)(GK2XIM*@V6Z^%.G+*RD)B0I<A1#,9Y:(U1F!(5B!L2 2+
M+$$@$#W0S6>RD\ TY= =+,JDBZ)K8L%!'!^\R@5_>(') +/@UW(8F/*YU+6X
MMGE"5$J4HK.DI">JB>@2!O9'3?;P\+LKJQWY! [[[<#?;87OOYC!/$"I4D4?
M,D>?<GRY%C\+Q.T^AJ>3-JNSLWV;6[6PF=8PY;$Y$&1"CAE4&,XWRM28K3JW
M$26F)!9??:06I+K3++BJ\W1H9%ZH6S4RS9^1)#(&1ER[01*BI$HH,A*+K&H!
MCJW(W-O+=9S&7;IS)EXGRV2C91"P>,RH[D^+(003+3$H6'NW6FQL+4_#/'8B
M755V3O)4Y;IF;5&7'5!KWTI1-CQU-2GE/NJ*$K8#Q;:2M)YU:+GJX<>R,996
M&?9R)RX(5H6CR[$L\:A&<.0^Z!BH-FSP#FC[932EA+D#7@4R^(LBOF 3H8ZE
M&A=)()4%O( 4,&3]+45SS/V1?R+&/,=91:FW>89<KDQG 8TNI8B0ULNNI;4\
MW(9D])A7MYX$\R,A/T)56.*"?Q82P\5YBL<T(3[DD16-]9W;7&[!6-$FQ>*$
M'M$9/$DS$#QR1J3ETA)>*4M8:*;4Z,B$E2KH-0%BMZ+=]@87C4YVSI5/K<6E
M7H!Y49(:6Z"7%GX5F.A0420E!1RHV>YZ@,MT#(Y+.'/12YF60 K'XK*%0N:8
MTBKKU D!6U!?B,19CV@ZEG\K]BDCR\,98L_AJUN@!I"S%JK8ZE -BJ&(ORRP
M#S,M8(5MIT)T=DE23].GL?<:[#Q=E<,6K=M5@\"QVVVKUKY56(8%TE; HW2C
MU ' JMJL7L. ,0_$C+D!WL1Z:U $=>8:((T.G8]3T[]NGB&OU^/X5B\[!64;
MV+K;;:R%]2*/'IA*V5(<&B0=Z.NG^>WAB U7_$8-P&6_US1_7TP?T&0.Q%MI
M4K2@0!HG1/YDGKHGY>W<@^*LT)8#< T1=7M\*WKG<?/G%5HQLO\ =((Y/G?
MKSVH]O4XEMVOI<WH;JIL(3#Z[FFFU,HC^;<EPIK*FY,1;C:DK ?;);"@0M)5
MM"AT\;M[%^U/4.D9[*]/SN<>?H,TGA3Y;,U+%EUG0PZT+AO#B7Q#XJBT",[:
M=C?'OV@^P60ZAD\YUOH^0AA]I\DBY[(YO+KHDGGR4L6;6.=(RJS.WV<!'>W+
M$H"-;:N/M9YMN.?E/M\OX3<8Y*^,]=ATY8Q?*+N0_ R>5B*'(]BA^VM'(#_V
MY,@XY)2[+=BO6T>I=>I(>07=?;V<2HE]S]I_8[V7GZ'G.I9#I<>4ZA&D;1KD
M6B@26*5S"I.72:6-V1_$T:8XI,R(Y)(LN,M!/F1B/97JG7?:7.=#ZMT/J[1Y
M3/3IE^L]!ST+9Y8<VI,69BR>88)FLB3.T3+$9)8(TD+.[2MX2=J:ZK8E1V)C
M(YX\IEB7'Y@-*8DM-O-KU\U(<2=#8!]R/'G&2(H64#@E;-62&()W[[$5M575
MG'98I#(%<V-0W[>I \@#MY['<\G3D\!<[$,DIFD[4]">=C-@ @/M#F  [?>2
M-'0.P!TWKQ)E7(E53P.!ML=P=P >3Y[DCXXBSJ6FH<G8GTY'I0XXX/GB;>&U
MJW*HJ68E0*9$!@* /7:D 'KH=04ZT1T/0ZZCQ'F%(DD"]CQ>W<CX\WSB2!P5
M0G^\*7;CM\!P?E],3,RHJ3O>^@(_ DGV\5R"#7I?IVK\,6!N; J[OXB@+_';
M$;9!&3,SC''T@%R%'ON<[ZI0\EMM.QKMSH [D]]#KLVH]H#?9AZ\7^N-_+MB
MFP!F#'<E?.N.VWD-Q]-AO@%O*L1YLV0\VEQIV0$.)=ZH4R]'0V0KF_J_S:MD
M_P"EOY^"U["JX].?EZ<$4+/T$@BP>*H\'F^>1Q5<XKYPTJ)BLAXEP<=4V:"O
MR&"W7A2OYIMQ^O\ 7FM1SOE]-N0HI(3OE/0^WA3Q@^&Y/O.FX% >Z2+XY/?X
M#$$"T\P6@@==(XY6S1-79WY.*Z.='HP T7%\A/R2 HD@?P_+Z^-TQDB0*H@D
M<G_L@4".]FC>'MA05&<3H'E4 GL=;V?Q_#\_"P)OOR=\.965,1D[V$@:_/77
MY^V^O;POU],-@0XDN>G QB&.QBV%DH;/54N=\*E1]C_-U_3Z*W[#PL6<M8:1
MSO15-QZ$UJ^0)'SQ#,GN?P']OA8MEJ((\N/C?/P_7.&"0=I)Z  ;[_+73\^I
M_+L?#ZF\S]3A@Q+;]]@/*SAC>27/N[( Z_/9]B>O8=?S]_#JI8[WQ=U?'KA,
M_(XH\WZ_A>&PQ5Z(2D[)Z#1.NFN_7W/3J.^O$Z1LS @:B.VV_/;L-]_EZXJR
MYQ$4@L18JS5ZCQ0V-GL.^ 3CU+H^&?!V[M[3+$X]Q.RFNCGAK3,5+5_8P:LR
MUNV^;VE$N2P4UK%%5Y)*J%RUI+S--;6\&!=NUD:LG=%]D_9S[2R9W-1*\"2J
M(<NSE#G)R-4.6&D@Z99C%&K,4B:26&*1U24:N9=4]L\ZWM'E.B]'Z>,]E81,
M_7<Y.\D,&4'A,D4,,B@^+F89'AGERZG4$H2:0=1YZ<,J![)GX[H^,36X/?39
M$Y^;*9M)%SF;S4R--]"X@RTPL@KZ]N;-EC(WZYF>\NSAUS8(9LU)Z1UN8Y/I
MN8GS4OVC-];R>3RN1H&"%.EY>;*SG-)D72NG6<LF1&4BN$R++-$*M<9;I\TL
MV:2-#&,I$QS"J%+!9BI10).9 ^IBDBZ7)_V@8:6Q<.CBEIL%22#TUU[_ "Z[
MU_GL.GCA_5)/>)%;V*!%?WJ-?'S /;&^9:PBW9]VM^>2;/QX[=L$H&@!\AKQ
MK1Y.U;W6+6/?#86%]5;6-#:5EW3RG8-M3V$.TK)K!2'X5A7R&Y<.6R5)6D.Q
MI+33S:BDA*T).CKP2@D[;5O=7A%%D5D<6CJRL""0RL-+*:[$$@X-:[BQQ%K*
MY%7"R62U$9C5L6*'X55*E0131I\*EEUD^9!>GUEI2P;2PKZ:YKY,:WJ:^4[
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M4#!.536CDFE#$:ML=-LQCSY;B_NJV/N  %("!T2@  )2E* $H0G24)'*D)2
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M6<@$".*,L(,O%JC@@B:62010Q,[E(P9#2ZF"[A0J[8U/V>]D9>GRR]2ZO/\
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M>5;SR H=? SUHB/?3S\S^NV*$=;@'N=OGS\;[7MOBU%O-;B1W'EJY0AD>_\
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MI/3Q')N!Y"AW-"CS\.^$M78/QOS)V]/AN3ON<5'R.;&MN/TM]+@<<I,AI74
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MN0ZD.J>+"TS,F6;*1(#_ &>8Q$T[LV9,PZE T:JJ-9,9 96TZAU[VA]I\O)
MW1>@0YJ$+*,S'F\S'%F$=&(01Z94C.H)-8IA:GW@.>@%%P@B9BEN1PZSW%,V
MJTD)F/19*HUK3D<OJMV]+J380GHRB69;,AIJ1#?2ZU-CQ5-.<FCYOV9ECG$3
M%%)8V9&50!94,K+K212>&#!2*8,0;.&7]J$F0@)ZW[/=7Z5G-%PY<QF5,S0M
M_"FE&6(6( ^*[(8XRKZG9$+XC%F5P#M&@A''FA9DN-L+3SXOD#<1#C[>5+2V
M_*DHCHCK:&$Y,F6E]+*H3E8ZS)0T^Y':>N#V'F4%C(C%&(81A&HA\D@ T.Y?
M4_4<F%*@LYG!6,J&;$@_:-[4ZT:'V,SY@E5949\ZFMX'57CE010R1M&06(9'
M=?<<$W&V*,57'_&,@DO0);4_%[1HG<2^:^%9<26D2&UM2E^GZ27([K#[2+!B
MO?<;>;]-A16G=OJO[/>J=/R\F;B&4ZID8P6DSG2LP,TL04L&\> *9X C(ZN[
MIX:LA4O9 QU[(=6C=D\0M&9 IJ:HAJ/]Q9&)C9UO<+(30+E54&F&?YA>'<-T
MLJRB-(ZG3D&+96+'0E/23 B28Z@5 @%+JMZ/?6_&*@]@_:7.QK+EN@]1EAJU
MD&5:,,I&Q7Q?"+ _[MW7GL<VW4\FONG,0J17NM-'J (L%E+ BQO9 OMY8,\)
MXDTF=6<.GQ>V@7%E82&(L:%'D)1,]9]Q#38<BOEJ2RDJ7U6ZTAM "E*4$@D8
M7J'LYG^FDIU#(9G(MI-#,P2PEB!8T^( &^"V3O\ X3C%=8ZSE\GDILV\\4>7
M@A>:2=Y%7+Q+&K,TDSLX1(T4:I6=U"Q@DD"C@A\QJ(KYLN'5.RNP:JK!N!*?
MB18K\.TL*EM49-HTMQ:I@<<L%2GF@5^DTQ(Y6E<G*D5,Q[-](S^5@3-]/AS;
M[L6E17\,R*P(4/JT$J;#@ [T.^/F+[2?\H']IF1]NO:?.](]LNJ=)Z)E>KYB
M+IN5RL\63A.6R>8"Y<S2941/F#^Z8R03RRY>8O;1% B@H\MF(W.7Q\@1E,NZ
MJ,\#LI=I;/RS!AF$S&Y(#\9YM"%_$V#DI:GWME29$5II/W5*4KQ[^U'V#_T:
MZ[!#E$:++=2FS_4LEF)958Q:(4;,95W!]YES$K-&Q8!H2@"@I(Q^N'_)?_Y1
M/3?VT>P,>9FS>6G]H/9I<ITGVBR.6BBA:27,-.<CU&. ,VB#,9++CQ&2.ES&
M7S;$!%"J(<88>#< LPQ*!A/#).=6%RQ9R<KG3+;X&&8ADRFOCI\?X20](D+E
M(4J06YD-M303':YG5KDM82/V(ZFV0R\O6,IUS+R:G:":7+RPY69= D2)5FC0
M-JC=2)1(J #20S@XZOT[]J_LOUGJ^9Z5[.>TWLKUB?**3GLKT[JV0SV<RR+*
M\,DT@R^895:.6*6*2+PVE#JQ*JFDF@V&T5SG&4Y[>3(YJ)T%BPL;4.J5#0@6
M=DY_1X2%DK#!#<A#0*R&8R4-E:M@D\VD.6R>5RT0=I3,0 -/AQK#"^G6IU.S
M:RJ@@C<N:/(Z!TC,//U#-D^'I7*NNMFU/(78:)"4.GPB$<^Z"225!L,,6@X9
M\2,EOY$_!.%SM50\-JCX*E;L'&W)DO+LA;KHKF2-V4IU"5.UK5D^] BO-I6R
MA$93T-#Y"Y"]R]G?V/\ 4/:+IL.?GSZY"3/B0S!U:5F!)4U&@**0H]Q2U#2
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M=_0 C?<_AT'BN2;-< ?B:KN/U>(G^_6UGO78 4/COSQVKS.:J&WIMD:2VAM
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M\L<9]K^LYW]I7[0\W[79[+RK'E&@C59$C8+T[**PR_3F@20A#&S2%6,LRA)
M?&9A[EC\Z\LZLQ\O60R8D=R)Q!R*O398>U(L)58W517;:-9+CNJ:D)0]-R&O
M:D)?>L0Y':18MM+;;"'GE:S)[2?9>IQ+(Q^PPMX<QC0-)(VEE+$G=@AW44
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MRVP[+?LY4V1-?4N1->??<<<5B,[UZ?,3>--*6=6]V@ @4V3&$/NK'O2J!2*
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M]??6M1*UK)VI2M^_CE_5UV=BJ*69GI%"JI8[A56PH%Z54$@"A="\;)ER75Y
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M55])5UU33PX\C%I3,]4^OD1H$Z ?2CR&$//+EO($:8D3)-,9J1Y5=B&9=]3
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M@;NN31LU5@[]J[\GGRP;M/1%5S<::X4I#K$P*1R<Z5L*4I!;4L'E44K6CF2
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MQ3N)OM*&VEGU"5D:WM(T$G\-;(/8[Z>- UG6P8%2C,CJP(964T0RG=6#;$,
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M[SJTH;;0I2E:!/BY#E&FECACC:665U1$4>\[R, BCU)8#G8 FO.E-FF[$U8
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MUOIT.=A5A-''*SI)!("?>BEA>&6-K)#F-U#6>QW>+-S >#6/T-0J32X?BM-
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M^!W)\L%"9*J]/KI_;;=;*#\BE0Z].QZ;]]=_IX.,Z2NY%5N!O8\N_/E_45I
M2!0\[LUM0OCO5\?'%%/,OY7,2XT>8; ^+5NJI<A4;M4G.\:LXK[T;*ZZK+DW
M'Y3084&5SV&ITFGFHFH^'E5;C"5K48#3#VX]#]LNM>ST<\?2\W- )8LU&@4K
MX<9SB1Q9B11I)CE9886#H0VN"(V"MXBG63,91,H5B:%<[%F[<'6@6-TFAC/'
MAY@^%XJ&T;231:[L9F&2-_ KAQFFHD&+",:-%C(0S&C1V60TRPPPV$-M,--I
M2VRTVD(;0$I0D)  U26=F9G=F=W)9V<EG9FNVDD;4SL3]YV8L22+\Y8U*^IH
M;$U7T'IW],5/L9"GUK4K9.U#MVVKKU^6AO>SO]Y\8Z_Y<>5?PW^&^+T) !OD
MG;R[#^=X; 2$[/5)V-#O_=]??PAZ>OUO?\;Q/B0<:;4IIM0WH()'3H0I:CW/
MS"AV'U\2D6% [+?Y#]>GPP#>>W//J 2/T?X[$\A /J+/LP$[)/<IZC\=]_P^
MGB(I[Q/8!21?!H>OG>WK6$&V [V!P*JQ\JKBL11: N6,@I[<R1S:Z#E0D?OZ
M=O\ K\"2%6OCM=\W\#6+260*\ORVP58S5?>3.=2H ]&]IWS)ZCF V.YWKMTZ
MCIKPRIL !M9-6;'8"_B3?Z&%))5B]AQQSP3^=<W?&#.;&2E"'&TGE) Z;ZGN
M#O\ +^&O"DC4 ;?WMC9[ ]CY71O^&&C>R;L@@<5Y@_RQY-JI$Z.AUG8+;"4Z
MVH \@]_;J/;Z]-^(RM^]L31H$[D<5_G\N^)E<\$T#Z?QV\_YU@59COHD)!3]
MY"TD\V^A201S==ZV-:!V1O77P)%U5 @W7;S]#7%[>6) Z@GFJJZYORW.]_'@
MXG23GDNT?OI\ZDI56>1I93-GF7EDF:REJ9+LO1B/SLIE.,0%SI2)3U05+IWG
M(4 NUZA&'-.<P[M(QCCU2$:F)F+;,S&B92*+$$KNA*K[NV*_V=%6,)))HC!*
MKIA"FU"V0L2@L%!&H^]3-343B-+;)LK1E*,AF6#EE.CY##R>*Y9AR<GXR#+5
M/ALH=DNNS6Z]AU:T)@-2T,H0HC060YX!YI/$\0L2^L26UL-2-J MK:KVTV!Q
M58EB@3PR@72C1M&=-+[K#2U!15FN:L]_+"6ML+NZ:HJF?+?73XO =BUD'UGQ
M$8]6PGV*W_AENK83+>D64@.2&FFU.-(:0KFY%*5'XC.JHS$HBTHLZ0"S,=CM
M9+T2 /.[ )G$:*[2!0&<VS4+)TJ@%]Q2C8WOQSAUEMK0^.0E/+\]]^^^O?KL
M?3Q7D)5]B0" ?KW!-_YXF5=0[\D'CC\J_$@X?(%L_$2G[R@![]1V]_EW[ ?P
M\2+/2UJ-UN0M^OI5;FN.^!:(%C[H/SWKG@_+Z_5YDWT&W8;C7-;6VK*2 &[*
M#$G-]QL<LIIT#\ -$#>OG/%G70^XS(6V)4T3>VY"[CM1-5R#@#EPH-.?@!Z[
M=SS56:&*7\>O)'BO%7+JWC)P2N:S@YQQHWZVP;L&JF)(PG+9U$IE_'WLDH!&
ME08MM3S(D)^LR.-53W8KD6.]*J;*3%@/P^E^RGM\G3,J.B>TN0/M![.2/K&6
M>0P9WITCL#)-TW-JPDCU 7)E=4<,N^K[Q+4ILNY#F-B&=/#+#^^IH@2 WJ6P
M".2"HTFP,'$'RI9-A.)UKN!7U?7<2ZSAM&Q^LN8RI<:#"RFIX5RL(QYSUBFU
M=M*1G,,CS/B7=M7;<]-UE5S'LY<!Z9"8DHVM?:'V5S&:BDRW78>FJV;$V83/
M*L.;FRTG6'ZGG1)7A1O+F,NF3Z>HB C@RL+1(663'%^JR]?GS&8R'M1[#YOK
M726S;OEYNGM]J580HAA<#PY&AF2,>*"L@E>5CK8!6NX^/G+Q762<CJJIJ9'L
M[:/2.QY"WX\NF8DA%)*LD$(>CV,R,/4G18;;S"%H6XV8ZEIB-:CU++^Q?6YL
MH<_UK(0]5DD\/,9[I8T19JV*CQBR^ &D70X<DO&Q*BQ2XQ?1\[^T#V7ASIZ#
M[/=4S/L\L FR_3.O*[2Y&8QW)'E?"=,WF$@D+KX<,3K*BWI#DL(;N>,O$+%[
MNO@Y-@E+14$O)<,I',D^U%R*B.QE>5<08\F7]HNQHS!_5S"<1Q^XN5OIC1&\
MAS"MHVY+GW%N9F#V0]F<BDYEZ)FLZT&2SV;CS4^;$T4_@?9X\LJ^&R0*,UF<
MY%$H"*P$$SD!-EL9/VD]H_:CP3E_;?IW2\W/-X2]*R_343-15!;_ +O-_P"L
M2A98IM\O+*H4QJ[K)JKFMQ3\V/FLX7Y(CB1$XD>7K+>&65R<:MJ_A/G4JNQR
M^QJJRKA-&XILU=9DT)JG?LU14F1A\&?93Y$FQRMZJKTT27+>'&3E<Q[+>Q>;
ME?)1=)Z]T^:$9Q!U#HS'JT4B9/.R9'[1-TMXP\22R1/,!!F"%C5R P4*>J="
MS748>G01=3S<>8S.7RT9S6<G5\N,S)4+RDF,S1I(HS,2^'1!*-[^H5AMXS_I
M3,_8X3T=KPNX .X3F&0KG09&5<07K"ZPJKE0F9!=5B@JZ2"[EDGU6D(!G?9L
M> ^XRB1 LV%+>2V6_9!/%F<VRYM?:&/*0KF/[-Z*8X.L2*X5HXLWD<]X6;R9
MD1C[\>7S-,* )8 Y5NH*PC;7IBDLB:5EBB47I#,Q+ JQ-(QDCH#]X 6 %:*G
MB+)N[>;.X[^=3+.)DN9;STR\9X?6LNJIU-8IQEP?&;*/B6)TT&3)2SG7"+*+
M3-,.7%QNKEL6>.W%;+AV;E:_S[GD.GYG(I%E.D_LU7(3^&FG,=1Z3G,YF0T_
M3<[,C9F;J"QP 09^#+PSR;PJDXU,,8N;-ZV\5\_4*NP"))&$!%4HDA)4WN?]
MJS"^.*E+RP>4FWXLYD_FV7.\0L+X'LXVNLNEY=;6\7*.)EPU86:U6U15S)+1
MQ:HDP55B9E7<53\^/+AS J+#$EMJ1)U#KG5X)H^GY"+V?ZEUZ1LE)!D.F=#Z
M-F_[.'V:/QX>HYC+9;0N9@S6I5$&9D32Q,C1-&$;'=3ZWENDY%^H=6F_LW*9
M=99)WS4V80O$$B\-HD>=96?Q!,0([>0,GAQLH4XZ18;Y9_*5'N&**KKK/()U
M9!6]&8M[<3 B&B4VX^VS(BPXK\= E*;<>C-.QU*6KUN1125C">UF3_:#[/=(
M3K.<R/1,AE)9A'..F],Z?#-%)(AT-/HR@96D"LBR+(Y+D N=0.-1]C_VJ^R7
MM?US-=!Z/U'/RY^.!\RCYN+.A)XH=*RMEES;R2 PAT;WXXF">^@I&(N-&ATM
M+6Q*^DKXU;7P&DQXL2(TEMIEA">B$ZVI7-H%2E%2UKVXXI2R2>.-UGJ?5I1E
M99YI4=C:R2NZV=MD)*_   ?08Z*.C]/Z=XF:6&!9F)DDG2&-)78G46EE51(V
M]$ZF-5> ;'./]+_*A2<.F8BY#=Y*%/'N&%J<;3<N/M,-QFVTMJ3(C;=4EZ0P
MXM$<H475 (>2SUGJ7[$<[E/8N7VF;.@9_+Y<]1S.0>)?#^R:0Y E+!_M C(N
M/P]-V VUGA/3/^4-T_J/[0%]D(>F%NF3YO\ LK+=6BD>25L^K^ 7>!8V7[%X
MZZ0X?Q"M'2"#@Z\P6!1N(E'>5#TAN-RI+L*6Y'^,;B/0^K3BHOJLEYO22AQH
M/(*DJ/WM@ Z[^S;VZ'L1U<YKPA/%(BY?-0^)X331,Z,2KA6TLA!*$J:W JR1
MM_[5?V=1_M#Z&.GR9ILGFHIAF\AG/"$X@S2JT=RQDJQBDC=E=8W1J (.H"H'
MX$<&D\,Z&GI9BA)D3;VWR5]QQMU"S&==4Y!CK]9UYU3I*V%O%3KA'(VV%<K2
M3XI_M;]M<M[:^T']IY..:&"/(Y7))#.R,X>)7:>0%"R!7D<Z>2=%F@51;'['
M?83->P/LN.CY^?+YS-OU'.YV7-96.2.-XY65(0WB .9%CC#-JW74$!9E9VL)
M-F(JT3YY;+JV8[SS;21S+==20B.RGW*GW2AI &P2K9Z;/CE%6HW]T<[>9W]>
MX&U@]ZK'7V/NDWV._KQ^> SB!2W-5PPM+@%Q<L8S=,V8!4.=N;#=$@I]^5"7
M%) ^[T3S?M$@'EU"R   602>_F=]SZUY;<'$;ZQ&QJS6Q/XUVL'O=[>@Q.G!
MS*:_#N%& QG9334NTHF;F4@.(20Y:+58)"@.O,$2@/O=>4)UT\2JS++.5)&I
MA8TJQM=2[V-M@/C],5'@CGBB)+ C6=B0;8J#8OL5V]-NV.6L4%FR"-Z!! WU
M_K#\]Z5\]]/KXV=2011/(_/&=?<;=COZ<\^7SP3)TM3Q]CU[>W*.G\3[?EXF
MP'W!N-1U!3Z"KOO\]_GAFL:1F;'6VM*5AP+"@M((4"-$'Z=^A![_ (GQ=AF:
M(BF NA1-@7WKOY^N(F35ON:L\61WV^8'.U;>=T.\W'":UJ<2H\[P 3*:W1%L
M<5O9=*[)CS$5IM(UU%GQQ')<9DU]A(8?><8#2GJ=5S%<66)4@*W_ -F?:X]'
MDD$XGS&5D;+N8XF*LD\4@59U*LC$?9GS4$PUC5'*N_[L!L/U#(93-P309PHB
M+#/)!++&C1QS>$2@F1@Z^!)+'&NO2SI,58^X/=KY@G![(W*VHD\2+%C+\CBJ
M$EFQ=KJU)C)4K^9*)D.''D6#CJ$-.NR)BU^HYI8;2OU'',W[7^T'2NN9H/DD
MS#Y. J^7.:FFD:1M*$RF.8N85+ZHQ#$RH5C5V#,UXK]'@=.D9;+NJ)!/HS+9
M:.""-44@-%#(4C1R5'^TIZ<@EB=L6YQ3&3"0@E'+H=M$?AT_CT&SKI[^.9]1
MS)D< -8NK!H #T\O*_.MKQL,"Z=JX/85L%H#SH#B\2*ICD1K6NGUV>A]NG?7
MC"L;)V/QO8_ ;D?EBP6(.XV)J[ Y],,TALI5S#\3K8   V-_70/;PU&KHUY]
ML&#1O]'TPU2&^^CTT===]];WKMU_AX<;42-K\MC_  PCL=C\#?\ +#,^CJ=#
MOT.O?VZ=/S\2!A=<"A\-Q?R_&SY;W(K@T#SZGG]?'>\-;[.AS#9U]"=[/;O[
M#9)UU]_$R\$>A(XY[C?F]KOROUQ.&U&B!1JNU4.WQ_IAO6@'KKI[CY?4?Y_A
MVD(L5_+8_+X_3D^8;J?(_G_,8]CLR7G4L16G9#KA 0TTA2W"20  E.R>NNO+
MKOV[B'<4=QZ[@_(X@E2-A4A L5OLOX[7\3Y<XEFEX/\ $&\;YX\!J(A2 I/Q
MCX:*ATT &D/?>UKN >_@M6P&]]S9O]?A_#%G+Y5'U,;(/- @[;5O\N+L$5BW
M'ZG9&S9XKE"*:_<M,7P'$:*"QCD#'&T-93AU'@]75W-PE=[32,WKH5CB:\DJ
MZNY<A1XMXQ0N3X]O6QK"LGB6%@@V?K1%>7EZ^EWAD"+'+$K($EFD=C(9 ?"E
M:4E$)1O"8K+X;L@8LAD TL585'XGW>5L6-0F[P)W%9M%B>#8Y4VTJ';U-S%L
M<0Q7%Z!ZZC6-=-@PY\N3(QUQZ&N8U/1"B2B&D(EI1)0!8WL":[[\_CZ8RN52
M$J_ASB77+,[H-)4K++*X0JP9@H#@&JU$ V5V+EEWF NKRDRJDJ&%U[>8YYG6
M4WLZ:F)/LY55EB^'TMBE38/,N28ZF+7!FI]A(CK:<F*<8:+@9^*;?1D(_N\D
M[G8G@]O7?T\ZVP$>0171G8'PH88U06%5X_M +%;&Q28J =AOMQ5>K!]^8VOU
M5J62 #S$JWUU_9\O!K.; "USN&/D?GZ=^?+%Y44"J'T'PXWQ%V1X="MV'F)<
M:/*8?20ZQ)90\TZ._*XTZ%(4G8ZA0UL#QE,GU"7*LCQS/#+&P>.6*1DDC;MI
M="'5A9]Y2#5C;;$<D0<4P# G=2H((\C^%FL5LO?+-@<R5\8U2.0)0=0\'JZ7
M)C+2XVLN(Y.9Q:6TA>REMI"$ $I(*20=R?VSZMFX5ASLT.>$:>''+G,IE,QF
M(MJ$B9M\N<V)!]X2-F';4";-XI?V=E@7*(T8E"ZQ&[JKZ&L!@K#W0>4/NG:P
M!B!.(WE]EP9,:5%J;/)\:BK+OV5#L[*).AH2U()KUB$\D/54B0]SJE-QG)<%
MI<A,5R XOXY6S=,SO2O:0Q#/=03H7M#'&(!U.50,CU7+AXRT>=8@QY;/Z$ B
MSS +.XBCEMRI.,S66;+>(\2O+#H-1:V A9;?4JJU%% * $!E5V"LQ"H.F/E"
M\H7&3RXV]Q>PN -QQ3J,OQNHH\@J5Q;2_;;AK12R7;.HMHJKJ!C=FY<&?)EM
MKVEF*S C,JB*97,-7/R9)24GFRV85P"S%8=41:7-.461%2671EHLH$.PDEE?
M=:IN4=9SLOM3'EDZ;UO/]%S'3<YF9X)QXT,32+%X>C,B05)#)[RHFME0G5I)
M"@](9?E3R*S].RQ:'7TE3+6LKI\MR?'J^VI7$ON1W&)#"K-^6XPT\TXV'5M*
M<0E.U*>0E;PT?,Y7+RG7ES(Z-I.EU8%30- 4019('! %UQBUT?VJZE!"8.MA
M/M, 1%S&6:-DS-@$N(;7038/ 4DDA4%@,:O*Y*<3J1FN,J=6E.F:29"MRDKB
M.SDI4H3(ZN8Q6N<)+0/\XTG]IUL*:#I^7(]^4H6KW?"9J);3N=2\DU0!O@=L
M927VMZU&1]DZ09XZO5+FXXF(H;A$24:=]F+#ML!BA&9P>*^$VEA%RKA+F==5
ML3IS,"_JHS.35DR%&EK89FN_8ZG9L?UFPVZXTW$DI84M2%OKY.8Y/^P(ID'V
M7/Y#-LZAO!$QAS(]/"S B#&Q0T.^JO=)L#&[].ZRLBQO*3$YC0R*0659&4:E
M5T+K[K'222M@$T+"XKEQ!\Q-3AB&(42ON<FR.>2U7X_20Y*Y*W_49:#<U];/
M)!*79$=#S:D.S&?52M<,-[6*\/0&6;1G6CZ;$'2.2;-AD8-)918X*,TS/I(7
MPUTEJ4N P.,M+U1$4>&6E>M6E&L%!N6U%51=KK4VYVKN(!7QEXZY.R;:&YCF
M)5KT'XV%&2RBRGOL/44G(Z]:GY*)T50G08<V.VXH12U.B.1Y,9@E)\;_ )/H
M7L9 H$T_6NJ2A!J:,9?ID!?[;ELDP16$TH53F%FU>^3"5(W;2,+)UKJ6II#%
ME88$4OJ\3[4S($$@9=#(K%E-*MK; @5W***!Q1XMU%K7VN5+F8FJ6U%:LDU5
M1 @Y4F%.4)34%<-I<QZL:=BEF>9$--;.4HP&'IP19-Q"E;V5Z0T,C= ZYDLT
M4G"@=>A;-94T(A-X,W3&>#Q=4KY:8QZBJJY">(%PES74.HL4BEA,2()#+)D)
MWRKL9)8_"]W-QB4J$\1S$Y5=:JS!K .8/E)Q:Q3%8E2,D$!MUQ;]*Q90&*1U
ME^1$FO06(D"CK9$>J<L(,>P34"6Y6L3DN2F(;;KKBE:OU3K.1D@F@R46>0RH
MJG-9OJ?C9@(A>O$^QQ90.Q266,M,T@*NP*%=2G+9#IP"%<Y!D\TZ F!DRT\$
M$()!TF!\SF/%TD:XPSA%<!BK:1B_?#_"XU)#A0HL9$:+$CLQXT=M 2U'88;#
M;3:$@  !*0D:^6CL]?'/LYFTTK$GW%&D?"B!9KX_'&:AA"KH%T0;+#>[)LGD
MDDW\>23N)_K(BUJ88905N+6AEM*4]5*64I Z?7H._OU\81FU=N#SY_A^M\7T
M 52QX44/+8?JOXXEVP0AEU$1!VF$RU#3KM_,("'#^*G0M7XD[\!O^7]?UO\
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MK$AM( .R]')Z#N6D]3KQ(R@IYDT=_P! >Z+/;C:MAAE8JQ/]T@78)X \NQL
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M/,5]<(=?Z$"#]IW[?N)M_D(QA&YQ6QJ0=O<1\/4?=2KH+/T&U1R2.Y/OW[^
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MN<2-##[+25<ZAR@%)V>XUU[[[=B1X>+]Y(JW8OGT)VLD#Y@CSJM\%*%CB9B
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MR%1[Q[ZF957R.KL,"MQ:JNK>QM704KL9CTI*.A]%I;A++ /^BPUZ;*0-@(0
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MJ#= GS(_7\?Y1-,U4NJZ\^"?G?S_ "K$+^9BQ;>X:5T=G6V,WJ$DIUT*J'*
M02.G-]T[ ^8[^.I_LO/^O]5&X_U2$6=KN9AMO9O\L:A[6+67RC$ W)+MZ!%/
MZV\O+%<,1H<18X:VV89&SB\FTF9+,I<>B93(XB,LR6<>H8]I>,U0P*,XTJS=
MD9#CC27<BF0:UE"T@/!+DEUGJF9>8YN.&+Q@BQ+),T(RQT^+*4C+_:&!"!8I
M=HD9C7!( .I1JGALQ"DEB%#ZS]U26KPQS;*/>('EO>"W'^'G#WT*QC-*&NQ6
M[IL7N\GNH5S>YC, K&,2=BU5AQ%1CL1ZPI%WG$.TQV1CV.XK5PKZOQ<R8V1M
M2W9]-?3ZDL^9MV@D::-YHXHRB0+;&>W7*F5@LGAY9)!)+*[1O-31$!9(EG1$
M*KJ 4JI)!+&@$V,E"Q;E=*H VF[&ZL8]H<-P[)9'%NSF&!68]CN/T2:&PPV!
MF5[!C7MCF^'5$9^GKLDEUU[.%K4?K(D,95*@M-+EN+99:ELU<9,\DT\0R2KJ
M:2623Q%G:"-C&N7G=A(T2M&-#^%9A#$@;DJ7)$*I\0[4 **AR 2R@:0U-N+'
MO5^0P4'R[K8L*_'[3**:KGN9?&P=FS@P[>W:N;^_S[B-@5&DLK5#1 JF)_#"
MZL9D[TD26:>4VZ8<VS2U5N1#J0*M(D,C*(#F-#%$*11Y;*YB3<:K<KFXU52:
M+@C4J6X+P=PI8 ZM (!.HL[H-MJ *$\71X)H'['."%*Y17B\AR6'#N7*7AWZ
M+LV%.KZ/&)O$.-!SZEEIR!^=!J+*:YP^IL@ASH=T:FDA3K1F0FV=A5\V]J%+
MGW\2/PHRT8?-6%96DE7*ELO(OAA6=0,R\;*8]<C*A&@,RQNZQ'21JW*IWI5U
MTXW) O0#8-#>[H$@+K.%D%5_Q5Q^[M;6%,X>5LE<)$:IA./6EM^NF.X3"BSD
M/7"8M='<L<BB+DO,3YS+;0==8E2&FT+D6&S;>'DY$1&7-. 27:D3[/+F"RTA
M9B%B- JI)V(!.R5-W!)U)P:O?4J@$DBMV[$_S2YOPN;PT5*_U@^UF).791A%
MJIBEFPY,._PQRA1?+JXDYYERXJ%?K#&;J9CQJ)LN3%G1Y]74J;97(++YOQU<
M"+01##F$)D5@\<XE\(.R@B-P(R74:U52K*[V0'(H"R"=3*:!&Z59 .Y'O"B:
MWNP,2YD' ;&5-V&-X?D3TO*:[/>(E;4O7%<Y"&1XW176 8=3_'R6[1^II=91
M89+'K);$=]5NZI:;)58RB A%.+J$WNRSQ!86RV6=PCAO"FDCS,[A5*"23]RD
M1=21H%% UL3*8UW"FR'< D<J"BBZ) W+4>_>ML0WQ(X<M\/Y]9"8R>ER;X^/
M.6\NHEUTDPY-992:N4EP5EG;,B&^_%<<K7I$B)8/,I=18U-3,8>AHNY7,G,J
MS&&2+25H.&&H,H<5J1#J (#@!E!HH[J0V ==! U!N>*[$CL3L:L71KD#%T[#
MU'(% VGVQ+#$@;)U_N1I!T .AV\>8?:)?^?^ML!_WSSA/GMF)*\O+S/TQU[H
M[ =+R   K*Q <V+4?.^_H+'?!]C=<A%(PE;8Y@M162.O,I1(/UV/X;_+ /[S
M$[\#TVOGZFQWXXWQF(_= !J[))Y/'P^''KM@G1%!3RD=-%.NI.M:^0/\?#I:
MG4!L#N!0\OPK_.AAI!XBE31)VVNJ.U"Q=FS?RQ!''SRXT/&O%94-Q**_)FX#
MR,=R-E4AF562%J2\&GU17$+D09"VRQ*:<#JDL/OJCI#JCS]X_9;^UC,^QV:B
MCS$LLO2&D4YW)(Z7,E:3+%XB-4\5AT4,HE(TM_=QY^_:W^QW(>WN1G:.""'K
MT,3CIG4Y$=FBD:196BG,3@29:0K^\\2.4QDAXWC*R>(GX'>6K'N$,"%-7*GW
MV4_ IB2KF<^%-(26T(]"!#;;BQ&V(K*1#C27(OQIB\X<6GUW4&3]I7[9^J^V
M2YCIF5(R71'G$D65C53-(L1(C?,SD%V,GWY(E98HV"JJ$KJ%;]EG["?9_P!@
M7RG5I@_4?:*++&.7J$S.<O%),@$J9/+DE$53:)*09I%+'4JMI-2N*GQ*<QX@
MJAJ2B0,LRST%EH/ .INY_*?2*T!>R.Q<0#O95T/CKOLRN6D_LPYM/$A$.3,B
M%BH9/"4,"PH@403VV]=JGM']L&3Z@N0E,&:T9@9>41K)X<H)*MX;6KFP  10
M+ \C'UA!,5C,<'@XY0*R#$L&X79._E>06?$-K*,GF<1+3":M-G@<:B9>X>*Q
M8769U5151<C9C6-I5SV;B%;S)294&NZ1#E^F,W3NHRI_JV=SW5,FF2RN6Z2V
M3RL/38L_(8NHMF"O4_MOV?(S2S2Y5GBBFB:"2"-"DDW",QU7V@"]0Z:N<F,V
M4R?3,R^;S.:ZK'G,S+GYLC$9.GG+7TX9,3YR*.&+,(DCQ2+,DTC!HXK59%PC
MX=06.(>6U3,M.'6.*2I7"2OG7B(SR)\*^I\'O,@NK)]YI(J*/.)J*>&FR>C1
M+(6AEKEENAL6%<?7,9M,]E<G*\39F+,K]O:*$L@5X7SD>7BC"FY7RPUMX89H
MV0II_>H1Z RTD>:Z<,RJR*DD&J$3, [D,(3*[$WH9QJ0[*4<-8TD#F[GM4WA
M#./6EGPSB\7\FSN_S-B6F'D][.Q[%Z_"Y#->[1XS/X:7T:+.S:-#;.5VDZRE
MY+10,?ML6?\ U?<0]/D2N[].F.:1LOE.J/TC)]-RG3FA$F7RR3YM\ZAF^TYJ
M/J<#.F19V^R0I%'EIY<S#FA]J!$:IYLZS$\6<GS74.FCJF=ZAG^HB8)-F6R^
M63)R^"L&6;(3*&SB0J,Q*\K3Q102Y8G+;R,TY\'.$^&V5UA&71L5QYC#:S&L
MJ>SS(LO?XRTF6U7$;'>$\*=:T7$&D96:N31N\1\BI7,<E\+*UR0,2=@PL@GC
M(9B_&N^TO6\U%T[J^4S6;G^V9J7++D<MEATB?)3=-S/5V2#,].E &8$_]G9:
M89I.J2A?M*R299# HK8O9#HT4W6>BYS(96)LME!.V?S,_P#:<><ASV7Z8K3Y
M;/1R'[+H^VYA&RQR"$_9PB9B192YP:Q\0JN(&3Y?"A*Q*KI8-;3MLV%6K.3C
M,!-MEV'X>Y=0/U@><RI3<1N]E7DMJZ:>'PL2R]* A#<5MKG&5ZA)T]\O*?M#
MR^([%&&6\9S%!/F!$WA 9>V,2PJ8B*9HR7W;';,YDX\Y%+$P0(8]!92^D*[)
M&775J?97)(8,*#>Z=CBCF?<,Y>%<79V S$7=Q7U,JFE1[.=$@,F33VE/#MZ^
M8ZFEN+VE7#?8G-/LSZBZM8%A&Y9D9]33X;3Z"Z?[1Y7,= AZM--EX6FAF\1(
MYF(&8A>2-X5$T.7F\77$=44D$3(WN,ON[^5NH^R>=A]I<ST3)Y;-S(F9C$<D
MD!!^S3>&5S#F$RQF*I*\5)&5@ 0?>H?HUX>06X&.0W?3;:0Y#C. -MM-)(7%
M8<4KE0E* 5E7.L@;4X5+)*B2?G#[9=0EZG[0]3E9F+_;IHPK$DHD<K1QQWN3
MIC"@76D*5%!1CZ!^R'3(^D]"R,$8 2/+!F8(%\225?&EEH#EY'=C>Y+ GWF.
M*:6F12<OB9C<(#@B9SFJ9+#Q*@%8AB2C4XTP@ G;-HXS)O' " !+:*@HD:QL
M66G2( (:" LU<D\DWON3W._PQ<DGBES#2%@%+E4#=P!0KL!6]#C;:B+LSC<9
M%_05GQ30683:FVP05!(<" 0D#M_O0[]]#J=>,8_[IV4W9W)&UD[[\<7\L9*M
M8!&D>>H[>5C;T-WZ8AKA?+1D^(9#B+B?5G4Z5W58TO[Q?K)"O2LHB!TTF-,=
M:F('LJ6^KH"3XWJ("6)TH:D)=?@Q);G:Q9(X[XPG6O\ 4.I93/W4.9'V>8CD
M3*/W<A.V\BU'O8-<#G%=,GK#6V$B.$D)ZK;!UM(4I0U[]CTZ$D;&^X\5C5T+
MH;;_ *\\;'EY&D5#_=T;DGS (\A\.=O+DC,;FTE0_:&Q^X@;[=N_AL6@#8'P
MXYHB_P L$,1\H6GK]TD;^>CT)Z'6QOP@+^A/T%X=U %@6#>W;TY\]_,8.F(U
M=F=0,:M'DQY<92W:"R7L?#O*/WX+JCVCR"=I"ONATZ^[S(4DKU#<@:1ML=_U
MMBN6:-A(@)VIE!&XK^[1WX_ @;\0+?XY:8]-=@6<5UA;:E!*RD^DZE)(#C3A
M 2M*M;!'77M[EJ(O;@T<7$=9%#(>194G<?'B_E_# E(:[G74:UKYZ[?W^W7P
MV"PUN-A0W^_MVU_9\Q[^%A8:78Y6HH2E2E%6DA*2HD_\T $D_/Y^$M@BMSOQ
MY?#R^'&P'G@:*D,H//'8_EZ_E57@BI.'5U=NH4MAV+')ZK4C[ZAWZ @!&Q[K
M.]_U2.OB>MP>#W_D?/"DD1:)V)%D"N1SP=OF?PQ/]#@E9CD4.O(:;#:0IQ3A
M!4I0!)4H]2I1]AOJ?N@>WA>>W]?UZ_EBG)(7(TW3#8=MMR3P3S?Y5SACO[SX
MH*BPP68B1KIH*=Y>GWAK[J.Q"3U(T5#>_#_K?]?KX8DCCKWB#N1MZW_(?(UW
MP!+0%@ DC1WOPL62+VL_A_+"%;.MA0(&]?0_@2.OA8KM%1[[G:OUM\/IC5R!
M*AH'0(T>I[^WU]^GA8CHJPJZL#X^8V_+&]UE!:+A!"@.H&]_(:W^(4?;Y:[>
M%B>104+$40+H?Y'GTK\[:G!LGIT Z[_$Z_/\/"Q*O ^ _+&I*.523U[@]?D?
M"P^'!304A!!))2-C78_A[CZ[_M\+]?KY_#"M?,>NX\_U\\8%D+ Z*^FAV)'R
M UOZ> T@;KN>1=5A=Z[^7?Z85QF?VDK! T".FM'L-;^77V\#I)/O"K\JY_'U
M.' )O;CGTPI=82A)4 >IZ@Z/O[]-]S\^G@"*PB"/2^WT_5<[82AHK5H :/L.
M_P#9KOX6&&_Z_7X85",H!('?H"/;J0!HZ_'9/O[>%AZ_+]<7M^/:L.#3 0G7
MX?B/GU'3?X#7X^%@@^DJ0!8\QZ57/QX(LFZO#LPR-) !WH CWWKVZ?V]A\O"
MP0F:^!W\^_S_ ,^^^^%[:>5.M=E:(/N=;Z]>_3V^7A8E1]=AJ!) VL'N:[^H
M^%X5H/96A]?RZ?\ 5X6$=F O8$?SPN2E*22DD\P'?7L/;H/GX@+$\UM?&&)L
MWC6^YRIY3LE0.OD-:_MWX TMD59]>_ZOR\L.OWA\_P CAI<)*MGOK_'PXJMN
M.V+<>Z_/^ PD<;YB5*4 G\/;?3OOK_GIX!EW+$@#O\./+FOQPS*;)) %^OP'
MS_CA,=+?" /N<VP1WZ [ W^?7V\1&B: L<@_';\C?.(&(L@'8->WD!?Y^?'?
MC"2<.=]I0Z@<R>WL"5*)W\NH[>_A6=^+[;\[6/UZ'?;$;%3N"*_F2?QO;T(Q
M*?"N@786T1:ARE+ZG&TD$@.NI4&E: Z^@4A]>QKE;6.O0>"4 FC>_?@_@/EB
MCFY0B$U:U\CV%;B[.WD>QQ>^U?1C'#AQ:4B/+RI]=)6-['JII("(;-A(2>_H
MR$PFFQ[J39*5L?>W;F?PLHS533_NX[)OPT*ZW;<V#Q7-_#;4XE.:ZN%+7'D5
M^TS#^[]HD!*7L=D:4BK!J/DF[@Q+S*5#F<;2 E .U :(&M=>W76OX>,(=R?B
M<; 6&IFO8]]]]SW^8_5X?8G(ML%)"DD 'E.^X[].@[@]=>&L#DUB%CN=^3M_
M#$69=0-5.65-[&0AEJ^#L.:-)2E<^(T7$.DCJ5OLN]3TYEA7OKP())5@!=T:
M)VV-;'S/J3\L8TV'=2*TJ".[$70/D.X\[VXP^JIG%1W.@YBCU$:/OK9_'H0>
MGOW^?@[&X [[?#MZ[[@\=NX-B2P%FOAO\?T/A7.%%$MJ3%=KIJ$J4V%%GF&R
ME2=C[O4'J"1H="E2OP\/9&W]W@^8O;>A_':@-\0^8WKCZ@?/Y_&\%'#"S-39
MV&,NK CK:^W:9*B>8LN2WXEO%0#_ %8TQIF2H?>(^T@>@T/$<OO'6-^VW  V
M7DV20/GAO(C@BC?P-'RY->6]8F:2VE"MIZI6 I!]BE0/?IW3HI/R(^6O%8^Z
M17]X[WVW[?7#T*W'J=N_X_QPUO,I*CR]/WD?30V-#Y].G7H/! @\8A(HGR^!
M'Y_A^9P5X],1%C/17$AZ.XH^NTO7*H+ ^\D=@K8.CWT._@@X0[U1VH]_\OIY
MX<+=T3^AN/Y? W5X8,LPR-/:3+JW$%'WPXPOJI(7['EVM(_:&B"-]E$:)3J/
MO+9 'IL;!VOY#X>NPEB8BP1M>]\ 5VO?XCZ;;XB9C$)T23S?#+5RK(!24'H0
M1H;ZD'>^H!\14QK\-@*]31!!'E1&)+0;ZN-A=UQQQ^6#/[%F/P4-%GD6A>B%
MD <H!'L%=?<=NO<@=/$U$WWM=.W:Q0[CYGC\,-=,-)M3R=MC?K7:[QKA8<GG
M2N0YK6B4I]NNQM1T3VV=:UU]_ ^$0;)4 ^1*_"N1SO\ $8-GH;$'ZGCT'X?@
M#@J^&K8" %H:44)'U7H=>NCU()T"1TZGP1$:C8@'MN-R.+_7? V["C9&U6+J
M]MK_  K@ ;C ;=W#BUJ;9_FF@G25=.904-$=.B='8Z?3KU\1,UDC:N^YY^-^
M=7OW/RL1II .][[';TX_$7OVQ6OS <RN'$16R2K-J0D>W_8'+.W3?R)V3V\=
M._9<W^O]4V_^A8*&YK]\;H77X8UCVM&F'(D;W+*:JS]Q/T/ABI57E>74]9-I
M:;*,BJ::R+_VC55EW9U]9/,J.B)),R!%DLQ91D14(C/^NTLNQT)9<YFTA(["
M\$$C+))%$[J!I=HU9UHV &86M$DC2=CN-\:0NM055V4'<@$@&Q6X!HWP11V!
MYVLG6YQ/SAVLA7M]FUG7S8:7&9U[)S*_K(=!-O8M5)M2S$CW4YVC3?U<6+*<
MK*^=ZUK5LQ&8\FSAL1TQ5E<N',<<"LK;K&L$3M*L;.$LE%$GAR,5#NM(Y8D(
MQ.) )'TABS;$V2[ +J )V!.FP+H'<51(V04^.\8<91-M,?I>)>/(9IV+ZQL*
MBMRBI0UC\ABQ5%N9LR$Q'2BG>BQK4L6+[@@NL,6);>4VU)*5))DI=*22966W
M,:J[PO<H*:HPI+>^&*6H]ZRMBR,1A9E)*K(M"R0K ::(!/.Q%[DD<[XRD8?G
M\?)E890G(\DN:9JMG?9V,LW-C(@268IM'/AX4%#TAERBGW]G&<E-LH2Q-E6#
MK2T&<XIUO&RQB\>3PXT?6-<NA P)T"V8@'Q%C0A2;*A01[HJ91)80 L0 :&J
M[&^RC_"2=QWL[871HW'.'&A&&CBS%A8I<(HJTQ4Y@Q%QK('7%52*:$6DH:IK
MEQZW76HKF/AIRG+14,,E4XMNB6Z>Q;4<F6F3Q'#> 3+$ &\1K)\2.DU:S:T@
M-^[L7[S;W7]TT/OT#P -]C9K;SH>J*)B'%]FWN84+&>)+5]9T[\C(8L:FRA%
MO8T%P_N2]<L-1A-ET]K)9)?<G(<A3GVB7"ZXCH[SY+0C-+EC&D@$9+PE%D0&
MM!)TJZ"ZTD,H.U##5*213V1N*:])\QS1KOR>=\*)N)<8\LC1,DM,<XFY-$9J
MDNPKZ=493<Q6J2)'7/0Y%M)$:2VBJBQ%+F)6R^(C,=2Y"2ELE?@!F,G"S0I)
ME(6+TT8>&-C(Q"G4@8>^6I=Q9-#<[88K*U$K(PK8D,=AOL=]AN?+#)D3?$8,
M1,BRK]=S%R=A8@7^0_;I8R&*EZ+9N)B6MD/3MHZ9!A6"PR_(;#RHLM7WRTYX
MEA;+68HO #1&FBC\,&,T4%HNZ'3:BP#0*\6,.6DV=@:8$ FZ.X)HD[]CA)/N
M;K()"K7([JUO;$LML*GW5C,M)A882KT63*G//O\ HM J]-LN<B 2$I!/B>.*
M.-2L:)&@LA4146SN=E %DBR:W^.^&9B:!))KDDDDDU6_KMY]N.>AT: 'H] Z
MI(Y3B.&+'0_\DJ4]1V([=M]>OS\>6O:0C^W^L#8WU+.@BSL/'<7V^0'P[8['
MT@_\UY"A59:$@\?W1ZFJX[;8/JT^DR(X">0*"B=Z(U^T.71)!&NN^G;KW&N.
MW.W(K>J\AV /P\KQF-/![@'ZGX]A9K\</*='6NHV!_JZ^'%=M_AO\MORQ$00
M=^3O^JP[QY+;38;5[[" 0#K>SHD'IU/]GOXF$<FDE5-'AM-'< <[@?,XC+QJ
M1J8 @D5=7M=#FV !-"SM=5C6^M)2@)Y3RGMOKV('3?MTT1KY_A*<O.H9WC<"
MN2IX/<FJ[59)%GG ',)K"J\9((I0039H@$ \GX T#0H8Y9<1N7]>LY2=$C,L
MHZ:W_P"WR>3T]_\ /S\>P.DRF+*Y%^ ,IEK[?]R0GC@ <5N#VK'#,\GB/F%[
M^))7_$P^G'TQ&#O"/C)D"8%@BVXG2N'$N[C2,5HHC.42<38OF)$F1RT$)MU=
M(+%;U?8R$R(#!E_%QI[Z$!R)(7XZ-#[:=%R65TKD,A)U@99X<SFI6RPS#0%
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M48=I%.^QH':^>?+"J2TA10$J&SW5TT.^N;K_ (:^OB-VO85MO?/Y8C\0L18
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M!Q6_ ' XV_IAY;B+2- $A)Z@C1_(=B.GS_#Q 03N:W/GQ?PLX.P.36-DNO\
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M!"D@DT=N*]=_Z>>*U>\219L\G8;;][^ALGSQ,<G J2OC0XK<9ESU6)C*WG4
MGU"8JE\NP V-!H)2GEZ(T.B=> %@[WQL=CN;K;?D6._)W%XB,A)]T\ $@BNY
M7R\QVO\ &\0$[36&"YBU/C,EROG)>C/A"=$*!+K)]^J25$'IL;'0'H?.S<C?
MO7-7VY_/MVPQ;50OD[]ZW(X\O+OM788E55#:Y)%4^+%N,R4E26FUZ6L="/47
MOIKJ"C8V>_3L! VHCZ'GZ'Z?SP)KM=UO?XUZ<8")&!6K[CC3,I;DAK:@A+BN
M9Q"=<R$@G7,=<R0=[.@= [ T;JJWKYV?UMY87Z_7],.V-O7=)(?@.N+?2AIE
MXH<'-_-O*=9])QM:=)4EV*_SH(5K8YB#L>!%;E1WWYYXO>^_P )VPVVY'GR?
M/BO,_#UH829([0.R6ILO&HZ;!AT.LSH27(4MEY(!2ZQ(BN,N,NI.RE;:DJ21
MTV=>)%O:N-P;)(WOD?/ZUAP"1?(KXB_/:OX7VK?![AG'"7%>9K[=M^V@I(;2
MZL@749M(T@EQPH;LTI &_B%-2E_>4J4\O2#"^7!!(]UO,;@WZ'^0Y[\%M-[#
M;>ZV%D8L_09'3Y"PBQI)S$YIM90Z&U<KT5T)VN/,CN<K\1\(5]YE]MMP)4%
M<J@HU&1E'O UQ?;RY]>V&]:-CSVV^H_'CFO-^EV7(V2G370[)(.A]"=:Z?\
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M,  .8_> ZG>A\M'V\2#HO5@=NE]2&VY^PYFSQW\$;_7Y8;^T<A_U[)\?]8A
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M>6C8PRF(2*#,(G968!J^<7[<NK>T_4O:G,93KT&8RW1LIG,ZGL\QRCQ9+-Q
MP%\Q'FRNG.S&*3+C,Z)7CR\CB$*A16;G1$G6U;>>O;(@3JIST%QU%02'4H(]
M/X>0P%IYW$M*:(<0ZVB0I:9+274J2GL"Z@03132M=CQ>_;RV\Q>_&.*.(GA
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MLLA(A$F:(]W4MIEP1P3*2":.XTH5/8G$@-R8U:VNMJ8WP<<@-O);(4](Y3S
M2'DI25(V ?10EMG82I2%K'/X8&K[V*/D0>1V/QWK\#BE/F9<PP\2CH-HBV$0
M &O^TP!/O$7N .!C?'4F4%(/\VZDD!*M@]=$$#?WNA[D:'7>AXB=22#M7  V
MK:O+BQYW?XP^/IL4;'WA8/'?SXH;#M\,82FDQFRE2%%Q8(03\^VQ[=.^NNM>
MW3P%$$<[<CS!]?PV^&!,JZ; .^PKS^M[8T0:=R0Z'I"24;! /WMJ]ORT?<@_
M+ZEZ$_+@ ;[\<@^0[&]KJ)GH FSZ<GY^7?@<^6^#J-7CE0$)TD="3K8WT! Z
M#73I_=X;6%OBS5<UMSY_#U]>\36U&R#O\.-O/SXX\^<$4&M()*1OW*U#6B01
MO6QU]AH[/OH=?$3,7[$$_3:SSR>;KMM7K$TBH:()/-_'<#S_ (5^)7#AI9 [
ME1'<C1(^O<I'TW]2?$9(&VWQ^G'G\:WO$&MV:P2!?%\ ]OG6,K-"?Z.KISCU
M!K74)(3K\-'?_G'P(_G].WX8(G>R=SW/D"-K/Y?EAAE2V6T<JGFVRGK]Y0]M
M@=.Y_+ZGIXD063M8KY<C#;6?,[]P>P[#CY\^56&"/?M..J:3]]QLGFY=:[ZV
MDZT>GML[[@^)2*.^^VVWGL>U^F_87@36XVL7=6!M5;=SY G8]\:+=M^\BKCF
M&#L'TGQLJ97K04/NC[@/^^(YMJ&^4<P!\-L/(?0?KOA* />))'PK\=_AM?.(
M:L)<ZI4MB9ZC,ZKE,K2M"BA24H5SMO-+20L!2-.(6E0)Z%)!Z>'5B5U#W6!-
M63OVL;5\Q6PXVO%@"P:%6*/)L&J/%;61L*%D^A,)2ZS)JQ+=M&AS$/Q&BS-<
MC^I*,]E14U)DI95%C[1M*"IM'.^@*2[U<6L,S-J+#<Z5#5_>V(-6//<\?EB.
MBK!;J_COW[#MV^)\L"TN5DE44P86,#(HJT@-AZU:8(2-!I,66Z_( :1OH)=>
MA]I((,AS2=N"IHD%3L?>HB_(<GCS^&]DXF7@ G>MKY.PW'XUL-KVQF[>9/!$
M%J7BL>E;G/-QG9+-NQ:?"J7]QE+I$:(2I7[*.4.)"ON_=!"B3#:Q1Y%[FS=\
M"O,U5\GG;#;&S?&XOCB[VHG;87Z\XD*+B$!Y*G9DF>Y*6T=N1YC\(HYP""V(
MBV2G>][ZGV.]G=<DJ20/,$GOON=ORPX'<'?O=?'MY]N:&([S;AU/$-<J%8R;
M>,R"I^OMTLOO^D3O^CSVFVGE.-IV )*9!7UVZ#U\2!]5"M^ !\K)^G'.']?.
MOQH8$^'$I--.4RMQ9K'%$!*U:+"MD+;<2?V5-+Z#N?J1X=N#7)\N>?X7Z?+G
M#B@;(L;@BKOFOH>+( Q:R"B.II#D9:7&UI"D+2=A6P-I/R4.WMU^A'BK)]39
M_J?7]'$C<*!W% 50 V(K\!R1MA8'5,))V21L[Z[(Z'KV'RZ=NWX^(P-1KZ^G
M?]?+#"U( L70-\6?AV_'G'XT?TO:_4_2%\=EGNNIX'*/Y^7GA0?'NW]E.W[/
MO9H>66S0\^.HYP8XQ[2__?SJ-\^,O_\ *CP$\>L?\N/E[R'+O+M+X.9)GF=X
M;B\>GR3C8[Q3ML:M_P"6";BT*SDS<2Q&-16>%CA1CN33A5,4UU4W.69QCM<[
M=1LYPV7?Q(V/YSIDO5^JQ0=57/PY7+3SM)#TX9))D^P+.R!<Q.95S'VV6%=9
MDB>.#+RN(SEYUC8R8^=8(&>#PFD=%"F;Q2I\72"2BZ2AB5B5"E2TBC4)$+ +
MA5?H\N->08WPOR^AOL!GXUQ1FKJ8=]8#B1AU!C=Q_)EEG%N/77>2Y]PWQ/&K
MIJ3B&#96XN_X=7&=XG56-.] O[^H7(A+DN_M5TZ*7.02Q9I)LDOB-$OV2>6:
M/[9!D6>.'+9N::/3/F8!X6;CRT[K(&BBDI@J&2E9(I%9"DNP8^(BJ?#:6F:2
M-%;W$<EHRZ*5IF6Q8B[Y-<I8>3<R.+/!ECA$YPSJ^+#?'MVPXD)X9O8K<\1L
MBX0US#%3_)D>+\C))/$W$,KQ-&,,<*W+HJQRXR,0SAD)W)!./:" @QC(]0.>
M&<?(GI@3*?;!-'E(L^Y+_;/L(A&3G@G\8YP1_O4BU?:&\+ _96!OQ8O"\,2^
M/<GAZ&D>$>[X?C%C*CII$6KW2U:!JP10OT?O'&UX97'%2FFXC>4,7&N*&>8P
MQ3-\0+'^4+AMP=L,KK\\XAXGD\? %\.X5! _47,IM359SFN&9KD]?CTJ3C6)
MVQEU+=C$WM1TU,Y'DI%GBE:7)Y:8R'*I]ES>?6%LME9X3FOM;2M]I@5WRV7S
M&7@:51-/'I<JXR4QB,HTE0LKK6L^)'"6$DBL$\,*-#D+(Z2,%)5#M:"]\D.6
M8E=YA5YCQFX$8O5\-8>+*XGY=.O.(MIC/#_(,]5+=P#![5>,<,;^[R#-<PJJ
M^ROH-+@%)F*:2HJ+UW,I6,2\?O8=<47M'!/'EWR_3^IS/FVF^QP+%E$FS466
MTC-9E/&SD4<67@=TB:3,R0>)))&(%F66-F391D9P\L*B/3XKW(RQL_\ LT.B
M)F9W + 1J^E5;65*L Q2O)3QH@Y[PUX=3#A[-[Q9X\P?+WA4EO(C-I++*+FH
MX29%CF4)MJZ#,CN\/\GQKC;@.14&10A,D3:BPD255;*F6VGY![1=/;+9O-J,
MP8\CTQNJ9A3#ID2&.3/0RP&-V5AFH9NGYJ*6)J570 2$&PWV2;Q(H_=U2S"!
M#JM2Q$3*U@$>&ZS1LK"[4V0.,"/%+RSYKPAX8\,.)^67F+&)Q7IZ/(L=QJ U
MFAO&<?R6G>O*6X<N+'#:WA[?1GH+/HV[&"YSE]CB%PZWCN;0L;R$.U;4^2ZQ
ME\_G<YDH(Y]62>2*69CE_",L,@BDC$:9A\U$P8W&<SEH$GC!ERS314Y"3+O%
M''(Q6I0&50'O218.HH(V%;$1NY1O=<*VV)FO<?\ +GY?,5X+TW$C@[D7&S,N
M*_"O&^+V=9"SQ1MN'3&'4&?O6<C$L6X5,TU);UB\BKL8BUUOD67Y]69Q3+R.
MTE8W%P:+'QM^ROZ$<O5NJ3]0DRF?AZ?!D<[+D<M$<DF;.8ERRQB>;/&22-Q$
M\S/'%!E7RT@A19FS+&8)%*RP0+")(FF:6)97/BF/0'+:%BI6 8( 6>19!J)4
M(-%N/RO(GQPB<$U<=GH=6U1-X%5\7'</<B9PK*F.$]W<P*>JS==[^I#7"R0Q
M*%I6VWZL1.(CG$%O&Y:,I?PN/0(?GL2+[2].;J']FAG,OVF3(C,:LL(#G8HW
M=\N(OM)S@(,;Q^,V5^RF9? &8,I"D6R<P@,]"A&)=.F34(B=(<MH\*K(.@2>
M(%(8H%L@X\^'!#A?P:O;6'PVQ<8W&C>:_P [G#5AL7.06_)A7"+BAC>.\/*7
MGO;6S<5^KU//EPQ8K4JUM?5]>[G64I#;Z*_LSU'.]0C1LW-XQ/0_9S.$^'%'
M_K&?R<TN;DJ)$'[V1%;36A*J-47;$F=ACA9Q&ND#-YR(#4QI(718U]XG[H)%
M\GEB3OCHU^BWX&XKQN\G&7P+U+T6TIO,3G!I+F(29<!%GPUX.MVD8-%26Y$6
MP8AL(E,K4A>V&'6G6W&@3J?MA^T;-_L]]I\E+#''F<IU+HZ+F\I*WAK,<MF\
MVL#B54:2-XOM4NEDK9R&# [8KJW[,NG?M*Z-]ESDLN4S/3LXSY+/0Q^,\!S*
M0^/&T+21)+%.,M'XBET<-'&R2(5LW@N?T:V#6-=4UE%DTJEK(,>>_,3:UL6T
MMK.YE)1Z5A]L,/5RXD4>DRU(JQ%D0O3:#L1,26[)??K=-_Y1@7QCU+IL>8,C
MJ8#E<P<ND$%G5&T<D4XFDWVE+QDV/=  QHO6/^2_J;+MT7K4V5$>7*3C/Y;[
M2<QF!Q*KPM"((CM^Z$;!*(#MJ)Q:WRO>55/ ^99S)N?S<V-C'C-MM6<)ME=>
MXTEEM2V)!FR"IMMEH,L(;9C%+:E)=+@2TEOGW[4/VSP^UW1QTC(=.?IZ^.99
MY1G3*\Z!2HC$:1QD!M1:0-(T9.^@DDXWG]E'[!S[#]>DZ_U+JL74YAD_LN6R
MZY#[-% TC1M).&DFS&IU,>F)E6-@&:SV-XUUT=*=(#:P2$A2M?=.OF!VZ==^
MY^7CS.S%F9FHEB2:]23]=]^]^N/4:(@55 -!1N?3;S]-O08718Z(VW%%OF2#
MHCET!U)(.A[?7W/MKQ(@)-%J)( ]X$V3VWY_G@7*@6  5!-D;BKH7N?C_GBA
M_G6XD6&+XS3PD18;N,Y193<>R1Z08JG&67JJ7*@LH,T.1&6IAB2FW93S;GH+
M;9TE*7%*'JW_ )/WL_TS.=3S6:S2R?VAT_+Q9SIX#R1HLBS:)9)/"93)084N
MH#D$G'D;_E+>TG6NF] RF4Z<<NO3^KYJ?IW5'DBBD=HG@67+0QB4-H$YCS1,
MR N/!92  NKD$Z.%%! 1%8QR^F-4L&?96%9<7$B;#F1DQ?79DRDJ:2CT6P%R
M$*CJ0R\DH2C38!'LH#,E6_UB,:JTD1@[6=566-'8;V0!SN<>"W>Y!:4[-P"+
M!:@M5IWL#>MR 35X"<,M, ;O85_CF..U%<JYABT%*Z],K'VK)PM.A^.\XZI<
M2('&WG6(O*'TAR,GE+WJ-AF%D&6F\,ZY%B=AL$+E%UD+V!:M(W&Y':SB:)=>
M9@&:;1$'4.7NU0GWB:!)(JQO9(W/!Q^G/'^"F/? Q;.W2BU>99:<CE9<,1("
M ILL1SR!00#H%[G23_5V#X^4G5#)+UO,K*[%CF)=:Z@??\0^("PN_?NR.][\
M8^QG345.DP-&M11P0K%[I4&-8E6/2K454H 5!H@$#;')7SI<4>(5#QIB8AB-
M]<TN-4-;2V2XK,<TE+!NBMQZ-,-DP65V.O6B.<SREL,/I,9MM"H[KB_=/[%_
M8SV>;V/CZCG.D9',YW/G.Y>3,3"/,L^3$C1F-49#]GM08V0%7)4R[:M_ /[?
M/;OVF@]NY>D9#KF?RF1Z5'T^>')Y9Y,HD>=:$3F5Y(E63-[L'4RR-#H81B&P
M2R#'_-%Y@\OLIS]YET&9"QR"F"JI>QV$C';)4W3K>02XT 0KN1*AK?8:;37V
MC$=,>-KTU*>DNN7^H?L0_9ZV7GR\?3,QEVS4RRKF8LW*V9RX&BX,L9-<(C8*
MQTRPRD?=U:10P>4_Y1?[2X<[E,S-U#)9R++0-%)DYLC#'ELV6L>+F5@,<QG7
M4-$D,\(! 9ED76LAYP:\SN:Y[Q-EXMDO#%W!TTE<M=I9"W?FLV-G$?9C2)<!
MM=?&:^Q)2U%4#G?>EMI6T7EN;44<-_:/^Q3IWLE[+YCK^4ZW+F73.Q0PY:3+
MQ1*<M.X559U=V>>.R690$87MQCT7^R_]OF=]N/:S)>SL_08LFLW2\Q//F8,W
M-.R9S*IK)6-DC1,M(H=55]<J/IU/(IM;X54YS*[41X&E,P9(CNN) YE+*&W"
ME:MGE("PKIU*='821OS.R^&MW>H; 7W^O YV/IOCU.&#E=.PV8WWH#;8GD^M
M8L-"IPPT$K4Z5:2"5'E)T.^M[[D_3IT\5RI)O\@/QLCZ@F_2L3JMV-E XU G
MGR X&P\_B:QQ5D\=>$,20_$DY_0,R(SSL>0RM]X+:>96IMUM6F2 I"TJ2K1/
M4'KXZ<OLYUQU5TZ9FF5U#*P4458 @CWN""#B0]4Z>I*MFX05)!!8V"#1!VY!
MVPE/'K@W[<0\>_-][?Y:8\%_HUU[_P"E>:_X%_\ >PW]J]._ZY#_ ,1_E^/X
M8P_E\X.?_+"Q_P#_ $[W_P#@\+_1KKW_ -*\U_P+_P"]A?VKT[_KD/\ Q'^6
M,AQZX.=-\0\=_P#JA[?_ / [^%_HUU[_ .E>:_X%_P#>PO[5Z=VSD/\ Q'^6
M%4?S"<(HCS4B+Q)I(\AA25LOL3)++S2TD%*VW&VDK0M) *5)((/8CP2^SG7E
M.W2\U_PC_P![$4N?Z5,A27,Y>1&4JZ/[R.&JPRD;\"M]L2=#\Z'"=]A$'+<K
MQ#*XB4A(E/ONP;=I&N4!$YB(IIXI'WN:5$?>4KH7^51 E'0>OL-,O2LS(+V)
M0:E]0=8LWW:[!KL,:[/D^FQ.9.E]4&28MJ9 QFA\J$3D4-@*1U(Y%G8[#QT\
MJ=TYS0>+M#C7.3S0+^#*D1%.*ZGTI=<W*#2?;U%AD;/-Z:1S!*_T8ZPVZ]/S
M2'N'B% ^8TN; _SQ W4Y,N")Q!G2![LN2S*HU#@>%-X9(/< J0>Q%'&FRXB^
M7%(W7<8\ GNJ2=-PK:4I!.B=DR(;/I$]@E779'774)_97KZUIZ=,^W^%!1'8
MF^_S^>!B]H<N[U(9HE%$ZU!]VNX!):OB+).]8C^3Q)X5I<6A/$/$RP25(4U:
M)=  ZI"P$!0.CUTD]3V^4)]DO:(^\W2<UO6RJI]!O8';ZGZY!>O=([YU1MN7
M!7MZFA_&K-WAO?XF<*@V UQ+Q8*.^=KXQ_F&]:[,$'MOOV[[\"?93KXO_FK.
M6.VE>>PY[_C\L2+USI9_^BX:X%'5?-DCGMWL>F$?\I_"<$!WB1C"!L[*9CV^
MA^K"0=C>NOL=_/Q'_HK[0G?^R,YM_N#_ -[#GK?32;&;B85R#6_J#5?JA6-S
M7$W@RR]M7$K&">A2X[*E<F]]>HBE.^H(Z]='Z;7^BWM!_P#2G-_\"_\ O;=_
MP&!/6<@1MF8A1O9@=SMY;7Q@GQOC+P@JLGQJS>XF8XF% OJB=,?;??6AN+#L
M8[[[G*F.IUS33:U<C2%N+URI0I1 \$OLM[0AE_YISFS"_<6]B.VKG$;]7Z>T
M;K]JALJP^]1)*T"3Q\;\L?G]RCR%WUCDF06<?S&^641K*ZM;"-ZF0\64N?#S
M)[\ADN)3P;6E"_3<3S)YB K8!(&_'JV+VXZ<D42-TSKP9(T0C^SA]Y5 ('^L
M>8..._Z/YX[B3)FR:K-1D]^PWQ+<;@AQH@<3,)XL->9+RB_K9P^X?8GPTQ]2
MI_%Q=:G&<-X9Q^$U*)L-/"/<J>,3C-"5*#S8?LN:9Z38/H#'O[3=!?)YG(MT
MWVB,&:S4^;E'V%0_BSYPYZ0*PFV7QR=*T2$]VSSB8=&ZGXJ2B3)%T1(U_P!8
MCK2D0A4'UT 6;YWP82<7XV3L7PNDD<>_)$_E.!P.&U%1\498XUS,\.-<'I5(
M]PXQV8U9<,96!N1L8B8SCE U=,8/&RVTQ6DA8M>9':8^J77R:J]>]GEFS#C(
M^U @S3YN23)+DE7+>-GUD&;E4HZYD&9II9?#.9,"3R&:*))=+B5NB]4*("<A
MJ01JLOVF,OIA(,2T6,9"A5 ;P]3*H1F9=L.N>5/&S-JJTH4\;?(MB-+<_P M
MDBV@8M(X_.N65OYA6.&[7%&_GVV4X)E-]-M[E7"O%'8"Y5J]"H4-2:ZGA0J?
MX&M@QY;K7L]EI$D.3]JIY(ST[PVGR,(")THYO[%$B0>!$L<8SLX<*@:0E7D9
MI"SNGZ/U1P0/[/129RVG,KNV8\+Q269V8DF)""6.FM(I:41_Q/X:\2^).+6^
M-7G'CR54S&2Q."[>9VN.RN/,>XS&UX#XCE&"X+D=S\=PUMH$6Z5B^5RZ^]3C
ME914]HN#73_LB-8_:$NPLY3VEZ%DIHYH\G[3N86ZA]GCER$9CR\?4IX,SF8H
MPK([1B:!6B,KR.FMD\1ET*@2=$ZE(I4G(+J$.LKFD!<P(Z1L;8@'0Y#:0H:@
M:NR9;XB4MUF'E[XM89*\WGEOM^(_FE\Q^0<?^,<-FGXNX_BV!(L+B9>WF*89
M<N\)K&SM(/%G+X?#O-<OKDQ:RNJ5\&>&<-#]S,ARGXN/RGM!TB#JN1S*](ZY
M'E.C=)BZ9D&.5,LV:T1B*.?,()$1&R,#9K+P,6=W^WYMJ12H::3H_47@E0RY
M-I,UF&GE S$2JEL694:R2)G$;L!07P8A[QNH.X5<&<PX=XI></;'C)Y'N+?"
M_(;R#EDOAQQ3D<?I]!"S"NA/5D3+<=ML2X<X7G&*7JZM]=7:N8SEM3#R2M:@
MPLGA74>IJ&X&3SOM5T;.3Q9N/+>U&1SD4;P+F\ED8EE:!V#M!+'.V8R\\8<"
M1!- [0N6:%HR[EH8^A=2C5D89"6)B',<N94J& (#J4=)$:K!TNH< :PP5:E:
MHI>+]?7WU+_*K^CVF8O-RR1G6(X?]A\8*'$>%^6S,4QK")MQA&.XIPRQRMF"
MTQK"\-BY%5<0&,[HLNL<8K,DR^KOLG<L;F?4?KG0&:*7P/:Y)E@&6GG.7$D^
M=@6:7,+'F99Y)7&B7,9AHGRIRTD"S/% \<01%D_L;J@# CIVDN9$03Q*L3Z5
M0E%0K=JB!A+XBN4#N&>V,1Y5P@XK7O#L\+[SS->4C]67*3A?0'X>5QD^TE0.
M$+O$%[$29C?!Y[^?"^)>3?:CQ9_IVX "63%)>N0^U/L_#F_MD?3O:$3>)G9=
M\@"FK/#*B?W?&XK)PZ!?N^_R&VB?H?4_#$3/DM&F, #,Q749D*U1/_A'OY=A
MAJ\MOEHJN$/F&X%\5<H\ROEV>QOAMQ>X<YW?,4]AQBEV[U-B>6U%[9-5<23P
M:A1Y-@Y#@O)AL/S(C#LA3:'9+"%*=3%U_P!LLAU'H?6.GY;IW6_M&>Z7G\I!
MKZ>$3QLQE98H];^,VA=;C4U&A9HU6'R70LY#G,I,\F4T0YK+S.1F4)"13([$
M>NE30[G;'2U[S%\,GEEH915OH0#V5(6IPCJ-I1'*CO6@!LD].G3QY='LO[0;
M#^RLU_PJ?R;Z[8ZW_:&1%G[5&/74=A7P'\: [$6!>WXWX38@I@74)#J^K:MO
M0T(5O?WG)*&D:&MA1/4?3>W/LMU\&ATK-[_[BC?B@-7Y8)>I=/L7FX@!7)VV
MX/W?,5ML#VO$H</^*V%RHGPN5<3,6J4E7*V\[/>DN--ZT/5;AL.I*AU)Y5*)
MWT&_$+^RWM'?N]'S; [V$7R\[X^!_'&13K7144>)/J<T*C4,*\_?DC!/:Q>]
M;<G$F/9?Y?V4!]?'C'IKBB>6-$K9) "4JZNOR'8Q"20D)"65*/,-@:UX<^RO
MM)WZ7F[\E3MP-]= [$G;X8C'M!TWQ/=4% -B\L:DGMLI>QWL$=Z[8U5G$7@4
M'U&XXK8V]$(Z1XC\F.Z!OH"^IEX!6NY+6CLZ3U&J[^R_M+9T])SM;52+M8W-
MZK-W\-M_52^TN5%+",M1O=[)7OMN!>VQ([G!S!XD^6II*'F.)N+ #ETARPG)
M<!2H@>MS1T*"M!*AM1:<!^X=\R!,GLI[0E"3TK-ZM_[B_*Q?R^55BF/:%!SF
M8N;%*HHWOR-_G8OYG!_"\S?!BLC_  #7$W&4QD )"(LI]M*D G04E+"4.;([
MK!/77S\.OLK[1)QTC-FMON*=SO?WOU==\1R]6RV8(9\X&K8!G9@M<Z5X6]KH
M;CXXR/FBX,[44\3,8:Y@4A:Y#Y6VE0T2E(8("M$\O< GH-]HF]E?:,L3_9&;
M%DD6J[UY;T"3R:]/.XAU#(U7VJ(_.N-^PX%88)OFRX%UZE>CGE3/6.JU1U/K
MZG?=:VD@J5T^6DG?B0^RWM"5*_V1F]]R= W )/\ B[$?S&&.?R1.^:BXL;GC
M>_Y@_4'#K3^;'@9/>2AS/*.$M/(I2W77 $;">O-Z1WI1UL?(GMO0#V2]H3_W
MISM?]A:\_/X?A5[8%NH9-0-.:B(\K!_AW]?XXFNM\P?ERL:TF1QDP42V!OT5
MSY*7'AH@%L?!]'4]00% '>CS))'B5?8WVD<.PZ9F05X!46>^PU<7W(]1Q>*,
MO5\O#(H5RT))#: #VV+<@#M?RVK"!/F4\O,9PH/%K$D@'1YI4D%( ZC[L505
M\@4['R \5S[*>T@%-T;-BC1J, $[T=V\N_SOC%D=1RK+:S1WM8).P-U=7O5?
M7!#7>9CR^3I42!!XJXK(F39$>'$CHDR"M^5)=2PPRT#%&UNO+0A()'WE '7B
M&3V4Z_&C/)TK.*L:L[N4%!%!9F8WPJ@F_(8$Y^ G2LL9)VJ]R3Q0O^'P\\60
MCNQVD@*WT]@ 03\SUZ_X[\8 B@ NU\\[_0&O7CZ##[L2:OS_ %^CAIR#+:3$
MJ:SR3(;2)3TM7',NRLI:RF/#C)4A*G7"E*EA 4I(.DD[4-CN?$V7RDV;GBRV
M7C:::5M,<2"W=C9T@=S0\QW]*1<(K,QT@ $DC8 ;63V]=COBODKS;^7Y]92U
MQ6Q9Q1'+ZBI4D('?KOX8DA/OT ![$>,X/9/VB%C^R,YS?W ?I[WTWW\\0C-Y
M;GQD)'F2>UBOKW^7F6YSS&>728%&5Q@Q,!7=*9DGFUT/[1C=]]^_7?31\+_1
M;VD''1LYSR47;Y:OGV.$<[EAL9H_@";KU/G];W\]]]=Y@_+'7N^JSQ6Q(+5O
MF<<FREG9[D@QB .N^@^7@?\ 1?VCW!Z1FZ]%4;_\8KOY88Y[+$#]]']2?S'\
M\%B/-'Y;0D%'%[$ .V_BI.C^0BZ&NWY#PP]E/:0?]YLW_P  _P#?_/U'&V&^
MUY8U_K$?I9(_"J'RQ'&?\>?+K>QTO0.+F'"<VVIO2I3R4R&2=EE:OA4CF25*
M4R5= 5K22$D: >R?M(L@8=&SF^Q]P4!5?XCY[\_3$J9[+#F>,UY$G;?T]3]=
M\1/CWF6X,UC#U;8\2,<"&E$,N?$/*Z)<VG_N?J=#6_<:[CQ:7V5]HASTC-U_
MV%/R(#61QY\>IP;9S)-9^TQC;LW<$4?/Z#U\L'L'S5\ 4Q4I/$?'%/,J4 ?6
M?*EI)5H@F/TZ$@=?I\M ?97VBL_\SYPB_P#P:U7_ !]O\A@1FLIL!FD^1!&W
MQ'G=[[V*'DT7GF7X57<0L5&=XJ7D.,NLKDSELH#C+J'4%96P0$_<UO1[G7OX
M=?9+VD;_ +SYW8GA%-CX7Z_6L$N=R2 UF$J_\5WL-MQZ[^5>>"?_ &2W#%F'
M&?=XC8*7PA"7V(UR77F^5 *AZ980IQ(T0.3F))[>'?V0]I!=='SA#'CPQJ/;
MC6*&WIA_[1R=D#,)L.]]Z[V =_+U&QQJF>:?A'\&HCB1B;OJ-E+K3<MY3B H
M:(4T8X6%#L4D=SUZ=1&/93VB5A?1<[=]D&Q]1J->>W'8[8<9_*;7F(_K7)/.
MU#ZG@UWNOU[QZX1NVJ9=)Q5QFMDK63);=6^] EM@@^E+9]$*0X>J0^R4N)WL
M[(\&?93VCO\ ^]&;-_[B_GJY_,^>"^W9/OF(R0?/CD^6U5_/UD/$O-[PDK5-
MMR^(>-LH2Z&I;!EONM@)(2'HSA8!4TM)YD%02M'5"D[\"WLE[1'_ +TYS;_<
M7D[_ .+MZ<]]ZPEZADP:&8C-[[GBM^P&^YOY@XG ^;'R\24C?%G%!SAL@JDR
M!T4!^U_1N_?9]NWB+_1+VD!VZ/G-O]Q?_>Q,.H9,#_I,9^9X[<CRW/K>.!OG
MT\K"?,MYJ>)/&OAYYA_+C$P_,*SABS5QLGRW.:V\8>Q3A)@F&6S4^%!X<6T1
MI2+G';$,*CV,IM^*&'PL>J4(]/>POM3E?9_V3Z/TCJ'3.MKG,E#.DZP].:6,
M-)G,Q,NEQ*-7N2K9 J[YJ\<UZUT?-9[J><SD$F6,,\H:-FS"*Q 1%)*G<;J>
M=ZWPTV7!SBQ>XZS79EG_ .C?SK/F,$9X;5_&K,D\3;SB;%PZ'CJ<1J8LM+F#
MHX<9#?T&+-QJ+'<[S#A]D'$&BAU]2]695&L*:IFPLBGM+T**8O!%[99;+'-'
M.-TZ#)F/)G,-+X[E:_UJ**6:Y)<M!FH\K(S.'A*R.K4ST;J+* Z].=Q&(Q*\
MRF0(%T*#N(V94H+(\;2* I5P5!!W?X]YG+Y%HZ>-WD#JK7);J#D^9Y!57/%H
MW.:91!X1\3."35Y<NV6'V<.O'ZB<5\ICL8[BD+&\,J[,Q+.DQJK?7:"SKP]:
M]F(BE9/VL=(8VAR\4F0 C@A;/9/J)CC"!"W^LY*$F69I9W34CRN-&B0]*ZJV
MK?(*SD/(WVA0SL(I(=1+,0/<E:E0*@)U*HWN.,2X&\<\9QR@P:SXV>1+/.'5
M+PN5PBE</LVR#BM*QW(<5;XQ9KQWK)5O)H<&Q[)H>347$3/L@FT^38OD..6T
M:H?5CKLB12SKF':7)_:;V?FFES*9/VIRV;DSGVY<UE\@%EBF/3\OTQUC$AEA
M:&3*Y:)9(9HI4:0>* )%C9!7HG5%"H?L+QK%X)C?,)I9!-)."2K*P822,0RL
MIT^[>DL&<[7@]QSO.'LCAQ9\7/T?\FNC5^:X]A5LBVXJQ+/AGAN?Y/?9A?X1
MA$"%A4;$4X^S?Y5DLW&W<IQC*,APY=Y._5.]I5_#*CA'[2>S\6:&;3+>UBL6
MR\N90Y$%,YF,K#%EX\SF68F<RF*"%9A#-#%F!&OC1R"P4>B=4*&,_8"!K"'[
M0EQ)([.T: ,%TZG8J75V34=#+AF:X.\:(V4\5+_,^-/D/XB4O&F9CUKQ#X>Y
MC=<7I>%V]YB!D'$L@A-XM@U!E5!>XVF=;1ZZRH<HK9#E=?7]-8&=375C7R";
MVF]GQ#DHH,I[5923IZRQY3-9;IX&82*>O'B<RF:"6*73&726%P'BBD33)&KA
MO[&ZGKD+G(.)B&DC;,IH+)>EAI965EU$ A@:9E-JQ!.,6;\QV-9@UG<_CCY
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M6,U$; NB?7;9?CC\GF6_\:LF_P#*"Y_^R,GQZER7_0\I_P#6T'_\I,:-F/\
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M^X^/'Q[U7<8&[.+84LEV)/ARH$IKE2_#F1WHDEHN-I=;]5AY#;K?.TM#B>=
M*FUI6G:%)5X2L#3 AA?*D$&CO1!H[BN<#P=[)&Q!W(Y!!\P;V/'GY'0Q/<61
M]P*60 D\Q3V!UO0V1KOV.NW7O(6W//D>"=K^7ZNZVPK!!(V&VU>O'<=_J;)
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MO@X=O65=]#FEZ<))6E$Q0LXDHQ1NH?P&R[6'!#*T3; T5<$ZF1VC+"2AIH$
M5R0>=7;]5^+AB_F(R.D9XOMRH,K_ -K+EE;F.2'%,JR/ ?2L("<]2NM:;QR6
MTB9C<O\ E!M"_13TR(O]"K0A02TX'5)T^-_L@!'^J1/#'XL,>8&EO ]X^(-I
M!X"D. #[SWR*2O\ >WO4;--6^_-=CJ/.WXX4S/,U?4],Q6</*%SAFXUP^9X>
M19>'97D<%RN8<RC!LLN+^G#4N-(AY)E-IA*1E-L]-F2[B';OUSSHK:VEAUP#
MIB:R^8<9D?:#F&66&-M1\*>)$;9KCB6;]VM*JE P]YG9G+D; :=J!!X%@DBC
M5FMSWXO:L(^&'':3@&)7;#];+NLNE\3L5XD5,J=<W#5<+;&Z+,8#<[)$PK-A
M.2AZ;DY>G4EC%=8M&3(8D6R(4FSK[8LST_[1+&VH1PC+R9=E54+!)'A8JFI;
MBH1D*Z&TH'02%*I7H;V3J!W)K8'N-R+/%5YWA[B>:3,X^/Y=1FII'7\EAF)
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M-J'GVOCCOQ^J.%28C2.Z23\S_</;P)-]@/@/X\_4X1-_YW^OYWZ 8*B)5O\
M9Z]NA!^G;?;\_P"[P@Q'P&]&CO\ KRPV/F8CJ5;0\ML^Y0M23].J==_?K]/K
MX+7Y#ZD_/X^GU^#U9L@GC<[?B;^7UVP4X71"RS?#HS\J8&9658^PL(<4 4O6
M\-"R#T/5*CW)_=OQ2ZBY'3\^022,GFMJ _[A)S1/X[?'$T(J6/[NTB$&]^01
M0!_I\1C]),#@)@T0A:X\R2YRA/._(6M)UKHI(T".G8D]SU]_'ELSRE>  -Z-
M^GP_7J,;>T[D4&H;;@7QZ$@5V'?N;.(H\SF"T-'Y>>*X@5L:*&\7?4E3+3:=
MJ$J*GFY@.?>N^R#UZ]#XV#V3;_\ 6+I'&^;4\G?W6/'!^F*V<;5E)]^4-W0W
ML<B^_I^%8_/$Y5,J)6@!*^X(Z]?W?+\_'H^_RK];_P OAC4Z[#<WY#\#S7X=
MS5874C*_4F-+"@6FDN) [Z"P%:]]:/3K_?XD5=0:Z)JP3Z5_#8_'G@X18*8S
MYV":NK.UG?GBOY##^2GW(^8V1^_K_;XBPY4G<;@[[#CO1KBL2Q49G-PBJ_4O
M,,#QO+J=R949S4TN8+RB"JKE9!C];,CVM;*Q+)L8L?@,MQQS'W;.)(EOQ["#
M"IWXXA2XS<D57B6=_&AGDB<!X'>'PCJ$<C HPFCD75%)KTD $%F!U*:PX) H
MK8L$ WL2!7!'(K8^F)%@<=.)F-8M93G<<QK[$SZIQ;':6QEIMV)]>KA9P^=X
M55MQC:XN2QK7F8H9ST>9)L46&/R[R/(C18R&(MK4*K-D<K+*J^)+K@:61U!3
M2PS68&:9) 8RM%U%!=,@0@DDE'#ZV4&U !H"[' TV-[.VQ[7],-2_,=D:H1C
M#$<,;F-5N00*^W;.8-SZR1F7#>AX59K:Q4-Y<BN=G9/B6.5C,A,V#+@U,]#L
M['8=.XZI/@QTZ,-?BS%2T;,A\$JPAS,F:@4_NM06*:1R*8,ZD+(7 &&UGR'?
MSVL!3W[@?+M1WPY7WF#S3((N67AX=X="BW+;E1974"KS MU]EEV \0,'E2YE
MM)R>4JTR;*,>R#(IWVEE<JZL[&=CS4]I;S4"V;E@G3X4,2?:)F*4ZHS0^\L.
M8R\X 01#1%')'&NF((JB0KL66C#L3>CFK(U=P02=][%\^7GOAG8\S_$5G)YN
M6"!C+MC86EW;2&GHMTN(I[(.*]#Q@LFT)-^)+:',CQ^)7-.HE":S2/24(EBX
M$6YBD>EY<QB+5*%"(@W2Z3*OE5)]RC^[<M5:2X&VBT)6;L;<_BVH]_,<"MK[
M[B3\#X^18%%76.2X0TW18A.15\)\?QNBR2PJJ[((]/DC\N&K*YW%FMO&9=A.
MRMN=-5D-1Q+C,QYBV*:GJJ]A-/.K3Y$F1EBFN25=>:>22-7:,O& ?"7*M&54
M1$+H?+&Q;N['6LBL!N0*O858'SN^_E6_8;81<2N+/F'ID%S-N%KF!NP858U=
M?;.*9MB_VI+>S3A]D*+Z74V]Q&ALV%MD/!2DKYSM37PX+B8EM 1&CKATJ*)\
MOE<@]"',B;46*Z)8)=($,\?AAD0G2L>=D90S$BT))MS(SDW5;>HJCMR#R?=Y
MKMQ7$(<3N/\ E/$O#ZW$[JIQR&U FTTV18TC%Q"FW!QJLN*7&V[2*[=2:5[[
M$J+N;6PY+52S.] ^J[*7*F6TBRN9;(19:5I4>0EE=0KE65/$='D*5&'&MHU8
MC61=@"@H EF( ( H<CF]QQOO7/KY[G#[$\SV?VIMJRFPW&FLGS[(4W>5W%8_
MG*I>5Y=:4F08D]D3E&YF+N+5.07CV8SK"?-HZ2K;D7BH B,P*Y+U7*!NG01E
M&:63PX4*1(_@U%"KQRB/Q!%XCQH(E"J[L0EEBS4X$.3M6][\@VVP-$^N]=ZY
M%83VWF;XD/8[$PF748[6FFQ=.!6<V/'O8UC;UU5@TSAE6&\B"_-,]:4>+2Y=
M;%F,U4<N..R79S<HRYZ)9ID(5D\<2R.7E.856*,B,\XS+:"8]01Y0&9=1X%'
M92J)V -"Q1J[X(!))[ Z0:WO?DX*V_-WDS\&R@R,)X;0EY#D&1WN33XE5DD)
MS)CE9X@LW<"[<A96P\6Y51Q+R''FKJ*XQDL"EB4#%==PI-0B8\ Z5EV*GQLR
MK1I$D1+QE(_"$&@@&(U3Y=)2IN)I&D+H5?2&+NNZ@,MDL-[-EKX861J/RVO8
MW]*\U_$"'5*HHV(X)6UT9B!%QU4%K,5/X]"C8-B/#N9&K+*3F4FPFQ;[%,)H
MH5O'NI=I'=(G"&U"BSGHI%ND1+)J>2<N=1>S%4A:>;,*Q58@H*2S2%"@4\:M
M14'$BREA8 V%<$$#CSV!^F!BJ\SN;UDBND/X[A]R]2WM+EE&Y8M90E=9E^-Y
MQQ0S_'\E2JORF 9TRKNN+F6LIK[0SJ*= -8U9U4Z5$>F2FDZ?"U@22 /&\3Z
M3$=44D.6@D0W$P563*1$LH#J=>AE! "U&ZH6-Z-WR2-K_P![C@[?-/7^9'/(
M=!E% JEQR:SDU)5TB)RX]\U9T359PUC\)UR*>;!OXJRNRQ&)&9L8EL+.K<E1
M^2/ CU<JRJIY'I^79XY TH,;LY *%7+9@YH!U:,_=E)TE-+ -9)8*ZK418/E
M\*VJ[^'/]<2/E_F=SEG.+_*L1X?U>*X_F&0<5LYIF+BMRJ3*NI?$C(J.7%SV
M0]9Y18M_K#B^3<-,-R&A<QR5'Q6OS?"T^M565:W/IWH8.F1-"D3R22O#'E8)
M"ICI!EHW!@ 2,?NY(LQ-&_B R&&8TRG2P?6 UB@#9 ).]FP>=]P*K:Q@4G>9
MW.+FF@8W=X7AEE1MXG78=D-<MO+JUC+ZZF@8= I)=RJIRVM<A6E4,%Q^6Q-Q
MI=$9+[<R'9-S:.6JG1+_ &7&CM(DDR.9&E1CX3>$SM,SA-<36K>.X*R!Z!#*
M5D&O#B2^1VJQWJO7T'SN]C0'.%O$3.L<OJ"HP^BIK*1.S25/K\:>C6EBU=6.
M64%A@3V,J;5;(E/0;"GOYM7%<1*;O8[\P28MTU+"7P>8RD,D<C3R.JB$!I%*
MJ4$3K-XEZ2-2L@8C24(%%:VP^LFJ\ZJ^201]..PWQ*=KYG+&=25PC8ACS.61
M7LYBMW#[N5/Q,?QW+L-PO #3XY#>S!^"\VK$L573.F_K;)58P_'<HG8+L.M5
M5P+TU$=KED,)\ Z%$0:22*6>?7(?"!'[V4./#9=1!#@@MJ08\  $ V;V -#L
M2#MMZ8;+7S 9;D<)JVR7AWA.1U..Y3%OH,RRJ,O-#1WUY(G6+D2<W!RF+6VT
M?)XM))C?8N2BT8DU]!+%6PPDY Y/DCR$*,R)F9HF>)D8*\1=T32-2ZHM2F,N
MIU1Z2#(NLD^& 1:AQSY]MK[?KFMK.&N7YOLO<NF9S.%</N2&S60J^$Y#RIV*
MQ6PL=X@8E805-+RPJ>9R#'.).0UE@IU2G8*&ZR1CKE'*B%UYFZ7"4">-F*MF
M))BLN9()0]B+8I)EXV0#8VPDUAMH=9)HA6/&W:K7_%Y-7<^6 3/N/-_GF*V&
M-76+XFVU,OZV\A6J1DUE;XY'J*>/10L=QA_(<ENHU!0FNAP6)D.MB,+G)KZ]
M,IY;<)A")8,@D$BR++*:1D*?NT1R[F0O((XT+OJ+4S$Z=34!9LF) %@;^?;T
M [=MN#WLX5P_-#Q'3=1;5NJQXJBT$''$1HZLKK6S A9WBG$ /MRJG*8-G$L)
M%MA]7"DRH<^/ZE2Y*CAM$E<>7&$]-R^@H6DHR-(2?";WFAE@JGB92 LSD J?
M?H[BP6$C'M>U$;\ @\;<GFMMSOQ@F:\T.9Q[FONQP[X6EBAOL8RW'<;9K,NI
M,<I\IPK,,[S;%[6/&QK,Z2P4*^RXBY/">@.6*JN= E1W)<-VVAL6J;F1Z=E]
M6A\SFU$B2PS2HT#S/!F(8,O.MSP2I;)EXB'T%U*L =#%#2ZC'.^7E\)8C(%+
MQ"3Q"@F0,T6K1(C%?$(NG4Z22""H.*D\6>.&9\5*;&,3R_&\=I*_ HN,L*L*
MR-<Q9.6?J?B</!L6=MX<B[FTC\RKQRN$5F="JH#ZS*ENON.IEI0CK?3.FY/)
MR3YO*9B:<YPS, [1.F7^TYALUF!$RQ+*H>=]3(\CA2J@45U'SSU3,YXE,EG8
M$R\F5$2. LJ--X$*Y:%G!D:-JA6DD1%UJ6.HV 9<QSS)\7W)MUQ<@\(< ^R)
MV>OYA,S2-#XAOIH[:)Q6X*\4\DJ(;;N>.5;-?.XBT."S9QEP+&SKHF:V%53S
MJ^+*IFZ7'9GHG3]"=.;J6;$B9(9:/+.V3!E4].ZID())-.5$A9,E+FE32Z([
M9:.217<2F6[ENK9E9!GCD(#$<ZF8FG49@!-.=Z?FYXTU9AD4/F(X&.N-V03L
MB,%*!)>A<9<\Q")%H+G'*&3">Q3%8,BKNF+YI=IBDO ,_J:CUI%?D$&8PS?X
MCQGN+%<NOD0GW"Y32(BXS"9\:QY9/D()99'25PRSS'4OAG3*N8@9]FC(M)LH
MJZ6# >^"":*^BHG+1H0*#*K >086 .]41\CMR<!W$/BYF&4V6!V%Q3PL?A8\
MRS8X(B%76J*K[*JOLO$JY,%V^GVQNJ^G_4"-0?:$A^?+FS:2>S>6%C:,2W$C
M#E8(_&59#)K.G,:F75K;5(20BIH+^.7H *HD4H A&"U>]^1&XL7M\J[_ .<D
M(\R]\S6YQ6U6%X/31<Z=N+"<N YF[DJMO,CJKRFR&YJ9UCFLZ:AVVK;Y^-(K
MI[\^F2U"AH36EN5?IO _LV-FA8S32&'0H#>$-21NKQHRK"H]QDV*A7.ICJ!$
M920/M]WCOSS=G?\ G\\!W$CS1\0LCQ7.JDX3A%V+B%:V]U(=A9+)1B-9:\3<
MDS6SR>IKY&3OT\&RBY-Q*=H(-Z[72K6+33(%6W(=>=FR)FS=!]F<G-F(9IY\
MS''$R1QA6A4YB9<K'&F7=O"\1E,.5,KQAE74K,:6@-&]K_:3,]'RRKD5ADS4
MC%V$J,XBRJ/4D^E62@))(H@S$[R4 3N(\H_.CQAK.'K=!CV,T4O%\.:Q6-,N
M9=;9.3&;F-E*[6@N+&R9O&U-VL_':U[A6I+#;,*1PTC+I$PVK1(O?&X?Z)]*
M7-!I)I$FF.8,<*R1A3$<N(I8E0PDF-)77/@DEQG6$I8QGP<<MF]J>JYI)',:
M,JF(R2NK6)3-XD;FI*0ND9R@51I^S#17B#Q,14CS,\0FSA35?08E&L*'*,*R
M;XF/'REV3D=E@>0<2KO&:NZB#)_@7:]#O%3(84N+5PZZ3-B0Z4*EHFL395AE
M#T/)'[47ES!CER^:@TL8-,$>:AR,68>)CE]2N1T^%U:1G5&:6E"%53$CJN:'
M@!(X=44V7D!'CZIFR\N:DBCD42E2FK..I"*A8+'OJ#,R:#$O:^@Q]FY@383E
MG4)G5ZIJ5\TZM$J7!8FL<XYU,..P9#2%J^\5,+V3K?CGO7#ECU/-G+2(\8E]
M[PS:)(R+(Z6-K4OOVN^"#CNOLK+FWZ!T],Y'+',D6@B8'Q&CC=TB=@P# -&J
MD!@#7O53 E5$BI;:4I?5:R=)'<?(;W[G9/[OIXPY.X%U6Y[[4;OY?GQP<;&H
M!4FMSQ_"OGCU..B8A2GTZ;4""D] 4D]?;1/+T/31]CLD>"W_ %OSZ?Y=SM6'
M$084VP/8_P ?UMSYX:7X;M6ANO$A1B,K=<B**M*"'N0K;6.GWFR@#8WS)*%'
M2BH!7>WE_$G^6^(W71[NKW;)4V.]6-Q9K^.%.0W<IK*LE<*U**[^X4KJ0I15
M8R"2?ZI))Z['S^?@^GR5DLGS?V7+[FMOW*7\M^/+X 8GS<"/-.!I%324*.].
M=]NU>9_/=,)E=8$E]OTW2.KK("'!UV2I&N1T =3T"N^E'OXNDHWWEY ]Y1O6
MU$#S[ ;7Q6PQ459X?]DP(&VF0DJ;WYY YV4\[DC?">1 <907FEHDQ];]5GJ4
M@DZ#C?52#K77JG?3FWT\ T9&ZVP\]OQ\OG\<68<VK^[(IBD[(;-[UL>#V]-Q
MOA#XC((-'_/Z>?ZK%DL-)(_1_1Q]X;$/.-X  T/"PL9H1O[Q'<:[D^_AR>U[
M? #YXB<[UY;_ #W_ (8W>&P/'S'\?Z8L9"SWAK;8]PI_6J?G5?;<+**5C!Q6
MGQBBO<3R^ND9]DN:/2I-O89I0RJ(VS&52JB^JU8QD34[[*9E">6KA<*BQS9?
M,J^;$2P,F:<2B5Y726%A!'" $6%Q)H,0>-O$C(U$$6@9V._-T!54*.Y-W=]Z
M(JOKB8<5\QG!NA1B=Z>%U+$S"CXFTF6V+\#A5P^6R_5U/$N'DK<VBM6[:K^P
MYS?#^*U@K>&N8[8XF])COY0[+1D]LJ[JZLG3LXYE3[4YA?+/$H;-9@$.V6,9
M#IH;6OV@F?QA(LH!$6DQ+H9]8%; M>]"S5V>^VU"JHU\<-])Q@X"US=)]H8:
MQ<*A2BJ0U/X#\,/29F<^6BQR]3E?F]9,R)_(&[6K=A\-KJ2W@6!RUL&L.0UV
M&U-9>F^3SS:],Q34-BN>S-U^ZTQ4T+*@C*N#F%!GG%Z_#:9V2/6O<7YVB^N_
M.Y.VW ]:W5S>//!IT42!A4JX@8K3YA0XY67G#+A6TB-&E\6<OSG%I]O*I%UT
M&\?=Q[(JZJNZEZBBU%395<]RD:E1+Z7Z0C(9WW_WXC:1X9)&3,YHDG[+##*J
M"0.4 DC9XW\0NR.H<@H+;6FPHFK M5_Q$BR-KHBP?ESAJ1QNX1VOH&UP"FHK
M6-CM?!K<DHN#'">T9I<A?Q/AI'RN[EX(\[C^,9LW<Y3CG$ 5,+)7DQL5K\Y1
M=8ZS72ZJ)C[!G)9M2=$[NAD9FC?.9M2\8ES)B03 220:(I,OK:,$RM!HDU*S
M.6UK1+#3L!LBG22%!VV!W#5?&JQ55B5JO-_+A'Q:VS2SP;$V,9^V6)5=PW51
M\)[++[J8/,M296[)8N&<G=XJ8\XG@FW9X:<0D443AB[65SBV\K599 W%?JM#
MU!I%A2>8RZ"&S.O-+$BCIKQ %/"&5D'VW3-XHD;,AFKP@L=AM4=%M*G?[I":
MC^\!\RP]P$4?=K8$W6(=R;C3P8LY=I%K>&-&JGM865L6+XX88)B]O,E/\+XM
M'A,FO9@761+PA^IXB,)O;=S$+2H9L*]C[0=A3)EG;4\FS%D<ZH0OF7#HT15?
MM,\J ?:2\P<,D?BAX"403*Y#-I!151E;Q(P2 E\_W5!/NT*WM?>YK<CG>P?L
MQXV<*AQKX=\1>&V!?J]C.'V!G2JNMQBAP"\;85>3I<%B _17N1U,^_Q:LD1U
M8]G$V%"N'[>/%D7$*8W71%**+(YK[%F,OF<QXDDRA0S223I>@ E@Z1LL<K"I
M(59D$9(4@LULTR:E*J17(H+W[58L=C0]>,,C.?\  [%L:%'08Q/SRU-#D=1(
MR7,L QRAE2D7N;\+K9H"$_G/$F+57T;$,<XD4K>=4A@WT%[-(+%=%:<JVKYH
MOLV=DD+O*L">)&PCAS$D@'APYE?O"#+,R--)EI# ^J-A"Q8G64+ET !HDE3N
M0!=E3ONU&K 8;B_2\2#E''7@+)R$R<;X34J:&PM\-8MTR>$/#VGG'!X4[B:[
MF%) A-W^15M?D,V#DF$Q*W,*%S';Z0G'0J1.KI59$GVD,60SXCJ3-R:U24I6
M;S#CQB,MX3LWAQNT:F.<M"_B1CQ-@P9@K-*ANAL2+]U1M[U@>\:.Z[BC8YX.
M-+O&'RZHK:")5X3,KKBIQI^G5EL[@OPFR&60B7P_E1(EGBTG(8&*Y7:.HI\X
MAR.(<V)3Y*Q&O8'I5LA\R7HZ&4SY:37,&5Y-1B7-YN-=UG!*2B-I(5&N$C+@
MO&2C>\!0+B5/=%'8595#_AY!V)V-ML=^#AUS3S%\!KM4ZYI^%,3]9)M]Q1R!
M;N2\-\*N9)NLJK.+2<9N['(YF1SEY&TSD&6X3<V>*9'C5G24[F/A-*_+;I8;
M-X$'3\^@5'S9\-8\K&!'F)D71$V4\1%C6-?#)CBG198Y5=_$]\+K8H;.I%@4
M?>.ZJQLAZ-V;W*FJ(VVO;#+3\:?+NU(B3+;A>'HZKRKM<@Q>/PRX=NQ;Z:;K
M$;2UN(.7*N8EUAU?%CUV05\'AKCU6C"K6(MF-+761L@M&:LWR742I5,U3!'6
M.0YG, H-$JHABT%)F):,MF9'\939&HQJ7 .IIB#5@E0![WW;((-K6_N@ 'N1
M9IUX=\7N!%G48)39E@.)UV41[2VLLTO'N%N!_8<N2W9Y==0KBMGL75*$-IHY
M>.X>QPYL,;7A<QVN-HX]'MY+4^.$^4SZ-.\4\QC*J((QF9RZC3$K(P*/9+B2
M4SB43 -H * J4C)0!0@DDL= KEB.*X! J@.^!C^5[@ M\NV?"A.5S:EW$%0;
M-&(8?PZBY4B5(@Q>*BLBQ?%K"QJ,=7)Q2KA4>!-8](FM4E^]=9[N!?W<EMN0
MY//[:<T8E82@J9ILP8C3'+>')*BN]2L7G,FG7&$@HH@P6M*%BS[M&JNSO8%U
M8H#UMN2<;,ZXL<$KZ%F3.+8K'QJSLZ.I@U5Y'X%\,T?:RHC&=)L*Z70/9E95
M'#R5-<O<68&=8#S7B8V/,R54ZK6,Y.MS@RF<0P^+*9%5V9T.>S/N68-)600J
M^851'*3#/[A,A&O2:1%E.KL3Q2C?[UWOL=QN.*V%X3<)^,/!W%XV+UV;<.*F
MU:I,!LJJ3:GAI@N7S)6<3^*<[)7[FQB75I1/Y+ ?X=FJPZ*Y:WT9W'7(TDT5
M<PJ2_9R5FLEG)3*T&9==<ZN$.9GB40KE5C"*R+((V&9US-H0ZP1K;8*$K**!
M4$!3=J&.K58.^YVVW.W88,;_ (K\%*. (&.X]%=LIG"VKJ8AQC <-IHN+6^7
M^6G)L.RQAW/(M\]F&<.S\YS2 ]D<+*V NB?H[54&19SH[*9T*9;.L0TDATKF
MF9O%GF=I4AZC'-"1 8Q#"!#"P1HO]H'34%4^Z191Q_AX % E*/O79W.]@4;[
M\HG>+G 1[):^WC8G,I:*)D/$.W?Q9/!;A%DB9K]W;<1YV'65CD5[>&WLZRNJ
M\AP_'K/AWRP*&"Q2/7%#>M7-;5274,GGO"9/%#R,D">*<WFX] 1,N)D5$CT*
MS/'-(N8LR$R!'0HSX;4EW5"R:TJ>2U7?8 @:>-KYP[7?'?@5<7=8Z[P]?7BE
M$]E%7CN+CAY@4-NCQ^P\P4SB=0R5SXMT95^Y#P:T>QR5BETX[4HFUSM>FZEU
MF5W5A%9.GYZ.-ZS($KB-Y)!F)V+RKD%RSBBE(#,FL2I3Z7U:%>)%+ZT_PV!=
M#2NWOZAQSL:(]*X). K(.+7"*56.4M=@-=.5/Q_+X&291(X6\.,7M+R\F</I
ME5@]S34]),L8O#Q%!FJZJ;:0\.MHR+2%3+O)2IL^_MZ-<D64S>H.T[*5>%HX
MAFLQ*J(N85YU=W53F/$AU!&F0Z6?0*6-'P)9>*!V-G2H)-'2:'%$[T=P+\QB
MJ2(K8'[ /OM0!Z@>WTW_ -?C+&@=R0=K"[;>NQLCY?# 8R#?(HD= 0.GR_/_
M !Z_COP.FZK<6=]^/6Q7TYPXV^A_$$8WHU\NO?\ ZO"9:.W![8;&9 /?PX44
M21N+YL=L+'QZ#H-_3_(/@=-"SMY?'G?XU]:P^HD5>WP&/4Z&B1H=R!T]O[O#
M!2>/Q_6_ZWP^K8#R^AWO?]?3!QP\>1^OV"@'H,PQD$:WT^VH0'77R!\8_J*5
MT_J!.Y^QYJJL$'P).WQXP<0)DC-B_$3:Z-ZA\,?J;;>03RI;)2HD<P T._4]
M.F_[O'EQMQS5>>V]@\\>GQ/.-KL;WYC?R_0-GL*^>*T^;-Q*/+SQ<95^T<3?
M*.HU_P +BA6_F1]TCIUV>O37C8O9( >T?2/_ *[4GXZ'\SB#-[Y:8@7[A^%$
MBMP/X?#'YR"RH)"TZ4D@'OU&P#U'Y_X^/2)V^/?]?K^6N>[=4 ;-;5YCFN^-
M>I#!^(CE*74= #U0ZGNIM8!V4J_?OZCPE<@V#N//;L0+O^/X8%E5MOA8XV'<
MC;CL-COY8,^&/$*EQ++V+3*Z%,R$*G(JY$AFIJ,B>I+.VHK&LJ<D@X[D*F*6
MZF8]8RXMM&KK*1$0\]%28MC5SVXEE#CS2O+%HC(!UQL=3O&'5)%9XC)%;H)%
M!0LH)"M11U)5A7;FZ'SHD;&CL:YNQ\>,6ZM?,/PGGQ:3,YF%8S8Y"[D&)8S&
M59XAA]S8HX;X;@N"5]U+O,#IYN.T]582<YP^'*P]J!DM-*3BM]E^-Q9];5,5
M3ZL0N2S0\2$2.L>B64F.:>-?M$T\[H(YY%D=E$$Q$MQNOB1PR$.Q<8DU+][O
M8 !4'W0%Y H#<6!?<CBL-G^R%X1W618XB_PBR=P/#KDW%)7QL4P.18R&FN,=
MWQ#D8O+B@U<*!19)CMLG'IQ,FX8HW& PS5WT-V0N07]GYI(Y#%.HGE0J[&6<
M*"<HD D!.HM)%(NM0 I>[+(:HBZ&B1P01L+V:R*V'&W/KO9MDKN./#YR%5P+
M+":^I>JL7H<?HLHJ, X?VUIC<Z'@>$45[D!HY[%37YI87F1XS=SU+RBS^+@)
MRVRR"OLH>1HYW3?)3JSLL[,&EDDDB>?,(L@,\[I'K4LT*I'*B 1K1\)49&CV
MP <;6 *6@:7:E NMK)(.QWWOMA<OS </K$8^J]QA=O/JJ>CHVK%?#_AX@8RW
M28CQ?Q6';T]8VXW69"ZU9YM@^<C'[)FFK7+?#TTRIJ6XU9>-1C(YA=>A]"N[
ML5\?,7)KERDI1VW9/<AG@\0%G"2ZZW=#('%+[NVPW&^RL 0!MW!WVV\C>-<O
MCKPLE>I4/\,X3N.R9E1(M943$.'M3D5S+K+#@\J=?LR&JF<UCLR^BX-GTU6.
MP7Y^.4LSB+8U+35K5/V;DT_L.:%.,R1*%<*#-F&C0,N;TQZ2P\01F:!?$8+(
MX@5_=<+1:AL*V[\<VN]5W \]K(WLDC'%KC)A.:?8S.*8HG'V*[(ZJ_L?@:6%
MC=?:2X6.T]'+FQZ*+>9']G2[%50F5(0[=6:UO.+>D3I,AQUU3Y;)SPE_$E\0
MM&R+<C2,JF1W"ERD>H+KH4B[;!0 !@':Z"BM[(%#@ 'OWOC\> ):MO-CB643
M[MZUQR7CL*YLUSUUM%P[X7Y#0J>;XAWN62;%>,7L:#4_;>7X[95F+Y7:OF9-
M#U2N<W)L:.<K$X]9.ERQ! LBLR+0+YG,)(+RZ1!?$0EBD4BM+$HTBGHA9%\5
MGU@DD@+SM[O<W=<610_'RN+^'_$/A7CF)9;,NL;K53+?B1*MH6%,XEBN4JG8
M<YC]LVWA4G*<G:3>XMCKDZ?#:5D6.O2;J)(KF;&-5+N&*NTJK4^7S,LL(21]
M*9<*TWBRQ:9O$3]\(HSHDDTJQ\.0!"&*EM&I60(YKN>PW!%$;[@>1'Q&XP;L
M^8OA;40F86,X1)HTG#6L<L+&%A.&_:]BW4YMPGS7'JVU?7;K18O,+P?*:N=F
M$!..R%/Y/%R"%B$>36(K/$+=/S+FY9E?]]XB*9IM(+0YJ&1E&BU!\>)A$=8J
M,HTI#:L%J45VV NA9((([B^_<;G Q#\Q7"^P7+D9WP;JK^QM8C5996=;CV%T
MLN/$N,SXB-9C,K(T*H8KT7CO"?,:2@Q*UD1E.8QEV'T.00T)771WR9Z?F5"B
M#-M&JDLJO),ZDI# 80UL3H&:B>250:DBE>,[,1A:A_A!OR '<W5<#2=N:(!&
M'7'N,? K*X=1BV2\.*''(5SG.09!GEP:'%ZU>+8%>QN+C&3P,%OOB'W[*WK:
MC,L,L>'U"K%8<J)E/#JE@N6%_#=JHU2,F4SL1>6/,22%((XX$#R,)9XSE/":
M=" %5FBG7,2&4@Q9ESI1@=0 J?=9*LVQH4 ;%@]SN*%7>U[#$=Y-Q9X9<2,!
MKZN5C]=A>54<O,[V-$QG!JBGIYB\BRA<RMQ7[2AW,V9;L5T.S2N!;RX.)QJ*
MAQU-$*O)+&5!L(]N"#-9:0DR-F('6&.YIW=D\..FE *@)J*D&-6D+R2%]4:
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M889!4^JQBQ8LM9#(YA#*T4PC9B\L=RSNK2ELI(@E5J/AALO)$]$L\4IV4G2
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M6,.KE/>XX(U[T-@2;\R<"0\CN_\ W)_OK_B5]"?^5OT\5_\ 2_\ \W?^U_\
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M1)U^H?8 =O\ CG]-^WAO]-!=_P!E_+[9M]/LF%]@_P#&_P#J?_'CX^0 '?\
M[5D;/O\ J'_ZY>'_ -->/^;"*[#.T/I]DPOL'_C?_4_^/'@_1_@'8XM'MKK@
M?X?^&7A?Z;'OTSCBLY78C_JI\\+[!_XW_P!3_P"/&S_V/_J1_*UV&_\ B'^'
M_AG]?#'VU)%?V:/EG/\ Y7"^P?\ C?\ U/\ X\8_[ '_ -^S_P#$'_ZY>'/M
MK8H],^F=_P#E,+[!_P"-_P#4_P#CQL_]C]Z:_E;]M?\ $/\ ]<_"_P!-B/\
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MC_\ CPBG?H]VXP/)Q9'W01_Q"UV (_[]#KO]3T[^(V]M.QZ;\/\ 7.*)!/\
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A]=O#+[<%K_YL K_RP_\ _+@1TO5?[_\ ^U>=_P#C,?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g551455g19a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g19a20.jpg
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M 0$! 0$! 0$! 0'_P  1" %4 ET# 1$  A$! Q$!_\0 '@   @$$ P$
M         P0% @8'"  !"0K_Q !@$  ! P,!! @#! D" P(%#@\! @,$!081
M  <2(3$($S)!<8&QP10B40EA<K(5%B,S0D-2@O"1H1<DT1C"&2=BTN$E-#E5
M6'.2DYBWP]/7\28U.$5&1U=G='=XE**VQ/_$ !X!  $$ P$! 0
M  ,  0($!08'" D*_\0 8Q$  @$"! (( P4& P,%"P(7 0(#!!$ !2$Q!A(3
M,D%1<8&QP0<B80@4<I&A%2,S0M'P-%+A%B2"%V*RPO$8)35#1%1SDI.4TE-6
M=(.ST]0))C958V1UHL-%9865I;2UU>7_V@ , P$  A$#$0 _ /EWU[ QA\%1
MR/C[#2PL5Z6%BI':'GZ'4DZP\_0XB_5/EZC!M&P'!3V/)/MI8B_5/EZC M+
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MGD/ >FIMLGA[#%:3L\_;%+7/S3ZG61D[//VQ3Q-*Y'P/IJ"[CQ'KAFV/@?3
M-6%W'B/7 5W'B/7!V>8\3Z:-VGP'JV'?K'R]!AY'(^/L-/B.#'L)\?\ KJS'
MNOA[8A4?P5_'[/B2;_=M_@3^4:@.LW_#Z8HKL/ >F&F.:O >NI]A\1Z-B+[#
MQ]CAUOO\O?1$V/C[# ^P>)]%QV?WB/%/YM&79_#V. ON/#W.)-O]TK\7_FZA
MBF_\4>'L<=IYCQ'KHJ;'Q]A@+]<>/_5.)-K]VGS_ #'4\1&WFWJ<2+?83X:"
M_6/EZ##X.WW^7OHJ[#P'I@:]=O/U&'3R3X>YT^)+V?A7WP?2Q3'\OXC_ -7%
M2.T//T.EBZVQ\#Z8:':1^$>AT0]5_P 1]1BF=U_!['#4?]\C^[\JM#Q##_\
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M!X\N_&-%38^/],5IE)8&VG+OX$WP75E.J//U. 8;C<QX*]=.-V\?88J3=<^
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MPW&YCP5ZZ*A)!)[_ &&*DW7/@,'7VCY>@U+ L.#^'\)_[NEB#[#Q]CAE/(>
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MAH+]8^7H,/@[??Y>^BKL/ >F!KUV\_48=/)/A[G3XDO9^%??!]+%,?R_B/\
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M1UZ=*]K6/^\*8Z@FVQ>5P#KRFY!P/<71SNJCH<=M^9$N2*C>4&<)IM3"<E1
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MS2PL<TL+'1( ))  !)).  .)))X  <23RTZJSLJ(I9F(554%F9F-@J@7)))
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MZ@.NWA_3!FZB^7H<,:@_6/EZ# \'3R'@/34<+#:2G>&<@#&?'//_ #O^[4B
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M<J@;]_T[\4RQ/;_>O]<23797Q]/IX:1).Y)\<,Q-CJ= ;7UQ6%*)''O'</\
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M) 4;,<UG1C1T$3$V+D6,U3( PIZ2-A),P)9HH4EFC7 GP_SWC[-!0Y7%T-)
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M"LQ W;F([!L<;SDWV!^)I:Y5XAXMHHJ%HB>@X>HWJ<RZ4DV?GS'GIU@&BE0
MWRL1V#%;NQ"Y&U+,:7 6RG>QU_7L.J 5@$H(6E2R",EL[O#A@ C6:RS[4_#$
ML"',<DKZ.JY 9($J!4A=-2'Y38$W'+?Y;7OK?&%SK[!7'\%5(N2\3\/UV7\]
MH9:R',*:LC'-;H:I(2L73H "YC^0\P"C0X(-B]RH(0M^)UG!0;2'$@H*<E65
MMDYSPXCO [N!5^U1P<9&4Y+GS(&MTL*TS1&]M 9'1]#HUQ8$::&^*K?8,^)/
M(';/.&A,0"8E.8J--!NK6N!<G6Y.P-A@;FR:Z&4J*%T];;0.4ID)+A.3E"_V
M6 L9)QDC&,G(U?3[4OPYYHDJ$SFF+'5)*#I&2Y.C-%SH;BS?*=B%/S XQ<OV
M$?C'^^:DEX?JHUZCBL" C2Y"RE918W'SJ.\:$$HN[/;H8;<D"G=:EI!+B(\H
M.OA)W3O!@[B,#F4I.0.2>&MKR?[0/PWSBJ6EBS=Z1YB#&U;&85U^A8LHL>T"
MV-&XE^QU\=>&\MGS:HX7I,RI:6]SDV=-75#@?S/0K*4B<@&\84$'38G%NJCR
MV%E$EK<P0D)>ZYE0QR!^3 41S!(P>[AC75Z#.LKS50<OS*BK@PNAI:N,DJ5N
M"P6S!B""0>V][''G'-.'>(LE8C.LDDRDJQ1UKJ3-(V1U-F5B 4++KS<ORA@>
M4E=,,  *  P,#AS_ (<\^_QUF1L/^W]>W&'ET0E;"Y&JW /A?YK=P;6V^N&T
M I&"<_?_ )_G'3D@DVT&,:H(Y=;CFT_2_P"9U\2<$1VAY^ATV+S;'P/IAH=I
M'X1Z'1#U7_$?48IG=?P>QPU'_?(_N_*K0\0Q>]IWC7[+J@J5"FJ845-B5$<W
MG(,]E(4>HF1MY*748*@AQ)0^R5%<=YI9WM1'6;R],87/,FR_.J,TU? ) #>*
M9;+/3N=.>&6Q*'0<RD-&]@)$=1;&^>SS:71=H$$JC$0:S&;2JHT=UP*=:XA)
MD15D)^+A*60D/)2E;*E(1(;:4MHN2QY]XBX9K>'YQT@,]%*Q%-6HMD?<B.9;
MGH9P 3R$E7 +1LX5^7)&EC6\<TL+'-+"QS2PL+S(D:?%D0IC*)$64RMB0PX,
MH=:<24K0H<^(/ @A23A22% $+!8)YJ::*HIY&BGA=9(I$-F1T-U8'Z'L-P1<
M$$$C&D5]6A(LVMNP#ONT^1O2:5*4,EZ*I9'5.* "3)BJ/5/@ ;W[-\(0A]"=
M 86/T[,>CN%\\AS[*XZ@!%JH3T-;"/\ Q<UKAU!);H9E^>(DFWS1EF:-SBTT
M9PG' _\ 4G03<N0#:_;Y8V0V U%P.RWEAI2DM-I4I.]G X8SD@GO\-$ ! -@
M=!J1J=.W%)F/,UB0+FPOV7P%E1=<#8SDKR/INCC@\\#'/SQQQJ,A6)&8VLJ@
MFXWN!OW[C^]K5)!)6RK"A(+ORFUQ8@:6U_N^+BBQ"4@J63@\N_Z#(QR[AGZG
MZYUAY:L*3L/S[;[;=IWWOO?&XPY;(P"'F[!8[Z:?6QN3X:ZG EX+BP,?(H(^
M[>3P5CESQQ_WSK(07Z)+ZF50X/;;Q[O, Z?3&MYCR_?9[:)0%Z61!HC2D6#,
MNQ<$@\Q!8'MP_%_=J_&?RIT5_P"+'C&#^!)_Q?\ 1&'?Y?\ G]6F;<^)]<6%
M_P /^7JN#(YI_"G\@U!^J?+U&!'?R7T&"HY+\3ZITE[/PK[X)#UQX'$JUV!Y
M>@TR;'Q]A@$_7'X1ZG!T<SX>XT+$L%U)?YOPGVP.3L\_;$HWW^7OJ.&?<>'N
M<--=WXA[:9MCX'TQ##6@86'H_91_=ZJTL33<^'N,-:6"X^7_ %Q?'N#!4<CX
M^PTL+%>EA8J1VAY^AU).L//T.(OU3Y>HP;1L!P4]CR3[:6(OU3Y>HP+2P'#&
MEA8*CD?'V&BIL?'V&%BO4\+!D=D>?J=%38^/L,!?K'R]!AL\_)/H-0?K'R]!
MBL=_)?08"3A9)Y<CCPQ_]XU/EN.S55UMKI_=L3"W V[-?S_J!Y?3&?ME2DU.
MF2H:CO.0)"2E)X$,2 5H/?E/6!U/T!&<#.M$XIO355/(I(##F:UQXDB]C?Z_
M4[8WOA9NGI9X39C&S*+_ #$"PM:^@-NP; VU[+_N2UEU"BU%EIK+PBN/QP!Q
MZ^..N:W>&?F4@)(R,[P23DX&)RO-_NU<"Q-B3VFP!.HT.VHT^G9>^,IF>4-5
MY3,OU/*3N"+B^EAY>/=KK&%<"",82>9X_3!^_P!]=;4\RAAV@'\QCD;#ENI[
M 1^6F+NL6TYMZ7#"HD8J0VZLO3Y0&\(=/9*3)D$'@5 %+3"20ER2ZTV2D+R-
M7XYXLHN"N'*_/*H))+&@@R^E)L:S,9@PIJ<6((6X::H9?F2FAFD4,RA3HOQ
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M;^!E9(QNC1U56AN5%[G4J#J2=23OMW6^M\.9WB/*68FX^8L2=0#N3L 0/S
M&*C<%*<96XEI);6"XPD-HWMT)WG'%I05$*;2D%0)/5IWP>(!T(-95',R@7L
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MB68L>;E-Q>X&YQC.K;$9T)E3M-J3C_R]:VV\WNA:%I4I"0I* O?4,$+(*,'
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M[W^9B;@M_F.Q)/:._::2D)2 ,< !P&...>@JW-(OC_7_ $P[KRPN/^;K]2%
M)\[8-_+_ ,_JT1MSXGUP1?\ #_EZK@R.:?PI_(-0?JGR]1@1W\E]!@J.2_$^
MJ=)>S\*^^"0]<>!Q*M=@>7H-,FQ\?88!/UQ^$>IP=',^'N-"Q+!=27^;\)]L
M#D[//VQ*-]_E[ZCAGW'A[G#37=^(>VF;8^!],0PUH&%AZ/V4?W>JM+$TW/A[
MC#6E@N/E_P!<7Q[@P5'(^/L-+"Q7I86*D=H>?H=23K#S]#B+]4^7J,&T; <%
M/8\D^VEB+]4^7J,"TL!PQI86"HY'Q]AHJ;'Q]AA8KU/"P9'9'GZG14V/C[#
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MCFWC<![_ "XP)=.R:;2U.RJ"OXV%U7Q"&7 $STL@;RDMO!81)6D$806VUDG
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M*FGFR0%MK4 0<$1DUY;'8F_]#BK74%+F5'4459$):>>/D<;,IN"DB-8\LD;
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MD<=+N^NV.)5G#&?T-S4955\BWO)#']ZB ':TE,944?5B/SQ>B5)4D*2H*2H
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M-F70@VHM&!T(.HV.&_VHS4;M$.W:;;O_ (V%?_#5;7?_ '''V=/_ ,F.3_\
M:#I_^27AS_S[/O\ W^#_ .PL-_M/F??#_P"K+_\ 7L=?^&HVM_\ N-_LZ/\
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M=91E,#%6JIRP5;W+,Q9MK7UN?,[Z'&$SNKI\ERG/:^H0$9+0QU47-IRAX@X
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ME9)E2N+I/G4\:TN41,"#\DF:3TJ2\P_AEB 388^@H         #  '   <
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MR/C[#2PL5Z6%BI':'GZ'4DZP\_0XB_5/EZC!M&P'!3V/)/MI8B_5/EZC M+
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MHVE:$M8B9 Q:-MU=>36X([-=1X8V/II8J22IIG6.5E5?O++SBF4,&:4PCYI
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MBIL?'V&%BO4\+!D=D>?J=%38^/L,!?K'R]!AL\_)/H-0?K'R]!BL=_)?08X
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MK<Z?0:V]<< =0[UF_O$J459P1G''A_ID$<\DYT4.">W734#M_O??%>_;_?\
M?ICH**2 5 ;RLC!Y+/#!X=W XX@#CD8.IWVT&GT_N_\ =[]JQ+09*D*6VI7
M]H@9)4 !C>R, YX8SR''O,@!8 [FX\^PBWY=V]NV[DZ$FPM;7QOIW?D/UWO2
MG3PA;8WB0K!3]5$8WE# [25<.)[\\N&F'RDW\".W^_K?U%XAM1:]Q8Z]FNH/
MIIWXW(V3;0YZ)$=I]QS=8"-UYLNB2TA6ZA2BIK>("0-U:D8X'Y^9Q7DA;5]
M!<D:\P -]+C?N\-\;1E]5$0D$P8QL"&L >RUEN1K<C?< D"XUW"NZD1[WMM,
MM*D*34HX:>?*@^&)+#A;8>#I'690\DD$CB@I//).S<'<657!?$F1\34;2,:&
MKZ.>G4$K44]0O031R ,O, C,P#-8, 2 1C5OB%\.LL^*W _$7 .<K9LVHZIJ
M"K"J4HJNGB,^55 F8,T<\58D;(%1^<@*38WQHQ-A/4V9,ICPR]!EOQ77/E!<
M>9<4VM6ZE2ANJ"4+0>'RKX@<A]9<HS*#-LKH,UA4JF84L55&A #)%*O,B$ L
M!RGF%@S:]IWQ^<?B7AZMX5XASOABK:5YL@S.KRJMDF3E>?-*25DK:ENWGG4T
M[%2H( !.^%TJ"<YSQQ[ZR>,%;>Y L;=OL,1-P,B12W5I!*HSC;X YX!+:\_<
M$.E1_#GD-:YQ13]-E;.!=J:5)@?^:28W'A9^8C_F7[,>E?LJ<1-D?Q5HZ!Y0
MM)Q1EF89-(";)]YBC&:43D$?Q#-0-2Q'>]4R[.<8[US+'U*QS2PL<TL+'-+"
MQFBS%I?I,0C 6TIQM9'/]DXH('+@0T4^>>0(UTW()S/E-/KS/$)(#KMT;MR#
MRC9+?V<?)?[2N21Y%\8^)_E*4V<#+\]@ &K',**(5C;6//F4-<;@W-['4'&0
MV"&\[W?].([M92_RV^M_TQPPJ2U]+7'Z6PVQVQ^)'KJ3[CP]S@:[CQ'KB2U7
MCZZ^.)R_PG_"<$_E_P"?U:,VY\3ZXDO^'_+U7!D<T_A3^0:@_5/EZC COY+Z
M#!4<E^)]4Z2]GX5]\$AZX\#B5:[ \O0:9-CX^PP"?KC\(]3@Z.9\/<:%B6"Z
MDO\ -^$^V!R=GG[8E&^_R]]1PS[CP]SAIKN_$/;3-L? ^F(8:T#"P]'[*/[O
M56EB:;GP]QAK2P7'R_ZXOCW!@J.1\?8:6%BO2PL5([0\_0ZDG6'GZ'$7ZI\O
M48-HV X*>QY)]M+$7ZI\O48%I8#AC2PL%1R/C[#14V/C[#"Q7J>%@R.R//U.
MBIL?'V& OUCY>@PV>?DGT&H/UCY>@Q6._DOH,5(YGP]QITW/A[C$3NOC[''2
MVRH*Y<>.#],Y^FB2CG0*#8CM/EB)< C?0GT(TQ]$W1#HR:#T;MD\()".OMUZ
ML$8QE5P5>I5XJ/UWOTD"">[ Y :ZQP]%T.2T"6&L)E-A:YFD>6_UZ^_;CYN?
M&&N.8?$OBZ<DMT>8I1"_8,NHZ;+[=NWW:Q^MSC=/9;:K5WWK1*;*2F5 9J-,
MG56DL5"G0:Y7:.S5H#=7I%J,U23#C5>Z)%.>DN4>AMR$S:J\RJ+ :DS%,QGG
MSVO;+LLJIXR8YFAGBIZAH9I:6DJ6IYC3U->U.DCT] DRH*FJ9.BIU8/,T<8:
M1=3X:RQ,VSBCII5$L"ST\U52I/3P5M;2)50+5TF5I4RPQU>9R4[R-2422=-5
M.AC@624I&^0ND;=<6XKMIT2-4/CI='@3D71\.]M253$W?(K=2;EJB1]L-7JE
M[,2F+8A6C1:M^D400B?17(,2.]3X$&9(P_!E ]'E\TCP]%'4S1&AYUR(3G+D
MI8&C$C\.4\&6/&U=+F-33]"928:E99'6:66-,_\ $',XJ_-:>*.<32TE/,N9
MB-^)S3#-I*VI64Q)Q;55.<I*F6PY31U7WA8 )Z-H(HWIX(9I->M;AC0L?,;M
M/N=5[;4MH%V%PN-UZ\;BJ,8D[P3 D5.4NGM)/>VQ!$=AO.?D;3DGGKBM54BK
MKZR87M-4RNIW 0NW(-]0$L!X8^H/"V5C)>%>'LG"\CY?DV6TTNEKSQTD0J'(
M_P TDYD=M!\S'3$"@X2D8Y$*_P#1HZ_*@^@M^ML9I2%#@WN1;3Q\1B&FNI4H
MH^88'/ZDC=  &23D\/OU0JI% <L;*JEC]18Z#7<FWY7PBIY96%B51F"]K$.H
MY1]3?37:^N/?'9I1X]A]'C9A;C,1F!+=M:DU&J?#'YS5:HV:A(D2$E *WW!*
M4M>0K&X$DGJSCP+QYF<V:\29Q(6+"&IDBA+$V6+F)Y-+@':UA:P'TQ]9_@7P
MW'DG!^24YC'23T-)65+QJ %>HB1T)N 38,5)U%V%M,9,V1V8]=5Y0(C=7I<5
M45$JH(:KE39IE.$MIH?#Q'9TPHB,OOJW$L*DK9C]:$=8\U@*%;A2@-14P.(^
M9(6YW-MPWRW[M#<ZG7ZC3 /M%<7'A[@'-*6&5HI\T84*("HDY058LMC<*RDV
MUOZ8V"NZR[LM)]M%RT*H4I$D%V'-?:2]3:BR5',BF5>,M^EU1@D$ID4^;)9<
MXA#A6"@==FD02'D(*V4<BC6,@=HV /CI8_3'SMI*;[OT=.K<R)''/SFYYFJ.
M8L+_ .8<H)[+G>VHQT\TMPK5G>!44H2L;I*1R'#(\2._/TT L6[+6T']<;!3
MBW*#K>WAV?T_7"JXB\)<<W!NYW1G&]G!.,)!X< %8Y^6H%@#:V,N%N+74;=_
M=J!I87%P-;[Z8"6T! 44(^90)2""D$<_X?\ ,Z<$&^XMIKWX?HR;6.^NG=<7
M[+ZW[\"4VG.\&^"22 .R2>? \R 0HXSCC]^7P)WZ-BMB;:Z7UOKH2>RXO8=Y
MTQ4[$W&NL^4=8E6XD+!/, Y0#\O<<G&<=YSI[_W[^?\ ?9AT?G8C;6POY6U_
M7;;&4=C-APKLN-4ZNC>MR@)1+F-I*&ESY[A4FETUEU92E2Y$M(=?0DJ<,9EP
M(0IQQL*R.64@GJ%F9T6%-)$;F#-8'FMI;<:7(^MK XQ'$==-1T/0P$2U#H"G
M(1=;V 5N:QT!UM?73LQNG;"*97KF@0*G;5,GVE)E3(,$J7%P\U$@/QG5&')4
M$,4R$ZV]+CKD,&3)6VN2'5==E&S Q3RD2#DA6X"GM"[:?46:Q)&^PQS]Z=Z.
MF^\P3<U5)^\<&Y(D< N-!V,6!M<GN[,:TQK>H=.<VCLRZ;;E6MFEU1VITE G
MQ"TYATK:;;JB6G6''V6U;K$)AJ4^2DEYE#6\#@5C@4/+);H@#:,&[:7(M>P/
M9?47MV8WB2KK)_\ 9Q8Y:E9>C85MB &8WY;_ # VN;D$"VPQB:E5F_JS#FP-
MGE,EO4J,_)6M#Z8,F8V]-CNE1CA8BMLK;AM*#:(S9)6A:\..+2!16>L<-]R1
M A6S<PUM:U@1VD;7/TVUQGJK+\II*JF&=U#&=@)HVB)Z-61@R\W, QL;7LIT
M.FF^*[4MVL5>M-HBTUU[X!Q3M4<D+3&A0T-+'6*E2'2AID(/RD*.^7 0A"UY
M Q,E'55+2@C[N]B'=C\@!_F)6YY;=ECL.W&8S;,LG7+5CBJ4J"Z%8XT5R][6
M4:J%O?MT.G?C8J;5;8I+*7'+DISTI+:/^59A3%@E/RJ0B46PT^@.("-[=;;)
M0K=400=5'R'[HRR_>8I68W(7I-=.]E&U]^VV.4_L;/*R69FRZI2CE(Y)F:+J
M@W4A><L;D 6 N 0=KG%DW34Z)6MG]X1E,4YNY9M_[-9=$*(W635V_3+?VKQ[
MA6Q.1'*8L150JUIJE0?B&U2G?@W0S)%.4['.L8C[-.1P;'M)3EWM>WS'ZVUM
M?'2^&::?+Q'')\B]#,&YC90Y>F*<RWZQ5);&UAJ- ;G6FH..16U0G8D9)#H5
M\6D.B003NA"EAPH4A0*BD%L9[E$:HRS.L9@)-N=9 1IJ+@'LUUT(_/&Y] ))
MA.IA>Z<C(02;$@DV([+"^N][7UQ>^Q0NM7M4]TE3:]G^U#>*\DC=V?W'E*,Y
MP#WCD<<>[5"HD<Q.2S,Q4J"3L#MJ2=K=@U\\9F&..-8FY JQU5"_*EKLWWJ,
M<K[ K;;4F^NG9IA*?=DK98<>D24,)*VF&W'UJ84!OJ##22=U1"1DMA/T)QK5
MF:HDDCIE+L>?F'+<CD4@R ]Q9;6MI<"Y QW^D6BHI:R9J'*Z=GGF5JMAR /)
M!$(&F8H-(VN;V8BYL-L$VD6E35-6Y<]!,F/;]Q,-Q93+R7TJI%>B1XHJS.)&
MXE;3J'6IL=Q*OE+BV%+ZQL%5[.<O6&*CJZ92D%2&C6!QRRQR1E%=G '(0Y8%
M2I)-M0- "<&YY4.,YRS,4IOOF6S)+35U+(DE+F$%0)G I^6\BM#T2JW2HA+.
M"MU!(P[4Z NESGX+KBEN,.8*5CJU'>"5HRV21E2%)40E2Q\W,G(UK<ZF-WA8
M&XMJ-0;B_:-/ @7WMKKT++ZO[U"*DH0 K1\NG,6!N6TTY3>W@-A:^-Z.C/*H
ME+MUARF+C"M1:A\=,:DQH[SB93#_ %K"@TZV\'HZ5A"BA;90L@MK"T+.M4S5
MJF.9.A4A4"/SCJ<UVOH=R+#0@@]M\<0^(D>9BN9KRFG:!!="RJ%9I 5O<$-R
MG4K;L-^[:C[2C;S=G30I]J7MM$B6M0JWLIMN31*,FVH4JG193E3E,S:O+F&H
MU"IS'G9[T1E+,1,IN%"0VGX6.''9;[V4'$E9F<\73)"#&H3E@5@&)MSL>=F-
MV-K $ #86))UKX34\/"M74TM$U140YE-')+TC!V5XU9$4 +$@"<[78*7:_S-
M8*!XBK;;WEK5DODI4E*2$)_9G"TKR,@X^8%)X#.,\-9;5OG92&-CR[6M8=_:
M!>]]CWX]+L:@&S,@) .QOJ P_ET(YN_S.&X4FG;Y#K4MMT)<ZMYAP!2=Y)"0
MH;NZ\UD_M&\I*AD @J.;,#QDA6O<=BG7?L.WY7^MNS#5J5<JR%8T8(6%W%P=
MQ8:;&WMV8VSV(W%-I];:6E^75:(N/(IZ=Q3)3'1/WZ;'^)0Y%>1'<5-+. ^V
M&WXTI;&^C'6:VSA^ODI9^AOTD3D$*^H OL;DZA; ZG7'#/B!D5#5T3S2T\%)
M7 L4Z(,DLIN/G'(-VWU.E[_3&'^E%LF;LVMTFZ[=9;A6M>OQ1E16$-_"TFYX
M:UHJL%MM"4EF%(6#*IPW6D*;2Z&4=4VEMK!\4Y,,OJ:6NIXFCAK9).92-8B3
M<E[?+RF]UL2;;VQOOP=XSFSG+,RX=KY5FS3*4BZ-223-0*O(*J(L>;HXPJK+
MS<IYKV4C7&H#K+I*1E.XA1 4 0 >1"@<G(X<QK5NC[C?L&AU/9^?9X''7RP(
MM;?3374^9]3XZ&PU)"#NJ2259()&,$]X*2,I(QW?4YXG2Z,@C4'M_73\]_ ]
MN!6L?J.VVO=],4EL_*K=R.)Y?0G)R<9(R,_=Q/,Z);\N_P#7\[:V!\\*QO>^
MEM1;Q_[=.S?Z'8XK!S@ '& 5<,$\ .7$'EX_72.I) -[DZ;[Z>?Z89A<$ J/
MJS!%':;LQ 'GN=!J1BZJ:ZO@D85A0ZM &5*)X*X=Y XC\6!S +L2=51B=-!;
M7ZZV'ZF^@P"0 ?\ C +:F34Q:;@R@<ESLHO<W%@;&VYFS+9)M-:@P+RJ,"/9
M-GN-K4W<%]5&!:--J+ /S_H-FM+C5*Y2M0P4V_!JB67"E$A3!5@'Z!GB-[(2
MI Y[@';NU-["X /Y7Q0CXEHH:N*G1I*J?I%5D@3FY%Y@"[,;(%%UTYN8@@J#
M;&X&S"IHJ=&J])?6XTIJ,W+8:<.\7"%+<=6T 0E&YO,K"TDI*58&0#JB\?1P
M.O*'= TBV[&%R">8[7[AWVV-ND&='2AJ%EEC5ZRED*Q$=*[0NLBI<E5 +=<$
MV T .QUJVET%RDW"Y.&1&K:G):2M8WD2VTH1)04\"E*PE#K>,I*22DD8U]%_
ML[<9#BC@>GH)@[5^0I#35#DJ5>*:2H^[A/G+_((G#%E&Z@#'Q6^W)\)ZCX??
M&#,,^4+%E'Q!J\QS^F+-S%,QBAR\YFK<EU42&HIV0+>[<Y/+>V,;@A6"#P(5
M_L0./L=>A0"I92;D6-_$?7'B+F62))%(^8L+=HY21KX[C%+Z ['D,G(#K+J"
MH?PA2"G./NSG_,:KUL J:2I@(N98)8P/J\;*/R)![-;8V+@O/7X;XQX6SQ"5
M&4Y]E.8R,#8=#2U\$LZO_P R2%7C<;%&8'?&*]<8Q]N]]L<TL+&Y%TVKT>H5
M.NK9U3XC,*XK6V/VKM H&V=6T$34WQ?51M:T+MK5GOVL?_P>%#J+=P5>W+8H
MM$9B7O0:M38$NZ:K4Q&K](8UZ"?-F>"K=BT,^83TDN7?="OW:F2:H@CJ!/I-
MTB&%)IY92U-*CLL$<?-%(=9IZC.'>GK'<O#49C/2399]SY#24J3U%/'4=/\
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MZVE:(#Q11Z<A@;$J%*V[3<K<]NUA?OTQDUHS+60N_+98*D-8A26>2E92$W(
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M$J-<-JSD1OVD;XN?1GGDPG\)5+73JBB#4T-LMAR&E+P4+^6JD]5&2Q40M9U
MZW?N1;?L!&O?C&Y]7]#ETT$:VEJ$-CSV,=^XA?FM;4V&Q[CC=2[Z!19TF%=5
M1>33X5,H3\FB4JNOP8=.%QR8P9ASW8;CI=;D0T/J=C,O-E$&5+ZYY#;X5'&R
MYBB<G32@&)=8XKZ.E[KK8VN#;8Z6M?&BY%45+1/20Q!IP2KS7-^<=9BMOIMS
M#O'U\V-O&T(5V]5H4&7*!2T+@QX%/ %/>*BM4J6A;H_:./2D)1UV$H<89"H^
MZA:1K2JRK,KE@G(@T$8.G+L-;=VEK=FVQQV'AC+!3Y<[3OSS.;FZ@68[V-];
M$D=E_';$=JHH54J#N]3VFE9<<0@A2]Y/RE "=]1405$ J.$@)3QQDX;,'D%N
MC&A%R">:]S]0;?0=UR/K/B>2OI<L44<[\]QS634+_,="=+;7[1H<7Y<<6 [2
MY3#_ %;+0;!0HD!*7 A9;*?F !!"@0D $$:Q*S3ET# D%E!!.A4L+WN-CKN+
MV)-M1C2^'VJ8JV.H@#EI98UG8Z!XV=1(I%C8,A(^A.E[8U_I-SUZU)ST^COH
M2\6GH[BGFNN:+3PPI6ZK="5A6%M.9WD'EG6<I:RIHV8J#RF_+=M%^H(O>VP&
MGUWQUVORBBSNDBCS",,E@%CY1IM8<QMH+=H&ITOMBW'G5UZH=8%,MR9;Y)'%
M"5ON!:E.'/RH"UY*@#Q4K*1Q. R3O.SLYNS?S#2W;];D_D+W/US-+2I1420J
M.DCIE40 @#HUZMKW).A(]1H,7I2ZBNE[,+XMF31ZM(-2VE;*JP:W'A==;]/%
M"MK;#$--JM1#J3&J]6%=,NAPPR[\?"HEP/\ 6M&F;CX+$$7)OKOW7\/SV/E;
M$@JR5<$O,B!::K3D)_>MSR49YE2UBB='RR&]E:2,6//<8IK49#ZW764*#;JO
MV3@&Z &-\DIP3Q5UB2L9!&,D<>$7VTTUU-K7^NHM^8N-^W&2@^63Y9+7!%R"
M=#V$7%[]G=;MM?&3]@55D?K;4*9)4Y(CJL'::@L+5NC=38E?*"V5 X*2,9QV
M5'/#.:E00(R3^M_[O^N]L7*BE3HHV0@L9Z=V?Z)*LMK7_F*@;Z;VO;&FU7M>
MMKC.R68+YB-A2''^J5N(1S/S#@KY58RG@<\#C6HU4\2/8/=CS C:U^\"YVU[
M ,=XH\RH1,B/4*KU"Q3\H(8H715*:D7Y>4?,0"=2!IC%TJ,0VZM.\"RI3;C9
M*BDKY @*)*>.>0(X^&<8QUU[1<7M]-/KO^GY=#I^0I$R,&5E)!/=8'0 VUW^
MAV&A&(=,0OK3A 5UF$I3D E8 !3QYG@ ,G)/=IK"]_S [?+\^S4XR!)" C>P
MU)\/]?+7LUAW8I;F+94KX92"4J#R5-[BDJPI)!&4[I![6,C!Y')1MIKX?6^G
MY:^F(K^\'-M8V[]K'7\SW]FNF"O.H6VI(:"MW"2O 4-[!P0H'DKF%<,9X\\:
M5B;"_C]?&^WU![SW7Q%A8D7O]<6^I+C:RTG+2EG>"D)&\,G_ $Y<\'PXC3GQ
MMAL<ZQPC*G$JQA"@4X6L@'!SRX=_ <^!!XZDC%#?0_Z?W]/I; 7Y2KIR]8FY
MOM??2P_OO&)-,IU:A("3U^6624)'6(WUA&\"HY.$I2"<J.[A6\#\VK2$R.C7
MY" --[V'E;78:[CMQ@YZ=V^5%#J-"I/*K?4[V&M[$8]+>A_=5'D7C1*5#I4U
MV<_(C"I0E O0Y;4:72T/(8IS*US4S#2HSV:FO?95474J=;4TM2-="X4K*<U7
M(1T8Y;,">8-H1VA1KN>Z^/,_QBR?,?N#SU$]N5G-.J ,8!>ZA6#ZFUK648PS
MTE>B-(V;;7-H O>[+1V46*[6'JO;(N&I*J=U2*%5Q\?'_1^S^W&ZI=#:$J=+
M,=RKPZ)39"D]7&FR VLIT_B;+$I<YJA3S"*&)P( J K4(3=F!YAR  G_ #:W
MN==.G?#;CMLYX0X9DAIZFOS>F1Z2KII0R1FJ46999RK$<EN8VC8@6NJWOC "
MKNV$6$JFLV38-0VIUYF.M*[JVO+52K:C/-++;3],V:6U4U_LRIPE)N6[*PF4
M VMVFQ$J=C#"O*@90@!N  ][<H)L3;O&NY[-A>V-\;+>(LQ>>IJZP95"\;])
M39?+_O C(/.*>K*KT,Q4$1RB!C&Q!"M:V,?[0MK]_7E2'*'<5VSDT"(MXTZR
MZ%&AVM94%MXG_P!96I;T:F4)A0;"5*7\ M]U\)?>><=^=3/*P5@);-:P(%R+
M]VNMP3N?3"R[*Z>BG1X:6%I^8$UM6AK*QS8_/-43&TA(.O1K$3M?OP,MQIQ#
M*FFDMK:*MYX'YUK40XD$ !)2VG(WB!O9P1C5;<7:[-V.3;6VHM<[B_;O;&UQ
MNZD&0HZVL8T3HD-P;'E!8?*=1O8V[<,LK;+2U*4KXE3R"WNGY%-G?ZW(^H6&
MR!QSO'O'&2ZVOJ#?TL=SJ>_0C4D'?"<\S!_$#6Y&_P!;^=A_6[Z(]^T:4K
MW 205A6]S5C'(=_'''/#4"MVL=/F-M/']-OS'9AE:Q! N1^O=X=WI;&\6R=2
M9-%I0BE1G,/K;6B.VIMX!96MH-X4 Z-U.5;I.#P(WLZBZ\O-;MM;LV\R !KW
M6[.S&PY3S23NI8@&(L+F]K:Z"_:=M >WL-L\;7P_5[1E.AEWKX=,I#DE;K2V
M773">9^(44+5NG!"DI<2?G2D*&0<#K/P&S"#+_BOPPTY(%6*VAC4FRF2IB3E
M)-CL5T%OFYB=-L>?_M@9)4<0_9OX^6 <KT(RW- U@[Q-E6;4DO-&+K<RPM-
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M)P!Q4<9'$YSC/?P\]?5=D)L6[!RZ?\W2YT[?[.V/SW=+^\94+%7=YF:34AI
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MM"2%2X'P4TI0-Q]/+5:VNH[?[WVO??;RQ8:F1C8%TN0+(0 >S46.]]+;B^^
M5JY-E%X5!F/4J!7=F%<=+T<U:U6EW+:$AI>"M$FV*E(8J]*;)"BY+I=<JK+:
M2&V*,A "RK$7TO<;6.G?>_UMJ!I;\[*4M53Q$+R%8UYKL"6)0$W'S"^P.H'T
M!PY5=D=5=9?D66:)M&I++2G9DZSY:9E2I4<#K2_5[7DHA753VVU%"%2ET==/
M+B%MM3G0G)8L+-S74=UK7%C:W;;MM]2>ZXDG=V7I"RMI:Y^6_9S=O*#J1?8W
MOL,:_5Z(PX'75*=1-@(91(RRMOK'L;JE("TI+:Q@I6V1G"4D#CQ$QB.JD\P
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M]'$MB"P#V.X1Q=/K?0Z]N(MQ6?DWE!!XN)'#"#R!)X*X\>.1QT"3<=UOUO\
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MJRKT]. ZS RHH)-@]V O<FP! \1VG'/^'<QERSEI*Z0K-%6/2](R@<RQ.8P
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M4\(I:"ERI;CRHS#:G%GJ8RCU+0620A.$@?*!M?$W$>7T6:5=:\B12K,6@"D
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MO$X0,?*,ZXGSLQU-];B_83W7V]!CW$L:*&"J%#$$@;$C8GO(MA-N4M"7DM!
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M%7[)Y.O(''O!:-/F643JO.C"2DJF13,T0<3T[+);F'2H%20(;!C(A[0?K?\
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M8#8@:'?2V.'\)\"Y]4YO#2/EC4M12<J?>7D/*+68-:]K7()6_;XG&PS]?9N
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M0<'FZNX&NMS?M%QMX'LTQE4F8. 0PT!!L=>S^FGY:Z81*5EU.4%81E6$Y25
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M83V4%/GCXI<$B,KG66QNIO.U:Z*2M_W9A#%1IUI@O-8[_6WM_P"S'\6WGG'
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M!!#&H^5(HHU6.-!V*H"@$Z8I$-.>)!'@/^FB]$K:::=M^[M[1^F"/RD'LO\
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MSX>XPUI8+CY?]<7Q[@P5'(^/L-+"Q7I86*D=H>?H=23K#S]#B+]4^7J,&T;
M<%/8\D^VEB+]4^7J,"TL!PQI86"HY'Q]AHJ;'Q]AA8KU/"P9'9'GZG14V/C[
M# 7ZQ\O08;//R3Z#4'ZQ\O08K'?R7T&*D<SX>XTZ;GP]QB)W7Q]CAA',^'N-
M6TZH\_4X"VY\3ZX.E)4%;HRH 8X@>I _UTY[/U[>S\][;8;#G)/]OMI\,VQ\
M#Z8Z1R/C[#3KN/$>N*C==?+U.&05*;"%*4I"%**$%2BA)6$[Y2G.Z"O=3O$
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M(Y$=WT[N.<\/OU9L.[?? \5ELJ&1@8SPQQ)\M#:-3J1L.S3T_IA7MW>8!]<
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M4'23X\<?_LYUGAQ?G#$ <%YL;BX_W[+-N_\ C_WOMC4C!EXWS>E'_P!)J?\
MZUAMOH'=#Y[]W]K#T9E9_P#W0])$?=W[.QWZ.O$^?/HO!&;D]WW_ "L>M0,
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MU9500-.R]A?MMOOM^7;@*L8R>95T)L>8]_=8:[V()[;6Q<#49MM( Y<\<O\
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M>8[8_$CUU-]QX>YP!=QXCUQ):KQ]=?'$Y?X3_A."?R_\_JT9MSXGUQ)?\/\
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J1PS[CP]SAIKN_$/;3-L? ^F(8:T#"P]'[*/[O56EB:;GP]QAK2P7'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g551455g22a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g22a22.jpg
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MU@O)O<VU6FV>2VQ^5&J(UIU/:NQI0-=YY(::B,7ETJ9,=8P!!!8(.0=6&O\
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M$^2^_P"C/>17],1S]A#_ ,>WH:CR7V7^">H44 H!0"@% * 4 H!0"@% * 4
MH#,?&[AKQJXC?U(4X]ZO8P%]M^5][;,-YGY=+I+-)'A]79JZ-R><R"32%PR&
M6($,0H7 FF$"6($+"!S+ZYW\X5MO";V2PEY+]^?7S-.4(* 4 H!0"@% * 4!
M RI+!>,2-'-J^?8+ 3"6;$7E?$F\P4'N,,FH[*V"E\7SBU[HM,K)J7LXS3O;
M#*__ *WJV:^Y)?TRYO9[+F]O+Z]">M^5O^_S_P U"B@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4! QQ+%(>XPP:/F=KGI4K=$CE?)QGDM)S"V;M.]\
M$[_0O\U,GPO'X;VQ&.&F..:N-K*9B+EYK>7/[O\ L^:^F">H44 H!0"@% *
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M^L8/UMP?SYC%].YS,GM[=&T83POTE$Y(Y'3+D%K.&2H\.C^RBSQX",WA =Y
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MD *%7.;4GJ-U!I36>DY$*;S/:&KD,DW5_P"I,<+XAB;=@]S"I$7.+9DZ?O\
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MD\-O,N>^-EN]ML\]V^_&&)\#.1_.W:G5JTUKD3Q8B6HISU63V>S]\3\-+O\
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M+1H4F. $%(U,H@YO+A91=BK=OBVL]17$XE^'9[)IM-;YSY-8QN_R>#I3T_\
MCUN7BYQ<@FFM][Q)\@]D1Y]*7Q*>$GDF*8,QQZ1DC 2&"3<V+'9L>!0P6\;
M!)B6EWAMVT:8?-LS:)M![09D\O*27+9<MECR2Y\S:%""@% * 4 H!0%2[E_3
M##]^:_QY2AB?)??]&>\BOZ8CG["'_CV]#4>2^R_P3U"B@% * 4 H!0"@% *
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M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * B :*Z+)?!PD-14R+R%;'
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,OU1B;>%N^?5]&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g551455g23a23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g23a23.jpg
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MKJA?3APIL(2RE=/ J%BO&3R-..);QL'DA &\RR]"6E:%4>H,V:W5?[JS2-)
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M,I/NCX.Z&(LHX@A9&*3'&D<EE7]QACDXD('4L&"!BK,OT;8!#:)WHE0#*_\
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M3"&>Q.]1NHSM#365EZ>M4,P[;RK+;A9>4@KBT(U>7,5P5D*N?8)"O)542=I
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MRGY_@O\ P,E?]W_J.65Z!CZEKRT?=R,MCT#'U+7EH^[C&/0,?4M>6C[N,8]
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MT[3+$T89HG;;BDJR> 3?(B>(ZXI!:K3,Q$A"RM@-$TO!@JA20?# >.X>)_\
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M2O$ MNM11FEVRFV&E1#":(X^ $T1F^-5VHO'852A6,Z%BXO\W'I3A><0Q[#
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M2<OE]5/PK1%P8JCO)!$R(8U>1U>1V0KQE:0HBNTH<M'''$Q,<:(M^"[8Z\N
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MXNIM)RN5B/)(UU5M:TU7;"\+KQ&37ZC=;)9E5J\NC07J_P"BTJG3^GW+_?\
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M(2.)2.B/6$K8A3\MVL#VI$C&<_V>-1+LEJS+$M1;S*!3)>?TG4:?38RJO8B
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MBS%2DBN&XDDQF/4FT+*=\M'BQ4%POAE('?W/F\Z\<8QQC'&,RH/]]A_YJ/\
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MCE5N10DM$T8[FXRR'?(@E6UM@#HC0[WY\YG7CC&.,8XQCC&.,9N'<Z7XR/\
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M:5611S;2H^^2*-Z"ML\E'AMG8.\:'GP/)!/@>2/@G\2/I^&?N%J\8-^3[.@
M!_R)+LQ'J0N/%^3+D9FY?E)] PW\F2]DD1RZ_CL=<S/FY6I693_I(:61_P ^
M1VV IY.S;4<=+Y)\#@FA\#BNOS1H !\ #]P _'__ *?_ '/XY^D:S@-R(TMN
M&#1+AQVH<.2@:RF1%B,9=RQ%C/)8PXQ'9R^_EIAI26F\O.Y0E.7%]KN2$%3(
MY5B68<FTS'6V(WHDZ&R?)T-_&-#YT-_&]?3\,_D+60X:C#8Z$"@-XGRBN$0A
MC$5&"DY#S<TEA+##:<3YC<F0W*F8QZQ(1(>0ZXM+KF%&DD8[:1V/%4VSL3P4
M@JFR3[5*@JOP"!H>!@ #X 'DGP /)^3^\_4Y^".K11<8@(6'5\H&:]5]$((B
M8TT8WZBI"X7R($F.[%1ZFIMM47Y+6/5U-HRU\C*$YP261'[B2.DGGWH[*_N_
M.]P(;W;._/G?G!52-$ C\" 1X^/'QXS6-@:'%['KTNN%BYD-'F2H4QXA43I:
MKE771^%)C-2Y0MUE!8?Z-:VG@YI@D'D)]&M^ X]'BN,;5K4E65946*0J&4+/
M&LJ /\E0WE&V-AXRCCSI@"0:N@<<26'QY5BI\?N^1^P[!_#/[2NGZGZ^K]4K
M59%#6(%*A2X-=E$?6SAV&DFXX^9F.V,TY/.S"A^6_(G6 K,(/D#D^3)F$Y,J
M0^ZXI8MV+,DTLTK%K#!I574<;%=!!VHPL:I& %C15"QJ J   82-$5550 H(
M4GR1OR?<=L23LDD[).SFRR]6"9\)T;.&UZ:.?8A17A\L3&DPGHHU>71T9V*]
M'6PXQ <SER$RMO+<5><K82VKY^9++*C!TDD5P6(=796!8:8A@006'ACO9'SO
M+<5T1Q&B "-#1 ^ 1^ ^GX9KM,T0$HI"\F LF2\8V-;7[G;"I<B0*S9Q3(L6
M!'PXSDM:T# 0&OA1(4$"'-Q1@Z'#RZB.LA-)39NL]J6RM=).(CJPB"%$0(JI
MS>5F('EY))9'DDD8EV9M$\515JJ*A<C>W;DQ)V2=!1^X!0  /  _$DG&UC4Y
M3H$TK$IC&$[$VHW\Z7/GRULBTM9S^3\F<HSG'^S..WY^<Y^?X+_P,LOU_83_
M ,[_ /G+$[G2_&1_W'/NY&3CN=+\9'_<<^[C&.YTOQD?]QS[N,8[G2_&1_W'
M/NXQGX<I3[J?D.R(CB/E(5\AQI:T_*;6EQ"ODJ3G'RD+2E:,]G:E:4JQV9QC
M/)!(\@D'SY'CY\'_ -QX.,BR&L!Q:>"*$X@8@2JY"25KD^7!3(F B<T02K\R
M<*D.-J=@RI0,P5$R'HZFUO#R$N*YE33ZTYLLDB+(B.RI,H2558A9$5UD57 .
MF D1' .P&52/(&00"02 2IVI(\@D%21^!T2/W$C);--E9^;,N-G'9G'9E#F?
MFS\V<?/C\F<?-GZ>4R<_":0ZA+2$/0TH8[,,(2RI*6<);4TG#2<)QAOL:4IO
M'R,)[&U*1C_1SG&9V?)V=GY\_/G?G\?/G]^,B\ZN&J.1[/F&%S8H@F6!BG,P
M$9*Q@A";"(SQ+$[+?K#(^;/'#YLN(VXEB1*@PWWD+<C,J1;NR=LQ<V[1<2&/
MD>!D5617*_!959E!/D!F \$Y&AOEH<M:WKSK>R-_@2 2/KH;^!DQW.E^,C_N
M.?=RF3CN=+\9'_<<^[C&.YTOQD?]QS[N,8[G2_&1_P!QS[N,9[1ZG*9D,/9E
ML9PT\TYG&$N=N<(6E6<8[<=G;G&.S';QC/6?5Y,N9)DIE,(2^ZIS"5)<RI.%
M9_)G.,=G;_W<8S$[G2_&1_W'/NXQCN=+\9'_ ''/NXQCN=+\9'_<<^[C&.YT
MOQD?]QS[N,8[G2_&1_W'/NXQD6<UG!LP4O7+#'$&P%@%SPAP*5A)G#"X<K$=
M@DQ9&%);<CS($^$^_%EQ7VULR([KC3J%(6I.;QR212)+$[1R1NLD<B,5='0A
ME=6&BK*P!!!V" 1D$!@58 @@@@^001H@CZ@CP<SFJ,MG'8T[";[&FF/]!E2<
M^A9PI++6<X3C.6VL*5AM&<Y2C"E?)QCY6>VI8GY)/DGY^I^3^\_7)ST73)"T
MJ0N5%6A:<I6A;:U)4E6,X4E2<ISA258SG&<9QG&<9SC..SD?'QC(DWJX;9(:
M1U@AA34!!$&83#*0$38R2E:-0;'7B&&9#;C?K84\,'F!C_R?20B4*-,84A]E
M"\7CEDB;E&[QMQD3DC%3PE1HI5V"#QDC=T<?#*S*=@G((##3 $;!T1L;4A@?
MW@@$?@0#DQW.E^,C_N.?=RF3CN=+\9'_ ''/NXQCN=+\9'_<<^[C&.YTOQD?
M]QS[N,8[G2_&1_W'/NXQDB-K<B"Z^XN2RO#L1^/C"4KQG"GL8QA6>W'Y,=GS
M]GS_ $<8R.[G2_&1_P!QS[N,8[G2_&1_W'/NXQCN=+\9'_<<^[C&.YTOQD?]
MQS[N,8[G2_&1_P!QS[N,8[G2_&1_W'/NXQCN=+\9'_<<^[C&.YTOQD?]QS[N
M,8[G2_&1_P!QS[N,8[G2_&1_W'/NXQCN=+\9'_<<^[C&.YTOQD?]QS[N,8[G
M2_&1_P!QS[N,9EP*O)AS(\E4EA:674N92E+F%*QC\V,YQV=O_?QC/%^I2G7W
MG<2V,8==<<QC*7.W&%K4K&,]F.SMQC/9GC&>7<Z7XR/^XY]W&,=SI?C(_P"X
MY]W&,=SI?C(_[CGW<8QW.E^,C_N.?=QC'<Z7XR/^XY]W&,PB6O63 Z>(+)&$
MQ16%*&DQL^)B7!(#YS#D6;!FQ'VW&)427&=<CR8[R%M/,N+;<0I"E8S969&5
MT9D=&#(ZDJRLI!5E8:(92 00=@C8R" 000""-$'R"#\@CZ@Y^X-!P-A0QP]<
M&' 'Q8\*%$CLK;8BQ(K2&(T9AM*<);989;0TVA.,80A*4XQV8X9F=F=B69F+
M,Q\DLQV23^))).    /  T!^ &>[=*>90EMJ1$:;1C.$(;:6A"<9SVYPE*4X
M2G&<_/G&,8QG/S\@DGY)/[SO)S^YIDA64Y5*BJRA65(SEM><H5E*D94G.4]J
M590M:,YQV9^2I2>WL5G&8_\ GYQD3_9<-]NMV?U,+WB9$.@&3GJ"/:K(1^:R
M1D"6IWH_6&ATB?'CS'XC;B6'Y,:.\ZA;C#*D:=V3MF'N/VBXD,?(\#(%*!RN
M]%PI*AB-A20#HG(T-\M#>M;^NM[UO\-^3^.A^&3'<Z7XR/\ N.?=S/)QW.E^
M,C_N.?=QC'<Z7XR/^XY]W&,=SI?C(_[CGW<8QW.E^,C_ +CGW<8QW.E^,C_N
M.?=QC+ XQCC&.,8XQCC&.,8XQCC&?.7J]H&_MJ;TU+1--W.T:]'S=!=11*7>
M1^QML4FM46_Q[MTZ#*!>9];UXY&K>W+16(9BWS:WJ_9TV)3K*/59&B+BX+<]
MISZ3H]CI]2A<GNP0V67J'356NU:I/+/7,'4FL0++8!EIQ2LD*RVJJM-$W:*#
MEQ.<=A)9)8UC9D!BE)</(H5^405N*$+(P!;2.>)&_IO*GL74/U$;)E1J:_5)
M(]EO<&F"MC@TN@[/J=KTFW3>OGIZIK>O]A6TH8(@MEIVQJ(M>+M)-5$14*_&
MHU+LA!^!8J/:@Y[/7%T[IM8&;NAB:=Y(VGL5)H;QF^S_ %&;U%>%$5ZIJ7$K
MP".9YY#8GB4-%/$\>4::5R%XZ^\B+!4D5H]6X5XLQ)5^Y&78E0H"J?#*0V58
MWU*=1("@T+1D"FWHJY8M%7R#<C1G75X1?!)\KJC?-MK]OKFQFKX_+DL#[#3J
M=4)D<EK"+&B6&QP!<"]O6&7!"QNL=,Z;)//?:>N@BOUS"B68#7>-+G3X9():
MQKA06BGGG!6T28HF=JXC5G-.],%2(*QY1,&)1N?(QRL&5PWD;55.T'N.@Y)
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MWP#2]5V#6>Y+?8;P].-[&K*]&">G#4Q&1(J<.DDCEXN-A@ K^.INU=ENVS9
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MQF+WR=\ WYZOA<8QWR=\ WYZOA<8QWR=\ WYZOA<8QWR=\ WYZOA<8QWR=\
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MH=AX(( M3<.A3&Y]2]-TK<VL:/LW;8;9>E36Q%D*A4S+-9!D[B$-;7K8M^=
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M)J[P53;E6::L%L-W%OF0(B6&INDWII#FU=VC0A"LB.PC([2,J$A^3\%**^T
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MGA7>)UF?U"H\'&)E#GO))&T6A[U=2NPPW4.A4N'4H.6V# J.!(;9!U[2"&_
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MU&&?K%.W))(B"M0K36)ML\<T73H:4ML\3([]J=6LJPW(P4-Q#GCG*8F6O)&
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MFFHUX*R3V!)-(\G;2.1ZH+\H917D9I9$E>>/2;C$;.'/<E?FT:%E65V<JFE
M'(E0_CW+S "@J%W?4>@MKTJUZED; V)C8\+70+<,F19IDNSOEUFK[*H0^NUB
M"]<K+>+<2KL$2&MYTQ+LUP)26CA$ -"(C5\3"&BL+O4J=B&Z*U7TK6I*($2B
M()PKBR\LS""*O LK/)!&BQ0J#&LCR;E<N]XXI%:/D_,(LFR>1.W*<5!=G8J
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M0,R,[*(:HG8JS2L\DLDDLL9[C..W% D2@J?;$5?M%-.65!)H$#?)RGD  *H
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MC$@38^)"S'8"]O6]$CBVB>+!22I\'SXRQ*]U#Z=M1ZL54%<4S+5;N\_LBK.
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MC\!023H;.@-DZ'G]V,R.1C'&,<8QQC'&,<8R4"?XM _S"/\ YXQF)-_ODO\
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MK0(5TE<>>')59)&)9I4FG$A8RN3'8CX\""PYF1N1)+N=^7_'SH@> I5>( 4
M1^MNDJK:IL-1,55-L7!IP>_180PW(FFWR-@V')I#9.V%BT[+DE\H*KM"%50
MQ%;A1(0:<9Q(1-E3DOL7M=6L7(IDF6,-.]8LT:B,)%6$Y2!$7P$>6P\TA8LS
M.L>N*KHHX%C*E2VE#C1.R6<KMB3\D!0H^  3\[SI/V43_1\W[*][G/*S;'LH
MG^CYOV5[W.,8]E$_T?-^RO>YQC'LHG^CYOV5[W.,9DPQA%$N*M4"8E*9+"E*
M5&>PE*4NISG.<Y1V8QC&,YSG/S8QQC,@L.(.DIKC<*6XVN0M2%HCNJ0I.<_-
ME*DHSC.,_3C/9QC([V43_1\W[*][G&,>RB?Z/F_97O<XQCV43_1\W[*][G&,
M>RB?Z/F_97O<XQCV43_1\W[*][G&,>RB?Z/F_97O<XQD4<IL:S"IH*R5:/8
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M0&"N4)4_4!E(\Z/P=:(.;YJO_L\<_P!Y6V_^9]MYYY^?X+_P,T7_ '?^H_\
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M:Z]C#F?4:[+F66QD'0 OU$/DD?-DDPDSBL^0_N_4K\AK,]J9S4=9*Q9M]J1
M@60>/=*!%$O<;D_&.->7%% H(8ASU&H[@*OH:Y*=[!_82S'0T-DGY.8A+IJT
MJ0*&#3%$#!"UEMU"NMJ(5^,R(EV<QK6V0+U5&C3T5M*WA;%P%P+"3&QLQ8QX
MBPXZ:3/3-((ERO4[JHD9G=TBAL00K(>8B2U"U>8H#\.87:-&.S&I CX\5XC!
M$23P )9&8@:+%&#J#^SD Q T"?)WL[O7G!FN.,8XQCC&.,8XQCC&.,8XQCC&
M.,9!R*S7Y=E$7&2'@/VH"#L-:"GW(Z%%!@"V3ZP4LPB'*SCTC, X1I=3FDHZ
M,X1)D5X4XYC*HC6<:"601/"'81221RO&">#20K*D3LOP6C6>95/R!(X'YQR.
M(Y!M#D 5!^H#%2P!_ E5)_</PS3(NG:!'9N\*0$;*B+]L(7M(T!,*P0"1KJ'
M34'X14,/>1Z(7E)ZD!;@MEC_ %:[DHE8^S! E*<7L;M@F B0H]>L]1)$]LA@
MD,P9'8';[CGD@V?_  .,7YJ@97MI[AK8=PY!\CD..B/P\J&\?[MGY.05JZ;]
M$W@FT8MNK*@>)M'25C7+(#$N+F%#*:U@SDHE*TMF!QA5-J+Y8(51,"DY57K\
MR</?E"(#T?2+J5^!"D-N:-#&D?%7("I'W>WP^J,G?F".G%T$L@5@'8&&BC8@
MLBD@D^1]2 #O\=\5V#L'B"1L#)"XZ$TSL*3+F7G6M2MDJ?8!5GF2#XIDD](,
MA0*ZN.><7*](K,-JNOS0KPGMP(FCB9F+-@R&C15,RL/4+M8*(+,T(6-XE$;E
M0$>3NL !_N,@5P_YZLB%6!C3B:*-_P Y%;R&\C?D#B/X<21KX()!'DYM-(H8
M"@0CL,"B8I5EN-MO1R:1E*G$"-@N)N6:(O2);B4K5%@ID,! <3L]$(K8H,$B
MX3#&QTIRGL26&C:3C]U##715'%5C@C6-0!^+:+R'Y>1W<^6.65 @('^YF<[\
<DEB2?/[/@?@H ^!FY\PRV.,8XQCC&.,8XQG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g551455g24a25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g24a25.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .8"70,!$0 "$0$#$0'_Q  ?  $
M @,! 0$! 0$         ! <%!@@*"0," 0O_Q !=$   !0,! 0L(!0<)! @%
M! ," P0%!@ !!P@)"A$2$Q086%F8U=85%A<:5Y:7U!E6=)69(2(Q,UJ4V"-!
M5).TQ-'2UR0R-+$U.%%S=Z:UMB4G0U-B-E*S\&%QD?_$ !T! 0 !!0$! 0
M           % 0,$!@<"" G_Q !A$0 ! P(" PD+!@D* P4'! ,# 0($  4&
M$0<2$Q05(3%45I/1TQ8705%35Y&2E9;2(E)5E*'4"#)A<8&BL=7P&",D8V:C
MI<'BY3,T<B5"=';A-C=&L[2UMD-B9?&%LL+_V@ , P$  A$#$0 _ /?Q2E?X
M(00!$,8K!"&UQ"$*]@A"$-M^XA7OO6M:UK7O>][VM:UM^]*5SO#E"0W <O&V
M3E!D-NL'-!S-*FV:GY!*/8%<IF;C%F\V6J5SDJ<5C'&5;.SJ@'KU1C>>A$WA
M/-*2EF"5Y?\ BN_Z7?L6O'6\Z==LRL=W59'ML/@AA8%;DN4L;$KU_P E:U3*
MSGJC36UI4M@8\,+<H;D0R$9R$(QA2&$B3V$*Q>_?Z!BW7 :18R%P/<2E0 4(
M1,-!>A"(-J/>CU+F]'NS<CE_&SS\-1^I(\!VHG@3:KP)X$XO!6-YMFVQZYW
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M62X0HDM\4K8TDA4811# 96%>1&/5C6*Y&.5,EMS4#@7:T/DP:U>+MK#AC'C
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MIQB(#>4R/I2$U*D,"I2%J$]JUW2;><$GEVM<,8&)9FLCR$G"O-LEV;;$5P%
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MP+6M.6!E1!273J1)%]S+FIK%F&[ZD7!,$(/!!O<&V3?[GI5?<S.GX9PT&2K
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M!V]=3VH^2M]+NJG/<TS=0'B+WAS1X-IW/W3SE3O5@=O3:CY*WTNZJ<]S3-U
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M+BB;?-CW*5D;-&,U-KD]6<%_!YO]HOL#%9;1HPC:-G1[E!#*B1EDZ]U112G
MEE=)M-K$J 7;"&P+Y+VN<53- UX5/W'HWS3FW,,'6*LRZ-)?H^/:%!B..Q]^
MFV.)6UOS84I/) K:T$37(Y)&ABL *@;3)8@T!+"=>R->Y%V H.Y#?($"#(:D
M&^@OB/1'%**/*"\;U1%5KW':X1>/+7$<G"GRFM7@3Z,&YSD76$H^'@15:N:9
M\?!PI^94KL:H.KE*4I2E*4I2E*4J(E_6+?M?]V34JB<;OS_Y)4NE5K^1B$$
MQ! (P00B$$ +@L,8K6O>P W,$ NPA7_(&XQ@!OWMPA!#OWLI7-D"0SAKT\R%
MKR#9R-D#;')J@$X/CKY4D3PF2MZXH+M(K%3G):!M>5:H*OE#6TSE]:DQ8"#$
M94?">**L2J$_%?\ ]*\7YOS)^SKKRQKXENJ\Q<M,@\U3%PH:M2.'EW?M"X;E
MQ81P[Q\%PN:&[D&X6FZ0-PN%[KK;V\KO<^QEZ[A&/H:2.!)$=VZ$")#_ ",1
M?\;4;M?Q'ZGX^M^+\GYO!E6!JS?^Z[@\'"SB\'V5$\S]UL?7A+]_Z"OD*O;H
MT*<G=ZF).TIJSOG?:.GF?NMCZ\)?O_05\A3=&A3D[O4Q)VE-6=\[[1T\S]UL
M?7A+]_Z"OD*;HT*<G=ZF).TIJSOG?:.GF?NMCZ\)?O\ T%?(4W1H4Y.[U,2=
MI35G?.^T=/,_=;'UX2_?^@KY"FZ-"G)W>IB3M*:L[YWVCIYG[K8^O"7[_P!!
M7R%-T:%.3N]3$G:4U9WSOM'6]XRB>ZG2IW'#,F3(M1! K#;R0E/(=#=CC$7(
MU/%A!=H2D.5O]KY/<7)#0&\&U_R\'A6OF6^1H)29'6?&>L-'KMT1F)\U9JNR
MRV1$)^-J_BKG^C.M2QV+'),(WMF!S##BMT9B64I=[E&R3ND&T5R7$987_+;=
M$W0-S-94R36U523E>)[J..GCV9B&8 2X[$6T>;I"F0Z(!'%@LRMUG#AW?4ZA
MUO83M9<,/*SABL 0;%\$GBPA]W21H&6<9;;&>V%_-[%',Q1GF@F;3_BE4G_%
MU_QE_-P95BZ.1:01X-LS-(1Q'Q>U)^^Q0[UH-^=SFK U4M0@P$RMBPVNV V_
M*1=IF7:.6N_,_=;'UX2_?^@KY"L#=&A3D[O4Q)VE;OJSOG?:.GF?NMCZ\)?O
M_05\A3=&A3D[O4Q)VE-6=\[[1T\S]UL?7A+]_P"@KY"FZ-"G)W>IB3M*:L[Y
MWVCIYG[K8^O"7[_T%?(4W1H4Y.[U,2=I35G?.^T=/,_=;'UX2_?^@KY"FZ-"
MG)W>IB3M*:L[YWVCIYG[K8^O"7[_ -!7R%-T:%.3N]3$G:4U9WSOM'6Z8[B6
MZIBYQ&#,@S,H^% =4]Y*21(-#-C3&NW"X\(+M:4EPM>]^#_P9H#][?X K7K+
M@R-!23(ZS8SUB(1NW1&8FS4?ARV9$?ZJY^*M8QF/&;\*WUF#C#%BAUO,EC(5
M8"C9/X-DYR3QDAY(FMEND;A9Y:Z95F,NQ3=0I\X7&89EX4F/1(6?R,0ID&B.
MYH#+-:6R_?N_IU+KO"6V.%:RDX5K6O\ R5@E<"UKUUD:!5FE6V1GMAZH]FCF
M8HS1VHW:?\8BD_'UN-?S<&51&C,.D@6#[>S2/(%(Q8AIRSBAWJ0;@+,,L%$2
MTA#!S;#4*+LAH[@_G54FLJUGYG[K8^O"7[_T%?(5';HT*<G=ZF).TK?M6=\[
M[1T\S]UL?7A+]_Z"OD*;HT*<G=ZF).TIJSOG?:.GF?NMCZ\)?O\ T%?(4W1H
M4Y.[U,2=I35G?.^T=/,_=;'UX2_?^@KY"FZ-"G)W>IB3M*:L[YWVCIYG[K8^
MO"7[_P!!7R%-T:%.3N]3$G:4U9WSOM'3S/W6Q]>$OW_H*^0INC0IR=WJ8D[2
MFK.^=]HZVJ#1'=5Y<RBPYO-"3H>%_:A2<HF0:%K&F,5EA-W0!=VY(4OL(2/C
M;6NB-+5;]_Y 83.#>LF'(T&)*C++CN6*AAK(1&8FS4*/3:(FS)KYJS-$U?E9
M\2I4!BL>+'89O[<+%8/$CK1<$L)"+"5C+LL4B0'/2:PD-6MD[-524QX,D_G6
MJS61=LS+%=T^'S.YF$I=9' [M#59&0JD.B81MEUB!<M%OR(A4Y\&]^*WK&&W
M+M^7BPVMOUE7:1H#68Y;7&(V)LV9(YF*<]IDNO\ \8BOX\N-<O%6LZ+0Z3Q8
M3"W2;)#(Q1NV8I" WG:S<*O9N-N5G""%K(S7SU1[3BVBJZJI\S]UL?7A+]_Z
M"OD*C-T:%.3N]3$G:5T75G?.^T=/,_=;'UX2_?\ H*^0INC0IR=WJ8D[2FK.
M^=]HZ>9^ZV/KPE^_]!7R%-T:%.3N]3$G:4U9WSOM'3S/W6Q]>$OW_H*^0INC
M0IR=WJ8D[2FK.^=]HZ>9^ZV/KPE^_P#05\A3=&A3D[O4Q)VE-6=\[[1T\S]U
ML?7A+]_Z"OD*;HT*<G=ZF).TIJSOG?:.M@B<1W5R"4QH4JFI!L7#(&84D+*D
M&A.QAC %Q37> %W1(RUEAC;K* @ND, IL*]N(&$W@"M?C2-!R28ZR8SECH<2
MG1&8ES4.T;M4^01'<+-;\54=\U<\JA\0LQ*ZP7QN'R,'?G6>YMLCR+%5C+NL
M(Z6U[TDL?&5C9NQ5R2&/!DB[5KAZR+O^;(KNG,^7IC,%RWD4)\A(0C)5R'10
M(SRU94OY<,-Y(2J<> )/=%:UN-XCA6%Q8;"X=[YUXD: 5EMWIBD;%V+$<CF8
MI1=MK/UU_GRJ_+5U/_V^+PUI6B<.E46%R-TI202<2;ZRU$2/O*UF]:AB;E:J
M68 (>NATEJN;-MJJW7<J:B)4'F?NMCZ\)?O_ $%?(5%;HT*<G=ZF).TKINK.
M^=]HZ>9^ZV/KPE^_]!7R%-T:%.3N]3$G:4U9WSOM'3S/W6Q]>$OW_H*^0INC
M0IR=WJ8D[2FK.^=]HZ>9^ZV/KPE^_P#05\A3=&A3D[O4Q)VE-6=\[[1T\S]U
ML?7A+]_Z"OD*;HT*<G=ZF).TIJSOG?:.GF?NMCZ\)?O_ $%?(4W1H4Y.[U,2
M=I35G?.^T=9=@B&ZP@OK*)^FR<;'9W;;O0 2#0A88FFRPF[B$%TR(*BPQ(^.
ML'B!!.W[VXH5C.#>UT$C0@A@J:.Y0H4:E34Q+PCUTUT^21'?BY_B\/BX:CKP
MR_.M-T2T$:R[+;IR6M[UCJQMQ6,5(3G(=K@JULG9*[;-<+)%VC59FBVCG.+;
MIJ42IM'@66<BA]H^2%Q*5R'16(8I'9W>;KC 7DQ2M?8L2&[8&UBS I.$$=R@
M6,N:(4E>9/X/ZRA[T12-CH!J$1S,59J?:$UE_GRJ_+9[/BR;XN'.N>Z(P:7!
M8<G-TKR@2<0K>Y+H1(Z6-K$LRP;<@&.2QQX\372<EQ<JD8LC5<W6<H]DC:7\
MS]UL?7A+]_Z"OD*B-T:%.3N]3$G:5U/5G?.^T=/,_=;'UX2_?^@KY"FZ-"G)
MW>IB3M*:L[YWVCIYG[K8^O"7[_T%?(4W1H4Y.[U,2=I35G?.^T=/,_=;'UX2
M_?\ H*^0INC0IR=WJ8D[2FK.^=]HZ>9^ZV/KPE^_]!7R%-T:%.3N]3$G:4U9
MWSOM'3S/W6Q]>$OW_H*^0INC0IR=WJ8D[2FK.^=]HZFML0W679Q;[N4W3B;K
M+4MUX0R#0;PA(K'E\JL'BD(3>%<CC+6XL5C-_>X%["WKU['(T):[-I'=J:[=
M?)F),]3636XB9\6?%P^*L6<R[K"F)">B3%BR$B*Y0ZJ2E$_<ZNVB*S)"ZBKK
MHK,OQD5,TJY<[1?=,*A_9QX#E=T,<"U* O1:N0Z+A#&^V=5USA@\YBU:O@W(
MN3;_ &<84M[VWPAX7"O>6O4G\'Y3BWGBD:'8_P ZCF8JX2Z[LE3;E5WXFKQ?
M)_3G7+]$,?3&&RW1NEF7'E7A;IG;'Q]X6HVV[E BM=O''CQ\]U(=?YYKC</X
MVIJ)5&^9^ZV/KPE^_P#05\A4-NC0IR=WJ8D[2NM:L[YWVCIYG[K8^O"7[_T%
M?(4W1H4Y.[U,2=I35G?.^T=/,_=;'UX2_?\ H*^0INC0IR=WJ8D[2FK.^=]H
MZ>9^ZV/KPE^_]!7R%-T:%.3N]3$G:4U9WSOM'3S/W6Q]>$OW_H*^0INC0IR=
MWJ8D[2FK.^=]HZ>9^ZV/KPE^_P#05\A3=&A3D[O4Q)VE-6=\[[1U^R>'[K2L
M>1=1-TUR+'%\=:T@T%[]R>&'C+6X*&PM^X.%O;U[7W_T7M>JM/H3UDSCNRS3
M/Y&).+/AXGY\7BX:MF;<MB78N1#;-^R55%EM-5=3/-,LM;+//@\?!5Z9YB^Z
M65#JPWP!*A(6<*)PM(0*Y%HQ%<QV\H"XL0/.@"M3O6+XRPN2B GOOVOO7OO7
MJ9O4G\'Q2@6SQ2-%LW;9',Q7POUODJFW*J_B_-X/'PUR/0_'TTAMMY32U,CR
MK@Z<!;0Z.F'VHR&@%20CMXHT<.:GR5-NCB<>JJ,JA?,_=;'UX2_?^@KY"H7=
M&A3D[O4Q)VE=@U9WSOM'3S/W6Q]>$OW_ *"OD*;HT*<G=ZF).TIJSOG?:.GF
M?NMCZ\)?O_05\A3=&A3D[O4Q)VE-6=\[[1T\S]UL?7A+]_Z"OD*;HT*<G=ZF
M).TIJSOG?:.GF?NMCZ\)?O\ T%?(4W1H4Y.[U,2=I35G?.^T=/,_=;'UX2_?
M^@KY"FZ-"G)W>IB3M*:L[YWVCIYG[K8^O"7[_P!!7R%-T:%.3N]3$G:4U9WS
MOM'7WKTJ1C:D',LG%FS+&'XL:$]I PHLC8<:\NO1RBPGB[^H)><*YXPXUH$M
MQW:@@1NZ:1*!WMPT:]"4 Y'4+I#D:)72;:N!K?<' V!]\=C-N,)-MK!4"JE\
MB7-Q,V*1$W,V.UBM<I-MM!J/DVAT.F,,._-TN2H\B:LZ.ZR%"N'W"2"HC)(&
M@;##A*-[3(Q[BS#2'&:0;0BC[$SY/2VD:'ZUHA$W1)K-S1A/+\F-6&B8E6),
M5OD$/;4EU)PK!?7Y=*?),BX:81!:=.V8WB)K>,LVZIS?;G!,)Y]>CV YF.L,
M"X00HU-HDV8.2CW9)_PQM#KBX<U57RCH[/@8/+)>RC0J(NU<UR^#5:J9?G7/
M)?T-;^FNNZA*N4I2E*4I2E*4I2HB7]8M^U_W9-2J)QN_/_DE2Z56HJXLTU$L
M*(4G(SS$J@LE6G**//2FC*&$M200>6<0<<0.X32RCBC2C!A" PL8!7#=2N4,
M--1#%IJE3&CE#Q*T+&@R,P$K'N.2F-JT2V/)E[%(FZY4V>Y/+',^TK;7Y>[.
MSW)GT\Y_7NZ1,L(;D2)L0*\O_%?X/DK^S\R?LKP12S0QLJ'.529R?-M@U1QZ
M<) \KGB/"T+9T<Q,+HK<5)[@S"<DTV*3.%VM68<ANN3EED*[D<H*  LP(;?4
ML+$F,F0HC!X *4;(L=HRIB*WL0C&B8C2:BQE5FNU$=JJJJW/)554SJ)V8/#(
MR7PH@7Y(OA3C\%:_S"MDIUY+3V",]>.:RNZ;&OF\+[RV_P"ZTV8.4_W+^NG,
M*V2G7DM/8(SUXYIW38U\WA?>6W_=:;,'*?[E_73F%;)3KR6GL$9Z\<T[IL:^
M;POO+;_NM-F#E/\ <OZZ<PK9*=>2T]@C/7CFG=-C7S>%]Y;?]UILP<I_N7]=
M.85LE.O):>P1GKQS3NFQKYO"^\MO^ZTV8.4_W+^NG,*V2G7DM/8(SUXYIW38
MU\WA?>6W_=:;,'*?[E_75KX.T/;+!ERO"W2-;:)IF;XC<CS&Z,<Q/.J'RN?=
MN6EW3\K/FAY2?@%#,4<8,H8;<3O;V_>U[2-IQ3CH5QB$!HU+*,TBJR.N)[:S
M:KJ.16ZSHBHG!FN:HO%7/M*MLL=TT>XH@7O$O<U:I,$3)E]6$:4EN&DR,]I5
MCC*(AM<C6!U&$:J[7@7P+D-0FB/9;R#+LK=Y;MF6F R%8!@NXQ*^A;.CE=I$
M3&F=.0'ER:9)R3^5I2B%_" 2"P>5<"^_<-Q7N7O%6.RW2421HS)#,[8Z\=,3
MVU^SRCB:U5<V(C7*]J(_@3@UM5<U157!T-6G#]HT;8;M]@Q6F*[3'2[;DOZ0
M#PTG[6^7(QTW,8IB"W+)(:%DXCM;<^NF37(U*8YA6R4Z\EI[!&>O'-17=-C7
MS>%]Y;?]UKI^S!RG^Y?UTYA6R4Z\EI[!&>O'-.Z;&OF\+[RV_P"ZTV8.4_W+
M^NG,*V2G7DM/8(SUXYIW38U\WA?>6W_=:;,'*?[E_73F%;)3KR6GL$9Z\<T[
MIL:^;POO+;_NM-F#E/\ <OZZ<PK9*=>2T]@C/7CFG=-C7S>%]Y;?]UILP<I_
MN7]=.85LE.O):>P1GKQS3NFQKYO"^\MO^ZTV8.4_W+^NK+PYH;V5C3E&#N3!
MMJ&F6/2)_2'ML<YB&=DGEA4'A\6BY4=-32B.,W[WXTPL80<'?N&]K5GVO%..
MAW"&0&C8LDK#L<,"XFMS=JY.%&ZRQ%1JKX%5%R7ARK1])5NLUQP%BJ#=\1=S
MULE6B2*;>]QFD;V@=JZ\E0#(-YD9DB*-CVN>CM5%15K:-1NB;9>2/*[T[S';
M)M..Y I;V"RR*7T,9R=+MX2F9$60.ZY+,DY!]U1(0*-\!(>#QG OOW#>]\F^
MXJQX:YF))T9%A&<T.M'[I[:_51!,1JJYL1$57M1'<7!GEPY9UKVA*S8<LVCJ
MT0,.XO3%]J%)NKP7U+?(A))>6Y22'%N8QC$'N8SG@S<1=?4VB(C7(E49S"MD
MIUY+3V",]>.:A^Z;&OF\+[RV_P"ZUUG9@Y3_ '+^NG,*V2G7DM/8(SUXYIW3
M8U\WA?>6W_=:;,'*?[E_73F%;)3KR6GL$9Z\<T[IL:^;POO+;_NM-F#E/]R_
MKIS"MDIUY+3V",]>.:=TV-?-X7WEM_W6FS!RG^Y?UTYA6R4Z\EI[!&>O'-.Z
M;&OF\+[RV_[K39@Y3_<OZZ<PK9*=>2T]@C/7CFG=-C7S>%]Y;?\ =:;,'*?[
ME_76^XMT,;*=MR3 W!EVUS3)7=%+6%4V1_F'YW3>6EQ#DG,3-G*39L:6GY:<
M$!%CC"Q@*X?#$ 5@WM?,M^*,<LGPWBT;E.5DD#AA7$UN;M7M(U6CUEB*C==4
M1N:HJ)GGDM:ECV!:IV"<6PKG?=Y+=*P[=X\Z\;D,?>N*:"=AYZA8\;S)%&YQ
ME$Q['$1FJUS57-+$U,Z*MF!)<H*'6:[8UIQN^F,3*4=&.8UG)VN00609Q*FZ
MU+,4Q)EU%A"OO!*M</ WKWO6?B#%>/37%Y)6C$L$JB$FP[J+:3)J(J-<KFQ$
M3-W"N67!Q</'6DZ";)AFR8 CP<-XT3&5L;=+D5MZ2VR(*..0C%-%2.8QR-W.
MJ(FLI,GJ[61$1:Y^YA6R4Z\EI[!&>O'-0G=-C7S>%]Y;?]UKL>S!RG^Y?UTY
MA6R4Z\EI[!&>O'-.Z;&OF\+[RV_[K39@Y3_<OZZ<PK9*=>2T]@C/7CFG=-C7
MS>%]Y;?]UILP<I_N7]=.85LE.O):>P1GKQS3NFQKYO"^\MO^ZTV8.4_W+^NG
M,*V2G7DM/8(SUXYIW38U\WA?>6W_ '6FS!RG^Y?UTYA6R4Z\EI[!&>O'-.Z;
M&OF\+[RV_P"ZTV8.4_W+^NMCAVB+9,QZ715_(VW+2[',<D8W@EJMH)SX&[F:
MV.:5:6WV$"9J!ANM&19-OA(/%;C=\))E]X O8\8XP@/9./H^5@83VRS/-BBV
MB"T494,1Q2OBZ@QM8Q5>1WR6-17.X$6HN^6!F)K)>,-@FF";$%KN%D":-#+)
MD"+=8AH R@CL>QYS#>='B"U['%>C6-<U7(J?862[G$A6LTN-9VQSM!&\,0?X
MP@0M0V?32L5E&A0JW TT2XEPSHPNC4ZDFJQ)7%F=FE"Z-:A.)*O3DJ #*!I9
MOPDK=BS9WBU8?A283V.C#/ Q&.7&(^,8HRJTXK3LWJTFLQ=7-/DHJ*J*BK$8
M'T$WW0-;)F ,1RKL2[!N9KM(9>;0^TS0,N,2%L1;D)-F+LE$!IQE:96DVSLF
MIDN>L>J-&=8.?V7!?Q&59[]O]F?\:_VFMSW!_6_J?ZZ>J-&=8.?V7!?Q&4[]
MO]F?\:_VFFX/ZW]3_73U1HSK!S^RX+^(RG?M_LS_ (U_M--P?UOZG^NGJC1G
M6#G]EP7\1E._;_9G_&O]IIN#^M_4_P!=/5&C.L'/[+@OXC*=^W^S/^-?[33<
M'];^I_KIZHT9U@Y_9<%_$93OV_V9_P :_P!IIN#^M_4_UUEX_N2\QB?F1[Y_
MYJSR.[MKKR0>E\18%7D]82KY.,SG$&\6$_B>*$/BS.!85Q< >]P;W Z<=D81
M>Y=';(C":JWK)':CD=JJN]*\"Y9+P+Q\51UXL.^UINEJW6Z-OG;IMOW0P.N\
M&[(Q8VV:S:LUW"VFNUNNS65J)K-SS2TLY[F#,SM*FR7<]T$1NWQ\F.^3DFFT
M3F6?R%W>5O+1*/3VV<$9OE+B;E<0/@!(#?C1<+@@DKQ^$#OM*')[D61M0# :
MC+YKZVJ0I-97;SL\IDB:O!JYY\.2<]T1Z)N]9AN;A_NB/B#=E[DWC=A[?N%X
MMO!MT+<K0[OFZS&;W[9";5N;CN;LTU=9]+>J-&=8.?V7!?Q&5$]^W^S/^-?[
M374]P?UOZG^NGJC1G6#G]EP7\1E._;_9G_&O]IIN#^M_4_UT]4:,ZP<_LN"_
MB,IW[?[,_P"-?[33<'];^I_KIZHT9U@Y_9<%_$93OV_V9_QK_::;@_K?U/\
M73U1HSK!S^RX+^(RG?M_LS_C7^TTW!_6_J?ZZ>J-&=8.?V7!?Q&4[]O]F?\
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MIDCGN_ZW*[+\B)Q(G\9UUU4+5RE*4I2E*4I2E*5$2_K%OVO^[)J51.-WY_\
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MV>>?!E^C/CX*[Y]$V*_9IC_W-CG=M:YNV9RN3TY?CJ]DGB3T)3T38K]FF/\
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MIG*UJ*KE6H/5W]I_UGIWO]J$[SJ*[Y^$>:*?5K9\%=-W*?RZ^E_73U=_:?\
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M:#CRY8D:X@7.&K3OS8K5<C7*K4T;UKK0+[#M7_N=AC_72L+O-8E^D+'T\_\
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M)L]5O57[IM VA5$I3K$>BS28D5I#RE*54FTY8>(4IE)!@32%"<\J&@-)/)-
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M#:/;9KPC6HMJN6:(F?\ 0I3N'+A^4H45W#X51%7C5$XJE'D&KWJUS=57.5O
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MD:M-:L?F9P(_Y9:&/"T16M:00(PS%HK)5-T2ZYMCFX"10;>ZDS@GFF _,X/
M#=OMRTJONDET[#F&0RE0.T&&Y&>-N4<2,5KMNY5S&C'+\I<G*J<'$F#H6B8.
MAZ-,-QL&W6Z7?#8TN^]UPN<9(TZ0K[[<R3-N#<\74V4]TH(_YAFL$8W?+UM=
MU*>AC8$=,S77\#(CW141N_25] X=]H&[6NI:L7RA?53JIZ&-@1TS-=?P,B/=
M%-WZ2OH'#OM W:TU8OE"^JG53T,; CIF:Z_@9$>Z*;OTE?0.'?:!NUIJQ?*%
M]5.JGH8V!'3,UU_ R(]T4W?I*^@<.^T#=K35B^4+ZJ=5/0QL".F9KK^!D1[H
MIN_25] X=]H&[6FK%\H7U4ZJ>AC8$=,S77\#(CW13=^DKZ!P[[0-VM-6+Y0O
MJIU59V&,0;"Y'E2"JH9J\UN.TI(D"0;&VNF$HBF;UB^UA\60K/\ )Z7BB16N
M+A#Y05O;UOSOYKR%JN.E)MQANBX>PT60AFJ$9+D9K'OX<D<[;-R3QKK)^>M%
MTFQL,2< 8K!B:XW"W6 MHD-NLZ"!#S(T159KECAV$C:$14:C6[$F>:YIX4VG
M4EB;8CN66GQ9D[5CK3CLQ,;X_9R:6'"\17-:<L#(A"DNG571KKFW-36+-,WU
M N"8(0."'@[U9-_N6E9]T.Z=AO# ).H%'C#<S/&C4$W45KMN[C9DJYKQY\"<
M5:[H.A8(A:.;1'P3>+M></-E75T6?=(J19I#/N4ETMA [EBZK12%(,:[%-8;
M6NUG9YU1'H8V!'3,UU_ R(]T5#;OTE?0.'?:!NUKKFK%\H7U4ZJ>AC8$=,S7
M7\#(CW13=^DKZ!P[[0-VM-6+Y0OJIU4]#&P(Z9FNOX&1'NBF[])7T#AWV@;M
M::L7RA?53JIZ&-@1TS-=?P,B/=%-WZ2OH'#OM W:TU8OE"^JG53T,; CIF:Z
M_@9$>Z*;OTE?0.'?:!NUIJQ?*%]5.JGH8V!'3,UU_ R(]T4W?I*^@<.^T#=K
M35B^4+ZJ=5;_ (IP_L)TN3("IBNK_6^Y24B7,!K"WN.$8B0@6NP'-.)"E6'>
M3DW%)CE%BRSC./*X !"%Q@=[?K-MUQTH-GPG1\/8;(=)0%"Q]Q,UCRH1NHUZ
M[9,FJ[)'+FF29\*5J&D"/AZ1@;%P+_.G0;&7#EX'=IL,*&E1;<^"=LL\86Q-
MM#B KWB9LB:ST1-1V>56/J>Q1L3G/*2A7E/5=K0C4M$P,@%#7'\,1%>V@2 (
M,Y*:6INE7W$8;OF7&&ZC?#P0VX ?Y\_$-RTKDN3G7##>& 2-B)%8&YF>/4R7
M45%V[^%4XTSXTK1] L' <'1_'!@6]7B]6%+K<WLG7:(D28LMQ![I$H=RQ,AC
M5&[-VR^4BK\IW@YY]#&P(Z9FNOX&1'NBH/=^DKZ!P[[0-VM=GU8OE"^JG53T
M,; CIF:Z_@9$>Z*;OTE?0.'?:!NUIJQ?*%]5.JGH8V!'3,UU_ R(]T4W?I*^
M@<.^T#=K35B^4+ZJ=5/0QL".F9KK^!D1[HIN_25] X=]H&[6FK%\H7U4ZJ>A
MC8$=,S77\#(CW13=^DKZ!P[[0-VM-6+Y0OJIU4]#&P(Z9FNOX&1'NBF[])7T
M#AWV@;M::L7RA?53JK<,>8=V$">?P<^/:PM<2]_(F$9.8T*W"$1)1K'@MZ1#
M;$BLWR81Q290M"02>9QQ/ *&,7&E[W#ME0;CI/;-AN#A_#;S)*CJ)C[B9&O*
MA6*-KEVR9-<[)%7-,D55S2M;QF&QFP?BL-YF3(EH+AN^CNLN,)"R8MM):Y39
MTB./9%VAP15*43-D37(UK=F_/56Y=56*=BJZY,2*<L:J]9L8E%HHU%%ML<PU
M$G!O$U!7.XDJFZBZ9POR@T\:L!A=SP\$)1=^+#PN$.5Q)<]+)+@UUQPUA>.?
M<PT:P-S,1BC1Y5:Y7;=_RE<KT5,TR1$X/"O,/P?(&CZ!@20# -\O5\LBX@N!
M"S+Q#2'*;<'1+<AP-%N2'F%@6QGL?LES<1Z:ZZNJWFKT,; CIF:Z_@9$>Z*@
M-WZ2OH'#OM W:UW/5B^4+ZJ=5/0QL".F9KK^!D1[HIN_25] X=]H&[6FK%\H
M7U4ZJ>AC8$=,S77\#(CW13=^DKZ!P[[0-VM-6+Y0OJIU4]#&P(Z9FNOX&1'N
MBF[])7T#AWV@;M::L7RA?53JIZ&-@1TS-=?P,B/=%-WZ2OH'#OM W:TU8OE"
M^JG53T,; CIF:Z_@9$>Z*;OTE?0.'?:!NUIJQ?*%]5.JMBB&&]@R3+8N:SZQ
M=<BIW*D3(8UI5.#XB6F4N('-,)"0H,\EE< @Y38HLT?&E\$L0A<8#>X5K\6X
M:34DQU%A_#CB(<2C:ZXF1KGH1JL:Y=LF2*[)%7-,D\-0N)!6@F';^.Y2I4>W
M$LMT9/D &CS A/@G;*,%FS)KE$!2/&W9OUGM1-1V>JOVD=]BYL]M9D+7:FU&
MKO-<*@L#Y/CB0NSTQ0B*-K*X)UB1X(*<S9 RJ0<><9/6A(%4D5G-YRA22E3F
MF' -O? Q[I$TAVB_Q+7?L,60%T/;1R(L>WR9$UIH:R9K&E1PI)%1ZDCR<V.U
M7HP;7*Q$5%7D?X.=IT>PL$75FCR_WJ^V1<4S7RYE[AM@R171;59&&C#%N.'K
M1VQ&P2M)LW9E,5NT75U&<MCV+>QK#F&'X'MM+\BFY-G[<6Y0YG2IH.M:GP!K
M@J;+(2I8CA:B)HWGE20? 97-Z0NAY)A*A,E/('<P.NIC[':P3W+N4BI$BN5A
MR.W2UX\FH_64#I"'</)?^(P;F(J*U7(J95WO81M9&;9=9>%$X.'ARX]7+]&>
M==P^J;:4.D]J&^[,;>&JU_OSWKZ(M?K2^VJ[N$?SW_J]5/5-M*'2>U#?=F-O
M#5._/>OHBU^M+[:FX1_/?^KU4]4VTH=)[4-]V8V\-4[\]Z^B+7ZTOMJ;A'\]
M_P"KU4]4VTH=)[4-]V8V\-4[\]Z^B+7ZTOMJ;A'\]_ZO53U3;2ATGM0WW9C;
MPU3OSWKZ(M?K2^VIN$?SW_J]53&_<H6E1M<$+B3J<U!C-0+$RTH!C9CBY8S$
MIX#P!,L&.!%< A%VL.P1!%P;WWA6OO7KVS35>QO8]+1:E5CVO1%=+R56JBHB
M_P ]Q<%8TRT FPY4,A2L'+C'C/<S4UVL.)XG.9K-5NLUKU5N:*F:)FBIP5]N
ML!: ,(X?Q8]XK>B%>6HV\SX4\-)GR1L-*1R!O:3(LF4H$S8F1 *XMLLI#81P
MU!MA+E(;&6 ((0Z]CC27>\<7:'=Y((MJD0[>MM8VVK(1I +))*52+(*9RN4C
MT3Y*M;DQO!GFM<_T4:);)HELUSLUFN-SN@+G<]\S%NJQ%*,K8P8B#'N2/&9L
M]0".77:YVLY>%$R2MAQYL]-'.*LZO&I2!X/CK#F=Y0M[89+B7"1'EMS<V-2=
MH3)6..JG@Z,,PA)DP3%*QO9B'%6J,,/4K#16*L5JTG$M\EVX=ID7 I( W/>@
M%:)-9[WJ]7$*C$,3A7)J.(K6HF36IPY]1:$37J]K$1R\&?#Q)XDSR3T<==GU
M!5=I2E*4I2E*4I2E1$7ZHS[6N_MA]*HG%^EW[5J72JTI2E*4I2E*4I2E*5$2
M?H4_:S_^=J51.+]+OVK4NE5I2E*4I2E*4I2E*4J(E_6+?M?]V34JB<;OS_Y)
M4NE5JK\F+5*,['("H^TOZ-=DR/('*[F-98]E3J$CMR9\:2DI!I1SBB<@H@WL
MN-3HP(3EIEQF'V(*&I54XU9@,^ Y[9.U,K8W+",@V9#V5 _MI;Y'&1J.B4<?
MS4TEDTQ<@HG%BCK?>)!#(ER B %1%(VDMB).0TH5>7_BN_Z5_97A/D^M;3.V
MR60MRS808FDZM ^.R)5)5$DR\ ^0J4J]00>^'!3PPP@)KL:6)>8$DPPH(U K
M%C$"P17^FX=@NKX<5[=(TT+71@.02#A9"1PFJ@TSD(N3$753-$7).%*B]J/D
MS5_+FO#^7B\-8/GQ:7^H$Q#[S9C\$UD]SUW\Y4[HX/WBFU'R5OI=U4Y\6E_J
M!,0^\V8_!-.YZ[^<J=T<'[Q3:CY*WTNZJ<^+2_U F(?>;,?@FG<]=_.5.Z.#
M]XIM1\E;Z7=5.?%I?Z@3$/O-F/P33N>N_G*G='!^\4VH^2M]+NJG/BTO]0)B
M'WFS'X)IW/7?SE3NC@_>*;4?)6^EW53GQ:7^H$Q#[S9C\$T[GKOYRIW1P?O%
M-J/DK?2[JJTL*:T=-3OE*'-J#89XE@2M6XGED2\F2Y>XUC'9O6#NI!8^)H2K
MW,"$27>&J)#?C][A7OO!%(VG#5Y+<8HV:4Y\-[B*C9*"@*HEU'+K(CI;$X<M
M7A<G'X>)=!THW*';< 8FFR\)AQ;&CPA/+ATJEV=T:LR,Q OV4:41$&YR2,V@
M(J;'B3\9)^?-9FFUCRO*&MRV'V)\EK4H&*Q\U427+ECGJYL<:#P"'9-%G FU
MT)9@&VW 5FVX*.V_Q8M\L%R]89O0;G)&32M/GO;L<Y2B@9DS )R(J-EO1-1%
MV>2.7@9X%X$PM#]U@W31UAV?"P8'!<8Z7398:$XRCMVRO5Q"]6[6)#)_32#=
M/76CC^5*7+73(CZ>Y\6E_J!,0^\V8_!-17<]=_.5.Z.#]XKI>U'R5OI=U4Y\
M6E_J!,0^\V8_!-.YZ[^<J=T<'[Q3:CY*WTNZJ<^+2_U F(?>;,?@FG<]=_.5
M.Z.#]XIM1\E;Z7=5.?%I?Z@3$/O-F/P33N>N_G*G='!^\4VH^2M]+NJG/BTO
M]0)B'WFS'X)IW/7?SE3NC@_>*;4?)6^EW53GQ:7^H$Q#[S9C\$T[GKOYRIW1
MP?O%-J/DK?2[JJQ\0ZT]-#IDV%-Z+868EA2I6^I"2)45)LO\8Q&"X>\O!QT2
M1E7$5O;UK#4DAO<6]<=OT7SK9AN\DN$1C-*4Z(]QFHV2@H"J%5_[Z(LIJ9IX
M,W(F:\=:5I'N$2!@7%$R3A<6*(\>TR"%P^12ZEU8BMSB/V<>23)^>:JP!')J
M\#?"FS:A=9.F]@RD\M;IL1L4916IT##<V9J)+ENQSG8UF1& +'9+%W$BW(P"
MLEM8"H?YI=KWL"][AMDWS#-Z#<C#)I6GSWHP*K)<* BOS$Q43)LMZ?(3Y/ Y
M>+AX:@-#%W@7;1]:9T' X,#QB2;HUF'0N,HXJCN,ECS-4T.$1=UO:LE<P-3,
MBHCG(B+5)<^+2_U F(?>;,?@FHCN>N_G*G='!^\5U3:CY*WTNZJ<^+2_U F(
M?>;,?@FG<]=_.5.Z.#]XIM1\E;Z7=5.?%I?Z@3$/O-F/P33N>N_G*G='!^\4
MVH^2M]+NJG/BTO\ 4"8A]YLQ^":=SUW\Y4[HX/WBFU'R5OI=U4Y\6E_J!,0^
M\V8_!-.YZ[^<J=T<'[Q3:CY*WTNZJ<^+2_U F(?>;,?@FG<]=_.5.Z.#]XIM
M1\E;Z7=5;UC'6MIF<<C09 DV$F)(FI62IB3)Y.7)LP<8P''.*<!;N"QL02EW
M$@&*R@-C%) +W+M81H+;][9EOPW>'SH;&:4)\=SY(6MD(*"JA52-1"HBRFIF
MQ?E<+D3@XTK5,=3HL/!>*Y<C#H\0@C8?NQS6)[B(R[B%",]]N>HP2'HV6U%
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M_P U,E\2^A:4Y4F_I!']<7_FIDOB7T+2HJ)4FY*3_M!'^[?_ .L7_P#N%_\
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M(EXOB$Y)8%43B_2O[5K=T:-&W(TK>WI4R! @3$(T*%&04E1HT:4H)"9*E3$
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M(TO>X:3(SVEW,$HBF1Y&L"K&$:Y4+GGDF2Y'4)H7V5S_ )=E;O+-LLR0"0+
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MC(I&HQZM5JHY&NR56JBHN62HM:AI EV&)@?%TJ^VH]ULT?#EX-=;8*46*6?
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M;I%W)+3<QWA5[AH\HG->K,T>$QAH[6$I-H,C6[]I'P!<-&6+)V$+I<[-=ID
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M;==L-3%$)#JNKJ;0C&9_C.1,ZVK4E*MA01EI[*RIB_:8+)J%OC_E-1$Y/IZ
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M2E*4I2HB'_A[?]ZI_M)U*HG%^EW[5J72JTI2E*4I2E*4I2E*5$1?J1_:U_\
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MI2E*4I2HB+]49]K7?VP^E43B_2[]JU+I5:4I2E*4I2E*4I2E*B)/T*?M9_\
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M^I_*JT(<ZI?NYB+]V5'3;5?1"66,(\I.]KW4*C+6]'.0[_F&J33 7_)&;_I
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MZCU5B(<;Q+(SV:$:K5=GEG_C)!YG) <9'XI(GHN[>]NP36QG7K"AML:1C<)
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MC/(,4L6WB2!&"2-*BRA(\;B1I<4QHQVC((NR*]1%$1&$;>%M5\H;8!-L4PZ
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M%-)D-'MY5P*!]SD&<[;3GBR$E UMU:#7O;B/_0+;]@:__2&^OR8F_P#.2_\
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MKP?SJJ375:T]%NZT/:-_YOT8=WU';LT+\E_N+]\5;[JSOG?:.GHMW6A[1O\
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M8P-9ZQ(P@Q7/>X*O=+:3GW2[Z0<77*]X>BX.NTR]RRW##,*"Z%'M$G61I(R
M<Y%4KE;MY$E&M;-D%+,8QC#M:FZ2/<J9D@C;+';Z[>1A9^1<%8#30(X2GD:
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MZ7I#Q)8YF-="93Z1\+VK'-DA2XN)L4X<'W18(P\4:#6R*"VN..UA*\RR124
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M%8E&N6(VXY6 DS=]%\S%,I;ZEZ?B0]G$ZU[S2L6VP%JO9);XQ5O8ECB8)SX
M)2!2(4@\DUB"&4K1N<G---MOP/!;A9V'&8.BXA.R]IB*#@&]R+]AH4 4T#,-
M2$F',=H[K*A+)=/ (JZR,"<P8[RHU]0&1C'3#=W&^,T?6MI<T S1WD<S+M+5
M3*5Y/ CDSVS*ILSE&15Z1"3N91:)&RJ'D;PY+D,OB3"V-W*-A;.O4M(R19,P
M1W6QTF;M+8JV\<IVV4L&+)':Y+FSXQ4>!SBDDLC)& (MNN$LYM3476S#L#=;
MIT.WGCMO*0[<@;RU+L6&Q8Z!N<V&6]PV+:I@%'):T0H9)CIDB0&[VF!%!M/]
M;H]B51.D3<F\W7",+UZPYU<G*0G,Z%J8$!S8P66LH%TZ9ER4]UD*60.Y*!T<
M)8]-4'6LCU9G?U"58E5CS,0LM13/W:&<$(FQP ALDED3"M/+V4I16J2(C00W
MPH[C1PV^+(NHY47=,1A!$'2/;\)DOH(PTMTBV'D&?+DR;@2(&);X[XL!#PD-
M?(9A$EW$5PF,CRI%WFQ;$>%.2'.($XBX)TBN-0P9(NCSLW/SRDA3FOD2Y*JD
M)"UK?BWZ \D-6,[FB;DY1 SI"[0MNY%=<D<$Z<4B-N4H!<I-E@N%[6ZD%,CG
MB1B7, 80B#AO%(B.B7?:(.2 IGN<C(<>YFVFR(%[]Q-1S%UGX4JU8;2R!-;Y
MD>=,%9)4BXG$2X--&GMGV% N-#E C,&-S[A+LT90[<)QC6XOU"(C!4'6VUH5
M>ES3SFC&K'C#3""*YVP-'\%PW$3XTYU9LCSE<ASXRS%X8CO+:&##.7%R)C2F
MR05K-*:,J6M-=$29=A+7%692R?B7&.&;W+OF.5GX5Q9+Q5<L0Q9&%9-EM0BX
M2DVV-+;N8MT1@EB2B)"15D$FL._:N:DQ1.W4KOTJT>XSPU!PQHQ;:L=8$M^!
M;-A&=$QU"Q'?#@Q["O,V"Y)@;&YYVW""-]R<B1!6PD4:A:[<#3MW"UG&&BG%
MFDM.YY SY)<OX<#(V"=RI/I_Q;G#(31$&]"2V.%E,3G>0B59ZA_=C+$J$IJ!
M(2TW3 6-ZI28:>O.2GLW2M)M^T@O!:,)0L.8DW%+M5O?BZ^X7L\BXF*XX59<
M+5:'":R&!NLQ[3$=(1ZC*P;6M"U[9/&-"N%M$S)-_P ?7+%^#DN4"^W4> ,+
MXXQ#$L\<#(TA"6J^XA&9[Y\MZ,()\<+(JB::.4KG/D.$2%2,DRUJ-B6L"0@B
M&JO'3O,\S.L0;)1E6!R=B7X>NE<>2$,Y"E4_)36%*AQ\D&%(C,,3B<F0"8XA
MO5#6J31*=HAX?P9<='4-;A@&\Q[9AJ/<3P+!=H,L.(]H':.DO8.(1LMY;N1%
M(1$>@93GM>8:"&U!Z3<L6:1;1I?N#;1I4P],O.,I=GBW3%5AN< ^#U%)4(X;
M"DG#=;Q P^)R""YPUDPFC>R.5QRO4O8D>GNE/.9[DU2UTQ1)X_BW(I,"LLS_
M )'?X<YK\%*D(WC)><X$)O<6_P Z,TY2R6?(),YF7$H=@H_-5M$E2!,$I%SB
M9:<?86:"1;P8@@S+]9G7;9X1LT2X@#BH94C63"MV0HBK!PS8K(V)! WY,?:;
MO.CR*FS3L-OOVBK'+Y,6[2L)W.!A;$;+"TV/L1S[/)D8%*!9N)L<V'<\@&^F
M-,4XE?<;G)<JDE(#>J,X0M92+\=VN/1)UE&14\>L!WC[6H".$'21T!'2SVI1
MDJ+L3:N?W$U2UI6\!L==#0NIZP](E;;*CW(\:8MO$:5]''F7$$&ROF9QI<AB
MI=&P@+,<R0RR3Y9@Q M8<AE;, U0,&TA#*-H&H13(UWQ]%M]IE73$([>B3+?
M&(CK(ZY2DMS2128DMD&,>?)>6**.CK=*?NHAGA#&0A))%$V.KF[4[LN.0KI.
MS%D0M#92O@T?9GYMDSHY$M2Q00W*IE+VC>F3HC61!,2S/)1*)^"K?##Y2W6#
M=L7(C&5MCXTJ]**!)5US,K W69)B'@@ Z0)CS#MMND?]F1R"N3W28SGEBJ.*
MUMO.JH814DFE)<'#NVND-K;+'VDFQVZ%/CW.3)9%,1D<MXN\1%O,D1K,,<*8
MU@9Z%G/?=8Z(L60%T*+DF%BQRY^:*]4Q0] F<)<Z7<VI9-D]U88,J&0<B.4#
M4999>&\LH!C2&%KSH"8&UR3@(99ON9K%8ER[T#?$+)=R*\-N @9 [6[9K=1H
M]I6L1F'I.4:4J(1%"V[-7Y35+;_YALK)M\'#DI;1(+"L\<1[O*67$->Q;5MB
M*YCP/*XF+(2K,AHJA5#NL+FIJO2/=E60^#3\U9VIHO&;MEBP#<H\:N<"R5*A
M23R@N321K0JBKJRRE91;LPMK,] L>2GL>%RLM3)4B)6F2D[):Y,B1NY#JY4!
M,:$*N&P;M1T&#(*-VS5PW.CRSR8RJQS]10[)Y"%&\CM0O4.+$6V[F1J+(M[S
MG:PI"L5[;G<HH"L4S6&:R7 C0YC=H,:%20AQ"" PA,TBI2H2K#Q&?#DN5<:J
MLAJ7%% DT\B1\S6-!RQ,Z)(N2_(#'U4@4-UPN)"I.VA4FDG-P@N!0P6&B%94
M$J]H?$++D2P7MEG8$MV?:;@RV"D-$\!)[HA4BL*PR*%XWG5C7-,BA<BY%39J
MZM@PD2SBQ3ALN(2R0V$=^M)+R:(\PY0;6R>!T\L<D94DC,.,A7L?'5)#'(C@
M*A497W\U69C@DBPGJN23[-^ Y3 )RUQ4_3@R8=FAR_*SR^,J7_X6')9+<L&N
M?421P):+N_G$8[(B )EQQHF\XAL)!\CX!PW=8>)\ DM&%\6P+O:I$]N,Y.)+
M8P-@C19)/Z0MD<<:#BE(%TG<ZPTCE<KQ-8AVO,Y?OO2KC"Q7#!6E85_QO@*Z
M6"^1;4_1Q"P?>G2,5S9T,2;F3$K(QG'G !(9#67OB^6(;6'>3<SV16)\X=*F
M1HHRZ1]>L8ELY86J12J#XJ:H+'Y!(T"-XD(6E=/35;;%6QQ6%K'0+;9P3F'H
MVHDZR3EI0AEE\H!<?9L?6:X2M(>B>=;[5+D0X%TODBZS(<(Q8T-3CM+1FGG"
M-P@*;8O1A)#F[39.1%747+YST5XCM4+1'IXM=VOD"+<;I9,+1;%;[A<0!F7!
M(I[ZXL:U19!FFE)&W0QQ Q&/0.V:YS6[1%76-(.<)DQHI#")ME]P8=-D'CD@
MR!-\:"=VA(MR$G >D++Q9$;KB1O@"\DR-:VM4G:V%6D;CF-8_.+N#@W.,-D-
M(N%K;*)$NELPZ*7C6Z3(=GM=[2-)(.SO5I%6_7'9.2*JV6$,QX)Y8WF;*'$#
M'7@:C8O1#C>\00W"R7O&$BWZ-K';I^(+WAI9D0)L0C:4+6X6M&V8Z<UN)+D>
M-%N<: 449\(TZ1+1,W/?TME]XTS9<P1+,PRI?B!3D"8XJ32PZ0)9V^7U"D:G
M5#\0E/@!6.3%HD"/#+$P% 86<5VOD*&,H6]>0K-5B"O*TG#D;&^'L5V_#D 6
M(F6BVW\EO;#):HJ8/?@=D1Y&W=UY:)"DQ+*EN67);M]J6<8HG#:--DO2L7S-
M&>+<"77&-TD80+B"\85%=B7 5]G+I"'I.)/$%]@9AQ3* 6#(-O:D"&Y8NP!;
M8\>0PKB92&_.'&\7C#BACSH^HXTH2B?I@"0F2>3CCZ>[,QM\%5(T+4'SFBH5
MD@7F/+LF9T?E5,!4J.LL<3TS(RNJQ+V:]SYP2S 1"3F$2);5AM@P4F/W3+-=
M1D+(7<,]1PQ)&CODDW.]1C8HPM?)D@&3YRPW;+9(# E3P6T@=W7A+@ZYW-;>
M-T*""Q%$"(F^=K0UP.Z;+%##NH32E(AI)!PH4HHI#I'H$!B8GQ,"/HSO(#D2
M?&A2A(M=G1].;XPUM;DO=$$U=$Y"0#T^.#^)*8R0L21"P.C6M3K+A$H1^ 3+
MNLN7%>LPK4F <V=N$@HX(C33I!P" :V >XBQ8H8>T25<T(69'D">)%U'^Y-N
ML*084X:6\+]P26.MBW,1IDJ<^/:XL60>4"]21,$V;.DW!6.A679 @28IA&R<
M0'^25G@:4Y_3-K4Q&.MXC#G1J0-4B5."8B4BD[2V/T?0$H)9*2W&[BVJU:RQ
M*>5OZL#>04Y%B8%IRUA8ZPI-W(V&\QY;8^^5RCR"GA#"]T!($@\285QK? <%
M G&(>N^WQ!J9S@.28)HI<I<8EA&^>.+%@/DK:+/*A@BW$T@3+IOI$BS[<!D>
M[75LG=,8QC(P=VGF2.)LEJP#D/ @U5,F]N:)?*FIH,XYI;)(^-[6;QX5/&MR
M)T5)D1G*0?F*.&F**%QX?S3=_C _D%:I^V&-(MMOD26ZL@\*(:0W44>J8H!O
M*W47A9D1SDU%X6\2\5:K>(\>)=[K%B.UHD:Y3H\9VNA=:.&4487;5. F8VM7
M73@?GK)P+6MUFU'5]&=F5DG'.,\Y2QPFTFC<$D;]BB61G%D^F19(HK$L@.9S
M;=O7/*A3<*5N3GHB5J<Q<J.3IAIA*FDU0"SM:PN-:;[+>;WA:WAMD&;=842_
MV^=?K3;5<D^X6@#3;449C,WF>PKA/00VO>A$'(:Q=SJJ?1?X,^),.X9QQ=I%
MZN=ML5QGX4NULPM?KRC=Z[3?Y+XR@-,(3(4<9 C,-QS.&-1*6(XC=UY.Z_S[
MDK%I\>TE1S5!FG&V9,WQK/K;(<AY0P<XI5(HQAHM:XG'-KC*X2UL*HA196='
M%P2&I VOR<AM5+6HNRY,4Y.?.L)62_,F:09N!<,WK#>%YN$SP[/8L4A(Q)N)
M%&%K3!M]TD2V/9J-FB5YRGB/<9@CKLWJ$'7<?8DPN^!HEMND_&F&\98WMN/8
MUQQ%BC!$@1%MF#4+)>Z+(NUDB0"C>AB6R0UD6/%GL'%(>*W;#;)E6?K!R]"Y
M'@/5*VY&S5@*6L4UD,3=],[%@R8B73]U$UJMY,;E1*TJQ!?"4:(EF$X&R'RD
M@3JT3H>0<F7)XJ4F@M'6';G"Q;@0UFPSBVWR[9#GQ\;2L4VU!6B.AQ_+;822
M!YQ7$(Z0@6P]B9XR@:YKQ/GN?M&E_%UEN6 M*,;$>-<!7>!>I]IEZ-(&![PI
M\02G12?S3\4BB&5)PP!9"<=]PW3'$4,E["#D,M0Q\<83U82]MQ<W37/.<GF2
M (F+-B'%D6(=&Q9*8"U.*%$WY2SBYI&]/9^6/D0QH[+(KC9YD0G5<)]D2\U"
M TIO-$+H^)]']N-?36S">%HT)76R3B*_3W@..#=CA*4UAPL AG[D%%N-[CCG
MWJ-#2.+<D,32JUQDRXY@G2Q=XV%X]YQYCB;<D9>(>$<+6L<J,6Z6&(< 8^*<
M<211QI.-.L^&YA;7AN9<5E'W=<3O US([G+I.N&+Z:F*(1M3BP&%F^;&9'E"
M*/(L&3YXGK:[X'(;4XXG(LEG.B]R"S9(-=+V*4)0G)E:P@]<8K).Y(5=-*:+
M9^-I5QG,ORXF-:VV:"687%-HCVD\?%;S.2X0[(T @K)LK0(KF/5KQC<T2#<W
M:.UX73?:]&L&SVTF%FX+CWMV)+F&W!P/?IE^C3,",BC=:KCB5\D\EL+$;Y2Z
MA HX93,>=Q6OV+=GQFXM41;$+N3Y,1#<01?%;ZR'K7A:59:L=FIA62E& @M>
ME*4DJE3JX@6W*&$QK(;0%)AH3B%IYO20R+B<L=VW*@5GW^)*8*,)RB%'D2QP
M"J]P2.8Y@XX%$CFJT[SJYZ&:\36\:D1;1%!,8L8#I#;5A:=!>:8=J'/+C0#7
M0+1M.)I6&)*DH;4<CHK(R-$X#V&>_;R&''2Z6'ID*:!%HO*PFZ]G*7N:*,IF
M^'Q<LB5/J,Y?-6ES<RYK)%_E"!-QLG1&*!-042E2E;SEA@(Y\N]"M[2%?=E+
MN=#(H;< LYYKE/<^!$(T5L. #K7"#L;N9L$K6)(4C!O,P;5EV0,.GNI! '8F
MAW6L94DW>2&VCCV>V-'=)XG'O465);>[E(W388RW,#R+$0!""CO,YO\ "V+X
M_<&<E8VM[8T7*:,AJ%*2TE(?7JPFUJD;U&G(]Q:)B[MQ:9,N1Q^*G$N<5BWE
M0YT(\E6?%2TQ6TU%/O 9+Q',>1K2;,P9-POB150\B%&G :&3;8QG/>$LR>UT
M>?/V#([ED+%&)!R*'MF'Y$1IHL>+$5D3$!"A2YCGS46/%N4VV2GR8EXEQVC$
M85OM;V2K5;$E/DLW(LXQW%B<ZUN=<[I2E*4KWMQ'_H%M^P-?_I#?7Y,3?^<E
M_P#B3_\ S7U^]=M_Y"%_X2+_ /3BK9:QJS:YWU!N#&VD8S4/S1=_1"RQC,@3
M8"<R.*F)3EF1X8@9Y,-E8T"Y)+$T3E2N./1J%Z&WH@G$)FWRB"SX:C6JJG^2
M_L6M"PK*H?-< 94DD-9'AC1KG7*2=>7(Y0]RR3.*IJ;+L[:\25PD5O*R)_<8
ML@CISHPK#5:AA4V&U*W%U6IE+FL5Y)^*[_I7Q>+\G'^?P\=>#"6:K=BJAE4E
M12/9393?)"CD#RE?GHC6AE=N(>'E.XJ271T);R%MB$)3@N >K+1DVL4E =8@
MNU@ M:OJ6%9<?.AQ'"QG$&)T8#AC6PPG*,:B8K&*Y6YN5K<FJY>%<LUXZB5?
M'S7,+E7-<UVBIG6O\[?8>=4CECMN9<^>K)WDTA<]H?N_!^"J:\?R#ND7JISM
M]AYU2.6.VYESYZF\FD+GM#]WX/P4UX_D'=(O53G;[#SJD<L=MS+GSU-Y-(7/
M:'[OP?@IKQ_(.Z1>JG.WV'G5(Y8[;F7/GJ;R:0N>T/W?@_!37C^0=TB]5.=O
ML/.J1RQVW,N?/4WDTA<]H?N_!^"FO'\@[I%ZJ<[?8>=4CECMN9<^>IO)I"Y[
M0_=^#\%->/Y!W2+U59F&]2VQ;E63X:PQ79899B\B6NUA-$@MK;S#>[6M1IE"
MXM3P2%]C!_\ #7+N7;?"98=P&!$6(8;V9. <88NCR,,WC%=IGVN]@- GPYN&
MH!HLB,8;D*,H]1%5%:GR7-5KV/1I!N:]K7)#8@TC%T3VB5I&MS+B*?A%8UVA
MDMDQ(LX<ADL 1/CG>BL8YKS(YZ$:X;QH\;V/8]S5^PK_ +I@PAI=< 8%C.B"
M3I&''+8RM;8G8<ML2)L F7,Z%ZM<HE1 S%(U!HW,9S@K5&G*W!P,5+U9YZE2
M::/1_P"3HF%6CP_;[S;HT*V""&.&-;3,",;Q,,B(CI3GN>JD5Q2$<\A2*\I'
MO>]SEN8:TP3M-5G!I/NJ7 MQQ9(N,J8^YR12)KCP[E+M;E(0(V :/*"FY@ &
M,$6+L8P1C$)C&X7UMW%O0IG_ ,9H[X!JG>5F?3\;Z@7[S4]NY/)KZR?#3UMW
M%O0IG_QFCO@&G>5F?3\;Z@7[S3=R>37UD^&GK;N+>A3/_C-'? -.\K,^GXWU
M OWFF[D\FOK)\-/6W<6]"F?_ !FCO@&G>5F?3\;Z@7[S3=R>37UD^&GK;N+>
MA3/_ (S1WP#3O*S/I^-]0+]YINY/)KZR?#3UMW%O0IG_ ,9H[X!IWE9GT_&^
MH%^\TW<GDU]9/AK<L>[JLQKD&;1J%(]&TX;E,E="&LE<IS$P&D)1G\+>--+*
M@5C!A#P;_F@O:][WM;?M65"T%S9LN/$;B*(-T@C1H]UO,K6J[PJB2<U_,G'6
MM8RQG'P=A>^8HDP33062 6>6* K!E.T2M39C>1JL8YRN3Y3D5$3/@7BKTB:6
M,\MFI3"<6RTT1Y?%T;T<\-MF9R6)UZE.='G56R*!W5IBB2CBE!J$9Y-[$EB"
M6,(1@L*UZYICC"4C!&(YF'),P,\T,<0JR0#>(;VRXPI+409%<YJL:5&NS545
M4547*L31CCV)I+P=;L7PK?(M<>>:>!L.449S#= F&A/<I!(UCD(X*O;DB*B.
MU5X4SJK,_:T#\$Q&:RH&EG5AE"\+>$#39IQKBU,_+Y999+6V+<JAI8)"$U["
M?9P\J-)7)TPG-. H Q(N/$<1'VVQ)<3QPK=[/#W0-S]I+F*-@,@.-E(79KL\
MM74(N;M1V? [+)=Z>34S_FR.R5$^2W//-43@X>'CKIG%F0!91@<>G0H/D''%
MY C"L\S,IQTN*3QCL*][62R&/E.#H!M66WM\2?EQ]PVO;?%:_P"2HJ9&W')+
M&W1&E;)VKMX95-&)_P#N$56LUV_EU4JXU<T1<E3/P.3)4_.G#E5@UC56E*4I
M2E*4I2HJ'_@D?V5/_P#P@I5&\2?F3]E2J56E*4I2E*4I2E*4I2OCGMG_ /JI
M8Z_\>(U_[ R?7T5^#+_[=W;_ ,ISO_N]CKX^_#1_]UN'O_/MM_\ Q_%%>8NO
MN:OS(I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4KWMQ'_H%M^P-?_I#?7Y,
M3?\ G)?_ (D__P U]?O7;?\ D(7_ (2+_P#3BK9:QJS:@K&QM<3$)K@WH5QK
M6L"XMABQ(G5&-S@ DY.!<A&>6,218!.H4$!5)[EGA)/.*L.P#1A$I6N3:0Q.
M(1IP<I9PRF)6:4UJTJ%E=GY:Z*'T\#:! D88\WN;T\*EQBG@&)V]O5J.(X]4
M<$"5.H.*45,T5%XEX%K&-4"Q2XMC<X,\+@*YI7($:QK7(XXP*DBQN5)RST2I
M*I C&!0F4)AE'$'@&,!I0PF!$*PK7O?23)1,DD'1$X$1"DR1/%^-5-5OB3T)
M4_T:XZ^H,*]U6+Y"FZI/*#],3XJ9)XD]"4]&N.OJ#"O=5B^0INJ3R@_3$^*F
M2>)/0E/1KCKZ@PKW58OD*;JD\H/TQ/BIDGB3T)3T:XZ^H,*]U6+Y"FZI/*#]
M,3XJ9)XD]"4]&N.OJ#"O=5B^0INJ3R@_3$^*F2>)/0E/1KCKZ@PKW58OD*;J
MD\H/TQ/BIDGB3T)6*?(GBZ,M2M]7X^8!I&\)9A]F/'5I&Z<$TXM/825FC; Z
M/:VX1G!$=9"@4"3I[&JC[%IB#CBZI+E(N:29"*G$J&(BI^E'51PV/16O8QS7
M<"M<UJM5/$J*F2I^>OV:H9BN0-;8^M4.@SFU/+<A=&MQ)C+(:2N;5Z4I4@5D
MF#0<(9*A(:2:2*^]>Y8@_DM^BBRY2KFLF0JKQJIB*J_I5U48,8VHQ@V,8WB:
MQK6M3-<UR:B(B<*JO G&M3_1KCKZ@PKW58OD*INJ3R@_3$^*O62>)/0E/1KC
MKZ@PKW58OD*;JD\H/TQ/BIDGB3T)3T:XZ^H,*]U6+Y"FZI/*#],3XJ9)XD]"
M4]&N.OJ#"O=5B^0INJ3R@_3$^*F2>)/0E/1KCKZ@PKW58OD*;JD\H/TQ/BID
MGB3T)3T:XZ^H,*]U6+Y"FZI/*#],3XJ9)XD]"5C'J)XFBS.ZR5ZB$&:F=@;E
MCPZ.1L69K%H&]N3F*UBL?%-PS;A((*,,X)0!FCX/!+ ,=PAO5)4I%S23(14X
ME0Q$5/TZU4<QCT5KF-<UR9*US4<CD7C145%147Q*E;^C3I$J4A.A3E)$A90
MITQ)%DI9)>]:X0!3V 7Q.]:_Y07 $0;[]A!L+?M5ESWO<KGN<]R\;G.5SE_.
MJJJKZ:,8P;48-C6,3B:QJ-:F:YKDB(B)FJYKXUX:DUYKU2E*4I2E*4I2E*PD
MBD3/%&=6_/RH:-L172EF&%)%K@J.4KEB=N;D"!M;4ZQR='-S<5:1M:VIM2*W
M%S<525 @2J%:@DD:E(X_,TG8FM_CZGE;,Z)"U* X296B-XG\I=R5*!>0E<&]
M8F, -,M;G!*E7MZLDY&M3)U1!I(%*S=*4I2E*4I2E*4I2M>DDJ8(BD;UTB<
MMR9UD,<BK>.Z=6J$J?Y:]H8ZP-Y9*).I.L)<[N*1.-0,L*1$4,Q<X*$J!,I5
M$J55DGBF#M2K*YPR:19#/&:#RXNZU@E4?D#0!MDR1K4%HW-(E>$;.>X(SVA\
M57:GYMLL8G1(L/,;5ZL(!B+FK'B*]X9EDG6&Y2;7,-'?$)(BN:TCXSR",\*J
MYKDU'% %ZIEGK#;P\%:WB?"&&<9P VO%-FA7NWQY;)X(DUCGB',$$\<<AJ,>
MQ4(T,F0-%5?Q2OX.'.JUY@FC;H]8]_<%GSM;5WVM)'/"\=,/LJT7O!Z'/-[A
M_H#=O3F":-NCUCW]P6?.T[[6DCGA>.F'V5.\'H<\WN'^@-V].8)HVZ/6/?W!
M9\[3OM:2.>%XZ8?94[P>ASS>X?Z W;TY@FC;H]8]_<%GSM.^UI(YX7CIA]E3
MO!Z'/-[A_H#=O3F":-NCUCW]P6?.T[[6DCGA>.F'V5.\'H<\WN'^@-V].8)H
MVZ/6/?W!9\[3OM:2.>%XZ8?94[P>ASS>X?Z W;UK\GT7:%X:U6>Y+@G';8V7
M<F9HLI$T.ZK?<) [HF)I(L2B.4J+V4N;BD),.XKDZ,D9BU::F0IU*DEWVM)'
M/"\=,/LJ=X/0YYO</]";MZCQC1MH6F(7LR/8#A"PJ/R%ZBKFH/C$F:TP7V.N
M*EH>T:%2[ 0IW<IN=$:M >O:#%S=RI.<46K&( K6=]K21SPO'3#[*G>#T.>;
MW#_0F[>MHY@FC;H]8]_<%GSM.^UI(YX7CIA]E3O!Z'/-[A_H#=O3F":-NCUC
MW]P6?.T[[6DCGA>.F'V5.\'H<\WN'^@-V].8)HVZ/6/?W!9\[3OM:2.>%XZ8
M?94[P>ASS>X?Z W;TY@FC;H]8]_<%GSM.^UI(YX7CIA]E3O!Z'/-[A_H#=O3
MF":-NCUCW]P6?.T[[6DCGA>.F'V5.\'H<\WN'^@-V].8)HVZ/6/?W!9\[3OM
M:2.>%XZ8?94[P>ASS>X?Z W;UKTKT7Z%X1'G25RG!..VJ/LB>RMU<AM#NJ+1
M)KFEDW4&DH3E2JY(!F@N<860,))7#/.N DLPP+OM:2.>%XZ8?94[P>ASS>X?
MZ W;UCHUI%T$2]UDK)'<'X^<'.(J[HGY/=@D"(*4ZSJ^L(AIE+AR5*ZI0/D7
MDC*8N:#UR$MV8G9N,4!6(%));OM:2.>%XZ8?94[P>ASS>X?Z W;UN7,$T;='
MK'O[@L^=IWVM)'/"\=,/LJ=X/0YYO</] ;MZ<P31MT>L>_N"SYVG?:TD<\+Q
MTP^RIW@]#GF]P_T!NWIS!-&W1ZQ[^X+/G:=]K21SPO'3#[*G>#T.>;W#_0&[
M>G,$T;='K'O[@L^=IWVM)'/"\=,/LJ=X/0YYO</] ;MZ<P31MT>L>_N"SYVG
M?:TD<\+QTP^RIW@]#GF]P_T!NWIS!-&W1ZQ[^X+/G:=]K21SPO'3#[*G>#T.
M>;W#_0&[>L+(=$FB6+M"I\==/$/&@1B2@. SQ23R1R&-8K(0IP)&2. =7I>,
M2E24$8$+>H$25<Q2=8M,2<<6[[6DCGA>.F'V5.\'H<\WN'^@-V]8>):1= L[
M\I7B.%L:O@&D+(8M.2M3N%,$J2,+?)V0],J4&DIUZ=P9'5"M+4(#5)!8C3$A
MYA2U,J3$N^UI(YX7CIA]E3O!Z'/-[A_H#]O6Y<P31MT>L>_N"SYVG?:TD<\+
MQTP^RIW@]#GF]P_T!NWIS!-&W1ZQ[^X+/G:=]K21SPO'3#[*G>#T.>;W#_0&
M[>G,$T;='K'O[@L^=IWVM)'/"\=,/LJ=X/0YYO</] ;MZ<P31MT>L>_N"SYV
MG?:TD<\+QTP^RIW@]#GF]P_T!NWIS!-&W1ZQ[^X+/G:=]K21SPO'3#[*G>#T
M.>;W#_0&[>G,$T;='K'O[@L^=IWVM)'/"\=,/LJ=X/0YYO</] ;MZQ+YH?T4
M1UK5/#EIXA@D:3B+&@:HS(G]Q,&I4DI""DC.P^4G=><8H/*+"0A0J3OSKCN"
MQ8!B"[[6DCGA>.F'V5.\'H<\WN'^@-V]:S$=*>SYGC@L:XAA[&#\O;XO"9FN
M(1-KOOHXYD5,[K86N4F'&E$DG/B%C<%Y+888%U2H+(UK@A2)71K-6.^UI(YX
M7CIA]E3O!Z'/-[A_H#]O6^<P31MT>L>_N"SYVG?:TD<\+QTP^RIW@]#GF]P_
MT!NWIS!-&W1ZQ[^X+/G:=]K21SPO'3#[*G>#T.>;W#_0&[>G,$T;='K'O[@L
M^=IWVM)'/"\=,/LJ=X/0YYO</] ;MZ<P31MT>L>_N"SYVG?:TD<\+QTP^RIW
M@]#GF]P_T!NWIS!-&W1ZQ[^X+/G:=]K21SPO'3#[*G>#T.>;W#_0&[>G,$T;
M='K'O[@L^=IWVM)'/"\=,/LJ=X/0YYO</] ;MZQCQH;T5,38L=W#3S";HT)5
MC3@-T=?GI>9PAA+ 2B:&82]V<E1QHP%)T3<B5*U!HPED$&#%8-W?:TD<\+QT
MP^RIW@]#GF]P_P! ;MZMNVH+#K8F:0$NSZ%&ZQV/R1F-18[R0L1KHZ_MA*UB
M<$BI)$E"<XA0AX)0@!-N>B5)E3:N+3.*%8E(YZYSGN<]RJYSW*YSEXU<Y555
M7\JJJJM=<8-HF,8QJ-8QK6,:G$UK$1K6IXD1J(B)XLJO:O->J4I6GS>&()TR
MEM"QQ=V4](YMSRU/L?4)4KXRNK6H">G7-IZY$Y(@&C*N>A4@5(%1"A L5IC"
M;A.O<*E9MB9&N-,C-'&-(! RQ]J;V1H0EC-, B:VI(2@;T@##AF'# F2$$DA
M&:88:*P+",&,=[BNI65I2E*4I2E*4I2E*5K,RBZ2:QAYBB]6J1(7Q)="N-2)
MF5<88B&:6)6C.02-I?F%Q0.*<)C>YMSNS.+>O;E2I(I2F%G7WE*R#"RH8TQ,
ML=;+*+-K TMK*W66*U*]79"UHR4*2RI<L,.5K5'$$%V.5JCC5*DWA''F&&C$
M*ZE9:E*4I2E*4I2E*4I6G3Z#,>1XJX0^1 -&U."AH6CN26@/&4N8'IND+0IY
M(ZHG-H7 2.[4A4FMSPV.3.XE$C0NS<O;U"E(<I61B49:X5%8S#F0)X&6)Q]F
MC30!2;QZD+8Q-R9K0!4'\$'''!2I2K&F\ '&#L(5@AW]ZRE;!2E*4I2E*4I2
ME*4K#2)A;90PO,;>""U+6^MBUI7D&ITBH!B5>G,3';Z9>F6(CA! 9<0 *TBE
M/<80\:0:#? )2OYC,;8H;'&&(Q=L3,L;B[,V1]@:$81!2-;,SHR6]L;TUAB&
M.Q*1&G)(+N,8QW"7:XQB%>XKJ5FZ4I2E*4I2E*4I2E8*1QQLE+>G;'8!PTJ5
M]BTC*"0<(@=G.'R9HES*,0PVO<1);RR(#%!-_P U00$P@5[!,O>E*P,#@2.
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GI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g551455g59q43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g59q43.jpg
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M]OY;\+P<Q!]QB_1I]&#;?[9OSC].#PXK3Z;ZH^W\M^%X.8@^XQ?HT^C!MO\
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M^@>C3"ZT]./^;P$='-1^KR<,WEF&HFEMQ'./IZ\;BUO6=]*NJ?I*/?Z5UXB
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M'BM-_)X/T,?]7&/&*@CZ_-<?A7U'YV\>SLQO+6U8B%_"RINO\_I3?_G?7?\
M'C!I:;A3P7&[YJ/7J/D_Y8!4S[C/-8[_ )U].OSMXOC>6M:Q$-:LJ6X?W]E/
M+^JL(M2TU_\ 1X3T7ACOV>;P._&?&)P=9Y2#O^=<VZQY718CJ-M]\9>&=8?3
M94OV]E/PK&IIJ;?XO!T'YF.PZ#YOI[C??A3GY_NTMC^%?OU!W<1U\1ICX%:5
MC]-E2W#?^?LIO_SK&32TQ!_B\ _ZJ/\ JXSS\_W:6_Y1^[CC[X9UA]-E2_;V
M4_"L)&E@ !YB'H(YI.FP/F]GMUOA1*F>]N>EZOG'W\>/'4]6,#UC6 E&U5U*
M''2=E 'R]U8U\6ISKS$-QN^:3OMY/IZNS#A:F?0&:7J/.O\ UOC3",U95@("
M4:KJ6X?W]E-V_P#;?#?V;[ &$WI:??S$-NCFD]/F\>/7VX=QU4]]9I>OYQ]Q
M[^'T81J5C6 Z#5=2]%^_LIPW6_-?'7Q:B(6P@]+3G7F(=-_S2;OS>&'T53-N
M,TA&_P"N,=#QW\/2=V&MQ6%9 -_"RIK!H/Y^RMM^@V[J\0]>$O%Z?[A#^B3^
MKP^C$E'42Z'G7MN\]M.S7=[L-*]8UD _/;4P\0_/Z5\GZJX\.O=IC!IZ?[A#
M8Z'YJ/N^QX[O1UXD8IY"+<X][_;$WT[>/9TC#4K659:_HMJ<+:?K]*;AXA^:
MO%\5L:-30?<(3;=\TFXGLW\#O)\GKP\CFDW;;Z<-HZCTZ]MM]CAG<UC6>MJN
MJ?Q3\J&H?_U7IZ@Z<)^+T_W"']$G]7CB2AG?3RV.[>S'L.O3N]>FF&-Q6=:?
M3=5'$!_/^6TZP_-8:<>OL#!XO3_<(?T4?]7XXXE896T\H^D\>._>-Q/1AB/6
MM:D,)1J^J-^GY_RVX?\ ^L'^@0P>+T_W"']$G]7XUP_21R+;;7'WQ^/1H!88
MQ\.*T^F^J/M_+?A>#Q>G^X0_HD_JXWVW^V;\X_3BQLL*UK(T^\ U6U.8.\[@
M;&GI40OW;'ZV%V.NHX9UM/ (EM!"/G!_JT^U?[W&Z,Q)NS'3I/2.O%8U;\]5
M3?9!,_?%SB,@^L0_DH_V%PT?SV_&;VG$?PKC7!@P8,&#!@P8,&#!@P8,&#!@
MP8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&
M#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P
M8^@(@-PP VU&,$ BQPJ34]NCJ'JZ!]@75KZC>/5\<,(.G ]Q^/6/W'"Y-2^@
M[O1[>?>'$ <*U^WX^.KLL2R=-D]6ZQX=76/CM5E-T;^(=/6'6''IW[\*JW3N
M]G;U$^C=NMANR]&_V_OZ>G?OOA<BK>P"/Q]0^W8.@X4[,(.E]1VGZ1U]/3[5
M93"4;A\&_B"_J'HX#OL(7%96OU$?%QAHZ7OIQWVW=G4>CAN.MB593<0\8>KV
M]&-]1J.J_;^_7U@];5EOH="/5A:0]P#IZ?;B&[I\]ET;CV7'QWVUZ1ON,,W3
M9)Z-WQT@\,*2&OQU#VO\>' /'>#ZQ[O<<-G6W#0_%OHPI*;<(;PX854VL"=/
ML3T]7;U=W1AE(A4D\#\?YCZ<*2FN&_0?,/3VAYP\6%D:VAX[NH_OPT9;'J.[
MZ,;BFL-^(?"#I#]D'MT;[!==3K;T>O3O_=I<G",B[0/K^.K"LIK6$-?7[>G"
MN\:']Q]7?NTQ'NNR3P!X6]V[IXVWB_3O*;<(='M?AV]&,@W]_P >SJPWM8[)
MU!W'W'=]-S?0G3<4VR(&"^R.H]H]/4/C !L(8,:$6T^.C]WTC"@HVM;=>Y?6
M ^?M#B.#"9WZ[B-==QW7U[MW:<* ':"X;^'4/7[;AP83(*GLW'&9#6'JW#U?
MC#^C?@P'I&X^KJ[NGCZL*"C80$/8,:,.RQ]1Z>P[CW'&1J+:W&[=J.CM&\=5
MQIC< W"_3A+=\>K&RG[$\-Q]EO:/W8!TUZ-_9^+?Y0XX-VE[\1TVZ^L;CW'B
M,;B_'?T=/4+\.._J.['W!OQGLP8T"V(UW7[;:@>CWVX"ZRM<=?$?'QZ,)E2V
M&X=8^+B'BZ-UNG&CK;3@?BV'*-QXC?U_Y^WNPE4* A<.CMT_$/5KOZ,-B+&W
MP</8WW>D?1\=?1A$J0# .G;QN'"^O'RW"^\;808;)ZCN^C$C#(.)^.CN]ATP
MS+)[RCO#4H[]. V]73INQKB2B>UNK?V<#W?&_#0L3>/;^,+]?M;&IU!'$>OV
M;Q<=1O;=B01MW5K]( '<-W1KOPUK)W 0MTAQ\7#AK<<),+'J.H^-/8.(X8?1
M/8CHWCL.\>\##$Y2M>X;QUT\_MKJ(<,8W?'T8E8)-VM_CWC7HN,,#M(;7 -2
M]FH7XC8>P<9W?'#IX=HQ*1OH-?WCA]'&V_?;#?C&'6+(RO\ U_>?O.X_TV/P
MSKOK2_E!^R^-TWGL]XQ%ZM^>JIOL@F?OBYQ#0?6(?R4?["X;/Y[?C-[3B/X5
MQK@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P
M8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#
M!@P8,&#!@P8,&#!@P8,&#!@P8,&#!CZ B W#&02#<8P0"+'"M-2]M=?3U#[:
M^E=&W'T]7[^CZ#ALZ7N#O]O[O9A>FI>P>3V]K#U" X7!OJ/CZ0?I!UN,,W6U
MQPZ>(_>,*2FMJ&FNH= ](?W(\0X>/"RM?0^GW'KZ#Q'6#A!EMKZO>.KI' ]1
M&'%)0#!8;>/?X^D-.WB&H84!L;CAAM(G$?N'[CZCJ-;85$-L" #N'VL/6' >
M(;K865KBX["/=\>HX:.G1O\ 7U@^G0[CO&_"LAK"%MPB%NH?;?\ BQNIL=!O
MT'IW? ON.[0M76X-^%[_ ![,+2&XAO#0?;H'VZ<.5:QUW'U=V&3+P.[@?CC\
M;L*2&W"'C#U87!X'=>X/0>GZ<-W7>I[OCVX4E-8;\!]K^+X\**;Z'>-_T_'T
M882):X/7;J_R]8PI*.ZW#=UAT>L/-J(871KZ'>/6,-R+&V-Z9K:?0CJ'4/1[
M=>X U75OH/&^_7IW[^%SNNVC:6,'<+WW#V]77TZ=6%)36&P[K^?XAW>?3&_6
M-=W>/W7OU[NBS!TN2IW\/\M.O3IT&%)!^A'</3P]NKCC.\>SK^/@[AA$Z@WW
MC?\ 3V<#W'<+':0;7*/: W[;#V\!].#&A&\'L.%)#6'7L-V]/9ZL&$R+Z<1J
MNN\='=\:8W;AOPX]77ZA\6X P8T'0=Q]70?CA?&T@WT'Q?%[<.K!OP:@]!&-
MY#<!X[NK^GT]N$F'I'K' ^X]=NG&3P8:6ZN(W_2.J_1C;C3?IWC?OZ.._=NZ
M#PPI>XVAIT_'5O'5PUQ\ +>KXOBZL UQF_KW?'7O'?NM@$0#?[=/DW]F,6U/
M0;:>D'3LM\6QNK6(Z./9P]!N>G7'P0V@$/:X>WD'&&%P=WT?'=A=6L;]Q^/6
M.["0Q;#;IW=0]'MU7'#=U](^#Z,.XVL=_6/H[_C?A(H6P]6ODXVWW$.'781X
M8;L+CKX?'7A_$]B#T^WH]QZ>S#8X3TN&\-0MQ ;"(<.T/)O'".)*)[@$<.ZX
MZ/=Z,-"Z=]0#?YAZ@\>OB ..,'I]/9^[?QX@;\24+\.%M+^KLZ.P]6&E8EKZ
M=/XPQJPW^D=O'Z=Q)\KIP]C;Z1_EP[+=.&=RE<!T_HX#I^*P7Z<)6]6)&"3=
MU>KIX<#KU]F&%PEON%[;PZO1^,--^#$O#)N^.T>\885B;!Q#@.H>U_'NZ<9]
MWL]'M/$8D$-Q;T?'7WG0G%B97_K^\_>=Q_IL?AE7?6E_*#]E\+IO/9[QB+U;
M\]53?9!,_?%SB&@^L0_DH_V%PV?SV_&;VG$?PKC7!@P8,&#!@P8,&#!@P8,&
M#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#'3>4?),S7SDI]2J*?
M3@X6#%P9LP>U0\?QY9<R0F*Y6BTV47)*KM6RI>84=*$10.XVT4#K*(.01L.6
M<F<SS6 U4(AA@VME'J&=.>(N&,06-RRJ19F-EVKA2Q5@O'>7/AQY$<@<V3(\
MS?,<QS,1":JILF@IJHY>' :&.M>HK*1(IID/.I C22K%L22I&DL)DMHON=F>
M!O@SV6P__&ZA#_PIB0/(G-1OGH?TLW_U/BGQ_51^#^3S<KY5]]!EG_UY/Q?&
MPON<^>9AL$]EK]O*A#TTIC0\C,T&^:B_23?V&'*_5,<@W-AEO*@=M#EONS<X
MW![G!GL/]GLM->/?VH?YJ83/)#,A?YZCTX<Y+_8X>)]49R(>ULOY27(O8T67
MBVE]?^--,; ]S<SW'^S^607Z9VH_YI83_@KF(_UM+^DD_LL.D^J Y&ONH.4/
M?1T'NS(XW%]S6SX-;]$.6(7_ +^U'TV^E+"?\&:_7YRFTW^7)V_<L.D\.O)!
MQ<4.?_[I0_\ URQO+[F?GV?=4.5_CG:D_FCA)N3]8M[R4YMT,_OC&'<?AIY*
M2 %://!?=>DH^.O#,#U>G&T/<R<_AM:HLKAON_/ZI/YHX3.1U2BY>$;_ +)^
M''1,/8_"WR:EML4N<:]--2C_ .G?BQQL#W,3E "-O"+*SQS]2?S0PF<HJ!]G
M$>PM[T&'<?A.R"3S:;-!VP4WNK#VXV![F!R@3#8*CRKW7UGZF_F=A,Y9.!?:
MC])^C#Q/"!DSD 4^8BXOK#3^ZI.,P]R\Y08ZA4F57\(*F_F=A)J*5;W9=.OX
MW\,/8^6662FRPUO?'#TVX3D_Y8V![EQRA!_MDRI#0!UJ"I^/91HX1:%EOQM?
M=;AVGXX7P^3E'126M%4]Z1]_^MX8V![EIRAS;JDRHW7OX05/ZZ-]O+A!CL>=
MZK'WX?QYE!*+JDPZBJ \--)#TC&?^]8<HBP#X2Y3V'=^B&I_YF8;-5QI?:#Z
M<++?=?[;#Z-N<("@BYMK;IMP)_R!Q\_WK'E#\:ERG\50U./_ (-MY^W#9LUI
MEWI-T:*G]IPP_CH)I;;+1ZVL"6&_^8> O@_WK+E#:_HERH"V^]05-V_2=A%L
M]HUWI4'2^B)_:CHP]3(:R2VS)3:VWO(-]OP1Z<8#[EMRA "XU+E3]OZF_F=A
MLW*;+U%S'5#_ *N/^VP_CY(YG+YLM$.V68=/13GH.,/]ZXY0OTR94_P@J;^9
MN&[\L,J2]XZTVZ(HNFW&<8?1\@LXD\VHR\7 (O+4"][_ /1CT?1@_P!ZXY0O
MTQY4_P (*F_F=ANW+G)U%S#7]T,!_P#IG#Z/P8Y_+YM1E??/4CH_Z)UX^#[E
MSRA M^B3*G7ZH*EX=M'!A!O"#DB6O#F6M[6@I^'_ /EX>)X).4KVM590+[KU
M-5[J(_&Z^/G^]=<H3Z8\JOX05+T7W^!UL-G\)60)>\&:$C_H]/TV_E>'L?@5
MY5RVV:S(];;ZJLXB_#+R<8C[EYR@P_MCRJ_A!4OE^<_\?5AH_A6Y.(;&FS;=
M?2GI>O\ Z:#P]F)"/P"<LY;;-9R?%^FLKAT?_BT].,!]S Y0)=]1Y5AO_L_4
MO#LH_#=_#!R73?39P>RFI??7#L[</8_J=N7$FS:OY.#:W7K:_KZ,K[\8&]S#
MY0)=]196>*?J3^:&&K^&ODFE[TF>&W12T?3;CF PZ7ZFKEXY &8<F;D7UKLQ
M'_[JQK_WLC/[Z8LK?M]4G\T,-V\.?)!-]'GW=247OS$;N/1AY']2[X0I-V8\
ME1UMF&9=-N&4$_Y8^![F9G\0?GBRN[._U2>JD=.H<('P_<C8SK1<H>SQ.@UX
M_P#NGZ\.!]2CX19!IF?)+J)S#-/_ *R]'#WVQO#W-7/H@V-4.6%^.S.U&/9_
M:D'CZATX62;ZHSD1'J<OY2$ D:45!KPXYH-]M_5U6PH?J0/"7*+C->1PX$G,
MLU&O=DAO;@>.XZ8R#W.+/0GPJ@RT$0_OW4(Z:WO^A373T]5\)M]4QR"0ZY=R
MG/90Y=_]=AN[[&V-E^HR\*,GFYQR*[\SSCK&[Y!-P=;WMIW8R#W.O/!,0_1!
MEN.NEIJH- TT^=;AP'&I^JA\'Z[\MY5&VAM099OW7_Y8PH/J)?"NVJYSR&L>
M!S7.AOO_ /!XWQO_ -[VSK /?3^7%PX]^:@"UO\ ^U^' >BX;K6;GZJ[P<QG
MRLLY7=&F794;[]=<Z'TX/_L&?"TXN,ZY" $<<USOT_\ HZ-1T]%QKC(ON?\
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MY=4>+YGD^:104V;Y>7+^+RU-+!45434M8B.]+4P3S0R%)8BZ5$,T4?F+PT>
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M514R4E=)2P]OR+.4;(>"J;"B8]X_JY] 1C2&;UI1*L[!/ZL@7E3THVK6$)4
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M-I+&<HHH)IQ,G**O".0*<2,DD0J! GC*0O,:D1++>^Q'-Y:*;V-KD@ 8FH?
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MR, :=7*3HZ!AO5^6$3OM9X+#;ISV;E#30;;53!K?I -_7A%J'DUQY*51N/\
M\ LXOV?\B?NZ\2<6>\LI+;/+4KT7\(V4]O#E"1\=MD1W>?I!':SO5#@(_)[8
MEW=M6%'S8;M2\E5!OR0JVT_][_-S>_6<D^G3$@F:<NF\WEU;_P"<;+!T_P#X
M_P"K"4\IGP70V=JMMUQS^B@#_M5B'HPW:'DD-_(RK/5_P>YN3IT?\1>CKP\2
MN\(3>;R_ T_]\O+AIW9]Z.S&GOSGJ(7^3:H/3_P_P_I&L[='&^["!CY&@^5R
M(K-1_P"]SFIZM?\ B._NPN*WPD#=X0]GC_\ Q/RY?;GXQCWWSR'_ --9QO\
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M@=O5A%ZGPOJ2/^%B-2-X/AJR==-]['E4-VXGLZ[+$Y;.4=#9OW'JSQAS!?@
MVJ[JUO?2^MPOC!'@N_\ >QJS_P#,YGC>C_S7/[\)M5^&/>OA=B%M+GPXY(OI
MORNOKN-[&V%))3.,!US= 0ON'.V&$0Z0^>O6WGQD#P4$B_@LK#V^!?/B.O7^
M"OIX]^$7JO#.?-\,4(MP_P"'?(AVBYY8 DC_ #ZE!97-\!US9VK[K9T1)@MQ
MO:JAN&%5@\$QW^"NH-S<7\"^= G\[DL.CTWPV>M\-0&GADC &^WAXR+U6Y8'
MZ,;PD\V]!'->_3_PRQ8Z\=0J>U\++2>"1O.\$[F^X'P+YOIKT'DMU:<?3AJV
M9>&T7'_#. >.SX>,E]W+ 7[L1^1IZIIEXI(3%44W*OEBD*J]D<Q*9?.U"I$!
M-(#N7$XJJ<J:92D( G$"D "A8  ,6_*N4_);):./+LEY*\I\IH87=X:++?!M
MRIH*2-I7,DI2FILAAA0R.6=V5+LQ)8W).*'G?)'EAR@K9<SS[EAR3SK,YEC2
M;,,U\*O(_,JZ5(4$<22557RDFG=8HU5(U9R$10B@  83EHN2#096C[#N_1M2
M8Z^*8'XO+B77EWE9M;*.6@ZSR$Y86'?\BVZL5Y_!QG%O^7.0-_\ XQN0_K_X
M^QM"CI&_ZZ4EUCX9TM8#:A?26W"&_B.HAN##I.766?\ N1RSL=#?D+RO -__
M )&Z]^G;ANW@YSBW_+?($]%O"/R&Z./_ !^--;=/1TX4%I"0M892D]- M6%,
M#Z)0=VX=V%UY<98?_5/++JOR'Y6@\;;\G' 7[;@;L,9O!QFYN1G7(,6UU\(O
M(?IZL_.O ]8Z\;RTD_XR=*W#HJ^FQ\=PDQ_IQLO+;+;V^2>6 Z+\B>58X]>4
M;AZ+:=K)_!YFP(89UR#Z&_\ NB<B+'_]>C3MMP'#&[P3?:#WSI>X:"(593@A
M;C>TE?K#2P#Y<;_PSR[_ -R^5W?R+Y4C_P#=.$F\'N;C7Y9Y"]WA#Y$DGH/_
M "[Q'1O-^NVX*6>Z#WRI@;AK:JJ='72PZ2.E^CS8V_AEEQ_]5\K>_D;RH'MR
MK"+<@,V!O\L<A]/_ ,H'(RUM;[L\(Z/1O.-P4P]M89"G!'I"J*?'L']<1U]>
M-AROR\_^K.57?R/Y3#OURO\ ?U81;D#F@/\ RQR(L=1_Y_<C?1IG7HX=>/H4
MV]+J,A3MPW@%300^B0'&XY64!_\ 5O*?OY)\I![<L&$FY#YH-3FW(T].SRZY
M(-KKT9T=^_U<,;/!]V40'NZ!ZK5#"B&[J?#P]> \IZ)MV7\I "-=KDMR@77@
M=<N'8>K&HY&9CYIS7DCTBW+7DJ>T:9N>T<+ZG'T\"YW@]A-/[_1%A#Q/.%[#
MVXQ_"2C/_,.4'?R;ST>F^7CUXU')#,%T.9\E3;=L\L.3#;Q?AFI_?PW8U#!N
M0_KR&$/W[BK[]_ZJ'QVZPPK_  @I& _B6>Z:&_)[.@.K?0CLUZN.,'DI7C?F
M/)GNY6<FS[,S/;TD:;[C ,,X_;D0-]XA,Q@V-<=D='0[^-K<1QD9[2G_ )GG
M7?D6;CVT8QH>3%</_6')PVW;/*CD^>O2V8W_ 'X.]*X:"YBAW[I>--VAHZ'<
M(VMT6QO\M4Q_YIF^NFN2YH/;2C&1R>K!_P ^R ZZ;/*/(S[,PW [NJV$JD2N
M4;]T1MMP_GI'W$+VOHY\E^C"9S2!@1XOF8Z-K*<R'MI=.OJW7PNF250U-7DN
M[6V?9.?1:N/P<(58Q8!'YLPZ;A),1"_59QKTATCTX3^4(3<<Q7]^6UP]M.-<
M.DRFI!UJLIZ#;.<K/LJS_GT8:W$<H(#\U9]("#YH;7@%P6'HL/E'7=H*R,Z<
MW5CMHJL>V$=/'KP^CR^<:&?+C;6ZYGE[:CHM4'MMAC<,5-XJ->(#9VV&]NQ4
M?%NX]=L^,H;62HZ1>FJ![8^(N,/8Z25=\U'8C[&NI&/7:TIO;?W895VIBW 3
M(COW+HFU\1QW_'C8RJWV,MC;?%*->!\T=/'30=&'2PNN^2#NJ(3KP\USO]V&
M)TD-A$;<?@B!@M_@C;3K'@ !H.-0U^GO!'M P\C)7>RG=YK*U[C4>23NW]%\
M2C+=,0J!W8->]#CHW=VL/Z-_ ,,LQU@3\JN\VTV'Z3\7.)FED-S;7R3[1?HW
MZ'3I.*TJWYZJF^R"9^^+G$1!]8A_)1_L+AV_GM^,WM.(_A7&N#!@P8,&#!@P
M8,&#!@P8,&#!@P8,&#!@Q+FM#5$\9,WZ2<.BV?H=TM!?U32\6NLWYU5#G@:2
M4PU=D3%5!4A3*($ XD,)1$+"+=JJ!69+R%D.RVS#,Z@V!L&6,J2 1>Q.\7 .
M-EBD8!@$"D7&TZ D7.MBR]&-WR/ZD_94S_#FB?YP8QXW#^%_W>H_LL;<S+TQ
M_I(_[3!\C^I/V5,_PYHG^<&#QN'\+_N]1_98.9EZ8_TD?]I@^1_4G[*F?X<T
M3_.#!XW#^%_W>H_LL',R],?Z2/\ M,'R/ZD_94S_  YHG^<&#QN'\+_N]1_9
M8.9EZ8_TD?\ :8/D?U)^RIG^'-$_S@P>-P_A?]WJ/[+!S,O3'^DC_M,'R/ZD
M_94S_#FB?YP8/&X?PO\ N]1_98.9EZ8_TD?]I@^1_4G[*F?X<T3_ #@P>-P_
MA?\ =ZC^RP<S+TQ_I(_[3'T,OZDN'OZ9#K\.:)T^Z#"D59 )%/SIL?Y-4'_V
M6#F9.)C[I(_[0XWI9=U2LHFBB:FU5E3D2222K:B5%%5%# 4B:9"SXF.<YA I
M"% 3&,(  "(@&'IS"  D\X  22::J  &I))BL !O. 1.38!;G0>6G];$)6(L
MW6506#8504.BJ3WH["B9A(<MRB)1V3%$+E$0&UP$0UPZ$NT PL00"#KJ#NXX
M3((-CH1C7M&Z?,'Q8SMGH'K^G!C+YI[6P<X;V\F_1Q]N,V/1\?'#ITWXQ$Q@
MXAYA]&#;/0/7].,8R]\.XQ1\GQ8-L]7QWXS;?J-.B_T6QD &XCKU6]88V5KC
M7?U ^X8QBZZ<IUM(03!]8AMLG,FL &.*Z9A(*92% 3G.(  @4I3&$!O;0<5B
MLK6AJIHR;;+$V)W*=03>UA;IMBQT5+%-21RDB]V0C9!8LI("A;%F8@ @"Y(U
M MA\+0JBMC';@D3>"?O><'3^JF*(@7ZQ,PCH%U!N),-?E11N<$]-]W8/>?1Q
MPZ7+-NQ8;"[POD;1_'(%A^*I.[5B"5QL/1)$B&.=$I2$*)A'9 ;  < #4>H
M"X[@# ,SN;!P23TZDXW.6HH)-@%%SHIL!U!;^@8UDH@"EVUDDR'4]]LF$@;
M6  ( B.HE"VT(:"<3"%@$ #)S,'0/<#0&^_I/?[+8U7+18%[!FUV3L>2."C3
MAQMH6)(T.-(TJV,8Q$4NZCE'9$K5,%@*;B4ZI?F"1@Z%52#H/'3&?E C5F"
MZW8V] WF_4#Z,:&CAN0@,K V(B57L>AGL(T/4[J<:'U#O%6BPI,B)F*05"E%
M0IEC"F(& A2)%.03' -D/FHZB&F%:?-HTGC9Y 5VK-8Z;)N"=X.E[[ANX;\-
MJS+)Y*6811!9-C:12ZF1F3R@H6-2MV(V1\X1KK;%>]ZK;P+[>+%O N 0JD$
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M_E"^[#:7REN-2+:6M<^OL/JTQ.4TVR;-I<=/3N(Z+D>O74"\<>-Q!.XW'R7
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MX[&Y+M.M:K2J>'<'2*XAD4I=-590B0(QRIA1>*"=0+)HI+ @94^A2[9><,
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M\7)Z?5NOBZ44UPITW#0:]?5NW \=,,0$NJ*9MQP$0M^R +WOPN #Y W!?#8
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M-3RY=%5QKRB%1/S1D\8.:H5H1(C0 5"4][21S[2*+B-9%)4Y-4AV@VT5/,V
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M&0;K6Z+#?"9DZ+GM_P _CJQN(2=3OMV'LU&O;IN]&XK 1W$OV (>GTXT,FG
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M5QK@P8,&#!@P8,&#!@P8,&#!@P8,&#!CX;</8/HQD;^YO8<8.[O7VC$OJO\
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M*7"XA)OQ#CN=JCNPLBJT,6T+@)'U6-@+]V%$%R;[KG=PU-[]FAUX8>F*!!$
M$-X#>]A'3^C3APPTFC3RO)&MK]=[8E(5&AWWMT[SZO4>![7\C8@"'O0O:P<=
M^^][AVV##(A+W"BX%KF^[H&N[XXX?JGMO<]/5QX^W6]\*TV9!M8 T&^_SZ;[
M7MP'J#"3!+ ;*Z': MH#KJ+#??K[\.5CZ1IH=0-XMN'"_3^_"U-FGK[T!$;7
M'LMH :C[=.$&V-= =K6UM^^USZMY.'"Q<"!;N)/NXGZ,+"-$[@.R%[6\0Z
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MCX5U"W%5#G"A<Z&V8;;Q3'0_#79T-OT #8D,X@,L D47:$EC;>4-@W;;1NH
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M>GXW87I-S#:P6#B/&V_0-P7\7EP@T@'&YX<;G=VGNPNL?3J?5])^-..%Z;8
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MQ%9T;4-*>BHJS_1T>&B_F&X>UNSR8L'3Z?CX.[HOBI@[C_-/9_ENZQ?&X!N
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MS'.<P@4I2@ B)C"  &HCCBX!)  ))T  N2>@ ;\=S)"@LQ  %R20  -Y).@
MZ3BL76:&3AU%.Z*_RZ56 #$45-4E.N!2,6Y;+JE=J B)3 ( 54Y!N%@"^'HH
M,RMI1U@' <Q,-^N@V1?ITQ%OF^2$G:S++"3H3XU3-;A9B)#;O(ZL.T#G;5G*
M#H;(V64IVA::IRDZ9.X*[I:04?OI<THP:-VC-5J+9).GD$&K=)Q*1)74B=:8
MV5A6:E:E;FL7*+,UDBBREJ7FY,O;F><86+\VJQET!1=E&V2?)N&\E@;:8HG(
MCDX]-5U/*-,Q-1%G:FJ-.K!A%S\K3JDS!V,DJ!]G:949/+4K<G$[Q3\=0QYE
M^ZO-$W')FB'!@#;8YJTPNF-KC\U@*N:'* [P 2N-H>D2!CTE]2C.\/A@RV-;
M[-3DV>02"]@56D\8%QQL\"X\M?5AP)+X%ZZ1@-JFY09#-&;7(9JB2G-CPND[
M7MOM;'YIIQ$5XE^0OPBH&6);?MMQ!P6W7M)A;KQ]4%\X?N]_^=L?(\-LO<[M
MH@]C74^HXE=/N%SO*6E&CENR<-YNG9!!V[V>Y&JAGC4 <.MH2E[F0YX57 &,
M4H)$/M"  (@500TM4'5W0TTX9$^N.O-M=4TOML-%L+[1'9B+4LM9"JLB$SH%
M>3S%8.I5GN?,5@"US:U[Z8ZA,[=+5/FT22E&,X]=5'/.WTQ%%(6)EI!.KE!6
ME(PI#J)E8/EW"CID"9SD!LHD!3F"QAA^3BQ?).5&%9TC2*-$BJ;\]"GBHM%)
MHIVT50CW&K*;VW8KG+TS?*F;>,-3O(\TC22TUN9F?QO6:.Q(V)"Q= -P8#K/
MQXF#NCW2 6%2GY0%4@XECI0 -L@&\ !V*MN&PB/1BP+Y%6";6GC(/6Z7ZMVS
MPZ3W8HU&.=IU<#RH)0">.R003VDE3W8Y@JAN4CMX00]XL3G #J5*8#_]L#>;
M#J15DC>-O-8%#V-Y)_5.+'0,T,O.KHRM'(IZU(;VC%17$4/??"*78-]<F.P;
M_M%'#6D8O0TNUYZ1B)^GG(2T3WZ]I#?%LV%CS.O"?6WGY^/HYNHV:B,#=IL2
MBV*DJ,3(R"JA!L:Y5"CU[( .[@(@-[[[CTXI>;;<&:2R(=EKQRJ>U%W]-R#<
M;K&W5CL_)@)59+##* R;,\+CJYQF%KC0@,I!X$ [\0B8(4P$<D"R;@H'MI8J
MFT *%\NM^(B8 W8C\P0,RU*"T=2A<]"RC25>YM0>-ST'%VY.2LJ2T$K7FH',
M8)WR4["]/)8\"@V; G9 6^\8A[KZ+Q_ZV*]-YY[!B^4_#M'M.-I@[MB3)@%U
M6^T!>L4_?%[;I&$@=8=6'=O&\LV-\E.6V=;7YL!AVWC8J >/1OQ%W&79ZLA-
MH:Q5+'@.>NK7/5,@<G@IUQ'F;M1L<P%V3I'"RJ"@;2:I=P@8. VW&+8P#;>&
M@PL50].= 'C<A9(GU213?1AP(X,+$<#:][+64458B[1:.:,[4-1'I+"XU!4\
M5^V0W5AO%[$.B<>5X(J1Q@. A[]JJ<I5D1&VFT80*HG>X%4N CH!@O<<.5R\
MUB[>7E6U!:GD=4FAOUMLJ\=R K@WX,-H$X@:C.1EEHLX5HM?FZV&)Y*:H'"Z
MQJSPS'4O$5*BUU<J1AP0<*0I5$D]@7RHD,J;X96Y"^^2*6P@4RHB(G-O* "0
M!VN#R*KFR)6ABYLUTX43-<.E,@'D(H&C3$L78G:15V  Q)(@*JAIN5\D55/S
MZY12%Q31V,,E=,2!/*Y\^.F786*/9V)782M=%"[7<_)U7856UF(AZ@W=_,:=
MKIHR< !TEY"B)A)>48%2$;'[OA'LPT.G<!42$!-H4!"S<HJF?,>2Z5U%*]/4
M5V59IE+3P-LR4T^9T$]-'(C@71J;,(X)(V/FLH-M=:-R6RZ*@Y49MD%;&L\5
M!F.4\H*6*H4,E2F1YE%5&/9;R6-9E55412*-&4L&-DT_=?'P[1=G$3D&8K%Z
MHP1<)+*"X=MWC5^W165;/4SN 5526L@L58BQ%TET&Z@G52(HW6^(,=(LD=-6
M4S<U4&)7#2&2:.5)D5GCE5G+%6(1]M7#AT1BS*"C?766K=7J:2J'/0"5E*J$
MB>)X79$DA(0JI4;2E"I1D=ULK$2*FIV:9LTIQ"7<MVCQM-S#APZ6#N1O)(&D
M%TD7C,%E5=M-N1$(HZ)5EED5F&P>_.(G51H*N*):Q*N2..6.LJV>5@(XZA#.
MZK)$&9B5C"BF9-IG5X;&^TI9:NI)931O3(\L4E)2HD:?.O3N(49HI=E5LSEO
M&0Y15=9MI=S!:+Y1]9Q]%<D+-.JWCU./0I_*Z9%PNZN@=NXCH\Z#M)9)7FU"
M.TCH+@H@8"J\Z0Q;7PK04TF:4>2Y731M/49CF&29/' JE99)ZG,J2BDA*D;2
M2"\G. K=-EF(LI.-WD6CS:NK)6"0T<.99DTUU>-88:.HJDE5@=ED-DV"#8W4
M W(Q_.  P[0B(WN.H]O'MQ]:%-B.C=W?NQXQ9;@]._M/7VX7I&U >/9Q#7S]
M@]&'*-;3A\>S?PX[\,Y5N+CX(^D>S#@0;[K:V\0ANZ^KQWPNIMZ_W]77KQ '
M'#-A?OL/H]>FG3U8G-(&_,M9!P&C9"_2 ]\X?Q]7GPA6$#Q8W_YRG?\ -R_'
M;;&8!<R]/,MZG3UC7KU.(2'O3:\=![> ^/TWZ,+C47&\:CLWWM[2>@#CA)@;
M^KMZ#W^V^%J9MU^.@]O3P]AQNI]6H_%.\<2;$>H<#A$C>.C5>P[QQ^G'Z</<
M[:(Y+5/\A3D^9O9Y4]R%H>(F^6/FS2.>59\JV@7M05I560$#1="2=34ADU,1
M<%++%S)8)OEG='-SJ-)MK)NR.*9>)(#4#1]R'E75YQ)RBS"BRZ;/W9,EHYJ"
M#**D1019A)45*135L;2(#3/LA9C9D*CYU21&5FZ".F%'%+,M)8U4BRM4Q[3&
M!40LL1 /EBYV>-V\G3:!;X7.'W+LN8O))RT@,O\ DH-,N3<G#,"L5<R,S,NU
MY5>-Y5"2N<-/9#4MRKYZ'1=3$GENPC)2F9C,.#-'O$IF?5IN6K!Z_BZ<C@BA
MJ/EB:;.:N2ISHU7RG3P>*TM3S8;*3XE+7S9/$Y6-:EF22.F<,ICCYU( K2/M
MZ\YE8DIHA'2[',._.21@VJ+3+"E21JT8!4NMB&;99R5 (Z:I2D.1;5]"<K#,
M?+>!]S5?YX929%\AQMF-F?566[MSR#:6Y0E9YQYLP-:.J&C3TLY;1<=4M"!1
M\),O*?IM'+>4K-*(6?1Z23>951BIJOE#!/D]+53<J4H*S,,^-+2Q5=N4,V70
MT-') L[B4,S15'/21B60U*0M(%8DQW52*A=*J6-,N::*&CYR1H[T2SO+*'*C
M9L%9-@-LKS;.!<;[5#F)G;[EM159T0UR)HCDF2D'5_NF^6C+,>J9K+PK]_0W
M)KCJ9Y/<UFI466JL\D1]2F4LAFS!YEHTN[52>$CJ-<2L=3S=A$S2Q5I&DHN6
M553U!KZC.U>#DI5FEBCJF5:G-&ES*.CCJA$=F>M%')2\ZMQMSA'E+/&"K667
M*(I(Q%'1V?,XA([1@E*>U.TK1LVJ1&19-DZV3:5; F[6^>>YG*\F;EC(/JSY
M+=4517;3ET59E.DE25'TUFO0V9$1FG4\ER;Z;I&H? R2S*J**J*EF$-*TY*1
MU<T;ER$#-&HQ[3-0R@F<(+1GE@N;Y$4ASJ*&F;D]!6@S5$M%44CTD*YI-/#S
MR4D313.Z2H]//4F1.?66--"D_P E&EK;R4;M(*]H0$C69)1*QIE1MAI6#* 5
M8.D95N;*,=<?FF2&UN-]/BZ-WQX[8 63K].H/2>G%+("L>TGZ1NUTUW:D$X4
M@-A >CV]&-%-C?T]A^C?:WLP$7!'3BRVP_\ !]$?9G5(^6%H_P"+"U";5TQW
M@TT'JGJCB'SL'Q&EZ?&:L=A$5'].&H!N #TXL TQ41O(W7T[^'K]^-I!WAXP
M_'YO/C!%P1T_ QF^X\1IW:VX=%QC9C!\I3T_^(?'3N.-]UCT&W\T[NO3=V@X
M,:#46[!V'4CAH-XXGAIC?&0#H/2&H;N&_KZ!TZ,:8,9EWVZ=W8.H>(-0$>D0
MP840\/CI]%[Z]8[M2Q>(=OQ^H;X1<6/4?@_'7AU&VG6#ZOBX[,)%"@.MM.OH
M\>^PZ=>&Q%B1T8?QMIIPU'8?7V]N&]8@& =^MP&^HZ<?%\*^[7?IAN18D=&)
M.%KZ=7IZ/5?$KRW)>>=WT$(EP ]/ZM8:>G#2L^M+YOUP>=N\UO7B:H6\LZV\
M@WN+ZAEX Z7^C',]6_/54WV03/WQ<XKD'UB'\E'^PN.@/Y[?C-[3B/X5QK@P
M8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,;BN7:92D3>.4R%OLD(LH4I;C<;%*<H
M!<=1L&HB([Q'&K1HQN5!/20+^GC[MV, L-!NX:D>K7XX8^]V/OV\[_SA;_S,
M:\U%]HOHQG:?X8_1@[L??MYW_G"W_F8.:B^T7T8-I_AC]&#NQ]^WG?\ G"W_
M )F#FHOM%]&#:?X8_1@[L??MYW_G"W_F8.:B^T7T8-I_AC]&#NQ]^WG?^<+?
M^9@YJ+[1?1@VG^&/T8.['W[>=_YPM_YF#FHOM%]&#:?X8_1@[L??MYW_ )PM
M_P"9@YJ+[1?1@VG^&/T8 >/P$![N=Z"']<+?^9C988MH>0OH& ,_3;L8_0,;
M2OW]P_-KO>']<K?[>%N9B/V"]6@)OU8W#O?SB=YU)Z#U]&'B+)M&*(B-]1$1
MU$1$=1[=1\M]^-); 6&EAIZ=WJ/I.)&F%[6Z0?6?1P'[\6A#-[[ 6W  #IQ$
M _%Y.C4(&K??NXV%^_7OTQ9Z&/C8\+:W]O5OZQUZS1%INL4+C;IOQ\O7T<0#
M=B)>6U[W)'H^/:<32Q7T_P NTG?[[@[\.J3*]KA[!?R[M;:<0'?ALTIX&PX^
MGXU-SAVD-[7'<.L?ON+#?<$\<.J#"]K%OVV]'&P;M^_AH&&KS!>/M)/9V:[^
MC#M(@.&O&W??IW[].OMPZI1UP"X7W=G7N ;#TVW]&F&CU/[K[^VVNA[!T865
M.@6&[2W 7Z=>W=KOPZ(QH<0'4=P;O+;XPW7XX:O4]?;[+;]/2#WX66(GAH1Q
MZ_@6(OQ[GMI&>^)[S01 !#C8;!QZ+AT=."BKY*:NIIT;5)D!'!E<A74G=Y2,
MPT%Q?I Q&\H,HBS/(LTHYEVEDHYF4\4EB1IX)%%B R2HK#IMLVL;8[_]SCJZ
MK*+Y4%&P-.3[FGF>9*4A14\X1:-7PBT<LEY%@LBRD"JQYWS65CV9FCAVW<D;
M@=:[=PFHHW60\.^34=?R&J<RJ(5FJ,CJ*>KIB24)6:5*:>(NA#\VZ2AV564D
MQBS*=<<9\ V>U]!R^H<MI:J2FASZ&HR^J*QQR6V(GJ89%CDO'SD<D-D9U<*'
M:Z."5/Z?5<I:3E56KJLAE,PGK0P*)J5J^[YQ8+@!=ER2DFB,?1+9R79 2.&=
M--UBB%P4VA$1\+C,*B,,*81T:MH12J4DM]KXP[2517[UIV'5CWVV34<Q1Z[G
MLS=#<&ODYV':%K.*)!'EZ.+:,E(K#IQ9#=LW:(IMVJ"+9ND4")(-TB(HID*
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MU--(A(^=C5@/LD8@,IZ00?2 =X!PQSNDCK<KK()%#7AD>,D7V)8XV>-QT%6
MU'"X.A(QO<&$[MV8PW$5U;^(Y@ .P   #&E<2U9.Q-R:F8G](<-LOC6++:&-
M/-2AI@.OYA"3VDW)/$F^.G^2S4?>7,6EA.8.:\(&[!<I]2'95$FI#+IF*.@D
M+SYE! ?>@8P".E\6S(G\<Y-9[E]_+I0*V'I'DB3R3KYKTQ)L+_.:;].?\H5^
M3.7O)3-Q815[G*JB_FGG"U,2XX[4=>MM_P!9ZA?]V^4-655(969:+-XYA./'
ME TN^>&:',R-&)J1I&Y#*H/W@)/Q57:.$D"$D6:JG<ZYC@4$]L_QPY:Y?4<F
M.5F?\G,LB%=399FE=3TQD9(ZJGH(ZJ>.C>H4M%!42-''LCFGIN<*.>;0*-KZ
MD\GYZ7.\CRO.JZ8T4U?1TT\RHK203U<D$,M2L)59)J>-7DVCSD=0%#HNVY.E
MA(S"T;$NGK=L$C'13P[11%5LNC,'?J()K+O7 G.9,%UIMX9%V@5JB1NDLJ]*
MY,DB*)ZJE4]-222I$)Z>FE:)D>)UJS,R!VFDNQ7;DK)=F5!&@C5FE$A5-DS+
MTJU%3'$\G,SU,0E#*Z-2B%794A0* VPM)$'B<R.795B*;3[8Y:Y>R=(TAR+^
M4?4%5J1Z;A7*JK$7,D\'83=SDK%JLD2M4%C&1*Z>+JD8,DRD%<6W,,><,F4
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MXN<5R#ZQ#^2C_87'1G\]OQF]IQ'\*XUP8,&#!@P8,&,TR<XHFG>PJ'(0!'4
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M& 3C_P VHH@0X#T 9+G 'IZ[#CHDBAX2A^R5[=H!(Z]]CCBN7/L2AN.VFG2
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MIC44<N_QN;\VF]7\7/#VXT:H !_B\/9>?U_/>G3"XL[ 7 1R]I34;#9_7/\
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M")1"U@N8+DUT#:O;3"]/##"H6*-(U/E%4 4$VN3IV=7'=<XH6=U<KLCU$KS
MD(YD8N>;.V"+DDV%@;#HMQQ*WBP.$2KAH)TB[5N!BC8P!U 8#6ZL.@-%'7KW
M@FQ].*K1C9J-GH.G98V/>+'$=S&_-*C)V-A&0A&:R@\!6YM5%0/\$2 &&D(V
M0Z?:2LH[K$$>GX.+K&+F)B;[:)<]8!!]8].N.3GP[,F8."C54.T4E4A\H H/
MEZM=9_)S&$\):%U'689D;U"4XM.4^5E=0 -8<RC8](6>!EUZB8!BNZI+M-3F
M_8+E'Q"!R^D0Q$<H%VJ1&^TF0GL*R+[2,="Y%/LYFZ?=*1P.LJT;6] )[L50
M\^#X@_C!BCR;V[/=CN-#N]/[*X3R3@7,64X_#(L":@])B$'WP_7 )3#PN(VP
MM73FHRZ-F-W654<WN2RJ=3ULI#'K)QIE5&M%GDT:"T<E.TT0MYJO(@*CJ1E=
M1]Z!TXB@) 4AG*P""29_>%W&74 ;@F6X?!MJH?Z$NX!,.E>2,!.?EN(D8;(&
MAED&H13P &KM]B-UR0,7)Z@F1:2"S3R)>1MZT\)T,KV^R.Z)#Y[[[*"<+HF3
M.JY40>&VTW13%+M?!(8W]3#4+$4#WM@^BM:US#AY0US23F*I;;2H.RH;S58W
M\@#<$=;K;74+Q+$PV=92D-&E30IS<M'LNY6^VZ*0><)UO)&1MDFWD[7!5&-3
M9'N60='#WY(\5CW$-#&3,)$2CUBILB(<2E-;7#:GC\7JIY@-I,OYV4$[BR;4
M< -K"[2,A(TT#6W8SF50*W*Z*G)YN7.33064C:6.51)5L+\%@64 VMM,@._"
MIM)JN#&;OU.=:KF #B8I0,@(B.RLD8H ).;&PB74HDVB[-QPI#FDL[+3YC(9
M:2H(60E4#P,2-F>(A1LF-C<KJK)M+;6^(JMY/4]#&:W(X!39E1IMPA7D*5B*
MOSE)4AF8.*A 5$GDR++L/MC9.'R$;+1M1,$E-PJ*%(< ]ZJFJBJ0#%[=K4-Y
M1#7=J_R6DGROE-00R_922".1?,FBEAE0.AUT-[$7.R01<VN8#E%F=)G_ "*S
M:JI]"L,)G@<_.TM1#44\C12"P-UM=6L ZD,+7('[N>054!U.3+DR^19R;Q@G
M2#MA-.V[<5T&9R3<A)Q:H)E$7CLX(R3@KDC)NY43(Z067*FFD<<?,3ZHEA1>
M&OE<R13R1[5#'7O%'MI3,,LH9*<LBL9&<!Y.<2!)2(YHY&V54X^A7@<"UO@I
MY*%I88Y6I3-1I*Y1YXY)YTF&TP$:*2D91IG0%XI$4DD8[ DV9*U1:E9N7S*+
M(BX6&1(U%LJ^%XVYA%NU)(-A,M'JMUE5W;@&Y4EP[D3:.%0,Y%#B=3$,X6,0
MR2PTJI(_C/-[!F,L>PD<2SQW>!HW9I)-@*WS8B=O+V>FT\IREI3+'#-4,Z((
M#+SBP\U)MM)(8)++,KHJ1QERRGG&D1;1[;49U5HT*=."BD'\R_IQ1S!.%'+=
MC%M7#V.[H9M) JBQWR!6BJW<K?N-K($411;F750,=7FDHY<P;*T2&F,DM12A
MX98VA2.%9HP_-O'+*KAXMIHX%02(X6+G)(@795)(Z 9F[33\U%!5E)XF6622
M8Q2E&D1XXS&4FV1),SM&Z%Y.;CEV4#_S;\\8&N:9SCS/A,S4 0S 95U4PU@4
MAC'15GG4LZ>/W350Q2&59/5G O&2HD)SK1=%38+M;(?4;D/6Y)F'([DQ5<FV
M<Y"^1Y;'E2R+L314=-2QTT5/4(">;J:80FGJ8[GFYXI$N=F^/)W*6GS&FY09
MS#FX7Y3&95;UK(Q:.2>:9YGFB8V+PS<X)87L-J)T:PO;%68M6(3"A$W#L#XA
M]7G'"J'3L]G#",B[^@^W_/7#BD:^G3YA] ><;6OATIN!TCX!_?T@X82+8D<#
M?]_QUX6D-8;].OC^B\H6'JUMNPNIT_SW?NL1<] Z<-F%C[>W]X(/?;#FF:Y0
M'>/BZ?->]O\ "ON#"BFQ[?@'>._JOAI(MB;?'1Z].^YW86)FTTX:AV?T^G"X
MOZ-1ZK]O ]@.&3C4]!^#\=>%J9M>H?;\6'"G2X[1[P;=6_LMQPQD6QOW'W'X
MZL+"&T#I#V_%APIW'@??]&_M&&KKJ>@_'[\*R#J \!] X6!ON/H.[XX8CY%L
M2#QOZ>/TX4@.F_J'L'?Y-_'4;X<*VXC?QPU(WCN/OPJ3&X6'>'] VZK^G"XW
MD7WZC=Q]9]P&_#.=;B_'4\=]SZKW [1QPJ(-P#JT]O%C8:;NFX[?C7#!M"&[
MCV?'KMA0 W #>7UZ\+;_ !8#\?'MQHPM[#V\+]9!%^N^%!1\X7\8:#ZN&^^N
M#&C><&^V%CVZ^L^JXMA00;AV:?%[=6#"1&RW?Z1T>XXV$&P]NGQ8R>!Z?:/@
M$GKP6T8='E#=NX^D6-NK&[&@XCN[CNUZM1IC;>--_G=XT/I%C:W''WAV:^@!
M]7D'"8T)'7;NU!N;Z#CQW<,;@W /2+X^EZ.D!#0;=8=6N[VUU.A(Z,9^--_P
M=WNZ<BCJ ZZA?=XC>>P]F#&Z=_3NX'0^NQ[CC%4MPO[7#=Y0N&$G&H/3\>_#
ME#O'1J,(U  0OU7'CU#?MWX;,+$^D?'JP_B:X]??N.)MEP%IYT/]Z7 >5XP'
MR6L =@XC:Y;H ;VYP']5O??$WE[^6QW_ #9T[67V'')=6_/54WV03/WQ<XK4
M'UB'\E'^PN.J/Y[?C-[3B/X5QK@P8,&#!@P8,;FWZI;?]80_[TF,-N/8?9@'
MG)^,/8<2*NOGZK+[**A^_#S#>E^L4_\ LT/["X4F^NR_E'_:.-%)4C5=?5-"
M470M,5!6E85+((1-.4I2D-(U#4D_*.C;+:-AH2);NY*3?+FN"+5FV674$!V2
M#8<*33PTT3SU$L<,,:EY)976.-% N6=W*JH'2Q Z\:!2Q 4$DZ  7)[L6WG=
MR5N4IR:Y2FX;/[(C-;)^1K%)=6DD*_HF>IPM3@U,U3>)T^X?LTFTPY8*/V*4
MBTCUG#J/5?,TWJ*!W2!5&=#F^5YDLKT%?25:PD"8P3QOS5]HJ9 &NBMLMLL0
M VRQ4D*;;O%)';;1EONN-_9T]=L1RJ,A<\*)S53R+J_)[,VF\ZEWL)&MLI9B
MAZD8YCNI&I6;.0IY@THQ:.+4+IY.,I!BZB6R$>HM((.VZC4BI52"*D699?/2
M&NAK:66B578U:3QFG"Q%ED8S;7-@(58.2P"D&Y&,&*16V"C!K@;-M;FUA8=-
MQ;IQ)<].2IREN3&I3Z?*%R'S6R9"JT7*U,KYBT3.TNSGP9%0._1B7TFS09/G
MD<5TU-),6ZZCV.!TV%\@W!PCMI4.<97F?.?)]?2UO-6YT4\R2-'>^R753M*&
M((5B+,0=DFQQEH94MMHRWW7%K[MW3:XOT<<0W-3)S,W)*9IZG\U:1D*,F*KH
M:DLRZ>8R*\>NK*4-7<829I*HD#1SQZD1I-QARO&R2ZB3M-,=ERW04]YA>DKZ
M2O61Z299DBGFII&4,H2>!MB6(AU4[2-H; CH)&,-&Z><MK@'>#H1<'0G?BLK
MATAY0P[QI@N'2'E#!@P7 =P@.#!BPLMX.:J67FX*G(>4GYN2I&=;QT/"Q[N5
ME7Z_-)*<RRCV**[MTKS9#GYM!%0^P0QMG9*(@PKW2-8GD=(T6: L\C*B*.<W
MLS$*HZR0,*P@DN +DQ. !O)MNPVKY=Y@LHNH9I[0E9-(>D)88&K99S2\XA&4
MO. Y;-!AJB?JL2-825!V]9M>]\FJU=]T.VR',\ZND4S@5-,S1(M1 SS)SD*"
M6,M*EB=N)0UY$LI.T@(L";V!PELL-HE38'4V.F@%CT&^ECQP[J9/9N)3+JG%
M<K,QTZA8PGA*]@CT/4Y)EG3G/F;>$#J+-%@^;PG=)3-^^JJ!&'/E%+NCG V<
M:BMHR@E%73&-GYI9!/$4:2U^;#[>R7MKL [5M;6QMLM>VRU]]K&]MU[6OOPW
MMLM,QWC:F7C3+^MW3.M7"K2CG;>DYY=M5CI %!6;4RNG'F2G7"()*\ZC%G=*
M)\VIME#8-;8U5,#*IJ( T VIE,T8,*Z:R@M>,:C5[#48Q8Z:'7=H=>SI[L:W
M67.8;*/J.7>T'6C2*H^2+#5=)NJ6G6\?2LN9=NV+%5(]58$;0<D9P\:(%8RB
MC5R99TW2!(3KIE-E*JF+Q*M1 7F4O"HEC+2K9O*C :[J+$EE!  ))L#@V6U-
MC8:$V.AZ#T8=@R=S<+.'IHV5F8P5&C!#5"L -$5,$VE37=(LO")2*&,[N)!=
MV?F3OL9 &'=/S#NCG?>8R*ZEV!*:REYKG.:YSQB'8,NSM<V'#V,EM=@':MK:
MV-@C[0&RU]#;9.ZXUW;NO=B54KEMF$[;TQ(-:#K-S'UB\48TD^0I><69U2^3
M%1-5G3CE-@9&;=)F07*HWC#NEB"BL!B *9P*VJJNF'/(:B -""TJF6.\2G4&
M0;5T! WL!O%M^)R@&JWM;0<.&I._@>[K&E^@Z>RXKMJWFWSRB*N:L:3>DCJJ
M>N::F6[2F9 YTDRL:@<JLBHPSPZBZ"9&LD=LL8ZR1 ((J$ :9F-7!L@+/$3*
MNW&!*A+IOVHQM>4..TMQ:^NF+]EVQY(VENP&RNT+M]M8;S8;[#KTW"YFN4V9
M/?8('Y'=<]_1APJ$(7P1GPEA@!7!H$X6.[WB\&&[K_,O?,$19"X^8<_SERXJ
M\E7#LEN>CV=HI<.FSM6!V;[5KV&Z]R-3UV")H;!S+'L[07:+KLAB+[-[VO;6
MU[D<+$X=8S+JM7C.!D&U'U2XCZG>&CJ;?(4_++,ZAD"'63.Q@W*;0R,L\*HV
M<)F:L#N%P406*8@&3.4&$U5&"PVTVE%V&T+J.DB]P-1J;#72PU$FAA4L#)&&
M0;3@NMT46U;6X&H))&MQ;33$J0RXK1LA-NW-'50W;4PN1K4KE>GY9%"GG2HD
M!-M.+*-"IQ"Z@JI@1)^9NH85";)1VBWC):E#;RT.T#LV9=>M1?4#J' DVW8=
MQM$2@YV/:D%XP'4[8UOL6/E6&MQ<=>)PSRFS"/)(0H4'60S"\66<0B2TO.#)
MK0G/ W"728 P%TI%BX'F D")&:"M9+G=L;8C):I=3M*1>U]H;(/1?=>W^5K8
M>(:;9YPSP!-L1ES*FP'M<(6VK;5K&UP;:V-L/$7EW5CAG"R#:E*C7CZB?!&T
M\^1@Y-5G/2(*K-QCX9TFU,A)ON?;N$.Y&2BZ_.MUDMC:24*5A+4CRKL"0!?6
MUM^MN';TG=B23Q=6=#+"'C7;D4R(&B2VT6=2052Q!VFL ""=]\35IEO5S=.8
M6<4E4B"--J)(U$LO 2B24 LL!3)(S2JC4I8I54#E,FF^% QP.79 =H+Q<]2;
M7N3H>/1ZNG>>O73$E U.3'_&("9]85$L9,H%[F(!R74'0E+[C?=?%J4/R<\W
M,RJ[IO+*C<O*DDJXJQ+NJ A'<<I"G>1P%445F%'DV,>P:0:":*JCB:>.D(Q
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MNBSZ=E>6QRAY6H*?E::>R%>N54(^89+,'2T8V8,8^+E$T5RE,9G+L62,DS6
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M<(X[;$_FH!?'+T\8#2!#!N-(K&#L%!T(83KOKN6?EV_[G4XL^0ZKFYZ:<?\
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M *4X 0!L&.M^ :AJZ_PF\CWV=ELGR?/,XKQ;9V(SE'R($*J;*6J\ZALNZR.
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M!:.X-O-?:&I&([#HG?2S-(XB<5G21E!,(B)BE-SB@B._X!3>+=BKY=$U;FE
MCDNTU5&\C,22P5A)(2=]RJL2<7C/IH\LR+,I(56)(*&6.%4 14:2/F8@H%@+
M.ZVMQQV13@<UESF2XL'S=W1$6!N-W$C)R8E#ZX(<!$..S?AIV*?7,LG77R8\
MQFMK:ZQ0Q ]W/GT]8QYRH?(Y.\J)+#RY<BI;\;25=74D#M\3!/XH[OT;>XT,
M5G')-KU^S2<*R,)G?+2;(&=^[-LM&4RV5!  *<51!%P=4S44U2.P1!N9%7G
M+CY=?5MPM)X6Z*>-)'FH^0G)VHBYDVF!&<<L(V,=K[1"N7,=F$NQL%&V@#]&
MOJ-IDC\%51#*R+!5\L^4$$O._6K?)O)>12^HV060*) RF(OMAUV;X]O*?%H:
M$BE&)@.U68METU0"QEA<)E6475^B%==50ZK@Q_FAESJ&4NH)AQYAH.9-%2M
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M'"'X[?W@>DZ89.-/C>/W7] [W-H;YHF'0H6VO08!]'HPHQ\D]GMW8;.M]GM
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M]I.*YJG0A>LY1\A0#$#GY^;C'2Q/H1A[\=+Y$B]94GHIK=EY0;>KXOB&H 5
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ML,2QK:.EDACJJNFIY*IQ%3)//%$]1+I\W LCJTKZCR4#'4:8G,&("!! 0$!
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M2S4[K2S@&4 )4$F%.?AUVRD@16NR*+FR%U\K'?\ 5" +4]RDX@I=8A[EF_1
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M[]0-65J^%G/<J@S.HH*;,>1]9-4PTXIRU5)05] U.2*F"HCO *B<@B/;"R,
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MRJJ*FJRJH:GB'DK1D^_"I9A1VZ3AY%RR>1BSXSL'+J-!V@J<C98YFYA'G.:
MQA''TXRJ;*\WRG+,THJ>,T.:45'FE(&C07AK:>.I@<H%*JYBD3:M>VHO;'EF
MNI:C+ZVLH:AAXQ15511SV)*\[33/%* 2?*7G$:U[7WVUQ&TJMJQ D.FC5-1H
MIT\90\ FE-R29(,ZI!(J>'(1R4L8=4@B50S($!4*(E/<!$,2)IJ8ER8(R9 !
M(2JGG -P?R?*(W@M?77#2[=/9OT/I]7KQK6JBIW#.4CW%2U O'SKT9*;8K3,
MBJSF9$545Q?RK8[@R,B]%9NW6%T[(LOSJ"*G.;:1#%!34P*,((P8UV8FV5VH
MUL1LH;75;$BRV%B1QP7:Q&UH=_7K?IW]9OA::NJX/(+RQZTJT\JYC^]+F3-4
M<P:07BN<%;O8L\%X+A6/%415%D=0S;G!$_-[0B(X-)2%=@TT6QM;>QL)L[>X
M,!LV#6TO:]N."[G4MKNOKNN3T])OA*E5E5H)1""%45&BA3ZAUH%%*;DDT819
M0#@HM$)D<@2-5.!S[:C($#'VS 81 P@.334Q+L8(RT@V9"40EUZ'.S=OYU]=
M<%VT&U8#4;]#U:Z?YZWUQD-550NVEF#BI:@793SL)"<9K34BHVFGY5$50>RR
M!W)DI%V"J"*H.'A%U@412/M[29!#9*:F#(1#&IC%HB%6Z"WFH0!LK8G1;<1Q
MQI(6*F[&QT8#=KQXVZ.C=B23;IR]I"F7CQPN[>.YZM'+MVZ54<.73E<:>57<
M.%U3'56764.91550QE%%#&.<QC"(B1A$J:A% 4"*F50!8"QF  '  6L!8"VG
M#&A%X4!-_*EU/3==??BU^25RB*AY)G*.R=Y1U+0,35$WE%6C"JVU.3AE4HR=
M;HIKM).*7=(D568*/HMX];-)-%%PK%O%&\BDV<G:E041SC+8\XRRMRR61XDK
M(&B,J6+1FX9' -@P5U4LA(#J"I(O<)13&"5)@ Q1@UCH#?0@[[;R+V-M]L=^
M4M[H+R8*1G^4?1\)R3,U!Y-/*PHFBXO-_+V5Y5+R1S30KNA<TY?-B"JRB<W?
MD3-CQ-/A*RPP\K1DS3$_X0-FI)>1GP?N'+=2KR<ELWFBRV5\UI?E/*9YVHZA
M,J"TO,5%*E))#-2>-D-)LIMI,LL?-WV%CV0#A3QR!&F3F'YF=5$B\]=]I7,@
M*.$! VC8K8EKW.I(Q=LI[M[/U!7;"N9#D_I-58[E]9)\LQO%0N;+]HDM1^1>
M0L=D%362\I(/Z)E)&8DI2GH6(F9W,Z27<&>RZ+LPT,5)RB5FWC\'JI T S(D
M-D%;DQ:2D5K3UU>U?)6HJSHJ(DCNB4J@60K\^;':PV:DL',(_P!+CJ;"2WDQ
MQ<T(R=DDL18EVWF_DZZ1%/W7QP6$@H0F0SHK2%Y,W+KY.YD0S8$6KM3EIYB3
M5?#61F8Y=\P0,NQDFD6M &Y[PR&+;OAFJ:^9M&[K^ C,\C_*()DS/(LQOXF;
MJ,DIDI^8#>,WO4;)82:<QM%=B3>6YS39 7F=T%7#]<&IJI"^UYGV%P-DCRK7
MN+C'052>[[U<^KO++-RE<A&].9AQV9F7F8^=4,I4^7!LL\S%Z#H*<R_/'PK*
M%R'@LTH%U*,JADI:"G*LS7S"=T$^4",B$9*#%5B=A#X,T$%51RYDTM,U+44M
M _,U(J:45%1'4;3L]>])(%:-4DCAI*=:E;N^Q)Y0R^>G:CD6$"021R2C:CYN
M384H0"L(D4D$D%Y'YO0*"NF./H_ET\G"D*0Y7>5&77)?S/A\IN510V5*1HRI
M^4N6KJSHO-W)RO:GS(I&M$ZK>90MRS5&+ST^R:3M#.HU*6DV,,NN2MF;V<7.
MPG6Y+9M42Y-5U.:TDE;E$]9Y<.5\S!/15U/%2S0&):WR)Q'&S1SJVPC. :=E
MC&TQ^4*>-:J..ED6*J2($-4;3)+"[R(^US7E)=@"EKD+?;!8XZ*4]V[JLE6<
MMNK(S(=DV>\IRK'>9F22S[,@[^1Y*.;DYDC4/)^JK,>F)!*AF1:SFIS+JH5(
MX$U&=(IM%6#!0ZCLB:A%&(\'"&#(H7S$D97"*3, M-LIG%%'7Q9C#2RJ:AC
MD=5$'!!FVMIM!<'&6SXAZQQ +U#<Y!M/<TLQA:!Y5^; <M&Y'V TXZXK?.[W
M5Z0SIY([/D_#E2\HW,%]E%DYD76]>4]/99>!E8T%DLYB%H)5[3+C(X^9R<I+
M%@851VP^38>FH26BTI>G(F.2<N8HTAE?(1LOSWY3-:*BE2MK<PIZ>6.K$\-1
M7!Q)LRBO%+LISD@#>("61'*2NY4.6U5G(GH_%N9YN0PPP/(K1;+Q0$%?(YGG
M;G9&@FV5(N@&HQY#)^]$ \7E_'CHXT OPMZ=V*V-[#K'K ^C%MUII4\B ?\
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M>014RL)F5R1I*Z8BVK/-^G++%*H0[>;H2L4A3,F:Y%4A5=)@*9@$IS 0HE,
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M;@'E_%@(T(Z1[<9OHIZ"?<?IQLQHVJ7Z@?9C<;UMP+#Z!ZL'MV>WMKC4ZKV
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M'&?U6-]^E]+8L>0:9O/(1<03550>KQ=9)A^L@ Z[8@\R<"=T*6"Z*9Q*-KB
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M+V-+;41-%2@-]FP= J  <1&X<,6CD]Y%7GL1TV:R"4WW?/4X8F^GVMSBJ<M
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M:V%'ECTJL#9FF5QE1#"#A#9[I7$DI)B<CD;B?81,H)DMH )SR[S8N.W;V/\
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MQ9E#'DB!=-GG?E"J";^;:Q7%JQ&8.?3^*CUGV2]%PTL=HB>59R><R ((O#$
M546*T+0]0 NDF:X"=<Z%A$"IBN4.=%A+194DCA,SJI8]H\VZ98=HK?0NLM7
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M&_&1QZQ[P?=C4>:>H@CT'Z-.O&\NX.S&I&JGK(](/T8V&C,.D@_K#Z<?0U$
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M,-FYVZ5/U. '717,87T0(B*!%2)EL+:U@YY0;C?40TTPI_"KE"&#+!E/DJ5
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M:;8>\W$V=!&^C>/E;RNC<L(<A8<Q##8^/+<PE_+N!>[;0N-R[.A-\2C^!SD
MR;"UG*1/XQ43WM0-I/S=H[%[6CV#Y6A?:.T-!AL?9K4<]3.08^K4A.%MH%H,
MUAO<1L*  :^ZPB-N'1A*IY5<KZA740\GXRZ@;0^4&(M;IM?06U])Q(9?X+>0
MU!+%(*WE)*(F+!"N7*#<$;PQ(L3>XXXC2E940K\-"L-]]#00:_Y+$0<VY8'>
M>3_1YE?].+;'R7Y&1>;)RB':V7GVCAA*>I:!/?:;UD-]_P T@@__ -6$&S#E
M>V\\GMUO-S$>_>>K#U<DY(+NEY1#KMEI)].-R-49=)-U4.X*S,*FW\T[JA"B
M&T4"A[T$! =FUPU"XCKA2/-.5L<+Q\UR<9FVK2$YH"NTH4'9!MI:^_4]6$9N
M3W)2:HBG\>Y2HL>Q\T(,I8-L,6-V+ C:O8V&@&F&L)3+@!OW+6O^7A/4D&&)
MJ>6!T_\ -LCK7,Q_XL2?R?R1(L9N4G79,J]AQEWWRY_:M:!_[^$U[?F?HPGS
MW++_ .#/85S0CU,/7?Z<'*N1A.LW*@=B91<]M\*FE0Y>M7"+CN2LU.95(J!!
M7A"E,)# 8 $02$0U#>&[&\-7RUAFBF"\EFYJ17"GY6&T5((%PQMJ-=#A"IR+
MD154T].U3RL03Q/$65,G;9#@J3LFP)L>G7=B6!F;0H$,F$55VR8Q#B'=4-J8
M@' HWYC@"AP\?4&)W^%/+P$$4W)(D @$OG(-B03N[!BJ?\&G@Z(*G,^65F*L
M?XOD>I4,%/GC<&([\;#9I4.9!)N:*JT4D5%54P[JA=HIERI%4#:YBXE'F2"!
M1N!3;1B@ G-?3^%/+\,SK3<D-IE53>3.[$*6(TOO&T=;ZZ [AC?_ (-?!P42
M-LRY:%$9V6U/D5P7"!M=O<=A3;<#<C5C?T?AO=88B*C&D<7*N=V&A#)$V:B8
MG $^<.8A0$62=]DI@+\ H!:P7M<?.LG@EY7M+/(,UY,L9ZBHJ&+4^:J=NIGD
MG<6#-H&D(!VM0 2!>V/1:<N.0JQPIXERN41000!4ER8C9@B2%2"5&]4!(MH2
M0"0+X5K^ZTQ+@4BGROG@1(H511+OY'&YXR9@.F43&;CLD*H4IS !1,?9 NT!
M1,!FLO@@Y:2; ^5>2FP&#,II\V.V5(902;V4, 2 +FPU O=>/EYR"3:)HN61
M<J55A/DH"AALL0-G5BI(%R0+DV)L1PIRG.430_*2K:.K%_3=44ZM'0R<05%H
MXA5S."%5,XNLH<E]E%554J0 ([0'.L()F5,D2Y\CN2'+KDE#F44=9R3J1F58
ME6R&/.5CA:.".F7FP&%WECB1I6('E!5&T%#&#Y09_P"#S/6H2]/RSA-#3-3A
M]O(V>023/.VT2NBH\C+& ?-NQ +;(YK'Y'G *S\9H/T[/JQ=!_#SB>2/<N<^
M]L5P_P#!WP'+3O.1^Y<8_P#!_P  K'_&A0_U1QM;EST\D_S<X_K8U/\ P>\!
MRROUG)/ZN,+T'T5=_C0W^SC<?PVXGDMW#-OI^G&">0' <L>]LE_JX^#X"\ J
MV_6,/_LXS_YZ?_!?_P#6V-">0? <KNJ[9-_5Q@/@1P"JNNXQ'Q8V'\,>)Y,]
MRYI_6QC_ ,Q.CE;Z<G_JXQO1? *H_P :)'_5#&P_A?Q/)ON&:>\XU_\ ,?HY
M5^G*/HQB/@;P"IO&,5Z@QL/X6<3R=[AF7TXU)Y$\!RI[VRG^KA8D:D+ (!4F
M\1U-&;K?6AOX=?##E/X6D@WY.\"-,S[===WI[<,Y?X%6(MRHWV\[*>@_>X7D
M&DQ#=45K#;6-X (#]#T8<K_"SIY.WTOIF72-VO3;#!_X%VT'*CCQRG[4\-GM
MX]&'! :5$?>A4&_2XQW5O "]F' _A5]D>3_<,Q^G#5_X&6&G*??TY5U]6%I/
M!B^@3U[\1CQ#X/3;72VO3??ATG\*/)N<@X;AF/5;CZ<1\W\#N Y3<-YROH[#
MPZSKZ<+"#386MW\M?>(L+[^( 'KPYC_A)IKD=C<#2OOK<=-N_AT'$?-_!#RM
M.4E]..6=5OL?2?5A63P?UL$S;3BR^+HOATO\(=D:Y-Z*[Z<,9/X):6'*+CO.
M6?1V>O"LG@_[W]>.%M66_KT\N'0_A!Q.3[SPK=USU]ENKCQQ'2_P6N=.4%[C
M><NZSIY/QH<*"]XM-)?>%M6=K\+Z=N',?R[IKE.\<*S0Z=>[T<<,7_@S?09[
MJ.)R_P#J_&N-R0PFR(%"4L _1"TOPZ P\'RU]D<K[A5^\]F(Z3^#F\#.]W30
M<.[K_P \*BC$" ?KEN_Z+PTPHORO<:Y:#?32J/IU&&#CD^'T&<7  %S1#@;;
M@=_'3HZ2,* [UW"P/]-=>Y^ @%K '&X>V@[#Y3M9O$>[QCA?I[;^K3?ANYR0
M-<#-;@@ZFDZNKHQF QUM >Z"-[BAOOKP\F_QXW'CW'Q3NY[WX;M\D^6 ,QXG
M4TIX6&X;]/3NQO\ S%_TK_Z.-@*PD7--J>B7Z?=AO_Q;KL^/:"_E>+\""=V,
M@[FM[WG]!'X7-^+=Y\9_C'V7,6N/-YR^_KQH11W&SXS<KQYKH(UMO] QB;8^
MAVO\*WJQNVU8%MG>1I?W]F$SL7\G:N0#Y5MV[AQ[-,6%EI<9YYLZ?G2XW]'=
MK#MPSS 6AC%[GG->TJQ]^'E#]=;\F?VDQQG5OSU5-]D$S]\7.*'!]8A_)1_L
M+COS^>WXS>TXC^%<:X,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8
M,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!
M@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,
M&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P86(Z@ ?6X<)I8_>_^'#:
M3[+J/OM[\.:6X+\;AY;X<C?IPU]&(\V(U^+Z>_"YN(W#7@'H'X@\F%\-G\T]
MWMPYDO>_28-P]@=71A9#H.D:^LV]F&,NX[M;;M>-NKHPM)N[!PYCX#H:WK&&
M$HW]E_1_EA>3>(>WMKA=/-'?[3AD^X'X^-,*B: 'MQ'#H&X!Z1?#*;?WCV#Z
M1Z<*P&WE ?)?"T9MW-?V89OO'9[SA0AH!NW#K#"4</QA[,+2;@'VWC\>,C>H
MZ_;;Z,,F/E@:ZF^H_&!^.W"DHVV!&_#U"/HQGBWQ]D,).+,>ZWHM[L* X]H^
MG&N$V\Z3XZ<* U .P,9&A!Z",)KO(Z00,;B;A[?4&-&\T_''&1O7L/M:V,\8
M?<.WW'&PWC\0>W%BY9?K\[_>A?\ TUAAC7ZQ)<@7D!X_<SVXD*$$RL!]S)_6
M3'&56_/54WV03/WQ<XH<'UB'\E'^PN.^OY[?C-[3B/X5QK@P8,&#!@P8,&#!
M@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,
M&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@
MP8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&
M#!@P8,&#!A6@(:?X/F&PX63S1\<<-I=-KM]I!PY([B]H>@,.QO[F]APP?>?Q
MA^T,.#?>'8'H'"X-_21Z#;#5_-/=[1AS+\( ZP'RB/L'5A9-P^.)^G#*7<=^
M[_Q'U>["TFX>WU!APFA)Z&/NPPEX_BGWX7$W^+UAA=-Q[?HPR?<.WW'"LGP0
M\?I'#E=WH_97#&7>>P?^'X[L*L+1\>[WX9OO'9[SA2CO4[0])L/,,9=_>WM&
M%A!][V#;U^O!NPQ8W8&VZ_K8?3A47<7L'^((^JP]5\9.]NLGVW]V$WWCL]YP
MH+K?2W'R@ XQA/>S'IMIVWTZ\*"[@[ ]&#"*BYMT@CT@XWDW#;=M#;S8PU['
M_+M_R[L;#>M_7KQ/QZ\98PX\GL-_=[\94^:>D$>C%B9:[7?YWLB4![T+?" 1
M"W=<??<(:WQ'5^UXNMK7YY?.!(ML..!&)3+=GGWV@Q',MYI -]N/I!TW\,<9
MU;\]53?9!,_?%SBBP?6(?R4?["X[T_GM^,WM.(_A7&N#!@P8,&#!@P8,&#!@
MP8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&
M#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P
M8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#
M!@P8,&%*/#L'TX7CW+V^_#>7[+N]V'1'<7M#U8<@\1Q'J.(]]Y_&'[0PN;C8
M0OV>01#U^;#@=7;Z=<-F&A'QIKAT*-C#INMOXZB/D'"R'R>PV]_OPQDXZ6T.
M_OU[,+B;A#K]O1A=#?:[;^G_ "PQETUZCZO\\+4N'UH>K#E?LOQC[L,7W#M]
MQPK)N'M]08<KN'8/9AG-[0/:3A8&H#V>L,*IO:V[2WKPRDX=_NQO1^&?VXX>
M88R\?QC[\+2;K=8^:WQX.%^SUW^C#%]X-K6"CTE3?XUPI ; 7LMY2"&-B+L>
MUCZ+G"3[^[WG"D-+]OJ#&N-#HUOO5/T^W"@NX.P/1@PBGG#O]AQN)O-T7T#R
MX&W-V'&?M.T^T?3C/&AOL&_WOL7WWQMQ7M?VG%BY9?K\[_>A?_3&&&5?]80?
MA$/I23Z,267?7W_)-^VF.,JM^>JIOL@F?OBYQ0H/K$/Y*/\ 87'>W\]OQF]I
MQ'\*XUP8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#
M!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8
M,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!
M@P8,&#!@P8,&#!@P8,&#!@P8,&#!@PI1W!V#Z<+Q[E[??A"3>W9[L.J7#ZX/
M5APNX=@]F(YMY_&_\6%J/P@[1_CX<+N'8/9AN_V7\[WX= O<1'3@'B$=?/A9
M-Q[?<,,9+V).FC =U]?7A:GQ\7KPO'Q[O?AA+J .D'W87)</K0]6':\>LGVV
M]V&+[AV^XX5DW#V^H,.%W#LPRGX=WOPK+\'_  0])<*Q\>[WX9R<._W84(_"
M/[<</,,9>/XQ]^%I-U^L?/;XL'"W9ZK_ $X8/O ZE]6S].% ;B]H^8#8W/G'
ML/K4X3??W>\X5!O-V^H,:83/G_S![L*"[@[ ]&#"2><._P!AQM3X^+UX'^R_
MG>_ /L?QC_X<;,:'S.Y?=C?BO:_M.+%RR_7YW^]#C_36&&-?]83\>/\ 8EQ)
M9=]??\DW[:8AU4<G'G*EJ)3PRV><G9<]O!Z]MM^X-:_?P+VO:]@OT!CF$.8V
MBB',[HT'USH4#[3'H)H+LQVM[$^;U]N&/Y6[ZL_N=_+N%/E+\#_2?X>,<Q]_
M^K_>P?*W?5G]SOY=P?*7X'^D_P /!S'W_P"K_>P?*W?5G]SOY=P?*7X'^D_P
M\',??_J_WL'RMWU9_<[^7<'RE^!_I/\ #P<Q]_\ J_WL'RMWU9_<[^7<'RE^
M!_I/\/!S'W_ZO][!\K=]6?W._EW!\I?@?Z3_  \',??_ *O][!\K=]6?W._E
MW!\I?@?Z3_#P<Q]_^K_>P?*W?5G]SOY=P?*7X'^D_P /!S'W_P"K_>P?*W?5
MG]SOY=P?*7X'^D_P\',??_J_WL'RMWU9_<[^7<'RE^!_I/\ #P<Q]_\ J_WL
M'RMWU9_<[^7<'RE^!_I/\/!S'W_ZO][!\K=]6?W._EW!\I?@?Z3_  \',??_
M *O][!\K=]6?W._EW!\I?@?Z3_#P<Q]_^K_>P?*W?5G]SOY=P?*7X'^D_P /
M!S'W_P"K_>P?*W?5G]SOY=P?*7X'^D_P\',??_J_WL'RMWU9_<[^7<'RE^!_
MI/\ #P<Q]_\ J_WL'RMWU9_<[^7<'RE^!_I/\/!S'W_ZO][!\K=]6?W._EW!
M\I?@?Z3_  \',??_ *O][!\K=]6?W._EW!\I?@?Z3_#P<Q]_^K_>P?*W?5G]
MSOY=P?*7X'^D_P /!S'W_P"K_>P?*W?5G]SOY=P?*7X'^D_P\',??_J_WL'R
MMWU9_<[^7<'RE^!_I/\ #P<Q]_\ J_WL'RMWU9_<[^7<'RE^!_I/\/!S'W_Z
MO][!\K=]6?W._EW!\I?@?Z3_  \',??_ *O][!\K=]6?W._EW!\I?@?Z3_#P
M<Q]_^K_>P?*W?5G]SOY=P?*7X'^D_P /!S'W_P"K_>P?*W?5G]SOY=P?*7X'
M^D_P\',??_J_WL'RMWU9_<[^7<'RE^!_I/\ #P<Q]_\ J_WL'RMWU9_<[^7<
M'RE^!_I/\/!S'W_ZO][!\K=]6?W._EW!\I?@?Z3_  \',??_ *O][!\K=]6?
MW._EW!\I?@?Z3_#P<Q]_^K_>P?*W?5G]SOY=P?*7X'^D_P /!S'W_P"K_>P?
M*W?5G]SOY=P?*7X'^D_P\',??_J_WL'RMWU9_<[^7<'RE^!_I/\ #P<Q]_\
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M+>4 ^=[L']W.K"R9S87\6W_ANB_X+#-\NN;<]N)'UO\ O]6-Z7)RV1']&-]
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36)*@RO9G;Y^]XF_U7W\?X3'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g551455g78c79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g78c79.jpg
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M 0$!            !P4&" D#! H" 0O_Q !3$   !@(!  0*!P8"!P0(!P
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M[H%SF>)2PR' )V'I?="K^H(GW0+G,\2EAD. 3L/2^Z%7]01/N@7.9XE+#(<
MG8>E]T*OZ@B?= N<SQ*6&0X!.P]+[H5?U!$^Z!<YGB4L,AP"=AZ7W0J_J")]
MT"YS/$I89#@$[#TONA5_4$3[H%SF>)2PR' )V'I?="K^H(GW0+G,\2EAD. 3
ML/2^Z%7]01/N@7.9XE+#(< G8>E]T*OZ@B?= N<SQ*6&0X!.P]+[H5?U!$^Z
M!<YGB4L,AP"=AZ7W0J_J")]T"YS/$I89#@$[#TONA5_4$3[H%SF>)2PR' )V
M'I?="K^H(GW0+G,\2EAD. 3L/2^Z%7]01/N@7.9XE+#(< G8>E]T*OZ@B?=
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MS[/O"H_</;]Q4JT;[DT_\+5_]):"KMY]I^U6;N'L'V*Z1"E 1 1 1 1 1 1
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M6=+=239H[28IIHOB3D$U(X+EJT;GR<J#I=/&#'R3Q539\7P^#.-5^%O1+1S
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M33,GBI:VO.)U%-">\F-L3JXOJ&Z\<CVE[F!_9!L;8$#06D.?\TM=8D$$M;J
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MFK&I]]1_KW_:M[HUPLE 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 10#R-^Y$5^*F/Z1."[-Y]GWA4?N'M^XJ5:-]R:?^%J_P#I+05=O/M/
MVJS=P]@^Q72(4H"("("("("("("("("("("+%_9?,GCWJ/=5,X[W:U6E+<5_
MA8*R5NH5?46Y-A%S7;+;'='AY^?L6OJ!:*K3H1Q:6+N,<2UPG()A&X0.^DW#
M..\5YDIL;7\GM"R'[1U[Z.]>=>PWT2.RAB0==:,?H[#+HB2C;#U?R_DFN7":
MZ)T,+F3RL19(R?C%4)G)0HSTKOW5^_\ 7U1V9K:PX?UB\K6Q&K]:MEH*8E34
MBSS%1LIF\'*8;R9DXZ:@I!)10K?),MR(N\9^CN$CF*2"#8J3#6.O$1D')YZ&
M*WB<.32JYI1B5&,*S540=FD%<KX(RPU7251<Y<F3P@JFHFKXIR&Q@H7.69B#
M.F[$LK&F>NR>4:LROFN73E/*&76%&[?"N55B?1L9<>,F0Q?(8RMX?)XR8$7P
MA.PCI/*S69BG*.'CN/RJA(M%D\/V&%<OF.3IK&+AXRP@MEVVSGRS;"*N5B$P
MF?P$6*'%?B?IOBS9^24EJZXVNR37)S>5MY.;"CK;8:M,9A+1LIXL]=H5)I7J
MY7G<;2C*^5+!I3BD_(&33-A6??F(8XYO&,>K,:CPJ*JCIHVX/AM/A5,:=DK'
M24],T-8^<R32ATQ ^>Z,1,)W1M5&1M87D$G7>7F]MA.^U@-GMN?6LJR6.O*)
M.%R3T,=!F=!-VL248F2:J.4".FR;A3"^2('<-E".$"*Y*95 Y%D\&3-@V>$5
MUR$GH-0[U-.9BE#QIV:<B0DBS,=@>1*0\>1Z4JV<M3OR*IG9E7PGET50AD,'
MP<N<D7$E9*ZNU=/4)^%69,6*,F]=I2K%1JSC7*2RS>0=."+Y2;L5T6ZZJ+M4
MY&ZJ2*RA%#$3/DI%;*>U]9*W1]KI*_5$]ZC:/&[,D*H6>C<SC/7LQ(2D5%W1
MPQ^D>62K3^0A)=HUF#%PR56CG>"K9PD;."?X_P <0KF4LE=101<K3T*DV<,L
M2;=PI*,4T%XW+5R^Q((JF7PFJRRR9NWF'9#&0RU:N7'E/)(*G*151NX;NT$'
M35=%RU<HIN&SENJ19!P@L0JB*Z"R9C)JHJIF*=-1,QB'(8IBFR7.,@BY@1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 10#R-^Y$5^*F/Z1."[-Y]GWA4?N
M'M^XJ5:-]R:?^%J_^DM!5V\^T_:K-W#V#[%=(A2@(@(@(@(@(@(@(@(@(@(@
M(M7O)+H[[%O'FUI[F37-NT&K.M6T&BT-6AWG2MMV&=ZG2MM2^TR6*MVJK\@M
M1HUR==J2I89L6P56^0K++4LDYB)4JIHTI6!&J6D'?<6-MMK;18WY+":L] A7
MZ%1HFKTW=>N%7#"(XTN+'!W'C PL6H=QW[CSL'?EN6MF^]6MMO1)=HQEXA-W
MLZ\O!/[,PEH%_K>I3R=MED&[:"C8 L ,E.N?+?\ K>7: X#8,K6_3?R*IZOZ
M"M/6=CX\R:?(NOSC+2[G4C]_,9X_-(K9\4II?>NT]X0L)QTV 3:KXW'>G;$7
MV>K3=SUMI#WHMYK\(3#9]!]:*MV,H7W!V;[^79M !N+;;6N-HL=NU8:<?NA/
MWY<F.TZGL6.@N-E7AM?\<*=KZ;F-=:K=S.\K-I/<=_V<_LW(FIZ$Y&W%'<!K
M"PF*\RM>SYK8NH[[<K&TA)\FO:OV/02E8V[?)[?MV'HI+[D';Y?+L%Q8VN-G
MJ&VV>6<=>Z"NFP<W3+0EO%*)ME++QWCX2X5/5TG&W>IU?3FG=VZIN]0UO>K+
MMNY6ZDP&T%-O1L^UCS2\VPIS?755K[MA<VK*)>04J"^X(MOO<WS<';K>2Q%_
M+>ZMFH]!K:*+3(MA3N36MJ9>8"YT.2B'E-XK%K>J%*U3>-&X>+<O,SNIHW>:
M*\SO38].W'*6S8&W<7IBUG[A6ZL5W25HF,^C*O8FOOV'=8;1<?.#M]MP(V"W
ME.U97<(>C$><-][N]O([<I]OBW/&;4^@'T'$:9>5BSV6;UAKS26N4=D6*^6C
M:NS9&-P[AM+-"(Z_UZQHM+53FVJ]D866Q56.LKTH+KC])._._J]?E_0M=?#?
MH([$VT7I1'DM,ZOI$ZPC^*RVT- 5;1=1<5VWL-";@GMNVBM<@I^!VW:*GOC8
M%X+/O-<EVBDW90\)0#'BG-0MGTU\4\#8![ K%]KV]>V^W;;=<; /MVW&RT\/
M>@E@Y1UN5D]WC4$:KLJ0.5JWCN/,>UM=LKLKS6U?S)FF')6SEV;A'D)-PN=;
M9TMJ^=7AJ,UH.OK'*&4@[$8QXQ<1?B#P-U&ONV7M;>;[FZNS9LN/SM]R!NLN
MNUZ!2EUJ(GF5!V[1*WF9;NEI"M*<<8M?6-^?1/-20Y8ZY@-V4)ALV+0VEK&F
MT]Q&\>EJ&[DHC+^E0[.1AYRLL$6U.;2FONV>K?M_-U3;9L)VGR[<U2I'H#85
M:I/H&)WK2(B8L.B&&K+-/H\<VR'D;#!\KK#RFANQ+2)VQ$.ZCI57%D/HZ<TT
M:6F73S259I=4CM@Q)H(CE0FOZO+??ML1;*U]YO;\XDD>17HET&E&4I<Q$S=V
MU9:K0OQ<@N/56<V/3&P7U6H$PAR=VUR/MESI2?UD2[*KD-9R[46H3:E0NT(]
M&%BX4IEYF;I\L\UPG%MOZ .%^J:WMWWWB^ZVW98GUVYFZV^<9]02.@./VGM)
MR]L97N3U=0*[2GMPC:5 ZYCK"O!,$F9Y)A1JQD\'5F:WD\?1HABL[PU1*0KA
M\_=Y7>KRJDW).9)SWG-3B"A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M=PZ-:ISZ5!LL)MGR\8<GT>7;,I#Z2K(-U6;1EAG],?N/)I,4'!ET,*<F_23
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M7U[IZ^:KBFD$G:SUTCP&-;$8]5A;JO#?"174VD. Z0U.%X-%787I+1X]75V
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ML17#*O5G"SFI5!VHO6(G]*_ =14-9X*M$:FII*2JGFIL1?+43P4L\TKO'.)
MNEE:RTC]@#G=G2NN+.H,.<#0T_ASPKQ-I?"#I'3PQ"FBAGHHXZ>-L\4<3&X7
M0AK(HZC6E9$!_--=4XDT1ZO9XSC<>IB];@?]93D9_'[=?M4O7]>&V/%.%>C,
M/^I4WPUKO7?YSO>/5/K*<C/X_;K]JEZ_KP>*<*]&8?\ 4J;X::[_ #G>\>J?
M64Y&?Q^W7[5+U_7@\4X5Z,P_ZE3?#37?YSO>/5/K*<C/X_;K]JEZ_KP>*<*]
M&8?]2IOAIKO\YWO'JGUE.1G\?MU^U2]?UX/%.%>C,/\ J5-\--=_G.]X]5Z6
M_P#"][:VI?\ F9O>+O>S-@W6,9\8Y9^TCK;<['9&#5^7:FKVY7K=I,R3UN@[
M*W<.$"N4DRK81762P?!%3E-J;POT-%38#ASZ:CI:=[L7C:Y\%/%$XM-%6$M+
MHV-):2 ;$VN ;7 671.<97 N)'9G>2?ZS,UZO.>_->F<$-#/-PVB#<6^9D9Q
MC4*%2&D@G$K6FV235\_3;.I4[5_U1#Q\7%R4I*RF(]\9%%JFT0;+OGS-%34.
MB&BU5I;B[<,IY6TT3(7U-75.89!3T\;F,+FQAS.TE?)(R../79<N+BX-8XCO
M^AFB=7ICC+,*IIFTL3(7U595OC,K:>FC<QA<V,.9VDKY)(XXXR]@)<7%P8QQ
M'F Z4'I45.:/1?-[-2F]DT3N#77+C4T-=Z_5KM)YRYKEFUIO%S"3,+8XY&OR
M+R%E74$\0D8ETUP>+DXM##A1VDXC7B^X-'= 3HKIDV"H?%BN&UV"5\E+/-3,
M%IH*K#Q+%+"\S,;+&V5CF2-=:1DAU0TM>T9'A*T$JM!YZ1G>^_4%>'NI*L1&
M"020:HGIYHP^1K7L$D;VN:\ME8^X#7->UOE=^L/O_P#CEN'VF77^MC;'BK"_
M1M!]3I_AK5NN_P YWO'JGUA]_P#\<MP^TRZ_UL/%6%^C:#ZG3_#37?YSO>/5
M/K#[_P#XY;A]IEU_K8>*L+]&T'U.G^&FN_SG>\>J?6'W_P#QRW#[3+K_ %L/
M%6%^C:#ZG3_#37?YSO>/5/K#[_\ XY;A]IEU_K8>*L+]&T'U.G^&FN_SG>\>
MJ?6'W_\ QRW#[3+K_6P\587Z-H/J=/\ #37?YSO>/5/K#[__ (Y;A]IEU_K8
M>*L+]&T'U.G^&FN_SG>\>J?6'W__ !RW#[3+K_6P\587Z-H/J=/\--=_G.]X
M]4^L/O\ _CEN'VF77^MAXJPOT;0?4Z?X::[_ #G>\>J?6'W_ /QRW#[3+K_6
MP\587Z-H/J=/\--=_G.]X]4^L/O_ /CEN'VF77^MAXJPOT;0?4Z?X::[_.=[
MQZI]8??_ /'+</M,NO\ 6P\587Z-H/J=/\--=_G.]X]4^L/O_P#CEN'VF77^
MMAXJPOT;0?4Z?X::[_.=[QZI]8??_P#'+</M,NO];#Q5A?HV@^IT_P --=_G
M.]X]5ZL/\+!LK8U[W%RX;7B_W6Y-X_6FM5V"%KM4[8D6*R]IL*:RS-*7?O"-
ME5B$(151$I#J$(4I\YP7&,:9\,=)24U%@9IJ6GIR^JK \P0QQ%P$,) <8VM+
M@"38&]KFRSJ(DF2Y)V-WDGRG->T<:$7(("("+!_DUS =:7WCQ/XV:XHC?:^Z
M>36Q7*#FK'GU:^TUYH2E,5)3;V[;')MXJ;RT951JK'1]9B7K-J2[61]B CI!
M%T@N9(K!MPYU[!O,G<!]^0VJ^>:?*BI\,>-NR>0%J8.+ XJL:WCJ/1XW*AYW
M96SK*[1@==:YK[9NDX>.96WVM_&Q?A9-'B\>P4?S"C91I&N<E*&M+B /_@>4
MGV*;]8S%WL.N*%/[+J4?0MB3=.K4M>J/%3V;3&TZW2,.S=V&L,;+F.B<3S:"
ME5G48E+%C61'Y6V'*:!"*%\)0=YMM'D.ZZO@$0$0$0$0$0$6(G/S:EYT=PGY
M3;AUE,$KVPM:Z/V%<J;.*1L7,IQ5B@J^\?1;\\5-LI&(D"MG22:F6DDQ=LUL
M%\1=NHGG)<\WHU1T^(Z08-0U<9EI:O$:6GJ(P]\9?%+*UKVZ\;FO;=I(UF.:
MX;P05\Y7%L;W--BUI(.PV('KV+P&?M#'2V><W%^PKC]\KQZ6^3#0GT0_^\<3
M_&+B^]3_ $G[+/X54(C_ !!?2Q24K&1S_DQ%JL7\@R9/4\Z-X^)X4:.G*2#D
MF5#:J7*GXZ*AR^.9%8I?#XV4E,8R3.-6^#+0IE'5O&$O!933N!\8XB;%L3R#
M9]4]AL1N<Q[3_6:X7!R*.JJ#5TH#S<U, %F;;F5MK=FZ*2^6I+&^_P";(QUG
M#UB^,?.3'QG'BE6\=17PFRW(KY=@OA1<Q9PD9A+.'-;=84E+&W)] DJVHELL
MM>)QZW)6/RJVWUCML_6)!.J'%T3]8D50@L->D>#/6, AFH[8SW+\DM(J']*@
M  &D;3'JM;L[5S.SJ(BU@.'NJR\&+%(=6DPN5W>:7%&/T5.)GPE:#XMY/)K_
M !!72R1DQ+1K3DM&H-8^2?L6R)]&Z&4.BW:.E4$4C*/-9*.U#)IIE(8[I0[D
MV<9,N<RN39S^JM%X,M"WT=(]^$2%[Z:!SR<1Q0'6=$PNN'5FM>Y/YVW/:OS5
MJZJ;O53JR#5[Q-:S8;6[1UK=FWL[6W:GS/-^;94W]H8Z6SSFXOV%<?OE>,GY
M,-"?1#_[QQ/\8L?O4_TG[+/X4_:&.EL\YN+]A7'[Y7A\F&A/HA_]XXG^,3O4
M_P!)^RS^%/VACI;/.;B_85Q^^5X?)AH3Z(?_ 'CB?XQ.]3_2?LL_A3]H8Z6S
MSFXOV%<?OE>'R8:$^B'_ -XXG^,3O4_TG[+/X4_:&.EL\YN+]A7'[Y7A\F&A
M/HA_]XXG^,3O4_TG[+/X5NSZ!7I5N='-OF9=-2<E=QLK_08CCQ=;Y'PK?6NK
M:>="TP]^U;!Q\EF4I5,KTLJ5",LLRWRR6?*,%<N\++-E%V[91'7_ (2-#-'=
M'\!IZ[":!U-4OQ2GIG2&KK)P89*:LD<S4J)Y6"[XHSK!H<-6P(!<#DTLTLDC
MFO=K ,) U6C;K-%]@!W$KU]C1RSU@_S6Y@.N+[;1E,H%$;[?Y!\EMSU74FF-
M1*3ZE:)/(Y>MI?:%VG9UM%3SNOTK6.O$9:QV2R)P4LA%NE()!XTRA(F.0I O
M>YL "2?L'M)V<_(IVY&[]UWQ;T7M+D)MB4ZIU_J:H2ENL"Y,IY>/2LD\)QL%
M$)*J)$=S]EEUX^NUYAY0AI&<E(]B0V#N"Y! "2 -Y-EU.,6Q-G;;X^ZBV?N;
M6#?2^S+_ $>&MEKU8A/.+*:D.IQ#Z>RA7LJ[AH!UULE%+,%IJ,7C$U8&86?0
M1G4EF-ZR=D-@2 ;B^PYJ2IR]T>L.TX^RW*J5Y^JW(\293EBB(EVJT44513=)
MMG[QNL=N=9NND1<I,I&415(4V3)GP7E*+!,:Q*)T^'81BE? V0Q.FHJ"KJHF
MRM:U[HW2012,$C6/8XL)#@U[7$6<">"Q/2?1K!:AM+C&D.!X35/B;4,IL3Q:
M@H*A\#WR1LF;#55$4CHG212L;(&ECGQR-#BYC@*-_I>U-_%#7?YUK7]3&7^2
MFE/]FL?_ +GQ'\,N._+[03^VNB7_ /H\'_&*\8>;A;"Q3E("7BYR,6.HFC(P
M[]I)L53HGRDL1-VR57;G.DH4R:A2J9RF<N2&Q@V,X'$U='64$[J:NI:FBJ6!
MKGT]7!+33M:]H<PNBF8R1H<TAS26@.:01<%=@P_$L.Q:E96X57T6)T<CGMCJ
M\/JH*RE>Z-Q9(UE13221.=&\%CPUY+7 M< 00H7Y$_<F+_%++])FQ\6;S[/O
M"RG[A[?N*QLYL[^V)QKX4QFS-9K04'-F?Z*I<ML>UP;NSU+2].V!;:C3[?N>
MT5UD[CUIF%US S#R>6:*/FK CA%L[ECJ1+9\@MS^C&&4N+8S'1U8EDC["MJ&
M4L$C89Z^>FI9IX*"&5S7".2JEC;$':KG6):P!Y:121Y9&'"P_-!<=H:'$ N(
M\H%[V6*_VE#_ $G'SM;C+W4.D9BJ!H;?G)C86_\ 4MCUY24X2F:<?UB(<:[:
M5'7,?=JG;;LE,W"MINY%C-5)DPK\JXFY1DGB&\$OSWY)MQ!\<KZ:?15]5B6&
M812X96PU<YDGKVS/%4Z>K=3SPT_9P3%K71SN=*P1,<=>[*=L6W (FLU[W.:6
MBP;;8 +@FY -K6O<J+#=-1?2OZ=<G7'VAH:B4U#S"O%J;P>W9*U7"Y6;C%"Z
MOM"+'1\N\HE,:V*-=PFPVZ<Y%VJF5^Q$4;W*9R2$@M8X<;'S/R!IBV>G;B=2
M:X5V!4T)EH6004\.+R5D)=B+&U-087MDI28WPU$L5C!'>26LM2QWAUP=1NKJ
MR$V<2266/S387V'<1>]]P%S),?TQYWSW6L'C2VL%)2Y\A'_'R:M<'R?2N^FF
M\ZK&:.>U.2UOL&A:4M%BVDA8Y'>U?J<HY2US4ZE0KA!S<%>+I"JN:ZK.8KM!
M0UM7)XPK RGPMN*1PR81W:O,0?B+9VU=+4XA#%1F)N&RSL!JYYZF"2.6GIY
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M#<FQ&LS7&RVT6V7!W^2VU;AQT59"Q5YH?_#_ &C_ .Z5?]?8#9O@A_IUAO\
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M6S2.>&$BSC _S5R_^4-7TW<< PL/:ZK[U45SV @OBIQ%V#'/&]HGD<\,\CC
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M-+R<,GXA%L[C\J7[N5]7&<'P;#F$B7>,_2H]HLE T<P$  81A_S6AK3W:+6
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M[-DH,T4:0DKS7J^QD(2KOG$N:/A$9IZ_81R$N5-^" D @>7>?+;+V9Y^590
MH0$0$0$0$4"<B?N3%_BEE^DS8NS>?9]X5'[A[?N*E&B_<BF_A6O?I#,5=O/M
M/VJS=P]@^Q74(4H"("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("+"*]<5;K,[,G[92MIM*I5[SLO6^T[;&*PUG-:F-@U^SA(9XTK5BKMZ
MK4>\K]SK<(E"3%?ND%9HV.R[>R,4D1R=L5IJ_%= L4J<<J\0PO'H\/H,4QO!
M<>Q"!U-7'$(JS"(Z6FDCH:RCQ6ABDI,2HJ5M-4TF)TM=!"9)9J=K7F/L_0&C
MWABP"AT3PW!<?T/GQG%]'M$]*M#\%JXZ_"1@]1AFDL^(5\$^*X9BFCV+5,&)
MX#BN(/KZ#$L!Q'":NJ$%/2UCW1-E,\0PO1RH1$S!37^DLJYH6P52X)QF:T<D
M5VSA]OP=YGK6W;EF<&1F)V@U*JZW3<',L9D@RD9,QG))(T>EU^F\#;*>JI:H
M8WK&FJ\/Q$4YHW"G.)4VD5+BM77L9WJ[*FKPK#Z#!6N.MV3(YI_GB8PM[M7_
M .5'+74&(T!T3,8Q##<9P1U6,6#JWQ%7:$8AH]AV#2RF@M)0X=I'C6,:5/C:
MU@J)9Z6D B=2-J7[!7M';2,K8Y![8+6X966 <UYW7#S'@K;)L[;-FCA[%1Q6
MQ3LI0Z3<_P#Z9ARIG!WCP^$\96QXFW9<+9-45DTM97OBK:1]')1&I_S*)DC&
M,?+!"& Q3EK#_*ZY(,DA ^<+>:(-():6CPNE@PS!HI\*Q*+$X<5;0_\ U6HE
M@EEFC@K*HREM12-?*W^0,3;M@@:76C^=B"VXN;=1U TT;*W_ $W<=?TZ/K41
MKUM9=2W!K.$95>12<1$C8;!5MN5]TRL\7'H(,6-@J",*ZP[2ZV,5-RLN0^NV
M:"Z0MT=CT6GQ?1O$<(PV*BI\'96Z/XC'5-BH9FOIIJRLH-(:.2*O@A8R**LP
MYM+)VC34$![W-.[IO"]H2_3>;PA46C6G6!:2X[4XK6Z32X3II@DV'NGQ>E?%
M74N&8;C&A6)0U&$UE3))45&&8V^OA[%XH@711L<V[M*\3CZWO&=B7;8UFV9;
MF]'UK5&,V\E[9"*K/Z7%6F+F)>QQ[6UN(JXEF$K"@2+2MK.<>09([RY9%W).
MW+\_(:,Z '!<4\<XGC-=C>(LPO!</BJI*C$*5SI<-@KX:FHK88\0?3XB*EM:
MUL#,0CJI*5L.N)I)I'RGA-/?#,W2K1X:,8!HMA.B>"R:0Z5XS44$%%@N(,CI
ML?K,'JZ*BPJIFP:*MP,T+\+D-6_!9\/@Q!U5V;J6&E@BIFYC#8ZT:@(@(@(@
M(@(@(@(@(@(@(@(H$Y$_<F+_ !2R_29L79O/L^\*C]P]OW%2C1?N13?PK7OT
MAF*NWGVG[59NX>P?8KJ$*4!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!% G(G[DQ?XI9?
MI,V+LWGV?>%1^X>W[BI1HOW(IOX5KWZ0S%7;S[3]JLW</8/L5U"%* B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MM^8(GWL+'(\"EQF.(3MS2>^%6_,$3[V%CD>!2XS'$)VYI/?"K?F")]["QR/
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BG@YR%R?.,%P8Y2YSX38QF[ 03<$;,O6%1Y!&P@[<_:O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g551455g89m10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g551455g89m10.jpg
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MMF-U=GBT151D=('_Q  = 0$!  (# 0$!             0,$ @4(!@<)_\0
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MAH$3OZ_UROI,_72PR&@1._K_ %ROI,_72PR&@1._K_7*^DS]=+#(:!$[^O\
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M=#MD;W':;_*;/W!UB; 6O:B?<_=UE-?Z[4B\%W!(-_S?B,VQPZO-$):B*ME
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M(E$2B)1$HB41*(E$2B)1%4!/_-1G_P"8,O\ ^2E7%_\ 0[_E=^A1;[=U@_\
MB5\</_[E-I?_ '*\KY[DA_V7P'_TRE_^V%MU_P#OM5_Y\G_N*Z^:^C6HE$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB415[HK)^KA[L<A[/6'NBG^GA^]9ZR
MMCD="G163]7#W8Y#V>G=%/\ 3P_>L]9+'(Z%.BLGZN'NQR'L].Z*?Z>'[UGK
M)8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'(Z%.BLGZN'NQR'L].Z*?Z>'[UGK)
M8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'(Z%.BLGZN'NQR'L].Z*?Z>'[UGK)8
MY'0IT5D_5P]V.0]GIW13_3P_>L]9+'(Z%.BLGZN'NQR'L].Z*?Z>'[UGK)8Y
M'0IT5D_5P]V.0]GIW13_ $\/WK/62QR.A3HK)^KA[L<A[/3NBG^GA^]9ZR6.
M1T*=%9/U</=CD/9Z=T4_T\/WK/62QR.A3HK)^KA[L<A[/3NBG^GA^]9ZR6.1
MT*=%9/U</=CD/9Z=T4_T\/WK/62QR.A78?W6"/GGO=#.)QTS"%W;9:7@,D7#
M8:\705QM HGC?)-9)'-/.ULL;XWOCE>ULK7M\]KU\UR/GA;R;PIKIHFD0RW#
MI& C_:9N()N%N5X/=D^X_P!3>@_\#5UX=%9/U</=CD/9Z^E[HI_IX?O6>LM.
MQR.A3HK)^KA[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_T\/WK/62Q
MR.A3HK)^KA[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_T\/WK/62QR
M.A3HK)^KA[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_P!/#]ZSUDL<
MCH4Z*R?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<C
MH4Z*R?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<CH
M4Z*R?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<CH4
MZ*RCJV>['(>S_P#>U.Z*?Z>'[UGK)8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'
M(Z%.BLGZN'NQR'L].Z*?Z>'[UGK)8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'(
MZ%.BLGZN'NQR'L].Z*?Z>'[UGK)8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'(Z
M%.BLGZN'NQR'L].Z*?Z>'[UGK)8Y'0IT5D_5P]V.0]GIW13_ $\/WK/62QR.
MA3HK)^KA[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_T\/WK/62QR.A
M3HK)^KA[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_T\/WK/62QR.A3
MHK)^KA[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_T\/WK/62QR.A3H
MK*.K9[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_P!/#]ZSUDL<CH4Z
M*R?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<CH4Z*
MR?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<CH4Z*R
M?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<CH4Z*R?
MJX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/\ 3P_>L]9+'(Z%.BLG
MZN'NQR'L].Z*?Z>'[UGK)8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'(Z%.BLGZ
MN'NQR'L].Z*?Z>'[UGK)8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'(Z%5 3%I/
M8J-O>.'K6L09WO>X@AR6MX2G\=_]GKB^HI]EW^/#_2?_ -5F1_\ $FR[(Z%;
MW]U7CYY[W2/C<=LPA=VU<<2&T%6[EL->KMUTLY(\O@HBLDCFFJGE;X\<\,LL
M<K?':][5\_R2GA;R9P)KIHFN&&4H(=(P$'FQN()N%MUX/=M5N/\ T\G0?^(K
M0#HK)^KA[L<A[/7T7=%/]/#]ZSUEJ6.1T*=%9/U</=CD/9Z=T4_T\/WK/62Q
MR.A3HK)^KA[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_T\/WK/62QR
M.A3HK)^KA[L<A[/3NBG^GA^]9ZR6.1T*=%9/U</=CD/9Z=T4_P!/#]ZSUDL<
MCH4Z*R?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<C
MH4Z*R?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<CH
M4Z*R?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/]/#]ZSUDL<CH4
MZ*R?JX>['(>ST[HI_IX?O6>LECD="G163]7#W8Y#V>G=%/\ 3P_>L]9+'(Z%
M.BLGZN'NQR'L].Z*?Z>'[UGK)8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'(Z%.
MBLGZN'NQR'L].Z*?Z>'[UGK)8Y'0IT5D_5P]V.0]GIW13_3P_>L]9+'(Z%?V
M.O%(KR8/^Y-ORZ\6K]&L,AH$\4BO)@_[DV_+HEAD- GBD5Y,'_<FWY=$L,AH
M$\4BO)@_[DV_+HEAD- GBD5Y,'_<FWY=$L,AH$\4BO)@_P"Y-ORZ)89#0)XI
M%>3!_P!R;?ET2PR&@3Q2*\F#_N3;\NB6&0T">*17DP?]R;?ET2PR&@3Q2*\F
M#_N3;\NB6&0T">*17DP?]R;?ET2PR&@3Q2*\F#_N3;\NB6&0T">*17DP?]R;
M?ET2PR&@3Q2*\F#_ +DV_+HEAD- H0T0*LQ;6N+'6_=V^*S)*UK?'?\ DLG=
M2W_UWO?_ +T4 !X@'SV^.S( *;XI%>3!_P!R;?ET5L,AH$\4BO)@_P"Y-ORZ
M)89#0)XI%>3!_P!R;?ET2PR&@3Q2*\F#_N3;\NB6&0T">*17DP?]R;?ET2PR
M&@3Q2*\F#_N3;\NB6&0T">*17DP?]R;?ET2PR&@3Q2*\F#_N3;\NB6&0T">*
M17DP?]R;?ET2PR&@3Q2*\F#_ +DV_+HEAD- GBD5Y,'_ ')M^71+#(:!/%(K
MR8/^Y-ORZ)89#0)XI%>3!_W)M^71+#(:!0DQ OQBZ_W6QY/ A_QW8(6QO?OY
M+EM;.^-\<LK<MKY8VPQRPMEC?++.V>-L'1K^W1\7^I2POP' ='I_R4WQ2*\F
M#_N3;\NBMAD- GBD5Y,'_<FWY=$L,AH$\4BO)@_[DV_+HEAD- GBD5Y,'_<F
MWY=$L,AH$\4BO)@_[DV_+HEAD- GBD5Y,'_<FWY=$L,AH$\4BO)@_P"Y-ORZ
M)89#0)XI%>3!_P!R;?ET2PR&@3Q2*\F#_N3;\NB6&0T">*17DP?]R;?ET2PR
M&@3Q2*\F#_N3;\NB6&0T">*17DP?]R;?ET2PR&@3Q2*\F#_N3;\NB6&0T"A/
M1 N_@G(+87Y'J%[\U@AGR6^7\=^3#'FXV_GG?G6Q_GC?EHEAEINUX7'FW^A3
M?%(KR8/^Y-ORZ)89#0)XI%>3!_W)M^71+#(:!/%(KR8/^Y-ORZ)89#0)XI%>
M3!_W)M^71+#(:!/%(KR8/^Y-ORZ)89#0)XI%>3!_W)M^71+#(:!/%(KR8/\
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M.$KZCV3N+ALVI$1JY"<8GIQLUB TH.)X,GP=7696'R7!9T&?'QQ3;%P?YB0
M-K@2;[]JQX6W#??A>_1'?=P_XL<X[L1F(QT8+VSN/N;O#AP^&^(?"?2!"<0O
M?6E4!0;: I;.^N29.50KB-@(05K&63NS] FVBZ2N1F)'\6Z0U\3;%NFP>2&V
MW6/#@=Q:=X'"_57@7<<N* 3I;6[<GK#4NQ0L:XO#>])[P#[/WS$1_#K/HP3T
MBGJD.48DM <'VC-;0&1QJ5XX;!PAXC3!N,%UVV1XH3=2<D8$$2;8N=Y_IL'
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M#'//OF>..-LL^;;'GY6M:V6?-Q^+'G7Y;\VWQ6Y>2WQ47!?5$2B)1%!?6Y?
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M1WR^%[48_GTL<CH4N,QJ%C#=6OM+<0VJ)[I';V(>5ZRV;''T3FT;QE;T#D9
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MO7RN_4Z-?V^KXW]"G3]0_?X^"IU%4HB41*(E$2B)1$HB41*(E$2B)1%!??\
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MKL3Q0_ZSG?0QSW?I<9#K[4L<SU=B>*'_ %G.^ACGN_2XR'7VI8YGJ[$\4/\
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M/5V)XH?]9SOH8Y[OTN,AU]J6.9ZNQ/%#_K.=]#'/=^EQD.OM2QS/5V)XH?\
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M,"BY4CR8W-RQR*W!+XS G;%\V%PV\S);=?,G=Z/CXZ,NN.-"$L>4L1U[L]C
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M$L6*=E#+2LII:26D<YG*#%VL$P8*)X;W-3TSHGQ!SB^KPIL+V/V"R.>T;6O
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MV)X1)/) 7\0/?=NF[,Z#M3?D-3V)X1)/) 7\0/?=NF[,Z#M3?D-3V)X1)/)
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MV)X1)/) 7\0/?=NF[,Z#M3?D-3V)X1)/) 7\0/?=NF[,Z#M3?D-3V)X1)/)
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M*1259&U)22.N115I: &R@ \S-9K*E@) ;*V2-O[[R(Y;TW*BF[GJ.;I\9IV
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MV#)S-O=[-WJ2),E];6^N]_TW+"VO."#>HZ#F8S*C,F5F#V+ZRB&RYECL*%!
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M(KXI\.?'O*_RG?*=4<KJA^%84^6GY.4\NX?S1RXM+&Z[:FI:;.;3-< ZEI7
M$$">H;SW-QTWH#D)R$AY.0MQ#$&LGQN>/>=SX\.C>/YH(';PZ=P.S45#>.^&
M$\UMOG[5GV7-\#^7S.5\WQ_BSQYW+S_D?(QRYW.^CGS<+\GRLK?%7X^OTE3J
M(E$2B)1$HB41*(E$2B)1$HB41*(E$4$9?E&C[\M[\K%I?EOG92]^5!/X[J8X
MXXJ7O\_/QQQMG_%;&UK\EAXE0<!Z!Y^OI4ZBJ41*(E$6)D]%:A2%R<(G  &
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MA=L[U?MU\_#R;_\ \&-/>FFOO#3YOO)SQWC>E![JGADQKQ5A>M7[=/AY-_\
M^#&GO337WAI\WWDYX[QO2@]U3PR8UXJPO6K]NGP\F_\ _!C3WIIK[PT^;[R<
M\=XWI0>ZIX9,:\587K5^W3X>3?\ _@QI[TTU]X:?-]Y.>.\;TH/=4\,F->*L
M+UJ_;I\/)O\ _P &-/>FFOO#3YOO)SQWC>E![JGADQKQ5A>M7[=/AY-__P"#
M&GO337WAI\WWDYX[QO2@]U3PR8UXJPO6K]NN?+N[7$1@V1>YZ/U+BS<+N&J#
MO+IQBV7<LTVJKMNBO<_9)1=JD^9*N$<,\E$$WC7-7''%PE?/B/\ X?\ DR7N
M8,=QDO:UKW,!P_;:QY>&.<WN6X:\QO#7$6<6/ )+3:^&+' T/.$88&.<YK7?
M[9LES0TN:'<]8N:'L+@#<![2;!POP?#R;_\ \&-/>FFOO#7+YOO)SQWC>E![
MJIX9,:\587K5^W3X>3?_ /@QI[TTU]X:?-]Y.>.\;TH/=4\,F->*L+UJ_;I\
M/)O_ /P8T]Z::^\-/F^\G/'>-Z4'NJ>&3&O%6%ZU?MU>>O>[Q; 4FD>1VEIN
M$(0!<@DA)W<)<R&TH8#5K9)*$1*)@N['/5V&>6#O(<XQ0\8(HJ,TWK%5;!VE
MHXE_\/N&BAJ781C6(.Q%L9=2LKVTQI))6[Q%,8((Y6-D +!*TNYMQ#RR0-+#
MM4/RQUIJH!B.%4@HB\"H=2.G%0R,[B^(2RNC>YEP[FW;.V 6!["0X>C.!3V'
M;0A\?G\ D(Z50^4#TB@,Z*6[\T>M%>7&]KVO;!9LZ;+8*-7S%TD@]'O47#%\
MW;NVZR.'F?$<.K<)K:G#L1II:2MI)#%44\S=E\;QO\X<QS2'QR,+HY(W-DC<
MYCFN/[I15M+B-+!6T4\=32U$8DAFC-VO:?,;.:YINU['AKXWAS'M:]I N%/_
M )D[^;D\!'_%^\Y?ZP3Y>7E_=<GS<G,_><MK]]^39&M+HU_;Z_C=TK9Z?J&?
MG^K]\^A3J*I1$HB41*(E$2B)1$HB41*(E$2B*"^Y?]CY.3^O-_G[Y\WR_F[W
M_/\ N[Y^[^G_ "HBG41*(E$2B)1$HB41*(E$2B)1$HB41*(H(R_.&C\N=?/G
M,6E^??++.^7*W3OSKYYXXY9WR^>^66..67+RY8VO>]K#Q/\ IU="@X#T>GKZ
M5.HJE$5OA)7'9&_E0L(5;$7\'D*44EC5OWSO@.1+1N/2](4\Y^&&/A.<:ED=
M,6[UDHGX*6;<N=E.^)ID_=?N,ICV1I[';EV6!H?81X4/64[PMAD>3)JB$DKK
M633<KOT@Q15%NVS67[VR7SS3PQQM>Y%)!G1,D')EP;U,@.5<D&:;I+%7##)R
M*(NA)!*V*R::G.:D6+IKG>^%L<LT<LD[YIWQSR(IS5XT?)9+,G3=XC@X>,\U
M6JZ3A+!V/=KL'[7)1++/#%PQ?-G+)XA>]E6SMNNV6QP624PQ(K2G^Q85JV.+
M2R>GVD>!IO1XM!==)V\>DS)AVFP"Q\"'&MWIF120X061'@XX!'D3AH@LBQ%C
MW;I5-'(BQK;BATCC$UY@YE90<T0ER.O[QPS ]AA-F+SQR)3D#.$L=0%XHRVN
M1EQ".*8R4;&F$,<F249Y\B8,G 5-1]B5L?CAZ;\+>=?/[4>CNA[J;=+W_BL?
M,!^O2@;H1/\ ^D -/"R#9X,AAS5?1;^DX)*'XYZQ+M01:(LR:P1\Q-X-KB7C
M9XJ45/=<6^@6[6*.FLR*G\IHVF;H".AVO=ESD[=/71P3&)XF9CD-AYT_%W</
MDIT3'I$PDXT.^$G'J8EXW2?XJMTR6649CM"$P&&MYY+2CL5'7BH!H/M:/R,A
M(2I24O&8Z.  \-%B7LQ,2<T1(,QXZ+# +N1.7ZUF28N[G%1+ BQN7XK^'T$#
MATD);%:)A)P--&P[]L"E1%,: BY5@ E\CFZ0X$[7UI&81(";&/3N1[&2BH.#
M2!Q@#EK\,6QS9XE;'X\_#57"YXA-.L]CN=4/)HW:31F[6%NT'0B0-XXVD#>%
MY;)<1!>=K"<((E.D-<89[#7@><EQF24#QRF*@/&.8Y$K$L>/Q_IY^%U>\,V!
M"-B,2!.#2H'*V HX=C1-R$((/L&!V-&2$?-C75D<[Y(N&1<4_:7Y^-DW%D/"
M6N:[15%=0HKPHB41*(E$6.]@[;UIJE$8XV/-H_#&Y?-WX"X//L&2&3<=9M<H
M2<K9VND/""+/6-S)XAFU"A[/F5R;]IX6V[Z2QR5)9[YTR0V"MJACLV&N]C-R
M3\&XAZ!MFH90/C 5I2_CBK?%2^*<E:Q6^4J4CF>=C?1=)>18L+A6Z[Y,K8Y%
M8ZBG%3K38V[8?J;64GBD]82'4^U]G$Y''CZ3_P 6H0"8:5BP"[%N@CFV,QN9
M6V@<<"Y8Q>*!G:\.=M1+@GE8AD.*6.7F^O)8GB7' T/[D_HU)1G7S((OM7=F
MJ[/ .YV\DVA%L](L)\2,; V?J):" ;P?61A+7KQ@QE+.;RC)H;EFOAKX>EC*
M;NAQ6VZ^_P"L6'U&^_\ U5[P_B0V&>AXO>,EU#&X-PT%X:6V5:=F-K/5=IQO
M6C6)$9D'FLWU%_1BU"A6A8.Q;N'@(-M>32N/IF!F!0%B_0D \$2W0-YO;S?4
M;_LI>C9AL2ZL99.=#034.N=C.IIL48-5W4L7W",)[ +G=G%2$XU8KK<?'1AB
M0R(Z9?RUE#]M3M.-R MDV;9$1*+T@-(?3<]6O'J"RW--\:9UU)6$-G6S(;%9
M42:A'[4 :-LV12XN1FG4;!F'#512RC$&3D;-:/MC;VS<3D<R;",GF)!ZS;KE
M+')4.4\0^L@3V5!!\RA!"3P-KTCG 4M+6D:3C>OX^; -MIS1P3>-'31TUU;'
M35STE9-.^7:/?%$>,NP#J0,'6)%51.[H%C#0<HFTM@D+=.T98SD3-><AR 6-
MRG6;0TIMV/92A;$4R>I:P?1>4LI285:C6P_$ ]=$$!^-KI8DMEO]"N> ;-@&
MTA;XQKZ5AY6P%$\PI;,6XY[@07Q9,2EAAA@MBB_%/E1)068;-2#9LLZ#E199
MM@J.),G2Y%?5$2B)1$HB\6T8D@&&\4_%E(),_9,@I[9$QU,15<JI77Q!;6WH
MT!SQ9NDM?'-1/^BQI/VKE>V%[(6>)74OA=7'E]Q5--45W)'D=34L;Y)Z?"J'
M&(FM#BTU&$<GWU&'M<1NO_%GX<]K207;!M>Q7E.">&EY1\IIJA[6135]7AKR
M2-KF<2QAL-86M)&T/X<VM:X\&[8)/!<#07!T-7AM HDQ<B9--ESB1G6H(ZP;
M*[+VWJ+4C]W@.&F;9*7O'#AW9#+7,.79*Y8RD?$2A6'V;R66YMZYOFKW8K-R
MB=%+32/PN@IJ=]13O<W"\'QG&8V&26#<>ZJ>GPR3$ZUL@'<DE;##6EU+1!RX
M-CI&X?%@HDCG8W$*N>9L,T;3B&)89AKW!D<N\F"::N;04A82*AM-)+36GJ2U
M8J+PK6$>'*2 A#@RTS4%:X!O]3Y30WA'XKL69RG8>;A%ZX0.*2S,8SUU"@9$
MP(7EN1&+RZ:H#S9-OF.6CN';PUV*U,@IXZV<4+9L3GCQ@4,!J:O#:&EPT-,;
M70"C$S\2KJB."9M'S5714+I((G"05)ZZ6DP^!AG?2Q&J,5#"_#353""FKJNH
MK26O<)NZ2QE#2PR2Q&JVZ>JJPR61IC, KSK4FHF3@TH)8])-=+D]S9%MGO9=
M=NXUJPB1V6B]= &;5BY8BR,M.C0T=DG>#HPI:?MY:/C\08 WP\B7OK,QG&9&
MP":3N7$VQ8'S.$LHPYN*25E/1RXE4/=(U\T=)3RSU-+M4TT1PYU')4ULE1'+
M% LSL,PQCI3&P3T+I,5YS$'U)#J".FFJ8Z&%K6.9&^IF9%#/::.05K:ED-,R
M%\<DJP/IACJ9Z3/VV>8,C<$X9L)00DS"!2(Y4DEK^2K!E;NRLLCJB9U$]@.R
MCHY)!S@4,69,LW#>Z]KV^AQR3&(XJ?\ A4$$I-=AHF+ZB>*41.Q&E;.W8AHJ
MH&G=3F7NF5SF&&'G) UVRNFPIF&ODF_B$LL8%)7&(-ABD89!15!A)=)4P$3"
M81\PQH=SDNPTN;=<VJH?&Y0;V!DW&O)JM&8PZ-P*$O7%P1*?$;RR. T&3YF'
M)Y%%KC8X8*RTJ!BIK(NND"<(LRB8]!^30XXO6U5)!AP=*R@;55;(,1KF-[HB
MPZ(4=54.DC?-"(ASM3!#1PU%7 (6NJ&E\)E='$[EAM+3U$U<6QOJS3T[I:*D
M>[F9*R3NF"$,>V*3G#S<$LE3)#3RF0MA<&R!C7R#+S+6>OE 298C$1S0*5 [
M0*S>5MYVNZ9Z>E48<RP9$]>QZZ1==B8*E'@( 8;-9)TG(34-,QPF..!RXM]*
M7'3/Q7$14&&.ME?/#485#04;\/:Q^-4E6RCEK,2J0Z%LD,,3*BHA<ZE[DCH9
MJ*2:J;*V:.D;V3,/HS$)'TT;8I(<0DK*AM87-PNHIW5,=-10VE+)9)'PP2M;
M/W0^KBJF10.B,;ZEU3&PW1B+YC'5(D(*DV<\X>]<KDR>P#31J6*3N'$U-Q'7
MN0XFR:I XG*1":,:6&^+VX=0NDXD;V1L;(B4\4M;C[F25+:R:&*3#^4>)MBB
MPV![X8</K8A@D#.=BD>ZHK:2;:JFR\XZ<0N;2LI9-J8Y8Z7!P]D!I8I)&UF"
M4)DDKIFMDDK*60XI,\QR,8(J:HC @,98V(R!T[IV6B$NT4A;G5,$&NX\W=:]
MQBN\9ZZV.YEV+<I#Y0\,2D/"@>0D>^;BTY9(VFO-=]_C\B&$2,K$&6F$=;1U
M)!:08\!65S<7KY65#F8D:O ,.;AC*(NBK:1D%)/75'.R1F8T=*_$L3V:FFEB
MBHYH'FJ=5%S:8\NY:5V'4<;H&NH138O6NKS4@24U0Z6HCI(3&QXC%3.RAH;P
M3QR25,4S.8$#09U86T=;P2)Q"3Y-!*#!(,0B3/6D^3DZI)]N9,@@NI)3:82[
MU<7:+V;)YEQ[P",&9PQ7(9#)8].2,AFX1[#"L3Q"KK:0/F=(9XZR3%,/-((F
M8&8G-%+3F?8;+W7MN$,D=3+**YHEKJ-D%+&&NT\1H*.FIJG9B:P0OIF4%8*@
MR/Q7;!-1,(=MT?<VR#*Q\,<9I"8J2I?-.\N&J-?7KYM*(E$78YW/SN@<QX.)
MC8*:N1E.BY2124F,.35[ZZ!NE>]H9S&'8+J8(MC;9'!.Q(;=1!E)&2&#-YFW
M>MQA,=^9?*-\G-%RVHN?@YJDY04D1%%6D694,%W"BK2T%SH'.)YJ6SI*61Q>
MP.C=+%+]UR*Y:U7):JYJ7;J<'J'@U=(#=T3C9IJJ4.(#9F@#;9<,J& ,>6N;
M')'[#M>3^&[3CXG8.OI"-E,.E($43!'1:JJK9XV4<%<<\<\5,<+M735;!1H^
M8+I($ASY!TQ)MV[EOWG#Q3B.'5V$UM3AV)4TE)6TDKHJBGE #V/%CQ%P]CVE
MKXI&%T<L;FR1N<QP<?4E%6TF(TL%;13LJ:6IC;)#-&;M>PW' V+7-<',D8X-
M?&]KF2-:]I:+^K26TE$2B)1$HB41*(E$2B)1$HB41*(H3W_TG\/]>;_Q=]_^
M?YN]?VO[N^?NOI_RHBFT1*(E$2B)1$HB41*(E$2B)1$HB41*(H(R_.&C\N=S
M^<Q:7Y_.SSY_*@G?G<]3'#/+G?/SL\<<\N7ERQM>][6IXGT_'!0;P/0%.J*I
M1%UV+\.FRY+O^<OY!G.@6G)AOB=SPST&VX<U[G)P3GA4X;=:Q!T8RU[,8_+%
MD6L]A$V18L,U$'@]\%0,JH(C'S!T_+E?=T7MTB]MY/3Z0L1N- \2TJ$\/1[;
MPG:<W-:U'<&9V7 HUNY&.&74]CNM-HQ3B +,\Q&T(7&7Y5E*I5&#$C?*F&[>
M3BV+^\86D*Z> MX2XW@>>Q(N+7%LST'H7Q-M=\;KDUK5J& 397.,3$))KS1A
MM5VNJLR<\6TQDDNCTN:K<2D)C*($?P^-XFB%07U'N-Y*&$D(0%]E$V<=Q8NR
M"UC>W ]'F%NC/CO&_?Z;0<<.'$K"  Z+06,[?Q@H[>/&S))?'6FWSTHD4W6V
MQNU2?\/>QXN8QXTM"GQ\:!Z_*RT-)1![988HALZ1-Y<4UD?+-<=E!27!R&X<
M1D-_0>GJW>9;H3_76VF<6X1)LFP)[JG?#H>%R'84<</(C'I?L9T7T9-]02J4
M1M4J:%:^8[&'E9NM)D&9.4!XT\#J2T R/M'!06\Q*9]%^T<>G]U2)8ON&3[%
MU+Q#,N'B=69ZGRVG!'6HCTJU$ELHW'-HB8 YMMV(-FVQ'NN6L@B9F%YQ-N D
M6R )Q] 9AL$@A=N73$123D^OCZ=#\'>!Z1B">Z%W/O?9!?;MXK,]&M)/..%*
M/LPB4HUOAM0#$-"&]\261[;*.1!:=0-@6..]T-XX%C3(E,#EHU#AY PBV?%K
MQF-$W6 N.D]/$VW>G=Z/WQH'X=][00_HLD2U[Q#2,M"H1Q6Q#:FP=$[;TL+E
MFSY[/=N:0D4?V_(%MO;6BRZ0C;X&"FI8K#1ZJU]7E4DM?M![.+!(PY?E=Q!W
M@;Q8&^1R!X>?CQS6X>WXANHFOI[9340E/AFI-OP[9P[3(H*$CNTK@2&I]FZI
MEXL_,S^W2.LYO+(RZVBUGK' <I"1&3B$NQPPE(2) .ZR*"V\'+<?KU_U6G;G
M0/$& B.\%6NDR4K+<6.H>):#HQ3&5:U3;:-D.W.(3?VT8:VV8X(S1J.< "\9
MW^U6VJ_U>ZV,JPD6OB[4$QEJ9"-N"16X-LAU[@/VW>G?97T(X=]PC^*89*7<
M7V&4&,=_H3IU*'LOU[GPZD=;H\,-M)J21Q LI+GLK+>CUICT>=%<HGEAD66<
MN\CN4$4LVS*7%@/-;Z[W^L>8_P":WUT;P_ZAX;8:KK[2D,9P6'KF'4@6",7I
M5^@J=(MF2!<NHL8?$'69$XX9>.3[O)>ZYR2/S,F*YNSYPP1>D))X^CZLEF2B
MB41*(E$6F/%[PGFN*@+E&$=LO()&2FM=I:UD<?7!R"2AGF&RV00>C.!@<1L.
M"A+SZ&-!A%O%B,X%;! ,$#Y7%&,H*N7:SLJ#8W^/T^./0J\5X4(\;)JO24E?
M9LWO$'-M\$F34=@R7>*3CA\E_#X0B^!)N_Q=-<6X66K&4#Z5KO;+,D1V+1-+
M/PI(E]UO-;KNN#47#C-H#.-:RN8[:#3@?I_2$LT-! P?5K:#.E(Q)36H2>$@
MEQC"8R7 Q+46NGPS(CE'A4.B+U5^X>"8?';)>"KDOQ\Y!_7M_P U9XS@V>]-
MV1&33R)&=>!-Z;0WV#C@S4_B78:TAVBZGC@I%Y1M-]/I"W*PE!/8AUBZ%QV!
M0TF>%MQP8R9<A,SHTZ3=Y]?\AUW5RQ'ALV "APO1TBW$#F?#2&B)/7*<$*ZL
M4PVC)-:.(J_AXJ!SO;JVPWX8Z+&!7R+-V;":JBDU.HAQ2A24*$59"1D!+CH%
MCZ=P/F%OWW*WA?"7-WDYT4>V5MN([$!<.S^0N(&7STTK'-\&V)G46QM-(C)]
MNACLYV*)(]'ME%#1U6%:MU_D=E8H(83P$X-WC1Z2^X^?COW<;\/\STJZI?PB
MQ61#-U!QDD,!A^W^'@)P^X7(9DY@3BX\.>W)(<Y(D>DYU\<..G;W;[C_ '<1
M()IM<(\/P0>]Y4318DO?4G=NR\WF6(9;P$DYS)]L'93NXD61V) ^*#7@E5[&
M3I.31Z/\3">*60Y^:.[*, WP;4S-!B!UP!AT0UR+3C+)-G)$3IS/*242]K;N
M!!T[>GC]0%E>L^X&H;L.4;^-EYI)68K=4**1\* $H-F&.K93,&D&;;(F\8?)
M+<KUS-W.H=/F7(9\SP9L3D8E1"Z[Z^QI"BF2Y%O,?TX#ZM_U&W0%F#0&D'.F
MV$O7-G@LJEDU.,2AH^#"S((U59" K(,&&W1G^S]ORESDQP0>N;N7\V=HVS(J
M-V+ <S020HAZEL%11*(E$2B+P(\0 8P7XAM^9"A1(I;'>.PV6>0]B[>VQ>E9
M\?;C&F62"*E[.B3C#-!@AER+O%L<DD,%%+7QM_0[DW/##R9Y.<[-%%?D_AD@
MYR1C+LAPZF=*\;1%V1-(=([@QI!<0#=>,<;BEDQW&N;CDDMC%<P[#'/L^2MG
M;&T[(/\ -(X$,;Q<00T$JQ(]K*9R1PZ8L([(<B6%\V@T>G&I$\<&#2,B QIR
M!;78"W230BT?R!G@ZR)J,6C=QD@-6<X%2(MD][&IQ6AI6LDDJ:81$!\LAJJ9
MC88'4U15-J'<Y*POB?'3/+.:$CW-#I6M,,4LC-*##ZJ=SF,@GVQ=K&"GG>Z6
M83PP.A;L1N#7M?.P.YPL:TVC)YR2-C[SDW#WLN*1-[)246D^:X&;3R'2X>UC
M)1TTB>$&&PE^H=,&F^"K1L+,YS')$:X73;M%D1"[Q!ZY1<862T:7E)A=961T
ML572!M108?6T4CZJ%CZPXA+71BG@@<0]TL(HMJ5K2YX=,UCF-<TWVJC!*^FI
MGSR4]070U=92U+&P2.;3"CCI'F:65H+&QRFJLQS@UI$9>U[@X6MJ*:^9E(V\
MG,NDR$-A;8Q>.LWUACDZ=DL@39H$'PB*@4%V")!4*/>#G\@>DS 02);%!"2Q
M#,B8$CWVU68D^&JCH*.E=75SX>Z7Q\ZVGIZ6F+W1QS5E0YLCHFSR,DCIF103
MS3/BF+8Q%!-)'KTU$V2!U94U#:6D;+S#7\V9IIY@T/?'30AS!(86.8^=\DL4
M<39(P7F26-C\BQ/A^'S-R';!-FA5\9I/5-=ZZ>Y1F68LI(=;!XL8)9F+9#K$
M(NR!],P \X]5'E&;1XJ\<M'! (UP+N>LK.4<M"R9\^%3M-#AXQ+$X^ZZ/;I:
M=T]7#%S-I#'5OJ.X:B2G8V2)[V"-KVQ3O,+=^FP1E6Z)L.(1$558:*A>:>IV
M)YFQ4\LG._R;=,R'NJ%DSRR1K7%[FN?"SG78;F$0=PQP"9OW;9P[-1*-2[-!
MO93G#VDK&I&Q#5SEG:ULW"P1V-)7R2YR5T2"-L<LKVRO7>45:RN9421L>UD%
M9548<ZW^(^CF=3S/:!O#6SLEBLZSMJ-UQP7555*ZE="Q[FN=+34]26MO>-M3
M&)HFNN!=QA?')<7!:]MB5:-;BUDHB41*(E$2B)1%5@0(U*#0J.1P40.GSI!H
M*#!A319\3*$WRV#9FP8,VV"B[ETY74P2112PRS4SRMCC:][UAJ*B"D@FJ:F:
M.GIZ>-\T\\SVQQ111M+GR2/<0UC&-!+G.(  N5EAAFJ9HJ>GB?-/,]L44432
M^221Y#6,8QH+G.<X@  $DE>R3N9/"!..$?4I<5L66$"$MGV864EX,W?7=Q/7
M[FZ9%"PP7?'OC9U('"'>;2HLQ7LQ=.6K-BU3<M1;<N4\2?*GRTH.66.1RX91
MQ1T6'1R4L&(.CV*W$FEX<99KV<VE8X'N.&1O.,:^21Y8Z9T,7J?D!R7J^3.%
M21UU3))55KV5$M&V3;I:%P:6B.*UVNG>".Z96'8>YD;&!S8A))V75^8+[Q*(
ME$2B)1$HB41*(E$2B)1$HB410GMN7P3XK7Y'S>_QV4OR?Q_';O=[<E[?RNIR
MI_2M\U$4VB)1$HB41*(E$2B)1$HB41*(E$2B)1%!&9<X:/RYW/YS%IES^=GG
MS^5!._.YRF.*F7.Y>7G*8XYY<O+EC;*][4^,D' *=1$HB41*(M,FO&GK 2S3
M1D;N22!V-CK&<3*2PW6LK1AT+@1S9<]UF)ELG7?.RF8<8R/0 XR,)X$"9>S0
M81ER A**,BKP,5L?CS+<VBB41*(E$2B)1$HB41*(E$2B)1$HBTOW7*]SA>*K
M0 /40>+RZQCA]XJ2TAAT]VM*]6PUU<#L;@]9B),JYC&L=M6,28!:1%!8-!]%
MFO@8J4R=1L?8]_<#C!46L;YCHOGYPM2H5Q0;"UQ#'Q^9,&3^<YS;BC$$GY[:
M\]/ZU@.97NGK[0#!P7<D6T>&E=8Z9#2YL74E[^&Q60#=8058(/4A()RZ:L(/
MW/ZE4C3^7S?]V_GL3;4JY#N[MR[,VEJF"QR7:1(RS5_',MK'I_$DI41U^;%%
M.YX;XV@1>2C7[2:+DDS 4B?Q86@:6SW3;PT2&-.)6S<9J#V%2PMP.]M]_P#S
M6W?OPWW"O+<&_)]L?@@F<H'PZ51"9&]/9E%Y=%I6XBT+8S%K+T(@9C<?GH0K
MCLL J\(-7S@>:913)X. .4W.+I8LE=DH5:!M ;C^XM<%8JUILZ?ZU7D"AMFX
M82(=Q+[2@K;2,QXH=NS8)JQ_KS@_V[L@<5D.X=E7#N#D W4.BD8V&!&2^//M
M>:_C$R$S5J%'[&#E,0I2U]!T#?OMP'#?NZ3NR*HTBXQYLQV'I^5&FP2\LCH'
MB,U9L11X)-P76FHC!4IP621C.-S-F4PV<S2B$(CNP1[U[*H).Y[%'[20"'SF
M9P./EIF:U^0"X/I'3O/$;O/D#O6TG%NAN(CM/A?:Z7G!"/384IN&<C(]8X1#
M:^VB4A\1!K(Z^V4/;*.VCV(2\<2,@$2CUD9=0(H7'S\"U<R",#<5"X_'^BT(
M+<0^RMF2[^F+4LLVP@UUYQ@;)F3K42Y@\V(DHWJ/@UT43W'PVR6#H$7 IQ(6
M+QSMR-CH@XQ>!(WOA5K+6F*I8;B15+EN%@;;P=_UFQ_3ZE=@O<.QYUM?<6WQ
MFS)M_1OMZ7=RTDVDH\PE)UM%@^DY)Q[2W438]&AB#QN/2'\1D'B^>QI&^29-
MWTHA>P@L1D^3\6 8LFY7=8;O^*^[IV0>KA]5^E6/#-G[UAER,N@IE[*MD2N+
M=T,8:^A[#B/VCOF1;#V5 R^S)9J;&></,Z;#(CJ*'QI2 )109(X _D*O2&10
M?7"[D**F.*;PIQL#F+FP&[T_%P+YKLRT/'N'$<IJ^:Z_WA)=A2;8,4(JQ\_)
M.(6;2U[N5#Q<V)2&0D(*7F2\8,EA-D;D,DA<08)ZW36=@H^PB@3-4+8H;[Q8
M;CT ;M^>7UK<JBB41*(O"].ML*ZOW]Q;7;"/&A.3;!V4.C)#)_FTM$):RVHY
M("9NDG9JJL^)@&*1FX%--P-582%X*.W=JIB51A'WSAV#C%N3G(W:GYF*EPS"
MI:N,1[?=M')A#(YJ!SB]HCBJ9##W02V424S)J?8:9A+'Y K<2.'XWRGV8N<D
MJ*[$(Z=Y?LBEJ6XDY\=6!LDOD@8)>9 =&63OCFVB(C')\$N*ML0V(XF6$!LT
M"Y;#UM*FD51D&&2+6,1.:G]E3**9/U F5UUI]L$UC)ERRS/)(0LA=DF,>LL&
M2++G%R1='AK:$XB7S##<4HWU;J8ASZJLH:?"Z*LYL5 V1AV'0=RMA;(#,UW.
M&6.0R.?'\HVOKG57<6S":Z@J6TS9Q9M/35<U?54VV822:VME%09"VT1;L"-[
M-D,QQANI%BB%9"PY6S"/:_W'#1^!(\FZ6<E=PN)H-,2TCW@8V;J$;0F3BXZ^
M1112L0<QQF1LX;(YIL&O9G C(Z>2::$R5.)8)72&.G+&LAP5M#+!1Q[4KGB+
MN^EFJHW.<[FVU3X]EQ!D?HC%@P1,BBEYN"AQ2D8))@XF7$W5<<M2^T0:7]R5
M$<#P W;= V0.:+,;1(].H8X@ _7>P(_)'XZ.S"132-%X@=&AR*+N7"(F&DP<
MLV, S31ZR?(0>-+"B#>[-R"<(E,EVAU$DD@.SU.'US<1EQ+#JBECEJ:*FH:J
M&MIY9HBVBFK)J6:%T$\#V/8ZOJFS1NVVSM,(:^G,3G2X8*RE=1,H:V"=[(*J
M>KIY:6:.*0.JHJ:*HBE;+#*U['BCIS&]NRZ$B0ELPD#6<YS<I:T('ZW@2\J@
ML(1,34R6 -IF0=MY"O+70YNE@?Q9-@C,OD.C0$"$S5>,,L':C1V\3;LD7MF*
M'&#!(>[Y,3Q!M)B%>Z"A@AJ'4,;'4S:-DKG&GYQ]0^$2U5143@,D!8'LC+I'
M1\XZS8I)W(R@HG5-'1B6KED@%4]PG-2Z,#G]AL+)2R"&"(ET=G%CG@-#]AMG
M;%F&$ZE*Q]$?D*:8!(C'1H[-S9XHS$0N(@X:'14=8H-;+JXBP#/OJEFZ5LE+
MY?)_G?=PVB.'T@IW2"9YJ*VIEE#-@/FKJVHKIG!FT_9!EJ'V&TZPZ5JUU5W9
M4F<,,;1#301QEVV614E+#2Q OV6[1$<+;G9%ST*QZWUJ)1$HB41*(E$56! C
M4H-"HY'!1 Z?.D&@H,&%-%GQ,H3?+8-F;!@S;8*+N73E=3!)%%+#+-3/*V.-
MKWO6&HJ(*2":JJIHZ>FIXWS3SS/;'%%%&TN?)(]Q#6L:T$N<2  %EAAFJ9HJ
M>GB?-/,]L44432^221Y#6,8QH+G.<X@  $DE>N7N;?<VPO"V%9[5VJS'G>($
MZ/OS,.5%\,U8,?(\U<$"7Q[X@YDKE!3)O(Y&WRRPQPR6!@UKB[D"!_QQ\I_R
MGS\K)WX1A#Y*?DY3R;S_ #1RXM+&Z[:BH;N<RE8X!U-3.L20VHG'.\W'3^F>
M0?(.'DY"W$<1:R;&YF>9\>'1O%G00.%VNG<T[-14-N+$PPGFMM\_:^G;_>3N
M_);XV(^W+R*<M^1<G?DO>_[J]K<O+:V%N^6Y;]]Y<;H\GXYT:_M]?QNZ5^D]
M)] _?XX:]$ZBJ41*(E$2B)1$HB41*(E$2B)1$HB@OO\ TGQ6O_MS?Y[*7Y/X
M_CMWN]N2]O[\^5/Z5OFHBG41*(E$2B)1$HB41*(E$2B)1$HB41*(H(R_.&C\
MN=SN<Q:7YW.SRYW*@G?G<Y6V*F7+\_.4QQSO\^=K9<MJ'B?C]-VB@X#T#XW[
M]5.HJE$2B)1%K$APD:D;QO8T53PDOBK:.LF.I91;(UC=S>)#Y=MJ;-[#EO K
M6:$O'>Z)I?-[?!:V32XIO9&UV&2CA\?&J?'QHMG:(E$2B)1$HB41*(E$2B)1
M$HB41*(HV3-IF\0(9M6V;]JV=,VS[)!+)XW:/E6:[UJ@YOC=9)L\6'#UG2">
M>*3A5BS46QSS:H7P(K,E^OQ<HC)J/#W[^#NS#=XCA*8:SC:$B%J$3&!\DNSQ
MD "11][B6+8YNS@V0 #820W<O4CPHF@]=)*D5F:<T)$-,CC+<:^*RPS(96G,
MBTHE(Z%LB>9IK#Q.OA?BD/ HC!X3%6 B$A&$<8CXC$P+91MD4?D,'QH_("A0
MJ3=9>N'$W'W$7%CKBLK98Y#+L6UQ^6.2MU\L;LN]>#7MDO>ZV5KI<EU;W4OR
MYWYU%%QJ@0:[S,BN&%+$%+IY*/E1S-1XIDBS?#D<LW6:-U\KI#RA-@G?+.]T
MV9%\UQY$';C!0BHX: P2."D04>A42!!&S8LS;A@T<#BQ3=F>63<'6J(]BS0:
M)-C2Z*2Y9!-'%(BLDFH\P6SPQRL15_ 6,2N/R3',4\A*.387?!HWPN-;YHIM
M\VX^^*=KLT<T$DD<DF_>T\D4TT[XWPPQQL1<" $&U<YO6P84W>9OG1/-V@.9
MI.<R3YLDS>D<UTT<5<GSQH@BU=.[YW<.&R*2"RF:2>&-B+XM'8_:R6-@0>V*
M" 9JCC88RM9%M''F1&/-TK60Y$T )#/)\&2PY$Q;S+)TQQ07ROG<BIX.#PJ,
M$"I:-1"+QXJ>6S<'"8./B1) RX474<J+E7C!HW<D5E'*RKC-5XHMGDNJHKEE
M=3/+*Y%'"Z\@$;D)Z71V#0\!*Y5E;*42<+&0HN0R3+%3ON.1XTQ9($C&5E?W
MEKD'+B]E/EVOSOCHBO"B)1$HBP7CPY</)>ZA4KHC3!0F37<$")-_J^%OGQ!\
M\74<.WKUZ^!9O';MTNHHNY<NL\UUUL\U5<\L\KY7[R/E/REACCBBY0XY%%$Q
ML<44>+5[(XXV-#61QL;4!K&,: UK6@-:T    !=2[ <#E>^27!L)DDD>]\DC
M\.HWO>]SBY[WN="7.<YQ)<YQ))))).\_7[,/#5YO.C?])8#[OUS[Z^5/E+C_
M .<8C[RN/>]@'B/!_P LHO8)^S#PU>;SHW_26 ^[].^OE3Y2X_\ G&(^\IWO
M8!XCP?\ +*+V"?LP\-7F\Z-_TE@/N_3OKY4^4N/_ )QB/O*=[V >(\'_ "RB
M]@G[,/#5YO.C?])8#[OT[Z^5/E+C_P"<8C[RG>]@'B/!_P LHO8)^S#PU>;S
MHW_26 ^[].^OE3Y2X_\ G&(^\IWO8!XCP?\ +*+V"?LP\-7F\Z-_TE@/N_3O
MKY4^4N/_ )QB/O*=[V >(\'_ "RB]@G[,/#5YO.C?])8#[OT[Z^5/E+C_P"<
M8C[RG>]@'B/!_P LHO8)^S#PU>;SHW_26 ^[].^OE3Y2X_\ G&(^\IWO8!XC
MP?\ +*+V"?LP\-7F\Z-_TE@/N_3OKY4^4N/_ )QB/O*=[V >(\'_ "RB]@G[
M,/#5YO.C?])8#[OT[Z^5/E+C_P"<8C[RG>]@'B/!_P LHO8)^S#PU>;SHW_2
M6 ^[].^OE3Y2X_\ G&(^\IWO8!XCP?\ +*+V"KD<T/HZ'&6<BB.FM4Q60#[K
M78'8YKN( S+&[A!5JXNS*# [5ZVNNV66;K717P[Z@JJCGSDU,\;X*KE#C];
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M@-]JO_:*6&0T"7.9U*=)I'U@-]JO_:*6&0T"7.9U*=)I'U@-]JO_ &BEAD-
MESF=2G2:1]8#?:K_ -HI89#0)<YG4ITFD?6 WVJ_]HI89#0)<YG4ITFD?6 W
MVJ_]HI89#0)<YG4ITFD?6 WVJ_\ :*6&0T"7.9U*=)I'U@-]JO\ VBEAD- E
HSF=2G2:1]8#?:K_VBEAD- ESF=2G2:1]8#?:K_VBEAD- ESF=2O_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
